<SEC-DOCUMENT>0001564590-22-007860.txt : 20220301
<SEC-HEADER>0001564590-22-007860.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301072009
ACCESSION NUMBER:		0001564590-22-007860
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PMV Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001699382
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463218129
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39539
		FILM NUMBER:		22693934

	BUSINESS ADDRESS:	
		STREET 1:		8 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 642-6664

	MAIL ADDRESS:	
		STREET 1:		8 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pmvp-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T18:28:25.7830368+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:pmvp="http://pmvpharma.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
pmvp-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000028" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001699382_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000030" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001699382_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000031" name="dei:EntityCentralIndexKey" contextRef="C_0001699382_20210101_20211231">0001699382</ix:nonNumeric>
			<ix:nonNumeric id="F_000032" name="dei:AmendmentFlag" contextRef="C_0001699382_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000341" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000345" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000347" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000703" name="us-gaap:OpenTaxYear" contextRef="C_0001699382_20210101_20211231">2013 2014 2015 2016 2017 2018 2019 2020 2021</ix:nonNumeric>
			<ix:nonNumeric id="F_000704" name="pmvp:IncomeTaxExaminationPeriod" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000425" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000433" name="pmvp:OperatingLeasesExtensionPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000445" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001699382_20211231">P10Y7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000571" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001699382_20200101_20201231">P7Y1M17D</ix:nonNumeric>
			<ix:nonNumeric id="F_000572" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001699382_20210101_20211231">P6Y10M9D</ix:nonNumeric>
			<ix:nonNumeric id="F_000573" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001699382_20210101_20211231">P6Y10M9D</ix:nonNumeric>
			<ix:nonNumeric id="F_000574" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001699382_20210101_20211231">P5Y9M18D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001699382_20210101_20211231" decimals="INF">0.0035</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000586" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001699382_20200101_20201231" decimals="INF">0.0031</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000587" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001699382_20190101_20191231" decimals="INF">0.0149</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000588" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001699382_20210101_20211231" decimals="INF">0.0130</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000589" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001699382_20200101_20201231" decimals="INF">0.0151</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000590" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001699382_20190101_20191231" decimals="INF">0.0251</ix:nonFraction>
			<ix:nonNumeric id="F_000591" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000592" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20200101_20201231">P4Y11M1D</ix:nonNumeric>
			<ix:nonNumeric id="F_000593" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20190101_20191231">P5Y3M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000594" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20210101_20211231">P6Y5M8D</ix:nonNumeric>
			<ix:nonNumeric id="F_000595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000596" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20190101_20191231">P6Y4M13D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000600" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001699382_20210101_20211231" decimals="4">0.7650</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001699382_20200101_20201231" decimals="4">0.7070</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000602" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001699382_20190101_20191231" decimals="4">0.7207</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000603" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001699382_20210101_20211231" decimals="4">0.7990</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000604" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001699382_20200101_20201231" decimals="4">0.7760</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000605" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001699382_20190101_20191231" decimals="4">0.7269</ix:nonFraction>
			<ix:nonNumeric id="F_000607" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231">P6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:PreferredStockValue" contextRef="C_0001699382_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:PreferredStockValue" contextRef="C_0001699382_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommonStockValue" contextRef="C_0001699382_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommonStockValue" contextRef="C_0001699382_20201231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="pmvp-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001699382_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_20220225">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-25</xbrli:startDate>
					<xbrli:endDate>2020-09-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200925_20200925">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-25</xbrli:startDate>
					<xbrli:endDate>2020-09-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_20200925_20200925">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-25</xbrli:startDate>
					<xbrli:endDate>2020-09-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-25</xbrli:startDate>
					<xbrli:endDate>2020-09-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_20200924_20200924">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-24</xbrli:startDate>
					<xbrli:endDate>2020-09-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_pmvpSegment">
				<xbrli:measure>pmvp:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_utrsqft">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>utr:sqft</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_pmvpLease">
				<xbrli:measure>pmvp:Lease</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_pmvpMember">
				<xbrli:measure>pmvp:Member</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211119_20211119">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-19</xbrli:startDate>
					<xbrli:endDate>2021-11-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandThirteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMinimumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtRangeAxis_srtMaximumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;font-size:16pt;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001699382_20210101_20211231">10-K</ix:nonNumeric></span><span style="font-size:16pt;"> </span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">!</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000001" name="dei:DocumentAnnualReport" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000003" name="dei:DocumentPeriodEndDate" contextRef="C_0001699382_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000029" name="dei:DocumentFiscalYearFocus" contextRef="C_0001699382_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000002" name="dei:DocumentTransitionReport" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;<ix:nonNumeric id="F_000004" name="dei:EntityFileNumber" contextRef="C_0001699382_20210101_20211231">001-39539</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001699382_20210101_20211231">PMV PHARMACEUTICALS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001699382_20210101_20211231">46-3218129</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityAddressAddressLine1" contextRef="C_0001699382_20210101_20211231">8 Clarke Drive</ix:nonNumeric>, <ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine2" contextRef="C_0001699382_20210101_20211231">Suite 3</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0001699382_20210101_20211231">Cranbury</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0001699382_20210101_20211231">NJ</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0001699382_20210101_20211231">08512</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0001699382_20210101_20211231">609</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0001699382_20210101_20211231">642-6670</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:Security12bTitle" contextRef="C_0001699382_20210101_20211231">Common stock, par value $0.00001</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="top" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:TradingSymbol" contextRef="C_0001699382_20210101_20211231">PMVP</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:bold;">None </span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000018" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001699382_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000019" name="dei:EntityVoluntaryFilers" contextRef="C_0001699382_20210101_20211231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000020" name="dei:EntityCurrentReportingStatus" contextRef="C_0001699382_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000021" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001699382_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityFilerCategory" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top" style="width:17%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:17%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntitySmallBusiness" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:17%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:17%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000033" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000025" name="dei:EntityShellCompany" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2021 (the last business day of the Registrant&#8217;s most recently completed second fiscal quarter), was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000027" name="dei:EntityPublicFloat" contextRef="C_0001699382_20210630" decimals="0" format="ixt:numdotdecimal">1,229,389,330</ix:nonFraction>.  Shares of the Registrant's common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded because such persons may be deemed affiliates. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 25, 2022 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000026" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001699382_20220225" decimals="INF" format="ixt:numdotdecimal">45,450,699</ix:nonFraction>. </p><ix:nonNumeric id="F_000269" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2021.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5__MARKET_FOR_REGISTRANTS_COMMON_EQ"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">Reserved</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A__QUANTITATIVE_QUALITATIVE_DISCLO"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8__FINANCIAL_STATEMENTS_SUPPLEMENTA"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9__CHANGES_IN_DISAGREEMENTS_WITH_AC"><span style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A__CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B__OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10__DIRECTORS_EXECUTIVE_FICERS_CORP"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11__EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12__SECURITY_OWNERSHIP_CERTAIN_BENE"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13__CERTAIN_RELATIONSHIPS_RELATED_T"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14__PRINCIPAL_ACCOUNTING_FEES_SERVI"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15__EXHIBITS_FINANCIAL_STATEMENT_SC"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form <span style="color:#000000;">10</span>-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;expect&#8221;, &#8220;plans&#8221;, &#8220;anticipate&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;target&#8221;, &#8220;project&#8221;, &#8220;contemplate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our financial performance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the sufficiency of ou</span><span style="color:#000000;">r existing cash, cash equivalents and short-term marketable securities to fund our future operating expenses and capital expenditure requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our need to raise additional funding before we can expect to generate any revenues from product sales&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the implementation of our strategic plans for our business and product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size of the market opportunity for our product candidates and our ability to maximize those opportunities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and investigational new drug applications, or IND, and other regulatory submissions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our estimates of the number of patients for each of our programs including patients expected to have certain p53 mutations and the number of patients that will enroll in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing, progress and focus of our clinical trials, and the reporting of data from those trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain regulatory approval of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our plans relating to commercializing our product candidates, if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the expected benefits of potential future strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competing therapies that are or may become available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek accelerated reviews or special designations, such as breakthrough therapy and orphan drug designation, for our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">existing regulations and regulatory developments in the United States and other jurisdictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our plans to rely on third parties to conduct and support preclinical and clinical development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of the ongoing coronavirus disease 2019, or COVID-19, pandemic or other related disruptions on our business</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the &#8220;guardian of the genome,&#8221; and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 <span style="color:#000000;">biology</span> was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target the top ten most frequent, or hotspot, p53 mutations that are collectively associated with approximately&#160;10-15%&#160;of all cancers.&#160;&#160;In addition, we are expanding the utilization of our platform to target certain cancers where wild-type p53 function is silenced.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. The Y220C mutation is associated with&#160;1.0-1.5%&#160;of all cancers, including breast,&#160;non-small&#160;cell lung cancer, or NSCLC, colorectal, pancreatic and ovarian cancers. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in <span style="color:#000000;">amino</span> acid position 220. While we are in the early stages of discovery and development of our product candidates and our novel approach is unproven, we are initially pursuing a tumor-agnostic development strategy and initiated a Phase&#160;1/2 clinical trial in October 2020. Our strategy is to seek approval under an accelerated pathway, and we believe our Phase 1/2 clinical trial has the potential to serve as a pivotal study. In October 2020, we were granted U.S. Food and Drug Administration, or FDA, Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.&#160;&#160;We cannot guarantee that the FDA will agree with this strategy of utilizing the Phase 1/2 clinical trial as a pivotal study, which could require us to conduct additional clinical trials prior to seeking FDA approval. In addition, we are leveraging our precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A better understanding of mutations that drive cancers have facilitated the development of precise, gene- and protein-specific drugs known as targeted therapies. Targeted therapies have the potential to transform treatment of some cancers by providing robust clinical benefit to patients. In many cases, clinical responses can be dramatic enough to support expedited regulatory approval of these therapies. Further, recent advancements in next-generation-sequencing, or NGS, have accelerated the development of targeted therapies. A recent study found that 75% of oncologists in the United States employ genetic sequencing. We believe p53 mutations are particularly well-suited for the evolving precision oncology paradigm, as a single mutation can cause p53 malfunction, and p53 is one of the genes commonly sequenced, to our knowledge, in NGS panels. We believe that our precision oncology platform offers a substantial opportunity to expand the number of patients who will benefit from targeted therapies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our innovation <span style="color:#000000;">engine</span> consists of three complementary drivers:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">deep understanding of, and leadership in, p53 biology that enable unique insights into drugging individual mutations as well as targeting certain cancers where wild-type p53 function is silenced&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to design on a structural basis selective, oral small molecule product candidates&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">assays, screens, preclinical model systems and biomarkers that enable us to assess and optimize orally available selective small molecule drug product candidates for specific p53 mutants, and for inhibitors of wild-type p53 function</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 and Pipeline</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product <span style="color:#000000;">candidates</span> that are designed to structurally correct specific mutant p53 proteins to restore their wild-type function. In addition, we are expanding the utilization of our platform to target certain cancers where wild-type p53 function is silenced.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An overview of our development pipeline is shown in the table below.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000001.jpg" title="" alt="" style="width:607px;height:372px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In Discovery, we screen compounds against biological assays to identify lead compounds with selective activity to our specific mutant or wild-type p53 target of interest.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In Lead Optimization, we modify the lead compound to improve potency, selectivity, pharmacokinetic and toxicity parameters and physical chemical properties important for clinical development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In IND-Enabling Studies, we conduct preclinical studies, in accordance with Good Laboratory Practice, or GLP, required for an IND submission to the FDA.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, PC14586, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. The Y220C mutation results from tyrosine being substituted by a cysteine at amino acid position 220 and is associated with&#160;1.0-1.5%&#160;of all cancers, including breast, NSCLC, colorectal, pancreatic and ovarian cancers. There are currently no products approved by the FDA, and we are not aware of any other products in clinical development, that selectively target the p53 Y220C mutation.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53. <span style="color:#000000;">Our</span> approach has yielded a highly selective product candidate, which we believe can maximize the potential therapeutic potency and minimize risk to normal functioning cells. In preclinical studies, PC14586 has shown selective&#160;on-target&#160;activity (<span style="font-style:italic;">i.e.</span>, primarily functions in cells with the p53 Y220C mutation) and exhibited robust anti-tumor activity evidenced <span style="color:#000000;">by</span> potent tumor growth inhibition, or TGI, and strong tumor regression as a single agent. In these studies, PC14586 also induced the expression of Macrophage Inhibitory&#160;Cytokine-1,&#160;or&#160;MIC-1,&#160;which is an established biomarker for wild-type p53 activity that can be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measured&#160;non-invasively&#160;in the blood in animal models as well as in humans. Further, preclinical studies have demonstrated significant synergistic effects in combination with&#160;anti-PD-1&#160;therapy.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a Phase 1/2 clinical trial for PC14586 in October 2020. In addition, we were granted FDA Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation in October 2020.&#160;&#160;We dosed our first patient in this clinical trial in the fourth quarter of 2020.&#160;&#160;The Phase 1 portion of the trial is designed to evaluate escalating doses of PC14586 to determine the <span style="color:#000000;">maximum</span> tolerated dose, or MTD, and recommended Phase 2 dose of PC14586 when administered orally to patients. Safety, tolerability and effects on biomarkers such as&#160;MIC-1&#160;will also be assessed. The Phase 1 portion is also designed to assess preliminary anti-tumor efficacy in patients with advanced solid tumors that have the p53 Y220C mutation. In the Phase 2 portion, we plan to evaluate the objective response rate, or ORR, and duration of response, or DoR, in patients with advanced solid tumors that have the p53 Y220C mutation. We initially intend to pursue an accelerated approval on the basis of this Phase 1/2 clinical trial for a tumor-agnostic indication for PC14586, subject to discussions with FDA and other health authorities.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the mechanism of action employed by PC14586 to structurally correct a specific p53 mutant and restore wild-type p53 activity <span style="color:#000000;">could</span> offer a unique value proposition in oncology, and is a strategy that can be pursued broadly across other p53 mutations. To that point, we are developing a pipeline of candidates targeting other p53 hotspot mutations. We have other preclinical programs that have demonstrated biochemical validation, for which we are leveraging knowledge from our PC14586 Y220C program. We believe we can scale our discovery and development principles across all p53 hotspot mutations to streamline the process of further developing our pipeline.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to targeting p53 hotspot mutants, we believe that our expertise and platform can also be applied to target certain cancers where wild-type p53 function is silenced.&#160;&#160;We are deploying our deep understanding of structure-based small molecule design, assays, screens, preclinical model systems and biomarkers to create a pipeline of therapeutics in this field.&#160;&#160;We believe that we can continue to scale our platform to develop novel therapeutics that structurally correct mutant p53 or modulate wild-type p53 function where it is silenced.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our vision is to become a leading precision oncology company by designing, developing and commercializing novel precision medicines for every patient with a p53-driven tumor.&#160;&#160;We believe we are well positioned to leverage our deep experience in p53 biology, precision oncology platform and foundational knowledge acquired through our lead program to bring these therapies to patients. The critical components of our strategy include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Advancing our lead product candidate, PC14586, as a tumor-agnostic, oral small molecule single-agent therapy for cancer patients</span><span style="font-size:10pt;color:#000000;">. We have designed PC14586 to be an orally available, tumor-agnostic therapeutic and, if approved, we believe it could become the first agent to address the p53 Y220C mutation-defined patient population. In October 2020, we initiated a Phase 1/2 clinical trial for PC14586 in multiple solid tumors with the p53 Y220C mutation. We plan to conduct our clinical trials in this genetically-defined patient population and leverage learnings from recently approved tumor-agnostic drugs to inform the clinical and regulatory pathways for PC14586. If successful in achieving clinically meaningful anti-tumor efficacy in patients with p53 Y220C mutations across a range of solid tumor types, we plan to meet with regulatory authorities to discuss the potential to pursue approval for a tumor-agnostic label under the FDA&#8217;s accelerated approval pathway.&#160;&#160;In addition to the recent Fast Track designation by the FDA, we also plan to explore pursuing other expedited regulatory pathways, such as breakthrough therapy designation and orphan drug designation for PC14586.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Harnessing the power of our precision oncology platform to discover and develop additional differentiated product candidates that are designed to precisely target p53 mutant protein and inhibitors of wild-type p53 in cancer</span><span style="font-size:10pt;color:#000000;">. We believe that the general principles for our PC14586 Y220C program can be applied to other p53 hotspot mutations. Using our extensive&#160;in-house&#160;expertise, deep understanding of chemistry and decades of experience researching the p53 protein, we believe that we will be able to leverage and apply foundational knowledge from the advancement of PC14586 to the discovery and development of small molecules targeting other p53 mutations. We are advancing several early-stage programs focused on targeting the p53 hotspot mutations and certain cancers where wild-</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">type p53</span><span style="font-size:10pt;color:#000000;"> function is silenced</span><span style="font-size:10pt;color:#000000;">. In an ongoing effort to bring forward new product candidates, we plan to continue to invest in our precision oncology platform, including our high-throughput screens that allow for quantitative visualization of the conversion from mutant to wild-type p53 in a dose-dependent manner.&#160;&#160;We also apply our oncology platform in developing product candidates that</span><span style="font-size:10pt;color:#000000;"> target inhibitors of</span><span style="font-size:10pt;color:#000000;"> </span><span style="color:#000000;font-size:10pt;">wild-type p53</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;One example of such a program is</span><span style="font-size:10pt;color:#000000;"> wild-type p53 induced phosphatase, or</span><span style="font-size:10pt;color:#000000;"> WIP1, which we have advanced into the lead optimization stage of development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Leveraging the advantages of precision medicine and our expertise in p53 biology to pursue accelerated approval of our product candidates</span><span style="font-size:10pt;color:#000000;">. For our lead product candidate, PC14586, we are actively working with physicians and leading academic centers to enroll patients with the p53 Y220C mutation identified through NGS in our Phase 1/2 clinical trial. In order to rapidly confirm mechanistic and clinical proof of concept, we utilize assays to measure target engagement and biomarkers, as well as assess clinical responses in patients. We expect this strategy, which we also plan to replicate for our other future product candidates, will enable a rapid determination of target engagement and has potential to serve as a predictive marker of efficacy, thereby providing clear decision points for clinical development and efficient advancement of our product candidates towards approval. If we obtain early and encouraging clinical results, we may seek breakthrough therapy designation from the FDA, which, if granted, is intended to expedite clinical development and regulatory review. We intend to maximize the benefit of our product candidates by pursuing a tumor-agnostic approach.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Identifying and exploring combination therapy approaches for our product candidates</span><span style="font-size:10pt;color:#000000;">. Though PC14586 has demonstrated clear and robust tumor regression as a single agent in preclinical animal models, we believe that the mechanism of correcting the structure of mutant p53 can be complementary to other oncology therapies. Leveraging our expertise in p53 biology, chemistry and cancer pharmacology, we plan to identify and explore combination strategies with multiple cancer therapies. For example, chemotherapy and radiation therapy, approaches that result in deoxyribonucleic acid, or DNA, damage and upregulate p53 are natural candidates for combining with our product candidates. In addition, we believe that p53 plays a role in influencing the tumor microenvironment. Therefore, immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 agents, could also be considered as potential combination agents for use with our product candidates. We believe that our unique expertise will enable us to prioritize therapeutic strategies and optimize outcomes for clinical studies.</span></p></td></tr></table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our History and Team</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have established a leadership position in the discovery and development of oral small molecule therapies targeting mutant p53. Founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D. and Thomas Shenk, Ph.D., we have built a <span style="color:#000000;">precision</span> oncology platform and chemistry discovery engine that leverages more than four decades of research experience and unique insights into the p53 protein. Dr.&#160;Levine is widely recognized for his seminal contributions to the field of p53 biology, having discovered p53 in 1979.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a team with significant experience in drug discovery and development, with particular expertise in the discovery of small molecule oncology programs. Dr.&#160;Mack, our President and Chief Executive Officer, was previously General Partner <span style="color:#000000;">at</span> Alta Partners and co-founder and Vice President of Genomic Research at Eos Biotechnology, where he led the advancement of multiple product candidates prior to the company&#8217;s sale to Protein Design Labs. Winston Kung, our Chief Operating Officer and Chief Financial Officer, was previously Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer of Celgene Cellular Therapeutics. Leila Alland, M.D., our Chief Medical Officer, is an oncologist with 20 years of experience developing oncology products in the biopharmaceutical industry, most recently as Chief Medical Officer of Affimed. Deepika Jalota, Pharm.D., our Chief Regulatory and Quality Assurance Officer, was previously Vice President in Oncology Regulatory Affairs at Bayer and led the tumor-agnostic regulatory strategy for larotrectinib (Vitrakvi) in collaboration with Loxo Oncology.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our company was founded and continues to be supported by world-class scientific advisors, including our scientific advisory board, </span><span style="color:#000000;">or</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> SAB:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Scott Lowe, Ph.D.&#8212;Chair, Cancer Biology and Genetics Program, Sloan Kettering Institute, Chair, Geoffrey Beene Cancer Research Center, Memorial Sloan Kettering and co-founder of ORIC Pharmaceuticals (Nasdaq: ORIC)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Richard Heyman, Ph.D.&#8212;Vice Chair of the Board of Trustees at the Salk Institute, former Chief Executive Officer of Aragon Pharmaceuticals (acquired by Johnson&#160;&#38; Johnson (NYSE: JNJ)), co-founder and former Chief Executive Officer of Seragon Pharmaceuticals (acquired by Roche Genentech), and co-founder, Chairman and former Chief Executive Officer of ORIC Pharmaceuticals (Nasdaq: ORIC)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Michael Jung, Ph.D.&#8212;Distinguished Professor of Chemistry and Biochemistry at University of California, Los Angeles, and co-founder of Aragon Pharmaceuticals (acquired&#160;by Johnson&#160;&#38; Johnson (NYSE: JNJ)) and Seragon Pharmaceuticals (acquired by Roche Genentech), and co-discovered Xtandi, an&#160;FDA-approved prostate cancer drug licensed to Medivation (acquired by Pfizer (NYSE: PFE)), and Erleada, an&#160;FDA-approved&#160;prostate cancer drug developed by Aragon Pharmaceuticals and acquired by Johnson&#160;&#38; Johnson&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Arnold Levine, Ph.D.&#8212;Professor Emeritus, School of Natural Sciences Biology, Institute of Advanced Studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Guillermina Lozano, Ph.D. &#8212;Chair, Department of Genetics, The University of Texas MD Anderson Cancer Center&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Frank McCormick, Ph.D., F.R.S.&#8212;Professor at the UCSF Helen Diller Comprehensive Cancer Center, co-founder of Bridge Bio and Onyx Pharmaceuticals and initiated and led drug discovery efforts that led to approval of Nexavar, an FDA-approved drug for liver, thyroid and kidney cancer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Charles Sawyers, M.D.&#8212;Marie-Josee and Henry R. Kravis Chair in Human Oncology and Pathogenesis, Memorial Sloan Kettering, co-founder of Aragon Pharmaceuticals (acquired by Johnson&#160;&#38; Johnson (NYSE: JNJ)), Seragon Pharmaceuticals (acquired by Roche Genentech), and ORIC Pharmaceuticals (Nasdaq: ORIC), and member of the board of directors of Novartis (NYSE: NVS), and co-discovered Xtandi, an&#160;FDA-approved prostate cancer drug licensed to Medivation and Erleada, an FDA-approved prostate cancer drug developed by Aragon Pharmaceuticals and acquired by Johnson&#160;&#38; Johnson&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Thomas Shenk, Ph.D.&#8212;James A. Elkins Professor of Life Sciences in the Department of Molecular Biology at Princeton University&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Karen Vousden, Ph.D.&#8212;Chief Scientist at Cancer Research UK (CRUK), Group Leader at the Francis Crick Institute and member of the board of directors of Bristol-Myers Squibb (NYSE: BMY).</span></p></td></tr></table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background on Targeted Therapies</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer is a genetic disease that results from changes in a person&#8217;s DNA that causes cells to grow and divide uncontrollably. Genes are the distinct segments in a cell&#8217;s DNA that can encode proteins with structural or functional roles in the body. Alterations in some genes can lead to the expression of mutant proteins with impaired or abnormal functions that can cause cancer. Cancer has historically been both diagnosed and treated based on a tumor&#8217;s organ site, such as the breast, lung, ovary, brain, pancreas, skin, bone or blood.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent advances in genetic sequencing and a better understanding of the genetic alterations that drive tumor development and growth have facilitated precise, gene and protein-specific drug development, known as targeted therapies. Targeted therapies have the potential to transform treatment of some cancers by providing robust clinical benefit to patients. In notable cases, the clinical outcomes have been dramatic enough to support expedited regulatory approval of these therapies. For example, Retevmo in RET-altered NSCLC and thyroid cancers (Lilly/Loxo)&#59; Ayvakit, in platelet-derived growth factor receptor alpha exon 18 mutated advanced gastrointestinal stromal tumor, or GIST (Blueprint)&#59; Rozlytrek, in solid tumors with a neurotrophic tropomyosin receptor kinase, or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NTRK, gene fusion (Roche)&#59; Vitrakvi, in solid tumors with an NTRK gene fusion (Loxo/Bayer)&#59; Zykadia, in anaplastic lymphoma kinase-positive, or ALK+, advanced NSCLC (Novartis)&#59; Zelboraf, in advanced melanoma with a BRAF V600E mutation (Roche Genentech)&#59; Xalkori, in ALK+ advanced NSCLC (Pfizer)&#59; Tagrisso, in epidermal growth factor receptor mutation-positive, or EGFR+, advanced NSCLC (AstraZeneca)&#59; and Qinlock, in GIST (Deciphera), all received approvals within five years of first dosing in humans. This time period is significantly reduced compared to conventional drug development timelines. Despite this progress, a recent analysis found that only 8% of patients with metastatic cancer</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have tumors with genetic profiles eligible for treatment with an approved targeted agent, which leaves a large opportunity for precision oncology.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is an emerging change in the development of targeted therapies, in that cancer is increasingly being targeted through a tumor-agnostic approach <span style="color:#000000;">with</span> a focus on selectively targeting a genetic or protein mutation irrespective of tumor type. For example, there are now multiple tumor-agnostic product approvals that are based on a genetic mutation that defines the disease, as opposed to the tumor type. These include the aforementioned Vitrakvi and Rozlytrek approvals as well as the pembrolizumab and dostarlimab, or Keytruda and Jemperli, respectively, approval in metastatic microsatellite instability-high, or&#160;MSI-high,&#160;or deficient mismatch repair, or dMMR, solid tumors. We believe that these approvals represent a fundamental shift in the development of targeted therapies and will increasingly lead to cancer being characterized for treatment in a genetic, rather than in a tumor-specific, manner.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The widespread recognition that cancer is a genetic disease, as much as it is a disease defined by histology or anatomical location, has driven the increased use of genetic sequencing, which is now employed by approximately 75% of oncologists in the United States. As DNA sequencing technology advances, the availability of well-defined genetic sequencing tests increases. With the increasing number of approved targeted therapies, we believe that physicians will seek a better understanding of the underlying genetic and protein abnormalities associated with a specific type of cancer in order to determine the optimal course of treatment. Advances in genetic sequencing are leading to transformations in the discovery and development of new targeted oncology drugs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe p53 mutations are prime targets for precision oncology, as more than 50% of all human cancers contain a p53 mutation. Identifying the specific p53 gene mutation and structurally correcting the corresponding mutant p53 protein can potentially serve as a basis of treatment for these cancers. Diagnostic tests are currently used by physicians in their practice to identify patients with p53 mutations. Given the high prevalence of p53 mutations in cancers, we believe that an effective way to address p53-driven cancers is by targeting individual p53 mutations using a precision oncology approach and significantly expanding the scope of patients who can benefit from targeted therapies.&#160;&#160;In addition, we believe that our platform can also be leveraged to expand our pipeline by identifying targets that modulate wild-type p53.&#160;&#160;Given our deep understanding of and expertise in p53 biology, we believe that pursuing product candidates that target inhibitors of wild-type p53 can also expand the scope of patients who can benefit from targeted therapies.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background on p53, the Most Frequently Mutated Gene in Human Cancer</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The p53<span style="font-style:italic;">&#160;</span>gene provides instructions for the production of tumor suppression protein p53 and is the most widely mutated gene in human <span style="color:#000000;">cancers</span>. Since its discovery in 1979 by our&#160;co-founder&#160;Dr.&#160;Arnold Levine, p53 has been extensively studied by researchers and the pharmaceutical industry due to its central role in preventing the initiation and proliferation of liquid and solid tumors. p53 has long been referred to as the &#8220;guardian of the genome&#8221; because it regulates expression of a number of genes that comprise the body&#8217;s first line of cellular defense against cancers. Among its multiple biologic functions, p53 regulates a variety of tumor suppressive responses including cell cycle arrest, DNA repair, senescence and apoptosis.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p53 is a transcriptional factor, which binds to the promoters of its target genes in a sequence-specific manner and regulates their expression, thereby controlling cell cycle and cell death. p53 is activated when DNA damage is detected and when oxidative or <span style="color:#000000;">other</span> <span style="color:#000000;">cellular</span> stresses exceed thresholds for normal cellular function. p53 activation facilitates the repair of the cell&#8217;s damaged DNA or triggers the killing of the damaged cell through a process known as programmed cell death, or apoptosis, before the cell can become cancerous and proliferate.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under normal cellular conditions, p53 is kept at low levels by expression of murine double minute 2, or MDM2, a ubiquitin ligase that promotes the degradation of p53. Upon p53 activation by damaged DNA, and other types of stresses, p53 is upregulated and blocks <span style="color:#000000;">the</span> proliferation of&#160;pre-malignant&#160;and malignant cells or eliminates </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them by inducing apoptosis. Mutant p53 loses the ability to eliminate the proliferation of&#160;pre-malignant&#160;and malignant cells. Given that the mutational status of p53 in a tumor has a strong impact on sensitivity to commonly used anti-cancer drugs and radiotherapy, p53 is important both as a biomarker and as a novel therapeutic target.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key challenge in the development of&#160;p53-targeted&#160;therapies is the vast number of p53 mutants that lose tumor suppression activity. To date, more than 25,000 unique p53 mutations have been discovered. The p53 hotspot mutations occur as a result of site-specific <span style="color:#000000;">substitution</span> of one amino acid for another and lead to loss of tumor suppression function for the p53 protein. Strategies that attempt to restore wild-type p53 activity in a&#160;non-selective&#160;manner (<span style="font-style:italic;">i.e.</span>, regardless of which p53 mutation the tumor is harboring) are likely to face significant challenges, as a &#8220;one size fits all&#8221; drug is unlikely to address all p53 mutants and could have the potential for&#160;off-target&#160;toxicities. We are focusing on targeting the p53 hotspot mutations and certain cancers where wild-type p53 function is silenced.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Focus: Top Ten Most Frequent p53 Mutations</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:92%;">
<tr>
<td valign="middle" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="middle" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr style="height:2pt;">
<td valign="middle" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#0C0C0C;width:auto; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">p53 Hotspot Mutation</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Among p53 Mutations</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R175H</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.6%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R248Q</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.4%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R273H</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.0%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R248W</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.5%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R273C</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.3%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R282W</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.8%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">G245S</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R249S</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.0%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Y220C</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.8%</p></td>
</tr>
<tr style="height:2.5pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V157F</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.0%</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach to Targeting p53</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to bring precision oncology therapies to a greater number of patients. Decades of p53 research has unveiled its potential as a precision oncology target, but prior drug development efforts have been unsuccessful. Mutant p53 historically has been classified as &#8220;undruggable&#8221; due to the difficulty of restoring wild-type p53 function. Mutations in p53 can give rise to mutant p53 proteins with different conformational structures. As a result, we are designing oral small molecule therapies that selectively target a specific p53 mutation while not binding to wild-type p53. We believe our novel approach designed to reactivate p53 function through the structural correction of mutant p53 protein to wild-type p53 represents a novel therapeutic strategy to target p53.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug <span style="color:#000000;">development</span> efforts leverage our understanding that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">mutations throughout the p53 protein can drive tumor formation and growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a mutant p53 protein resulting from a specific mutation can potentially be structurally corrected by a selective small molecule, thereby reactivating wild-type p53 activity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the p53 hotspot mutations comprise approximately 30% of all p53 mutations and each p53 hotspot mutation represents an individual therapeutic target for drug discovery and development&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:10pt;">in addition to p53 mutant cancers, certain cancers result when wild-type p53 function is silenced</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we can address certain key limitations of current-generation precision oncology therapies by applying our platform to identify and <span style="color:#000000;">generate</span> therapies that address functional deficiencies associated with specific p53 mutations and certain cancers where wild-type p53 function is silenced. We believe this will allow us to design and develop potential therapies for patients with a high unmet medical need for whom there are currently no targeted treatment options.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Innovation Engine</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have built an innovation engine that allows us to discover and develop potential targeted therapies for mutant&#160;p53-driven cancers and cancers where wild-type p53 function is silenced. This engine consists of three complementary drivers:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Deep understanding of, and leadership in, p53 biology that enable unique insights into targeting individual mutations and targeting certain cancers where wild-type p53 function is silenced. </span><span style="font-size:10pt;color:#000000;">We have leveraged more than four decades of research experience and developed unique insights into p53 biology, a field that was discovered and established by our&#160;co-founder&#160;Dr.&#160;Arnold Levine.&#160;Additionally, our SAB consists of some of the most prominent thought leaders in p53 biology.&#160;p53 is a highly complex gene, and thousands of distinct p53 mutations have been identified. A blanket approach to targeting mutant p53 has significant challenges, as a &#8220;one size fits all&#8221; drug is unlikely to address all p53 mutants. Based on our experience and expertise, we are developing oral small molecules that each selectively structurally correct a specific p53 hotspot mutation.&#160;&#160;In addition we are developing small molecules that target certain cancers where wild-type p53 function is silenced.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Ability to design structure-based oral small molecule product candidates that selectively target and correct specific p53 mutants and inhibitors of wild-type p53.</span><span style="font-size:10pt;color:#000000;">&#160;&#160;Designing molecules for p53 mutants requires an intricate understanding of the p53 protein structure and the associated biology. We leverage structure-based technologies to give our oral small molecule product candidates access to challenging binding sites that are generally not accessible using conventional small molecule drug discovery approaches. For each target, we take detailed data from structural and functional studies of mutated p53 proteins to design development candidates against the challenging binding sites. Our design techniques help us to identify potential product candidates that can selectively target a single p53 mutant, while sparing wild-type p53, and for certain cancers where wild-type p53 function is silenced.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Assays, screens, preclinical model systems and biomarkers that enable us to assess and optimize selective small molecule product candidates.</span><span style="font-size:10pt;color:#000000;">&#160;We test our product candidates across a diverse set of human cancer cells based on research and understanding of bioinformatics and functional genomics. We also identify and monitor pharmacodynamic biomarkers and surrogates of clinical activity to help measure target engagement, including&#160;MIC-1,&#160;a serum-based biomarker. The biological insights we generate help us to better target various p53 mutants based on their structure and biology. In addition, we have built assays, screens and preclinical model systems and biomarkers that help assess and optimize our product candidates that </span><span style="color:#000000;font-size:10pt;">target certain cancers where wild-type p53 function is silenced. </span><span style="font-size:10pt;color:#000000;"> We develop innovative preclinical</span><span style="font-style:italic;font-size:10pt;color:#000000;">&#160;in vitro</span><span style="font-size:10pt;color:#000000;">&#160;and</span><span style="font-style:italic;font-size:10pt;color:#000000;">&#160;in vivo</span><span style="font-size:10pt;color:#000000;">&#160;models to advance potential therapeutic programs for translation to the clinic.</span></p></td></tr></table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidate and Development Programs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our <span style="color:#000000;">precision</span> oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced. We own worldwide commercial rights to all of our programs. An overview of our development pipeline is shown in the table below.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000002.jpg" title="" alt="" style="width:607px;height:372px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In Discovery, we screen compounds against biological assays to identify lead compounds with selective activity to our specific mutant or wild-type p53 target of interest.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In Lead Optimization, we modify the lead compound to improve potency, selectivity, pharmacokinetic and toxicity parameters and physical chemical properties important for clinical development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:8pt;"><span style="font-family:Times New Roman;">In IND-Enabling Studies, we conduct preclinical studies, in accordance with GLP required for an IND submission to the FDA.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to initially seek approval of our product candidates in most instances, including with PC14586, at least as a second line therapy or for patients with no satisfactory alternative treatments or where the cancer has progressed following other treatment. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA customarily approves new therapies for a second line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapies, usually chemotherapy, antibody <span style="color:#000000;">drugs</span>, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves unsuccessful, second line therapies may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">PC14586: A Selective Structural Corrector of p53 Y220C Mutations</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p53 is the most <span style="color:#000000;">widely</span> mutated gene in human cancers. The vast majority of these mutations occur as a result of missense mutations that are found in the DNA binding domain. p53 Y220C mutations are found in approximately </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0-1.5%&#160;of all cancers. This particular mutation is expressed in a large variety of solid tumors, including breast, NSCLC, colorectal, pancreatic and ovarian cancers. Our lead product candidate, PC14586, is designed to be an orally available small molecule that structurally corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wild-type p53 in a normal cell is at low to undetectable levels, but an external insult such as UV radiation or exposure to a carcinogen results in activation and upregulation of the protein. In these instances, wild-type p53 pauses the cell-cycle to survey the integrity of the genome, and if the damage to the genome cannot be repaired, wild-type p53 induces a potent program of cell suicide or programed cell death. Given wild-type p53&#8217;s profound ability to induce cell death, it is tightly regulated in normal biology by an auto-regulatory loop with MDM2, a downstream induced target of wild-type p53 transcriptional activation. MDM2 production results in degradation of the wild-type p53 protein and&#160;re-sets&#160;the cell to normal function.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of a mutant p53, there is a loss of p53 wild-type tumor suppression function due to a loss of downstream wild-type p53 transcriptional activation, including MDM2 induction. A consequence of this dysregulation is the inability of the cancer cell to degrade mutant forms of p53, resulting in a profound accumulation of mutant p53 protein in the cancer cell as shown below for the <span style="color:#000000;">Y220C</span> mutation.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Y220C Mutant Cancer Cell Lines Contain Large Pools of Mutant p53 Y220C Target Protein Relative to Normal (Wild-type p53) Cell Lines</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000003.jpg" title="" alt="" style="width:606px;height:446px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While treatment options such as surgery, chemotherapy, radiotherapy and immuno-therapy are available for breast, NSCLC, colorectal, pancreatic and ovarian cancer, there are no approved precision oncology therapies for the subset of patients with <span style="color:#000000;">the</span> p53 Y220C mutation. The availability of an oral small molecule selective for the p53 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Y220C mutation may offer a novel precision therapy for this population, which we believe could potentially change the treatment paradigm for such patients.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mechanism of Action</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 is an orally available small molecule candidate that is designed to selectively bind to the crevice created by the p53 Y220C mutation, and thereby restore the wild-type p53 protein structure and tumor suppressing function. In the diagram below, wild-type p53 protein is compared with a mutant p53 Y220C protein and a mutant p53 Y220C protein with PC14586 bound in the crevice created by the Y220C mutation. By docking into the crevice created by the Y220C mutation, PC14586 is designed to restore the wild-type p53 conformation and function.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000004.jpg" title="" alt="" style="width:605px;height:344px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, we have demonstrated that PC14586 rapidly converts the large protein pool of mutant p53 Y220C protein to wild-type structure. As seen in the graphic below, in an&#160;<span style="font-style:italic;">in vitro&#160;</span>study, PC14586 induced conversion of p53 protein from <span style="color:#000000;">mutant</span> to wild-type conformation in a dose-dependent manner as evidenced by a decrease in mutant p53 and an increase in wild-type p53, while total p53 remains relatively unchanged.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Demonstrated Structural Conversion from Mutant p53 to Wild-type p53&#160;</span><span style="font-style:italic;">in vitro</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:14.38%;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000005.jpg" title="" alt="" style="width:292px;height:228px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 selectively binds to the crevice created by the Y220C mutation as this molecule does not bind to wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q and R282W, as demonstrated by the lack of activity (as measured by p21 and MDM2 gene <span style="color:#000000;">expression</span> seen in the below diagrams). PC14586 only binds to the crevice created by the Y220C mutation, and none of the other tested p53 hotspot mutations, as illustrated by gene expression changes in the Y220C cell line when PC14586 is added in increasing concentrations.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, structural correction from a mutant p53 Y220C conformation to a wild-type p53 conformation by PC14586 restored&#160;p53-dependent&#160;transcription of downstream targets, which is indicative of wild-type p53 biological activity. For example, as shown in the figures below, p21 and MDM2, two of the downstream targets of p53, were selectively upregulated by PC14586 in a dose-dependent manner in cells where the p53 Y220C mutation was present. Since PC14586 is highly selective for the p53 Y220C mutation, it did not affect expression levels of p21 and MDM2 in tumor cell lines containing wild-type p53, p53&#160;knock-out&#160;or other p53 hotspot mutations as noted in the figures below.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Induced Transcription of p21 and MDM2 Only in Cell Lines with the p53 Y220C Mutation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000006.jpg" title="" alt="" style="width:605px;height:222px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical In Vivo Data</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 exhibited single-agent anti-tumor activity in a dose-dependent manner against mutant p53 Y220C tumors, evidenced by both potent TGI and tumor regression. Oral once-daily dosing over 21 days of PC14586 was </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well tolerated in nude mice (ten mice per dosing group) bearing p53 Y220C NUGC3 </span><span style="color:#000000;">xenograft</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tumors up to 100 mg/kg, as evidenced by the lack of body weight loss, which is the generally accepted surrogate for toxicity in mice. PC14586 demonstrated dose-dependent TGI at daily doses ranging from 25 mg/kg to 50&#160;mg/kg and robust tumor regression at 100&#160;mg/kg daily.</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Single-Agent Administration in NUGC3 Xenograft Model Resulted in Tumor Regression and was Well Tolerated</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000007.jpg" title="" alt="" style="width:605px;height:296px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical animal <span style="color:#000000;">studies</span>, PC14586 exhibited fast absorption and a durable plasma exposure, which resulted in robust target engagement that correlated with compound exposure levels. Target engagement was demonstrated by the decrease in mutant p53 Y220C and the increase in the wild-type conformation.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Along with tumor regression, in acute dose pharmacokinetic/pharmacodynamic, or PK/PD, studies, oral administration of PC14586 to xenograft mice bearing the NUGC3 (p53 Y220C) tumors resulted in conversion of mutant p53 protein to a wild-type <span style="color:#000000;">p53</span> structure as illustrated in the figure below.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the mutant p53 structure chart below, the amount of mutant p53&#160;decreased at 8 hours after PC14586 administration on day 1 (QDx1), and the amount of mutant p53 rose by the 24 hour time point compared to the 8 hour time point in the QDx1 portion of the x-axis. When another dose of PC14586 was administered on day 2 (QDx2), the amount of mutant p53 <span style="color:#000000;">decreased</span> at the 8 hour time point and rose again by the 24 hour time point. The pattern was repeated on the fourth (QDx4) and sixth day (QDx6) of dosing. In all the PC14586 datapoints, the amount of mutant p53 was less than in the vehicle dosing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the wild-type p53 structure chart below, the amount of wild-type p53 increased at 8 hours after PC14586 administration on day 1 (QDx1) and the amount of wild-type p53 decreased by the 24 hour time point compared to the 8 hour time point in the QDx1 portion of the x-axis. The pattern was repeated over the second (QDx2), fourth (QDx4) and sixth (QDx6) days of dosing. In all the PC14586 datapoints, the amount of wild-type p53 was greater than in the vehicle dosing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When </span><span style="color:#000000;">viewed</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> together, the two charts below show an increase in wild-type p53 corresponding to a decrease in mutant p53 at each of the PC14586 administration time points, which indicate the conversion of mutant p53 to wild-type p53 with the administration of PC14586.</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In&#160;<span style="font-style:italic;">in vivo</span>&#160;Studies, PC14586 Converted Mutant p53 Protein to a Wild-type p53 Structure</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000008.jpg" title="" alt="" style="width:605px;height:226px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, functional p53 activity in the tumor tissue was also demonstrated (<span style="font-style:italic;">i.e.</span>, the induction of wild-type p53 downstream targets). As illustrated in the figure below, PC14586 was observed to induce the expression of the p53 downstream target&#160;MIC-1,&#160;a clinically validated secreted biomarker of wild-type p53 activity. The administration of PC14586 was associated with an increase in MIC-1 plasma concentration in comparison to the vehicle dosing.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Increased Plasma Concentration of&#160;MIC-1,&#160;a Clinically Validated Secreted Biomarker of Wild-type p53 Activity</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000009.jpg" title="" alt="" style="width:212px;height:256px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also <span style="color:#000000;">created</span> a human p53&#160;knock-in,&#160;or HUPKI, mouse that expresses a p53 protein with the human p53 DNA binding domain and the p53 Y220C mutation. The HUPKI mouse presents spontaneously with sarcomas at six to eight months of age, which we can harvest and&#160;re-implant&#160;in a wild-type mouse to create a mouse tumor model that has an intact immune system harboring a human p53 Y220C mutation. We believe this syngeneic mouse model better represents the patient population that we expect to see in the clinic, as compared to mouse xenograft models that incorporate human tumors in mice with no immune system. While some patients with cancer may have </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weakened immune systems, we believe that few patients have severely or fully dysfunctional immunocompromised systems, and therefore a syngeneic model may better represent the patient population than an immunocompromised mouse model. In addition, with an intact immune system, this model allows us to test anti-tumor activity of PC14586 in combination with immune checkpoint inhibitors.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As illustrated by the table below, PC14586, administered as a single-agent at a daily oral dose of 100 mg/kg for 70 days, demonstrated regression in tumors that express the p53 Y220C mutation in the syngeneic mouse model. The durability of the response <span style="color:#000000;">was</span> measured by median survival, where median survival for a 100 mg/kg dose of PC14586 exceeded 156 days, even though drug treatment was discontinued on day 70. This compared with median survival of only 17 days for the vehicle.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Tumor Regression and Durable Responses in Syngeneic Mouse Model</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000010.jpg" title="" alt="" style="width:556px;height:211px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Note: Each line represents each mouse where each group has 10 mice</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:68%;">
<tr>
<td valign="middle" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr style="height:2pt;">
<td valign="middle" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#0C0C0C;width:auto; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Group</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Median&#160;Survival&#160;Time</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Days)</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:2pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vehicle</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:2pt;">
<td valign="middle" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:auto; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 100 mg/kg</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#62;156</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Note: Dosing ceased on day 70 in the PC14586 arm.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 also exhibited anti-tumor activity in combination with&#160;anti-PD-1&#160;therapy in syngeneic mouse models with the human p53 Y220C mutation. The scientific rationale for such a combination comes from the emerging literature suggesting an interplay between p53 and the immune system, which is the key mechanism of action of cancer immunotherapies such as anti-PD-1 antibodies. When PC14586 was administered at a sub-therapeutic daily oral dose of 50 mg/kg for 70 days in combination with a therapeutic dose of a&#160;PD-1&#160;antibody, regression of tumors that express the p53 Y220C mutation was observed. As illustrated by the table below, median survival for a sub-therapeutic dose of PC14586 combined with&#160;anti-PD-1&#160;treatment exceeded 156 days, even though drug treatment was discontinued on day 70, compared with median survival of only 24 days for&#160;anti-PD-1&#160;treatment alone.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 +&#160;Anti-PD-1&#160;Combination Showed Regression of Tumor Growth in Syngeneic&#160;Mouse&#160;Model</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000011.jpg" title="" alt="" style="width:554px;height:342px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Note: Each line represents each mouse where each group has 10 mice</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" style="width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2pt;">
<td valign="middle" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#0C0C0C;width:auto; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Group</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#0C0C0C;padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#FFFFFF;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Median&#160;Survival&#160;Time&#160;(Days)&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vehicle</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-PD-1&#160;200 mg/kg</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 50 mg/kg</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:8pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PC14586 50 mg/kg +&#160;Anti-PD-1&#160;200 mg/kg</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:auto; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#62;156</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Note: Dosing ceased on day 70 in the PC14586 +&#160;Anti-PD-1&#160;arm.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Development Plan</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a Phase 1/2 clinical trial for PC14586 in October 2020.&#160;&#160;In addition, we were granted FDA Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation in October 2020.&#160;&#160;We dosed our first patient in this clinical trial in the fourth quarter of 2020. While we are in the early stages of discovery and development of our product candidates and our novel approach is unproven, we are initially pursuing a tumor-agnostic development strategy. Our strategy is to seek approval under an accelerated pathway, and we believe our Phase 1/2 clinical trial has the potential to serve as a pivotal study. We cannot guarantee that the FDA will agree with this strategy of utilizing the Phase 1/2 clinical trial as a pivotal study, which could require us to conduct additional clinical trials prior to seeking FDA approval. However, based on the pivotal studies conducted by other companies to support the approval of other products, such as studies conducted by Agios (Idhifa) and Blueprint Medicines (Ayvakit), Amgen (Lumakras), as well as the pivotal studies announced by other companies for their product candidates, including Mirati (adagrasib) and Turning Point Therapeutics (repotrectinib), we believe our Phase 1/2 clinical trial has the potential to serve as a pivotal study. In our Phase 1/2 clinical trial, we have enrolled patients with advanced solid tumors that harbor the p53 Y220C mutation, characterized by NGS of either a solid or blood-based (circulating tumor DNA) biopsy.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1 portion is designed to evaluate escalating oral doses of PC14586 to determine the MTD and recommended Phase 2 dose of PC14586 when administered orally to patients, as well as to assess safety, tolerability </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and effects on biomarkers.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1 portion is also designed to assess preliminary anti-tumor efficacy in patients with advanced solid tumors that have the p53 Y220C mutation. The trial is planned to primarily evaluate once daily dosing, but may also assess more frequent dosing schedules, such as twice daily, if the drug pharmacology or patient tolerability suggest this could be a more efficacious approach. In the Phase 1 portion, we plan to enroll up to 30 patients with locally advanced or metastatic solid tumors that have the p53 Y220C mutation determined using NGS, whose disease has progressed during or after prior standard of care therapy. Multiple biomarker assays will be used in the trial to assess on target and on mechanism activity, and preliminary clinical efficacy in patients will also be assessed.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2 portion of the Phase 1/2 clinical trial is expected to enroll up to 100 patients. We expect to enroll a population with a variety of locally advanced or metastatic cancers including breast, NSCLC, colorectal, pancreatic and ovarian cancer. The planned primary objective of the Phase 2 portion is to evaluate the anti-tumor efficacy of PC14586 in patients with the p53 Y220C mutation, as shown by objective response rate. Other secondary endpoints planned to be assessed include the duration of response, progression free survival, overall survival and endpoints to evaluate the safety and tolerability of PC14586.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient blood and tumor samples will be collected prior to the start of study treatment for retrospective, confirmatory mutation testing using a central clinical trial assay. In addition, blood and tumor samples will be collected and stored to facilitate future development of a companion diagnostic test.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PC14586 Phase 1/2 Clinical Trial Design</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000012.jpg" title="" alt="" style="width:624px;height:410px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the data from our Phase 1/2 clinical trial show robust activity across the tumor types, we initially intend to pursue an approval from the FDA under the accelerated approval pathway for a tumor-agnostic indication. This strategy is based on approval pathways utilized by pembrolizumab (Keytruda) and dostarlimab (Jemperli) in&#160;MSI-high/dMMR&#160;cancers and larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) in NTRK gene fusion cancers. If we observe clinical benefit in certain tumor or cancer types but do not have sufficient data or powering to support a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tumor-agnostic indication from the Phase 1/2 clinical trial, we may seek a tumor or cancer specific label and evaluate additional trials to pursue a broader labeling for PC14586. We believe that the results of the Phase 1/2 clinical trial in PC14586 with respect to the endpoints of ORR and DoR, along with the safety data from the clinical trial, have the potential to support approval of a new drug application, or NDA, subject to discussions with</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> FDA and provided we can obtain data from a sufficient sample size across the tumor types. While accelerated approval cannot be guaranteed, if we obtain accelerated approval, we anticipate that the FDA will require the conduct of a post-approval commitment to confirm clinical benefit.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek orphan drug or breakthrough therapy designation from the FDA. In addition, we may engage in health authority interactions with agencies outside the United States such as in Europe and Japan, for example. We plan to collaborate with a partner to develop a companion diagnostic test. Further, we expect to initially seek approval of our product candidates, in most instances, including with PC14586, at least as a second line therapy. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">WIP1 (Wild-type p53 Induced-Phosphatase): Our First Wild-type p53 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The WIP1 phosphatase is a member of PP2C family of serine&#8211;threonine phosphatases.&#160; WIP1 was identified as a p53 target gene that reduces wild-type p53 levels and negatively regulates the DNA damage response pathway which can lead to tumorigenesis.&#160; WIP1 is activated by DNA damage&#160;and is responsible for turning off the DNA damage-response pathway&#160;after completion of DNA repair.&#160;&#160;In addition to reducing wild-type p53 levels, WIP1 also negatively regulates several proteins upstream of p53 in the DNA damage signaling pathway&#8203; such as ATM, ATR Chk1 and Chk2.&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000013.jpg" title="" alt="" style="width:535px;height:412px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;margin-left:84.62%;text-indent:5.24%;color:#303030;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(1)</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;margin-left:84.62%;text-indent:5.24%;font-size:8pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#303030;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(1) Chart is sourced from Pech&#225;&#269;kov&#225; S, Burdov&#225; K, Macurek L. WIP1 phosphatase as pharmacological target in cancer therapy.&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">J Mol Med (Berl)</span><span style="Background-color:#FFFFFF;">. 2017&#59;95(6):589-599. doi:10.1007/s00109-017-1536-2. </span><span style="Background-color:#FFFFFF;color:#333333;">(</span><span style="Background-color:#FFFFFF;text-decoration:underline;">http://creativecommons.org/licenses/by/4.0/</span><span style="Background-color:#FFFFFF;color:#333333;">)</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WIP1 causes a decrease in wild-type p53 which ultimately results in tumorigenesis. We are generating molecules designed to inhibit WIP1. Our WIP1 program is currently in lead optimization and continues to progress towards selection of a development candidate, at which point we would initiate IND-enabling studies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">R282W: Our Second Mutant p53 Program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R282W is the sixth most frequent p53 mutation and accounts for approximately 2.8% of all TP53 mutations. The R282W mutation results from arginine being substituted by a tryptophan at amino acid position 282 and is considered a structural mutation. This structural mutation is thermodynamically unstable and cause the protein to lose shape and therefore its wild-type DNA binding activity at physiological temperature.&#160; This results in a lack of p53 transcription and pathway activation.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000014.jpg" title="" alt="" style="width:286px;height:264px;" /></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are generating <span style="color:#000000;">molecules designed to structurally correct the R282W p53 protein to restore its binding to the DNA.&#160;&#160;Our R282W program continues to progress towards lead optimization.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">R273H: Our Third Mutant p53 Program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R273H is the third most frequent p53 mutation and is found in approximately 4% of all p53 mutations. The R273H mutation results from arginine being substituted by a histidine at amino acid position 273 and is considered a DNA contact mutation. DNA contact mutations affect residues involved directly in DNA-p53 binding but do not alter the p53 protein structure. R273 is one of the most frequently altered residues in human cancer (6.4% of all somatic mutations), with the alteration to a histidine (R273H) being the most common of the R273 mutations.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000015.jpg" title="" alt="" style="width:600px;height:492px;" /></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The R273H mutation causes a decrease in binding between the p53 protein and DNA, resulting in its inability to activate transcription of p53 target genes. We are generating molecules designed to enhance and restore the binding of the p53 protein and DNA. Our R273H program continues to progress towards lead optimization.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Pipeline Programs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our PC14586 Y220C, WIP1, R282W and R273H programs, we are focused on developing a pipeline of product candidates targeting other p53 hotspot mutations and targeting inhibitors of wild-type p53. These programs have been developed internally using our precision oncology platform and expertise.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are able to utilize the same general principles and similar drug discovery methods developed from our PC14586 Y220C program across other p53 hotspot mutations to facilitate the discovery of additional new product candidates. We study the structural and functional properties of the target. We use assays, screens, preclinical model systems and biomarkers to assess and optimize selective small molecules for specific p53 mutants. Specifically, many of the efficiencies from assays and model systems developed for our PC14586 Y220C program are being </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applied to other p53 hotspot mutations. In addition, the key insights gained from the medicinal chemistry campaigns are being leveraged across other p53 hotspot mutations. By leveraging our team&#8217;s depth of expertise around p53, we are positioned to accelerate our efforts to expand the pipeline of therapies that selectively target p53 hotspot mutations.&#160;&#160;In addition, we have applied our platform to expand our pipeline into targeting certain cancers where wild-type p53 function is silenced such as WIP1.</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is intensely competitive and subject to rapid and significant technological change, as well as strong defense of intellectual property. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53 mutations and certain cancers where wild-type p53 function is silenced. We are aware of other product candidates that are in clinical development as potential treatments of various cancers through the modulation of p53. There are many product candidates that may affect the p53 pathway, such as through MDM2 inhibition. We are aware of molecules in development that also are being explored for p53 upregulation/activation in various stages of preclinical or clinical development being tested by Actavalon, Aprea Therapeutics, CDG Therapeutics, Cotinga Pharmaceuticals, Innovation Pharmaceuticals and Senhwa Biosciences, among others. We are also aware of selective small molecule inhibitors that are designed to target wild-type p53 containing tumors through the&#160;p53-MDM2&#160;interaction, which are in various stages of clinical development being tested by Aileron Therapeutics, Ascentage Pharma, Boehringer Ingelheim, Daiichi Sankyo (out-licensed worldwide rights to Rain Therapeutics), Kartos Therapeutics, Kymera Therapeutics, Novartis and Roche, including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted therapies for patients with genetically-defined cancers. If PC14586 or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will likely need to develop our product candidates in collaboration with companion diagnostic companies, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with current Good Manufacturing Practice, or cGMP, requirements which impose certain production, manufacturing, procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP requirements and other aspects of regulatory compliance.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining and defending patent rights. We also rely on&#160;know-how&#160;relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements&#59; to defend and enforce our proprietary rights, including any patents that we may own in the future&#59; and to operate without infringing the valid and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceable patents and other proprietary rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our existing and future product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue further patent protection covering, when possible, compositions, methods of use, dosing and formulations. We also may pursue patent protection with respect to manufacturing and drug development processes and technologies. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that is directed to or claims an&#160;FDA-approved&#160;product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. This process is called &#8220;patent term extension.&#8221; The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a&#160;product-by-product&#160;basis, from&#160;country-to-country&#160;and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws and their interpretation outside of the United States are also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have, or may obtain, blocking patents of which we are currently unaware that could be used to prevent us from developing or commercializing our product candidates and practicing our proprietary technology. Further, defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties or redesign our products. Doing so may be impossible or require substantial time and monetary expenditure. We may also elect to enter into a license agreement to settle litigation or to resolve disputes prior to litigation. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. Should a license to a third party patent become necessary, we cannot predict whether we would be able to obtain a license, or if a license were available, whether it would be available on commercially reasonable terms. If such a license is necessary and a license under the applicable patent is unavailable on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed. This scenario could materially adversely affect our business. Even if we obtain a license to third party intellectual property, we may later decide, or it may later become necessary, to terminate the license. If we do so, we may no longer be free to use the technology protected by the patents no longer under license. Also, if a competitor developed the technology </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protected by the patents no longer under license, we would not be able to block the competitor&#8217;s progress. If the competitor&#8217;s product was competitive with ours, then we may suffer economic harm from the competitive product.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its scope, validity or enforceability and our issued patents may be challenged, invalidated, deemed unenforceable or circumvented. These scenarios could limit our ability to stop competitors from marketing-related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Moreover, any efforts to enforce our intellectual property rights are likely to be costly and may divert the efforts of our scientific and management personnel. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may also be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent directed to such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally file a provisional patent application with the U.S. Patent and Trademark Office, or USPTO, first and then subsequently file a corresponding&#160;non-provisional&#160;patent application. This process enables us to establish an earlier effective filing date in the subsequently filed&#160;non-provisional&#160;patent application. To benefit from the earlier effective filing date, we must file a corresponding&#160;non-provisional&#160;patent application, such as a utility application in the United States or an international application under the Patent Cooperation Treaty, or PCT, within 12 months of the date of the provisional patent application filing. Based on a PCT filing, we may file national and regional patent applications in the United States or foreign jurisdictions, such as the European Union, China, Japan and possibly others. To date, we have not filed for patent protection in all national and regional jurisdictions where such protection may be available, and we may decide to abandon national and regional patent applications before a patent is granted. In addition, the patent grant proceeding for each national or regional patent application that we file is an independent proceeding. As a result, it is possible for a patent application to be granted in one jurisdiction and denied in another jurisdiction, and depending on the jurisdiction, the scope of patent protection may vary.<span style="color:#244061;font-family:Calibri;">&#160;&#160;</span>As of February 28, 2022, we owned two issued US patents relating to methods of use and composition of matter of PMV compounds, including PC14586, at least 11 pending US patent applications, and at least ten pending foreign patent applications, each of which relates to methods of use and composition of matter of PMV compounds, including PC14586. The two issued US patents are expected to expire in 2037, without taking into account any possible patent term adjustment or extensions.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approval</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, preclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrates the drug&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quality, safety and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Drug Development Process</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s good laboratory practice requirements and other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before each trial may be initiated&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an NDA after completion of all pivotal trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA advisory committee review, if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP requirements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and&#160;<span style="font-style:italic;">in vitro&#160;</span>studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product&#59; chemistry, manufacturing and controls information&#59; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the&#160;30-day&#160;time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB or ethics committee for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, FDA may require, or sponsors may voluntarily pursue, post-approval trials, sometimes referred to as Phase 4 studies, that are conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, such as with accelerated approval drugs, the FDA may mandate the performance of post-approval clinical trials as a condition of approval of an NDA.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 1 and Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or&#160;</span><span style="font-style:italic;">in vitro&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing suggesting a significant risk to humans and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trial plans and future planned clinical trials may be adversely affected, delayed or interrupted by the ongoing COVID-19 pandemic. We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects participating in clinical trials during the&#160;COVID-19&#160;pandemic. For example, the FDA issued guidance in March 2020, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic. In June 2020 and June 2021, the FDA <span style="color:#000000;">has published a number of industry guidance documents, including updates to previous guidance, related to cGMP requirements, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities, and drug product manufacturing and supply chain inspections, among others. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NDA Review and Approval Process</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other&#160;non-clinical&#160;studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees&#59; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a&#160;non-orphan&#160;indication.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing complies with cGMP requirements to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA to address all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with&#160;pre-&#160;and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a&#160;non-compliance&#160;letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions. For example, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life- threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor of a Fast Track product has opportunities for frequent interactions with the review team during product development and, once a NDA is submitted, the product may be eligible for priority review. With regard to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review, accelerated approval and breakthrough therapy designation. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires&#160;pre-approval&#160;of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval Requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose certain production, manufacturing, procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical studies to assess new safety risks&#59; or imposition of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fines, warning letters or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical holds on clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product seizure or detention, or refusal to permit the import or export of products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">mandated modification of promotional materials and labeling and the issuance of corrective information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such&#160;off-label&#160;uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of&#160;off-label&#160;use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of&#160;off-label&#160;use and has enjoined companies from engaging in&#160;off-label&#160;promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s&#160;FDA-approved&#160;labelling.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drugs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan drug designation, or ODD, to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater of than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States of that drug or biologic. ODD must be requested before submitting an NDA. After the FDA grants ODD, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has received ODD and subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same biologic for the same indication for seven years from the approval of the NDA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of ODD are tax credits for certain research and a waiver of the NDA application user fee.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received ODD. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketing Exclusivity</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five-year period of&#160;non-patent&#160;marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or&#160;non-infringement&#160;to one of the patents listed with the FDA by the innovator NDA holder.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from accepting ANDAs or 505(b)(2) NDAs for drugs referencing the approved application for review. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical manufacturers are subject to additional healthcare fraud and abuse laws, regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal anti-kickback, false claims, civil monetary penalty, consumer fraud, pricing reporting, data privacy and security and physician payment transparency </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws and regulations as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by&#160;non-governmental&#160;third-party payors, including private insurers or by patients themselves&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information&#59; state and local laws which require tracking gifts and other remuneration and transfer of value provided to physicians, other healthcare providers and entities&#59; state and local laws that require the registration of pharmaceutical sales representatives&#59; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act of 1996, thus complicating compliance efforts.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of being found in violation of these or other laws and regulations is increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts and their provisions are open to various interpretations. These laws and regulations are subject to change, which can increase the resources needed for compliance and delay drug approval or commercialization. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Also, we may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of&#160;non-compliance&#160;with these laws, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs and imprisonment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a&#160;plan-by-plan&#160;basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific, cost-effectiveness and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests that are used with applicable pharmaceutical products require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, third-party payors are increasingly reducing coverage and reimbursement for pharmaceutical products and related services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Affordable Care Act, or ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%&#59; required collection of rebates for drugs paid by Medicaid managed care organizations&#59; imposed a&#160;non-deductible&#160;annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected&#59; expanded eligibility criteria for Medicaid programs&#59; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; and established a Center for Medicare Innovation at the Centers for Medicare&#160;&#38; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. <span style="color:#000000;">Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. Specifically, there have been several recent U.S. Presidential executive </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orders, Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, in 2020, the U.S. Department of Health and Human Services, or HHS, and Centers for Medicare &#38; Medicaid Services, or CMS, issued various rules that were expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, importation of prescription drugs from Canada and other countries, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of these new rules. As a result, the Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. Pursuant to the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of approved products, which could have a material impact on our business. In addition, Congress is considering drug pricing as part of other reform initiatives. The impact of these and future reform measures on us and the pharmaceutical industry as a whole is unclear.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA Approval and Regulation of Companion Diagnostics</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our product candidates may require use of a diagnostic to identify appropriate patient populations for our products. These diagnostics, often referred to as companion diagnostics, are medical devices, often in vitro devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed for our product candidates will utilize the PMA pathway.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and&#160;<span style="font-style:italic;">in vitro</span>&#160;companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication at the same time. The review of&#160;<span style="font-style:italic;">in vitro</span>&#160;companion diagnostics in conjunction with the review of our therapeutic treatments for cancer will, therefore, likely involve coordination of review by the FDA&#8217;s Center for Drug Evaluation and Research and the FDA&#8217;s Center for Devices and Radiological Health Office of In Vitro Diagnostics. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2022, we had 54 full-time employees, including 19 employees with Ph.D., M.D. or Pharm.D. degrees. Of these full-time employees, 35 employees are engaged in research and development activities.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.&#160;&#160;Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors and consultants.&#160;&#160;The principal purposes of our equity and cash incentive plans are to attract, retain and reward </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel though the granting of stock-based and cash-based compensation awards, to increase stockholder value and our success by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in March 2013 under the name &#8220;PJ Pharmaceuticals, Inc.&#8221; In July 2013, we changed our name to &#8220;PMV Pharmaceuticals, Inc.&#8221; Our principal executive offices are located at 8 Clarke Drive, Suite 3, Cranbury, New Jersey 08512. Our telephone number is (609)&#160;642-6670.&#160;Our website address is www.pmvpharma.com. Information contained on, or that can be accessible through, our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the name &#8220;PMV Pharma,&#8221; the &#8220;PMV Pharma&#8221; logo and other marks as unregistered trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate in any way that we or their owners will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable owner to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Internet address is www.pmvpharma.com. We will file or furnish periodic reports and amendments thereto, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K (and amendments to those reports), proxy and information statements and other information filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, with the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statement, and other information regarding issuers that file electronically, which may be accessed through the SEC at http://www.sec.gov. Our reports, amendments thereto, proxy statements and other information are also made available, free of charge, on our investor relations website at <span style="text-decoration:underline;">ir.pmvpharma.com</span> as soon as reasonably practicable after we electronically file or furnish such information with the SEC. The information contained on the websites referenced in this Annual Report on Form 10-K is not incorporated by reference into this filing.&#160;&#160;Further, our references to website URLs are intended to be inactive textual references only. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K and in our other filings with the SEC, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could materially adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Many of the following risks and uncertainties are, and will be, exacerbated by the coronavirus disease 2019, or COVID-19, pandemic and any worsening of the global business and economic environment as a result. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors Summary </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock risky include, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we have incurred significant losses since our inception, and we expect to incur significant net losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we have not generated any revenue from our product candidates and may never generate revenue or be profitable and our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we will require substantial additional capital to finance our operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our discovery and preclinical and clinical development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs targeting p53 hotspot mutations and certain cancers where wild-type p53 function is silenced is novel, may never lead to marketable products and may not ultimately represent a significant market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we are very early in our development efforts and are substantially dependent on our lead product candidate, PC14586. If we are unable to advance, obtain regulatory approval for and commercialize PC14586, our business, financial condition and results of operations will be materially adversely affected&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interim &#8220;top-line&#8221; and preliminary data that we announce for our initial open-label Phase 1/2 clinical trial for PC14586 may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. If the interim, top-line or preliminary data that we report differ from actual results, our ability to obtain approval for our product candidates may be adversely affected, which could materially adversely affect our business, financial condition and results of operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the subset of cancer patients that we are targeting are expected to have certain p53 mutations and we may not be able to identify a sufficient number of patients whom we can recruit and retain for our clinical trials to obtain approval for our current or future product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our novel approach to the discovery and development of our current and future product candidates is unproven, and we may not be successful in our efforts to use and expand our platform to build a pipeline of product candidates with commercial value&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals for our product candidates, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we currently rely, and plan to rely in the future, on third parties to conduct and support preclinical and clinical development, and these third parties may not meet expectations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if we are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our success depends in part on our ability to protect our intellectual property&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to develop companion diagnostics with third party collaborators, which must also separately be approved as medical devices by the FDA.</span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Limited Operating History, Business, Financial Condition, Results of<br />Operations and Need for Additional Capital </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company with a limited operating history. We commenced operations in March 2013, and our operations to date have been primarily limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and, more recently, clinical studies, and establishing arrangements with third parties for the manufacture of initial quantities of product candidates. In September 2020, our lead product candidate, PC14586, received authorization to proceed under an investigational new drug application, or IND, with the FDA. Then, in October 2020, we received Fast Track designation for PC14586, from the FDA, and in the fourth quarter of 2020, we initiated patient dosing in our Phase 1/2 clinical trial of PC14586. We have not demonstrated an ability to successfully conduct or complete any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a company with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our financial condition and results of operations to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">viable. We are still in the early stages of development of our product candidates. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We have financed our operations primarily through private placements of our preferred stock and our initial public offering. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant net losses in each period since we commenced operations in March 2013. Our net losses were $57.8 million and $34.4 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $167.7 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Additionally, the net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue our research and development efforts and submit investigational new drug, or IND, applications for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conduct preclinical studies and clinical trials&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fail to demonstrate adequate efficacy or an acceptable safety profile in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities, whether alone or with third parties, to commercialize any product candidates for which we may obtain regulatory approval, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain, expand, maintain, enforce and protect our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">hire additional clinical, regulatory and scientific personnel&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operate as a public company.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have not generated any revenue from our product candidates and may never generate revenue or be profitable. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to become profitable depends upon our ability to generate revenue. We have not received marketing approval for any product candidate, and we have not generated any revenue from any product sales. We do not expect to generate revenue unless or until we successfully complete preclinical and clinical development and obtain regulatory approval of, and then successfully commercialize, at least one product candidate. We dosed our first patient in our Phase 1/2 clinical trial of our lead product candidate, PC14586, in the fourth quarter of 2020, and we have not yet reported any clinical data. We are continuing to transition from a company with a research focus to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a company capable of supporting clinical development and commercial activities. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In addition, all of our other product candidates are still in preclinical development and have not been evaluated in humans. We face significant translational risk as our product candidates advance to the clinical stage, and promising results in preclinical studies may not be replicated in clinical trials. All of our current and future product candidates will require preclinical and clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Our ability to generate revenue depends on a number of factors, including, but not limited to: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful enrollment and timely completion of our clinical trials for our lead product candidate, PC14586, and timely initiation and completion of our preclinical studies for our future product candidates, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development of PC14586 and our future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to complete IND-enabling studies and successfully submit and receive authorization to proceed under INDs or comparable applications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether we are required by the FDA or other comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to demonstrate to the satisfaction of the FDA and comparable foreign regulatory authorities the safety, efficacy, consistent manufacturing quality and acceptable risk-benefit profile of our small molecule product candidates or any future product candidates, and such regulatory authorities&#8217; acceptance of our tumor-agnostic development strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timely receipt of necessary marketing approvals from the FDA and comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over alternative or more conventional therapies, such as chemotherapy, to treat solid tumors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative cancer therapies and competitive product candidates and technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient demand for our product candidates and any future product candidates, if approved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining coverage and adequate reimbursement by third-party payors for our product candidates&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">addressing any competing therapies and technological and market developments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">attracting, hiring and retaining qualified personnel.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing our product candidates. Successful completion of preclinical studies and clinical trials does not mean that any of our current or future product candidates will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates, which would materially harm our business. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain indications. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused on developing orally available small molecule, tumor-agnostic therapies targeting p53 mutants and certain cancers where wild-type p53 function is silenced. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between advancing our lead product candidate, PC14586, as well as developing our other and any future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. In addition, if we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the cancer or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for, PC14586, and advance our future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had $314.1 million in cash, cash equivalents, and marketable securities.&#160;&#160;Although we believe that our available cash and cash equivalents will be sufficient to fund our planned operations through 2023, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, progress, results and costs of researching and developing our current product candidates or any future product candidates we choose to pursue, and conducting preclinical studies and clinical trials, including our clinical trials of PC14586&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and characteristics of any additional product candidates we develop or acquire&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to any future license or collaboration agreements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing our product candidates or any future product candidates and any products we successfully commercialize&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of building a sales force in anticipation of product commercialization&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish future collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any product liability or other lawsuits related to our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the expenses needed to attract, hire and retain skilled personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs associated with being a public company&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing, receipt and amount of sales of any future approved products&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-5.24%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any committed external source of funds and adequate additional financing may not be available to us on acceptable terms, or at all. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Product Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our discovery and product development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs targeting p53 is novel, may never lead to marketable products and may not ultimately represent a significant market. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discovery and development of precision medicines for patients with genetically defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Further, despite decades of research on p53 as a target for precision medicines, prior product development efforts have been unsuccessful. Although we believe, based on our preclinical work and p53 research generally, that the top ten most frequent, or hotspot, p53 mutations have potential as precision oncology targets, clinical results may not confirm this hypothesis or may only confirm it for certain mutations or certain tumor types. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, even if our approach is successful in showing clinical benefit for tumors harboring the p53 mutation targeted by our lead product candidate, PC14586, we may never successfully identify additional product candidates for targeting p53 through our platform. Therefore, we do not know if our approach of treating patients with genetically defined cancers will be successful, and if our approach is unsuccessful, our business will be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because our approach targets genetically defined cancer patients and not specific tumors based on tumor or cancer types, we are initially pursuing a tumor-agnostic development strategy (<span style="font-style:italic;">i.e.</span>, pursuing approval for a potential indication based on a specific genetic mutation rather than a specific type of tissue). There is currently a limited number of approved tumor-agnostic therapies and we may not receive approval for a broad tumor-agnostic indication or may be delayed in receiving broad tumor-agnostic approval. If our Phase 1/2 trial for PC14586 does not support a tumor-agnostic indication, but we observe clinical benefit in certain tumor or cancer types, we may decide to pursue a tumor- or cancer-specific indication which may require additional clinical trials. Further, even if our Phase 1/2 trial for PC14586 is successful, the FDA may not agree that such study can serve as a pivotal study, which would require us to conduct additional clinical trials prior to approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are very early in our development efforts and are substantially dependent on our lead product candidate, PC14586. If we are unable to advance PC14586 or any of our future product candidates through clinical development, obtain regulatory approval and ultimately commercialize PC14586 or any of our future product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are very early in our development efforts. We dosed our first patient in our Phase 1/2 clinical trial of our lead product candidate, PC14586, in the fourth quarter of 2020, and we have not yet reported any clinical data. All of our other product candidates are still in preclinical development and have never been tested in human subjects. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of PC14586 and one or more of our future product candidates. In addition, our product development programs contemplate the development with third party collaborators of companion diagnostics, which are assays or tests used to identify an appropriate patient population for our product candidates. Companion diagnostics are subject to regulation as medical devices and must themselves be approved for marketing by the FDA and comparable foreign regulatory agencies before we may commercialize such companion diagnostics with our product candidates. The success of our product candidates will depend on several factors, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to continue our business operations and product candidate research and development, and adapt to any changes in the regulatory approval process, manufacturing supply or clinical trial requirements and timing due to the ongoing COVID-19 pandemic and otherwise, including complying with new regulatory guidance or requirements on conducting clinical trials during the COVID-19 pandemic&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">timely and successful completion of preclinical studies and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receipt of authorization to proceed under INDs for our planned clinical trials or future clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA acceptance of our tumor-agnostic development strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful patient enrollment in and completion of clinical trials, which may be impacted by the COVID-19 pandemic&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful development with third party collaborators of companion diagnostics for use with our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safety, tolerability and efficacy profiles for our product candidates that are satisfactory to the FDA or any foreign regulatory authority for marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receipt of marketing approvals for our product candidates and any companion diagnostics from applicable regulatory authorities, which must be approved contemporaneously&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of any required post-marketing approval commitments to applicable regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates, if any product candidates are approved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">effectively competing with other cancer therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintaining a continued acceptable safety profile of our products following approval.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these factors are beyond our control, and it is possible that we may never obtain regulatory approval for our product candidates even if we expend substantial time and resources seeking their development and approval. If we do not achieve regulatory approval in a timely manner or at all, we could experience significant delays or an inability to commercialize our current or future product candidates, which would materially adversely affect our business. If we do not receive regulatory approvals for our current or future product candidates, we will not be able to continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating cost-effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production in accordance with cGMP, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenue from product sales. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability analysis and approval by FDA before implementation, which could delay our clinical trials and product candidate development, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety and efficacy. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not previously submitted a NDA to the FDA or similar approval filings to a comparable foreign regulatory authority, for any product candidate. An NDA or other relevant regulatory filing must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. We cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval. Further, even if they are successful in clinical trials, our product candidates or any future product candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights for each product candidate, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The subset of cancer patients that we are targeting are expected to have certain p53 mutants and we may not be able to identify a sufficient number of patients whom we can recruit and retain for our clinical trials to obtain approval for our current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patient populations for our current product candidates are limited to those with specific p53 mutations, which represents a substantially smaller subset of the generally treated cancer patient population. We expect our future product candidates to be similarly limited. We will need to screen and identify patients with these targeted mutations. Further, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations with each p53 hotspot mutation will be large enough to allow us to successfully conduct the requisite clinical trials necessary to obtain marketing approval for each mutation-specific product candidate before we can commercialize our products, if approved, and achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our novel approach to the discovery and development of our current and future product candidates is unproven, and we may not be successful in our efforts to use and expand our platform to build a pipeline of product candidates with commercial value. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to use and expand our platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers. Although our research and development efforts to date have resulted in our discovery and development of PC14586 and future product candidates, PC14586 and future product candidates may not be safe or effective as a cancer treatment, and we may not be able to further develop PC14586 and develop any future product candidates. Our platform is evolving and may not reach a state at which building a pipeline of product candidates is possible. For example, we may not be successful in identifying additional p53 targets for which our platform can develop safe and effective product candidates. There can be no assurance that any development problems we experience in the future related to our platform will not cause significant delays or unanticipated costs or that such development problems can be solved. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, even if our product candidates are successful in correcting structural deficiencies associated with p53 mutants, such success would not provide a guarantee of the effectiveness of such product candidate in total tumor regression <span style="font-style:italic;">in vivo</span>. There can be no assurances that one or more of our future product candidates would succeed in correcting or restoring function of specific p53 mutants <span style="font-style:italic;">in vivo</span> and that such mutation would be the only genetic mutation resulting in a patient&#8217;s cancer. In the event that a patient&#8217;s cancer is the result of other mutations or factors in addition to a p53 mutation, even if we correct or restore the p53 functionality, the patient&#8217;s cancer may persist. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue which materially adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our clinical development and ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain FDA approval to market a new small molecule product, we must demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the FDA. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs in the United States. We dosed our first patient in our Phase 1/2 clinical trial of our lead product candidate, PC14586, in the fourth quarter of 2020, and we have not yet reported any clinical data. All of our other product candidates are in preclinical development. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support further development of our programs. While we have received authorization to proceed under an IND for our lead product candidate, PC14586, we cannot be sure that we will be able to submit and receive authorizations to proceed under additional INDs or similar applications with respect to our other product candidates on the timelines we expect, if at all, and we cannot be sure that submission of IND or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">timely completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s good laboratory practice requirements and other applicable regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">timely submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval by an independent Institutional Review Board, or IRB, ethics committee at each clinical site before each trial may be initiated&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining sufficient quantities of our product candidates for use in preclinical studies and clinical trials from third-party suppliers on a timely basis.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if clinical trials do begin for our preclinical programs, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety or efficacy to obtain the requisite regulatory approvals for any product candidates we develop. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities. Successful preclinical studies and clinical trials cannot provide assurance of successful commercialization. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective before we can seek marketing approvals for their commercial sale. Success in preclinical studies does not mean that future clinical trials will be successful. For instance, we do not know whether PC14586 will perform in its clinical trials as PC14586 has performed in preclinical studies, nor can we predict how our future product candidates will perform in future preclinical studies or clinical trials. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval, limit the size of the patient population to which we may market our product candidates or prevent regulatory approval. In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we succeed in developing and commercializing our product candidates, we may never generate sufficient or sustainable revenue to enable us to be profitable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience as a company in conducting clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience as a company in conducting clinical trials with the initiation of our Phase 1/2 clinical trial for PC14586 in October 2020. In part because of this lack of experience, we cannot be certain that our clinical trials of PC14586 and ongoing preclinical studies of our other product candidates will be completed on time or if the planned preclinical studies and clinical trials will begin or be completed on time, if at all. Large-scale clinical trials require significant additional financial and management resources and reliance on third-party clinical investigators, CROs and consultants. Relying on third-party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. For our lead product candidate, PC14586, we are working with a global CRO to lead our first-in-human open label Phase 1/2 clinical trial and we expect to rely on additional CROs in the future. There can be no assurance that we will be able to negotiate and enter into additional agreements with other CROs, as necessary, on terms that are acceptable to us on a timely basis or at all. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to use existing commercial diagnostic tests or develop, or enter into a collaboration or partnership in the future to develop, novel companion diagnostics for some of our current or future product candidates. If we or our future partners are unable to successfully develop, validate and obtain approval for such companion diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As one of the key elements of our product development strategy, we seek to identify cancer patient populations that may derive meaningful benefit from our current or future product candidates. Because specific genetic mutations will be used to identify the appropriate patients for our programs and our current or future product candidates, we believe that our success may depend, in part, on our ability to use existing diagnostic tests and genetic sequencing, or to develop novel companion diagnostics in collaboration with partners. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. In our Phase 1/2 clinical trial, we are working with physicians and leading academic centers to enroll patients with the p53 Y220C mutation identified through next generation sequencing, or NGS. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have little experience as a company in the development of diagnostics. As such, we expect to rely on future partners for the design, development and manufacture of appropriate diagnostics to pair with our current or future product candidates. We have not yet begun discussions with any potential partners with respect to the development of companion diagnostics and may be unsuccessful in entering into collaborations for the development of companion diagnostics for our programs and our current or future product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities outside the United States as medical devices and require separate regulatory approval or clearance prior to commercialization. Moreover, the FDA generally requires the contemporaneous approval of companion diagnostics and the associated therapeutic. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we, our partners, or any third parties that we engage to assist us, are unable to successfully develop and supply companion diagnostics for our current product candidates and any future product candidates, or experience delays in doing so: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the development of our current product candidates and any future product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not be able to obtain approval of our current product candidates and any future product candidates that require companion diagnostics on a timely basis or at all.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these events were to occur, our business would be adversely impacted. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The COVID-19 pandemic could materially adversely impact our business, results of operations and financial condition, including our preclinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. In addition, the COVID-19 pandemic and varying government responses and restrictions are creating disruption in global supply chains and adversely impacting many industries. We continue to monitor the impact of the COVID-19 pandemic closely. The full extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.76%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred&#59; supply chains have been disrupted, especially with respect to goods from China&#59; facilities and production have been suspended&#59; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have our administrative employees continuing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their work outside of our offices and limited the number of staff in any given research and development laboratory. Our research and development teams are currently operating under heightened protective COVID-19 protocols, which has altered our operations and processes. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in enrolling and retaining patients in our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption or delays to our sourced discovery and clinical activities&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance, which FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID-19 pandemic&#59; a list of all subjects affected by the COVID-19 pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered&#59; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. In 2020 and 2021, the FDA has published a number of industry guidance documents, including updates to previous guidance, related to cGMP requirements, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities, and drug product manufacturing and supply chain inspections, among others. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to revolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading prices for shares of other biopharmaceutical companies have been highly volatile partially as a result of the COVID-19 pandemic and the trading prices for shares of our common stock could also experience high volatility. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the COVID-19 could materially and adversely affect our business and the value of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, contract manufacturing organizations, or CMOs, and other contractors, consultants and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials on a timely basis or at all for our product candidates if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. For example, our enrollment for clinical trials of PC14586 will require patients to have the specific p53 Y220C mutation. If we are unable to locate a sufficient number of such patients, our clinical trial and development plans could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment of patients in our clinical trials may be delayed or limited as our clinical trial sites limit their onsite staff or temporarily close as a result of the COVID-19 pandemic. In addition, patients may not be able to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#8217; reluctance to visit the clinical trial sites during the pandemic. The drop-out rates in our clinical trials may be increased during the pandemic. Clinical trial patients who become infected with the COVID-19 virus may complicate the clinical trial data, procedures and analysis. These factors resulting from the COVID-19 pandemic could delay the anticipated readouts from our PC14586 clinical trials and our regulatory submissions, and increase the costs associated of the clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment may also be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">size and nature of the patient population&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">severity of the disease under investigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">availability and efficacy of approved drugs for the disease under investigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient eligibility criteria for the trial in question as defined in the protocol&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">perceived risks and benefits of the product candidate under study&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved or future product candidates being investigated for the indications we are investigating&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinicians&#8217; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in or temporary suspension of the enrollment of patients in our clinical trials due to the COVID-19 pandemic&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to obtain and maintain patient consents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient referral practices of physicians&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to monitor patients adequately during and after treatment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">proximity and availability of clinical trial sites for prospective patients&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion, including as a result of contracting COVID-19 or other health conditions or being forced to quarantine, or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, we may introduce an alternative formulation of PC14586 into the dose expansion phases of our future clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA customarily approves new therapies only for a second line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapies, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second line therapy. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. But there is no guarantee that our product candidates, even if approved as a second or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the p53 hotspot mutations we are targeting, who may have their tumors genetically sequenced, as well as the subset of people with these mutations in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our assumptions and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A variety of risks associated with marketing our product candidates internationally may materially adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to eventually seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing regulatory requirements in foreign countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from preclinical studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impact of the COVID-19 pandemic on our ability to produce our product candidates and conduct clinical trials in foreign countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign taxes, including withholding of payroll taxes&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties staffing and managing foreign operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the United States&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geo-political actions, including war and terrorism.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with international operations may materially adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is intensely competitive and subject to rapid and significant technological change as well as strong defense of intellectual property. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we are aware of molecules in development that also are being explored for p53 upregulation/activation in various stages of preclinical or clinical development being tested by Actavalon, Aprea Therapeutics, CDG Therapeutics, Cotinga Pharmaceuticals, Innovation Pharmaceuticals and Senhwa Biosciences, among others. We are also aware of selective small molecule inhibitors that are designed to target wild-type p53 containing tumors through the p53-murine double minute 2, or MDM2, interaction, which are in various stages of clinical development being tested by Aileron Therapeutics, Ascentage Pharma, Boehringer Ingelheim, Daiichi Sankyo (out-licensed worldwide rights to Rain Therapeutics), Kartos Therapeutics, <span style="font-size:9.5pt;">Kymera Therapeutics, </span>Novartis and Roche, including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted therapies for patients with genetically-defined cancers. If PC14586 or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will likely need to develop our product candidates in collaboration with companion diagnostic companies, and we will face competition from other companies in establishing these future collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates that we may successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond our lead product candidate, PC14586, and those we currently have in preclinical development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of future product candidates we may develop will depend on many factors, including the following and the other factors relating to product development described elsewhere in this &#8220;Risk Factors&#8221; section: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">generating sufficient data to support the initiation or continuation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining regulatory permission to initiate clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">contracting with the necessary parties to conduct clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timely manufacture of sufficient quantities of the product candidate for use in clinical trials&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse events in the clinical trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize additional product candidates, which would materially adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we successfully advance any future product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our future product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may adversely affect our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have only recently initiated a clinical trial for our lead product candidate, PC14586, as is the case with all oncology drugs, it is likely that there may be significant side effects associated with its use. PC14586 or future product candidates may be used in populations for which safety concerns may be reviewed by regulatory agencies. In addition, we expect that PC14586 will be studied in combination with other therapies, which may exacerbate adverse events associated with the therapy. Further, our product candidates will be used in patients that have weakened immune systems, which may exacerbate any potential side effects associated with their use. Patients treated with PC14586 or any of our future product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients enrolled in our PC14586 clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially adversely affect our business, financial condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to develop our current or future product candidates in combination with other therapies, which exposes us to additional risks. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to develop our current or future product candidates in combination with one or more currently approved cancer therapies or therapies in development. For example, our preclinical studies have demonstrated robust tumor regression when sub-therapeutic doses of PC14586 were used in combination with anti-PD-1 therapy. Patients may not be able to tolerate PC14586 or any of our future product candidates in combination with other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies or dosing of PC14586 or any of our future product candidates in combination with other therapies may have unexpected consequences. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also evaluate our current or future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with PC14586 or any future product candidate, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could materially adversely affect our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be adversely affected, which could materially adversely affect our business, financial condition and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of precision medicines as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications for which our product candidates are approved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential and perceived advantages of our product candidates over alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to demonstrate the advantages of our product candidates over other cancer medicines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product labeling or product insert requirements of the FDA or other regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations or warnings contained in the labeling approved by the FDA&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction of our product candidates as well as competitive products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of treatment in relation to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of our sales and marketing efforts.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-5.24%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates receive regulatory approval but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although our product candidates differ in certain ways from other precision medicine approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates and a decrease in demand for any such product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would adversely affect our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may materially change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or future product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a covered benefit under its health plan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safe, effective and medically necessary&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">appropriate for the specific patient&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effective&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our business, financial condition and results of operations, our ability to raise capital needed to commercialize product candidates and our overall financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates third-party payors for any approved products that we develop could have a material adverse effect on our business, financial condition and results of operations, our ability to raise capital needed to commercialize products and our overall financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, may be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. Even if we obtain regulatory approval or clearance for such companion diagnostics, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. Medicare reimbursement methodologies, whether under Part A, Part B or clinical laboratory fee schedule may be amended from time to time, and we cannot predict what effect any change to these methodologies would have on any product candidate or companion diagnostic for which we receive approval. Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the companion diagnostic tests that we develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our product candidates or products that we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injury to our reputation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiation of investigations by regulators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs to defend the related litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of management&#8217;s time and our resources&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to trial participants or patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of revenue&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">exhaustion of any available insurance and our capital resources&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize any product candidate&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decline in our share price.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other comparable foreign regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other comparable foreign regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never commercialized a product candidate and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for the product candidates which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may affect our ability to commercialize our product candidates, if approved, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our product candidates, ensuring regulatory compliance of our company, employees and third parties under applicable healthcare laws and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates upon approval. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenue from them or be able to reach or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Process and Other Legal Compliance Matters </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our lead product candidate PC14586, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted IND, NDA or equivalent application types, may cause delays in the approval or rejection of an application. For example, FDA has recently issued guidance on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the COVID-19 pandemic, including recordkeeping and implementation of contingency measures in response to the ongoing pandemic. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including our Phase 1/2 clinical trial design for PC14586, or require us to modify the design of our clinical trials, including additional procedures and contingency measures in response to the COVID-19 pandemic or as required by clinical sites, IRBs, FDA or other regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our tumor-agnostic development strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication, or a related companion diagnostic is suitable to identify appropriate patient populations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or other comparable regulatory authorities may fail to approve companion diagnostic tests that may be required for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks, or that a product candidate has an acceptable benefit-risk ratio for its proposed indication&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our third-party contractors may fail to comply with regulatory requirements or otherwise fail or be unable to adequately perform their obligations to allow for the conduct of our planned or future clinical studies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would materially adversely affect our business, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical studies, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain orphan drug designation or obtain or maintain the benefits associated with orphan drug designation, such as orphan drug exclusivity and, even if we do, that exclusivity may not prevent the FDA or other comparable foreign regulatory authorities, from approving competing products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may seek orphan drug designation, or ODD, for any eligible product candidates we develop, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing and making available the drug will be recovered from sales in the United States. Our target indications may include diseases with large patient populations or may include orphan indications. However, there can be no assurances that we will be able to obtain orphan designations for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, ODD entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has ODD subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product was designated. The applicable exclusivity period is 10 years in Europe. The European </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusivity period can be reduced to six years if a drug no longer meets the criteria for ODD or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain ODD for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained ODD for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek and fail to obtain breakthrough therapy designations for our current or Fast Track and breakthrough therapy designations for future product candidates. Even if we are successful, such programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate. We may also seek to obtain accelerated approval for one or more of our product candidates but the FDA may disagree that we have met the requirements for such approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track designation. In October 2020, we received Fast Track designation for PC14586 from the FDA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular future product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Further, even though we have received Fast Track designation for PC14586, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek breakthrough therapy designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Like Fast Track designation, breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately from Fast Track or breakthrough therapy designation, we may seek accelerated approval for one or more of our product candidates. A product candidate intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval if it is determined to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adequate and well-controlled post-approval clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials for accelerated approval products, once approved. We cannot guarantee that the FDA will agree any of our product candidates has met the criteria to receive accelerated approval, which would require us to conduct additional clinical testing prior to seeking FDA approval. Even if any of our product candidates received approval through this pathway, the required post-approval confirmatory clinical trials may fail to verify the predicted clinical benefit of the product, and we may be required to remove the product from the market or amend the product label in a way that adversely impacts its marketing. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, PC14586, is in early clinical development and all of our other product candidates are in discovery or preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our preclinical studies and clinical trials may not be successful. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that our preclinical study and clinical trial results will be sufficient to support regulatory approval of our product candidates, or that FDA or other comparable regulatory authorities will find our planned clinical strategy to be acceptable. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Failure or delay can occur at any time during the clinical trial process. In addition, the COVID-19 pandemic is still evolving as of this time and much of its impact remains unknown, and it is impossible to predict the impact the COVID-19 pandemic may have on the development of our product candidates, our preclinical studies and clinical trials and our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our PC14586 Phase 1/2 clinical trial is, and other clinical trials we conduct in the future may be, open-label in study design and conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in obtaining the FDA&#8217;s authorization to initiate clinical trials, completing ongoing clinical trials of PC14586 and preclinical studies of our other product candidates and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will begin on time, not require redesign, enroll an adequate number of research subjects or patients on time, or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of financial resources to commence and complete clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing with our tumor-agnostic development strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in obtaining regulatory approval or authorization to commence a clinical trial, including delays or issues relating to any future companion diagnostics which we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining IRB or ethics committee approval at each clinical trial site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruiting an adequate number of suitable patients to participate in a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of clinical trials of our product candidates may be greater than we anticipate, for example, if we experience delays or challenges in identifying patients with the mutations required for our clinical trials, we may have to reimburse sites for genetic sequencing costs in order to encourage sequencing of additional patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">having subjects complete a clinical trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">having third-party contractors fail to complete their obligations in a timely manner or failing to comply with applicable regulatory requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">addressing subject safety concerns that arise during the course of a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adding a sufficient number of clinical trial sites&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining sufficient product supply of product candidate for use in preclinical studies or clinical trials from third-party suppliers.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product candidates, the commercial prospects of our product candidates may be adversely affected, and our ability to generate revenue from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical studies or clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially adversely affect our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, our entire pipeline and platform would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in funding or disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including for 35 days beginning on December 22, 2018, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. In May 2020, FDA announced that it will continue to postpone domestic and foreign routine surveillance inspections due to COVID-19. While FDA indicated that it will consider alternative methods for inspections and could exercise discretion on a case-by-case basis to approve products based on a desk review, if a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following potential approval of any of our current or future product candidates, the FDA or other comparable regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements, GLP requirements and good clinical practice, or GCP, requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">imposition of a REMS, which may include distribution or use restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">requirements to conduct additional post-market clinical trials to assess the safety of the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, warning or untitled letters or holds on clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of our product candidates&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies and regulations promulgated during the Trump administration as well as those implemented by the Biden administration may impact our business and industry. To the extent any current or future executive or legislative actions impose significant changes in or burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine oversight activities, such as implementing regulations through rulemaking, issuance of guidance, and agency review and approval of marketing applications on a timely basis, our business and clinical development plans could be negatively impacted. It remains to be seen how the Biden administration and new leadership at the HHS and FDA will impact our business. If we, as well as our contractors, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or are not able to maintain regulatory compliance, we may be delayed in obtaining regulatory approval, lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates, if approved, and generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements&#59; (ii) additions or modifications to product labeling&#59; (iii) the recall or discontinuation of our products&#59; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Other legislative changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, for example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. In 2020, under the Trump administration, HHS and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of the rules As a result, the Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, the HHS has released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases, which may adversely affect our profitability. The impact of these and future reform measures on us and the pharmaceutical industry as a whole is unclear. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the demand for our product candidates, if we obtain regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to set a price that we believe is fair for our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain coverage and reimbursement approval for a product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to generate revenue and achieve or maintain profitability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of taxes that we are required to pay&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of capital.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and material adversely affect to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. The laws that may affect our ability to operate include, but are not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment and exclusion from government healthcare programs. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal civil and criminal false claims laws, including the False Claims Act, or FCA, which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent&#59; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government&#59; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the federal Physician Payment Sunshine Act, created under the ACA and its implementing regulations, which require applicable manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other non-physician healthcare providers (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as ownership and investment interests held by physicians, as defined by law, and their immediate family members&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources&#59; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities&#59; and state and local laws requiring the registration of pharmaceutical sales representatives.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock or stock options for services provided to us and may be in the position to influence the ordering of or use of our product candidates, if approved, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our clinical trials or enrollment or continued enrollment of patients in any future clinical trials, we will be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations. HIPAA impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain states have enacted additional laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA went into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended on September 23, 2018.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, California passed the California Privacy Rights Act, or CPRA, which amends and expands the CCPA. Although the CCPA includes exemptions for certain clinical trial data, the law may increase our compliance costs and potential liability with respect to other personal information. The CCPA and CPRA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could materially adversely affect our business, financial condition and results of operations. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer and President, our Chief Operating Officer and Chief Financial Officer, our Chief Medical Officer and our Chief Regulatory and Quality Officer. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could materially adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we rely on our founders and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting relationships with our scientific founders or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2022, we had 54 full-time employees, including 35 employees engaged in research and development activities. In order to successfully implement our development and commercialization plans and strategies, and as we are a relatively new public company, we expect to need additional managerial, operational, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identifying, recruiting, integrating, maintaining and motivating additional employees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory agencies&#8217; review process for PC14586 and any future product candidates, while complying with any contractual obligations to contractors and other third parties we may have&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">improving our operational, financial and management controls, reporting systems and procedures.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to successfully develop and, if approved, commercialize PC14586 and future product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of PC14586 and any future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize PC14586 and future product candidates and, accordingly, may not achieve our research, development and commercialization goals. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems, and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the COVID-19 pandemic. To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. We cannot assure you that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage to, our data that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notifications and follow-up actions related to a security incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in a loss, destruction or alteration of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach of our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could materially adversely affect our future revenue and financial condition and increase our costs and expenses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net operating loss, or NOL, carryforwards may be unavailable to offset future taxable income because of restrictions under U.S. tax law. Our federal NOLs generated in tax years ending on or prior to December 31, 2017 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are only permitted to be carried forward for 20 taxable years, and therefore could expire unused. Under the Tax Cuts and Jobs Act, as amended by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited to 80% of current year taxable income.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had federal NOL carryforwards of $159.9 million and $97.7 million, respectively. As of December 31, 2021, we had state NOL carryforwards for New Jersey and California and Massachusetts of approximately $155.0 million, $4.9 million, and $4.6 million, respectively. As of December 31, 2020, we had state NOL carryforwards for New Jersey and California of approximately $92.8 million and $4.9 million, respectively. Some of the federal and state NOL carryforwards expire beginning in the year 2033. We also had federal and state research and development credit carryforwards of approximately $6.6 million and $3.5 million, respectively, as of December 31, 2021 and 2020. The federal credits will begin to expire in 2034 if not utilized. The California state credits carryforward indefinitely and the New Jersey state credits expire starting in 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change (by value) in the corporation&#8217;s ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change taxable income or tax liabilities may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine whether we have experienced an ownership change or the annual limitations, if any, that could result from such an ownership change. Our ability to utilize our NOLs and certain other tax attributes could be limited by an ownership change as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations. There is also a risk that due to federal or state regulatory changes, such as suspensions on the use of NOLs, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A portion of our chemistry-based product development and sourcing of certain manufacturing raw materials for our product candidates takes place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently contract certain product development and manufacturing operations to third parties outside the United States, including in China, and we expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in China to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, including COVID-19, could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially adversely affect our business, financial condition and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. Future appreciation of the local currency could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in China. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Reliance on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct and support our preclinical studies and clinical trials under agreements with us. We are continuing to build our internal chemistry, manufacturing and controls, biology and preclinical development capabilities to supplement activities conducted by third parties on our behalf. As part of this personnel build out, we may incur additional costs or experience delays in engaging directly with other third-party CROs and CMOs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical product produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be adversely affected, our costs could increase and our ability to generate revenue could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates. We will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other comparable foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other comparable foreign regulatory authorities. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our anticipated reliance on a limited number of third-party manufacturers exposes us to a number of risks, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must inspect any manufacturers for cGMP compliance as part of our marketing application&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards and we have no control over third-party manufacturers&#8217; compliance with these regulations and standards&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our third-party manufacturers could breach or terminate their agreements with us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or man-made disasters&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and the manufacturing processes required to develop, our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and manufacturing processes required to develop, our product candidates. There are, for certain of these components, relatively few alternative sources of supply and there is limited need for multiple suppliers at this stage of our business. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, ingredients, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. These suppliers may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would materially adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates may be interrupted for an extended period, which could materially adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in or for our product candidates, if required, may not be accomplished quickly and would create increased cost. If we are able to find a replacement supplier, the replacement supplier would need to be qualified, would need to process our technology transfer and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source ingredients, components and materials used in our products, any interruption or delay in the supply of ingredients, components or materials or our inability to obtain ingredients, components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure by us or our third-party manufacturers to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to commercially produce our products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, if we enter into future collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into future collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek, in the future, to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and when we seek to enter into collaborations in the future, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If conflicts arise between us and our future collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If conflicts arise between our future corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Future collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our current or future product candidates. Our current or future collaborators or strategic partners may preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could adversely affect our product development efforts. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">increased operating expenses and cash requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the assumption of additional indebtedness or contingent liabilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the issuance of our equity securities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and/or acquire intangible assets that could result in significant future amortization expense. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. We will only be able to protect our product candidates, proprietary technologies and their uses from unauthorized use by third parties to the extent that valid and enforceable patents or trade secret protections cover them. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition-of-matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our products for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in issued patents in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, inventorship or scope thereof. Such a challenge may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. This will require us to be cognizant of the time from invention to filing of a patent application. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates. These candidates include PC14586 and others, their respective components, formulations, methods used to manufacture them and methods of treatment. Our commercial success will also depend on successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our pending and future patent applications may not result in issued patents that protect our technology or products, in whole or in part. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we delay in filing a patent application, and a competitor files a patent application on the same or a similar technology before we do, we may face a limited ability to secure patent rights. We may not be able to patent the technology at all. Even if we can patent the technology, we may be able to patent only a limited scope of the technology, and the limited scope may be inadequate to protect our products, or to block competitor products that are similar or adjacent to ours. Our earliest patent filings have been published. A competitor may review our published patents and arrive at the same or similar technology advances for our products as we developed. If the competitor files a patent application on such an advance before we do, then we may no longer be able to protect the technology, we may require a license from the competitor, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future we may in-license intellectual property from licensors. We may rely on these licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be in-licensed. For example, we cannot be certain that such activities by licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. These pharmaceutical compounds may be covered by intellectual property rights held by others. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would adversely affect our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, and may allow our competitors access to the same technologies licensed to us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of business we have decided not to pursue certain products or processes and have terminated certain corresponding intellectual property license agreements, and we may do so again in the future. If it is later determined that our activities or product candidates infringe this intellectual property we may be liable for damages, enhanced damages or subjected to an injunction, any of which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain unresolved. In recent years, patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the U.S. Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term of another patent that is commonly owned or names a common inventor. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition, interference, derivation, <span style="font-style:italic;">inter partes </span>review or other proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors or use such information to compete with us. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be adversely affected and this would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our patents are found to be invalid or unenforceable, or if we are otherwise unable to adequately protect our rights, it could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. Likewise, our current patents covering our proprietary technologies and our product candidates are expected to expire through 2037, without taking into account any possible patent term adjustments or extensions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other countries. Competitors may use our technologies in countries where we have not obtained patent protection to develop their own products and further, may infringe our patents in territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement or protection of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign countries could result in substantial costs and divert our efforts and attention </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We have contract research and manufacturing relationships with contract organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment (such as annuities) and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any issued patents we may own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of our intellectual property rights could be challenged or invalidated despite measures we take to obtain patent and other intellectual property protection with respect to our product candidates and proprietary technology. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S. and in some other jurisdictions, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to challenges to the validity of our patents, there might be invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a product candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. The cost of defending such a challenge, particularly in a foreign jurisdiction, and any resulting loss of patent protection could have a material adverse impact on one or more of our product candidates and our business. Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). Any efforts to enforce our intellectual property rights are also likely to be costly and may divert the efforts of our scientific and management personnel. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits or litigation at the USPTO to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our future licensors is threatened, it could dissuade other companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. The USPTO hears post-grant proceedings, including PGR, IPR and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the possibility of post-grant proceedings could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours for a meaningful amount of time, or at all. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union and certain other countries. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be expected, and our competitive position, business, financial condition, results of operations and prospects could be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate. Any of the foregoing could adversely affect our competitive position, business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. United States Congress has in recent years considered legislation to reduce the term of certain drug patents in order to ease generic entry and increase competition. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Also, former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around our patents. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain. Defending against such lawsuits will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business&#59; substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees&#59; a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us&#59; however, the third party is not required to grant the license&#59; if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products&#59; and redesigning our product candidates or processes so they do not infringe&#59; redesign may not be possible or may require substantial monetary expenditures and time. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an <span style="font-style:italic;">ex-parte</span> re-exam, <span style="font-style:italic;">inter partes</span> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is common in the biotechnology and pharmaceutical industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future enter into license agreements with third parties under which we receive rights to intellectual property that are important to our business. These intellectual property license agreements may impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also in the future enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain licenses in the future from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that there are no third-party patents which might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to sublicense patents and other rights to third parties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to transfer or assign the license&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The price of our stock may be volatile, and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K, these factors include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse results or delays in preclinical studies and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial, including due to the suspension of a clinical trial by the FDA or other regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse developments concerning our manufacturers or our manufacturing plans&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to establish collaborations if needed&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to commercialize our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key scientific or management personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated serious safety concerns related to the use of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">introduction of new products or services offered by us or our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to effectively manage our growth&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and growth of our initial cancer target markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to successfully treat additional types of cancers or at different stages&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated variations in quarterly operating results&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our cash position&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the market valuations of similar companies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">overall performance of the equity markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our common stock by us or our stockholders in the future&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trading volume of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in accounting practices&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ineffectiveness of our internal controls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant lawsuits, including intellectual property or stockholder litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, political, industry and market conditions, including the new presidential administration in the United States&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other events or factors, many of which are beyond our control.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. In addition, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would materially adversely affect our business, financial condition and results of operation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in September 2020, there was no public trading market for our common stock. Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. Furthermore, an active trading market for our common stock may not be sustained in the future. The lack of an active market may impair investors&#8217; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable may reduce the market value of their shares and may impair our ability to raise capital. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market.<span style="Background-color:#FFFFFF;">&#160;&#160;We do not have any control over these analysts.  </span>If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships, alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 69% of our voting stock. As a result, this group of stockholders may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our capital stock. Any return to stockholders will therefore be limited to any appreciation in the value of their stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. These provisions, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish a classified board of directors so that not all members of our board are elected at one time&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">permit only the board of directors to establish the number of directors and fill vacancies on the board&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">eliminate the ability of our stockholders to call special meetings of stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prohibit cumulative voting&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">authorize our board of directors to amend the bylaws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a super-majority vote of stockholders to amend some provisions described above.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section 203 of the General Corporation Law of the State of Delaware, or DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction): </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any derivative action or proceeding brought on our behalf&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any action asserting a claim of breach of fiduciary duty&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any action asserting a claim against us that is governed by the internal affairs doctrine.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or Securities Act, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we are not obligated, pursuant to our amended and restated bylaws, to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we maintain a directors&#8217; and officers&#8217; insurance policy, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may materially adversely affect our cash position. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would materially adversely affect our business and the trading price of our common stock. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 404 of the Sarbanes-Oxley Act and the related rules of the SEC and Nasdaq, which, among other things, require that we maintain effective internal control over financial reporting.&#160;&#160;In addition, Section 404 requires our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. We are also required to disclose changes made in our internal controls and procedures on a quarterly basis. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 404 of the Sarbanes-Oxley Act, <span style="Background-color:#FFFFFF;">we are required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. We are also required</span> to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements of these rules and regulations are difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. <span style="Background-color:#FFFFFF;">In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended and anticipate we will continue to expend significant resources, including accounting-related costs, and provide significant management oversight.&#160;&#160;</span>Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. <span style="Background-color:#FFFFFF;">In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. In addition, undetected material weaknesses in our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">If we are unable to assert that our internal control over financial reporting is effective, or if, when required, our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline, and we may be subject to investigation or sanctions by the SEC</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to increased risk of securities class action litigation, which is expensive and could divert management attention. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and cost of, and level of investment in, research and development activities relating to our current product candidates and any future product candidates and research-stage programs, which will change from time to time&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to enroll patients in clinical trials and the timing of enrollment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and outcomes of clinical trials for our future product candidates, or competing product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">competition from existing and potential future products that compete with our product candidates and any of our future product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delays in regulatory review or approval of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of demand for our future product candidates, if approved, which may fluctuate significantly and be difficult to predict&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish and maintain future collaborations, licensing or other arrangements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to adequately support future growth&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential unforeseen business disruptions that increase our costs or expenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future accounting pronouncements or changes in our accounting policies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the changing and volatile global economic and political environment.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters is located at 8 Clarke Drive, Cranbury, New Jersey 08512, where we lease a facility containing 18,446 square feet of office and laboratory space pursuant to a lease agreement that expires in June 2022 with an option to renew on a month-to-month basis for up to one year. We also lease 6,297 square feet of laboratory space at 3000 Eastpark, South Brunswick, New Jersey 08512 pursuant to a lease that expires in July 2022 with an option to renew on a month-to-month basis for up to one year. In January 2021, we signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey 08540.&#160;&#160;That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities in New Jersey.&#160;&#160;Finally, we lease 3,292 square feet of office space at 420 Bedford Drive, Lexington, Massachusetts 02420 pursuant to a lease that expires in August 2023, with an option to extend for an additional three years.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our current facilities are suitable and adequate for our current and near term conduct of our business operations and that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of February 28, 2022, <span style="color:#000000;">we were not a party to any legal matters or claims that, in the opinion of management, are likely to have a material effect on our business. In the future, we may become party to legal matters and claims in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.&#160;&#160;Regardless of outcome, litigation, or other legal proceedings can have an adverse impact on us because of legal fees and settlement costs, diversion of management resources, and other factors.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5__MARKET_FOR_REGISTRANTS_COMMON_EQ">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#8220;PMVP&#8221; since September 25, 2020.&#160;&#160;Prior to that date there was no public trading market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2022, there were approximately 8 holders of record of our common stock.&#160;&#160;We believe actual number of stockholders is greater than this number of record holders.&#160;&#160;The approximate number of holders includes holders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.&#160;&#160;This number of holders of record also does not include holders whose share may be held in trust by other entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This graph below is not &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into this Annual Report on Form 10-K or into any other filing of PMV Pharma. under the Securities Act, as amended, except to the extent that we specifically incorporate this information by reference therein, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on January 4, 2021 and its relative performance is tracked through December 31, 2021. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPARISON OF CUMULATIVE TOTAL RETURN</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among PMV Pharma, the NASDAQ Composite Index and the NASDAQ Biotechnology Index</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gv1ubg3hw41v000016.jpg" title="" alt="" style="width:510px;height:347px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our common stock.&#160;&#160;We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future.&#160;&#160;Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors might deem relevant.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no unregistered sales of our equity securities during the fiscal year ended December 31, 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 24, 2020, our registration statement on Form S-1 (File No. 333-248627) relating to our IPO of common stock was declared effective by the SEC.&#160;&#160;The IPO closed on September 25, 2020 at which time we issued 13,529,750 shares of common stock (including the exercise in full by the underwriters of their option to purchase an additional 1,764,750 shares of common stock) at a public offering price of $18.00 per share.&#160;&#160;We received net proceeds from the IPO of approximately $223.2 million, after deducting the underwriting discounts and commissions of approximately $17.0 million and estimated offering related expenses of approximately $3.3 million.&#160;&#160;None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates.&#160;&#160;Goldman Sachs &#38; Co. LLC, BofA Securities, Cowen, and Evercore IS acted as joint book-running managers for the offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 4, 2021, our shelf registration statement on Form S-3 (File No. 333-260012) was automatically declared effective by the SEC for our future follow-on offering. The potential gross proceeds from this future offering are approximately $150.0 million.&#160;&#160;The company has not issued any shares of common stock pursuant to the offering.&#160;&#160;There has been no material change in the planned use of proceeds from the follow-on offering as described in the Form S-3 Registration Statement.&#160;&#160;None of the expenses associated with the follow-on offering were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchases</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED"><span style="Background-color:#FFFFFF;">Item 6. </span>Reserved</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in &#8220;Part I, Item 1A. Risk Factors&#8221; and in other parts of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A discussion of our financial performance for the year ended December 31, 2021 as compared to the year ended December 31, 2020 appears below under the captions &#8220;Results of Operations&#8221; and &#8220;Liquidity and Capital Resources.&#8221; A discussion of our financial performance for the year ended December 31, 2020 compared to the year ended December 31, 2019 can be found in our Annual Report filed on Form 10-K, in the &#8220;Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;, under the same captions, filed with the SEC on March 3, 2021, which is available free of charge on the SEC&#8217;s website at&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">www.sec.gov</span><span style="Background-color:#FFFFFF;">&#160;and our Investor Relations website at&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">ir.pmvpharma.com/financial-information/sec-filings</span><span style="Background-color:#FFFFFF;">. These website addresses are intended to be inactive, textual references only. None of the materials on, or accessible through, these websites are part of this report or are incorporated by reference herein.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the &#8220;guardian of the genome,&#8221; and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 <span style="color:#000000;">biology</span> was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target the top ten most frequent, or hotspot, p53 mutations that are collectively associated with approximately&#160;10-15%&#160;of all cancers.&#160;&#160;In addition, we are expanding the utilization of our platform to target certain cancers where wild-type p53 function is silenced.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation in March 2013, we have devoted substantially all of our time and efforts to performing research and development activities and raising capital. We are not profitable and have incurred losses in each year since our inception. Our net losses were $57.8 million, $34.4 million, and $25.4 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $167.7 million. We do not currently have any product candidates approved for sale, and we continue to incur significant research and development and general administrative expenses related to our operations. We initiated a Phase 1/2 clinical trial in October 2020 for our lead product candidate, PC14586. In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. We dosed our first patient in this clinical trial in the fourth quarter of 2020. We expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization&#59; acquire, discover, validate and develop additional product candidates&#59; obtain, maintain, protect and enforce our intellectual property portfolio&#59; and hire additional personnel. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company that we did not experience as a private company. We expect to continue to incur significant losses for the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such agreements as and when needed, we may have to significantly delay, scale back or</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discontinue the development and commercialization of our product candidates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to use third-party service providers, including clinical research organizations, or CROs, and contract manufacturing organization, or CMOs, to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates as well as the development of future product candidates. Research and development expenses include personnel costs, including stock-based compensation expense, third-party contractor services, laboratory materials and supplies, and depreciation and maintenance of research equipment. We expense research and development costs as they are incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we are at a very early stage of development, we do not allocate our costs by product candidate or development program, as a significant amount of research and development expenses include compensation costs, materials, supplies, depreciation on and maintenance of research equipment, and the cost of services provided by outside contractors, which are not tracked by product candidate or development program. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. Substantially all of our research and development costs are associated with our lead product candidate, PC14586.&#160;&#160;We initiated a Phase 1/2 clinical trial in October 2020 for our lead product candidate, PC14586. In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.&#160; We dosed our first patient in this clinical trial in the fourth quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical program, the ability of any future collaborators to successfully develop our licensed product candidates, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facility. We have incurred additional expenses as a public company, including expenses related to compliance with the rules and regulations of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have increased</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our headcount significantly to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">support our operations </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a public company. We also expect to increase our general and administrative expenses as we advance our product candidates through preclinical research and development, manufacturing, clinical development</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and commercialization.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to amortization of premiums and discounts on our marketable securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2021 and 2020</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations data:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,493</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,933</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,560</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,800</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,009</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,791</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,293</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,942</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,351</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,942</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,351</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,823</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,434</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,389</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,846</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,440</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,406</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations data:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,296</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,999</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,436</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,706</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,392</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,493</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,933</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,560</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $36.5 million for the year ended December 31, 2021, compared to $23.9 million for the year ended December 31, 2020. The increase of $12.6 million was primarily due to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$0.3 million increase in research expenses, largely driven by increased contractual research organization costs focused on discovery research&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">$</span><span style="color:#000000;">11.7</span><span style="color:#000000;"> million increase in development expenses, primarily associated with increased effort advancing our lead compound PC14586 through </span><span style="color:#000000;">the</span><span style="color:#000000;"> Phase</span><span style="color:#000000;"> 1/2</span><span style="color:#000000;"> </span><span style="color:#000000;">clinical trial&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$0.5 million increase in expenses for personnel related costs and stock-based compensation, primarily driven by the rise in the Company&#8217;s stock value subsequent to the IPO in September 2020.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $21.8 million for the year ended December 31, 2021, compared to $11.0 million for the year ended December 31, 2020. The increase of $10.8 million was primarily due to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$5.5 million increase in personnel related expenses due to increased headcount to build out general and administrative infrastructure&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$1.1 million increase in finance and legal support, $0.5 million increase in business licenses and fees, $1.9 million increase for directors and officers insurance, and a $1.8 million increase due to facility and equipment related costs for the Company&#8217;s new headquarters in Princeton, New Jersey.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to amortization of premiums and discounts on marketable securities. Interest income, net was $0.5 million for the year ended December 31, 2021, compared to $0.7 million for the year ended December 31, 2020. The decrease of $0.2 million is driven by decreased interest rates from cash investments in marketable securities and U.S treasuries as of the year ended December 31, 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial condition is summarized as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,467</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188,955</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities - current</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,696</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,696</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities - noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,911</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,911</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,074</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,422</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,348</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital:</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,286</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,761</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,475</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,219</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,410</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,809</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total working capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,067</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,351</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,284</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. As of December 31, 2021, we had cash, cash equivalents, and marketable securities of $314 million and an accumulated deficit of $167.7 million. We have financed our operations primarily through issuances of our convertible preferred and common stock. In 2019, we sold an aggregate of 5,469,606 shares of our Series C convertible preferred stock to accredited investors, generating gross proceeds of $61.9 million. In July 2020, we sold an aggregate of 5,321,864 shares of our Series D convertible preferred stock to accredited investors, generating gross proceeds of $70.0 million. In September 2020, we completed an IPO of 13,529,750 shares of our common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of common stock, at a public offering price of $18.00 per share</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for aggregate gross proceeds of $243.5 million. We received $223.2 million in net proceeds after deducting underwriting discounts and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commissions and other offering expenses payable by us.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;In October 2021, we filed a shelf registration statement on Form S-3, which may result in aggregate gross process of up to $150.0 million. We did not sell any shares pursuant to the shelf registration statement and did not receive any gross proceeds in fiscal year 2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In January 2021, we signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey.&#160;&#160;That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities.&#160;&#160;Payments under this lease will total $19.6 million through May 2032. </span><span style="color:#000000;">Amounts related to future lease payments as of December 31, 2021 totaled $20.4 million, with $1.4 million to be paid within the next 12 months.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Plan of Operation and Future Funding Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our capital resources primarily to fund operating expenses, primarily research and development expenditures. We plan to increase our research and development expenses for the foreseeable future as we continue the preclinical development and move into clinical development of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our product candidates, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to our significant research and development expenditures, we have generated substantial operating losses in each period since inception. We have incurred an accumulated deficit of $167.7 million through December 31, 2021. We expect to incur substantial additional losses in the future as we expand our research and development activities. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash operating expenditures were $46.6 million in 2021 and $32.7 million in 2020, and we expect to increase our investment in operations in 2022<span style="color:#000000;">.&#160;&#160;</span>Based on our research and development plans, we expect that our cash balances as of December 31, 2021 will be sufficient to fund our operations at least through 2023. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing and amount of our operating expenditures will depend largely on:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and progress of preclinical and clinical development activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and scope of preclinical and clinical programs we decide to pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of milestone payments we may receive under any future collaboration agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to maintain future business licenses and research and development programs and to establish new collaboration arrangements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs involved in prosecuting and enforcing patent and other intellectual property claims&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost and timing of regulatory approvals&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the period indicated (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,571</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,739</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,065</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash (used in) provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,584</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,911</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,231</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,972</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,805</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188,133</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,144</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,971</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2021, was $46.6 million, which consisted primarily of net loss of $57.8 million decreased by non-cash charges of $7.2 million and a net change of $4.1 million in our net operating assets. The non-cash charges primarily consisted of stock-based compensation of $5.3 million, depreciation of $0.9 million, and non-cash lease expense of $1.0 million. The change in our net operating assets and liabilities was primarily due to a decrease in prepaid expenses and other assets, an increase in accrued expenses, and an increase in outstanding payables. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2020, was $32.7 million, which consisted primarily of a net loss of $34.4 million decreased by non-cash charges of $2.5 million and increased by a net change of $0.9 million in our net operating assets. The non-cash charges primarily consisted of stock-based compensation of $1.9 million and depreciation of $0.3 million. The change in our net operating assets and liabilities was primarily due to an increase in current assets, accompanied by a decrease in outstanding payables, and an increase in accrued compensation and accrued liabilities in 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our investing activities used $143.6 million of cash during the year ended December 31, 2021, which consisted primarily of purchases of marketable securities of $256.8 million, along with purchase of property and equipment of $1.3 million partially offset by maturities of marketable securities of $114.6 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our investing activities provided $28.0 million of cash during the year ended December 31, 2020, which consisted primarily of maturities of marketable securities of $42.6 million, partially offset by purchases of marketable securities of $14.5 million and purchases of property and equipment of $0.1 million.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financing activities provided $2.0 million of cash during the year ended December 31, 2021, which consisted primarily of proceeds from the exercise of stock options. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financing activities provided $293.0 million of cash during the year ended December 31, 2020, which consisted primarily of gross IPO proceeds of $243.5 million and Series D Preferred Stock issuance proceeds of $70.0 million, offset by equity issuance costs of $20.6 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the amounts reported in those financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the accounting policies described below involve a high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non -refundable research and development advance payments are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or services are performed.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met&#59; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>vendors, including research laboratories, in connection with preclinical development activities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>CROs and investigative sites in connection with preclinical studies and clinical trials&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure all stock options and other stock-based awards granted to our employees, directors, consultants and other non-employee service providers based on the fair value on the date of the grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable. Non-employee option awards are measured at the earlier of the commitment date for performance by the counterparty or the date when the performance is complete, and compensation expense is recognized in the same manner as if we had paid cash for goods or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We classify stock-based compensation expense in our statement of operations in the same way the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant. Using the Black-Scholes option pricing model requires management to make significant assumptions and judgments. We determined these assumptions for the Black-Scholes option-pricing model as discussed below.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected Term</span><span style="color:#000000;">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. As we</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">do not have sufficient historical experience for determining the expected term of the stock option awards granted, we based our expected term for awards issued to employees and non-employees using the simplified method which is presumed to be the midpoint between the vesting date and the end of the contracted term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Risk-Free Interest Rate</span><span style="color:#000000;">&#8212;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#8217; expected term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected Volatility</span><span style="color:#000000;">&#8212;Since we do not have a trading history of common stock, the expected volatility was derived from the</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">average historical stock volatilities of the common stock of several public companies within the industry that we consider to be comparable to our business over a period equivalent to the expected term of the stock-based awards.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Dividend Rate</span><span style="color:#000000;">&#8212;The expected dividend rate is zero as we have not paid and do not anticipate paying any dividends in the</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">foreseeable future.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Fair Value of Common Stock</span><span style="color:#000000;">&#8212;Prior to our IPO, the fair value of the shares of common stock underlying the stock-based</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">awards was determined by our board of directors with input from management. Because there was no public market for our common stock, our board of directors determined the fair value of our common stock at the time of grant of the stock-based award by considering a number of objective and subjective factors, including having valuations of the common stock performed by a third-party valuation specialist, as further described below.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of recent accounting pronouncements, see Note 2 of the notes to our audited financial statements for the year ended December 31, 2021 included elsewhere in this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A__QUANTITATIVE_QUALITATIVE_DISCLO">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had cash, cash equivalents, and marketable securities of $314.1 million and restricted cash of $0.8 million as of December 31, 2021.&#160;&#160;The company&#8217;s cash equivalents consist of interest-bearing U.S. treasury securities and money market funds. Our exposure due to changes in interest rates is not material due to the nature and amount of our money-market funds and short-term marketable securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates&#59; however, we may contract with foreign vendors that are located outside the United States in the future. This may subject us to fluctuations in foreign currency exchange rates in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8__FINANCIAL_STATEMENTS_SUPPLEMENTA"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Stateme</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">nts and Supplementary Data. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Audited Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Ernst &#38; Young LLP, Independent Registered Public Accounting Firm</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (PCAOB ID: <ix:nonNumeric id="F_000034" name="dei:AuditorFirmId" contextRef="C_0001699382_20210101_20211231">42</ix:nonNumeric>)</span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets as of December&#160;31, 2021 and 2020</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"><span style="text-decoration:underline;">Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2021</span><span style="text-decoration:underline;">, 2020,</span><span style="text-decoration:underline;"> and 2019</span></a><span style="text-decoration:underline;"> </span><span style="text-decoration:none;color:#auto;"></span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><span style="text-decoration:underline;">Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) E</span><span style="text-decoration:underline;">quity </span><span style="text-decoration:underline;">for the Years Ended December&#160;31, 2</span><span style="text-decoration:underline;">021, 2020, and </span><span style="text-decoration:underline;">2019</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows for the Years Ended December&#160;31, 2</span><span style="text-decoration:underline;">021, 2020, and </span><span style="text-decoration:underline;">2019</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top" style="width:89.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Notes to Financial Statements</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10.16%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of PMV Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)&#160;and our report dated March 1, 2022 expressed an unqualified opinion thereon.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB.&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.&#160;&#160;Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.&#160;&#160;Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />

<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:15.35%;"></td>
<td style="width:2.49%;"></td>
<td style="width:82.16%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;margin-right:0.64%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for Research and Development Expenses</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;margin-right:0.64%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in Note 2 to the financial statements, the Company is required to estimate research and development expenses from its obligations under contracts and purchase orders with vendors, clinical research organizations, clinical manufacturing organizations and others and for clinical site agreements at each balance sheet date.&#160;&#160;The Company recorded accrued expenses for the research and development expenses, which are included in accrued expenses on the December&#160;31, 2021 balance sheet, and prepaid research and development expenses, which are included in prepaid expenses and other current assets on the December&#160;31, 2021 balance sheet. The amounts recorded for accrued research and development expenses and for the related prepaid expenses, within the aforementioned balance sheet captions, represent the Company&#8217;s estimate of the unpaid and prepaid research and development expenses based on the progress of the research and development services compared to the amounts paid for those services through December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;margin-right:0.64%;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing the Company&#8217;s accrued research and development expenses and related prepaid expenses involved a high degree of subjectivity due to the estimation required by management in determining the progress to completion of services that have been performed that will be invoiced by the vendors, clinical research organizations and consultants and under clinical site agreements subsequent to the date that the financial statements are issued.</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;margin-right:0.64%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the accounting for research and development expenses. This included controls over management's assessment of the assumptions and accuracy of data underlying the research and development accruals and prepaid estimates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To test the research and development accruals and prepaid expenses, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual and prepaid expense computations. We also evaluated management&#8217;s estimates of the progress of a sample of research and development activities by making direct inquiries of the Company&#8217;s operations personnel that oversee the external research and development activities and obtaining information directly from certain service providers about the service providers&#8217; estimate of costs that had been incurred through December 31, 2021. Additionally, we assessed the historical accuracy of management&#8217;s estimates when evaluating the current period estimate. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the financial statements were issued. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:17.95%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <ix:nonNumeric id="F_000035" name="dei:AuditorName" contextRef="C_0001699382_20210101_20211231">Ernst &#38; Young LLP</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:17.95%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:17.95%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000036" name="dei:AuditorLocation" contextRef="C_0001699382_20210101_20211231">Philadelphia, Pennsylvania</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:17.95%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2022</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">172,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">361,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001699382_20211231" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">301,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">364,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001699382_20201231" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets, operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001699382_20211231" decimals="-3" scale="3">221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001699382_20201231" decimals="-3" scale="3">201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:Assets" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">331,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">365,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001699382_20211231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:Liabilities" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,009</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:Liabilities" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000078" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001699382_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000079" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001699382_20201231" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021 and December 31, 2020.&#160;&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001699382_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001699382_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001699382_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001699382_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding as of December 31, 2021 and December 31, 2020.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000065">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000066">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, <span>$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000086" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001699382_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000087" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001699382_20201231" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction></span> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">44,777,818</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021 and December 31, 2020, respectively.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000067">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000068">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">476,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">469,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001699382_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001699382_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">109,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001699382_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">308,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">359,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">331,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">365,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS">Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,009</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:OperatingExpenses" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OperatingExpenses" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OperatingExpenses" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:InterestIncomeExpenseNet" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:InterestIncomeExpenseNet" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:InterestIncomeExpenseNet" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="pmvp:OtherNonoperatingIncomeExpenseOther" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="pmvp:OtherNonoperatingIncomeExpenseOther" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="pmvp:OtherNonoperatingIncomeExpenseOther" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (losses) gains on marketable securities, net of tax</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000130" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20210101_20211231" decimals="2" sign="-">1.28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000131" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20200101_20201231" decimals="2" sign="-">2.40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000132" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20190101_20191231" decimals="2" sign="-">8.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20210101_20211231" decimals="0" format="ixt:numdotdecimal">45,137,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20200101_20201231" decimals="0" format="ixt:numdotdecimal">14,364,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20190101_20191231" decimals="0" format="ixt:numdotdecimal">3,035,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S">Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit) Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">17,396,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:SharesOutstanding" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">3,012,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C convertible preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="-3" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000195" name="pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">5,469,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000143" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">33,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available for sale investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000152" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000154" name="us-gaap:SharesOutstanding" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,046,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">75,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series D convertible preferred stock, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231" decimals="-3" scale="3">208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000197" name="pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,321,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="pmvp:ReclassificationsOfTemporaryToPermanentEquityShares" contextRef="C_0001699382_20200101_20201231" decimals="INF" sign="-" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">238,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">9,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of issuance costs of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; $<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">13,529,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">223,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">223,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000168" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available for sale investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000177" name="us-gaap:SharesOutstanding" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">44,777,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">469,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">109,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">359,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options and common stock issued under the 2020 ESPP</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000181" name="pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">655,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available for sale investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance As of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000190" name="us-gaap:SharesOutstanding" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">476,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:StockholdersEquity" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">308,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CASH_FLOWS">Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:ProfitLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:ProfitLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:ProfitLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; activities: activities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:ShareBasedCompensation" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:ShareBasedCompensation" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:ShareBasedCompensation" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:Depreciation" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:Depreciation" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:Depreciation" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premiums on marketable securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">62</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="pmvp:OtherNonCashLeaseExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of property and equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">143,584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">223,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">292,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents, and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; restricted cash</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">188,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">288,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001699382_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash&#8212;beginning of period</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">361,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash&#8212;end of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">173,289</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">361,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001699382_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash investing activities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease incentives used for leasehold improvements</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="pmvp:LeaseIncentivesUsedForLeaseholdImprovements" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued purchases of property and equipment</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash financing activities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock to common stock</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="pmvp:ConversionOfConvertiblePreferredStockToCommonStock" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of warrant liability to common stock</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="pmvp:ConversionOfWarrantLiabilityToCommonStock" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of cash flow information</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income tax</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000270" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_FINANCIAL_STATEMENTS">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">1.&#160;&#160;Formation and Business of the Company</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#8217;s headquarters are located in Cranbury, New Jersey. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2020, the Company completed an initial public offering (the &#8220;IPO&#8221;) of <ix:nonFraction unitRef="U_xbrlishares" id="F_000319" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925" decimals="INF" format="ixt:numdotdecimal">13,529,750</ix:nonFraction> shares of common stock, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000320" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925" decimals="INF">18.00</ix:nonFraction> per share including the exercise in full by the underwriters of their option to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000321" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200925_20200925" decimals="INF" format="ixt:numdotdecimal">1,764,750</ix:nonFraction> additional shares of commons stock, for aggregate gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="pmvp:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001699382_20200925_20200925" decimals="-3" format="ixt:numdotdecimal" scale="3">243,536</ix:nonFraction> and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#8220;PMVP.&#8221;&#160;&#160;The Company received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001699382_20200925_20200925" decimals="-3" format="ixt:numdotdecimal" scale="3">223,176</ix:nonFraction> in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.&#160;&#160;In connection with the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000324" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925" decimals="INF" format="ixt:numdotdecimal">28,188,110</ix:nonFraction> shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net losses and negative cash flows from operations since it&#8217;s inception. During the year ended December 31, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction> and used $<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,571</ix:nonFraction> of cash for operations. As of December 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001699382_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,726</ix:nonFraction>.&#160;&#160;Cash, cash equivalents, and marketable securities were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">314,074</ix:nonFraction> as of December 31, 2021.&#160;&#160;Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs.&#160;&#160;The Company believes it has adequate cash and cash equivalents to operate for at least the next twelve months from the date of issuance of these financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000271" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000271_dcnt_30ff77f4-e0f9-4fec-a6fa-ff51a1060cab">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2.&#160;&#160;Summary<span style="color:#000000;"> of </span>Significant<span style="color:#000000;"> Accounting Policies</span></p><ix:nonNumeric id="F_000282" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_30ff77f4-e0f9-4fec-a6fa-ff51a1060cab" continuedAt="F_000271_dcnt_d8cb2b79-4e27-40de-bfb1-88a2075e51b6"><ix:nonNumeric id="F_000283" name="us-gaap:UseOfEstimates" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.</p></ix:nonNumeric><ix:nonNumeric id="F_000284" name="pmvp:ReverseStockSplitPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company&#8217;s board of directors and stockholders approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to affect a <ix:nonNumeric id="F_000329" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001699382_20210101_20211231"><ix:nonFraction unitRef="U_xbrlipure" id="F_000330" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001699382_20200924_20200924" decimals="4">5.2651</ix:nonFraction>-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock</ix:nonNumeric>, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</p></ix:nonNumeric><ix:nonNumeric id="F_000285" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000285_dcnt_6a1be7a8-d082-4d63-a53e-6506fcfcd04a">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;3 - Inputs are </span><span style="color:#000000;">unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions</span><span style="color:#000000;"> that are unobservable.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_d8cb2b79-4e27-40de-bfb1-88a2075e51b6" continuedAt="F_000271_dcnt_593ba103-30dc-445d-92c3-c717be92449c"><ix:continuation id="F_000285_dcnt_6a1be7a8-d082-4d63-a53e-6506fcfcd04a">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p></ix:continuation><ix:nonNumeric id="F_000286" name="pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its<span style="color:#000000;"> marketable debt securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of December 31, 2021, the company&#8217;s long-term marketable debt securities have maturity dates no more than two years. The Company&#8217;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity.&#160;&#160;Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the years ending December 31, 2021, 2020, and 2019, the company recorded, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">550</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">152</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">62</ix:nonFraction> of amortization, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2021 included a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:RestrictedCash" contextRef="C_0001699382_20211231" decimals="-3" scale="3">822</ix:nonFraction> deposit at the Company&#8217;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000287" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.&#160;&#160;The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company&#8217;s only existing leases are for office and laboratory space.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable&#59; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company&#8217;s leases contain residual value guarantees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_593ba103-30dc-445d-92c3-c717be92449c" continuedAt="F_000271_dcnt_fdd86b82-6dd7-48a3-8c64-191babbb52a8"><ix:nonNumeric id="F_000288" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally <ix:nonNumeric id="F_000335" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001699382_20210101_20211231">five years</ix:nonNumeric>, except for leasehold improvements, which are amortized over the remaining term of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</p></ix:nonNumeric><ix:nonNumeric id="F_000289" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000290" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Income/Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" scale="3">78</ix:nonFraction>), $<ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">3</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">10</ix:nonFraction> in other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax for the years ended December 31, 2021, 2020, and 2019, respectively. The Company presents comprehensive income in a single statement within its financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000291" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All costs associated with research and development are expensed as incurred.&#160;&#160;Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits&#59; materials&#59; supplies&#59; depreciation on and maintenance of research equipment&#59; the cost of services provided by outside contractors&#59; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.&#160;&#160;In the event that we prepay fees, we record the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000292" name="pmvp:ConvertiblePreferredStockPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000292_dcnt_7af3a004-22b0-43b1-9c12-1d0a7e985f1e">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_fdd86b82-6dd7-48a3-8c64-191babbb52a8" continuedAt="F_000271_dcnt_66dc5f23-973f-47f5-9a90-7dfe026a13c3"><ix:continuation id="F_000292_dcnt_7af3a004-22b0-43b1-9c12-1d0a7e985f1e">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Company. The Company&#8217;s policy is not to accrete the carrying value and related issuance costs of the convertible preferred stock to its redemption value until it is probable that the security will become redeemable.</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> The convertible preferred stock converted to common stock in connection with the Company&#8217;s Initial Public Offering </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;IPO&#8221;) </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">on September 25, 2020.</span></p></ix:continuation><ix:nonNumeric id="F_000293" name="us-gaap:DerivativesPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liabilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company may issue certain financial instruments with embedded features which may be accounted for as separate derivative assets or liabilities, dependent on their specific contractual terms or other conditions. These derivative assets or liabilities are required to be measured at fair value at issuance and <span style="color:#auto;">remeasured</span> at the end of each reporting period. To determine the fair value of these instruments the Company uses a discounted cash flow analysis, as these instruments are not quoted on an active market. Increases or decreases in fair value from initial measurement and each reporting period are recorded in the statement of operations and comprehensive loss as change in fair value of derivative liabilities.</p></ix:nonNumeric><ix:nonNumeric id="F_000294" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000294_dcnt_e5b16615-7c76-4dd8-9721-e38326243b0d">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Stock&#8209;Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s share-based compensation program allows for grants of stock options and restricted stock awards. <span style="color:#000000;">Grants</span> are awarded to employees and non-employees, including directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,<span style="font-style:italic;"> Compensation &#8211; Stock Compensation </span>(&#8220;ASC 718&#8221;)<span style="font-style:italic;">.</span> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock <span style="color:#000000;">awards</span> and stock options.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting <span style="color:#000000;">conditions</span> is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#8217;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be <ix:nonFraction unitRef="U_xbrlipure" id="F_000339" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_20210101_20211231" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> as the Company </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_66dc5f23-973f-47f5-9a90-7dfe026a13c3" continuedAt="F_000271_dcnt_9d044a55-6253-42e3-9161-c4b052a989f1"><ix:continuation id="F_000294_dcnt_e5b16615-7c76-4dd8-9721-e38326243b0d">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a<span style="color:#000000;"> </span>liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</p></ix:continuation><ix:nonNumeric id="F_000295" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise for which separate discrete financial information is <span style="color:#000000;">available</span> for evaluation by the Company&#8217;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as <ix:nonFraction unitRef="U_pmvpSegment" id="F_000340" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment.</p></ix:nonNumeric><ix:nonNumeric id="F_000296" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the &#8220;two-class&#8221; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a <span style="color:#000000;">participating</span> security). The Company&#8217;s convertible preferred stock are participating securities as defined by ASC 260-10, <span style="font-style:italic;">Earnings per Share</span>. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a <span style="font-style:italic;">pari passu</span> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric id="F_000297" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000297_dcnt_24ac8f0b-8208-4081-a817-6d655d7826bb">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC 740, <span style="font-style:italic;">Income Taxes</span> ("ASC 740"), which requires that <span style="color:#000000;">deferred</span> tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_9d044a55-6253-42e3-9161-c4b052a989f1" continuedAt="F_000271_dcnt_14510089-1778-49ed-b9db-04b6fc7e45f8"><ix:continuation id="F_000297_dcnt_24ac8f0b-8208-4081-a817-6d655d7826bb">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</p></ix:continuation><ix:nonNumeric id="F_000298" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000298_dcnt_4faf7ffe-fc78-46cf-b7d8-fd8357a53fd1">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842), as amended by multiple standards updates, in order to increase transparency and comparability among organizations by requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The most significant change arising from the new standard is the recognition of right of use assets and lease liabilities for leases classified as operating leases. The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. Under the standard, disclosures are required to enable financial statement users to assess the amount, timing, and uncertainty of cash flows arising from the leases. Companies are also required to recognize and measure leases existing at, or entered into after, the adoption date using a modified retrospective approach, with certain practical expedients available. Comparative periods prior to adoption have not been retrospectively adjusted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the standard effective <ix:nonNumeric id="F_000342" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric> using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, the Company recorded ROU assets of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101" decimals="-3" scale="3">970</ix:nonFraction> and lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101" decimals="-3" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction>. The standard did not have a material impact on the statement of operations or statement of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, Income Taxes &#8211; Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_14510089-1778-49ed-b9db-04b6fc7e45f8" continuedAt="F_000271_dcnt_84db095c-b0a2-49c7-881c-57dc295f16e7"><ix:continuation id="F_000298_dcnt_4faf7ffe-fc78-46cf-b7d8-fd8357a53fd1">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of an enacted change in tax laws or rates in the</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">adopted</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> this standard as of</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000346" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric></span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The adoption did </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">t have a material impact on the Company&#8217;s financial statements.</span></p></ix:continuation><ix:nonNumeric id="F_000299" name="pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#8217;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions.&#160;&#160;The Company continues to monitor the impact of the COVID-19 outbreak closely.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000271_dcnt_84db095c-b0a2-49c7-881c-57dc295f16e7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000272" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">3.&#160;&#160;Financial Instruments and Fair Value Measurements</p><ix:nonNumeric id="F_000300" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company&#8217;s cash equivalents and available-for-sale securities&#8217; carrying amounts and fair values as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">227,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">227,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">227,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">310,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">310,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">269,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">240,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">240,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">240,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">360,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">360,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">240,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents <span style="font-weight:normal;font-style:normal;">&#8211; As of December 31, 2021, the company had cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:Cash" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,508</ix:nonFraction> and cash equivalents of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,960</ix:nonFraction>.&#160;&#160;Cash equivalents consisted of money market funds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,960</ix:nonFraction> and corporate debt securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">128,000</ix:nonFraction>. Cash equivalents of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">360,041</ix:nonFraction> as of December 31, 2020 consisted of money market funds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">240,033</ix:nonFraction> and corporate debt securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,008</ix:nonFraction>. Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities<span style="font-size:12pt;font-style:normal;"> </span>&#8211; <span style="font-weight:normal;font-style:normal;">Marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:MarketableSecurities" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">141,607</ix:nonFraction> as of December 31, 2021 consisted of corporate debt securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:MarketableSecurities" contextRef="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,362</ix:nonFraction> and government debt securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:MarketableSecurities" contextRef="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,245</ix:nonFraction>. There were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,696</ix:nonFraction> current marketable securities and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,911</ix:nonFraction> noncurrent marketable securities as of December 31, 2021. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:MarketableSecurities" contextRef="C_0001699382_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> marketable securities as of December 31, 2020.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:nonNumeric id="F_000273" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">4.&#160;&#160;Property and Equipment, Net</p><ix:nonNumeric id="F_000301" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery &#38; equipment</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,989</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &#38; fixtures</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20211231" decimals="-3" scale="3">161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not placed in service</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20201231" decimals="-3" scale="3">51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001699382_20201231" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-weight:bold;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Depreciation<span style="color:#auto;"> expense for the years ended December 31, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:Depreciation" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">307</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:Depreciation" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">318</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:Depreciation" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">388</ix:nonFraction>, respectively.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000274" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">5.&#160;&#160;Accrued Expenses </p><ix:nonNumeric id="F_000302" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="pmvp:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="pmvp:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001699382_20201231" decimals="-3" scale="3">99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000275" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000275_dcnt_5c13a15c-3866-409a-afc1-eb60a83e700f">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">6.&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, the Company executed a noncancelable operating lease for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000411" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630" decimals="INF" format="ixt:numdotdecimal">13,000</ix:nonFraction> square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $<ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000412" name="pmvp:InitialBaseRentPerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630" decimals="2">20.00</ix:nonFraction> per square foot. This location operates as the Company&#8217;s current headquarters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, the Company obtained an additional noncancelable operating lease for about <ix:nonFraction unitRef="U_utrsqft" id="F_000413" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630" decimals="INF" format="ixt:numdotdecimal">6,000</ix:nonFraction> square feet of laboratory space in the same corporate center at an initial rental rate at $<ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000414" name="pmvp:InitialBaseRentPerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630" decimals="2">22.00</ix:nonFraction> per square foot. As a result of the additional space, both leases will expire <ix:nonNumeric id="F_000415" name="pmvp:OperatingLeaseExpirationPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231" format="ixt:datemonthyearen">June 2022</ix:nonNumeric>, with an option to renew on a month-to-month basis, with an increase in base rent as per the lease, for up to an additional year. <ix:nonNumeric id="F_000417" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231">Both leases include a common area maintenance expense for $<ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000416" name="pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231" decimals="2">3.00</ix:nonFraction> per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000418" name="pmvp:ManagementFeeOfBaseRentPercentage" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231" decimals="2" scale="-2">3</ix:nonFraction>% of the base rent.</ix:nonNumeric><span style="color:#000000;"> </span>The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company executed <ix:nonFraction unitRef="U_pmvpLease" id="F_000419" name="pmvp:NumberOfNoncancelableOperatingLeases" contextRef="C_0001699382_20180801_20180831" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> noncancelable operating leases. One lease for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000420" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831" decimals="INF" format="ixt:numdotdecimal">6,000</ix:nonFraction> square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $<ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000421" name="pmvp:InitialBaseRentPerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831" decimals="2">15.50</ix:nonFraction> per square foot and a management fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000428" name="pmvp:ManagementFeeOfBaseRentPercentage" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831" decimals="2" scale="-2">3</ix:nonFraction>% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000275_dcnt_5c13a15c-3866-409a-afc1-eb60a83e700f" continuedAt="F_000275_dcnt_00bc3d87-abc2-49c2-ac23-ff352aed2382">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease expires in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000422" name="pmvp:OperatingLeaseExpirationPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831" format="ixt:datemonthyearen">July 2022</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><ix:nonNumeric id="F_000423" name="pmvp:OperatingLeaseRenewalTermDescription" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with an option </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to renew on a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">month-to-month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> basis</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with an increase in base rent as per the lease,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for up to an additional year</span></ix:nonNumeric><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The second lease is for office space in Lexington, Massachusetts, that expires </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000424" name="pmvp:OperatingLeaseExpirationPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180801_20180831" format="ixt:datemonthyearen">August 2023</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with an option to renew for a one-time, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000425">three-year</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> extension. The initial annual base rent is $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000426" name="pmvp:InitialBaseRentPerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831" decimals="2">28.50</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per square foot and will increase $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000427" name="pmvp:InitialBaseRentIncreasedPerSquareFoot" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831" decimals="2">1.00</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per square foot at the end of each rent year.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180101_20181231" decimals="INF" scale="3">165</ix:nonFraction> on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.&#160;&#160;As of December 31, 2021, the remaining rent incentive pertaining to the Lexington, MA lease totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:DeferredRentCredit" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20211231" decimals="-3" scale="3">64</ix:nonFraction>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company signed a lease for <ix:nonFraction unitRef="U_utrsqft" id="F_000431" name="us-gaap:AreaOfLand" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210131" decimals="INF" format="ixt:numdotdecimal">50,581</ix:nonFraction> square feet of office and laboratory space at One Research Way in Princeton, New Jersey.&#160;&#160;The Company intends to complete the relocation of their headquarters from Cranbury, NJ to One Research Way in Princeton NJ in late 2022. <ix:nonNumeric id="F_000436" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231">That lease term extends through <ix:nonNumeric id="F_000432" name="pmvp:OperatingLeasesExtendedYear" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131">2032</ix:nonNumeric>, has a <span style="-sec-ix-hidden:F_000433">five-year</span> extension option, and is intended to replace our two existing facilities and the space is expected to become the Company&#8217;s future headquarters</ix:nonNumeric>. Payment under this lease will total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:OperatingLeasePayments" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131" decimals="-5" scale="6">19.6</ix:nonFraction> million through <ix:nonNumeric id="F_000435" name="pmvp:OperatingLeasesExtendedMonthAndYear" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131" format="ixt:datemonthyearen">May 2032</ix:nonNumeric>. The Company received a lease incentive of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:PaymentsForProceedsFromTenantAllowance" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131" decimals="-5" scale="6">4.1</ix:nonFraction> million from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022. <span style="color:#000000;">Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement.&#160;&#160;</span></p><ix:nonNumeric id="F_000303" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the&#160;year ended December 31, 2021&#160;are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:OperatingLeaseCost" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:VariableLeaseCost" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:LeaseCost" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000304" name="pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in the balance sheet for leases where the Company is the lessee as of&#160;December 31, 2021&#160;were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:85.26%;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets, operating leases</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001699382_20211231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000445">10.02</span></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000446" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001699382_20211231" decimals="4" scale="-2">5.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000305" name="pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases for the year ended December 31, 2021&#160;is as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.84%;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:OperatingLeasePayments" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leased assets obtained in exchange for new operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000275_dcnt_00bc3d87-abc2-49c2-ac23-ff352aed2382">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000306" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments, net of reimbursements, remaining as of December 31, 2021 under operating leases by fiscal year were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" contextRef="C_0001699382_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,814</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&#160;&#160;Amounts representing imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense recorded for the years ended December 31, 2021 and 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,691</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">561</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.&#160;&#160;This sublease agreement expires in <ix:nonNumeric id="F_000460" name="pmvp:SubleaseExpirationPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20210101_20211231" format="ixt:datemonthyearen">August, 2023</ix:nonNumeric>.&#160;&#160;In April 2021, the company entered into a sublease agreement with the previous tenants of the office space at One Research Way in Princeton, NJ, from <ix:nonNumeric id="F_000461" name="pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430" format="ixt:datemonthyearen">April 2021</ix:nonNumeric> to <ix:nonNumeric id="F_000462" name="pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430" format="ixt:datemonthyearen">July 2021</ix:nonNumeric>. As of December 31, 2021, sublease income for the Company was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:SubleaseIncome" contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231" decimals="-3" scale="3">116</ix:nonFraction>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="C_0001699382_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> purchase commitments with third-party suppliers.</p></ix:continuation><ix:nonNumeric id="F_000276" name="us-gaap:PreferredStockTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000276_dcnt_abbbc878-ef8c-4df1-bdf9-3f93f25acf00">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">7.&#160;&#160;Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000465" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal">22,883,426</ix:nonFraction> shares of convertible preferred stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000470" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001699382_20191231" decimals="INF">0.00001</ix:nonFraction> per <span style="color:#auto;">share</span>. <ix:nonFraction unitRef="U_xbrlishares" id="F_000466" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,657,903</ix:nonFraction> shares were designated as Series Seed convertible preferred stock (Series Seed Preferred), <ix:nonFraction unitRef="U_xbrlishares" id="F_000467" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">8,076,985</ix:nonFraction> shares were designated as Series&#160;A convertible <span style="color:#auto;">preferred</span> stock (Series A Preferred), <ix:nonFraction unitRef="U_xbrlishares" id="F_000468" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">7,672,560</ix:nonFraction> shares were designated as Series B convertible preferred stock (Series B Preferred) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000469" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,475,978</ix:nonFraction> shares were designated as Series C convertible preferred stock (Series C Preferred).&#160;&#160;As of December 31, 2019, the Company had an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000471" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000472" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></ix:nonFraction> shares of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred (collectively, &#8220;Preferred Stock&#8221;) issued and outstanding.&#160;&#160;All share amounts presented are reverse-split adjusted.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000276_dcnt_abbbc878-ef8c-4df1-bdf9-3f93f25acf00" continuedAt="F_000276_dcnt_47365d58-f54a-4cbd-97b6-8273737ecc96"><ix:nonNumeric id="F_000307" name="us-gaap:TemporaryEquityTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="color:#auto;">December</span> 31, 2019, the Preferred Stock consisted of the following (in thousands except for share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">authorized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preference</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">conversion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Preferred</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000473" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,657,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000498" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000478" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,647,102</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000493" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,647,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000474" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">8,076,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000499" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000479" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">8,076,982</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000494" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">8,076,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000475" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">7,672,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000500" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000480" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">7,672,556</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000495" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">7,672,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000476" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,475,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000501" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000481" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,469,606</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000496" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,469,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000477" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal">22,883,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000502" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000482" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001699382_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001699382_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">169,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000497" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001699382_20191231" decimals="INF" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000503" name="pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">5,321,864</ix:nonFraction> shares of Series D Preferred Stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000504" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200731" decimals="INF">13.1533</ix:nonFraction> per share, resulting in gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731" decimals="-3" format="ixt:numdotdecimal" scale="3">70,000</ix:nonFraction>.&#160;&#160;In connection with the IPO on September 25, 2020, all of the Company&#8217;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000506" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925" decimals="INF" format="ixt:numdotdecimal">28,188,110</ix:nonFraction> shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The holders of Preferred Stock have the rights, preferences, privileges and restrictions as set forth below:</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of Preferred Stock are entitled to receive non-cumulative dividends prior to and in preference to any declaration of payment of dividends on common stock, when and if declared by the Board of Directors. Any additional dividends will be paid ratably to holders of common and Preferred Stock, with the holders of Preferred Stock participating on an as-if converted basis. <ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:DividendsPreferredStock" contextRef="C_0001699382_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> dividends have been declared or paid as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voting Rights:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of each share of Preferred Stock are entitled to voting rights equal to the number of shares of common stock into which the shares could be converted. As long as any shares of Preferred Stock remain outstanding, the holders of Preferred Stock, voting together as a class, shall be entitled to elect <ix:nonFraction unitRef="U_pmvpMember" id="F_000508" name="pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> members of the Company&#8217;s Board of Directors. The holders of common stock, voting together as a single class, shall be entitled to elect <ix:nonFraction unitRef="U_pmvpMember" id="F_000509" name="pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> members of the Company&#8217;s Board of Directors. Remaining members of the Company&#8217;s Board of Directors will be elected by the holders of a majority of the shares of Preferred Stock and common stock, voting together as a single class.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidation Rights:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of Preferred Stock have liquidation preferences, before any distribution or payment is made to holders of any common stock, in an amount per share equal to the original issue price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000510" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20211231" decimals="4">1.8517</ix:nonFraction> for Series Seed Preferred, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000511" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20211231" decimals="4">3.7266</ix:nonFraction> for Series A Preferred, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000512" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231" decimals="4">9.6093</ix:nonFraction> for Series&#160;B Preferred and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000513" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20211231" decimals="4">11.3121</ix:nonFraction> for Series C Preferred, as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like, plus any declared but unpaid dividends. If the assets and funds to be distributed among the holders of Preferred Stock are insufficient to permit the payment to such holders, then the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000276_dcnt_47365d58-f54a-4cbd-97b6-8273737ecc96">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of the payment of the full liquidation preference of Preferred Stock, the remaining assets of the Company, if any, shall be distributed with equal priority and ratably to the holders of common stock and Preferred Stock, with the Preferred Stock being treated as if the Preferred Stock had been converted to shares of common stock at the then applicable conversion rate. Notwithstanding the foregoing, the aggregate distributions made with respect to any shares of Preferred Stock may not exceed the greater of (i) an amount equal to two times the original issue price plus any declared but unpaid dividends on such share or (ii) the amount the holder would have received if all shares of the Preferred Stock were deemed to have been converted into common stock as of immediately prior to such liquidation, dissolution or winding up of the Company.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Conversion:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Preferred Stock is convertible into shares of common stock, at the option of the holder, at any time after date of issuance. <ix:nonNumeric id="F_000514" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" contextRef="C_0001699382_20210101_20211231">Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction> and the initial offering price to the public is at least $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000516" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20211231" decimals="INF">11.3121</ix:nonFraction> per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like).</ix:nonNumeric> As of December 31, 2019, the conversion price for each share of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred is $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000517" name="pmvp:ConvertiblePreferredStockConversionPrice" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231" decimals="4">1.8517</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000518" name="pmvp:ConvertiblePreferredStockConversionPrice" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="4">3.7266</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000519" name="pmvp:ConvertiblePreferredStockConversionPrice" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="4">9.6093</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000520" name="pmvp:ConvertiblePreferredStockConversionPrice" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="4">11.3121</ix:nonFraction>, respectively.</p></ix:continuation><ix:nonNumeric id="F_000277" name="pmvp:CommonStockDisclosureTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000277_dcnt_3a1ffccd-cbaa-4fe4-9da1-ffd1daae47ad">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">8.&#160;&#160;Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company is authorized to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000521" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000522" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001699382_20211231" decimals="INF">0.00001</ix:nonFraction> per share, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000523" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000524" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001699382_20211231" decimals="INF">0.00001</ix:nonFraction> per share. As of December 31, 2021 and 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000525" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000527" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000526" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000528" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">44,777,818</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.&#160;&#160;As of December 31, 2021, <ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:DividendsCommonStock" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> dividends on common stock had been declared by the Company.</p><ix:nonNumeric id="F_000308" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000308_dcnt_c2a0092a-0c56-457b-9f95-7157da88b3c6">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had reserved shares of common stock for issuance as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000530" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000531" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,090,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">4,951,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">4,609,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000534" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">801,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000535" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">400,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000536" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">9,999,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000537" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">9,101,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000277_dcnt_3a1ffccd-cbaa-4fe4-9da1-ffd1daae47ad"><ix:continuation id="F_000308_dcnt_c2a0092a-0c56-457b-9f95-7157da88b3c6">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000278" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000278_dcnt_96b0d1c0-f6ed-4984-86b1-75c260e8907f">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">9 &#160;&#160;Stock Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by the board of directors on September 24, 2020.&#160;&#160;The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan is <ix:nonFraction unitRef="U_xbrlishares" id="F_000538" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924" decimals="INF" format="ixt:numdotdecimal">4,406,374</ix:nonFraction>, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of <span style="Background-color:#FFFFFF;color:#000000;">(i)&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000539" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924" decimals="INF" format="ixt:numdotdecimal">4,406,374</ix:nonFraction> shares of common stock, (ii)&#160;five percent </span> (<ix:nonFraction unitRef="U_xbrlipure" id="F_000540" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924" decimals="2" scale="-2">5</ix:nonFraction>%) of the outstanding common stock on the immediately preceding December 31<span style="Background-color:#FFFFFF;color:#000000;">, or (iii)&#160;such number of common stock determined by the board of directors no later than the immediately preceding December 31.</span>&#160;&#160;For 2021, the board of directors exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of <ix:nonFraction unitRef="U_xbrlishares" id="F_000541" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101" decimals="INF" format="ixt:numdotdecimal">1,363,084</ix:nonFraction> shares, effective as of January 1, 2022. As of December 31, 2021, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,951,680</ix:nonFraction> shares available for issuance under the 2020 Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the board of directors on September 24, 2020.&#160;&#160;A total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000543" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924" decimals="INF" format="ixt:numdotdecimal">400,752</ix:nonFraction> shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000544" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924" decimals="INF" format="ixt:numdotdecimal">801,504</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="U_xbrlipure" id="F_000545" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924" decimals="2" scale="-2">1</ix:nonFraction>% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year.&#160;&#160;For 2021, the 2020 ESPP reserved shares were increased under clause (iii) by <ix:nonFraction unitRef="U_xbrlishares" id="F_000546" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction> shares, effective as of January 1, 2022. On November 19, 2021, employees exercised their right to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000547" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211119_20211119" decimals="INF" format="ixt:numdotdecimal">10,480</ix:nonFraction> shares under the 2020 ESPP.&#160;&#160;As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000548" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000549" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">47,066</ix:nonFraction></ix:nonFraction> shares are issued or outstanding, and there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000550" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">801,464</ix:nonFraction> shares available for issuance, under the 2020 ESPP.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2013 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company adopted the 2013 Stock Plan (the &#8220;2013 Plan&#8221;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.&#160;&#160;Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.&#160;&#160;The Company chose to forfeit the remaining shares.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000278_dcnt_96b0d1c0-f6ed-4984-86b1-75c260e8907f" continuedAt="F_000278_dcnt_8549d87a-e02f-456a-b572-73825a77224f">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000309" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in 000s)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">4,609,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000557" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001699382_20201231" decimals="INF" format="ixt:numdotdecimal">4,090,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001699382_20201231" decimals="2">3.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000571">7.13</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000552" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,343,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options retired under 2013 Equity Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000553" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandThirteenStockPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">237,542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000554" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">807,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">807,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000565" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001699382_20210101_20211231" decimals="2">29.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited / cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000555" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">43,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000559" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">43,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000566" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001699382_20210101_20211231" decimals="2">6.89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000560" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">608,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000567" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001699382_20210101_20211231" decimals="2">2.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">4,951,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000561" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001699382_20211231" decimals="2">8.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000572">6.86</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000569" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001699382_20211231" decimals="2">8.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000573">6.86</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001699382_20211231" decimals="INF" format="ixt:numdotdecimal">2,668,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000570" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001699382_20211231" decimals="2">3.48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000574">5.80</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000581" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231" decimals="2">20.03</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000582" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231" decimals="2">3.34</ix:nonFraction>, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options vested and exercisable as of December 31, 2021 and 2020 is calculated based on the difference between the exercise price and the fair value of our common stock.&#160;&#160;The intrinsic value of options exercised in 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,534</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231" decimals="-3" scale="3">245</ix:nonFraction>, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the total compensation cost related to nonvested service-based awards not yet recognized is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,708</ix:nonFraction>.&#160;&#160;The weighted-average period over which the nonvested awards is expected to be recognized is <ix:nonNumeric id="F_000584" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001699382_20210101_20211231" format="ixt-sec:duryear">3.1</ix:nonNumeric>years.</p><ix:nonNumeric id="F_000310" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">estimated</span> the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35% - 1.30%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% - 1.51%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49% - 2.51%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.44</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.92 - 6.40</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.27 - 6.37</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000598" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000599" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.50% - 79.90%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.70% - 77.60%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.07% - 72.69%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000278_dcnt_8549d87a-e02f-456a-b572-73825a77224f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000311" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used to estimate the fair value of stock options granted and stock purchase rights under the ESPP are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000606" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" decimals="4" scale="-2">0.04</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.50</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000609" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231" decimals="4" scale="-2">77.83</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">Expected Term:&#160;The Company uses the simplified method to calculate expected term described in the SEC&#8217;s Staff Accounting Bulletin No.&#160;107, which takes into account vesting term and expiration date of the options.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility:&#160;Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk Free Interest Rate:&#160;The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000610" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001699382_20210101_20211231" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> in the valuation model.</p><ix:nonNumeric id="F_000312" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">S<span style="color:#000000;">tock-based compensation expense recorded under ASC 718 related to options granted was allocated to research and development and general and administrative expense as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" scale="3">836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" scale="3">302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" scale="3">606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000279" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000279_dcnt_94ef4eb8-e78e-4215-aa50-87942254bcf1">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">10.&#160;&#160;Income Taxes</p><ix:nonNumeric id="F_000313" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The income tax provision for the years ended December 31, 2021, 2020, and 2019 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Provision</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001699382_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000279_dcnt_94ef4eb8-e78e-4215-aa50-87942254bcf1" continuedAt="F_000279_dcnt_216a73b4-1624-4950-b1ca-04664136b400">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000314" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000314_cnt_1">A reconciliation of income tax computed at the statutory federal income tax rate to the provision for income taxes included in the accompanying statements of operations for the Company is as follows:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&#160;</p><ix:continuation id="F_000314_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision at statutory rate</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000629" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000630" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000631" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000633" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000634" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000635" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000636" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000637" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000638" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000639" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001699382_20200101_20201231" decimals="2" sign="-" scale="-2">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000640" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000641" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001699382_20210101_20211231" decimals="2" sign="-" scale="-2">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000642" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000643" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000644" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001699382_20210101_20211231" decimals="2" sign="-" scale="-2">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000645" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001699382_20200101_20201231" decimals="2" sign="-" scale="-2">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000646" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001699382_20190101_20191231" decimals="2" sign="-" scale="-2">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000647" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001699382_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001699382_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000649" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001699382_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, 2020, and 2019, the Company&#8217;s effective tax rate is below the federal statutory income tax rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000650" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20210101_20211231" decimals="INF" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000651" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20200101_20201231" decimals="INF" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000652" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001699382_20190101_20191231" decimals="INF" scale="-2">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% primarily due to state income taxes, net of federal benefit and the Company&#8217;s position to establish a full valuation allowance on its deferred tax assets.</p><ix:nonNumeric id="F_000315" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax <span style="color:#auto;">assets</span> and liabilities are presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,511</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001699382_20201231" decimals="-3" scale="3">748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001699382_20201231" decimals="-3" scale="3">830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="pmvp:DeferredTaxAssetsOperatingLeases" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,175</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001699382_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets recognized</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001699382_20201231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="pmvp:DeferredTaxLiabilitiesOperatingLeases" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Fixed assets and depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001699382_20211231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001699382_20201231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001699382_20201231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">159,886</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,665</ix:nonFraction>, respectively. As of December 31, 2021, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">154,972</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,912</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,640</ix:nonFraction> respectively. At December 31, 2020, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,805</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,912</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" scale="3">950</ix:nonFraction>, respectively.&#160;&#160;Federal net operating loss carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,515</ix:nonFraction> expire beginning in the year <ix:nonNumeric id="F_000683" name="pmvp:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2033</ix:nonNumeric>. <span style="font-weight:bold;font-family:Arial;color:#000000;"> </span><span style="color:#000000;">State net operating loss carryforwards begin to expire in the year </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000279_dcnt_216a73b4-1624-4950-b1ca-04664136b400">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;"><ix:nonNumeric id="F_000684" name="pmvp:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2033</ix:nonNumeric></span><span style="color:#000000;">.&#160;&#160;</span><ix:nonNumeric id="F_000685" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="C_0001699382_20210101_20211231"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards related to tax years after 2017 </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of $</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="pmvp:OperatingLossCarryforwardsAmountsDoNotExpire" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,371</ix:nonFraction></span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">do not expire.</span></ix:nonNumeric><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company also has federal and state research and development credit carryforward of approximately $</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,588</ix:nonFraction></span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,470</ix:nonFraction><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s of December 31, 2021</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, respectfully</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The federal credits will begin to expire in </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000688" name="pmvp:TaxCreditCarryforwardExpirationYear" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2034</ix:nonNumeric></span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> if not utilized.&#160;&#160;The California state credits carryforward indefinitely and the New Jersey state credits expire starting in </span><ix:nonNumeric id="F_000690" name="pmvp:TaxCreditCarryforwardExpirationYear" contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"><ix:nonNumeric id="F_000689" name="pmvp:TaxCreditCarryforwardExpirationYear" contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span></ix:nonNumeric></ix:nonNumeric><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company accrues interest and penalties related to unrecognized tax benefits in the Provision for income taxes line item in the statements of operations and comprehensive loss</span><span style="Background-color:#FFFFFF;font-weight:bold;">. </span><span style="color:#auto;">As of December 31, 2021 and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001699382_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001699382_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t accrued any interest or penalties related to uncertain tax positions.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If the ending balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,654</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20201231" decimals="-3" scale="3">877</ix:nonFraction> of unrecognized tax benefits as of December 31, 2021 and 2020, respectively, were recognized, none of the recognition would affect the income tax rate. <ix:nonNumeric id="F_000316" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000316_cnt_1">The following table summarized the activity related to the Company&#8217;s unrecognized tax benefits:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p><ix:continuation id="F_000316_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, beginning of year</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20201231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20191231" decimals="-3" scale="3">543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year tax positions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001699382_20210101_20211231" decimals="-3" scale="3">734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001699382_20200101_20201231" decimals="-3" scale="3">329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001699382_20201231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#8217;s tax <span style="color:#auto;">years</span> 2013 to 2021 will remain open for examination by the federal and state authorities for three and <ix:nonNumeric id="F_000705" name="pmvp:IncomeTaxExaminationPeriod" contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>, respectively, from the date of utilization of any net operating loss credits.</p></ix:continuation><ix:nonNumeric id="F_000280" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000280_dcnt_2f309d82-5afb-48ed-840a-7d81a177f129">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">11.&#160;&#160;Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock does not participate in losses. The Company excluded all outstanding stock options and restricted stock awards at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.</p><ix:nonNumeric id="F_000317" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true" continuedAt="F_000317_dcnt_e7823bd5-58fc-4f2d-b4c5-0b51e4afabee">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000706" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000707" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">10,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000708" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000709" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,090,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000710" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,767,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000711" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000712" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,090,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000713" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001699382_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">25,644,914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p><ix:continuation id="F_000280_dcnt_2f309d82-5afb-48ed-840a-7d81a177f129"><ix:continuation id="F_000317_dcnt_e7823bd5-58fc-4f2d-b4c5-0b51e4afabee">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000318" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:NetIncomeLoss" contextRef="C_0001699382_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000717" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20210101_20211231" decimals="0" format="ixt:numdotdecimal">45,137,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000718" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20200101_20201231" decimals="0" format="ixt:numdotdecimal">14,364,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000719" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001699382_20190101_20191231" decimals="0" format="ixt:numdotdecimal">3,035,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000720" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20210101_20211231" decimals="2" sign="-">1.28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000721" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20200101_20201231" decimals="2" sign="-">2.40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000722" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001699382_20190101_20191231" decimals="2" sign="-">8.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000281" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001699382_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">12.&#160;&#160;Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has consulting agreements with <ix:nonFraction unitRef="U_pmvpMember" id="F_000723" name="pmvp:NumberOfConsultingAgreementsMembers" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> members of its board of directors. The total of consulting fees paid as of the years ended December 31, 2021 and December 31, 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231" decimals="-3" scale="3">110</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20200101_20201231" decimals="-3" scale="3">112</ix:nonFraction>, respectively. In May of 2021, the <ix:nonFraction unitRef="U_pmvpMember" id="F_000724" name="pmvp:NumberOfConsultingAgreementsMembers" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> members of the board of directors were awarded <ix:nonFraction unitRef="U_xbrlishares" id="F_000729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531" decimals="INF" format="ixt:numdotdecimal">5,781</ix:nonFraction> options of company stock each, as per their updated Scientific Advisory Board agreements. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> amounts owed under the consulting agreements as of December 31, 2021 or December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended December 31, 2020, an investor provided $<ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231" decimals="-3" scale="3">65</ix:nonFraction> of financial consulting services to the Company. The Company has paid the entirety of the fees as of December 31, 2020. <ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:DueFromRelatedParties" contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> amounts were paid or owed to the investors as of the year ended December 31,2021.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9__CHANGES_IN_DISAGREEMENTS_WITH_AC">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None<span style="color:#000000;">. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A__CONTROLS_PROCEDURES">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, the Company conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule&#160;13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (&#8220;the Exchange Act&#8221;). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is also responsible for establishing and maintaining for us adequate internal control over financial reporting, as such term is defined in Exchange Act Rule&#160;13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the&#160;<span style="font-style:italic;">Internal Control&#8212;Integrated </span>Framework&#160;(2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by <ix:nonNumeric id="F_000037" name="dei:AuditorName" contextRef="C_0001699382_20210101_20211231">Ernst &#38; Young LLP</ix:nonNumeric>, an independent registered public accounting firm, as stated in their report included in this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inherent Limitations on the Effectiveness of Internal Control</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting during the fourth quarter of the year ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of PMV Pharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control Over Financial Reporting</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited PMV Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).&#160;&#160;In our opinion, PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB),&#160;&#160;the balance sheets of the Company as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated March 1, 2022 expressed an unqualified opinion thereon.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control Over Financial Reporting</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &#38; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000038" name="dei:AuditorLocation" contextRef="C_0001699382_20210101_20211231">Philadelphia, Pennsylvania</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2022</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B__OR_INFORMATION"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">B.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Othe</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">r Information. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None<span style="color:#000000;">. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10__DIRECTORS_EXECUTIVE_FICERS_CORP">Item&#160;10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included under the captions &#8220;Directors and Corporate Governance,&#8221; &#8220;and &#8220;Other Matters&#8212;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; in our definitive proxy statement for the annual meeting of stockholders to be held in June 2022 to be filed with the SEC on or before April 30, 2022, or the Proxy Statement, and is incorporated herein by reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11__EXECUTIVE_COMPENSATION">Item&#160;11.&#160;&#160;&#160;&#160;Executive Compensation.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included under the captions &#8220;Executive Compensation,&#8221; and &#8220;Directors and Corporate Governance&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12__SECURITY_OWNERSHIP_CERTAIN_BENE">Item&#160;12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included under the captions &#8220;Beneficial Ownership of Shares of Common Stock&#8221; and &#8220;Directors and Corporate Governance&#8212;Equity Compensation Plan Information&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13__CERTAIN_RELATIONSHIPS_RELATED_T">Item&#160;13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included under the captions &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Directors and Corporate Governance&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14__PRINCIPAL_ACCOUNTING_FEES_SERVI">Item&#160;14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included under the captions &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15__EXHIBITS_FINANCIAL_STATEMENT_SC">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules. </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:6.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:39.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:4.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:6.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:10.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="top" style="width:0.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1699382/000119312520257820/d95525dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">001-39539</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 29, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1699382/000119312520257820/d95525dex32.htm"><span style="text-decoration:underline;">Amended and Restated </span><span style="text-decoration:underline;">Bylaws of the Registrant, as currently in effect.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">001-39539</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 29, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex41_11.htm"><span style="text-decoration:underline;">Description of Securities of the Registrant.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10-K</span></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-39539</span></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">March 3, 2021</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex41.htm"><span style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement, dated July 17, 2020, by and among the Registrant and certain of its stockholders.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">33-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">4.1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 4, 2020</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex42.htm"><span style="text-decoration:underline;">Specimen common stock certificate of the Registrant.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-248627</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 21, 2020</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1699382/000119312521290972/d231282dex44.htm"><span style="text-decoration:underline;">Form of Indenture.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3ASR</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-260012</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 4, 2021</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex101.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex102.htm"><span style="text-decoration:underline;">2013 Equity Incentive Plan, as amended, and forms of agreement thereunder.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1/A</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 21, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex103.htm"><span style="text-decoration:underline;">2020 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1/A</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 21, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex104.htm"><span style="text-decoration:underline;">2020 Employee Stock Purchase Plan and forms of agreements thereunder.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1/A</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 21, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex105.htm"><span style="text-decoration:underline;">Employment Offer Letter, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.5</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex106.htm"><span style="text-decoration:underline;">Employment Offer Letter, dated August 17, 2020, by and between the Registrant and Winston Kung</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.6</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex107.htm"><span style="text-decoration:underline;">Employment Offer Letter, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.7</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex108_331.htm"><span style="text-decoration:underline;">Employment Offer Letter, dated February 22, 2021, by and between the Registrant and Deepika Jalota, Pharm.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex109.htm"><span style="text-decoration:underline;">Employee Incentive Compensation Plan.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.9</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1010.htm"><span style="text-decoration:underline;">Change in Control and Severance Policy.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.10</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1011.htm"><span style="text-decoration:underline;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.11</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1012.htm"><span style="text-decoration:underline;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and Winston Kung.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.12</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1013.htm"><span style="text-decoration:underline;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.13</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex1014_338.htm"><span style="text-decoration:underline;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 14, 2022, by and between the Registrant and Deepika Jalota, Pharm.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15+</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex1015.htm"><span style="text-decoration:underline;">Outside Director Compensation Policy.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1/A</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.15</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1016.htm"><span style="text-decoration:underline;">Consulting Agreement, dated January 1, 2016, by and between the Registrant and Arnold Levine, Ph.D.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.16</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex1017_340.htm"><span style="text-decoration:underline;">Consulting Agreement, dated May 21, 2021, by and between the Registrant and Richard Heyman, Ph.D.</span></a><span style="text-decoration:underline;">, as amended on July 16, 2021</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1018.htm"><span style="text-decoration:underline;">Lease Agreement, dated March 3, 2015, by and between the Registrant and Cedar Brook 2005, LP, as amended by the First Amendment to Lease dated April 24, 2017.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">S-1</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">333-248627</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.18</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">September 4, 2020</span></p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex1019_6.htm"><span style="text-decoration:underline;">Lease Agreement, dated January 8, 2021, by and between the Registrant and BMR-ONE RESEARCH WAY LLC.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39539</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 3, 2021</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1699382/000119312521290972/d231282dex12.htm"><span style="text-decoration:underline;">Open Market Sale Agreement, dated as of October 4, 2021, between the Registrant and Jefferies LLC</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3ASR</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-260012</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 4, 2021</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex211_332.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex231_918.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:underline;">Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex311_334.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex312_335.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*#</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex321_336.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*#</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="pmvp-ex322_337.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:10.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-right:84.62%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;"><span style="font-family:Times New Roman;">Indicated management contract or compensatory plan.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed<span style="font-size:13.5pt;"> </span>filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the<span style="font-size:13.5pt;"> </span>Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made<span style="font-size:13.5pt;"> </span>before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained<span style="font-size:13.5pt;"> </span>in such filing.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected not to include summary information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:8pt;">
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David H. Mack</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David H. Mack, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:5.07%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David H. Mack, Ph.D. and Winston Kung, jointly and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:28.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:39.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:28.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David H. Mack</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David H. Mack, Ph.D.</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President,&#160;Chief&#160;Executive&#160;Officer&#160;and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Winston Kung</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Winston Kung</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief&#160;Operating&#160;Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal&#160;Financial&#160;and&#160;Accounting&#160;Officer)</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Heyman</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Heyman, Ph.D.</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director and Chairman of the Board of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arnold Levine</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arnold Levine, Ph.D.</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Thilo Schroeder</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thilo Schroeder, Ph.D.</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Laurie Stelzer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurie Stelzer</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr style="height:5pt;">
<td valign="middle" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:30.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Charles M. Baum</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charles M. Baum, MD., Ph.D.</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;1,&#160;2022</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kirsten Flowers</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2022</p></td>
</tr>
<tr>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kirsten Flowers</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:28.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>pmvp-ex108_331.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex108_331.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:88.47%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.8</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:26.46%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5rlbv12cydj000001.jpg" title="" alt="" style="width:326px;height:62px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;margin-left:1.09%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="PMV_Pharma_-_Amended_and_Restated_Employ"></a>February<font style="letter-spacing:-0.2pt;"> </font>22,<font style="letter-spacing:-0.3pt;"> </font>2021</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.09%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deepika<font style="letter-spacing:-0.15pt;"> </font>Jalota,<font style="letter-spacing:-0.35pt;"> </font>Pharm.D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:73.16%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o<font style="letter-spacing:-0.4pt;"> </font>PMV<font style="letter-spacing:-0.3pt;"> </font>Pharmaceuticals,<font style="letter-spacing:-0.3pt;"> </font>Inc.<font style="letter-spacing:-2.35pt;"> </font>Dear<font style="letter-spacing:-0.3pt;"> </font>Deepika,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.27%;text-indent:6.81%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter agreement (the &#8220;<font style="font-style:italic;">Agreement</font>&#8221;) is entered into between you and PMV Pharmaceuticals, Inc. (the<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">&#8220;</font><font style="font-style:italic;letter-spacing:-0.05pt;">Company</font><font style="letter-spacing:-0.05pt;">,&#8221;</font><font style="letter-spacing:-0.4pt;"> </font><font style="letter-spacing:-0.05pt;">&#8220;</font><font style="font-style:italic;letter-spacing:-0.05pt;">PMV</font><font style="font-style:italic;letter-spacing:-0.6pt;"> </font><font style="font-style:italic;letter-spacing:-0.05pt;">Pharma</font><font style="letter-spacing:-0.05pt;">,&#8221;</font><font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.55pt;"> </font>&#8220;<font style="font-style:italic;">we</font>&#8221;),<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>amends<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>restates<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>full<font style="letter-spacing:-0.45pt;"> </font>your<font style="letter-spacing:-0.45pt;"> </font>earlier<font style="letter-spacing:-0.6pt;"> </font>Employment<font style="letter-spacing:-0.55pt;"> </font>Letter<font style="letter-spacing:-0.4pt;"> </font>dated<font style="letter-spacing:-0.5pt;"> </font>August<font style="letter-spacing:-2.35pt;"> </font>11, 2020, reflecting your promotion and related compensation changes. This Agreement is effective as of the date<font style="letter-spacing:-2.35pt;"> </font>hereof<font style="letter-spacing:-0.15pt;"> </font>(the<font style="letter-spacing:-0.1pt;"> </font>&#8220;<font style="font-style:italic;">Effective</font><font style="font-style:italic;letter-spacing:-0.1pt;"> </font><font style="font-style:italic;">Date</font>&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.09%;margin-right:2.08%;text-indent:6.8%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Position</font><font style="color:#000000;">. Your new title is Chief Regulatory and Quality Officer, and you will continue to report to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the Company&#8217;s Chief Executive Officer. This is a full-time position. While you render services to the Company, you</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">not</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">engage</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">other</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">employment,</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">consulting</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">other</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">business</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">activity</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">(whether</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">full</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">time</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">part-time)</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">would</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">create a conflict</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">of interest with</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the Company.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:0.95%;text-indent:6.81%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:78pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cash</font><font style="font-weight:bold;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Compensation</font><font style="color:#000000;">.</font><font style="letter-spacing:0.15pt;color:#000000;"> </font><font style="color:#000000;">Your</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">2020</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">salary</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">$362,250</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">per</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">year,</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">increased</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">$390,000,</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">effective</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">as of March 1, 2021, payable in accordance with the Company&#8217;s standard payroll schedule. This salary will be</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">subject to adjustment pursuant to the Company&#8217;s employee compensation policies in effect from time to time. In</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">addition, you will be eligible to be considered for an incentive bonus for each fiscal year of the Company under the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company&#8217;s Employee Incentive Compensation Plan (the &#8220;</font><font style="font-style:italic;color:#000000;">Incentive Plan</font><font style="color:#000000;">&#8221;) or any successor plan. The bonus (if any)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">will be awarded based on objective or subjective criteria established by the Company&#8217;s Board of Directors (the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Board</font><font style="color:#000000;">&#8221;) and/or the Compensation Committee of the Board (the &#8220;</font><font style="font-style:italic;color:#000000;">Compensation Committee</font><font style="color:#000000;">&#8221;), as applicable.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Your</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">2020 annual target bonus of 35%, will be increased for 2021 and beyond to be 40% of your annual base salary. The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">terms and conditions of your bonus will be set forth in the Incentive Plan, and the Board and/or the Compensation</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Committee</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">reserves</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">authority</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">pay discretionary</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">bonuses.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">determinations</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Board</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and/or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Compensation</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Committee,</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">applicable,</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">with respect</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">bonus</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">final</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">binding.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.08%;text-indent:6.81%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Employee Benefits</font><font style="color:#000000;">. As a regular employee of the Company, you will continue to be eligible to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">participate in a number of Company-sponsored benefits. In addition, you will continue to be entitled to paid</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">vacation</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">accordance with</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company&#8217;s</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">vacation</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">policy,</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">effect</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">from</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">time</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to time.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.27%;text-indent:6.81%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Equity Awards</font><font style="color:#000000;">. You have received equity awards from the Company and these awards shall</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">continue to be in full force and effect and governed by the terms set forth therein, as modified by the Company&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Change</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Control</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Severance</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">Policy</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">participation</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">agreement</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">thereunder</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">(the</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Severance</font><font style="font-style:italic;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-style:italic;color:#000000;">Policy</font><font style="color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.27%;text-indent:6.8%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Severance &amp; Change of Control Benefits</font><font style="color:#000000;">. You will continue to be eligible for benefits in the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">Severance</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">Policy.</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">Accordingly,</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">your</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">potential</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">severance</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">change</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">control</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">benefits</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">terms</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">and conditions</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">thereof</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">are</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">set</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">forth</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">your participation agreement</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Severance</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Policy.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.27%;text-indent:6.81%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Proprietary Information and Inventions Agreement</font><font style="color:#000000;">. As an employee of the Company, you will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">continue</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">have</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">access</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">certain</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">confidential</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">information</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">you</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">may,</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">during</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">course</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">employment,</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">develop</font><font style="letter-spacing:0.35pt;color:#000000;"> </font><font style="color:#000000;">certain</font><font style="letter-spacing:0.35pt;color:#000000;"> </font><font style="color:#000000;">information</font><font style="letter-spacing:0.3pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">inventions</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:0.3pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:0.3pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">property</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.3pt;color:#000000;"> </font><font style="color:#000000;">Company.</font><font style="letter-spacing:0.35pt;color:#000000;"> </font><font style="color:#000000;">To</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">protect</font><font style="letter-spacing:0.35pt;color:#000000;"> </font><font style="color:#000000;">the</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:1pt;margin-bottom:0pt;margin-left:1.07%;margin-right:2.08%;text-indent:0.01%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interests of the Company, your acceptance of this Agreement reaffirms that the terms of the Company&#8217;s At-Will<font style="letter-spacing:0.05pt;"> </font>Employment, Confidential Information, Invention Assignment, and Arbitration Agreement that you executed in<font style="letter-spacing:0.05pt;"> </font>connection with your hire (the &#8220;<font style="font-style:italic;">PIAA</font>&#8221;) continue to be in effect. In the event of any dispute or claim relating to or<font style="letter-spacing:0.05pt;"> </font>arising out of our employment relationship, you and the Company agree that (i) any and all disputes between you<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>Company<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.2pt;"> </font>be<font style="letter-spacing:-0.15pt;"> </font>fully<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>finally<font style="letter-spacing:-0.1pt;"> </font>resolved<font style="letter-spacing:-0.2pt;"> </font>by<font style="letter-spacing:-0.35pt;"> </font>binding<font style="letter-spacing:-0.2pt;"> </font>arbitration,<font style="letter-spacing:-0.15pt;"> </font>(ii)<font style="letter-spacing:-0.15pt;"> </font>you<font style="letter-spacing:-0.35pt;"> </font>are<font style="letter-spacing:-0.15pt;"> </font>waiting<font style="letter-spacing:-0.2pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>all<font style="letter-spacing:-0.3pt;"> </font>rights<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>jury trial but all court remedies will be available in arbitration, (iii) all disputes shall be resolved by a neutral<font style="letter-spacing:0.05pt;"> </font>arbitrator who shall issue a written opinion, and (iv) the arbitration shall provide for adequate discovery, and the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-0.1pt;"> </font>shall pay<font style="letter-spacing:-0.05pt;"> </font>all but<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>first<font style="letter-spacing:-0.25pt;"> </font>$125<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>arbitration<font style="letter-spacing:-0.05pt;"> </font>fees.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.07%;margin-right:2.27%;text-indent:6.8%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Employment Relationship</font><font style="color:#000000;">. Employment with the Company is for no specific period of time. Your</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">employment with the Company continues to be &#8220;at will,&#8221; meaning that either you or the Company may terminate</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">your employment at any time and for any reason, with or without cause. Any contrary representations that may</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">have been made to you are superseded by this Agreement. This is the full and complete Agreement between you</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">and</font><font style="letter-spacing:-0.75pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">the</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">Company</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">on</font><font style="letter-spacing:-0.75pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">this</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">term.</font><font style="letter-spacing:1.45pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">Although</font><font style="letter-spacing:-0.65pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">job</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">duties,</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">title,</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">compensation</font><font style="letter-spacing:-0.65pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.75pt;color:#000000;"> </font><font style="color:#000000;">benefits,</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:-0.7pt;color:#000000;"> </font><font style="color:#000000;">well</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">Company&#8217;s</font><font style="letter-spacing:-2.4pt;color:#000000;"> </font><font style="color:#000000;">personnel policies and procedures, may change from time to time, the &#8220;at will&#8221; nature of your employment may</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">only</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">be</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">changed</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">in</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">an</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="letter-spacing:-0.05pt;color:#000000;">express</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">written</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">agreement</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">signed</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">you</font><font style="letter-spacing:-0.65pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">duly</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">authorized</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">officer</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">(other</font><font style="letter-spacing:-2.4pt;color:#000000;"> </font><font style="color:#000000;">than</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">you).</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.81%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;">Tax</font><font style="letter-spacing:-0.15pt;font-weight:bold;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Matters</font><font style="color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.09%;margin-right:2.27%;text-indent:13.61%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">a.</font><font style="margin-left:113pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">. All forms of compensation referred to in this Agreement are subject to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">reduction</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">reflect applicable</font><font style="color:#000000;"> </font><font style="color:#000000;">withholding and</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">payroll</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">taxes</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">other</font><font style="color:#000000;"> </font><font style="color:#000000;">deductions</font><font style="color:#000000;"> </font><font style="color:#000000;">required</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.09%;margin-right:2.08%;text-indent:13.61%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">b.</font><font style="margin-left:113pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Section 409A</font><font style="color:#000000;">. The parties intend that the benefits and payments provided under this</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">shall</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">exempt</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">from,</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">comply</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">with,</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">requirements</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">Section</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">409A</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">Code</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">(as</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">it</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">has</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">been</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-2.4pt;color:#000000;"> </font><font style="color:#000000;">may be amended from time to time) and any regulations and guidance that has been promulgated or may be</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">promulgated from time to time thereunder (&#8220;</font><font style="font-style:italic;color:#000000;">Section 409A</font><font style="color:#000000;">&#8221;), and any ambiguities or ambiguous terms herein will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">be interpreted to so comply. Each payment and benefit payable under this Agreement is intended to constitute a</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. The Company shall in no</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">event</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">obligated</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">indemnify</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">you</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="color:#000000;"> </font><font style="color:#000000;">taxes</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">interest</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">may be</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">assessed</font><font style="color:#000000;"> </font><font style="color:#000000;">under Section</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">409A.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.27%;text-indent:6.81%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:77pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Interpretation,</font><font style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Amendment</font><font style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">and</font><font style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Enforcement.</font><font style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">This</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">together</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">with</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">PIAA,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">Severance</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">Policy</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.5pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-0.6pt;color:#000000;"> </font><font style="color:#000000;">participation</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">agreement</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">under</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">Severance</font><font style="letter-spacing:-0.55pt;color:#000000;"> </font><font style="color:#000000;">Policy</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">your</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">Equity</font><font style="letter-spacing:-0.4pt;color:#000000;"> </font><font style="color:#000000;">Award</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">agreements,</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">supersede</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">replace</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">prior</font><font style="letter-spacing:-0.1pt;color:#000000;"> </font><font style="color:#000000;">agreements,</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">representations</font><font style="letter-spacing:-0.45pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">understandings</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">(whether</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">written,</font><font style="letter-spacing:-0.35pt;color:#000000;"> </font><font style="color:#000000;">oral,</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">implied</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">otherwise) between you and the Company, including, but not limited to any initial offer letter with the Company,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and constitute the complete agreement between you and the Company regarding the subject matter set forth</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">herein. This Agreement may not be amended or modified, except by an express written agreement signed by both</font><font style="letter-spacing:-2.35pt;color:#000000;"> </font><font style="color:#000000;">you</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">duly</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">authorized</font><font style="letter-spacing:-0.3pt;color:#000000;"> </font><font style="color:#000000;">officer</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:-0.25pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:38.99%;margin-right:40.26%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*<font style="letter-spacing:0.05pt;"> </font>*<font style="letter-spacing:-0.1pt;"> </font>*<font style="letter-spacing:-0.05pt;"> </font>*<font style="letter-spacing:-0.1pt;"> </font>*</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.89%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.2pt;"> </font>are<font style="letter-spacing:-0.2pt;"> </font>extremely<font style="letter-spacing:-0.25pt;"> </font>excited<font style="letter-spacing:-0.25pt;"> </font>about<font style="letter-spacing:-0.05pt;"> </font>your<font style="letter-spacing:-0.15pt;"> </font>continued<font style="letter-spacing:-0.25pt;"> </font>employment<font style="letter-spacing:-0.15pt;"> </font>with<font style="letter-spacing:-0.35pt;"> </font>PMV<font style="letter-spacing:-0.35pt;"> </font>Pharma!</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:39%;margin-right:40.26%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">signature</font><font style="font-style:italic;letter-spacing:-0.25pt;"> </font><font style="font-style:italic;">page</font><font style="font-style:italic;letter-spacing:-0.1pt;"> </font><font style="font-style:italic;">follows</font>]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:1.87%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#444444;font-size:9.5pt;font-family:Arial;">2</font></p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:2.04%;text-indent:6.71%;color:#444444;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Signature_page"></a>To<font style="letter-spacing:0.25pt;"> </font>indicate<font style="letter-spacing:0.35pt;"> </font>your<font style="letter-spacing:0.3pt;"> </font>acceptance<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company's<font style="letter-spacing:1.1pt;"> </font>offer,<font style="letter-spacing:-0.1pt;"> </font>please<font style="letter-spacing:0.55pt;"> </font>sign<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.1pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>letter<font style="letter-spacing:0.4pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:0.2pt;"> </font>space<font style="letter-spacing:0.65pt;"> </font>p<font style="color:#626264;">ro</font>v<font style="color:#626264;">i</font>ded<font style="letter-spacing:0.05pt;"> </font>below<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>return it<font style="letter-spacing:1.35pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>me.<font style="letter-spacing:2.5pt;"> </font>A<font style="letter-spacing:0.2pt;"> </font>duplicate<font style="letter-spacing:1pt;"> </font>original<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:-0.75pt;"> </font>enclosed<font style="letter-spacing:0.95pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>your<font style="letter-spacing:0.75pt;"> </font>records<font style="color:#626264;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5rlbv12cydj000002.jpg" title="" alt="" style="width:636px;height:366px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:1.87%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#444444;font-size:9.5pt;font-family:Arial;">3</font></p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>pmvp-ex1014_338.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex1014_338.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-top:4pt;margin-bottom:0pt;margin-left:27.61%;margin-right:7.63%;font-weight:bold;color:#010101;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.12%;">Exhibit 10.14</p>
<p style="text-align:right;margin-top:4pt;margin-bottom:0pt;margin-left:27.61%;margin-right:7.63%;text-indent:4.12%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:27.56%;margin-right:22.67%;font-weight:bold;color:#010101;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.07%;">Change in Control<font style="letter-spacing:0.05pt;"> </font>and Severance<font style="letter-spacing:0.05pt;"> </font>Policy<font style="letter-spacing:0.05pt;"> </font>Amended<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>Restated<font style="letter-spacing:0.1pt;"> </font>Participation<font style="letter-spacing:1pt;"> </font>Agreement</p>
<p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;margin-left:2.16%;margin-right:1.06%;text-indent:7.52%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amended and Restated Participation Agreement <font style="font-weight:bold;font-size:10pt;">("Agreement") </font>is made and entered into<font style="letter-spacing:0.05pt;"> </font>by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the <font style="font-weight:bold;font-size:10pt;">"Company") </font>on<font style="letter-spacing:-2.65pt;"> </font>the<font style="letter-spacing:2.3pt;"> </font>other.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.15%;margin-right:1.27%;text-indent:7.6%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with your recent promotion to be the Company's Chief Regulatory and Quality<font style="letter-spacing:0.05pt;"> </font>Officer, you are entitled to receive an updated level of severance payments and benefits upon a<font style="letter-spacing:0.05pt;"> </font>Qualified<font style="letter-spacing:-0.1pt;"> </font>Termination,<font style="letter-spacing:0.8pt;"> </font>subject<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:1.1pt;"> </font>the<font style="letter-spacing:0.75pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.1pt;"> </font>conditions<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.65pt;"> </font>Policy,<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:0.3pt;"> </font>set<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:-0.2pt;"> </font>herein.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:2.18%;margin-right:1.27%;text-indent:7.46%;font-weight:bold;font-style:italic;color:#010101;font-size:9.5pt;font-family:Arial;text-transform:none;font-variant: normal;">CIC Qualified Termination. <font style="font-weight:normal;font-style:normal;">Upon your CIC Qualified Termination, you will be entitled to the</font><font style="letter-spacing:0.05pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">following</font><font style="letter-spacing:-0.15pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">benefits,</font><font style="letter-spacing:-0.1pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">subject to</font><font style="letter-spacing:0.4pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">the</font><font style="letter-spacing:0.55pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">terms</font><font style="letter-spacing:-0.25pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">and</font><font style="letter-spacing:-0.55pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">conditions of</font><font style="letter-spacing:-0.35pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">the</font><font style="letter-spacing:-0.15pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">Policy:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Equity</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.7pt;"> </font><font style="font-weight:bold;font-size:10pt;">Vesting: </font><font style="font-size:9.5pt;">100%</font><font style="font-size:9.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">then-unvested</font><font style="font-size:9.5pt;letter-spacing:1.3pt;"> </font><font style="font-size:9.5pt;">shares</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">subject</font><font style="font-size:9.5pt;letter-spacing:0.9pt;"> </font><font style="font-size:9.5pt;">to</font><font style="font-size:9.5pt;letter-spacing:1.55pt;"> </font><font style="font-size:9.5pt;">each</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">your</font></p></td></tr></table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:17.45%;margin-right:1.91%;text-indent:0%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">then-outstanding equity<font style="letter-spacing:0.45pt;"> </font>awards<font style="letter-spacing:0.9pt;"> </font>will<font style="letter-spacing:0.35pt;"> </font>immediately<font style="letter-spacing:0.75pt;"> </font>vest<font style="letter-spacing:0.35pt;"> </font>and,<font style="letter-spacing:0.2pt;"> </font>in<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:1.15pt;"> </font>case<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.45pt;"> </font>options<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>stock appreciation<font style="letter-spacing:0.05pt;"> </font>rights, will become exercisable (for avoidance<font style="letter-spacing:0.05pt;"> </font>of doubt, no more<font style="letter-spacing:0.05pt;"> </font>than100% of the<font style="letter-spacing:0.05pt;"> </font>shares subject to<font style="letter-spacing:0.05pt;"> </font>the outstanding portion of an equity award may<font style="letter-spacing:0.05pt;"> </font>vest and become exercisable under this provision). In the case of<font style="letter-spacing:0.05pt;"> </font>equity awards with<font style="letter-spacing:0.05pt;"> </font>performance-based vesting, unless otherwise determined by the<font style="letter-spacing:0.05pt;"> </font>Company and set<font style="letter-spacing:0.05pt;"> </font>forth in your<font style="letter-spacing:0.05pt;"> </font>equity<font style="letter-spacing:0.05pt;"> </font>award agreement, all performance goals and other vesting<font style="letter-spacing:0.05pt;"> </font>criteria<font style="letter-spacing:0.3pt;"> </font>will<font style="letter-spacing:0.2pt;"> </font>be deemed<font style="letter-spacing:0.3pt;"> </font>achieved<font style="letter-spacing:0.25pt;"> </font>at<font style="letter-spacing:-0.4pt;"> </font>100%<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.1pt;"> </font>target<font style="letter-spacing:0.1pt;"> </font>levels.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Salary</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.25pt;"> </font><font style="font-weight:bold;font-size:10pt;">Severance:</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">12</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">months</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.65pt;"> </font><font style="font-size:9.5pt;">Base</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">Salary,</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">payable</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">in</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">a</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">lump</font><font style="font-size:9.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:9.5pt;">sum</font><font style="font-size:9.5pt;letter-spacing:0.55pt;"> </font><font style="font-size:9.5pt;">on</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">61st</font><font style="font-size:9.5pt;letter-spacing:-2.5pt;"> </font><font style="font-size:9.5pt;">day following</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">CIC</font><font style="font-size:9.5pt;letter-spacing:-0.35pt;"> </font><font style="font-size:9.5pt;">Qualified</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font><font style="font-size:9.5pt;">Termination.</font></p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Bonus</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.2pt;"> </font><font style="font-weight:bold;font-size:10pt;">Severance:</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.55pt;"> </font><font style="font-size:9.5pt;">100%</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:1.2pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.85pt;"> </font><font style="font-size:9.5pt;">target</font><font style="font-size:9.5pt;letter-spacing:0.9pt;"> </font><font style="font-size:9.5pt;">bonus</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">for</font><font style="font-size:9.5pt;letter-spacing:1.5pt;"> </font><font style="font-size:9.5pt;">the performance</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">year</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">in</font><font style="font-size:9.5pt;letter-spacing:0.9pt;"> </font><font style="font-size:9.5pt;">which</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">your CIC Qualified Termination occurs, payable in a lump sum on the 61st day</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">following</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">CIC</font><font style="font-size:9.5pt;letter-spacing:-0.3pt;"> </font><font style="font-size:9.5pt;">Qualified</font><font style="font-size:9.5pt;letter-spacing:-0.35pt;"> </font><font style="font-size:9.5pt;">Termination.</font></p></td>
<td valign="top" style="width:6.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">COBRA</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.25pt;"> </font><font style="font-weight:bold;font-size:10pt;">Coverage:</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">Payment</font><font style="font-size:9.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:9.5pt;">or</font><font style="font-size:9.5pt;letter-spacing:0.55pt;"> </font><font style="font-size:9.5pt;">reimbursement</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">COBRA</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">Coverage</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">or</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">COBRA</font><font style="font-size:9.5pt;letter-spacing:1.5pt;"> </font><font style="font-size:9.5pt;">Benefit,</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">as</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">applicable,</font><font style="font-size:9.5pt;letter-spacing:1.15pt;"> </font><font style="font-size:9.5pt;">for</font><font style="font-size:9.5pt;letter-spacing:2.1pt;"> </font><font style="font-size:9.5pt;">up</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">to</font><font style="font-size:9.5pt;letter-spacing:1.55pt;"> </font><font style="font-size:9.5pt;">12 months</font><font style="font-size:9.5pt;letter-spacing:1.1pt;"> </font><font style="font-size:9.5pt;">following</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:1.4pt;"> </font><font style="font-size:9.5pt;">CIC</font><font style="font-size:9.5pt;letter-spacing:0.8pt;"> </font><font style="font-size:9.5pt;">Qualified</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">Termination.</font></p></td>
<td valign="top" style="width:8.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.16%;margin-right:1.91%;text-indent:-0.06%;font-weight:bold;font-style:italic;color:#010101;font-size:9.5pt;font-family:Arial;text-transform:none;font-variant: normal;">Non-CIC<font style="letter-spacing:0.05pt;"> </font>Qualified<font style="letter-spacing:1pt;"> </font>Termination.<font style="letter-spacing:2.25pt;"> </font><font style="font-weight:normal;font-style:normal;">Upon</font><font style="letter-spacing:0.45pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">your</font><font style="letter-spacing:0.9pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">Non-CIC</font><font style="letter-spacing:0.95pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">Qualified</font><font style="letter-spacing:0.35pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">Termination,</font><font style="letter-spacing:1.05pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">you</font><font style="letter-spacing:0.45pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">will</font><font style="letter-spacing:0.7pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">be</font><font style="letter-spacing:0.25pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">entitled</font><font style="letter-spacing:0.6pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">to</font><font style="letter-spacing:0.05pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">the following</font><font style="letter-spacing:-0.15pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">benefits,</font><font style="letter-spacing:-0.3pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">subject</font><font style="letter-spacing:0.05pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">to</font><font style="letter-spacing:0.55pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">the</font><font style="letter-spacing:0.3pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">terms</font><font style="letter-spacing:-0.35pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">and</font><font style="letter-spacing:-0.3pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">conditions</font><font style="letter-spacing:0.15pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">of</font><font style="letter-spacing:-0.15pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">the</font><font style="letter-spacing:0.2pt;font-weight:normal;font-style:normal;"> </font><font style="font-weight:normal;font-style:normal;">Policy:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Equity Vesting: </font><font style="font-size:9.5pt;">A number of then-unvested shares subject to each of your then&#173;</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">outstanding</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">equity</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">awards</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">(excluding</font><font style="font-size:9.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:9.5pt;">equity</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">awards</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">with</font><font style="font-size:9.5pt;letter-spacing:0.15pt;"> </font><font style="font-size:9.5pt;">performance-based</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">vesting</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">and excluding</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">any</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">equity</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">awards</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">granted</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">on</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">or</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">after</font><font style="font-size:9.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">IPO</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">Date)</font><font style="font-size:9.5pt;letter-spacing:0.3pt;"> </font><font style="font-size:9.5pt;">equal</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">to</font><font style="font-size:9.5pt;letter-spacing:-2.65pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">number of</font><font style="font-size:9.5pt;letter-spacing:1.1pt;"> </font><font style="font-size:9.5pt;">such</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">shares</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">otherwise</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">scheduled</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">to</font><font style="font-size:9.5pt;letter-spacing:1.15pt;"> </font><font style="font-size:9.5pt;">vest</font><font style="font-size:9.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:9.5pt;">during the</font><font style="font-size:9.5pt;letter-spacing:0.75pt;"> </font><font style="font-size:9.5pt;">6</font><font style="font-size:9.5pt;letter-spacing:-0.25pt;"> </font><font style="font-size:9.5pt;">month</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">period</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">following the date of your Non-CIC Qualified Termination</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">had you remained</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">employed</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">with the Company (or any of its subsidiaries)</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">through such date will</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">immediately</font><font style="font-size:9.5pt;letter-spacing:1.05pt;"> </font><font style="font-size:9.5pt;">vest</font><font style="font-size:9.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:9.5pt;">and,</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">in</font><font style="font-size:9.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:9.5pt;">the case</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">options</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;"> </font><font style="font-size:9.5pt;">and</font><font style="font-size:9.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:9.5pt;">stock</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">appreciation</font><font style="font-size:9.5pt;letter-spacing:0.8pt;"> </font><font style="font-size:9.5pt;">rights,</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">will</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">become</font><font style="font-size:9.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:9.5pt;">exercisable.</font></p></td>
<td valign="top" style="width:4.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Salary</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.2pt;"> </font><font style="font-weight:bold;font-size:10pt;">Severance:</font><font style="font-weight:bold;font-size:10pt;letter-spacing:0.55pt;"> </font><font style="font-size:9.5pt;">6 months</font><font style="font-size:9.5pt;letter-spacing:0.3pt;"> </font><font style="font-size:9.5pt;">of</font><font style="font-size:9.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">Base</font><font style="font-size:9.5pt;letter-spacing:0.15pt;"> </font><font style="font-size:9.5pt;">Salary,</font><font style="font-size:9.5pt;letter-spacing:0.7pt;"> </font><font style="font-size:9.5pt;">payable</font><font style="font-size:9.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:9.5pt;">in</font><font style="font-size:9.5pt;letter-spacing:0.55pt;"> </font><font style="font-size:9.5pt;">a</font><font style="font-size:9.5pt;letter-spacing:0.15pt;"> </font><font style="font-size:9.5pt;">lump</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">sum</font><font style="font-size:9.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:9.5pt;">on</font><font style="font-size:9.5pt;letter-spacing:-0.2pt;"> </font><font style="font-size:9.5pt;">the</font><font style="font-size:9.5pt;letter-spacing:0.7pt;"> </font><font style="font-size:9.5pt;">61st</font><font style="font-size:9.5pt;letter-spacing:-2.45pt;"> </font><font style="font-size:9.5pt;">day following</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;"> </font><font style="font-size:9.5pt;">your</font><font style="font-size:9.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:9.5pt;">Non-CIC</font><font style="font-size:9.5pt;letter-spacing:0.1pt;"> </font><font style="font-size:9.5pt;">Qualified</font><font style="font-size:9.5pt;letter-spacing:-0.2pt;"> </font><font style="font-size:9.5pt;">Termination.</font></p></td>
<td valign="top" style="width:3.81%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.58%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">Bonus</font><font style="font-weight:bold;font-size:10pt;letter-spacing:-0.3pt;"> </font><font style="font-weight:bold;font-size:10pt;">Severance:</font><font style="font-weight:bold;font-size:10pt;letter-spacing:2.35pt;"> </font><font style="font-size:9.5pt;">None.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#010101;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;">COBRA Coverage: </font><font style="font-size:9.5pt;">Payment or reimbursement of the COBRA Coverage or COBRA</font><font style="font-size:9.5pt;letter-spacing:-2.5pt;"> </font><font style="font-size:9.5pt;">Benefit, as applicable, for</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">up to 9 months following your Non-CIC Qualified</font><font style="font-size:9.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">Termination.</font></p></td>
<td valign="top" style="width:6.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#010101;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:2.15%;margin-right:1.27%;text-indent:7.63%;font-weight:bold;color:#010101;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">"IPO Date" <font style="font-size:9.5pt;font-weight:normal;">means the effective date of the first registration statement that is filed by the</font><font style="font-size:9.5pt;letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">Company and declared effective pursuant to Section 12(b) of the Exchange Act of 1934, with respect</font><font style="font-size:9.5pt;letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">to</font><font style="font-size:9.5pt;letter-spacing:0.7pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">the</font><font style="font-size:9.5pt;letter-spacing:0.5pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">Company's</font><font style="font-size:9.5pt;letter-spacing:0.3pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">common</font><font style="font-size:9.5pt;letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-size:9.5pt;font-weight:normal;">stock.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:2.17%;text-indent:0%;font-weight:bold;color:#010101;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other<font style="letter-spacing:-0.65pt;"> </font>Provisions</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.17%;margin-right:1.06%;text-indent:7.61%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You agree that the Policy and the Agreement constitute the entire agreement of the parties<font style="letter-spacing:0.05pt;"> </font>hereto<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>supersede<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>entirety<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>representations, understandings, undertakings<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.05pt;"> </font>(whether<font style="letter-spacing:0.05pt;"> </font>oral or<font style="letter-spacing:0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>and whether<font style="letter-spacing:0.05pt;"> </font>expressed<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>implied)<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>parties,<font style="letter-spacing:0.05pt;"> </font>and will<font style="letter-spacing:0.05pt;"> </font>specifically supersede<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>severance<font style="letter-spacing:0.05pt;"> </font>and/or<font style="letter-spacing:0.05pt;"> </font>change<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>letter,<font style="letter-spacing:0.05pt;"> </font>employment<font style="letter-spacing:0.05pt;"> </font>agreement, or<font style="letter-spacing:0.05pt;"> </font>equity<font style="letter-spacing:0.05pt;"> </font>award<font style="letter-spacing:0.05pt;"> </font>agreement&nbsp;&nbsp;entered into between you and the&nbsp;&nbsp;Company<font style="letter-spacing:0.05pt;"> </font>and/or<font style="letter-spacing:0.4pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>its subsidiaries.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.17%;margin-right:1.27%;text-indent:7.51%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement may be executed in counterparts, each of which will be deemed an original,<font style="letter-spacing:0.05pt;"> </font>but<font style="letter-spacing:0.5pt;"> </font>all<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>which<font style="letter-spacing:-0.3pt;"> </font>together<font style="letter-spacing:0.4pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>constitute<font style="letter-spacing:-0.3pt;"> </font>one<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>same<font style="letter-spacing:-0.15pt;"> </font>instrument.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.18%;margin-right:1.06%;text-indent:7.61%;color:#010101;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing below, each of the parties signifies his, her, or its acceptance of the terms of this<font style="letter-spacing:0.05pt;"> </font>Agreement, in the case of the Company by its duly authorized officer, effective as of the last date set<font style="letter-spacing:0.05pt;"> </font>forth below.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:38.57%;margin-right:37.08%;text-indent:0%;font-weight:bold;font-style:italic;color:#010101;font-size:9pt;font-family:Arial;text-transform:none;font-variant: normal;">[Signature<font style="letter-spacing:0.05pt;"> </font>Page<font style="letter-spacing:-0.35pt;"> </font>Follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:1.56%;text-indent:0%;color:#010101;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:2.18%;margin-right:1.06%;text-indent:7.66%;color:#030303;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>By signing below, each of the parties signifies his, her, or its acceptance of the terms of this<font style="letter-spacing:0.05pt;"> </font>Agreement, in the case of the Company by its duly authorized officer, effective as of the last date set<font style="letter-spacing:0.05pt;"> </font>forth<font style="letter-spacing:0.1pt;"> </font>below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gw0ad20d1dfx000001.jpg" title="" alt="" style="width:629px;height:160px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:26.6%;text-indent:0%;font-style:italic;color:#030303;font-size:9pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">[Signature<font style="letter-spacing:-0.45pt;"> </font>Page<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>A&amp;R<font style="letter-spacing:-0.55pt;"> </font>Participation<font style="letter-spacing:0.4pt;"> </font>Agreement<font style="letter-spacing:-0.2pt;"> </font>(Jalota)]</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>pmvp-ex1017_538.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex1017_538.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.48%;"><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Exhibit 10.17</font></p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-right:15.18%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">PMV<font style="letter-spacing:-0.3pt;"> </font>PHARMACEUTICALS,<font style="letter-spacing:-0.3pt;"> </font>INC.</p>
<p style="text-align:center;margin-top:17pt;margin-bottom:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AMENDED<font style="letter-spacing:-0.1pt;"> </font>&amp;<font style="letter-spacing:-0.15pt;"> </font>RESTATED<font style="letter-spacing:-0.05pt;"> </font>SAB<font style="letter-spacing:0.05pt;"> </font>CONSULTING<font style="letter-spacing:-0.1pt;"> </font>AGREEMENT</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:15.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.04%;margin-right:1.46%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T<font style="font-size:9.5pt;">HIS </font>C<font style="font-size:9.5pt;">ONSULTING </font>A<font style="font-size:9.5pt;">GREEMENT </font><font style="font-weight:normal;">(the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Agreement</font><font style="font-weight:normal;">&#8221;) is made and entered into by and between</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font>PMV<font style="letter-spacing:0.05pt;"> </font>P<font style="font-size:9.5pt;">HARMACEUTICALS</font>,<font style="letter-spacing:0.05pt;"> </font><font style="font-size:9.5pt;">INC</font>.,<font style="letter-spacing:0.05pt;"> </font><font style="font-weight:normal;">a</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Delaware</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">corporation</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">(the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Company</font><font style="font-weight:normal;">&#8221;),</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font>Richard<font style="letter-spacing:0.05pt;"> </font>Heyman,<font style="letter-spacing:-0.05pt;"> </font>Ph.D.<font style="font-weight:normal;">,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">an</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">individual (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Consultant&#8221;</font><font style="font-weight:normal;">),</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">effective</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">as of</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">May</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">15, 2021</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">(&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Effective</font><font style="text-decoration:underline;letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Date</font><font style="font-weight:normal;">&#8221;).</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">R<font style="font-size:9.5pt;">ECITALS</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.04%;margin-right:1.46%;text-indent:7.47%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Consultant and</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">have</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">previously</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">entered</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">into</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">an</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">SAB</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Consulting</font><font style="letter-spacing:-2.9pt;font-weight:normal;"> </font><font style="letter-spacing:-0.05pt;font-weight:normal;">Agreement</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="letter-spacing:-0.05pt;font-weight:normal;">(the</font><font style="letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Prior</font><font style="text-decoration:underline;letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Agreement</font><font style="font-weight:normal;">&#8221;)</font><font style="letter-spacing:-0.8pt;font-weight:normal;"> </font><font style="font-weight:normal;">pursuant</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.7pt;font-weight:normal;"> </font><font style="font-weight:normal;">which</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">has</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">appointed,</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:-0.75pt;font-weight:normal;"> </font><font style="font-weight:normal;">Consultant</font><font style="letter-spacing:-2.85pt;font-weight:normal;"> </font><font style="font-weight:normal;">has</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">agreed</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">to serve,</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">on the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Company&#8217;s Scientific</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Advisory</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Board</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">(the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">SAB</font><font style="font-weight:normal;">&#8221;); and</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.04%;margin-right:1.46%;text-indent:7.47%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">W<font style="font-size:9.5pt;">HEREAS</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">PMV</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">Pharma</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">Consultant</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">desire</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">amend</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">restate</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">terms</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prior</font><font style="letter-spacing:-2.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:-0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">in its entirety</font><font style="letter-spacing:0.15pt;font-weight:normal;"> </font><font style="font-weight:normal;">as set forth herein;</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.04%;margin-right:1.46%;text-indent:7.47%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-size:9.5pt;">OW</font><font style="font-size:9.5pt;letter-spacing:-0.2pt;"> </font>T<font style="font-size:9.5pt;">HEREFORE</font><font style="font-weight:normal;">,</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">consideration</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">mutual</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">obligations</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">specified</font><font style="letter-spacing:-0.25pt;font-weight:normal;"> </font><font style="font-weight:normal;">in</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">this</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement,</font><font style="letter-spacing:-2.9pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">parties agree</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">that</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Prior</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">Agreement</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">shall be</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">amended</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">restated</font><font style="letter-spacing:0.1pt;font-weight:normal;"> </font><font style="font-weight:normal;">as</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">follows:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">ONSULTING</font><font style="font-size:9.5pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">S</font><font style="font-size:9.5pt;color:#000000;">ERVICES</font><font style="font-size:9.5pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">E</font><font style="font-size:9.5pt;color:#000000;">NGAGEMENT</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">The</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">hereby</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">retains</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant hereby accepts such retention, to perform consulting services for the Company as</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">set</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">forth herein.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">S</font><font style="font-size:9.5pt;color:#000000;">ERVICES</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant shall provide services described in Exhibit 1 (&#8220;</font><font style="text-decoration:underline;font-size:12pt;font-weight:normal;color:#000000;">Services</font><font style="font-size:12pt;font-weight:normal;color:#000000;">&#8221;) for the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">OMPENSATION</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company agrees to pay Consultant the compensation set forth in</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Exhibit 1.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">T</font><font style="font-size:9.5pt;color:#000000;">ERM AND </font><font style="font-size:12pt;color:#000000;">T</font><font style="font-size:9.5pt;color:#000000;">IME </font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">OMMITMENT</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">This Agreement will commence on the Effective Date</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and will continue from the Effective Date for a three (3) year term, unless terminated</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">earlier</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">either party according to section 1.6 below.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">P</font><font style="font-size:9.5pt;color:#000000;">AYMENT</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">T</font><font style="font-size:9.5pt;color:#000000;">ERMS</font><font style="font-size:9.5pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:9.5pt;color:#000000;">AND</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">E</font><font style="font-size:9.5pt;color:#000000;">XPENSE</font><font style="font-size:9.5pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">R</font><font style="font-size:9.5pt;color:#000000;">EIMBURSEMENT</font><font style="font-size:12pt;font-weight:normal;color:#000000;">:</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.52%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.4.1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">P</font><font style="font-size:9.5pt;color:#000000;">AYMENT</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company shall pay Consultant on a quarterly basis, effect on the first</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">day</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of each calendar quarter.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.52%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.4.2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">E</font><font style="font-size:9.5pt;color:#000000;">XPENSES</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">The</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reimburse</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">actually</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">incurred</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">performing</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Services,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">including</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">but</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">limited</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">travel</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">accommodation</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses,</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">so</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">long</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">are</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reasonable</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">necessary</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as determined by the Company and, where such policies exist, comply with the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company&#8217;s expense policies.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant shall maintain adequate books and records</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">relating</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reimbursed.</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">submit</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">timely</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">manner</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">original</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">receipts</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">along</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">invoices</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">summarize</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">form</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">acceptable</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the Company.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">I</font><font style="font-size:9.5pt;color:#000000;">NDEPENDENT </font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">ONTRACTOR </font><font style="font-size:12pt;color:#000000;">S</font><font style="font-size:9.5pt;color:#000000;">TATUS</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">It is understood and agreed that Consultant is an</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">independent</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">contractor,</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">an</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">agent</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">employee</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company,</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">authorized</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to act on behalf of the Company.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant agrees not to hold himself or herself out as,</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">give</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">person</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reason</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">believe</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">he</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">she</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">an</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">employee,</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">agent,</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">joint</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">venturer</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or partner of the Company. Consultant will not be eligible for any employee benefits, nor</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">will the Company make deductions from any amounts payable to Consultant for taxes or</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">insurance.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">All payroll and employment taxes, insurance, and benefits shall be the sole</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">responsibility of Consultant.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant retains the right to provide services for others</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">during the term of this Agreement and is not required to devote his or her services</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">exclusively</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the Company.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">T</font><font style="font-size:9.5pt;color:#000000;">ERMINATION</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">The Company or Consultant may terminate this Agreement at any time</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">giving</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">ten</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">(10)</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">business</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">days&#8217;</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">written</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">notice.</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">may</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">terminate</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">immediately upon written notice and without prior notice if Consultant refuses to or is</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">unable</font><font style="font-size:12pt;letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">perform</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Services</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">breach</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">material</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">provision</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement.</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">In</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">event</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">termination,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">cease</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">work</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">immediately</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">after</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">receiving</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">such notice of termination, unless otherwise agreed to in writing with the Company. At</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the time of termination of this Agreement for any reason, Consultant shall return to the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">all</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Confidential</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Information,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Service</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Product,</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">materials</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">belonging</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the Company, and shall notify the Company of any compensation earned and expenses</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">incurred</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">up</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">termination</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">date,</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">which</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">compensation</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">paid</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">within 30</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">days</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of the</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">receipt of</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant&#8217;s invoice</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">same.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">ONFIDENTIALITY AND </font><font style="font-size:12pt;color:#000000;">A</font><font style="font-size:9.5pt;color:#000000;">SSIGNMENT OF </font><font style="font-size:12pt;color:#000000;">I</font><font style="font-size:9.5pt;color:#000000;">NVENTIONS</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">As a condition of this Agreement,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant agrees to all the terms of Section 1, Exhibit 2 (Confidentiality) and Section 2,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Exhibit</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">2 (Assignment of Inventions).</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">S</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;color:#000000;">URVIVING</font><font style="font-size:9.5pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">S</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;color:#000000;">ECTIONS</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Sections</font><font style="font-size:12pt;letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">1</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">(Confidentiality)</font><font style="font-size:12pt;letter-spacing:-0.8pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">2</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">(Ownership</font><font style="font-size:12pt;letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Inventions)</font><font style="font-size:12pt;letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.8pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Exhibit</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">2 of the Agreement shall survive any termination of this Agreement for the period of five (5)</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">years</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">from the execution of</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">A</font><font style="font-size:9.5pt;color:#000000;">SSIGNMENT</font><font style="font-size:12pt;color:#000000;">; B</font><font style="font-size:9.5pt;color:#000000;">ENEFIT</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">This Agreement is for the personal services of Consultant and may</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">not be assigned by him or her, nor shall it be assignable by operation of law, without the prior</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">written consent of the Company.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">This Agreement may not be assigned by the Company, nor</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">it</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">assignable</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">operation</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">law,</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">without</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">prior</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">written</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">consent</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">The</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">parties&#8217; rights and obligations under this Agreement will bind and inure to the benefit of their</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">respective</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">successors, heirs, executors,</font><font style="font-size:12pt;letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">administrators and permitted assigns.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">G</font><font style="font-size:9.5pt;color:#000000;">OVERNING </font><font style="font-size:12pt;color:#000000;">L</font><font style="font-size:9.5pt;color:#000000;">AW</font><font style="font-size:12pt;color:#000000;">; S</font><font style="font-size:9.5pt;color:#000000;">EVERABILITY</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">This Agreement shall be governed by and construed</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">according to the laws of the State of New Jersey without regard to its conflict of laws rules. If</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">provision</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">found</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">court</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">competent</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">jurisdiction</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">unenforceable, that provision shall be severed and the remainder of this Agreement shall</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">continue</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">in full force</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">effect.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">OMPLETE </font><font style="font-size:12pt;color:#000000;">U</font><font style="font-size:9.5pt;color:#000000;">NDERSTANDING</font><font style="font-size:12pt;color:#000000;">; M</font><font style="font-size:9.5pt;color:#000000;">ODIFICATION</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">This Agreement, together with any Exhibits</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">attached hereto, constitutes the final, exclusive and complete understanding and agreement of</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">respect</font><font style="font-size:12pt;letter-spacing:0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">subject</font><font style="font-size:12pt;letter-spacing:0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">matter</font><font style="font-size:12pt;letter-spacing:0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">hereof.</font><font style="font-size:12pt;letter-spacing:1.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Any</font><font style="font-size:12pt;letter-spacing:0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">waiver,</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:4.78%;margin-right:1.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modification<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.85pt;"> </font>amendment<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>any<font style="letter-spacing:0.85pt;"> </font>provision<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.9pt;"> </font>this<font style="letter-spacing:0.9pt;"> </font>Agreement<font style="letter-spacing:0.9pt;"> </font>shall<font style="letter-spacing:0.9pt;"> </font>be<font style="letter-spacing:1pt;"> </font>effective<font style="letter-spacing:0.85pt;"> </font>only<font style="letter-spacing:0.9pt;"> </font>if<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:-2.85pt;"> </font>writing<font style="letter-spacing:-0.05pt;"> </font>and signed by<font style="letter-spacing:0.05pt;"> </font>Consultant and a<font style="letter-spacing:-0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>officer.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">L</font><font style="color:#000000;">IABILITY</font><font style="font-size:12pt;font-weight:normal;color:#000000;">. Consultant represents that he or she is experienced and qualified to perform the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Services</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">hereunder</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">use</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">his</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">her</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">best</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">efforts</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">provide</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Services</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">highest</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">level of skill and professionalism.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Except for the foregoing, Consultant makes no warranties</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with regard to the Services and none shall be implied.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">In no event shall Consultant be liable</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for special or consequential damages, either in contract or tort, whether or not the possibility</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of such damages has been disclosed to Consultant in advance or could have been reasonably</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">foreseen by Consultant. In the event this limitation of damages is held unenforceable, the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">parties agree that because of the difficulty in foreseeing possible damages, Consultant&#8217;s</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">liability to the Company shall not exceed the amount of any payments made by the Company</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">under</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">liability</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">payment</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">construed</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">liquidated</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">damages and not as a</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">penalty.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">N</font><font style="font-size:9.5pt;color:#000000;">OTICES</font><font style="font-size:12pt;color:#000000;">. </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Any notices required or permitted hereunder shall be given to the appropriate party</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">at the address specified below or at such other address as the party shall specify in writing.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Such notice shall be deemed given upon personal delivery to the appropriate address or sent</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">certified or</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">registered</font><font style="font-size:12pt;letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">mail,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">three</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">days after the date</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">mailing.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="letter-spacing:-0.1pt;"></font><font style="letter-spacing:-0.05pt;"></font><font style="letter-spacing:-0.05pt;"></font>If to the Consultant:<font style="letter-spacing:0.05pt;"> </font>David<font style="letter-spacing:-0.05pt;"> </font>Mack,<font style="letter-spacing:-0.05pt;"> </font>Ph.D.Richard<font style="letter-spacing:-0.45pt;"> </font>Heyman,<font style="letter-spacing:-0.45pt;"> </font>Ph.D.</p></td>
<td valign="top" style="width:27.23%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:8.52%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>CEO<font style="margin-left:234pt;">264</font><font style="letter-spacing:-0.05pt;"> </font>Torrey<font style="letter-spacing:-0.05pt;"> </font>Pines<font style="letter-spacing:-0.05pt;"> </font>Terrace</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.52%;margin-right:31.19%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMV<font style="letter-spacing:-0.1pt;"> </font>Pharmaceuticals, Inc.<font style="margin-left:234pt;">Del</font><font style="letter-spacing:-0.3pt;"> </font>Mar,<font style="letter-spacing:-0.3pt;"> </font>CA<font style="letter-spacing:-0.3pt;"> </font>92014<font style="letter-spacing:-2.85pt;"> </font>8<font style="letter-spacing:-0.05pt;"> </font>Clark Drive</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:8.52%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cranbury,<font style="letter-spacing:-0.05pt;"> </font>NJ<font style="letter-spacing:2.9pt;"> </font>08512</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">[remainder<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>page<font style="letter-spacing:-0.15pt;"> </font>intentionally left<font style="letter-spacing:-0.05pt;"> </font>blank]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:12.96%;text-indent:0%;font-weight:bold;color:#444444;font-size:9.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>In<font style="letter-spacing:-0.05pt;"> </font>Witness<font style="letter-spacing:0.55pt;"> </font>Whereof,<font style="letter-spacing:1.15pt;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">the</font><font style="font-size:11.5pt;letter-spacing:0.5pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">parties</font><font style="font-size:11.5pt;letter-spacing:0.7pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">hereto</font><font style="font-size:11.5pt;letter-spacing:0.75pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">have</font><font style="font-size:11.5pt;letter-spacing:0.85pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">executed</font><font style="font-size:11.5pt;letter-spacing:0.9pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">this</font><font style="font-size:11.5pt;letter-spacing:0.75pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">Agreement</font><font style="font-size:11.5pt;letter-spacing:1.2pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">as</font><font style="font-size:11.5pt;letter-spacing:0.55pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">of</font><font style="font-size:11.5pt;letter-spacing:0.7pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">the</font><font style="font-size:11.5pt;letter-spacing:0.6pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;">Effective</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.86%;text-indent:0%;color:#444444;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><img src="gfifg3pi0xun000001.jpg" title="" alt="" style="width:594px;height:155px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:17pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.98%;text-indent:0%;color:#444444;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV<font style="letter-spacing:-0.15pt;"> </font>Pharma,<font style="letter-spacing:-0.15pt;"> </font>Inc.<font style="letter-spacing:-0.2pt;"> </font>SAB<font style="letter-spacing:0.05pt;"> </font>Consulting Agreement</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:32.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">S</font><font style="font-size:9.5pt;color:#000000;">ERVICES</font><font style="font-size:12pt;font-weight:normal;color:#000000;">:</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Advise and consult with the Company as a member of its Scientific Advisory</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Board (SAB)</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">matters</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">may</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be mutually</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">agreed</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the Company and</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.75%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">OMPENSATION</font><font style="font-size:12pt;font-weight:normal;color:#000000;">:</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Cash</font><font style="font-size:12pt;font-weight:normal;color:#000000;">. Consultant will be paid $15,000 per year in quarterly installments at the beginning</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">each</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">quarter,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">increased</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">cash</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">compensation</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">commencing</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">next</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">succeeding</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">calendar quarter</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">following the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Effective</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Date.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Equity</font><font style="font-size:12pt;font-weight:normal;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant will receive an option grant of 5,781 shares of Company stock at the</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">prevailing option price as determined by the Board of Directors (and subject to the other</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">terms and conditions of the Company&#8217;s Equity Incentive Plan), vesting in equal amounts</font><font style="font-size:12pt;letter-spacing:-2.85pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">monthly</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">over</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">36 months beginning from the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Effective</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Date.</font></p></td>
<td valign="top" style="width:1.87%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">E</font><font style="font-size:9.5pt;color:#000000;">XPENSES</font><font style="font-size:12pt;color:#000000;">: </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant shall be reimbursed for reasonable expenses incurred in performance</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultants&#8217;</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">obligations;</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">provided</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">these</font><font style="font-size:12pt;letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">expenses</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">invoiced</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">on</font><font style="font-size:12pt;letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">monthly</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">basis</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">are approved by the Company.</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Domestic air travel, if approved by the Company, shall be</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reimbursed</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">at</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">business</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">comparable</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">rate;</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">international</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">air</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">travel,</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">if</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">approved</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall be</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reimbursed at</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">business or comparable</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">rate.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.04%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.74%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">T</font><font style="font-size:9.5pt;color:#000000;">IME</font><font style="font-size:9.5pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">OMMITMENT</font><font style="font-size:12pt;font-weight:normal;color:#000000;">:</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">provide</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">consulting</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">services</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">at</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">reasonable</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">request;</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">(not</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">exceed</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">5</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">days</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">per</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">year</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">during</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">term</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">without</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">prior</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">consent</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company)</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">term</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">agreement, or</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">agreed</font><font style="font-size:12pt;letter-spacing:-2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">between</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Consultant and</font><font style="font-size:12pt;letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Company.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.75%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">C</font><font style="font-size:9.5pt;color:#000000;">ONTACT</font><font style="font-size:9.5pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">P</font><font style="font-size:9.5pt;color:#000000;">ERSON</font><font style="font-size:12pt;font-weight:normal;color:#000000;">:</font><font style="font-size:12pt;letter-spacing:2.9pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">David</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">Mack,</font><font style="font-size:12pt;letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">CEO</font><font style="font-size:12pt;letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">(</font><font style="text-decoration:underline;color:#0000FF;font-size:12pt;font-weight:normal;">dmack@pmvpharma.com</font><font style="font-size:12pt;font-weight:normal;color:#000000;">;</font><font style="font-size:12pt;letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-size:12pt;font-weight:normal;color:#000000;">650-224-8240)</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:14.73%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV<font style="letter-spacing:-0.15pt;"> </font>Pharma Consulting<font style="letter-spacing:-0.05pt;"> </font>Agreement</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:14.75%;margin-right:15.18%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2</p>
<p style="margin-top:11pt;margin-bottom:0pt;margin-left:1.04%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality<font style="letter-spacing:-0.05pt;"> </font>and Assignment<font style="letter-spacing:-0.05pt;"> </font>of Invention</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.75%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Confidential</font><font style="font-weight:bold;font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-weight:bold;font-size:12pt;color:#000000;">Information</font><font style="font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">Subject</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">limitations</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">set</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">forth</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Paragraph 1.2,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">all</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">disclosed</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company to Consultant or generated by Consultant in the course of performing the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">Services</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">&#8220;Confidential</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information.&#8221;</font><font style="font-size:12pt;letter-spacing:1.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">In</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">particular,</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Confidential</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">include, but not be limited to, information relating to any compound, chemical, peptide,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">protein,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">complex,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">conjugate,</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assay,</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">biological</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">material,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">virus,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">extract,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">media,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">vector,</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">gene</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">sequence,</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">cell,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">cell</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">component,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">cell</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">line,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">formulation</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">sample;</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">procedure,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">discovery,</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">invention, formula, data, result, process, idea or technique; any trade secret, trade dress,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">copyright, patent or other intellectual property right, or any registration or application</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">therefore,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">materials</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">relating</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">thereto;</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">relating</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">foregoing</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">research,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">development</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(including</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">pre-clinical</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">clinical</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">development),</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">manufacturing,</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">engineering,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">marketing,</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">servicing,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">sales,</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">financing,</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">legal</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other business activities or to any present or future products, prices, plans, forecasts,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">suppliers,</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">clients,</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">customers,</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">employees,</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">consultants</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">investors;</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">whether</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">oral,</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">written,</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">graphic</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or electronic</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">form.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">The term &#8220;Confidential Information&#8221; shall not include information which Consultant can</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">demonstrate</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">competent</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">written</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proof:</font><font style="font-size:12pt;letter-spacing:2.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(a) is</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">now,</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">hereafter</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">becomes,</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">through</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">no</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">act</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or failure to act on the part of Consultant, generally known or available in the public</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">domain;</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">(b)</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">known</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">at</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">time</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">receiving</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">evidenced</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">his/her</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">records</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">reasonable</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proof;</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(c)</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">hereafter</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">furnished</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to Consultant</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">third party, as a</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">matter</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of right and without</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">restriction on disclosure.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">Consultant shall maintain all Confidential Information received from Company in trust</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">confidence</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">disclose</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">without</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">prior</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">written</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">permission</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Confidential</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">third</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">party</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">use</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Confidential</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">unauthorized</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">purpose.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">In</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">particular</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">without</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">limitation,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">use</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Confidential</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">support</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">patent</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">application</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">related filing.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant may use such Confidential Information only to the extent</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">required to perform the Services.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant shall not use Confidential Information for</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">purpose</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">manner,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">which</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">would</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">constitute</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">violation</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">laws</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">regulations, including without limitation the export control laws of the United States.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Nothing</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">construed</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">grant</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">rights</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">licenses</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(a)</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">under</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">trade</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">secrets,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">trademarks,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">inventions,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">copyrights,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">patents</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">intellectual property rights, or (b) to retain, distribute or commercialize any Confidential</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Information belonging to Company, in either case, except as necessary to perform the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Services.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Other Employer Information</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant agrees that he or she will not, during his or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">her</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">engagement</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">improperly</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">use</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">disclose</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proprietary</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information or trade secrets of his or her former or concurrent employers, companies or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">clients, if any, and that he or she will not bring onto the premises of the Company any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">unpublished documents or any property belonging to his or her former or concurrent</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">employers,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">companies</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">clients</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">unless</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">consented</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">writing</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">said</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">employers,</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">companies</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or clients.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Third Party Information</font><font style="font-size:12pt;color:#000000;">. Consultant recognizes that the Company has received and in</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the future will receive from third parties their confidential or proprietary information</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">subject</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">duty</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">on</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">part</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">maintain</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">confidentiality</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and, in some cases, to use it only for certain limited purposes.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant agrees that he</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or she owes the Company and such third parties, both during the term of his or her</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">engagement</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">thereafter,</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">duty</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">hold</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">all</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">confidential</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proprietary</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">information</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">strictest</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">confidence</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">disclose</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">it</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">person,</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">firm</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">corporation</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(except</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in a manner that is consistent with the Company&#8217;s agreement with the third party) or use</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">it for the benefit of anyone other than the Company or such third party (consistent with</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company&#8217;s agreement with the third party).</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">acknowledges</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">his</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">her</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">breach</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">may</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">cause</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">irreparable damage for which recovery of damages would be inadequate, and that the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">therefore</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">entitled</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">seek</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">timely</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">injunctive</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">relief</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">under</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement,</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">as well as such further relief as may be granted by a court of competent jurisdiction in</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">connection</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">breach</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">enforcement</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">obligations</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">hereunder</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">o</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">unauthorized</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">use</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or release</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of any</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such Confidential Information.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.75%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;">Assignment</font><font style="letter-spacing:-0.1pt;font-weight:bold;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">of</font><font style="letter-spacing:-0.1pt;font-weight:bold;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Inventions.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Disclosure of Inventions</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant shall promptly and fully disclose to the Company</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">all</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">ideas,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">improvements,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">inventions,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">know-how,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">techniques</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">works</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">authorship developed by Consultant during his or her performance of the Services for the</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company (the &#8220;Service Product&#8221;).</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant agrees to keep and maintain adequate and</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">current</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">records</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(in</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">form</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">notes,</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">sketches,</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">drawings</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">form</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">may</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">required by the Company) of all work performed relating to the Services, including all</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proprietary information developed relating thereto, and such records shall be available to</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">remain the sole property of</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the Company at all times.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.78%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Inventions Assigned to the Company</font><font style="font-size:12pt;color:#000000;">. Consultant agrees that any and all Service</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Product shall be the sole and exclusive property of the Company.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant hereby</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assigns to the Company all his or her right, title and interest in and to any and all Service</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Product.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant explicitly acknowledges and agrees that all works of authorship</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">contained in the Service Product are &#8220;works for hire&#8221; under the copyright laws of the</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">United States, and that</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the Company shall own the copyright in all such works of</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">authorship.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:3pt;margin-bottom:0pt;margin-left:8.52%;margin-right:1.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant further agrees that the Company is and shall be vested with all rights, title and<font style="letter-spacing:-2.85pt;"> </font>interests,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>patent,<font style="letter-spacing:0.05pt;"> </font>copyright,<font style="letter-spacing:0.05pt;"> </font>trade<font style="letter-spacing:0.05pt;"> </font>secret<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>trademark<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Consultant&#8217;s<font style="letter-spacing:-0.05pt;"> </font>Service<font style="letter-spacing:-0.1pt;"> </font>Product under<font style="letter-spacing:-0.1pt;"> </font>this<font style="letter-spacing:-0.05pt;"> </font>Agreement.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.49%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:12pt;color:#000000;">Obtaining Intellectual Property Protection</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant agrees to assist the Company</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in every proper way to obtain and enforce United States and foreign proprietary rights</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">relating to the Service Product in any and all countries.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">To that end, Consultant agrees to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">execute,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">verify</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">deliver</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">documents</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">perform</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">acts</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(including</font><font style="font-size:12pt;letter-spacing:-2.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">appearing as a witness) as the Company may reasonably request for use in applying for,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">obtaining,</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">perfecting,</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">evidencing,</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">sustaining</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">enforcing</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proprietary</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">rights</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assignment</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">thereof.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">In</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">addition,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">agrees</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">execute,</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">verify</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">deliver</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assignments of such proprietary rights to the Company or its designee.</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Consultant&#8217;s</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">obligation</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assist</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">with</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">respect</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">proprietary</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">rights</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">all</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">countries</font><font style="font-size:12pt;letter-spacing:-2.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">shall continue beyond the termination of his or her engagement, but the Company shall</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">compensate Consultant at a reasonable rate after such termination for the time actually</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">spent</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by Consultant</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">at the</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">request</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">on such</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">assistance.</font></p></td>
<td valign="top" style="width:1.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.52%;margin-right:1.46%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Company is unable for any reason, after reasonable effort, to secure<font style="letter-spacing:0.05pt;"> </font>Consultant&#8217;s<font style="letter-spacing:-0.5pt;"> </font>signature<font style="letter-spacing:-0.5pt;"> </font>on<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.45pt;"> </font>document<font style="letter-spacing:-0.4pt;"> </font>needed<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>connection<font style="letter-spacing:-0.5pt;"> </font>with<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>actions<font style="letter-spacing:-0.4pt;"> </font>specified<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-2.9pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>preceding<font style="letter-spacing:0.05pt;"> </font>paragraph,<font style="letter-spacing:0.05pt;"> </font>Consultant<font style="letter-spacing:0.05pt;"> </font>hereby<font style="letter-spacing:0.05pt;"> </font>irrevocably<font style="letter-spacing:0.05pt;"> </font>designates<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>appoints<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>Company and its duly authorized officers and agents as his or her agent and attorney in<font style="letter-spacing:0.05pt;"> </font>fact,<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>act<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>his<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>her<font style="letter-spacing:-0.25pt;"> </font>behalf<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>execute, verify<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>file,<font style="letter-spacing:-0.15pt;"> </font>with<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>same<font style="letter-spacing:-0.2pt;"> </font>legal force<font style="letter-spacing:-2.9pt;"> </font>and effect as if executed by him or her, any such documents and to do all other lawfully<font style="letter-spacing:0.05pt;"> </font>permitted acts to further the purposes of the preceding paragraph.<font style="letter-spacing:0.05pt;"> </font>Consultant hereby<font style="letter-spacing:0.05pt;"> </font>waives<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>quitclaims<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>all<font style="letter-spacing:-0.15pt;"> </font>claims<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>nature<font style="letter-spacing:-0.15pt;"> </font>whatsoever<font style="letter-spacing:-0.05pt;"> </font>which<font style="letter-spacing:-2.9pt;"> </font>Consultant now or may hereafter have for infringement of any proprietary rights assigned<font style="letter-spacing:-2.85pt;"> </font>to the<font style="letter-spacing:-0.05pt;"> </font>Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:36.9%;margin-right:42.62%;text-indent:-0.28%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="PMV_SAB_Agr(R_Heyman).Amdt.2021.07.16"></a><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>AMENDMENT<font style="letter-spacing:0.55pt;"> </font>TO<font style="letter-spacing:0.05pt;"> </font>SAB<font style="letter-spacing:1.05pt;"> </font>AGREEMENT</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;margin-right:8.52%;text-indent:7.07%;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment to the SAB Agreement (this <font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">"Amendment") </font>is hereby made and<font style="letter-spacing:0.05pt;"> </font>entered<font style="letter-spacing:0.15pt;"> </font>into<font style="letter-spacing:-0.5pt;"> </font>as<font style="letter-spacing:-0.85pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>July<font style="letter-spacing:-0.75pt;"> </font>16,<font style="letter-spacing:-0.6pt;"> </font>2021,<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.85pt;"> </font>and<font style="letter-spacing:-0.7pt;"> </font>between<font style="letter-spacing:-0.3pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">PMV</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.5pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Pharmaceuticals,</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-1.55pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Inc.</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.4pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">("PMV</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.4pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Pharma"</font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:1.05%;text-indent:0%;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Richard</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.35pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Heyman,</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.3pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">Ph.D.</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;">("Heyman").</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:34.32%;margin-right:53.12%;text-indent:0%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;margin-right:8.33%;text-indent:7.08%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS,<font style="letter-spacing:0.05pt;"> </font><font style="font-family:Times New Roman;font-weight:normal;">PMV</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Pharma</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">and</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Heyman,</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Chairman</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">of PMV</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Pharma's</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Board</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">of</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Directors, entered into the Amended &amp; Restated SAB Consulting Agreement as of May 15, 2021</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">(the</font><font style="letter-spacing:-0.5pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-size:10.5pt;">"SAB Agreement");</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:8.72%;text-indent:7.06%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-family:Times New Roman;font-weight:normal;">PMV Pharma and Heyman desire to amend certain of the terms of the SAB</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Agreement</font><font style="letter-spacing:0.4pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">as</font><font style="letter-spacing:-0.65pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">set</font><font style="letter-spacing:-0.35pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">forth</font><font style="letter-spacing:-0.25pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">herein;</font><font style="letter-spacing:0.25pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">and</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.07%;margin-right:8.52%;text-indent:7.01%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, <font style="font-family:Times New Roman;font-weight:normal;">in consideration of the foregoing premises and the Parties mutual</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">desire to continue the discussions referenced in the SAB Agreement and herein, it is hereby</font><font style="letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">agreed</font><font style="letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">as</font><font style="letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">follows:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.21%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11.5pt;">The</font><font style="font-size:11.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:11.5pt;">SAB</font><font style="font-size:11.5pt;letter-spacing:0.95pt;"> </font><font style="font-size:11.5pt;">Agreement</font><font style="font-size:11.5pt;letter-spacing:1.35pt;"> </font><font style="font-size:11.5pt;">is</font><font style="font-size:11.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:11.5pt;">hereby</font><font style="font-size:11.5pt;letter-spacing:1.25pt;"> </font><font style="font-size:11.5pt;">amended</font><font style="font-size:11.5pt;letter-spacing:0.8pt;"> </font><font style="font-size:11.5pt;">as</font><font style="font-size:11.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:11.5pt;">follows:</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.15%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.49%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:10.5pt;font-family:Arial;">Compensation:</font><font style="font-weight:bold;font-size:10.5pt;font-family:Arial;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">Heyman shall, effective</font><font style="font-size:11.5pt;letter-spacing:2.85pt;"> </font><font style="font-size:11.5pt;">as of September</font><font style="font-size:11.5pt;letter-spacing:2.9pt;"> </font><font style="font-size:11.5pt;">1, 2021, waive any</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">further</font><font style="font-size:11.5pt;letter-spacing:1.05pt;"> </font><font style="font-size:11.5pt;">compensation</font><font style="font-size:11.5pt;letter-spacing:2.45pt;"> </font><font style="font-size:11.5pt;">for</font><font style="font-size:11.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:11.5pt;">his</font><font style="font-size:11.5pt;letter-spacing:0.65pt;"> </font><font style="font-size:11.5pt;">continued</font><font style="font-size:11.5pt;letter-spacing:1.05pt;"> </font><font style="font-size:11.5pt;">services</font><font style="font-size:11.5pt;letter-spacing:1pt;"> </font><font style="font-size:11.5pt;">on</font><font style="font-size:11.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:11.5pt;">PMV</font><font style="font-size:11.5pt;letter-spacing:1.1pt;"> </font><font style="font-size:11.5pt;">Pharma's</font><font style="font-size:11.5pt;letter-spacing:1.3pt;"> </font><font style="font-size:11.5pt;">SAB,</font><font style="font-size:11.5pt;letter-spacing:1.1pt;"> </font><font style="font-size:11.5pt;">provided</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">that Heyman</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">shall</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">retain all rights to any and all SAB compensation</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">accrued</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="color:#1C1A1A;font-size:11.5pt;">on </font><font style="font-size:11.5pt;">or</font><font style="font-size:11.5pt;letter-spacing:-2.75pt;"> </font><font style="font-size:11.5pt;">prior</font><font style="font-size:11.5pt;letter-spacing:-0.15pt;"> </font><font style="font-size:11.5pt;">to</font><font style="font-size:11.5pt;letter-spacing:-0.4pt;"> </font><font style="font-size:11.5pt;">that</font><font style="font-size:11.5pt;letter-spacing:0.1pt;"> </font><font style="font-size:11.5pt;">date.</font></p></td>
<td valign="top" style="width:10.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#2F2F2F;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11.5pt;">Except</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">as expressly provided</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">in this Amendment,</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">all other terms, conditions</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">and</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">provisions</font><font style="font-size:11.5pt;letter-spacing:1.35pt;"> </font><font style="font-size:11.5pt;">of</font><font style="font-size:11.5pt;letter-spacing:0.35pt;"> </font><font style="font-size:11.5pt;">the</font><font style="font-size:11.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:11.5pt;">SAB</font><font style="font-size:11.5pt;letter-spacing:0.8pt;"> </font><font style="font-size:11.5pt;">Agreement</font><font style="font-size:11.5pt;letter-spacing:1.2pt;"> </font><font style="font-size:11.5pt;">shall</font><font style="font-size:11.5pt;letter-spacing:1pt;"> </font><font style="font-size:11.5pt;">continue</font><font style="font-size:11.5pt;letter-spacing:1.2pt;"> </font><font style="font-size:11.5pt;">in</font><font style="font-size:11.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:11.5pt;">full</font><font style="font-size:11.5pt;letter-spacing:0.45pt;"> </font><font style="font-size:11.5pt;">force</font><font style="font-size:11.5pt;letter-spacing:0.55pt;"> </font><font style="font-size:11.5pt;">and</font><font style="font-size:11.5pt;letter-spacing:0.65pt;"> </font><font style="font-size:11.5pt;">effect</font><font style="font-size:11.5pt;letter-spacing:0.9pt;"> </font><font style="font-size:11.5pt;">as</font><font style="font-size:11.5pt;letter-spacing:0.25pt;"> </font><font style="font-size:11.5pt;">provided</font><font style="font-size:11.5pt;letter-spacing:-2.7pt;"> </font><font style="font-size:11.5pt;">therein.</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">Each capitalized</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">term used</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">and not defined</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">herein</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">shall have the respective</font><font style="font-size:11.5pt;letter-spacing:-2.75pt;"> </font><font style="font-size:11.5pt;">meaning</font><font style="font-size:11.5pt;letter-spacing:0.5pt;"> </font><font style="font-size:11.5pt;">assigned</font><font style="font-size:11.5pt;letter-spacing:0.2pt;"> </font><font style="font-size:11.5pt;">to</font><font style="font-size:11.5pt;letter-spacing:-0.5pt;"> </font><font style="font-size:11.5pt;">such term</font><font style="font-size:11.5pt;letter-spacing:0.05pt;"> </font><font style="font-size:11.5pt;">in</font><font style="font-size:11.5pt;letter-spacing:-0.2pt;"> </font><font style="font-size:11.5pt;">the SAB Agreement.</font></p></td>
<td valign="top" style="width:13.28%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F2F2F;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:4.16%;text-indent:7.06%;font-weight:bold;color:#2F2F2F;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">IN<font style="letter-spacing:0.3pt;"> </font>WITNESS<font style="letter-spacing:0.3pt;"> </font>WHEREOF,<font style="letter-spacing:0.4pt;"> </font><font style="font-family:Times New Roman;font-weight:normal;">PMV</font><font style="letter-spacing:0.7pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Pharma</font><font style="letter-spacing:0.65pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">and</font><font style="letter-spacing:0.4pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Heyman</font><font style="letter-spacing:0.55pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">have</font><font style="letter-spacing:0.1pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">entered</font><font style="letter-spacing:0.55pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">into</font><font style="letter-spacing:0.15pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">this</font><font style="letter-spacing:-2.9pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Amendment</font><font style="letter-spacing:0.45pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">effective</font><font style="letter-spacing:0.1pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">as</font><font style="letter-spacing:-0.45pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">of</font><font style="letter-spacing:-0.65pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">the</font><font style="letter-spacing:-0.25pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">date</font><font style="letter-spacing:-0.55pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">first</font><font style="letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">set</font><font style="letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">forth</font><font style="letter-spacing:-0.4pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">above.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<div style="width:100%;">
<div style="float:left;width:36%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><img src="gfifg3pi0xun000002.jpg" title="" alt="" style="width:569px;height:141px;"></p></div></div>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>pmvp-ex211_332.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex211_332.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-weight:bold;color:#000000;font-size:10pt;">SUBSIDIARIES OF THE REGISTRANT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>pmvp-ex231_918.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex231_918.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We consent to the incorporation by reference in the Registration Statements: (Form S-3 No. 333-260012) of PMV Pharmaceuticals, Inc., (Form S-8 No. 333-249094) pertaining to the 2013 Equity Incentive Plan, 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan of PMV Pharmaceuticals, Inc., (Form S-8 No. 333-256346) pertaining to the 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan of PMV Pharmaceuticals, Inc., and (Form S-8 No. 333-262308) pertaining to the 2020 Equity Incentive Plan of our reports dated March 1, 2022, with respect to the financial statements of PMV Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of PMV Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, Pennsylvania<br />March 1, 2022</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-weight:bold;">&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>pmvp-ex311_537.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex311_537.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David H. Mack, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of PMV Pharmaceuticals, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) </font><font style="font-size:10pt;">and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))</font><font style="font-size:10pt;color:#000000;"> for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:5pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2022</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:42.35%;">
<tr>
<td style="width:1.2%;"></td>
<td style="width:6.56%;"></td>
<td style="width:34.59%;"></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMV PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David H. Mack</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David H. Mack, Ph.D.</p></td>
</tr>
<tr style="height:33.15pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;margin-right:8.38%;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer<font style="font-size:12pt;color:#000000;"><br /></font>(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>pmvp-ex312_335.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex312_335.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Winston Kung, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of PMV Pharmaceuticals, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) </font><font style="font-size:10pt;">and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))</font><font style="font-size:10pt;color:#000000;"> for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.02%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:5pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2022 </p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:42.35%;">
<tr>
<td style="width:1.2%;"></td>
<td style="width:6.56%;"></td>
<td style="width:34.59%;"></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMV PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Winston Kung</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Winston Kung</p></td>
</tr>
<tr style="height:55.5pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;margin-right:8.38%;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and Chief Financial Officer<font style="font-size:12pt;color:#000000;"><br /></font>(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>pmvp-ex321_336.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex321_336.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.41%;">In connection with the Annual Report of PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David H. Mack, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.7%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:5pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2022 </p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:44.7%;">
<tr>
<td style="width:1.27%;"></td>
<td style="width:6.92%;"></td>
<td style="width:36.51%;"></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMV PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David H. Mack</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David H. Mack, Ph.D.</p></td>
</tr>
<tr style="height:33.15pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;margin-right:8.85%;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer<font style="font-size:12pt;color:#000000;"><br /></font>(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.41%;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>pmvp-ex322_337.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
pmvp-ex322_337.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Section1"></a>Exhibit 32.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.41%;">In connection with the Annual Report of PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Winston Kung, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.7%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:5pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2022 </p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:44.7%;">
<tr>
<td style="width:1.27%;"></td>
<td style="width:6.92%;"></td>
<td style="width:36.51%;"></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMV PHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Winston Kung</p></td>
</tr>
<tr style="height:14.25pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Winston Kung</p></td>
</tr>
<tr style="height:60pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-left:2.65pt;padding-Right:2.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:1pt;margin-top:2pt;margin-left:0pt;;margin-right:8.85%;text-indent:0pt;;text-align:left;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and Chief Financial Officer<font style="font-size:12pt;color:#000000;"><br /></font>(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.41%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gv1ubg3hw41v000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000005.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D 24# 1$  A$! Q$!_\0
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M#\6MVTFEE3^E<E!/4@@A*22F3$E)TZ<H!)"<@L!1)!)0= +*)*+T$!918 A
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MHWHMMR1X9K24L H<MBCH!Q: F*DROTVC] .3BT4TWE)ITTW>IU.)6M1,F6+
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M>:];/<<.3H@RH;E($*4H:2G7$N%DWOU8KF9&Y9\D_@NTZYVNFK&9VT-&>D*
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MPKVRQ0^ 'R9&QCFH85+25</9%4;L6+3&*G%*]LFG!6#4>ZAK?B2DP0C'2G)
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MUFUP*6NK(P)YH>YQ2>.@2&H"^!.D!?E!SQ@J<;[KFH?3=MD\]Z<;+?NN)/\
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MVW\Q#M;'#AB>?488PZZ::6\.O/P0I]:^[_EY2%?:T*9"6,"8@H@&]_\ "46
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M[[7\)DTH@\UD$797B6UHL?7" 2%P0DJ'6(+I.PJXO(53"K&'9K>>\QY<L9G
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M , 8 P!@# & :,NQ\^MC<*OO(1[]Z<,[4?"N/FSGXO[M?U,V2YHYC & , 8
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M$WB(T2<+7D(6S0#%K?C_ *>GA[?#H!Y]P5P]'H.IM)^_ZQ[4$=?R>BZ?+\6
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M?^H&^F]>&P[]3AQR[PX@QENH+["6'T?(9<8=K6NHSXHU=P6_;L!8M>'3U=<
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M\7+6E_FEF0N+,KI%#5;.@*D[<Z/CVA0K8\:ND+ B+>DQYK:-6^,Z8*G9SFB
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MJ.L'V0($$C0-"0]P%4J%*3AJ6UAJ4W2=G%TE:Z<E_P#'5U+XZV)S.O\ X/\
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% 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gv1ubg3hw41v000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H!,L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJ"[O;73[9KF]N8;:!<;I9I BC)P,D\=: )Z*0$$ @Y!Z$4M !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT0_\]H_^^A1]HA_Y[1_]]"L&BCV"[A]8?8WOM$/_ #VC_P"^A1]HA_Y[1_\
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M:%8>'[ 6EC$5!.Z21CEY6[LQ[FM*BBO5225D>2VV[L****8@HHHH X7XE?\
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M!W Q@%NI' _*GW-M;WEN]O=01SPN,/'*@96^H/!H5-\DH][_ (@ZBYXR[6_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGIDA0.:MT[.UB;J]SAKGXK^%$\.G4HM0CEF:/*67_+8OCA"O;GC/3WIOPO\
M#4FE_#^TM=6ME,LTC7)@F0'R]W &#T.!GVR:ZF/P]HL5[]MCT?3TN\Y\];9
M^?\ >QFM*DHN]V-R5K(X/_A$I?\ A;']K?V5;_V/_9?D[\1[?-WYQLZYQWQ7
M<06\%M'Y<$,<29SMC4*,_A4E%4DD)R;"BBBF2%%%% %W3/\ CY;_ '#_ #%:
MM96F?\?+?[A_F*U:XZWQG;0^ ****R-C,\0Z.GB#P]?Z1),T*7D+0M(HR5!X
M)%8OA3X;>%_!RH^FZ<KW:CF[N/WDI]P3PO\ P$"NMHH \Y\8?#^Y_M)_$_A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-^(
M-[:V7_"+?:=.BO?/\0VD,7F.R^0YWXE&.I&.AXYKLJX[X@:H^E_\(MLM;2X^
MU>(;2V;[3")/+#;OG3/W7&.&[5V- !1110!DS65PT\C+'D%B1\P]:9]AN?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9AME@?NK+6M5CQM\/_[9N%UW0)DT[Q' /EFQB.Y7_GG*.X]^H_ 8YG0_$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFOX O]-^%>L:-;N-0UK46\^=PP422EE) +$#  [XSSZXJ6K[(M.WQ/J2Z/\
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M^_\ '7H%>?\ QI_Y)=J([F:V _[_ "4 >@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %96I_
M\?*_[@_F:U:KSV<=PX=RP(&.#6E.2C*[,ZL7*-D8M%:O]F0_WI/S'^%']F0_
MWI/S'^%='MH'-["9E45J_P!F0_WI/S'^%']F0_WI/S'^%'MH!["9E45J_P!F
M0_WI/S'^%']F0_WI/S'^%'MH!["9E45J_P!F0_WI/S'^%']F0_WI/S'^%'MH
M!["9E45J_P!F0_WI/S'^%']F0_WI/S'^%'MH!["9E45J_P!F0_WI/S'^%']F
M0_WI/S'^%'MH!["9E45J_P!F0_WI/S'^%']F0_WI/S'^%'MH!["9E45J_P!F
M0_WI/S'^%']F0_WI/S'^%'MH!["9E45J_P!F0_WI/S'^%']F0_WI/S'^%'MH
M!["99M_^/:+_ '!_*I*:BA$5!T48&:=7(]SL6B"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\_^-'_),[W_ *^+;_T<E>@5Y_\ &;_DG%Q_U]VW_HY: /0**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O/_ (R_\D^D'8WMKG_OZM>@
M5Y_\9/\ D0P.QO[4'_OZM 'H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M3&EC0X>15/H3B@+CZ*C^T0_\]H_^^A1]HA_Y[1_]]"G9BYD245']HA_Y[1_]
M]"C[1#_SVC_[Z%%F',B2BH_M$/\ SVC_ .^A1]HA_P">T?\ WT*+,.9$E%1_
M:(?^>T?_ 'T*/M$/_/:/_OH468<R)**C^T0_\]H_^^A1]HA_Y[1_]]"BS#F1
M)14?VB'_ )[1_P#?0H^T0_\ /:/_ +Z%%F',B2BH_M$/_/:/_OH4?:(?^>T?
M_?0HLPYD245']HA_Y[1_]]"C[1#_ ,]H_P#OH468<R)**C^T0_\ /:/_ +Z%
M'VB'_GM'_P!]"BS#F1)12 @@$'(/0BEI#"BBB@ HHHH **** "BBB@ HHHH
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MS@^M6J "BBB@04453L-5L-56X:PNHKE;>8P2M$V0K@ E<],@,*!ERBBN(O\
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MB?\ /[_Y"?\ PKS.BC^RJ/=_A_D']KU^R_'_ #/3/^$KT3_G]_\ (3_X4?\
M"5Z)_P _O_D)_P#"O,Z*/[*H]W^'^0?VO7[+\?\ ,],_X2O1/^?W_P A/_A1
M_P )7HG_ #^_^0G_ ,*\SHH_LJCW?X?Y!_:]?LOQ_P STS_A*]$_Y_?_ "$_
M^%'_  E>B?\ /[_Y"?\ PKS.BC^RJ/=_A_D']KU^R_'_ #/3/^$KT3_G]_\
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M_"5Z)_S^_P#D)_\ "O,Z*/[*H]W^'^0?VO7[+\?\STS_ (2O1/\ G]_\A/\
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M@**/[,P_G]X?VIB.Z^X[_P#X3C3/^>%W_P!\+_\ %4?\)QIG_/"[_P"^%_\
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M^*K@**/[,P_G]X?VIB.Z^X[_ /X3C3/^>%W_ -\+_P#%4?\ "<:9_P \+O\
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M04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**H0445!>7D&GV<MW=2>7!$NYVP3@?0<TFTE=C2;=D3T5S/_  L+PM_T%/\
MR7E_^)JYIGBW0]8O!:6%]YTY4MM\IUX'7D@"LE7I2=E)?>C5X>M%7<';T9M4
M445L8A115/\ M2R_M;^R_._TWRO.\K:?N9QG.,?K2;2W&DWL7****8@HHHH
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MK_N#^9K5K,U&*1[A2D;,-G4#/<UK1^(RK? 4*JZCIECJUFUGJ-I#=6[<F.9
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M3@#KP.:FK'\5_P#(IZK_ ->LG\J^PG)QBVNA\73BI347U*/_  L+PM_T%/\
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M?]WEZ'5@?]XAZG?T445\L?6A7 >./^0U#_U[K_Z$U=_7 >./^0U#_P!>Z_\
MH35Z&6?[Q\F>=FG^[OU1S-%%%?1GS)D^(/#]IXDL([.\DFCC242@PL <@$=P
M>/F-:U%%2HI-R6[*<Y.*B]D8MKX9L[+7Y]8M9;B&6X'[V%6'E/[D8SG//7^=
M4[OP-I=Q>2W5O/>V$DIS(+.;RPY]Q@_I7345FZ%-JS1HJ]5.ZEY&7I.B:=X=
MLI([*(HI^>61B69\=R?Z5R=^=.\7^.-)%B5N(;%#+=3*/E(R"BY[\_S->@$
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MX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O6-(_Y MA_U[Q_^@BO)Z]8TC_D"V'_7O'_Z"*\C-O@CZGL9/\<O0H^+?"]C
MXQ\.7.BZ@76*;!62/[T;@Y##\?TS7"QV'Q=\+Q+%9WND>);.)0J+<+Y,Y4=L
MY S[EC71?$OPC>^+?#D2:5<"#5;&X2[M&8X5G7^$G]1[@5SMO\3/&%E"MKJ_
MPVUF34% 5GLE+PR-Z[@I"C\37AGOFMX<\6VGQ!MM7\+:]I,^F:I%$8[VP=S\
MT;<%E88..1^8P3G-<;\#/">CK>ZSK(MW^W:?J4UI;OYC86/:!@C.#U/)KJ/
M>@>(+KQEJOCCQ+:)IUU>VZVMM8(X8Q1 J?G([_(OYG@<"LGX?Q:OX<\0>(_#
M%UH6JP+J.H7%Q;:HD):V12IVDR= ?E&/<@<&@#GM2M_!9U;4)?B5XI&K:L]R
MWE66GRS/%;)_"@"+PPY&#_/-;/P:U-/^$M\2Z-IMQJ3:#!'#-9PZCGS(LCG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /&JP_&/_(GZI_UP-;E8?C'_ )$_5/\ K@:^NK?PI>C/C:'\6/JC,T7P
M9H\WAVV-]:K=7-S CRSR$E\E1PI[ =!CTJAX<MI]8\):QX?FO61;6X:V2X9=
MQ$8(.,9]B/H:=H]SXPM_#]A;VFGVEW');1M!=-,%\M2H(#*>21TX]*OP^"D_
MX0ZXT>XN-UU<N9Y;@#_EKD$'Z< ?GZUQ1@I6Y(='?I?RO^IW2FXW]I/JK=;:
M[VZ>A&/ASI7V-%^TWAO$0*EWYQW+@<8'0#V].]6O VJW>IZ++'?/YES9SM;M
M)GE\8P3[\X_"J44WCF"P73AIUF\JKY:WYG&W'3.WKG\/PJU%X+B3P9+H9N6\
MZ8F5[@#K+P<_3@#Z5<(VGS4H6LG?I?LO^"14E>#C6FG=JW6W=_\  #Q7H>O:
MQ',EAJB16ICP;0ICS3W!<<X/3'2K7@S4[?4_#D)M[46HMF-N\(.0K*!T/?J#
M^-9L=QXYBLUL/[,LVF5=@OS<#;Z;MO7/X?A6UX9T)?#VC+9^9YLK.99I/[SG
MK^@ _"JIINMSQ36FM_PM?]-"*C4:/))IZZ6_&]OUU-BO-/$VC26OBV*RT^Y-
MM;Z_\ETBCIM(+$?7^I]:]+KF->TF^O?%F@WMO!OM[5G,S[U&W.,<$Y/X5>*I
M\\%IU7YZ_@1A*G)4>O1_E=?B=!96<&GV4-I;1A(85"(H["L[7_$5IH%LIE#3
M74ORP6T?+RM[#T]ZUV)"DA=Q X'K7FMA9>+K76KG5[GP[#=WLQ^1Y+J/]RO]
MU1NX],__ %Z=>I*FE&"W\KV^[\!8>G&HW*;V\[7^_P#$Z7PSHMY%=W.N:NP.
MIWB@&,=((^R#\AGZ5>U_Q%::!;*90TUU+\L%M'R\K>P]/>J^D:AXDN+MDU31
M(K2 1DATN%<EN,# /?FN4L++Q=:ZU<ZO<^'8;N]F/R/)=1_N5_NJ-W'IG_Z]
M9.I[.FHTT]>MG]YLJ?M*CE5:TZ77R1T/A_0[V.2]UO5B#JE[&5\I>D"=D'OP
M/R_&H_AL5/@RWVCD2R;OKN_PQ5_1M0\1W-\8]5T6*SM]A(E2X5SNXP, GWK*
MAT[Q#X8OKQ-&LX=1TVYE,R1-*(VA8]>3V_\ K>]$4H.,XIV5T]'?6VO<)-S4
MH2:N[-:JVE]+["P M\6[G;T73ANP>G*__6IGPQPGAZ[B<$3QWKB4'KG:O^?P
MK2\-:)>VMY?:OJ[QMJ5Z0&6+E8D'11^GY"JEWH.KZ/K=QJWAPP2)=G-S93':
M&;^\I]>3^9ZU,83BU5MU>G6S_P"&*E.$DZ5^D=>EU_PYUSNL:,[L%51DL3@
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M_7H_LO\ Z;?^._\ UZ/:P[A[&?8SJ*T?[+_Z;?\ CO\ ]>C^R_\ IM_X[_\
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M%%% !1110 4444 %=-X'_P"0U-_U[M_Z$M<S73>!_P#D-3?]>[?^A+7+C?\
M=Y>AU8'_ 'B'J=_1117RQ]:%<!XX_P"0U#_U[K_Z$U=_7 >./^0U#_U[K_Z$
MU>AEG^\?)GG9I_N[]4<S1117T9\R%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7K&D?\@6P_Z]X__017D]>L:1_R!;#_ *]X_P#T$5Y&;?!'U/8R
M?XY>A=HHHKPSWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN=1O#)"\CDF4DR <;6)ZKSTK<\/V>HZ=X&6XTV>>]O+BWC>&&XE&R(XZ+G@
M9SCV%9WA^TEG^%.H6R(SRXG 5!DD@]!^502:B^L?#,V.CM*]U9Q11W<2H0P7
MG('KT[=@:S@U&TWOR?,TFG+F@MN?Y6)+J)+6S,U[X]N$U()EHXK@%%?TV+V[
M5)=W-UXB^%GV^ZNYHYXE=I#$=HFVDKA@.W?'J*2SU;PP;+[/H.@M<:D8]BQ?
M9<NC=/G<] #U.:/#\3W?PFO;6)&:9%F0HHRVX'=C'KR*(V;<4[IQ>S;UT_$)
M7BE*2LU);I+37HN@Z&WN-)^%T]Y#J5ZTDUM%(FZ8_N.1PF/NCFKVJ:SJ7V+P
M_I&FS;+_ %*%2]R_S%%"@LW/4GG\C68=7L]0^%5U:6[L9[*UBCG1E(VMD#\>
MAJWJEM>6L'AGQ#9V[W(L8%6>*,98HR $@?0G\Q5<WN^X].5;>NI/+>7[Q:\T
MM_30?J>C:WX>TZ75;'Q#>W<ENOF307;;TD4?>P/X>,_XTGB/7+VYT_PU>Z7*
MT$M[<( F\[26 ^5L=0":36/&5MKFDSZ7HEM=75]=H82GE%1&&X.XGIQGVIFM
M6#:7;>"[%F#/!?0HQ'0G(S^M.;C:7LG[ME]]Q04KQ]JO>N^G2W43Q!IVL^'-
M*;6X?$=[<3P,AEBF_P!4X+!>$Z#DUW5K-]IM(9P /-C5^#D<C-<]\0O^1&U'
M_ME_Z-2MC1?^0%I__7M'_P"@BNJFE"LX+:R?XLY:LG.A&<M[M?@B]11174<@
M4444 %%%% !1110 4444 %=-X'_Y#4W_ %[M_P"A+7,UTW@?_D-3?]>[?^A+
M7+C?]WEZ'5@?]XAZG?T445\L?6A7 >./^0U#_P!>Z_\ H35W]<!XX_Y#4/\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XU1117V9\0%%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XU1117V9\0%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M=-X'_P"0U-_U[M_Z$M<S73>!_P#D-3?]>[?^A+7+C?\ =Y>AU8'_ 'B'J=_1
M117RQ]:%<!XX_P"0U#_U[K_Z$U=_7 >./^0U#_U[K_Z$U>AEG^\?)GG9I_N[
M]4<S1117T9\R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K&D?\
M@6P_Z]X__017D]>L:1_R!;#_ *]X_P#T$5Y&;?!'U/8R?XY>A=HHHKPSWPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XS_A O\ J)?^0/\
M[*C_ (0+_J)?^0/_ +*NSHKM_M#$_P WX+_(X?[-PO\ +^+_ ,SC/^$"_P"H
ME_Y _P#LJ/\ A O^HE_Y _\ LJ[.BC^T,3_-^"_R#^S<+_+^+_S.,_X0+_J)
M?^0/_LJ/^$"_ZB7_ ) _^RKLZ*/[0Q/\WX+_ "#^S<+_ "_B_P#,XS_A O\
MJ)?^0/\ [*C_ (0+_J)?^0/_ +*NSHH_M#$_S?@O\@_LW"_R_B_\SC/^$"_Z
MB7_D#_[*C_A O^HE_P"0/_LJ[.BC^T,3_-^"_P @_LW"_P OXO\ S.,_X0+_
M *B7_D#_ .RH_P"$"_ZB7_D#_P"RKLZ*/[0Q/\WX+_(/[-PO\OXO_,XS_A O
M^HE_Y _^RH_X0+_J)?\ D#_[*NSHH_M#$_S?@O\ (/[-PO\ +^+_ ,SC/^$"
M_P"HE_Y _P#LJ/\ A O^HE_Y _\ LJ[.BC^T,3_-^"_R#^S<+_+^+_S.,_X0
M+_J)?^0/_LJ/^$"_ZB7_ ) _^RKLZ*/[0Q/\WX+_ "#^S<+_ "_B_P#,XS_A
M O\ J)?^0/\ [*C_ (0+_J)?^0/_ +*NSHH_M#$_S?@O\@_LW"_R_B_\SC/^
M$"_ZB7_D#_[*C_A O^HE_P"0/_LJ[.BC^T,3_-^"_P @_LW"_P OXO\ S.,_
MX0+_ *B7_D#_ .RH_P"$"_ZB7_D#_P"RKLZ*/[0Q/\WX+_(/[-PO\OXO_,XS
M_A O^HE_Y _^RH_X0+_J)?\ D#_[*NSHH_M#$_S?@O\ (/[-PO\ +^+_ ,SC
M/^$"_P"HE_Y _P#LJU-#\,_V->O<_:_.W1F/;Y6W&2#GJ?2M^BHGC:\XN,I:
M/R1<,#AZ<E*,=5YO_,****Y3K"BBB@ JCJ6D6>JQ;+J++#[KKPR_0U>HJHRE
M%\T79DRA&:Y9*Z.#O?!%Y$2UG,DZ]E;Y6_PK'ET'5H3AM/G/^XN[^6:]4HKT
M(9I6BK2LSS:F4T9.\6T>3_V1J?\ T#KO_OPW^%']D:G_ - Z[_[\-_A7K%%:
M?VM/^5&?]CP_F9Y/_9&I_P#0.N_^_#?X4?V1J?\ T#KO_OPW^%>L44?VM/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_SVC_[Z%%F',B2BH_M$/_/:/_OH4?:(?^>T?_?0HLPYD245']HA_P">T?\
MWT*/M$/_ #VC_P"^A19AS(DHIJR(^=CJV.N#FG4AA113)I4@@DFE;;'&I9CC
M. !DT)7T0-VU8^BL;_A*]$_Y_?\ R$_^%'_"5Z)_S^_^0G_PK;ZM6_D?W,P^
MM4/YU]Z-FBL;_A*]$_Y_?_(3_P"%'_"5Z)_S^_\ D)_\*/JU;^1_<P^M4/YU
M]Z-FBL;_ (2O1/\ G]_\A/\ X4?\)7HG_/[_ .0G_P */JU;^1_<P^M4/YU]
MZ-FBL;_A*]$_Y_?_ "$_^%'_  E>B?\ /[_Y"?\ PH^K5OY']S#ZU0_G7WHV
M:*QO^$KT3_G]_P#(3_X4?\)7HG_/[_Y"?_"CZM6_D?W,/K5#^=?>C9HK&_X2
MO1/^?W_R$_\ A1_PE>B?\_O_ )"?_"CZM6_D?W,/K5#^=?>C9HK&_P"$KT3_
M )_?_(3_ .%'_"5Z)_S^_P#D)_\ "CZM6_D?W,/K5#^=?>C9HK&_X2O1/^?W
M_P A/_A1_P )7HG_ #^_^0G_ ,*/JU;^1_<P^M4/YU]Z-FBL;_A*]$_Y_?\
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M_"CZM6_D?W,/K5#^=?>C9HK&_P"$KT3_ )_?_(3_ .%'_"5Z)_S^_P#D)_\
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M6T[_ '(IKA$9OH"<FBZ%9E^BCJ,BN;U[Q)<VFL6N@Z-:1W>KW,9F(F<I%;Q
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M2977G@AV(QR:2BT4Y)ZW.(C-QH%_X>/B#PWH\MN+J.WL=3TF0QE'<;5)CX+
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M'_GG&@5?R%.@MX;6!8;>&.&).%2-0JCZ 4H4G&?,WW_&W^0ZE92AR)=OPO\
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M** ,R[M)Y;EW1,J<8.1Z5#]AN?\ GG_X\*V:*V5:25C%T(MW,;[#<_\ //\
M\>%'V&Y_YY_^/"MFBCV\A?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
M'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X
M\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5X
MF-]AN?\ GG_X\*/L-S_SS_\ 'A6S11[>0?5XF-]AN?\ GG_X\*/L-S_SS_\
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MO. _X0?4_P#GO:?]]M_\31_P@^I_\][3_OMO_B:[^BC^T\1Y?<']EX?L_O.
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M/^$'U/\ Y[VG_?;?_$T?\(/J?_/>T_[[;_XFN_HH_M/$>7W!_9>'[/[S@/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP-IY/J!5C1?%^B:3\/[+5I+S5KFVFN)8+?[=^^O)Y?.==@"YW'((4=E STH
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M7<PR5/S$' Q@\D4 >@T5R^J>.;'3]8FTFTT[5-7OK=%>YBTVW$GV<,,KO)8
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M)I\.LZAI%KI.L:A?V#A9X;*V5RJE58/DL!@[L =20<#B@#L**YS_ (3K0?\
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M\[2]6^%":Q*()TTV\CD,[;2&\F+"DD]>WX4 =YK7C7P]X?O5L]2U$1W3)O\
M(BADF<+_ 'F5%)4>YP*GF\4Z)!X9;Q&VH1MI"H)#=1@N-I..B@GJ<8QQ7F>F
M_P!IVGQ#\8Q'Q1IVAWDMTLP6]L1*T]OM&QE=I$RH&00,X-;_ ,-+BQTWPWK>
MIS:TLVG2ZI-,;R>W6TM\Y"LT?SL/++#@Y')Z4 >AHZR1K(ARK $'U!K UGQS
MX<T"]:RU'4=ETB>8\,,,DS1KZL(U;:/KBN@5@RAE(*D9!!X->2VNLSS^)?%D
MFG:QHGA>"WOS%>27B&:YG9% \W#N%5"/NX&.M 'I$/B+1Y] _MV/4K8Z5L,G
MVHOA H.#DGISQCKGBL[3/'WAG6'FCL=2\R2&$W#1M;RH[1CJR*R@N/\ =!KR
M*PR_P=T^ZF9KC3+?Q0L^HDQXWVPF.XE1T&2I([5ZG?:UX5OO%7AV-=FHZJ3(
M]C)9R!_LZ%/G=RK<(1QSG)QQ0!E>%?B=IVH:%K.IZO=M#'874I=A9RJJ0>9L
MC_AY/3(Y()Y KLM2U[3='M;6YO[GR8;J>.WA;RV;=(_W1@ XSZGBO([@K=_!
M7QQ:0.DES%J5X\D2L"RJ+C<21U' S6K\0/$&D7V@^$+:SU&VN)IM7L942&0.
M=@/+$#H,D#GN: .\UOQAH/AVYCMM3OQ'<R)YBP11/-(5Z;MB*6 ]\8KF_''C
MA1\)]4\2^$]4C:2%HEBN$0-L8S(K JXX.&/!'>LR[U6XE^)7B.#3+_1O#\UM
M!;I=7NH*TLUPNTL"B,ZJJ*&P2.IQGMCA;J;[1\'?B3*+X7RR:VCBZ6,()LRP
M?.%' !Z\4 ?1M<I=_$GPC8RSQ3ZN!);RR0SJEO*YB9&*MOVJ=HR"-QP#@X)K
MJZX/X;VT#V_B_=$I\_Q'?K+Q]\;\8/X4 =//XET>VBTN62^C,6J2K#9/&"ZS
M.PRH!4$ $#J<"I;C6]/M-:LM(GN-M_>H[V\6QCO"#+'(&!C/<BO&;"1;?X8_
M"^_N'$=K;:Q&9IG.%C4M* 6/8=LGBNKU75M/U'XW>$X;*\AN'M[2\\WRG#!-
MR# )'&>.GT]: -^X^)G@^U9UFUE08Y&BEQ!*PB97*'>0OR#<",M@'J.*G7Q_
MX5?6(M*76(6NII/*CPC&-W_N"3&PM[;LUQ6D00I\(?'SK&H>6?5V<XY8C> 3
M^ 'Y5%KJ)#\$/!AB4(5?2W7:,88["3]<D_G0!O77CN+1/B5JNF:SJ0BTV.R@
M>UMQ#O=I6+;MH12[<#IR!76Z;XCT?5](?5K'48);!-WF3;MHCVC+!LX*D#J#
MC%<1;W^DV'QVUDW\T$%S+I=NEO),P4=264$]S@''^R?2N3\1QS:KHGQ.O] W
M2Z3<7%EMD@^9)C'C[2R8^\,8R0><'F@#U+2_B!X7UG4(K&QU59+B8D0AX9(U
MFQUV,RA7_P" DTNJ>/O#.C:G<:;?:GY=[;[#) L$CL P+ X53D8')' XSC(K
MSGQ SZEHVB6[^.]/OH;B\M_[/M]+T=#,'5@5*_O_ ) N.3V&1[5U/A^-#\:_
M&,I4&1;*R4-CD J<C]!^5 'H/49KE6^)'A!+\V;:W"'$ODF7RW\D/_=\W;Y>
M?^!5J^)X;NY\)ZS!I^[[;)8SI;[3@^84(7'OG%>=QZ_X53X"FT-S:*!I)M7L
MRP$OVGR\%-G7?YG/3W]Z +WCKQO-9>,='\-V.KS:6LRR27EU%I[7#CY08U0%
M&4@YY(!QWQ7HKR+:6;2W$I*PQ[I)"O) ')P/Z5Y=9P7EMXT^&,&H;OMD>BSI
M.&^\'$*9!]\]:](UO_D :C_UZR_^@F@##@^)7@^XGMX8M;B)N GEN8I%CRX!
M52Y7:K8(^4D'VK5USQ-HWAM(6U:^6!IR5AC"-))(1UVHH+-CC.!WKRZ+6?##
M_L[I80S6CS2Z8+9;-&!E>\*X "#DMYGS=/?WJ]?7M];^,M!TJ.32]-UN#05,
MNJ:H6DR"0&CB3<JEMRY+'G&>V<@'8-X^T&X\-:GK.G7PN([!<2J()"\;GA0T
M>W>,G';U]#6-I'C0:YX"T?5'UQM.NWN+:*ZF.GLRO*Q&8E5EQAL[=XR!US7.
M>$KAKKQ=\0I&UF+6&.GP!KR"%8XY&$;CY0I(P/NYR>G6GO<07'P8\%B&:.0Q
MWFF(^Q@=K"1<@XZ'VH ]#UKQKX>\/WJV>I:B([IDW^1%#),X7^\RHI*CW.!5
MB3Q1HD7AY=?;48CI3;,7299?F<(.@)^\0#Z=\8->9:;_ &G:?$/QC$?%&G:'
M>2W2S!;VQ$K3V^T;&5VD3*@9! S@UF7%O"_P7\62Q:@^HVMWK2.)3:"WB<FY
MA#F)0[9C)!(/'?B@#U/3O'OAC5M5CTVRU5)+J7)A5HW19L=?+9E"O_P$FLCP
M[X_M]8\=>(-&>=A!:M$MGFTD3@1[I2[%<#YLXSC( QGJ5^(<,:77@ED15,?B
M*WC3:,;5,<F0/;@?E5"PFLO^$W^)=K=[I!+';%K:(CS94^R?,$7.2<9'UH Z
M&U^(OA.]OXK.#6$:2:3RH7:&18I7[*DA4(Q^A-=17A4>MW?A_P (Z3>6.N:/
MXG\/A[=+72KZW07J#("(FTD&5/<<;37NM '+ZE\1/"FD7L]I>:LJRV[;9_*@
MDE6$^CLBE5/L2*OZCXLT'2K:QNK[4X(K>^!:VF.2D@"%\A@,?=&1GKP!DFO)
M].UN:[\%ZO?6FN:+X;TN66Z)T[R3/=LY8@B0N_WW/8*>","K6BQI/H/PC69!
M(HF=L,,\K"Y'Y$#\J /2]#\7Z#XCN)[?2[\2W$ #2021/%(H/0[7 ..1SC%8
M_B+XC>'M/M-5M+?68EU*WAE566-FCCF"G:I?:8PV<#:3UXQ4&I1$?&?37APD
M\F@W*[_I*FW/T)KF_#6KZ!I_P0O-.U>X@ANK>WN8-0M)W'G&<L^05/)9B1CZ
MCGB@#T+P5J-UJ_@C1=1OI?-NKFSCEEDVA=S%02<  #\*36_&?A_P[=1VNIZ@
M([ET\P01Q/-)M_O%44D#W(Q5;X<?\DV\.?\ 8/A_]!%8'AV]L=)^)OC./5[B
M&VOKE[>:WDN'">9;"/ V$GD*<@X[T =>_BC0H_#ZZ\^J6PTIE#+=;_E.3C ]
M\\8ZYXJ'1/&?A_Q%<R6NF:@)+F--[02Q/#)M_O!' )'N!BO-[^^\.M/X8UC3
M[22#PK;^(+IKF:49A:=E(2<<L!'YA.#P!Z"M_P 07]CJWQ/\&Q:/<PW-]:M<
M37+V[A_*MC'@[R#T8D8![T -T3XF:;9MKT/B36!Y]KK%W!$B6[.8K='PFX1J
M<*.?F;KCK7:7GB31M/T-=:NM2MX]-=59+C?E7#=-N/O$]@,FN7^&]K T'B_=
M$A,_B._64X^^-^,'VQ7":!-%:>'/A3J>J-C1K9[I)Y9#^[BF8$0,WI@A@">E
M 'K>A^,-!\1SRV^EZ@LMQ"H:2"2-XI54]]C@-CWQCD5G?\+,\(M*T4>J/+(I
M=66&TFD*E2P((5#@_*V >H&1D5C:O>V>K?%_PDNCW$-S<V<%V]_);N&$<#(
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MKE@,FK4=C9PWLU[%:P)=3A5FG6,!Y OW0S=3CMGI5BB@ K._X1_1?[4_M/\
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MR&.6:2U1G=2,%68C)!'&#6G10!0O-#TC4;**RO=+LKFUA $<$]NCHF!@84C
MP/2GV^D:;:3QSVVGVD,T4/D1R1PJK)'G.P$#A<\XZ9JY10!GPZ#H]NEVD.DV
M,:7AS<JEL@$_7[^!\W4]?6HX/#6@VL"06^B:;#"DRSI'':(JK(OW7  X8=CU
M%:E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R5S'
M"[JA=E4D*.I]J?10!XUHGA72_$_PLG\4ZK+)+KM]:W%R^I>>X:$C> J\X5%
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M:GEN5LDC@C#HRB3$3*R\D$<E!GCUZ5NT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^UC3/-(,:#:5W%#]XE02!Z<T =!I?Q \+ZSJ,5A9:H&N9@3"DL,D0FQUV%U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',
M>"/#EYX:L-4@O)()&N]4N+R,PL2 DA! .0.?7^=5?#_A._\ #'B_4YM-FMAX
M;U'_ $AK1F8/;W/\1C&,;&[C(]NE=C10!R_P[\.7GA'P)INAW\D$EU:^;O>!
MB4.Z5W&"0#T8=JM^,;+7M1\,7=EX;N[>TU*<!%N)V91&I/S$%02&QP#CO6[1
M0!YWX8T3QSX<M+/3+:P\(P:=&X\WRI[EI6!/S-DK\SGGD]Z?>>'O&5AX]UC7
M_#YT&2WU&&",IJ$LRLOEKCHBD=2>]>@T4 <1IOA77M1\46?B'Q=?6$DNGHXL
M;'3D<0Q,PPTC,_+-CCH .M=LRJZ,CJ&5A@J1D$4M% &1_P (KX=_Z &E_P#@
M''_A6G#!%;0)!!$D448VI'&H55'H .@J2B@#E]#\.7FF>._%>N320-:ZO]C^
MSHC$NOE1%&W C R3Q@G\*RXO#7BGPWJ6JMX7N-(FT[4KE[PP:CYBM;3/C<5*
M [E)YVG&/6N\HH X6[\"ZG<>%]-@?7Y9_$&G7@OX=0N 64RY.4*YR(\$K@'@
M8^E6;?0_$^KZLMQXFO;*'3X[:6#^SM,EE,=P9!M+2E@,X&<#'!.<UV-% 'G$
M/A3QO8^'&\*6>K:0=)$1MHM0E23[5% <C;L V,P7@-N'TK77P8]GKG@Z6PDB
M&GZ#:W%LZR,?,</&BJ1Q@_=).2.M=A10!S&E>'+RQ^('B#7Y9(#:ZC!;1PHK
M'>IC4AMPQ@=>,$USJ_#[5AX0U/2/M%E]HNM>_M-&WOM$7G(^"=N=V%/&,9[U
MZ310!R^N>'+S4_'?A37(9(%M=(^V?:$=B';S8@B[0!@X(YR1^-0-X0EN?&FO
MZE>M ^F:KIB6)B5CYG&X-D8Q@AO4UU]% 'G,'ACQY9^'E\+VFLZ7'IL<8MX=
M442K>1P#@ (/EW@<!@P_/FM^;PW=-XQT'5DN%>UTVRGMI#,[&5V?9ANF#]TY
M)/>NGHH Y*\\'MJ7BK6[R]:)M,U/2$TYD5CY@.Y]QZ8'##!SUKF]6\&^/-1\
M$R^$1JFB"R2%8([S$JS31IC:KK@JN< %@3QVYKU&B@#C-6\+:O%X@L?$?AZY
MLDU.*R%C<V]X&\FXB!W#YEY5@<X.#1;^%-7U>TUQ?%FII+_:L'V9;*R=_L]H
MF",INZN2<EB!T]*[.B@#RS7_  ;X_P!<\%R>%I-4T,6R(D:W8$JRW*H1M#K@
MA.@)(W9QC !KU.BB@#F/"7AR\T&_\1SW4D#KJ>J27D(B8DJC  !L@8/';/UK
M>U&W>[TR[MHRH>:%XU+= 2I S5FB@#B9_!^H2_" >$5FM?[0&G+:>86;RMX
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M*?-RI!?++UY "],$_-7H5% '##PWXF\/:SJMQX6GTJ6QU2X:[EMM2\Q?(G8
M.ZL@.X-@$J<>QIEMX&UC2_#FS3=?*:])J3:I<W+(RPW4K?>C= <^61@8![ U
MWE% ' Z9X+U*Z\8)XBUV#1K5HK22V^SZ6KGS]_4RNP4L .@QWSFJ]GX6\<:'
MH;^&M'U72?[+4-':W\XD%W;1L3QM4;69<\'(^E>C44 5=-LVT_3+6S:YFNF@
MB6-IYVW22$#EF/<GK5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#QOX??#SPIXDT*^O\ 5]'BNKI]3ND,K2.IP)#CHPK=\,._A'Q_
MJOA%KR>71QIHU:S^TRES:H'V.FX\[<\C/3'U)RO!/B6X\*:1>Z;?>%/%,LW]
MH7,JM;:5(Z,K.2"&XK5T?0=5\3ZWX@\2:Q92:4+_ $XZ5I]M,098X#DL[@'
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M$SRM(8H-6=(TW'.U5[*,X ["MW0M&70M/-FNH:C? N7\W4+DSR<XXW'MQTH
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MM8U?5K?P]<:39SK'#:M?3S/=3J.6+K([;!GH, ^M>@T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %96M:!:ZZ^F-=23(=.ODOH?*8#=(@8 -D'Y?F/3!]Z** -6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gfifg3pi0xun000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfifg3pi0xun000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@!(H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHSSBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBD4DCD8_&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV\.6%IJ>FV\MZEJD<[?V9OW,%P?FQSWYSWK.^#UC--XSO=1M8'33XH9(]Q)
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MK?G\O_?->T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=(TF6273M+LK.208=[>W2,L/0E0,U)J.CZ;K$:1ZE86MXB-N1;B%9 I]0"*
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MU"; 0!25B'4LXX[=LYS7::WX;TCQ%:BVU:QCNHP<J6)5D/\ LL,%?P-85O\
M"KP9;3I,FD%F0Y"RW,LBD^ZLQ!_$4 <5KFLZYKWP5O-1UM(4>XNH?L_DQE,Q
M"5,,02>I!Q[8K2^%7AK0=5\$K<ZAHNG7<YN)%\V>T1WP#P,D9Q7HVHZ-I^K:
M<VGWULLMF^W=%DJ#M((Z8[@?E1I&C:?H-@++3+9;>W#%@BDGD]3S0!X9#:VU
MC\=XK:TACMX8M0"I%$@5%'E] !P.M2_%F[N]?\=V^AV,1G>V188XD8?-*XW'
MJ0!QCKZ5[ ?!V@'7AKG]GK_:0?S//\Q\[L;<XSCI[4Z#PCH-OK)UB+38AJ!9
MG-PQ+-D]3R>M '@OB/2_B&^B1_\ "06$PTO30"G%L!",;1CR_F(Z>H_*NFL]
M<DU;X"ZM!=NS2V&+?/5B@*%"1Z8.W_@->T7=I;WUG-:742RV\R%)(VZ,IX(K
M&A\$>&[>SN[2'2H4M[M56XC!;;(%.5R,]J /,_ACX%\/>)?"US=ZM8F>X6[>
M-76>5"JA%(&%8#JQ/3N*S[?3T\'_ !KL].T>>>.V>6*-U=R=R.@+*3W&>?8X
M]*]MTG1=.T*T:UTRT2VA9S(R)G!8@ GGZ#\JJWWA30]2U2+4[O3TDOHBI2?<
MP9=IRN"#V- 'B_C2YBM/C8+FXD5((;JT>1V'"J%0DUU'Q%^(^B77A6ZTK2+U
M+R>]4Q.R*=L4?\1)(ZXXQ[UW&I^!_#>LZB]_J&EQSW3@!I"S#.  ,@''05!%
M\.?"$,JRKH-HS*<CS 7'XAB0: .;^"VCRV/A:XU":(QF_GW1Y&"T:@!6^A.[
M^?>K/QF_Y$89_P"?N/N?1J]!CC2*-8XU"HHPJ@8 'H*I:MHVGZ[9_8]3MEN+
M?>'\MB0,CIT- ' _##PUH6I^ ;*YU#0M.NKAI)@9;BT1W;$K@<D9]OPKBO#]
MM#9_';R(8$A@CO[A(XHEVJBA'P !P!C'%>[:7I5CHNGQV&G6ZV]K&6*1J20-
MQ+'K[DFL^+P=H$.NMK<>G(NHF0RF<,V=Q!!.,XY!/:@#QS6CI"?'"].OQQ-I
MN_\ ?"?[O^H&"1]<5UP?X0 Y"Z0"#D81AS^5=;J/@+PSJVH2W]]I2374V#)(
M9'&[ P. <=A5/_A5O@S_ * PZY_X^)?_ (J@#J+2Y@OK.*ZMW$D$R!XW'1E(
MR"/8C!KP#0=+LU^-R6/V=?LL6HSM'%SA=@=D_(@?EZ=?H"RLX-/L8+*U3R[>
M"-8XTW$[5 P!D\]*QX/!7A^VU\ZY#8;=2,C2F;S7/S,"&.W.WD$]N] %'XF?
M\DXUL8)S;X.!GC<*\0&F+/\ "S^TE!$EEK! ?;GY7C0'![#<%KZ2U+3;35]/
MFL+Z$36LZ[9(R2 P]..:RH/!7AZVT*XT6+3E&G7+^9+"97.YN.<DY'W1T/:@
M#Y_A$NKZ'XT\07*@R2/ N[' 9[A6(_)5KNO"^N-H'P,OKU'$4YEFAMR& )D=
MMH(]P23Z\5Z%#X$\-P:)<Z/%IH6PNG62:/S7R[ @@EL[NP[U'+\/?"\VE0:9
M)II-G!,T\<7VB4;7;@G.[/Z]Z /!?#5AXS@M9;SPWIUU);W4;023)!&ZNN<%
M?G'3/7'I[5I_#W4+[PA\0HM-OH'MS=L+2YBD&"I/*'KZD?\ ?5?0>FZ99Z/I
MT-A80^3:PKMC0,3@9SU.2>O>LC5? WAS6]2&HZAIWG7@"CS1-(A^7[OW6'2@
M#RK&?VA^1D?;,?\ D"LKXE^'I/"WB.[^Q(\>EZO&&*@?+O#AF7\& 89_O$5[
M>/!N@#Q#_;_V ?VIOW^?YK_>V[<[<[>G'2K>LZ!I?B"S6TU6T6ZA5Q(JL2,,
M.X((- 'G_P .->T[PY\+X;[5+@P6WVR6,.(VD^8MQPH)[5Z#H>MV'B+2TU+3
M9FEM9&95=HV3)5BIX8 ]0:YCQ+X9TW3? LND:9X>GOX3)F"TAF?(D;.'+%LX
M!.3S6EX T"Y\,^#+'3+S9]J3?)+L.0&=BV,]\9Q^% '(?'-)&\/:8ZC,:W9#
M<]]AQQ^!K-\,?"#0M;\.:=JES?ZD)+F!9'2*2/8">PS'G'XUZEKOAO2?$MM'
M;ZO:_:(HWWH!(Z8.,=5(/>KFGV%KI=A!8V40BMH$"1H"3M ]SS0!S<7A32?"
MG@_5K?2K8Q^9:RM)([%G<[#U)_D.*\Q^#N@Z5K5UJT>IZ;;7B0I"R">(-L)+
M],\\@?I7N]Q!'=6\MO,NZ*5"CKGJ",$5C^'_  AH7A=IVT:R-L9PHDS-))N"
MYQ]YCC&3TH \2^,.AZ;H>O6D6F6$%I#+9[BD"!0S;VR<=.F*]+\=_$6/P2MA
M;Q68O+F=?,>,OL"1#C.<$9)X'T-;VO>"O#_B:ZCN=7L#<S1Q^6A\^1,+G.,*
MP'6O'?BSX9U2V\3'5[NYAGL[Z5+>UC!)>,!?ND$ 8ZGKSF@!WQ@G6;QAI<^W
M:DEA$^?0&1SS]*[_ ,6?$KP_;^&[M=,U*&]O)HVBAC@;)!88W$]@.M;FJ>!?
M#WB![>?5K!KB>& 0HWGR1X4=L(P'4FJ,7PG\$Q2!UT7<0<X>ZF<'ZAG(- '$
M?!BUCTO2];\0W3-%91HL2RE21M0%G.!UQD?D:]4T'Q'I?B6S>[TF[%S DGEL
MP1EPV <88 ]&'YU8DT?3WTF32OLL<=A)$T+6\0\M=C#! VXQU[57T'PUI/AF
MUEMM(MFMX99/-=3,\F6P!GYB>P'Y4 :U%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)GFE
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S =NC ^M>P5X_\ &R!M/N] \0VX*SP3&,N!W7]XG/L5;\S7KL3K)$LB'*L
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MY[\0<#Q=X)D"@NNH$ D< %HP?QZ5Z%7G/C!VNOBIX.L5Y$1DG8#L.O\ [3H
M]&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<))= '&+=#N8?CM/Y&N[50BA5 "@8 ':O/\ PC$OB3QIK?BN0EH[>4Z;8@]
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M8_X4 =UX<F>X\,Z7-*NUWM(F89SSM%:=4-#LSIV@Z?9$$&"W2,@G."% J_0
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M'MWG!+2 DX.",'IG(/'OUKB_%BQ^/_%G_"+^';:UM3:%WN[MX@ S+\O!0'(
M8@9QD\<8H [_ ,#>+;OQ=%J5[)9+;V,=SY=F^?FD3'.X>H]1QSCM779'K7%P
M_"OPDMA;P/I:&:*%8S<Q.T4C$?Q$J1DYYY]O2MJQTJW\/QR3?VI>&SAAQY5U
M<!XXE7)+;F^;I_>8C H V&=41F9@JJ,DD\ 5S]GXY\-ZAK8T>SU:">^.0(T#
M$,1R0&QM)]@:\R\9^,AXJT^&19;JS\-M<_9Y(X,?:[]P/X!G:8\G&03SU!Z5
MU7@[P'<6&O)KFIK:1""'RM/LK7)6W0CJQ*J6?!().>I.>> #T6BBB@ HHHH
M**** "BBD)P* (YYX;:!YIY4BB09=W8*%'J2>E>!^._$-_XXU".VTQY/L!F%
MO8VZG#7<F?F?']T>IZ?7.-'XB^/X-?F'AZP6[%K'=&.Y>!%>6X96PJQ '!!/
M0GVXXP>O\#> O[(O/[;U-83>^6L5I!&"4M80  /F .\CJ<>OJ20#M-(M9+'1
MK&TF8-+!;QQ.R]"54 D5=HHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KF=>\#Z1XAUJPU:[6>.\LG5D>%]N\*VX*W'(!],'DUTU% !1110
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M98C)^@QSZT =J[K&C.[!549+$X %<+JWQ>\)Z5,T2WDE\ZG!%G'N&?9B0I_
MFN#O/$NJ?%ZZM?#EK]GTJW">?<B20OYA5L?+@#< ""%..1R>!7H4&E>%_AEX
M9>]>&,M"NY[APGGSOZ*6(Y/90<#M0!QGC+XLZ+K_ (,U33-/%[;WMP@B"SQ
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MWZ[17::E\+_A]:6;7%UIL5I!'RTINY(P..Y+8K!T#X>_#GQ.+E],6\<6SA'
MU!FZC@\,>#S^1H Q?[8\>Z@H,GCWPW:1DG(%_;@C\50G]:@?2=?O7VW7Q:TE
M!@Y$6KN>/H&7O7<GX)>#B?\ 5WX_[?'-'_"D_!V"/*O_ /P,>@#B(/A_HMV?
M^)O\3[2YR3E([F,Y'U>1N_/2L7QYX7\(Z!HMNWAO6$U&^FGV/BZCEV+M)SA
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M9$EYIM[%);^=$(P4=E.,% .GH1SV.:CUWQ-#X:^*">+Y;26]TG4+%/L<\3@
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M!2T )FN&^+>C'5_ =TR F2R872@=PH(;_P =+'\*[JF2QK-&T;@%&4J0>X-
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M_P *:/!B@8_X2'Q$?<ZBW^% '3T5RW_"%#?N_P"$C\1_3^T6Q_*G+X,"D_\
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MXAUVXODA=K>*6Z3:SX. ?D]: ,[XI:IITVC#PRMH^H:K?$"VM(&(9&'(<XZ
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MPZ$>GIG]B:EG_D:=6Q_URM?_ (S4-SX9GOH&M[SQ!J-Q"WWHY;>S96^H,&*
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MS1O GAG0'273](MUG3E9Y<RR ^H9\D?ABNCHHH 0@'J,TM%% !1110 4444
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MU];)<VEQ%<0/RDL3AU;Z$<&IJI:3I-CHFG1:?IT @M8L[(P2<9))Y//4FKM
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MAC"LYZNW\3'W)R?QKQ_X@>!;/PQHFFW>FW5T%%W''=K/.S_:&))60CIN'/0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $P*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(T6BWFOW*[KG4I3MD)R2@/)_P"!,6/X"O4:BM[>*TMX[>!%CAB0(B*,!5'
M _"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\0:/XVC\+>);J&_2[@,MA?QP^49"N=R,HXS@$_EZ\3_"[5K:\\&6NG;O+O\
M30;:ZMG.'C=21R.N#_B.U9NL7]MXB^+7AJSTR9;@Z.+B>]DB.Y8@R@!21QG(
MQCWH ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;E[K4?\ 6K(X*+SGCC/7U)KI:** "BBB@ HHHH Y/Q!\-_#'B6_:_O[%Q>L
M&GAF:-F &!G!P>.,XS@"M+P]X3T3PK:R6^C6*VR2$%SO9V8CIEF)/X=!6U10
M!P]Y\(?!%]=RW5QI#--*[2.WVJ7EB<GC=QSZ5?\ #OP[\->%=0DOM'L7MYY(
MS$S&=W!4D'&"2.H%=310!R>O?#?PUXBU$ZC>VDRWK *\\%P\;.,8P0#@\>W8
M5I>'?"FB^%;-K71[);='(+MDLSD=,D\GO],UM44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F>: %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$9&/6@!:*
M0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
4*** "BBB@ HHHH ***3/M0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gw0ad20d1dfx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gw0ad20d1dfx000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9!4<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB>\\^2-I0BIN /'"@#OV%<)\7/B7XDTCQ8='\*7IB%C:>=?E+>.3!)SSN4X
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MG\:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^$$.G1#[;(L$<F9"P!'SJ>!N4<=R: /?J*\RO_&.M1? )?%,=PJ:N;.)_/\
M*4C>9%0MM(V]">,8KS?3/%_QKN_#Z^)K>07ND*KN7,%KAE0D-E5 ? *GIZ4
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M5.#(5<L%!P>N,=#7TW7AOCWP=XAU3XX:'K%EI4\VG0RVC27"XVJ$DRV>>PH
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M-M8V\$GA^SGDBC5&E=3N<@8+'GJ>M '-_L^^($U+P+)I#S;KG39V 0GD1/\
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MA+_Z"E<MXK\3_$;Q_H?_  CMIX#U#2UN& N9I58+( <X!=5"C(!/)Z=:]:\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9GB#18_
M$6A7>D375U:PW2;));5@LFW/(!((Y'!XZ$TWPYX=T[PKH5OI&EQ%+6 '!8Y9
MR>2S'N2:U:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+BYCM4V+D[W.%S[9K2'(S0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY1^=>@:A%J,5K:Q:1]G4I*BR"8<>4/O8QWQTH TJ*** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH'%K<JPG9I"TDI88)9SR36Y10!YYXYTB&RT+1[%/#UQJNE68\L_992MS;;5
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M5O%K,VJ*\YGFB$3*928P <\+T!]ZO444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS_P %#?X^\93'[PN53/L/_P!5>@5P'@?_
M )';QG_U^#^M;4_@GZ?J95/CCZ_H=_1116)J%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF1A]T>PKZ"TC4[76-*M[^R=GMIES&S*02/QYH NT444 %%%% !1110 4444
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MG.<_C6LD:11K'&BHBC"JHP *=10 4444 %%%% !1110 4444 %%%% !1110
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MSPE_X#W'_P 77;U&UQ DR0O-&LK\JA8!F^@[T <9Y/Q1_P"?SPC_ . UQ_\
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M=F\\,4B1R2HCR'"*S %C[#O1-<0VR;YYHXDSC=(P49_&@#C/)^*/_/YX1_\
M :X_^+H\GXH8'^F>$O?_ $:X_P#BZ[8$$9!R#2T <1Y/Q1_Y_/"/_@-<?_%T
MIA^*&>+SPET[V]Q_\77;44 <0(?BAGF\\)8_Z][C_P"+H\GXH_\ /YX1_P#
M:X_^+KMZ* .(,/Q1[7GA'_P'N/\ XNCR?BC_ ,_GA'_P&N/_ (NNWHH XGR?
MBAM/^F>$LYX_T>X_^+I/)^*/_/YX1_\  :X_^+KMZ* .(\GXH8_X_/"6?^O>
MX_\ BZ/)^*/_ #^>$?\ P&N/_BZ[>B@#B3#\4,\7GA+IWM[C_P"+I/)^*/\
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M3\4?^?SPC_X#7'_Q==O10!Q'D_%#'_'YX2S_ ->UQ_\ %T>3\4?^?SPC_P"
MUQ_\77;T4 <28?BA@8O/"6<<_P"CW'_Q=)Y/Q1_Y_/"/_@-<?_%UV]% '$>3
M\4?^?SPC_P" UQ_\70(?BAGF\\)8_P"O>X_^+KMZ* .(\GXH_P#/YX1_\!KC
M_P"+I1#\4,'-YX2Z<?Z/<?\ Q==M10!Q'D_%'_G\\(_^ UQ_\71Y/Q0Q_P ?
MGA+/_7O<?_%UV]% '$>3\4?^?SPC_P" UQ_\71Y/Q1_Y_/"/_@-<?_%UV]%
M'$>3\4?^?SPC_P" UQ_\72F'XG[CMO/"6.V;>X_^+KMJ* .($/Q0SS>>$L?]
M>]Q_\71Y/Q1_Y_/"/_@-<?\ Q==O10!Q'D_%#O>>$O\ P&N/_BZ/)^*/_/YX
M1_\  :X_^+KMZ* .(\GXHY_X_/"/_@/<?_%T>3\4?^?SPC_X#7'_ ,77;T4
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M)^*/_/YX1_\  :X_^+KMZ* .)$/Q0P<WGA+IQ_H]Q_\ %TGD_%'_ )_/"/\
MX#7'_P 77;T4 <1Y/Q0Q_P ?GA+/_7O<?_%T>3\4?^?SPC_X#7'_ ,77;T4
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M<(MC#%() ?O;\\8]L5BS>/GBTCQ3??80?[#F,87?_K<#.?:LZ?4Y/#/Q"O\
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M2N%&3A1DX_*J7AJ^EU+PQI=].<S3VL<DA]6*@G]:;XF(/A36,'I93?\ H!H
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M7(:KX,O9==GUC1=?NM,NKE52X3:)(W Z$*>A^E0+JFO:?X/NY?$]Q'IEU;W
MB2]@02B5-P ?8.A/3':M+7/'&B>'KJ.TNYII;IUW^1;0M*ZK_>8+T'UH L^&
M/#=OX8TV2UBGFN)9IFGGN)B-TLC=2<<5MUSEMX[\/7FBWVKP7I>RL,?:)!&W
MR9 .,8YZU2@^)OAFXU2"P2YG#7#^7#.]NRPR-Z*Y&#0!V%%<Q+XAM+'Q)JR7
M.K,8K*S6>6T^SG$*_P!_=_%GTJG'\4O"TMY! MS<;)W"1W)MG$)8]!OQCVH
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M@6.O6 TO!CBN7A;[1#%_=&."<<9KT4D*"20 .2338I8YHQ)%(LB-T9#D'\:
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MIX/TBW-P;GR[6-1,8RA<8X.T\CZ&O/KYXX[KXJ0LZ+*UJC*A(R1]GZ@5ZV
M, 8 K*N?#6BWE_-?7.F6LMU-$89)6C!9T(P5)[C% 'F6HPQQ?LV601 ,6UL_
M3N94)/ZUJ>(4L[CQXZ:D9/L<GAV<7!C!+;"1NP!SG%=])H>F2Z.ND/8P-IZJ
MJK;%!L 4@@8]B!4ITRR-^M\;6(W2Q&%9=HW!#_#GTH \9@U&\\->']-N+#7-
M+U_PZLT2VUA<1;;I 6P N.K#/<5[)K$=Q+HE]':9^TM XBQ_>VG'ZU1@\'^'
M+;4O[1AT6Q2\SN\Y8%#9]<XZUMT >3Z=K/AR/X(3VDUU;*T5E)#/ S .)\'@
MKUSNQ4&F3066I_#F\U%UCL?[*>*.20X19BJ;<GL< UZ)/X0\.7-\][-HEB]S
M("KRF!=S \')Q5N?0M*NM*32Y]/MI;%%") \8**!TP* .#UNXAU7XFVG]BRQ
MSW$&D72W$D+!@N[[@)'?/2HO"6L^&K'X.06^K20&*WM6COK1V'F%P3N4KUW$
MUZ!I6A:5H<+1:7I]M9HYRPAC"Y^N*K3^$/#MSJ?]HS:+8R7F[=YS0*6)]<XZ
MT <-I>H6%G\8#*[+9VMSH4/V99SL^4$''/<"N9ENX+Y?BY<VLJRP/''L=3D-
MA2./Q!KV;5?#NC:X(QJFF6MWY?W/.B#;?IFF)X8T.."[ACTJT2*\01W"+$ )
M% P 1W H X7QK:P#X?\ A&#RE\L7VGJ%QQC*U9\2Y7XT>$]G!:TN!7=7.DV%
MY;6]M<6D4L-NZ/$C*"$9?ND>F*6;2K"XU&WU":UB>\MU*PS,H+(#U /:@#Q7
MPB==@\+WT*^+M&TV.&>X%W:W=D&D5MQW;B6!.>O2IXM/@BTWX86HNA?6PNY&
MCE,)C#+U'RGD5ZI?^$/#NJ7PO;[1;&XN<@^;) I8X]\5>GTG3[F6TEFLX7>S
M;=;DH/W1QCY?2@#D-0^3XTZ5M !?1Y@??]XE+\,Y(Q%XC@WIYR:Y=%DR-P&X
M=J[%]-LY-2CU%[:-KR.,Q),5^95)R0#Z9 J&UT/2[+4KG4;6P@AO+G_73(@#
M2?4]Z -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUOJ-E=W%Q;V]U#+
M-;MMF1'!,9]".U6:X#P/_P CMXS_ .OP?UJXPO&3[$2E:27<[^BBBH+"BBB@
M KBOBA8WVH>%$CM+6:[A2ZBDN[: X>6$'+**[6N<\7W>MZ=96M_HUN;I;><-
M=VRC+R18P=ON.N* .#-S\-_$\%KI]E(F@ZM'(K6K/!Y,T;@\=>&],$FNLU'5
M[72?&MG%=6T<KPZ/+<-?$D.$0\C'3GK7,>+/$FD^.-"GT;3= U.?6+A0D!N-
M/>+[.V?O-(PPH'UJUJ'AK4+CQ!IVGSB1A_PC<UI+=;24$AP.6Z9H 2;Q]XN7
MPM+XM3P_9_V/Y9EC@>=O/V=G/&,=\>E:^K^-=6M[WP[8:7I<%S=:S:F8>9(5
M6(A5//'3FN,U7Q)JVG_"B[\,WGAW4%U&VL3;RSB/-ML48WB7H>.U=1#9W+^+
M/ EREO*T$6DR+)*$)5"43 )Z#- %K1O%NJSZSK7AWQ!I]JE[96?VH/;2$QS1
MG([\BLVW\:W=AX>\+0Z-H<#2:L7CCM_-(6(C)SGTXR:EET^]/Q;UZ[%I/]FD
MT)8TF\L[&?)^4'H3[5FZ)IE_'%\/!)8W*_9GF\_=$P\K*MC=Q\OXT =%HWBW
M68?%-SH/B:SLX)$M#=QW-I(61E'W@<\C%9W_  FOBZXT.X\36>AV3:-&'>.!
MYF%Q)&N?GZ8[9QZ58U?2;B_^*:$P3"TETB:!K@1G8I;C&[IGVK _X235-#\
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M(!RP_A&<Y]*H1^,?$.D>)-*TWQ%::88M4D,43V,S,T3]<,".GO6)>Z-JUO\
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M>(=;3P_IBWKP-,#-'#M5L??8+G\,US_A&QU+4M>OO%NJVYM&NXEM[.T;[\<
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M.!R.]9FK>%IKSQ5/K/A7Q#'::S;PI;75NZB2-P!E0X!R#C%/T?Q3KEIXKM-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3\Q5CG)QTKF- E_LSXE6NDZ#K]SJU@UN_P#:$,DQF$#CHQ8YP<]J[#Q)JO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gv1ubg3hw41v000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4#! 0$ P4$! 0%!04&!PP(!P<'
M!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q<B)"(>)!P>'Q[_
MVP!# 04%!0<&!PX(" X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>
M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P  1" %R >$# 2(  A$! Q$!_\0
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M+B<92PUO:/<RJUHTK<Q[O17'6%YX_P!6LH+ZWA\.:9!/&LD:S&:YD"D9&<;
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MA6VC>*M5BE\66J;=0A>W%LY;^\J9(9/1UX/MTK3^)<R6_@'6II+HVJK:/^\
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M<'$_A>QNO5K74\?D'0?SH Z:BN9_X2J\A_X_O"'B"#U,<4<X_P#(;D_I2_\
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MV<M@Q[4+9 [],5L5R7C'_D<_!_\ U]W'_HEJ .MHHHH **** "BBB@ HHHH
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M345DV7B?PY?$+::]IDS'^%+I"WY9S6JCHXW(RL/4'- "T444 %%%% !1110
M5R7C'_D<_!__ %]W'_HEJZVO(_BW\.?&'BCXE^%-=T#QEJ>DZ3:2G^U+:&Y*
M *!PT0[,P^0^QS0!ZY12*-JA>3@8Y.:6@ HHHH **** "BBB@ HHHH ****
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MX;RTF2:WG0212(<AE(R"* )J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M^P[#[7')'<_9H_-21MSJ^T9!/<Y[TR+59[@_Z#H/B*[;T33)4'YR!0*U=/\
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M\\0:G:Z5!J=V(UMT1Y&C:0DK%OZ$XX+' S7FYCBYX=1]G:[9$X5I+]TK]SZ
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MDDG\:TZ*]##82GAT^7=]3&I4<]PHHHKJ,PHHHH **** "BBB@ HHHH ****
M"BBB@ KE_'VH7316_AK29"FJ:OF-77K;P#_6S'Z X'^T16WKNJ6>BZ3<:IJ$
MGEV]NFYB!DGT4#N2< #N36+X(TN\WW/B36X]FKZEC,1.?LD _P!7 /IG+>K$
M^U &]I-A:Z7IEMIUE&(K:VC6*-1V4# JS110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C?Q%\$_
M$KQ%\9]+U/1]=M+#P?:6\#WEI=DS1W<J2,V/)!'(^7YB1SCKBO9**  4444
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M@\+Z'::!IOV2V:2:1W,MS<RG,EQ*?O2.>Y/Z# ' K5H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "H-1NDLM/N+R169((FE8+U(4$G'Y5/6;XI_Y%C5?^O*;_T T 3Z
M)J$>JZ-9:I"CI%=VZ3HK_> 90P!QWYJW6%\/?^1"\/\ _8,M_P#T6M;M !11
M10 4444 %%%% !1110 4444 96@:RNK7&J0K;M%_9]XUJ26SO(53N]OO5JUR
M?P^_Y"/BK_L-2?\ H"5UE !1110 4444 %%%% !1110 44CLJ*69@J@9))P
M*XV?6M3\62O8^$Y3:Z8"4N-;9<AO5;8'AV[>8?E';<: +?B/Q!=R:B?#GAA8
M[C6"H,\SC,.GH?XY/5O[J=3U.!S6EX7T&TT"Q>&!Y+BXF?S;N[F.9;F0]7<_
MR'0#@5+X>T73M!TY;'38/+CW%W=F+22N>KNQY9CW)K1H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#HL=@L[W,NYI;BX<8::5R6=R.V23QVK4VC=NP,],TM% !1110 4444 %%%%
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M[_R(7A__ +!EO_Z+6MVN*^"7@*#X;_#S3_#*73WES&N^[N79CYLQ^\1GHHX
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MZW?_   HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g5rlbv12cydj000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5rlbv12cydj000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +U!2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BH;FZM[.$S7,T<,0ZO(P4#\34J.KHKH0RL,@@\$
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y34?#&
MJ_VE<7NCZY-:_:#ND@D&Y"?49SCMVSQ75T4 <UX=\*'1[ZXU*]OY+_4KA=KS
MLNT!?11VS@=^PQCI4VB>&AHQU0BY,OVZ=I?N8V D\=>3SUXK?HH Q/"OA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\Z[JN)\.[9?B5XNE4$A?LRYQW\O!_P#0?TKMJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **@O;VVTZSFO+R98;>%2\DC
MGA0*ATK5;+6].AU#3YQ-:RC*. 1T.""#R""",&@"[1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%8'B/Q?IGAM%6X9IKMQF.UAP9&]\9X'N?U-<
MQ#H_BKQF3=ZM?S:/I[@;+&W)5L=]W0G/^UG_ '1W /1J*\MTG1AX/^)^GZ7I
MEU<RVUY:LUPDTN3_ !D,0!CJ@ .!U->I4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5YUX2(TKXH>*-(.X+<[;R$9&#_$
M_OUE ]/E->BUYQXJSH7Q0\/:X2%MKQ?L4IQQGY@,_7>O_?/M0!Z/16/;Z]%>
M:C%;VBK/;LS(UPC\*P4G ]>G45L4 %%%% !2,<*32UR_Q UQM!\(7<\>[SYA
MY$6T9(9@<G\%#'\* ,SX9W"ZI!KFM=9+S4&Y_P!@ ,H^HWD?3%=W61X7TA-#
M\.V5@JJ&CB'F%1C<Y&6/YUKT %%%% !1161XEUQ?#VB37_DM/(I5(H5SEW9@
MJCC/<CL?H: -?I65?^)=$TN3R[[5;2"3_GF\HW?EUKF;;P[X@\3VZW'B759[
M*&0!AI^G_N@/]]N2<_W<GZ]JUK#P!X9TY2(M+BD)Y)G)ER?7#9&?H* (_P#A
M8WA3G_B:'@_\^TOY_=Y'O4@\?^%2Q4ZS I']]67^8K27P[HJ(472;%5/! MD
MQ_*HY?"OA^?)DT73V)ZG[,F?Y4 5D\<^%I&"C7]/!/3=.J_SJW;^)M!NSBVU
MK3IR>T5TC?R-4V\#>&F))TJ(9_NLR_R-4I_AGX6G/-C*N3D@7$F#^9H ZJ.>
M*50T<BNK#(*G((J0'(R*X!_A#X=SOMY+R"09(9#'D'\4S^M-7P5XHTIF;1O%
MMRRG(\J[)< >Q?>/R H ]!HKSI]9\?Z%<#^T--M-4MAC,EL&!]SE<G/_  #'
MO6MH_P 1=%U2X6UG\W3[ACA4NP%5F] P)&?8X/M0!U]% .1FB@ HHHH ****
M "BJ6KZG;Z-I%UJ-T2(;>,R-CJ<=A[GH/K7F=CXLU[3/"6I^)]8NN;]@--M&
M0;$)S\PX!V >O4)G/S4 5?B5XFEU?4I/#UEN:UMG43*B@M//D;47UP<>F6!]
M*]1\/Z7%HOA^QTZ) H@A56QW;'S$^Y.2?<UY%X<T&2/QSHNF77FSS(O]I7[,
M/NR[2R@^ZDH2>YD->WC@8H **** "BBN;TWQOI&K>)+C0[-II+B /F39^[;:
M0&P<]B0.F/3- '24444 %%%% !1110 4444 %%%% !7#^,O&TVF7/]B:)";C
M6)0 "%WB'/08SRY'('0#D\<&QXY\8CP]:BSL0)=6N1B%-N[8"<!B.^3PH[G\
M:;X'\&#0(6O[]C-JUSEI'9MVS)R0#W)ZL>Y]J (_"/@1-*F_M?5I'N]9D)D:
M1W+",D8/^\W;/X# KLIIH[>%YI75(T4LS,<  <DD^E25YW\1=6GO;RP\&Z?)
M&MSJ;@3LW.R// _':Q/LI'<4 -\&02^)O%5]XQN8V6'=Y-@""/D&5]>>,^OS
M,W3%>C55TVPATS3;:QMU"PV\8C0>P'\ZM4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !112$A02> .M  2 ,GH*\F\;ZG/X]=M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 5Y[\5HI+:PTS6H,^;87088'7^(9_X$@&/>O0JYKQ_;_:/!.I8Q^[19>?\
M9=6_I0!T44B2PI)&P9'4,K#H0>]/K#\'7)N_!NCRM][[)&K<?Q*H!_4&MR@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH 9--';PO-,ZQQQJ6=V. H'4DUY;,+OXG>(RD;2P^&;)P5<
MJ9F[D>YZ#^Z.>"P%6O%5_>^,M?'A72"XL(9!_:%T@.W(/*YZ8&.G\38'137?
MZ9IMKI&G0V-G'Y<$*X5<Y]R2?4DD_C0!8@@BMK>."&-8XHU"HBC 4#H!4E%%
M !1110 5A>-'1/!>L;^C6KJ.<<D8'ZD5NUQ/Q/NY8_#45A;KOGO[E(549SP=
M_ '/)51W^]0!J^!D:/P5I08+\T <;3D88EA^AK;N[J&QLY[NXD6.""-I)';H
MJ@9)/X5%IEFNG:39V*'*VT"0@^H50/Z5PGC_ %2?6=4M?!6F,/.NR#=OMR(U
M^\ >1D8!9AGH /XJ (?!%M)XI\5:AXPOH?W:/Y5BK?PCD?3A3CO\S/Z4OQ;N
M&N$T/0X6(EO;K/'X(O\ X](#_P !KOM)TRWT?2K;3[52L,"!%SU/J3ZDG))]
M37DWQ:U V_B_2S&=LMK;><C#DJQ<X/X%,]* -73X4\5?$6+[/$?[%\.H((CD
M;3*IQQ_P(#\(QZUZB.!BN8\ Z ?#_A6V@EB"7<P\VX/4[CV)]A@?A6WJFJV6
MC6$E[J%REO;IU=S^@'4GV'- %LD 9/05Y3XT\?OJK2Z'X7F+ (S7>HQD[(HU
MY;:PZ #JPZ=!DGB.36?$GQ+NY;'20VE:&I*R7#!MTHZ8+#OC^ 'ZGG%,\7:/
M8^$_#]GX:T6,O?ZK*JSRMS)*JD8!(' +E1CIC=[T -^$OAQ9;AM99"+>V8QP
M(R@9D( 9OP4[1_O-7J>KNL>BWSL<*MO(3_WR:K:99V7A?PW!;O-%#;VD/[V9
MR%7/5G)Z#)R?QK@/%/C;4-;T;4AH5OY>C11O'<:C,N/,!^7;'GH3D#/)YZ#K
M0!UWAS6+*Q\!Z!<:G>P6^_3H"6FD"[F\M<XSUYJ6W\=>';J7RXK\_P"^\$B+
M_P!]%0!]36#X;^&NEQVMI?:I)<7]TT*G;,_R)D?= ZX&>A)''05J^+-?T;PE
MI*12VD,LDH(MK%4 WXZGIA5&>3_,G% '3-=0+ 9VF00JNXR%AM ]<^E9EMXK
M\.WETMK:Z]ID]PYPL45W&S$^@ .:\UT?P%>:S]IU/7W_ +*TN5C<_8XSL121
MDOL8E8^.[ MUX7%9MGHMAXI\:6L7ANR\G2+"5'DO-S,90K EB6Z$XPH'J6Z<
M  ]TKC_'?BJ#1+:'3O,9;B^#*Q126BAQ\S+@CYOX5YZG/136OXD\16?AG1WO
M;O+-C;#"I^:5\<*/ZGL,FN#\)^&;SQ9JA\6>)$BDCGPT%MM.TH,[1@C[@ZC^
M\>>G4 N6B:[\0F6>>:;2?#_\$<##S)U[9)!!Z?[O.,-]ZNNT_P ):%I<UO/9
MZ;#'<6^[RY@OS_,"#ENIZ]ZV418T5$4*JC  & !3J "BB@G S0!QGC'P.^O7
M4&IZ7=M8ZM 0%F5RFX?5>01S]1P?;R_Q8WBB.>+P_J'B,ZG>2MM-C:2'"@]I
M"$0'/HQ/'/ YKNO$_CR]O]0?P[X,C6\U$AQ+<@C;#C@[2W!([D\ X')XKEY=
M 1=3?PSHLHO=>NPYU;4I6.(P<%T7T!SACU.0IZ_* 8O@SP5_;NJQP0)OL()!
M]KNHR-N2&.(_;@#/7)W=,5]!6%C;Z;8PV=I$(H(4"(@.< ?S^O>J^AZ+::!I
M,.GV:GRXARS8W.>[' ')K1H ***@NKRVL;=KB[N(K>%!EI)7"JOU)X% $]17
M%S!:0-/<S1PPH,L\C!5'U)KS[4_B7-?77]G^#].;5+DCF9XV$:#UQP2/<E1[
MFH;3X>:IXBDBO_&6K33N27%I"<)'D=NP[=!GCDGG(!NW'Q+\-I<?9[*>XU.X
M()6+3[=IB_T(&#^!K<T;59M6MWFETJ^T]0<(MX(PSCUPKMC\<&I-*T;3M$M?
MLVFVD5O%P6"#EB !ECU8X Y/-7Z "BBB@ HHHH **** "BBB@ HHHH ****
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M/Q#XBQ_9\;9MK4#Y)!G. #_!D#)/+D?W0 ?4U4(H50  , "DCC2*-8XU"HH
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MJJ(9;ARMF@<.(D'''ICE>Q^\?XJWM=^('AW00R2WRW-TIP;6T(DD!]P#A?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4\8:)JNJ7FDW>EBW
M+V,C2[9V(!;*E>W/0YY'!KJZ* ."N_#WBOQ((;77KC3K>Q5@\B6@8E\9X.3D
M'D<@X&*Z/Q+86USX2OK68K% EON!. $V?,I^@*BMJJ.L:9'K.E3Z?---#',
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MQ/S)"!GM_M(3^>>G%:FB6OPPT=5:.XAO)U.-UU&7<%3UV;0%Y[A17I/]FV)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DD2)=TC!5'<G
MI]<;\303X0D(QD31D9]0>/UQ0!U45_:3R>7%=0R/_=60$U8KCY?A]H%YIX:V
MMY+6X>/*3)*^4+ =B>>V0?2H?!6OW;IJFE:O*'N=*;:TV<ED&5.3U)!0\]<$
M9YS0!VU%<4_Q 9;<WB^'M5:QV[A,8MO&3U!.!T[GN.G.-34O%]AINE6&ILLD
MME>2*@E3&(P03N;)' P<]Z .AJK=:E8V5Q;V]S=PQ37+;88W<!I#Z*.]1ZMJ
MD&CZ1<:C<!C% FY@O4]@!GN2<5S=[JNEZA=>%[R^TRX\^[8R6FY\>22%.6 ;
M!/*XZXH [*J%WK-A9:G9Z=<3A+J\W>0F#\VT<\]*R]=\61:1>0Z?;6<]_?RK
MN6"$=!V)/X'H#TYP*Y2ZUHZO\0- WV4EG<6S/'/%.HW D'IQRO<$8SUH ].J
MK+J5C!=):S7<$=Q)]R)I &;TP.IJT.E>2^,[*74?&MY'&)?.AL4GA9!RI4[L
M@]OXOQQW(H ]:JK<:G8VMPD%Q>00S28V1R2!6;)P, ]>>*J>'-5&M>'K._XW
M21@2 #HXX8?]] UY3XEG?5[V]UH@_9CJ*:;;R*G5%5RY_P!H9P0?=A0![716
M-KFN3:3]GAM=-NK^[N WE1PK\H*CJ['A1T&:S-/\87#:S%I6LZ2^FW,XS ?,
M\Q7]L@8!_$]NF: .LHK U_Q.NCSV]G;6<E]J%QDI;Q$ @8)W-Z#Y3^M,T?Q%
M>:AJ$FGZCH\]A<",RKEO,1T! ^\.,_,./K0!HZ/K=CKMM)<6$CO'&_EMOC9"
M&P#C!'H16C7G/@;6+72?".L:A=,5BBOFR3C+G9&%4>I/ [<UVFA:E/J^DQ7T
M]F;0RY9(RVXE,_*W0=1@X]Z -*BBB@ HHHH **** "BBB@#@/ (/_"5^,BP8
M9OR.5X^_)W^A%=_7GUY=KX'\=7%_="1=%UD*9)1EE@G'&2.P(_GZ"NYM;VUO
M;=+BUN(IX7&5DB<,K#V(H L44UY$C4L[!5 R23P*YW5?'OAK20%EU2&:9CA8
M;8^<Y/N%SCZG H Z2N-\3^/+?2[D:1I,/]I:U)E4MXSD1M@GYSZXYVCG'H.:
MRI=2\8^-<PZ5:2:!I3<-=70(GD7/\('W>/3_ +ZKI/#'@O2?"\6;6+S+IA^\
MN).6/L/[H]AZ<Y/- &?X8\&26U\=>\07'V_79"3OS^[A&,!4'L"?S..I)[.B
MB@ KS+Q)?6EE\8=)N;ZY6WMK:R+L\KJJC(F'&>I)VC Y/%>FUEZGX<TC695E
MU"PBGE5=H=AA@.>,CG')_.@#SO5-8U'XEZE_8FAQ26^BPR@W-Z^0)1V^7@XX
M.%ZG@G %>E:/I-KHFE6^GV:;885"^['NQ]23R3[U-96%IIMJMK96\5O GW8X
MD"@>O JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 F1G'>EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&?7&>F36AJFA0ZKJ6F7LDTJ-82&150C#9QP?Q _7UH YK2MO_"V]7,S$2&V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%=[)X'N=6L[>2PO(9UA:*XBW%6\Q5(QQG(/'UKL+>&.WMXH8E"QQH$51V &
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4WS$W[-Z[_[N>:)'6.-G<X51DGTKQXW<Z7\/CEU?RY=3:+&WGR -
MHYQG@!E^HZT >QT53U#4[;3-*FU&Y?%O#&9&(YR.P'N>@^M<G+X_N[:R74+G
MPW=Q:>_W)VD4>N"0>@)QCUSQF@#N**P+WQ-]A\*MKDVG7"!2 ;9RH?E]@.<X
MP<@_0U5TOQA)J^J10VNDSM8.S(;W)V*RJ2<C;TR,9SWH ZFBN3;QE<7=U=0Z
M'HLVII:N4EF698TR!DA2?O')''OGI6AH?BBRUK3Y[K!MFMB1<13,-T6!G)P>
MG7\C0!N45QH\;WUS'+=Z?X;N[C38\_Z27"EL$9*K@DCKR,],>N-JS\2Z?>>&
M_P"W5DV6@C9WW8RNW.5..,@C'!H U9I4@A>60X1%+,<9P!532=6M-:T]+VRD
MWPLS*"1CD'!KC[CQIJ5UH<]])X;GBTJ5&1;I;E789! 8H,8&>IS],UI?#8Y\
M#V8 P!),,9S_ ,M&H ZPG'6BN$^)E[>1:/Y"VLJV9*LUVDX3#?,-F =WH<BM
M[1]8OY;"XN-8TP:9# @99#=+*)%VY+97H!C\: -VBN)B\8:[?VTFHZ7X::?3
MQDHSW 220#.<+SW^O0]371:!KEOX@TM;VW1X_F*/'(/F1AU!_0_0B@#4HIDK
MF.)G",Y4$[5ZGV'O7%7'BGQ2EHVJ+X9$>GH&+1S3XFVCHVT=/4C![_6@#N**
MPG\2Q-X/?Q!;0LZ"!I5B<X.1D;21GN,<9K#;QGK%WIKZKINA>98PQDRM)*07
M8#+>6 ,D+R,XY[=,4 =S4-W<QV=G-=2Y\N&-I&QZ 9/\JRH/$]E-X6_M\B1;
M8*25VDMD$K@#OR,#UXKF;OQ+K]WX=FO[C0U32[RW9 89=\D2LN [#NO.>,$#
MG'% ':Z7J,&KZ;#?VP<0S E-ZX.,XZ?A5RN<\!'/@G32.A5L<Y_C:K6N:AJM
MLT%OI.F?:YY<DR22;(H@,?>/7)SP/8T ;-%<?IWB/6K37;71_$%I:+/=*6BF
MM7.PX!.-K$GM^HJ?7_$E[#J\6B:-9K<ZA*GF%W<!(ASR1U/J>G!'7.* .IHK
M TC4]8^U7%MK=@ENL47FK=1-F)AW'4X(]ZQ8/$GBC73+=Z%IEJNGQML4W;$/
M*>Y7#<8P1@CN.>"  =S17,7WBX:7X8M=2O;&2*]N %2R9L,7[C/I[_3O6;<>
M(O%.AVZZCK6F61T\LHD6V=O-A!/4Y)!ZXP._?F@#N:*Y/Q;XKE\/G39K:..>
M"X<F7C+,@ X3D#<<C'\JS]0\3>*-"\G4M5TVT_LN60(T4#,TL&<?>/0]">!R
M2!Q0!W,DL<0!D=4R<#<<9/I3Z\T^)\MY-:69:.U.F&=&BE$IWM(5?J.FW;GO
MGGK74VVK:KINCWNH>)8+:!8,LHM6+;@.W)ZD].>_.* .BHK@SKWB\V!UQ;'3
MQIOE^=]G+L9?+VYSN''3_P#5QSLW7B^T@\'CQ L3LCJ-D7?>3MVDCISU- &K
MK&IIH^DW&H21O(L"[BB8W-[#-2:;?QZIIEM?0@B.XC610V,@$9P<<5YWX@OO
M%+^%;B35[2U:RO% 46^=]OR&!?/!!QMXZ9ZUT6FW.H6_PTL)]+ACN+Y;*$QI
MR5;A<]P3QDXS0!UE%4='GO+G2K>:_@\BY=<O%_=_4U>H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4:;IUMI.GQ6-G'Y=O%D(NXG ))ZGGO5?6M T_7[=8;^'?L.4=3AD/L?R]N*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !@'J*KK8623><MI LN<[Q&
MV?KBK%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 8'I1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP_.N@CD2:,21N'1AD,IR#7%:AX,LD\*W9NP+B_:(N]P^<ENOX5-\,KF:?P=
MDQW&)WC!SU - &IX@\*6&OPCS-\-PAW)/$<,I_K^-<_#_P )=X627S FK:?$
M"VXD*Z*/Y_K7?5PWC?7BV-"L68W%QA)2O\(;I0!SOAGQGITNOWVKZG%=QR3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM-H=I99/FDD?[S&@"Q9V5MI=DMO;1+'%&. HKF_"LL^NW]UKT[9MRQBLT/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)P3N(SSU!X_*M32M3M]8TR"_M=WDS+E=RX(YP01[$$4 7**** &R,%B9F.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?<Y ..OZ>M,;Q9K&-Q\(Z@(]N2Q=<]\C&,\8_P .U=;4%Y,MO933,,JB%B*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSN"8[$=0?7G- 'J2L&4,I!!Z$4M8/@N1I?!VELV[(@"D/U&.,?I6]0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\[!PI1-Z$GGJ,*>GI2^/=&O=9TNRBL(3++'>*[88+A-K G)(XR0>/0?AUE%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *3(]:KZAD:;=%25/DO@@X(X/>
MO._"/AA=?\/0ZC<ZIJ<=T6D7,5VQ4%7.T]^01ZT >FT5PFCZGJN@^+%\.:I<
MF[MIU9[:XD.7YR1D_@PQZCCBMG5/&6FZ;?R6"Q7E[>18\R&SMVD*9&1DXQTP
M<9S@YQB@#HJ*PM*\5Z=K-A=75KYVZU!\^ H?-0@$XVCKG!Z9Y!'4&N3TOQZR
M^(=7-RNH7%AN4V\,5J6:(=&) &X=CCGK0!Z316/K?B73]!A1KMG:23/EPQ+N
M=\#/ [?4X&2!WJ#1O%MGJ]Z]DUM=V5VH9A#=PF-F4$<C/U_S@T ;]%8\_B6Q
MM_$<.AOYGVN9-ZX7*XP2,GWPWY&MB@ HHHH **** "BBB@ HIDLL<$3RRNL<
M:*69V. H'4DUYC?_ !^\$V6H_9(VU"[0-M:YMX 8QS@_>8$COD ^V:+ZV"VE
MSU&BLO0/$6E>)]*34M'NTN;5SC<H(*GN&!Y!]C6!XP^*'ACP3,+;4KF66]*A
MOLMJF^0#U.2 /Q(H>FC!:['9T5Q/@_XJ^%_&MS]DT^XF@OB"PM;M CL!UQ@E
M3ZX!S4WCGXCZ/X ^Q?VK;7TWVS?Y?V5$;&W&<[F7^\*'IN"UV.PHKQ__ (:.
M\'_] W7/^_$/_P =KL_ _P 0M)\?P7DNE6]["MHRK)]J1%)+ XQM9O2FDV)M
M(ZVBBBD,**YZU\8:?=^-[WPG'#="_M+<7$DC*OE%3MX!W9S\P[5T-'2X=;!1
M5:_O[32[&:^OKB.WM85WR2R'"J*\S/[0?@D:A]F']IF'./M0MAY?3KC=O]ON
MT=;!TN>JT54TS4[+6-.AU#3KF.YM)UW1RQG(8?Y[5P7B+XX>#_#FJ2:>[WM]
M/$Q27[%$K+&PZ@EF4'\,]*'H[,%JKH](HK$\,>+=%\8:<U]HMV)XD;9(I4JR
M-Z,#R*I^+_'WA[P1 CZQ=E9I03%;PKOEDQZ#L.V20/>AZ;@M=CIZ*\^\+_&?
MPCXJU&/3X)KJRNY6VQ1WL83S#Z JS#)]"0:]!IV8KA16!J7C#2=,\4:7X=ED
M=]2U'=Y<<0!\M0"=S\\ X('6M^ETN/R"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"O?X_LZYST\IN^.Q[URWPQ(;P7;L"QS)(<-U'S'_ /7^-==-
M'YT$D1)&]2N1VR*XC3_ FLZ79BSL_%<D%L,_NXK-1UZG[W!Z]* &>(0M_P#$
MC0[6-06MQYTCC'&"6 /X*?\ OJK=SKVK7VM7NG>'M/M=]LW^D7%TQ"[L8'"]
M>F.O\)Z8K6T/PM8Z&TDZL]S>R_ZVZGYD;IGGL.!]<#.<5G7W@VY_M6ZU#1=:
METI[P 7*QP*^\YY;)Z'!/T)H PO!45TOQ"UPWB1"X,&9?)7$>XE2<=_S[YZU
MH>%P/^%A^)P W C))[YSV]N:U="\'6^A:W<ZE%=2S-/%Y967+-GY2S%B2225
MS^-0:AX+EFUJYU33-:N=-FND"S^4@;<1CD<X'0=0?;&3D PM4&I2_%.5-/%L
MMY'9*T+78;9LXSC'4Y+?AN[BM.+0O$E[XCTW5=4DTM/L;-C[-Y@<JPP0<]?H
M>F36OKOA:#6I;>Z6ZGM-0MQB*ZA.& ]".XY/YD="<MTWPY>VNHI>W^O7E\T8
M(2(_NXAD8R5!^8]>OMZ9H VWAMVN$F>*(SJ,(Y4;A[ ]:FK"O/"UK>>*;77W
MGF6XMH]BQC&T_>ZYY_B/3%;M !1110 4444 %%%% &#XS\.S>*_"MYHD.HFP
M-T%5IQ%YF%!!(QN'4#'7O5O1= T[0=#@TBSM84M8HPA4( 'XY+#N3U.:TF8*
MI9B H&22>!7E>M^+-4^(%]-X:\"R&.R4^7J.N8_=Q+W2+^\Q]1^'K1K\*ZC\
MWT(?A3!!!X]\<KHZA-!2Y1(E3_5B49W!?8<].V*ZOPOX"M] \0:SKMU<IJ.I
M:E<-*L[P;6@C/2-26/'3D8S@<<5L>&/#6G>$]!M](TR,K!$,LS?>D8]68]R:
MR/&?CZR\*^586\+ZCKUT,6FG0<NY/0M_=7W]C3;M9+M;U$KRNWU=SD?BQ:6O
M_":>"I=-C1?$,FHKAXQAVA!&[=CJ![]LTOQ9N;>S\?\ P^N;J>."WBO9&DEE
M<*J &/))/ %;W@CP5?VNIS>*_%<ZW?B2[3:%7'EV<?\ SS3^1/\ ]<GG/C%I
MUIJ_C;P%IU]%YMK<W<D<L>XKN4F/(R""/PH5TX16]P;34F]N5_DST'_A._!_
M_0UZ'_X,8?\ XJMFSO;74+2.[LKF&YMI!E)H9 Z,/9AP:X;_ (4E\//^A>_\
MG;C_ ..5U$6CVF@^%9-+T> P6]O;R+!&'9BI()ZL23R>YJ9-*+8)-R2.#U/X
MD>*=:U6\L?A[X:BU2&RD\J:_NG"PLXZJF60''KN_#&#6IX1^(&I7VO?\(UXM
MT4Z-KAB\V$*X:*Y ^]L.3SU.,G@'GBO,?AKI/Q/O?!D$OA;Q-I%GIOFR 03Q
MJ9$?=\V[,+')Z]3P1756O@+XFWOB_0M8\2>(-'O8M+N/, B!1PIQO VPKG('
M0FK2LTF*3NFT9FJ^))/#7Q\UZ:UTZ;4=0N=/BM[2TA!S+(1&>3V  ))]JVHO
MB=XP\.:I:Q^/_"T&GZ=>2^7'>VD@982>F_#L#^:G&3@XJ32%MC^TIK[2X\]=
M,C\G/TCSCWQ_6MGXU_9_^%4ZOY^W),7EY_O^8N,>_6H3Y:<7O_P[+:YIN.VW
MY(UO'/@__A.=(M-..I&ULTNDN)U6/?\ :$7/R?>& <YSST'%;4FEZ5#HCZ?)
M9VJ:8D11H#&!&$ Y&.F,54T&X^P>"=,N-4F2#R=/B:XDD.T)A!N))Z5Y]?ZE
MJOQ>NGTK0FFL/!Z-MO=2*[7O,'F.,'D+[_GZ&I1LW!?UTN1&5TILR_AW?3:+
M\)O&6HV3.-/AN+I],+$\*%X(SVSC\<UV?P?T*TTKX<:7,D$8N;Z+[1<2[?FD
M+$D9/? P*N^+M"MK/X4:QHVF6ZQ6\.FR+#$O;:I/XGBG?"ZZCN_AEX?DC8,%
MM%C..Q7Y3^HIW7O6_NK\PULK^;_(Y31[:#PS^T%J&FV$206>KZ8+IH4&%$BD
M\@#IT8_\"-=3:^ K=?B'?^+K^Y2^FFC2.T@D@XM !@[26.2>><#&3ZUSCG[=
M^TG%Y3;EL-%Q+@9VEF/!_P"^Q78>+_&ND^#+!9[]VDN9CMM;.$;I9V]%'UQS
M[U*=HQ?K^;&U>4EZ?DCB_CS:V#^$K.;RE_MHWL2:>Z#][N)Y (YQC]<5W6M1
M^(7\*^3HDMM%K3I&@FN!E$)QO;'<@9(X//:N2\*^$]8U[Q#'XS\:J%O$!_L[
M2QREDIZ$^K_Y] /2J=K1L^]_Z_4+WE==#P/_ (1 ^%/C-X-:YU*XU+4K[SYK
MR[G/WW"D# [ =A7OE>5^-/\ DN7@/_KG<?\ H)KU2A.\%\_S$_C?H@HHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y;XA:)K?B/P?=:1H-U;VUU<E4DEGD9 (_X@"JDY/3I
MT)KSG1O GQB\/Z7#INE>*/#]K9PC"1I"I_$DV^2?<\U[?122M?S&W<X;P3I?
MQ$L=2N'\8Z]IVHV;0XACM4"E7R.3B).,9[FN%'PU^*-KXMU+Q%IVOZ%!>WKM
MF23,K(F>%!>$[0!@<>E>YT4^MQ=&CR.'P_\ &]9XS-XQT1H@P+J(5R1GG_EW
MKI?&/@_4?$/BSPGJMI-:I!I%RTUPLK,&8$K]T!2"?E/4BNWHIIV:?;45M_-6
M"BBBD,\FU#X8^)]#UB\U'X>^)8],CO9/,FL;M-T2L<Y*Y5Q^&WCUK1\,_#S6
MQXCMO$GC7Q#_ &QJ5JA%K!$FV&!CU8< $_\  1^/&/2**%H#U/*M=^%NK:O\
M1M2\36^L)IQ>WC%A/ [&6*90HRRX"E" P(R>O2H;;X8^+/$6IVL_Q"\30ZE9
M6<GF165H@5)#V+X1!^A/O7K=%$?=M;H#U."^*GA+Q!XR\/6^D:%=V=K$9=]U
M]HD= Z@?*HVJV1GGGT%<K9^$?C5I]E#9V?BSP_!;0H$CBC@0*JCH!_H]>ST4
M+2X/6QR'@K3/&=K:WT7C;5K'4VE*B#[,@ 5<'<#B-.O'K7%_\*S\=^%Y[B#P
M)XMMK72IY6D%K>QY\G/924?\QMZ#K7L=%#WN"T5CBO /@)O")O[_ %'4I-4U
MK47#75VX(R!T4 ]O_K=,5QOB3X=?$/4?B)<>*=*UC18&4[++[06D:&,# PK1
M,H/4Y'J>:]GHH>Z?8%LUW/'_ /A'OCG_ -#GH?\ WY7_ .1Z]7T]+N/3;5+^
M5);Q8E$\B#Y6? W$<#@G/859HIWTL*VMSBO$/A#4-6^(_AKQ%!-;+9Z6LHG2
M1F$C;@0-H"D'\2*[6BBDM%8;U=PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gv1ubg3hw41v000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2*!VP# 2(  A$! Q$!_\0
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M0K\/?^B6R_\ \#Q?E_U$^7XL/^(A<9?]#_&?^ T/_E/]7]+?T]?\15O[:_\
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M*M_;7_Z-P_9;_P"_WQ;_ /FTK^86BC_B%?A[_P!$ME__ ('B_+_J)\OQ8?\
M$0N,O^A_C/\ P&A_\I_J_I;^GK_B*M_;7_Z-P_9;_P"_WQ;_ /FTH_XBK?VU
M_P#HW#]EO_O]\6__ )M*_F%HH_XA7X>_]$ME_P#X'B_+_J)\OQ8?\1"XR_Z'
M^,_\!H?_ "G^K^EOZ>O^(JW]M?\ Z-P_9;_[_?%O_P";2C_B*M_;7_Z-P_9;
M_P"_WQ;_ /FTK^86BC_B%?A[_P!$ME__ ('B_+_J)\OQ8?\ $0N,O^A_C/\
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M]7]+?T]?\15O[:__ $;A^RW_ -_OBW_\VE'_ !%6_MK_ /1N'[+?_?[XM_\
MS:5_,+11_P 0K\/?^B6R_P#\#Q?E_P!1/E^+#_B(7&7_ $/\9_X#0_\ E/\
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M^_WQ;_\ FTK^86BC_B%?A[_T2V7_ /@>+\O^HGR_%A_Q$+C+_H?XS_P&A_\
M*?ZOZ6_IZ_XBK?VU_P#HW#]EO_O]\6__ )M*/^(JW]M?_HW#]EO_ +_?%O\
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MO_O]\6__ )M*/^(JW]M?_HW#]EO_ +_?%O\ ^;2OYA:*/^(5^'O_ $2V7_\
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M &]B];/X:'E_TY_J_H?T]?\ $5;^VO\ ]&X?LM_]_OBW_P#-I1_Q%6_MK_\
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M0K\/?^B6R_\ \#Q?E_U$^7XL/^(A<9?]#_&?^ T/_E/]7]+?T]?\15O[:_\
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M&X?LM_\ ?[XM_P#S:5_,+11_Q"OP]_Z);+__  /%^7_43Y?BP_XB%QE_T/\
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M]7]+?T]?\15O[:__ $;A^RW_ -_OBW_\VE'_ !%6_MK_ /1N'[+?_?[XM_\
MS:5_,+11_P 0K\/?^B6R_P#\#Q?E_P!1/E^+#_B(7&7_ $/\9_X#0_\ E/\
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M;^VO_P!&X?LM_P#?[XM__-I1_P 15O[:_P#T;A^RW_W^^+?_ ,VE?S"T4?\
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M_P"!XOR_ZB?+\6'_ !$+C+_H?XS_ ,!H?_*?ZOZ6_IZ_XBK?VU_^C</V6_\
MO]\6_P#YM*/^(JW]M?\ Z-P_9;_[_?%O_P";2OYA:*/^(5^'O_1+9?\ ^!XO
MR_ZB?+\6'_$0N,O^A_C/_ :'_P I_J_I;^GK_B*M_;7_ .C</V6_^_WQ;_\
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M6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N,O\ H?XS_P !H?\
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M6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N,O\ H?XS_P !H?\
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M\%C/^4I/[<'_ &6;_P!TOPE7R=3_ )+K!_\ 9(YI_P"KK)CZ.G_R2.*_[*/
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M7CM>Q?M%?\G"_'?_ ++!\0__ %)M0KQVO9P'^XX+_L$PW_IF!Y>+_P!ZQ/\
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M83P> 2>#Z&ID=)%5XV5T895T8,K#U5E)!'N#0 ZBBB@ HHHH **** "BBB@
MK]7/^"'_ /RE#_9D_P"OKQS_ .H9JM?E'7ZN?\$/_P#E*'^S)_U]>.?_ %#-
M5KYSC#_DD^)O^Q!F_P#Z@8@]OAK_ )*/(?\ L<Y9_P"IM$_//XX_\EM^,?\
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M?_)"\)_]B++_ /TQ$_G/C7_DKN(_^QOC/_3@4445]F?,!1110 4444 %%%%
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M9D+(S2#]);C_ (.F_P!H2&ZNX!^R5^R&1;WEY;JS:GXV#,MO<RPJS?Z=C+A
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M?T=?M&?&;XJR?\'-7P4T#_A/O$T6@>'O%_PQ\#:-H-OJMW;Z+9>%/$>BS?\
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M&)WBTR&WBC6VB=D3Y6(K[9_X)(65NG[<_P#P6UUG0[>P7XAV?Q*L+3PQ=>7
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MK7SG&'_))\3?]B#-_P#U Q![?#7_ "4>0_\ 8YRS_P!3:)^>?QQ_Y+;\8_\
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M6EDW>4?\%#O%OB+X@_\ !N)^Q[XS\::K=>)/%6KP_!*YU+7M6E>^U2\NDO\
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MU7*5#^SZM1U&H4ZDU4K0IQS7 F#KYQDV&>'Q&"R[%T<QQ&)QF'S; YG@L7'
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M0Z+8_%'X_?$"V^&/@_Q%JB2>3/:^'+ZYL-2GU$03XMS=-;6]E-/F.TN;EHY
MG]0O@FW_ &7+3_@W]_:XT+]D+5?BUXE^".@Z3X\TG1_$?QCBC@U7Q'JL&L^$
MY=8UGP_I&T'1?"UU>2[].TF>..XL[I;SS%#G-?#'[%G[9W_!,+]L3_@G7\%/
M^"</[?NN>)/@S>?"A]+TWP_XHBO=6\->%O$,VBSZEJ>F>)(?']AIVH^']!N1
M#?2V>K:;XMCM8[F4A[-YV=GBX\/QYQ=7R;-:M++ZN)Q&3\6_V/F&,PV25JF8
M8;)5AEB98^?#WUY2>-IRE"C5HK%\E&$G.I!2A)OIK<(<-T<SRZE4QT,/1S/A
MV.9X3#5\TI0PE?,W7]@L)#.7A>7ZM.*E5IU'0YJLHJ,)N,T?B]^V'_P2F_;#
M_8B\%:#\4?BOX;\'^+/A)XADT^"S^+'P?\5#QYX"M[O5@YTJUU'5/[/TJ[LV
MU(12-8W;:>VFW(7]W>ME<]5^Q=_P1R_;C_;O\"W7Q1^#?@_PGX<^&RW$EIHO
MCCXJ^([OPEHGB^YMY&AOD\))8:-K^J:K!I\RF"ZU!M/MM,,X:&VO;B6&=(OU
M _X*5?\ !,+XF_#W]A.#XP?LO_M\^)_VIOV&/A,+O44^&%_XKTW5- \"^$9]
M8:VEU7P=K7AC4;S1O&]MX<U*ZQ>V>J3)?VTDP72['9'(D7ZK?M_Z7^SGX3_X
M)F_L._#?Q]^VG\5/V'O@IJW@SX<-9^(O@G\+O$_C*3Q]JL?@'3=<BT/6-0\&
M>7>>&K9M0N]0\026YNK9=2U 2+,TOV62-BOXC9I/*<BH99C\!F&:YQGN8975
MS##\/YS4GEU#+Z,,3.GB.'H.>85,VE2JTE*A2;PZ4IRA)TX^W3H\#X".99K4
MQ^%QF"R[+<IP./IX6MG&60AC*N-G[!3HYU.,,''+X5(U+59KVSDHQDE*2I/^
M.O\ ;/\ V!/VG?V!_&VD^"?VB_ \6CGQ+;O<>$?%_AF\D\1>!O%WDE5N[70-
M>CM;5YM3LW=%N=)O;*QU0*Z2QVDD#+*?K_X9?\$,OVW_ (B^!O /CK7=5_9Z
M^!L7Q1M+34/ 7A#X^_%^W^'_ (_\2V&H)#+IMWI_A9-$UBZ?^T(;FVFMK0R#
M4=MS"DUG#,3&/TB_X*'_ /!0G]A3XI_\$V_A'^SOX&_:>\8?M5?M"_ CQ]\)
MO$_@OQY\0?@SX^\!>(?&&G^#?$$#ZU<ZGJ?B#0+;18;B[\,I]AO;E=3FFU..
M&/*RR2.P^LOB/\;/^"-7_!:?1?A5XN^.WQQ\3?LJ_M*_#7P5!IVACQ#XHD^&
M-OX2U>[O1<(NEZKK]O%X(\:6]GJ\$E]HS:-KMGJ,<,T$=XUO-MMUUK\:\:TL
MGRK$XS)<=ER^OYK@LZS6APUF.,G3I82%&65X^AD>)K8+&4<%F7MFZU6M*;P\
MJ%2G"//*,%C2X5X4GF688?#YMA<:_JF7XK*LOJYW@L+&=3$2FL?A*N;4*6)P
MM;%8+V5J=*G&FJL:L*DFX*4C^5?]L']AS]I/]A3X@6?P[_:-\"_\(S?ZQ;7-
M[X6\1Z3>KK7@SQC8V4RP7EYX:UV*.$726LTD:7%M>6UC?Q&1&>T",&KY)K]X
M_P#@MI^PE^U+^S%K_P +/BK\7?VI_$_[7_P@^($">&/AK\2?%U^L6O:)>V.C
M0ZC%H=[X=L[JXT2"UO\ 1;9+S3-<T)[F#4;>VS?W"W3I&?P<K]+X4S?^W<@R
M[,WCL#F-2O2DJ^*RVCB</A)UZ525.I&&'QG^U4)PE'EJTJZC.-12:C&+BE\+
MQ#EO]D9QC< L+B\'"C4C[*AC:M&OB(TIPC.$I5\,E0JQFI<].=.Z=-QNW)2;
M****^B/%"OUG_P""&?\ RE(_9H_W_'G_ *A^H5^3%?K/_P $,_\ E*1^S1_O
M^//_ %#]0KYOC+_DD>)_^R?SC_U7X@]SAC_DI,@_['65_P#J;0/SZ_:*_P"3
MA?CO_P!E@^(?_J3:A7CM>Q?M%?\ )POQW_[+!\0__4FU"O':]G ?[C@O^P3#
M?^F8'EXO_>L3_P!A%;_TY(****ZSG"O[3/V(IOV3/V:?^"%'@7]LWXL_L7_!
M/]HWQ1X5N?&0UB'Q-X%^'9\6^)Q<?%C7]#LA>>-?$_@[Q/=XTZU,$4(N+>Z"
M6MO';Q+&JKC^+.OZ][)@O_!JEEB%'VCQ)R3@?\ESUSN:_+O%*G]8P?"."G4K
MPP^/XYR/!8N.'Q%?"SJX7$T\;3K4O;8:I2K14XO>$XR32DFI)-?H'A]4]ABN
M(\5&%&=;!\)YKBL.ZU&E7A3KT:V"E3J>SK0G3;B_YHM-7333:/4?V1OV@?\
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M&26)V1U*L0>,L_\ CSM/^O:#_P!%+7<?#O\ Y*/\-_\ LHO@3_U*](KZBO\
MPZW^"I_Z2SP*'\2C_CI_FC^D[_@YI^"/P8^"OQ,_92LO@W\)/AK\)[/7O!'C
M:ZURU^&_@CPYX*MM9N+?4;%;:?5(?#NGZ?'?S6R,R02W2RR1HQ"MR2?Y@NX
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MJT\%:C>Z'JE[#'<-:W7BSX@^$_'&HZ_X@>-VN=1T^Q71[#3KAOL=ND: )'\
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MI2E%0_).OVX_X-_?^3]M=_[-;_:(_P#4/%?B/7[<?\&_O_)^VN_]FM_M$?\
MJ'BOON//^2-XE_[%&+_]-L^/X0_Y*C(?^QGA?_3B/P]LO^/2#_KF*M55LO\
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M56!MHI;BZC.FMHFD6KW5M!!-))IZZA_:+B-A!9S/A:_1W]E__@J_^P;\!_\
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M,LSDHJ&89I6@DH149^PIT,/4K8BK>":4/?\ PN_;1_X)]?M/?L$>,O#O@_\
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MNP_["6F_^E]M4=20?\?=A_V$M-_]+[:@:W7JOS/VY_X.#?\ E(5_W;Y\"?\
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M@'Q-);*KWMCI6O\ V2QD35+%'22YTS4K'3[X1,9X8)H$>1?$OV;OA9H?QO\
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MW2K<LG&4:E*22OS3^4XJRK)<O678C)L72G'&4ZZQ>7K-,#FU7 5J$X1@Y8O
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MR_:]_P"R5_#G_P!2[5*_MZK^%_&W_DXV<_\ 8/E/_JKPA_6?A5_R166_]?\
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M+U[##RC"AC)2EB:-:,J;CB85>:2E&NJFCLK']-_[/_\ P7=_9-_9B^'WQ,^
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MAE\<LQ%"<J:IJ,E#,*:J8+$I0E!XK"5>>=.<4XQE2A(_3G_@NE^U]XH^"?\
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MX.665:M;!4L!A,)@L-1K5_\ >*CPV&HTZ%2>(C[E9U:<_:4VX/W9-/\ I?\
MC3_P7G_9OU+X&_%/X4_LR?\ !,[X4?"'6OB^;Y_%FK>,]/\ ASX@\*7%_JEO
M<V]UXDO?#/AKPWI7]N>)+87=Q-IUUJCR6\=P^^>%T=U/S!^P_P#\%>_!_P
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M#2+_ $GPU\0(M/%H(]6L'NK75+&XLWTBZAF0O:>;&#7J?PQ_X+"_L:?L@_\
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MGF+KX?$U9TL9CL/0Q&)PB4<-B,5@Z&(IX7$5J,4E&=6C)M*TN97OWX;B[/\
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MN+/][Q?_ "/4FEB_XWP6;7U;_=O^G)E_K1G7_03#_D1_ZN?[OA_^12VF\/\
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M%JB^"= T6]2WO[*_NGANYYI!97)BNH%2>%'KW+6/^"[/[(5I^TG9_MG^!?\
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M*QF*A4PF$K4'BXI*.*HT*M"=+#UXJ*2J4(4Y62O?EC;](;C_ (*3_%+XB_\
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M1110 4444 %%%% !7ZN?\$/_ /E*'^S)_P!?7CG_ -0S5:_*.OU<_P""'_\
MRE#_ &9/^OKQS_ZAFJU\YQA_R2?$W_8@S?\ ]0,0>WPU_P E'D/_ &.<L_\
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MR>:8/!5\OP]?VM51AA,3-5*U-T5-49.4TGSR@YQVC)+0]"&:8VGEF(R>%5+
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MMC;6]KJGAN3P%J&F/K$N@W4.G:;;Z?9WU]*EM;)<Q7(F#P^7T'Q)_P""M/[
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MP)^TGX.\1_!CQ5\5Y_CWHFF:18ZAX=\6Z'X9A\-?8-)\2:;)+?0:OI]])?\
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MZ\4I?:A_:.J::-<E=@+'6I4@75+F_:ZU)XX%CM[B*)FCKU3]BG_@N39?!/\
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M\0M/[1?_ $7;X+_^"CQ5_P#&J/\ B%I_:+_Z+M\%_P#P4>*O_C5'_$9. /\
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M^OW??_*%N'J/SHW#U'YU_5[_ ,0M/[1?_1=O@O\ ^"CQ5_\ &J/^(6G]HO\
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M7S?W!_Q"_C/_ *%?_ES@_*__ #$^OW??_*%N'J/SHW#U'YU_5[_Q"T_M%_\
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M?VB_^B[?!?\ \%'BK_XU1_Q"T_M%_P#1=O@O_P""CQ5_\:H_XC)P!_T.X?\
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M^X\S_B%_&?\ T*__ "YP?E?_ )B?7[OO_E"W#U'YT;AZC\Z_J]_XA:?VB_\
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M?R_ZCO-_<'_$'.+/^?V3?^%N(\O^H+S_  ?8_@BHK^]W_B%Z_8N_Z*+\5?\
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M;^X/^(.<6?\ /[)O_"W$>7_4%Y_@^Q_!%17][O\ Q"]?L7?]%%^*O_?[1O\
MY#H_XA>OV+O^BB_%7_O]HW_R'1_Q'_@;_GQG_P#X;\/Y?]1WF_N#_B#G%G_/
M[)O_  MQ'E_U!>?X/L?P145_>[_Q"]?L7?\ 11?BK_W^T;_Y#H_XA>OV+O\
MHHOQ5_[_ &C?_(='_$?^!O\ GQG_ /X;\/Y?]1WF_N#_ (@YQ9_S^R;_ ,+<
M1Y?]07G^#['\$5%?WN_\0O7[%W_11?BK_P!_M&_^0Z/^(7K]B[_HHOQ5_P"_
MVC?_ "'1_P 1_P"!O^?&?_\ AOP_E_U'>;^X/^(.<6?\_LF_\+<1Y?\ 4%Y_
M@^Q_!%17][O_ !"]?L7?]%%^*O\ W^T;_P"0Z/\ B%Z_8N_Z*+\5?^_VC?\
MR'1_Q'_@;_GQG_\ X;\/Y?\ 4=YO[@_X@YQ9_P _LF_\+<1Y?]07G^#['\$5
M%?WN_P#$+U^Q=_T47XJ_]_M&_P#D.C_B%Z_8N_Z*+\5?^_VC?_(='_$?^!O^
M?&?_ /AOP_E_U'>;^X/^(.<6?\_LF_\ "W$>7_4%Y_@^Q_!%17][O_$+U^Q=
M_P!%%^*O_?[1O_D.C_B%Z_8N_P"BB_%7_O\ :-_\AT?\1_X&_P"?&?\ _AOP
M_E_U'>;^X/\ B#G%G_/[)O\ PMQ'E_U!>?X/L?P15^W'_!O[_P G[:[_ -FM
M_M$?^H>*_HE_XA>OV+O^BB_%7_O]HW_R'7T+^S)_P0:^!/[(GQ*N/BU\%OBK
MX]TWQE=>#?%?@.6XURQT36+$^'_&>G'3-:C%FUO#BZ-OM:UN/,_<RHK%'7*G
MP>)_&W@[..'LXRO"4<Z6)Q^7XC#4'6P5"%)5*D$H^TFL9-QC=ZM1DU;9GK9#
MX5<399G65YAB*N5.AA,;0KU52Q=>=3DIR4I<L7A(IRMLG)7::N?YR=E_QZ0?
M]<Q5JO[VD_X-=_V+8T6-/B+\5MJC S/HQ./<_8AFG_\ $+U^Q=_T47XJ_P#?
M[1O_ )#KWO\ B/\ P-_SXS__ ,-^&\O^H_S?W'D+P;XLLE[;)ME_S&XCR_Z@
MO/\ !]C^"*BO[W?^(7K]B[_HHOQ5_P"_VC?_ "'1_P 0O7[%W_11?BK_ -_M
M&_\ D.C_ (C_ ,#?\^,__P##?A_+_J.\W]P_^(.<6?\ /[)O_"W$>7_4%Y_@
M^Q_!%17][O\ Q"]?L7?]%%^*O_?[1O\ Y#H_XA>OV+O^BB_%7_O]HW_R'1_Q
M'_@;_GQG_P#X;\/Y?]1WF_N#_B#G%G_/[)O_  MQ'E_U!>?X/L?P145_>[_Q
M"]?L7?\ 11?BK_W^T;_Y#H_XA>OV+O\ HHOQ5_[_ &C?_(='_$?^!O\ GQG_
M /X;\/Y?]1WF_N#_ (@YQ9_S^R;_ ,+<1Y?]07G^#['\$5%?WN_\0O7[%W_1
M1?BK_P!_M&_^0Z/^(7K]B[_HHOQ5_P"_VC?_ "'1_P 1_P"!O^?&?_\ AOP_
ME_U'>;^X/^(.<6?\_LF_\+<1Y?\ 4%Y_@^Q_!%17][O_ !"]?L7?]%%^*O\
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M7_4=YO[@_P"(.<6?\_LF_P#"W$>7_4%Y_@^Q_!%17][O_$+U^Q=_T47XJ_\
M?[1O_D.C_B%Z_8N_Z*+\5?\ O]HW_P AT?\ $?\ @;_GQG__ (;\/Y?]1WF_
MN#_B#G%G_/[)O_"W$>7_ %!>?X/L?P145_>[_P 0O7[%W_11?BK_ -_M&_\
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M]7O+C4M4NY=+\52RW6H7LK7%Y<22>1'ODFGDDD9MB;BQ;:N<"G_Q"T_M%_\
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M3@#_ *'=/_PFQWE_U">;^X%X8<9JS_LM=/\ F)P?E_U$^OW??\ _\'!P*_\
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MU1_Q&3@#_H=P_P#";'>7_4+YO[@_XA?QG_T*_P#RYP?E?_F)]?N^_P#/+]H
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MO_C5>U_Q&3@#_H=P_P#";'>7_4+YO[CS/^(7\9_]"O\ \N<'Y7_YB?7[OO\
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M%_\ 1=O@O_X*/%7_ ,:H_P"(R< ?]#N'_A-CO+_J%\W]P?\ $+^,_P#H5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K
M_=/X?S%.IK_=/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &I]Q?]U?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :/O'\?Y)3J:/O'\?Y)3J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IZC_/\2TZFGJ/\_Q+3J (
MXON#_/85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/X?S%.IK
M_=/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_P"ZO\A3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^
M\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* &GJ/\ /\2TZFGJ/\_Q+3J (XON#_/85)4<7W!_GL*DH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0]#]#_ "H'3\3_ #-!Z'Z'^5 Z
M?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &O\ =/X?S%.IK_=/X?S%.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&YG2UMY[F0,8[>&6=P@
MRQ2%&D8*"0"Q53@$@$XY% $U%?S$7_\ P=K?\$J--OKS3KR']I2"[L+JXL[J
M"7X/V\,L-Q;2O#-%)%-XLCFBDCD1D>.6-)$8%9$5@5%3_B+C_P""3_I^TA_X
M:.R_^:^OTY>"WBW)*4?#CC)QDDXM9!F#332::?L-4TTT^MT<?]H8#_H,P_\
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MT<!_T&8?_P '0_S\U]Y_4%17\OO_ !%Q_P#!)_T_:0_\-'9?_-?1_P 1<?\
MP2?]/VD/_#1V7_S7T?\ $%?%S_HV_&?_ (8,Q_\ E'FOO#^T<!_T&8?_ ,'0
M_P _-?>?U!45_+[_ ,1<?_!)_P!/VD/_  T=E_\ -?1_Q%Q_\$G_ $_:0_\
M#1V7_P U]'_$%?%S_HV_&?\ X8,Q_P#E'FOO#^T<!_T&8?\ \'0_S\U]Y_4%
M17\OO_$7'_P2?]/VD/\ PT=E_P#-?1_Q%Q_\$G_3]I#_ ,-'9?\ S7T?\05\
M7/\ HV_&?_A@S'_Y1YK[P_M' ?\ 09A__!T/\_-?>?U!45_+[_Q%Q_\ !)_T
M_:0_\-'9?_-?1_Q%Q_\ !)_T_:0_\-'9?_-?1_Q!7Q<_Z-OQG_X8,Q_^4>:^
M\/[1P'_09A__  =#_/S7WG]05%?R^_\ $7'_ ,$G_3]I#_PT=E_\U]'_ !%Q
M_P#!)_T_:0_\-'9?_-?1_P 05\7/^C;\9_\ A@S'_P"4>:^\/[1P'_09A_\
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MYK[P_M' ?]!F'_\ !T/\_-?>?U!45_+[_P 1<?\ P2?]/VD/_#1V7_S7T?\
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MS\U]Y_4%17\OO_$7'_P2?]/VD/\ PT=E_P#-?1_Q%Q_\$G_3]I#_ ,-'9?\
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M ,$G_3]I#_PT=E_\U]'_ !%Q_P#!)_T_:0_\-'9?_-?1_P 05\7/^C;\9_\
MA@S'_P"4>:^\/[1P'_09A_\ P=#_ #\U]Y_4%17\OO\ Q%Q_\$G_ $_:0_\
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M_P -'9?_ #7T?\1<?_!)_P!/VD/_  T=E_\ -?1_Q!7Q<_Z-OQG_ .&#,?\
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M?1_Q%Q_\$G_3]I#_ ,-'9?\ S7T?\05\7/\ HV_&?_A@S'_Y1YK[P_M' ?\
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MH :GW%_W5_D*=34^XO\ NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ=UCXU^!K>5] ETV*TT;QMJ/A^;XN+>J(()(]3N-/.AM<O'&T::?+*RPO\
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K_=/X?S%.IK_=/X?S%.H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K.UC_ )!.J?\ 8.O?_2:6M&L[6/\
MD$ZI_P!@Z]_])I::W7JOS _PP/B;_P E(^('_8[>*O\ T^7U</7<?$W_ )*1
M\0/^QV\5?^GR^KAZ_P!Z\N_Y%^!_[ \-_P"F8'Y@]WZO\PHHHKL$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^\?Q_DE.H
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M !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110!^9/\
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M;ZXU34[V]U;6KS4=:UG5]6U.[NM2U?6=8U"^U75M1NKF_P!1O+F\N)IG]]H
M**** "BBB@ K.UC_ )!.J?\ 8.O?_2:6M&L[6/\ D$ZI_P!@Z]_])I::W7JO
MS _PP/B;_P E(^('_8[>*O\ T^7U</7<?$W_ )*1\0/^QV\5?^GR^KAZ_P!Z
M\N_Y%^!_[ \-_P"F8'Y@]WZO\PHHHKL$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7];_\ P;,?\%GY?V2_B;IG[#W[0WB.WMOV
M;_BMKDR_#/Q)JESY$7PJ^)NO:BLHT^1W7R!X5\;:A>7#W+R302:=X@E65!??
MVKY=E_)!3E=D971F1T8,K*2K*P.0RD<@@\@CD&OC/$#@7)?$;A;,N%<]I7PV
M-A[3#8J,(RQ&69C2C/ZGF6$<K<M?#3G*Z4HJO0G7PM1^QKU8OHPN)J82O"O2
M>L7K'6TX/XH2\G^#2DM4C_>#CDCFCCEB=)8I462*6-@\<D;J&22-U)5T=2&5
ME)5E(()!I]?R&_\ !LK_ ,%IC^U9\/+3]AG]I#Q&\G[0OPE\/0GX7>+M8NT>
M7XN?#73$2U33Y[B>4W,_C;P6@@MM028'^UM%FT_4+26>>#5+>P_KRK_&CCG@
MK._#[B?,^%L_H>RQV7U?<JPN\/CL)57/A,?A*C2]IAL51<:D&TITY<]"M&G7
MI5:</T'#8BGBJ,*U)WC-:KK&2^*$O[T7H^CW5TTQJ?<7_=7^0IU-3[B_[J_R
M%.KY$W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
MH^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &GJ/\ /\2TZFGJ/\_Q+3J (XON#_/85)4<7W!_GL*DH *Y
MGQ=XU\'?#_1+CQ-X\\6>&O!7ARTDABNO$'BW7-,\.:);2W#^7!'<:KK%U9V,
M,D[_ "1)).K2/\J GBNFK\#O^#FB""Y_X(W_ +4Z7$$4Z)9^&KA$FC254GMM
M72XMIE5U8+-;SQQSP2 !XIHTDC9756 !^U%U\9?A!8ZSX;\.7OQ5^'%GXA\8
MVT%YX1T*Z\<>&;?6?%-I=#-M=>'=,EU-+W6[>X',$^FP7,<PYC9A5O7?BM\+
MO"_B?1_!'B;XD> O#OC/Q"$;0/".N>+_  _I/B;7%D=DC.D:#?ZA;ZIJ0=T=
M$-G:S!G1E7)4@?YZ_P#P4,_X)3? [X%_\$)?A!_P4QL?''QL\0_MWZ+X:_9O
M\5S?'G5OC+\2Y[RS/Q)\<^'-*U#P]X-\.2>)3X>\$^'O#R^++H^%+;PYINFS
MZ/';Q"&4222N=_\ X*K_ /!-?X>>!/\ @BU\,?\ @JUXT^)GQO\ B5_P47U*
MU_9S\5:[^TAXH^+7C ZR+?XD>*M-C@\/>&_#6B:GI7@KPEIGA'3M?6S\.R^&
M?#^EW\<MM+J]]=WNO:CJ6J78!_H(^.?B7\.?AC86>J_$KQ_X*^'NEZC>C3=/
MU+QOXIT/PI87VHM%).MA9WFNWUA;W-ZT$,LPM89'G,44D@38C$6/%?C_ ,">
M!/#I\7^./&OA/P;X3#V:'Q/XJ\1:1X>\/!]094L$.LZM>6FG![YG5;1?M.;E
MF40AR0*_B\_X.3M8OOB)_P $<O\ @FGXC\;-!XBUC7_V@_V?[W6+O4;6"X^W
MW5_\,/&%G?SSQ3)(C/?6L]Q!=D@_:(KFXCEW)-(K??W_  =# #_@@G\3P0 1
MK7[*^T' ((^*'@0?*#SD*2..=I/;- 'Z._\ !5'_ (*M?!K_ ()D?LFW/[2N
ML6NG_%K4M>DT[3OA=X$\,^+O#]M<^.-0UQ'72M7M[Q[JXEF\'V\YMGUC7M&L
M=7%G:W$<L<$S21HWW-\!/CGX%^.GPL\-_$/PMXX\!>*EN_#VC:CXHF\$^*='
M\1:3X=U;4-(M]5N]+O[O3;^\2PFLTG):&^DAN%A7S9$53FOXL/\ @XL_9O\
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M%F_,'@CX5>#M9\8ZG:6=Q9+K&MP:-927SZ7X>M;NX@_M35KJ*-OLMC:F:ZG
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M03>[MNWYMW?;730****^<-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB++>W.;1$NTU+7!%9W4;/>09CVE8Y48 ^N?@]_P7J_;1^%_QJ^ O@7_@J?\
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M2LKJUOK9GT[5M/NK74]+GN=/NK>XD^\9K*P;3I=.GM[<Z6;)[*:UE5?LAL#
M8)()%;Y/L_V?,;JWR^7D'BO&?V?/A7^SO\(_A_8^&/V9O!OPQ\&?#>W8PV6G
M_"NST.W\/;[8>5Y8FT,O#.]LH$2+)-(T" 1H$3"T >YT444 %%%% "'H?H?Y
M4#I^)_F:#T/T/\J!T_$_S- "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 -?[I_#^8IU-?[I_#^8IU !1110
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M?#UCHNE>([VUTZPDL7DNX]3UZ#0[JX:\TY9X+9OML5I_5?10!_*G_P $H/\
M@D_\:+O_ ((0_$__ ()T?MC^ ]=^ GQ#^)T_QJT::UU"^\+^(=1\-'Q?KVL:
MCX5\66EQX9UGQ#H=Y]D-[9W\4)O9&62-HKB!70H?E?X.6W_!S9^Q=^SO8_\
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MCMXJ_P#3Y?5P]?[UY=_R+\#_ -@>&_\ 3,#\P>[]7^84445V""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M26-VD:*,L[O;R*J*.[,Q  [DU>HH3MJ!_D!^,O\ @AW_ ,%<M>\7^*M<L_V
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M\_\ U_I:G^KN$_Y_XG[Z7E_TZ]?O\C_'?_X<2_\ !7K_ *,&^/7_ ()=)_\
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MH_XG7\1?^B6X(_\ ";B#_P"?_K_2U/\ 5W"?\_\ $_?2\O\ IUZ_?Y'^._\
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M?_ES1_PXE_X*]?\ 1@WQZ_\ !+I/_P N:_V(**/^)U_$7_HEN"/_  FX@_\
MG_Z_TM3_ %=PG_/_ !/WTO+_ *=>OW^1_CO_ /#B7_@KU_T8-\>O_!+I/_RY
MH_X<2_\ !7K_ *,&^/7_ ()=)_\ ES7^Q!11_P 3K^(O_1+<$?\ A-Q!_P#/
M_P!?Z6I_J[A/^?\ B?OI>7_3KU^_R/\ '?\ ^'$O_!7K_HP;X]?^"72?_ES1
M_P .)?\ @KU_T8-\>O\ P2Z3_P#+FO\ 8@HH_P")U_$7_HEN"/\ PFX@_P#G
M_P"O]+4_U=PG_/\ Q/WTO+_IUZ_?Y'^._P#\.)?^"O7_ $8-\>O_  2Z3_\
M+FC_ (<2_P#!7K_HP;X]?^"72?\ Y<U_L044?\3K^(O_ $2W!'_A-Q!_\_\
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M$%%'_$Z_B+_T2W!'_A-Q!_\ /_U_I:G^KN$_Y_XG[Z7E_P!.O7[_ "/\=_\
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MB_\ 1+<$?^$W$'_S_P#7^EJ?ZNX3_G_B?OI>7_3KU^_R/\=__AQ+_P %>O\
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MWNV^K9[@4444@&I]Q?\ =7^0IU-3[B_[J_R%.H **** "BBB@ HHHH ****
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MK_=/X?S%.IK_ '3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO
M\A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H
M^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &GJ/\_Q+3J:>H_S_$M.H CB^X/\]A4E1Q?<'^>PJ2@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\J!T_$_S-!Z
M'Z'^5 Z?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &I]Q?]U?Y"G4U/N+_ +J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :>H_P _Q+3J:>H_S_$M.H C
MB^X/\]A4E1Q?<'^>PJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!#T/T/\ *@=/Q/\ ,T'H?H?Y4#I^)_F: %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_P!T_A_,
M4ZFO]T_A_,4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS->%3?'2WCBDD_X5G\6'V1NY5/"#L[;5)VHOVOYF.,*.,G R.M/'QQ@^8?\
M"M?BM\LL\>?^$1?!\J:2+<O^E\H^S?&PX:-E;O@ 'N=%>&_\+Q@_Z)K\5O\
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M^%XP?]$U^*W_ (2+_P#R70![E17AO_"\8/\ HFOQ6_\ "1?_ .2Z/^%XP?\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8.3_P *U^*W )_Y%%^PS_S]T >X)]Q?]U?Y
M"G5X%9?'JVNX%E7X8?%R$ A=D_@Z2-^%4YQ]K/'/7/X5;_X7C!_T37XK?^$B
M_P#\ET >Y45X;_PO&#_HFOQ6_P#"1?\ ^2Z/^%XP?]$U^*W_ (2+_P#R70![
ME17AO_"\8/\ HFOQ6_\ "1?_ .2Z/^%XP?\ 1-?BM_X2+_\ R70![E17AO\
MPO&#_HFOQ6_\)%__ )+H_P"%XP?]$U^*W_A(O_\ )= 'N5%>&_\ "\8/^B:_
M%;_PD7_^2Z/^%XP?]$U^*W_A(O\ _)= 'N5%>&_\+Q@_Z)K\5O\ PD7_ /DN
MC_A>,'_1-?BM_P"$B_\ \ET >Y45X;_PO&#_ *)K\5O_  D7_P#DNC_A>,'_
M $37XK?^$B__ ,ET >Y45X;_ ,+Q@_Z)K\5O_"1?_P"2Z/\ A>,'_1-?BM_X
M2+__ "70![E17AO_  O&#_HFOQ6_\)%__DNC_A>,'_1-?BM_X2+_ /R70![E
M17AO_"\8/^B:_%;_ ,)%_P#Y+H_X7C!_T37XK?\ A(O_ /)= 'N5%>&_\+Q@
M_P"B:_%;_P )%_\ Y+H_X7C!_P!$U^*W_A(O_P#)= 'N ^\?Q_DE.KP<?'2W
M,K1_\*S^+.09!N/@]PIV16<A(/VO[K?:0B'^)X9QQY?,W_"\8/\ HFOQ6_\
M"1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#
MW*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,
M'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\
MA(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)
M='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z
M)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_P"ZO\A3
MJ:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -'WC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 T]1_G^):=33U'^?XEIU $<7W!_GL*DJ.+[@_SV
M%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0
M.GXG^9H/0_0_RH'3\3_,T +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 U/N+_NK_ "%.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 T?>/X_P DIU-'WC^/\DIU !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T]1_G^):=33U'
M^?XEIU $<7W!_GL*DJ.+[@_SV%24 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (>A^A_E0.GXG^9H/0_0_P J!T_$_P S0 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
M7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #4^XO^ZO\A3J:GW%_W5_D
M*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'W
MC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 T]1_G^):=33U'^?XEIU $<7W!_GL*DJ.+[@_SV%24 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0.GXG^9H/0_
M0_RH'3\3_,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY<?G.ADV)NVC^K.@ HHHH 0]#]#_ "H'3\3_ #-!Z'Z'^5 Z?B?YF@!:***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;/Q-&_B2.QGN!?2:9J4EC SS01#^I:+X#_!"#QLWQ+A^#OPNB^(KN9&\>1>
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M\/YBG4U_NG\/YBG4 %%%% !1110 4444 ?!G[=W_  4N_8\_X)K^%/!/C?\
M;!^).J?#7PS\0_$-QX5\*:AIO@'QYX];4-=M=-NM7ELY;/P'X=\17UD!I]E<
MSBYO;:"T)B\KS_.>.-_S*_XBK_\ @A__ -'5^*O_ !'']HS_ .=?7[P_$/X.
M_"3XNVVG6?Q6^%_P]^)EII$\ESI5KX_\&^'?&%MIES-'Y4MQ80>(-.U"*SGE
MB)CDEMUCD>,E&8J<5_&S^S?^SQ\ =0_X.P/VQ/AC?_!#X27OPVTG]CE=7TKX
M?W?PZ\)7/@K3-6/_  I,'5-/\+S:2^B6FH,+JZS=P6*3'[3<?/\ O7R ?U5_
ML4?MX_LQ_P#!0OX3W/QN_91\=:A\0?AM:>(;_P +2Z[J/@[Q?X)F_MK2R!?6
MJZ/XUT70=9*PL0OV@V @EZPR2+AJ^PJ_F@B_:U^+7P2_X.$OAS_P35^#UG\,
M_AC^R!XF_99'QOUWX:^!_A3X&\,RW_CV>7Q?I\VH-KFCZ/9ZC%'+_8^G7$D<
M;J7D@*%_)D9*[_\ X**_M_?M0?L^_P#!8+_@EM^R-\+O&NDZ+\#_ -J2W^(;
M_%[P]>>$?#^KZGJS^$X+B[T]M,\0:A9S:IHWFX2&Y%C.@>- 4V2,SD _H@HK
M^3/]M+_@IU_P4^\#?\%N1_P3O_8UT7X6_$S1O'W[-VC>+/!7@WXI6=KX9\(^
M!O%U_=Z\^M_$CQG\0-$T;5O&+>&/#^D>'Y-FA66GZF]_K&I6,(2*W\S/SW\#
M/^"K_P#P7"^%?[9_Q1_X)4_M"?"_]G']H;]M+Q;X5L/&7P2^)WA;5[CP%\$/
M &AZE!.MSXG\>W5KX1T_Q%KO@C2#&'A&F>#9?$TFH[;.XMKBR+WT8!_:A17\
MJ'_!*_\ X*4_\%*K+_@I[\9?^"5'_!3S_A4?CWXH^'?A9+\8?"/Q1^#&F#2_
M#<.G1?\ "*&+1X%&A>%Y=5TB_MO$;R0ZE?Z!8ZC:W^GW5I,L\!@N),S]I3_@
MIQ_P5$_;9_;M^-G[!?\ P1KT+X'^#M-_9<MM,?XV_M0?'9YK[PJ/%$S2+=>#
M-&M(/#_B^$"266TMK:ZM/#FLWANK/6[;4(M'\O3;VZ /ZPJ*_FC_ ."</_!4
M+]M_PW^W#JW_  2J_P""K?@/P!9_M-_\(-<?$3X5_';X.^9%\,?BYX?MC;23
M6D%I<6&D-'JHM;EI8I+31]-#'3M1:^TO2E?38KOX>^*G_!4__@KW\0?^"OW[
M=O\ P3%_8QB^%OB;5-#3PM;_  0\6_$_1]#\.^!/V=M%3X;>$O'/BWQSXYUK
M3?#GB#Q'XUEO]2UM?#_A[1GT762EUJ$4EQ:O90W5Y8 ']GM%?)_[$GAC]KGP
MA^S;\/\ 1?VY_B/\/OBI^TY'%J=S\1_%GPKT#_A'/ 3W-YJ=U<:9I/AZR:PT
MJ:ZM]$TI[33)=9GTK2)=;N;:;53H^D"[73+7ZPH **** "BBB@ JGJ/_ "#[
M[_KSN?\ T2]7*IZC_P @^^_Z\[G_ -$O50^./^*/YH3V?H_R/\\;Q+_R,&M?
M]A.]_P#1[UB5M^)?^1@UK_L)WO\ Z/>L2O\ ;&A_ H_]>J?_ *0C_E\S'_D8
M8[_L,Q/_ *>F%%%%:G&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #XI9(9(YHG:.6)UDCD0E71T(965AR&5@
M"".A%?U@?\$HOV[T^.'@ZV^!?Q-UF)OBKX+T\KX>U"\F"W/C+PQ9*JIDR$&X
MUC2(BL=SM+R75HBW38=9!7\GE=C\/_'OBGX8>,O#WCWP5JMSHGB?PQJ5OJND
M:E:N4EM[JW;<N<$;XI%W131$[987DC;AS7YIXJ>&^7>)G"^(R?$^SP^9X;GQ
M619E*-Y8',%!J*G))S>#Q22HXRE&_-#DK1C*M0HM?NOT?/&[.? WCO"\08;V
M^+X=S'V67\6Y)3G[N992ZJE]8H4Y2C26:Y;)SQ.6UIN/O.OA)5*>'QN(9_H7
MT5\;?L1?M<^%_P!KOX.Z7XQLGM=/\<:-#;:5\0_"\<P>32-?2$"2[MT.V1]'
MU8H]WILY0#8SV[[9[>51]DU_E+G.3YEP_FN/R7-\+4P>99;B:F%Q>&J+WJ=6
MF[-Q:]V=.:M4I58-PJTI0J4Y2A*+?_0#P[Q#D_%F195Q)P]CZ.9Y+G6"H9AE
MN.P[O3Q&&Q$%.$K.TJ=2-W3K4:BC5H5H3HU80J0E%%%%%>8>T%%%% !1110
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MS_A5OQF\#&6SBOKW1+6]L[&6RFM'ODBM3]FM_MSZ9KC?9TCM8R0#^BRBBB@
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M"\\9W!B\!?"'PQ';3&#QCXHBC;_34LA#+K-[IUP8(Y="L[E;6:76+G1],U,
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M0[^ZMKZ./PU8?">'4OB!8>)7M=0L86U&]G\8:>?L.KVT]B)FLYXIOC+_ (*
M?\%-_P#@H%XW_;PD_P""8W_!)?X;_"K5/C9X*\!:7\1_C=\>/C9-/=_#?X9V
MNJ7%PVG>&+S3+"QU26*[O;*U8SW%S8RW(N+_ $LZ;;W41OC;@']+5%?S=_\
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MIZC_ #_$M.IIZC_/\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH *_C/\
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MAX[TC3+CQ1XEO=$<R1>9HFIVQT[1KVYYLKF\:VFN;&RNKV]@^[_BM_P<]?\
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MFETI[KQCXD\%?'O5?M.K6&OW.GI#=W?V#0#XETVVBN3-;PWNOHXBE? D /\
M2NHKY#_:<_;+^&/[+O[&WQ)_;2\6"ZU[X>?#WX2WGQ4BT[0)K%M3\51)H?\
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M&Z+_ &IX8UI%5;Q+&[4YU/0+J0_:-$U.:&SNKNQ>-[RPL+L3VD/U30 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?\
M=7^0IU-3[B_[J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :>H_S_$M.IIZC_/\ $M.H CB^X/\ /85)
M4<7W!_GL*DH **** "BBB@#YA^(W[:'[+'PA^-WPY_9N^)WQO\$>!_CE\7A
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M\CJB#+,P4$U^)O\ P7'_ .56SX7_ /8G_L3?^G[P?7I?P>^#7_!LI/\ L;>
M=6^+6D?\$PK/Q1)\#])O/'FJV_B#X,0_$BVU<^&4?6+V%K?56\3Q^*X[CS98
MS%$=074 -J9^6@#^ISX>_$?P%\6?".D>/?AEXP\/>._!FO6XNM'\3>%]4M-8
MT>_A/4P7EG)+'O0_++"Y6:)ODEC1@17FO[1_[5/[.O[(7@&'XH_M-?%_P7\%
M?A[<ZY8^&K?Q9XZU/^R])FUW4H[B:QTN.813.]U<Q6ER\:+&1MB;<RY7/\F?
M_!H5J?CG3_@[_P %!;7P-'XCUS]E7P[^T-XD;]F^/5Y]6N+>\,-O=7!TW0Y-
M3>6>."]T/_A&;F^6UMU$FNZAJMS=^;JLMX!^3/\ P<7_  D_X*F?%K]FCPK^
MVU_P4(\6^$_@SX.C^(^F>"O@K^Q#\-=5O]=T3P+I_B3[7=7WBOX@>(V2PB\4
M>/);6STZR%Y>:39C3+:SEBTS3]-?4]4-V ?Z4]C?6NIV5GJ-C,MS8ZA:V][9
MW"!@D]K=0I/;S('"L%EAD1U#*K889 .15JN1^'__ "(?@G_L4?#?_IFLJZZ@
M HHHH **** $/0_0_P J!T_$_P S0>A^A_E0.GXG^9H 6BBB@ HHHH ****
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M_P!JVWGBD@N(-._:BAG@F1HIH98]#\4))%+$X5XY(W5D='4,K*58 @BOJ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_[J_P A3J:GW%_W
M5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-'WC^/\ )*=31]X_C_)*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^PS$_\ IZ84445J<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=]\+_AIXP^+_ ([\-_#OP)H]SKGB;Q1J
M=MIFG65LA/SSR!7N+B3[EO:6L6^XNKB0A(8(Y)&R%P>&@AFN9HK>WBDGGGD2
M&&&)&DEEED8)'''&@+N[N0J(H+,Q  )-?UP_\$L/V$X?V>/ <'Q=^(>F ?&#
MQ[ID,D%G=Q*9?!7ANZC6:+3%#9\K5[]6\S5)(]ICB\JS#2JC.?R_Q8\2\O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\ *@=/Q/\
M,T'H?H?Y4#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :_P!T_A_,4ZFO]T_A_,4Z@ HHHH ****
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M&WO_ (;9/_FVH_XF0\'?^BJJ_P#ABX@_^=?G_5F'_$D7TC_^B*P/_B6<*_\
MSW/YN**_I'_X<):+_P!'&WO_ (;9/_FVH_X<):+_ -'&WO\ X;9/_FVH_P")
MD/!W_HJJO_ABX@_^=?G_ %9A_P 21?2/_P"B*P/_ (EG"O\ \]S^;BBOZ1_^
M'"6B_P#1QM[_ .&V3_YMJ/\ APEHO_1QM[_X;9/_ )MJ/^)D/!W_ **JK_X8
MN(/_ )U^?]68?\21?2/_ .B*P/\ XEG"O_SW/YN**_I'_P"'"6B_]'&WO_AM
MD_\ FVH_X<):+_T<;>_^&V3_ .;:C_B9#P=_Z*JK_P"&+B#_ .=?G_5F'_$D
M7TC_ /HBL#_XEG"O_P ]S^;BBOZ1_P#APEHO_1QM[_X;9/\ YMJ/^'"6B_\
M1QM[_P"&V3_YMJ/^)D/!W_HJJO\ X8N(/_G7Y_U9A_Q)%](__HBL#_XEG"O_
M ,]S^;BBOZ1_^'"6B_\ 1QM[_P"&V3_YMJ/^'"6B_P#1QM[_ .&V3_YMJ/\
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MEX/PA.<>)J]6482E&G#(L]4ZCC&ZIP=3+H4U.;M&+J3A!-^_.,5*2TH_0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -3[B_[J_P A3J:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 -'WC^/\ )*=31]X_C_)*=0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4T]1_G^):=0
M!'%]P?Y["I*CB^X/\]A4E !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "'H?H?Y4#I^)_F:#T/T/\ *@=/Q/\ ,T +1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/Y
MBG4U_NG\/YBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 U/N+_NK_(4ZFI]Q?]U?Y"G4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_)*=
M31]X_C_)*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -/4?Y_B6G4T]1_G^):=0!'%]P?Y["I*CB^X/\]A4E !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "'H?H?Y4#I^)_F:#T/T/\J!T_
M$_S- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 -?[I_#^8IU-?[I_#^8IU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_
M[J_R%.IJ?<7_ '5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 -'WC^/\DIU-'WC^/\ )*=0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4T]1_G^):=0!'%]P?Y["I
M*CB^X/\ /85)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*
M=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT
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M3_OH?XT>9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\
MOH?XT>9'_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/
M^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^
MA_C1YD?]]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[
MZ'^-'F1_WT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'
M^-'F1_WT_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH
M?XT>9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?X
MT>9'_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_
MC1YD?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1
MYD?]]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-
M'F1_WT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F
M1_WT_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>
M9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'
M_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD
M?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]
M]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_
MWT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT
M_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?
M3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'_?3_
M +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/
M^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\
MOH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[
MZ'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^
MA_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH
M?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'_?3_ +Z'
M^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_
MC0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\ OH?X
MT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^-
M #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^A_C0
M ^BF>9'_ 'T_[Z'^-'FQ_P#/1/\ OI?\: %3[B_[J_R%.J))8]JXDC/RKT=3
MV]C3O,C_ +Z?]]#_ !H ?13/,C_OI_WT/\:/,C_OI_WT/\: 'T4SS(_[Z?\
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M ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT
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M_"W_ * ^I_\ A2^(?_EE7MM% 'B7_#//PM_Z ^I_^%+XA_\ EE1_PSS\+?\
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M'U/_ ,*7Q#_\LJ]MHH \2_X9Y^%O_0'U/_PI?$/_ ,LJ/^&>?A;_ - ?4_\
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M#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\
MX4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?
M_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>V
MT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE
M_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS
M\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z
M^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4
MOB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\
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M5[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM%
M'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\
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M#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\
MX4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?
M_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>V
MT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE
M_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS
M\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z
M^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4
MOB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\
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M_N)5[=10!X/9_LW_  FM(1'!HVJJC$.0WB?Q$WS%5'4ZEGH!5O\ X9Y^%O\
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M $!]3_\ "E\0_P#RRKVVB@#Q+_AGGX6_] ?4_P#PI?$/_P LJ/\ AGGX6_\
M0'U/_P *7Q#_ /+*O;:* /$O^&>?A;_T!]3_ /"E\0__ "RH_P"&>?A;_P!
M?4__  I?$/\ \LJ]MHH \2_X9Y^%O_0'U/\ \*7Q#_\ +*C_ (9Y^%O_ $!]
M3_\ "E\0_P#RRKVVB@#Q+_AGGX6_] ?4_P#PI?$/_P LJ/\ AGGX6_\ 0'U/
M_P *7Q#_ /+*O;:* /$O^&>?A;_T!]3_ /"E\0__ "RH_P"&>?A;_P! ?4__
M  I?$/\ \LJ]MHH \,'[.GPJ$ID&D:KN)D8_\5+X@QF2.TC;_F(]UM81CH"I
M(P6;,W_#//PM_P"@/J?_ (4OB'_Y95[6/O'\?Y)3J /$O^&>?A;_ - ?4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &I]Q?\ =7^0IU-3[B_[J_R%.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :>H_S_$M.IIZC_/\ $M.H
M CB^X/\ /85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/X?S%
M.IK_ '3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\A3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.
MIH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &GJ/\_Q+3J:>H_S_$M.H CB^X/\]A4E1Q?<'^>PJ2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\J!T_$_S-!Z'Z'^5 Z?
MB?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?
M]U?Y"G4U/N+_ +J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH :>H_P _Q+3J:>H_S_$M.H CB^X/\]A4
ME1Q?<'^>PJ2@ HHHH **** "BBOP%_X.;_B'\0_A7_P1V_:)\<_"SQ_XW^&/
MC?1O%GP._LGQE\._%>N^"O%>FI>?&'P=9W\-AXA\.7VG:M:0ZC83W.GZA%;W
M<:W=A<W%K,&BE92 ?OU17\8'[.7_  ;[?'?X\_LN_"GXW0_\%J/^"E?A_P :
M?$OX7:+XV@T=_C/XPD\,Z7KVLZ4+V"TDN!XR.J-I4%TR+)*KF[\@,RMYF#7T
MA_P;5_\ !03]ISX]VG[:G[)'[6_Q(E^-/CC]B3XIZWX/TKXR7=A:6-YXC\*:
M3K^M^%I(-4N[>1!J<UOJOAS4KJPO9[2&Y319M/34+O4;\W5], ?U7T5_FM/\
M=?V=_P!LG]JG]O+XT_M7_P#!<;]J[]@OPPO[8/CGX8? 7X4_"KXJ_$%]'U3P
M1X0T_1K+_A);;POX:U*ZLO#GAJ6Y=8+74[?3;#1+JZ2]GFOI[QYY)/[+?V!?
MV:?%7[*G["_CVQ_9N_:_\=?\% ?%7CO3_$GC_P""OQ<^/_CIO&4.H^(-3T/R
M/#&C7?BC^W-6W>$K/5([>:XMHKFWEMXC=0&-9B2 #]>**_@W_:__ &&O^"K7
M[(G[&OQ#_P""I_[2W_!6?XP> ?VV_AIJ-]XT?X'>'O'-O=_LNWMO;ZY>6&A^
M!M!\(HMEX:U[6=:\.2P6FD6E]X5N4;7+BUFO9;C4+=+^OZ_O^">?QY^(/[3_
M .Q%^S%^T!\5?"$_@/XB_%?X0^$O%_C#PK<Q3P2Z7K>HV"F\!@N;>TN;<7;I
M]M6WN+6UGA6X$<MO ZF)0#[*HHHH **** "BBB@!#T/T/\J!T_$_S-!Z'Z'^
M5 Z?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)"@LQ  !)).  .223P
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M /$7H_\ T0>O]/0_XJ48_P#Z,UA/_%@5O_H*]?Z>G^A)_P +&^'W_0]^#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0 4444
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MX5*56G*,Z<X-QG&2E%M-,****R-@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\A3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.
MIH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.IV.BV_ANV\2>%IKDW5OIT%@ER^MQ& ,]U*EU(/+< _&G_@IK^R'^SA\._\
M@V,OO#W@[X3>$]%M_A_\#?@[XR\+ZI;Z7:?\))9^*8-=\.7TNNW/B0P?VQ?Z
MCJ-Q<W1U:YN[J634TNKA;QI3*S']N?\ @BC(TG_!)3_@G:[9Y_9&^!X52\CB
M-%\!:*L<2&5Y'$<2!8XU9VVHJKGBJ?[7_P#P3J\0?M1_\$O]<_X)Z67Q:T?P
M3K>N_#/P/\/)_BM<^"[WQ!I5O_PBU_HUS?ZI%X-B\3Z-=R?VC;Z9-#:6K>)4
M^Q2W$<TL]VD#0S?47[#7[-UY^Q[^Q_\ LX?LN:AXMMO'MY\!/A!X'^%D_C.S
MT:7P[;>)W\&Z%9Z)_;<6A3:EK$NDKJ(M!<_V>^JZ@;7S/)^V7&SS6 /JRBBB
M@!#T/T/\J!T_$_S-!Z'Z'^5 Z?B?YF@!:*** "OX\$OK#PA_P>#7\GB:_LM&
M7XB?L.0Z)X)^VW4,3>(]9MX]"U&72=.1G#3:BFG^'-;OC:*#,;/3[BX"F-"1
M_8?7XE?\%4?^"*/PL_X*/>+/AO\ '[PE\7?B#^RY^V)\$+62/X1_M!?#:83R
MV#QO<W6F6/C#PV\]F/$&BV&I7)O733-4\/Z[<VZRZ.NOVVDW^HVUR ?,'_!V
M;>V=M_P1=^.=M<7=M!<ZA\1/@-!86\TT<<U[/#\8_!=Y-#:1,P>XDBM+>>YD
M2)6*00RRMA$)KY)_X+>6MU8_\&L/P]L[VVGL[RU^&?["D%U:743PW%M/%XG^
M&J2P3PN \<L3@I(C ,K @C(KU'0?^#<3]H#X[>/O .L?\%0O^"J?QR_;G^&/
MPN\4Z)XT\(?"&#PJOPS\-WFMZ5<33SP>+9[OQ3XWNM5TR^7[- $TAO#^HVL*
MWL:ZC+'?E(/UY_X*Q?\ !.F7_@I)^P;XR_8G\)_$?2?@9;^)M<^&.H:=XPN/
M!LWC/3M!T[X<>+='\30Z9!X8L_$/A5[A;V'1XM,A==9MDLUE^T&.X\H02 'X
MF_MR_L@?LU_#O_@UZUS0/"/P@\%Z5;^#?V:?!'Q$T'44T33GU^#QR;_3-;N/
M%5QKS6O]IWFMWNIWEW=W]]/<-/>37$LL[/*Q>OSF_P""D_B7Q!:?\&R7_!'G
MP;-<7R?"GXDZU^R/X6^.LT:W1M[;X;6'@P^(8I[S48IXSH]O;>)M&\/);7A6
M94G>&VAA666*>#^L3]I/_@G?K_Q__P""6NN_\$ZX?BOI'A;7->^#'ASX2S?%
MF7P;>:OI5N^C'3ENM=C\&+XETZ[D2ZBLI/(TYO$R- \J>9>S+&=_%O\ \$A_
MA)\1O^"3OP]_X)7_ +1'B>\\?^%?!7P<\$_#3_A:/A#3O^$.UZU\2_#^TL!X
M:^(WA;3+^\\20:/JNF:OIEEK-OI&J7.OZ3.T1TW5XM6TZ6X@G /BW_@KQ^R7
M^QUH/_! [XRZ9HGP>^%&A^&_A-^R[I/BWX)75IX7T2UN?#OC#3/#5G+X7U+P
M_J*6T5Y'K%RU]=1K*LS2S"\N5*'=M'YW^+?^5.*#_LV#P/\ ^I/X<KW72_\
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M\5MHUAX!\"B?41K/AGPEIMY86VG"2:S@BOY+R0Z;%:R^(?\ !#'P-\-_CO\
M\%B/^"T'Q<_:"\'>'?%_[2/@OXXZ[X4\+3>,]$MKO4_#_P (X-?N?"?A2_TO
M2-5;4([6/7_"OAK0H6U2,HVK65E;3BWM8HX;:U_8G_@F=_P2<^-W[&7Q.^(G
MQ[_:8_X*&?M"_MG_ !E^)$-O9ZR/$>I:EX/^$J16$*6.GZE!\-3KOB-/[=CT
MJWL["XNI];N+*5K47L%A:7,TQ;YS_;D_X(#^*OB_^V#K_P"WA^P1^W!\2O\
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MO OC'2++7_"WBSPWJ%OJNA:_HNHPI<6.IZ7J%J[P75I=0.DL,L;%61@:ZZ@
MHHHH *IZC_R#[[_KSN?_ $2]7*IZC_R#[[_KSN?_ $2]5#XX_P"*/YH3V?H_
MR/\ /&\2_P#(P:U_V$[W_P!'O6)6WXE_Y&#6O^PG>_\ H]ZQ*_VQH?P*/_7J
MG_Z0C_E\S'_D88[_ +#,3_Z>F%%%%:G&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %=!X5\4^(/!/B/1?%OA75KS0_$7A[4;75=&U:PD\
MJ[L+^SE6:WN(6(924=1NCD5XI4+131R1.Z-S]%14ITZM.=*K3A5I582IU:52
M$9TZE.<7&=.I"2<9PG%N,X23C*+:::;1K0Q%?"UZ&*PM:MAL3AJU/$8;$X>I
M.C7P]>C.-2C7H5J<HU*5:E4C&I2JTY1G3G&,X24DF?VY_L#?ME>'_P!KWX16
MFKSSV=E\3O"D-II?Q$\.Q-Y;QWXB"Q:]8V[L9'TC6=K30RQF6*WN#-922B>%
MXU^[:_BY_P""7,?QU?\ :J\('X)':4);QX]^MT_AL>"O-B_M@:X+=D!+1?)I
MN&%Q_:#0>1\GG5_:-7^6?COP!E?A]QQ6P.38JA4RW-,/'-L+ET*G/B<GAB*M
M2,L#B(ZN-%5(3G@)2DZD\)*FIWE!U*G^^WT4_%S//&'PIP.><29?B:&=Y/C*
MO#V89M.A[' \1UL!2HM9O@6K1E4JTZD*>9PIPC1I9G3Q,:,84G&E2****_%C
M^E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!J?<7_ '5_D*=34^XO^ZO\A3J "BBB@ HHHH **** "BBB@ HHHH ****
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M "/\\;Q+_P C!K7_ &$[W_T>]8E;?B7_ )&#6O\ L)WO_H]ZQ*_VQH?P*/\
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M(Q%64JV(KU*E:M.=2I*3****\D]X**** "BBB@ HHHH **** "BBB@ HHHH
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M%J^JW]Q-I^KR75IJ*_:&LX;58;B(B-9(G!4 _DP_8I_9W\':G_P5TU/]@?\
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MW=Z7K9:&XB^TC2S8RL(+J6L?_@O5_P $+_$?_!85_P!GW4O /QA\$?!/Q/\
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M["=[_P"CWK$K_;&A_ H_]>J?_I"/^7S,?^1ACO\ L,Q/_IZ84445J<84444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 -3[B_[J_R%.IJ?<7_ '5_D*=0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 -'WC^/\DIU-'WC^/\ )*=0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4
MT]1_G^):=0!'%]P?Y["I*CB^X/\ /85)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MYM>TL/"&'R]*$Z6,=<HHHK^8#^Y0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?]U?Y"G4U/N+_NK_(4
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :/O'
M\?Y)3J:/O'\?Y)3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J
M_P A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!H^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &GJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3
M_,T'H?H?Y4#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH :GW%_P!U?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH ****
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M_,4ZFO\ =/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_R%.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &C[Q_'^
M24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH :>H_S_$M.IIZC_/\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3_,T'H?H?Y4
M#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :G
MW%_W5_D*=34^XO\ NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH :/O'\?Y)3J:/O'\?Y)3J "BBB@ HHHH **** "BBB@
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MM#?N@0I. 2#G%/%Y^T3\W_$F^%0'FS!,ZEXCSY0FD$);$3#>T.QI #@.6
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M.^V?M$_] ?X5?^#+Q'_\9H^V?M$_] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\
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MFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\ 0'^%7_@R\1__ !FO<:*
M/#OMG[1/_0'^%7_@R\1__&:/MG[1/_0'^%7_ (,O$?\ \9KW&B@#P[[9^T3_
M - ?X5?^#+Q'_P#&:/MG[1/_ $!_A5_X,O$?_P 9KW&B@#P[[9^T3_T!_A5_
MX,O$?_QFC[9^T3_T!_A5_P"#+Q'_ /&:]QHH \.^V?M$_P#0'^%7_@R\1_\
MQFC[9^T3_P! ?X5?^#+Q'_\ &:]QHH \.^V?M$_] ?X5?^#+Q'_\9H^V?M$_
M] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\ 0'^%
M7_@R\1__ !FO<:* /#OMG[1/_0'^%7_@R\1__&:/MG[1/_0'^%7_ (,O$?\
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MT3_T!_A5_P"#+Q'_ /&:]QHH \.^V?M$_P#0'^%7_@R\1_\ QFC[9^T3_P!
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M?M$_] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\
M0'^%7_@R\1__ !FO<:* /#OMG[1/_0'^%7_@R\1__&:/MG[1/_0'^%7_ (,O
M$?\ \9KW&B@#P[[9^T3_ - ?X5?^#+Q'_P#&:/MG[1/_ $!_A5_X,O$?_P 9
MKW&B@#P[[9^T3_T!_A5_X,O$?_QFC[9^T3_T!_A5_P"#+Q'_ /&:]QHH \.^
MV?M$_P#0'^%7_@R\1_\ QFC[9^T3_P! ?X5?^#+Q'_\ &:]QHH \.^V?M$_]
M ?X5?^#+Q'_\9H-Y^T3@_P#$G^%6<''_ !,O$?7''6''6O<:* / [*]_:4,(
M^V:)\)EER,>3J7B,Q[-HQUC8[LY]!BK?VS]HG_H#_"K_ ,&7B/\ ^,U[>GW%
M_P!U?Y"G4 >'?;/VB?\ H#_"K_P9>(__ (S1]L_:)_Z _P *O_!EXC_^,U[C
M10!X=]L_:)_Z _PJ_P#!EXC_ /C-'VS]HG_H#_"K_P &7B/_ .,U[C10!X=]
ML_:)_P"@/\*O_!EXC_\ C-'VS]HG_H#_  J_\&7B/_XS7N-% 'AWVS]HG_H#
M_"K_ ,&7B/\ ^,T?;/VB?^@/\*O_  9>(_\ XS7N-% 'AWVS]HG_ * _PJ_\
M&7B/_P",T?;/VB?^@/\ "K_P9>(__C->XT4 >'?;/VB?^@/\*O\ P9>(_P#X
MS1]L_:)_Z _PJ_\ !EXC_P#C->XT4 >'?;/VB?\ H#_"K_P9>(__ (S1]L_:
M)_Z _P *O_!EXC_^,U[C10!X=]L_:)_Z _PJ_P#!EXC_ /C-'VS]HG_H#_"K
M_P &7B/_ .,U[C10!X=]L_:)_P"@/\*O_!EXC_\ C-'VS]HG_H#_  J_\&7B
M/_XS7N-% 'AWVS]HG_H#_"K_ ,&7B/\ ^,T?;/VB?^@/\*O_  9>(_\ XS7N
M-% '@ZWO[1OG,#HOPI\O,FT_VCXBW;1':>7GY#R9#=;_ )>%6'&26S/]L_:)
M_P"@/\*O_!EXC_\ C->WC[Q_'^24Z@#P[[9^T3_T!_A5_P"#+Q'_ /&:/MG[
M1/\ T!_A5_X,O$?_ ,9KW&B@#P[[9^T3_P! ?X5?^#+Q'_\ &:/MG[1/_0'^
M%7_@R\1__&:]QHH \.^V?M$_] ?X5?\ @R\1_P#QFC[9^T3_ - ?X5?^#+Q'
M_P#&:]QHH \.^V?M$_\ 0'^%7_@R\1__ !FC[9^T3_T!_A5_X,O$?_QFO<:*
M /#OMG[1/_0'^%7_ (,O$?\ \9H^V?M$_P#0'^%7_@R\1_\ QFO<:* /#OMG
M[1/_ $!_A5_X,O$?_P 9H^V?M$_] ?X5?^#+Q'_\9KW&B@#P[[9^T3_T!_A5
M_P"#+Q'_ /&:/MG[1/\ T!_A5_X,O$?_ ,9KW&B@#P[[9^T3_P! ?X5?^#+Q
M'_\ &:/MG[1/_0'^%7_@R\1__&:]QHH \.^V?M$_] ?X5?\ @R\1_P#QFC[9
M^T3_ - ?X5?^#+Q'_P#&:]QHH \.^V?M$_\ 0'^%7_@R\1__ !FC[9^T3_T!
M_A5_X,O$?_QFO<:* /.O"=Q\49+B]_X3?3O!L%LL$9T__A'+W5)9I+GST$JW
M)OXMB0B')1HU9C( " IS7HM-/4?Y_B6G4 1Q?<'^>PJ2HXON#_/85)0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ'Z'^5 Z?B?YF@]
M#]#_ "H'3\3_ #- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 -?[I_#^8IU-?[I_#^8IU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 -3[B_[J_R%.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 T?>/X_R2G4T?>/X_R2G4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #3U'^?XEIU-/4?Y_B6G4 1
MQ?<'^>PJ2HXON#_/85)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37
M^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #4^XO^ZO\A3J:GW%_P!U?Y"G4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_)*=31]
MX_C_ "2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #3U'^?XEIU-/4?Y_B6G4 1Q?<'^>PJ2HXON#_ #V%24 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0.GXG^9H/0_0_RH'3\
M3_,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U/N+_
M +J_R%.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 T?>/X_R2G4T?>/X_R2G4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #3U'^?XEIU-/4?Y_B6G4 1Q?<'^>PJ2H
MXON#_/85)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
MZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #4^XO^ZO\ (4ZFI]Q?]U?Y"G4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_ "2G4T?>/X_R2G4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2,P4%F(55!9F8X"@#)))X  Y)/ %+5/4?\ D'WW_7G=?^B'IQ5VEW:7WL&[
M)OL<*?C%\(P2#\4OAR".H/C?PR"/J/[3I/\ A<?PB_Z*G\./_"X\,_\ RTK^
M ;Q!<3P:WJT$$TL,,-_=10PQ2/'%%%'*R1QQQH0B1H@"HB@*J@*H  %9'VV\
M_P"?JY_[_P O_P 57]SP^AYEDX1FN/L<E.,9)/AS#Z<R3M_R.O,_RMK_ +2'
M-:%>M0?@_E\G1JU*3DN.\2E)TYN#:3X0T3LVEZ?+_00_X7'\(O\ HJ?PX_\
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ML=_XCF'_ /GT'_%2?-/^C.X#_P 3S$?_ $'^O]/3_00_X7'\(O\ HJ?PX_\
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MHKYT^P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR8?8O$,>IZGX.\#SRVNI1E9(T71%2%MT0GF*;S^@!=00I90QZ D GZ#J?PH
M=12;EW;=PW==N1NQZXZT*RM]U@V#@[2#@^G'>@!:*:K*W*LK#IE2#_*E9E49
M8A1TRQ 'YF@!:*0$,,@@@]"#D'\12;TY^9?E^]\P^7Z\\?C0 ZBD#!AE2"/4
M'(_,4M !1110 4444 %4]1_Y!]]_UYW/_HEZN53U'_D'WW_7G<_^B7JH?''_
M !1_-">S]'^1_GC>)?\ D8-:_P"PG>_^CWK$K;\2_P#(P:U_V$[W_P!'O6)7
M^V-#^!1_Z]4__2$?\OF8_P#(PQW_ &&8G_T],****U.,**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJS\*^'=*\.Z->:YX@\5^,-4@NI])\-Z-8VB-OO;Y+.X</,T<44,,LKMMC(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J
M_P A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!H^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &GJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I*
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MV>@^'+S0-=M8M%\1G2WDU7P_#KCZM>Z!=W&GZE-:Z=>V]I%=:FMMIEW^;?\
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MG6MWXJL;+PA-9CQ#J/B73[19?)\*VM@=>O+Q#86EC/?&.UD^.?VW?'7[=_\
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MW6]!O-/U*WM);Q-3LI[47"!K:1K6X0X91\_?M1?\%%O^"K'_  4__9;\0_\
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M::UH5Y8:E;QWEC<W%G=1Q7*)<6T\L$JO&[*?DK]OG]K7_@H1_P %[_A#H_[
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M]L.\_9$_X*Q:#_P3<^'_ /P4ET/_ (*1?L6_M ?#+6/$'P3\:ZK\4_!_Q?\
MB%\-_BEX?BF\0ZCX7U;QWX9OKO[5<ZKI<?B>[N=(NI[A1I.DZ&NC66DVND:B
M^I<_:^!/VGO^"_W_  5%_;9\%:E^VE\=OV6?V+_V&/&%]\(/!/A']GS7;OP!
MXYUGQ[H\B:#XEU/4KMP8]1\SQ)8:Q+-J>IVEU87>BKHR:#!:207>HZS^I_\
MP2C^/'C?]K/XV^,/&VH?\$2_"'["OP3\',EU\*/C)X_\ >"?AM\9UU?[ NGZ
MMI\_A!O!6C^*;?4'O)-4CM]4TR#2=+N/#\]M(E_=27%Q;K^7^H6O[;7_  07
M_P""HO[9_P </ _[$'QI_;-_8F_;E\10_$'09?V>;/4?&GC3PK\1M8:_\1^)
M;?5]!TO2]6UC1]0?Q*=:FU.ZU/2YO# T*[\,0Z-K0U:]U#2K, XK]G#X3_'S
MX#_\'27P_P#@]^T'\<[S]I+7/!W['EZO@+XO^(O#>F>'_'VM_"J\U&V3P=HW
MCZ31H[;2=9\1>'_L6HV]SJVFZ=I=G>2W$]REC%+/,S_W5U_$C^RKX8_;\^-?
M_!Q%\+OVXOVIOV3/&W[/O@WXI_LW>+_#G@/PVUAK/B]?ASX#\.:I8KX(T[XL
M>.= TN\^'V@^-?%MK=:EKMIH$'B:?4(;3=:ZA96%_;2V[?VW4 %%%% #7^Z?
MP_F*=37^Z?P_F*=0 4444 %%%% !156^O;;3K*[U"\E6"SL+6XO+J9SA(;:U
MB>>>5B> L<2,['L :_FV_9+_ .#EO]G?]JS]N/1/V,;']G_XJ_#RQ\:?$/XL
M?#7X:_'WQ-K>AW?PN^(OB'X63:PLL?AB>RLDDO/^$BMM(-SI\4=U))9_;;&"
M_$<UQ$K@']*=%%% !1110 4444 %%%% !17F_P 8?BY\/O@)\+?'OQG^*_B*
MU\)?#;X9^&-5\8^-?$U\'-GHGA[1K=KK4=1N?+5F$-O"A9VP%4?,[*@9AXE^
MSK^USX3_ &K_ -E71_VK_@1X4\3>+/"7C7PIXA\6?#'PUJ*0>&?$GCNSTQ+[
M^P;:./6?(M] N?%<]G%#8_VNT:6 O(9-0:,)*J 'UK17S?\ LN?&#XP?&WX:
M#QE\;?V9/&W[)WC(ZSJ.G'X6>/O&_P /_'VOII]I($M-:?7?AIK&N^&#;:FG
M[ZWMH=2FNH$PMVD,NZ-?I"@ HHHH **** "J>H_\@^^_Z\[G_P!$O5RJ>H_\
M@^^_Z\[G_P!$O50^./\ BC^:$]GZ/\C_ #QO$O\ R,&M?]A.]_\ 1[UB5M^)
M?^1@UK_L)WO_ */>L2O]L:'\"C_UZI_^D(_Y?,Q_Y&&._P"PS$_^GIA1116I
MQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !75^!_&OB7X
M<^+O#OCGP?JMWHGB;PMJUGK6C:G92O#/;7ME*LL9W(REXI &AN8&)BN;:2:V
MF5X99$;E**SK4:6(I5</7IPK4*].I1K4:L%.E5I58N%2E4A).,Z=2$I0G"2<
M91;333-\+BL3@<5AL;@Z];"XS!XBCB\)BL/4E2KX;$X>I&MA\10JP<9TJU&K
M"%2E4@U.$XQE%J23/[COV&_VO?#7[7OP>T[Q;;>3IGCK0UBTCX@>&1(IDT[6
MHHPK7]HH):72-6 %W8S 9C60VTZQ7$3QK]I5_%U_P2YUOX[Z3^U5X/@^"5H^
MI)J4@M?B!I]Y/-;^')?!>\'5+K7)$258S8Q;KC3)EA>Z6_$4-NT8N)B?[1:_
MRQ\=/#W >'?&U;+\IQ5"KE6:8=9M@,%&LJF+RJC7JU(2P.)@Y2J1ITZD)/!5
M:C<J^%Y')RJ0J2?^_'T6/&#-O&7PMP6>Y_E^)PV?9/BY\/YOF,L,Z.7Y]B\#
M0H2_MC+IQA"C)XFG5A_:%"A%4\)F,<31IQC1]B@HHHK\9/Z1"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWP[H'PJE\/\ _"06_B)-"N==L]]GK]]8B^348[2:RMH-/>:\:]:")+>3S@5
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M/A[;^&9]-UKR[FUF>WO-:L]2Y7_@G'^SQ^TK^VW_ ,$&?VQO^"5'Q=\(>/O
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MUSQ+)H7AW3=-_P!/UW5TT2QOGT[2K,RQ">_NUAMHV=09 3B@#Y,^(W_!T/\
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M$C:>2QM-!\->,IO"D^I^,K=Y(#=>(]1L+Q;N\LX-6MH-,G6*V@_N;_X)M?\
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M78?\) /['CUK7-$-]#X<DU"2"R'B!=-6]GBM'G8 '\UW_!PGX^;QIXH^ _\
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MIXP^+UC)J/AK5->TG3['Q%9K<6KLUUH]Q>Q?9I["^+_8M4TVXNP#^MVBBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBI/*E_YY2?\ ?#?X4>5+_P \I/\ OAO\*+/L_N#FC_,OO7]=5]Y'14GE2_\
M/*3_ +X;_"CRI?\ GE)_WPW^%%GV?W!S1_F7WK^NJ^\CHJ3RI?\ GE)_WPW^
M%'E2_P#/*3_OAO\ "BS[/[@YH_S+[U_75?>1T5)Y4O\ SRD_[X;_  H\J7_G
ME)_WPW^%%GV?W!S1_F7WK^NJ^\CHJ3RI?^>4G_?#?X4>5+_SRD_[X;_"BS[/
M[@YH_P R^]?UU7WD=%2>5+_SRD_[X;_"CRI?^>4G_?#?X46?9_<'-'^9?>OZ
MZK[R.BI/*E_YY2?]\-_A3DM[B1UC2&5G=@J@1MDEC@#IZT6?9_<"DFTDTVVD
MDFFVW:R2ZMW5O5=SJ? '@7Q/\3?&?AOP#X-TNYUGQ-XKU:ST;2-.M8I)9)KJ
M[E"!W$:2-';VZ;[F[N&7R[:UBFN9BL43L/[:?V(OV2/"_P"R+\'=+\'6*6VH
M>-M72'5?'_B=846?5M;EC4M:0. 6CTK2P?LMA!O<E$,TTDTSF0_$W_!)_P#8
M._X4=X/B^._Q0TJ+_A:?CG3XW\,Z7=VX,_@CPE>1))'O\P$QZ[KBD7-VZ!#:
M6+6UD,R"XEE_:&O\Z_I&^,"XMS.7!O#N*Y^&LGQ'_"ABJ$[T\ZS6BW%N,H_Q
M,OP$N:G0LW3Q.(4\5[\(864?]H_H8?1Q?AMD$?$;C' >SX[XFP2678'%4G&O
MPMP_B>2I'#SISNZ6;YK&-+$8]RC&M@\-['+FJ57Z_&L4445_+1_=P4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #4^XO^ZO\A3J:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 -'WC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 T]1_G^):=33U'^?XEIU $<7W
M!_GL*DJ.+[@_SV%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (>A^A_E0.GXG^9H/0_0_RH'3\3_,T +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBG4U_NG
M\/YBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]F'_ *-Z^"W_ (;/P=_\J*/^&4?V8?\ HWKX+?\ AL_!W_RHKW^BC_6#/O\
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M7_=7^0IU-3[B_P"ZO\A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_P A3J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^\?Q
M_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &
MGJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3_,T'H?H?Y4#I^)_F
M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_P!U
M?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_R%.H **** "BBB@ HHHH
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M .!GB;_YG*_2C_A4WPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?#_\ \(WPY_\
M*V@#\U_^(@+_ ((T_P#207X$_P#@9XF_^9RC_B("_P""-/\ TD%^!/\ X&>)
MO_F<K]*/^%3?"S_HFGP__P#"-\.?_*VC_A4WPL_Z)I\/_P#PC?#G_P K: /S
M7_XB O\ @C3_ -)!?@3_ .!GB;_YG*/^(@+_ ((T_P#207X$_P#@9XF_^9RO
MTH_X5-\+/^B:?#__ ,(WPY_\K:/^%3?"S_HFGP__ /"-\.?_ "MH _-?_B("
M_P""-/\ TD%^!/\ X&>)O_F<H_XB O\ @C3_ -)!?@3_ .!GB;_YG*_2C_A4
MWPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?#_\ \(WPY_\ *V@#\U_^(@+_ ((T
M_P#207X$_P#@9XF_^9RC_B("_P""-/\ TD%^!/\ X&>)O_F<K]*/^%3?"S_H
MFGP__P#"-\.?_*VC_A4WPL_Z)I\/_P#PC?#G_P K: /S1N?^#@G_ ((S6UO/
M<2?\% _@>Z00R3.MO+XMNIV6-"[+#:VWAB6YN)2 1'!;Q2S2MA(HW=E4U],_
MX.$O^",6JV%MJ%M_P4!^"\,%W'YT4>I0^-]'OD5F.!<Z9JWA*RU*SEXYAO+6
M"8#!* $9_3&X^$GPJ>"9'^&7P^96BD5E;P7X;964H00P.FD$$<$$8(ZU%8_"
M+X3P6D$,/PO^'D,4:E8XHO!7AJ.-%W,=J(FF!5&23A0!DF@#\X?^(@+_ ((T
M_P#207X$_P#@9XF_^9RC_B("_P""-/\ TD%^!/\ X&>)O_F<K]*/^%3?"S_H
MFGP__P#"-\.?_*VC_A4WPL_Z)I\/_P#PC?#G_P K: /S7_XB O\ @C3_ -)!
M?@3_ .!GB;_YG*/^(@+_ ((T_P#207X$_P#@9XF_^9ROTH_X5-\+/^B:?#__
M ,(WPY_\K:/^%3?"S_HFGP__ /"-\.?_ "MH _-?_B("_P""-/\ TD%^!/\
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MS_HFGP__ /"-\.?_ "MH _-?_B("_P""-/\ TD%^!/\ X&>)O_F<H_XB O\
M@C3_ -)!?@3_ .!GB;_YG*_2C_A4WPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?
M#_\ \(WPY_\ *V@#\U_^(@+_ ((T_P#207X$_P#@9XF_^9RC_B("_P""-/\
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MZ2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\
MX1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ S
MQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1
M_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\
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M\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\
ME;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7
MZ4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\
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M?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\
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M_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\
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MZ2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\
MX1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ S
MQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1
M_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\
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MQ]H%YO@<Q.3I^M^#M/OA$64F&?[/Y%Q'B6WEEB97.K_Q$!?\$:?^D@OP)_\
M SQ-_P#,Y7Z,:;\'_A+;VWEV_P +OAU!'YCMLA\$^&HDW-@L=J:8JY8DDG&2
M3DUH?\*F^%G_ $33X?\ _A&^'/\ Y6T ?FO_ ,1 7_!&G_I(+\"?_ SQ-_\
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M .5M 'YK_P#$0%_P1I_Z2"_ G_P,\3?_ #.4?\1 7_!&G_I(+\"?_ SQ-_\
M,Y7Z4?\ "IOA9_T33X?_ /A&^'/_ )6T?\*F^%G_ $33X?\ _A&^'/\ Y6T
M?FO_ ,1 7_!&G_I(+\"?_ SQ-_\ ,Y1_Q$!?\$:?^D@OP)_\#/$W_P SE?I1
M_P *F^%G_1-/A_\ ^$;X<_\ E;1_PJ;X6?\ 1-/A_P#^$;X<_P#E;0!^:_\
MQ$!?\$:?^D@OP)_\#/$W_P SE'_$0%_P1I_Z2"_ G_P,\3?_ #.5^E'_  J;
MX6?]$T^'_P#X1OAS_P"5M'_"IOA9_P!$T^'_ /X1OAS_ .5M 'YK_P#$0%_P
M1I_Z2"_ G_P,\3?_ #.4?\1 7_!&G_I(+\"?_ SQ-_\ ,Y7Z4?\ "IOA9_T3
M3X?_ /A&^'/_ )6T?\*F^%G_ $33X?\ _A&^'/\ Y6T ?FO_ ,1 7_!&G_I(
M+\"?_ SQ-_\ ,Y1_Q$!?\$:?^D@OP)_\#/$W_P SE?I1_P *F^%G_1-/A_\
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M_P"!GB;_ .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\
M_P (WPY_\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!
MGB;_ .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (
MWPY_\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_
M .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_
M\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9R
MC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/
M^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B(
M"_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/^%3?
M"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B("_X(
MT_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/^%3?"S_H
MFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B("_X(T_\
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)!(#8->P4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gv1ubg3hw41v000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000008.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #C ET# 1$  A$! Q$!_\0
M'P !  (# 0 # 0$           @)!@<*!0,$"P(!_\0 6!   00" @$!! ,(
M"@P-! ,!!0,$!@<! @ ("1$2$Q05"A9W%Q@A.#E5F+8B,3=9=GB5M]77)#I8
M=92QL[2UN-/F&2,E-#5!4G22EI?2UE%7<YDF-D-A_\0 &0$! 0$! 0$
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M;[=T/;"6H<>NYO&I*'@P< < < < < < < < < < < < < < < < < < < <
M< Q*?,)45@LU%P0YI&)P2B4C80V2J,V)%..RIX'>-X\<4'E&C\8_T$EU&;_=
MF18O&+K5OE!VT<-U%$=P.46H_-+V=ETUZ'S^12P&UZ\5]":/K'R:K.HA$6;E
MOV(OR4=@:3#%7[] 'JY@C6(V#28V8%QD5>QX1II,V+%PQ5!^P@D.KH2VE%VV
MZ,X457WS2[<4SUTO)]W7&]3)_9\EMHR/NDWXJI?WW@HC>JJ:U@T/2F?;F016
MGR2"V(Q\Z,&15,.8D$6#G&A*+E4-EI$]^+/N,N.!L*4HMMJAWOA3BV7*UT<1
M>6W=3ROW5'JPO-CUBJF9H;=>[EZG4C9W:ITYJIY#0%FVE/:6(3N'LZPE2KP^
M:"J02>[0U_+V0)3<--)4)U$BM1S?:6CA*I66\TU5)7NDG#GFMZLN4R?[L=IU
M;*ZQ]KK-Z#=[H9%+&Z.5K<-C6Z"KR*U%=BKL["(#-ST?KJ?,YP-D&()EX<K\
M^SV>#FJ17?=D42SHKACE/&/#>Z^GU3,2::VJ7>(F5KGB8O0/<:P^N==]-GG=
M>Z)%=K3NW6AZUAM[$X#5M5PRCS$6Z]!KR?5(;$5\%"(EDI''F$[+1"1O-%B;
MYU&R(APBGG8=HH[7V?2 U+JV5"IRIEQ,3X28\MYEI 0%19S"NC-T3(T:Z- _
M(7( "5AU?'5X9UY-3:?QU%P3<R8D,U*31S&X8.EX6) 4"+XUB2I!D]VNX@@1
MYOKUZY&NB/Q+I.F;Q*B=,7=^'$\$W]("ZF,[9B4+!B%2]?&6_6'>13XM:-20
M^9AU>V4:B4NKMS$J$D$L0M:TP,2 3V(/K?.0@4]T@&A EC+,S\@*Y1#[.J]G
M:=''NS-\934$]NVO=$SUMM/K72,'H&9=@;4[2JW$SKN-Q670N$LV3ZG(D&F9
MI232&</AX@4'6"DW+I4GA==PUT%K(LQA8D\8#G E*9<I1&9UY)E3O9GR5=K[
MDK3K?>W3V+=DZ:HK6O>T,O[>RJ&=;:<[$RVH931LS!0)U!#C"R[ @\)WVBI.
M-VJ<?*1&7/Y1)HVU$E $5*XW5:L<G@]>[STU[RU2I<M-VB[4IJ95IW0FEG@;
M9O/M3VZJVS.AEV1/LE'Y[U'[06'U=A;7UZ[# -4NJHL>*1SZ]V[=]TO%E)!5
M]GV;(I4P==?H?&MQD/4?*,XI)!CO9$D4WWUU&))[2ARI=G+Y1N6KSN)$>5.X
M>Y%3,^O:G61.W1];FY;.->Q\QZU4S6W8OLK$HZ-C#5: +5Q2UG[NPDFC1"2+
MO_NC&&,<D)N."6 Y08TU6?>Z=#*4G,M)Q:7"SPUW:;R&G77R?=FY?8WC7J06
M^@O::.=@Y;VRC%X7,&B.**G"*M!?")K@974DW= 7=76/48*1BIA<<:9QUPRF
MKA$6.JES\(Z=(D!KI7O2G2ULPLISF^[=SZR4/6OR[*]@FG4:3$NIUD557?=F
MQ"M>T5,9-8==FG!O>+0"RIC,Y$2B\;=O3(,*&)5NZCHO!K4>0DFA@>?8LT1N
MBFN1CI:VKI[,-YU:2TX[SY!7EW1L1O6\:H3JQ9-SW59)[M5J/J9A.X!#_E$"
MZDV8YJN<3@M,I4[9B,*RJ38&LX+&&+1X0)NGZC<F[#I-,O%PV<MM))4_W*4N
MS.XTU8OEVNNH+Y[9+6)U5E0?KUUNZ1TGV86 $3T'!W /D%F.R6I$1,VNLG/M
M4WNA=L]K]H%"(+(A"\+D!\B2+ Y'&GNHU42J8:FJIKA:-8XSUK<R2'8ORQ0G
MKS(.Q$;=4E8,\*=?!_3-Z\818S&T2$W<=S9D6A<2$QI PLQ:H$HR_%9W(:E7
M[1H3V=-T6[MGKA1?08J9ARDGM?VI5/N=N)HJU?.I6-!6UM35[TOO6,U@#:F/
MOC0!;L)0:TKJ@K>Q!OK$Q< A.\L92CL?B,Q@I'IS9S^I!Q!M"(P<;K[_ #5X
MW<--$F[#:E74O1Z1?5+A+6"]W@@< < < < < < < < < < < < < < < < <
M < < < B ^Z#]0R<Z9661I,"]G(Z[)GV,8R%T9EJSII=%A0F/UW,9R@CO(<L
MDW9J'Q2-BE!6K;$?:*A1Y8>):&4-2'!LN(FT1U3/BY-8RWQ2= )P A$7DO7D
M<]C]>TMCKM&A+6?6N&:9I1)\\+,:\DFH2=CMIN#"FG[N01S,VWD+Z,R-;ZQ1
M]X--II/]!NU5OUGKWK<]\95G8R.=^-/I194GF\SEU,;NI18;.J&TJ-B+*MR*
MO7#VC= 2-1R<3M%)Z$TB\\@32-!!P&Q8MH&GB EE\H5D:PQR[:.!BJ:CAP3\
M5=<'8R6M>@/46H3$2/UY3S0 9@I>Z#\6)*3"PC3H8:[$#HJ+NHGLI():5^8/
M;!:PJ-[F5RF'NZ;]BN5'Y9%"I=X_#:;GC&BTQIIZPC[5=]#^J-2S.E[!K>J=
M(A+NOE3NZ,J<H)FEB:)Q^IGC@F]W@Y48M+EA,V$M7YDH2%[3MA)7H8F\5)B7
M3)_C1QH]>NP.IN9<S=\]Y'?'BHZ^RSMQV/[776Q0MLE=-DT#94/A3U::QJ.0
M0G0E61"! V\O#!9]I#+I1^L422G4>1GT,<#X@2=JHC!RKK9T4=C=MPDK0FI3
MS+;ZLQQ-UA?'-TF 6Q.+L']?8BI8-BHV.E*G)5_*#T5<*7$RR,MM\'K<Z>)5
MO%2]H#=UA]AFHI$PA>9L7;YI(GI% @]3<#-JJ(EQY8[-.2W&9]:>E76+J G*
M]>O%6M8$XF^D>;2<HYDTUFQXF+B#-R.B$=Q(K!DDJ/,8E$6#UXSBD/'$6D7C
M;=VZ2"B&.KA;&X-MQ+P:W:>,SHRQO37L>TZ_@D;73L=>XD7V)18&T+;VZYVW
M47M-K4F\MVJ-K8RCK?<CF;MX,E)<%]MC.">"N?C.!M/$Z1QC=.8X8,JK/H)U
M)IV:QRPJXJ1..2N'3ZXK.B#S$VL<L/BDTO\ 'M!EOD8U'CDO)QP$PFK5DCN\
MCHL2UC0Y[N[)A! PD^?.W -MY>B74L=AX$2\;?2:#6VE>,9HH2QLAI,;-GPP
MFYEEA%P *470 D$8MEY&X&9EQ" 1IE8@:4&T9<" Q@< -NW2)5Z,5*CQKUF-
M=534-Y274L7S8Q %XG_'W&X/:-<">N@E*'7'& ,(FXMY.K3++:PF+2M.=1F%
MPHP6G+XW5L0CTS1;RD)%ZP(P\$+.M&1-DP0=,FBB(;569WO3+RSW2?C&Z.FK
M 86D7I#!.<CB=-GTC+ZR+<<I.Y5U^:@&%0S<R&5GVP*03^'C(R&$)S\Z,(S,
MT%0=!I$=+BRI9H^&;3Q.]=3REN3W(S@]T-ZG22H/N$%*C:_<R1M4W>0P2-EL
M^!G8Y;\BE9V;%[&B$\"2H=/X9*W$EDTA?(E8I* R[!N9(B1^6H=TJPV"7,SI
M&^R41#LU!NZFZ:K+K[6T9J*G8DQ@]=P]!Z@ CK!R1?:M]B9-Z:*O7A0R])&C
M)8P9(D#!DT:(D"Y@J^>$23YT\<K+;@VVY>6;.X,' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' *NW/A]Z4.:8[B4/F)2I&!]X[=7NJ[-6\ET3,)
M3'ZV#YN+0A!'Y7G6, 8Y)1_S"/"<-G^H[XX@WRNLW<X23%;=4TO6E0N2GS\S
M,;*\7G5BTAID,>'38<)-=,(]T+4'1Z4)C&K#K]%Y8SF04>,TW%.LM9,T*L&J
M.#NVRNFP]/X7X#&<^]X&T]^*MKKW]9A=L>(CJM;TPGTH-';WC8JTY+5,]L6M
M8/;IB-U5,;-IG>,IPJS#L'39N1SV7IBXB$$%]]]\ C";1 V\!;2UF-D;$-IV
MUA-*=SRN7?N9-VR>OE4V=5-T4X5BPX!$[^@$TKBRW$+8"XR>,@)['3<8.N,E
MF0_.^YG4=(2V[ D]1>[M'CI1S[M3.ZNJC)."N?R'>.B5=KNKW7'HU632NQ5#
M0N2U6SL"R+!F<P:VQ7E<U"WCT=9Z5*%C,.?B)E-IW7*DY@1]_*I-"A0P>=6W
MT0*X,+Y#"Z:MENK6\633;WWM#AV3ZCX+[\5R/83N8<MPS9$NJOKT2Z#Q'IWB
M*419,BK>P";87;,_E4FB$@8-HR]BCNH3T$E0L#[&A7,E;$6*N@MN$23T)NP5
M44I:[3JEWT4=ZGCK)NP=XM^M46LT)8M9&[RID8/:4DUD545#<LL@M3V+CKI&
M1<+IY6?1\8K\Y*[16( 0$8=MQLD#,):$"#V$U9R)'1?"XS:<0X>8;NU-W!YO
M=CHQ,>V/9/H]:0>S3560_K2Y[)O)C(J^FYZ"7,V>VY60:(0YY6),=&S@-QNR
M,#%M)<RE;AH)=QMXY9[#SVKM9A@%5"J69A<,S_J#&3/AXZGO*PKBIXS(^P]9
M1^ P&Q:M,DZTO.61F27!7MP29Q-+8B]TE<_':3EI84N?$Y"??Y:C#2+TF]0"
M$Q [9!B@"K:<V;E.ZF&K*/6XR8[XF^I9NQHK-4DK8 PR,$:3.J=>([:LE']<
MI-(^N043'J3D$HJ_=1RW?/8$)CT<;-6+(F- G-X^+=RL.>>)KKN VGPF]X4W
MSXYRM'!N[M/TFJGM@5JV7RF36U5UJ4F_E#NJ[GH>PR-9VC#6LX&- \W!,3[1
MN18O8[+QPX:V/!S @DU<ZCVV4M4-O?95&)M3AIY34^NHTG#O%+UBKUWUP-0D
MS=<=F76NU[5N<+8*-IDRD[M&<WNL'5NUY=TB/LBSFP6UJZ 13.8)[Z"W#@<U
MP-&NAK%59!0;M.^+I+&$L1N@^^X\777).@>L/7N-2"YH$&Z>RK:84)8<&L3(
M&UXB7<M9..+:J2K4,X9$F)X1+S@<PT=@]M' ]PEJAELX03<8#:NW"]Y0UIE/
M?O4F#[>'GJN/@U:0Z#2WL559FI3%Y/X=:M<74<!6]H#['2-S*K=A!V;NV11Q
M*(G)C"R#O720M")\8Y8-2(T^V+[OB+P-IS+AS$II-/94+UK=.S:/>E?B2ZE2
MYQ($G?W6Q\8F'5$#TYFD%'6@:VBTSJF(8,;0HI*=BJ121F+!A[LX^)A9>YD.
M5U"NVI$NT*NMEU%@536ZU6TK8?5&[&-T'F#O$3UE3:V%F3S/L-9$@M1]UD)3
MR:V1;2\JEQUYU'F3J;4ZIDBY"(M1R#!^Y3'&F D>Q'%13-#7#1J26($WP;3X
M?BT^)0^[&XVY97CRI>R+\+]B$IM?E:RZ:[U@K;L>IZY)-6T*NY6F76SBME;/
M&1_*)8@M&VV=0VJ\<.QA<K'TTP9M0D-QLWV&2XBUIB4G$YS_ *U5[D[^#!P!
MP!P!P!P!P!P!P!P!P#2\.[$4I85O6G0\'L0!*K8I(3#3-L1$&HY(+0-O8"\F
M;Q1D?*(-MP;4\1S$#B[B,ZDU)$(9),"!D6/8FPC@B-APGHY2ZHGQ/$JCM+25
MWSJR:ZK"22"222I)!)8I.EU*UM !$6$EALI(0B5@P]AR6&!Z_F!./2L23!EV
MD-DY]5B]8.]5]=$T%%-0::2;UQ@D'P8. . . . . . . . . . . . . . .
M . . . . . . . . . . . . . . . . . . . . . 8UM,X?I*DH)O*XUI-
MUA.QY&&['1>LJ6!Z+9;[F4H]EU@NH)T<:[(;$=&>6>JVN4LK8WQG7@&2\ <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < A9KUNF\-[,7QV.J<I6@A_;E,==*P81J01LO@8T,5;<=]V!8TL/\
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M.C?RD?D"^P_H5_C[6<%/H4_JJ\*"PS@D< < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < U](K:JJ(.VK"6697T7?/I(-A
MK)G(IG' CMY+S37#T/%6K<D2;+.)(699P[&@TM-R;]KG#AJU52SC?@&P> .
M. 5T=J_QX/%K]K/:/_5"M7@U8JY?5%B_!@X X X X X X X X X X X X X
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M!P"O.C?RD?D"^P_H5_C[6<%/H4_JJ\*"PS@D< < < < < < < < < < < <
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MZH5J\&K%7+ZHL7X,' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MPIC;&BF^N,;9TX'J\ < < < < < < < < < < < < < < < < < < < < <
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MC!7-_.-).#I1T*?TT^"(^\%'[8-9_N;U]_ B*?Z!8<'SS-^ . . . . . .
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M\Q:J;*ZXVVW9-6VV<8]CU]C.=<[4VVT]&XP92DDG%VD2KY)0X X X X X X
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M,D"11E&3!)PQ8K/-]&J;IRFFCNXVU1UWRIG&N1NS4DVZ6E&J:U6\NEX)' '
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M[^_VSK[[1AHLAMLW1]/:75]YZ):YQG.,^O-2G5+FX,;C1OE<U_65WA+67VU
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M/?:*:>NN15%.W5$Q9LX>[[^DD7]V$(U<7EW4SJ6R*5A=4$NQ$B/C<T7?RHK
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M*Z_%E5])]7@BNOE$EL?3O\1[N=_>22?S?N.15FCG]473BOE]&5.<L@R:%?\
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ME&3-V3(N6K;9)!=\[5TW<*#F>CP!P!P!P!P!P!P!P#1UY7M'J$;5:4E@8V^
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MW[9Z3BU;%]82"^(19!Q(#.C@&/$N[WX\.-^V^\FYP8. . . . . . . . .
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M7*_>7YZ\8NGY^(]SGL]BR<U?]5_[)^?>]Q57I*_G_P#S/Y1['_)__.?C?_\
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M*?A%;UY#K>J*9Q.8DKAJRT+G;9(VW'CSN,PMY7M=TU/SEI1P\PQ*XK[F+M4
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M%H@2@#>6"S* AT((%C,).2"+RA"01\P%D@8\4:%A+C55'* V7,[\K1WF'O\
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MA,220<L'[7?.NN=V[INJEMG7&=M,YQC@&(AZ:J".Q!K7T?JJM@4"8E&AME"
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ED6B:YB2/LYWQN.OM4DJ4K)J6N./#16.QC@Y#@#@#@#@#@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gfifg3pi0xun000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfifg3pi0xun000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %<!3 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!,#.<#([TM%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB-HC*)3E<CKR,>G%=!\&3_Q+=6R2<W"?A\M '8^+?%%OX6T@WD@$LS.$BAW
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MRW4LR&1E$@!09 !Q[\_E7ENDG^Q?$?A3565HH+E49V+< [VC<_E@_C5_Q_\
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M=KX5T^.>5?-GF;;#"IP6]3]!QD^X]:Z/M7G/Q:T._P!3TVRN[&!YVM7(>.,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%M;_ &Z]A XD?=B-21R.YX-=[!#'!!''$BI&B@*JC  ]* %BB6) B *HZ #
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M@#WIJRQO]UU;'H: 'T444 %%%% !1110 4444 %)GFEKF/'7B&3PYX;FNH&
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MX_M6I3$"*W3D\],X_055^'^E^)K.ZU:_\03DI?LLL,#2;C%][(/8<%1@?W:
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MO(/B9XKU :X^A03O:VBQHTCH.6)]<<X]J /5I]1L[:58KBZABD?[J22*I;Z
MFK =67<"".Q%>#:3X9\*W4"MJ/BS$[J&(B38%Z'^('^=.G\%V4+,VF^-;5<
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M>P/8>M>NCI0 @&,TZBB@ HHHH **** "BDR*6@ HHHH **** "BBB@ HHHH
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MW/4#@>^0 <MX!T^T\2?$W4[CS6?3;&ZFU&WC)X+R2?*2/3C/X"NQ\3_$6?\
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M28:*XB:&3_=88/Z&O'=-^&WQ$TJR;2K/Q+86^F.Y8[)9"P!XX&SC/7 8<]Z
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MQ WARS<]-\DK,/?[F ?SK!3X87FH-%)XV\3373M*%C@MI"(RQ'JPZ]>@' H
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MO_"5^)->5!X<\/RVBD'-QK/[I0>WRH6;\>* .]K*O_$>CZ9N^W:G:V^WKOE
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MY&>2<=SBN\_MG2P<'4;0<9_UZ_XT 5=(\,Z3HL86SLHD8?Q[<M^=><?$!?\
MA'_B+HVLVZA#/M,I!Z[7 ;\U8#\*]2_MK2L9_M*S_P"_Z_XUY1\6;JTOM8T,
M6TZ3LH;=Y<@8 %EQ^)P?RH [+QOXT7PK91Q0H)=0N%/DQGH ,99O;GCU->4:
M-I6K^/?$):XGDE0LQFN&Z1KGD+VSSP*]'\5^$M(\4ZQ#?RZ]' L<(A:-61@0
M"3P<\'D_E74:0FAZ)IZV5C<6L<,*C<!*O7 ^9O<XZT &GZ/I'AO36>WMH8$B
MCS)+M&Y@!R2:\7L-+MO'/Q$N4@9H+&:1[DD#G8,=/3)(_,UZ]XG:UUKP]?:7
M;:I913W$80&288Y(X..>>G?K7/?#_P .V7A6.XN=0U73IK^?Y=T$X*(@QD#.
M/XL]J ,;X@7$0?3?!&A0J SJ9$0< Y^4'_T(_2H_B1''X>\-:+X<L]R0-N>;
M'\>W'7UR6)K8T;0Q9_$2^\07>I:6]K(9&A*W.7&[@<$8X7(ZUN^)=!\/>*UM
MC?7R*T).QXIU!(/4?I^E '!^!KCQ9JDUF-+:*WTFRD2.8%0%D'!;_>;'>N@^
M)?A$7-L?$6F Q7]F#)(4XWH-N6_WE5>/I77Z6^A:/8165C<6D5O$/E43*>I)
M]?K4U[?Z9<V<T+:A;*DBM&S>:O!(^OIVH \F\%&[\9?$(:OJ&V3[+&KR8'RA
M@H5<#MR"U>A_$ ZP/"MPFBQ/)<2$(_EC+*AZD54\$Z'I7@^QN($UBUN7N)-Y
MDW(IP!A1U]/?O74_VMIQS_IUMQQ_KE_QH X+X?>!(;>R35=9L@;^1RT<<G(C
M7C''KQG\:])"@=JJ?VMIW/\ IUMQU_>K_C3?[8TP$@ZA:Y';SE_QH O451&M
M:8>FH6N3V\Y?\:#K.FA2S7]L%'5C,N!^M %W ]*7%4AK&FD9&H6I^DR_XT?V
MQIH )OK8 C(/G+S^M %VBJ?]K:<2 +^V))Q@3+_C2-J^G*FYKZV"^IE7'\Z
M+M%,CE250T;!E/1E.0:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !2$9%+10!QUM\-_#T&NR:NT,LMP\K3;9'R@8MNSCZUV& #2T4 (>AKQ7
MX@Z?*WBBUTJQU:ZEO-9G_>6Q/RPPMQ_0]?>O:CP":\@\.W*1?&GQ)+KTD,5Q
M%$1:O(X $>5VX/3.PKQU&30!LVWPL6TMX[>V\1:C#$G1$  SSS^M+<?#O[+
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M> \C7M2!&<?-QS[4UOA1$RLK>(-1*MC()&*])JMJ%W%86$]W.P6*&-I&)/0
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M7]:R+CXVP2H#HWA^_O#CG>".?^ !J%F^)?C/R0L \.Z>\G[QV&)=OT;D_D*
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M*V]P.<_Z]NM=S10!P'_"I?#ACVDWI;.2WGG^5"_"+PR/O?;6.0<FX/Y5W]%
M'%/\*O"KMN^RSALYRLY%-;X4>%&7:;:XQC'^O;GM7;T4 <2/A1X5!!%M<<'.
M//;%/_X59X5V!?LDQQW\YLUV=% '&#X6^%1_RY2;LYW><V>H/]*0?"OPMD%K
M6=P#D!IV(Z8KM** *>EZ9;:/IT-C:*RP19"!FR1DD]?QJY110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=XI^&F@>++Q;V[-
MY;7@ 4W%I*$9E&<*005(Y/;/O78T4 <9H'PL\*>'I8YX;%KNZC.Y;B\;S7![
M$#A01Z@#I79;1G-+10 4444 9>N^'M,\2:<UCJMJMQ;L=VT]589P0>H(R>17
M)Z9\*[31HC'I_B;Q+;QEM_EQW<87=TS@1XS7H%% 'G+_  <T"]U$7NJZAK.I
M28VL+NZ!W#L"RJ&Q^-=UIVE66DV,=EI]O';6T8^2.-< >OXGN:N44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5*_T?3]56,7]G#<>42T9D0$QDC&5
M/53[BKM% '(VGPQ\'6-U'<P:)")XW#K([LYW#&#R3GH*ZP(%''%.HH \C\:9
MN?C1X4MI'(BB"RJ%XYWEORRBUZ/X@U:UT+0KO4;N15CAC) 8_>;L![DXKS_X
ML:;J=MJ^B>*-*M&N'L'"RK&/F^\"N0.2#R#CIFLBRTGQ3\4=3@NM>MWT[087
MW&V=2ID*]@#@\\_,??% $7@3P=JUQ9GQ?IXL]/OIYVEL[3R?]&\HYR GWE!R
M0,,,"NLMOB+J&D7PL/&.DFQ9FPM[;H3;G/3G)(^M>@6\"6\"0QH$C10JJ!@*
M!T%)<6L-U"\,\22Q.,,CJ"#]0: ,@>+]!-B;P:Q9&W"[M_FC&*XVXOKKXISS
MZ5:K+:^%XR/M%V 4EN&'(5,Y&WH>0>@KHY/AMX0DN?M#Z#:F4=P6 _+.*Z>"
M".VA2&&-8XHU"HBCA0.@% 'SMXPFN;3QY:Z7::29+;13&NG6BQMM?@-N;!&<
MMC)X^[]<][IWP[O?$M^FL^.KDSW 8/%I\#8@C7'W&!!)'0\$>^>:]-\B/S?-
M\M?,QMW8YQZ9J2@!B1JD:HH"JH   P /2GT44 %%%% !1110 A (P>AI @'J
M:=10 W8,YH"!>!T].U.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .:\?KN\#ZK@@8ASSG!P1QQ7!_![2/^)A?ZLP^
M6-1:Q$8Y)PS]O9.G')KTCQ9976H^%M1L[&..2YFA98TD. 3Z9]?3WJCX$T&?
MP]X6M[.Z15NF9I9@K;L,QSC/? Q0!T]%%% !2-]TYZ4M(>E 'DMR$E^/-NDO
MS*.0#V(@)&/Q%>M]J\B\2"33_C5I5PS$1S^45*^I#1D?GMKUP=* %I#TI:P/
M%7BBS\,Z2US.P:9_E@ASS(WI0!ROQ,\2S"-/#6F!)+N^_=S+SD*W11SU/OGC
M-=7X2T"+PYH-O8QY,F-\S$Y+.>O^'X5P7P[\/7.LZG)XKU8^<68M 7YW,>-P
MYZ#H*];H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $(S0!@YI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !11FB@ HHHH **** "BBB@ HHHH
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M65I#I/Q@N])BV?V??PL)+< A?F7=T'3D'\Z7PWX8TM_B?KUH\(-O8".6&#^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCUA_R*,0.1UG_.O0L48]Z //SXE\?<_\4C!P,X^T_I3?^$F\>$Y7PA$0./\
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ML,@?:,;?8^]>@X%+0!Y^/$/C\,,^$[<CC_EYI#XC\>@_\BK!T_Y[UZ#28I6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gv1ubg3hw41v000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000006.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? ET# 1$  A$! Q$!_\0
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M?&KEMCRSU=UQC&.JT*I?F])2<+2-GW#Y,>5'0OH"F_8ELP*>A;M%V7+T]>)
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M-<KEY))&!\6>0^0/GC^:F9X]^/F@O#3<B.H<E=",>? !\99Q"P+QLVS(7&1
MUZL_;(0V)3.1%@$1[VX75TNL 8,%'"77X5=])ZUSA0YQ=N0,^8 &??S7=O.W
MGVLO+--PZAJ=%/PE;P/@]Q&Q9,N0/O6O,DDYJ7EM+EBJSA^[_,<D!-=/]0MW
M^%%5-LG]J**?.B@DDDG<GFH.?_!K\*:EK8SJ'6AQ7[&P?[61OG%&^KC;>6Q5
MEZ-[DNIB,H%M,T:]8.^9#OHQP';"DXNFZZVFF!X9_1KHIUN\QRQG S@^N,_F
MNU1SX[_-L1OXKZ(C;2S@TC,V#*+A?5^PN2RVU&J7+-@JD>E]N;IA&2\0'N?2
M,6NOP4*K!U6JY!=0YRPX/?83X(7$C!QRQR&<;8&<9VQM_)8J._&9X^CD0H&
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M)A$PB81,(F$3")A$PB81,(F$3")A%A!TECA@@;$B9 $*%8TX;M9&,'%6#T@
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M;:E3$*L+SQ%3!:X!$:'4?*9K(F+">R?A!M=IN;4[4;6>A^JGZJZ9E A-S-R
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M]#FBHAM!#\.=QG;TK8! (!W)!&>NV-R !G?I@ #/FI1UQ[(]!0_SUY^DU_\
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MC\>8DSQTCTW;J<L0X0:_+$W723(>R<NUT4>RKS4&#ORF>2HS73:RSC^X&(A
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MUI'99W'9Y84#H6)1.>A6 -I-Z$F5!2:R9S7EA0N4N^EW*1CF466Q*N(^213
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M@ <@';KRQZ#J,#?*SOS$^)O-1_Q?[,]*R>JQ#^_65$D3:D]9GYNR3X/Q2+B
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MIP-MN8)Q[ ^1\P>>^ //?1[']#^]F#1LC$I98;6ND@OH!W05KR.#'0TPN>0
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M;&S!PJ#KV$[.MH5  C\H5<AH5&@ W]5K]/UQJ4+B23DC/D?KYGS/,G<K)_$
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M#VIH&Q0>1+'._M%2TSE%LDPB81,(F$3")A$PB81,(F$3"+0.9U5G4GW&N)E
M.IGHGWQN/\R&.[D_[SRRVS4XV*T\V5_<^1W&VO?/X/U6F7.T.M:0Y^W5^\DT
MZ.\?IT=WIU.TZ.\[W1C.-'>DR:<8[SX\:MU3NX]6K0S5J+]6ENK66=V7YQG4
M8P&%W/0-.=.RW_**ZAC<-@^7JQLV=,)E$9=.[3N.GXN%M&(US4-O7V8)T9$2
MEE,(NK/(76\7F[".P]8K/;1%B%RPD6[GSIS) PSF4*QQ9D(*1G\#Y@;[>?R6
MA +M\)Q=QYL%1F0$S+" 02MQ](S$4&NZPH= 87?S5C6]6(3JUN!LBC$96LI(
M:.C<<[N24MCCE?EIWWVV7>H.7)3\6_YC;.V_+GMSVV7V6$9\*@8E>OG^5O\
MAF&\Z-V'J>WX_$GEL*3&LS5KV//;C$SX%+*]74L-A9\FL)C+YD&"UX>ZL5+L
MN,T,#MQ,KC;4J4#.0?/89Q[==O3=:U"[#\6TBC7,SA%:WX*F!L-;4*A,>=^=
MO8I:^))'EYE&;+NN6':WG$!<6](1KR>'8O(IE<TWC[W9N62$8.W,R)Z2MQI(
MI.3GET/-H'D,=/D.G3 4OO/6J=[IBOWGG_IIW3I@.I(8-VR4.=H]C9(1>GW?
M:B<FZZD3)[V5)$.B(HYPW*AB&W0I\R8.&:C)N4'.3GGU79L*$PB81,(F$3")
MA$PB81>=+Y9J-\SH7Y0$7:T=\=M<VKZV>6_(Y_[ ]I5%'Y=&Q>J4C<!_00UO
MIX6B+6069/F\G:I@-2:6-&C:*PB3[9,R1%-ERS+T83@[OP,;-)',\^HP/;F1
MZE3X^(J8Q:9^*8NM#ZSH^M \6LZ\:ZWKS,(["^>+%(5S;,LA9&X*8:*]*+[@
M=G.PBLI'*KN7W?ZIX]1Y(D$D4WBQ5?\ >YDY .YR=P-CZCE_ *S7"JH6^N/"
ME1^RNHXM8LFM"(.P4%MBIR#VKY0,CCB7T]>K2*L;>JN5:,QV2MUXK.FT*C"9
M!\%0"3$5L7PI&I4#4<O.W!6#BWECF#OT(S@^XS[>8*Y1\M0]F)^+;VB*'(<M
M1XSSA+Q[%MQOOKANS9C$6S5#CI3KM3KE%!/A/G???7>]<ZWUUUOZ[W#N1]C]
M$9]X?/Z%64Y*JF$3")A$PB81,(F$3")A$PB@N0__ )\]ICA.O];K7Q>%1D13
MG?\ GL2_I:UX\X:QQHIQU^1!PXJFG21$UWS]O*K0K;@-SSOER-XWQVT>;%P=
M)+]RX\8S.IXNCXN'+74-=4/!&'-;=+O''".8=%:9FXTR'.H/]-NH;SI[4P/=
MY.KZEA# >A--2N<XCHZJ8>8&)T9Q*VZ81,(F$3")A$PB81,(F$3")A$PB\Q$
MXM3QA\A5K>4V/K:N(D L>PIG\A5&G;$KSTW.J+.02K?*UN&H_'8+83>)20(5
MF46N9NT1,= 96>%, QA<P_B2:J9EZAT7IAS<ANX^'/P@\P#GD<8)'+T]%Z/*
MOC==PVMX)$*C81P55L6B0".5Z,B"C5:+CH<$&-AL>8@%F2J[584T&-FR#-5%
M=;E1%/GO:JG777?1>?NM[PB815Q?$9_=Q^5_^2#7_G4LPI=S/N?JK'<*$PB8
M1,(F$3")A$PB81,(F$5('RY0"_\ U06JKRGY=(%>Y:&8/[JN-FQE+2*!F,$_
M>!T:@*4B>/2@MH5>F)0TD16-1ERMVD\7AK\PIIOT(:ND_M/917V'AB*Z<4<3
MQQ"DF?'9K0^2E=53/KC#)4UYIV,BE?$R&F=3Q5-2UH+!61PC4)7-/)<2P5MQ
M=36VW.=WC :NJ#9!&QL.H1PB0ES0XOD$CHXSLXQ.=MH!5U(%L]9@PS0DX[>$
M6HD<V(.U$DD%'3U!FBDZ<*((.':"/:Z_*BO:2+IRDGUUOA-PMQSI3KXW.YCY
MYG1M#8W2R.C:"7!K'/)8T.<UCG -( )8TG&2UIV'5L!#&!QRX-:'' &2  3@
M$@9.^ 2!T)66SR5DPB81,(F$3")A$PB81,(F$7.[/KOFSHUS&NYM8D!UR2:D
MOWVL94M#Y+UMJFX3_0]%D&SKO8UQ^H^]TT_%]JRB#?O?6OQ:ULH(]2/94I-?
MAMG:'K/=\]^D)!J+?V@O)9IVB9D2=S;8N$G^N%MSC\&VFY5OMYRBX-_I?L49
M\J(Z;ZZ4WUHHTG5G/E[\O(C&?;&V?-785G7_ #6D8XC/$TL&>:X?NWW[_9DH
M6ETGZV[_ !_ZGV87;->^F#;\?^J-OQ?1#[U/IUU]^_H5OGG\/X *%]S5#?D;
MN6Y[*I^,]3^.^AZOJ6$R).-VZTIBV*QEM.EI^X#F(O)3<0E( G")6)G>VQA#
M73,_$"8HF^%!I@G,W*4:*1CZ^H.W+TY<Q^6%Q(/2_N%\^\]5I>L3C=P5#5PV
MM)7."<=N,6->V1=8*9N96Q,V,[-P,"<F-=T:LUB9.%Q<2$AREC32/:DTQ11$
M-AL/V4Y SC.^1N.A^9WQS]UJ WX]+^B<B]!N)+,*S]-1.T:2J(*4"2T-)Z3D
M%OV3%/15F7),G,RG$#FYHS'B:HR7.$H\9&M^8OV_-1V*=1<)74!XCY4F=AT(
M/,=!Y#]?/<K]5_(%WM!J)%Q20L_!]VO:TPK:IH=ZFM"H_07EB-R^&4N  !:C
M]%0T\';<Q"2RZ V=/[6J!L8:Q!,A9,3'QXP?$5UL*=)ML,^63C;(]/;\>HWR
MK-O-45M>$497,5O"3H3"T0X9=O*#J!'1O:FU2I!R&&.I%H!%>I82C\?7$QXM
M,E8S'EYB4%NY0X"C%RRC)$H.,G'+\/RWQ^)7<L*$PB81,(F$3")A$PB81>4K
MV'\H5-1B]+G\M>QS=1V9%HE\FU2 5:LNOS:TM>-0[Q.[\[0X[+I:,29UH7"D
MC(FTRAO8\V3=2*Q6?[J]9L&Z@/AFDU+UTY (_N9R'#.K)]?+HO15Y3N?SE?%
M&P^>>3RD>*41QR0B\)W$X:7K^-CF\2?+@G@4-$34>BKH,P$/&:S%NV2!LV.N
M$M=,M=M]\=]%YD$'?FI%X4)A%7%\O?\ =B^W_P#I\G/_ &?&0[D?8_169]X?
M/Z%6.Y*JF$3")A$PB81,(F$3")A%RN[[9 454D_MN3)KNA4%CCTQH8SUOHB?
M*_YC2/Q@2GKGO:QJ4GW(R.A6_/'73@J49H:UO:FLV=EM<][NM!:J8ALM=4,A
M[QW]7!%NZ>IE)( AI8&R5$SLC3%$]W18]74LHZ::IDR6PQE^D;N>[DR-HZOD
M>6L8.KG +GWDRIS]24R(:3M1N[MJ?%SMMW63;[UTD_MBQWW4AE;=NIKOOE07
M&>W#2%1S[-ZX2C$9"M^...$=<ZV'%5U@NMXF?0AS+50Q06JS1.V,=JMT8IZ5
MSA@$2U(:^MJ,Y)J:F8DG*\+;3/IJ5HF(-3,Y]35N&X-3.=<@!Y:8\B&/&PCC
M8.BDKG.+/3")A$PB81,(F$3")A$PB81,(F$5$3*M_P#]/Q=?HZVZ;0JKQI-O
M1\:-6"=LV/OJP2V>+2:-.GI>T>AATE'FX2P9-&WG[F\FPN%%Y(:!N$"71EFT
M49N](E?,@&<O ]S\NNV>GGT5MGF<S1<B\_4Z=\R(@F_GLM7T;?4VA& )&+QY
M*O7 ])2-<!HZ7'""84=R.VCIL.?#&#IJG]$U6J76M\Z*ISDYYY.<\\]5_OT/
M>D;\ZU4>LN0,'T@>(.!4<A$&"=M]2>S+)EA%N @%;1--UWP@I(9G)GP\.T7<
M]ICA*"[HZ;<L0(HH0:D S_'T'4J'5:?*)Y]5\T>6[R]!R!*GI'Z4IB,6TPAP
M>,V38K 9R9'LG)0:W.0^$E^.TQ3UYRRY4)I#';K7/Y>6FN==_:0C!(\B1O@<
MCY$K[OB =MW_ ,;'DU\T4VJU>U^3=ME=\*)[4;N9M*5D5-IJ\\*I[[3[YZ^Q
M3CA3GZ_;WSSUK>M$=S/N?JK)<*$PB81,(F$3")A$PB81,(L!*I0 A$8D<SE1
M-L%C$2!%I+(C#WO[&@H&"8."98BZ[UK>^4&3%JNY5WK6]ZX3Z^FM[^FM^]+3
M3UM33T=+$Z:IJIXJ:GA8,OEGG>V.*-H_O/>YK1ZE4DD9#')+(X,CB8Z1[CR:
MQ@+G./H "2HI>,(P?(Q&8^C9^+<B;)]3R1"SWX@CQ]I&&5BV'\!Z/KAQSK>M
M(+1:NTQY,ZT_&EM*<RB9+=\?D<][WU/&-3!'5TG#U!*V6W<+TSK9'+&<QUER
M=(9KU<6G^TVJN!DB@=D@T-+1M!PT+76J-[HI:Z9I;/<9!4%I^]%3ANFC@/D8
MX,.>,#]])*>94S,X];1,(F$3")A$PB81,(F$3")A$PBY-<UBRNKX?Q)H;2MC
MWT8Z+LANX-5K^MQTFX:.DG:BYSIQ:<]KB,?M@_INDB[3YD/1/I1ZVVT'N4^7
M*B$'VS^O5%0"S^:GV6X^2=UY#[^.V?[@Z(MPM_9NEN,\^F6S5&%<25*>.90O
M;/'GSJ(N2&_TG"/\0H!OT:J:36Q'\FUS&UHU'.,'\O0\\XZ\O;??"+T!TY84
MILV&\2>84U8E$F>R;]AU [/?5T1E";9I^'\!?MS5TZL2+;8$?R=_H^.)'T0Y
M_ K^L9-?JE^2R*H+V]:MQQ?T7ZE7 #_3TCK^F?(_G*P6KBBKM&5K'JA-36:^
MK1\JLJ8Q!=P_,SH8@,@<;.G^ , LP@-C,#)_@AQE9RD'*E8#ERYGGUQC;]8]
MUUQ:56_NPJB[ ^AYS==IQ./4C9'H'NIA:+GS; Z/&5>-(6@F]BP .^YL*PO2
MAQG*9)2(,4@YM5HE)XB8!# 5<0]ZZE)-M^6#R!Y]<?(=<G'N5$X=[5OJT]^D
M13.0VY')]/[;\-#:PJ A7\XHYS6L0M>?;83*EV=D61! S*(S(_78E\UFMF)=
M2$CU.'\C?5"F]9M8.DQ?K]?K\4T[[XP =P0>6=^?G[9_%=2I2W)[;)Z-TYZ+
MONPJ?B%60/UU,9F2&6:/@\FDT@ICT_)X"M%Y'?H'@,_ED:\OU$G#?XLEL<?Q
M56P'LL'3*T&;9VR)QYN_7Z_7NA'4#F1RZ9'EO@NW('3'P[*POPM9<FM"DBQ.
M0S7JTV$3N:\ZR@MP=_LW:EM5S6UIR>'PR;N7D<:,(X:(JB128 Q)H^R9A):9
M D)2,:-&AA)LD4'GY>8\L_P4R<*$PB81,(F$3")A$PB815J7'\O_ ,=5 6O-
M*/MOT3Q$[4KQTQ93*(ZJF[S[H(N3'-2P_P#,0C%:F@[I%Z.>-G39TP(NFJW"
MF^>%MJ)J\<%<,<1D 8\\@?4J8/G[T13WJ6L1%R41+]SFMSKXP.%2/<>E,7VZ
M>@"3@061_9YD$CQ]#](0:KM_R.1:*3C[/S-E%D.^%>BJ00<'G[@_F-EVK"A5
MA_)O\B##P?7,7W%A\.EEU3\CP\C$3F9Y$)'Q%=1L_&65EV/)%-$Q1!R, MY(
M'CP$2)=:+'9K*(^@BC^QL9,2$%9K=1/0 ?GT4</F,]ET^.\9>SZ#_8[X)S K
M19,>/D\?\R^A)'33GJ6Q@3( [[B^@=:D*8_9?VXNS_<CFYSH0%>\NQI9ZR(,
M'K9"#R/L?HI8#D';KU;GEY$Y_)7EY*HF$3")A$PB81,(F$3")A%7%:<F?7S[
M8K;S Z2B?$ H9N%]2V0W0F7ZL[*BK/\ 5#*1C9**J 6G;;@'/.75C%1Z1(LT
MY1C<#+/WS#LNP%/OH=LIF6/@RX\2M-4:^^NFX8MSG4>B"FB?IEO53%5"=X<9
MZ'1;HI#'$[-37Q1L?W+Y8]%4R&LNU/;R(^YHPRXS@2Y?(X9;1QNCT C1.#.X
M!SAB.%SB-8:;'<^>+>IA$PB81,(F$3")A$PB81,(F$3")A%XOWOJ/X];.9^F
M?!@VK/D>MPW$?7=U612^ZT@GFH1<ODRV9#/#QR7O?/DD:WE'K*+QQ[9967R
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MP:Z^_LX+M_Q3Q3J/NS2U8IO$,:7N;XTP^#TAHSWG?:"< .R0N\=V6\;MX?\
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M"K)I<]=^BYKY;DE;4_P0@:$38LW-L.:X&QRPFL=8+D&EV,DSD3C9D4:"N2D
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M'-*[DR&",/FGD.T<4;WNV:5X553'24\U3*<1PQN>['-V!LQHZO>[#&-&[G.
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M8:2TBC(BC-J[)\<Z<*-T?NTGR7B>9WSN=\8SZXZ>RD%A0F$5<7Q&?W<?E?\
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MOLX_)WU]NOI])H;=;[7 *6V4-';J4/=(*:AI8*2 /?C6\0T[(XP]^!J=IR[
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MZ/EDFVT2%F"3-UREI5%ZXYZ_)T5'$%SB.1)Q[94CK.M2M:6A1>Q[<GD3K6!
M=LN3$OFQT='(^P5)OFPL8V7)E'#9MIX4*/&8P6RY4Z=DB3MJP9(KNW"*/95
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MU_\ 0U:#K?\ 36FU"7LK]?\ ;_+>JXUSO_CKK>LD<>\.G[GV])Z,X0XM<?\
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M>VRLC(9GIU6,A46C#9))QRW<A5MJ;T33USPL?9]6R-+JHT,C]7*JO/'-;J
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M>U>$=OAT,(1_;!QOI'O[D4EOKQKZ;YZU]?Y1^QO&SOZ[BBMF\_\ C%XI<_\
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M<5%(Z0.(P3-3,E!8<ES-!/3.O3WS"@*X'EVYRP@%>C*4L^XA43KW_)NKY,=
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M*Q%P37N<CF-]^>!CXO///IOO@E2V\^?%6=HGW0:]*C)E5;>O=7-ZMO8<M&X
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/81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gv1ubg3hw41v000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000011.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %6 BH# 1$  A$! Q$!_\0
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M>OKK>O\ ]?X?PWO6_P#_ 'K^.O\ ^]?QP"/?'E#S@E3 7SPE3<'3I..&Q\E
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MN_\ M<_D@(;I/?UWK[K2>N=_9UK'GG4X597^-.D?RKR=BP/!D8 P!@# & ,
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MVW$XAPK]=[WOKZ<17E/77_Z)_37\-9%[WT_!?B?5&R7M/YZG0;E.8P!@# &
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MU]=_7!YZLN?+<RP+!D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8!"[Y& NY'X2]9 =2R)P7DO1D^8*2Z=2=M"X<!1<!''"[Z2
M2QT$D?Z>$\H[43=E689X6:)J;4"_AR^F+I 6GZEG.BE^B(1?#G9PVQF%^\#Y
M62E&@7[IDU.W_P @?I3W8FTT^1L32?X3KT/5E9[JM-SIAWO:,/\ SSB9<HI[
M.]C_ -)AOQPU6HC/_JJ?9N7O-T62RSUEYWA%L%*.DMH@&-J *=FM^R2'H<$2
M9",5)7RT<1D\ODR@MD]: $$-RL*N,&E7#0U(&:KIZ!'$F@Y^LV&8<3%L3W_3
M-,-ODK\?+BJT-.YU/X\.MP@Y:PA2:>>?1<#<.A3:15Y#^YR<'S6J !&(56K+
M[8KF)L[;ES0'6;^22P>&92MP^1((L@X7RLILTUOE.)MC)N.E?6=!>AI58$+J
M.<+2:15FKS^I6CJ)36,-78WJ6S6 \R:&E99'08FQ(9U.:WGL0YFD!?22*]R&
M)&1O)?:Z'&E0::S^.3],JS-#PG_.H^EO] 3Q/_B$][X&BZOVI+!<$/D?MV+M
MB]:DT&KH:Y:.6Y!L^2279.&*R/:;M!XBOST@LU5;]*)N$EN>DE$>N^%.=\;Z
MUL#\P#X4S(N*>\?3MI F"((! /$OM6W(^Q;:43; X_JMURP%NWVMWVJF@R$&
M6B"/7:G2FDN>=]=];^N]E?S]'J^)>BE//%2I<3,-.=^GZ9VL>%!S.LK?LCDF
MJU%C?/7Q*_%W6JKAXJDU9#$(P/\ 8<K.=NUU^DT&J#-GL0JY56ZY33;\<]J]
M<)I8.%5U.KKKF\_T_P"[ZF/_ +-L Z"_#MY<>*<;X<2<O?$B<?:U_/[Z5] V
M<(;J][^G\=K,0[17GKZ[^J??'\?ZM"_%CCJC2%V21>E@YC & , 8 P!@# &
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MV5I-:Y4:PIH^?,X=!HH_GDCDQ,D)<L'KY?ST-5Z8]'2\)*_"WM]W"R7YX,#
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MQ@]OPFGK6NE/N&_*CA?O[2SESVLY7447544ZIS;;<N[9G^"# & , 8 P!@#
M& , 8 P!@# & , 8 P"+'N6.NI?XM]:Q1E(6T2=R7S==@%O)WW1_A@ 5+5S(
MV'!8AU%(M-Y3H>QVO]^__3,/DTAVSX6T$"$B>VK505975>_I[E9GPUR2(DS=
M[1^/+07\RC<9JKDNQAWIOY%[[59MWB\T1&*O@'NZOH0P@3)YL:^_*.JW5)NC
M'#5VVD6TFP8*HM+ZQWG\(U5-MKQ\M*Q$_3F.>"]7I=#A5)OVLEPNORKVBCTI
MQRJMPC]C[[I)/>]=J<I?>)_>]<<[TG]YQ]O>OM<_6F#^')$?VFV6X?,^T7JO
MX=FKRY1Z3=K_ $4W]RV[UWOE=7Z(K;^[2WWW]$E-_9^G'7T _LDX;K=KIHKH
MK*-5=(N>$E>%.VZVTTUM(K\\=;Z25VBJDKI-37/>TU$^_I]GOG>P(">5?^]W
M\G_^D'Y__P $?G+!JK%'^+_YU%@.#)^7/\7MIR,E\@\[K0;7[N5Q[U=ZQ\W1
MJ8SIF@]ZYKT/%_>U2^@'*A!ZDT<,N!<U&UH6CBK%XLQ5>OEAKIJZ[X&NF3MY
M^SU5PJ*6VDU2X3UFF+*[E.&GIKN?J,8/*, 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8!'CUJ!9RCS1=T>(!7LC9&*[D3!T"&
MT^+] /RJ*[3KCMDTI0VFJ(LY=;7\WB'$4^VIC?\ S=7G?.\%65UWC[Z=2LKX
M?ZM.5?*?435M1CNKZV,#J*6B<O,^#:N\"2&:29EU;_$TCSZOX$BF8G(R%,W4
M1("9G(MI,$5YL6!@![=9@=(%Q:G,2VW>SJXH6E\7O8W9[)]GW_YDM^9C!%?5
MO(JLC_Q]^U_4\/:Z)R<I8LULSRXA1+UD#-M&[ 0'B<->;M9T*_""G<N/GNFZ
MA3\;&OPC882!4IK,/BIIY+BF_P!BOYU\N/IT*6YBZZGG24+UU,9FA()N%A4N
M91WTX( 6[XBKYE"*,'?OA*ZATS1&>M9"@3+K'+52[EM?!TT8LW'%C#1B+PJ^
M5B%EJ54[V4_2M%DE[XX^1Z>VU*K[<76/BJD#@=5[NL>RIJM['E$_JL?QZ5],
M4*K4<]C,8+6;*+$G_(>B@\L26B<.C!=T4)RP<WA&QP\6XT#IA4M:N+M0[)RI
MB%>'.(SHLM\MWO7WH3Y)_4TSK=*PD@8SQ'XRC+KFR:<M^D3FRK.]/<11?IK%
M+J@M?RD@*VT,,M(2!@&<@'3O3X<U)K$!91JS$:A+&7AIZ4[-EL^#)S8?M)]N
M0,7YD@=4$I9&$SI$K?LO+QE4^+3/I#6?B3U%$(>X6"].]$.6Y&R9Y"^!JW;?
ME-X\:Z2:]*J<=<ZC\_WL=/AINJVD=/JI=[,IR^ 7S]%BU4>5W=HH Y?6]Y>I
M?9,XEL E8%H0BKN TYXBG5$GMR%$@L[8GPISOT,8&DQ[T:FS1;M_N5>GFGO?
M"--_%?S.)35-*E=>)=/,,S8I<?B+S=Y^^/*L8?YX1K_T%?OI'P1Z"OR902@T
M!A(SYQN7T21]<0R"CY2%&HFIPFCW!HG&XE" R!)@U5A28$=I-Y$^AS1KS\\Y
MQR(N)NN7]--:2FRA<+A3:SOUFYW38.(P!@# & , 8 P!@# & , 8 P!@# &
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M_IWK2[QOO?TZVGO)&UOU>QW^-G:*+6WJ2:[>7/T+\IYQ@# & , 8 P!@# &
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M *)2;^-_/S<6HUFO<0@O17HB*29DG">XP/\ RYP[5&Z[>::?C7 E6*/\=?\
M*KFR@7]KKO8K!T_C]@$9?)I&AD]LV]E$E>.%TFA6!\P$+!7SAHI]>'":CL[+
M.>>%-?8ZY:+I[^NE>M:'7X"EU/E'?_HPC]E%\$U-,XU+_D&FT5?=VG6-OG*N
MHXRWD$C'C1#7FH.0MDE7 %,IL1(=R,=:G8S2Y5JZ;C" QUV&1'JH]:T\\\_(
M^-4YX9M";4+,O6/-3MVP<!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MJ'$Q3CHE^"YS!@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MQV]</'W;0<S338!!.G/(D /YTP",6#/ZH['%MO+DD/@@P!@# & , 8 P!@#
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M1_$.C) 6I*8F:;BQ*HA1'IG"5^<IOUV@N+P9& , 8 P!@# & , 8 P!@# &
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MBQ<<]+P*0R>/;=H$@SGI0?LFD<$\J<#92&CLE:E@ T1J''[_ #!OW!!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M#XB1(>&'$#!9ZV&BA3)T2)D7JR;=FP'L4%'3QZ[<*]<I(-FK9)1==93KE-))
M/OOOK7/.]X!HJDO6/F+THL;:^??05.W0\C;5@^D#"L[$BTQ(A!Y7:G(LB5'@
MR;QZP'$ND5N![]R@FS>J(KIMEU>T5>>!6FLIKJFB06"# & , 8 P!@# & ,
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MA5WVN1,&'[TH2=.GSMPNH(9U@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MC.P$HRS-5/8\TG5$WP[UZ@G4-?1 GR3D==1NN#Y-J2LC:BL>E4?,D=-UBXU
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M9Z[^_?<<NU?M..=*:%;;RVXQ+F#=6"# & , 8 P!@# & , 8 P!@# & , 8
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MPBMM#OOKKC7>OKO>"M0VGE-KL;0P08 P!@# & , 8 P!@# & , 8 P!@# &
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M17[O[K]-5174?^Z^GV?N_P FB <=]W]-?3Z?8_#?9^GTU]/I],$-KX P!@#
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M4B[[CZ_S-$&[#K?\_GC!E8JZ)?=.?M'J6"X,C & , 8 P!@# & , 8 P!@#
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M[/=*;Z_\6^OM?7?U^N#5?U5<FUVL3\P9& , 8 P!@# & , 8 P!@# & , 8
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MSH7R8,C & 5_ ?\ .H6M_P"7]Y__ ,1?I?!=%U?M26 X(<4OR,?'C>-O?/\
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M2EGJ2<R;T&:9D>M_SNGHEQ9'Y*IQUO?X9,:DSXWI)NGSR+5E\H791^">&"#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@',+\GWF
MR$#_ $ >D-9^+*A))22L#%E128P+XO*^]G/_ $][ *SZ>\S.I;]G3>*DGU1B
M^N!L-)/9>6)0M](7LYFIAY9+%S"'(]0=*:G_ %.S7\[IA6Q=3KB8C!TJ0I)^
MA#8DB5 CHJ41C(%(E& ZB*PB./TQ33AX!%+-^>&ZHX.XTH/8J(<<(J-FZ727
M//&^=:',U7QY9\UID:H+\4+47)2B6GX"F"&J_C&G=6L=*IKILX*O^6_>1IJ@
MZ11>M6XOILDT?HHOFO"+Q)-?D67N^YBCGP_XW>10]!77EJ@7$,E$UYL>0Q96
MJ(5V!,SKE@\$\RD@,Z#;:.#&@Y(F$_%=I;Z_(RA4+]/RHF^:. XJMWW?FB-/
M_*:BDW^.OU<W;I)H((5(^1111XY22122("^$TDD^-<\)II\<\\<<<<ZYXYUK
MGG6M:UK!:/J7K[,L%P9& , I/]M^K8,K\G7QJ^(#H^1.1BLWDWIB<F1P$F1
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M-US]$>TB"CM+6_Q?7?8U5HMJ5]YJ_)8-@R, 8 P!@# & , 8 P!@# & , 8
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M CX5HH])$GJWTZ[^[0;I=[Y1135<N5=IMVJ*SA5)+L9S@Y"Z+]"#/1?DO]I
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M#B/3C[Q46V#T(_C^U6W&G:'=@DR+I'@<#Y5>C$)4-RI;4+DL],IWVL728,#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .;WYG
M0$+W<H>7[8U%(K3$>=.$8;")EY<^1NX)G.%6LNL(D&B(6R/']P0"LXVQDA[G
M0MB$E8)])QY=14V9)=QP@ 18#=.V$W#<T\MU>.L'0I7W3CJ!0CIV,<A'740C
M73D,\:.&#L0XV&9;6&.F+LF:=,G+!3[35=HY,EG#=5+I%8F_4XZ=*C!EV ,
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M/ !Y"$=2UT^_%J2<PFJDS"J"TAR_@_.Z4U$3HWZJ4\Z]#<U:?M,+^<> [?\
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MZE"7"$H"\1@LBS+HE4U'0J^"N%OBWVBS>7,=;VO<WA'OVI.?F_?8[SJZ\SA
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MQ]9$&G8UK-X<F=ASZ51&3!FQ58@"(LVHS-4)2XVFVFG;W62V_!D8 P!@# &
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MM,^"RK_C9)-)P(13V)7[<:<M19SS4?=/\%8RWPX$&;XU*H;?T KJ;MYI'Y5
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M$& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M93"G!^..M-][1*=Z41^\$::RH\^SW65J2*P08 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , C]Z8\XPOU/6*=6SHY-(R,:3FN+($2*OBX\'+ 4RJ
MB< [#A1@40*ACX_A0;*(Z+>*).Q+M%PFCT@HG]GO>\%3ARN:OS4/[,A?8/Q
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MH]%]WZDJ,$& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#63R3[Z6EN3-D3]&8VI)F_ UI))R6:BV**+SSH1U-Q.F/-N2LM$KDWL$& ,
-8 P!@# & , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gv1ubg3hw41v000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000014.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,[ X$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ@A[Z>OW_P"04444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IR?>'X_R--IR?>'X_R- $U%%%
M !1110 4444 5Z*** "BBB@ HHHH **** (V4DD@?R]*;L;T_E_C4U%6IM::
M$.">NNO]=B':WI_*FU.>A^A_E4%7%MJ[[DR7+:U]?^ *#@@^]3!L],TT*"!Q
MU'O3@NWIGFHE)276ZV_ J*DK;6>OGL+5#5+"/5+22TF&Z.52K@]\YZYZC!J_
M3&8KC\>*S:ON:)M.Z/F74_V4_AKXAU(ZEJ^DVL\C/O;= C$DG..1C_#ZUU.G
M?LS_  >TU%6#PI9[E ^?RX5)([X$7!_$U[:9V4D ?S]*E61F/<=>.?45?-+E
M4;NR[BE).;>TG;;Y?UWL>?:=\(_ FE,#9:);Q =%"1XX^B#/IC'TQ57QG\-?
M#&K>'M0M1IMO'(T+>6PC4G=@K@<=><@\GBO3-XS]XY_&FS1>=&0YRN#P<GKQ
M0KIINZ^6Z707Q*U[W\[Z_?Z:'\N7[9'[+6MR>(KB[TNRE,+7$A7RXVQC<<<
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MU[!<6BDW#U'YTN: N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<O9P6]KWO;3OV9Z5^T=^PAK7P4\-_P#"0P:A/&T48FW>8PY"[NV/\^E>\_\
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M\QN5%<A\8'>K54P#O_,_@<C/^>:N4V[I>7Y67_!^\F&B:\_S2"BBBD4%%%%
M!1110 4444 %%%% !1110 4444 %.3[P_'^1IM.3[P_'^1H FHHHH **** "
MBBB@"O1110 44A.!FF>9[?Y_S[TTF]D)M+=DE%(#GD4M(8TJ"<\_Y_"EVN2"
M.G&?S_SGFD0EC@@@>O\ /GZ<\XKD_$_BZS\.VTDDLB@IGJ1G\,TW?1._E_P
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M7@GC;XH06T<\5O< R[6P%8$Y[=#^G_U\>!^/?C/%;Q2PP7 +<J-KC.<D>O\
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M/Z+JA69X6AQ%*=V6PO&&R.AK1\!_L<ZO\'OA_P#;;6SEBNA:$_+&P;=Y8)[
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M[XY_7^GXU&\K!#M/Y?3V^G^1Q3O(=P"1CCU ZX^M5KT&VA,@!P.XSQT^OO\
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MV5OZ7^2#KU%'3H***0Q,#T'Y4$9ZTM% # BJ<C^G^%/HHH!*VW]=/T"BBB@
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M%3F$_P#?)]1US5,_!G[.<"!L]?N'/_ZZ_1(Z;:-QY*\GT'K]!_.LZ?P]:22
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M /6KUOQ_XCBL;6YDDD (1CDG_/;]*^2="@N_BEXK@T:T$DPDO$CV*"W_ "T
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MM+2[LNO9_</\)>&M.\):'8:;:0QQ&VMTB8H N2HP>@'3I_DUTV_?@CT_^O\
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MZA9:ZO\ R+-%4P[ ]!Q_^KW]:E,A'5OT_P#K4FK=4_34:DG=[6'E"23QR?\
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MKTZ^M.*YI7E>]OSM]W;YVV+C5G3]V-N6ZN[>C_'J9GBSQ$J2R.7 &YN^./\
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M]=/Z]"XT:L5\#?6^NBLO+_@$I 8D#&/?I0T.3G/]/Z&@%001(A''<=^.G/\
MGZ5.-I!^8<?C713=.:;A4YUO??LNFO5+KU)<6E[R:VWVZ/JOZ17,1P!UP>QY
M[^HH6(C/4?D?Y5.2OK^>!_4T#GIZ9_"M.:226WR?ZD*,7M]U_3YD?E^_Z?\
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M']UK6^>GX>I_ =_P5+_9;UKX>^/+WQEI]G+# FH2W.]8V4;1/O'(X_PK[O\
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MV\K&WXW\=VEOYC23J'^8\D9).??KS[?I7RQKGB_6-<N6M],228.Q3Y 3U)]
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MUIM^!\,_!7]AKP1\-M.M8KG2+22:)$!)AC)RH YX)'XYYXZ8KZSL/A)X(L5
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MU\/M?@B>/4[8[T4@B6/GCZ]QT/3^5>D6_P 5?"%R@>/4(2&Z?O4[C_>QGO\
MYX_C.L?BA\8?AY*EG<#4CY#!6R9OX< ]<?GTX_ ^OZ%^V5\2[>-(I$O\@;?^
M6G_Z^G7BO/AXC\18)>RQ625)N.CFXRU:LMU\K_GN>JO"_A;'1C7PW$-.*G[W
ML^>&E[.UG_3^\_K<D^)_A&&)Y?[0APH)QYB<C&>N>E?'7[0O[3OA;1-(NH4U
M"!,1N,K,N>X'?\/6OY^]:_;7\=VNFW$MQ)>Q*L98%FD7H/4GCKT]NM?!WBO]
MJSQG\7O$@\,VUU<R23W @PLCL?F;'8^_''7FO.S#Q#XBS>B\OPF73PD\3^Z]
MJDU*/,DNW2]_/9'HY?X<<+9-768XK-H8R&$_>J@W%QFXVTML]W^/D?H+\1/B
MMKOQ"\:^3X8NIKB.6Y(Q"[,.7X^[^GM]*_8_]BSP!XB@TNROM:$ZN41\2@^B
M]R._7&:^+_V!/V2;RX&F>)O%=DTHF$4^9XR<AOFR"Z]NOU^@S_0?X>\):-X<
ML(+73;:.%8XT'R*JY.T \#W'Z>M?6\#\"8G)8+-<PKRK8S%/VC<I-VYK.VM^
M_P!Q\=X@<?T.(5'*<#0CA\%A+0A",;)\O*D]$M[7O\C<M6$=K'%W1 OXCG^?
M%3)]T?C_ #JJ(S&QZX)/'Y^P%64^[]3_ /6_I7ZTM(Q[_P##?=U/R!_&[)VM
MIOY#Z<GWA^/\C3:<GWA^/\C0,FHHHH **** "BBB@"O2$ ]:6B@!  .E+111
M<!-HSG'-*#CFFLV#C'^?RIOF>WZ__6JN67;\B7))[Z_,HZQ90ZO9RV$T8=)5
M(.X CD8/;W(_G7YS?'?]G!9VNM3TNTS(PD?*)T/)[ GCL?3Z5^C[L=W'!!/Z
MX-27-E9WML\5U%'*CHP;> 2,@Y_'K]:6JZO1NWZ^A<'9WM=2W_#ROMT/Y^=)
MT;5O"NM?9KI98MDVWD,,8(Y'3/ KZ;.J7KZ$1%(Y+0]CZKW'T_+TYS7LWQN^
M&>GQZC+?V=NJ@.SC:H&.K<X_Q]:^?HM06UC>S=/E5"AZ8R!S_GUKHBUR+FBG
M)7>VOE\_N[>F:O3J^Y.T7HUO;;^D?$'Q8?4TU&2;=(#YK'C(ZL<<?Y].N*]
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M6JCPD<17O=U9J[;T=WONU_P2,Q\1>)\<G2AC9X>@U94XO1+3333R^7I?\_?
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MNB6AGN);22-WCCW,Q8/@$@9X# 5]M2?(#M&#SSD]OSK'GTS3=4;R]3ACGCY
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M"2QU8Z8) '$WE@;L=#CO[_K[9K]9OVG/'OAW3/#FI6.GM "D,J*L>W ^5AP
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M/0#V_6I4)(Y]:>8R<<<9SU]CZ4FW;Q@]<U#E=;*^FI5O-_U;_+\QNY?7^?\
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M;2\E=8W&<.W0'G.#T]^A^E?6Y'XX+,:M*GBZ2H7<5)RT>\4[WM:_Z]CQ,^\
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M8NFJ"(:F23^^"X$V?ICCMZU_H->(M"T_Q3I<^D74,<D<L;H0ZJ?X=G.1T_\
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MU?4[21[>;$F9(V(PV"#R.O.>.I_6C^T3_P $_KK6]7MX=*T]O)\U1*$B/0D
MYPON?RK]\/V?_"%OX3\&6>GFSCAG2"$,3& W"_,,$=SCGT'I7KMWX>TBXD,]
MQ90RG(;E!Q@\8SG\_P#)_7L#P3EF'RVAAUAX>UM&56I9<SEHWK:_]?=^.8_C
MK-L3F.)K3Q-1TW-QI4^:\5&^B71:6Z^1^5_[%O["WA?X::39ZI>Z9;IJ,:1N
M7:! V\ 'J5SU[_TK]88(8[2UBM8PJQPQB-   ,*,=!Q66-1T;2T,*O':HH/R
MC:HP./4>F,'TKS?Q?\3-*TV!Q;7"-(BG&&&<_@??UXSCK7NRQ.5</9<_;UJ-
M&E3@K^^HR=K)V2=TN_\ F?,QPN;<08VU.A6G*H[WY)."O97OI^>W97/3;K4K
M:R5GDE48!X)'Z=/3Z9KSG6/B5IUJQB$BD@\8*GG/^1[_ )"OD/Q5\7=7OIY(
MK-Y&#L5&TDX'(_S_ #[UH>#=$UKQ5.LUT9,,P/S;AD'OSQ_7K7Y%G/BTJV*6
M7<.QEB:DI*+G#W^5Z)7:OV;U]/(^ZH<!4<NP7UO.:L:<HI2Y+I/2S:MO>W]=
M_H6;QA)JBXM2PW=,''4?Y[\']610:Q,"^9<?>!Y^O'4=_P *ZGPS\/UT^*-I
M0"<#.>N0!_B?Z>E>D)96UM& T:X ZD#' ]?7\LU]3D^69]F-%8S-J]3"TG%5
M'>3BDG9N[NE_P_J?+8W,\OP\W1P%&%2WNIVN_E=:M_?L?)?B[Q5J/AEE:5W7
MYOF))YQ_/C/?C\ *]6^&7CVVUFQ\R>ZC#*.-S@>G8G\>F/I7A?[3&J:78Z=/
M(9(XY%4D#('..O'/Y9ZG\?RBUS]H?QQX:2ZA\-&YF568+Y.]LXS@_+GL.,\]
MZQQ/&-/*ZSP. D\6XOEE*#YU?1._YGKY=PU+-\+]<JQ^KI_S>ZM;6M=+U_ _
MH3N/%^EJ[J;V#Y2>DL?;VSZC_P#5VXG7OB[HNAQL9+V ;<G_ %B>_OQD5_-5
M)^UA\=Y+]D^RZIM9CSMF]?Q'^>,U>N?B_P#&KQ5'ME@U(;^.5FP-W'N><]<9
MQBN"7%7$=:\:&&FHOJH[7M===-+_ *GLT.#<EI4_:8K&04TDK<RZ6O;5=K[?
MF?M%\1/VV?#?A6*<?:82T>_[KH?NYX&#QZ?UK\T/CS^VS+\5M-N_#6AM*\LY
MD@41%CRX91C;DYYKQK0/@9\1OBE=1)J0O@LY 8.).=QR>#W_ ![U]Y?!/_@F
MY;Z9=VNM:L Y#I,RRC@D8)'S<=^GOWKC_L#B+B2K#ZSB:M"CS)RBFTG%\NCU
M_,[*&.X?X:IRK4*5/$5TO<;2E9V6M]7T7ZGYL_ G]BGQ-\1/&EOXIUNRGD@E
MNEN,RQ.00S%CU'IU_P FOZ6/@)\,K;X9>&+72X8A%M@B1@%"\A5]O;UKM? /
MPXT'P-I<%C:V%NCPHJ;UC7^$>N!Z<9_7->BR+'M&T !>>X'MC_.*_4^'^'L-
MD5#E@N:K*/+.I:]]$KWOK?6]O+S/S7/N(<9G^(]I6FU1C).%.^R332MT6@;M
MSL<DC_\ 5C@?2HR06SU'%(K]<?\ ZNM-;.#CK7T5*+5Y/K?;U7]?(^?G.]DM
M;6WUVMM^/WEG.>G-%549P3G/Y8_I5D'(!]J)1Y?F.,N:^FPM.3[P_'^1IM.3
M[P_'^1J2B:BBB@ HHHH **** *]%%% !111G'7B@ HH!STY^E+CD @C)% %0
M2+!(SN,+@DGCC ]?P/'?K7YP_MP^*O#<OAC4+.]>&21K>5%!VD_=Q_GW'6OO
M;XA:K%H/AF_U)F"&%'()('\#'V] .O<5_.#^UA\8I/%6NWNEI=EE65TP'ST8
M=L^@_P#UYIP@W+1-ZW[[M=/D--VE9V;6^W5?UU/QK^)/PTNM<\>76HZ1&RVW
MVUW!0';CS"<<<=/J*^CO"%]=>%=+M;";<TQ14QWW8_I6ZA@L())V17D8ELX!
M.23W..:]0^$7PGU/XI^(;-8+>1XO/CR%4D8+#C@=J[I-0235KI:?\%VZ_P#!
MU,Z<'RRG>\KO]//]=O+?U7X#?!_6OB+KMI>26LKVKRHQRK%=I(/ICH<?05_0
M!\'?V;_".A:!:/J&FPO/Y2;E,2[MV!G)(X[]CU_+$_9E_9_T_P ">'K1[NSC
M69(DP7C7=NPOMUP/PZ5]BJ5A400KM51@ <8P/H!TKFJ\LFKM75K>777S^[[@
MI2DHMQ5D[\VFM[V_KKHSSNX^#'@&8<:/!'[[$/;UVCTKR[QC^SCX4U6TG2WL
M8/G5P (USR#STX/Y^W<GZ:"%L,6/T_$_YS4N]1\I'N?\^X]/QK/DUV3OU6]M
M/ZZCC4::FFU9OJW=V_#[M3\;/B!^P3I_B*YN7M].4Y+8 B'\63QUY_\ U5^6
MW[0O[']Q\/KF=?[/<1 MG$3 ;?7./0'C/^!_K?C6-1N55!/4X R>OH/6OEW]
MI'X.:9X\\,ZA="TB:ZC@E;Y4&[=Y9YX&<D@GT^G%)*-VHKLE=[-;W6VO]7-5
M4J5$G4ELK^[Z*RZ:]?O/Y+?"7[*NA^-9UCDLHC,S\AH\L?F[\>G'X>E?0%K^
MP?X;TV!5NM,AVR <F$8Y] 1^6/ZYKV6WL]0^%?Q%>"]MWCL4O6 W*0NWS,9Y
M XQT_K7WC;:I8^.-+M3I4222^4N0BACD#';GJ/QZFM91E3]Y6OVZ+;]?7_-4
M9*3DI_#T;U;>GXZ_UU^7/V=?V6/"G@358KZTL[> ^8"2$53R1P/?BOT.OOV>
M? GC[[*NK6MK<;50'>B/UQZ_A^%>"C1_%^E2*+:TN BL#Q&W0>N!_P#7Z^QK
MUWP3XTU?29HO[5\V,*1G?N'3Z\?YXHJ1<Z:E?73]/QT]?4SI56JLH.-EM'31
MK3[_ .O0^G/ /[)7PM\-00S6NDV@==I'EV\>01@CL,<C_/-?0^G^$-+T*%(]
M-A6%$P %4+@ =..U><^!OBCHU[!'"]PN\JHP6&>P&.W^<5Z]'J*7P0VQW(<-
MQALY'7/3O6:D]-TK*Z738KE7-T;;WZ>5M/Z9$XD4<$]P1UST'TJFUP\;#W('
MU_+UK;>,[?F&#_+_ .L:I-9JYR>?Z>O./_U4[Q;O+;3[[KY>GY-CLDO/3T2L
MG^HZ"<..3Z=_Y=?TJV#T/;@UG>0T?3KUX^OY]JL1R]%;J=HY/YU:;N^VEN^R
M_#\3G=T[O3S9?# \#-/4X(-1HI'/'0?K[5,J[LYSQBLI*S:7E^1K%W6O?\OZ
MN0W9"PM,3@1H6_0]?S_SV^#OVA?CO;Z%:W.F0W824*Z "0 Y(8=B._3Z=J^M
MOB/XMM/"_A^_FGE"'[-( 2P!^[[_ /UO4\5_-M^T]\5[K7/&,]OIMTTF^[9
MJ/N_Y:>Q]_3C.*_,O$WB&ID>4PI89OZUCY>QIJ+]Y<S44]-4[GZIX7<+K/\
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M(Q@9S^?^?2OG']H3QS'IOAN\@AE5'$,@P#SDJ<^_7'_UL5]%7UQ':Z?/+(0
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MC-#'(/,(!Z X&[')/^'&#7Y'>'O#&@P>(QXD\+)%._G>>OE!6Z-N&-N?Q/\
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M'KU]/KWY-=CX.\)W'Q0"/-.[B<Y^9B?O;1WSGK[=Z^HQ?%?%7&%"K3RG$8?
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M-M9NX[0&ZOI+EMK+EVW,PQC&3U/\OP_?G_@CU+X^U+5=.N-6CNX[!FB91()
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MD8'US_GO^%.P#U _*DVX.6]L9XY_3TI=P]1^=?H"U2LGZ6]%^?Z6/S>_]/\
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M]<?7IS7MFI?&_5_!09)DF/EYR3NY &!_3CIQ7U_X/^$VCZ#H5E:K$BLL$:N
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M9'IUQ_\ 6_=,HR[%T*\I.3A0GLG9)WU[]M/O/P'-,QH5Z4%-*I5V5DVU:W_
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M]T_V9M*DM--M95(V-&A_-5YX_P _C7L>#LJV+Q.,QLIM*=5RY+V3]Y.Z5O\
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MQO4GB'@,\3HU8R<8SGHF[I+XN_Y>9]3Q9PG3L\?DR4\/)*48PMIHGTZV\O\
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MD?BH^N:A- DC,)G9!SP=Q(]>_P"F3^&A^R3^SW<>,?%5IK[6S,//27<4R/O
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MO_AGG%?V[_M<DCX)^*".HMI3_P"0)*_S^?B5XQD\/_M'32&0H$UIR><<>?\
MX?IGZ4I7=*R[_J_0UH.U:[=EHOR_+^MC^YC_ ()_:-8V7PRM7BMX\FQ@PVU3
MP5B![8[D?C7WS-INF2MOGLK5VQRS0IT]_EK\9?\ @GW^TKH%I\-K.UO;R O]
MA@!5Y%[+&1W!STZ8S[@8KZY\:_M<Z#8-)';7,0"K@;77W.>I].M10C*2ENFF
M[_<K=O\ A^G0K&-0J)M7C/EM:VVE[^?Y7OL?:;'0;'A8+2-LC[D**<Y]< ]:
MLV]W;W'$+ J>P/'0\?K^E?DQK'[7D,[N8[O^,@8?U/'?Z5[_ /!3]H"U\1SP
M13W:G>RCEP>O'3.!U_SD5HXU&U[VG75N^WY[?\ Q4Z*B[0L^FWD[Z:7O\C[G
M8.LO(XR.>G3Z_K5T8[=.E5;6YMM3A6:"17#*C#!SU'L?>G[FC+9!(R?7_9_Q
M_P ]*EWV=].C",>JUYOZ6G1:Z$[' )J+S".NW_/XU(%5\Y./KV_I^?X4QH5)
MR&/;^M7%1ZZO3]-/O^9,N:^GZ>73[O\ AF2!@0.1S2TP1<#[Q]_\BD9"N,!N
M<]O_ *U0]&U_5NA:O97_ "^\>2!UXH# ]#FJSHY' (_#Z?A3(UD0%F#=/3D<
M_G2'_5NO]?UV+Y<D8XIM11S(QPQVXZYX[?6IG*C&WYLYX!STQ]:!:H2B@[AS
MM;]/\:I2SLA)VMQVY[9_#M_GI32OY?\ #@7L$=0?RI#R"/6L^*_:5MNQC^#?
MX^G_ .OJ:T"K%<[2#UQWZ^G7]*%JTN[ @15)((R3SS^M-D"KT'/;'8]#4+S-
M"22C=3C(/TX[?A_2F+*TO.QOR]?TY^M3=)Z^OKY7[K_AC13=DHWO:WY+^K_B
M2("TB98XR.OUKR7X]ZO;Z5X'OYY2N1#*<G'39TSV[].>GM7K063&\*PQWQ_G
M_/7O7PW^V]XO;PY\.=1D,A3%M*>N!G8PZ^X_3UYKR<_Q$*&4XR:ER2="2AZM
M:6VMKT[=NGJ\/T)8C-\!":YZ:KP=1O91YDG>^EK/KIZ=?Q.^(/Q$;4O&=W96
MI#,UPZX4Y/+$#@ _ACKQ^&^/AMXL\0:4MY:V]Q@J&RJ,>,9SG\>!TKPC]GJ&
M+XH_%MHY9 Z_;\$$Y',OU]OQK^E3P?\ "CPAX=\%1"\@MP_V,-ED3.?+'.2,
M^I]>_%?D/A[P-EE;&8CB#.J:QCK59<E.=I63=DTG>R]Z^GJ?M'B5QWCJ&"PO
M#N3U70P^'HTVY0?*I-).VB7]6/Q^^#%AJ7@Z\VZS"VU&PWF@X&#_ +7_ -;\
MJ^^O"7BSP5JES%#=/;1L2H(+(#G(7U]O_P!=?+7[1/B;0?#-QJ$>DF)9 TH7
MR]H/<#IUQ]?QSG'Y]:7\2?&,NN>;937*Q";C:S@8WCTQS^GO7TN?^&G"M7%3
MS26$I4H6TBW!::/X6TO7_AS\[RCBS.<50C@U4JNM>S:4G=Z:NWW?C;<_H\L=
M$\$W-M&\#VK%E!X9#DG _/CW]JJ7WA'P^0[1K">X/R_X>W?].,?E5X'^,OBJ
MSM;;[7<SD*JYW.3C'?FO;8?V@KM(E6:X;)7!^?';G)_+_P"L<U^89WPYP-2P
M>*]C"B\;R-4H7A?F5DO/M\CZ"CD_&6*K4YP]NJ;DFY_O-KQ;OTV7_#6/4/B5
M%IFDI*$V#!;!&/; ^N/\:^"_B)XJTVUBN6>9$X<$;AZ$Y_SSW]:]VUSQ7)XU
M5E6Z^9QTW<Y.!V//T]O:OG'QO\#?$GBI)4L!-+YN0-N3G=GGC/;T_6OP'!\!
M<0YEF4Y8;+YO#<[Y)[I1NK67DM?UMO\ TEPCG^2\*9='^VLSC]<Y-:<W:5[)
M===_R5MDC\C/VK/%%KK&EZI:V$PEG9)%54.22<XX&3[_ %S7Q%^QS^S)XM^)
M?Q8M)[C3;AK0ZBC!FA;;M\\'.3Q]WW_6OW>TK_@FWXT\7:VMQJ%E<O:R2@MO
MC8KM)R>WH?R'3K7Z]_LL?L,>%?A/%9W<VF017L01F<PH'##&3G;GJ,=<\_2O
MZF\.^",;E5%3QT6G%)J#5K;/7[MS\(\4O$+"YUC73RU*4%))U(V]Y76W]=^M
MT>^?LC?!O_A4W@?2;81>4YL8D8;=O)CQT_X%_CG%?6E]:VVIQ/;74*R!D9,,
M 1\V0#@_7\JM1PPV-I#;0@*D2JJA>P4>W_Z^]0I)\S,,Y_F2?\]:_;:5-P@H
M2]^+5G&UULKZ=]M_D[:GX=.;J5'6DVI7OV?1W/B/XR?LPV6N-/JVG1*DP+N!
M& #GEAT_S[U\':_/XP^%]^MM&MPEO ^-^' "J1U(]>W/TK]SG;SB8YE&Q@<@
MXY!QP01^'^(X/A7Q9^#&@>,=,N6AM(C=/&V"J+G)!YXYZ]/P(KY[/.$<MS>A
M*5&G&AB[-QK0TM+1WTM9WZ_YZ>]D?%./P%5T<1.5;"72C2DT]+I/=OI_D[*Q
M\=_";]IW3U@CMM5OT6==J[9).><#'S=\]^E?:?@SXE:?XB*/#.CH^""".=W'
M;KG^O!%?CO\ $7]E[QSX:UN;4-+CNDM4E,@"!PNU3[<8P.>.];WA?XOZ[\,(
MX;744G#0!0[.&ZKC).>.WN>,U^,K-.,>",P<,1"KF>5QEH_>DHQNE>^NVW74
M_2YY;P[Q%@HU,'4IT<PG%-T_=BW+EC9;[WT777:Y^ZT3QRH'!!!Y!SZ@?Y__
M %U6DN[2W&9'5<=22!Z\=3QQWXK\N=&_;ATA;-8[J^BBE5=I#R*K @CKDCGO
MR.IKA?%O[<.F)#,T&I1G"G&)1[],'T[^P'2OLWXP97"E%N@XU&ES4M5[VFEM
MSY6AX5\18K$-?5VJ"EI66SCIJM[]]?NW/UPN/%F@V*L;B^A3:"3\RCH.G6OG
MGXJ_'OP]H.CWIL[V(RQ1.5(E7)(!P>#UX_E7XI^+?VUM2UBZEMK34'&_<HVR
MD=>AZ]N/\CGY,^(/[26N76HIITVH2R+>,(\>:2,.Q'.">W^>N?B>(?&'%8W#
MSP&58&=*O7:IPJ*]TI6CO?3?_A^GZEPYX(T*4HYAF^/C*CAX\[HMQ5W&TDM-
M[VL?6WC7X[:W\6O&[>&K>YED@EO!#M5F(P7V\#&._K^%?K=^RS\%+;PCIEGJ
M^HVB2R3Q)(#-&K#<R @G<,$;B,C'0=.<U^=7[%7[.$?C.YL_'-VH;<\=R6<9
MZNK'D]_P[<YYK]UK?^R_#>D6]@)X8Q:VZ1CYE4_*N"2,\'C'K7Z!P!P[1R[+
M(YMFTH3Q>+M5E4J23Y/A=M;O2^J^_K;\TX[SR>)S*62Y3S4\%A)^R481:51*
MT4URK;S\SC_B;\)/"OQ*T*XTO4=*L'F>,I'-Y$2L P(P651GKP3^> !7XP?'
M/]D6P^'$VH7^F6B1%S(Z[$"XSN((('X_Y.?VO3Q_HEL[K+?V_<X,J]L^_P"'
MM_/Y _:2\6:'K&F73_;;:151^-Z]%4X'7MT_^OR:\0XY+G'#^*PZKTI5TG*D
MX-*7/%+1V>G3JC?PYJYQD/$>$K^QJQPLI1C6YD^1Q;CW\M&O\S\0O"7C/7/A
MCXFAN7NIHH4N5X+L %5Q[X]CZ"OWW_98^,T7Q)T:UA>X$DJ6R\%\G(0].23S
MTK^<GXW:]9S:E);V!5G28\H1NX/MSZ>_YU]"?L@_M,CX9:Y96&HW)AC>5(SY
MCXX)*]SC&.N?85^0^%'%^.RS%SRC-:[^K0FHT7-OX%):Z]+/R_4_;/&'A'+\
MXP%+.\FP\?KDJ7/55-6<I.*;V[?UN?TE>-M830M'FNV;8#')\V<<J.!^O^>E
M?B-^TW\1-1U>^NXK69S"))02A. ,^W3\>/;[QK] OB!\:M$\;^!#<Z?J$&^2
MV+X21>6://0'C)(^G'TK\F_&NJ_VC+J%IY37$LCR*K ;^I8<'GKQWY%?I''_
M !+"="%'+)/&.JK*,/>492LNFV]_(_*O#?(84Z\\7F26'E2EJJED^5-73O;9
M+YGR)JWAW_A*-0MEC8RSF=-RCD_>&0?KZ^O/-?NG^PAX 30M#MY+NT 80J0S
MICG9G(R.Y&1[XZ5^>O[/?P!UKQ'XK@O[NTE^RFX5P&0A<>8#Z8P,Y_F*_?#X
M=>![;P;I-G!#$L;+#$K8 '\(SG\#S^->KX;\/XFE@_[3S9-8F=I4E):I.UEK
M]VUSB\3.)<+BL8LMRJ2EAJ:Y:C@[IRT[>G5NWR/19@(\A1M&T8QP,'C^?YU6
MW-D_A^?(_P *GN)5]L@>N??CWZ?S[5''&&'3W[CV[5^I0@_:^TE+W%96[-6_
MKIZGY!.:E[J7O*UVMW^/EV)U<GKCI3ST/T/\JBVMTQ_G\:D484 CU_G5R2W3
M5NW;046]FGZV?E^)&B[CCU__ %?Y^G0UY;\8]1DT;PI>7L;%62.3D<=%/U]<
M8_QKU?=M(/N/Y_TKA?B/H#>*?#5WI<:[GE1P .>H ]JYL3S_ %;$QC?FG2G&
M/JXI+OU.G"JF\5AI5+<E.M"<K_RIJZ^>G_#'\YOQI^*=SJOB*\LYKACB:10&
M8G&&.!_D9X[\5XE#JF5D=6R#DY/K[>WZ\U]+?M+_ +/VH>%-7OM6>-HTWO)D
M@CN6]NGU_2O@B[\2R:<TEJ%:1U8K@<G@X_F!QCGK7\B9_DV+H9IB95J,I.=6
M4E=/1-Z/JW;7RWUV/[8X6S[+Z^482C0JPC3A3@GJDKI13T_S=_30Z'7=;^T7
MJZ?NR9GV8SD_,WU_S_+](?V+?@6]QJMEXBDM"R;TEW%,CL>OMZ\_K7Y5^&K/
M5_$7B_3S]BF,37$7S;&P 6&?S!''?Z"OZCOV/_"5KI?P[LYI;=5G,, Y4!AE
M23SVY%?H/ACDD:N+J8BO1:5%<R;C;71JWJ_/3<_,_%_B-?5:.#H5+N346XR[
MZ.]K=+^G330^J&G@T;0HC@1I;VB(%/&-L>#^1!_SQ7YW_M"?'+^S4GL[*Z_>
MDL@5'YR.!T_GP:^F?CAX[C\/:5>VD4H5PC* &YR%;CCT]..O2OR:_L;6?B1X
MR"R1S2V[W?.=Q&W>2<]1@CCK]>G/U?&&:XS%YA1R3+Y247)0JN%]M+WL]--/
MZ1\-P9E."PF KYYF:CI'GH1E_-;2U_/JMSMOA9X'UGXJZ^E_>B62%I=_S!B,
M%\\YXY[?_KK];/ASX!TOPAI4-O\ 8XA*B* WEC.<8/4=?_K5PWP/^%MGX,T>
MTF,")*8E)RH!W%0>^.1S_G-?0\A!QC&/SQP/3\:^WR#(L/E.%IM12KRBI5*C
M5W=I==[ZOL?!\0\08G-\74]_]Q";C3IKX;:6T6G1$3R!OEC&U>!P,8_+C\!Q
M[TT+CW/J:>5"].I]B/\ />H5R&QZ=?U_QKWN5>]---;7Z-:7_P"#_P  \&4U
M[L;6V[>2U_IBLQZ>Q_GC^G%,"D'.#D_7T'IS_P#7S4Y7HQ&?3\/;UJ2+#;BP
MP!ZC_P#73D^>GRP?*]-5TZ7[W81C9N4E>^W];?UYC8N3\P_SD#/\_P"=<;XY
M\3V_AG3I[EW5 D18_,!C"Y[GZ56\>>.M)\':;->W-Y%"8HR3N=1TY'?VQ[5^
M(_[5_P"WK8Z='J6D6%XLTA26)1')DEL$#E3@?_7/3.:^/XGXGP_#^7U94IQQ
M&/Y;4Z*LVY;)Z;?\/W/K^%.%L3G^8T*=:G*CE\IIU<19I12:;7^7X^?0_M5_
MMAZ%X>M;^W;5HHI8UF7'G '(W =QT/'7_&OYJ?C]^V)J/B/Q8-/L-0>6*ZN3
M'\LA;(=MHQM;OGTY[=:ROCGXI^(7QFU^[DL/MPMKB9]NWS-NUW..AY^4^O%5
M?A9^Q=K/B74+'4]5CD>6.1)3Y@)YW*Q^]WX./6OYTH5*.8XRKG/$N-YE.;G3
MP<G=4K.\8\MWTT9_1F*IU\KPM+)>%\$J=.,8PK8^*2]HK)2ES+R5^O3L?L;_
M ,$YO@_I_BQ+#QIK3ASF.Y(F(P>%?G=[CC\\5^]>K_&O1/".@QZ)I:0J]I;O
M;JT> <["@Z#Z=2>.GO\ B9\#7U?X-^'K;1+(2+LA6/"9'(4+V]O;\*]OM?$V
MNZK.;R]AG:-B6;<&(QGGJ/3\\Y&:]'&>*6.P=/\ LSAC)95%*+A&O3IM65DG
M+F2^?5'%2\,,F<H9OQ'GL*E:ZG+"RJIW>C<;2>C=TM#L?BW?:O\ $BXGW)(\
M4COZD8)SW/3_ "!7AVA_ _P]9W@O-3AA67?G+A0<Y'/(_P /Y5Z'KOQGT'PK
M:LMVD:2*I^\ #G ]?S-?$?CS]J$ZKXD@T[2;D(LTZH!&V/O.!QMSZ]*_,HY-
MQ=Q%FCK8C&5:<JTTYT;R3A=K1[6^>W8^QJ\391DV7+"X++HPH4H<M.ORJTHI
M))I[:V/T*M="ATZU6/2I]L8  $9..@';CV_6KVE:3K5S,#"LLV6QC#$=?S_#
M'Y9Q7>_LT_#'6?B'X2M]6G$DH>&-\D%OO 8_#YO?UK[S\ _!.RTF8#4+<?*V
M<.@[Y]>?\\YK]KX=\%<'B:<*N;2E4DTG+FG)WT5_B]6?C&=^+.80JSI8.LH4
MXR:]U6TT_P"!IL?$FC:%XA@*LUE*,8/W#GTZ<GN?KV]*]3TJPUB4K%):R#M@
MHW?/J.?\_C^@J> _#$:@"RBX Y^09]SQWJE=>%_#-F=^V*/'/\/'/<]/\],]
M/O<-X;<)9-:JL/248_:ERJS6O57>WJG^/Q&(XWS3,5*G-U9SGLTY-ZI7VOO?
MRZ'R[I'POGUM5,D1!8#MTSZ9P!_/BNRB_9Z1XP2VW(SC<HZYSW'Y=O05Z]_P
MDWAC00VZ^MXO+YP943IGU(Z=/P_&O%/B!^U5X/\ ",<@&KV(9 ?^6T9/?WZ=
M.:[:F*X-RN+E+%47RQ_@Q4;MJUDM+>6]O+8\RCA.)L;5YZ.&K.,FFI-2MK:W
MQ=O[MRAJ'[.=L@=WE (!)^;D\'C.>O'M[XKPOQ3X$T+P5=B^NKV-!"V]LN
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MV:WN)<+)'T9L<$YS]./TKN_#WP"U'Q5<*D<+99O[O7)YQ],]S7KDW[++^&K
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M^/+?]-$X_7FOYZ_#?Q*^(6HVZ3M]LY&>3)]<=O;]:ZM?B+X_MG1V^V87D<R
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MA;R6-O;+&T:\QQ1EB2,]0,_AFM3S8B<*@!R.<8/'/;^7_P!:O@C]BWX_:?\
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M_ND'CM]>X-?S+?#;Q=XA6:W5IYHP"@/SD<=\^_\ GTK[Z\%:Q!<PPRZI>JP
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M]DCX'0WGQ%L[>[LCM6\0?,G Q(.YQ_7WK^MSX/>!K3P9X7TZ"TC$0>TBRBJ
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MMO=-PN\]<9SS^-21JZ_><YQZY[_2IE"46I1O=^?EY_Y^GEJJC:M)JR\K_?\
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MUWJKW_;+_@I9H</B[1+@64D4KQVQ V$$G;&PYQGJ>OZ^WXG_ ++OB:\^%GQ
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MGDWH($_(#CCYSGC/\Z_&O$?.UC(TLARZI*=>M5@IJE=RW2=U'7KY6UM<_4^
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MM(LX'I$G^-?<<#_[C/?5+7;I'_@^A\)QQ+_;()/;?OT^3V/9@XP 2>,#_/\
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MK7V._P#%]O(TOR.YN%8D'@_-NZ_CGUZ"OUS\)?#'P_X,MHH=-@B01JJ\(!G
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MW_-?*W9&C*$>2ZV5V]>W?T/J[Q!_P6D^'&FJ7CCMT4<C[A]^_;\?UZ^=2?\
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MQ7"M3$*.-J89-U\/.2?GROK?3U_4X+X">*_''Q8\56EA>374J27"(P9G;@N
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M_JVW1'Y(>'IK="AC=5 QP",<?YX[\XKU:RF5E7';N,'C_#]<$UQWB+X+^+_
M-S+)J%K<I#'(26:-P-N?<8Z?SI^@:W$[K;N<.N%.[.<CKQ_];]:[)\LX<J?]
M:/MW?Z]CB=5NI&44U)?%IITOTW_J_5_0?A+7[[3)87@D==I!X8CG=G\CU_\
MK5^@_P (/CU<:.;>WN[IB!LZN>W'<G_/7TK\S]*NU)7!'('3ZCMW_3^E>DZ5
M?2PNDJR,"/0X)YZ_T_SBLH0DDXSM;:RWZ>7E8Z*OL.:,J=_:V7,]$ME^6OE^
M!_0%X!^+&G>)X$W7*;B@ZL.I4=^.W7_.*'Q*^)UAX>M)$CN4W,#T8=2#CH??
MBOR?^'OQ1U#0]JQW$G8?>/ICI_\ KS^=:OC/QSK?BJ9 )I2IQ_$Q'IVSV_PK
M%M1=DM=.GI_7KOJ"A*6LI*RU[/IY;^?R/<=?_:+FT&_6X-RVQI!CY^Q8>X]:
M^S/@=\3[?XC6*S^:&;9NX;N ?QSZ?X5^-'C/19[VQC:1VWJ Q/.>"/U/K_2O
MIW]EWQVG@PI;W-QM3[IWMCJ?<C_ZWUI23NWT_P"&7;?72_;R",_=<9/6^FK3
M]//]'JS]@WC^7"Y_GTQCWJ#RW_NFO+M-^+_ARZA1I;J$/M&<2J.<#KD]_P!:
MTS\5/# 7=]JCQQ_RU3.?SJ(3WMWZM+MM_7GT*G!JU[KJK==G_7GZ'?;'R!M(
MS[>GTI0A!'3@^_\ A7):;X_T+4Y!';7$;$^DBGZ?KQ7:1R1SHKHP(89!!!]_
MY=:IREO:R[V(2BFDWK?KTV_I>6FMBK/G:?<8'US_ /7JE&2' ]R#_GUK9V*?
M<55=45NHYYX S^?K]/\ ZU5&HHQLUW_/3\]/,B<)2DFMD_1VT7X^HH? X'/Z
M5"&)8CZ_GFG=?T_SSZU.D/&3ZGW!^M3"<=TK?C\OU_I%24G;6_3T?G\O^&(I
M'D ^7=MQVYZXZ?F:HRZ5I-^I^VVL$Y(Y$H&,=/4?4\_X5#K7B33=$A>2[EC7
M8/XF7H!UKY#^+G[3GA[PO97#6]Y"DD<3XQ(HY ./XL_SZBIIJ-2;@_FWMI;O
M_P -OU+GS0C&I%.]]?.ZCJK;?+YFM^T)X<^'VG^&[Z<)8P78AE.U3'\K >O8
M_3)Q7\J'[7/C^Y\,ZY>'2+XI$D[XV2$#&X\<'_/Z5]5_M5_MT:K=_P!I6ME?
M2-'F5<)(2,?@2,<_A7X7_$#XF:Q\6=9^PHT\TL]R5X)8DL^,8Y/<CIG^G+7X
M?R[%\ZQ="F[Z7C%<VJ6O_#,]'#9[F>$498:M-6M[LI-IO32W_ \^EC[+^"G[
M0^H75REO=Q27PR%Y!DR.<GOZ?_KKZA\2_&36+33Y;C1-)GAN&@;:T<)4@E>#
MPOOW/7/X^H_\$W?V$;;QK'8ZGXDLVVS!')F3@!AGDL!T'-?O#_P[X^$A@2)[
M:!BJ@,?(R"0!G&5]1_7CI7Y5G'@WP[C\=]=H8G&4:L97<8U)1ANGHEIT]'Y:
M(_3,B\6<XRFA[&K1PM=35FY04FM$NVFG?Y6U/X;OBO:?M,?&+QW'9Z,^MQVD
MUT%58S< ;6DXQC@#&>@'MGK7](/_  2^_9.^+?@S2]*USQ?/?L0EO*XN3*3T
M1C][![?J>QK]9?#7[!?PD\-Z@FHVVGV;S1NKJ3;+G*G/=:^R/#OA[3?"^FPZ
M;IUO%!#$H4>5&J9V@#G 'M7V>2\/O**=/#QJ5)4J22C*3<GHEYO5[?B?)\0<
M1T\YJU<0Z,85JMW)17+'7E>EDGI_GV)8M\>G6]N2=\<4:$=\JN/KS_\ 6JS
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M+P:]DHR=I3MHG;1N_P!^IW^('#=3+\5_:>%CSX7'_ON>"O&*E9I7M;[K>A[
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M=N:L]4^7VZ5AJYM]);O3>_YVW?4I[6OK9W2W]?O(UN9.AP<].!4[,<9/./\
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M/B%+/3Q=W$_1%8@MGH >Y/3\>U>*?M+_ +0D.G:==6=M=A76)T^5QUQCU_\
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M6XVMAJL7&5.HX)/2ZNDO7S^_H.>48([_ .<9_3H:6(Y'U_H<5$"K=>I[?_7
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M28$..O)^7TKQOX;_  @_X1>W@B$6T*!_#C& .O\ /\*^B(;2TL84,NT%5Y_
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M&B\O7H?W'G7AAD>,R/*\OK4(16#]E-U%%)\\;-ZJVESZ-_:"^)4$_P!M>TF
M#^8<*P'KZ8S]?<=:_'_XJ>,"TUS+/,0"S\[NHY_ CT/OP*^@_B'XUN9[&9KB
M9B0K$Y;TR??]<\>QK\T/B9XJN->OFTRQ+R2O,8\(23DG';V///OZ5ZF182I7
MK3Q.*3K8G$5'-U'K;F:EU\^WIY/S\\KX7(\OA@<+90HTU"\=&U%+JNZ1RR:#
MJGCWQUI]MIRO<1274894!88,BYR!SC'>OZ^O^"<'[-FF>&_ NFZQJ&G1QW:V
MT,A9X@&W$ ]QZGZ9X/M^0G_!.#]DB?QAJ^G:WK=@SCS8I098B?XE8<D$]^.@
MK^L'X?\ A&T\":%:Z3:1+'%'%'&50!0-@ Z8_P FOZAX!X>AA<.L97@I.44Z
M=]XMI./9JS\_0_DSCSB"6+Q%3#4&X)7YUW2WZ=OON=S'Y<,2V\8"I&JHH X4
M#&.GYD5#Y1#]>Z]R?Z>]2(ZNQ88R3T'8YXZ>G_ZZGK]04O>:M[MM/P[IIGY7
M%-I-O7NGTOMI_G?;4!QQZ4444%A43;CQ@X!XX-2T\E,].IZYQ_GZ4)M-/L)V
ML[K1V_-6*Z$0_._"[3D_0#KGITK\./\ @K-\9K/PSX2N;);Q8W^SR1XWX.?+
MP.G?VQZ^E?M]K;-'IMRZ?>6-L?\ ?)Q^N*_C-_X+G^/=>TP7,49G$0DE!()V
MX^@..GM]>,@?/<1RK?V?6ITFTZR:;71::OR/H.&^2ECJ=6HN;V;]W3TT7H[6
MMKJ>+?L#V-Q\1?BW%J<:&Y3^T@V[!88,N>N3S@9^F<^W]*/[2/AMK?X2V=J(
MRCQ6**1SQMC'M[G^1K^=#_@AEX@TC6=>MWU2:'[2;E,^8PW9W+ZDGKZ]^HZU
M_5]^T/X9CUKP&YLT$L2V9*[%R,>7[ ^AQGUZFOF<'EK?#F,H+WZSBY<ZM?;[
M^MMD?43S=1XDP>)JW5-2BDM;)-Q7=I7/S,_9 O?[,UW[/))M/VG&"<9^;\,>
MG;/ICI^\OAQDFTBTD!SNC4Y'^Z/\\]\U_.%X'U^7P/X],+DPJ+T@Y.T??(Z'
MZ=_H>.G[S?!;QM!XB\-66)E9_*3N#SCZGL.A^@]:G@/-XUJ=;+JDK5L*Y1Y7
MHVD]-_P_R-./<AKTZU+.(Q<J.,2DFM4KI;ORVM\T>PNY7..V",9S_G^GO1%.
MS'D'\1_G_(]JL2P9R?4_Y]/SP,8ZU&J)&22#D>N/\^G^'K^D7C*SM:6MUKV7
MX=C\S:E=6=UI?;RNOS^XE#]./U_^M2LV,8P:JL=Q!!]^2.O7O4D9_O>O<>U7
MRJ/*^^K_  =OZWW)YF]E;;SZJ_Z_\ DWGV_S^--+$G/\JF 4] /RIK;1VY[8
MX_44[QZ1OM^G]>?S8-26O-]_R_K\.K(;FSAU&W>"X3>K*PP1D<@C!S[X]>GX
M5^0O[77PTGMM2FU'3+0H$=G+1H1T.>N/J?7'%?K^DHC!SSR/\^U>5?%+P!I_
MB[0;TR0H\IB;;D G)!QCY?7_ "*\7/\ *UFN7UL+)64HMQOOS6TL][Z/_(][
MAS.*F3YA0Q46VN>,9KI9R2=]NC7>_0_*[]F7XDMH%Y!INH711EE"%6?&,,!Q
MD^WM[U^PWA_7;/6=.MYH)%<M$O0Y[9]2?\:_ CXG^$];^&_BZ2\LXYH;9+MF
M^4%1@.>F,?7KS]#7Z%?LQ?%YM9M+6QNY\NBHF';)SA01R>WK^5?EG".>UL@S
M*ID&8*2I3JVI3GHDN;2S=MMOZ=_UOC7A_!Y_E5'B7*Y1]I&DG7I0M=RLFVTK
M[>9^@F,,!GW_ ,\U:3I^/]!5&"1;M1+&P*L >.1R/T_SWJYL;V_S^%?M7[NR
ME3:<:BYDUUT5WZ?UV/PA.>L9KWHZ/39Z)_BNO<EIC,0<#'2GTTE>^,_3_P"M
M3COM<'MO;;7YC$^]]!_];^M2U"F=W\ZFJI_%\ON_K<F&WS_1!1114%A1110
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M[?YZU?6,H.Y]_P!>E+-+#!DEL8Z<C_Z_YBN5U7Q5IU@K&6XC7@GEP.GY=_\
M]7>LXMRO97\]D]O7_AK7-7*+^*Z2>_\ P/ZU^9U'F*C<D<>_UZU5N];L[.,E
MY8Q@=V Y^N?UX_E7S'XV^-NFZ1!<-;WL;,BO@"09XR<=3S_2ORF_:,_;J\2>
M#H+Q]-2>58EDP8]QZ!O3_P"O^-5&"C+WEK_*M>B=M]O^&%-\VB=M;7\[V_KU
M/UN^)?QLT3PM;RR7%W!&$#')D4<<Y].1]3UKX[U;]L?X?7CS:?)JMIYYRH7S
MDSN.>V[W_P#K$<5_*'^TY_P51^(^H3W6FQI>Q!W:/),@(RQ&?P_+J*^0?!?[
M2'CWQ+<OXAO-7N8$#^<RM.X&,Y/!;T&/<8^E:-7:<59JUT^MDG_7;8B*25HO
MFMN_DK_TS^O/Q[\0=)UW=?V5W&\&?,RD@/RY)[''TQ^5>$^-/VFO#OA_PQ>Z
M-!>)_:#0R1H!(-_F%6 XSGV_+UK\B/@/^U/JWC:\A\)K=O=SR%;<?O-YR?EX
MY/<Y/O7Z)^!_V&/'/Q3UVPUZ9;DV5Q)',RD/M*,P.,'VX_R::3BNE]/1Z_=V
MT[C7*I73YI2]VZ3]W9?<?&$.K_$CQ;XRFU.".]ETV2X=U($A0HSEA[8 QTKZ
MDT9'>.*TU6,I(4"L'&#G&.<CCKQQ7[@?#3]AOPSX=\*P6EYI<!OD@0,S1+N+
M! #R5Y.>?\*^=_C;^R#<Z/%<:II=JR)'N=0B8X4;AT';'TJ5.;^'W=>K\TO3
M^OD7&G3H/W_WR=GKK9Z>O7I;]3\RO$'@E(X#=Z<-QP6^49XP#_#W&>N37#03
M75MF&Y# @XY!'3KU[\5[U<-=:#>RZ5JD)559H_W@(& =IZ\=O\@UR/B/2+2Z
M5KFUV9.3\O8D<_4]ZT<92491G=IJ[^Z_7^KZ"5>GS.+@HZ:1Z:6L]?\ /\['
MDMY=B,E@?G&<?Y'/X>V<5]5?LHZSK;>,;)8WF\G[1$,#<%^\!V[?T->%>'_!
M4^OZG%;E&VF0+C'&"??Z\_A7ZT?LP_ G2]':SU"54$@,<F3C/4>F.:WE-N/(
MU=I>7EM\^VKT.>-%*]24G:]TKM=OT/UO\$RO-X9TMY,ES;H#GG^$5TQ9",%<
M]>"O'YU@>'&B@TZWM8R"L2A1CZ?KT_D.,5MYYQ@\^@XKB<;MMQNKO\_O^XT4
MHO1=5VT\E_PQ"4"L6"X]P/\ #OFE!^8'W[_E4U(>01ZBA-+3E5OT^[[K6$HM
M;/Y6T_/_ (/F-90_IUZXS3@,?GFH2".#4PZ#Z#^5#326K:81=WJK2MK^ M%%
M%26%%%% !1110 4444 1LQ#'GTX_"DWM]/\ /O4M%5?;1:;^?X"L]==WVV\B
M&,LSD'ID9^G)'T]:YCX@ZM_8GA#6K\':T%E,RGOPASCWKI?.",2..>X]/QZ^
MOO7(^.=)D\2^'K_2D&3=6\D7'?>N.W8=?\:RQ492HS]FK2E#1KN[?IY#H27M
M(INZC-.[T6EOQV/X._\ @J;\<O&_C?XD:AX0T.YOG,FH2VX2%I"/FEV8PIP>
MW7TSD5]\?\$=/V/_ !#->Z3XI\7V,T@F>*?==1DYW;6ZNI]<\\9_,?H)XN_X
M)56WC'XK_P#"::IIR3VYOOM1,D>X8\T2=UQW[_C[_L?\&_@YX9^%'A;3]*TB
MQAM9K2WC0E(U0[D"K_" >WZ]37R&!R/EQ_MY4U[[3G)I:MM:M_UL?7XS/YRR
M^.'56_)'EBD]E9:?U;;9[KUW1M'L/#^GPV%E#'%%$BI\BA<X&!TYQQ4[AC(S
MC^+GMQU]?8T%GEZGC^O^35K' R < #I7V$J,%RQMI%726VO3SVL?'PJRE)R:
M?9N77;[_ %_IP*H)&1SW_ 9J< #I47\7_ OZU-5M)6Y>WW#NW?[O7[NVQ"T(
M8_Y_+OFGJ@3I^?\ GZ4^BAMO?4226W4*0J#U'\Z6J\CX/3V_(TXIN]G;3[_(
M&TK7[_JORW#-18;=]<X)_/\ R* "W.>A[\^E-O;B.T@:5VQ@'O[=N,]Q_@:Y
MW4IQA.I5:A&DN9R>BLK._P#7IYEQ4I3C"$.:4WRI+75V6F_<I7^L0:9:RS3N
MJA S$D@=,_3L*_.;]I#]HK3-(M;NRM+M5N,/&%1^=V,8X/'YUT/[2OQM?PQ;
M7%I:3E7D5T&UN<D$=N_OWK\\/#7PQ\3_ !SUI[YO/EMWG+$$LPVL2?I@Y[]Z
M_"^+>+<RXGQ_^JV00E"FY\M;&4[_  Z)IR3L[=E8_:N$.%L!PYAEQ'GLXMJ*
MJ4<-.S3D[->[+SM\_4^<O%#^.OBKJ\@L1>3032';MWE<-D=N._-:VB?L?^,M
M0(GN;2Y!?#<QMW/?C]>U?MS\#_V8M"\(VMN^J:?$\J!2Q>,%B0!W(Z^OY=*^
MO(O!WA>W14CTVV4*, A5Z#IGC'^<]\U]%P]X5Y9@,)&>-?UC&5$I5)R3E*^G
M-=O76_>_X'G9_P"*N:XS%.E@8_5L'2?)3C!\JY4U;1-)W\O^ ?S ^+?V3?'.
MEVDCV%G=%E0XVH^<@#MC_/O7QKXR^#GQ@TR:519:CY:%L?NY<8!QZ=,?T/2O
M[2I?!GA:X0I+I5I*#@'**3^G^?3%<!XD^!/P^UR"0/H=FCD'GRD/7_@((_/C
M KLQ/AEDM>,^6,8597Y9)*][*W33?M_F88+Q8X@P<X7JSJT4US0<KW6FEGOV
M_'NS^&N]\&_%.R\2V,C6E^"DR$Y27LXXZ=0!TYP*_HF_8<_X3#5?"EII&L17
M C,$:'S _<$?Q#WZGTP:^T]=_8T\%7NHBYCTBVPK C$*= <_W<?EC]:^B_AE
M\(]!\"VR16=G%"44 %4 Z'V&?\^YI\-\!0R'&SQ"Q%U/2WEII:]O6Q'%7B'6
MXDPM/#O#J#C9KUNKM6U_R^\^0/B%X.C\(3?;HU*2LQ8X7')(/;ZYZ@_E7H_P
M?\83MY0F<[!A>2<8Z=S^8]?K7LOQ:^'S>(+&>YC0D1AF&!GA03UQ@=,?SSGC
MX-;Q9-X+UG^RP#&1,4].C$=,=A@\<9KR.(\/5X>S.&=T(N5-23J)=5=7V78T
MR/$4\^RN64UU^]4;4Y-I-:)*S?\ P?F?K!I]_!?VRM&P+;.2/7CW[9[\_P!;
M9+)D'J><]Q^=?.'PI\9_;K: RR@[PO!;UQV^GMT^E?2"RI.JR+@@CKP?3]?Z
M8K]*R?.*>=9=1S"DU%2W@M6GINM_ZT/SS,LLGDV+J82K'F2DVIO:VEK/;1?>
M*CL?H/2IW)"Y'^>*;'CG _3T//ZTV9@!^8_,5[-.7M&G;U^27>]]=#S)O1M:
M;6^]=0C<L?;'U_O?X4-'O;!! R><<?K]*(>@^A_G4Q..33DES-6WM9?<3'X4
M[]?*W337\/4KM&%X![?U[U&(@&# ].P'!J=CDY'I2 9.*T248K2VFOS_ "U$
MY2;LFVM+?AW*&OZ'IOBC2;O2-1@CGM[J(HRRHKA=PQD9!^AQU'X5_./_ ,%)
MO^";5MJUM?\ C#P78*+GRY[E3:P@'=@O_ N0<COTK^DAF:++ ]O\Y'MFLG5-
M(TGQ-I\^G:Q;PW,4RO$RR*#A6&.,C'OCO7F9C@Z&.I2H54G&2:3?2ZUUO=,]
M+ 8RM@:T,13;YH6]U=[J_E^A_GM?"SXS?$[]DOQFUMK;ZC!:65Z5 E,JJ%C?
M'? Z _GWQ@?TF_LI_MS> _V@]%L=!\17MJ;BXCB@(FD3.Y@%Q\Y/))_/IZUI
M_MP_\$P=$^*@U'4_#.DQ1S2>9*&AA .XEF'W1GG';GI7\V/Q0^%WQ3_8B\7P
MWL,E[:6=G<^82&E1-J2 Y/.,>_'%?F\LOS'AO%2J47*K@:DFY4MX\KM?35;?
MTS]$CC<MS[#P^L6IXRWN5;V<6K6\[W_4_L6\4_L=>$_$^G#7O#CP2&=#<*8"
MC?> 8?=X/4_3IZU\>^)OAGX\\!W,UOI$5V4A+!=BR=L8Z8QQTQ7EW_!-7_@I
M%:_$BPT_PSXDU999U6*V=)9@Q)VJA7#'.<^HS7] ,>@>%/$UE!J7V"VNH;R)
M9%DVJ20P&<G!Z?R.>]?2QR_*L_POM(4(4ZFTWU3TOHNV_9/N>#/.,SR6N\/4
MJ3JT4_<;U35T]V^WX,_ 6]\1_&"V.TQZB%4^DPZ%?6O5/AO\5/%^E7</]MO=
M( X#^87'H#G/\_\ ]5?L#J7PF\$7L;8TNU!.0?W2<GZ[<'U^N.U?/7C?]G+3
MK\2'2[1(V8_*4C"GOTPO7^>.W6O Q7AY07OX2O*-35JS:L]/3R_JQZ6'XYJ3
M;IXO#)T7NVDU:RU^7Z$/A7]H/0([2'[9>(L@50=SCK@=<G'KQ_\ 6KO;?]HK
MPNTBH+R(\]2X.0>>.>V:^0;S]E?Q2\S?9VF1-V1C<,9.0!U'K_ASSD:C^S9X
MQTFW:X$EP2BDX!;J,GZ?F*YJ&7<19/K"<Z\(-*S;>UM+-_K]V@ZM3A[,Y>\X
MX>=1]-.BZ;(_1[1/BWX;UA0L5U$6?;C#J>O;_.#78C6[.YPT<L9!P!\R].O7
M//7]>.U?B=J>K>-_AY<,2+EUAQP"^/E/M_A@5S5[^VIXJ\/2"WDAN?DX)._L
M.OK_ )QFMI\=9S@)JG7RISC]JIRRTV^7>[^1/^HV7XR*GALQ7+=-1YDNVEM/
M^'/WMM;NWP<.F3QG</<_YX].G2N/\>^&;76='NY0J-,L3%20#G@G@^OJ/TK\
M7='_ ."@>J  W D4C^\6]\]??_\ 7TKK9O\ @H=&UH8I[@ %<$%\>N0<^H/_
M -:NK!\>X.O&K3Q-.4.>+337622V?G^.SWNY^'V8TI4J]"I"K&G*+6OO-1Y;
M:\W9:LWO'B:SH?B-HCNCMDG;H<+M#?7&/7ZGH*^Q?@1X\L8X8+62X5I"JJ1N
MSUX/&><?R_7\4?C5^VM::HY-@JR32-@%.3DXYXSUX_, >I^@OV-?B!XC\?:G
M;3NDRQ-)'C.[&-RG^1X&?<5^?9#0QD>-WB\&I0RZM*\TKJ+NU?3:^O7]#[[/
M:&%EP8H8R4*>/HJT:=U=\J2VWMIY>NY^^B7*W4"RQ<JPR,>GU_ ?SID;-SUZ
M_P"?\]1FJ7AN&2+2+9)<[S&F<_[H_7)[]ZU%_B'O_P#JK^C(6:NUVU?F?SO*
M_-%]_P!-QJ YY!Z>E2T45+;>YH%%%%( HHHH **** "BBB@ HHHH *<GWA^/
M\C3:<GWA^/\ (T 34444 %%%% !1110!7HHHH **** "BBB@ I"0.O%+3'!(
MR.W;'KB@!]02SQQ#)89]*K7=XMM'EL#'],\?I_G->9:SXJC64QI(.IZ']/\
MZ_K3TMUOT[=/^"#373^OE?[CT66Z\[Y4.?7_ /4.O^?K388V4[F/? !/?'&/
MS_SBO.].\1QCYW<?F.^>G^?ZU6U7QW;VJ,%E&1G&".N!TY_^O^%:N]..BWM=
MV?7[M-KF--*I55Y<K3]+V^_^EKT/9!<1QH-Q'Y_Y_'ZUS.K^*;2P1MTT:X7/
M+ '/'/\ GU_"O [WXJHJ2CSL%5)ZX' _GG_.:^*/C5^T?!HCRPF_".2R@>9@
M^W?/3CCV[4H1O'FDK?<]$TOZ^YFU9.#M#7:_K_P%?I\C[+\;_&BQTE)B;A,
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MOV4YV:VWMOY=NA]QB,/',< JB2E545;OJHZ/?SUZV/[P)(@B@CUP?R_^M_\
MKIB3 ]4!QCMT],?Y^E<SX-\1P^+-$M-1A?<LL,4F[/7*C/\ ,=L^O/7H&!B8
MC&1_^OVK]%HSA6IJ<'\6WY['P-13I3E&>O*TI*^J_K\WY%OS8U&=H'T&.W3I
M^F:HWMO!J$+0O$C*V1R!DY&/3_']:D"[\<GGMGCC_P#5FG[2F.,?Y]?\]:BI
M!IV<G)=K*SV7;3Y[/N0I-ZI6UZ-W6W_!Z_I;Q?Q%\"?#'B8R->PQ8DSGY,]2
M<]!_GUXKP7Q5^PSX!UE)98HH3*P8XV!3R/< 'Z?SK[D#L.AJ03'OZ]A]/_K_
M /UZQQ& PM>'[ZC3DFE]E7V7E]]]#JH8_&4?=IXBK"UG92TTM_EM^9^+OCS]
M@RRM3,-+MS_%CRU^O3 _S^@^,_&7[$/BY)95LX+O;D[=JOCJ?3/M^/%?TU-;
MVDHS+%')_OJ".?K_ "/K]:J/HNB2GY]/LW/^U$OM_P#6KYZKP?E523G[%1UN
MVH[O3=_U^)]!0XQSFC2C26(;LDE>3OTW7>WWG\QO@K]@#7M7U" ZQ:W!19@3
MYB/C QG[PK]J/V:?V8]'^%NG6S);HDD:(<[1D$ <=,]1^-?8XT/1;;YX]/M8
MFZC9&!SZ\<_YX[U:A>-!MA7:!GY1QZ8/3C_&O3P&183!*]&*NGNTKW7+_6_F
M>;C\_P =F'N8FM)M]+MIW:\_7=>98*^2BHGW5 &/;I_A3H@,$G&3Z_CZ_P!*
M2@G'->PG96Z?\-_E^)X]M;_I^OI_704]3]325'YGM^O_ -:GJ<C..]%G:_08
MM%%%( HHHH **** "BBB@ HHHH *<GWA^/\ (TVG)]X?C_(T 34444 %%%%
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M23SCD?UKZT\&>#KZ)VU/4&=,Y?Y@1QU[_P"1U[5\H_M::5;:OH]Y';X>1(I
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M)]"./P%6QQQZ5;LEH[I_@U_PXHN\F_)?U^!&R K@#O\ C^=1B,KR ?KG_/\
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M"%E \M26^4X/3CD 8_GV^B'1!@QKCMP,?_7_ ,_2GJPD5HW (88(/.0>"/\
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MN1QCKS7]K_[.GQST'XH^"]#EM+J*6X:RC!*N"3E1C...I]!U%?Q7_P#!2?\
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M?GO]YY!??L]_";47,EWX4LI&;J3'%SSGO$?6LA?V8/@PK^8OA"R5LYR(X?\
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M%% !1110 4444 %578AOQ/X\FK50.FYB<'\/S]#ZT":NUY?YI_H+YHP1[?\
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M/YTTDD$;3G!^GYUP.E?$_P /:O@VMQ$V<8_>*>O3OW'/0]*Z1O$5A]\2QD$
M_>'T[\4N==(M^:OY=WZ^?W7;4))V;UW73MIIU5S4)*$'!X(/\S_3_P#57(>.
M]9L+#2I_M,BA6B8%6([@]L]<?YXXLW_B[3HK:23SX\JI.=R\8Z]_\]*_/O\
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MI@N(-2N5MY$WH5D<*<C/0$CK@U_8G\9O@!X8\>>&M8\^TA:\:UF9/W:]=C<
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MGWA^/\C3:<GWA^/\C0!-1110 4444 %%%% %>C..M%12AB!CCGF@:U:7=CB
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M%,5V$*MDXDX]\?XU\R>*/B5J7B*[5-0=P[2\A]PYW'CYCV[_ -:_>_5_V;/
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MJ3G"E4BK)-/U6C737;?JS]-[,_\ $NMO0P1C\Q4H.$S_ )ZU6M5/]FVJ]PB
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M6@#D ^O-5X0I'/7_ /6?QJ<$'IVK)O77=_C:R-+6277]+*WZD#* V>>/\/\
MZ]/#D<<4UNI^M/!3 SC./3_ZU:-I*-U?3_(Q2?,[::O6WFG_ ,'S$WM[4OF-
MVX_$_P#UJ"4P<8SCT_\ K4P GH*F\?Y?Q_X!24OYOPO^8XR,1C/\_P#&GH[<
M\^G]:9L;VIZKMSSG/M3;5K);V?IMI^""*E>[;TZ?*W<<^Q@2X],9Y'3!]ZK>
M199RT2[NQQ[8[C_&GMEB0N3QQU]*HR^8K=QR/RX_/\<FE%-O:^OR-7**CK+M
MIKY*R-!=@^5!@'TX[=O_ -5/Y!)W'_ZV/\GBJ<;$+D[L^N#]*F!9NA)X]?7\
M:5M;/3U_K_@$IZ:;/_@?UW[EA9>@Y/7Z_P Z?OYZ<?K_ )_SFJ@!/ J5 0.?
M6JDHVNFM%M^I,6WNO._3I_P^XYV@<?O%1NG#*K?S';'\J0/"HQ$JKGLBA?R"
MBH)%#\*<?ISS]/SJ*4):H99)0-H)/.>G/KCH/3_Z^3E9V_J_X?G_ )FT5'J_
ME>W9_/\ S[V+Q<#[S$#'8X_S_.G@[E^1C]>/?IVSS^E?//CSXL6F@N8UF4;2
M1]X=/SQVYJAX,^->GZJ1$]PF2<#YA]![YS_]?WT<6HIOJ[6ZK;?^O^!G&\IR
MBD_=5[]'HOZW^\^D'D9,9//3G\.?Y_\ ZJ9YCN<!NOH>/TK+T[4+75HEE2=3
MD @!ASWXR?KGWZCM6TD**/E).>IR.?TIMJ#^7Q/IM;?\-_7H0O>UNTK[=-+=
MOZ15=WSY>20V ?ZCZ8X]\BOG#X]_"[3O$7AV\N6MXWD$<AW;<MD+GVQG_P"M
M7TUY2[@QY(]O\^E>'_'7QC9>&_"5\TL\:-]GE8Y8==C>_H/U]C4PES.UTE>_
M:^W3HK_YZO0M/EN[-K1-/6W?^M=ON_G@^-OC,_"&+6[:.;R%59E"[MHXW>_K
MQ7XA:G\3[CQG\3_/CN#*7OP/O%NLV.Q[U]E_M_\ Q>BU*_UR&TN 2&N!A6YZ
MD>O;/Y_G7Y5?LK_:O%OQ5M+9T>7=J:#GYO\ EL.W^<5T2DTK/2RV]+??K^>^
MIFX^\K*\7U^[3=G]0/[)_P"SK??$NPTF\E#@&.!NAQ@XS_+^?K7[E?"SX'6G
M@&RMXMJF2-$R>"<@#K^7?G]:\&_8G\#?\(]X*T6<0>63:P'E<?P CM].:_02
M0L,!1USG_/\ ]>N1QBYN5M;_ .3^?3<ZI2E&$87T\OZVO<IJQB41#)"^@[#(
M_P _S[584Y --"]=PYS_ )Z4^J,2)^OX?U--4_,/K_/BG/U_#^IIJ]1]:V^Q
M_P!N_H9/X_FOT)Z***Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H
MS.^X #((&>.G)_P%7JIRR(K<XZ]_\]^N/\*N#?-I'FTV_K]3.I9I7ERKOKY$
ML: @,W49SG/88SU]*K:B?]%<+R=I'&#VJSU4D'CKZXZX[8/IQ^E5\;Y%1\D$
M<@].>/USCW^M<\IQM*E+W95/=Z.S>GWZIFD>9.,H^\XZM=UHW;KT_K9_!GQS
MU">S$YD4JAW>W<].WYX_I7Y]:_=6NJ&="%9LL.O.<GZ__KX'K7ZB?M)^&/M.
MB7EQ;1%G6)V^5<G@-[>M?SN_'+X]77PEOK[[3;2E8I)/X3R%8^W/4]/\:_BW
MQDX&SI9]]=P5*=>G7>DH7:2DU:]E9=WY']H^!G%&21RGV>+Q-/"5\/9RC)I7
MY4K^M[;Z_P"7T9=^%KH6E[/;6NX*DAW!3CA2?3\?H<?7\0?VP/%LMCKEQILN
M8Y#.4V]#][!X^O3KW-?7_A7_ (*:^&$LK[3KZU!E>&2,;QW*E1U'KGZ?G7XO
M?M:_'>Z^('Q .JZ3IT[VCW@?]W&Q7:6W=AC.,X]>W6IX PG$&6QEEV-P514_
M9\\9RC*TG96C=KTLKZ[>D^)7$F2YMC8U\'6IRE&?)*<6K>;TZZ=_S/Z&?^"1
M?BRPT#6=.N=4G6%9)8B"[ 9!*8P3US^'3ZU_6=I^KV&MVD=Q87"S1NJ2!D(/
M!4-SCZ__ %Z_@[_8+\6^*-:N-#M=(L[NVE#P!BJ.O=.X''K7]GW[,T&MP>#[
M-M::0S-:1']Z3N^[[]O<#OSWK^B^ L3F[G5H8S#RH86-W!26CM:UKKJM-OS/
MYNXTPV"]I#%8>O&M4E%<]GTLM7;1V_0^E5&TL/IV^M/JJ)MTQ )QD#ZG</R_
MD>:M5^H2Z>:3^\_/H3YU?L[?@@HHHJ2PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *<GWA^/\C3:<GWA^/\ (T 34444 %%%% !1110!7IRXSSZC
M'UIM(>?S!H#7IN>:_&.2X3P+JXMP2[P2C ]/+:OY2_VC7U&/QSJ37B/Y?VF7
M!8''WN.OX?\ Z^G]<WB'3X=:TZXTV0!A,CK@C.<JPZ'WQGCCN:_$;]M7]F-X
MHK[6M/LBSMYDN4CYY&[KCW_SQ6D;WC?I[R^;5OQ_R$FUS<KNVTFO-6_$_#2\
M=9&+6[%3SDJ<="?ZYY]ZZ[PSKUW90RQO<2,"K 9<]Q[GZ]?_ -7.:GHEUHFH
M7-K>(\6R1UPX(Z$CO]/SZ]Q20-!$H(D4!O4\X/'<GKG\*ZTHSMM9[]_P[]/\
MC.G[5*4VW=;>6N^]]OZZ&[\,[Z=?BM8:@S$*M]$V><8$BGD__7K^N;]G7QC#
MK7@+1K9) SQ6L2X#9.3'@\>Y ^M?RC?"W1;._P#$EM-YB!O/0[LC@[P.OX_A
M^/']#7[-GB&V\,Z)8B2\0JL<8V^9Q@#Z]?3KU]ZYL5'D<5'T7KIY6Z]6:89>
MU]I.H[6^6UDG]VI^E:0NN#CW]>2,=.*>8F7[I^O?],?XUX[<?%O31$C)-'GY
M=V&'7@G/?_"H+/XM6=PY3S5/0#!']#].M9.FTDWWTN]>FWK;\Q\SD]->FS^?
MF>T^4Q&3UZX_EVJ%_P!WR^,#K^':O.A\1[+;AI$!QU)'7^?ZUCW_ ,0;.5&"
M3H#@CAASC]<__7[4]7&_1?\  _ -;I6W_I7]3UP7MJ  64' _BJ9)X7R5P<X
M'7VSU_&OE^[\=XERLX(+=FX S_GI_2M:Q^(\4:C?.O _B?OT_P _SI6V;V;W
M_K^M!.]M%?\ X<^@KB]@@!+L!CWZ8'K[_K5:/5;:0D!@?Q''(]_\BOG36/B-
M'<*1'.HXZA_<@8.?0_TK$LO'OE-\TX(S_>_E]*:7,TEY?HOON]27*T;[->7W
M[GT_>>)-*TQ"]Y<1Q 9))8#C\?Z5SW_"S?![$K_:,+,.Q:/MQW-?FU^U!\8M
M5T#0IKC3IY/,\MB/+8^F/X?UQTXK\P_"_P"T7XYU6_N5DN;E%5VY+O@#<??'
M08Z9P*<H3C))-:]?Z[?\,73J49P;DG=:-;+3[^ORV^7].EIXRT#4L1V=U#*S
M8 "NO&>F,?E72PH64.,88<<]L_3VK\1_V>_C5J=WKD$6JZ@X3S%#>9*<8W+W
M)^O'I]*_5ZS^+7AJVTVU\W4+?>8UR3*O!XX^]]:GD<M>VEGY6?X:#;CHHI6Z
M._=+]%^'0]>$.#G/Z_\ UJ=L/<C_ #^5>,R?&WPFA_Y"-K]/,C]_]KVJOJGQ
MV\':?I\MVVIVB[$9N94[ G^]_GZYJ;J]K_(KV<N7F2]W^M#U;5M3M])@>29T
M0;<Y) [9Z?3I7S9XW^*Z()X+:8?Q*-K>Q';_ #D?@?FOX@?M1Z3K]Y+IVEZI
M%(Q9H\1RJ?0=F->=6>L76KL9GD+[SD9)/4>YX_S]*V5.#L]--;^?FM=W:_4P
M:G%W?7RT2TTZ>7GW,[XG^);O4GDD,S\Y.,D?_7_SBO*_"7B[4=-U ;)Y,!Q_
M$V.W'X_SKU+7/#MWJ<3[(688/.W/L.U>3WVB2:#(\TT10JQ/0Y]NWMWXZ_@[
MQE+E>RM\FM[>;_K34MN4*::TE*U[+5IN*]?\]STOQ3^U[-\.(83=7ACC098-
M(5&T#KC/M_\ KKVCX*?\% ?A_P"+3#:W^L6IN&(4AIUSN)4<Y.?_ -?&*_/;
MQG\!-:^.=K+::1',TKHR+Y>XX)X'('OQQSQZ5\<:W^PM\9?@UJ+:ZLNHQ6J/
MYW!E "J=WL.G?T/YRZ4FU)+FC>WHOS3^?0U<J7)R7Y:F^O?3MWWZ[G]6:?&3
MPC>:,^IV=_#(#"74"52.02""#[9Z]^]?C3^V]^T_%%9:CIUI?  QRH LO;#C
ML1Z_X5\5Z)^T3XH\*Z2^A:E?SB6!/*8/*V>%V\Y;_)K\]/VD_B]>:[-<S27;
M/NW]9#ZM[_CG\/>ME"":GTZ;NS\OFM_+YF2O/]WS:K63[JR\]]OO['PW^T3\
M19/$.OW\9N3(]S)( "V22Q[<YZ__ %N*^G_^"9/P!U?Q+\2]+U>2TE>V-]#)
MN,9*[?,0\D_7GBOSR71=7\>?$;3[6TADN(Y;R-&VAG'S2 '/!_\ U>@K^UK_
M ()?_LN:?X9\!Z7XBN]/6*Z$-O(6:(!MQ1&SDC]/QYK*JKZKI;[KKM_6I=*?
M+-P:O#H[>GZ6_P" ?L#\,/"UMX5\(Z+9QHJ%+&W# #!#; .>F,]3_P#JKT1F
M#8Q_G_.*I-&8H([=.D2J@QZ #'Z>G^-2PJRI\W?'7\_ZUBKO=65[7^Z[MV^8
M2=TM;N^W9-]_+T_0FI,CU%+480Y!XZ@U2MK=V[>?]?UL0V]++U\M4.*@\G-
M4 YY_P _A3J*+NUKNP66]M?Z_P @HHHI#"BBB@ HHHH **** "BBB@ HHHH
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MMRC ($)!7!XQ@=L?RZU^D6C:;%HUC'9V\8C2%1& @VC"C';V_P ]*Z-II""
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MD9X!]CW_ )5^G,_.Q5[,.G3&.G_ZJY7)5&K.UF_ZMY_\,S>2=-;;I:+S:?\
M7Z$$Q8R$KTX'].A[U*G3\:4+@<X/X4ZB]E;?L_N_/Y?,FVM^ZU_ ****D844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -VJ.W]?YT
MN!TQP>:6B@!FP9SV]/\ Z^:7:,@XZ4ZBBXK?CK_7^0$9_P F@#' HHHN,;L7
MT_G_ (TA13_G_'-/HIW:VN@>N^O_  !  .@I:**0!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %.3[P_'^1IM.3[P_'^1H FHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gv1ubg3hw41v000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2*!VP# 2(  A$! Q$!_\0
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M0K\/?^B6R_\ \#Q?E_U$^7XL/^(A<9?]#_&?^ T/_E/]7]+?T]?\15O[:_\
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M*M_;7_Z-P_9;_P"_WQ;_ /FTK^86BC_B%?A[_P!$ME__ ('B_+_J)\OQ8?\
M$0N,O^A_C/\ P&A_\I_J_I;^GK_B*M_;7_Z-P_9;_P"_WQ;_ /FTH_XBK?VU
M_P#HW#]EO_O]\6__ )M*_F%HH_XA7X>_]$ME_P#X'B_+_J)\OQ8?\1"XR_Z'
M^,_\!H?_ "G^K^EOZ>O^(JW]M?\ Z-P_9;_[_?%O_P";2C_B*M_;7_Z-P_9;
M_P"_WQ;_ /FTK^86BC_B%?A[_P!$ME__ ('B_+_J)\OQ8?\ $0N,O^A_C/\
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M]7]+?T]?\15O[:__ $;A^RW_ -_OBW_\VE'_ !%6_MK_ /1N'[+?_?[XM_\
MS:5_,+11_P 0K\/?^B6R_P#\#Q?E_P!1/E^+#_B(7&7_ $/\9_X#0_\ E/\
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M^_WQ;_\ FTK^86BC_B%?A[_T2V7_ /@>+\O^HGR_%A_Q$+C+_H?XS_P&A_\
M*?ZOZ6_IZ_XBK?VU_P#HW#]EO_O]\6__ )M*/^(JW]M?_HW#]EO_ +_?%O\
M^;2OYA:*/^(5^'O_ $2V7_\ @>+\O^HGR_%A_P 1"XR_Z'^,_P# :'_RG^K^
MEOZ>O^(JW]M?_HW#]EO_ +_?%O\ ^;2C_B*M_;7_ .C</V6_^_WQ;_\ FTK^
M86BC_B%?A[_T2V7_ /@>+\O^HGR_%A_Q$+C+_H?XS_P&A_\ *?ZOZ6_IZ_XB
MK?VU_P#HW#]EO_O]\6__ )M*/^(JW]M?_HW#]EO_ +_?%O\ ^;2OYA:*/^(5
M^'O_ $2V7_\ @>+\O^HGR_%A_P 1"XR_Z'^,_P# :'_RG^K^EOZ>O^(JW]M?
M_HW#]EO_ +_?%O\ ^;2C_B*M_;7_ .C</V6_^_WQ;_\ FTK^86BC_B%?A[_T
M2V7_ /@>+\O^HGR_%A_Q$+C+_H?XS_P&A_\ *?ZOZ6_IZ_XBK?VU_P#HW#]E
MO_O]\6__ )M*/^(JW]M?_HW#]EO_ +_?%O\ ^;2OYA:*/^(5^'O_ $2V7_\
M@>+\O^HGR_%A_P 1"XR_Z'^,_P# :'_RG^K^EOZ>O^(JW]M?_HW#]EO_ +_?
M%O\ ^;2C_B*M_;7_ .C</V6_^_WQ;_\ FTK^86BC_B%?A[_T2V7_ /@>+\O^
MHGR_%A_Q$+C+_H?XS_P&A_\ *?ZOZ6_IZ_XBK?VU_P#HW#]EO_O]\6__ )M*
M/^(JW]M?_HW#]EO_ +_?%O\ ^;2OYA:*/^(5^'O_ $2V7_\ @>+\O^HGR_%A
M_P 1"XR_Z'^,_P# :'_RG^K^EOZ>O^(JW]M?_HW#]EO_ +_?%O\ ^;2OT)_8
M(_X+X_M-_M7Z?^UC=^-_@O\  GPU)\ ?V<?$GQE\,+X5E^(136O$&C3^5;:5
MKW]K^)KYAH\PYG.G_9;T'_5SC/'\/E?MM_P1F_Y W_!2;_LQ/QU_Z6FOG.+/
M#;@; \/X[%83AS T,12E@53JPEB7**JYC@Z-2W-7DO>ISG%W6TG;4]OASCGB
MS&9QA,/B<ZQ56C4CBN>G*-&TN3!UZD;VI)Z3A&2UW78^OX/^#K#]MB6"&4_L
MW_LM@R11R$"7XM@ N@8X'_":G'7ID_4U+_Q%6_MK_P#1N'[+?_?[XM__ #:5
M_+Y9_P#'G:?]>T'_ **6K-?2/PK\/;O_ (Q;+]_Y\7Y?]1/E^+/#7B%QFTG_
M &]B];/X:'E_TY_J_H?T]?\ $5;^VO\ ]&X?LM_]_OBW_P#-I1_Q%6_MK_\
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M0K\/?^B6R_\ \#Q?E_U$^7XL/^(A<9?]#_&?^ T/_E/]7]+?T]?\15O[:_\
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M&X?LM_\ ?[XM_P#S:5_,+11_Q"OP]_Z);+__  /%^7_43Y?BP_XB%QE_T/\
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M]7]+?T]?\15O[:__ $;A^RW_ -_OBW_\VE'_ !%6_MK_ /1N'[+?_?[XM_\
MS:5_,+11_P 0K\/?^B6R_P#\#Q?E_P!1/E^+#_B(7&7_ $/\9_X#0_\ E/\
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M;^VO_P!&X?LM_P#?[XM__-I1_P 15O[:_P#T;A^RW_W^^+?_ ,VE?S"T4?\
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M_P"!XOR_ZB?+\6'_ !$+C+_H?XS_ ,!H?_*?ZOZ6_IZ_XBK?VU_^C</V6_\
MO]\6_P#YM*/^(JW]M?\ Z-P_9;_[_?%O_P";2OYA:*/^(5^'O_1+9?\ ^!XO
MR_ZB?+\6'_$0N,O^A_C/_ :'_P I_J_I;^GK_B*M_;7_ .C</V6_^_WQ;_\
MFTH_XBK?VU_^C</V6_\ O]\6_P#YM*_F%HH_XA7X>_\ 1+9?_P"!XOR_ZB?+
M\6'_ !$+C+_H?XS_ ,!H?_*?ZOZ6_IZ_XBK?VU_^C</V6_\ O]\6_P#YM*/^
M(JW]M?\ Z-P_9;_[_?%O_P";2OYA:*/^(5^'O_1+9?\ ^!XOR_ZB?+\6'_$0
MN,O^A_C/_ :'_P I_J_I;^GK_B*M_;7_ .C</V6_^_WQ;_\ FTH_XBK?VU_^
MC</V6_\ O]\6_P#YM*_F%HH_XA7X>_\ 1+9?_P"!XOR_ZB?+\6'_ !$+C+_H
M?XS_ ,!H?_*?ZOZ6_IZ_XBK?VU_^C</V6_\ O]\6_P#YM*?%_P '5?[:SSVT
M;?LX?LN!9KJUMV(E^+60MQ<10L1GQIC($A()R 0"0>A_F"J2#_C[L/\ L):;
M_P"E]M1_Q"OP]_Z);+__  /%^7_43Y?BP7B#QDVE_;^,W7V:'E_TY_J_I;^X
M/_@IY_P7N_:;_8>_:@_X4;\.?@O\"?%_AS_A6'PW\<?VQXVE^(0UO^TO&?AJ
MQUK4;/&A>)M.L!96EQ=-#9?Z.9S"J^?([@LWYY?\15O[:_\ T;A^RW_W^^+?
M_P VE?(7_!P;_P I"O\ NWSX$_\ J!:/7XA5\WP?X;\#9APMP_CL9PY@:^+Q
M>58*OB*TY8I2JUJE&$ISDHXA1O*5V[)+5V2/;XEXYXLP?$&<83#9UBJ.'P^8
M8BE1I1C1Y84XS]V"O2;M%:+6]M]=3^GK_B*M_;7_ .C</V6_^_WQ;_\ FTH_
MXBK?VU_^C</V6_\ O]\6_P#YM*_F%HKZ3_B%?A[_ -$ME_\ X'B_+_J)\OQ9
MXG_$0N,O^A_C/_ :'_RG^K^EOZ>O^(JW]M?_ *-P_9;_ ._WQ;_^;2C_ (BK
M?VU_^C</V6_^_P!\6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N
M,O\ H?XS_P !H?\ RG^K^EOZ>O\ B*M_;7_Z-P_9;_[_ 'Q;_P#FTH_XBK?V
MU_\ HW#]EO\ [_?%O_YM*_F%HH_XA7X>_P#1+9?_ .!XOR_ZB?+\6'_$0N,O
M^A_C/_ :'_RG^K^EOZ>O^(JW]M?_ *-P_9;_ ._WQ;_^;2C_ (BK?VU_^C</
MV6_^_P!\6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N,O\ H?XS
M_P !H?\ RG^K^EOZ>O\ B*M_;7_Z-P_9;_[_ 'Q;_P#FTH_XBK?VU_\ HW#]
MEO\ [_?%O_YM*_F%HH_XA7X>_P#1+9?_ .!XOR_ZB?+\6'_$0N,O^A_C/_ :
M'_RG^K^EOZ>O^(JW]M?_ *-P_9;_ ._WQ;_^;2C_ (BK?VU_^C</V6_^_P!\
M6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N,O\ H?XS_P !H?\
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M6_\ YM*_F%HH_P"(5^'O_1+9?_X'B_+_ *B?+\6'_$0N,O\ H?XS_P !H?\
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M\%C/^4I/[<'_ &6;_P!TOPE7R=3_ )+K!_\ 9(YI_P"KK)CZ.G_R2.*_[*/
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M7CM>Q?M%?\G"_'?_ ++!\0__ %)M0KQVO9P'^XX+_L$PW_IF!Y>+_P!ZQ/\
MV$5O_3D@HHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K]MO\ @C-_R!O^"DW_ &8GXZ_]+37XDU^VW_!&;_D#?\%)
MO^S$_'7_ *6FOE.-_P#DE\R_QY;_ .K; 'T7"G_(_P #_AQG_J!BC\0+/_CS
MM/\ KV@_]%+5FJUG_P >=I_U[0?^BEJS7UCW?J_S/G%LO1?D%%%%(84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7[<?\&_O_)^VN_]FM_M$?\ J'BOQ'K]N/\ @W]_Y/VUW_LUO]HC
M_P!0\5\EQY_R1O$O_8HQ?_IMGT?"'_)49#_V,\+_ .G$?A[9?\>D'_7,5:JK
M9?\ 'I!_US%6J^M/FULO1?D%%%% PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OU<_X(?_ /*4/]F3
M_KZ\<_\ J&:K7Y1U^KG_  0__P"4H?[,G_7UXY_]0S5:^<XP_P"23XF_[$&;
M_P#J!B#V^&O^2CR'_L<Y9_ZFT3\\_CC_ ,EM^,?_ &5#QQ_ZD-]7E]>H?''_
M )+;\8_^RH>./_4AOJ\OKVL'_N>$_P"P:A_Z:B>5B/\ >*__ %^J_P#I<@HH
MHKI,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I(/^/NP_["6F
M_P#I?;5'4D'_ !]V'_82TW_TOMJ!K=>J_,_;G_@X-_Y2%?\ =OGP)_\ 4"T>
MOQ"K]O?^#@W_ )2%?]V^? G_ -0+1Z_$*ODN O\ DB^%_P#L29?_ .H\#Z'B
M[_DJ,_\ ^QIBO_2PHHHKZT^="BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /VN_: _Y0._\$Z_^SK/VGO\ T^^)Z_%&OVN_: _Y0._\$Z_^
MSK/VGO\ T^^)Z_%&ODN#O]SSG_LK>+/_ %?8X^BXE_WG*_\ LF^&_P#U38,*
M***^M/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^L;_
M (-0O^2Y?M>_]DK^'/\ ZEVJ5_;U7\0O_!J%_P ER_:]_P"R5_#G_P!2[5*_
MMZK^%_&W_DXV<_\ 8/E/_JKPA_6?A5_R166_]?\ ,?\ U/Q!_G;_ /!RE_RD
MRUC_ +([\./_ $V+7X#U^_'_  <I?\I,M8_[([\./_38M?@/7]:^'?\ R0O"
M?_8BR_\ ],1/YSXU_P"2NXC_ .QOC/\ TX%%%%?9GS 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'T-^R+_ ,G7_LR?]G ?"#_U/M!KZB_X+&?\
MI2?VX/\ LLW_ +I?A*OEW]D7_DZ_]F3_ +. ^$'_ *GV@U]1?\%C/^4I/[<'
M_99O_=+\)5\G4_Y+K!_]DCFG_JZR8^CI_P#)(XK_ +*/ ?\ JLS(_->BBBOK
M#YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _9W_@WR_Y2T_LW?\ 8L?'K_U2GC2OQUUS_D8/$O\ V,_B7_T^ZA7[
M%?\ !OE_REI_9N_[%CX]?^J4\:5^.NN?\C!XE_[&?Q+_ .GW4*^2P?\ R7'$
M'_9,<*?^K/BX^BQ/_)*9-_V/N(?_ % X;,RBBBOK3YT**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OUG_P""&?\ RE(_9H_W_'G_
M *A^H5^3%?K/_P $,_\ E*1^S1_O^//_ %#]0KYOC+_DD>)_^R?SC_U7X@]S
MAC_DI,@_['65_P#J;0/SZ_:*_P"3A?CO_P!E@^(?_J3:A7CM>Q?M%?\ )POQ
MW_[+!\0__4FU"O':]G ?[C@O^P3#?^F8'EXO_>L3_P!A%;_TY(****ZSG"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_;;
M_@C-_P @;_@I-_V8GXZ_]+37XDU^VW_!&;_D#?\ !2;_ +,3\=?^EIKY3C?_
M ))?,O\ 'EO_ *ML ?1<*?\ (_P/^'&?^H&*/Q L_P#CSM/^O:#_ -%+5FJU
MG_QYVG_7M!_Z*6K-?6/=^K_,^<6R]%^04444AA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?MQ_P &
M_O\ R?MKO_9K?[1'_J'BOQ'K]N/^#?W_ )/VUW_LUO\ :(_]0\5\EQY_R1O$
MO_8HQ?\ Z;9]'PA_R5&0_P#8SPO_ *<1^'ME_P >D'_7,5:JK9?\>D'_ %S%
M6J^M/FULO1?D%%%% PHHHH **AFN;>WV_:)X8-Y(7SI4BW$=0N]ER1D9QG&:
M26ZMH C3W,$*R<QM+-'&'P 3L+L V 0?ESP1ZBG9]GKMH!/13=Z;/,W+Y>W?
MOW#9LQNW[L[=NWG=G&.<XJ**ZMIU=X+B"98_OM%+'(J<$_.48A> 3R1P":0$
M]%4?[4TW_H(6/_@7;_\ QRK,-Q!<*6@FBG4'!:&1)5!]"4+ 'VIV?9_<.S6Z
M?W$M%%5YKNUMBHN+FW@+ E1--'$6 ZE0[+D#(SCI2$6**H_VIIO_ $$+'_P+
MM_\ XY5J*:*=/,@ECFC)(#Q.LB9'4;D)7([C- [-;I_<24444""BBH9KB"W4
M-<30P*3@--(D2D^@+LH)]A0!-12*RNJNC!E8!E92&5E(R"I&001R"."*9+-%
M GF3RQPQ@@%Y76- 3T&YR%R>PSD]J )**KM=VJQ+.US;K YPLS31B)CSPLA;
M83P> 2>#Z&ID=)%5XV5T895T8,K#U5E)!'N#0 ZBBB@ HHHH **** "BBB@
MK]7/^"'_ /RE#_9D_P"OKQS_ .H9JM?E'7ZN?\$/_P#E*'^S)_U]>.?_ %#-
M5KYSC#_DD^)O^Q!F_P#Z@8@]OAK_ )*/(?\ L<Y9_P"IM$_//XX_\EM^,?\
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M?_)"\)_]B++_ /TQ$_G/C7_DKN(_^QOC/_3@4445]F?,!1110 4444 %%%%
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M9D+(S2#]);C_ (.F_P!H2&ZNX!^R5^R&1;WEY;JS:GXV#,MO<RPJS?Z=C+A
MQ(P"3D  X'SA_P $S?VAM7_:P_X+K_!C]HKQ!X=\*^$=<^*?Q!\9:[JGACP3
M)<R^%M%N8/A%KVEBUTEKUY+OR7BL8[B3[0[2&>:0_=*TLLRC%<,X'B//*/!%
M/A?%8#AK-<1@\P_ULQ/$<:F(HT%7IT)X"N_9PBY455=647I2]CI[1CQ^.I9Y
MB\BRJKQ54S_"XS/LMHXG!_ZNX?)'3HU:RHSK1Q=%>TE)1J.DJ2:7O^T=_9I'
MKGAS_@V&_;^UW4O&-C??$/\ 9[\+VWAK5[K2M#U36]7\:/;^/XK2(.^K^&[3
M3_#5UJ-CI<LC"""3Q#:Z7+(^9!'Y(+C\?_$'[#G[3/AS]K23]B*Z^'ES=_M#
M_P#"4VGA:T\*Z?<P7-E?M?VJZE9:_;:LK_8QX<N-%==<_M.65(H-/.9S'*"E
M?T=?M&?&;XJR?\'-7P4T#_A/O$T6@>'O%_PQ\#:-H-OJMW;Z+9>%/$>BS?\
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M&)WBTR&WBC6VB=D3Y6(K[9_X)(65NG[<_P#P6UUG0[>P7XAV?Q*L+3PQ=>7
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MK7SG&'_))\3?]B#-_P#U Q![?#7_ "4>0_\ 8YRS_P!3:)^>?QQ_Y+;\8_\
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M6EDW>4?\%#O%OB+X@_\ !N)^Q[XS\::K=>)/%6KP_!*YU+7M6E>^U2\NDO\
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MU7*5#^SZM1U&H4ZDU4K0IQS7 F#KYQDV&>'Q&"R[%T<QQ&)QF'S; YG@L7'
M4Y5U3R_&*G1]A5J4TE5^N0BJ:;J1BXTY2?X)_M7?\$-/^"@/['WPNU3XR?$'
MPAX&\<^ O#R?:/%6H_"#Q1J7B^]\)Z;O2-]:UW2=0\.Z!J$>CPR21K=7UA!?
M1VBOY]T(;>.6:/YB_8Q_X)X_M+_MWS^,Y_@=HWA:P\(?#NT6[\<?$[XD>)$\
M&_#;PP9+9[R*SU+Q&UGJ#B]DLXWO#%!93)!:J9[F6"/YJ_I'_8)_;Q_X)E?L
M>>'/CCX4\=?\%2?CU^UMX"^.6GW$>N>'OBS^SM\7FM-!U/5K6_M/$&I6FHOH
MNNRPIXCL-2N+?4]&=K33W"Q/%!&8V!^(?V&OV2/BOX^_81_:+^+?Q4_;R\9_
MLE?\$P[CQE\16NO!OA#PI::]JGQ,TE/$@M=2N[W1AIT6N+INK(MCI=I96E_>
M:M>2VZVEOI;6J-M[Z'&?$^&RW-Z><>QP-?#9AE&$RG/<;PSQ#E]+-89FY>VP
M^"R"M0ECL9FN%E2G2I8:G.%*M[2G4J3A"#=3DK<+9!6S#+7EDZF+H5L'F6(S
M'*L-GF38NK@'@%!TJV*S>G46$PN Q$:L)U*U6$JE+DG",92DN3\^/VH_^"0/
M[8O[)_P:M_V@_%</PI^*?P8:<0ZK\0O@+\0%^(^@>&T>XBM(+W7K@:3I!ATV
MYO)DLX]0L%U"UCNR(+J6W=HP_/?LK_\ !*C]K']K;X7:A\</""?"WX6_!FSU
M0Z+8_%'X_?$"V^&/@_Q%JB2>3/:^'+ZYL-2GU$03XMS=-;6]E-/F.TN;EHY
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M(\5&%&=;!\)YKBL.ZU&E7A3KT:V"E3J>SK0G3;B_YHM-7333:/4?V1OV@?\
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M&26)V1U*L0>,L_\ CSM/^O:#_P!%+7<?#O\ Y*/\-_\ LHO@3_U*](KZBO\
MPZW^"I_Z2SP*'\2C_CI_FC^D[_@YI^"/P8^"OQ,_92LO@W\)/AK\)[/7O!'C
M:ZURU^&_@CPYX*MM9N+?4;%;:?5(?#NGZ?'?S6R,R02W2RR1HQ"MR2?Y@NX
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MJT\%:C>Z'JE[#'<-:W7BSX@^$_'&HZ_X@>-VN=1T^Q71[#3KAOL=ND: )'\
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MI2E%0_).OVX_X-_?^3]M=_[-;_:(_P#4/%?B/7[<?\&_O_)^VN_]FM_M$?\
MJ'BOON//^2-XE_[%&+_]-L^/X0_Y*C(?^QGA?_3B/P]LO^/2#_KF*M55LO\
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M56!MHI;BZC.FMHFD6KW5M!!-))IZZA_:+B-A!9S/A:_1W]E__@J_^P;\!_\
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M,LSDHJ&89I6@DH149^PIT,/4K8BK>":4/?\ PN_;1_X)]?M/?L$>,O#O@_\
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MNP_["6F_^E]M4=20?\?=A_V$M-_]+[:@:W7JOS/VY_X.#?\ E(5_W;Y\"?\
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M@'Q-);*KWMCI6O\ V2QD35+%'22YTS4K'3[X1,9X8)H$>1?$OV;OA9H?QO\
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MW2K<LG&4:E*22OS3^4XJRK)<O678C)L72G'&4ZZQ>7K-,#FU7 5J$X1@Y8O
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MR_:]_P"R5_#G_P!2[5*_MZK^%_&W_DXV<_\ 8/E/_JKPA_6?A5_R166_]?\
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M+U[##RC"AC)2EB:-:,J;CB85>:2E&NJFCLK']-_[/_\ P7=_9-_9B^'WQ,^
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MAE\<LQ%"<J:IJ,E#,*:J8+$I0E!XK"5>>=.<4XQE2A(_3G_@NE^U]XH^"?\
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MX.665:M;!4L!A,)@L-1K5_\ >*CPV&HTZ%2>(C[E9U:<_:4VX/W9-/\ I?\
MC3_P7G_9OU+X&_%/X4_LR?\ !,[X4?"'6OB^;Y_%FK>,]/\ ASX@\*7%_JEO
M<V]UXDO?#/AKPWI7]N>)+87=Q-IUUJCR6\=P^^>%T=U/S!^P_P#\%>_!_P
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M#2+_ $GPU\0(M/%H(]6L'NK75+&XLWTBZAF0O:>;&#7J?PQ_X+"_L:?L@_\
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MGF+KX?$U9TL9CL/0Q&)PB4<-B,5@Z&(IX7$5J,4E&=6C)M*TN97OWX;B[/\
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MN+/][Q?_ "/4FEB_XWP6;7U;_=O^G)E_K1G7_03#_D1_ZN?[OA_^12VF\/\
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M%JB^"= T6]2WO[*_NGANYYI!97)BNH%2>%'KW+6/^"[/[(5I^TG9_MG^!?\
M@FH;/]J:_CT/1/%WQ"\5?%>"^TN3PS&HM_$]WX7\.Z5;VVFZ?X[U'3\V.F>*
M;VS>98=J:L;Q.!_,G16D_#CA2I"E"IA,?-TL)B,!*I+.LY]OB<!B:SQ%7!8V
MNL<JV,PCK-SC0Q,ZE.%W&$8Q?*1'C?B&G.K.%?!P]IB*&+C3CE>6^QP^+P])
M4:>*PE%X5TL+B?9I1E6HQA.5KMMI-?L=^T/_ ,%6-+^(G_!3'X9_\%'_ (._
M!S7/!>N>!_\ A&9]9^'7Q#\4:7XCM-=O=%TJ\\,:B+'4_#UGIO\ 9]GJ/AFZ
M$4"3"::VU=#=-(;8B$?2_P"V#_P6H_9M_::^,G[-/Q[\-?L+3?#KXK_!3X]_
M#SXM>.?B')XB\"W?CSXC^$/ *77D_#J/Q3IN@6VH16T\URL]K+K#WEC:26L#
M"V!W5_.U172^ ^&7/*JGU*LJF399/)L!4CC\?"4<LG&</J==PQ,?K5**J3Y/
MK*JRBWS)\RBU@N+\]4<QA]9HN&:8^&:8N$L'A)1>/A*$OK-%2HOZO4DZ<%/V
M/(I15FK-W_8G]M__ (*V^*OVBOV[?A-^W3^S_P"#->^!'C7X0^&M$T?0]*\4
MZUH_C$7U[I5[=378U'^S;.SL;G0M8L+N73;[39XI'*.TZN)$A*?ILG_!R-\"
M-=U#P_\ &/X@?\$U_!?B+]K+PSX<FTS1OB_;:QX->TTS51!.EHVE:EJV@W?C
MRPT))9<R6<>MF_6 R1V]U$Q0Q_R@45SXKPYX0QN$RS!5\LFZ648-Y?@ITL=C
M\/B(X"4I2G@JV)H8FG7Q6&E*4FZ6(J58WE*R7-*^N'XVXDPN)Q^*I8^/M,RQ
M*QF*A4PF$K4'BXI*.*HT*M"=+#UXJ*2J4(4Y62O?EC;](;C_ (*3_%+XB_\
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M1110 4444 %%%% !7ZN?\$/_ /E*'^S)_P!?7CG_ -0S5:_*.OU<_P""'_\
MRE#_ &9/^OKQS_ZAFJU\YQA_R2?$W_8@S?\ ]0,0>WPU_P E'D/_ &.<L_\
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MR>:8/!5\OP]?VM51AA,3-5*U-T5-49.4TGSR@YQVC)+0]"&:8VGEF(R>%5+
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MMC;6]KJGAN3P%J&F/K$N@W4.G:;;Z?9WU]*EM;)<Q7(F#P^7T'Q)_P""M/[
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MP)^TGX.\1_!CQ5\5Y_CWHFF:18ZAX=\6Z'X9A\-?8-)\2:;)+?0:OI]])?\
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MZ\4I?:A_:.J::-<E=@+'6I4@75+F_:ZU)XX%CM[B*)FCKU3]BG_@N39?!/\
M9@M/V/?VOOV7]"_;$^"?AH&W\$V.MWGAX:CI^CB[>_M/#_B"S\7Z9K&BZW8:
M/>2SOHMT;5-1M+><V9N&M;:UBC_G\HK2KP'PO7RV65ULOG5H3S%YO/$3QV/E
MF4LTDK2Q\LT>)_M!XIQ]QU?K-_9^Y\.A%/B_/Z6.CF%/&QA5C@UET:$<+A(X
M&.7Q::P2P"HK!K#J2YO9^Q^/WKWU/V7_ ."F7_!5WP?^W5X)^'GPB^$_[)7P
MW_9W^%_PZ%D^D7#:9X9U?XC6R:?";>S\/Z%K^A:9ING^&O"4*-(\FFZ5;13W
M9<P74TL#,I_/']DGXN?#WX"?M)?"#XU?%+X=:A\6?!?PQ\6VWB^_^'>FZCIF
ME2^)[[3+>X;1K:>]UBUO+%+.UU5[349TDMV:4V:(C(QW#YVHKU,!PYE.69-4
MR' T*M#+JM+$TJD%BL5.O-8M26(F\74K3Q7MJG/)^U595(.SA*+2MYV,SK,<
M?F<,WQ=6G5QM.I0J0E]7H1HQ>&<70@L-"G'#^SAR17L_9\DE=23N[_UM_&/_
M (.(?V%/VA[[0M2^._\ P2M7XP7_ (8M;JR\.W?Q&\1?";Q=-H=I?21RWD&E
MMK?A2\^Q1W,D,33+;^7YAC7=G%?A5_P41_:J_9I_:Q^(GP_\6?LR?LCZ!^R#
MX:\+>#;[P_XF\)>'HO!\-MXNURYUJ74+;Q%/'X,TC1[$36E@Z::INH);DHGR
MRB/Y1^?-%>1D7 7#G#>)H8G**.84)8>%6G1HU,XS7$X2G&M&4:B6#Q&,JX6[
MYY23=*\9OGC:=I'IYOQAG>>4*M#,JF"K*M.G.K5AEF7T,3.5)Q<+XJCAX8C3
MDBFE42E%<DKP]T****^S/EPHHHH _:[]H#_E [_P3K_[.L_:>_\ 3[XGK\4:
M_:[]H#_E [_P3K_[.L_:>_\ 3[XGK\4:^2X._P!SSG_LK>+/_5]CCZ+B7_><
MK_[)OAO_ -4V#"BBBOK3YT*_9W_@GQ_P58\)_L1_LC_M2?LS:Y\$_%?Q%U+]
MHF]UN[L/%VA^+]"T'3?"XU7P)!X.ACO],U+3KN\U!K:XA.H2M:S1"6!A;IY<
MH,E?C%17E9SDN79_@O[/S2C+$81U\-B?9QJU:+]MA*T,10EST9TYVA5IQDX\
MW+)+EDFFT>CE>:XW)\5]<P%6-'$>QKT.>5.G57LL12E1JQY*L9Q]ZG*2O:\;
MWBT]2*",Q0Q1$[C'&B$@8SM4#./?%??'_!-/]LO1OV!?VN?!G[3>O^ -9^)N
MF>%?"WCKP[)X0T#6]/\ #VIWDOC#09-'@O(]4U2VN[..*P=_/FA>$O.@V1NK
M<U\&45TYC@,+FN QF68ZFZN#Q^&K83%4E.I2=2A7@Z=6"J4I0J0<H2:4H2C*
M.\6GJ88'&8C+L9A<=A)*GB<'7I8G#S<8S4*M&:G3DX34HR2E%-QDFGLTT?K5
MHW_!2[PQI7_!5^[_ ."DC?"#Q/+X:N?&E_XL7X2+XIT5?$D:7GA.;PTMFWB<
MV']CM)'/*+UI!8A6A!@ $AWU] >&O^"X?B#X>_\ !3'XF_MY_#_X.7L'@+XQ
M^$M&\"?$'X+^)?$>F7NLW_A_2H;21)]-\46%G#866KV^JV5OJ%C,;1H?*1K*
M\6>&60-^"M%>!7X)X:Q5EB,N]M'^P*?#/)4Q&)E!Y-2G"I2PSC[:WM*=2G"I
M#%?[U&<5)5DTF>O1XJSS#_P,;[)O.9Y_S0HT%+^TZD'3J5K^SO[.<)2C+#_P
M'%M.G8_IU^#?_!=S]CG]F?XY>,?C+^SK_P $T[KP)J/QHU36=6^.NL7OQ8L]
M0\7:O-.!=Z-9?#O_ $5_#?@_1UUJ2[U'7]*2P2QO_-B-G;VMPC3/\=_ ?_@K
MGX._9^_:Z_:6^.NC?LG>#?B5\)?VEO%6HZ_K7@CXJ#PYK'Q7\(6.NPSIXATC
MPY\1+/2X[$6.KG4-3MKG3;FQDTR:PFMUF@>XA:1OQ.HKDI>'O"M)8Y/!XNN\
MRP-#+L=/%9MFN*JXC"X6I"KA8RK5\9.K">&=.G"A4ISA.G2A&E%JG[ITU.-.
M(*CPC6)PU%8#%U<=A(8?+LOH4Z->O3=.NXTJ6&C3E"NI3G5A.,HSJ3E4:Y[-
M?T*_#+_@L+^QO^R##\6/&7_!/_\ X)VZG\$OCK\5=-FT>Z\>_$GXRWGQ!\.:
M%87,\]VZ:1X<24R:?':WTL=Y9V&FR6>G&6".*ZMYK;]V/D__ ()T?\%;OC1^
MP5\6?BCXSU30[?XV> /CSJ-UK?QF^'^MW<>GR:[XDO+N\O+CQ7H5V\<MCINM
MW)U&_M;^*XMIM-U&RN5BO+>4VMJ8_P FJ*Z8\#<-/"YGA,1@:N/AG,,/3S*M
MF6/Q^8XS$T\'9X2#QN,Q-;%4XX645+#JE5I^RFE.%I*YA+BS/?K&7XFCBJ>#
MEE<ZU3 TL#A,)@\+0GB/]YE]5P]&GAYO$KW:_M*<_:0;C*\6T?TG?'O_ (+L
M_LZ>(/V??B5\$?V7_P#@FM\)_@O<?%>34)?%.I^,=,^'7B'PP+W5;>:VO/$T
M?A?PSX<TN+4_%D"7$[Z??ZL9[>&:0R21-E@?YKRH965P&5]^Y=H"D.264*/E
M5.2JH!M5,*!@4ZBN_(>&LHX:HXBCE%"M26+K+$8FIB,9C,;7K58P4(RG7QE>
MO5?+!<L4I**70Y,XSW,L]JT:N8U:=1X>E[&A"CAL/A:5*FY<TE"EAJ5*"YI>
M])N+;?6UD?T)?L:?\%UK'X1_LP6/[(/[9?[+6@?MC?!WPG!:V7@*+5KOP\NJ
M6VDVMXU]9Z+XNLO&6F:SHFO6NA3,1X>OXK2'5;:%_LMQ<RVUM:1Q_.7_  4X
M_P""O7C[_@H1I/@KX4>%OAMIOP"_9K^'$]M>^%_A5I%];WM[J6HV=J+/3KGQ
M1=Z;!9Z/+:Z% !'H&E:58VEA8D?:/)-S^\/X]45Y^&X$X5P>=//\/E4*>8_6
M*V,@_K&*EA:.-Q,5'$8S#X"5>6"H8JLOCK4J$9W;DFI:KLK\7<08C*UD];,)
M3P2HTL-+]S06)JX6@[T<+6QD:2Q57#TG\-*I5E&VCNM HHHKZX^;"BBB@#^L
M;_@U"_Y+E^U[_P!DK^'/_J7:I7]O5?Q"_P#!J%_R7+]KW_LE?PY_]2[5*_MZ
MK^%_&W_DXV<_]@^4_P#JKPA_6?A5_P D5EO_ %_S'_U/Q!_G;_\ !RF<?\%,
MM8S_ -$=^''_ *;%K\!MP]1^=?W@_P#!3#_@AK\<?V[OVE5^.F@_%3X;>&[,
M_#OP5X1GM/$EIKM[JEWJ7A_2H;74;]Y+&%8$AN+M96A0;F,9#L4)V#\^_P#B
M%I_:+_Z+M\%__!1XJ_\ C5?N7!WBEP5E'"O#^68W.*=+%X'*L'AL335#%SY*
MM*G&$X\T,-*+L[O236A^4\3>'O%>9<0YSF&$R[GPV,S'$XBC-U\+!RIU*EXO
MEG7C):7T<4]-MC^4+</4?G1N'J/SK^KW_B%I_:+_ .B[?!?_ ,%'BK_XU1_Q
M"T_M%_\ 1=O@O_X*/%7_ ,:KZ7_B,G '_0[A_P"$V.\O^H7S?W'A_P#$+^,_
M^A7_ .7.#\K_ /,3Z_=]_P#*%N'J/SHW#U'YU_5[_P 0M/[1?_1=O@O_ ."C
MQ5_\:H_XA:?VB_\ HNWP7_\ !1XJ_P#C5'_$9. /^AW#_P )L=Y?]0OF_N#_
M (A?QG_T*_\ RYP?E?\ YB?7[OO_ )0MP]1^=&X>H_.OZO?^(6G]HO\ Z+M\
M%_\ P4>*O_C5'_$+3^T7_P!%V^"__@H\5?\ QJC_ (C)P!_T.X?^$V.\O^H7
MS?W!_P 0OXS_ .A7_P"7.#\K_P#,3Z_=]_\ *%N'J/SHW#U'YU_5[_Q"T_M%
M_P#1=O@O_P""CQ5_\:H_XA:?VB_^B[?!?_P4>*O_ (U1_P 1DX _Z'</_";'
M>7_4+YO[@_XA?QG_ -"O_P N<'Y7_P"8GU^[[_Y0MP]1^=&X>H_.OZO?^(6G
M]HO_ *+M\%__  4>*O\ XU1_Q"T_M%_]%V^"_P#X*/%7_P :H_XC)P!_T.X?
M^$V.\O\ J%\W]P?\0OXS_P"A7_Y<X/RO_P Q/K]WW_RA;AZC\Z-P]1^=?U>_
M\0M/[1?_ $7;X+_^"CQ5_P#&J/\ B%I_:+_Z+M\%_P#P4>*O_C5'_$9. /\
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M^OW??_*%N'J/SHW#U'YU_5[_ ,0M/[1?_1=O@O\ ^"CQ5_\ &J/^(6G]HO\
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M7S?W!_Q"_C/_ *%?_ES@_*__ #$^OW??_*%N'J/SHW#U'YU_5[_Q"T_M%_\
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M?VB_^B[?!?\ \%'BK_XU1_Q"T_M%_P#1=O@O_P""CQ5_\:H_XC)P!_T.X?\
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M^X\S_B%_&?\ T*__ "YP?E?_ )B?7[OO_E"W#U'YT;AZC\Z_J]_XA:?VB_\
MHNWP7_\ !1XJ_P#C5'_$+3^T7_T7;X+_ /@H\5?_ !JC_B,G '_0[A_X38[R
M_P"H7S?W!_Q"_C/_ *%?_ES@_*__ #$^OW??_*%N'J/SHW#U'YU_5[_Q"T_M
M%_\ 1=O@O_X*/%7_ ,:H_P"(6G]HO_HNWP7_ /!1XJ_^-4?\1DX _P"AW#_P
MFQWE_P!0OF_N#_B%_&?_ $*__+G!^5_^8GU^[[_Y0MP]1^=&X>H_.OZO?^(6
MG]HO_HNWP7_\%'BK_P"-4?\ $+3^T7_T7;X+_P#@H\5?_&J/^(R< ?\ 0[A_
MX38[R_ZA?-_<'_$+^,_^A7_Y<X/RO_S$^OW??_*%N'J/SHW#U'YU_5[_ ,0M
M/[1?_1=O@O\ ^"CQ5_\ &J/^(6G]HO\ Z+M\%_\ P4>*O_C5'_$9. /^AW#_
M ,)L=Y?]0OF_N#_B%_&?_0K_ /+G!^5_^8GU^[[_ .4+</4?G1N'J/SK^KW_
M (A:?VB_^B[?!?\ \%'BK_XU1_Q"T_M%_P#1=O@O_P""CQ5_\:H_XC)P!_T.
MX?\ A-CO+_J%\W]P?\0OXS_Z%?\ Y<X/RO\ \Q/K]WW_ ,H6X>H_.C</4?G7
M]7O_ !"T_M%_]%V^"_\ X*/%7_QJC_B%I_:+_P"B[?!?_P %'BK_ .-4?\1D
MX _Z'</_  FQWE_U"^;^X/\ B%_&?_0K_P#+G!^5_P#F)]?N^_\ E"W#U'YT
M;AZC\Z_J]_XA:?VB_P#HNWP7_P#!1XJ_^-4?\0M/[1?_ $7;X+_^"CQ5_P#&
MJ/\ B,G '_0[A_X38[R_ZA?-_<'_ !"_C/\ Z%?_ )<X/RO_ ,Q/K]WW_P H
M6X>H_.C</4?G7]7O_$+3^T7_ -%V^"__ (*/%7_QJC_B%I_:+_Z+M\%__!1X
MJ_\ C5'_ !&3@#_H=P_\)L=Y?]0OF_N#_B%_&?\ T*__ "YP?E?_ )B?7[OO
M_E"W#U'YT;AZC\Z_J]_XA:?VB_\ HNWP7_\ !1XJ_P#C5'_$+3^T7_T7;X+_
M /@H\5?_ !JC_B,G '_0[A_X38[R_P"H7S?W!_Q"_C/_ *%?_ES@_*__ #$^
MOW??_*%N'J/SHW#U'YU_5[_Q"T_M%_\ 1=O@O_X*/%7_ ,:H_P"(6G]HO_HN
MWP7_ /!1XJ_^-4?\1DX _P"AW#_PFQWE_P!0OF_N#_B%_&?_ $*__+G!^5_^
M8GU^[[_Y0MP]1^=?K3_P0Q!?_@J3^S.J@L2_CS 49)_XH_4>PYK]5/\ B%I_
M:+_Z+M\%_P#P4>*O_C5=U\-/^#;[]M+X)>-]#^)WPD_:9^%'A'Q_X:FD?1?$
M&E6OBK3K^Q2[3[-?K!=FPOA$;BS>6%LVTFY6V_)G>/*SSQ3X$S;)<VRNCGU"
ME6S++<;@:52KA\<J=.IB\-.A"=1K"74(RJ7E;6T7;4]#*?#SB_+LTRW,*N4S
MJ4\#C\'BZD*>)P3J3AAJ]*M*$$\3;FDH24;Z7L?RU_M%?\G"_'?_ ++!\0__
M %)M0KQVO[Y;S_@V8_94\57=SXG\:?$SXEW/C+Q'/)K?BRZL9]*-E<^)-38W
M>LW%H9;!)?LTM_+.\/F*K^65+ $D"O\ \0O7[%W_ $47XJ_]_M&_^0ZX,-X]
M<#T,/0H2I9ZY4:-*E*4<!AW%NG"$'*+^O:Q;3:O9V6J6MNJMX0<5UJU6K&KD
M\55J3J)2QE=22G+F2DE@VDTI6=F[-/5V/X(J*_O=_P"(7K]B[_HHOQ5_[_:-
M_P#(='_$+U^Q=_T47XJ_]_M&_P#D.MO^(_\  W_/C/\ _P -^'\O^H[S?W&?
M_$'.+/\ G]DW_A;B/+_J"\_P?8_@BHK^]W_B%Z_8N_Z*+\5?^_VC?_(='_$+
MU^Q=_P!%%^*O_?[1O_D.C_B/_ W_ #XS_P#\-^'\O^H[S?W!_P 0<XL_Y_9-
M_P"%N(\O^H+S_!]C^"*BO[W?^(7K]B[_ **+\5?^_P!HW_R'1_Q"]?L7?]%%
M^*O_ '^T;_Y#H_XC_P #?\^,_P#_  WX?R_ZCO-_<'_$'.+/^?V3?^%N(\O^
MH+S_  ?8_@BHK^]W_B%Z_8N_Z*+\5?\ O]HW_P AT?\ $+U^Q=_T47XJ_P#?
M[1O_ )#H_P"(_P# W_/C/_\ PWX?R_ZCO-_<'_$'.+/^?V3?^%N(\O\ J"\_
MP?8_@BHK^]W_ (A>OV+O^BB_%7_O]HW_ ,AT?\0O7[%W_11?BK_W^T;_ .0Z
M/^(_\#?\^,__ /#?A_+_ *CO-_<'_$'.+/\ G]DW_A;B/+_J"\_P?8_@BHK^
M]W_B%Z_8N_Z*+\5?^_VC?_(='_$+U^Q=_P!%%^*O_?[1O_D.C_B/_ W_ #XS
M_P#\-^'\O^H[S?W!_P 0<XL_Y_9-_P"%N(\O^H+S_!]C^"*BO[W?^(7K]B[_
M **+\5?^_P!HW_R'1_Q"]?L7?]%%^*O_ '^T;_Y#H_XC_P #?\^,_P#_  WX
M?R_ZCO-_<'_$'.+/^?V3?^%N(\O^H+S_  ?8_@BHK^]W_B%Z_8N_Z*+\5?\
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M;^X/^(.<6?\ /[)O_"W$>7_4%Y_@^Q_!%17][O\ Q"]?L7?]%%^*O_?[1O\
MY#H_XA>OV+O^BB_%7_O]HW_R'1_Q'_@;_GQG_P#X;\/Y?]1WF_N#_B#G%G_/
M[)O_  MQ'E_U!>?X/L?P145_>[_Q"]?L7?\ 11?BK_W^T;_Y#H_XA>OV+O\
MHHOQ5_[_ &C?_(='_$?^!O\ GQG_ /X;\/Y?]1WF_N#_ (@YQ9_S^R;_ ,+<
M1Y?]07G^#['\$5%?WN_\0O7[%W_11?BK_P!_M&_^0Z/^(7K]B[_HHOQ5_P"_
MVC?_ "'1_P 1_P"!O^?&?_\ AOP_E_U'>;^X/^(.<6?\_LF_\+<1Y?\ 4%Y_
M@^Q_!%17][O_ !"]?L7?]%%^*O\ W^T;_P"0Z/\ B%Z_8N_Z*+\5?^_VC?\
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ME_U'>;^X/^(.<6?\_LF_\+<1Y?\ 4%Y_@^Q_!%17][O_ !"]?L7?]%%^*O\
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M7_4=YO[@_P"(.<6?\_LF_P#"W$>7_4%Y_@^Q_!%17][O_$+U^Q=_T47XJ_\
M?[1O_D.C_B%Z_8N_Z*+\5?\ O]HW_P AT?\ $?\ @;_GQG__ (;\/Y?]1WF_
MN#_B#G%G_/[)O_"W$>7_ %!>?X/L?P145_>[_P 0O7[%W_11?BK_ -_M&_\
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M]7O+C4M4NY=+\52RW6H7LK7%Y<22>1'ODFGDDD9MB;BQ;:N<"G_Q"T_M%_\
M1=O@O_X*/%7_ ,:KZJAXP< TJ%&D\\IMTJ5.FVL-CK-PA"+:_P!EVO=KR1\_
M5\,N,JE6I465V4ZDYI/$X.Z4I<R3_P!IW2;OYH_E"W#U'YT;AZC\Z_J]_P"(
M6G]HO_HNWP7_ /!1XJ_^-4?\0M/[1?\ T7;X+_\ @H\5?_&JV_XC)P!_T.X?
M^$V.\O\ J%\W]Q'_ !"_C/\ Z%?_ )<X/RO_ ,Q/K]WW_P H6X>H_.C</4?G
M7]7O_$+3^T7_ -%V^"__ (*/%7_QJC_B%I_:+_Z+M\%__!1XJ_\ C5'_ !&3
M@#_H=P_\)L=Y?]0OF_N#_B%_&?\ T*__ "YP?E?_ )B?7[OO_E"W#U'YT;AZ
MC\Z_J]_XA:?VB_\ HNWP7_\ !1XJ_P#C5'_$+3^T7_T7;X+_ /@H\5?_ !JC
M_B,G '_0[A_X38[R_P"H7S?W!_Q"_C/_ *%?_ES@_*__ #$^OW??_*%N'J/S
MHW#U'YU_5[_Q"T_M%_\ 1=O@O_X*/%7_ ,:H_P"(6G]HO_HNWP7_ /!1XJ_^
M-4?\1DX _P"AW#_PFQWE_P!0OF_N#_B%_&?_ $*__+G!^5_^8GU^[[_Y0MP]
M1^=&X>H_.OZO?^(6G]HO_HNWP7_\%'BK_P"-4?\ $+3^T7_T7;X+_P#@H\5?
M_&J/^(R< ?\ 0[A_X38[R_ZA?-_<'_$+^,_^A7_Y<X/RO_S$^OW??_*%N'J/
MSHW#U'YU_5[_ ,0M/[1?_1=O@O\ ^"CQ5_\ &J/^(6G]HO\ Z+M\%_\ P4>*
MO_C5'_$9. /^AW#_ ,)L=Y?]0OF_N#_B%_&?_0K_ /+G!^5_^8GU^[[_ .4+
M</4?G1N'J/SK^KW_ (A:?VB_^B[?!?\ \%'BK_XU1_Q"T_M%_P#1=O@O_P""
MCQ5_\:H_XC)P!_T.X?\ A-CO+_J%\W]P?\0OXS_Z%?\ Y<X/RO\ \Q/K]WW_
M ,H6X>H_.C</4?G7]7O_ !"T_M%_]%V^"_\ X*/%7_QJC_B%I_:+_P"B[?!?
M_P %'BK_ .-4?\1DX _Z'</_  FQWE_U"^;^X/\ B%_&?_0K_P#+G!^5_P#F
M)]?N^_\ E"W#U'YT;AZC\Z_J]_XA:?VB_P#HNWP7_P#!1XJ_^-4?\0M/[1?_
M $7;X+_^"CQ5_P#&J/\ B,G '_0[A_X38[R_ZA?-_<'_ !"_C/\ Z%?_ )<X
M/RO_ ,Q/K]WW_P H6X>H_.I("/M=AR/^0EIO_I?;U_5S_P 0M/[1?_1=O@O_
M ."CQ5_\:H_XA:OVC4*NGQV^"^^-DEC/]D>*AB2)A)&0?*P"KJI&>,CFE_Q&
M3@#_ *'=/_PFQWE_U">;^X%X8<9JS_LM=/\ F)P?E_U$^OW??\ _\'!P*_\
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MU1_Q&3@#_H=P_P#";'>7_4+YO[@_XA?QG_T*_P#RYP?E?_F)]?N^_P#/+]H
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MO_C5>U_Q&3@#_H=P_P#";'>7_4+YO[CS/^(7\9_]"O\ \N<'Y7_YB?7[OO\
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M%_\ 1=O@O_X*/%7_ ,:H_P"(R< ?]#N'_A-CO+_J%\W]P?\ $+^,_P#H5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &I]Q?]U?Y"G4U/N+_NK_ "%.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :>H_S_ !+3J:>H
M_P _Q+3J (XON#_/85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K
M_=/X?S%.IK_=/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &I]Q?]U?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :/O'\?Y)3J:/O'\?Y)3J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IZC_/\2TZFGJ/\_Q+3J (
MXON#_/85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/X?S%.IK
M_=/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_P"ZO\A3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^
M\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* &GJ/\ /\2TZFGJ/\_Q+3J (XON#_/85)4<7W!_GL*DH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0]#]#_ "H'3\3_ #-!Z'Z'^5 Z
M?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &O\ =/X?S%.IK_=/X?S%.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ&YG2UMY[F0,8[>&6=P@
MRQ2%&D8*"0"Q53@$@$XY% $U%?S$7_\ P=K?\$J--OKS3KR']I2"[L+JXL[J
M"7X/V\,L-Q;2O#-%)%-XLCFBDCD1D>.6-)$8%9$5@5%3_B+C_P""3_I^TA_X
M:.R_^:^OTY>"WBW)*4?#CC)QDDXM9!F#332::?L-4TTT^MT<?]H8#_H,P_\
MX-A_GYH_J"HK^7W_ (BX_P#@D_Z?M(?^&CLO_FOH_P"(N/\ X)/^G[2'_AH[
M+_YKZ?\ Q!7Q<_Z-OQG_ .&#,?\ Y1YK[P_M' ?]!F'_ /!T/\_-?>?U!45_
M+[_Q%Q_\$G_3]I#_ ,-'9?\ S7T?\1<?_!)_T_:0_P##1V7_ ,U]'_$%?%S_
M *-OQG_X8,Q_^4>:^\/[1P'_ $&8?_P=#_/S7WG]05%?R^_\1<?_  2?]/VD
M/_#1V7_S7T?\1<?_  2?]/VD/_#1V7_S7T?\05\7/^C;\9_^&#,?_E'FOO#^
MT<!_T&8?_P '0_S\U]Y_4%17\OO_ !%Q_P#!)_T_:0_\-'9?_-?1_P 1<?\
MP2?]/VD/_#1V7_S7T?\ $%?%S_HV_&?_ (8,Q_\ E'FOO#^T<!_T&8?_ ,'0
M_P _-?>?U!45_+[_ ,1<?_!)_P!/VD/_  T=E_\ -?1_Q%Q_\$G_ $_:0_\
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M_P#!)_T_:0_\-'9?_-?1_P 05\7/^C;\9_\ A@S'_P"4>:^\/[1P'_09A_\
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MYK[P_M' ?]!F'_\ !T/\_-?>?U!45_+[_P 1<?\ P2?]/VD/_#1V7_S7T?\
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MS\U]Y_4%17\OO_$7'_P2?]/VD/\ PT=E_P#-?1_Q%Q_\$G_3]I#_ ,-'9?\
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M ,$G_3]I#_PT=E_\U]'_ !%Q_P#!)_T_:0_\-'9?_-?1_P 05\7/^C;\9_\
MA@S'_P"4>:^\/[1P'_09A_\ P=#_ #\U]Y_4%17\OO\ Q%Q_\$G_ $_:0_\
M#1V7_P U]'_$7'_P2?\ 3]I#_P -'9?_ #7T?\05\7/^C;\9_P#A@S'_ .4>
M:^\/[1P'_09A_P#P=#_/S7WG]05%?R^_\1<?_!)_T_:0_P##1V7_ ,U]'_$7
M'_P2?]/VD/\ PT=E_P#-?1_Q!7Q<_P"C;\9_^&#,?_E'FOO#^T<!_P!!F'_\
M'0_S\U]Y_4%17\OO_$7'_P $G_3]I#_PT=E_\U]'_$7'_P $G_3]I#_PT=E_
M\U]'_$%?%S_HV_&?_A@S'_Y1YK[P_M' ?]!F'_\ !T/\_-?>?U!45_+[_P 1
M<?\ P2?]/VD/_#1V7_S7T?\ $7'_ ,$G_3]I#_PT=E_\U]'_ !!7Q<_Z-OQG
M_P"&#,?_ )1YK[P_M' ?]!F'_P#!T/\ /S7WG]05%?R^_P#$7'_P2?\ 3]I#
M_P -'9?_ #7T?\1<?_!)_P!/VD/_  T=E_\ -?1_Q!7Q<_Z-OQG_ .&#,?\
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M?1_Q%Q_\$G_3]I#_ ,-'9?\ S7T?\05\7/\ HV_&?_A@S'_Y1YK[P_M' ?\
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MH :GW%_W5_D*=34^XO\ NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ=UCXU^!K>5] ETV*TT;QMJ/A^;XN+>J(()(]3N-/.AM<O'&T::?+*RPO\
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K_=/X?S%.IK_=/X?S%.H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K.UC_ )!.J?\ 8.O?_2:6M&L[6/\
MD$ZI_P!@Z]_])I::W7JOS _PP/B;_P E(^('_8[>*O\ T^7U</7<?$W_ )*1
M\0/^QV\5?^GR^KAZ_P!Z\N_Y%^!_[ \-_P"F8'Y@]WZO\PHHHKL$%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^\?Q_DE.H
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M !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110!^9/\
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M;ZXU34[V]U;6KS4=:UG5]6U.[NM2U?6=8U"^U75M1NKF_P!1O+F\N)IG]]H
M**** "BBB@ K.UC_ )!.J?\ 8.O?_2:6M&L[6/\ D$ZI_P!@Z]_])I::W7JO
MS _PP/B;_P E(^('_8[>*O\ T^7U</7<?$W_ )*1\0/^QV\5?^GR^KAZ_P!Z
M\N_Y%^!_[ \-_P"F8'Y@]WZO\PHHHKL$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\1:3X=U;4-(M]5N]+O[O3;^\2PFLTG):&^DAN%A7S9$53FOXL/\ @XL_9O\
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M%F_,'@CX5>#M9\8ZG:6=Q9+K&MP:-927SZ7X>M;NX@_M35KJ*-OLMC:F:ZG
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M03>[MNWYMW?;730****^<-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB++>W.;1$NTU+7!%9W4;/>09CVE8Y48 ^N?@]_P7J_;1^%_QJ^ O@7_@J?\
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M2LKJUOK9GT[5M/NK74]+GN=/NK>XD^\9K*P;3I=.GM[<Z6;)[*:UE5?LAL#
M8)()%;Y/L_V?,;JWR^7D'BO&?V?/A7^SO\(_A_8^&/V9O!OPQ\&?#>W8PV6G
M_"NST.W\/;[8>5Y8FT,O#.]LH$2+)-(T" 1H$3"T >YT444 %%%% "'H?H?Y
M4#I^)_F:#T/T/\J!T_$_S- "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 -?[I_#^8IU-?[I_#^8IU !1110
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M?#UCHNE>([VUTZPDL7DNX]3UZ#0[JX:\TY9X+9OML5I_5?10!_*G_P $H/\
M@D_\:+O_ ((0_$__ ()T?MC^ ]=^ GQ#^)T_QJT::UU"^\+^(=1\-'Q?KVL:
MCX5\66EQX9UGQ#H=Y]D-[9W\4)O9&62-HKB!70H?E?X.6W_!S9^Q=^SO8_\
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MCMXJ_P#3Y?5P]?[UY=_R+\#_ -@>&_\ 3,#\P>[]7^84445V""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M26-VD:*,L[O;R*J*.[,Q  [DU>HH3MJ!_D!^,O\ @AW_ ,%<M>\7^*M<L_V
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M\_\ U_I:G^KN$_Y_XG[Z7E_TZ]?O\C_'?_X<2_\ !7K_ *,&^/7_ ()=)_\
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MH_XG7\1?^B6X(_\ ";B#_P"?_K_2U/\ 5W"?\_\ $_?2\O\ IUZ_?Y'^._\
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M?_ES1_PXE_X*]?\ 1@WQZ_\ !+I/_P N:_V(**/^)U_$7_HEN"/_  FX@_\
MG_Z_TM3_ %=PG_/_ !/WTO+_ *=>OW^1_CO_ /#B7_@KU_T8-\>O_!+I/_RY
MH_X<2_\ !7K_ *,&^/7_ ()=)_\ ES7^Q!11_P 3K^(O_1+<$?\ A-Q!_P#/
M_P!?Z6I_J[A/^?\ B?OI>7_3KU^_R/\ '?\ ^'$O_!7K_HP;X]?^"72?_ES1
M_P .)?\ @KU_T8-\>O\ P2Z3_P#+FO\ 8@HH_P")U_$7_HEN"/\ PFX@_P#G
M_P"O]+4_U=PG_/\ Q/WTO+_IUZ_?Y'^._P#\.)?^"O7_ $8-\>O_  2Z3_\
M+FC_ (<2_P#!7K_HP;X]?^"72?\ Y<U_L044?\3K^(O_ $2W!'_A-Q!_\_\
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M$%%'_$Z_B+_T2W!'_A-Q!_\ /_U_I:G^KN$_Y_XG[Z7E_P!.O7[_ "/\=_\
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MB_\ 1+<$?^$W$'_S_P#7^EJ?ZNX3_G_B?OI>7_3KU^_R/\=__AQ+_P %>O\
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MWNV^K9[@4444@&I]Q?\ =7^0IU-3[B_[J_R%.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :>H_S_$M.IIZC
M_/\ $M.H CB^X/\ /85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
MK_=/X?S%.IK_ '3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO
M\A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H
M^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &GJ/\_Q+3J:>H_S_$M.H CB^X/\]A4E1Q?<'^>PJ2@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\J!T_$_S-!Z
M'Z'^5 Z?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &I]Q?]U?Y"G4U/N+_ +J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS->%3?'2WCBDD_X5G\6'V1NY5/"#L[;5)VHOVOYF.,*.,G R.M/'QQ@^8?\
M"M?BM\LL\>?^$1?!\J:2+<O^E\H^S?&PX:-E;O@ 'N=%>&_\+Q@_Z)K\5O\
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M^%XP?]$U^*W_ (2+_P#R70![E17AO_"\8/\ HFOQ6_\ "1?_ .2Z/^%XP?\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
MHFOQ6_\ "1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD
M7_\ DN@#W*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]R
MHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_
MT37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_X7C!_P!$U^*W
M_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?BM_X2+__ "71
M_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6
M_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_
M .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO
M#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-
M?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_
M /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)='_"
M\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z)K\5
MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?
MBM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R7
M1_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\
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MO_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z
M/<J*\-_X7C!_T37XK?\ A(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_
MX7C!_P!$U^*W_A(O_P#)='_"\8.3_P *U^*W )_Y%%^PS_S]T >X)]Q?]U?Y
M"G5X%9?'JVNX%E7X8?%R$ A=D_@Z2-^%4YQ]K/'/7/X5;_X7C!_T37XK?^$B
M_P#\ET >Y45X;_PO&#_HFOQ6_P#"1?\ ^2Z/^%XP?]$U^*W_ (2+_P#R70![
ME17AO_"\8/\ HFOQ6_\ "1?_ .2Z/^%XP?\ 1-?BM_X2+_\ R70![E17AO\
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M,K1_\*S^+.09!N/@]PIV16<A(/VO[K?:0B'^)X9QQY?,W_"\8/\ HFOQ6_\
M"1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)='_"\8/^B:_%;_PD7_\ DN@#
MW*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z)K\5O_"1?_Y+H ]RHKPW_A>,
M'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\ ^2Z /<J*\-_X7C!_T37XK?\
MA(O_ /)='_"\8/\ HFOQ6_\ "1?_ .2Z /<J*\-_X7C!_P!$U^*W_A(O_P#)
M='_"\8/^B:_%;_PD7_\ DN@#W*BO#?\ A>,'_1-?BM_X2+__ "71_P +Q@_Z
M)K\5O_"1?_Y+H ]RHKPW_A>,'_1-?BM_X2+_ /R71_PO&#_HFOQ6_P#"1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_P"ZO\A3
MJ:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -'WC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 T]1_G^):=33U'^?XEIU $<7W!_GL*DJ.+[@_SV
M%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0
M.GXG^9H/0_0_RH'3\3_,T +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 U/N+_NK_ "%.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 T?>/X_P DIU-'WC^/\DIU !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T]1_G^):=33U'
M^?XEIU $<7W!_GL*DJ.+[@_SV%24 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (>A^A_E0.GXG^9H/0_0_P J!T_$_P S0 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
M7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #4^XO^ZO\A3J:GW%_W5_D
M*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'W
MC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 T]1_G^):=33U'^?XEIU $<7W!_GL*DJ.+[@_SV%24 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0.GXG^9H/0_
M0_RH'3\3_,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY<?G.ADV)NVC^K.@ HHHH 0]#]#_ "H'3\3_ #-!Z'Z'^5 Z?B?YF@!:***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;/Q-&_B2.QGN!?2:9J4EC SS01#^I:+X#_!"#QLWQ+A^#OPNB^(KN9&\>1>
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M\/YBG4U_NG\/YBG4 %%%% !1110 4444 ?!G[=W_  4N_8\_X)K^%/!/C?\
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MN.P[O3Q&&Q$%.$K.TJ=2-W3K4:BC5H5H3HU80J0E%%%%%>8>T%%%% !1110
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MS_A5OQF\#&6SBOKW1+6]L[&6RFM'ODBM3]FM_MSZ9KC?9TCM8R0#^BRBBB@
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M"\\9W!B\!?"'PQ';3&#QCXHBC;_34LA#+K-[IUP8(Y="L[E;6:76+G1],U,
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M0[^ZMKZ./PU8?">'4OB!8>)7M=0L86U&]G\8:>?L.KVT]B)FLYXIOC+_ (*
M?\%-_P#@H%XW_;PD_P""8W_!)?X;_"K5/C9X*\!:7\1_C=\>/C9-/=_#?X9V
MNJ7%PVG>&+S3+"QU26*[O;*U8SW%S8RW(N+_ $LZ;;W41OC;@']+5%?S=_\
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MIZC_ #_$M.IIZC_/\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH *_C/\
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MAX[TC3+CQ1XEO=$<R1>9HFIVQT[1KVYYLKF\:VFN;&RNKV]@^[_BM_P<]?\
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MFETI[KQCXD\%?'O5?M.K6&OW.GI#=W?V#0#XETVVBN3-;PWNOHXBE? D /\
M2NHKY#_:<_;+^&/[+O[&WQ)_;2\6"ZU[X>?#WX2WGQ4BT[0)K%M3\51)H?\
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M&Z+_ &IX8UI%5;Q+&[4YU/0+J0_:-$U.:&SNKNQ>-[RPL+L3VD/U30 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?\
M=7^0IU-3[B_[J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :>H_S_$M.IIZC_/\ $M.H CB^X/\ /85)
M4<7W!_GL*DH **** "BBB@#YA^(W[:'[+'PA^-WPY_9N^)WQO\$>!_CE\7A
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M\CJB#+,P4$U^)O\ P7'_ .56SX7_ /8G_L3?^G[P?7I?P>^#7_!LI/\ L;>
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M HHHH **** $/0_0_P J!T_$_P S0>A^A_E0.GXG^9H 6BBB@ HHHH ****
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M_P!JVWGBD@N(-._:BAG@F1HIH98]#\4))%+$X5XY(W5D='4,K*58 @BOJ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_[J_P A3J:GW%_W
M5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-'WC^/\ )*=31]X_C_)*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^PS$_\ IZ84445J<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=]\+_AIXP^+_ ([\-_#OP)H]SKGB;Q1J
M=MIFG65LA/SSR!7N+B3[EO:6L6^XNKB0A(8(Y)&R%P>&@AFN9HK>WBDGGGD2
M&&&)&DEEED8)'''&@+N[N0J(H+,Q  )-?UP_\$L/V$X?V>/ <'Q=^(>F ?&#
MQ[ID,D%G=Q*9?!7ANZC6:+3%#9\K5[]6\S5)(]ICB\JS#2JC.?R_Q8\2\O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\ *@=/Q/\
M,T'H?H?Y4#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :_P!T_A_,4ZFO]T_A_,4Z@ HHHH ****
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M&WO_ (;9/_FVH_XF0\'?^BJJ_P#ABX@_^=?G_5F'_$D7TC_^B*P/_B6<*_\
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M7TC_ /HBL#_XEG"O_P ]S^;BBOZ1_P#APEHO_1QM[_X;9/\ YMJ/^'"6B_\
M1QM[_P"&V3_YMJ/^)D/!W_HJJO\ X8N(/_G7Y_U9A_Q)%](__HBL#_XEG"O_
M ,]S^;BBOZ1_^'"6B_\ 1QM[_P"&V3_YMJ/^'"6B_P#1QM[_ .&V3_YMJ/\
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MEX/PA.<>)J]6482E&G#(L]4ZCC&ZIP=3+H4U.;M&+J3A!-^_.,5*2TH_0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -3[B_[J_P A3J:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 -'WC^/\ )*=31]X_C_)*=0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4T]1_G^):=0
M!'%]P?Y["I*CB^X/\]A4E !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "'H?H?Y4#I^)_F:#T/T/\ *@=/Q/\ ,T +1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/Y
MBG4U_NG\/YBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 U/N+_NK_(4ZFI]Q?]U?Y"G4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_)*=
M31]X_C_)*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -/4?Y_B6G4T]1_G^):=0!'%]P?Y["I*CB^X/\]A4E !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "'H?H?Y4#I^)_F:#T/T/\J!T_
M$_S- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 -?[I_#^8IU-?[I_#^8IU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[B_
M[J_R%.IJ?<7_ '5_D*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 -'WC^/\DIU-'WC^/\ )*=0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4T]1_G^):=0!'%]P?Y["I
M*CB^X/\ /85)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*
M=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT
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M3_OH?XT>9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\
MOH?XT>9'_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/
M^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^
MA_C1YD?]]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[
MZ'^-'F1_WT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'
M^-'F1_WT_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH
M?XT>9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?X
MT>9'_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_
MC1YD?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1
MYD?]]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-
M'F1_WT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F
M1_WT_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>
M9'_?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'
M_?3_ +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD
M?]]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]
M]/\ OH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_
MWT_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT
M_P"^A_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?
M3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'_?3_
M +Z'^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/
M^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\
MOH?XT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[
MZ'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^
MA_C0 ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH
M?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^- #Z*9YD?]]/\ OH?XT>9'_?3_ +Z'
M^- #Z*9YD?\ ?3_OH?XT>9'_ 'T_[Z'^- #Z*9YD?]]/^^A_C1YD?]]/^^A_
MC0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT /HIGF1_WT_P"^A_C1YD?]]/\ OH?X
MT /HIGF1_P!]/^^A_C1YD?\ ?3_OH?XT /HIGF1_WT_[Z'^-'F1_WT_[Z'^-
M #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^A_C0
M ^BF>9'_ 'T_[Z'^-'FQ_P#/1/\ OI?\: %3[B_[J_R%.J))8]JXDC/RKT=3
MV]C3O,C_ +Z?]]#_ !H ?13/,C_OI_WT/\:/,C_OI_WT/\: 'T4SS(_[Z?\
M?0_QH\R/^^G_ 'T/\: 'T4SS(_[Z?]]#_&CS(_[Z?]]#_&@!]%,\R/\ OI_W
MT/\ &CS(_P"^G_?0_P : 'T4SS(_[Z?]]#_&CS(_[Z?]]#_&@!]%,\R/^^G_
M 'T/\:/,C_OI_P!]#_&@!]%,\R/^^G_?0_QH\R/^^G_?0_QH ?13/,C_ +Z?
M]]#_ !H\R/\ OI_WT/\ &@!]%,\R/^^G_?0_QH\R/^^G_?0_QH ?13/,C_OI
M_P!]#_&CS(_[Z?\ ?0_QH 4?>/X_R2G5$)8]Q_>)W_B7T3WIWF1_WT_[Z'^-
M #Z*9YD?]]/^^A_C1YD?]]/^^A_C0 ^BF>9'_?3_ +Z'^-'F1_WT_P"^A_C0
M ^BF>9'_ 'T_[Z'^-'F1_P!]/^^A_C0 ^BF>9'_?3_OH?XT>9'_?3_OH?XT
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M_"W_ * ^I_\ A2^(?_EE7MM% 'B7_#//PM_Z ^I_^%+XA_\ EE1_PSS\+?\
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M'U/_ ,*7Q#_\LJ]MHH \2_X9Y^%O_0'U/_PI?$/_ ,LJ/^&>?A;_ - ?4_\
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M#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\
MX4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?
M_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>V
MT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE
M_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS
M\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z
M^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4
MOB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\
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M5[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM%
M'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\
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M#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\
MX4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?
M_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>V
MT4 >)?\ #//PM_Z ^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE
M_P ,\_"W_H#ZG_X4OB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS
M\+?^@/J?_A2^(?\ Y94?\,\_"W_H#ZG_ .%+XA_^65>VT4 >)?\ #//PM_Z
M^I_^%+XA_P#EE1_PSS\+?^@/J?\ X4OB'_Y95[;10!XE_P ,\_"W_H#ZG_X4
MOB'_ .65'_#//PM_Z ^I_P#A2^(?_EE7MM% 'B7_  SS\+?^@/J?_A2^(?\
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M_N)5[=10!X/9_LW_  FM(1'!HVJJC$.0WB?Q$WS%5'4ZEGH!5O\ X9Y^%O\
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M $!]3_\ "E\0_P#RRKVVB@#Q+_AGGX6_] ?4_P#PI?$/_P LJ/\ AGGX6_\
M0'U/_P *7Q#_ /+*O;:* /$O^&>?A;_T!]3_ /"E\0__ "RH_P"&>?A;_P!
M?4__  I?$/\ \LJ]MHH \2_X9Y^%O_0'U/\ \*7Q#_\ +*C_ (9Y^%O_ $!]
M3_\ "E\0_P#RRKVVB@#Q+_AGGX6_] ?4_P#PI?$/_P LJ/\ AGGX6_\ 0'U/
M_P *7Q#_ /+*O;:* /$O^&>?A;_T!]3_ /"E\0__ "RH_P"&>?A;_P! ?4__
M  I?$/\ \LJ]MHH \,'[.GPJ$ID&D:KN)D8_\5+X@QF2.TC;_F(]UM81CH"I
M(P6;,W_#//PM_P"@/J?_ (4OB'_Y95[6/O'\?Y)3J /$O^&>?A;_ - ?4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &I]Q?\ =7^0IU-3[B_[J_R%.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :>H_S_$M.IIZC_/\ $M.H
M CB^X/\ /85)4<7W!_GL*DH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/X?S%
M.IK_ '3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\A3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.
MIH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &GJ/\_Q+3J:>H_S_$M.H CB^X/\]A4E1Q?<'^>PJ2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T/T/\J!T_$_S-!Z'Z'^5 Z?
MB?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?
M]U?Y"G4U/N+_ +J_R%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &C[Q_'^24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH :>H_P _Q+3J:>H_S_$M.H CB^X/\]A4
ME1Q?<'^>PJ2@ HHHH **** "BBOP%_X.;_B'\0_A7_P1V_:)\<_"SQ_XW^&/
MC?1O%GP._LGQE\._%>N^"O%>FI>?&'P=9W\-AXA\.7VG:M:0ZC83W.GZA%;W
M<:W=A<W%K,&BE92 ?OU17\8'[.7_  ;[?'?X\_LN_"GXW0_\%J/^"E?A_P :
M?$OX7:+XV@T=_C/XPD\,Z7KVLZ4+V"TDN!XR.J-I4%TR+)*KF[\@,RMYF#7T
MA_P;5_\ !03]ISX]VG[:G[)'[6_Q(E^-/CC]B3XIZWX/TKXR7=A:6-YXC\*:
M3K^M^%I(-4N[>1!J<UOJOAS4KJPO9[2&Y319M/34+O4;\W5], ?U7T5_FM/\
M=?V=_P!LG]JG]O+XT_M7_P#!<;]J[]@OPPO[8/CGX8? 7X4_"KXJ_$%]'U3P
M1X0T_1K+_A);;POX:U*ZLO#GAJ6Y=8+74[?3;#1+JZ2]GFOI[QYY)/[+?V!?
MV:?%7[*G["_CVQ_9N_:_\=?\% ?%7CO3_$GC_P""OQ<^/_CIO&4.H^(-3T/R
M/#&C7?BC^W-6W>$K/5([>:XMHKFWEMXC=0&-9B2 #]>**_@W_:__ &&O^"K7
M[(G[&OQ#_P""I_[2W_!6?XP> ?VV_AIJ-]XT?X'>'O'-O=_LNWMO;ZY>6&A^
M!M!\(HMEX:U[6=:\.2P6FD6E]X5N4;7+BUFO9;C4+=+^OZ_O^">?QY^(/[3_
M .Q%^S%^T!\5?"$_@/XB_%?X0^$O%_C#PK<Q3P2Z7K>HV"F\!@N;>TN;<7;I
M]M6WN+6UGA6X$<MO ZF)0#[*HHHH **** "BBB@!#T/T/\J!T_$_S-!Z'Z'^
M5 Z?B?YF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** &O]T_A_,4ZFO]T_A_,4Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)"@LQ  !)).  .223P
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M /$7H_\ T0>O]/0_XJ48_P#Z,UA/_%@5O_H*]?Z>G^A)_P +&^'W_0]^#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &I]Q?]U?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :/O'\?Y)3J:/O'\?Y)3J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IZC_/\2TZFGJ/\_Q+3J (
MXON#_/85)4<7W!_GL*DH **** "BBB@ K^=;_@ZJ_P"4)O[3?_8U_ ?_ -73
MX)K^BFOS\_X*??L%:/\ \%+OV./B)^R!X@^(^K?"C2/B'K/@75;WQKHF@V7B
M34]/7P1XQT?Q?':V^E:C>V%I*-2FT>.QFEDN T$$\LL2F54( /YMOV3?^"0'
M_!8[XJ_LI? [5= _X+M_$3P+\(_'/PK\,3V7POTKX*O+_P (YX-UC3(@_A2P
MUYO'UO(7M=/EDLH-1-@FU]LPMF5=C?NC_P $\O\ @EW^S-_P2&_9@^+GA?PY
MXF\>>/Y_&K^(_B3\??C#XYO&U7QUXPN?[)D_M66,:-;6GV*PL-.ADCLK/3+9
M+RZD5M1U&;4-;N;O4+G]#_V;_@XG[/?P%^$OP/C\0S>+8_A9X%T'P2GB:XT^
M+2;C7$T.S2S74IM-@GNH+*6Z""1[>*XECC8E4<KBO9;JUMKZVN+*\@BNK2[A
MEMKJVGC66&XMYD:.:&6-P5>.2-F1T8$,I((P: /YP?V!/V%/^#>#]L#]G;XI
M_$#]DG]EC]GCXJ?#&3QY\0]!\8>/OB3\,CXJ\;^&?%A@^W^(#HOB/XN6.J^-
M/#&B6,.H1ZKX571KRP\.6EB\%UX8CCTU;=A\%_\ !ME\=_"_[)G[-7_!5%/'
M_C+7[/\ 8N_9)_:[^)-O\,_%>JRZKKNA^$_ACI>K:Q:W5UHDC+<SW6D2P6*:
M[K5_!<7*+=-=WEVXD:9V^K/BC_P; ?"FX^+/COQG^RI^W+^V#^Q;\+_B_P"*
M-5\6?&#X#_!3XA>(-+\ ^,M1U^_N+S6X(8=-\2Z$FGZ;=V]W<:3;:9>V6LV.
MEZ0+?3M.M[>VMUC;]IOV6?\ @G1^RK^R'^R2?V*OA9\/X9O@=J.B^(]'\7Z1
MXFG.M:CX[/C"":W\4W_BO495234+O6([B5)"HB2WB*);+'LW$ _&/_@II^R7
M^SC_ ,%?/V:/!/\ P4P^"W[4?C/3=&_9^^'7B3QW\&]!U2U\/W?[.?C_ %?P
M3XB7Q+;S?&7X<>*]%?4M=LGU30ELK:*+5]!O([*Z:6SFAGNK>[B_1S_@B+^V
MUXX_X* _\$Y/@9^T3\2/!VC>"?&^HV^L^#O$6F^&=,?1?"M_?>"-0?03KGAC
M1WDG.E:'JT5M'=6&FK/<)8PL+:.YN$C6>3\E[C_@U!^$FG:WK7@/P#^W]^VE
M\/\ ]B[Q'K$NHZW^QIHGQ$\0-\.=0L+W]YJVBWEV?%$-EJ-MJ=SON+F\U;PS
MJ&IRR2RF:]E+(8_Z;/V?O@'\*OV7O@YX!^ OP3\*V?@SX9?#70+/PYX5T&R&
M1;V-F@7SKJX($E[?W3[I[V]G)FN)W9V(&U0 >QT444 %%%% !1110 AZ'Z'^
M5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0 4444
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MX5*56G*,Z<X-QG&2E%M-,****R-@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH :GW%_W5_D*=34^XO^ZO\A3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.
MIH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.IV.BV_ANV\2>%IKDW5OIT%@ER^MQ& ,]U*EU(/+< _&G_@IK^R'^SA\._\
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M_J*6T5Y'K%RU]=1K*LS2S"\N5*'=M'YW^+?^5.*#_LV#P/\ ^I/X<KW72_\
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M\5MHUAX!\"B?41K/AGPEIMY86VG"2:S@BOY+R0Z;%:R^(?\ !#'P-\-_CO\
M\%B/^"T'Q<_:"\'>'?%_[2/@OXXZ[X4\+3>,]$MKO4_#_P (X-?N?"?A2_TO
M2-5;4([6/7_"OAK0H6U2,HVK65E;3BWM8HX;:U_8G_@F=_P2<^-W[&7Q.^(G
MQ[_:8_X*&?M"_MG_ !E^)$-O9ZR/$>I:EX/^$J16$*6.GZE!\-3KOB-/[=CT
MJWL["XNI];N+*5K47L%A:7,TQ;YS_;D_X(#^*OB_^V#K_P"WA^P1^W!\2O\
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MO OC'2++7_"WBSPWJ%OJNA:_HNHPI<6.IZ7J%J[P75I=0.DL,L;%61@:ZZ@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!J?<7_ '5_D*=34^XO^ZO\A3J "BBB@ HHHH **** "BBB@ HHHH ****
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M "/\\;Q+_P C!K7_ &$[W_T>]8E;?B7_ )&#6O\ L)WO_H]ZQ*_VQH?P*/\
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M(Q%64JV(KU*E:M.=2I*3****\D]X**** "BBB@ HHHH **** "BBB@ HHHH
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M%J^JW]Q-I^KR75IJ*_:&LX;58;B(B-9(G!4 _DP_8I_9W\':G_P5TU/]@?\
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MW=Z7K9:&XB^TC2S8RL(+J6L?_@O5_P $+_$?_!85_P!GW4O /QA\$?!/Q/\
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M["=[_P"CWK$K_;&A_ H_]>J?_I"/^7S,?^1ACO\ L,Q/_IZ84445J<84444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 -3[B_[J_R%.IJ?<7_ '5_D*=0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 -'WC^/\DIU-'WC^/\ )*=0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -/4?Y_B6G4
MT]1_G^):=0!'%]P?Y["I*CB^X/\ /85)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #7^Z?P_F*=37^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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MYM>TL/"&'R]*$Z6,=<HHHK^8#^Y0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** &I]Q?]U?Y"G4U/N+_NK_(4
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :/O'
M\?Y)3J:/O'\?Y)3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J
M_P A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!H^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &GJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3
M_,T'H?H?Y4#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH :GW%_P!U?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH ****
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M_,4ZFO\ =/X?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_R%.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &C[Q_'^
M24ZFC[Q_'^24Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH :>H_S_$M.IIZC_/\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3_,T'H?H?Y4
M#I^)_F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :G
MW%_W5_D*=34^XO\ NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH :/O'\?Y)3J:/O'\?Y)3J "BBB@ HHHH **** "BBB@
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MM#?N@0I. 2#G%/%Y^T3\W_$F^%0'FS!,ZEXCSY0FD$);$3#>T.QI #@.6
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M.^V?M$_] ?X5?^#+Q'_\9H^V?M$_] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\
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MFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\ 0'^%7_@R\1__ !FO<:*
M/#OMG[1/_0'^%7_@R\1__&:/MG[1/_0'^%7_ (,O$?\ \9KW&B@#P[[9^T3_
M - ?X5?^#+Q'_P#&:/MG[1/_ $!_A5_X,O$?_P 9KW&B@#P[[9^T3_T!_A5_
MX,O$?_QFC[9^T3_T!_A5_P"#+Q'_ /&:]QHH \.^V?M$_P#0'^%7_@R\1_\
MQFC[9^T3_P! ?X5?^#+Q'_\ &:]QHH \.^V?M$_] ?X5?^#+Q'_\9H^V?M$_
M] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\ 0'^%
M7_@R\1__ !FO<:* /#OMG[1/_0'^%7_@R\1__&:/MG[1/_0'^%7_ (,O$?\
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MT3_T!_A5_P"#+Q'_ /&:]QHH \.^V?M$_P#0'^%7_@R\1_\ QFC[9^T3_P!
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M?M$_] ?X5?\ @R\1_P#QFO<:* /#OMG[1/\ T!_A5_X,O$?_ ,9H^V?M$_\
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M%% !1110 AZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37
M^Z?P_F*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #4^XO^ZO\A3J:GW%_P!U?Y"G4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_)*=31]
MX_C_ "2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #3U'^?XEIU-/4?Y_B6G4 1Q?<'^>PJ2HXON#_ #V%24 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (>A^A_E0.GXG^9H/0_0_RH'3\
M3_,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 U_NG\/YBG4U_NG\/YBG4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U/N+_
M +J_R%.IJ?<7_=7^0IU !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 T?>/X_R2G4T?>/X_R2G4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #3U'^?XEIU-/4?Y_B6G4 1Q?<'^>PJ2H
MXON#_/85)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A
MZ'Z'^5 Z?B?YF@]#]#_*@=/Q/\S0 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #7^Z?P_F*=37^Z?P_F*=0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #4^XO^ZO\ (4ZFI]Q?]U?Y"G4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #1]X_C_ "2G4T?>/X_R2G4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2,P4%F(55!9F8X"@#)))X  Y)/ %+5/4?\ D'WW_7G=?^B'IQ5VEW:7WL&[
M)OL<*?C%\(P2#\4OAR".H/C?PR"/J/[3I/\ A<?PB_Z*G\./_"X\,_\ RTK^
M ;Q!<3P:WJT$$TL,,-_=10PQ2/'%%%'*R1QQQH0B1H@"HB@*J@*H  %9'VV\
M_P"?JY_[_P O_P 57]SP^AYEDX1FN/L<E.,9)/AS#Z<R3M_R.O,_RMK_ +2'
M-:%>M0?@_E\G1JU*3DN.\2E)TYN#:3X0T3LVEZ?+_00_X7'\(O\ HJ?PX_\
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ML=_XCF'_ /GT'_%2?-/^C.X#_P 3S$?_ $'^O]/3_00_X7'\(O\ HJ?PX_\
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MHKYT^P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR8?8O$,>IZGX.\#SRVNI1E9(T71%2%MT0GF*;S^@!=00I90QZ D GZ#J?PH
M=12;EW;=PW==N1NQZXZT*RM]U@V#@[2#@^G'>@!:*:K*W*LK#IE2#_*E9E49
M8A1TRQ 'YF@!:*0$,,@@@]"#D'\12;TY^9?E^]\P^7Z\\?C0 ZBD#!AE2"/4
M'(_,4M !1110 4444 %4]1_Y!]]_UYW/_HEZN53U'_D'WW_7G<_^B7JH?''_
M !1_-">S]'^1_GC>)?\ D8-:_P"PG>_^CWK$K;\2_P#(P:U_V$[W_P!'O6)7
M^V-#^!1_Z]4__2$?\OF8_P#(PQW_ &&8G_T],****U.,**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJS\*^'=*\.Z->:YX@\5^,-4@NI])\-Z-8VB-OO;Y+.X</,T<44,,LKMMC(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J
M_P A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!H^\?Q_DE.IH^\?Q_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &GJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I*
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MV>@^'+S0-=M8M%\1G2WDU7P_#KCZM>Z!=W&GZE-:Z=>V]I%=:FMMIEW^;?\
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MG6MWXJL;+PA-9CQ#J/B73[19?)\*VM@=>O+Q#86EC/?&.UD^.?VW?'7[=_\
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MW6]!O-/U*WM);Q-3LI[47"!K:1K6X0X91\_?M1?\%%O^"K'_  4__9;\0_\
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M::UH5Y8:E;QWEC<W%G=1Q7*)<6T\L$JO&[*?DK]OG]K7_@H1_P %[_A#H_[
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M]L.\_9$_X*Q:#_P3<^'_ /P4ET/_ (*1?L6_M ?#+6/$'P3\:ZK\4_!_Q?\
MB%\-_BEX?BF\0ZCX7U;QWX9OKO[5<ZKI<?B>[N=(NI[A1I.DZ&NC66DVND:B
M^I<_:^!/VGO^"_W_  5%_;9\%:E^VE\=OV6?V+_V&/&%]\(/!/A']GS7;OP!
MXYUGQ[H\B:#XEU/4KMP8]1\SQ)8:Q+-J>IVEU87>BKHR:#!:207>HZS^I_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWP[H'PJE\/\ _"06_B)-"N==L]]GK]]8B^348[2:RMH-/>:\:]:")+>3S@5
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M/A[;^&9]-UKR[FUF>WO-:L]2Y7_@G'^SQ^TK^VW_ ,$&?VQO^"5'Q=\(>/O
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MUSQ+)H7AW3=-_P!/UW5TT2QOGT[2K,RQ">_NUAMHV=09 3B@#Y,^(W_!T/\
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M$C:>2QM-!\->,IO"D^I^,K=Y(#=>(]1L+Q;N\LX-6MH-,G6*V@_N;_X)M?\
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M78?\) /['CUK7-$-]#X<DU"2"R'B!=-6]GBM'G8 '\UW_!PGX^;QIXH^ _\
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MIXP^+UC)J/AK5->TG3['Q%9K<6KLUUH]Q>Q?9I["^+_8M4TVXNP#^MVBBB@
MHHHH 0]#]#_*@=/Q/\S0>A^A_E0.GXG^9H 6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/X?S%.IK_=/X
M?S%.H **** "BBB@ HHHH \<_:!^%%_\</@Y\0/A9I'Q%\:?"+6_&'AV_P!*
MT+XG?#R\ALO&7@36Y8F.E>*- >ZBGL)[[1[T0WL=CJ=M=Z7?^4;34;2ZLYIH
M)/YG_'W_  2^_P"#C;Q?<^(?AK/_ ,%KO ^M? /Q&+WPUJ,NI_ 'X<:+\2+O
MP!J+2VEW9SW&B?"5I%UZ31Y#:RZA9^+;,SW#23A[>-OL]?UAT4 ?!7_!-7]@
M+X9_\$T?V1_AU^RE\,-6U/Q+IWA#^U-5\0^,-83R=2\7>+_$5_-JOB+7Y[03
M7$>GQ7M_<2-:Z;!,]M80!+>V$4"1PQ_>M%% !1110 4444 %%%% !1110 44
M44 %%%% !5/4?^0???\ 7G<_^B7JY5/4?^0???\ 7G<_^B7JH?''_%'\T)[/
MT?Y'^>-XE_Y&#6O^PG>_^CWK$K;\2_\ (P:U_P!A.]_]'O6)7^V-#^!1_P"O
M5/\ ](1_R^9C_P C#'?]AF)_]/3"BBBM3C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***^K?V/OV5/&?[6OQ<TCX?>'$GL-"A>/4?&GBCR=]M
MX;\.PR+]KNBSJ86OYP?LVF6S[C/>2(?*EBBF6O.S;-LOR++,=G&;8JG@LMRW
M#5,7C,56=H4:-)7D]+RE.3M"G3@I5*M24*=.,ISC%^YPUPWG?&&?95PQPYE]
M;-,\SO&4L!EN!H)<]?$57]J4FH4J-*"G6Q&(JRA1P^'IU:]:<*5.<E]D_P#!
M*_\ 86N?VB?B!'\6OB#IDB?!WX?:C'(L-W"1#XV\3VY$L&C6ZR(1/IFG-LN-
M8G&(FD\FP1IG-[##_7+!!#:P0VUM#';V]O%'!!!#&L4,,,2".*&*- J1QQHJ
MI&B *BJ%4  "N#^%GPP\'?!KP!X8^&O@'28=&\+>%-,M],TZTB7YY!$@\Z]N
MY3E[F_OIB]U>W4K/+/<2R2.Q)KT&O\J/%CQ*S#Q-XHKYM6]IA\HPG/A,ARV3
M5L'@5*_M*JBW&6-QDDJ^+J)R][DH0DZ-"DH_] ?@!X*9-X&\!X3AO!NEC,]Q
MSIYAQ7G<8-3S7.)TU&<:3DN>&6X"'^R9;0?+RT8RQ%2/UO%8JI4****_+S]Q
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBI/*E_YY2?\ ?#?X4>5+_P \I/\ OAO\*+/L_N#FC_,OO7]=5]Y'14GE2_\
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M%% #4^XO^ZO\A3J:GW%_W5_D*=0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 -'WC^/\DIU-'WC^/\DIU !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 T]1_G^):=33U'^?XEIU $<7W
M!_GL*DJ.+[@_SV%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (>A^A_E0.GXG^9H/0_0_RH'3\3_,T +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBG4U_NG
M\/YBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]F'_ *-Z^"W_ (;/P=_\J*/^&4?V8?\ HWKX+?\ AL_!W_RHKW^BC_6#/O\
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M7_=7^0IU-3[B_P"ZO\A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?S%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_P A3J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H^\?Q_DE.IH^\?Q
M_DE.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &
MGJ/\_P 2TZFGJ/\ /\2TZ@".+[@_SV%25'%]P?Y["I* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $/0_0_RH'3\3_,T'H?H?Y4#I^)_F
M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH :_W3^'\Q3J:_W3^'\Q3J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :GW%_P!U
M?Y"G4U/N+_NK_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!J?<7_=7^0IU-3[B_[J_R%.H **** "BBB@ HHHH
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M .!GB;_YG*_2C_A4WPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?#_\ \(WPY_\
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M ,(WPY_\K:/^%3?"S_HFGP__ /"-\.?_ "MH _-?_B("_P""-/\ TD%^!/\
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MS_HFGP__ /"-\.?_ "MH _-?_B("_P""-/\ TD%^!/\ X&>)O_F<H_XB O\
M@C3_ -)!?@3_ .!GB;_YG*_2C_A4WPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?
M#_\ \(WPY_\ *V@#\U_^(@+_ ((T_P#207X$_P#@9XF_^9RC_B("_P""-/\
MTD%^!/\ X&>)O_F<K]*/^%3?"S_HFGP__P#"-\.?_*VC_A4WPL_Z)I\/_P#P
MC?#G_P K: /S7_XB O\ @C3_ -)!?@3_ .!GB;_YG*/^(@+_ ((T_P#207X$
M_P#@9XF_^9ROTH_X5-\+/^B:?#__ ,(WPY_\K:/^%3?"S_HFGP__ /"-\.?_
M "MH _-?_B("_P""-/\ TD%^!/\ X&>)O_F<H_XB O\ @C3_ -)!?@3_ .!G
MB;_YG*_2C_A4WPL_Z)I\/_\ PC?#G_RMH_X5-\+/^B:?#_\ \(WPY_\ *V@#
M\U_^(@+_ ((T_P#207X$_P#@9XF_^9RC_B("_P""-/\ TD%^!/\ X&>)O_F<
MK]*/^%3?"S_HFGP__P#"-\.?_*VC_A4WPL_Z)I\/_P#PC?#G_P K: /S7_XB
M O\ @C3_ -)!?@3_ .!GB;_YG*/^(@+_ ((T_P#207X$_P#@9XF_^9ROTH_X
M5-\+/^B:?#__ ,(WPY_\K:/^%3?"S_HFGP__ /"-\.?_ "MH _-?_B("_P""
M-/\ TD%^!/\ X&>)O_F<H_XB O\ @C3_ -)!?@3_ .!GB;_YG*_2C_A4WPL_
MZ)I\/_\ PC?#G_RMH_X5-\+/^B:?#_\ \(WPY_\ *V@#\U_^(@+_ ((T_P#2
M07X$_P#@9XF_^9RC_B("_P""-/\ TD%^!/\ X&>)O_F<K]*/^%3?"S_HFGP_
M_P#"-\.?_*VC_A4WPL_Z)I\/_P#PC?#G_P K: /S"UO_ (.&?^"+^AZ;/J=Y
M^W]\';BWMS"'BT:Q\?>(=0;SIHX4,&DZ#X.U+5+D*\BF4VUG*((@]Q/Y<$4L
MJ:B_\' G_!&AE##_ (*"? H!@#AKOQ.K#(S@J?#8*GU! (/!YK]&]1^$'PFN
M+5HI_A=\.YXF9-T<W@GPU)&VUMR[D?3&4X8!AD<$ CD5<3X3?"O8G_%L_A_]
MU?\ F3/#GH/^H;0!^;/_ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_
M G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS
M_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\
MSE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO
M_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IO
MA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:
M?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__
M .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P
M,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6
MT?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_
M !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G
M_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_
MZ2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X
M1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ S
MQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T
M ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'
M_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!
M?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-
M/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_
M G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OA
MS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\
MSE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *
MF^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_
MP1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'
M_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"
M?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_
M )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.
M5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__
M !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%
MG_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_
MZ2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\
MX1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ S
MQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1
M_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\
M$0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]
M$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I
M(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&
M^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$
MW_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!
M^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\
M*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_
MP1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^
M'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"
M?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/
M_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.
M4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;
MX6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!
M&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_
M /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_
M\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\
ME;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7
MZ4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\
M$0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?
M]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I
M(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A
M&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$
MW_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_
M  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1
M 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T3
M3X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@
MOP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X
M<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?
M_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'Y
MK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ
M;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!
M&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?
M_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_
M\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^
M5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1
M_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA
M9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:
M?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1_P *F^%G_1-/A_\
M^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P
M,\3?_,Y7Z4?\*F^%G_1-/A__ .$;X<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5
MM 'YK_\ $0%_P1I_Z2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I
M1_PJ;X6?]$T^'_\ X1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1
M 7_!&G_I(+\"?_ SQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T
M33X?_P#A&^'/_E;1_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@
MOP)_\#/$W_S.4?\ $0%_P1I_Z2"_ G_P,\3?_,Y7Z4?\*F^%G_1-/A__ .$;
MX<_^5M'_  J;X6?]$T^'_P#X1OAS_P"5M 'YK_\ $0%_P1I_Z2"_ G_P,\3?
M_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\ X1OAS_Y6T?\
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MZ2"_ G_P,\3?_,Y1_P 1 7_!&G_I(+\"?_ SQ-_\SE?I1_PJ;X6?]$T^'_\
MX1OAS_Y6T?\ "IOA9_T33X?_ /A&^'/_ )6T ?FO_P 1 7_!&G_I(+\"?_ S
MQ-_\SE'_ !$!?\$:?^D@OP)_\#/$W_S.5^E'_"IOA9_T33X?_P#A&^'/_E;1
M_P *F^%G_1-/A_\ ^$;X<_\ E;0!^:__ !$!?\$:?^D@OP)_\#/$W_S.4?\
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MQ]H%YO@<Q.3I^M^#M/OA$64F&?[/Y%Q'B6WEEB97.K_Q$!?\$:?^D@OP)_\
M SQ-_P#,Y7Z,:;\'_A+;VWEV_P +OAU!'YCMLA\$^&HDW-@L=J:8JY8DDG&2
M3DUH?\*F^%G_ $33X?\ _A&^'/\ Y6T ?FO_ ,1 7_!&G_I(+\"?_ SQ-_\
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M .5M 'YK_P#$0%_P1I_Z2"_ G_P,\3?_ #.4?\1 7_!&G_I(+\"?_ SQ-_\
M,Y7Z4?\ "IOA9_T33X?_ /A&^'/_ )6T?\*F^%G_ $33X?\ _A&^'/\ Y6T
M?FO_ ,1 7_!&G_I(+\"?_ SQ-_\ ,Y1_Q$!?\$:?^D@OP)_\#/$W_P SE?I1
M_P *F^%G_1-/A_\ ^$;X<_\ E;1_PJ;X6?\ 1-/A_P#^$;X<_P#E;0!^:_\
MQ$!?\$:?^D@OP)_\#/$W_P SE'_$0%_P1I_Z2"_ G_P,\3?_ #.5^E'_  J;
MX6?]$T^'_P#X1OAS_P"5M'_"IOA9_P!$T^'_ /X1OAS_ .5M 'YK_P#$0%_P
M1I_Z2"_ G_P,\3?_ #.4?\1 7_!&G_I(+\"?_ SQ-_\ ,Y7Z4?\ "IOA9_T3
M3X?_ /A&^'/_ )6T?\*F^%G_ $33X?\ _A&^'/\ Y6T ?FO_ ,1 7_!&G_I(
M+\"?_ SQ-_\ ,Y1_Q$!?\$:?^D@OP)_\#/$W_P SE?I1_P *F^%G_1-/A_\
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M_P"!GB;_ .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\
M_P (WPY_\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!
MGB;_ .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (
MWPY_\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_
M .9RC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_
M\K:/^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9R
MC_B("_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/
M^%3?"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B(
M"_X(T_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/^%3?
M"S_HFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B("_X(
MT_\ 207X$_\ @9XF_P#F<K]*/^%3?"S_ *)I\/\ _P (WPY_\K:/^%3?"S_H
MFGP__P#"-\.?_*V@#\U_^(@+_@C3_P!)!?@3_P"!GB;_ .9RC_B("_X(T_\
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)!(#8->P4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gv1ubg3hw41v000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000003.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &_ EX# 1$  A$! Q$!_\0
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M<6E"L\03WAZ7J"RQ 3EF@3$D$E@VVY>++F8(& , 8 P!@# & , 8 P!@# &
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MM,N2%62*C7/FCV?SWQCHSD)8D.JB)VPT\AX;<CS7<^LDW::NF6]*Z9X7%%L
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M8Q(&YTCK^C)5*TZ9W:UA258L3!)5'"K3I;3Q1?-0I3I"]G*CR4Q.A #LU0:
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M@T!Q0]:WL.]@,+$( M:%K8=]T6^F];UOTZW@#2E.(\:4)Y.U1983AIM&@V>
MH>]A :,G0O"!+&((@A'L.@BWK>M;WO6\ BB_<G1PCF-!>+<]BR=C9;PJN0S6
M@;*(=S%">;SNLE0E%OU(\,QB K3+)6"&N<:L&*JR7!:FE,<U- ");E4/'IS$
MQ<W.#AK<\'OUI[+MMTM,$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M7^$.:IC#).X)EZ8H7<5IRR3-ZWL@O812C^DM3IJGL4K4]:,T&"@P!@# & ,
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M=/YY,>4F*&X<>U$@$.N@J5!:I-K:(0MI/YV'S\>^;NWB7=X^<2*RXUQ&ZX7
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M+&(8A.*6[I?S8UQBWNU+?+C!F5#!48 P!@# & , 8 P!@# & , 8 P!@# &
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ME>V8]U2I7_;,(BZ?2)!X(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M.))8D3*J"-Z]>O@13<JGN=*XO'E)E[P5& , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M=I44)T'A*;OFF^5&.J)483)E\P5& , 8 P!@# & , 8 P!@# & , 8 P!@#
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M'>>6M=-=/J8 WK6_1O .+P)?I]'K]?J]/^S  20!Z]WKKK]G>_Z>N.0.7U8
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MO[-D1&$1=&P]OCOP.H7C;-I1:D=-M&S+CF$91P9ZN;D%;M@WM:/L ;UGE)%
M&F5V.^OBF.PPMSZ.:EACY38E=G$M,N>M.2E$A-3 ZFU&K&$DE.V%K_X5Q8UK
M['_A(TR)K4DQFT5-7,,]\Z4<XON5YVRX\2X[8?EDV1@D[/QU5RLVMTVR)"H4
M/22/&,YT/0KU!HT4=3E;"2$3I/=.V%I1QQ[<=4P9/\%1@# & , 8 P!@# &
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M# & -[UKU[UK]_ & , 8 P!@':L7ZN,WVU;O[63D58/@_<33BN*]Y,/,!G&
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MBB2&8C*6GMS]16S[::_LBC+T8OA\44KP7'X,C_F4Q# & , 8 P!@# & , 8
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MC$2-6Z;-HRY,_/:]"U,)BO3VS;3 =5:01^G=LV5H?CZ3PH%;^OU8 P!@# &
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MQ)C-; +0=^GIOT=?3Z=X)EX2XV29"FMD:F9K3,K8@3(VM(G"E3H2"0%IRTX
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M2S7)@7: F6%!]&M*D9I9A0Q:UTUH>M:%K6M:UZ/3H"(AW9$2E*6'33R*E@#
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M?*5X+C\&7HQ?#XHDAF(REI[<_45L^VFO[(HR]&+X?%%*\%Q^#(_YE,0P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# /'N _\  '[W7YL X])R-"[VB2M"
MZ]>]H =;]&][]?3KZ][Q'J6#FP"GGJ)1B1]SR\P-#OX/?4O;BWIEFP;Z;UU#
MX<L?3?3>_3]G .A/JFM%)0B#X%$C"A!V'8!,+;O7=%Z-Z]*?T?\ M]+ .>-5
MI 8<<8HB\286,XW>]C,;6U*E&+>_1OJ(HL._5UUZ_IX!*&GO^\D'_H:_ZR_,
M=>KM^!DHU]GQ(L17@NG?N;O);EWR&*K>VDL\@-24QQXA3M&2Y$54-3P,EXD$
MQ2K]29N.;SI#8%E/RV3JCVHCP3>A3)&\*M1L2@8L9FFY)7.^7.,X=B6&]O:6
MVM;LR8W)^6([BKC4$KVD+MXB7%PXYB5"PL>HN*QH',B5JV RV'$QYK]CZ:=1
MMV>7QJ='I[2EJ1116! B4F]T2;8E5.(O;52:<NZ,>^XH.L^'?:1LT/X^<8YM
MRKJ!BXS\>G^M &6S2K5:T(Y67;5],GH=PFK)H$3[J#P1%*6UG96.UI%&GZ0J
MY8RI5Z$AN0@>G,2@)IO>BY:<)PZ4WKPU:D\+L8DM?;'9<\G)M5G:@<<&&UZ)
M)I#G9;CMR)KUZ=V&?I[2@-KRZ2TPX2E@F D9ZZ*.5>I62L%B=C/9DGLC-=UR
M94M$2A,-1(Q$KYN-T3OO;N]=QD3JOBY)8!SEY8<K%TF8U\8Y"59QL@+#%TA"
M\#\P+J1(L<EY7.YYQ(6\U(\[FR/;8!$<:<7I&J\:"7L17>$3\U+8V^^%\#]X
M)\7I+Q.K6U(1*9*QRE;/^4'(R^$"U@(7D)4#)=-F/$Y9V-6%Q))-&ZLZ)R+1
M.1I(1)#%18Q)3#"MA%L34YC=2EW*":^"HP!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# (D2W]<[]]M5O\ OQYGIP7!>XP58OB_>4]DD# &
M , 8 P!@# & 7(JS]=&_M:K_ *Z?*5X+C\&7HQ?#XHDAF(REI[<_45L^VFO[
M(HR]&+X?%%*\%Q^#(_YE,0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# +TT]_WD@_]#7_ %E^8[35V_ R6>OL^)>_,9D& , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!'N00"4+WQV6I
M4)0TZI>J/('M8D!L11AHA %L SM"#O8=ZWW1:UO7JWK6\RJJF%?JV,Q.FJ7=
MKVHZ?S:R_P!SR?AZ+X_)TZ=O)^!&A5LYKQ'FUE_N>3\/1?'XTZ=O)^ T*MG-
M>(\VLO\ <\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"K9S7B/-
MK+_<\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"K9S7B/-K+_<\
MGX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"K9S7B/-K+_<\GX>B^
M/QIT[>3\!H5;.:\2M('#G]B?=KG)(62F\24$]\*I,=OPA@BMAUW"C1BZ;T 7
MIZ=-=/3OTY6NI-7/7OWEJ:6G>M6[<7HS&9"@+#87.0-B%,UD@/.(7^',",XH
MG6B_%SB^]H1PP!WOO##KIK>]^GKTZ:WEJ6D[]G@5K3:22U[BT7FUE_N>3\/1
M?'YDTZ=O)^!CT*MG->(\VLO]SR?AZ+X_&G3MY/P&A5LYKQ'FUE_N>3\/1?'X
MTZ=O)^ T*MG->(\VLO\ <\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;
MR?@-"K9S7B/-K+_<\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"
MK9S7B/-K+_<\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"K9S7B
M/-K+_<\GX>B^/QIT[>3\!H5;.:\1YM9?[GD_#T7Q^-.G;R?@-"K9S7B/-K+_
M '/)^'HOC\:=.WD_ :%6SFO$>;67^YY/P]%\?C3IV\GX#0JV<UXCS:R_W/)^
M'HOC\:=.WD_ :%6SFO$>;67^YY/P]%\?C3IV\GX#0JV<UXCS:R_W/)^'HOC\
M:=.WD_ :%6SFO$>;67^YY/P]%\?C3IV\GX#0JV<UXCS:R_W/)^'HOC\:=.WD
M_ :%6SFO$>;67^YY/P]%\?C3IV\GX#0JV<UXCS:R_P!SR?AZ+X_&G3MY/P&A
M5LYKQ'FUE_N>3\/1?'XTZ=O)^ T*MG->(\VLO]SR?AZ+X_&G3MY/P&A5LYKQ
M'FUE_N>3\/1?'XTZ=O)^ T*MG->(\VLO]SR?AZ+X_&G3MY/P&A5LYKQ'FUE_
MN>3\/1?'XTZ=O)^ T*MG->(\VLO]SR?AZ+X_&G3MY/P&A5LYKQ'FUE_N>3\/
M1?'XTZ=O)^ T*MG->(\VLO\ <\GX>B^/QIT[>3\!H5;.:\2YE<QEXCPW?;JG
M 1I6%#HCN*"#^]LC:O9G7P(Q]WN^%!T[W3KU]'7IOI2MIQ#V_ O0FIE8\"Z&
M4+C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MD5)C0'IU*906$XA0G.+$(LXDXH8#"C2Q" 8 01A%L.];P5.? & , 8 P!@#
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MS=O1SV'F[]P_O*S(7FOS[8P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M+"()8 [T'0QGNX P#'1P&_9%[2__ $B\R_X6>)F"U7]'^ZOB9%\%1@# & ,
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MX;,;?S_W.7_S?\E/YZ;"_P#K^;&_\!="/^D>CG_9L@__ $'P/TUG?^U,O_\
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MOX@R#\)G$Y?T)]LU_4K?[RP-VC.EYMD8 P!@# & , 8 P!@# & , 8 P!@#
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M,S,0F;$1RUS6+%ZX*0D(#EZI4H&(PTXPP<E"I< 8!CHX#?LB]I?_ *1>9?\
M"SQ,P6J_H_W5\3(O@J, 8 P!@# & , 8 P!@&'+MWOH=D_\ X?U9^-R3-O\
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M/.'Z2S;DGYYE'YMU]G9]0K6I66A?\SJT]'1W1!OGYT6-Q# & , 8 P!@# &
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M:0W(Q4N;@# ,=' ;]D7M+_\ 2+S+_A9XF8+5?T?[J^)D7P5& , 8 P!@# &
M, 8 P##EV[WT.R?_ ,/ZL_&Y)FW_ )#?VA9!]0SI^$K.+],/8=O^^R;[VDT5
M,[PFGQ@'T+>RB^AW\5ON>*/QHD.>?_RJ?M!Z4_:%/X7)S=O1SV'F[]P_O*S
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M(?[/G'7[D#]^.BO-[_DZ>P>D/VO8?@J#AO3O^>9!]6M/O37"SL2<$+Q\=O;
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MUM&<#>4J[F7QFA7(%RAJ2 JY:YS!O,C")[.D*="&+RMWC8#0.I[:T&G[6 ;
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M#;=[<O:R&G ;]D7M+_\ 2+S+_A9XF8+5?T?[J^)D7P5& , 8 P!@# & , 8
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M_:P?>A_-@@>#+_:P?>A_-@#P9?[6#[T/YL >#+_:P?>A_-@#P9?[6#[T/YL
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ME3S)90\-T?8&A+LP!.E+F\NRE(W($^SC2BM'*E)1>S#  [W>&'6P,4W/"R+
M8[#KF=5/SF@M0$Q&NHO<$6I;R.\6"UV[&DUN11ELN;6#$:TB4TLFQ*M=(1*H
MY"8B3!SX[Y#D;^YSDI^$!E$J:Q:F-=+=^*=ZN<):IF^^]Q",AG&VPYY;= 4W
M9]HUVKJ6Q9[7$3E<TK5=M?XU#)$],Z5<YL9I3LC;GE+XHI.'W$#VW-[ZWEB
MA>T"-U3K$Q0AW-Q??CM+V8(+66Q9Z>MXM)%C0UIIS8R."3>:PBH$4JBL:F-F
M;@[:G6.+7&1RIT;&\LL"IP96]Q>UAH6AB->FTUU4$ 5)PG"5W*;WL,0O"&_W
MNS[P@O*Z)7O8?*BA>=+3-:[=26:+KVJ)</[4J5Q=9U4-4/%3,[E*A56F4U<[
M6#'K+GDA>G8<EM%DC3ZMD9L6L"#EMPM4H^;$0YVRFE?.O!8=D0YSFX*# ,?W
M.KE_%:!11FBPS\-/W5REKV[HWQZN:2,I#I4M8VQ'FF(QF"/EM. QJQ1I@76/
M:< :6=V<F-PC"U_5)(Z\*T:][8T+P+4J;\4HE+%K7'9/!7ZB*W9OS/FQ&^1-
MV<>N1"2RI!6S)!V:?,;A:;N[6;,*5FQZ*O$BJN%_(Y+7D$KZ\&&UEC_.Y_ D
ML4.DK_5T;A8V">.#0ZOB*)QYZ]77\0]&$UC@\+^R6T\+[D]2N;>:K!48!@.Y
MN\Z#+ND9?%3CC9+A1EM1V^VMN;7&VY$VU+7_ "P35;9"NMK6J:JYQ#YX5=87
M*OK0 UNTEBS*RUY+;M8H/(JVK*0K6V9BDJ872A2U*W7Z.#EK"].Z^YXX0\BG
M BZ;FO.GI/)[G1HEJMCM661&OK+;:BLF@D%W5DV-L=<(_:2>EK<5N$_KHQ2Z
M.[_#'!G>EZY*XNL+726/*SXR^LY@A6I).%LOP</9*NV>YWDW<$%K+DNZIN/D
M&6V5=$\8*\A*!:W-8WM_4C+"L>'A2%&SL3.@2E*71^D#PK%I,TL#(A<'ES/Z
ME(4)XPBUH2DVX2DUR+2[1?FC>G(]@-X:5;!)ZZ0%TF<OXTJ8'RU;T=4<XN/N
MW1K0VO7\MK&SXI!8B5<%<E,[8*4$(9\UWCQ\F/@UB>$2NL']X.E@NJ:?Z3</
M&:7-.QJ&V^Z'AC$;,L+>7F1P^*2&111R@D@?8VR/#["'E>SNCO#GAR;$RQSB
MSHYQY<YL+BX,"TXYJ6+F5Q7M*M0D,4-ZQ2D,*.&,94N 18Y:<MZ^X>P>*36?
M,LDDGLWFXH)&V.,KX$QJ%+DA@TWM"1N;I)K1FU=5]&F"*UQ6TYE[PZR:9-!1
MB1A$UM0')^<6IJ6B4F^R]]Z7'%I7&)OBERGLF*\LX5 F>Y[*Y_LG*RLC)J\/
M\"5HW2F:?GD0Y"3:,VG)6E>]D,R&D(+6-8N<4CLCJE2JV_/<U;X<T,K JE4G
M<G52+-78*G1;QQ:?ZO'!WJY<(-@O!08!#KE):4,<^/EZ;A_*^NZ)/KU2P-%I
M7&FDL8=E5+-()6PF3EN<0>.*PQ6P'J%!?XY"O*B;3JVRUX9'% VK5J5.E.$J
MYJ4WL6WD^)87L\K2Y#.LANNA+<>U-RPR@?8^RPODTMA%GPEXFKZYS&TD#]5T
MM7V3&XPAMB75C&(W URZY*S;@P>:M4R9EP^\\FJEK@):4)W2YE*'&%]SNG8[
MU&R#)_@J=))9+'89'7V7RY]:(Q%8NT.+_))(_N*1H8V%C:$AJ]U>'AT7&D(F
MYL;D1!RM:M5G%)TR<HPXXP!8!"T!B*[4?D')P\?^,\TX>7P\ MR;77!+&HV/
MT>!NL^0\D(:1$Y,D=F)KK=(]MJ6V:G"3,HY*[&),=FMB9XTW%2-1)XNX-[2_
M(7O]<,-9:E7M-70TYNCP<J$M;NOP>0[BW-+[G]'Q"3\G:E;*0O%4HE"*<UPQ
MR)IED?9SFB6OC2RK8_(F=[?B'9F?HXB:'U$K4JTK@8!QWXZTM)W>;R!#B7#E
M:GZU[=^!(+! P!@%A.5:%:Y\7N2+:VHU3@XN%"7"A0($*<U6M7+5=>2(A*C1
MI2 &'J52D\PLE.G)+&:<:,!98!#$$.Q*Q7%>\C?5?/CB4SUA7#0Z6X0A<VJ!
M0]M<41\,L0)Z-<ACS<E5I3@^Q'?=-3J"C"C ]=]!@%KKOI@0]C[F6FD=O]GM
M((0?7Z;D!.XHP+I;=$L>/8<IMIB6/N^0DOF,VMI@>#"XB<0K89(]3I^&B#I,
M6\Q,.T"J&O,?=6Y*X@$Q5_5;['JN7KO*(,<.RE$\!>R9NH1K"R9 G**1HK:(
M0%@?K :+) ,+<&,;1[4QU^;7!'$EHR1K8Y'9A.F!M4%-TN>2E()5+!/N\BKG
MJ;]D:^2F#S<R/T@VS"NY:QS2+2=BH1>ROZ)ZC9[XM9?".[?6A+@<@;W61.KX
MF0"4Z3DOI^G@H(' &C]A\Z(^=&R_=X)<+B3_ .B$\//\\J/_ %.L3_E'!$/8
M^YC]$)X>?YY4?^IUB?\ *.!#V/N8_1">'G^>5'_J=8G_ "C@0]C[F/T0GAY_
MGE1_ZG6)_P HX$/8^YC]$)X>?YY4?^IUB?\ *.!#V/N91,VYD\&+!+BQ4DMX
M!X(=-HW8#)I-&;)2;)DD45#5LYY^RHCKQA,4<8+9R0S_  1X=Z"/736!%6Q]
MSUD9I/)NSQE:F^3G'E';I*;D@< RT6Y"JGA"5T3DG,H$C0F/,K,YT+CB)B90
MPU+%U;BNC@(8ZR".":QH7QQ">)BK8[MWECOQ*A)L3LZA.41<WF_9G)S8PB@3
M<X)7Y'/36N=(JBG4BLFFDDX:FZO&UO<DM2324N[U"4K6G94P!B0I9 2_HFIM
M3) BJ(A]SNG'OWE2U%=W9^TP[-;E&+_F[LFBL,/K>NH_+U%N22.UA7:E:R+S
MX="VU7$P]UO&;&8RF Z20Z1RA.UQYH94K^0SI?$!@U4]3[L?7J^3QD%S=G-(
MZ&1<<E=M*R:X;%<9<6T@$=GBYQ3.$/G#;8L?4*-O<#=FE[3I94T(%BMFD;0\
M1]X1E&-+VTN+6H4)#0BIN6F^PM_'W3LKH]%'.$EV$X.L:>W%K<GIN?$=K.('
M8QJG%I6$4G7#%$RS#42F0W'.MKDX1 "I;UZ1"(02D"?80^=,PY:C!^M1[9TL
M[-9V8WABF=Z3VQB7N!2FLU"Z>.-P/CBDATH'5P]MK.<&*)"&0YC-IR K&1R:
MDR1RT]MKC*7=4[RR12!]<P^=J36NY>MKNP*--;^RS5.<0>E]QRMP>(@YL[T2
MY*6^; /<76.66BMN/J0EI*V3)(@F;9LW(59S)6::"QV0-*)#&I6T/T<;T#6F
M#YU]SOW/"([;ML]]YW36X]F<P)FX$9ORR(NZM3"="D,IC;I;3-+$U<*4 F=5
M7*9_10TM<DC)K&2RM)2Q$--+6[<5BKZTR=OE;(ED&!\ZY0X6J+N/'SU-HN1:
M5R=GE;KZ^ODDOB;-09C!6JMY\TPM;<L,;I[$8X?,ED3;9&HC\:1/A>XPX6!+
MUR!0P/#&<YB>1HI0.0-2)M;T8+26I[5<[O6_L+713?991%DG[&AM1Z4)[.@M
MK5Y,3!LTX:2UL=N:$4Y74X*:V:+UW'XS&3E,2H:M6YN!&&)G0MI[2O="$7E5
M\>%JP/G;'=A=LEKWL["2O/9GRHGQ9SO6<#1-4Y=;%@#48"Q7..U7*I$LG:R4
M+H+$WVOW>*;!(A6;.D:LF7,DL"UM#]Y"C6V)E9X^WM(15_5?<[^/<O\ ELOU
M4O*'@#236^L\!MM2E0R)QC#HYZ>6RVI&L.5Q"K:\IQE-,='R-KG12:"$5=$D
MRU4N6JUKFYIUSPO5*%[BJ.&#53Q3[M\_$NO^B$\//\\J/_4ZQ/\ E'!$/8^Y
MC]$)X>?YY4?^IUB?\HX$/8^YC]$)X>?YY4?^IUB?\HX$/8^YC]$)X>?YY4?^
MIUB?\HX$/8^YF 7YHUO&N>57".K:\XZ+Y)<$V9N5,(F;I&857MB.;JABK=4E
MX,:Y]4$>Q4KN-Z9WD3&WFG=[?=4N:0'3?A.NA>A--S==KN6*UN#;(P8Q@# &
M 68OSD/2O%VN5EN7_8;'5];M[U&X\MELATNVV)7>6O2./,"4_P G(URDL"MT
M7IRSU8D^D3:ETH<W10B:T2Q8G$I-N$FWL1A8K[G]R]NUWL.+QKV!-4?M:UFB
MC():<*A0^0*+A/<@QQSR$=/FB('M:6Z>/W("MCD-X\8^2>TS?$&F7S)OB%O(
M4\32%*D#UZY%HI48W7N^-);MC3N:O>M7W&6JG>*T<J:W[8O9;/I[9=DVNT,$
M2.=)FGKYK;8/747DLUF3!7$'9JY@D$1@C;;)[#ECH!TF'LPG2S2Y*D=IBXIV
MY* (K+A+4KXWN+^2W;"4F"#'EV@?-YOXI53)A0%QA$CNU.B871;%USNGD3K3
ME5/3SIDE/*2P:?BS@=<$RIJGTVU$AEB2O8VYNCF%&%$8L8&73[*XZ+4J<</>
MXE4S@F\%/&_ M7Q[OYUY?N_&N.J)ZQI4#+5TIN6RZ^G=3QF8VE?5.2N*EU93
M-JS54RHU%:<6T%Z DTSL?S3B*'9$ABY!,::AML<;;58F\&HOAXW/8UC&UJZ7
M@NU,R'TM2]<\>ZVCU15(QJ(Q742$[ABT9-?'Y^2QQO>'MQ?A,+(HD3F[+FV-
M-"ES/01F-I51;)%F$ANCL>0MS(V($"<0VVY=[9=+! P!@# .M>7AMCS.ZO[R
MK+0,[&VKGAU7':'LI$VMB4U:N5FZ+",S9:9*0:</0 #'L(-]T(A=-; UQ.3_
M #+%RK'PS(747#T+A)KIKODAQDXV7C-&]_CG,ZFIE6UJQB'(+>/;X>Z5?QLL
MN8)G\^PN+\;MJ6R9NE-FU_IK7EMKW'ENF=\2\0W?JAM+]5SJP;BY-K!-XK'+
MEQ"B-VFN]RV_?E<1VIG*>2F/,=)5+K582*=4G04,@<28FVMI-8M8(-,3PC=;
M)1V#9;7$VR13!EAI,U"WHY(N4F*TZ 0XN2;=U^J7+OCA"[";>"I8GD5R"@/&
MJN3+"L)Y:F% N?&B%1M=)5#LS0X^?2TPYM@S/-9NWL,A;JVC,ADGB# LL"4I
M"8O'U+DCVX*=GJD2-6)2;POU]QKA\FW>#]H/:]95Q)Y;(V6;W?/%M%V!Q&F2
MA@5<L>SEY$L53O1KQ=%2MR4DLNQ.(L]AC$!HY$1A\$MIBY()*&6<1Y]+<WYP
MCJ872T4VE.O26%2=T7X5*^(AIRHDV+*"H&+4^WGRHZ'U>S7;8$-K!JO>7U+#
MS8#$Y_)ZVBXHZV.;=$Q.3F%J:VM.J7-D?*4*E;HFCH&IH6N"I,T-Q208W?YW
MDAL @%S;Y22>G$=-0.H);4,7L&[^048H!79UM$+Y76]%KI1 I[.F5WGD1C$J
MB#RYOTW4PE)7U;1M?+(<@>YK,F$:Q\TE)\G.@E+&9:2F%CBM<.,=C.N9BRN5
MUPVS5=@2&OY]5U 5^IXS<FJK<*-;@M5K6_;< J:UWMV:)J_RF:*VBJ$D*>HX
M$FMFDXE^32U4?N;2%\U&8J=H,(:NUI[(;7O7(F[7D#CM70.&UM$0NQ<5@489
M(A'"WZ1/\M>2F./-R=J:RG*32ER>)&^K"D24DLYS>G1>XJA!V8I5&F;V+8AN
M6WMO*QP#!SSTY'V[:TY.XAU_7[Q6L17WDSUR?>,UNJ9T-$+7E584BAYCV13;
ME)*U9R[9K>FYM1#;)&4SD5!7QT.;YY''2(ND)6Q,]<XN0O2M>Q3$)W-Z,P[G
M#U<\3K.$?%R^KUK-LBO,VP+P>*\X\\@V&3TZ@?C6U!Y]6*%N%;VY#$UGR>?0
M=1=]K0>C+OCJM/4%N'/-1OUUQEO+?)_$W)I<QI7 0VM25ZOXO&%@I6*5RP1G
M9P5*?ELC30^*R:7+&Y]=TD6C[S(E33%F5?)),Z)F1N4N1[='8ZU$J'1^?5I2
M829I96T@Y>Z+S4Z%(48H/+!L#6DF_:'P+F#92=^JNYX<TV5QHYS0:3<&E<YI
M.^E_'2ZX]8'$2OXI)*<M:RXA 96TPFXE;Y?UI-!9"OQ:S*JE1,5(/@!Q9:PE
M6,FCHJ]2G2]*]2HJ=Z[DYO3OOC#+MQ$XHR:!2B\+TO\ BE,-]OWQ>*&\R(!5
M8%TMKJDY"VU$PTR)UA4PE\5BCZ\67-HVUNJ^SK&0Q&$G2)1)%C&!K-;TJAR>
MQ5N82F$HEXM3.UW+9)D%P5+36?=U=TZ[U&S6 [J60^[;1;Z<@:SR6X*FA1/W
MB,2F4,3,\NR9.8@8/+Y$1<&9B/=3TQ;M)EK,P(MG+W1.7@F&YW*7P->KD#QH
M!R<M*2LM6V7>W+:(6]RQ>JQY#LK_  JS]TE7)%?7VU2*1/\  +G?+)9H91DZ
MXCU1,5<!IV;T1$G8,^G=5RJ"3I'*7MYE3"2+*Y7I*Z5A-Z<3<VTWBJL$[M1G
MFXV\:XAQFB<GCL<E$^L%]GL\>;-L2R+2=V9[GT]G+XTQZ/*W^0JXY'HG'"E
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MMZD9#&V<A;:$(/M%<PQ&32M[C20155+[K[EJPNE-)_JO%*YMJ(SB8*# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#&
MYVAG N2\RH'(4E=W].J;G+E 5T$-8UZUSF-!SEJ\I"D3*&>5,H<4J9HET;E
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M:.1ML2LS&TI=GF''[3MS8B2HR-G&FF[*)!X0P8^HMB,2H\ 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MDD$$EA"64246$)99980@  (0A#H.M:P#EP!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (A\EN'D'Y".D4L!I<6NH.
M0,$.1I81R5C-1T7/;EAT8"I6GNL4BL@N>M+'3QYN<Q.2U22L9T:-U9W0T2]L
M6$@5.R1S$IM78IZI<<;FB\]&TQ ^.]15]2-9(%C=!*TC2",1XAR7GNKJ<F1Z
M$-0Y/#HIWM0YO;PO.5.SRXFZ")<Z+5:KP9>C=%A!N6WM+JX(& , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
6P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gv1ubg3hw41v000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (? QT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V^SLX)K5)
M)$W,V<G<?6I_[/M?^>7_ (\?\:-/_P"/&/\ '^9JS0!6_L^U_P">7_CQ_P :
M/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE
M_P"/'_&C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4
M5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\
MCQ_QJS10!6_L^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/
MM?\ GE_X\?\ &K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_G
ME_X\?\:/[/M?^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!
M6_L^U_YY?^/'_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7
M_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C
M^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\
MGE_X\?\ &C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10
M!6_L^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X
M\?\ &K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/
M[/M?^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY
M?^/'_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS1
M0!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_
MX\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\
M&C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_Y
MY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-%
M %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_
M (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^
MS[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7_CQ_QJS10!6_L^U_
MYY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C^S[7_GE_X\?\:LT4
M 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\ GE_X\?\ &C^S[7_G
ME_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QJS10!6_L^U_YY?\ CQ_Q
MH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &K-% %;^S[7_
M )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/M?^>7_ (\?\:LT
M4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_ )Y?
M^/'_ !JS10!6_L^U_P">7_CQ_P :SK^-;><+$"H*@D GU-;58^J_\?2_[@_F
M: +^G_\ 'C'^/\S5FJVG_P#'C'^/\S5F@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ K'U7_CZ7_<'\S6Q6/JO_ !]+_N#^9H OZ?\
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MU#>3-/-93-:F9CDN%9<$_GC\*LZCX/LT\(R:N]S=RZQ%:_:%O3.P92%S@ '
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MG\/)+C[*VIQ^;GI^/X9KLXE*0HAZJH!Q6?KVB6OB'29=/NMP5\,KKU1AT(H
MTZY'Q7_R-'A3_K[?_P!!%+!8^-[>);,:GI$D"C:+N2*0SX]=OW2?K4NK^%[R
M\TS3?LVILVJ:=)YL5S<#(D8_># = ?;. ,4 0>.O^/CPW_V%X?ZU3\0V!U/X
MC:;:&YFMXGL7\TPMM9U#$E<]@>,X[5/>>'/$FL76FW>IW]@&L[R.86]LKK'M
M!RQR026Z8' ZUKW&BW,OC2SUE7B%O#:O"RDG>6))X&,8_&@#E+OP['I7C.PT
MG2+NZT^PU*%S<10RL2=G/!.2">!GZU;32K;POX_TBWTGS8;;4(IA<0&1G5BJ
MY#<D\YKH+_1;FZ\7:5JR/$+>TBE216)W$L,# QC]:34M%N;SQ7HVJQO$(+%9
M1(K$[CN7 QQC\R* ,_3/^2G:Y_UZ0_TI(_\ DK<O_8('_HP5-JF@ZQ%XC;7-
M!N;19IH1#<07@;8P'0C;SFDTGPYJMKXL?6]1OX;EI;,PN$4KL;<" JX^Z .I
M.<YH B\($#6?%1)P!J!R?3BN=O;;PI<6US):6&MZK<JK#^TH5EEPXSSOR!P?
M08KL-(\/S6=QKQNGC:+4KAI$$;'(4@CG(X//O678^'_%.GZ3_8<%_IBV"AD2
MY\I_/"DD_=^[GGKDT 4IHX]?^$J7NIJ;BY@M9)(Y&8Y#KD!N.IP.];7@S0=+
MT_1+'4+6T6.ZN+./S9 S$MD GJ<=:ETKPW+;^!AX?O)4\QH)(GDBR5&XGD9Q
MGK3O#-AK^F6Z6.IS:?)9V\(B@:W#^8V. 6SQT]* .:T+2?[;^&>H6('[QKB9
MHO\ ?5LK^HQ^-6;OQ))?_#2"6$YU"^"V*KGDRD[6_3)_&N@\)Z-<Z%H[6=T\
M3R&>23,1)&&.1U YK'LO!5U;^,&OY+F%M(CG>Z@MP3N65P 21C&!]>P]Z ,[
MQ"?[)?P_X81;Y[ 0EKA+%299PHZ<<X)R3CUJ&U2/3]?TN7PWH.N6,;S".\2>
MWD$3QG W'<3@CKFNN\0Z!-J=Q9:A87*VNI6+%H9'3<K C!5AZ'U^M%E'XKDN
MHCJ,^DPVZ'+K:)([2>V6P%'YT ;U>=61\0KXO\4-H2Z:V)HS(MYOR3M. NWC
MUZUZ+6%HVBW.G:]K=],\317\J/$$)+ *"#NX_EF@##\&RHT&M:W=R22ZT&9+
MV-U"^44!PB@$\<=>^*Y[2VTW6K :CKNBZ_J=].S-Y\,,ACC&>!'M8  8_/-=
MQ#H%S:^,;O4X'A.GWT 2ZA8G=O' (&,$8]3W-4;'0_$GAZ-[+1;K3)].WL\2
MWJN'AR<[05^\/KB@#%^R3ZE\-M1_MNTNC+IYE-F]XK)+M"_*Q'<\X[]*Z+P9
MH.EZ?HECJ%K:+'=7%G'YL@9B6R 3U..M:3:9>7_AZZT_5+N*2>YC=&D@BVJ@
M88  )R<>_6JGABPU_3+=+'4YM/DL[>(10&W#^8V.A;/'3TH I?#G_D6'_P"O
MN;_T*L_PW_R+/B[_ *_;O_T$5;L_#OB31);FTT?4+!=-GF:56N8V:6'=UV@?
M*?Q-6M$\,7>E:#K.GR7*327DTSQ2ECDAU !?CKD<XS0!F^"?"]E/HVEZQ>O-
M<WJHK0.TC*(5' 55!QCUSUR:JZ-X>MM>\0>(UU&6>2SBOVQ:+(41F/\ $VT@
MG&!CTY]:[+P[ITVD>'K'3[AD:6"/8QC)*D^V0*JZ!HMSI>HZS<3O$R7UUYT8
M0DD+[Y Y^F: ,GP<CZ9X@U[0HY9'LK1XGMUD<L8PRY*C/;I79UA:9HMS9>*=
M9U21XC!>B(1JI.X;5P<\8_(FMV@ HHHH **** "BBB@ HHHH **** "BBB@
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MUQ_W[H LT56^V?\ 3M<?]^Z/MG_3M<?]^Z +-%5OMG_3M<?]^Z/MG_3M<?\
M?N@"S15;[9_T[7'_ '[H^V?].UQ_W[H LT56^V?].UQ_W[H^V?\ 3M<?]^Z
M+-%5OMG_ $[7'_?NC[9_T[7'_?N@"S15;[9_T[7'_?NC[9_T[7'_ '[H LT5
M6^V?].UQ_P!^Z/MG_3M<?]^Z +-%5OMG_3M<?]^Z/MG_ $[7'_?N@"S15;[9
M_P!.UQ_W[H^V?].UQ_W[H LT56^V?].UQ_W[H^V?].UQ_P!^Z +-%5OMG_3M
M<?\ ?NC[9_T[7'_?N@"S15;[9_T[7'_?NC[9_P!.UQ_W[H LT56^V?\ 3M<?
M]^Z/MG_3M<?]^Z +-%5OMG_3M<?]^Z/MG_3M<?\ ?N@"S15;[9_T[7'_ '[H
M^V?].UQ_W[H LT56^V?].UQ_W[H^V?\ 3M<?]^Z +-%5OMG_ $[7'_?NC[9_
MT[7'_?N@"S15;[9_T[7'_?NC[9_T[7'_ '[H LT56^V?].UQ_P!^Z/MG_3M<
M?]^Z +-%5OMG_3M<?]^Z/MG_ $[7'_?N@"S15;[9_P!.UQ_W[H^V?].UQ_W[
MH LT56^V?].UQ_W[H^V?].UQ_P!^Z +-%5OMG_3M<?\ ?NC[9_T[7'_?N@"S
M15;[9_T[7'_?NC[9_P!.UQ_W[H LT56^V?\ 3M<?]^Z/MG_3M<?]^Z +-%5O
MMG_3M<?]^Z/MG_3M<?\ ?N@"S15;[9_T[7'_ '[H^V?].UQ_W[H LT56^V?]
M.UQ_W[H^V?\ 3M<?]^Z +-%5OMG_ $[7'_?NC[9_T[7'_?N@"S14$=SYD@7R
M)ESW9,"IZ "BBB@ K'U7_CZ7_<'\S6Q6/JO_ !]+_N#^9H OZ?\ \>,?X_S-
M6:K:?_QXQ_C_ #-6: ,/5M'U'4=0M+B+4+6&.TF\Z%&M&<YVE?F/F#(Y/0"K
MD^BZ=?%)=1T^QN[D(%:62V4Y^F[) Z\9-:%% ',VG@^+3K.Q_L^>&WOK1W87
M MAME#=0Z@@D8P/O9X'TK1LM)FM7O;N2Z274;H &;R2$0*"% 3<3@9S][))/
M/IJT4 8K: 8[*T2UNA'=VT_VC[1+'O$LA!#%U!&<ACT(QQV&*O:78#3=/CMO
M,\Q@6=WV[=SLQ9CCL,D\5<HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q]5_X^E_W!_,UL5CZK_P ?2_[@_F: +^G_
M /'C'^/\S5FJVG_\>,?X_P S5F@ HHHH **** "BBB@ HHHH **** "BBB@
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MT[_^/4?Z=_T[_P#CU %FBJW^G?\ 3O\ ^/4?Z=_T[_\ CU %FBJW^G?]._\
MX]1_IW_3O_X]0!9HJM_IW_3O_P"/4?Z=_P!._P#X]0!9HJM_IW_3O_X]1_IW
M_3O_ ./4 6:*K?Z=_P!._P#X]1_IW_3O_P"/4 6:*K?Z=_T[_P#CU'^G?]._
M_CU %FBJW^G?].__ (]1_IW_ $[_ /CU %FBJW^G?].__CU'^G?]._\ X]0!
M9HJM_IW_ $[_ /CU'^G?].__ (]0!9HJM_IW_3O_ ./4?Z=_T[_^/4 6:*K?
MZ=_T[_\ CU'^G?\ 3O\ ^/4 6:*K?Z=_T[_^/4?Z=_T[_P#CU %FBJW^G?\
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M;Q3JURQ%O$B^T<98_KFNJDT;398RC6-N ?[J!3^8YJS;V\-K"L,$:QQKT44
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M+J^Q7U*C0ESU9WCT7<R?^$IUHSI<&<E4(!78 A]C]:LZMXNNKJ>W>QEDMT1
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M;HY&U\):A<L&O)5A4<<G>V/PX_6NKTW38-+M?(@R<G<S-U8T_P#L^U_YY?\
MCQ_QH_L^U_YY?^/'_&L2R:6*.:,QRQK(AZJZY!_"N93P@/[5:5Y$-GNW",9W
M?[OTKH/[/M?^>7_CQ_QH_L^U_P">7_CQ_P : +"@*H50 H& !VI:K?V?:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&K:1;:Q:>3."&7E)
M%ZJ?\]JOT5,HQG'EDKHJ$Y0DI1=FCAM(\)W]GK\,MPJ&VA;>) P^;'3CKUQ7
M4_V'IGVUKS[%$9V.2QY&?7'3/X5H45A2PE*E'E2OK?4Z*V,JU9<S=M+:!111
M72<H4444 %%%% !1110 5CZK_P ?2_[@_F:V*Q]5_P"/I?\ <'\S0!?T_P#X
M\8_Q_F:LU6T__CQC_'^9JS0 4444 %%%% !1110 4444 %9NM:%8:]:"WOHB
MP4Y1U.&0^H-:5%.,G%W6XFDU9F7H?A^Q\/6C6]DKG>VYY)""S'MD@"N1\<>"
MS=-=ZY9RDRA \EOL^]@8)!SZ#.,5Z%16M/$5(5/:)ZD2I1E'E.&^'/B'[=IY
MTJX?-Q:KF(D\M'_];I],5W->.Z[;OX,\;QW5H,0EA/&@_N'(9/YCZ8KV%6#H
MK*<JPR#6V,IQ4E4AM+4BA)V<);H6BBBN,W"BO)_B'K-TOBB."VN9(A:1J0$8
MC#GYL_7!%=]!K\4GA$:V<8%L9&'^V!@K_P!]#%=,\-*,(S_F,HUDY./8VJ*\
M+TKQ-K&EW[:DDTLJR/B82$E)#UP?0U[%H6MVVOZ8E[; J"=KHW5&'44\1A)T
M=7JA4J\:FG4TJ***Y38***@2]M9)FA2YA:53AD60%A^%.S R/%OB!O#FD+=1
M1++-)*(T5SQT))/X"J'AOQW9:W(EI<)]EO6X52<HY]CZ^Q_6L7XJW'R:9; ]
M2\C#\@/YFN4UC3_^$?O='N(E(9[6&Y//_+3J?U%>E0PU.I15_B=[''4K3C4=
MMD>Y44V.198DD0Y5U# ^H-.KS#L"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K'U7_CZ7_<'\S6Q6/JO_'TO^X/YF@"_
MI_\ QXQ_C_,U9JMI_P#QXQ_C_,U9H *X;Q!-;P>)K@WNDG7(FM5\N&.+S3:$
M$_>7!"ALYW#GY>AQ7<UC/H]Y!J=W>Z;?PP?;-IFCN+8RC<HP"N'4CC'!S0!@
MV*I>Q>&]*GNDO[-[:6>5@2T<Q3:%4[N2%+=&[J,BH;K3FB\2S:79V(N=*B,-
MY+IR[ IW"12%5B%QN"MM) R*W4\+BUMK'[%>&.]LW=UN)8]XD,AS(&4$<$GH
M",8%3Q:+<QI?3F_']I7H57N5APL:C@!$W'& 3U)Y.>>E '.VUW%%;VEAJ+NM
MC9LYDCBC>4R.I+"/" Y2,%=QZ;@!G@UW,<B2QK)&P=' 964Y!!Z$5C7.@$):
M?V7<1V;6T+P+OA,BE'QGC<OS94'.?7(-:EE:QV-C;VD6?+@C6-<]< 8% $]0
MRW4,#!9'VDC.,&IJ* *W]H6O_/7_ ,=/^%']H6O_ #U_\=/^%6:* *W]H6O_
M #U_\=/^%']H6O\ SU_\=/\ A5FB@#R[XH-%-/IL\3;OED1N",8*D?S-=UHV
MJ6\NAV$C2_,UO&6^4]=HS7.?%*'=H5G/C_5W.W\"I_PK:\$3>?X.TYL\JC(?
MP8C^E=U37"P?9LYX:5I(U_[0M?\ GK_XZ?\ "J=WXDT>QECBNKZ.)Y/NJP/^
M' J+Q/X@C\.Z0UR0'G<[(8S_ !-[^PZUX]=VFKZI:3Z_<I)+$TH5YCZ^P]!T
M]!P*G#87VJYINR"M6Y-(J[)KE9/$WB'4KF(X!$DZY'\*_='U/ JS8ZV%\"ZI
MI$C?,98WB'L6&X?H/SKM/AMHC6.E2ZC.A66[(" CD1CH?Q/Z 5Y]XHTS^Q_$
M=Y:*,1;]\?\ N-R!^'3\*]*%2%2HZ72-K?(Y91E"*GWO^)TVBQ6[?"_4XWQY
MDCO*,KG[H7'_ *#4OPUUNTM$N--N)"DLLGF1?*2&XY'UXKH/#%IN^&RP8YFM
MYL^^XM_3%>5Z+J)TC6;6_P!A?R'W%0<9'0C-91C[:-6'G_7Y%M^S<)>1[S_:
M%K_SU_\ '3_A1_:%K_SU_P#'3_A5?1-8M]=TN.^MP55\AD;JC#J#6C7CRBXN
MS.Y--71R_C35T@\*7IMIV69PJ*5!!Y8 _IFO---\+W.JZ0]_;W$0=791"P(+
M8 Z'&._>O0/B;+Y?A9$_YZ7*+^C'^E6_A]%Y?@VT;_GHTC?^/D?TKT*565'#
M<\=VSEG!5*W*^QYQ!I&N:W>VMM?BY2*$>6)KA#B-,Y.#CG_]7:NA^)GV9X-*
M: Y\L/'T/3"X_D:].K@OBFF=&L9/[MP5_-3_ (4Z6)E5KPNK)7"=%0I2ZG0^
M'=2@;PWIOF2_.+:,-P>H4"M/^T+7_GK_ ..G_"LKP6_F>#]-/I&1^3$?TK>K
MAJJU22\V=,-8HK?VA:_\]?\ QT_X4?VA:_\ /7_QT_X59HK,HK?VA:_\]?\
MQT_X4?VA:_\ /7_QT_X59HH K?VA:_\ /7_QT_X4?VA:_P#/7_QT_P"%6:*
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MW_\ 'JLT4 5O]._Z=_\ QZC_ $[_ *=__'JLT4 5O]._Z=__ !ZC_3O^G?\
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M^G?_ ,>JS10!6_T[_IW_ /'J/]._Z=__ !ZK-% $$?VOS!YOD[.^W.:GHHH
M**** "L?5?\ CZ7_ '!_,UL5CZK_ ,?2_P"X/YF@"_I__'C'^/\ ,U9JMI__
M !XQ_C_,U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSGM0!U5%<]::_<WUK8PP1Q'4+@L9.#Y<<:,5:3&<X)&%&>IZ\$UT- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->*/!UMX
ME>&;SS;7$8VF0)NW+Z$9'X'W-=+15PJ2IRYHNS)E%25F9*>&]*_LB+39;2*6
M&.+RPSH-WUSV/?(KF+CX6:>TZ-;ZA<1Q Y='4.2/0$8Q^(-=[15PQ%6'PR)E
M2A+=%>>QM;FQ:RFA5[9DV&,],=JQ[?P1X<MITFCTQ-Z'(WR.X_)B17045$:D
MXJT6T4X1>Z"BBBH*,V?0-*N=5CU.:SC>\CQMD)/;H2,X)'J15DZ=9&[%V;.W
M-R.DQB7>/^!8S5FBJYY/J+E78*H:OI%IK>GO9WD>Y&Y5A]Y&[$'UJ_124G%W
M0-)JS/&@=6^'NOX/[RWD_!)T_HP_3Z'GH]?^),26D*:*-\\J;GDD7_5>V.[?
MI]:ZKQ1I<>K>'KR!XP\BQL\)(Y#@9&/Y?C7DW@FR%]XML4904C8RMD?W1D?K
MBO6ING7@ZM1:QW\SBFITI<D7HS:T+P7J?B"].I:XTJ02 L3(?WLG'&!V'U_"
MM1?A5;^4P?593)GY6$(  ^F?ZUZ'17)+'5F_==D;K#TTM=3R*\^&NMVOSVDD
M%UA\*$?8V/4[L ?F:9-X*\7QPFW7=+"_WD2Z&T]^02*]@HJEF%7K9D_58=#S
M&T^%EP]LQO-1CBG/W%B0NH^N<?I3+?X67IN\7.H6XMA_%&"7/X$8'YFO4:*G
MZ_7[E?5J?8QO#_AFQ\-QSI9M,YG(+M*P)XS@< >I_.MFBBN64Y3?-)W9LHJ*
ML@HHHJ1A6/JO_'TO^X/YFMBL?5?^/I?]P?S- %_3_P#CQC_'^9JS5;3_ /CQ
MC_'^9JS0 5S.L:/J;/JU];WENYN+4Q)"]FSNJ!3\BD2#J23TZD>@KIJ* .0B
MMK[3_P#A'M2N87G%O;-;SK;V[;XU=5VG9EF."N#CUS@4\VZ7M]JVL7>E27%F
M\,4$%K-;$O,4).[RV&0-S8!('0G@<UUE% '%W>F3Z>('G%Z1-%(9SIHD!24
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M"M]C_P"GFX_[^4?8_P#IYN/^_E6:* *WV/\ Z>;C_OY1]C_Z>;C_ +^59HH
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MI_PH LT56_M"U_YZ_P#CI_PH_M"U_P">O_CI_P * +-%5O[0M?\ GK_XZ?\
M"C^T+7_GK_XZ?\* +-%5O[0M?^>O_CI_PH_M"U_YZ_\ CI_PH LT56_M"U_Y
MZ_\ CI_PH_M"U_YZ_P#CI_PH LT56_M"U_YZ_P#CI_PH_M"U_P">O_CI_P *
M +-%5O[0M?\ GK_XZ?\ "C^T+7_GK_XZ?\* +-%5O[0M?^>O_CI_PH_M"U_Y
MZ_\ CI_PH LT56_M"U_YZ_\ CI_PH_M"U_YZ_P#CI_PH LT56_M"U_YZ_P#C
MI_PH_M"U_P">O_CI_P * +-%5O[0M?\ GK_XZ?\ "C^T+7_GK_XZ?\* +-%5
MO[0M?^>O_CI_PH_M"U_YZ_\ CI_PH LT56_M"U_YZ_\ CI_PH_M"U_YZ_P#C
MI_PH LT56_M"U_YZ_P#CI_PH_M"U_P">O_CI_P * +-%5O[0M?\ GK_XZ?\
M"C^T+7_GK_XZ?\* +-%5O[0M?^>O_CI_PH_M"U_YZ_\ CI_PH LT56_M"U_Y
MZ_\ CI_PH_M"U_YZ_P#CI_PH LT56_M"U_YZ_P#CI_PH_M"U_P">O_CI_P *
M +-%5O[0M?\ GK_XZ?\ "C^T+7_GK_XZ?\* +-%5O[0M?^>O_CI_PH_M"U_Y
MZ_\ CI_PH LT56_M"U_YZ_\ CI_PH_M"U_YZ_P#CI_PH LT56_M"U_YZ_P#C
MI_PH_M"U_P">O_CI_P * +-%5O[0M?\ GK_XZ?\ "C^T+7_GK_XZ?\* +-%5
MO[0M?^>O_CI_PH_M"U_YZ_\ CI_PH LT56_M"U_YZ_\ CI_PH_M"U_YZ_P#C
MI_PH LT56_M"U_YZ_P#CI_PH_M"U_P">O_CI_P * +-%5O[0M?\ GK_XZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %8^J_\ 'TO^X/YFMBL?5?\
MCZ7_ '!_,T 7]/\ ^/&/\?YFK-5M/_X\8_Q_F:LT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH **** "L?5?^/I?]P?S-;%8^J_\?2_[@_F: +^G_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML"&,8/(CR1N]\XXS73>';6YTZQFTZ=&\JUF:.V<G.^'AE_(';_P&M=5"J%4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=S>Z<EO8W<BI'(+C=(A?[F]=H SQT8X)%03^*+I(]5GBTH26VF3-'.YN=I8
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M[NV"LRQR^8C(V<,&(4]01@@=*TZ "BBB@ HHHH **** "BBB@ HHHH ****
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M-S!,\K,6&.,JNW'7O6Q10!SG]E:M>P6-CJ!LUM;62.1Y89'9Y_+(*_*5 3)
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M44 %%%% !1110 4444 %%%% !6/JO_'TO^X/YFMBL?5?^/I?]P?S- %_3_\
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M: +U%4?[5@_N2?D/\:/[5@_N2?D/\: +U%4?[5@_N2?D/\:/[5@_N2?D/\:
M+U%4?[5@_N2?D/\ &C^U8/[DGY#_ !H O451_M6#^Y)^0_QH_M6#^Y)^0_QH
M O451_M6#^Y)^0_QH_M6#^Y)^0_QH O451_M6#^Y)^0_QH_M6#^Y)^0_QH O
M451_M6#^Y)^0_P :/[5@_N2?D/\ &@"]15'^U8/[DGY#_&C^U8/[DGY#_&@"
M]15'^U8/[DGY#_&C^U8/[DGY#_&@"]6/JO\ Q]+_ +@_F:M?VK!_<D_(?XU0
/O)UNI@\88 +CG\: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gv1ubg3hw41v000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000007.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I ET# 1$  A$! Q$!_\0
M'P !  $$ @,!              D&!P@* 0,"! 4+_\0 61    8" 0($ @,(
M# H'!@<  0(#! 4&  <("1$2$Q0A%3$605$*%QDB(V%QD3(X.55T@9BAM]'7
M\!@T4E-S>9.QLO$D67>4P=CA)2="0V*V*#=$>)*BI__$ !P! 0 " P$! 0
M           #! $"!08'"/_$ $<1  (" @$# P(#!08#!08& P$" P0 !1$&
M$A,4(3$'(A5!42,R87'P)$*!D;'!"!:A)3-RT?$7-#9#4N$U4W1UL[1V@J7_
MV@ , P$  A$#$0 _ -_C&,8QEO\ :L[>*SKB[V#6E.1V%L&(JTY(4NC.)EE7
M4+9:&K!96#@7$[)'38Q#>2D"H-G$@Y.5)JBH=8PCX  :]I["0L:L:2V"46-9
M&*1@O(B-)(P!;QQ*QE=5^]U0HGWL,GKK \\:V9&B@+<RR(O>X106(13[%WX[
M%[N%#,"Q"@D0.6/JG<O--T'G=";<HF@KQN_BWJG3ERKS_1<9L>?UU$;.WI/E
MK$!HK8<4O/2D[-W.GO'49-3:]2G&)IF!>$5;Q40NJW*K-*R24T>E*9)?^<=9
MTJER2"0T]G%9%2?8;&A6CYLI^'5YITFK/),ZV1!'W%V>(:11E;,0NE((INE]
MQU%)5\\2V]<^OCL>AI79V[JQ&UF2-*\X$:=BS2<&/LDRJJ7U+>1=DTE1V$!:
M^-.R^3NY.54)QDJK1IJ+?NG:=I>7?4Y_=I=;=VK]EV-3:QI2-@821E(]FP>U
MY";92,0HV522]0N:Q)"9[&GJ4'C8W:_4%ZS>>1;%5JV@A:>Q!7C@[9(KP=J]
M.>*>0FO+.)FC9$"2PQR1Q0;*Q>$L;4UT\<5'L,5A[.ZLK!6D,TH\<E(QF2PD
MT2%95K2PK)WN&C\4^ISROV34]/Z[T]K[1D7R?DFG+J2W*>^$O<CJ6-;<-+0V
MIEN94AI"2<=9A<[.GI2%"J.I>5<(5=H[<GE4II5J4BU&6W U27=UDD.GI]&T
M.LK-:1E]=+%>V$NL_"X)PH@26&U1VI:X\+*T52$^G4V>8[,<"K;DU,\Z'8MU
M8W2D%B)2M-776KMVV4L;EIGB6E8HKZ5'64S6'/>$A^_+>)ZN/#BM:/XX;9Y!
M;6@-&R_(K4->VM7ZE/L[+*+I-)%NBC,H-W<+!/TUFT5->JCB+K^0JX(BFN"(
M%4]NOLZ:4;\]:*5IH5\4M>5E"-)6LPQV:SNHY"R-!+&9%!(5^Y0?;.5K;AO5
M$G=5242V:TZH24%BE:FI6/&3[F/SUY/&3[E."??G,K^,_,#C;S%K5DM_&K;-
M>VS7*A8@J=FE*\A+()0UC&.9RX1#U*8CHURFZ^&R#-V( @8GE."=E/&!BEH9
M>S)7&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QEL
M]R5>\W;5E_J.L[PGK*_V:HST%4=B*0A+(%)G96.79Q]G) J2$4657AEUBOFS
M,\@U(HX13\Q4"@(#4O02V:TD$,[5VE[%:5 2ZQEU,HC(9>UWB#HK\_8S!P"5
MX-FG-%7LQ330BQ'$Q?PL0$=U!,8<$$-&'[6D3C[U!3D=W(B=XH=-+E;Q@T-L
M32<3S6IZ$E9U&UIKVVJ5QCKT3LI;:AK&G/V"][<F+U?MCH[</;D4QA9QK(M(
M600C5CE@IF'.W9"WZ$\S25*4$$<=8ZV:FU*")>W7+4KQ2K9IS5%*R.;LS03R
MV8K,$_EB=F=Q(0*:1CUERS.TEC\1ANB[+(W]N:S8*>DM0VN#&@UZ"6*"M)6F
MKF-D4QJ4+-[9NE%='U:L^P)SDTK(<T;#R-I7*)#D$WU5"LZ)#[#U[3%]<5B!
M9Z5^D:K52B$H[V0B9.-<7!2:D'+]>0&<253;IHPJJTQKAJQZ8TIM]/.\W%A[
MK]3UTK;D2?\ =B)6C@J^C\7_ +N]6)W$[-,9)O(UAK[;%4L"W1U6OA$*F#TD
M&BM27M8\9+2AYQ9FL-;=U'FBLS1((AXV3UI+I*6F#UWJ!/4')R0H/(&B)<A6
M5]W;+ZP@;<SV;'\KY8M@WB1:A*SL6RKCYU/(1\G0WC28>%JAXMF@\0G4!7*K
MI+! R-KX4:'23=-5.D[=($/8EU-*UZZ&2*X>WP[!KLMV:2?PM$?7VD$"CPE-
MX9W6:6_,(Y=JW40ZGAMK&(XH]D*;:WL:MRXDIF@*T#1>179J<$@E4]X:3O1N
M@*!HG2^J]'UJ+1D:OJ.BUVAUYU.-F3Z3<1]?C4& /7JPH^6+V0514?O11(FB
M9VX5,FF0GA*'0OW'V%R>XZ)%YF7LACY,<$4:+%! A;[BD$"1PH6)8K&"Q))S
MG4JBTJT=96+]K32R2%0IEL69I+-F8HOVJT]B665E7[5+D+[ 9&=TJ6S=KR-Z
MQ#=L@BW01ZAKTJ2*"9$4DR_>/U6/A(FF4I"E[AW[  !W[C\Q'*>6\FBQC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9TN'"#5%5PY63;MT
M2'5676.5)%%),HG4554.)2)IID*8YSG,!2$*)C"  (YAF"J68A54$DD@  >Y
M))(  'R20!^>9 )("@L2>  "22?@ #DDG\@/<Y@K(]4/IUQ%]-K&3YJ<<&5Y
M3>C&JP2^U*J4R$D586XQSA_\0&*;OP7#RO1KODW/F"!/*\1@ <USZOM]-^V[
MO9.S^_R>!X^>._DGV[.><S,K5^3,/'P.6[N 4'!/+CGE?C^\ <SBC9..F&36
M2B7S23C7S=%VQD(]PB\8O6C@@*(.6CMN=1NY;K)F*=)9%0Z:A# 8AC%$!'9E
M9&*.K(ZGAE8%64_H5/!!_F,C1E=5=&#(PY5E(92/X$$@_P"!SWLUS;&,8QC&
M,9#'TL/VR76,_P!8<]_H.U7C&3.8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,B9YEVGEULW<5DXK:TU#JIYHB>TY!6&Y; W%6-FV&!L"
M$]:Y"$N*$(K3).!K<B_UA&,8>:D=4STTQF=GL;$*$9(QL?%OS.J:HEH;-K_9
M%6UUFB\2FNUF62):L^P%Q:TA6.^DENJ=6:L(9Z4CQWK FC:.K)<9C637M39Y
M;=V/8(X$H@2.1):M5*;6$#249)*UN6^EV13'*M=Z<7BF)LQ?1X(Z+TYMSBK5
M7^X>%7'FBR#I[<*\$ AQQK]"AK;4H&RR<'5[XAK>VP;FQTEE?*\S8V1*JV!P
M[DHI%^5!9TN3RSYU+L<<D=%Y$[9+.LHV[=.66.T:%N>%9):9FC 20PM[_NK)
M&6$3JLD;#.?%S!8O0QR^6.K?LUX+B125_5QQ$#SB*3[UX=I("X9HYC"T\+&*
M5.)"]4:AUOH^GM=?:FJ$10Z-'.W[R)JE>2.T@(<TFY,\=MX6,%0[:'CA<***
M(Q<<1M&LQ.8K-H@0PER-Y991$)9'D\$*01M(Q=Q$A8HI=B6?M[B%+EB%"H#V
MJH!(HXVE9%"F>5IY HX!E945G[1]H+!%+=H 9N6(+,Q-RLCR3&,8QC&,9#'T
ML/VR76,_UASW^@[5>,9,YC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&>(& ?EW_4/]7]_D/OWQC!3 ;Y?S_W^WN'\7V>^,9Y8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,\5#D2(=50Y4TTR&.H<X@4A"$ 3
M&.8P]@*4I0$3"(@   B/MC&42&S=<&KRUN"_4P:HW=F8+V8+1!_1]%^1QZ0[
M)69]=\.3=D=?]&,V.Y!8''Y'P>9^+C&5FBLDX23704(LBJ0JB2J9BG353.4#
M$43.41*=,Y1 Q#E$2G*('*(E$!%C.W&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG4H4 *(@ =Q,'?\_\ &.8(]C_L
M/<_P_C^GO[8S5/I&]+Y=.2V]4;-2NKGR&;5KE]>*56MK\=K::D<:8JL0-JC6
M+&IJTP;=34RQFO#@ZKUP62AIA.=)'/I,T@Y4?*,VSIQ?)2Z;G9BDELM+/<VW
MW5+?&WMQIL'C]FCUSUTC#0>)!&D<RHLHX9L=2#PV-[$JLT5>K (:6K 6[6[]
M-4FDJ1R_:9+S67>2&P9I.XV(69H^ !LZ[/EKW!ZZN4QK"L1]TV+'5>:>TBHR
MTRE7HJQVI"/5/!P\G.+%.G$Q[V1!!!X_,0_IFYU%2E,<I"C!:-A8'-5$DL?:
MJ"1BL8+.JL[%>6*QJ6D[5^Y^T(&!;N%BJM=YXELR/'7)YE=%[Y.Q06[4!X'?
M)P(U9@50MWLI"D9 B[ZH7+_3[7E;K3;$'Q\VKNK41N,=;J=IU"TN45JBH;DY
M27MK0HS3.QSR4U.O9B9UH+]E:YI_ RC!U-P:J:"T5!.W2(ENPQ#8C7U=?(5F
MO=:5ND*NTGC?T5^(Z_\ $MAM8:P9)4_#X8IJ\U832+ZF2!1,"LRK6F<T%LWK
ML1:"GTILNJ;NKKR+)?HK3G%>G1FG[A')^*22HT$XCB*1P6).QT\7=7@=1;ED
MTKTOQU?Q.EE.9;3F["\+F6QFT#<$]%JC/ZS2W&UVNO25+">V@BUI?JF2U3):
M0$\TDD;XN5F<XEAB(V7X)^'?V8W8^JVOBR3-X6Z/,BVQ7*"/O_$.^B\(D']G
M6S-W&4P())Y86UQV9V)$RP4^G;>N\!\1L#J>7P5HY@PD\8HS07Q(P#&S'6B(
M\#V#X_BM^I1R]VE5=0ZNU'6](UODZY:\OY/<LW=8JY36JB-^&%K9TJQQ]'AH
MJ=C9]!?:L[+0IH1Y*RSE*HL%WXND)EPV235@EMPM4EWE:-_PJET90ZRL4Y7_
M +7,M[86-7^%1SJOCC:*SK]G(;;QMW105OV2F=RF\,*B[-I9YE?8OU<>DZUJ
M-&2K&?PI-T=E)"W=)*$IVZ$1K+(G,LTK&4"((V6D=UA>%E*T;QKVKR4VY":(
MGN1NGJ_MB J,U#W.=53:/T46TRBV>UNM3**C6-G/4QZ"KH[9PY233<>04IQ[
M=?9TTH7IJT4C2P@0S5Y6 5WK6H(K5=G4<A9#!-&74$A7[E'L,Y.MN&]46=U5
M95FM59U0$(+%&U-2L&/N^XQ&>O(T1;[FC*,WN3F.W14VUKO>VRNJ]MW4UG:7
M/7-\Y\NYNI6ABVD6329BSZ5UBW*[0:R[./DD""NW63\#QDW5[IB/E^$2F&AE
M[)X<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MS5MZF?#[6X]3[ILU]G>N1L' <U]R\AD=_0-:Y.[WK<'/MZ;J5O9:\VKD1"WQ
MDPHK5C,E*Z%M3T(=%4OB15(=$PD%C-F+7U'A=:4:GZ\K:DPK7J-68.I0:E@G
M9>SSJD37HUO%1YYFQS[N0G)Z4.U:I&?S$P_>R<DZ%5V]=+N%5%#,96&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC+*\CDHMQH+=+6<H=LVE#O-6WIG*:THC
MR0CKG?V+NMR39S3:M(Q4I"R4?.V5%4\/'/F4O%N&;IVDY2?M#)@N1C-377/$
MVW*Z%HMPLO3\W>K12\KK+LWD3PABM<,X>HQ=>EN,EUU#I2-U-2;+;T&NRF6O
MI[Z'S6Q[W+/8Z;F[R]D+BHR6*W;J-F,F0T+HOJK:ZXL<4Z%1=Y\:J$ZH7&[6
MU9O]<W;I^][/NS*_Q3!U\28GM53VI4HA:/A88\!6DVP1[I8KZ%D')I5ZB[1,
M1C,S.G7OK8W)KASIW=>VRU<NQ;<A<V]I-2XQ]#5=5_5MA6RGD<0\7)2<R^8M
M7+6!;N/(<R;Q0BJJG=7MV*5C,V,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8SK4[^'V[?/Z^_;Y#W^0#_?Z\P1S_ /;^
MO_3YQFGJEJO<NPN7>ZKQQAU_U<)[527+NV-KM::+S:U'J'3#N\U^W,&>P7#7
M3TTT0LB],CG#8S%1LX!1].P;$J*2OB.F!,=+ P5^FY;!*:]K'J*C[4FY'^'M
MM[/DEM01@-X'L+9EFK ([+WJP[B2=.IU,OX_!#]VP%)8+ U?%:<6FTL)K15+
M$I9/4)6DJI!98F..3M /8@"[8VW*E;+]JZ^4NB7U?5UQM51G*_6]C-(5*Q/*
M1+R\<LQ9V=E".'\6A)/8958'S)LM(-4C.D4144 I1#*UVN]NM+72=Z_F4(TL
M?/D6,L/($(92CO'W1A^>Z,OWK]R@&Y4G2M9AGD@6PL3]_A<CL=E!*!^5D5D#
M]K,A4K(H*'V8G(?M/]'.UT;BS?N)M_Y8HWJE6.1K-[J-RK''JI:\V;7-W5.^
M1VQ8[<EPN"]SNSS:]D=6*)8#+(6PA/6QZ:K KUNV4(1#HR3MQJ)*JI3M]/7]
M;>T;PK_8J(UZRJU<ZX=D4T=SR$V3Y(W<M.S,[S=Z45A5GVB6BUNIOJ6SH[N*
M9B;.PCV(558W?>2$TU!%5!')''V0<*$B,<ES"=*=T;7DF\=\EK*ZY72/)V.Y
M>?X3OWM*@D@VW%#U9&AQB26GP=GK9J&WHR(UL]5/.BZ5266>_'2.SE,2 @0#
M4C7#T0U2[M"7_M36QU(UAMUYVD[2IG:=#5\? J>DICB81.);'D>8[+UY%L;"
M#55E"CTYJ1:*2*74BL5+\&&2)VL%PWJ?57%XB68+'\F0Z1ZD3KW4;#5/)^Y:
MWW=KY#D"RN&]5=<TRVO-H,.5$J6>WFE+T>0690T&[F9M%C)4U]%R!STQ:-8D
M,E.HIJIK:2PP,IIPQM!IY>G*G2EK7B0M+-J*5E;L)2Z5#PWC<-J=[(B:,G87
M56NHDC\>\5B599;LHBEVC=0?\SPW1&(TAVOI)-?PU928YJ(I-#"*A9#S4K/Y
MAV.LDC>GN.&J],Z?U;I6"K47-574=&K]!JSBS1<7+RHQ,!'MV)%W;I=EX1>/
MSH&?/S-TT$57BZJA$2 (%"_>N/?MSVY$CB,K+VPQ B*&*-%BA@C[B6\<$*1Q
M1]Q+=B+R2>2>?3JK3KI75FD*F6225PH>6:>62Q8F8*%4--/++*RJ H+D* ,C
M1Z4;)E'<B.L,RCF;5@R;]0MZFW9LFZ+5J@F&C]6#X$&Z!$T4B=Q$?"F0I>XB
M/;N(CE3+6338QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QD#'4O_=5NA/_ -M/*W^@A#&,GGQC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,9QV#[ _5C&=3C_%U_\ 0J_\!LP?@_R.,C-Z.?[G5H+^&;A_
MISV5F%_O?^(XR3C-L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,9ZKQ=!LB*KE9)!(#$**BRA$DP,<P$(43J"!0$YS%*4!
M'N)A I0$P@&8/OP .23P!^I/Y#W!Y/\ #W_08X^3^0!8_P %4$DG^  Y)) '
MR2!SFGPCIB7B.8F]+#MOA-U8]E6FT\O[-;(/<>H=IO\ 7VE)*G'LT2UI<JZI
M%?OD#&N(*OP[)NT?.'#&2<3D''ING)R>I&+9XZ6;QUNG$_\ <;<,[FU)M.)H
M1;DW-F<W+$([T2L\;0RV($C[ /,/VW=WG7J?B9M\X1KE62A%'7K:TA++P0Z:
MM ].M8Y5VG,PG2M,T@*%H5!B[/?<(;.F[H#^0LDMY*AD5124(IY:R?8%$5/"
M(^!4@B '3-V,41_& ,R#R >/8@D'\CP>/8_F.01R/;D$?.;?'M\<>Q'YC^!_
M0_P.>SF<8QC&,8QC(8^EA^V2ZQG^L.>_T':KQC)G,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S4/ZIO4UXSUSJK=-XLB;8/C
MX5[RY)--S@VJ22P%7L&IF];8!53&ETOCA DQ[.3J P!)N KE!3V(/OZWTUZE
MM+TJ\0H<=8I9?3]UM@2*M<VI/5 0GP$Q#A0/)]_VG@<D<YMI40W0QD_L'9ZC
MA.0/)\=GO]W'Y\#]<VL-4[*KFY-9T#;-/]?]$]E4VMWJM#*-08R0P5JB6LU%
M"_9 JL#1X+)XB+EN"RP(J^-,%3@4##X[9Z^QJ=E?U5OQ^JUMRQ2L^)^^/S5I
M6AE['X4LG>C=K%1W  \#G+L,J3Q1S1\E)461"1P2K@,I(/N.01[9<#*.28QC
M&,8QC&,8QC&,8QC&,8QC&,90&T9J\UVA6:9UI4HN]7YC&G/5*E-V=.F0T[,J
MJI(-6<I:%(^6"%8@*HK.GI(N07*BD<C9FNN=,@L9";M/FWU!=%[HI^K]A/N'
M$I<K>E3)!SKBLZ_Y2.:73X_8EHE:=K]I>>2#&'G*I1Y&^V:"F*Y5']JIS2.>
MS#%P9TW:1Q".%']?U_7_ -F3G4^0L$K5J])6R!1JUH?PL8[L5:;RJ4\V@)MP
MS15E(=O-HMVB,NA'/3+M49-)HV(^32*Y*W1!4$RL94>,8QC.EQ_BZ_\ H5?^
M V8;X/\ (_Z8R,WHY_N=6@OX9N'^G/9687^]_P"(_P"V,DXS;&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&43L?7%(V[1
M[+K;9%:B[?1KA%N(:RUN9;^ICI:-<AV5;KD Q%"& P%50<(*).6JZ:3ALLDN
MDFH6&>"*P@CE7N >.5""5>.6)Q)%+&ZE7CEBD59(Y(V5T=0RL",DBFD@<21G
MAN&4@@,K(ZE)(W1@5>.1&9'1P5=258$'(C5^CWQW);%J]%<QN?=<IWY%XOQ^
M@^;>Q6U/09N%#D9MVR*[]SL>.@U"HG9M(UE<&\<HDB=)-(QDQ,66/E@QG)O!
M"$[K)+E6*=Q68IV>5F12Q$W>67N8>W)S1^%X\*+3+@G]@.Q6"L.TQ(_>D?82
M!S$H ) //L,E4TQI76?'[7T)J[4558TZD0!7!F$0S5>.U%';U<[N2E).4DG+
MV5F9F5>**O928E7KR2D7:JCEXZ65.)AFFGEG96D*\1QI#%''&D44,,8X2&&*
M,+''&O)*JJ@<LS'EF8F&*".'R=@/=-(TTTC,SR33,JJTLLC$O)(RHJEF)/:J
MJ.%4 74R+)<8QC&,8QD,?2P_;)=8S_6'/?Z#M5XQDSF,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC(7.I9U7=L=.RU10#P(VOO+3LP-!@V>\:S
ML:HU>K*;&V%-2<'#ZZ+%2D7)2PS0NF;'PNS%(Q5&5;D%1+RU#"QDBW%7<6T-
M[:<@]B[AX\W#B]>9.0G6DAJ"]6"%LUCA6L7)K,HZ1<RU?33C5D)MHFG)-4TR
M%5116*FJ43AXA8S(W&,8QE'WW8%)U;49Z_;%M=?I%*J\>XE;%:;1*LX6"AHY
MJ03KNW\B^51;()D .P =0#',($3*<X@46,_,?ZPV\>6?,;J24S=/%Z)WS.:M
MMMD;PO JP5BBW*IM[K(5*)BVUUL&K&;A@S=3,@ZL*+]_,V(C<5Y&'*U<NSA#
M(M2)S"Q.H3B>8>/VCXED'C'!'$?#?9R"0>WCD$@_)YQP/?V'O\_ES_EGZ4O&
MYKLQCQ]T@TW2G'([@;:EUVAM)*(1;MXQ+8252B27%-@W:%*T0:DGP?E12:E*
MV(0 *@ ) 0,B)9F9F8LS,69F)))8\DDGW))Y))_7,@<#@? ]AEZ\QC&,8QC&
M,8QC&,8QC&,8QC&,8QC,6.;=BK%2XG[ZLUSUT;;%7A-=33^9U\5](Q1;&U1!
M(?)<3,0W=R\&S8JBG*O9V):N96#9L'$M&MUGS-!,S&0B<,-+V7DX[TOR_D]6
M4'DA":LV0YUE7$]D;0N4]>Z!7*+9$Y.#OFF=_2E;HZ7)?6E5EYN2?P%:Y":\
M+=J[86=E3KNRI%1%NW=,9LOD,!B^(O80'L("7Y#[!]GZOXNWU8QGGC&>J9ZU
M(DHN=RW(BDH9)14RZ94DU"F ADSJ"(%*H!Q\(D$>X&_%$ 'VQC/-P/=LL(?(
M4%!#M\O=,V8;X/\ (_Z8R,[HY_N=6@OX9N'^G/9687^]_P"(XR3C-L8QC&,8
MQC/E3$Y#5YD,C/2T9"QY5$T3OI=^UC69%53>%),SEXJB@"BIOQ4R"H!CF]B@
M(XQG,/-P]@9$DH*5C9J.4,<B;^)?M9)DH=,?"H0CIFJL@8Z9@$JA0.)B#[&
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MXL9F7C&,8QC&,8QC&.X?:&,<C]?Z/QC&,8QC&,8QC&,8QG'<!^0@/\>,9SW
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MS4A&OZWT_ET;G=MO::W!O3:#R-F.2[/83M*^A%3UTV-69NPL:>6VVW6U3B*
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M%6&G?MV;UN!2L]NW##7LS.6+=TL->&"&-@K!0J1(.U02.22:[RWEK/ RA""
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M(V)CPGJ=;:VT@U[2X?*Q)64L@_4G@/\ #XM1BZ$5\\WU-],JGU'UXAM1U/\
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MTJ*T00.>2W RS731^Z1*17^*FH]><D./^SXVPZWK%?UK#VC5=1F[%5+'5*5
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MFBV+AZ\7:,A1;JNEU$C*&I0Q+#%'$B)&L<:1K'& (XT10J)&  %50.T*JJ%
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MD[F1$YY,2>)5=R. TL8');VQS[@<'WY]_;@<<?/OS[\^W /P<_0[*FFB4I2
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M3K4B\,<EB>:1>) 6L2R$SR'R$L2[\GN_=(X[?M R1+*&7,B1ZT6N]<[.X5;
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MH-6K9 A$4&Z"9$DDR%33(4I0 /E:1I$B1QHL<:*J(B*%5$4<*JJ  %4>P '
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MQ.3#WR_5R<H^B6Z[QZX\I-)+SEUCG4.":9"@81 "@'MGL1_W55OS>C0D<_\
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M*-C*O6R>7+"-#-1JH&GMVJVROS5T4IZ37:M/+/=:64K'8B:,HT7I6D:1I(E
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M&U,HO/AU"5Y"P62?M\TFP3TIK%P 2-FM,C+V&9<"JNJ(NY62=NA()4Q5$B9
M#GYT,GC-^Q']']_[_7C&?G\_=*^V->:>Y\UM"M\Q.:E9V+<PU!+;GU1I^[NJ
M[K#5^H$(,81\[J:#:S11G.UK*TBFUG9Q;MH2#,5^9S*O2"_;!CYQ_7]?]?\
MIDVO!+J+QT!Q3U%H[@3H[G'U'G]8A7J*6]-M02.K*G(/IV:D+"Y;7S=6RWQ8
MU\]K:\P>"=EK;2R*(MXLJ;+UA$0$V 0?C_T/Z'^(_/'(/P>?R_Q_3,L4-3]9
M7DJH8^V.0VB.!U!? 0%*7QLJA]V;D!FH9R*C5YM393=G4H22(F=LDH]KU4D
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M>'K=P@-DS-=(]=/X[;BNH+!/1<%(LI;6=2A*[%UYDHHHZ18S<!QC/$Q0'W[
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MV/4WHZK6AS^V A,?D[@OV@9D,IPGY0VI4RFR>I!OM=$Y!(9CJ>D:SU,W I@
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M:M6WEBL0AG"JAG"JRYU#**&,/QCJSZ'=+=9;ZSU%M]EU#ZZQX0J5[M6."M'
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MX[FQUYU<Z-4KW$RDG,/G"LXS%\[EQEF3I=XX)*E0**C9P9207$Z+DP@O\_\
MI-H?K)5KW]'>V>SZ2IUR]ZC)M-!KMS!8GM3LUR(V+,PFB=IG$X1699"UA^5(
M ?ZO]>NK?^'+86]9U+1TVIZ^V%D1:O:0Z/J3<].7:E2C7C77S"O!2%*Q#%!$
M]1G/;-$%K1]KP@%,[PKO.N,*8&6W>.=H*4P@F:P:XMT,LJ7OW#SCP5M\DIO#
M\Q2(4G;]B4!S[)Z#ZPP=RQ=0]#7EY^R2YI-K5DD"\>[)4V+QH6'/(7N"\>Q
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M)7[K]%/^'SZ4]?7=ENM5U;N^JM%K*]O76J&SZ8LZ)HMCLJ<T5&<6_535[$U
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M*3D7K>,TM<>3$UI:-AM.Q]TA=BNJE5M'Z[-2V\I-VRN-&L(ZDK5+2,Q)MF+
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ME46."#5!142))G44\/A3*<X@7-)94AC:20D*H!/ )))]E55 Y9F)"JH!8L0
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M\;NWDD0<++$T?84:.9^3/9C2+76JY-FCM+\E&G9 :)G$>ML;'SRP2*)(5F2
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M5Z.K!V\*)$9WD:*-A<79W"5'8]LYF6D^P742;ESQXJ>A%V9*X1V6CI5:&O\
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M6N!$JPUHF,[--,A;8ESG9<QC&,8SQ$W;ZC#^@HC_ #_+^_Z,QS_/_(XQXO\
MZ3?_ ,1^O^_O]7Y\<_S_ ,C_ .OY'^B.7]?Z?^?^OZ'.0'O]O\8"'^\ S.,Y
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
JQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gv1ubg3hw41v000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000015.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'L E@# 1$  A$! Q$!_\0
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M@8YD"+:?6, QO54VVSFVUV2W,%C4A8J]=/\ M5:T8[8*T0X "1)P/ '<Q9R
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M,BJ.=EGI)QU(;4:T$E1CARWDC(%3LA3NFM;7E8$;EQ$$<R%Q&(PI+ER>T($
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MXUV]V5N&CJTUTYCO43+=L,BO-#$R16(X$EF25&_P^"O-KO&T==X;RUPJ#Z/
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M+2A"-;4I:U:2E*=?[VI2MZUK6O\ SO>]:UF(!/@#D_(9Y@$D  DGP !R2?D
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MVVVC6U+6K>DI3K:E;UK6]Y(!)  ))/  \DD^@ ]R<D L0J@LS$!5 )))/
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M.SSZ=M/K=\-8)9-EM)K]F6:,&)T>1))JM5).4X6$RJ 0P629[!Y'P0!^FY-
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MB-,!W&1PI#4:X&!^PIX9@50S#1#OQ;"E1JZ7;&D+4:VHM7L#6MRQSR0C[?-
MI66**)61P['[REP .6/G,]QH=-K.BNI'UJ7X)-EJ^GM_)0V,\%N6F!U-8U2M
M%8BKUF,<\;/(5D1Y .WOD;QQ>[IRUW7WCYJIK?WJ%Y%ROK7:Y=M#BM-J?MNP
MN65E93>OE/\ V7ES[@:M_:K;FG_^6TH4A5>J 0=.;6<\<W;M*@AX\CX'=<E
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MUUTLQX ^RS>3_P#F?KU],]STCU4H+-TWO54<<LVJO*J@GCEF: *H^98@#U)
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M;3^8B40((\V9HQ]@C<ZNUM);^L@J3-),CBI4BDY>%8K,A,L+J0>:SF1VF4^
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MY/VZU][:#8Y\AE+[6]Z2^,XI!#"_EMYIM>MIU[V:MFG*T%N":M,O!:*:-HW
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MEJVZLJN ZM'+#+&P925< JRL >&'GW!&<L*['2[!2Z6==LM?8215D1X+-6S
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M*_2=*:%S?=2(;$L.Y@>:37;4S30B65YOLELN)+U$L_\ E:&:3O7P.^)T=>\
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MR189$S##"*41O*.^L4:!IQP02.EAK-.U,O?+2DEB$4S0*W*!G5496(_PY 7
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M_G6W6?\ KG0"5-HWI2=Z4M0R4[W_ '_PVO\ I/\ \Z;%TM_^UU/_ +:.T/\
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M*5=&^&Y[74@$'@@\'V(X\<9JOV@HT4O2$$JF.>#H3IV*Q"X"RPS<6W,<T?\
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M=E[5"JH50  !G/\ <6K]CHF:YM;$T^TV_7$YM/+P&D&GTT=?T 4 127?A!
ML:)&JJH\9H]88:*L4!.5^=9;(A)V'DX:8'>VE++\5)A/A2#+JE?\4MNB/O(7
MM7_'25;WO^LJL4CQ2QRQGB2.1)(R!R0Z,&4\>_# >/?.=0RR0S130L5EBD26
M)@.2LD;!T8#SR0P! X]<\F,3[OJ$5]/CH?C*^/=#8M4A<87GM-N(//[E)5:>
MX[:^I1K5JFXN?%B7 I()H".Z0!!C#$/;GFAFXR(24L5UA/:/_3[GJJKO:S5/
M@Q0R6YJSV8HYHKU:FQKPNCLG:Q=J9F/I&6+R%0W=GZBW/34=O]H>OZNH_91
ML M;>E-,E>>OOJ6O+)6:.4!0Y+Z]YR3Q$6>:1E#JY[3$>I_-%E[A[<[-W;G=
M</Z]/<?I]3\G< M8KDJS;XBY4:/JM3J #6D$Q!73K= S'-#;5&01Y%@JE0M$
ML0.TP(S,MQ_P6J5^#7Z#4:R\P@BNSS[>_&WPY$G@G>Q)85B$D:E5E2X(Y>#&
MT\*!RK_",FDV]#:4-/TITKJ-M,J:[<W;74NPB/V:2&Y!;-J6W"Y*2OKJ-J/9
M)%,5^&]JI'(Y[G@S8?Z7:.RUSDM]X_UF[:Z(WP6[QO)X2SDA*&DAY:%I=<DK
MS3E%_N&HEX.C666=KM8E7'-%E10R?SH'92( %3>K/L4MNM=J0BN^QKM=EC4\
MQLDD\JUK';VKV2V(4$MA  @E)*CR2>>_M(372VM'MZM84[G4&J?;WH(^U8GC
MFOVX=?=,85?AVKU2 6;@4+&TKAU7N:1WJ+]2C]>7[GZ*JZU/N%VKZ<%:Y< P
MPXII_1G8?6L%2VG0WV]:6.>VLMDD5Y*T.LK%T0RMO;&W$;OI>+NU6N9N51>J
M)K,CABA^'1T<TY\CSP%[P>/=@/!(RQ] 518Z?U*OWQQ']H:VYY8G:*45]5TM
ML+<O;(A#)VQF7A@1P7/GR<DOFUAIOA#V=-^0^+<$Z'<H/K_)//%QJ59Y#5P$
MT_F$#2QI[C=HNG0[#*R<7"5>(>'J47)&'F%FS]ILA:M[9.D9)\[>FL\;724+
M=FW' ]*UM:KR6!,[2F4IL(8T*1N9'9YWC Y^XI#-P@\5RY+7Z@Z2TDU[8QT9
M]5M>I*C2VH[4PD@MQUMO5AC,,,GQ)&MRSP*H;_"602.%B7G-I<J6<VQC&92]
M=YVOWYZGM/"NB!R@/E#R:W R5ZK3,M(0$EV_O5[JSDG3]++A#@YH.A<GK,HY
M.#/MEQKLM?BP'&T2,?$?D'M%6=]#K:^PK/QL]J9!6G4!A2I5INR;@GE3/:F3
MX; @]E=64\?&(-WIS6.E-/0W-1VBW.\,LFOMH%84=;3LM7G:,D%?M-NU$T+C
M@]E:-U/'QB#Q'GG@ENYY[RD:OTOM5P[C7^&^=52GFQ70@X\BUT>M=:N2X.V-
M6"TC?C*N=A";I#=; M)@HIKU8+3&FMK<&T\[]FQV4=CIOXM:E7HR[+:JFT:J
M#'#8>A6$D C@ [((V>R9Y(HSV"8*RJH\9N-OL8[?09V-2A4UT^ZZG-3>BDK1
M06)-5KTM4S%!W&.O%.]Z6Q-!&!%]IA#QJB_<77'*7G,,BSM _82.<6#?!9&D
MQW5!M '5G718Z2D:?**!D12Y& E]PY@<C&HGXMDR(8FQOVUPI);,EN/-2/MA
M7U4C36S&;Z3R5"6685G5)U#*562,NK(6C8J_8P <*4++SR/OUCZU+L!VT-F?
M7DLMA*<R0V55T91+"\B21EX6*RK&ZA)2GPV958D9F&]-Z_\ 42DU>9]\XZ-Y
MKYW3OQ"^XS9PED*R%R&UN*&\]\MLD2^XQ.0UX8'1*VN_1NV0BN<R0PH2TOS>
MQ"[:M2ATU#^]OM5;:6;*D]/(J$HB$ /L[T+^8IJQ8QP56[C]K0R$M'&K-?&U
MFLZ-KKOUNU]W8V,;OT@HA=8UBY^'-N-C!, (YZ$GQ*T%0&5/WC$\AD:.!2U?
M?1_GBT\>Z)SGQQY\F9N1Y]VR?A>D<*K4^07+%^-^G<ZN<;/2O2>:W!\UZ?"H
M0U:W9"W*5(?N,M%NR$6#(?QT\0 UL-1L(;U>SO-LJ?'UL;U[TZ!5?>5+-=H%
MI7(B/ARSO(8D%D<2E#R_+1QL+3TM?J;?4[3K#J$QK:Z86*GL+$:H)>J-=L:=
MJLFIV,3HT5BU+,M:O%='9.D#LTA<P0LGH#80XVRRV\]LAU#3:'7U(0VI]Q*-
M)6]MMO6FV]N*UM>T(UI"=J^U.M)UK6<Y/!)(' Y/ ]>!\N3Y/&<,8@LQ5>U2
M20H)(4$\A>3R3P/')/)XY/G*\^NZB]>?+_>JT(E2I OEMO.B4IW\*5-0421/
M0B=*_O[=JEHP/6E?[3\_=K^]9L]),*^WULC'A!<@20\<\12N(I?'_P"[=LL7
M1]X:WJKIZZQXC@V] S$^T$EA(I_I_P!EW\'P?0^,R\^IQZ1L*_#'$ZM0I-L&
MV^I:A'G-%NH<+3J#@>>!W*0CSH\0T)\^-L-P.I5(GQ1SF5+C+*<RWM]U;8S]
MKZ4U/.]V4S=BKIGD"&1"Z":2T:T;%1VDF*$3V8^&4]T"GD $CHG0O3LD?7>_
M*+$LG3=NY#5DG0O6@N3;(ZVO9D7CEA5@:S?B 9&#U4D#<(0;I57SIZNF:Q60
M^@>P"J<.-!1 S]-X/QNDT&+@$L1X[.X6'G; 5=9504=^/0H;JF!OL8:0A S:
M=?&]'+M-,DLKU])\=R[M\?87Y[!E)8GXDD4:P*&?DLP[V/)_S'CDUJ?J?I6"
M>=Z/156[.TLK-?WVYV>S>S(SDM9>O"VOA5IFYD9")""Y#._'.?+Y!H-3YWW;
MV'6TD7BU=(B++R$>Q]0Z=<';K=[O3I'FHDQ34O'JBX@2+B(21,MD>'$1(;0+
M+K;JG/O(3M6IW5B6SK]),%K0598;C1TZ<'P*\%A+31SGM+R,\DB+ S/(Y8KQ
MQP#GGU=8EV&FZ4VJQ:^G4OP;91K=51CH4*5ZG?\ @6 D*22%Y9ZWV&9Y9F,K
M]P))7C*A?5 [7W&+[OQ7D/'N'R_=7:ASZ;]+MTZ*CYN<AG[;6K.U2JG/=+A:
MV&789&F44^339(VM0;3A][L.VH7\D<P"Y)#[;I>I2_=>QMV;J:^6S.NJCM3
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M +;B3DGP %"]Q)(  )) Y.6OH6-9.LNF _ 1-WKYG8^BI7LI.[M\E18R[$^
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M*G#WQ&G=_8PPMTEUME>ACK3S13SQQEHJJHT[@J!&LK_#0D$@GN?QPH)'DD
MD4NMK;MRK?N5H#+6U<4,]^4/&HKQ6+"587*NZO('GD2/B)79>[N8*@+#N/\
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M;0;TX8%>.1R;LYH,H>,8QC&,8QC&,8QC&,8QC&,8RLG=_,[7;)B"L\;V_P!
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MQ=X$U<21M9IRTK ,T$L]N/XLT,<;9Z9YZ*'G8.9A"_\ \UF8J1BB?[^/_=Y
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M:-B$F2."-W,9,<A5CM_;?.5SY_S;V! 1G1!;Q9(?E?+O5G,Z^,,BUV"Q$_\
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M7*U5&<*CQ@ED8'SEX^9^!_-]%M<+U&3C+=VGJD2^-*1/6>Z7^R]7MHIC*FR
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MI [,%8]@[O(&3;Z>]1^DK9PV]-4CS:/1:=>W&>-BS?6;M N7N8E.EGM4)<3
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M9Z^'81]PC0;*O!5J-(0WV6W.C#_"#\W6K?8).S^H"J/"ST7+\J-\O4/K]>?
M:!(8D)2T]#N4.F>$FVD;(*C)"NQ<4H5G3Z@OMU^VTC3CRUJKLM%(=.+,D3I=
M7<6:,H8L"J0U8)/A-&3PKI*[]QX[N?ND\ #*-:TL53I1+\]>6';IU7L--960
MR*T<536T9OL[P$]J2QV9I@[=HDY^X3PH&0AYQ].=#Z%V@T2].QJ.1]ZAKW<?
M*KS$:. 7_ \@NYM-L8$@8VG;\P5>:N75.LP*RG%.#PQ\NPQO88C.D[+;:>K5
MUZM6#_;M9)6K[L%RZ_%OUEL0LJGQ&M:=9Z,H4<&18R?O-R=[U-TKK=;HT>@)
M3N>GY]?2ZM5I6D3[1N:*7:TD<9X6%-?;2WI['8.&G2!F^^[$Z(Y5<YOC&,8Q
MC&,CTGD_.3>GQW9S:A#F=1AJB_1(>Z%LK)EX>J%R+\J9$1*GG%CQJ#C27EG%
M!#L'&LJ2(44Z&VVPGZ1<M"HU$3R"FTXLO7!XC><((Q(X'!<J@ 4,2%\E0"23
M]@V%U:#:Q;,JZ][/VQZBMVPO9^&L0FD4<=[+&H5.\D)Y* %F)D+/FSX\8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,^"0E8R);9=E9(",:)):
M#'=D#!PVWRWONVR*RLEQM+I+ND+VTPC:G7/M5]B=_;OXR5'<D(K.0"Q"J6(4
M>K$ '@#W)\#,TCDE)6.-Y"!W$(K.0H(!8A02 "0.3XY('OGVI4E:4K0I*T*U
MK:5)WI25:W_K:5:WO6];_P#&];^-YCF)!!((((/!!\$$>H(]B,\]7NGD(OOF
M6]LVV99F2.9^(>62?.N./QLK)1HTIWL5F*Z9VZTB)!>8:-*J,!"0?-=LR;1\
M:DLJ3):'V6*V^QTKIZXW3ZZ&LI,5CJ"VEJ\W@M^[7[Z>NA((/:LLLDUHLO#E
M?A\>#][LG1M]NEWZ1H<O6L=6;6O;VLJGMD&DFD;7:V%25;L6266Q?$B#O($0
M5E7GNH7TKZ-AD2G@<A1?2EAZ/*=F(&9\WPG0XA@>/H\?(<OM=_/8N\N.N;?G
M8-,_JJO**@8V&6T.7,&?PI!NA=;WE3K67MV?Q]='$VM6;[<\4I L/\:&I$D?
MW1(KLHG+&627EEC^\%!4WC5?M"M&;J6?8:V,3])UK<MR56C?[;9CV%/4UHF+
MQ+8(X>RQ%B><ADA[77L;OVJ^E!YTYS2O*_*[C8:+29'OPF[=7ND=!1#BF2;E
MOJEYL=>D4UXPP;2Z_$H3&#-BAP8T,.\.R.^4'LO;B]T?JO9[&78SUGN3FH8Z
MLB0ARD;B:K#(S2*O;\4EW<@RF0KR5#<9S/\ :=U#U#;WMC7W-Q<GUWV/568*
MB2&"D5NZNE<<_9H1%$X,TTA1I5D=5('>>,UARHYR[&,8QC&,8QC&,91;UB,1
MT;KGD7A(9NV!)CKKO:[P.AIDELZD\,BUS;4+)L.MN)1'V"X3-;92]O[%[?C]
MI97]R5_%ATQ6K2W>P9>62D*%<\E2EC8.$,J$$<M%!'+R/82 ^/'-\Z1[M=I^
ML.H@QC>IJ$TE)AP";O4,WV5S&3_YPZ^*\Y[?O*&5N1XYNY)1H$Q''Q$J&-(Q
M<J$5&R4>8R@@0X YAP4P,IAS2FWQBAW7&'V7$J0XTM2%ZVE6]9H$=HW5T8HZ
M,KHRDAE92"K*1Y!4@$$>01R,HT<CQ2)+$[1R1NLD<B$JZ.C!D=6'!5E8!E(/
M((!'G/*0NR'2-S]!<#K<KT:\4.L3\;Y_MO2ZO%+FYSE?@6G='FI/H47 #1Y+
MDY8C[+(2,333+#'@E#1].5(2[&MC"#!A]B>!%K:S8RQU:UB:-]G#4F<1QW>I
M)ZR)69RR".%80KRB%W!:8)$WEP6_56SULDVEZ8W5DZC57-DIZ@>E=L201;;K
MBYJH8M=+8D:#[/47[/6EN+%8EB5[\[0,_)>9_2S3IVHW/AK+OF6PTEZ#10R8
M#E$C%+2]3H$R.@5QM4#+#!9=( CX(AN.:/B=AI/#%'6,L+3R=-;Y5-'-!L.-
MM%8#_:5DNH_(GD5I.Z9E9B SR#O*OW=K,>0W'G/S9<J6];N_A=35+L<RW8Y]
MG!+_ (=N>&2826&BD?E':Q&7,-A6>)RPD5V7SF)=\Z7$4'E_ _/,/SFZ07U#
MO,O3:I9N2<W&'_RA?5YB<)E$='G@NB ['@U\QZI4I*W&6@F<E(<Z)>T(Q*!$
M;A'EZO\ 5IR6;6RVLEN&7I?;5)H=A<)^%]CC0)]FC>HP:3[92L) (5A219""
M8W"RCGLC:^?:;3=]7?:ZESH/J'77J^RMOQ2;30011P4*<FOD+S'8ZB<4?L:U
M%L16?AEHI )'"^A<1UY\05\D581#P[+KX3CC+S@CSC:5NBK>'6XPZL=>U-*<
M96MEQ2-J;6I&T[WS(@ D ]P!(#<$<@'P>#Y'/KP?(]\X$P 9@K!@"0& (# '
M@, P# $>0" 1SY .?1D9&,8QC&,8QC&,8QC&,8QC&,8QC&?%)DDA1L@8%'$2
MY@@)9(D2(\(.5*$L,..L1PS\@0( P0:ZA S+QI0PC3CJ5DD,LI6XG)0&959@
MBE@&<AB$!(!8A0S$*/)"@L0/ )X&9QJK.BNXC5G56D8,RQJ2 SLJ!G8*"6(1
M68@<*">!F<"_-G=/7[FYGVG+O<WY ]O3T'X]Y1;RVQB$I5]XIW>.MULB.D;U
M+,JVEU-.I[\=1XTL84K9TZ^ES>K1^]=?I1\/01_:+H\2;V["A<>G<-92D#I4
M0^1]HF[[;J2/\$$KES&\UG3A$?2R&ULD*]_4UZ +,KJ>2-/0E^(E*/D>+-@/
M<=2?NP>!E,+]XTM->-<\^J\55#TK/#[2O@7KTZ>&XVJF4%W3@FP._=&H)4+T
MN0NW.'7A1HQJJM'2/287;<H%_$R(LNT)NJV[AD0[+]^V-4A^[LM)%&US[58_
MS?$UU6PKT5KV27:43E%J2=P"R*Z VF/JBG<C7=GJ6YH6?E-YTU6A:]'L+@ ?
M[5IZ4X;6P5M@3(]J.SV14; <QK,DL48RG]I>.ZUXZE:2H'ODKZD](6>0D[AV
M'G ZI>R62G,5^!_F8^[2:A#[/?X?D$57:UJ@3\ET&:=.17B6)@24BATF_P 9
M:-%U#^]3-7-%-/K69(J5DA DC2R!)(6_PHJS697<3Q&O$J1S(J,CIQE_Z(ZX
MFVB7-2M2+IK4V;,/[HV/9"J"S+*D$U9V%>"L;-L2?$BDK0QQU[("NCH[')3A
M;97O6W>0O,'FB)YWY^X/Z.9YM/\ 0>>25U.N@4S(\*-MMI$A+(S1%QTOSBS7
M[45%ZDZ:388NVS0557)DS$4Z:QLB)ZTFHULFTVTMS8['4O:A@MPQ"L\8V*01
M,T#S$I9AK!R4GC1HHVLA41U4\^]VM-I=5:VW5%W<=1[CI6S?%;80QFA96#:I
M2IVA3GO&8V*^O>6M*EA:S05Q?<1QN%8"X*OI@T7C_K7S)1;9V#J_5P/2!G3G
M^S5F1FY8*E6+G?!JI#7JE<_D!)2;M-HEJ4%>-4]A^)M%NGFBXF+#C&=Q[2%(
M?T:]4S7M'MYXJE6H^I6C^[Y@D;VHK.PLR03V1(D,,8F: S'O2%&$CF3N+!2*
M5-UT^XZ;ZALU=54UO[A75'3S$I;O5;>SMV:ENT+0@K1_&FJRV6[HZT;I8*S*
M_P!P+GHO?B8HF,7"DQD>1#.": 7$OA#.QBP4MZ92$L!QM0JA$M)2UH;;6V=-
MZTC2/MUK6<R#NKB178.&[@X8APW//<&!Y#<^>>>>?/.<1#NKB1782!N\2!B'
M#@]P<,#W!@?/<#SSYYYS[]:UK6M:UK6M:UK6M:^-:UK^M:UK7]:UK7]:UK_6
M8YCG^XQC&,J=>.!67JWI2A=&Z++01W%N)1(UCY7SD59Y)<IV\]X\<SI%X')#
M'BM_X+"I#%YR(,_*NARTI+SZW8TQ@5E[=5ME#2U-JK5CD78["0PV[;!0L>N4
M(PJUB&+]UF7N-MF5 8XXXU[P[]MEI[JMK=!>HTH9EV^WE-?87W$8CATT8C=:
M%(J[2A[M@,U^1DB!@BA@0R))+QUOLB-.^V/$R=-I4L>F^L3OR*^W_MMMUOE(
M*_L^=;5^1:Y%G6OM^-?BT[]V_P#6M^E'D:#?'V-C3+^),EYA^7W#^?&;;1$#
MH;KWDG[T_2*#CW/[PV#^?IQ&3^/'CW'3^),.P_L#Z@$#* L2-SM@O";Y6UR6
MFAP;%SE?,3J? PK;:OS?,?7K; VF.EB%-J:6_-_G4WM9#B=_1L#WZ+IF17*P
M0G9UI0G):*U]M6>60^G+RUYJ[(/![8@O/"@YX[CMEZ4Z*GB8I6KG>4+(4=S1
M;!-BER:4D=O+34[E-HP?O 0]G<553F,_@SBW?>B]AL'$HCI5E\S="\:*[6KH
M/1>;PM(LH<Y<>U7^MO56@R\38H>1@++38\&@VV?> 9T.G9!8Z8V5%2A*]W7J
M>[0AU];8K!'L*N[6@E2M;:5>V#5P3P6+/,;I/%,[S1(KK(K<<_$#^1G3>O-O
MK8-31VE6)-IJ^IJ^IAIT-C\9.ZMT['L:4E]PCK8KVF>S"L;QSJ?O2]_Q/.;O
M>1[_ -<L8W9>>=MM=:O][XCU1[G[U^J],7SX2X1)%4K=IBI<VH:G[,)$2FV9
MY8QC<=*K!=VPAU@8;2MM[Y[MZU2+[!9IQ/!#?I+9-=Y3/\&0330R(DC*KM'S
M&&7O!< \%F\'.4=3:W75*_3NQUD,U:'>ZB2_+4EG^TK6GAVE^@\<$S(LC0E:
MD;@2EY S-RY!"K;_ #395,8QC&,8QF<_.J9[1Y"#U6D43FW!9"/N';.V]'JW
M1K=V.W#ZBX_IW09^VQ+LUSR%Y&:0:3$B2C""8P2ZC(-);4S_ "(C2MO)M=JQ
MT]?:E8M6]HCU];K:D]2#7UV[WI5(J[B.W)?4*LC1DAVK$J#SV,?&=+V=[H?<
MR:F_L-GU#%+2T6BUEO64])2;XTNJUM:G,L&RFW4:QI,\+%97HN8U/=\)R I[
M=RSR;*\EM_F!,=, V6J<:XUWBEW>9E/D28L]W[!:N<6^1G1H5#!(B(^:GH2X
M2)HKLAO<:@T -&S]*<?1X7=XEZ#<]\;PS[#8:RQ71/O1PUZ$%R!8VD+!N^.*
M6NJL%^^59ON< 9\6VZOAW%+JHRPR5;>[WG3]^C!%]^"I0TM/:4HZ[SED<RP5
M[%*.-Q'Q*8Y'/P^%4P-OQ1W+G5E])"\:MM99H?0>*!<AX,/-2<@'*\=AK7T"
M:L5UA$*8C"5/PM':N%OFN;;;(>?90Y U5[8HD8D]&R_]0ZVU#J6OP3-:J[%K
M^S,:(4OR0U8XJ\GEUXDL&"".WR%!/Q9AW,Y4[_\ ]<Z'95>F&W5.TVPUV]DW
M/4#011/#NIZFN@K49R#*G$]]J5.#:<JJL18MKWO+\,RC<_"%4I,+RJS>;&;!
M$=1X7<*1.4$>[]BZS/5(NKQKPU=O-+7%V2S6JOUL&T<\,G(A#\!6A%#/_HAC
M?I1JWD)^.OU+/8DO1;<QR4]E!9CM&O0HQSK,X:6M9#Q0P22M!;6*0B28]R]Y
M/<_&:JCU_;O3[>KU.:\VIW]*_!L&H:73U[B6Y5:UK[PEK5:EBU)4V<=>8K8M
M,'7XCO\ $D YT2RJYS?&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,9%W6^*<G[S5VJ7V.@5OHE7'E!IL6'LP"#1P9D-@H827C
MW/E!$?)C#FF,,'A/,%--$OH0ZE+B];^RCL+NMF-BA:FJ3,C1-)"Y1FC8JS1M
MQX9&*J2I!!*CD>,V&MVVRTU@V]5>LT+)0Q&:K*T3M&S*YC8J1W(71'[6!'<B
MMQW*"*K"?3>\]5<M^1Y+-]TX9)$*2IPKE7>>F1HV]I^?M2F"LL]::TAG^_\
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M:1*()E+=$1#5FKZ5;%"GN@10TK8FYY'!!\_(_7Z_0_Q\>1Z<8 ,?(Y'H/7U
M_N./)]#R?J#P]]X./T;G^NT2O1JO>I)CG$4)TQV-JYP1'1*#&(:4N_N32[_;
M IF0Y^MV2MM<D(>.3^$ NW4=L2(?LRQXH#P>!QYX\\\_G\AQ^?OY/C'E@?/+
M#D\>G\/H?<?HP5Y@]+=@Y5V6M^6;!:(@F$LA4W \O/O1UD=>;MD2%_*1'-!I
MM$H7'0L188",GG:P855YU,7+1PL$P*6/,QHT>/N"/0^P_'Z#QQY\_+V]I')
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M8 D<-SP/3*-NNF-SH1'+>JAZ5CS4VE.2.[JKJGGM>K?KEZ\G<!W?#9DF4?\
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M.];TI*M;WI2=ZWK>M[UO7QCT],GT],ZU3J54>>5X*I46MPU1J\:](OQU?KX
M\7#@.2\F9,R/Z4>(AL85!4I(&F+:8;;:2Z0Y^-"$?"=>L\\UF1IK$KS2L$#2
M2,7=@B+&G<S$D]J*J@DD\ 9]-NY;OV&M7;$UNRZ0H\]B1I9G2O#'7A5Y')9A
M'!%'$G))"(J^@R$O6OI.K^3>(V#L]PKTO9X6*EJO7E1,1L=G\IMQL$?68]R4
MD#-*$B8=LR2:V?($-O\ VIV@8<4LTD85[>=*].S=5[RGHJ]FO4EN"<B>SR4
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M"Q,4=;91C_H+7;PGP[Z?9I7 XM1ENT9]_4&L?G"=XN;[<H?9H*>ZQ57.7O\
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MU!WVKWOGSE0CJM2['69;D=V"G0VA(Y4F[5YU1@DF1>7T;?G)8(UZ/LPTDX"
M,U7VXX%K',^!Y)]QYY/CC^7IQ_?."^I52>X,]FY)S!Y%YZ]UKK_)ZS=-\VH\
M#/VA^L"DR9T-"4REB1Z):5=B8#^)7I*F1&(R,-_8< :1')9<5)'!'U'/CVY]
MO?\ CA2"/P/'/C\C].>? _OSEG8+PO\ 4NX[1:6YTCS_ #G28V2KH920.5W.
MNV>Q4&0(VI2(FT5P<\,YVRB,);_;)@&K76!?N_5:GGWON0E_'C\?U],>3Y
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MNGG1/5:5V"$9\Z=IYW&&R=2Z%6)>2C__ ,CP22%ITN6K\['0%@@0Y;0TM%"
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M_'*P?34L4S;><]!F)R-.&D1>@6:+E9*0VK;TK/25SNG0I56OO4IS_P!Q9O\
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M(06/^]#M,DS3A3 AKQ1CC+@#D'GGZ<>_S /CYCS_ "R 2?3Q_+D\?,\\^_\
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M9<0B/0*$-EXX]N?J?P^? ^?S/D?(Y@2>[Z _^WD?CZ\DCZ>GY\&L]9[)TO\
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M/\_3\>,](' ^Q<EZ7RZCSG-GOX&K%5R%;KU9FV&(.7B8E(:&(F/<C5DOM?\
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MAR$D&FCH6=O$N;*6.:23\GR<,/3BI3;13.@ ())_T_7O]?7,@JCR!^?S^O\
M;-8,C,L8QC&,\M'J#G]FH/N+V'-R;9+D?T:S<WO-<0RT\MIRO!\?J<4?*(0G
M2MZ;8EXV7C3B/A+2=P^U*7I*-_&2DCGCU/'ZX]^<\V ]SZ<_3U/@<^>#_;Y#
M*UES@ 6R= ,#B[*?422H9EEG9)*T(;62]^)*?RO*;:;0IYW:W-H;;1O>TH3K
M0+SP2?!/GCC\?Y>_R]?(R.2>1X(\_,^_SX\\^H]R3Z^V2CYL](3GGSK\3?HE
M*C@2VDP%L@_S-M(L5:()0^\!IQW>FF#AR$I-B3%?;^L>VA+VUA/%L.2>//(
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MWSO3NDZ_\;3OX_\ 77^]?']_'_G_ /=C_?\ 7RQP//IR1[^?[^GGT_VXTO\
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M,Q_7Z_WS/C@\CD?3V_A_I_KF?7<.L_4HX!=)B\"<?J/HWBZ]#J5$<7'=)MT
M&&*,P4>1SZ:*C+R@B0(2Z7H.G6'LCS.G'?F,8::3O)\?K^_^WR]O7(^]_/\
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M'YY\[\'Y^M=N\S>J*I,$\E+M)41<( E'X[9QZ^Q9C@2[G5%*VK0IT88E:Y<
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M"VR(1SY!3+KRY/K^O]!_3"\D GW_ -3^?Z\9=3(R<8QE7N]>*/)OI]QLKO7
M.9](F!Q7 @[3,UP4>ZQHSNV][;BKO%:C[;%Z0IIM;2H^:&4RM.EM;0K>][8R
MK_._I^W7R:[/$^)^[2D)6[ 2*7+<1]*#2O:>>/( 2ZV(#4>@,RT%V+GZTM/O
M,MG2%EZ3$C_<V\NI&K90C<ABOI^?R/Z_7UP9 P(/\??_ ('X?GF7_7PO?WGR
MP]RM%]Y7-1-.[,7-O=$F.;AC=_X1/QTBC013\E!C03MKJ6AZY^* )METYE56
MOX44824E)@"-9';R[O)]?//@^1Z >W!_,>?QS$Q@ >_;Z'R#X^7K\AXX/DGT
MS!'T[P^L\R57+]R>]1W2.4W:+:D52$2VEHJ@V9PHD>4I%A'0=(Z2H$AI/\;*
MI(6(<.^RUIU;J6WB\2/<>GM_H?K^AXS,'GD'P1[?W_V]O?-#_HU=W:KEROE)
M/<8D6C(B/+-KA>TK8M5'=69"6^&?9>_[)*4#2T>E+3NEZ3M0KVVUMA+^V5'(
M(_,?+]>V0_@AOR_1_C^'MF=W?Z4]Y0]<W6@!D.NQW,^EQL_29%_[].R-*+)C
M+KSZ7VOX3MQPZIR,&8^IO?RDE;S?_!:%)3CZ9D."/H<]C7TD9ELCA_3(!IW:
MV(+M-E>"0I6M[; EHB!=8UK7QI24J=&?7\;_ -K6M6M_\MY)]!\O('S\'GS\
MO7(7QR/7T//M\O'\/7^/D9>?TA,M0?%KP6XO[-O! QS7_G:W)*6 "^S7];_^
M[><5O>_ZTE*M_P#C)7_,/U^OK],/_E/Y?US(AF<0O6OESX^?[^?G_7_];_\
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M#..,+B(&14<P.$@IA2"0WIAN.F3C"P76SQ*]7YE 3@LI(1!*<@/!/L/Y_3]
M\Y@Q/(4>I]_U_/(^L/T_?,5SX9;.#W'GT?-05]1'DW*TL-HB+U+6&)(9-A[(
M-: 4(DXLV -'9570Q7]Q40"W_#MA.Q3Y@A6)/.9  <?3]?KC.#\S?3A\P>6Z
MU/UVHUV9O3MGC9*!F;!UB1 M\T16Y85X(^NCM#1$+7XZ,-#)($D51L$)(3 S
MNF)H^2:9&0RR?U^OX9YO>+T^6^C_ /6@K/,9,F18\[^BW2*-2Y^16XL>1H/3
M9%A-(8,.<_\ =WYKGG3PH"LV,YW;;ZHL8J<6R(+/#-8Q^.7ZX+].6F=8[7]5
MJ(E39+G=K ]M-6/F72Z^"T_(U]=\Y)3.M3$2< =MD&UTN9:Z='LSU7,(9:=6
M.R9''Q$N+'R@S(\>GL/RX]1^7CWY\^<V]\S<#A?-/':QR6%EW["F#T63)3Q
M+,5N6E9!_;Q1 T2.^4S$QS"-, 148@LU0,8&(.\<:^ATMY@#CGZGG)Y==:8:
M<>><;999;6ZZZZM+;333:=K<<<<7O2$-H1K:EK5O24IUM2MZUK>\9.09)])G
MK(_L#G,808TIIIU,BD<51Q0I*?N8D!]2KXT57(I]K>B(Z7L2) ^792HF#ILW
M';:/=R '@GTY/@?3_7Z?/U&8%B20H_/]>/P\YQS?(K987OVKG;V1DJ5IU(L6
M(W:98=[7^UM3MX&D:V#^7_CMW56YQ55HVG6F'T[2A:7('H/?W)_+CC@CQZ^3
MSD=A/J?U^/\ ']>,D"N<FH=9/;F1834G86MJ4BS60HNR6%E2]?:O04I-/&OQ
M3"D_\=!1&X\!M'PVR*VWK2-023ZYD% ]!YR1\C,L8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QF?GNWQ3</;(_+J,[W^P<LXA!SYDOV+G%>
MK(,B9UAH=V+.JR-6 J1';B'*W(QQ#XHDK$V6!<,D!IQ^&?E:]$[TR///T_7\
M>?Y99'E'*>'^5^=1E H$;6^<TZ-TIYQV0DAA3)F1VVV@N;L4[*D),G)HE#;2
M29&1)>>2PT.(Q^ $449ECP/<?/U_7X?RSM;/8^1$*^UCJG.'U?/Q]K-XK#BO
MGY^/CX1**W\_/]?'^_G)X/R..1\Q_'.ZQ4S#SHJ3H26C9@)6]Z29%'"R JMZ
M_P!Z20(Z\UO>O_.M+WO61P1ZCC'(/H0<Y+&3C&,8QC&,8QC&,8QC&,8QE7?8
M_D_F_M3S_=N"=,'2W'V,71M:LK(K14M1+K'-O*K=S@_RJ;VD^(*=6@D=#XZ)
M>&*E((MW0$H6E3&?\][N7'.J>>GNO>1>V1;D?T7A,TB\54Q*7U1EKHRG7&3)
MJL%D-M[/K)\/*.6R-?1K3K;*9  ]@,^(-#&9'ZX^OU_7\?&;9>'/2<13?,WB
MN2L\/:;'$QMFN]6G!*7,[A[0""W:9JCQTW%E_?\ #O\ C\=:TR3P+SPC)X$<
M4"X0*TYIU&7/CYGT'GR/7QP?F/E_KF!'+-\N ?Q]#]!YX]S_ *C3?V.GG$7#
M<EE.:VV<N,7=!K)8'963GOY)A+(2H8$,?0# X# )[3[\FV?^V$F5;?0X*6YI
M2-MMY+SYY_'@^_//G^/OY\>OMQBP ]/3^GT^GYY2=B65OXU]W]_&M:U\ZW\_
M/]__ +?[_P#^?_8*CV\>/R^?K^'\OGP<QS2_@OB_D/HWSM(&=+KSXMDF+/8_
M\4OD*0N/LT-'#@1T2PEMW_N 3<4/,#2Q/\%80I6$=)<=?_105M)*<#X/@_T/
M/ZXYX/\ OGH@\'U]?]/YGTY]?EG.>#>H]1Y=U;HOAKOTZJ>L'/M%27&K25I3
M;MEHT:S&E/B#[***-5%+AYR$G*H*29*E13+=SJ+DF\-1A]9&9@^?^?7^'Z\?
M/-6)24CX2,D)B5+9!C(H(F0D#2%Z0P($&RL@DAU>_P"DMLLMK6K?^_A._C6]
M_&L9)/'DY6#@] E'>@=.[I.6*Q&O=-5$MQU2DG];@ZDF*:<"6W"BM?C8T0B!
M%JU>EWEC)+18*_9%[)(9D=Z1D>0 #^/X?KU\_3TY.8+Y);\>/G^AZ CV\9:[
M,<SQC&93?5W\!N^Z_-!(M"TS'>BN.$%7_A,]^5(;Y,X,TR[,49\_Y1L8*YB
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MN/EZ9'++Z^1\_P!?WR9JW;H.U"#E1)C3G[(J#F6?SBO*?"=WK39H9 9!0,D
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MGT^<B+#0[7=>'V&;:GV*A+%B0TNH?0+IK2(*H66-<0$RTT ,6;7+:'N?$BF
MH=FPQ$J=$@BBRFV&9/D _D3\_P#7T/\ ?YF%Y!*^WJ./;_3\_P"/GS<?,<SQ
MC&,8SR@_4!VQ0O<O?KEK2&T.VSEEK>^[:5MN.1W&N31>U.(VG?\ M4)^-25:
M7\I1K>M;^=)R1XX/R/\ N/'\<CQY'GT/M\_D?3W_ -<JU.3R):QSTDW]B424
MS)G-I0G2&_QEFOO-Z0G7QI*?L<3\:UKXU_7_ )R>?)'CR3Z^1\A].?KYY_#G
MG'CP#Y\#V\'YG\?/MXX\^_&7D\<12I&29=_%]RC)Q;VU;U_\HT)'[)0YI6];
MUO6S'U-:W_>OR?UKY5K)!\$ >2>/7Q_$GCD^0./7C,&'!_(?KCV_#V_#-8'N
M<0%S"B8ZS1ZI2.BK##VH:/<*-9 <G()3RXHHT08AD>3;#<)==;#D6R@MN_8Z
MX.MQM"DY]H' /D\\\GW_ )^I^GKQYY'C, ?<'QP>>/GX]#[CU&7[J4@[(P0;
MA"]K*83^H2O>_E2W&-)TEQ6]_P![6XUMMQ>]_P"UJ5O/(\<GCT_7XY[J>1^'
MC\<[)D9EC&,8QC&,@_I?I/AO(#5Q70>DUR#G6V&B55Q!#LI9-,$:^X=U4!$,
MG2K31"?^3#KPC33J?^:5[1_RR>"?X<_ED$@>IS 7WS>('T).4V:Y\\1*#0O9
M(RQ%J*'>BELU!J&DQ#"]MR.AUN+V2S$;_3:_(3O:MK2SO32E(R[3V\^W@_7C
MCS[^GT_/@9Y@_>;GQSR/3WY\?3Y_Z^<ZS4J^7>H.A-0;\Y$2?(B)R1+LL6.R
MDH,(N:$G8EF"(*D 6')\,A,D6"T^4&(PK>G7B4ZW\+ ^!Z>"?! X\^PY//KQ
MR?/'X<\P203R?7U/X<C^'KXX]/;TS?+R58ZA;>3L3M2<,VTJ9E(J0'DW&WI0
M)^)?VR,W(OMK<_.9)!.,64TG;J]%R4^<8G\>B/PM0W)/D<>/'X?K\,S3T/SY
M\_V_+_?+/9CF>,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8RO':_*G!_01,?*=.H@TG9(D;045<8:2EZK<
M@ 4NN$(CF[-6CXJ6)BD$.NDIASR3(G]AQ;^P=NK4O;!\^,ZA0/$'G;GQ;)PU
M4D[84+M*Q-=!LLY=(X5U"].((8@9DQZNI,0M*5M&JB5&,;U_V'VOE7S/)_7Z
M_0\9':OR'S_7^GIEM=:TG6DIUI*4ZUI*=:UK6M:U\:UK6OZUK6OZUK7]:UD9
M.?[C&5(YCIB=[IT*SC-IV.;;.D+;<TG>U-?X=$<>Y M*UJ^WXV7/4>WJ9VE*
MD_B"6G2M_P!JW/\ XCZGD>GX'Z^WSX],P'^<_A_IP?QX/']_.6WR,SQC&,8S
MR0_58-W-^I>RA,[0X,U(<RB"%-:VG_MCUZDJD$.;1K6UK3]SXZ]JWO7PG\>]
M[2G[-/U^OT<Q'OZ^I_0_7KZ\^II8%)??I/SO^]?&_G_7_C^_C_UU_P"=?Z_W
M_K_QMCT\@^I_'S[>/ ]?!^@'IY(U'\N&'0/2//U/%L-:KZ;1$6V5G0K$O3!=
MI&3").;J]54XME)5JU,3D;,:%:=43J$@)9_]=]AEUI?H"1VCP1Q^?/@_/R?(
M^I]>.>,\SY+'Y$#Y_G]/3^?'IFXD=&M M:6O7QO6M;^-_P!;WO\ ]/\ U^/]
M?_SR?7VXYX]3SSY]QYX'ISSSP/ 'G,<E;GLFAQZ2CM[UI7VLF,I^?[^Q.]L/
M_P!?_9M3'QO7^_E7]:UK68,>?Y_P]N/ /Y?R'IGHA\D?G^OU[9*&8YZ8QC&,
M9AK]:WZE4]XGHO-N.\F42+W3T23*#PMG'2P\J@4>!+C1;%/!#JVX^Y:9HB3'
M@JIO8VV!E[F9AM_]^&#&(8_7Z_7]<R0X!P[T;;X_=RNE%OPQ<\4N9/L?0QI*
M(D)=9/\ W7)0@BT['E)1TM7RXLI*"5O[5]_WKUOYUD.>#[\C^7S /KQQQ_(?
M3S8KX'CU]/'CV(YY''S_ !]?&7+!Y:Q%;:;M\R(,Q]OYG!P'=J><2GXTI.GG
MV4*UKYW]F_PCO;^5:TA>M[3O/0#@#D^ /GQY/U\>/EF!\DGYDY**YR*?HTI6
MJD"]#12$N!(?2U^!1[B$#/EZTM2U..*(:<0T4Z0O93B']:<TA*TZWB /)'GC
MD@'P/H?7\N3Q[_E'U\_CD^^%>A$<\Z&[39%W:*WT/0X7_<7]K0-E$0ZJ',TE
M7_%/\@EQV'>TG25O.D1RW%;;$3K6/!//N?!^?K\N/GZ_0#ZYDIX/T/K_ &S:
M#,<]L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QE2O,FEND6<UQ&DN'Q;DL]\;7K\<A/=O\
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M/]OPR"&N8=GI#FT4^S0]FB].*=1I$@_SJ?\ [<6M:SX_^$OO-)N1+VO;TA)
M4JD.F$[6\[K[W-K3ER#ZCCZCR>?XC\?//O\ /G,.UA_E//T_7@_RSZW>A=DJ
MVU/V.D6AZ-:UK:B-U>+N*'OMVG[TZ/Y789*R"HVC2U;*5RHEM/S]RF4Z3^-3
M@$^H'//S\?Q_U..7'DCD>_I^?''^_P \HC]1WT@'+^90P((=Y8D[>8A%F,BB
M&YFN/!UK14T+#[F1T#O@R#EM"K^]Q%AC(">;<CBD%0[3.DK=@CCS[>G/Z_J.
M1\N<GNY\'D'GY\?KY\?A[<\>8MZ0(.,**,7MP@M]XAY7]_\ )U]Q3CFDZ_\
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M5=@B6TZ;6AM42^_(K:WM#P[LR\.K:5L:^(_7Z_7SX]< <CR/!X/')]/''O\
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MYMA274VLC<P.^C6OM>C/QH8C5HWK_;3S:'2VE?\ Z2"M;U_6_G<,?)'L/3^
M_P!,R0>.?F?Y?KG)ZS',\8QE7^V^?DW"3:Z7S=R/K/7(K]9Y9J_R 1E['C6]
M) B+08"VLL22!2VAJM7%A@R3K?RIA0LG#.DQ+L@\'SY'N/G_ ,9BPY'CU'IG
M)<;[FS<6WJQ=1B:Q?H4HB+FHJ9%:BBF)(5"7E1T@.DAX1B56+O\ =#( ((@;
M5$I39:F87$D+8 $?+T_C^O\ <<\'(5O0'P?Z_P"_]_X98E@A@IM+PS[)#*_G
M[76'$.MJ^-_&_M<;4I._C?\ 6_C>_C>1F>?KC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&0+0^_0/0^N]/
MY/!UVQ?_ -KDBLR5U=1'JJLI+*<:&E(:/=9-</0=$GK)C7M%!M)>.AYUM/XT
M ,.FLCD<\>X_7]_7TR>L9.1=T/M?*.4#/$= OE=KCC(ZBM1I1[;\X0RE.U?<
M' !_LS)GW:U\(_6!=TK>TZUO^]8X]_;() ]_U]?E^?&8?^NOJ'6?K,3,<\Y2
M(=2N?R&W I6=>>VU;K7'?:M#P3FAW-M5^%/UO>B@1W2) \9&F##F!"#8MS(#
MCSZ\'U ]/GZ^_D<?VS \D\'@#V!/KZ\<\<_+Z?QX.9'PB-)OD+(;^=#4(68Z
M+(?UO;;KD6 3#5F,7KYUK3\I99H)\#[OG2W(A[24[4G7VQ[GCT\\?A[>H/T]
M?Y>N9'RH'N>!^?OZ?+@Y='Z??EJ3[IUA)DN(XY2:X0%-= F'4;_"2(E_]@*K
MLK_K[I"TEL+V6E*DJ&BF3"][TZPPT1/H.3Y)]/?Y\\_7T/Y@Y!\D+[#R>/'\
M/I[?7SX'C/5:VVVRVAII"&FFD);;;;2E#;;:$Z2A"$)UI*$(3K24I3K24IUK
M6M:UK,<SRIOH63BZAT'E-YEC68\(2!Z%"$O.[WK\RAY/G?0@VD_&M?>Y]W/B
MFF6TN:<6X3\(0YO>])R'O^'^W]\P<>AX\\CC^H_GEM<QS/&,8QC,V/3W8>B=
M4Z&GR;YZ6ZF6+:6SUJ\"OOBLUZ.>9&6971Y8?6EQS L><P1<9L%W9XJC8VH0
M7Y;-)FM13]?Z?[YB3SX'S\GY<'\/7QX_XYMIP?@%(X%5&8"L#I,EGQA6IZSD
MCM,2$PH1*]#CM,M?+$5"@?D<1%08.TAAH6X^[LJ2*.D"Y)Y_M]![#) X'U]S
M\_QR<\C)QC&92>K:9'U;LE5KA(B'N;^CK?6)RUQYK"B:^"9S*;A[QU/9Z$ZT
M.!'6BI56$E-LNH5^]-AV4CY6Y,&?;D#SXXY/(XY_7IP/(^7RX\^; @D@\ CS
MQ\_U[_C] =)>:QBH7G=%B%!-QJHVH5T)4:RPV*U'['B1&M@M#-)0T.V']OZZ
M&&T)0TEO2$)TE.M9CF8]!^ SNV,G*^6/O<2N974N=#;N=B2^X(^:$P3(00!#
M*TM%-,_QV]D6 P!:OM.9CGA(6->0X)8+/7WT*UK(+XY)X'X?KCGGP?\ ;G O
MP> .3^OU^CG(M0/7; A:Y6<$@&'M)<;8<(>VZPOX3I2%1-0(A"Q?ZVK?V+Z9
M86MK^-_/Q_6.0/;GT]?Y^W'T\@\^HX]#'#GU/'Z^G]SD-W;R*Y8I$RY,7E^1
MN;L.N&+B9V,%W1;C#;>01NMW)#J)BWD@)<T^Y"2[5D)E:E(DJE8I)'R='R3N
M^@^O'CGY>GR]1Q[^1CLYY\^OT\_3S_7V/RRI5=H'3^+6>07SZR68:;_8(-/X
M]9%PT-:=B:=6XMSGUBAHMBJ=5@@6UM#P2IJM6?;VW]MV^9H9X![N\O!)/@_3
MCCQS[>_/)]#Z\\<GUS'R/H1[^OK\_7\1^'H?47!HWLKFTA7RR;E,LQTS%?R0
MAD8''DJL[LU#-_=(ULCGXC\O9A+0UM#NQQ8QN=@)L5M,C!6 I#CX0&''R\_E
MY].?3_3_ $ST#<\@\<CY>G'XY M?Z+["].6F?L/+G8_D/)(8XF$C!9\B,%/E
M'6=(;*?DI@:JW0^2LPSFU[*CZT5%U6O*<5$$3-@FP'B6W''K^' /G\?'R^O_
M !!);_*>./?TY^GS_E_#WL,'TGM?*6FF^TP0,I M:TAV_0"GYFN#MIW]OYY^
M5AX*,EZPA#"/V"CYR@MUEEU>FRK>*CY>U/@^G(_F2?UX_A\SQ'+KZ\,/Z?R_
MK^/T-F:U;8.UB-%Q!;;OY1F3$L;<86XH0C7RP:.Z,\0)(1S^_E(TK&$FQ9:D
M+T*8]MM>DXD<9F&!_P!/U_7.RXR<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QG\..):;6ZO?PAM"G%[_ /1*$[4K?]_^FM;Q
MC,X/IRNHFJ==KNZM9$G?I>2N<H8OY^"C[3U/L4^8ZC_YM?8LB07]B?O7]K"6
M$ZW]NDJ7D0.!Q[CG\_\ 3QX_/R?;!>>6Y^G]/'R_H/PSH?U->P=,YXODE7HM
MQF*G$W!BY/V-,$1J./DMQ#M:8 :5+#I1*##-(E#=.C!ECLE;=3LI#WX6?L#C
MS]![_KU]./\ C#$\\>>"/;\_I]#XY'.8\RI1)S+Y1A+Y9+_RX^24\X00\O>D
MJ4MYYU2G'5JW_M2U*5O?^]X/H.?UX7C,1_F;CUX;C\><BL]'RVY]V_C[=JWO
M>_Z_U\[WOY_UK^O]_P#I\_\ C,E_\A[>?(X]O7@?@?;T_,8;_P 2![ <'T^G
M]_QX_'.6\\\R=]!7F^\[J5BBH:4G&^3QBK#+,$/PP$>%=9MZ:>'4(EQP\H']
M^/=4.A3+#K[L>T^6&.\LYC'P0>>.?;Z\<D^1ZGCW]\D^.WW\GU\<> /R\@D>
MG'!X],]7W!^'4KSUSB'YQ2&'-A@:V7+3!>D;E;+/$--(D9Z6<1K25%F;9;0V
MRWK0X(;(P J$##-)UCF? 'IDR8R<RG^K?)N17$^4D-$J'41VP$%U*%[;62.K
MG71#U#Z5I6MZ3LB.%>5\)7_;*?E/Q\Y(_7\#\_'Z\9BWIS\O/\Q]#\OYG-6-
M;^=:W_ZZ^<C,AZ#VQC&<)9IEFN5NP6$C:=,0,)+3+VU[UI&F8L @YS:]J4C6
MDZ0PK:M[6C6M?/RI.O[TP? .5-\7\_-K--M%KLS6B;S=K$F0L,V^C7[T@\[&
M 2\E^;>]?+7S;)JS/+81O\:5.(1K6D,LH;R;U 'H!_7R3^?T\<<9@@\$_,Y<
MW,<SQC&?XI24)4M:DH0E.U*4K>DI2E.OE2E*W\:TG6M;WO>]ZUK6OG?]8QF6
M\N+)^V>H3O\ "2TK6^70M1FJO4[5&CB.2(M?L.G6Y:]"#2XA(2S>ER\3'P]=
MCBQ"$ZYS6Y&;_/'EV=(B,@>!R/4^/UY]1QZ<>XY/MGF?O-Q[#UY^?ZX^7H?3
M/VA);Z@/"0VZD]SZM]CK45K8T38X1\69:3%C[4@)H<0NTT^ZQSSC/V./Q$A#
MW >*5M$=%60X$5M>XY!]N#Y]/3Z>//\ ;C)^\/0\CZ^H_P!?UXS\[90O=?J0
M:/KUHL0/F;F1BW6[<#7Q@]6NR0A*%?\ P]#@-DL<]^?Y1^N2TJ=H8#@Q:]24
M;.LMNQCSP/0^?U^O^>!(Y//( _+Z _R_VY\9?[E_**?R2M@URJAO*_7##$.G
M)-U)M@FUALI905+2.VV]NJWO2G&Q!FQ8P+;BVXX$-C>FM1D@ >F23C)QC&=<
MM%1K%UBUPML@HRP1BUI>2+)BMD:8);^=LF!NJU^8$X=6_O&.#<8,&<UIP=]M
MS6E:8RJG;?,L=(4EPZD%=$F)6KOM3.J'(]7Z(?#=!@@T.)FJ$5_*6A]X)^;B
MUOMP,B*:"X)8AX9<D23"?RL>;/<?'GT^7C^?Z'I\LP*@ \#SQ^/Y_P"OT]!D
MV\.N%?MW/J^[7%";BPX:'W$["":BV"JZ:"V_7Y)N+99&;C5$!Z4')Q[0S+$9
M8HV<AVD?$;O!XY/'IDJ?''R\?Z?[_4$>V3!O6MZWK>M;UO6];UO7SK>M_P!;
MUO6_ZWK>O]ZR,RRI_0^6S7.5&=#XE'DK;&)=F;3RN*6VP/)I7O:Y:Q\U8<0H
M>"O/X4Z)?K2=)I]]6QL&7BFI@Y4P[(/S'/X\_K]'YG,2OGD>#^OU_;)5XOU^
ML]IIH5LK1XAS+K0KCRPU*TR\R:,@L"1'8=6LD<21&7^1L<K:GPRFC8QYUXB/
M?=4/C]?/^.2IY'GU'@CY')<R,G&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC/X<0EUM;:O[2XA2%:__ %5IVG?^_G_QO?\ XWC&
M>9GS5]1BA>%KUZJ\Q^@M//V;C):X7DT74HTMU5\U!6:]DL1A9KY3[4&_/ 6*
MLS84F>"'$1L,0=N1+V0$$.?///'T_7Z]_GF(7CGCSS\_^/Q\_P LJ5Z/]8]D
MZP1ROT=UDN!=YMT<NTQ%.J-3+/F([FT-!244UO6GQ E@HFIM19*S6#R2+3,[
MKBRI$.NA-P\*"\@?0_V]?T?'\L$<GP>2.#P>>/?CT_7@?7GO% I7H?NB!F>&
M>;>FVZ,*:TXW=;B&GE% VTI/_%\>R75H1<FW\?&U-Q4>60I.TJ9:=UM6TR2"
M ./EY^OI_0#Y9 4\L?'GD<?0G\N/']<OGQCZ05WMIX4[Z[Z/#-UYIQLAWC/%
MS)EJ-E4?=IS].V]%DAXB8)'5K6F) " B M/?\G )L124.*@GGZ?3) X_AZGR
M>?;Z< <_Q]/7G@?I\<?YE?/1ONVO\QK$S0N;<1[+.T/GYR]%RK<';!)%<+.B
M".V=,AN;AC-UJ7>/K4B^0)_B]EB&%I9>_A9(,"1_O^O[_+Y8(#?PY'^_]O\
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MR2LC38!S0;S)8\C0U6^-)92F0#2\IHM6V7']-KUI2'-(QX/T_B/3\?3Q^/\
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M*)4H@28EY!TDB3@92>#QS[>GK_4?EF)(YX\<^/!]_'X\<^@'X$>AYS8CP/\
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I,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g5rlbv12cydj000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5rlbv12cydj000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "/ N8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH 9G-'\-<GXZ^(?A[X<:0VI>)-9M-&M/X7NI,%S_=1?O,WLM>/^#O
MVGK_ .,6NS6'PU\)W6K:9:OY=UXBUJ3['91?[B ,\K?['R_\!JXTY2CS&,JD
M8RY3Z*8XKE?&WQ!\/?#O1)M6\1ZK;Z381?\ +6Y?&YO[J_WFX^ZM>?\ QP_:
M T_X!^#89M3EAU3Q%=)LL[& >4MPV/O[=S;(Z_,GXE?$3Q)\7/$<NK^)=0>\
MG'^JA7Y;>U3^[$O\*U[66Y/5S"7,_@.#%X^.']R/Q'UI\3O^"DEK#--:>!?#
MGVS;]W4]8=D0_P"[$GS'_OI:\%\0_MM?%_79&8>*4TR%O^7:QLXD_P#'MF[_
M ,>KB_AU\$_%OQ8O9[;PMH\FJ?9CB>8ND44?^\S_ "_\ K/\=_"[Q%\--;_L
MOQ-I,VEZAM\U4;YTE7^\CI\K?\ K[;#9=E-*?L'\9\_4Q.*G[YU=K^UI\7[.
M3S(O'-^__75(I?\ T)*](\%?\%#_ (E>'Y(EUR#2_$]O_'YL'V>;_@+Q?)_X
MY7S1]@H^PUZE3*<!5A[U$Y8XNK#X)GZA?!K]M;P#\6)[?3I[E_"^O2_*MCJ;
MKME;_IE*/E?_ (%M;VKZ+&W;[5^&7V&OK7]EW]L;4_ UU:^&/&]W)J7AQW\J
M#4Y?FEL?[F_^]%_Z#7P^9\/^P_>X75'O83-.?W:I^CU%4[:YBOH(IX)5EAE7
M<KHVY&6KE?('T(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Y_\?=ZB^"OAM?%_Q>\&Z-,GF076JVJSI_TR\U-__CN^N*KUK]E"YBM?VB?
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MD2E&'O2/1\"C KY]_P"&[?@O_P!#;)_X++K_ .-4?\-W_!;_ *&R7_P5W?\
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M+82MN?R/X5_X!]W_ +YKV(H".:_'ZD7AJ^I]_3G#%T/=/SF^P;_GKO?!_P
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M[=OQ(_X3SXZZAI\$^_3_  _$FFQ;6^7S?O2O_P!]/L_[95^D_P 3_&EO\//
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MK$B?\":A"YC5VCTHVCTKSQ_VA/A@GWOB#X7_ /!Q;_\ Q=:7A_XL>"_%M_\
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ML+:2XE_V?X/]^O;O /PRM_"X^V7C+>:D1\K$?)%_N_\ Q5>3C,PI8>/]\]3
MY?5Q$O[@OPJ^'B^#=+\Z=%_M*Y^>5_[J_P!VO1**0G;7P=2I*K/GF?H5&C&C
M'D@24445)L1^E?'?_!3'_DEWA7_L-?\ MO+7V)Z5\=_\%,?^27>%?^PU_P"V
M\M>KE'^_TC@QG\"9^<E=I\$O^2S^ /\ L/V'_I1%7%UV7P<N8K3XO^!IYY5A
MBBURPEE=VV(J_:$^>OUW'>_@YGQ-#^+ _:M#D<T_.:YC_A9?A$K_ ,C1H_\
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MK?2=3NK"*:7[[)%*\7S?]\U@5VTJT*]/VL#&4>0_1[_@FA_R2#Q)_P!AU_\
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M2\:+_P!B]!_Z47%<.0_\C"!TYE_ /J7]@7_DVS0?^OB\_P#2AZ^BQU-?.G[
MO_)MF@_]?%Y_Z4/7T6.IKR\=_O%7U9TX3^! =@T8-)69J>KVFB6$]]?7<=I9
M6\32RW$[JB1(OWF9JY#KN?*G_!266-/@GX?CW+YK>(8F5?\ MWN*\E_X)G6]
MRWQ#\6W"JPM(M,BBE_WFE^7_ - >O-_VQOVA;;XY^.+2WT;=_P (QH:2Q6<S
MKM>ZE;_6R_[OR)M7_8_V]M?57_!/GX777@?X6WGB3489(+SQ/*EQ'$__ #ZQ
M[Q"VW;QO+RM_N-%7V-2'U+)^2K\<SY^,OK&.YH'UH_2OQ8^.?/QL^(/_ &,.
MH_\ I1+7[3R<K7XM_'(X^-GQ!_[&/4?_ $HEK+AN/^U2]"\V^")]+?M#?M<:
MU/;:9\.OAS=3)<1Q06M]J>GES<2W&U5\BWV_/][^)/FW?^/^7>#_ -ASXM>,
M8$NY=*MM"BE195?6+M8F?=_>B3>RO_OK7T]^P?\ L^V7A3P5:^/=6LEG\1:R
M@ELVE3_CSM?X=O\ M2??W?W63_:S]?9-85<RCE\Y8? Q_P"WBZ>$EB(\]:1^
M0_Q%_9)^)_PQL;O4=3\/_;](M4WRZAIDJW$2ILW.[+_K55-GWV6D^ '[37B?
MX$ZS;K!<SZEX8EE_TS1Y6^3;_$\7_/)O\O7Z\[-XYY%?EQ^W9\%M.^%/Q+LM
M3T.%;31?$44EPMJOW([J)D\U43^%?FB;_@3UZF7YG'-)_5,;'<Y,3A)83][2
MD?I=X5\3Z=XT\/:?KFDW*WFF7T"W$$Z?QHU;O\5?'G_!-WQM/K/PLUOPY/(\
MW]B:CF#=_!%*N[;_ -_5E_[ZK[$KXS$X?ZO7G29[M"I[6E&9\X?MH^.O&_PS
M^%46M^"]02P$=VD.H7'V9)I8HF7Y67?\J_/L7[O\:U^>V@_#CXH_'G4%U*TT
MK7_%<\OR_P!JWS,T+;?X?M$K[/\ @&^OU_UK0].\2Z;+I^IV5OJ-A-M\VUNH
MEEB;YMWS(U:B1)&NU17H8+,G@:=H0]XYJ^$^L2YN8_)^V_86^,TT3._A:*)C
M_"VIVN[_ -&UQ'Q _9\^(WPOLUO/$WA2]TZR^^]W#LN+>+YMOSRQ.ZI_P.OV
M8P3TJK=6L5_;R03Q+-#(NUD<;D=:]&GQ%BE*\X1.:65PY?<D?F?^S/\ MHZ_
M\.=8M-#\9:A<ZWX4G98C<W3-+<V!_OJ_WGB_V?\ OG_;_2ZTN8KVVCGMY$EA
ME7>LB-N5E_V:_*?]LSX+VGP=^+;II,'V;0-8@^WV<2)\D#[MLL2?[K?/_P!M
M5K[<_84\<2^,OV?-'CNY&FN-&GETEG?^Y'\T0_X#$Z)_P"GF^&H3H0QN%^V1
M@J]6%6>'JGT97Y<_\%#?^3A7_P"P3!_[/7ZC5^7'_!0W_DX1O^P5:_\ L]8<
M/1Y\>C;-/]W/H7X%?&'2/@I^Q)X9\2:OF;8]Y%;6D9VO=3M?3[(D_P _=1J^
M*OB[\>/&7QXU[S-<OI7M7E7['H]EO^RQ?W-L7\3?/]YOFIW@_2_%?Q[U'P3\
M.](B5XM)BGBMCN_=0)+<-+<7#_\ ?2?]^D_BK],O@M^SQX4^!>AI!HEG'-JY
M4)>:U-$#<W!XW#=_!'\J?(O'R]V^:O2E*ADU6<ZL.>K(Y*<:N.A",/@/B+]C
MGX2>._#_ .T/X5U75O!VOZ5IMO\ :O/N[[3)8(EW6LJK\SK_ 'F6OT^W8%*H
M Z4FT;:^9QF+GCJOMJAZ]##_ %>') _&#]H+GX[?$+_L/W__ *4-7T5^T=^U
MEK6LKI_PW^'5S=H\,<%K?:AIN[[5<S_*OV>WV_/][^[\SL-OW?O_ #K^T$?^
M+Z?$(C_H/W__ *4-7VY^P=\ ;+PIX)A\?:K:B;Q!K*,]F95_X]K7/R[?]J7[
M^[^[L_VL_8XQ4</@,-B)PU/GZ'M:M>=*)\V>%OV#?BSXGL_M,^FZ?H*LNY4U
M.\VN_P#P"+?M_P"!5Y[\3_V>/B!\'XEN?$_AV:WT]GV+J-LZ7%O_ ,#9?N;_
M /;VU^RPY7AOTK-UK0['Q%I=UIFIVL5Y874;13V\Z[DE1OO+7CT^(L5S^_'W
M3T9972Y?=D?G3^Q[^UQJ7@KQ!I_@WQ=J$M_X8O&6UL[J=MSZ<WW4&_\ YY?P
M_P"S75_M>?ME:C'K%YX)\ ZC+8QVSM%J&M6[?O6D_BBB;^!5[O\ Y;Y=^//P
MV_X5)\6?$7A9&9[6SGW6SO\ Q0,B2Q?^.ML_X!7TC_P3Y^!-CXDOKWX@ZY;K
M<1:=/]ETJ*5,KY_WWG_X#N4+_P "_NU[.,PV I0_M-;=CAH5:\Y?53RCP/\
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MOTSZ HHHKXT^A/@S_@I]#O@^'<P^\CWZ?^D__P 35S_@F&S?V+\0%]+FS_\
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M'P<H?SGS>7T/:USZMHHHK\D/M@HHHH **** (QVKXZ_X*8_\DL\*_P#8:_\
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MWPW8%9I(E$MW=J/^/FX;[\O^?X56O2AP*6D;^*E*4IRYI!&/)'EB?BU\=?\
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MO^Q>@_\ 2BXK],#U%?F?_P %)O\ DN^C?]B]!_Z47%>]D'^_P/*S+^ ?4O[
MO_)MF@_]?%Y_Z4/7T6.IKYT_8%_Y-LT'_KXO/_2AZ^BQU->9CO\ >*OJSIPG
M\"!)1117(=@4444 0?P"OQ;^._\ R6OXA?\ 8Q:C_P"E$M?M)_ *_%OX[_\
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M3._#?P8DE)VI:*YCI/Q;_:#_ .2[_$'_ +#]_P#^E#U^P_A#_D4](_Z](O\
MT!:_'C]H/_DN_P 0?^P_?_\ I0]?L/X0_P"13TC_ *](O_0%KZ?-O]UPOH>!
M@/XE4W:***^8/?/S!_X*-?\ )?[3_L!6_P#Z-EKZ^_85_P"37_!O_;Y_Z6W%
M?(/_  4:_P"2_6G_ &!(/_1LM?7W["O_ ":_X-_[?/\ TMN*^PS+_D588^?P
MW^^3/H"BBBOCSZ ^%/\ @I]_R#?A[_UUO_\ T&"G_P#!,#_D#>/_ /KXLO\
MT"6HO^"GO_'A\/O^NM__ .V]2_\ !,'_ )!'C_\ Z^++_P! EK[/_F1?U_,?
M/?\ ,Q/M?4H&FL)XH_D=HV56]*_$CPE?KX5\=:/?:A WE:;J<4L]OM^?]U*C
MNG_CE?N%NR!7YK_MJ_LMZIX4\5:EX\\,V4M[X<U&5[B_AMUWO87#???9_P \
MF^]O_@_[YKCR#$TJ%6=*MM,VS*G*<8R@?HSI>HVNK:?;WMG/'<VL\:RQ2Q-N
M5U;[K5=?:W45^4/P)_;.\9?!C3HM'EBC\1^'8O\ 565U+L>#_8BE_@7_ &65
MJ^@&_P""F^E#3]Z^ [XWNW_4_P!H)Y/_ 'WL_P#9:YJ^18Z$O<AS1-J>84)Q
M]X^WG=0H)K\M_P!N_P",%I\3?BO;:9I$RW&E>'8FM?M"_=DNG;][M?\ N_(B
M?\ >KWCO]KSXJ_M#:@/"?A#2VT>WO_W:V6CLTMW(G\>^X_N_[JK_ +5</^T%
M^SO/\!/#O@A-4N?M/B#5UNI[Y(7_ ',&WRMB)_N;V^>O5R?!1PF+A]:E:1P8
MW$2Q%+]U\)]>_P#!-'_DBFN_]C#<?^D]K11_P31_Y(IKO_8PW'_I/:T5\YCO
M]ZJ>K/4PO\"/H=Q^V/\ #R3QA\+I-4M(]^HZ&_VU=GWF@_Y;)_WS\_\ VRK\
M]/M_^U7["S1+-$4=-R-]Y:_,K]JOX%7/P8\827^GP,_A34Y=]G*GW+67^*W?
M_P!E_P!G_@=?1\.XZ-.?U69Y&:83G_>P/,/[0_VJ/[0_VJYO[=1]NK]"Y3Y@
MZ/[>/[U?H=^R+\4HOB'\,+>PGEWZIHFVRG7^)HO^63_]\_+_ , :OS.^WUWG
MP6^,VH?!SQW:Z[:;KFT_X][ZT_Y[P?Q?\#_CKY_.,O\ K="\/C/2R_$_5ZI]
ME?M/_LRR>,6N/%GA.W5=<1=UWIZ_\OG^TO\ TU_]"_\ 0OB&YFGLYY8+F-H;
MB)O*EBF^1T;^Y7ZL^$?B#H7CWPO;^(-(U*&ZTJ6/?YP?[G][=_=9:_,?]I#Q
M?HWBGXU^*=2T)HYM*EG1%FB^Y*ZHBNR?[[(_SUXF08K$3G]4J[1/1S2A2Y/:
MQ.9^W_[5=%\/_#MWX_\ &6D>';'_ (^+^=8M_P#SR3^-_P#@";GKSK[=7Z$?
ML=? "X^'6A/XJ\16WV;Q%J2CR[>4?/9V_H_/WF_\=&W_ &J][-L=' T/[YY>
M#PTJU4^DM+TZUT#1[6QM46*ULX$BB7^ZBKA:_*C]L+XUQ_&7XN74NFS^=H&C
M)]@T]D/R2_-^]E_X$W_CJ)7T%^U'^U#>^.+F?X9?"F*XUR]O-UOJ&H:8K2[E
M_CBBV_7YI:I_L^_\$^VCF@U[XELC[6WQ:#;R;Q_VW?\ ]E3_ +ZKY#+/99<_
MKN*^/[)]'B>;$?[/2//?V-_V4[GXFZS:^,/$]HR>$+*4/!;3+_R$95_]I+_%
M_>^[_?K]-4547:O\-5+&T@TNTAMK:&.VMXD5(XHDVHJ_W56KQ.*\7'8VKF%7
MVM0]##8:.'AR0)****X#L"BBB@ HHHH C/2N/\>_#3PU\3M/M['Q-I$&L6L$
MOFQ17&[Y7^[NKL1S29Q1&4HRYHD<O,>._P##(?PA_P"A&TW_ ,?_ /BJGTS]
MEKX6Z+JMEJ5AX.T^VU"SG2X@N$W[XI%;<K?>]:]<HK7VU;^<CV-/^4?11161
ML%%%% $>0.E<?X^^%?A;XI65K;>)]&@UJWM9?-BBN=V%>NP4 4IYJ5*4?>B1
MR\WQ'C/_  Q]\(1U\#Z;_P!]2_\ Q=3Z/^R[\+/#^K6.I:;X.L;/4+*=+BVN
M$9]T4J_,K?>KUX#%#5M[:L_BF1&C2_E)****S-@HHHH \?U7]EGX6Z[JU[J6
MH>#K"ZU"\G:XGN'+YEE9MS-][UJM_P ,@?"#_H1]-_.7_P"+KV4'-+G-:>WJ
MK[9A[&E_*<=X"^&GAOX8:9-IWAC2(-'L9Y_M$L5N&PTFT+N_)5KL.WS4  4M
M92E*7O2-(QY1]%%%,L\Y^)GP3\&_&"&PB\8:,NL1V#.UL7GEB\HM][_5.O\
M=6N%'[#GP6'_ #)R_P#@RO/_ ([7O1..M.)R*J%:M3CRQF82HTI^]*)XQX/_
M &4/A;X#\0V6O:)X5CL]6LV9X+AKRXEV-MV[@LDK+7L^W\*08/0\TN?>IG4E
M4]Z4C2,8P^$DHHHH+&8^2O./'7P)\"_$S5HM3\3^&[/6+^*#[.EQ=!MZ1;F;
M9_X\U>DC@4PD'FE&4H^]$B48R^(YSP9X(T7P!H,.C>']/BTS38'9H[>'[B[F
M^:ND(I-V303BB4N;XB_A)****8!1110 S;Q7C^J_LL_"S7M8OM2U#P?8W6HW
MT\EU<7+M+OEE9][O][^]7L%(0*<9RC\)$HQE\1!9VT5A:Q6UNH2*)554_NK5
MNBBD61Y["N0\>_#/PW\4-+AT_P 4:1!K%C!/]HBBN V%DVE=W_CS5UX%&W)I
M1ER^]$CEYOB.$^'7PA\(?"PWW_")Z'!HGV_9]I%ON_>[-VW[W^^U=Y_#2  4
MM#E*7O2",>4:ZAUQBO%/&W[)'PL\>74MYJ/A&UM;Y_O7&GN]JW^]MB8*W_ A
M7MI&:3'K3IU*E+WH2"=.,_B/F/3O^"?7PDL;L22V.IWZ$?\ 'O<:@^S_ ,<V
MM7LOP_\ A+X2^%]A]E\,>'K'18W_ -:]O%^]E_WY?O-_P*NWQ1GWK6IB*U3W
M9S,XT:4/AB<-X_\ A!X0^*<EBWBC0K;6OL&_[,+G=^ZW;=W_ * M6_ 7PR\-
M?#+2YM.\,Z3;Z-97$_VB6&W& TFU5W?^.+77#':@X[UESU.7DYC3ECS<P$8%
M>;>-_P!G[P!\1]8_M?Q)X8M-5U,1+%]IGW;]G]W[U>DY%)D5-.I*,N:$@E&,
MOB.>\&^#]&\ ^'[70]!L8M-TJU+^1:0_<3<[.W_CS-71$9H!S2TY2YB_A'T4
M44P/'=8_9;^%GB#5[W4]3\&V-YJ%[.]Q/<.S[Y96^\_WJ]6MK6*SMXH(EV11
MKM5?]FK1S3-OO1*I*7Q2(C3C$EHHHH+/,?'/P$\ _$G6$U?Q+X:M-7U)81;K
M<3;M_E?W/O?[5=5X-\(:1X#\.VNAZ!8Q:=I=J7\BTA^XFYV=O_'F:M\\49"C
M)HE4E*/)*1'LXQ?,2T444%G"?$/X2>$OBDEDOBC0K;7$LF=H/M&[]V6QNQM_
MW5_*CX>?"?PI\+8KR/PMHL&C)>,KSI;LW[PKG;][_>KM\8[T8SWHYZG)R<Q'
MLX\W.24QTW4^B@L\-\:?LA_"KQW<SW-[X/MK2ZD^]<Z:[VF?]K9$VUF_WEKD
MM,_X)\_"2TN/-N+/4M13_GWN;]PG_D+97TWT[TA85T1Q6)A'EA,YOJ]*7V3B
M_A]\*/"7POLFL_#/A^QT6)_]:]M%^]E_WY/O-_P*H_'_ ,(?!_Q1DLI/$^@V
MFMFR#K!]IW?N]VW=_P"@+7<XSWHQCO6'/4YN?F-O9QY>4X_P-\.?#WPRTB73
M?"VDP:+9S3M<2V]L&V-)M52WY(M%=C14<U0.6(5S?BSP=I7C;P_>:'K=C'J&
MFWD6R6WF_B_^R_VJZ2BG&7+[T0E'F/R\_:$_8Y\3_">>?5?#\%QXC\*_>\V%
M=]W9K_TU1?\ T:G_ (Y7S?\ ;Z_=%@"N.U>(?$O]D3X:_%>6:\OM$73M4F.Y
MM1TEOL\S'^\W\+M[LIK[3+^)9T8^RQ6IX.)RM3]ZD?D[]L:C[8U?</B+_@F5
M$)'?0_'#11?PPZAIX?'_  -7_P#9:PT_X)G>(4;$_C33H8?[Z6<C/_Z'7T\>
M(L!/[1X_]GU_Y#XZ34I41E5FVO\ >2M/PYI&K^+M7@TS1--N=5U*?_5VEI%N
M:OO7P;_P39\(Z;-'-XC\2:CKY[0VT26<3_[WWW_\?KZ6\!_"_P (_##2EM?#
M.B6>BP-C=);Q?O)?]]_O/_P*O*Q/$U"/^[PYCOH974E_&/G+]F/]B^/P!>VO
MB?QPD6I>(H@LMGI\?S6]DW]]C_RTE_\ '5_!6KZ*\<_#73OB/:BQUJ[U)]&=
M0MQIEK=&WANO:5H\2,O/W=^VNVW T;<]Z^#Q&*JXJK[:K(^AH4*=&/)$Y;P?
M\._#7P]T]K'P[H5CHEMM^9;.!4+_ .\W\7_ JZNBBN64I2-HQY!]%%%,L***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gv1ubg3hw41v000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000009.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $  -0# 1$  A$! Q$!_\0
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M-CQ/P_4L^I;;6L]C+1M79J=;N2&(2N_;PERD6ALY=2"LF#%A4I"OQL( #(S
M_JNR&M"$2;M1A)ND\Q49D$WT<[1CZ :W*:22IPLYSF[F7,G^:S\6,B97S1E\
M;*[R[*[:DM779M_K[$[!'5;#H[$R9\ K%WI^9+P&&"#MERCY(ITA](#Q5N[=
M.,>UR>+_  4S0[$=5FE32IB8G9SNVE?@C6YGPF0QWT>J>/;;;*0K1V66Y]=4
MDTEC3J#LX!G*%)BWL)[&(Y9'48^M*)5:1FC5(\Z@0B08H)/,W#L>38D^VI)H
M+K>=-.J(U7X0K3IE+BN%K&VK[\5HW82UI&8F&UNQ>.MM@V75]OV;J&J2BIZL
MY).*C7#/8NTC<KD8$I8-;5^1*1X.8E5?0PZP#%RJ"SUBH&5Z'=C!%5"LE*34
MWF'T><W<YY(M@X,C@#@#@#@#@#@#@#@#@#@#@#@#@#@'.EY?-]]H-.-S])6]
M66+A'=<TP;FTMK83G$X4:[E]4";YIBM98[1.G8V3DL>7CT;L@@8^*CAH-@BW
M8KO'G:F#;VL!THI55-5KV5+4V;53Z7A+O-(:]>7FVF.\_D.L+8NU';S0*GM>
M[DNJC(2!A$&[=81NH-I5=6F1N-GV (3+I27L*7U[,D@;&22]<1D2E+5NMF-0
M:(JC@=*BE)=IM2YSJ6I=R37R[L$%^9"&0IO9Z.V^L]VZD2.$:Q%=P8=&IF3K
MF=.K9I(409A7'47?P25$!P6SD3I0(((5G+EPA<4N99N'[Q)BB_=,QG3/VM-2
MJ=U=XE/9[/E>",*/EQMZ,;B+R'9&J+2U:U@AWB\L;;X]3DI^IZ?&IF28V[!1
MD&F\9E4(>DS3>2DXX>=PA6MSTABV(B3N<,#X;%-4;(E!K2HLTWK5*=UE/WBY
MC6QGFP/S?27=@K3D<-:Q[64GK]5^PE>9.YA1%\L'E9V+9\<AC63M2$,*V)"F
M4F#N'+J/S:OIL)0-Q9X9$JXH/>W'3MF%-"U4I]I-PXE72NMGOG<Z20SA9T'%
M.G&?O%W(UBX74]G''VUEFJ2BF?LX=8X8^UGEEE[.&../7KZ8]=====<',]+@
M#@#@#@#@#@#@$8MQ;7,TQKS-YK&)8SA,O5>PJ&PN0NZKEMX*MI?8LZC4"CS<
M34D'*@I+/I"_)2-!E&X^T,#63@ZN/6./$02!//H57?'O2\W*14OKWKU9>VJ4
MML"/>6GR<!;-AY,%D^:&H'2](P!9E+XX/F4$F O7@I2[L<I!)E&R30N 8&2:
M9K%IBN.DK(870=ML1IM+]%$<9;\6JLW_ !L7,T!%KSA=>H1G82UXM=T[%%7Z
M#6SHQ7.%5+2>-=XM\P[F50ME(9&!82]'+)XV,NHLX&1LEBBT>C@ 3M9=@D,N
M-E'+ATY<)OM+R]V<$' ' ' ' ' ' ' ' ' ' *Z=PO&]5VYU@=3JPY?)A./>
MK>P6K>8(0R$+L?DE_-PF+V:)+OT%ETI/#'P$>5C>'IDPR?HIJ/45<4\<>#5-
M3IQQI?\ 5ROD,C5"O!KK%&(9G6QF73Z40%_H$CH,<"*= Q+L@ [NR2W\]M]L
M5:L5LF%C+V-)WAMNGDT> &SQNU67'OL>ET5Q=;F</4JM[0HCIRX6P>R'\.<)
MF#>SUMMMD[KVZD4XUC*Z?1"23<;74'=5/1Q9\T,.<(LQ@44&#B]FN#@P*8(6
M?+6YLT4<A6*+QKFR4(-GP:\::53#56[NL2VWQ? QX9X68K*C,F-;-;67ILXY
ME.FDLT;6PE82LH4F!I\U)(K)HV^C6$'B@W!&;1 E%4"F$JD.$E)R60/%2DB6
M>M&@\0U#6]DEVM>\RL9>#YM/"W'2FO.P]!V1M!8\]2OFL('3;64,JNI&N.J]
M@=?R0/)V.8N-UW"X^.DTUD3X(.QF<UE;DB0D&+)BIVV9K-L\W :W*:2LYW?J
M\<$N^2ZUBUQ8,6;'#/)3!FU;M<,\NNNLL\6Z."..>777V=99=8==]]=?9UWW
MWZ?9P8/ZN . . . . . . >+(8U')<*6!2L %DX-PX'NW :0BF)H4NZ$$6A@
M4Y6'$D'+-5P,+,&)0>MFCDHR(LFCUMDDY;HJX <FTCW]L,7LSMI'CGEQTVT+
MD$?VOLV%/Z%;Z8QVU3YH'"2K&$P":3"WL)"S[FTWE5<@8HVD#APJ[(Q%\Q[A
M))L =QG.+A1U5-J>Q75*LT\<5&EPDYB<YW.N/@Y#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'&+8&TL2U,V;VCJ>#^2[Q_PH8:VSNJP
M"-82C0V^KKE%?2>P[#)'Y+"3%H1 (:$%Y*/,/'2<C3R./4 4E5*"1S6/A6 ^
M."!UTZDGHJPKJI*8M-Z7&(X0N\[.N#D. . . 0<IRWK$E.^6[M-GI%D_K:HZ
MJTTD=>1KL6%;8QXU:C;852>O<2K0:W.$^S^<(B_>3<T3(M1OROKH.@/Z>$.G
M4W?1>_X+LNK]OR3CY2#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'&
M9#]P#-07WN?7POS):XZ(M&6^NSN>6KQ'3QK=_05R^M8KVZD;2T3)]JY?/[)6
MZSE<F%-UEV,2F)8\":,(]@P[CHM\^?/ [1:EZ*ZNRKIM=T0X2PL3$WF7V9\'
M$< < < K3U\_.@>23[C_ !Y_NFU_)N^B]:B[+J_2DLLY2#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@$=-MY%#8EKA;4CL"76[ H<(C6+H[,:%PD2MP1
MYMT3'II$(&C%!)X^N93=YM\.T& 8ITNRS=).V3AEFY3R%65COB.^;'-'UY!A
M%?D?B*=V\MF\&ZKWU:Q3>+Q)6=+"[_-VOZY=/KLUZ@%"2)-[DLIDIF>D,*FC
MO-7/M=ZFZZPRPS&X3RJ5_P ?J4KR;J\HY07P>2;8JVM9=3U)U5##!Q:TKM/7
M^F@S\:)"R#&-$+HMV%UP6D04/,B\<BQ0L-92%_C#FLT.AHLK*5P'TK>)A.B*
M2@S2DW?$-^";]BFJ<>4#;L'%\U(U:2:LAU;IZR+/O,3.:-KH#*[EL2OM^!FJ
M9^AI8TB<QG4,!9Q:-MRS)U/*-DC%I,I>;C$L$-XV&=9P5,:5*W5G90W:5,X[
MKK$SQ/VRO*QN/6[*[[&0DD+/A9M&O(@TJFN'M>B6Z>MAO3S;JK=8X'*SQE@Y
M0/39A( -@OYG/1TQ7Z:9R,8Q0 *@07;L:X#0K9_1RG72ZK9Q$*URT+6[<&TH
MY4&S:]W!;6V;DVLFY=A:Q,Y'15,-S=C67' \>@4P"3 G6T$^7@VKH(E/%HK*
M'L<:#A";F._%]CV[EPYPX,M*5$*5-W99W[O&QA>A=Q-[S\@WDAG3:MKAJI)2
MI= Q/T4O*O2593K#(<TVI]2*D8*JK.\1+WW_ %\N?]Y^[=^Z7]CKKW??)N^B
M]:@U"5T[O#G@7&\ID< < < < < < < < < < < < < < < < < < < < XZI
M-M63F.QVTK"V/(5Y4(V8@FVUTUO&8WI?064HUP$P.(3IV*AD7"2 95$C7=GH
MP%3;1>Q5RSM%W],!9Q1!T<'9,Y.9'9+LIJFB(3[3N[2W]R23VY0=;=F5C7ES
M0225A:T-CU@U]+V.(Z2Q"5#&Y<&8:I.4'S;%TR=89I^^9$&C0B.=I^[=CB3-
MF18KMWK5NNF.)H170W3-8;3XA;6BGU1M!/WA2H&:L-&*)0<@1D;*9$W8[VDN
M\G2Q6:#1TT*]E<G_ $3F3!E+'_3B0M4"*8LN]W?/SY:V#VT=,-3T)1<LTPUY
MJ;*3["@C48NPLO#1#E:RH])\\%I2&DZ+ENJU>#I8Z20(2QK@@DE*"C=L5/XD
M2+9!TF$NUW;%\1B#95/4K4^O\&8UK2\!C=;P4<]*$VT<B[#!BRR*G'RQ,R6>
M9]]J.B)8J_<*NR)0BX=$'BV7M.'*GLX=8@VWDA'KY^= \DGW'^//]TVOY-WT
M7K4-EU?I266<I!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P# [/D\MAD
M!D\I@M<&;=E@0?T]"UM'CT5C!R7N,7"&"HL2=G!<#$A[[X7-=RWS/&A8]91O
MTV5?-LEL5,0.77)])JKL>WI-+=]/)%XT8;:]VV-=3JLK:T3@SJCXF<L>5/93
M(@X2\(/';@IINQP<NU%"AE>QABL@(*O9::^(D)LH_=OGSJ=."TT51:54Y<<M
M2??!U?M739\U;/6:Z;EH\;HNFKE'+K-%PV<)XK(+I9X^O6::J6>*F&77?IEC
MEUWU]G?!S/OP!P!P"M/7S\Z!Y)/N/\>?[IM?R;OHO6HNRZOTI++.4@X X X
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MJHID(02U\_.@>23[C_'G^Z;7\F[Z+UJ+LNK]*2RSE(. . . . . . . . .
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MBZ*)'\DBRLF<-$$1& .IM)0K/:VT%C]@0YI8D#FU?D"\A ,)U$9)#GIV(EE
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MY%HSR(C%UV3-9 5-K'FDUX.41V"^'G1D%%H'#6$1MQB"K&/65!X*G'=E=A8
M_#5I;,[QLB:U>0,5K9<,+3&"$Y:F@26%3M[*';U5L@J5(D76';C(74[X<Q,I
M/$P[IWN[HL6@L'B%90N*5U7\<%1"#0:/!XG$(L":)L0T>C8!@@,#!QC1+KK!
M!D/8-D&R"?7KWTFGUWEEEEWEEV,Y,JX X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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*A"M?$G9?P<C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gv1ubg3hw41v000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000004.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %8 ET# 1$  A$! Q$!_\0
M'@ !  (# 0$! 0$           <(!08)! H# @'_Q !:$  !! (!! $# P$$
M P81!@\! @,$!08'$0 ($B$3"10Q%2)!418C,F$70G$D-3EY@9$8&1HE,U)7
M67=XEIBQL[35UPHX5J&VM\'1UC1#8H+A\/%355ARD__$ !P! 0$! 0 # 0$
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M5%:9)?S$0*>GBKF3I2TK7\;2"$I2AML*<=>=<4AEAEM*G'GG&VD)*E@=$ >
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MOV_=FX?J>XI\'@--9CM'(X?ZE0XJ\Z7H]74J?=AMY-E*@XIZNHU2X\B+7LM
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MLMN..K:0T3P21[ !X''K\^B..?7K^O0 R!#:B#R!?Q.#[,Q&BR3K+$F\Z@F
MS<_)MQONAL?,F1?93:-J?EPIPIJ9UY2S]JA4)B39.LHY#95(1,C1@\4%:&V7
MVFU)2\\E>AOZ=+]M< *50 +:F\FSSHK,=593HB=$3HB=$7YN.I:22H_QSP3Q
M_P#6?0Z(M3LLXH*@E5E.BPVD@E2WY++7H?D@.*1Y<#WQS_GS^.8XW&OM?TU1
MB;!^^BA&VSIO862LP*Z6M&$UJD<E!4V,CL/-"W'WT^BJLKU(#<-E?#<B1\TU
M:7DH@K9%]&\_/]EMO""?\Q=MQ;T+;D-ZK!;SW?I#1-%62,XFO&VGL.2:K'\<
MC,V.2R(T8*^XL_M%2X3,"N9<06/U.=,A1UR3]M'>>?"VTB 6T;;HWU6*14;.
M-SI,Z@N-&.FEE1W']]YIW=7L>/C[&646AJYQ!;J,B5"1<9M91I)6_8W[T"1-
M4K'(:VFFZ6C<M)C$N0B5:60D!53'K1C=OD7 TG7N%L@ 2WB+Z:?(<B #INK+
MY/BF/PL=968[4549*@ VVE+90E(!:^()XX/ *0 ?$^^".>8)-7[@L7AC.IGG
M%F&;,6N#>>V[@KEAM7<<-C8D'7F&M0ZZ9,<6FVG_  AA,5A)2@+=2TE"Y,A:
MEI;884M""5J<4H(2>=+0I!#G70%B.<N[_P .6"LABVG8]["BJ5DV4+E*CH*E
MIO9L>.I:T@J6(<9;<+CG@A"HR@/Q^.1U':]OVZ==?G&7O;TCWMRBWO,F"=I6
M3P[&SO,+V3L;&[6?#3$L9%'E\^L;G1D*4MEB:U'6PU(;:<\E,I5PXT5.%E;:
MEJ)7VYZ^2.9Y[RW0EVTYQR4$;;TU.J[*LE[(AV60W>(2I;M!DLZSN;1#:9CL
M>1.CR#*ERI-<BT7#CILCYK:>,=A_[OY6V4H>OFUH>S?SH0RH-PX .C<_GS)U
MO$=,>W+.,*O->UUIC2T-QO$P9,%12N=4V,,_',KYI2.?FCO D**4HE,+CS&/
M.-(86J@/;KO?76.PL%Z27LVXO+B_[05'F\LCE1\VUP64_(N=M'7T6"]\:EMH
M5,RFK8!6![0&VUJ)_CE/ ') (P6^^G4<U:9D1<Z:?.WHI'VC2_VCBN,!/QE"
MPZTLD<_(WR4D<?CV!_D?P>>>.IWWJZW1#D$00)> VIF_/EJST)SJUN,0LF6G
M%.)88D(#A0HA+J/VK4#[]*"20/( *\3R1SUDU,UB#$6ZF_1M9/(=!OV/8'35
M77TIG$&77PW4+0X%H0G@$$_O !]\^B.3_P OKGCUU0&?S^;SOU\MWY5WE^P-
MN;P!\U8F[J(^3PV@ V1X\ JX!'!\ARH ^TD#C\_S[YXXM^R.^A67(M_/+2^[
MP6*U2YI<L57N0/[6W=?"#*HX56N06YI03_\ W1V$]8-. 'P0\Q*9?2/:%H(!
M"VK_ #3Q &0',V+1>'/D/*8:-:S"XT!"VXC"D\>:W7'5*<?><(45.R'7 I;K
MSA/DMQ:BM:N2I2B>I+[6'S)8] -#Y2VS4(>;QHW1HOY7)(90W=:Y^^N7)Q1X
M.-NA+;@ \N"0#P3ZYY'O\GU_EU+V+S+,&VEC9@Q9]7:U=A(L(?6T,\P=W#D,
M=9'=Q2Q@T[:&WG#^U'D5*!24D?RGGUZ)']/ZC^.JVCP3Z:Q%WG>^H=9</:?-
MB_)[7@'9PT+_ #7>,JMMBUS5DP)5;509MNZP\DN17'XJHK$'S0OE*UMRYC4M
M"5 I*HW*@>""  T;E?S!]KV9Q95_TL\VYM,;QZ2P5S.M+"\<QLRF7X:7W(ZG
MFE-EYDI#S8<'B2V2%>"N"?%?'(/^$I4 H$5?<NTHS9,/^$M^4RM*D*;<64*"
M./P0%>*@0!^".#_'(/4;;G?GSEOY'1WW^SJ@NU-7XYCF,R8$29-G4BYC]PS7
M(NI4NB1:+ "IL: B0[7(E.AL(7(:9#JP "XH$='F8?GJ/+ZVTNJ_J+:1.WLT
MWFRXQ]Z>OJJ5AF-9Q30G1F,/)H>-EN$H>$K')\*YG242XR1Y."LG1&7(+R2E
MQDSIS9#B9!\(Y-K@G=F<B=+3UMLNE-Q+AM2/[FTN=0&B]U4;7FV,ZU[):$5V
M4I#(\783A=' 3Z"4\GCC@\#D#DG]Q]'J.S687.@.PN1);D+"ZTPJ'(SK]_;=
M7AU_WWUR6'*W)!,@2$!27FI7*2DIYX<;)Y2I/OT4GCGD'GGDZ<;][].=CNL^
M ::;[S]P;:#<MB-F=Q&M\\@.-27XTM[XUI9D>25OLDI/B?'QY(!!X2#QZX_'
MKH"&O[>98>NY=T%,^VOU@V;0,QV5+7LK:K)'WM9.0CP/R-N-K4A7/EY>/Y'*
M1Q_A(/XX//'/6)!+"[ER\F2UYO$3Y.MCF):&;7>_F'O'-6IT9WIJQ>PC5EY.
M  4E(67R#\8(Y44%0*D\^_('A)/!]=;<.-]M;:M_%N2P:7<]6^>NLW!:;-!Z
M,'Z@6%5]$N6]D4%MIMI(2'IK2%^2@$A"4J4%*45^@E(\E$< <^N@(:X G4,>
M;[_5[W6/"7;UY#ZZL+G8*LNP\HS3:\JAS"X;L:&JR7+L<PC"X%JW(K93G]L;
M:%27>62(KWQ2H[-?26,UNE9>1'?ERG'Y"6OB_3W7UK:1Y+3,X=PWBY:^HM,&
MS#4=2=48)+L<JIX33*8-?'$2O@,Q068T&*RA#;46.A'BEMMF.TAIEM "4(2E
M*0 !Q>_LN:L[O&MC:VQ*?E-G:QZNFQZKDVEO;37EHBQ8$1I;LEY]?M:OC0D>
M"$A;KKA0TVVMQ:4JA#O[:,>1Y]#J^R#6+=9'=Y?5<=,N:F]P+KUK+1*HZ-]I
M<>OB-!C]2GQ?-:FY5HX^V^F.I27"I,.%\2F%.*0[+E%"2EWW](]%L1MUDN\,
M& <;B=P(4G]L?:@O&)TC]#R/(ZN%-F)=5'C341U+=_:5K:EM-&P92X?\08F-
M%12"3P2.EH%]G>+!2JKQ:#JS?+F_DVRZKR\;VKJRF9OJ;)7<BAPD(7,H+YQM
MU#K21YJ;;LV&$SHLE2?)#<ATSH[:E#YHKQ\0+U6&?D=X?RNI6I=S8Q>U4.Q9
M*WXUC%:?9+7BH*;=0%>+B#RI#B.2A]M1*FG$K;6$J20(_E[_ "]&N=%>]UK&
M1O8V_%^]AN_L<2M;[2O$!KV20"/Y]_C\G^?Z=0V<7Z,2\:M>'?3R(!Y&G/\
M;V,;$,Y,''9N-8T]*G39T:+"ACY7'WE)0VE*%<DDDA/Y' !(!'/OGH UC8C:
M&#3SO(8V%K"-&O[NI1Q7NST]E3D:F@Y;03I<IKX&F8]I%<4^ZE'MI+04?)9
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M5K1Q((*PE7'[B#Q_(_H3R/1/X_CI'T_9'%OO'7;S6H60JUP_@921Z/))'OT
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M7Y [OOS<-J39UV+5TQU%MM3WJNY.EOJ"X1L"N8CQ+9AU:6VB\PMU2'6E+"0
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MC^J,5<??1*N6?O&5.J3$9IFW"J;;V !\BIU"%1H3"$J=4Z\VA* VF9(:A=@
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M1R?=CTBS_9;OJ_>IL$R(;D:=,M8;92Y"@Q'Y2PZ/\ <4E(8C^9X'$IZ."/W
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M:\%PHPP75K.;YQB%C#;F1WX:,BA65C!+7W$<R4H83\KKZ7@D2.%M\!*E *Y
M"25=3X=^,<CQG&Q,M4</!QZ*153)_P"M!9F%1DR!^FYL"M8^!7A@F](+2!#&
M21STFUE8MKL$UO49G'V$NFFV.5!EY8O,AG3;5YHR$)94[#CR%B!"66 64+A1
M8Y0TM:$^G%]?9RYB?VD,Y;>6!L="O$-1L3>P[D^O5838>IUXNC]7HD*8<CD_
M,EK^[#J4\D@I2H *X!*2>2?:5#@\BZ_3LMH9C9 =[1< Z^I;SAQ%Q5R^[D'\
M,ELLV<Y3*4N!N.77"$^31!\.2K]I_;Z\OS[ZJ>%^5WG4/#D[#FUV9ET(T'W5
MTU[61)+-K'>0MI'RM*=2M! '^L//GT?7D.""??'H"6%O2;J$,?ES&ZWK;>VJ
MS85M@>#5,9=K;9)E^.0X5=4DO34LMV\.79694@E3$2FKX\JWG2E%*(4."](*
M@6R2NWU!YBT=^JG??RZJ_P#U43HB=$3HB=$7DGD)@S5$\!,202?Z ,K//1%5
M=W/:[]1AT IW\@E4<E5M7N0J23<3ZE]Q1;^5A41B4]"#B@KP6GXBZ5.)4I2$
M%(S/U=_H#M,0ZWX1+EN7\D,^@,MZJJ.[NXW/[C.6-.8JU;86\[4Q[C*+JPC2
M8601ZVQE3857!I8TAI'VLFP36V$F1:NE3U=$3#->RJ;.;GU23?31H,<S+%I8
M>Y5\( ?^[8AB'Z>P,SI90%?Z<Q2VEMSKE,^^O>?%NXM[.9:6X6I8])L9K[\M
M(*R%$)> !]CC^+KS%K:Z[\KBRR21JW33E&VS^[J;]>]G%-DR6;.<Q)L)S22I
M$JPFR9+S 7^_P;DRWW'$@D#T%\GQ'//'1WL1\_JIXB?X#=6L_-6>USH:%BE^
MW5RR4M!LNM(="7?VMI)X9<*U?XOX]J]?Y^BUM $%Y[\]O**>,RQ^IK*]E^+'
M2A7E\7"CY!24@*!]^N1P>21Q[Y]=" QL(VWZ3/NI+B.IV57\CAX;>.!N]3\<
MJ.7&8[\5XQI"&UK\@A1'DVZVA?*FTO(<"%*<4E(^1?E&(M[R[EWT8WY2 ^U[
M[[]5#]CJ8S9#[N.6;,_]X^*).\(\A0XY2A$I!$9Y:B0 76XB/?\ B'5TD7-O
M./02>A5G0^[**KK#45CLJ)9U:X<TE8>:D,%#GX*"I 4.%)]<I<02A7HH)!!-
M[[9'*AY%',AWS"4_W<)3R6WI;H/PQVU']BED>E+4 4H:!"G%'CD("EIC,3SG
MKR]&UGU>DN 3T;6U^GERV(Z-ZFO\>J:2)605M-()#CZE*27I3Q2E*GGU@#E9
M  3P AMM*4)2$I2!02""+CI$:_M\E@APW87EVUKQS-:69:0H8FM5O^ZUH2CS
M2L D_'YCD!2D%82>1R3P?R>LB\:%C?I\P),L^C/JWI^WW"KC@[<C&)3=IA]E
M(I+&,ZDNL)*G:^8E!5Y0+JM+B&;&$HE2%L2 'XY4'H3\.4VT^BV=[>9_GR#"
M1HJ',"8:WGISL===E.N7]TNV&*B'3:^TE3S+F2'8=A=6V3.KQB ]_A:E,U,&
M%&N9[3X*G%L.S()C.<1Q+EI/W)CQ:-=& NS.(Y'W0 :EN3%_E]U6:VU%N'9T
M@V6P<D@-,R7C)D8[BM.BCJ^5DK6RN<J3,O5L^_C6R_;N-/()2\A25*081!'G
ML'83=^LG5Y9:\8#06$.X=NC=M>ZFW%*B/@D"/3OLP684=I*4QV$(0TV$@>U>
M*0.?Y)\BI7OD\\'JN6.\L!)OTWU;4$NL%S/U\[DGT=;Q7991RY:&H3\94D$)
M#2.$J'/KCD>)X]>@"03[_KTM<<GU;G$N7^CDAXK68%D;"X;-<^D(=2?%"D@@
MJ\AP//\ '/'L^SS^0>>J._.?1.^^]%*?FY[X(4D$CCQY'CZ]$GD^N/ZD>O?5
M1:_=N/PHZI<4\)'MUI/'D"?PM)/'LD<'^2>./7OHH=.1F=%43;>Q+GX30UBU
MR;.U6S6UL7S5\KUA8O(B0V&^/94[*=:;' YY(_ '4NQ;F)/OSY3L\K0 !W&N
ML<@9ZD3<JU.M-?U&M<2K\:JD%;B/*;<6+I\Y=Q>3/%VSM);Q 4XY(?Y2RCTB
M-$;CPV$H8CM(34)<_+D-EOW11.B)T1.B*M.;9H_199+J:F)*MK6Y=5!54PV$
MRGY<=2$%X%@I4$LM- J>?<*&F&?D4MQ#9)ZFL/SZ<GW8//H5L $.68#SOVSR
M^X"K)W-;QV7K#%\<K*FD;Q2TS>[BXICUI9O5$U,1*(4FSMY<6D@V2W5&MI8#
MS40RFQ!8M)E9]_%E0P[ F1C$N-7'*]^7N\D.H!3>3ZD<G8 MSY'D]94ZYQF9
M%;N,C8_M%?SF$O6%S>.*L+2:Z]^Y2GI4CR60>>4MI*4(3XH0A*  +J)^8^MI
M9O4E"=B)>&#M;W:1'(*2-6]KV%Y18"7_ &>JVC(4"T$1&4 (!YY*@D<\\E9Y
MYXYX'XZ?OMY _MLH2=[2.71K=-%:ICMMH,)E0IT5F.RPE]I#GVH"4 'C_&SX
M *"1R1R%?CUQQT/S;8?OROTE1]^]?N?56B>QND@4#B&8[*DL1BXB04IY6H)\
M@OG\<'GT!RD#UU0PLT:=_P ZJ%V+7TZZ=^JJ[E%M2L./1;EF-(@NI2'&'T(<
M:7XK#B201^U2% *"A[24@@\CUF3:+SJ]@XUC>\&%??OZ=N%#UKAF$Y&ZVNDD
MO5#CGD4I;<,R&E?_ .O&D*^4?G\-26TI'X22.@M)!U,0W(V]71:)?:MNZ-*9
M#]?^J0U)46+*N:7*8\3_ /U4)07HRP.$J2^E*/+GP6XG]W6D4 Y/B5@^\J75
MPG5*2H*=\6U):;6DGR4ZOQ"&DE*?W*5QP1QPI1\3#W+6=V]6-NH6A5#'R=^3
M@\M?)I=E9?1F34..0PDOM+G2$-HE33P'5\$'X&N>2TPVH#]G/DXI(6Z2H)"&
MKO:S>\]^H#9/;Z_:/Y8JTUC6QMD0E5L$)?5(CE)\2#PD(/F5D@)'(_J>/?'O
M^1-3V?<N/43IS"  1U:-R[=^BI#98978]D,[&[F S'EM/*;:\T_$)3:5>3+B
M/0)6A0'"DJ\VG4GQ(4 KI GU/W[CHJ', GH\=FW4J<8>[-UXOBTBAQ&JQC,K
M5N*E-%=9C+M&)D,-D)2S<J@!*\C*6O[N.^_-J9@* Y83[%Q:W.CP\WY'7EZ0
MYWU1@#RY:P^IAW];*$[3 =];?=%AM/9#\;Y"5_H.#U\+$JY@$J_N#,A>=]):
M 5XJ$VY?"Q^4)Y/2+W)&@NW/GS++?B BD1N3<[V]EN6)ZTBZMBHCP'([#"%>
M2F6&O%;RU*\UN/N _O<<4HJ<<6I2EJ42>>>>H+"?0O+<I):8YF[%8)-1<W[[
ME;Y_;NK;<3'=2ZA1(!*8KJF>?7^)P-E '(')/\CGGJ[:>7V@=FPF=]PI^UWE
M0B%+R5-O19B/$E"DJ3Z]CQ\2>%#CW_// (Z18W#7YVG79[[RG3O=618?$AEI
MYHE*74!8 )_J?^U_/X__  ?QU47Y365/,N)0LH>2DE"D\@^0'/"_QZ(''''K
MGGHISUGOY*L>S<VFT,"0XM];*P5(Y*SXJ_8?$GRX'\?GU_EU"VK-SW?=_9NJ
MT!M?1M]8TO?EYC:.W+#6J[%7,^M(?CE>P%JM),N0E1E,8\EYP8]7,E?MB(["
M\+=;2 @N2+%1?\RRR&P#0A.FV]WU<Z[#D K%]514@[LV=FR)M.,8O<HQ[%DT
MLEB:]CUO.K&+"PE2'1*:L37/L.+2S"1&2RB2OP4EZ26DG^\XG>C?=U7Y#J>^
M_1<3=SZE7!Q5RQI8[;CV+9+ R^?%;"@Z_2U[<N%>E/ 5Y.1JJQE6)0L*+B8:
MTI!6IL%+]'\W]&;SOJ5NDA[L\";.[M)U V+MI!NIIFVPNYQ&N:A0X)AOQV2H
M-A"EAP-I!4M?M;I/ Y6XI2E#GD\CT/;>GGYQNL$'7GZ';0:D6E]865S+7^)2
MFGI#U9 )0"MI80VA:N/^U4."23[_ )'\$<]"6L'=R^D#7V":7Y$<KQR<=ZT'
MS#.JK563)L?-$:O4Z%.MID(;^+P4 7VT*)"@!X_(A/!/I0'Y"D'7S]C_ "/)
M=/#<:/#F+VB2][Z4@J79??/@-%AS]LO(X2PS'#3+")J%2''W$D-M-L-J6\IQ
MQ7I*$(4I:OVI!5P.D7CKSM^WLLB@D\@3,.UWYN#?[*KF'SMF=R.0VEU?V-QC
M&"RDE%+414-QK:4DJ*C92Y4EEYR,IXJ CQ$H;^!I/E("GG?BCG_8:]3MWJ6%
ML 8UDB.5A>Q<7;0!S*4[M*OJJJESM=;*RFKREE ?KFLGL(UACDIY )$.>B%5
M1I\5J22$??-+EKBG^]^RF %I;?7D6;Y/\U!78&=S<OHSL(/9N=3PKN1W-V]S
MZNFW_@\R@8N'W&H-XS95]U23G&E*\DLV=-.L(C+ZFVUR$0YBHT\QP7E0T)"O
M$^A'L2/5OFRIIIJ_M^L7N]WBWJ9"Z78YOJGS[&(MC EPWX$R,%(\5\O*0H$>
MD)()_ \3^X\@ @$%(-L=SY_O+LW+589NG+7H?(K:=,U-A>93/LFF'F(?FTA@
MJ'BM9X_"4C@@#SY /LG@< _D8B[QO\SK^YAV?N\CV_DOHNBE>NQH*^.RRR\'
M0GY'0XE7BKD A/[C_A ]\_UZNFGWM'?-8EWD>C0;GF0!I ]L\C-Z]N$J3-_N
M7$>BVD\\J Y5R5<!/'^9Y_D#CH_?17OY=Z]5SA[SM^XOAN&Y!D%G8L0V8$-U
MX#Y05J6D!IEL 'GY%N+;2".!Y*XY ]]8JK% -=1 H !)DF2SP+3H^^JT [">
MGV\NV"I5V.Y0O9$;*;>\$B-+O;%%I!B3(LJ*[^G)B-QHZ'#(:0CY5MMJ=\0O
MR\%C@$#RZ_F3\7./9;/<7R65RV8<9; KI\()'BQ/'XC4!:) -3&+-(]WD:*J
M,,EF>IW8@@2#H '(@#0@S963;>CZEV95/,O_ &]3D,DQY*>06V)"D*<8> "A
M_C*/@<]#R*FU CQ5Y?)\!SV:&9R^/@5G#S&#72!6*C^J@U323! >3)=G(7D8
MM--5!IJ'B!<-[ZPT>RZ0M;/Q^?218S<=<M2X3?F[("8[:5EL#S; ^1:N![!_
M8""?9Z_KWA^)BXN2RN+CD58N)@X=6)4(I-1$D%G+F)DGU7SE0 -0!L2 ?;]^
MBJEN?-*.JI)[[[\=N.EEPK6ZM 2D)"B22KA//'KD_P >^?SUY8&N[_-VWZAV
M=TN=_:P^7,]2N8NMNR*\[RLJC;-RN_M,5T<J<_\ H%/3)$"_V#]L\\TY:1K"
M2TM%%B;T@%IFR99D6=XTP^NL_38CD"YD5G+7%MR[:GH1S+[.MFIGWE]@\M!8
MLYO EA9KUP_I(:WQJO><UONG<>$6[R5+0A^QQS*\?;<X(0E5;,H*RR?;1Z!X
MOVG' .5.E7"N@[T\K?NL^+< ^H]Q8G4@>4*:>V?5>"=O&93<>RZVD9#L?(6X
M]91['RQ0186A6RG]3Q>IC,)%+C463*@M3Z^'%*9UM\Z:Z;8VTF! +I^^??JX
M90DG]N6OE[#DNA/543HB=$3HB=$7BLHSLVNGPV7Q&>EPI49J26_F$=U]AQIM
M\M>;?RAI:PX6_D;\_'Q\T\^0(M&Q3"*C"8#M76?*ZZ^ZF7864HMKL+:<XA/S
M2YKB$( )\2EAAI*(\5D)98;0@<$A+FU_;OSYKBOWW3[?1?=-#V?.I9K."[3P
M[%H367J27:EO.,6%Q56.-ONH41 G?V:C8_:PFGTQF[%ARR<@F0Y66ICRQV?W
M,>\0RT'-)$1IJQ-WZMZ3STW$M_X[?SHCHG,.J#[:@I+H])!Y/DD\G^/P2.?R
M!_5V>^_20-+!^<<QU_8>L+J)J/>%!#JPVY(BK2XVDD?*E)Y0C]B@K]Q]@GD'
MD_T_GIWS[>]@'65_.5;UKG[H.P)32'6@GXELNC^Y2GR' 6D@_NX/(''//27=
MXLS<[]VNG?U[YV6/MMPR<BK"PJ0I];*24K"N$^QP23_)Y_VD \?@$=1[VB[Z
M2\CI+O)L=56,'> WN(^2I+LR\S:7/\,=9>?6"5E]/DD(5[] #D+">1Z( //M
M7KW1;41KIZ[)J1>[7GHQUCN_CP+8.T*"4AJ^@29C:G I+R6_!39)'I2>2"@#
M^0>.!R0.IYN+Q<=&TCKS-D+3#$:3]9!]E;:-GZ\@A-QK2$PX"A'+<AE$CDGC
M]H;6A:?1(Y!!X(]\<>WHX$$_8'5C,><IIY[?7Z.HTV=CLB^K Q#AB(TA(6VI
MA"6BE0_>.&T !)Y"??"3_'\= 7?4[BT<VYV<^2")"AS$57V/SD,V+DIA#"DJ
M0EU2PAUM)(*@3QRGA/*1ZX'/(X(ZO*]WW-N@Y'^4+7 C]A'J^GKIU"U#F..V
MF-)JWG&5_=-I2[Y$*0Y\J VIIP#R*$\<CR/\J()21Y=!V^L?/EHV@911;L[M
MD<=F2\GP">Y66*RX^ME"B]%=!"G"U*AJ4AJ4UY$\+;+<@)5RE:#[+Y,.YGU_
MA[_14_=SC,<$MGJ;+ZPLNH<X1)CE0B2$A13\C:U\^// ):60M//"OV^*B@^U
MP8Z6(=KV</H56>UIV'OJS^FVDQX_L5-LRE$=,@.+\>!X+6GD\'\H\AS_ ) C
MT/Z#I:Y]3IWN][E13#3:PL<QC-S"AN.A?CYR)!_:"1_A2CDJ)XX)2GDC^0!Q
MS&%YA]I>?,3J6^:+:Y/;_ BUDETR6I$IIM3J7&T+;4/!)4?!7B!^P>_2OR 0
M0?9&F7\V #DRQ??LPC]O]&Y"7\H6#P.X3!M'*F:ZI;]>\EE+RB2KQ'^#S/))
M' 'BKG@^N?8YZH]6WG1N3&Q+[D2$/3F--?.((5FEY51M1R^]/;:2T@J=\B4D
M?R?SR/?'H>B3S_ '%4Z]_-E"^7[QQ)B.]&8LF$H;*@M:EM\K\?(>AY$#CWP.
M?X]GUQU#_.C=]7VY51'@6.HV7E?^EQ#TQFBQF0JMQ=+/@FOM[MM(7-O/):5+
MDM4I6F% =87]NJT-@%E<BL2E( CI',[=^?EHEGW-^0>WG\F5NZ&_DNRFH,YY
M,@O^3;3O@E#B'6T..%+GBE(6'$I"02D+"PGGGS/%[]%E;QT1.B)T1.B+0XN&
M4U/>VN2M-NR;J_D.&;/DN?(\Q$'@6*V D)"(D%H-A;C38#DI\!^2XZ6V4LE2
M20VUOOS/>I*HC]1S6F9Y9J3%LZUYC3V5Y/J#,QF,NJ@)2[<R<*E8_<U66)IH
MWMZQG1E.TUR:N&E4RP8J'FX;$J:(T9V'OIR@^BM+/)(%XW%NG5PN4F'=V5#?
M,0653VU+^%I!;<5P?,IX*1QQ^Y/\A7! '/B?ST'7[^;\HW\U33TWZ] '+098
M7@,%T3TWW+X?C<:#(L;VM@#P :2_(;"W"/%*@VV.774^^%?&@\<_ZIZZ86!B
MXQ(PL.O$(;Q>$?I#_P#B+@4OH:B\W,KG7530'JJII$LY$@1&_I-U.&6]VV#7
M3+#%?D50I845)9^X^V4H^*@5E,KXUJ"1_P!JD@ DD<==,7*9G#_OP:P]B!X@
M^@>DD>X(TE8HQ<.O^VND]8]B'(\B%K]1W$UUFA53#R*!.#P^/X&K)A8Y)X2E
M*4.D'A1])2"KWQP>0.LG+YBD>*K!QZ:6N<*L <R32WF2RUX\,EAB4$[>(/=K
M/?7]X4+;1L\AMVGF:A2ES'E%*4>7" "2!Z*@I1)X])_=^.!^..(N>7R+?QK8
MRMV\QSW!\XGS"@JEK-QX[/1/5)DO,^0"HCJU_ I!/D4-^7)02/P22/\ (?DN
M^N^]OFK$R-2(+]+ ?S96WQ'8F4*@LL63)8)X2MLE3GB./?H )//O]P)'L@#^
M>EK>S.Q\M&'IJS&,^O1X_C[K8,@38Y!4O-(:/#P427.?)0*2/2>>1^1Q['(
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MLD&&E]?2+F!'0^2N#"ML.S3[5^KD0VY*FTJ4AE399>2H<@MJ22D_SQSY)/\
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M8D>CK846%7PHS$&%"@QFHT*'$BMI9CQ8T=E*68[##:$-LLMH2VTVA*$)"4@
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M4)<6&TQ@%>*XR/7Q!'"2 5@J*BKKZO+@X6#1AX='A>FDU@C]5550N;%R]S:
M&#+UF,U=1J))DB28;TAFD"==%8ZEK=PWMK%N+3*I:F6D\HBI;=:0A2N..6RI
M"P?$<'_54?05X'WYV'1B,":I<Q8G>3S/9*\<F@ @4O.X^<G]G4SUFW,_U[<5
M\B:];VE2EP-S66R5@H5QPZA#()/QD<%E:5!84>>" 1SJ.(*H!/2-K"W4<[KG
M52*K,&L["VEA'0=59_7G?1,7."+7';)^LAJ2$.3X<AI2&TD*\DS>6RE".2D)
M=0]XI 2A(2$@>#CY# QR:O#5A5DS50/TD@7JH(\,ZFDT/=WOVHQ\7!I -0Q
M P!(?H]XEKAF #,%T?U3W0:RV]4MP$3X";$+#:X8D,_>1E@D !LAMUQ*>.%(
M6VAU(X)2$J0I?I<SD\3+'Q1B4$L,2D, 2Q(KI<^&IX=VJAC=O,P<Q1BNWZ:@
M'-)NUHT(W]Q(>V&/T=48R7DAM]"QY)6 ..#[')/L<IXX_P#Q=>(XG9N3-]H-
MUW+ZWYJ0J:!3N+"%_ I"3QXH*5J1P.>./8XY_GW_ /@!A(D;D0_F/V-T67SC
M%Z0XXI3*67_E0X/$I3Y#AO\ )'Y!//Y'K@^SZZ&+1H>08S;31X37R]#'S\K*
MCF+PC5;"D2(:?%/#32VT?CCR6!^.?W#]O ]>CZ_H4;^<:/%FB>BNC69SK8MV
M.JZ>:X7_ -9@75'S6H*'GZY'B#_/')')]_[?Z](8&-H\K<CUT67EM>^_-93-
M*2EO*F1#M&HSI4VKX?F^/R0HCCE/D.?%0(\N>0?1 Y]BH2WJ//\ ?LPJ<YOV
MN,)@JR_'9Z*RY@)$^,J-R4GQ'FE$A"?!,EA?[4O-EP$MK4$*0K]PA\HY3:6O
M/\<UH&.1T[_E:[JO<S<4JL)*4L2HRI$2?"4M/#3T)]R),:YX3RV7V72RLA)4
MUX.%*%<@00_6YG8$"Y=QM>&4/?T.FA]"MHRKO"Q& V\(]M BEA2T.)$IHK;4
MD$+2I2E^7I22. !P>?7(Y%#QT]^]O;6L26:=K'OZ<ESOVEWOX&K)V)BLFKO@
MK2^[)=7.92VTZHA*?D>6XE )!4I04H$CCGT>E-)J(II%59J+"D4U5$EX  >8
ML!,<EHT@ U5U"D .22  !J2X Z]B LZ[],XR]4/&]75<PL6;K<49/9I7#@N-
M+4$N.UL=[XWI:4("_B>6EB*\ %LNOH\2?I<C\+Y[."FNNNC*T5,WB!Q*VJ;]
M1HIJH%-_\U?B?02O29OCN3RM-=6'35FCA@FKP5"B@-IXB*B;01207Z*2>VO!
M<+V5OO#,9W-;9#+OYDF59C%,KN&G:?)%5]/,NF*Z/'JU1JJ6PI<5EZ74643[
MB="#\="9+(D^.>)?"V?R&7.>IJHSN3H+8F-@@BK!_5X/%BX4FC#-1%!KIJKH
M\1 K-)(?7#/B#)<3HI&$*L#$J<445D'QD/41AUAO%4 "6--%1 -5+RN[<4UN
M)Q&:#&ZBOHZR)Y(C551 B5L&*E1)4&8D)IF.TDKY*@VVD*/)]G\?.6]K>GV[
M"]M)NW-SJ)%P_P!BVZ]S-&BZ0M4E00E0Y("1Y?NYYY_H?S[]?C^>>FF_U^:
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M7/BI27$J42I+JG."5@I4D*\5'\?P!UXXP\2JKPBBHU&U(IJ\1+L89VLN]1I
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M3^9F*,*FD'^[P8I!/AJ;W?PYD37G*LW52U.%15322P%6+72*8NXIPZJB6B1
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M2:U#'S/*D.M,B(V ?,N..+0/%"1Y<K4/%/L\\$]?M--%%%(IIHIHI!+4BD
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MN6R]?].:JZ#5BG\RFDTT$N"<.FJIC4U0_2Q-+$7*]_EL; HQJ,3$H%8%%0%
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M?Y>@AV]V('D?+LH0Y^KM\NIZ>:_.KM68]1'EQTM%32?C<#26_)23^%'Q/O\
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M ;_;9(J&S6U@;"3[8E3(]J^\[R2'H%5-\ DH"VRHAS.:^&>&9@44UTXE5--
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M:CX,,8F,,3%(HI\-(-59J8.22Y7W7]'ER*3B85%=8%(JJ9GJ  -34M2Y,L
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M?7 ZC"TW?:T::".5CS58GGT_;K]%[JE^%DS(2S)9=0L<EOE(6"1P/7!Y'O\
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M6&NSO>=('2[K-9;]+QKL6ZCJQ\[%Q]/VJ[Y=$PPRZR&4):2R&_01X\@'P/\
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M47)<O4227)N7CS2?"&#"& #  ,0 !8#0"(D67U::FBO8A$@1FVD,1(J&$MA
M\/%+2$I!4#[/^$ \$D>_0_'0F01#'W<0-H#Z:$%G*XL#!L0WMYZ_QHKD5MG7
M9E7R:FP;;?;DQ5)>;6E)!0>$DI"@>%H*@I*ORD@'G@$'3@V[_;U4#NQ\CZ7Y
M_OM-&=R5#NK[)IB7)2JEM'0R@*Y"/%W_  $>7I"^> ?P.>?Z<JD]?;7Z#Y<U
M5,W9I+:1@N9T45\2*VEV)<KK%)6E3;#-Y7U-],AM@$E/Q6L^?*6CV$?>A((
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M"PD?$.4ME+JDJ)(XX/!3Y<@GWQSP?9]=').G3S(DRVAU,%@BIEW OOY@:JV
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MOQ #K#W+#4&V]R7?<,NJ>GL9M\;NJS^[>C(4I"'FUH4$@\ \>1X])7Z]%0]
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M@'WZIZ$_+:1M.FTV4%6QEM+MU\O+S7[V.K\?J(ZT-1(Z$)3Z;;;2@ IXX)X
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M&DW'N&?4?5B'YBR\^)Y4WD.YHS57X.MM8]=R+%25\AN$IV A!'B.%*-@J"D
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MQD/ F\'[J*<I[7+]XJ?H\@JK3P/FVQ:,2*U[U["$N,??,.*_@%?VZ#[Y*1T
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MI_U1/]-'_P"DV_O_ #8=V?\ Y)='&X]0GY=6P_WJ?NG_ %1/]-'_ .DV_O\
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M%K#X]A_"]?#^&#C^+B9;"HX7_P!'N"G,?F9O+X6;P::VP3AX;Y;&HQL4XE=
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M6:B_M!6(%59)T%Q"?G,H$E3OO=*S8;M55_\ 4=_GN'(*NK)[%X;WU;8/?*<
MQE6(L=HLG#GLC%J$VR^XQG-V<?J\Q7BOSAAV_C:#F76!-9PY%,QG&Y)QK[H1
M_B;04\1\/AT=_O\ (*F^MM;?4[B[)[L^YC8W:%JN\[D,BU-EFMNT=FR[B\)F
MZ5U)K^5GF,6>+ZA9UO58W!E.R+R>'-L[JV9;Y@Y99W<X'3XA00L3JW*=B*5)
MI8 $LX)B7:3Y6 ^:AG&^Q'OEQ[#M(;N5V_TF2]TN ;5[K,GWU6YQW+8;=7'<
MGDO=AVTL:AM=V,9?4X-185KZLU_>UF+XYCNGHM28U%JC'A5T5G/MDA=H5)!<
M/# "##&U^I)WV4GZ,[*>_'Z>3=FCMRUGIKNEL]P]E?:-H');+.MK+UQ3Z=W7
MVP:[RO7B,CGU%KB]C,V%HC(49BJ^=I,?FU>:EZHFU8JXOZLW:-D)IJ,N/U5&
MSQ47:]Q.C'RGKEW&1\IB]C6]XN<OXW*S:-VH;08S"5AM=85&(2,I9U!>-Y _
MBM3;3[6UK,;>MDRW*.OL[2RL(58J+&FSYDEMR0X7/HJT_12_X*3L5_\  -CO
M_MMGT6\3^^KJNG%D[/8KI[U5#C6%HS"E.UL"9-761)T]MAQ<.'*LFX5DY7QI
M,@-LOS6ZZ>N(TM3Z(4I388<+"YX8']2[3-SVA;9[J]ETE_J*=V]7F9:]W]I&
MZ>B76R=<[IPRV;H?]$##,!,:-E.39M;6&-,ZS?K$-1,WC9CB\F%]N;%UB*6O
M"7 W8@V!!U^^Q!"\MEWN[ZDV^M=78+V2Y;EO<1D>BJ+N!VQK.RV[B6%89HS%
M\IN+*BQO#LDVW?4!KLEVI;VE/<04X?C6,2(E<[2VLRXOZZD%5<6Q" -8<B+E
MFD#:=2/HL/6_4KB[%UQV\W&A>WC96SMR=Q5[N/&*O2UW=8QKW_1?==N=[+Q/
M?*=Q['FOWV+8M7X%E\1.,07Z1G*K#-K.QJEXG56,"1+F0">&\A@Q\J@X8=/3
M4K\FOJ<8]#U)GM[E&C-A4/<7K_N3Q3L]F=K3%]AUOE&1=Q&PX.-7NN\?Q/8#
M-E&PFQP3*\-RRLS\;#L7Z>+389!R.QMZ:-843U2\3PGR8E^0)#[W#-])6VXM
M]1#$L>I.Z$=U^O[#M:SCM"P;'-K[;QFTRNGV51V.I<UK\@E89L'6V78Q$@*S
M>OO;7$LGPXTR<>J<DA9O3JQURH<<L::39%"+-()8'F/Y'D0HLLOJ+]PV XMC
MV\MW?3SVAJSM8OK/%F[/82-N8)F^Z];8OFUI J,<SK:O;AC54Y:4%%&D6]3(
MS&LQ7/LYS#"X$B7(M<96[56,9@KX08!!+.S%CJP.IZ@.8#P_5:VNJ:@JYEY>
MVU92TE=',NPN+:?%K:N#%3QY29EA,=9B1HZ?)/+S[R&QR.5>QT65K./;/UIE
MTO*8&)[#P;)YV#2W(&;0\>RV@NI>'SF?G+L+*8];827L?EM"-)+D>V1$>1]N
M_P"2!\3GB1>&%N/45G%R:=6[4UQ80L*KJNXS&9"SC&)<7$JB[KDV]+:9-(8M
M'&:&NMZE:;2KG6JXL:PKE)FQ'78Q#I(H6W[WHZ&T!VSYIW76N8TV>:JP^$V\
MS8:WR/$\C_M592;*/40Z/&+(W\3'[*S=GRDAYD7"%1HK$V4XE28CB"5 <MJI
MFR#<VG\2I,=R7*MKZUQG',O<8:Q+(,@SK%Z:DRAV2A#D9K';6QM(T"[<D-N-
MN,(K7Y*G4.(4V%)4DDC'8K%WVSK&BVOBF#.8S5*P>\UOGN>WNS9FP\.J1B\G
M#K/#XD&G."6$UK++VLO*[([6VF9G4QW,9Q1&/MPL@E1Y60TP=(T>8#=7^WFZ
MV"AVMJ[*<EG89C&R<!R/,*RLB75EBE#F..W&2U]-8-1WX%M.HJ^QD6D2LFL2
MXCT2?(BMQ9+4J.XRZM#S9447/OZEW^_GT\/^,>[<O_1E77ZY^%/_ &?\3O\
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M@F*6#D/%<;BPD9AF\F15JK:2[A(L[=\U!3#D$C0#6^N@&I\AN(?S[ZB_9EV
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M_P#=IDW115$^BE_P4G8K_P" ;'?_ &VSZ+>)_?5U747HL)T1.B)T1?X0"""
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M=$3HB=$3HB=$3HB=$3HB=$3HBX63_H38)$V#NC/-8_4-^I_H%C>VZ=C;[S7
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MN_6>!0]5V[$_ -A9M@#>78!L?$J#$[F/D&-Y#+L\9R6KNX=I0_IUE7SNBD$
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M<^HM$8[^A5[5D^,YW9G%3K[#%6#;LR&(U*F_N89N+!"WW8,$/26HDI: RLJ
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,.B)T1.B)T1.B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gv1ubg3hw41v000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gv1ubg3hw41v000010.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 BT# 1$  A$! Q$!_\0
M'P ! 0 " P$! 0$!          D'" 4&"@L$ P$"_\0 0!   00# 0 ! @,"
M"P<$ 04 !0,$!@<  0(("1$3$A05%B$*%QDB,4%8>9BXUA@C)3(W.4(D)B=1
M8S,U0U)A_\0 & $! 0$! 0                (! P3_Q  U$0 " 0,!!@4#
M P0" P$      1$"(3%!$E%A<9'P R*!H;$R0L$38G)2T>'Q,[*"DJ+"_]H
M# ,!  (1 Q$ /P#W\8 P!@# & , 8 P!@# & , _FMQTJDJGPJHAVHGWQRNC
MI+:J/7?.^>54M+)K([43WO7?&E454M]<Z^XGWQ]>=@>6]S\DGLN/>,K@\SOK
M0:D_E$BGR+B/CQ@5DO()7J"YY2RI\E,:ZO1[7(^*MX E&7-$I2?AFY[B+83S
MN-MC)EKTY76<O!UV:74GBAT[34O2S66[OCKO-ZIK\T%)U)=\EI4W"+&FE=TM
M;M>>9;O]0[D5."!,<NR8_H8GG?=5=RT%9<HC88Z=%,;%F$)@?[/Q0N]=H,1C
MM@W:=.!.PVDY4M-JF\PIQ9K1Q+O%I-<:N^7>VJDGWM/7HNJ+;MVBZL^4>8^6
MAE[Q5K2L>AM!UY*'E;Q*IX6\CZ!>+V#8ZXB4&BA*4&48Z?,"0TA!JD)*9=OA
MX9L-=*BF&D]C:B]XVF]Z5E;EH9Y4^3YC2\O]D,9>I<GH&5@/>=>>//.]&!HA
M4D6*DK+LFN LDC=;P*3M"0%L^B/7')J2'; MXLW(A$D""&U%FR8IDX&;+MA>
M3:;EXEJ7QPH5M=Y_*\??7HIXOX![&5/<?CN263\FL,\L7[5]PQ&"&7,P@"L"
MGIXQQ!YLDWET7EE?2)Z-#+!K-K0RQ=.'8DDR8%4&J:O;\%2O-=.*)34YE9XW
MNCM7GOYJZ(]#7C6E: ZTGD<K._)W9E9^=KX+2BJB("TIC5.C>S:!"N@$W)VK
M6P23?LT=W7)V=1,8WF.V:2::(Y=SI%,'0TIFZ2;4.R<:Q#RL/X9SGO.^?2)[
MUYY$^/OS%;#/SJ=] 1.W[?M;T!J#QNQ);$JVJ=BPX9Q:MXO-$7D05D<U./EV
M!(V;8.U(T.;MR8Q!=QM5'L8DH=34I0DIB[O>+PDGSG3*_3_'KZ,^-J@+,E'O
M6V6?L3A:Z896WDHI4T!%13T+=#ZSUF@:'5;.8./'1"KV<\2DNW:+$W'2JC C
M&&;XT7[X+I)"5QL*I^5;-FW+<*-;R\9R=1E7S/P2JZE]02R]_--WT[<_D,K1
M"-N><RY"NY3+W47]$S4!#*ZG->S"%RDY!)U'G#DXIV3T,,)$!K\6[#.6?#MP
M.[> J&VH::<WNDH4M.UG',P9ZS^9>VJ[\Y>^E(3Y0L.F/5/D**T])UXA<I:J
M)@#&5]?;]=C#[9=KU]910&7V"1;*)G84-.E2(F0$0C91.0M6LD9CAM-";HEI
MJJ<2KK*Q[X-FP_RF2'N^(-YC)^/;LYL_5*U#?5Z%UI=3:4-H*K)^8) 93-)Y
M(6DU7&D]015@@8(!(/U(2!H4\>*@D5MA'_' G9M,J):69;4843KK'&'$_CHK
MYA8-<D\H-H;\TW[4-$^NY5(X1Y+])3_5?;A-QRB/(E7+481B0"8%9_6G[;-0
MA)S7:LT -/VM12350X:);74;C70U-TW2IJ2F4N<0\WAV,J_$!Z!MWU#X"J6Z
MKUEVYU9LFF?H(4;DW0*-1O;YA"?1-J0:,-_T>(!@ !O^EQ:.!16E6@I!9YIE
M^=(*.B#AT[7&5I*J%B*?>E-^Y3+!(P!@# & , 8 P!@# & , 8 P!@# & ,
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M<=DXI5R\Y[/J$2KELH6$/.1R?;-LHT;$&ZCG3M 8JFMF/MJ;YS%O;W,BTAX
MZKVZIK?-LW03O:;V;Y4KWRS8O)* QV!AI,&@IB3$5Y/H7&'RC84O(64D4$O
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M3/O]Z]E>G?<=AK]_T[6_:+V;>VVB^^OZ>_OCFK)776_Z>>]?3>]:UO8JK/\
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M_-3K%-;]O\'TK<'F& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , F)\N'Z!QY*9NB4OLN%2H;?- %ZC*TS2@3T%;#JYA-F@R-;AH!6$F("HZ
M<.E#S9)LIP=((B.Q.R;(@D_:O51KP52KZ.SF7"B(R?@^+^<>AYM%+97]!GO5
MATD/D$81C2OJ?QU4/D L@R7&E.R',1"U'(#[*;#U%TV_14F94;.1#GEHT9IJ
M)/%NN<7KZJ/PA5%H25M'/SA^V[4WTM"\:CI56O6]J3Z/0EW;%C16HZV9&777
M#^:V1-2"8R-1*/L&Z:[Q^2(NU>==])(?E![?2CXFY9L4E7'&F)-S&B;?)9,3
MK>Y/);:]Y%YF<WE#FUXQ!J0>RJ".=E6[B.-!,#XL\HX-G%AO$8&)#H"IQ*'W
M;PTCIJ-Z_$O^!;6T=!#B8MO]ODZ@+^2+PV:J(_>PKTA GU71B7 ($8D"&CO3
MU.8RQFQ)1*/,8IL/J8&",N$$F9N)IA@#_F3@5=G@79 .BL]3#9<Q%]QM= )_
M"K5A$4LFMY0%FL"G $;)XC+(Z^1)!)  +MDW@XH->H==)KMG+=7CO7[]*)]?
MB26X36X[3Y&8)X_%9_TP]9?WE_R(_P":2?X*J^W^*_)3W!(P!@# & , E?\
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MVT6-!UTF#E\/?-4B8]=MTZ24<-G#-$BS[Y[25;I.4^DM:<B&5P_$W<<\\?\
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M-TN.)F^ZQ[CL' 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MK S*2ROV$E11%-5;2[EKM%/MHMSVK^:9;T\;?;YWOO[[3>G*/T^XAO2O/&\
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M 8 P!@# & , F5\MD(F1SR 6MB!3*%PB2^09W$?:[$E8((Q)(J2WY<T4M/\
M9TD( EP)1UR=4#),>$VI=BHIM3:7#A-13CO0JGZEES*A0GYDUK;4U7^'GPGZ
M&\]C:VN^]IO4Q7]:\0TY2\7AM=Q*9 )$&;]V'/\ T,=,V:6E,GD#.2S\C,KG
ME:$E,1YI'!#]VBDY; 6?>UU'(VJI.4D_J;NYX*+8_P!7R7=P0, 8 P!@# &
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M'2JJK8IIFS4M<FX6.$J_X/1/@YC & , 8 P!@# & , ES\6W_O:+^P?2??\
MZE/TS[R](RF-%U/YRQ&MZ</#O+]=[X[W_._(_H='=/V2/UZ32_4U^D>NTU>>
M^A57VK,4KW\WLV5&P2, 8 P!@# & , _ 5;Z>"R33;YP,TZ8/&^R317A!T.T
MNW42_/-EU-=<(N&GXOS"*O?/7":B?/?6MZYWK /(7\7R5&N/9GCRG(I<_P :
M+J0^2@]VQ\'8OD\A,R'I#VXH0J:71=V[M?;R#!P3<<F([(W-9"CVP+#3+67&
M!9").OTKKI_R.U<Q54U5%4/S1%-YM=M[E96FV[V!X.)([Y+_ '9>_D264\$J
M.%13J$GX1;=BWA==F4[Z,M&LJ=B\"(UR,!/)(Z\]B2C^+LB>I5*"YP_)N$PP
M8+%%'2ZR73A+E;'.GQ/LN^!5*33WRDE*3<SB378]\PEB0^X)^<-UW6!WRC'[
M7]:T!&246*R7NW"EA>1O*:WIR03A<JJY>PE[7EA: RN$QD0/"I&0^TP4E>G2
MS1ZX'(Z;LJ,WA-VM#<9G25UX2\P^3_DZE!J*WR6]KA() .Z9JCQW?BTBHF*V
MW.1/5>^THX0>0B,.H6/'3V?E9?!I6%(1F2&X^Q<!S#%TPD_ :-#&Y3AH#IQ$
MN74E,3Y8E^_L=7\[^I*3]5_+V;EU'2.0R4#&_C=ZCAAU(JTM&L7+<OOTZR)Z
M;H"K4AD*+D$/R3ULI^H#6+L=]SOMM^;_ #**Z*8QII*5%W_^2RT\EPVOX/,Y
MX9ZUP'A,4D4N*][[UQKD;&Q#PR^ZWWU_-XURU9*[WWO]W/T^N_W:P2?&2+6N
MYDP V"D8U5VK+;,DEJ2\PR)(,2)Z0OP;EA&4NU78PBFV91LJ8E11PGKE94RC
M)7;'A08NW;D<'NV8<K2E4JUE?KNUM!],7X(OC!!?'CYS4FZ,]E,JF_K.L_/%
MCV1&SXL6/'5]*A4)-F"$;CRK'6GCYBU(V$3'=N"GT<]\"6JOX$^UEN-#R>)6
MZW=1$I<IUG7N$73P0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8!/CY/8)<5B>2), IMA+)$NA.:M.VE *_L5&H[ M*AP,]!E+FK.$66N3!
M)Q"0R^#-R@])YH^!4)L?ST>1+-%3''70JF)O97NU*3BTJ\KN^#7OXBX#+X4+
M]).A=8VOY^\R2*>0AUYN\[7C<:-RV77*+&&:9VF>=$-V!:C^%Q>?2[\L_CT$
M)3TPNQ>"#\@0;CFDE024"IWS2WJZ5"?LI?&.&A8O!)(I]\N=9C_3/J"BW$#'
M_L;Y%!67(K>LG5ZTLWF: BIJ3&W#-"L:\Y$).RNJ3@1ZY-*"?M.'C[F-ZDK<
MA^8*MT193AD*5#:3_JLK/,Q#>%B<S&AU&/?,.U.QG@,IY8L45Z2/6GYUK*O?
M/+RPJ[[5E_/J:IY%=]32MW92#ON,QD-U7$)GKR8)/V;E[&9!$W8#A(KMXR?J
MC=F^94-[2W)QC.6O1SO-UJ4]Z>;K=H"F?0)JQH;3(6Z8R].@8Q<4XAD*DC$@
M +.8W,H^JF3.H-"CR(2E@_ E'@=P]8=.&Z:Z2WV73??0EJ&UN?;-?OB4,")%
M37IX_'RHTZ!.?(]\@A<*;#OFI,08$DO3<[>#B@LDR579D!S]FLBZ9/6BRS9T
MV53705424YZV-J^W^*_)4[!(P!@# & ?YO>N=;ZZWK7.M;WO>]ZUK6M:^N][
MWO\ =K6M?OWO?[M:P"7GQ"ZW)O(Y:^G&MZ?^LO2?J7TZMUO]_/8:RKTFJ%?[
M2[WK6U&W-7 (,FSWOZZX9\((\==\)<]]"J\QB$EQF%._62HF"1@# & , 8 P
M!@# ,(>F;;:T%YRON\GG:/#>GJ:LRSNOO_AVFIW!H89DJ+?\'7[E>W*PU-ND
MAKZ]+JJ\(\<]=]\\[&I2TEJXZF%_C>J1U1?@GR)5Y/A7B01Z@JX=R_:_XMKJ
MSN3QYG+9ZX6Z[_WG:KF9G3KA117ZK*=J]=K;VKUWO8VIS4WQ?33V-U\$C &
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M=<\<<ZUSSSSSK6N>>>=:UKGGG6M:UK6M:UK6M:U],$G_ %@# & , 8 P!@#
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M'E73?:O)4]MLV)R$KI0>;Q6W75.CA<E_?/J6XP<Q@# & , 8 P!@# & , 8
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MA*\2C::V:8E^:T-Z.(MC*UO!I;3_ ,2'RTM/+WII(?$O:M3@0;^H4?\ 9L"
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MFR([(WLIVF>K]DE#AK<R,<$"+_H(S?'?4.B)EZU)6SLI.>$IK\EXL$# & ,
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M3AV.(->N^.^>7#1PLEUUQUSKO>^=ZT!SN , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , PY??H"G_,%7'KHO>:LZ]K&,.@+$Y*
MGXXV5;L7<H/C8N ;[81T88+N%29\P-&(<M!Z^]+NT^E?MH\J*<#4FW"4MZ'2
M?.'LGS'ZY:2QUYUN"-66K!'HYA-0[!$R$D\3<&&ZSH-U(HC*18*4!VIE!L[4
M#OWP=!B5_)/N1[EQVR=\H@TUE1^>6\V9P8, 8 P!@# & , 8 P!@# & , 8
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M_:3_ !_@T.1^W & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# ,<SNGJDM$E"3-F5=7=B%ZUD*<NKHI.85&Y:1@4K1TGRE)
MH8]/C"#F+R!+2*/VS(15B13VBCOAQK:2>^0EK#S9\5N,C8 P!@# & , 8 P!
)@# & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>pmvp-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T15:17:50.5783086+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:pmvp="http://pmvpharma.com/20211231" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://pmvpharma.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://pmvpharma.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany" id="Role_DisclosureFormationAndBusinessOfCompany">
        <link:definition>100070 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>100090 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100100 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100130 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100140 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan" id="Role_DisclosureStockPlan">
        <link:definition>100150 - Disclosure - Stock Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100180 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100210 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100220 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100230 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="Role_DisclosureConvertiblePreferredStockTables">
        <link:definition>100240 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100250 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables" id="Role_DisclosureStockPlanTables">
        <link:definition>100260 - Disclosure - Stock Plan (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100280 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" id="Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Formation and Business of the Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
        <link:definition>100310 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100330 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>100350 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails">
        <link:definition>100370 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails">
        <link:definition>100380 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2">
        <link:definition>100410 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" id="Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails">
        <link:definition>100430 - Disclosure - Convertible Preferred Stock - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
        <link:definition>100450 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails" id="Role_DisclosureStockPlanAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Stock Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails" id="Role_DisclosureStockPlanScheduleOfStockOptionsDetails">
        <link:definition>100470 - Disclosure - Stock Plan - Schedule of Stock Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails" id="Role_DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails">
        <link:definition>100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails" id="Role_DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails">
        <link:definition>100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails" id="Role_DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails">
        <link:definition>100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails" id="Role_DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Summary of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100560 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails">
        <link:definition>100570 - Disclosure - Net Loss per Share - Schedule of Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="Role_DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" name="LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_OtherNonoperatingIncomeExpenseOther" name="OtherNonoperatingIncomeExpenseOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" name="ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" name="ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" name="ReclassificationsOfTemporaryToPermanentEquityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_OtherNonCashLeaseExpense" name="OtherNonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" name="LeaseIncentivesUsedForLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" name="ConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_ConversionOfWarrantLiabilityToCommonStock" name="ConversionOfWarrantLiabilityToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_CommonStockDisclosureTextBlock" name="CommonStockDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" name="ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" name="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pmvp_OrganizationConsolidationAndPresentationLineItems" name="OrganizationConsolidationAndPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_OrganizationConsolidationAndPresentationTable" name="OrganizationConsolidationAndPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_AssetsNotPlacedInServiceMember" name="AssetsNotPlacedInServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_OperatingLeaseExpirationPeriod" name="OperatingLeaseExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" name="OperatingLeaseMaintenanceExpensePerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ManagementFeeOfBaseRentPercentage" name="ManagementFeeOfBaseRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_InitialBaseRentPerSquareFoot" name="InitialBaseRentPerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_CranburyNewJerseyMember" name="CranburyNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_SouthBrunswickNewJerseyMember" name="SouthBrunswickNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_PrincetonNewJerseyMember" name="PrincetonNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_NumberOfNoncancelableOperatingLeases" name="NumberOfNoncancelableOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_InitialBaseRentIncreasedPerSquareFoot" name="InitialBaseRentIncreasedPerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_OperatingLeaseRenewalTermDescription" name="OperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" name="AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_OperatingLeasesExtendedYear" name="OperatingLeasesExtendedYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_OperatingLeasesExtensionPeriod" name="OperatingLeasesExtensionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_OperatingLeasesExtendedMonthAndYear" name="OperatingLeasesExtendedMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" name="LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_SubleaseExpirationPeriod" name="SubleaseExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" name="SubleaseWithTenantOfficeSpaceStartingPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" name="SubleaseWithTenantOfficeSpaceEndingPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_SeriesSeedConvertiblePreferredStockMember" name="SeriesSeedConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" name="NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" name="NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" name="CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" name="CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="pmvp_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_TwoThousandAndThirteenStockPlanMember" name="TwoThousandAndThirteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_TwoThousandThirteenStockPlanMember" name="TwoThousandThirteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="pmvp_DeferredTaxAssetsOperatingLeases" name="DeferredTaxAssetsOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pmvp_DeferredTaxLiabilitiesOperatingLeases" name="DeferredTaxLiabilitiesOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" name="OperatingLossCarryforwardsBeginToExpireInFutureAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" name="OperatingLossCarryforwardsAmountsDoNotExpire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="pmvp_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_IncomeTaxExaminationPeriod" name="IncomeTaxExaminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_NumberOfConsultingAgreementsMembers" name="NumberOfConsultingAgreementsMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="pmvp_BoardOfDirectorsMember" name="BoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>pmvp-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T15:17:50.5783086+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="pmvp-20211231.xsd#TemplateLink" roleURI="http://pmvpharma.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="pmvp-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:type="locator" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:type="locator" xlink:label="pmvp_OtherNonCashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pmvp_OtherNonCashLeaseExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>pmvp-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T15:17:50.5783086+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="pmvp-20211231.xsd#TemplateLink" roleURI="http://pmvpharma.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" order="12540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="13020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_Cash" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:type="locator" xlink:label="pmvp_AssetsNotPlacedInServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pmvp_AssetsNotPlacedInServiceMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtensionPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:type="locator" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="pmvp_OperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:type="locator" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:type="locator" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:type="locator" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentPerSquareFoot" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_PrincetonNewJerseyMember" xlink:type="locator" xlink:label="pmvp_PrincetonNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:type="locator" xlink:label="pmvp_SouthBrunswickNewJerseyMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CranburyNewJerseyMember" xlink:type="locator" xlink:label="pmvp_CranburyNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_CranburyNewJerseyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_SouthBrunswickNewJerseyMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_PrincetonNewJerseyMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentPerSquareFoot" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseExpirationPeriod" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseRenewalTermDescription" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCredit" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedYear" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtensionPeriod" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseExpirationPeriod" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SubleaseIncome" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="11680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConvertiblePreferredStockConversionPrice" xlink:type="locator" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_ConvertiblePreferredStockConversionPrice" order="11490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandThirteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandThirteenStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" order="13630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="14380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="14860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:type="locator" xlink:label="pmvp_IncomeTaxExaminationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_IncomeTaxExaminationPeriod" order="11620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:type="locator" xlink:label="pmvp_NumberOfConsultingAgreementsMembers" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_BoardOfDirectorsMember" xlink:type="locator" xlink:label="pmvp_BoardOfDirectorsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pmvp_BoardOfDirectorsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmvp_NumberOfConsultingAgreementsMembers" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="10590.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>pmvp-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T15:17:50.5793085+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due next twelve months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments net of reimbursements due year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability to be paid net of repayments after year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets, operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2021 and December 31, 2020. No shares issued or outstanding as of December 31, 2021 and December 31, 2020.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,433,684 and 44,777,818 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:type="locator" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other nonoperating income (expense), other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OtherNonoperatingIncomeExpenseOther" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Net</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (losses) gains on marketable securities, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of stock options and common stock value issued under employee stock purchase plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of stock options and common stock issued under employee stock purchase plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AOCI Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassifications of temporary to permanent equity, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and common stock issued under the 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and common stock issued under the 2020 ESPP, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Stock Options And Common Stock Issued Under Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available for sale investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:type="locator" xlink:label="pmvp_OtherNonCashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other non-cash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OtherNonCashLeaseExpense" xlink:to="pmvp_OtherNonCashLeaseExpense_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:type="locator" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease incentives used for leasehold improvements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:to="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:to="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:type="locator" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of warrant liability to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:to="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities: activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Non Cash Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash&#8212;beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash&#8212;end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease incentives used for leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentives Used For Leasehold Improvements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Productive Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrant liability to common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Warrant Liability To Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Formation and Business of the Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments and Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockDisclosureTextBlock" xlink:type="locator" xlink:label="pmvp_CommonStockDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommonStockDisclosureTextBlock" xlink:to="pmvp_CommonStockDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ReverseStockSplitPolicyTextBlock" xlink:to="pmvp_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income/Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ConvertiblePreferredStockPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConvertiblePreferredStockPolicyTextBlock" xlink:to="pmvp_ConvertiblePreferredStockPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk and other risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Lease Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:type="locator" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease amount reported in balance sheet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:to="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amounts Reported in Consolidated Balance Sheets for Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Amount Reported In Balance Sheet Table [Text Block]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of other information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reserved Shares of Common Stock for Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation Expense Related to Options Granted Recorded and Allocated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax Provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Provision for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Number of shares sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash used in operating activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of available-for-sale debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Gain Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adoption of accounting standards update [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update, immaterial effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Portion At Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure Item Amounts [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Reported Amount Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimate Of Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Priced in Active Markets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Government Debt Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Marketable securities noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Marketable securities current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery &amp; Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture &amp; Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds And Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:type="locator" xlink:label="pmvp_AssetsNotPlacedInServiceMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets not placed in service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AssetsNotPlacedInServiceMember" xlink:to="pmvp_AssetsNotPlacedInServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Not Placed in Service</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Not Placed In Service [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Workers Compensation Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseExpirationPeriod" xlink:to="pmvp_OperatingLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:type="locator" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease maintenance expense per square foot.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:type="locator" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Management fee of base rent percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ManagementFeeOfBaseRentPercentage" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentPerSquareFoot" />
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial base rent per square foot.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_InitialBaseRentPerSquareFoot" xlink:to="pmvp_InitialBaseRentPerSquareFoot_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CranburyNewJerseyMember" xlink:type="locator" xlink:label="pmvp_CranburyNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cranbury, New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CranburyNewJerseyMember" xlink:to="pmvp_CranburyNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cranbury, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cranbury New Jersey [Member]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:type="locator" xlink:label="pmvp_SouthBrunswickNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South Brunswick, New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SouthBrunswickNewJerseyMember" xlink:to="pmvp_SouthBrunswickNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South Brunswick, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South Brunswick New Jersey [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:label xml:lang="en-US" xlink:label="country_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington, Massachusetts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MA" xlink:to="country_MA_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">MOROCCO</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_PrincetonNewJerseyMember" xlink:type="locator" xlink:label="pmvp_PrincetonNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Princeton, New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_PrincetonNewJerseyMember" xlink:to="pmvp_PrincetonNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Princeton, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Princeton New Jersey [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of operating lease property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent per square foot</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Base Rent Per Square Foot</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease maintenance expense per square foot</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Maintenance Expense Per Square Foot</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management fee of base rent percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Of Base Rent Percentage</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:type="locator" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of noncancelable operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfNoncancelableOperatingLeases" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot" />
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial base rent increased per square foot.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="pmvp_OperatingLeaseRenewalTermDescription" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease renewal term description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseRenewalTermDescription" xlink:to="pmvp_OperatingLeaseRenewalTermDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of noncancelable operating leases</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Noncancelable Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term description</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Renewal Term Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent increased per square foot</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Base Rent Increased Per Square Foot</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:type="locator" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" />
    <link:label xml:lang="en-US" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance on behalf of lessor for construction of office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance on behalf of lessor for construction of office space.</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowance On Behalf Of Lessor For Construction Of Office Space</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining rent incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedYear" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases, extended year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtendedYear" xlink:to="pmvp_OperatingLeasesExtendedYear_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtensionPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases, extension period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtensionPeriod" xlink:to="pmvp_OperatingLeasesExtensionPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases extended month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtendedMonthAndYear" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease area of square feet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Land</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, extended year</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extended Year</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, extension period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extension Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases extended month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extended Month And Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Tenant Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets And Liabilities Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of repayments, due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Repayments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseExpirationPeriod" xlink:to="pmvp_SubleaseExpirationPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease with tenant office space starting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease with tenant office space ending period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease with tenant office space starting period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease With Tenant Office Space Starting Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease with tenant office space ending period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease With Tenant Office Space Ending Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series seed convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Preferred</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SeriesDConvertiblePreferredStockMember" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Offering Price to the Public</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends, preferred stock declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of members of board of directors elected by holders of preferred stock voting as single class.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of members of board of directors elected by holders of common stock voting as single class.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of members of board of directors elected by holders of preferred stock voting as single class</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Members Of Board Of Directors Elected By Holders Of Preferred Stock Voting As Single Class</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of members of board of directors elected by holders of common stock voting as single class</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Members Of Board Of Directors Elected By Holders Of Common Stock Voting As Single Class</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares liquidation preference per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference Per Share</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConvertiblePreferredStockConversionPrice" xlink:type="locator" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock conversion price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConvertiblePreferredStockConversionPrice" xlink:to="pmvp_ConvertiblePreferredStockConversionPrice_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, terms of conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Terms Of Conversion</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross cash proceeds from public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock conversion price</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Conversion Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends, common stock declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved shares of common stock for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future stock option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" />
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and thirteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandAndThirteenStockPlanMember" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Thirteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance, minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock outstanding increase</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Of Authorized Shares Percent Of Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance, maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, shares outstanding, number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees exercised their right to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Employees Exercised Their Right To Purchase Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Number</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares available for grant, retired in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares available for grant, exercised in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options shares available for grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandThirteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandThirteenStockPlanMember" xlink:to="pmvp_TwoThousandThirteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available for Grant, Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options retired</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Retired In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Options forfeited / cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available for Grant, Balance</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options retired in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options retired, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Retired In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options forfeited / cancelled, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Number of Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited / cancelled, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options weighted-average remaining life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Life [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted-Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted-Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted at grant-date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total compensation cost related to nonvested awards not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period over nonvested awards expected to be recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Provision</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New Jersey</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NEW JERSEY</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal statutory income tax rate</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxAssetsOperatingLeases" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Leases</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Leases</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets and depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards begin to expire in future amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amounts do not expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsExpirationYear" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward, expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TaxCreditCarryforwardExpirationYear" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards begin to expire in 2033</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Begin To Expire In Future Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, do not expire amount</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amounts Do Not Expire</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits, beginning of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to prior year tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to current year tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits, end of year</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:type="locator" xlink:label="pmvp_IncomeTaxExaminationPeriod" />
    <link:label xml:lang="en-US" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_IncomeTaxExaminationPeriod" xlink:to="pmvp_IncomeTaxExaminationPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination period</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options Issued and Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - basic and diluted</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:type="locator" xlink:label="pmvp_NumberOfConsultingAgreementsMembers" />
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of consulting agreements members.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfConsultingAgreementsMembers" xlink:to="pmvp_NumberOfConsultingAgreementsMembers_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_BoardOfDirectorsMember" xlink:type="locator" xlink:label="pmvp_BoardOfDirectorsMember" />
    <link:label xml:lang="en-US" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_BoardOfDirectorsMember" xlink:to="pmvp_BoardOfDirectorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Board Of Directors [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investor [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consulting agreement members</link:label>
    <link:label xml:lang="en-US" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Consulting Agreements Members</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount owed to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options awarded</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>pmvp-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T15:17:50.5793085+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 731f5aba7b664e92898a9106f82c2fd3 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://pmvpharma.com/20211231/role/TemplateLink" xlink:href="pmvp-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pmvp-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="pmvp-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="pmvp-20211231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:type="locator" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="13210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="pmvp-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:type="locator" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:type="locator" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:type="locator" xlink:label="pmvp_OtherNonCashLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pmvp_OtherNonCashLeaseExpense" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_ConversionOfWarrantLiabilityToCommonStock" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany" xlink:href="pmvp-20211231.xsd#Role_DisclosureFormationAndBusinessOfCompany" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="pmvp-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="pmvp-20211231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockDisclosureTextBlock" xlink:type="locator" xlink:label="pmvp_CommonStockDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pmvp_CommonStockDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="pmvp-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties" xlink:href="pmvp-20211231.xsd#Role_DisclosureRelatedParties" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pmvp-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ConvertiblePreferredStockPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_ReverseStockSplitPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_ConvertiblePreferredStockPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:type="locator" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="pmvp-20211231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:type="locator" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="pmvp_OrganizationConsolidationAndPresentationLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_Cash" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:type="locator" xlink:label="pmvp_AssetsNotPlacedInServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pmvp_AssetsNotPlacedInServiceMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SubleaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_SubleaseExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtensionPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:type="locator" xlink:label="pmvp_OperatingLeasesExtendedYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:type="locator" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="pmvp_OperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:type="locator" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:type="locator" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:type="locator" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="pmvp_OperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:type="locator" xlink:label="pmvp_InitialBaseRentPerSquareFoot" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_PrincetonNewJerseyMember" xlink:type="locator" xlink:label="pmvp_PrincetonNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:type="locator" xlink:label="pmvp_SouthBrunswickNewJerseyMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CranburyNewJerseyMember" xlink:type="locator" xlink:label="pmvp_CranburyNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_CranburyNewJerseyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_SouthBrunswickNewJerseyMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_PrincetonNewJerseyMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentPerSquareFoot" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseExpirationPeriod" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseRenewalTermDescription" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCredit" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedYear" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtensionPeriod" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseExpirationPeriod" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SubleaseIncome" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:type="locator" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ConvertiblePreferredStockConversionPrice" xlink:type="locator" xlink:label="pmvp_ConvertiblePreferredStockConversionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" xlink:type="locator" xlink:label="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember_li0l2" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreferencePerShare" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_ConvertiblePreferredStockConversionPrice" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:type="locator" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:type="locator" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:type="locator" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandThirteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandThirteenStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="14370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="14850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:type="locator" xlink:label="pmvp_IncomeTaxExaminationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:type="locator" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MA" xlink:type="locator" xlink:label="country_MA" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_IncomeTaxExaminationPeriod" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:type="locator" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pmvp-20211231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:type="locator" xlink:label="pmvp_NumberOfConsultingAgreementsMembers" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="pmvp-20211231.xsd#pmvp_BoardOfDirectorsMember" xlink:type="locator" xlink:label="pmvp_BoardOfDirectorsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pmvp_BoardOfDirectorsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmvp_NumberOfConsultingAgreementsMembers" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715287128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PMV PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3218129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8 Clarke Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">642-6670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMVP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,450,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,229,389,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001699382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2021.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714379992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 172,467<span></span>
</td>
<td class="nump">$ 361,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">124,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">301,286<span></span>
</td>
<td class="nump">364,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">16,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">10,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">331,568<span></span>
</td>
<td class="nump">365,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,627<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,219<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">10,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,009<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2021 and December 31, 2020. No shares issued or outstanding as of December 31, 2021 and December 31, 2020.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,433,684 and 44,777,818 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">476,363<span></span>
</td>
<td class="nump">469,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,726)<span></span>
</td>
<td class="num">(109,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">308,559<span></span>
</td>
<td class="nump">359,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 331,568<span></span>
</td>
<td class="nump">$ 365,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854711010552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,433,684<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,433,684<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854809630184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="nump">$ 23,933<span></span>
</td>
<td class="nump">$ 20,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,800<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">58,293<span></span>
</td>
<td class="nump">34,942<span></span>
</td>
<td class="nump">26,637<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(58,293)<span></span>
</td>
<td class="num">(34,942)<span></span>
</td>
<td class="num">(26,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OtherNonoperatingIncomeExpenseOther', window );">Other income (expense)</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(57,823)<span></span>
</td>
<td class="num">(34,434)<span></span>
</td>
<td class="num">(25,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,846)<span></span>
</td>
<td class="num">(34,440)<span></span>
</td>
<td class="num">(25,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (losses) gains on marketable securities, net of tax</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (57,924)<span></span>
</td>
<td class="num">$ (34,437)<span></span>
</td>
<td class="num">$ (25,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
<td class="num">$ (8.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding</a></td>
<td class="nump">45,137,656<span></span>
</td>
<td class="nump">14,364,475<span></span>
</td>
<td class="nump">3,035,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense), other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712640984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="num">$ (46,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,961<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (50,088)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,396,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,012,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available for sale investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (70,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(75,440)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">22,866,246<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
<td class="nump">5,469,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 168,933<span></span>
</td>
<td class="nump">$ 168,933<span></span>
</td>
<td class="nump">$ 61,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,046,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="num">$ (238,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="num">(28,188,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">$ 238,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available for sale investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 359,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,880)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">608,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP</a></td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available for sale investments</a></td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 308,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476,363<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="num">$ (167,726)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock issued under employee stock purchase plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock value issued under employee stock purchase plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of temporary to permanent equity, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715205512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 20,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714236824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (57,846)<span></span>
</td>
<td class="num">$ (34,440)<span></span>
</td>
<td class="num">$ (25,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities: activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on marketable securities</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OtherNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">191<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,571)<span></span>
</td>
<td class="num">(32,739)<span></span>
</td>
<td class="num">(22,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(1,349)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(256,845)<span></span>
</td>
<td class="num">(14,512)<span></span>
</td>
<td class="num">(43,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">114,610<span></span>
</td>
<td class="nump">42,571<span></span>
</td>
<td class="nump">46,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(143,584)<span></span>
</td>
<td class="nump">27,911<span></span>
</td>
<td class="nump">3,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,790<span></span>
</td>
<td class="nump">61,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">292,972<span></span>
</td>
<td class="nump">61,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(188,133)<span></span>
</td>
<td class="nump">288,144<span></span>
</td>
<td class="nump">42,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash&#8212;beginning of period</a></td>
<td class="nump">361,422<span></span>
</td>
<td class="nump">73,278<span></span>
</td>
<td class="nump">30,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash&#8212;end of period</a></td>
<td class="nump">173,289<span></span>
</td>
<td class="nump">361,422<span></span>
</td>
<td class="nump">73,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LeaseIncentivesUsedForLeaseholdImprovements', window );">Lease incentives used for leasehold improvements</a></td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Accrued purchases of property and equipment</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConversionOfWarrantLiabilityToCommonStock', window );">Conversion of warrant liability to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConversionOfWarrantLiabilityToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrant liability to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConversionOfWarrantLiabilityToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LeaseIncentivesUsedForLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease incentives used for leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LeaseIncentivesUsedForLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OtherNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OtherNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714472568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Formation and Business of the Company</a></td>
<td class="text">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc.</p>
<p id="NOTES_TO_FINANCIAL_STATEMENTS" style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">1.&#160;&#160;Formation and Business of the Company</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#8217;s headquarters are located in Cranbury, New Jersey. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2020, the Company completed an initial public offering (the &#8220;IPO&#8221;) of 13,529,750 shares of common stock, at a public offering price of $18.00 per share including the exercise in full by the underwriters of their option to purchase up to 1,764,750 additional shares of commons stock, for aggregate gross proceeds of $243,536 and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#8220;PMVP.&#8221;&#160;&#160;The Company received $223,176 in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.&#160;&#160;In connection with the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock automatically converted into 28,188,110 shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net losses and negative cash flows from operations since it&#8217;s inception. During the year ended December 31, 2021, the Company incurred a net loss of $57,846 and used $46,571 of cash for operations. As of December 31, 2021, the Company had an accumulated deficit of $167,726.&#160;&#160;Cash, cash equivalents, and marketable securities were $314,074 as of December 31, 2021.&#160;&#160;Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs.&#160;&#160;The Company believes it has adequate cash and cash equivalents to operate for at least the next twelve months from the date of issuance of these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716272392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2.&#160;&#160;Summary<span style="color:#000000;"> of </span>Significant<span style="color:#000000;"> Accounting Policies</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company&#8217;s board of directors and stockholders approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;3 - Inputs are </span><span style="color:#000000;">unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions</span><span style="color:#000000;"> that are unobservable.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its<span style="color:#000000;"> marketable debt securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of December 31, 2021, the company&#8217;s long-term marketable debt securities have maturity dates no more than two years. The Company&#8217;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity.&#160;&#160;Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the years ending December 31, 2021, 2020, and 2019, the company recorded, $550, $152, and $62 of amortization, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2021 included a $822 deposit at the Company&#8217;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.&#160;&#160;The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company&#8217;s only existing leases are for office and laboratory space.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company&#8217;s leases contain residual value guarantees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the remaining term of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Income/Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $(78), $3, and $10 in other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax for the years ended December 31, 2021, 2020, and 2019, respectively. The Company presents comprehensive income in a single statement within its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All costs associated with research and development are expensed as incurred.&#160;&#160;Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.&#160;&#160;In the event that we prepay fees, we record the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Company. The Company&#8217;s policy is not to accrete the carrying value and related issuance costs of the convertible preferred stock to its redemption value until it is probable that the security will become redeemable.</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> The convertible preferred stock converted to common stock in connection with the Company&#8217;s Initial Public Offering </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;IPO&#8221;) </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">on September 25, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liabilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company may issue certain financial instruments with embedded features which may be accounted for as separate derivative assets or liabilities, dependent on their specific contractual terms or other conditions. These derivative assets or liabilities are required to be measured at fair value at issuance and <span style="color:#auto;">remeasured</span> at the end of each reporting period. To determine the fair value of these instruments the Company uses a discounted cash flow analysis, as these instruments are not quoted on an active market. Increases or decreases in fair value from initial measurement and each reporting period are recorded in the statement of operations and comprehensive loss as change in fair value of derivative liabilities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Stock&#8209;Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s share-based compensation program allows for grants of stock options and restricted stock awards. <span style="color:#000000;">Grants</span> are awarded to employees and non-employees, including directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,<span style="font-style:italic;"> Compensation &#8211; Stock Compensation </span>(&#8220;ASC 718&#8221;)<span style="font-style:italic;">.</span> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock <span style="color:#000000;">awards</span> and stock options.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting <span style="color:#000000;">conditions</span> is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#8217;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a<span style="color:#000000;"> </span>liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise for which separate discrete financial information is <span style="color:#000000;">available</span> for evaluation by the Company&#8217;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as one operating segment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the &#8220;two-class&#8221; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a <span style="color:#000000;">participating</span> security). The Company&#8217;s convertible preferred stock are participating securities as defined by ASC 260-10, <span style="font-style:italic;">Earnings per Share</span>. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a <span style="font-style:italic;">pari passu</span> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC 740, <span style="font-style:italic;">Income Taxes</span> ("ASC 740"), which requires that <span style="color:#000000;">deferred</span> tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842), as amended by multiple standards updates, in order to increase transparency and comparability among organizations by requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The most significant change arising from the new standard is the recognition of right of use assets and lease liabilities for leases classified as operating leases. The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. Under the standard, disclosures are required to enable financial statement users to assess the amount, timing, and uncertainty of cash flows arising from the leases. Companies are also required to recognize and measure leases existing at, or entered into after, the adoption date using a modified retrospective approach, with certain practical expedients available. Comparative periods prior to adoption have not been retrospectively adjusted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, Income Taxes &#8211; Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of an enacted change in tax laws or rates in the</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">adopted</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> this standard as of</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The adoption did </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">t have a material impact on the Company&#8217;s financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#8217;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions.&#160;&#160;The Company continues to monitor the impact of the COVID-19 outbreak closely.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716458632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">3.&#160;&#160;Financial Instruments and Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company&#8217;s cash equivalents and available-for-sale securities&#8217; carrying amounts and fair values as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,607</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents <span style="font-weight:normal;font-style:normal;">&#8211; As of December 31, 2021, the company had cash of $3,508 and cash equivalents of $168,960.&#160;&#160;Cash equivalents consisted of money market funds of $40,960 and corporate debt securities of $128,000. Cash equivalents of $360,041 as of December 31, 2020 consisted of money market funds of $240,033 and corporate debt securities of $120,008. Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities<span style="font-size:12pt;font-style:normal;"> </span>&#8211; <span style="font-weight:normal;font-style:normal;">Marketable securities of $141,607 as of December 31, 2021 consisted of corporate debt securities of $99,362 and government debt securities of $42,245. There were $124,696 current marketable securities and $16,911 noncurrent marketable securities as of December 31, 2021. There were no marketable securities as of December 31, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716440600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">4.&#160;&#160;Property and Equipment, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery &amp; equipment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,261</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not placed in service</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,519</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,868</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,561</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Depreciation<span style="color:#auto;"> expense for the years ended December 31, 2021, 2020, and 2019 was $307, $318, and $388, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714190200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">5.&#160;&#160;Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,627</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714481272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">6.&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, the Company executed a noncancelable operating lease for approximately 13,000 square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $20.00 per square foot. This location operates as the Company&#8217;s current headquarters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, the Company obtained an additional noncancelable operating lease for about 6,000 square feet of laboratory space in the same corporate center at an initial rental rate at $22.00 per square foot. As a result of the additional space, both leases will expire June 2022, with an option to renew on a month-to-month basis, with an increase in base rent as per the lease, for up to an additional year. Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.<span style="color:#000000;"> </span>The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company executed two noncancelable operating leases. One lease for approximately 6,000 square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $15.50 per square foot and a management fee of 3% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease expires in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with an option </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to renew on a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">month-to-month</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> basis</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with an increase in base rent as per the lease,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for up to an additional year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The second lease is for office space in Lexington, Massachusetts, that expires </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 2023</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with an option to renew for a one-time, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000425">three-year</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> extension. The initial annual base rent is $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.50</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per square foot and will increase $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.00</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per square foot at the end of each rent year.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $165 on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.&#160;&#160;As of December 31, 2021, the remaining rent incentive pertaining to the Lexington, MA lease totaled $64. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey.&#160;&#160;The Company intends to complete the relocation of their headquarters from Cranbury, NJ to One Research Way in Princeton NJ in late 2022. That lease term extends through 2032, has a <span style="-sec-ix-hidden:F_000433">five-year</span> extension option, and is intended to replace our two existing facilities and the space is expected to become the Company&#8217;s future headquarters. Payment under this lease will total $19.6 million through May 2032. The Company received a lease incentive of $4.1 million from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022. <span style="color:#000000;">Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the&#160;year ended December 31, 2021&#160;are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,395</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in the balance sheet for leases where the Company is the lessee as of&#160;December 31, 2021&#160;were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:85.26%;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets, operating leases</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,060</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,193</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000445">10.02</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases for the year ended December 31, 2021&#160;is as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.84%;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leased assets obtained in exchange for new operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments, net of reimbursements, remaining as of December 31, 2021 under operating leases by fiscal year were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,609</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,814</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,925</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,477</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,309</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&#160;&#160;Amounts representing imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,193</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense recorded for the years ended December 31, 2021 and 2020 were $1,691 and $561, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.&#160;&#160;This sublease agreement expires in August, 2023.&#160;&#160;In April 2021, the company entered into a sublease agreement with the previous tenants of the office space at One Research Way in Princeton, NJ, from April 2021 to July 2021. As of December 31, 2021, sublease income for the Company was $116.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there were no purchase commitments with third-party suppliers.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716457176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">7.&#160;&#160;Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue up to 22,883,426 shares of convertible preferred stock with a par value of $0.00001 per <span style="color:#auto;">share</span>. 1,657,903 shares were designated as Series Seed convertible preferred stock (Series Seed Preferred), 8,076,985 shares were designated as Series&#160;A convertible <span style="color:#auto;">preferred</span> stock (Series A Preferred), 7,672,560 shares were designated as Series B convertible preferred stock (Series B Preferred) and 5,475,978 shares were designated as Series C convertible preferred stock (Series C Preferred).&#160;&#160;As of December 31, 2019, the Company had an aggregate of 22,866,246 shares of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred (collectively, &#8220;Preferred Stock&#8221;) issued and outstanding.&#160;&#160;All share amounts presented are reverse-split adjusted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="color:#auto;">December</span> 31, 2019, the Preferred Stock consisted of the following (in thousands except for share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">conversion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Preferred</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,903</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,647,102</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,050</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,647,102</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,985</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,560</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,556</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,627</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,728</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,556</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,475,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,705</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,883,426</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,933</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,385</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company issued 5,321,864 shares of Series D Preferred Stock at a price of $13.1533 per share, resulting in gross proceeds of $70,000.&#160;&#160;In connection with the IPO on September 25, 2020, all of the Company&#8217;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of 28,188,110 shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The holders of Preferred Stock have the rights, preferences, privileges and restrictions as set forth below:</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of Preferred Stock are entitled to receive non-cumulative dividends prior to and in preference to any declaration of payment of dividends on common stock, when and if declared by the Board of Directors. Any additional dividends will be paid ratably to holders of common and Preferred Stock, with the holders of Preferred Stock participating on an as-if converted basis. No dividends have been declared or paid as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Voting Rights:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of each share of Preferred Stock are entitled to voting rights equal to the number of shares of common stock into which the shares could be converted. As long as any shares of Preferred Stock remain outstanding, the holders of Preferred Stock, voting together as a class, shall be entitled to elect four members of the Company&#8217;s Board of Directors. The holders of common stock, voting together as a single class, shall be entitled to elect two members of the Company&#8217;s Board of Directors. Remaining members of the Company&#8217;s Board of Directors will be elected by the holders of a majority of the shares of Preferred Stock and common stock, voting together as a single class.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidation Rights:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of Preferred Stock have liquidation preferences, before any distribution or payment is made to holders of any common stock, in an amount per share equal to the original issue price of $1.8517 for Series Seed Preferred, $3.7266 for Series A Preferred, $9.6093 for Series&#160;B Preferred and $11.3121 for Series C Preferred, as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like, plus any declared but unpaid dividends. If the assets and funds to be distributed among the holders of Preferred Stock are insufficient to permit the payment to such holders, then the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of the payment of the full liquidation preference of Preferred Stock, the remaining assets of the Company, if any, shall be distributed with equal priority and ratably to the holders of common stock and Preferred Stock, with the Preferred Stock being treated as if the Preferred Stock had been converted to shares of common stock at the then applicable conversion rate. Notwithstanding the foregoing, the aggregate distributions made with respect to any shares of Preferred Stock may not exceed the greater of (i) an amount equal to two times the original issue price plus any declared but unpaid dividends on such share or (ii) the amount the holder would have received if all shares of the Preferred Stock were deemed to have been converted into common stock as of immediately prior to such liquidation, dissolution or winding up of the Company.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Conversion:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Preferred Stock is convertible into shares of common stock, at the option of the holder, at any time after date of issuance. Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $40,000 and the initial offering price to the public is at least $11.3121 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like). As of December 31, 2019, the conversion price for each share of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred is $1.8517, $3.7266, $9.6093 and $11.3121, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714161624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommonStockDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">8.&#160;&#160;Common Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share, and 5,000,000 shares of preferred stock with a par value of $0.00001 per share. As of December 31, 2021 and 2020, there were 45,433,684 and 44,777,818 shares of common stock issued and outstanding, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.&#160;&#160;As of December 31, 2021, no dividends on common stock had been declared by the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had reserved shares of common stock for issuance as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,609,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for employee stock purchase plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,752</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,999,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,101,447</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommonStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommonStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714485448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">9 &#160;&#160;Stock Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by the board of directors on September 24, 2020.&#160;&#160;The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan is 4,406,374, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of <span style="Background-color:#FFFFFF;color:#000000;">(i)&#160;4,406,374 shares of common stock, (ii)&#160;five percent </span> (5%) of the outstanding common stock on the immediately preceding December 31<span style="Background-color:#FFFFFF;color:#000000;">, or (iii)&#160;such number of common stock determined by the board of directors no later than the immediately preceding December 31.</span>&#160;&#160;For 2021, the board of directors exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of 1,363,084 shares, effective as of January 1, 2022. As of December 31, 2021, there were 4,951,680 shares available for issuance under the 2020 Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the board of directors on September 24, 2020.&#160;&#160;A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year.&#160;&#160;For 2021, the 2020 ESPP reserved shares were increased under clause (iii) by zero shares, effective as of January 1, 2022. On November 19, 2021, employees exercised their right to purchase 10,480 shares under the 2020 ESPP.&#160;&#160;As of December 31, 2021, 47,066 shares are issued or outstanding, and there were 801,464 shares available for issuance, under the 2020 ESPP.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2013 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company adopted the 2013 Stock Plan (the &#8220;2013 Plan&#8221;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.&#160;&#160;Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.&#160;&#160;The Company chose to forfeit the remaining shares.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in 000s)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,609,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000571">7.13</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,343,334</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options retired under 2013 Equity Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(807,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.22</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited / cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(608,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951,680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000572">6.86</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000573">6.86</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,668,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000574">5.80</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,952</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2021 and 2020 was $20.03 and $3.34, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options vested and exercisable as of December 31, 2021 and 2020 is calculated based on the difference between the exercise price and the fair value of our common stock.&#160;&#160;The intrinsic value of options exercised in 2021 and 2020 was $18,534 and $245, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the total compensation cost related to nonvested service-based awards not yet recognized is $15,708.&#160;&#160;The weighted-average period over which the nonvested awards is expected to be recognized is 3.1years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">estimated</span> the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35% - 1.30%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% - 1.51%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49% - 2.51%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.44</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.92 - 6.40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.27 - 6.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.50% - 79.90%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.70% - 77.60%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.07% - 72.69%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used to estimate the fair value of stock options granted and stock purchase rights under the ESPP are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.50</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.83%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">Expected Term:&#160;The Company uses the simplified method to calculate expected term described in the SEC&#8217;s Staff Accounting Bulletin No.&#160;107, which takes into account vesting term and expiration date of the options.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility:&#160;Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk Free Interest Rate:&#160;The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">S<span style="color:#000000;">tock-based compensation expense recorded under ASC 718 related to options granted was allocated to research and development and general and administrative expense as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,340</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,933</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">908</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716327080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">10.&#160;&#160;Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The income tax provision for the years ended December 31, 2021, 2020, and 2019 are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Provision</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision for income taxes included in the accompanying statements of operations for the Company is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision at statutory rate</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, 2020, and 2019, the Company&#8217;s effective tax rate is below the federal statutory income tax rate of 21% primarily due to state income taxes, net of federal benefit and the Company&#8217;s position to establish a full valuation allowance on its deferred tax assets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax <span style="color:#auto;">assets</span> and liabilities are presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,511</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,414</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,033</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,175</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,619</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,503</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets recognized</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,891</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Right-of-use assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,854</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Fixed assets and depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,891</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $159,886 and $97,665, respectively. As of December 31, 2021, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $154,972, $4,912, and $4,640 respectively. At December 31, 2020, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $92,805, $4,912 and $950, respectively.&#160;&#160;Federal net operating loss carryforwards of $27,515 expire beginning in the year 2033. <span style="font-weight:bold;font-family:Arial;color:#000000;"> </span><span style="color:#000000;">State net operating loss carryforwards begin to expire in the year </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">2033</span><span style="color:#000000;">.&#160;&#160;</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards related to tax years after 2017 </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of $</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">132,371</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">do not expire.</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company also has federal and state research and development credit carryforward of approximately $</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6,588</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and $</span>3,470<span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s of December 31, 2021</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, respectfully</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The federal credits will begin to expire in </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2034</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> if not utilized.&#160;&#160;The California state credits carryforward indefinitely and the New Jersey state credits expire starting in </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company accrues interest and penalties related to unrecognized tax benefits in the Provision for income taxes line item in the statements of operations and comprehensive loss</span><span style="Background-color:#FFFFFF;font-weight:bold;">. </span><span style="color:#auto;">As of December 31, 2021 and 2020, the Company had not accrued any interest or penalties related to uncertain tax positions.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If the ending balance of $1,654 and $877 of unrecognized tax benefits as of December 31, 2021 and 2020, respectively, were recognized, none of the recognition would affect the income tax rate. The following table summarized the activity related to the Company&#8217;s unrecognized tax benefits:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, beginning of year</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">543</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year tax positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">734</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#8217;s tax <span style="color:#auto;">years</span> 2013 to 2021 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716327080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">11.&#160;&#160;Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock does not participate in losses. The Company excluded all outstanding stock options and restricted stock awards at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,868</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,644,914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,846</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,440</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,352</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,137,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,364,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.28</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.40</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8.35</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716420216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">12.&#160;&#160;Related Parties</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has consulting agreements with two members of its board of directors. The total of consulting fees paid as of the years ended December 31, 2021 and December 31, 2020 were $110 and $112, respectively. In May of 2021, the two members of the board of directors were awarded 5,781 options of company stock each, as per their updated Scientific Advisory Board agreements. There were no amounts owed under the consulting agreements as of December 31, 2021 or December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended December 31, 2020, an investor provided $65 of financial consulting services to the Company. The Company has paid the entirety of the fees as of December 31, 2020. No amounts were paid or owed to the investors as of the year ended December 31,2021.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714415336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company&#8217;s board of directors and stockholders approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;3 - Inputs are </span><span style="color:#000000;">unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions</span><span style="color:#000000;"> that are unobservable.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its<span style="color:#000000;"> marketable debt securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of December 31, 2021, the company&#8217;s long-term marketable debt securities have maturity dates no more than two years. The Company&#8217;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity.&#160;&#160;Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the years ending December 31, 2021, 2020, and 2019, the company recorded, $550, $152, and $62 of amortization, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2021 included a $822 deposit at the Company&#8217;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.&#160;&#160;The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company&#8217;s only existing leases are for office and laboratory space.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company&#8217;s leases contain residual value guarantees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the remaining term of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income/Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Income/Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $(78), $3, and $10 in other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax for the years ended December 31, 2021, 2020, and 2019, respectively. The Company presents comprehensive income in a single statement within its financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All costs associated with research and development are expensed as incurred.&#160;&#160;Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.&#160;&#160;In the event that we prepay fees, we record the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Company. The Company&#8217;s policy is not to accrete the carrying value and related issuance costs of the convertible preferred stock to its redemption value until it is probable that the security will become redeemable.</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> The convertible preferred stock converted to common stock in connection with the Company&#8217;s Initial Public Offering </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;IPO&#8221;) </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">on September 25, 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Derivative Liabilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company may issue certain financial instruments with embedded features which may be accounted for as separate derivative assets or liabilities, dependent on their specific contractual terms or other conditions. These derivative assets or liabilities are required to be measured at fair value at issuance and <span style="color:#auto;">remeasured</span> at the end of each reporting period. To determine the fair value of these instruments the Company uses a discounted cash flow analysis, as these instruments are not quoted on an active market. Increases or decreases in fair value from initial measurement and each reporting period are recorded in the statement of operations and comprehensive loss as change in fair value of derivative liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Stock&#8209;Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s share-based compensation program allows for grants of stock options and restricted stock awards. <span style="color:#000000;">Grants</span> are awarded to employees and non-employees, including directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,<span style="font-style:italic;"> Compensation &#8211; Stock Compensation </span>(&#8220;ASC 718&#8221;)<span style="font-style:italic;">.</span> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock <span style="color:#000000;">awards</span> and stock options.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting <span style="color:#000000;">conditions</span> is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#8217;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a<span style="color:#000000;"> </span>liquidity event. Among other factors are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise for which separate discrete financial information is <span style="color:#000000;">available</span> for evaluation by the Company&#8217;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as one operating segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the &#8220;two-class&#8221; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a <span style="color:#000000;">participating</span> security). The Company&#8217;s convertible preferred stock are participating securities as defined by ASC 260-10, <span style="font-style:italic;">Earnings per Share</span>. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a <span style="font-style:italic;">pari passu</span> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC 740, <span style="font-style:italic;">Income Taxes</span> ("ASC 740"), which requires that <span style="color:#000000;">deferred</span> tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842), as amended by multiple standards updates, in order to increase transparency and comparability among organizations by requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The most significant change arising from the new standard is the recognition of right of use assets and lease liabilities for leases classified as operating leases. The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. Under the standard, disclosures are required to enable financial statement users to assess the amount, timing, and uncertainty of cash flows arising from the leases. Companies are also required to recognize and measure leases existing at, or entered into after, the adoption date using a modified retrospective approach, with certain practical expedients available. Comparative periods prior to adoption have not been retrospectively adjusted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, Income Taxes &#8211; Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of an enacted change in tax laws or rates in the</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">adopted</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> this standard as of</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2021</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. The adoption did </span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">t have a material impact on the Company&#8217;s financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#8217;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions.&#160;&#160;The Company continues to monitor the impact of the COVID-19 outbreak closely.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716282056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company&#8217;s cash equivalents and available-for-sale securities&#8217; carrying amounts and fair values as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,362</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,960</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,607</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;priced</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in&#160;active&#160;markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant&#160;other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">observable&#160;inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">inputs&#160;(level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Financial assets</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,008</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716310872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery &amp; equipment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,261</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not placed in service</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,519</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,868</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,561</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-weight:bold;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714156968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,627</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714347768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Cost</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for the&#160;year ended December 31, 2021&#160;are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,691</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,395</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Reported in Consolidated Balance Sheets for Leases</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in the balance sheet for leases where the Company is the lessee as of&#160;December 31, 2021&#160;were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:85.26%;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets, operating leases</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,060</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,193</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000445">10.02</span></p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock', window );">Summary of Other Information Related to Leases</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases for the year ended December 31, 2021&#160;is as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.84%;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">717</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leased assets obtained in exchange for new operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments, net of reimbursements, remaining as of December 31, 2021 under operating leases by fiscal year were as follows, in thousands:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,609</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,814</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,925</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,477</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,309</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&#160;&#160;Amounts representing imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,193</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease amount reported in balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of other information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714151176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="color:#auto;">December</span> 31, 2019, the Preferred Stock consisted of the following (in thousands except for share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">stock issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">conversion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Preferred</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,903</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,647,102</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,050</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,647,102</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,985</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,076,982</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,560</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,556</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,627</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,728</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672,556</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,475,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,705</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,883,426</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,933</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,385</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716283896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Reserved Shares of Common Stock for Issuance</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, the Company had reserved shares of common stock for issuance as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,609,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for employee stock purchase plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,752</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,999,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,101,447</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712538376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in 000s)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,609,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000571">7.13</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for issuance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,343,334</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options retired under 2013 Equity Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(807,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.22</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited / cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(608,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances, December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,951,680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000572">6.86</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000573">6.86</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,668,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000574">5.80</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,952</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">estimated</span> the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35% - 1.30%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% - 1.51%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49% - 2.51%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50 - 6.44</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.92 - 6.40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.27 - 6.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.50% - 79.90%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.70% - 77.60%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.07% - 72.69%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based Compensation Expense Related to Options Granted Recorded and Allocated</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">S<span style="color:#000000;">tock-based compensation expense recorded under ASC 718 related to options granted was allocated to research and development and general and administrative expense as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,900</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,340</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,933</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">908</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Stock Options</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used to estimate the fair value of stock options granted and stock purchase rights under the ESPP are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.50</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.83%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854716270168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax Provision</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The income tax provision for the years ended December 31, 2021, 2020, and 2019 are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Provision</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Provision for Income Taxes</a></td>
<td class="text">A reconciliation of income tax computed at the statutory federal income tax rate to the provision for income taxes included in the accompanying statements of operations for the Company is as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision at statutory rate</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax <span style="color:#auto;">assets</span> and liabilities are presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,511</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,414</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,033</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,175</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,619</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,503</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets recognized</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,891</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Right-of-use assets</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,854</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Fixed assets and depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,891</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text">The following table summarized the activity related to the Company&#8217;s unrecognized tax benefits:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, beginning of year</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">543</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to prior year tax positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to current year tax positions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">734</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits, end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714384568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,866,246</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,868</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,246,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,090,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,644,914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss per Share</a></td>
<td class="text">
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,846</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,440</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,352</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares - basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,137,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,364,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.28</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.40</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8.35</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712412184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="nump">$ 243,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,846)<span></span>
</td>
<td class="num">(34,440)<span></span>
</td>
<td class="num">$ (25,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,571)<span></span>
</td>
<td class="num">(32,739)<span></span>
</td>
<td class="num">$ (22,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,726)<span></span>
</td>
<td class="num">$ (109,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">13,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Option to purchase common stock</a></td>
<td class="nump">1,764,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OrganizationConsolidationAndPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization, consolidation and presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OrganizationConsolidationAndPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715347576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.2651-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="nump">5.2651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Amortization of available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Adoption of accounting standards update [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Adoption of accounting standards update [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712512072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 40,960<span></span>
</td>
<td class="nump">$ 240,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">269,607<span></span>
</td>
<td class="nump">120,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">227,362<span></span>
</td>
<td class="nump">120,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">310,567<span></span>
</td>
<td class="nump">360,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">227,362<span></span>
</td>
<td class="nump">120,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">310,567<span></span>
</td>
<td class="nump">360,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">227,362<span></span>
</td>
<td class="nump">120,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">40,960<span></span>
</td>
<td class="nump">240,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">40,960<span></span>
</td>
<td class="nump">240,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 40,960<span></span>
</td>
<td class="nump">$ 240,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714362680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">168,960,000<span></span>
</td>
<td class="nump">$ 360,041,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">141,607,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities noncurrent</a></td>
<td class="nump">16,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities current</a></td>
<td class="nump">124,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">99,362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">128,000,000<span></span>
</td>
<td class="nump">120,008,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">42,245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 40,960,000<span></span>
</td>
<td class="nump">$ 240,033,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854713510632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="nump">$ 2,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,868)<span></span>
</td>
<td class="num">(1,561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery &amp; Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember', window );">Assets Not Placed in Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,519<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854718667480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714389864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 3,797<span></span>
</td>
<td class="nump">$ 3,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,627<span></span>
</td>
<td class="nump">$ 4,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854707868904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>ft&#178; </div>
<div>Lease </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_NumberOfNoncancelableOperatingLeases', window );">Number of noncancelable operating leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,691,000<span></span>
</td>
<td class="nump">$ 561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember', window );">Cranbury, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of operating lease property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00<span></span>
</td>
<td class="nump">20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot', window );">Operating lease maintenance expense per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ManagementFeeOfBaseRentPercentage', window );">Management fee of base rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember', window );">South Brunswick, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of operating lease property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ManagementFeeOfBaseRentPercentage', window );">Management fee of base rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeaseRenewalTermDescription', window );">Operating lease renewal term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">with an option to renew on a month-to-month basis, with an increase in base rent as per the lease, for up to an additional year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_InitialBaseRentIncreasedPerSquareFoot', window );">Initial base rent increased per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace', window );">Allowance on behalf of lessor for construction of office space.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Remaining rent incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SubleaseExpirationPeriod', window );">Sublease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember', window );">Princeton, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities and the space is expected to become the Company&#8217;s future headquarters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeasesExtendedYear', window );">Operating Leases, extended year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeasesExtensionPeriod', window );">Operating leases, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLeasesExtendedMonthAndYear', window );">Operating leases extended month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod', window );">Sublease with tenant office space starting period</a></td>
<td class="text">2021-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod', window );">Sublease with tenant office space ending period</a></td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance on behalf of lessor for construction of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_InitialBaseRentIncreasedPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial base rent increased per square foot.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_InitialBaseRentIncreasedPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_InitialBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial base rent per square foot.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_InitialBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ManagementFeeOfBaseRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Management fee of base rent percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ManagementFeeOfBaseRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfNoncancelableOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of noncancelable operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfNoncancelableOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease maintenance expense per square foot.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeaseRenewalTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease renewal term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeaseRenewalTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtendedMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases extended month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtendedMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtendedYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases, extended year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtendedYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, extension period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease with tenant office space ending period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease with tenant office space starting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854718424888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Components of Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714730136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">$ 10,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">10,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 11,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">10 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712540328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Other Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 10,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715216376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths', window );">2022</a></td>
<td class="num">$ (2,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo', window );">2023</a></td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree', window );">2024</a></td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour', window );">2025</a></td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive', window );">2026</a></td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">16,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing imputed interest</a></td>
<td class="num">(5,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 11,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments net of reimbursements due year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of repayments, due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability to be paid net of repayments after year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854708749528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 25, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Member </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,883,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,790,000<span></span>
</td>
<td class="nump">$ 61,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends, preferred stock declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass', window );">Number of members of board of directors elected by holders of preferred stock voting as single class | Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass', window );">Number of members of board of directors elected by holders of common stock voting as single class | Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock, terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $40,000 and the initial offering price to the public is at least $11.3121 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross cash proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Offering Price to the Public | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.3121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Offering Price to the Public</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,657,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred shares liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,076,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,076,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,076,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred shares liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,672,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,672,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,672,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred shares liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,475,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred shares liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.3121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.3121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.1533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
<td class="nump">17,396,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Common Stock | Initial Offering Price to the Public</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members of board of directors elected by holders of common stock voting as single class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members of board of directors elected by holders of preferred stock voting as single class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712429896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Schedule of Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">22,883,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">22,866,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">22,866,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying value | $</a></td>
<td class="nump">$ 168,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="nump">$ 169,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="nump">22,866,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember', window );">Series Seed Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">1,657,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">1,647,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">1,647,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying value | $</a></td>
<td class="nump">$ 3,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="nump">$ 3,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="nump">1,647,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">8,076,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">8,076,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">8,076,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying value | $</a></td>
<td class="nump">$ 30,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="nump">$ 30,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="nump">8,076,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">7,672,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">7,672,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">7,672,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying value | $</a></td>
<td class="nump">$ 73,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="nump">$ 73,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="nump">7,672,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">5,475,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">5,469,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">5,469,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying value | $</a></td>
<td class="nump">$ 61,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="nump">$ 61,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="nump">5,469,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmvp_SeriesSeedConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712549192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,433,684<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,433,684<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends, common stock declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712548776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">9,999,151<span></span>
</td>
<td class="nump">9,101,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future stock option grants</a></td>
<td class="nump">4,951,680<span></span>
</td>
<td class="nump">4,609,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan', window );">Shares available for employee stock purchase plan</a></td>
<td class="nump">801,464<span></span>
</td>
<td class="nump">400,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="nump">4,090,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854707948536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,999,151<span></span>
</td>
<td class="nump">9,101,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation cost related to nonvested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over nonvested awards expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum', window );">Number of additional shares reserved for issuance, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,951,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum', window );">Number of additional shares reserved for issuance, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum', window );">Number of additional shares reserved for issuance, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares', window );">Employees exercised their right to purchase shares</a></td>
<td class="nump">10,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember', window );">2013 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,534<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock options granted at grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.03<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, shares outstanding, number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715392808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Balance</a></td>
<td class="nump">4,609,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance', window );">Shares Available for Grant, Shares reserved for issuance</a></td>
<td class="nump">1,343,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod', window );">Shares Available for Grant, Options granted</a></td>
<td class="num">(807,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod', window );">Shares Available for Grant, Options forfeited / cancelled</a></td>
<td class="nump">43,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Balance</a></td>
<td class="nump">4,951,680<span></span>
</td>
<td class="nump">4,609,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options</a></td>
<td class="nump">4,090,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, Number of Options</a></td>
<td class="nump">807,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited / cancelled, Number of Options</a></td>
<td class="num">(43,343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Options</a></td>
<td class="num">(608,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number of Options</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="nump">4,090,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, Number of Options</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Number of Options</a></td>
<td class="nump">2,668,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted Average Exercise Price</a></td>
<td class="nump">29.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited / cancelled, Weighted Average Exercise Price</a></td>
<td class="nump">6.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted Average Exercise Price</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Weighted Average Exercise Price</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract', window );"><strong>Weighted-Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 10 months 9 days<span></span>
</td>
<td class="text">7 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 68,506<span></span>
</td>
<td class="nump">$ 238,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">68,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 52,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandThirteenStockPlanMember', window );">2013 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod', window );">Shares Available for Grant, Options retired</a></td>
<td class="num">(237,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, number of shares available for grant, retired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted-average remaining life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandThirteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandThirteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714423656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">1.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.51%<span></span>
</td>
<td class="nump">2.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">76.50%<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
<td class="nump">72.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">79.90%<span></span>
</td>
<td class="nump">77.60%<span></span>
</td>
<td class="nump">72.69%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 4 months 13 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714256600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712567352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,340<span></span>
</td>
<td class="nump">$ 1,933<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714715464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Provision</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712571576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(37.00%)<span></span>
</td>
<td class="num">(30.00%)<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712144200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount', window );">Net operating loss carryforwards begin to expire in 2033</a></td>
<td class="nump">$ 27,515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsAmountsDoNotExpire', window );">Net operating loss carryforwards, do not expire amount</a></td>
<td class="nump">$ 132,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss carryforward, description</a></td>
<td class="text">Net operating loss carryforwards related to tax years after 2017 of $132,371 do not expire.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,654,000<span></span>
</td>
<td class="nump">877,000<span></span>
</td>
<td class="nump">$ 543,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2013 2014 2015 2016 2017 2018 2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 159,886,000<span></span>
</td>
<td class="nump">97,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforward, amount</a></td>
<td class="nump">$ 6,588,000<span></span>
</td>
<td class="nump">3,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 154,972,000<span></span>
</td>
<td class="nump">92,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,912,000<span></span>
</td>
<td class="nump">4,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,640,000<span></span>
</td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_IncomeTaxExaminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax examination period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_IncomeTaxExaminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsAmountsDoNotExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amounts do not expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsAmountsDoNotExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards begin to expire in future amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854715181688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 45,231<span></span>
</td>
<td class="nump">$ 27,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">4,593<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_DeferredTaxAssetsOperatingLeases', window );">Operating lease liabilities</a></td>
<td class="nump">3,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,619<span></span>
</td>
<td class="nump">31,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(52,728)<span></span>
</td>
<td class="num">(31,458)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets recognized</a></td>
<td class="nump">2,891<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_DeferredTaxLiabilitiesOperatingLeases', window );">Right-of-use assets</a></td>
<td class="num">(2,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets and depreciation</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (2,891)<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_DeferredTaxAssetsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_DeferredTaxAssetsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_DeferredTaxLiabilitiesOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_DeferredTaxLiabilitiesOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854809627128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning of year</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of year</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854714365144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="nump">4,090,970<span></span>
</td>
<td class="nump">25,644,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="nump">4,090,970<span></span>
</td>
<td class="nump">2,767,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854809627288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Computation of Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,846)<span></span>
</td>
<td class="num">$ (34,440)<span></span>
</td>
<td class="num">$ (25,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares - basic and diluted</a></td>
<td class="nump">45,137,656<span></span>
</td>
<td class="nump">14,364,475<span></span>
</td>
<td class="nump">3,035,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
<td class="num">$ (8.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139854712355912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>Member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options awarded | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember', window );">Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmvp_NumberOfConsultingAgreementsMembers', window );">Number of consulting agreement members | Member</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount owed to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options awarded | shares</a></td>
<td class="nump">5,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount owed to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Amount paid to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfConsultingAgreementsMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consulting agreements members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfConsultingAgreementsMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>pmvp-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pmvp="http://pmvpharma.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pmvp-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001699382_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="C_0001699382_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001699382_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200925_20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_0001699382_20200925_20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_0001699382_20200924_20200924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesSeedConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211119_20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandThirteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMinimumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtRangeAxis_srtMaximumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_pmvpSegment">
        <measure>pmvp:Segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_iso4217USD_utrsqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pmvpLease">
        <measure>pmvp:Lease</measure>
    </unit>
    <unit id="U_pmvpMember">
        <measure>pmvp:Member</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001699382_20210101_20211231" id="F_000028">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001699382_20210101_20211231" id="F_000030">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001699382_20210101_20211231" id="F_000031">0001699382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_0001699382_20210101_20211231" id="F_000032">false</dei:AmendmentFlag>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000341">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000345">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000347">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:OpenTaxYear contextRef="C_0001699382_20210101_20211231" id="F_000703">2013 2014 2015 2016 2017 2018 2019 2020 2021</us-gaap:OpenTaxYear>
    <pmvp:IncomeTaxExaminationPeriod
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000704">P3Y</pmvp:IncomeTaxExaminationPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831"
      id="F_000425">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pmvp:OperatingLeasesExtensionPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131"
      id="F_000433">P5Y</pmvp:OperatingLeasesExtensionPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001699382_20211231" id="F_000445">P10Y7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001699382_20200101_20201231" id="F_000571">P7Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001699382_20210101_20211231" id="F_000572">P6Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001699382_20210101_20211231" id="F_000573">P6Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001699382_20210101_20211231" id="F_000574">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000585"
      unitRef="U_xbrlipure">0.0035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001699382_20200101_20201231"
      decimals="INF"
      id="F_000586"
      unitRef="U_xbrlipure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001699382_20190101_20191231"
      decimals="INF"
      id="F_000587"
      unitRef="U_xbrlipure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000588"
      unitRef="U_xbrlipure">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001699382_20200101_20201231"
      decimals="INF"
      id="F_000589"
      unitRef="U_xbrlipure">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001699382_20190101_20191231"
      decimals="INF"
      id="F_000590"
      unitRef="U_xbrlipure">0.0251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000591">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000592">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20190101_20191231"
      id="F_000593">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000594">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000595">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_srtRangeAxis_srtMaximumMember_20190101_20191231"
      id="F_000596">P6Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001699382_20210101_20211231"
      decimals="4"
      id="F_000600"
      unitRef="U_xbrlipure">0.7650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001699382_20200101_20201231"
      decimals="4"
      id="F_000601"
      unitRef="U_xbrlipure">0.7070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001699382_20190101_20191231"
      decimals="4"
      id="F_000602"
      unitRef="U_xbrlipure">0.7207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001699382_20210101_20211231"
      decimals="4"
      id="F_000603"
      unitRef="U_xbrlipure">0.7990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001699382_20200101_20201231"
      decimals="4"
      id="F_000604"
      unitRef="U_xbrlipure">0.7760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001699382_20190101_20191231"
      decimals="4"
      id="F_000605"
      unitRef="U_xbrlipure">0.7269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      id="F_000607">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:PreferredStockValue
      contextRef="C_0001699382_20211231"
      id="F_000065"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001699382_20201231"
      id="F_000066"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_0001699382_20211231"
      id="F_000067"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_0001699382_20201231"
      id="F_000068"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001699382_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001699382_20210101_20211231" id="F_000001">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001699382_20210101_20211231" id="F_000003">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001699382_20210101_20211231" id="F_000029">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001699382_20210101_20211231" id="F_000002">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001699382_20210101_20211231" id="F_000004">001-39539</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001699382_20210101_20211231" id="F_000005">PMV PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001699382_20210101_20211231" id="F_000006">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001699382_20210101_20211231" id="F_000007">46-3218129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001699382_20210101_20211231" id="F_000008">8 Clarke Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001699382_20210101_20211231" id="F_000009">Suite 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001699382_20210101_20211231" id="F_000010">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001699382_20210101_20211231" id="F_000011">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001699382_20210101_20211231" id="F_000012">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001699382_20210101_20211231" id="F_000013">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001699382_20210101_20211231" id="F_000014">642-6670</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001699382_20210101_20211231" id="F_000015">Common stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001699382_20210101_20211231" id="F_000016">PMVP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001699382_20210101_20211231" id="F_000017">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001699382_20210101_20211231" id="F_000018">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001699382_20210101_20211231" id="F_000019">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001699382_20210101_20211231" id="F_000020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001699382_20210101_20211231" id="F_000021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001699382_20210101_20211231" id="F_000022">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001699382_20210101_20211231" id="F_000023">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001699382_20210101_20211231" id="F_000024">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001699382_20210101_20211231" id="F_000033">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001699382_20210101_20211231" id="F_000025">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001699382_20210630"
      decimals="0"
      id="F_000027"
      unitRef="U_iso4217USD">1229389330</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001699382_20220225"
      decimals="INF"
      id="F_000026"
      unitRef="U_xbrlishares">45450699</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000269">
&lt;p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2021.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001699382_20210101_20211231" id="F_000034">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001699382_20210101_20211231" id="F_000035">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001699382_20210101_20211231" id="F_000036">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">172467000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">361422000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">822000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">124696000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">3301000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">3339000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">301286000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">364761000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">3090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">569000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">16911000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">10060000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">221000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">201000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">331568000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">365531000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">3189000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">1607000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">8627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">4803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">12219000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">6410000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">10790000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">23009000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">6410000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000078"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000079"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000086"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000087"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">45433684</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">45433684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">44777818</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">44777818</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">476363000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">469001000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">-167726000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">-109880000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">-78000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">308559000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">359121000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">331568000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">365531000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">36493000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">23933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">20759000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">21800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">11009000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">5878000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">58293000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">34942000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">26637000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-58293000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-34942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-26637000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">449000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">651000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">1301000</us-gaap:InterestIncomeExpenseNet>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">21000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-143000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-8000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">470000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">508000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">1293000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-57823000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-34434000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-25344000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-25352000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-78000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-57924000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-34437000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-25342000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000130"
      unitRef="U_iso4217USD_xbrlishares">-1.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000131"
      unitRef="U_iso4217USD_xbrlishares">-2.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000132"
      unitRef="U_iso4217USD_xbrlishares">-8.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20210101_20211231"
      decimals="0"
      id="F_000133"
      unitRef="U_xbrlishares">45137656</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20200101_20201231"
      decimals="0"
      id="F_000134"
      unitRef="U_xbrlishares">14364475</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20190101_20191231"
      decimals="0"
      id="F_000135"
      unitRef="U_xbrlishares">3035243</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="INF"
      id="F_000136"
      unitRef="U_xbrlishares">17396640</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">107228000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">3012284</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">3961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">-13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-50088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20181231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">-46140000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000195"
      unitRef="U_xbrlishares">5469606</pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">61705000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000143"
      unitRef="U_xbrlishares">33916</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-25352000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-25352000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000152"
      unitRef="U_xbrlishares">22866246</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">168933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000154"
      unitRef="U_xbrlishares">3046200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">4969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-75440000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-70474000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">208000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_000197"
      unitRef="U_xbrlishares">5321864</pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">69790000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pmvp:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="C_0001699382_20200101_20201231"
      decimals="INF"
      id="F_000199"
      unitRef="U_xbrlishares">-28188110</pmvp:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-238723000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">238723000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">238723000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">9688</pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">194000</pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">194000</pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">20359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">13529750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">223176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">223176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000168"
      unitRef="U_xbrlishares">4070</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">1933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">1933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000177"
      unitRef="U_xbrlishares">44777818</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">469001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-109880000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">359121000</us-gaap:StockholdersEquity>
    <pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000181"
      unitRef="U_xbrlishares">655866</pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">2022000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">2022000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">5340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">5340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000190"
      unitRef="U_xbrlishares">45433684</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">476363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">-167726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">308559000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">-57846000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-34440000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">-25352000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">5340000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">1933000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">908000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">307000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">318000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">388000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">-550000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">-152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">-62000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <pmvp:OtherNonCashLeaseExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">974000</pmvp:OtherNonCashLeaseExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">19000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">-143000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-8000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-38000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">2732000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">275000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">191000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">-1230000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">1799000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">3894000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">3117000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">397000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">-46571000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">-32739000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-22065000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">1349000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">148000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">109000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">256845000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">14512000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">43452000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">114610000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">42571000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">46792000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">-143584000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">27911000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">3231000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">69790000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">61705000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">223176000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">2022000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">2022000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">292972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">61805000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-188133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">288144000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">42971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">361422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">73278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20181231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">30307000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">173289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">361422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">73278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <pmvp:LeaseIncentivesUsedForLeaseholdImprovements
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">-88000</pmvp:LeaseIncentivesUsedForLeaseholdImprovements>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">1391000</us-gaap:PaymentsToAcquireProductiveAssets>
    <pmvp:ConversionOfConvertiblePreferredStockToCommonStock
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">238723000</pmvp:ConversionOfConvertiblePreferredStockToCommonStock>
    <pmvp:ConversionOfWarrantLiabilityToCommonStock
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">194000</pmvp:ConversionOfWarrantLiabilityToCommonStock>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">23000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">8000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000270">
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;PMV Pharmaceuticals, Inc.&lt;/p&gt;
&lt;p id="NOTES_TO_FINANCIAL_STATEMENTS" style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes to Financial Statements&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021 and 2020&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands except share and per share amounts)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;1.&#160;&#160;Formation and Business of the Company&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Organization&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#x2019;s headquarters are located in Cranbury, New Jersey. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 25, 2020, the Company completed an initial public offering (the &#x201c;IPO&#x201d;) of 13,529,750 shares of common stock, at a public offering price of $18.00 per share including the exercise in full by the underwriters of their option to purchase up to 1,764,750 additional shares of commons stock, for aggregate gross proceeds of $243,536 and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#x201c;PMVP.&#x201d;&#160;&#160;The Company received $223,176 in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.&#160;&#160;In connection with the closing of the IPO, all of the Company&#x2019;s outstanding shares of convertible preferred stock automatically converted into 28,188,110 shares of common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred net losses and negative cash flows from operations since it&#x2019;s inception. During the year ended December 31, 2021, the Company incurred a net loss of $57,846 and used $46,571 of cash for operations. As of December 31, 2021, the Company had an accumulated deficit of $167,726.&#160;&#160;Cash, cash equivalents, and marketable securities were $314,074 as of December 31, 2021.&#160;&#160;Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs.&#160;&#160;The Company believes it has adequate cash and cash equivalents to operate for at least the next twelve months from the date of issuance of these financial statements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925"
      decimals="INF"
      id="F_000319"
      unitRef="U_xbrlishares">13529750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925"
      decimals="INF"
      id="F_000320"
      unitRef="U_iso4217USD_xbrlishares">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200925_20200925"
      decimals="INF"
      id="F_000321"
      unitRef="U_xbrlishares">1764750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <pmvp:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001699382_20200925_20200925"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">243536000</pmvp:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001699382_20200925_20200925"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">223176000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925"
      decimals="INF"
      id="F_000324"
      unitRef="U_xbrlishares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">-46571000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">-167726000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">314074000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000271">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2.&#160;&#160;Summary&lt;span style="color:#000000;"&gt; of &lt;/span&gt;Significant&lt;span style="color:#000000;"&gt; Accounting Policies&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company&#x2019;s board of directors and stockholders approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;3 - Inputs are &lt;/span&gt;&lt;span style="color:#000000;"&gt;unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions&lt;/span&gt;&lt;span style="color:#000000;"&gt; that are unobservable.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its&lt;span style="color:#000000;"&gt; marketable debt securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of December 31, 2021, the company&#x2019;s long-term marketable debt securities have maturity dates no more than two years. The Company&#x2019;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity.&#160;&#160;Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the years ending December 31, 2021, 2020, and 2019, the company recorded, $550, $152, and $62 of amortization, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash as of December 31, 2021 included a $822 deposit at the Company&#x2019;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.&#160;&#160;The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company&#x2019;s only existing leases are for office and laboratory space.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company&#x2019;s leases contain residual value guarantees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#x2011;line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the remaining term of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Income/Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $(78), $3, and $10 in other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax for the years ended December 31, 2021, 2020, and 2019, respectively. The Company presents comprehensive income in a single statement within its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;All costs associated with research and development are expensed as incurred.&#160;&#160;Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.&#160;&#160;In the event that we prepay fees, we record the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s convertible preferred stock was classified outside of stockholders&#x2019; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company. The Company&#x2019;s policy is not to accrete the carrying value and related issuance costs of the convertible preferred stock to its redemption value until it is probable that the security will become redeemable.&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; The convertible preferred stock converted to common stock in connection with the Company&#x2019;s Initial Public Offering &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&#x201c;IPO&#x201d;) &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;on September 25, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Derivative Liabilities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may issue certain financial instruments with embedded features which may be accounted for as separate derivative assets or liabilities, dependent on their specific contractual terms or other conditions. These derivative assets or liabilities are required to be measured at fair value at issuance and &lt;span style="color:#auto;"&gt;remeasured&lt;/span&gt; at the end of each reporting period. To determine the fair value of these instruments the Company uses a discounted cash flow analysis, as these instruments are not quoted on an active market. Increases or decreases in fair value from initial measurement and each reporting period are recorded in the statement of operations and comprehensive loss as change in fair value of derivative liabilities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock&#x2011;Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s share-based compensation program allows for grants of stock options and restricted stock awards. &lt;span style="color:#000000;"&gt;Grants&lt;/span&gt; are awarded to employees and non-employees, including directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,&lt;span style="font-style:italic;"&gt; Compensation &#x2013; Stock Compensation &lt;/span&gt;(&#x201c;ASC 718&#x201d;)&lt;span style="font-style:italic;"&gt;.&lt;/span&gt; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock &lt;span style="color:#000000;"&gt;awards&lt;/span&gt; and stock options.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting &lt;span style="color:#000000;"&gt;conditions&lt;/span&gt; is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a&lt;span style="color:#000000;"&gt; &lt;/span&gt;liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is &lt;span style="color:#000000;"&gt;available&lt;/span&gt; for evaluation by the Company&#x2019;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as one operating segment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed using the &#x201c;two-class&#x201d; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a &lt;span style="color:#000000;"&gt;participating&lt;/span&gt; security). The Company&#x2019;s convertible preferred stock are participating securities as defined by ASC 260-10, &lt;span style="font-style:italic;"&gt;Earnings per Share&lt;/span&gt;. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a &lt;span style="font-style:italic;"&gt;pari passu&lt;/span&gt; (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#x2019;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt; ("ASC 740"), which requires that &lt;span style="color:#000000;"&gt;deferred&lt;/span&gt; tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2016-02, Leases (Topic 842), as amended by multiple standards updates, in order to increase transparency and comparability among organizations by requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The most significant change arising from the new standard is the recognition of right of use assets and lease liabilities for leases classified as operating leases. The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. Under the standard, disclosures are required to enable financial statement users to assess the amount, timing, and uncertainty of cash flows arising from the leases. Companies are also required to recognize and measure leases existing at, or entered into after, the adoption date using a modified retrospective approach, with certain practical expedients available. Comparative periods prior to adoption have not been retrospectively adjusted. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes &#x2013; Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of an enacted change in tax laws or rates in the&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;annual effective tax rate computation in the interim period that includes the enactment date. The Company &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;adopted&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; this standard as of&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The adoption did &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;t have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#x2019;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a &#x201c;Public Health Emergency of International Concern,&#x201d; which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions.&#160;&#160;The Company continues to monitor the impact of the COVID-19 outbreak closely.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000282">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001699382_20210101_20211231" id="F_000283">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pmvp:ReverseStockSplitPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000284">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company&#x2019;s board of directors and stockholders approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/p&gt;</pmvp:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="C_0001699382_20210101_20211231" id="F_000329">5.2651-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001699382_20200924_20200924"
      decimals="4"
      id="F_000330"
      unitRef="U_xbrlipure">5.2651</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001699382_20210101_20211231" id="F_000285">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;3 - Inputs are &lt;/span&gt;&lt;span style="color:#000000;"&gt;unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions&lt;/span&gt;&lt;span style="color:#000000;"&gt; that are unobservable.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000286">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its&lt;span style="color:#000000;"&gt; marketable debt securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of December 31, 2021, the company&#x2019;s long-term marketable debt securities have maturity dates no more than two years. The Company&#x2019;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity.&#160;&#160;Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the years ending December 31, 2021, 2020, and 2019, the company recorded, $550, $152, and $62 of amortization, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash as of December 31, 2021 included a $822 deposit at the Company&#x2019;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.&lt;/p&gt;</pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">550000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">152000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">62000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:RestrictedCash
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">822000</us-gaap:RestrictedCash>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000287">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.&#160;&#160;The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company&#x2019;s only existing leases are for office and laboratory space.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company&#x2019;s leases contain residual value guarantees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000288">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#x2011;line method over the estimated useful lives of the assets, generally five years, except for leasehold improvements, which are amortized over the remaining term of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="C_0001699382_20210101_20211231" id="F_000335">five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000289">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000290">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Income/Loss&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $(78), $3, and $10 in other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax for the years ended December 31, 2021, 2020, and 2019, respectively. The Company presents comprehensive income in a single statement within its financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">-78000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001699382_20210101_20211231" id="F_000291">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;All costs associated with research and development are expensed as incurred.&#160;&#160;Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.&#160;&#160;In the event that we prepay fees, we record the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pmvp:ConvertiblePreferredStockPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000292">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s convertible preferred stock was classified outside of stockholders&#x2019; deficit because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company. The Company&#x2019;s policy is not to accrete the carrying value and related issuance costs of the convertible preferred stock to its redemption value until it is probable that the security will become redeemable.&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; The convertible preferred stock converted to common stock in connection with the Company&#x2019;s Initial Public Offering &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&#x201c;IPO&#x201d;) &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;on September 25, 2020.&lt;/span&gt;&lt;/p&gt;</pmvp:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000293">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Derivative Liabilities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may issue certain financial instruments with embedded features which may be accounted for as separate derivative assets or liabilities, dependent on their specific contractual terms or other conditions. These derivative assets or liabilities are required to be measured at fair value at issuance and &lt;span style="color:#auto;"&gt;remeasured&lt;/span&gt; at the end of each reporting period. To determine the fair value of these instruments the Company uses a discounted cash flow analysis, as these instruments are not quoted on an active market. Increases or decreases in fair value from initial measurement and each reporting period are recorded in the statement of operations and comprehensive loss as change in fair value of derivative liabilities.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001699382_20210101_20211231" id="F_000294">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock&#x2011;Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s share-based compensation program allows for grants of stock options and restricted stock awards. &lt;span style="color:#000000;"&gt;Grants&lt;/span&gt; are awarded to employees and non-employees, including directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,&lt;span style="font-style:italic;"&gt; Compensation &#x2013; Stock Compensation &lt;/span&gt;(&#x201c;ASC 718&#x201d;)&lt;span style="font-style:italic;"&gt;.&lt;/span&gt; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock &lt;span style="color:#000000;"&gt;awards&lt;/span&gt; and stock options.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting &lt;span style="color:#000000;"&gt;conditions&lt;/span&gt; is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized based on grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the of performance condition is probable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a&lt;span style="color:#000000;"&gt; &lt;/span&gt;liquidity event. Among other factors are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000339"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000295">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is &lt;span style="color:#000000;"&gt;available&lt;/span&gt; for evaluation by the Company&#x2019;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as one operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000340"
      unitRef="U_pmvpSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000296">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed using the &#x201c;two-class&#x201d; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a &lt;span style="color:#000000;"&gt;participating&lt;/span&gt; security). The Company&#x2019;s convertible preferred stock are participating securities as defined by ASC 260-10, &lt;span style="font-style:italic;"&gt;Earnings per Share&lt;/span&gt;. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a &lt;span style="font-style:italic;"&gt;pari passu&lt;/span&gt; (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#x2019;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000297">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt; ("ASC 740"), which requires that &lt;span style="color:#000000;"&gt;deferred&lt;/span&gt; tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000298">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2016-02, Leases (Topic 842), as amended by multiple standards updates, in order to increase transparency and comparability among organizations by requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The most significant change arising from the new standard is the recognition of right of use assets and lease liabilities for leases classified as operating leases. The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. Under the standard, disclosures are required to enable financial statement users to assess the amount, timing, and uncertainty of cash flows arising from the leases. Companies are also required to recognize and measure leases existing at, or entered into after, the adoption date using a modified retrospective approach, with certain practical expedients available. Comparative periods prior to adoption have not been retrospectively adjusted. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes &#x2013; Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of an enacted change in tax laws or rates in the&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;annual effective tax rate computation in the interim period that includes the enactment date. The Company &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;adopted&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; this standard as of&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2021&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The adoption did &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;t have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000342">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">970000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">1129000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001699382_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000346">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000299">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#x2019;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a &#x201c;Public Health Emergency of International Concern,&#x201d; which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions.&#160;&#160;The Company continues to monitor the impact of the COVID-19 outbreak closely.&lt;/p&gt;</pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000272">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;3.&#160;&#160;Financial Instruments and Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company&#x2019;s cash equivalents and available-for-sale securities&#x2019; carrying amounts and fair values as of December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;priced&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&#160;active&#160;markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&#160;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&#160;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&#160;(level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,567&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,567&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;priced&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&#160;active&#160;markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&#160;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&#160;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&#160;(level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;span style="font-weight:normal;font-style:normal;"&gt;&#x2013; As of December 31, 2021, the company had cash of $3,508 and cash equivalents of $168,960.&#160;&#160;Cash equivalents consisted of money market funds of $40,960 and corporate debt securities of $128,000. Cash equivalents of $360,041 as of December 31, 2020 consisted of money market funds of $240,033 and corporate debt securities of $120,008. Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;span style="font-size:12pt;font-style:normal;"&gt; &lt;/span&gt;&#x2013; &lt;span style="font-weight:normal;font-style:normal;"&gt;Marketable securities of $141,607 as of December 31, 2021 consisted of corporate debt securities of $99,362 and government debt securities of $42,245. There were $124,696 current marketable securities and $16,911 noncurrent marketable securities as of December 31, 2021. There were no marketable securities as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000300">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company&#x2019;s cash equivalents and available-for-sale securities&#x2019; carrying amounts and fair values as of December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;priced&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&#160;active&#160;markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&#160;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&#160;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&#160;(level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,567&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,567&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;priced&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&#160;active&#160;markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&#160;other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;observable&#160;inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;inputs&#160;(level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">227362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">227362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">227362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">42245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">42245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">42245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20211231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">310567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20211231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">310567000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">269607000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">240033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">240033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">240033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">120008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">120008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">120008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">360041000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">360041000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">240033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">120008000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">3508000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">168960000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">40960000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">128000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">360041000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">240033000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">120008000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">141607000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">99362000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0001699382_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">42245000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">124696000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">16911000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000379"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000273">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;4.&#160;&#160;Property and Equipment, Net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery &amp;amp; equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,989&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not placed in service&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;span style="color:#auto;"&gt; expense for the years ended December 31, 2021, 2020, and 2019 was $307, $318, and $388, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000301">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery &amp;amp; equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,989&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not placed in service&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-family:Times New Roman;font-weight:bold;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">2261000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">1989000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">9000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">9000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">161000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">73000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20211231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">2519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_us-gaapPropertyPlantAndEquipmentByTypeAxis_pmvpAssetsNotPlacedInServiceMember_20201231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">51000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">4958000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">2130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">1868000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">1561000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">3090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">569000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">307000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">318000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">388000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000274">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;5.&#160;&#160;Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000302">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">3797000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">3109000</us-gaap:WorkersCompensationLiabilityCurrent>
    <pmvp:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">4734000</pmvp:AccruedResearchAndDevelopmentCostsCurrent>
    <pmvp:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">1595000</pmvp:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">96000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">99000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">8627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">4803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000275">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;6.&#160;&#160;Commitments and Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2015, the Company executed a noncancelable operating lease for approximately 13,000 square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $20.00 per square foot. This location operates as the Company&#x2019;s current headquarters. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2017, the Company obtained an additional noncancelable operating lease for about 6,000 square feet of laboratory space in the same corporate center at an initial rental rate at $22.00 per square foot. As a result of the additional space, both leases will expire June 2022, with an option to renew on a month-to-month basis, with an increase in base rent as per the lease, for up to an additional year. Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.&lt;span style="color:#000000;"&gt; &lt;/span&gt;The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Company executed two noncancelable operating leases. One lease for approximately 6,000 square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $15.50 per square foot and a management fee of 3% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;lease expires in &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 2022&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;with an option &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to renew on a &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;month-to-month&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; basis&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, with an increase in base rent as per the lease,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for up to an additional year&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The second lease is for office space in Lexington, Massachusetts, that expires &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;August 2023&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, with an option to renew for a one-time, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000425"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; extension. The initial annual base rent is $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.50&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per square foot and will increase $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.00&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per square foot at the end of each rent year.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $165 on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.&#160;&#160;As of December 31, 2021, the remaining rent incentive pertaining to the Lexington, MA lease totaled $64. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey.&#160;&#160;The Company intends to complete the relocation of their headquarters from Cranbury, NJ to One Research Way in Princeton NJ in late 2022. That lease term extends through 2032, has a &lt;span style="-sec-ix-hidden:F_000433"&gt;five-year&lt;/span&gt; extension option, and is intended to replace our two existing facilities and the space is expected to become the Company&#x2019;s future headquarters. Payment under this lease will total $19.6 million through May 2032. The Company received a lease incentive of $4.1 million from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022. &lt;span style="color:#000000;"&gt;Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost for the&#160;year ended December 31, 2021&#160;are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts reported in the balance sheet for leases where the Company is the lessee as of&#160;December 31, 2021&#160;were as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:85.26%;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000445"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to leases for the year ended December 31, 2021&#160;is as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.84%;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.61%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments, net of reimbursements, remaining as of December 31, 2021 under operating leases by fiscal year were as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fiscal year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,814&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&#160;&#160;Amounts representing imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense recorded for the years ended December 31, 2021 and 2020 were $1,691 and $561, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.&#160;&#160;This sublease agreement expires in August, 2023.&#160;&#160;In April 2021, the company entered into a sublease agreement with the previous tenants of the office space at One Research Way in Princeton, NJ, from April 2021 to July 2021. As of December 31, 2021, sublease income for the Company was $116.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Commitments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, there were no purchase commitments with third-party suppliers.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630"
      decimals="INF"
      id="F_000411"
      unitRef="U_utrsqft">13000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20150630"
      decimals="2"
      id="F_000412"
      unitRef="U_iso4217USD_utrsqft">20.00</pmvp:InitialBaseRentPerSquareFoot>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630"
      decimals="INF"
      id="F_000413"
      unitRef="U_utrsqft">6000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20170630"
      decimals="2"
      id="F_000414"
      unitRef="U_iso4217USD_utrsqft">22.00</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231"
      id="F_000415">2022-06</pmvp:OperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20210101_20211231"
      id="F_000417">Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.</us-gaap:LesseeOperatingLeaseDescription>
    <pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231"
      decimals="2"
      id="F_000416"
      unitRef="U_iso4217USD_utrsqft">3.00</pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot>
    <pmvp:ManagementFeeOfBaseRentPercentage
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpCranburyNewJerseyMember_20211231"
      decimals="2"
      id="F_000418"
      unitRef="U_xbrlipure">0.03</pmvp:ManagementFeeOfBaseRentPercentage>
    <pmvp:NumberOfNoncancelableOperatingLeases
      contextRef="C_0001699382_20180801_20180831"
      decimals="INF"
      id="F_000419"
      unitRef="U_pmvpLease">2</pmvp:NumberOfNoncancelableOperatingLeases>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831"
      decimals="INF"
      id="F_000420"
      unitRef="U_utrsqft">6000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831"
      decimals="2"
      id="F_000421"
      unitRef="U_iso4217USD_utrsqft">15.50</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:ManagementFeeOfBaseRentPercentage
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180831"
      decimals="2"
      id="F_000428"
      unitRef="U_xbrlipure">0.03</pmvp:ManagementFeeOfBaseRentPercentage>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831"
      id="F_000422">2022-07</pmvp:OperatingLeaseExpirationPeriod>
    <pmvp:OperatingLeaseRenewalTermDescription
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpSouthBrunswickNewJerseyMember_20180801_20180831"
      id="F_000423">with an option to renew on a month-to-month basis, with an increase in base rent as per the lease, for up to an additional year</pmvp:OperatingLeaseRenewalTermDescription>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180801_20180831"
      id="F_000424">2023-08</pmvp:OperatingLeaseExpirationPeriod>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831"
      decimals="2"
      id="F_000426"
      unitRef="U_iso4217USD_utrsqft">28.50</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:InitialBaseRentIncreasedPerSquareFoot
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180831"
      decimals="2"
      id="F_000427"
      unitRef="U_iso4217USD_utrsqft">1.00</pmvp:InitialBaseRentIncreasedPerSquareFoot>
    <pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20180101_20181231"
      decimals="INF"
      id="F_000429"
      unitRef="U_iso4217USD">165000</pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20211231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">64000</us-gaap:DeferredRentCredit>
    <us-gaap:AreaOfLand
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210131"
      decimals="INF"
      id="F_000431"
      unitRef="U_utrsqft">50581</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231"
      id="F_000436">That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities and the space is expected to become the Company&#x2019;s future headquarters</us-gaap:LesseeOperatingLeaseDescription>
    <pmvp:OperatingLeasesExtendedYear
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131"
      id="F_000432">2032</pmvp:OperatingLeasesExtendedYear>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131"
      decimals="-5"
      id="F_000434"
      unitRef="U_iso4217USD">19600000</us-gaap:OperatingLeasePayments>
    <pmvp:OperatingLeasesExtendedMonthAndYear
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131"
      id="F_000435">2032-05</pmvp:OperatingLeasesExtendedMonthAndYear>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20210131"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">4100000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000303">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost for the&#160;year ended December 31, 2021&#160;are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">1691000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">704000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">2395000</us-gaap:LeaseCost>
    <pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000304">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts reported in the balance sheet for leases where the Company is the lessee as of&#160;December 31, 2021&#160;were as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:85.26%;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets, operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000445"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">10060000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">10790000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">11193000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001699382_20211231"
      decimals="4"
      id="F_000446"
      unitRef="U_xbrlipure">0.0575</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000305">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to leases for the year ended December 31, 2021&#160;is as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.84%;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">717000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">10318000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000306">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments, net of reimbursements, remaining as of December 31, 2021 under operating leases by fiscal year were as follows, in thousands:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fiscal year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,814&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&#160;&#160;Amounts representing imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">-2609000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">1833000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">1814000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">1869000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">1925000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive>
    <pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">11477000</pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">16309000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">5116000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">11193000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">1691000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">561000</us-gaap:OperatingLeaseExpense>
    <pmvp:SubleaseExpirationPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_20210101_20211231"
      id="F_000460">2023-08</pmvp:SubleaseExpirationPeriod>
    <pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430"
      id="F_000461">2021-04</pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod>
    <pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210401_20210430"
      id="F_000462">2021-07</pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod>
    <us-gaap:SubleaseIncome
      contextRef="C_0001699382_srtStatementGeographicalAxis_pmvpPrincetonNewJerseyMember_20210101_20211231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">116000</us-gaap:SubleaseIncome>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000464"
      unitRef="U_iso4217USD">0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PreferredStockTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000276">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;7.&#160;&#160;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2019, the Company&#x2019;s Certificate of Incorporation, as amended and restated, authorized the Company to issue up to 22,883,426 shares of convertible preferred stock with a par value of $0.00001 per &lt;span style="color:#auto;"&gt;share&lt;/span&gt;. 1,657,903 shares were designated as Series Seed convertible preferred stock (Series Seed Preferred), 8,076,985 shares were designated as Series&#160;A convertible &lt;span style="color:#auto;"&gt;preferred&lt;/span&gt; stock (Series A Preferred), 7,672,560 shares were designated as Series B convertible preferred stock (Series B Preferred) and 5,475,978 shares were designated as Series C convertible preferred stock (Series C Preferred).&#160;&#160;As of December 31, 2019, the Company had an aggregate of 22,866,246 shares of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred (collectively, &#x201c;Preferred Stock&#x201d;) issued and outstanding.&#160;&#160;All share amounts presented are reverse-split adjusted.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;span style="color:#auto;"&gt;December&lt;/span&gt; 31, 2019, the Preferred Stock consisted of the following (in thousands except for share data):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock issued&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;preference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock issuable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;conversion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,647,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,647,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,475,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,883,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;169,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company issued 5,321,864 shares of Series D Preferred Stock at a price of $13.1533 per share, resulting in gross proceeds of $70,000.&#160;&#160;In connection with the IPO on September 25, 2020, all of the Company&#x2019;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of 28,188,110 shares of common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of Preferred Stock have the rights, preferences, privileges and restrictions as set forth below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Dividends:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of Preferred Stock are entitled to receive non-cumulative dividends prior to and in preference to any declaration of payment of dividends on common stock, when and if declared by the Board of Directors. Any additional dividends will be paid ratably to holders of common and Preferred Stock, with the holders of Preferred Stock participating on an as-if converted basis. No dividends have been declared or paid as of December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Voting Rights:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of each share of Preferred Stock are entitled to voting rights equal to the number of shares of common stock into which the shares could be converted. As long as any shares of Preferred Stock remain outstanding, the holders of Preferred Stock, voting together as a class, shall be entitled to elect four members of the Company&#x2019;s Board of Directors. The holders of common stock, voting together as a single class, shall be entitled to elect two members of the Company&#x2019;s Board of Directors. Remaining members of the Company&#x2019;s Board of Directors will be elected by the holders of a majority of the shares of Preferred Stock and common stock, voting together as a single class.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidation Rights:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of Preferred Stock have liquidation preferences, before any distribution or payment is made to holders of any common stock, in an amount per share equal to the original issue price of $1.8517 for Series Seed Preferred, $3.7266 for Series A Preferred, $9.6093 for Series&#160;B Preferred and $11.3121 for Series C Preferred, as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like, plus any declared but unpaid dividends. If the assets and funds to be distributed among the holders of Preferred Stock are insufficient to permit the payment to such holders, then the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon completion of the payment of the full liquidation preference of Preferred Stock, the remaining assets of the Company, if any, shall be distributed with equal priority and ratably to the holders of common stock and Preferred Stock, with the Preferred Stock being treated as if the Preferred Stock had been converted to shares of common stock at the then applicable conversion rate. Notwithstanding the foregoing, the aggregate distributions made with respect to any shares of Preferred Stock may not exceed the greater of (i) an amount equal to two times the original issue price plus any declared but unpaid dividends on such share or (ii) the amount the holder would have received if all shares of the Preferred Stock were deemed to have been converted into common stock as of immediately prior to such liquidation, dissolution or winding up of the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Conversion:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each share of Preferred Stock is convertible into shares of common stock, at the option of the holder, at any time after date of issuance. Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $40,000 and the initial offering price to the public is at least $11.3121 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like). As of December 31, 2019, the conversion price for each share of Series Seed Preferred, Series A Preferred, Series B Preferred and Series C Preferred is $1.8517, $3.7266, $9.6093 and $11.3121, respectively.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000465"
      unitRef="U_xbrlishares">22883426</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000470"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000466"
      unitRef="U_xbrlishares">1657903</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000467"
      unitRef="U_xbrlishares">8076985</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000468"
      unitRef="U_xbrlishares">7672560</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000469"
      unitRef="U_xbrlishares">5475978</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000471"
      unitRef="U_xbrlishares">22866246</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000472"
      unitRef="U_xbrlishares">22866246</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000307">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;span style="color:#auto;"&gt;December&lt;/span&gt; 31, 2019, the Preferred Stock consisted of the following (in thousands except for share data):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock issued&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;preference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock issuable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;conversion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,647,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,647,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,985&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,076,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,475,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,883,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;169,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000473"
      unitRef="U_xbrlishares">1657903</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000498"
      unitRef="U_xbrlishares">1647102</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000478"
      unitRef="U_xbrlishares">1647102</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">3008000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">3050000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000493"
      unitRef="U_xbrlishares">1647102</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000474"
      unitRef="U_xbrlishares">8076985</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000499"
      unitRef="U_xbrlishares">8076982</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000479"
      unitRef="U_xbrlishares">8076982</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">30593000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">30734000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_000494"
      unitRef="U_xbrlishares">8076982</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000475"
      unitRef="U_xbrlishares">7672560</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000500"
      unitRef="U_xbrlishares">7672556</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000480"
      unitRef="U_xbrlishares">7672556</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">73627000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">73728000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_000495"
      unitRef="U_xbrlishares">7672556</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000476"
      unitRef="U_xbrlishares">5475978</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000501"
      unitRef="U_xbrlishares">5469606</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000481"
      unitRef="U_xbrlishares">5469606</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">61705000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">61873000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_000496"
      unitRef="U_xbrlishares">5469606</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000477"
      unitRef="U_xbrlishares">22883426</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000502"
      unitRef="U_xbrlishares">22866246</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000482"
      unitRef="U_xbrlishares">22866246</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">168933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">169385000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001699382_20191231"
      decimals="INF"
      id="F_000497"
      unitRef="U_xbrlishares">22866246</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731"
      decimals="INF"
      id="F_000503"
      unitRef="U_xbrlishares">5321864</pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200731"
      decimals="INF"
      id="F_000504"
      unitRef="U_iso4217USD_xbrlishares">13.1533</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesDConvertiblePreferredStockMember_20200701_20200731"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">70000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200925_20200925"
      decimals="INF"
      id="F_000506"
      unitRef="U_xbrlishares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="C_0001699382_20190101_20191231"
      decimals="INF"
      id="F_000507"
      unitRef="U_iso4217USD">0</us-gaap:DividendsPreferredStock>
    <pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000508"
      unitRef="U_pmvpMember">4</pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass>
    <pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000509"
      unitRef="U_pmvpMember">2</pmvp:NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20211231"
      decimals="4"
      id="F_000510"
      unitRef="U_iso4217USD_xbrlishares">1.8517</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20211231"
      decimals="4"
      id="F_000511"
      unitRef="U_iso4217USD_xbrlishares">3.7266</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231"
      decimals="4"
      id="F_000512"
      unitRef="U_iso4217USD_xbrlishares">9.6093</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20211231"
      decimals="4"
      id="F_000513"
      unitRef="U_iso4217USD_xbrlishares">11.3121</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="C_0001699382_20210101_20211231" id="F_000514">Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $40,000 and the initial offering price to the public is at least $11.3121 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like).</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_20210101_20211231"
      decimals="INF"
      id="F_000515"
      unitRef="U_iso4217USD">40000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001699382_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20211231"
      decimals="INF"
      id="F_000516"
      unitRef="U_iso4217USD_xbrlishares">11.3121</us-gaap:SaleOfStockPricePerShare>
    <pmvp:ConvertiblePreferredStockConversionPrice
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_pmvpSeriesSeedConvertiblePreferredStockMember_20191231"
      decimals="4"
      id="F_000517"
      unitRef="U_iso4217USD_xbrlishares">1.8517</pmvp:ConvertiblePreferredStockConversionPrice>
    <pmvp:ConvertiblePreferredStockConversionPrice
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="4"
      id="F_000518"
      unitRef="U_iso4217USD_xbrlishares">3.7266</pmvp:ConvertiblePreferredStockConversionPrice>
    <pmvp:ConvertiblePreferredStockConversionPrice
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="4"
      id="F_000519"
      unitRef="U_iso4217USD_xbrlishares">9.6093</pmvp:ConvertiblePreferredStockConversionPrice>
    <pmvp:ConvertiblePreferredStockConversionPrice
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="4"
      id="F_000520"
      unitRef="U_iso4217USD_xbrlishares">11.3121</pmvp:ConvertiblePreferredStockConversionPrice>
    <pmvp:CommonStockDisclosureTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000277">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;8.&#160;&#160;Common Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share, and 5,000,000 shares of preferred stock with a par value of $0.00001 per share. As of December 31, 2021 and 2020, there were 45,433,684 and 44,777,818 shares of common stock issued and outstanding, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.&#160;&#160;As of December 31, 2021, no dividends on common stock had been declared by the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 and 2020, the Company had reserved shares of common stock for issuance as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future stock option grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,609,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,752&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,999,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,101,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</pmvp:CommonStockDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000521"
      unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000522"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000523"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000524"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000525"
      unitRef="U_xbrlishares">45433684</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000527"
      unitRef="U_xbrlishares">45433684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000526"
      unitRef="U_xbrlishares">44777818</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000528"
      unitRef="U_xbrlishares">44777818</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000529"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000308">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 and 2020, the Company had reserved shares of common stock for issuance as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future stock option grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,609,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,752&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,999,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,101,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231"
      decimals="INF"
      id="F_000530"
      unitRef="U_xbrlishares">4246007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="INF"
      id="F_000531"
      unitRef="U_xbrlishares">4090970</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000532"
      unitRef="U_xbrlishares">4951680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000533"
      unitRef="U_xbrlishares">4609725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000534"
      unitRef="U_xbrlishares">801464</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000535"
      unitRef="U_xbrlishares">400752</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000536"
      unitRef="U_xbrlishares">9999151</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000537"
      unitRef="U_xbrlishares">9101447</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000278">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;9 &#160;&#160;Stock Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2020 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) was approved by the board of directors on September 24, 2020.&#160;&#160;The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan is 4,406,374, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;(i)&#160;4,406,374 shares of common stock, (ii)&#160;five percent &lt;/span&gt; (5%) of the outstanding common stock on the immediately preceding December 31&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, or (iii)&#160;such number of common stock determined by the board of directors no later than the immediately preceding December 31.&lt;/span&gt;&#160;&#160;For 2021, the board of directors exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of 1,363,084 shares, effective as of January 1, 2022. As of December 31, 2021, there were 4,951,680 shares available for issuance under the 2020 Plan.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2020 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was approved by the board of directors on September 24, 2020.&#160;&#160;A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year.&#160;&#160;For 2021, the 2020 ESPP reserved shares were increased under clause (iii) by zero shares, effective as of January 1, 2022. On November 19, 2021, employees exercised their right to purchase 10,480 shares under the 2020 ESPP.&#160;&#160;As of December 31, 2021, 47,066 shares are issued or outstanding, and there were 801,464 shares available for issuance, under the 2020 ESPP.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2013 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2013, the Company adopted the 2013 Stock Plan (the &#x201c;2013 Plan&#x201d;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.&#160;&#160;Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.&#160;&#160;The Company chose to forfeit the remaining shares.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in 000s)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,609,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000571"&gt;7.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,343,334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options retired under 2013 Equity Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(237,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(807,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;807,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited / cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(608,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances, December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000572"&gt;6.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000573"&gt;6.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,668,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000574"&gt;5.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value of stock options granted during the year ended December 31, 2021 and 2020 was $20.03 and $3.34, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options vested and exercisable as of December 31, 2021 and 2020 is calculated based on the difference between the exercise price and the fair value of our common stock.&#160;&#160;The intrinsic value of options exercised in 2021 and 2020 was $18,534 and $245, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the total compensation cost related to nonvested service-based awards not yet recognized is $15,708.&#160;&#160;The weighted-average period over which the nonvested awards is expected to be recognized is 3.1years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#000000;"&gt;estimated&lt;/span&gt; the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.35% - 1.30%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% - 1.51%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.49% - 2.51%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50 - 6.44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.92 - 6.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.27 - 6.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.50% - 79.90%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70.70% - 77.60%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.07% - 72.69%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average assumptions used to estimate the fair value of stock options granted and stock purchase rights under the ESPP are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.04%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000607"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77.83%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-size:10pt;"&gt;Expected Term:&#160;The Company uses the simplified method to calculate expected term described in the SEC&#x2019;s Staff Accounting Bulletin No.&#160;107, which takes into account vesting term and expiration date of the options.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility:&#160;Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk Free Interest Rate:&#160;The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;span style="color:#000000;"&gt;tock-based compensation expense recorded under ASC 718 related to options granted was allocated to research and development and general and administrative expense as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,097&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;908&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924"
      decimals="INF"
      id="F_000538"
      unitRef="U_xbrlishares">4406374</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924"
      decimals="INF"
      id="F_000539"
      unitRef="U_xbrlishares">4406374</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20200924"
      decimals="2"
      id="F_000540"
      unitRef="U_xbrlipure">0.05</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101"
      decimals="INF"
      id="F_000541"
      unitRef="U_xbrlishares">1363084</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000542"
      unitRef="U_xbrlishares">4951680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924"
      decimals="INF"
      id="F_000543"
      unitRef="U_xbrlishares">400752</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924"
      decimals="INF"
      id="F_000544"
      unitRef="U_xbrlishares">801504</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20200924"
      decimals="2"
      id="F_000545"
      unitRef="U_xbrlipure">0.01</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220101"
      decimals="INF"
      id="F_000546"
      unitRef="U_xbrlishares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211119_20211119"
      decimals="INF"
      id="F_000547"
      unitRef="U_xbrlishares">10480</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000548"
      unitRef="U_xbrlishares">47066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000549"
      unitRef="U_xbrlishares">47066</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000550"
      unitRef="U_xbrlishares">801464</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000309">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in 000s)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,609,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000571"&gt;7.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,343,334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options retired under 2013 Equity Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(237,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(807,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;807,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited / cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(608,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances, December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,951,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000572"&gt;6.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000573"&gt;6.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,668,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000574"&gt;5.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000551"
      unitRef="U_xbrlishares">4609725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000557"
      unitRef="U_xbrlishares">4090970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001699382_20201231"
      decimals="2"
      id="F_000564"
      unitRef="U_iso4217USD_xbrlishares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">238792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000552"
      unitRef="U_xbrlishares">1343334</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandThirteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000553"
      unitRef="U_xbrlishares">237542</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000554"
      unitRef="U_xbrlishares">807180</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000558"
      unitRef="U_xbrlishares">807180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000565"
      unitRef="U_iso4217USD_xbrlishares">29.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000555"
      unitRef="U_xbrlishares">43343</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000559"
      unitRef="U_xbrlishares">43343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000566"
      unitRef="U_iso4217USD_xbrlishares">6.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000560"
      unitRef="U_xbrlishares">608800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000567"
      unitRef="U_iso4217USD_xbrlishares">2.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000556"
      unitRef="U_xbrlishares">4951680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000561"
      unitRef="U_xbrlishares">4246007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001699382_20211231"
      decimals="2"
      id="F_000568"
      unitRef="U_iso4217USD_xbrlishares">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">68506000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000562"
      unitRef="U_xbrlishares">4246007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001699382_20211231"
      decimals="2"
      id="F_000569"
      unitRef="U_iso4217USD_xbrlishares">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">68506000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000563"
      unitRef="U_xbrlishares">2668149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001699382_20211231"
      decimals="2"
      id="F_000570"
      unitRef="U_iso4217USD_xbrlishares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">52952000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231"
      decimals="2"
      id="F_000581"
      unitRef="U_iso4217USD_xbrlishares">20.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231"
      decimals="2"
      id="F_000582"
      unitRef="U_iso4217USD_xbrlishares">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20210101_20211231"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">18534000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandAndThirteenStockPlanMember_20200101_20201231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">15708000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001699382_20210101_20211231" id="F_000584">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000310">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#000000;"&gt;estimated&lt;/span&gt; the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.35% - 1.30%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% - 1.51%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.49% - 2.51%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.50 - 6.44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.92 - 6.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.27 - 6.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.50% - 79.90%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70.70% - 77.60%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.07% - 72.69%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000597"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000598"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000599"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      id="F_000311">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average assumptions used to estimate the fair value of stock options granted and stock purchase rights under the ESPP are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.04%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000607"&gt;0.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77.83%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="4"
      id="F_000606"
      unitRef="U_xbrlipure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="2"
      id="F_000608"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="4"
      id="F_000609"
      unitRef="U_xbrlipure">0.7783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000610"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000312">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;span style="color:#000000;"&gt;tock-based compensation expense recorded under ASC 718 related to options granted was allocated to research and development and general and administrative expense as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,097&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;908&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">1440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">836000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000615"
      unitRef="U_iso4217USD">1097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000616"
      unitRef="U_iso4217USD">606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000617"
      unitRef="U_iso4217USD">5340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000618"
      unitRef="U_iso4217USD">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">908000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000279">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;10.&#160;&#160;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income tax provision for the years ended December 31, 2021, 2020, and 2019 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the provision for income taxes included in the accompanying statements of operations for the Company is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax provision at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2021, 2020, and 2019, the Company&#x2019;s effective tax rate is below the federal statutory income tax rate of 21% primarily due to state income taxes, net of federal benefit and the Company&#x2019;s position to establish a full valuation allowance on its deferred tax assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax &lt;span style="color:#auto;"&gt;assets&lt;/span&gt; and liabilities are presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,511&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets recognized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Fixed assets and depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $159,886 and $97,665, respectively. As of December 31, 2021, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $154,972, $4,912, and $4,640 respectively. At December 31, 2020, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $92,805, $4,912 and $950, respectively.&#160;&#160;Federal net operating loss carryforwards of $27,515 expire beginning in the year 2033. &lt;span style="font-weight:bold;font-family:Arial;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;State net operating loss carryforwards begin to expire in the year &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;2033&lt;/span&gt;&lt;span style="color:#000000;"&gt;.&#160;&#160;&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards related to tax years after 2017 &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;of $&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,371&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;do not expire.&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also has federal and state research and development credit carryforward of approximately $&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,588&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; and $&lt;/span&gt;3,470&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;a&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;s of December 31, 2021&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectfully&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The federal credits will begin to expire in &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2034&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; if not utilized.&#160;&#160;The California state credits carryforward indefinitely and the New Jersey state credits expire starting in &lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company accrues interest and penalties related to unrecognized tax benefits in the Provision for income taxes line item in the statements of operations and comprehensive loss&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;font-weight:bold;"&gt;. &lt;/span&gt;&lt;span style="color:#auto;"&gt;As of December 31, 2021 and 2020, the Company had not accrued any interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the ending balance of $1,654 and $877 of unrecognized tax benefits as of December 31, 2021 and 2020, respectively, were recognized, none of the recognition would affect the income tax rate. The following table summarized the activity related to the Company&#x2019;s unrecognized tax benefits:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits, beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits, end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#x2019;s tax &lt;span style="color:#auto;"&gt;years&lt;/span&gt; 2013 to 2021 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000313">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The income tax provision for the years ended December 31, 2021, 2020, and 2019 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">23000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000621"
      unitRef="U_iso4217USD">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000622"
      unitRef="U_iso4217USD">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000623"
      unitRef="U_iso4217USD">23000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000624"
      unitRef="U_iso4217USD">6000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000625"
      unitRef="U_iso4217USD">8000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000626"
      unitRef="U_iso4217USD">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000627"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000314">A reconciliation of income tax computed at the statutory federal income tax rate to the provision for income taxes included in the accompanying statements of operations for the Company is as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax provision at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000629"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000630"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000631"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000632"
      unitRef="U_xbrlipure">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000633"
      unitRef="U_xbrlipure">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000634"
      unitRef="U_xbrlipure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000635"
      unitRef="U_xbrlipure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000636"
      unitRef="U_xbrlipure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000637"
      unitRef="U_xbrlipure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000638"
      unitRef="U_xbrlipure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000639"
      unitRef="U_xbrlipure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000640"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000641"
      unitRef="U_xbrlipure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000642"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000643"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000644"
      unitRef="U_xbrlipure">-0.37</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000645"
      unitRef="U_xbrlipure">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000646"
      unitRef="U_xbrlipure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000647"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000648"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000649"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000650"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20200101_20201231"
      decimals="INF"
      id="F_000651"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001699382_20190101_20191231"
      decimals="INF"
      id="F_000652"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax &lt;span style="color:#auto;"&gt;assets&lt;/span&gt; and liabilities are presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;font-weight:bold;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,511&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets recognized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Fixed assets and depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">45231000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000654"
      unitRef="U_iso4217USD">27511000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000655"
      unitRef="U_iso4217USD">1587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000656"
      unitRef="U_iso4217USD">748000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">4593000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">2414000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">1033000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">830000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pmvp:DeferredTaxAssetsOperatingLeases
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">3175000</pmvp:DeferredTaxAssetsOperatingLeases>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">55619000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">31503000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">52728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">31458000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">2891000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">45000</us-gaap:DeferredTaxAssetsNet>
    <pmvp:DeferredTaxLiabilitiesOperatingLeases
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">2854000</pmvp:DeferredTaxLiabilitiesOperatingLeases>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">37000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">45000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">2891000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">45000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">159886000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">97665000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">154972000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">4912000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">4640000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">92805000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">4912000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">950000</us-gaap:OperatingLossCarryforwards>
    <pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">27515000</pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount>
    <pmvp:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000683">2033</pmvp:OperatingLossCarryforwardsExpirationYear>
    <pmvp:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000684">2033</pmvp:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="C_0001699382_20210101_20211231" id="F_000685">Net operating loss carryforwards related to tax years after 2017 of $132,371 do not expire.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <pmvp:OperatingLossCarryforwardsAmountsDoNotExpire
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">132371000</pmvp:OperatingLossCarryforwardsAmountsDoNotExpire>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">6588000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">3470000</us-gaap:TaxCreditCarryforwardAmount>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000688">2034</pmvp:TaxCreditCarryforwardExpirationYear>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001699382_srtStatementGeographicalAxis_countryCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000690">2022</pmvp:TaxCreditCarryforwardExpirationYear>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001699382_srtStatementGeographicalAxis_stprNJ_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000689">2022</pmvp:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001699382_20211231"
      decimals="INF"
      id="F_000691"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001699382_20201231"
      decimals="INF"
      id="F_000692"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">1654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000316">The following table summarized the activity related to the Company&#x2019;s unrecognized tax benefits:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits, beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to prior year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to current year tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits, end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;"&gt;&#160;&lt;/p&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20191231"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">543000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">43000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">5000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">734000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">329000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20211231"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">1654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001699382_20201231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">877000</us-gaap:UnrecognizedTaxBenefits>
    <pmvp:IncomeTaxExaminationPeriod
      contextRef="C_0001699382_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000705">P4Y</pmvp:IncomeTaxExaminationPeriod>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000280">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;11.&#160;&#160;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s convertible preferred stock does not participate in losses. The Company excluded all outstanding stock options and restricted stock awards at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,644,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of shares - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,137,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,364,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000317">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,866,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2013;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,246,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,090,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,644,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000706"
      unitRef="U_xbrlishares">22866246</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231"
      decimals="INF"
      id="F_000707"
      unitRef="U_xbrlishares">10800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000708"
      unitRef="U_xbrlishares">4246007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000709"
      unitRef="U_xbrlishares">4090970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000710"
      unitRef="U_xbrlishares">2767868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_20210101_20211231"
      decimals="INF"
      id="F_000711"
      unitRef="U_xbrlishares">4246007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_20200101_20201231"
      decimals="INF"
      id="F_000712"
      unitRef="U_xbrlishares">4090970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001699382_20190101_20191231"
      decimals="INF"
      id="F_000713"
      unitRef="U_xbrlishares">25644914</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000318">
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(57,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of shares - basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,137,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,364,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20210101_20211231"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20200101_20201231"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001699382_20190101_20191231"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">-25352000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20210101_20211231"
      decimals="0"
      id="F_000717"
      unitRef="U_xbrlishares">45137656</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20200101_20201231"
      decimals="0"
      id="F_000718"
      unitRef="U_xbrlishares">14364475</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001699382_20190101_20191231"
      decimals="0"
      id="F_000719"
      unitRef="U_xbrlishares">3035243</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20210101_20211231"
      decimals="2"
      id="F_000720"
      unitRef="U_iso4217USD_xbrlishares">-1.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20200101_20201231"
      decimals="2"
      id="F_000721"
      unitRef="U_iso4217USD_xbrlishares">-2.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001699382_20190101_20191231"
      decimals="2"
      id="F_000722"
      unitRef="U_iso4217USD_xbrlishares">-8.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001699382_20210101_20211231" id="F_000281">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"&gt;12.&#160;&#160;Related Parties&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has consulting agreements with two members of its board of directors. The total of consulting fees paid as of the years ended December 31, 2021 and December 31, 2020 were $110 and $112, respectively. In May of 2021, the two members of the board of directors were awarded 5,781 options of company stock each, as per their updated Scientific Advisory Board agreements. There were no amounts owed under the consulting agreements as of December 31, 2021 or December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fiscal year ended December 31, 2020, an investor provided $65 of financial consulting services to the Company. The Company has paid the entirety of the fees as of December 31, 2020. No amounts were paid or owed to the investors as of the year ended December 31,2021.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pmvp:NumberOfConsultingAgreementsMembers
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231"
      decimals="INF"
      id="F_000723"
      unitRef="U_pmvpMember">2</pmvp:NumberOfConsultingAgreementsMembers>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210101_20211231"
      decimals="-3"
      id="F_000725"
      unitRef="U_iso4217USD">110000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20200101_20201231"
      decimals="-3"
      id="F_000726"
      unitRef="U_iso4217USD">112000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <pmvp:NumberOfConsultingAgreementsMembers
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531"
      decimals="INF"
      id="F_000724"
      unitRef="U_pmvpMember">2</pmvp:NumberOfConsultingAgreementsMembers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531"
      decimals="INF"
      id="F_000729"
      unitRef="U_xbrlishares">5781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20211231"
      decimals="INF"
      id="F_000727"
      unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20201231"
      decimals="INF"
      id="F_000728"
      unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20200101_20201231"
      decimals="-3"
      id="F_000730"
      unitRef="U_iso4217USD">65000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231"
      decimals="INF"
      id="F_000731"
      unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_20211231"
      decimals="INF"
      id="F_000732"
      unitRef="U_iso4217USD">0</us-gaap:DueFromRelatedParties>
    <dei:AuditorName contextRef="C_0001699382_20210101_20211231" id="F_000037">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001699382_20210101_20211231" id="F_000038">Philadelphia, Pennsylvania</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MW1^59 G=R^W]S19D06HG$=.AF)\EZ0B:3LNI7\MW&J =-.O$X#B.X32*CM7
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M%#,$FQ\(%L>;;)/**;H$[63K!YG(Z;Z?\V@_YU$3E5BB7K*4Y3$'3,B@\0>
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MJI@Z8P<RS$E=JB>^_8ZMGI'A2WDI[1.V;:SG0%I+Q:L6K"NH*&O>Y*T]ASV
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MRT+?:RA,@-[/.5<[PR3H;LKH-U!+ P04    " "!.F%4*Y65A=8&   ['
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MXI5]W-"LH,( ].]KSM7KBQF@NR^\^ ]02P,$%     @ @3IA5!J5OY:9!P
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M=D_5D,O(Y((-DDYM&T$IQ??1%AB#(G9$=I8F'37"04M>ZD#[2]GI*,U8_.,
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M[Q:S93%=+=&G7P0S1CE8C =9+9%N99['F(/#$>ZP?'LG06P?*O*<G+)H,X"
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MVNB:TR49.]-#[I%@0JH!+B4,XI/6]:WSX@%:>KMUR)#?D*W[A2!$]:4@/_)
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MI.N1M+([5!QM'ZM"/,X"8B-A&+_#.]_8-BL#O,,+\3UW-F: HZ0,TUI&(WZ
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MNYBK?+CFKMI].N!&>[8AB+/'$^5!/MPC8J097"3BR,"1Z2)!6H5).:#<;0H
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M=RBUL==$A_,2DQ@]><,-_K+C=:-I8(X-X^'OV/@OY]MC$XG<>E"C=Y5-;]S
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MJ2QU%2_6U,91.P,Z7REE]XIS</@QS'X!4$L#!!0    ( ($Z850H.[)S90(
M "8%   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*5436_;, R]^U<(
MQHY!_)DF*9( 2=MA.Q0+VGT<AAUDFXZ%RI(G,4W[[T?)B9<-:RZ[6"+%]QY)
MBUH<M'FR#0"REU8JNPP;Q.XZBFS90,OM6'>@Z*36IN5(IME%MC/ *P]J993&
M\574<J'"U<+[MF:UT'N40L'6,+MO6VY>-R#U81DFX<GQ('8-.D>T6G1\!X^
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M>LC N  ZK[7&D^$$AJ=Q]0M02P,$%     @ @3IA5!(W?.DR"0  (Q@  !D
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M ;-._%R*=W6IX,5X'@F_422@DN6C4 \JK;W*A!2E*5-9IBJ7RUP)T\G(289
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MU<NE5X0<@"#&')(\W9-AG*20,3<?S$=G\\$/XB,"8.'1<*,2+C<Z@M$$[KN
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M8!;.!K,HF(=3_%G,$^]YGW^ZG,V">#(#)Z/9(E@F"5TM@P0\\5Y_*MG?Z_R
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MRL;%-.H/T7G@=!O:]48[:O[!K.FU1>,=:'VKM3L/?(#A_5[_"U!+ P04
M" "!.F%4;#3T+3@*  !:&@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6S%66UOV\@1_LY?L7"3P@%HFF\2)<<Q8"?.78K>Q;!S.1R*?EB12VD;OBB[
MI!7?K^\SNR1%V9*3%@4*!/&^S>R\/#,[0YUO:O5%KX1HV+>RJ/2;HU73K,].
M3W6Z$B777KT6%7;R6I6\P50M3_5:"9X9HK(X#7U_>EIR61U=G)NU&W5Q7K=-
M(2MQHYANRY*KARM1U)LW1\%1OW KEZN&%DXOSM=\*>Y$\]OZ1F%V.G#)9"DJ
M+>N**9&_.;H,SJYB.F\.?)9BHT=C1IHLZOH+33YD;XY\$D@4(FV( \>?>_%6
M% 4Q@AA?.YY'PY5$.![WW-\;W:'+@FOQMBY^EUFS>G,T.V*9R'E;-+?UYF?1
MZ3,A?FE=:/,_V]BS27C$TE8W==D10X)25O8O_];9840P\P\0A!U!:.2V%QDI
MW_&&7YRK>L,4G08W&AA5#36$DQ4YY:Y1V)6@:R[NFCK]PFX*7IV?-N!'JZ=I
M1WME:<,#M$'(?JFK9J79=96);)?!*009I E[::["9SF^$ZG'HL!EH1\&S_"+
M!NTBPR\ZQ$_JM*AUJP3[F+.W=0DL:V[@<"L*WH@,B[K1[&[%E2#O9NR&/P!T
M6/O'Y4(W"K#YYS.2Q(,DL9$D_J_L_#SMG&VIR3(^N_[:RN:!?:A22 I4VZU/
M*_'<]G&#_;_^91:&_FMSC%;-/'C]BFVX9GR]5O4];+!X8'1X47.5L3IGF52(
MHEII!LO=B74CRH50+(R-IWQO>[6YB;C(3&B&I&$8+16O&F(D!Y&T4:E>DS.T
MRZJZ.OG:\D+F$O<_VK13DDZDTKI/4;1A2PGX2*;-0-16<N\ZWT 7;+35P:V4
MZ]6)!8%=8KS*H#OI@H& 5>]Y ?F[VUE3&^T(5[QZ(%,&R6O8*,]E*A0XBG)=
MU ]"8+@U(3%-H1?R!JRBK?&JUE@4)M($16*"0V4)5:V0$GI)7A0/I)I0Y"6R
MKM2ZY3 J],J$-?;6#U*SV(W]J1LE\-1F)=,5L2\*MA#D"F1Q* N;K"D_&N?S
MXK#S7?+^WWC5(GNS+DB--H*#\;!!U."<-T*YN 4G&"_K%F83Y.'>:@4N-Y@X
MEJ^V8AY0W\4I',L).6NA"$0,XBA:QKIN(<#6A#N&RP0$0>9\%M95S2@=D $A
M+AV292DR@$W XH0[3*HE0X*RT(\"KXNUSL5]C+8J7<&JCR/RN5-/ O/Z[N;F
M?Q28ES!W Z/C;.S[;C()#P%L Z?],,J K#5$_S^!:D"0UM;A!*&9'[@3_SL
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M[]*TK,152-?+H'[$<)VF$_@9'#[7"#>J:9G\^MLOBRR=OS90*OF(VO*-0""
M+6J-%5 !E0]0*30@E866D47)6V81N 1!L&@FQWB 3Z7H*(W A "ZQL8R6='A
M#5"J=;?) "W2I:0CY*4=X[ ]TQ7M64!6UHXP5Q4@F6ZU:L!2F)+"=);Y*ZFV
M4''1.7])(L5!I/$BF27P#=DZ158YSX:<?*1:B0JU >I*'K6/9$A3Q4OF #=8
MLLXXE4Z.XT]V#?6(3E10LT>D#VFDOB M/_<TJ#T ;K?4+R;!NP'X;V1ZJ&N@
MJL1F0_RH,@-7F>Z3T">]"&Y.G/XK-F8'J[/ 9RQ]/?ZS+%K,9E%6S()[IC7Q
M,4YNV^FRIG[S@^Z?G-,D6B0)A?]N,Z:(&].Y/-+Q'^4Q*%RH*$GF-$HNDNAB
M3AJB^6Q.-!;!9V69>-YF&LV*(KI(B_]\.A^'[ :_!J^F%(>DGKEQ7D1%D?1C
M@L^G&8WO?2?%ZIR2I.EA -EY7*H67Q@&SETCYJ57-A104$RC-)]'L^DL2(LH
MGQ'R?!KD49)/24L^4C@JL.=@B$@ZR18#I<F!W&*23X,S>*Y5Q$?-MT&]\T^,
M2W@G;=^'Q]7Q%;OJF_=W\_X)_,#TCE/B!&[)-9G,IR'H_EGI)U:UOI5OE*6'
MP0]K>HE1.P/:WRIE#Q,78'S;U]\ 4$L#!!0    ( ($Z850;ZE0=+ ,  &@'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)U5P6[;, S]%<+8,; =
MI]V*(@G0M!O60X>B[;;#L(-BT[%06_(H)5[^?J2<N%G3%L,NMD21C^0C*4T[
M2X^N0O3PNZF-FT65]^UYDKB\PD:YV+9H^*2TU"C/6UHEKB5413!JZB1+T_=)
MH[2)YM,@NZ7YU*Y]K0W>$KAUTRC:+K"VW2P:1WO!G5Y57@3)?-JJ%=ZC_]K>
M$N^2 :70#1JGK0'"<A9=C,\7)Z(?%+YI[-S!&B23I;6/LKDN9E$J 6&-N1<$
MQ;\-7F)="Q"'\6N'&0TNQ?!PO4?_%'+G7);*X:6MO^O"5[/H+(("2[6N_9WM
M/N,NGU/!RVWMPA>Z7G?"ROG:>=OLC#F"1IO^KW[O>#@P.$M?,<AV!EF(NW<4
MHKQ27LVG9#L@T68T6814@S4'IXT4Y=X3GVJV\_,[K)7' FX5>8UNFG@&E:,D
MWP$L>H#L%8!Q!C?6^,K!1U-@\3= PM$,(67[D!;9FXA7F,<P&8\@2[/Q&WB3
M(<5)P)O\0XI;>"!EG HMX>#'Q=)YXMW/-_R<#'Y.@I^3_Z?R30"9OW/7JAQG
M$0^80]I@Q/S&\ P9'BJ$2]NTRFRA4@YRSH6[4)L5J!4A\M!XQXWD*_"=A0:;
M)9(#6X)F^=(J*F13:.+9L.3B@.BM5[7(#^!*9'>MT@6H8.]9;XN*P5"J#5RK
M #[4"Y0YEJ;0(2&\&X_3<,Z+;,0C[5H,0UEO8[@V<*.VXD-@1L'3L^!%=!Q\
MCZTZEG- IZ,/9V.P;5_?D$S/$T]2_@BH\FHDN;0<'>-I@G5;!'+O<\VTZ5+G
M<%%LM+.TA47P]L1I((J]!9?&@FKL6JBV'0.LF9$ ^DH]>@:/&;-T3%@,5VL2
M>X$KM<NY,L+[*[2GG),!;3;(:1*T9#=:]-Z]/Q6?I3;*Y)HQ#B*3_M(YE]?;
MX&774/%1=X7RBX;00^BW^UJ$YG@Y*T[@RQ,]@:X P\$%KG8^]Q&[9^WU0II"
M50POC6ER</LU2*MPQ\M0L._^(ARDPS-RT=^>3^K]&W2C:*6Y;VHLV32-/YQ&
M0/V]WF^\;<-=NK2>;^:PK/@I1!(%/B^M]?N-.!@>U_D?4$L#!!0    ( ($Z
M850HZ/XL9"$  "EJ   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+5=
M6X_;QI)^WU]!S 8+&]",1W+L.'$28#R.S_$B%\,3YSPL]H$26U+'%%MADS/6
M^?5;7U7UA1Q*X^2<!8)8$MG=U=5UO_1\>^?:CWYK3%=\VM6-_^YLVW7[;YX\
M\:NMV97^PNU-0T_6KMV5'7UM-T_\OC5EQ8-V]9/%Y>7S)[O2-F???\N_O6N_
M_];U76T;\ZXM?+_;E>WAE:G=W7=G\[/PPWN[V7;XX<GWW^[+C;DQW8?]NY:^
M/8FS5'9G&F]=4[1F_=W9U?R;5PL>P&_\9LV=SSX7V,K2N8_X\K;Z[NP2$)G:
MK#I,4=(_M^;:U#5F(CC^T$G/XIH8F'\.L[_AS=-FEJ4WUZ[^AZVZ[7=G+\Z*
MRJS+ON[>N[N_&]W0,\RW<K7G_Q=W\N[SIV?%JO>=V^E@@F!G&_FW_*2(R :\
MN#PR8*$#%@RW+,10OBZ[\OMO6W=7M'B;9L,'WBJ/)N!L@U.YZ5IZ:FE<]_V-
MG$;AUL6-W31V;5=ETQ57JY7KF\XVF^*=J^W*&E\\"I\>?_NDHZ4QP9.5+O-*
MEED<66:^*'YR3;?UQ0]-9:KA!$\(Y@CX(@#^:G%RQM=F=5$\G<^*Q>5B?F*^
MIQ$13WF^IT?FF]KQ_UPM?=<2X?SOB06^C M\R0M\>62!5Z6W'GA^UQIOFJX$
M54YA\N0TX-)O_+Y<F>_.]IBHO35GTW,7OVX-4?W*[?9E<\#&UK8IFY4MZ\+3
M*X:8J_/%MKPUQ=*8IJ#Y]F5KJL(V/*ZMZ&U#!-EMBP^-[>C)#<;Y8F,:TY9U
M?<![9H\G9<+?OK6TRKX&S?S7?[Y8+"Y?_NWJZAU_G+]\?%%<-0=PM&D-YJ?5
MNBV!730.<W>N*/=[.H%R69MBTUN!@O:W,R!->LYC\:'##OMNZUJ+/=-&L%!1
M^F)-P%0Z=4[-M(&F*MO*%]>N8FIG5 4XKVZN Y@%O3@]\L.^(BQD8S[$,70$
M6/!-1/3D!*\<_1/'O[FZ>95P\Y</#2*NV#@,63G"6-M 7%D_*^ZV=K7%CS1Z
M7_,! D@2XK7]I^R?X"Z]-S0S=HVGGA[X=;D*CVM;+FUM._ %WB$(=[83:!3-
M1# $*PD3VG)+YTFCEKTG^O5>]G4MNR+H/<VW8XHB_=*6C)^M)6E'HS&[I5GW
MK?-[$MZT7DOP],O?Z0L?O_4?:5OF$ZDFK^#TV'%'6H@!7+?FCYY (P(E$L,!
M&*!H"=   MY1H)>6J&ZU;5SM-@?ZL2*9VQXNBA,<_RQR_+.3'/]!</"#[^P.
M6)]B]C\W V-13CR>VR1]T.;HO*&T;7<0#F;. %XLR0A2(0TI7;P,C.[*CZ8P
M<14@E,BAW^VQ"*BE[(IRO6;\,^7L7<M,OP-N_8A\QJ126;^JG>];W@SHD(X;
M*Q\;(ZLPDRE#36X2XZ9 :<VM:7I=/%))U;>@L@0_BRK36E<-J1-*WC,%'L<(
MH5[(E01(S6NTEH79W99XLKPM;<WB"^/HW=N2ENF)+HF?7*L(M1UQ<&T)6!9Z
M2^9([QH>2-(+(H[ 6MEVU>]HVS0]\5&NI8_#1Q(2=H^IDG0]0B>KNJ_,C!BU
M8S8C&1Q9LW.S OJD;$E\\$$2K+7;,]6LG.^("4E4M;VI'GA/CPJRIQ+ZM>ED
M9E'FK$O;$JYJG!U3RFY'R",TKS[.0#>WQ.(6V-FS!@!+\T.>@#^=X_!8.&%N
MYA%2-ZNNIVT3B&2J>4BG&D2YAA(!^EK+JFS=NAV!X7S&"D(9M6DVQ$&@1;)(
M>;5U7^/<.V4@$;'8P_4OO[U]?3[_NB!:JLS.KFBEEHZ"%G MY$OX9HG:(-Q(
M5D8Q.8M TEHJ&7&<O&(\/\)$9?%@IN<'2E9LSD1X]Z1!2=AM22 2YDBL,)UV
MV*G_C$,%WY"J< =CSL.QZ;/*T#H5<\"Z[\#3V01!5-"O6S*'"80HEV>Y!"?
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M]W9ZP68RK,=-?2#Q4]>?+_MG.I$3S3<;JAK:H-]"Q 3SX+0Z3&9U:[K62<@
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M]M^[ OT:4160XMD243^K)CUH03FD%30JQU$?$KT;"_^#[/HP%Y\KY.!.0O)
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M$Y0<8RR;L?^'BQMZN665>+A71E@.2_8F#N4XFZ=@#G.\@'2/E8N#-36GV/E
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MA!M70C^9W'43"MWD!J02+1&L$<(![B4ZI+?=55)6$>U#W4<K(>MT.XY&2R(
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MR/R\7"73L%#WMB[O^#S:<(<A;YE#.)G"8 ]1<UXQ6ZLO#STX 6<02^2%LX3
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M(C2\R5.?J&%1#0<C.[<<#M+@JG'J&7<[*!N _J.4YGJP":9_B_5/4$L#!!0
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MSBQQK(*R#GB^E=(<%S;!,*@7_P!02P,$%     @ @3IA5$9HW3N)!0  '@X
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULS5=M;]LV$/[.7T%XRY
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M+N],G3WP>2DK?OQ!WI>@3\['!@W3YW'6&;EJC?A[C'@^?U=79J7YK,HA_];
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MQIB2?;F68V?,;]Z.]>RXMK#UI8]ZV0CAC]E[^41#;,>V$G#+6(29%UJ#]='
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MN<!O*3 D@,]G6KOM#1EHOLXN_P502P,$%     @ @3IA5*USJ$=6 P  =@<
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M1ALR2%0OLT<%430C*[J(@HL9Y1#,IC.B,?<^2\/$RSYY,,VRX"+.3G1 /G9
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M!?!^*X1^'IBK6_O/@,5_4$L#!!0    ( ($Z8521^R*'^P0  ,P2   9
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M[1;1?XJ>B\K4E9H7>JANK4MB7<QUW&7A:#Q*W=UA=0:"?&_<![T"C'K Z%V
M$A10F9<$3Q8OQPXO?8-76".YTH-'W?K&!S31*(R.D$^#_'@<#R/'/7+\)O(/
M78+$KM""<T97C#/-8) R/@$8)T>, R%GBIKTA,F;A/="4SY$DYR<X'42'!_S
M:5!T[85'1.Y!(S!-^#N5&U8KPF&-,N]JA/G(MK&U$RT:VQM60F.GL<,2OP4@
M30"NKX70+Q/3;OJO2_8/4$L#!!0    ( ($Z852KT=['>0<  -D@   9
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MIH'(31#YM:,+&L>Y)<GQ3V5TTLR9#SR\KJW_5C@OG7DAG"ZR^&<4BO7UQ)N
MD"[)-A8/V?X/6CE4  99S(O_8%_U-2<@V'*1)=5@29!$:?E-WJI ' Q ]L
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MZ[M=5'5/U5%\;2N!)ZYT76&;2UTK@C +]/R<<[7OF \TU>?D-U!+ P04
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ME3U ^S,IS6YB/U ]N?J_ %!+ P04    " "!.F%4"54Z10T#  "A"0  &0
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M@3  O5]RKG83<X![/=-_4$L#!!0    ( ($Z850H7A5N'0,  /D+   9
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M7::1'>CU:)\VVJ=6GF\R ]XFUP[KSGMM![;D7<E],^Q,[JR1.[/RK#-,]_K
MHP><E[CR'[ER0)C&K?>>G>XBG'36H0_I=7:^!QG,6I!GU?"]9PO@6<ENTA2,
M_3JY SN_ 3U<7:U=OQ,7O1U75<$]\40%\+WQED(=\)+*REPTLXU_O3:N[<7\
M2OM:X[6>:2I3?(OYGE"!<D@5I3>8J,N95SZS&DAV,,YKQZ3R<>8Q4]X<N%Z@
MWJ>,R:>!#M"X_>5_4$L#!!0    ( ($Z8518$W3M* 4  -P6   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;+58VV[C-A#]%<+8 KM &HN49,M!8B")
MNVB*O6'3;1^*/C#2V!96(EV2CI.B']^A9(MV)-/9!'Z1)7GFS.%P>(;B^4JJ
M[WH.8,A#60A]T9L;LSCK]W4ZAY+K4[D @?],I2JYP4<UZ^N% IY53F719T$P
MZ)<\%[WQ>?7NBQJ?RZ4I<@%?%-'+LN3J\0H*N;KHT=[FQ==\-C?V17]\ON S
MN 7S;?%%X5._0<GR$H3.I2 *IA>]2WHV"2/K4%G\D<-*;]T3.Y0[*;_;AYOL
MHA=81E! :BP$QY][N(:BL$C(XY\U:*^):1VW[S?H[ZO!XV#NN(9K6?R99V9^
MT4MZ)(,I7Q;FJUS]"NL!Q18OE86NKF15V\9HG"ZUD>7:&1F4N:A_^<,Z$5L.
M2;#'@:T=V!,'&NUQ"-<.X7,=HK5#E>I^/90J#Q-N^/A<R151UAK1[$V5S,H;
MAY\+.^^W1N&_.?J9\8U(90GD=_X FOQ,+K,LM_/!"W(CZJJRL_-V H;GA7Z'
M)M]N)^3MFW?G?8/A+4@_78>ZJD.Q/:$H(Q^E,'--?A$99+L ?>3=D&<;\E?,
MBSB!])2$](2P@-$.0M?/=P\ZW"?/=J<CSVC"9BK""B\\.!7D&O.4BQF(])'\
M]0'MR(V!4O_MB1(U4:(J2K0GRGO(0.'T:L/-TDCU2/(ZKL&XBAOHFE@_)*.G
M0?!35_Y?Z#?Y<;^=7,1-+F(OT"?45510'#4FFQ12:Y)RI1ZQ\%=<99K<P2P7
MQ$@"#XM< :8*)SL,NU)41QI4D:S8WH_9,*9Q$&!EW7=P'#0<!Z_B>$(R280T
M&XJ\E$MANA@.6@QIR,(AW4MQV% <OH8B,@2=JGQAI:2+V*O0-7:? LLVL]-D
M:_@1N-*$3PTHNS*'1$[)&QSI"0YU-U>GGA)*FK$G7G8W N. 1HJ*8"_FA<E1
M2'F:JN53B:L'F[1FP66_7C0^BQV.HX;CR,OQFU"0RIG(_[59PA3=@8!I;G07
MOU&[2@9QM%TC-<O:+MZR2X;#EMFD#1='X=Z*HX%K6X%W3)\QV<UT=_8BOS]6
M1FC+([*7V%X&=;7@):D4O>H*'9UEE_!6GZ7/T5T?%G-8[(B=@KJ&1,-7+;W.
MO(?M HI'23)HE]#:=+N&1L/!8+]F4M?DJ+]%?/8)1K7ZZXW-WNHYT(%:36"7
MIVM U-^![!2F"G#3]40R'<=.>GY4I!?YZ+G>0_W-Y\9M#>"!X_:SSAHF-Y>=
MZG8 +ZS5V<?--1WJ[PN;C<Q_Y"MH1$WGA(N,3. >/V86^&EBZ@529=<;TFD]
M38ZY[IQ>4[]@7W=5Q/[&3MLB.XB3I&/!M44[C*QH[UEOS,DQ\\OIK6GM''>1
MG$XR>L0<,Z>AC!U5(0[ 'U (YC28^37XAY?@ ;SHX!)D3F697P:K6<<%^ D_
M[W\#I>'1!^M$D<7'+ &G;NQU6^O.[';LHN-H-&3MU;8VW6EO+ GVMS?FM(_Y
MM>^%;>, *NYUF"^Q3B>9?U.\J8MK7N1(3>3<!^MDD8V.6!>A$[/0+V8OJ8LU
MY'9=1"/:415KP]ACN$O;*6?HWV&^L"@.H!XHBM );NA7Q$U1?( '3*N1XH1\
MY%KS=+[48+P=.MPZ0CGF&4KHE"_T*]^+2B1JE\@@"CI*I&TXBCNZ='_KV*\$
M-:N.3Y&(W2?4AVC-V^:(]K(ZF'SR_HJ>3>J#5@=3G_M^Y&J6"TT*F")D<#K$
MNE7U46K]8.2B.ER\D\;(LKJ= \>=F37 _Z=2FLV##= <:(__!U!+ P04
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M9JN:(UIS8^2F/N4\28-GIOIRC<=:4-8 WR^E-*\W]N#4'91G?P!02P,$%
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M.^<1Y5!58[[:&%FX2;F0AN:N6Z;T,J*R!G2_E-)L-M9!\]:._P!02P,$%
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M&V%6NNG$FHE5E>]-;I7%3L</"^Q>0;L ?+Y1V'ZT$[=!UP_/?P-02P,$%
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M*HT!W*^%T(>-^4 SG"?_ %!+ P04    " "!.F%4]P;H@$0#   Z"P  &0
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "!.F%4R<GI&I8$  "G)@  #P
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MLVKK>@9EW\P7*ZOM>U;;=\0^_@-02P,$%     @ @3IA5!,G[+KO 0  I2(
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MVV2SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U
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M\];4W7L^&WX@N7H%4$L! A0#%     @ @3IA5 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "!.F%4
M:3%7 N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "!.F%4F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ($Z850Y-R0>,P<
M ,P<   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "!.F%4?<N#9T,%  "#%   &               @(%W
M#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ @3IA5!CA
M_+2V @  .@D  !@              ("!\!0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( ($Z853[A2Q#F@0  ,L0   8
M  " @=P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "!
M.F%4-!42TI4&  ">(0  &               @(&L'   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ @3IA5(8\ZVV+ @  -0<  !@
M         ("!=R,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( ($Z850KE96%U@8  #L<   8              " @3@F  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "!.F%4&I6_EID'  !Z$0
M&               @(%$+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ @3IA5.?$E34C(   B&   !@              ("!$S4  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ($Z8531<X\2B00
M )$-   9              " @6Q5  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ @3IA5"_Z?93? @  ) 8  !D              ("!
M+%H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "!.F%4
M*#NR<V4"   F!0  &0              @(%"70  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( ($Z8502-WSI,@D  ",8   9
M      " @=Y?  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ @3IA5%H15<?."   &QD  !D              ("!1VD  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "!.F%4!3A-W6@#  #+!P
M&0              @(%,<@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( ($Z851L-/0M. H  %H:   9              " @>MU  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ @3IA5. _FA9#
M"   CA8  !D              ("!6H   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "!.F%44[H-&ZH#  #G!P  &0
M@('4B   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ($Z
M850;ZE0=+ ,  &@'   9              " @;6,  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ @3IA5"CH_BQD(0  *6H  !D
M         ("!&)   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "!.F%4V)-?HWT#  !&"0  &0              @(&SL0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ($Z850^;]C+L (  *8%
M   9              " @6>U  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ @3IA5"OF]G]Q @  )@4  !D              ("!3K@
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "!.F%4&XBZ
M6&\$  "O"P  &0              @('VN@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( ($Z853/M'C0ZP(  #D&   9
M  " @9R_  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M@3IA5.JPW2JS @  M 4  !D              ("!OL(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "!.F%41FC=.XD%   >#@  &0
M            @(&HQ0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( ($Z852X1%?F204  *D-   9              " @6C+  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ @3IA5*USJ$=6 P
M=@<  !D              ("!Z-   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "!.F%49O#"U4T$   8$   &0              @(%U
MU   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ($Z8521
M^R*'^P0  ,P2   9              " @?G8  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ @3IA5#?W;<U\!   J1D  !D
M     ("!*]X  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ($Z852KT=['>0<  -D@   9              "
M@4SO  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ @3IA
M5)KLNU%5 @  ;P4  !D              ("!_/8  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "!.F%4RE>]5;8"   /!P  &0
M        @(&(^0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( ($Z852FT?VS?0(  &@%   9              " @77\  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ @3IA5!IKV$G@ @  [@<
M !D              ("!*?\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "!.F%45<"HS_@'  #-*0  &0              @(%  @$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ($Z850WL?L^
M<P0  $(6   9              " @6\* 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ @3IA5)BU\NG4 @  \0@  !D
M ("!&0\! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "!
M.F%4=?5R +("  "F!P  &0              @($D$@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ($Z850D.UBY004   H7   9
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M970U,"YX;6Q02P$"% ,4    " "!.F%4':$IAWX"  !)!P  &0
M    @(%**@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M ($Z850H7A5N'0,  /D+   9              " @?\L 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ @3IA5%@3=.TH!0  W!8  !D
M             ("!4S ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " "!.F%4)YT%/GL#   T"P  &0              @(&R-0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ($Z851%7&KRQ@(
M '<'   9              " @60Y 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ @3IA5 IZ-"]- P  &PL  !D              ("!
M83P! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "!.F%4
M<(/A8MT"  "H!P  &0              @('E/P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( ($Z853W!NB 1 ,  #H+   9
M      " @?E" 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ @3IA5&C457 M P  '!,   T              ( !=$8! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "!.F%4EXJ[',     3 @  "P
M@ ',20$ 7W)E;',O+G)E;'-02P$"% ,4    " "!.F%4R<GI&I8$  "G)@
M#P              @ &U2@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M@3IA5!,G[+KO 0  I2(  !H              ( !>$\! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ @3IA5&(CYQC8 0  2"(  !,
M             ( !GU$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $(
,0@ %$@  J%,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan</Role>
      <ShortName>Stock Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stock Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables</Role>
      <ShortName>Stock Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Formation and Business of the Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails</Role>
      <ShortName>Formation and Business of the Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Convertible Preferred Stock - Schedule of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock - Schedule of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails</Role>
      <ShortName>Stock Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock Plan - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails</Role>
      <ShortName>Stock Plan - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails</Role>
      <ShortName>Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails</Role>
      <ShortName>Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails</Role>
      <ShortName>Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Summary of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Summary of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss per Share - Schedule of Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pmvp-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pmvp-10k_20211231.htm">pmvp-10k_20211231.htm</File>
    <File>pmvp-20211231.xsd</File>
    <File>pmvp-20211231_cal.xml</File>
    <File>pmvp-20211231_def.xml</File>
    <File>pmvp-20211231_lab.xml</File>
    <File>pmvp-20211231_pre.xml</File>
    <File>pmvp-ex1014_338.htm</File>
    <File>pmvp-ex108_331.htm</File>
    <File>pmvp-ex211_332.htm</File>
    <File>pmvp-ex231_918.htm</File>
    <File>pmvp-ex312_335.htm</File>
    <File>pmvp-ex321_336.htm</File>
    <File>pmvp-ex322_337.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gv1ubg3hw41v000001.jpg</File>
    <File>gv1ubg3hw41v000002.jpg</File>
    <File>gv1ubg3hw41v000003.jpg</File>
    <File>gv1ubg3hw41v000004.jpg</File>
    <File>gv1ubg3hw41v000005.jpg</File>
    <File>gv1ubg3hw41v000006.jpg</File>
    <File>gv1ubg3hw41v000007.jpg</File>
    <File>gv1ubg3hw41v000008.jpg</File>
    <File>gv1ubg3hw41v000009.jpg</File>
    <File>gv1ubg3hw41v000010.jpg</File>
    <File>gv1ubg3hw41v000011.jpg</File>
    <File>gv1ubg3hw41v000012.jpg</File>
    <File>gv1ubg3hw41v000013.jpg</File>
    <File>gv1ubg3hw41v000014.jpg</File>
    <File>gv1ubg3hw41v000015.jpg</File>
    <File>gv1ubg3hw41v000016.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="607">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pmvp-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 164,
   "dts": {
    "calculationLink": {
     "local": [
      "pmvp-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pmvp-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pmvp-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pmvp-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmvp-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pmvp-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 497,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 33,
    "http://pmvpharma.com/20211231": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 39
   },
   "keyCustom": 62,
   "keyStandard": 354,
   "memberCustom": 11,
   "memberStandard": 38,
   "nsprefix": "pmvp",
   "nsuri": "http://pmvpharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Financial Instruments and Fair Value Measurements",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment, Net",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Accrued Expenses",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Convertible Preferred Stock",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pmvp:CommonStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Common Stock",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pmvp:CommonStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock Plan",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan",
     "shortName": "Stock Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Loss per Share",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Related Parties",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Convertible Preferred Stock (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables",
     "shortName": "Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Common Stock (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Stock Plan (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables",
     "shortName": "Stock Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20200925_20200925",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Formation and Business of the Company - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
     "shortName": "Formation and Business of the Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20200925_20200925",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "pmvp:ReverseStockSplitPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "pmvp:ReverseStockSplitPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20180801_20180831",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pmvp:NumberOfNoncancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pmvpLease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20180801_20180831",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pmvp:NumberOfNoncancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pmvpLease",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Summary of Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Convertible Preferred Stock - Schedule of Preferred Stock (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
     "shortName": "Convertible Preferred Stock - Schedule of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
     "shortName": "Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock Plan - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
     "shortName": "Stock Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "pmvp:CommonStockDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock Plan - Schedule of Stock Options (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
     "shortName": "Stock Plan - Schedule of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails",
     "shortName": "Stock Plan - Schedule of Estimated Fair Value of Stock Options Using Black-Scholes Options Valuation Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
     "shortName": "Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted and Stock Purchase Rights Under ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapPlanNameAxis_pmvpTwoThousandTwentyEmployeeStockPurchasePlanMember_20210101_20211231",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails",
     "shortName": "Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Summary of Income Tax Provision (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails",
     "shortName": "Income Taxes - Summary of Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss per Share - Schedule of Computation of Net Loss per Share (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Schedule of Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Related Parties - Additional Information (Details)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
     "shortName": "Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_pmvpBoardOfDirectorsMember_20210501_20210531",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:NumberOfConsultingAgreementsMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pmvpMember",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Formation and Business of the Company",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany",
     "shortName": "Formation and Business of the Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pmvp-10k_20211231.htm",
      "contextRef": "C_0001699382_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MOROCCO",
        "terseLabel": "Lexington, Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pmvp_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance on behalf of lessor for construction of office space.",
        "label": "Allowance On Behalf Of Lessor For Construction Of Office Space",
        "terseLabel": "Allowance on behalf of lessor for construction of office space."
       }
      }
     },
     "localname": "AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_AssetsNotPlacedInServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets not placed in service.",
        "label": "Assets Not Placed In Service [Member]",
        "terseLabel": "Assets Not Placed in Service"
       }
      }
     },
     "localname": "AssetsNotPlacedInServiceMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of directors.",
        "label": "Board Of Directors [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Maximum",
        "terseLabel": "Number of additional shares reserved for issuance, maximum"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Minimum",
        "terseLabel": "Number of additional shares reserved for issuance, minimum"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_CommonStockDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock.",
        "label": "Common Stock Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockDisclosureTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk and other risks and uncertainties.",
        "label": "Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ConversionOfConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock to common stock.",
        "label": "Conversion Of Convertible Preferred Stock To Common Stock",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockToCommonStock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ConversionOfWarrantLiabilityToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of warrant liability to common stock.",
        "label": "Conversion Of Warrant Liability To Common Stock",
        "terseLabel": "Conversion of warrant liability to common stock"
       }
      }
     },
     "localname": "ConversionOfWarrantLiabilityToCommonStock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ConvertiblePreferredStockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock conversion price.",
        "label": "Convertible Preferred Stock Conversion Price",
        "terseLabel": "Convertible preferred stock conversion price"
       }
      }
     },
     "localname": "ConvertiblePreferredStockConversionPrice",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pmvp_ConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock.",
        "label": "Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_CranburyNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cranbury, New Jersey.",
        "label": "Cranbury New Jersey [Member]",
        "terseLabel": "Cranbury, New Jersey"
       }
      }
     },
     "localname": "CranburyNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_DeferredTaxAssetsOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating leases.",
        "label": "Deferred Tax Assets Operating Leases",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeases",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_DeferredTaxLiabilitiesOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases.",
        "label": "Deferred Tax Liabilities Operating Leases",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeases",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of stock options and common stock issued under employee stock purchase plans.",
        "label": "Exercise Of Stock Options And Common Stock Issued Under Employee Stock Purchase Plans",
        "terseLabel": "Exercise of stock options and common stock issued under the 2020 ESPP, Shares"
       }
      }
     },
     "localname": "ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of stock options and common stock value issued under employee stock purchase plans.",
        "label": "Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans",
        "terseLabel": "Exercise of stock options and common stock issued under the 2020 ESPP"
       }
      }
     },
     "localname": "ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_IncomeTaxExaminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination period.",
        "label": "Income Tax Examination Period",
        "terseLabel": "Income tax examination period"
       }
      }
     },
     "localname": "IncomeTaxExaminationPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pmvp_InitialBaseRentIncreasedPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial base rent increased per square foot.",
        "label": "Initial Base Rent Increased Per Square Foot",
        "terseLabel": "Initial base rent increased per square foot"
       }
      }
     },
     "localname": "InitialBaseRentIncreasedPerSquareFoot",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_InitialBaseRentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial base rent per square foot.",
        "label": "Initial Base Rent Per Square Foot",
        "terseLabel": "Initial base rent per square foot"
       }
      }
     },
     "localname": "InitialBaseRentPerSquareFoot",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_LeaseIncentivesUsedForLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentives used for leasehold improvements.",
        "label": "Lease Incentives Used For Leasehold Improvements",
        "terseLabel": "Lease incentives used for leasehold improvements"
       }
      }
     },
     "localname": "LeaseIncentivesUsedForLeaseholdImprovements",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due next twelve months.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10050.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments net of reimbursements due year five.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year four.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year three.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year two.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of repayments, due.",
        "label": "Lessee Operating Lease Liability Payments Net Of Repayments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 10060.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability to be paid net of repayments after year five.",
        "label": "Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ManagementFeeOfBaseRentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management fee of base rent percentage.",
        "label": "Management Fee Of Base Rent Percentage",
        "terseLabel": "Management fee of base rent percentage"
       }
      }
     },
     "localname": "ManagementFeeOfBaseRentPercentage",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pmvp_NumberOfConsultingAgreementsMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consulting agreements members.",
        "label": "Number Of Consulting Agreements Members",
        "terseLabel": "Number of consulting agreement members"
       }
      }
     },
     "localname": "NumberOfConsultingAgreementsMembers",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members of board of directors elected by holders of common stock voting as single class.",
        "label": "Number Of Members Of Board Of Directors Elected By Holders Of Common Stock Voting As Single Class",
        "terseLabel": "Number of members of board of directors elected by holders of common stock voting as single class"
       }
      }
     },
     "localname": "NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members of board of directors elected by holders of preferred stock voting as single class.",
        "label": "Number Of Members Of Board Of Directors Elected By Holders Of Preferred Stock Voting As Single Class",
        "terseLabel": "Number of members of board of directors elected by holders of preferred stock voting as single class"
       }
      }
     },
     "localname": "NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_NumberOfNoncancelableOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of noncancelable operating leases.",
        "label": "Number Of Noncancelable Operating Leases",
        "terseLabel": "Number of noncancelable operating leases"
       }
      }
     },
     "localname": "NumberOfNoncancelableOperatingLeases",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_OperatingLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration period.",
        "label": "Operating Lease Expiration Period",
        "terseLabel": "Operating lease expiration period"
       }
      }
     },
     "localname": "OperatingLeaseExpirationPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease maintenance expense per square foot.",
        "label": "Operating Lease Maintenance Expense Per Square Foot",
        "terseLabel": "Operating lease maintenance expense per square foot"
       }
      }
     },
     "localname": "OperatingLeaseMaintenanceExpensePerSquareFoot",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_OperatingLeaseRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease renewal term description.",
        "label": "Operating Lease Renewal Term Description",
        "terseLabel": "Operating lease renewal term description"
       }
      }
     },
     "localname": "OperatingLeaseRenewalTermDescription",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OperatingLeasesExtendedMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases extended month and year.",
        "label": "Operating Leases Extended Month And Year",
        "terseLabel": "Operating leases extended month and year"
       }
      }
     },
     "localname": "OperatingLeasesExtendedMonthAndYear",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_OperatingLeasesExtendedYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, extended year.",
        "label": "Operating Leases Extended Year",
        "terseLabel": "Operating Leases, extended year"
       }
      }
     },
     "localname": "OperatingLeasesExtendedYear",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_OperatingLeasesExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, extension period",
        "label": "Operating Leases Extension Period",
        "terseLabel": "Operating leases, extension period"
       }
      }
     },
     "localname": "OperatingLeasesExtensionPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pmvp_OperatingLossCarryforwardsAmountsDoNotExpire": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amounts do not expire.",
        "label": "Operating Loss Carryforwards Amounts Do Not Expire",
        "terseLabel": "Net operating loss carryforwards, do not expire amount"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountsDoNotExpire",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards begin to expire in future amount.",
        "label": "Operating Loss Carryforwards Begin To Expire In Future Amount",
        "terseLabel": "Net operating loss carryforwards begin to expire in 2033"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeginToExpireInFutureAmount",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_OrganizationConsolidationAndPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation.",
        "label": "Organization Consolidation And Presentation [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationLineItems",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OrganizationConsolidationAndPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation.",
        "label": "Organization Consolidation And Presentation [Table]",
        "terseLabel": "Organization Consolidation And Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationTable",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OtherNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-cash lease expense.",
        "label": "Other Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNonCashLeaseExpense",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income (expense), other.",
        "label": "Other Nonoperating Income Expense Other",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_PrincetonNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Princeton, New Jersey.",
        "label": "Princeton New Jersey [Member]",
        "terseLabel": "Princeton, New Jersey"
       }
      }
     },
     "localname": "PrincetonNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassifications of temporary to permanent equity, shares.",
        "label": "Reclassifications Of Temporary To Permanent Equity Shares",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split.",
        "label": "Reverse Stock Split Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease amount reported in balance sheet.",
        "label": "Schedule Of Lease Amount Reported In Balance Sheet Table [Text Block]",
        "terseLabel": "Schedule of Amounts Reported in Consolidated Balance Sheets for Leases"
       }
      }
     },
     "localname": "ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other information related to leases.",
        "label": "Schedule Of Other Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Other Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D convertible preferred stock.",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_SeriesSeedConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series seed convertible preferred stock.",
        "label": "Series Seed Convertible Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred"
       }
      }
     },
     "localname": "SeriesSeedConvertiblePreferredStockMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Of Authorized Shares Percent Of Common Stock Outstanding",
        "terseLabel": "Percentage of number of shares of common stock outstanding increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Employees Exercised Their Right To Purchase Shares",
        "terseLabel": "Employees exercised their right to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan",
        "terseLabel": "Shares available for employee stock purchase plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, number of shares available for grant, exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period",
        "terseLabel": "Shares Available for Grant, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period",
        "terseLabel": "Shares Available for Grant, Options forfeited / cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period",
        "negatedLabel": "Shares Available for Grant, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, number of shares available for grant, retired in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Retired In Period",
        "negatedLabel": "Shares Available for Grant, Options retired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRetiredInPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance",
        "terseLabel": "Shares Available for Grant, Shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options retired in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Retired In Period",
        "negatedLabel": "Options retired, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward",
        "terseLabel": "Shares Available For Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options weighted-average remaining life.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Life [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, shares outstanding, number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Number",
        "terseLabel": "Shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_SouthBrunswickNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South Brunswick, New Jersey.",
        "label": "South Brunswick New Jersey [Member]",
        "terseLabel": "South Brunswick, New Jersey"
       }
      }
     },
     "localname": "SouthBrunswickNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "terseLabel": "Exercise of warrants, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value exercise of warrants.",
        "label": "Stock Issued During Period Value Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_SubleaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease expiration period.",
        "label": "Sublease Expiration Period",
        "terseLabel": "Sublease expiration period"
       }
      }
     },
     "localname": "SubleaseExpirationPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease with tenant office space ending period.",
        "label": "Sublease With Tenant Office Space Ending Period",
        "terseLabel": "Sublease with tenant office space ending period"
       }
      }
     },
     "localname": "SubleaseWithTenantOfficeSpaceEndingPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease with tenant office space starting period.",
        "label": "Sublease With Tenant Office Space Starting Period",
        "terseLabel": "Sublease with tenant office space starting period"
       }
      }
     },
     "localname": "SubleaseWithTenantOfficeSpaceStartingPeriod",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward, expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward, expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred stock, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_TwoThousandAndThirteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and thirteen stock plan.",
        "label": "Two Thousand And Thirteen Stock Plan [Member]",
        "terseLabel": "2013 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandAndThirteenStockPlanMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandThirteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand thirteen stock plan.",
        "label": "Two Thousand Thirteen Stock Plan [Member]",
        "terseLabel": "2013 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandThirteenStockPlanMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://pmvpharma.com/20211231",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r207",
      "r220",
      "r250",
      "r251",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r513",
      "r515",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r207",
      "r220",
      "r250",
      "r251",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r513",
      "r515",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r220",
      "r240",
      "r250",
      "r251",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r513",
      "r515",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r220",
      "r240",
      "r250",
      "r251",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r513",
      "r515",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r238",
      "r239",
      "r514",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r238",
      "r239",
      "r514",
      "r531",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of premiums on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r183"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r50",
      "r51",
      "r52",
      "r503",
      "r523",
      "r527"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r59",
      "r60",
      "r61",
      "r91",
      "r92",
      "r93",
      "r347",
      "r518",
      "r519",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r285",
      "r286",
      "r287",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r95",
      "r96",
      "r97",
      "r98",
      "r107",
      "r150",
      "r151",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r193",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r326",
      "r327",
      "r328",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r423",
      "r469",
      "r470",
      "r471",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities: activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r252",
      "r254",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r226",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r277",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "positiveLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area Of Land",
        "terseLabel": "Lease area of square feet"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area Of Real Estate Property",
        "terseLabel": "Area of operating lease property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r133",
      "r141",
      "r145",
      "r159",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r343",
      "r348",
      "r384",
      "r432",
      "r434",
      "r486",
      "r500"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets And Liabilities Lessee [Abstract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r46",
      "r83",
      "r159",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r343",
      "r348",
      "r384",
      "r432",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r90",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Formation and Business of the Company"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Carrying Reported Amount Fair Value Disclosure [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r31",
      "r434",
      "r529",
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r31",
      "r78"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r73",
      "r78",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash\u2014end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash\u2014beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r73",
      "r394"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents At Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r92",
      "r94",
      "r150",
      "r151",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r193",
      "r281",
      "r282",
      "r283",
      "r325",
      "r357",
      "r360",
      "r361",
      "r385",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r404",
      "r423",
      "r469",
      "r470",
      "r516",
      "r517",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Adoption of accounting standards update [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r92",
      "r101",
      "r150",
      "r151",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r193",
      "r281",
      "r282",
      "r283",
      "r325",
      "r357",
      "r360",
      "r361",
      "r362",
      "r365",
      "r385",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r404",
      "r423",
      "r469",
      "r470",
      "r516",
      "r517",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r95",
      "r106",
      "r152",
      "r167",
      "r288",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r159",
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r218",
      "r219",
      "r222",
      "r223",
      "r384",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Reserved shares of common stock for issuance",
        "verboseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,433,684 and 44,777,818 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r64",
      "r494",
      "r510"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Income/Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r218",
      "r219",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r20",
      "r21",
      "r224",
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Common stock issuable upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r20",
      "r21",
      "r227",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Convertible Preferred Stock Terms Of Conversion",
        "terseLabel": "Convertible preferred stock, terms of conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r241",
      "r249",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Securities",
        "verboseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal State And Local Tax Expense Benefit",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal State And Local Tax Expense Benefit [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r321",
      "r332"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r321",
      "r332"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Unrealized Gain Loss",
        "terseLabel": "Amortization of available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r322",
      "r332"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal State And Local Tax Expense Benefit",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal State And Local Tax Expense Benefit [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r402",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Remaining rent incentives"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r322",
      "r332"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Deferred tax assets recognized"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r317",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r298",
      "r314"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Fixed assets and depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r76",
      "r181"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives Policy [Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r234",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Dividends, common stock declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r234",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Preferred Stock",
        "terseLabel": "Dividends, preferred stock declared"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r87",
      "r197",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r427",
      "r489",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due From Related Parties",
        "terseLabel": "Amount paid to related party"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r87",
      "r197",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r427",
      "r490",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due To Related Parties Current And Noncurrent",
        "terseLabel": "Amount owed to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share\u2014basic and diluted",
        "verboseLabel": "Net loss per share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r85",
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Income tax provision at statutory rate",
        "verboseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r300",
      "r333"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted-average period over nonvested awards expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Total compensation cost related to nonvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options Issued and Outstanding",
        "verboseLabel": "Common Stock Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r59",
      "r60",
      "r61",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r119",
      "r166",
      "r226",
      "r234",
      "r285",
      "r286",
      "r287",
      "r327",
      "r328",
      "r368",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r518",
      "r519",
      "r520",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value Assets Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r371",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r372",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r371",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Fair Value By Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r208",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Disclosure Item Amounts [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r208",
      "r241",
      "r242",
      "r247",
      "r249",
      "r372",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Priced in Active Markets (Level 1)",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r241",
      "r242",
      "r247",
      "r249",
      "r372",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r372",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r210",
      "r225",
      "r359",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture &amp; Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO",
        "verboseLabel": "Initial Offering Price to the Public"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r179",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r133",
      "r140",
      "r143",
      "r144",
      "r146",
      "r484",
      "r492",
      "r496",
      "r511"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r185",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r305",
      "r309",
      "r311",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r301",
      "r310",
      "r316",
      "r330",
      "r334",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r104",
      "r105",
      "r132",
      "r299",
      "r331",
      "r335",
      "r512"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total Provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxProvisionDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r296",
      "r297",
      "r310",
      "r311",
      "r315",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income tax"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income Expense Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r419",
      "r421"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds And Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": 10010.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Amounts representing imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r83",
      "r142",
      "r159",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r344",
      "r348",
      "r349",
      "r384",
      "r432",
      "r433"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r83",
      "r159",
      "r384",
      "r434",
      "r488",
      "r505"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r83",
      "r159",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r344",
      "r348",
      "r349",
      "r384",
      "r432",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery &amp; Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "positiveTerseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r8",
      "r39"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "positiveLabel": "Marketable securities current",
        "terseLabel": "Marketable securities, current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities Noncurrent",
        "positiveLabel": "Marketable securities noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "terseLabel": "Cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r55",
      "r61",
      "r63",
      "r77",
      "r83",
      "r95",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r111",
      "r133",
      "r140",
      "r143",
      "r144",
      "r146",
      "r159",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r370",
      "r384",
      "r493",
      "r509"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r140",
      "r143",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r412",
      "r421"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": 10020.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r408",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating lease, payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r417",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards Limitations On Use",
        "terseLabel": "Net operating loss carryforward, description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r40"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r47",
      "r48",
      "r50"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Unrealized (losses) gains on marketable securities, net of tax",
        "verboseLabel": "Other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments For Proceeds From Tenant Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r69",
      "r339",
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments To Acquire Productive Assets",
        "terseLabel": "Accrued purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r255",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2021 and December 31, 2020. No shares issued or outstanding as of December 31, 2021 and December 31, 2020."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Gross cash proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net",
        "verboseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net issuance costs",
        "verboseLabel": "Proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r280"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r55",
      "r61",
      "r72",
      "r83",
      "r95",
      "r104",
      "r105",
      "r133",
      "r140",
      "r143",
      "r144",
      "r146",
      "r159",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r342",
      "r345",
      "r346",
      "r350",
      "r351",
      "r370",
      "r384",
      "r496"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment, Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r182"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r184",
      "r434",
      "r498",
      "r506"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r184",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r18",
      "r487",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r215",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications Of Temporary To Permanent Equity",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r248",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r248",
      "r426",
      "r429",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r424",
      "r425",
      "r427",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r294",
      "r467",
      "r547"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r80",
      "r485",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r78",
      "r80",
      "r485",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "terseLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r80"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r234",
      "r288",
      "r434",
      "r504",
      "r522",
      "r527"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r166",
      "r285",
      "r286",
      "r287",
      "r327",
      "r328",
      "r368",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r416",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "terseLabel": "Option to purchase common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Common Stock Equivalent Excluded from Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Stock-based Compensation Expense Related to Options Granted Recorded and Allocated"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Summary of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r255",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r258",
      "r264",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r82",
      "r120",
      "r121",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r214",
      "r216",
      "r217",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanStockBasedCompensationExpenseRelatedToOptionsGrantedRecordedAndAllocatedDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Shares Available for Grant, Balance",
        "periodStartLabel": "Shares Available for Grant, Balance",
        "terseLabel": "Shares available for future stock option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options forfeited / cancelled, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options granted, Number of Options",
        "verboseLabel": "Options awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options granted at grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r260",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options Outstanding, Number of Options",
        "periodStartLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Options Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Options Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Vested and expected to vest, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommonStockScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Options exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Options forfeited / cancelled, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Options granted, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r271",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsUsingBlackScholesOptionsValuationModelDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndStockPurchaseRightsUnderESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Vested and expected to vest, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r82",
      "r83",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r159",
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r218",
      "r219",
      "r222",
      "r223",
      "r226",
      "r384",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r59",
      "r60",
      "r61",
      "r91",
      "r92",
      "r93",
      "r96",
      "r103",
      "r105",
      "r119",
      "r166",
      "r226",
      "r234",
      "r285",
      "r286",
      "r287",
      "r327",
      "r328",
      "r368",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r518",
      "r519",
      "r520",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r119",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r209",
      "r226",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r226",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveTerseLabel": "Number of shares sold",
        "terseLabel": "Issuance of common stock, net of issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r226",
      "r234",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Options exercised, Number of Options",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r45",
      "r226",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r226",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r226",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r83",
      "r149",
      "r159",
      "r384",
      "r434"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r414",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r401",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r401",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r401",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r303",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Summary of Activity Related to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r14",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity By Class Of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "verboseLabel": "Carrying value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference Per Share",
        "terseLabel": "Preferred shares liquidation preference per share"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value per share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r14",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Table [Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r210",
      "r225",
      "r359",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r95",
      "r96",
      "r97",
      "r98",
      "r107",
      "r150",
      "r151",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r193",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r325",
      "r326",
      "r327",
      "r328",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r423",
      "r469",
      "r470",
      "r471",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r88",
      "r241",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "Government Securities",
        "verboseLabel": "Government Debt Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r295",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, end of year",
        "periodStartLabel": "Unrecognized tax benefits, beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Interest or penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r413",
      "r421"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveCommonStockEquivalentExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average common shares outstanding",
        "verboseLabel": "Weighted-average number of shares - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfNetLossPerShareDetails",
      "http://pmvpharma.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers Compensation Liability Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://pmvpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r552": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r553": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r554": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r555": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r563": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r564": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001564590-22-007860-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-007860-xbrl.zip
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M$XD_?Q/(V-/) 59(F!D#361?7R,!7@A$5'[_34-1^Q'\ :2D@/_>$2'P]SU
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M%C T;)URZD5=WP_V77UE5(S_RAN+WE&Q%[X<8/=0H.Z?A(%R7_(8%M)+P'"
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M02@TH87(KSE(@VO+(/-J'MITWI6AC!^1_LJK3F8[#<M8KV^=^^QX3&$U,"U
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M,(&-P[Y$MRV)0T>P+[4<QV.K,3+O7TH7Y$?,^U:Z^7M>IJ.-;5^9-R^)8,4
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MF^@),&\4,R!\#Z1-(2:/1@R_Q2>[<-&4ZT#)3N;1<&O,;>F:6+^5V2=XVX'
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MVJ@[//S,NS)Y/-T 5$=8P^-/,=#9A+4J"-T)<QSU3YH#6A%90N4?6$D8T9L
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M5FJ9"#[1<*D1>*8KHN[HUDRM\/<:J5!.&"L+8Z]Q,M"!8A@L_0HT<W%O$+W
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MZAXE/DN2F7S =[\3? PK-#MKRA!>/55X^_G2A7KUSN)9WPO&4M,GUN8/^$)
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MKV@B\JF'GL:4=PPV"#4,6,:*_47F3H[(6AS#-]:0U087+$E0+";C&"08V"M
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M8&54+7'%,%,T2_I)XU[&%S#%'G-D3,J%]U"O,G/_ F,<10D!LT$.=3_Y;RD
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M/. /20E/_CK<\<8D6O$%3T2/?O9J5-!%NT54^'_K?S.>(P=<D/C&0.:I=;H
MS4I8,"$X!7$>$"!8(?Z>E=?1)H+Y?5TD.LFLJ:K?8B_-I7>K%N?6JU&T(G(K
M^NHM1V0_:';E.LEV@M-R;.M2">.%@L4;7PQ2!H8K0W,?-"2^)](K[*C2UG/W
M/LKG>%7/^MK4?9!^7E1#-=30:(\"X ?*6$^-+]F9XEBY<1D+="KVIR5BND+
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M1J-^8,=>8I9N1>EHI?Q#35O=G#T6V@R,E'B=?ZY>J2.!#U9M$5^NAZBJJ$O
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MD*Z;=I-H+B6[-<) A;VG9G-2N'LA[=E KYU;?:'W^#/^5X9Q.%)#G'53#&O
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M.?M]%)3@#2BFD%_D[NFK%/!&T2+6"1D(\/8KC&::O ZFY"BM+0[&>98:&U*
M8CG,,<!'J.KA0V89!;N0%-W<A.4!2/SW,; #// [RK.@T"2;DW L#4.&@1D$
MK.@]G)PC 1KZY0Z_KU!:#,.=#3F/9SSMW$:QKH5'K.&WS^_B8; [K"P<\#T
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M\"8WMT]P5[B8W46__*[M:_:OCZ]_';:F*Y9<^>S!,IVY1@%;>J Y8ECHB$D
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MR*W6_PWB?Z4D,.>W3<&R(40\%*S!?&8WX$7EVK(A\#H_AE(W&+Z%L'-T6*>
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MFRX0D7RN#\>1#Z[)?S*+Y1,[WVYM(N04=%KNI;%#+?IBJ<*-W(PIKX7MEY-
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MF)8,RC-OK_'.X:CG)I511IZ<FJXP-9?]/:%%^P_V6*KJL][.8Y(C2+"!MAR
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M!3;@8Q%@3HIQ=I-X-P!ML"O'N17)NBQ!'*$I*>9OQYGR-Q/8*UZ\S_$'8'\
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MUEAX#Z[##4E.LY)B5.KET:\?^;4*(]HX?ZO'AW\'@O-&<_X.!LY*,?'LN5U
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MPH6UP<9W7_B%&MPJ[N,<MGE56!;NWR^S>I'SCI=[ K+I8#DOC<$] ?D64:Q
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M=J^KL#E)N3)5B&T0_J[KHD?<N>WFI\%%?3C'[@2;H4R+;5LV#]3W"3[L$[D
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MS1LT/U;?1=S]9I)AXB,TZ6;76D8D=;.._!K]F/3<X-M-?M079Y$6(3*T5FB
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M8_IR^@U%O=_.+000^S+M:SI70>G"6\.$YJF$;.4>:V5^"C;@\M$GP6I0C^*
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M>WAQQ%H4T70M$^U0KY6"NJ7?'>V/U5A4/;H6MLVAVR1[8:Z-6.[U:H9$$ZM
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M$*V4\@H+:9 :D73K5AJ2H#J) G0;D+B]Z-5X)T$V50=+T.,?04L7U^='*;2
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M4S#Y=73,K'RQ047'4CC-1E6:NC90*U@BU9L"=W$)QH^0Q*A"-R)7$YO<P#U
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M.>Z\^EES:$8:0AZ4]I,X/M-!SQQ341301&'4-X):+Z;\&.5X<P,0JDP&K(Z
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M[I:#GFU!O_)ZR];URK9L>90&75#>_,_>'?SOLZ/XK\$Q7PE *TM(+U<$T[
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M49OY-FA\<7C <-F>!\ALS"8:!R:0=:77T/'8H$4$C-XYJ-;M%!18+YURQJB
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MT7^IY$S1GV\WF"PB?%&UVA\.RNTH:]WN?EO_(EWD$M]WNOI\GD;Y!3JWX4A
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M(T0'.W6D G>*_6+<S9R).QX&BT=V.W%=]\221Z;G%.=Z?T.IT#BVM#_0233
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M61(%<?RL+70P%DT^&ZY-;V.T)15 MS2)B^I2D$^;XX ?/2\TV^*%N%VFA+E
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MD]&KNQL(Z@1?'GCF%B+1?%#K/HKI<1P@%*$]V&+$U<M(F.M._X<Y_20*-EA
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MLF2$]_<\0[&MF>*T.Y68K2<3;^Z-NY7\@.O^]L.M7AM\5%Z\J=S+=<W/1 ?
M".]=!U!IUOKEI->3=^4L-O]P-YSY.16]$=QUQ*#'N>K3?H-X'[U3>53W*T>E
M) _A\Y5_#H1._<NQ<[S)1*SLE5[#UX4/]BC@LN-ZR!AC$U']@.>Q^7*;K5?<
M]Z*Z_WPU]_^,#DL#?_W(WW&$P3S#+I\C^HXSY4%!<'7_H"HSC$ &9<!)JB>:
M(70/<8_ "SI MAQ@KYT34CS?46P,"343^*O'.HBH7_[7+K[D<=:=>D0PN*H1
M.<#IDW P%;NF^BH%;H5ZV#H_]^[!=RZL+:Z%B,+MP+W'5ZG?:C@8?A82>X3K
MD^6AK2;7^!:%R],/?HA)>=Y5[!"1U?<MF&(N1 HS?O#4#$[CK>W;?YG*>V82
MG^[UW,]C>S*:/Z[1U68JML6R*+:T:+#D>'Z!W7Z1,V5&5^:MTA*\;0IT;!*&
M#IDK!,:0;)M<E5R?Z11_#*N:MPHNM"@5,[UL'96N4OY0[^ZT*:UHRW$S$\-"
M-^8:^R;12_VC!&.6G0UZ@Z-[VN MUYEZK,,U[)PR3=62E"U82&)B/'Y_.)(W
M9'//ELU'G%W[R3$I@LGNTB?.QN2V0G+=BFNIAU*@;#J*LA0-3E1E[4!5+"T@
MZ+.Q'K)G:K&,:$MQ5XBR4"55*[LH7+-7 [T5.F&2.]U'Z6_1F[G5(!7J>>9%
MOV9":OE&IZ1CTQD[BRX<V$J=#X2TO\.6!0A":W. %_:WP54;:(AH@/2,)'3%
M. +V)>2E15TJ=@/\\8L<.P%)  X@:/C,,3R,'ANCT:5J,U1_0?/YS8AK01?<
M_9\Y/!#(?4">OST$DS5]A?:Z2)8^SH6=DUA+T9T5];%:5%:$VFE:NHZ3YKNO
M%\4JS_7'E;_2WWGZZO9[4ULF7GS,@A*'RDP'99K)/OUE*M77E;\?SSR<LFA;
M_I%%59_XM--Q&P$3=WEAZ'GP5J)Z^XN/.2</W'_0>BA&H4$V7:WAH=ZE^)*X
M0CV?AYHJ.97/4G&;Z DP;Q0S('P/I$TA)H]&#+_%)[MPT93K0,E.YM%P:\QM
MZ9I8OY79)WC;@< %H]M/C(:R- [JCU9=S;379IR!UYUV\[7O@686DI!=?L$N
M)0:@HK#;<-JX'L=K-_6-R4NQ>L,LN;K,F!",R!=OG.YP2)2WP.15G%2?Q,FZ
M?H*CEX>E"'9>VE4_8<\WF2V$N>_P%L7'.)*L&#L1'2C$@R/A#*!^NEOC.B:*
M9:V>C-L3;MUWD383P[*D9'. F%Q5!>S&4--EI< JK_RJN/W5#.:5C+4OK8$/
M@E.RT1/CA)U8UGZD WG X^/;5FYW911.( *- Y#"W =\QDJ7JO ;YNSM[(5Y
M>]_=N$Y-/L7(][^(O7<S?O6@[!ZZ 4J%DFL:&O8@V3"7]HU[DQ,JW;Y3Q?72
MR$!>J%M%NVOQ0-.@R:C0:.OCZ),SIF)B*0:Q&R?%O@NBIHM<)'>,*767WR\.
M/=V4K*>AZFYF<B&(WMR4NT?P1^KD0VT=3>G4J-<PPAI\T=!>H<4TIHP/N$G_
M"/VP!11"69*$/^"47]$\FU'<+ 6Z2SX5)3X'[ZZ.Z;B1K;M2@A?R:K YL(^U
MP0E2K"U/\>O^P;]576E=HH5("UABB;8U?A&AC2<$L,1HG0XI).G"V"NO>X1"
M ]LR]0BWZW?I&U\+]*C#QR^ 9-F8OIVJ)V^DIY&T]>3A&H6'&X--[YPK#5\G
ML&3Z*:!PN!>R=85>+G)0&P6AS.%FPU6!M\8E]1W(72?:OL@/UIL'/0W-G9X_
M$>]L9FCNL_SMJ-9BF>:^4WY]U&K#>(?CK>61^0/Z)YAVN(]#:-JEE5S9"BB%
MOGWM$?OI%=2M-G*?K^,CVBV0!XE0Q?F!*A(M)U@K\<J\N2#,M($'M *O[N?_
M=/2K^UI$Z;5M] 89S9:+H@=9:&N9.[06G'Q7T,?$U\*F,6Y=M\OX)'<HR$H.
MT:[,]MZR/>=L6NU4O/99J7%9UDY$GGS:R#FV6X5\^-F%8#]&LF'F!24W)=NR
M2)\D*;L65Y\>O@R% M/*M!C9;4_3-3N[IY;4V["C"/A0F29P&UHV7("I&6[<
MQSI(12?@MVN4';:A86-AX;FZS$2P1L9A &O6?^5UX$NONITC@]\">B-'V2F=
M9\$^Z2!>3RQQ+]+!+R$X41C$,I#5YP"WC,E[,PM/./LWR+31]QA!\<D_'T+2
MVUUA@)*5\@]!#V@^P2G?"*R"%P,EW6-7 NGVS3@1.HJU(X1Y!!V_IZJVEO9C
MX08U4!BR&EWFG<9 )GZ*H8N!_E_^,'S#P/L'A6CF/Y=7.V>$6PU/IU]C)+/O
M& !( [+1]Z9S $H;2RR%D?(!J2$#>O@Z3SSH/L3.@15\4 *(R.,S+MA7QSIZ
M\TJV3-=^IC%SWWO'A\3;I1IC">W?'@;V+=Y4,0@SV!MT]4)L^XLUYQU'WBLV
M77F5(J-R?7-@#NCE6D(IN3![7HF\7&TY]?'Z#=%BJF_'F6C'N_$^7>B <P+-
MH2HCZ7Y-;T(B8[?9M%]JZ-?NK!@O^E!P/,GG55WU]TV\5-\6V^D8Z52K2[?&
M/J.2L31#(B1/0K\,7+2D^J,8MVD%GPN;P)%1R@U4(E:HVMG>FI:96$ O+>_6
M/TKN+#.0$7JI=3\K/?]Y??F<HVW;2*;X=[,='6UI2 (C6]QX1#^(*8;[4%=(
MNID7KDTCO U,QFG3-0O?]FP-%;&IR_UQHC=<N=![^R<'WSJ-40-\X)-W+]?3
M\^6<L#XQ<W8/IK+??^IBRC%WXGK'N=#>:$@GR@&J92I#;?9#N.WA9M"FYU@H
MN[.OWGJB#'T.NID?JK(\?*Y^L%Z=X#C[0SIIQ:K%4\]'.CECRL.5D1H><X+%
M1(PZCX"8LR?,I\NT]QKMB=<W*?WJR-,2X:YQ5.(L7;"\V#ML8W +D'%4PG1
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MO"I8X(D;.\_RAR^D2?,[;-N;R0%ET3G>;\V\G HCG%.M=]UJ*R_U#!=#0A'
MWQ"V%)R9#P17L[WH^RE)2FPS.BESIRD.)K* @C%2#_A240Y-G^9FM^("&WT_
MW?%,1]G&! <E(D[?]!7Q[]@>L?5(N/@7[5L-\PFG(.D<=P0DV6(ID?2>^]=+
M.C3K\5WREJ?%+&L(K_F!6'5EEJW>?.%P<^N34G2<\M]9GV==6E<7E\!Y#0=\
M%P_XZ#<]=T$L.Y0AIS%) ,G_BBQA^3=*%XBBM-SW"#"G.Y8D&^]Z#OZ*KJ')
ML,_7^T*;7R]>[,JLAX4_>4MV2''JA6>?:6JL!@5:!I6PNKF"%CAO-IQ3B%[+
M)O#Z69B_SN >%9=UP!<.7:BQ9X#[UNOZ(LR_I-,<-19I(WJ?;SC*$>9_S#?&
M)@9Y=&ET3?H[G0[[+\IG[2VPG_5WCZ_9.^4"ZHUH?>ZDE]\+G;J *H@&\O(Y
M/P_%,4F7SDM!;O4?8AF>-0[STU68B]@ R'T# 31BO33RF_E9G$BBW57]GL7"
MT)1QR]: 7*5V-_7)^\^;#1M(Z?9-T'"9A=5]&&ES$ O\#6-+I=/X!S1U<ZM
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M=-2C3OKN+IT>%'&(N']EF1=>5L'P)W[SE99"F4LN'FY9T$*N,'I &1TIEGO
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M87K[[84%*FV(L2GM^:;=IZ/M5T^%#728,/\SS5 DWZ/^86";>YI7:=#F$#G
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MD@#6[D,C!5[.N>HHZ4&?2U?I?SZU6U.<0-AY@VB>/+.0/P.0=C#L8YL#>#V
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M1QN?B3MGZ#AMK/Z]Y/VU2<K[[T4SRM,_-+MFN5.B!>&)<<<K)JT5)!,UJ23
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MZ\"M*Q?S?;<"3C+8)PR&)/X.1VE#3@]^QK[&[#BR I %3".>C!-G>2PA+9P
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MP,[]84URQX%N)HT!S6PAK%%YNI K@V?89NKV6]0E31[PM5=NE%"R]X[!I9-
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M!-!&34%BEM.K)_%*?#RZE+RX"J^7YTJ<?%SYSQ;73?0$>@=RKG81&R)\_31
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MU*J[QL0*9Y0C4=Z;7A=_4R>((W30EK$V+D54=M HN'QNG25VV#+S4H515$Q
M#VMRF46);J9\L091W':;Z]%L2'DE?H9VEFD+).,S5.@8Y+5)6GL*#R3S4A(
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M+84SN#5@D>E6@"]-+Q,*&W2QBV!W4\HPJL\.]2LP'.KW; '&&!QCU"L()MR
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M)YR#<A\*.YJP#E'RA3!)-"6B3<?<81;/C^Y]FN225W'-#S'A6;GS-1%N-4M
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M0O-ASE).MC]UG@P989+0^VOG$:(T77H5DX.D=T?NQE%OPZ5:VE"$HY'=TPX
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M^\Q$!8$O-%OY6%;<:=,P#Z^KN&%=<=G:\$;83WG+B<%0^;!GI8E80C/B8XG
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M8(2_ ]Z9F+(APW2O \U.E1MP7V!N;G;[(I(YO? <R_RUX3;C/&YZEJ:MQ;(
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M+$H]2;+;U//J8DGYLTC[U'OK_2>V#1=>"WR\[K"?D*MUK^!>O^QG?JFX&+M
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M[VZ1%HJ;0SY(WDDE,VA>JOB;/\*T"9ZN!+8XT%>R: .WM,4ZYLDL9$.^M&+
MI*_3,!Y/&X-1N!&KX/_TI^?P+"Y=$(;>RD6 ],M-#N8A(BBTWZVI[,1L /[@
MO[M5YN$[8 KYZ0VTGPW9X%O>"F=#^@6)2W =+:CY]L0F"/[A!M80\,VQ8W<9
M<U$/BN&50HLII2:P(86KY-UL1U*>#9FW KJOST%W) AL"&?M#&J3^S,+1/0N
MJA?XIL"&#.3",MB0SS(37^ELR'^B^65@52^?P[Z=B6/QN;3AEX1>,SO!AN'!
M<?R"9$.RM.'@0UXA<!^VV!!9^[@RQI?W9PT74&-KC/,C='UPL(-I*J )I @
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MKPHPBR-Z> 9Y]9*R0^HYH4=_/^)1QF1>]TO_XR.P%@>>Z.A_*CNGB"8*G_-
M*JK"!_Q$I+@Z'4@/ST1,JWJ,.L61F5>;/8LSQ>SH"IVYZ;MV]A%=DP23/J?R
M^]F#=277PZ,N=;[ZT6%DM4=I-IK\>@Q>U8>HF_;,8P+PT!;B5 GJ%;.*>Z'3
MMP4K+:F:\!7(#>R2Y4NIB:'3*Z%;^"7-4J/6.BWP#63;0 23:1E\JTLT,?]
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MJ&X6WHD_'YE!2]W\;G9K;9]H5C*$0N/F/@LJM(Z;" @?$<N^<<)R:6RQTM2
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MX#+7;ILJ02;17E@#PJ>"LC%8>['L4B<Q4##P77XLVLGFK[HUTM9;=OM"_*0
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M/.P2%/5H_')7U>P--BEXDZ<]5"W%+'@&L-2);%&_.;PD7)0#'HTEUJ@ZB3=
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MUKN:P(I*SPM,7>IJ)WI?&Z&?7O$D(NAK<6!^39]F_\FK,LOWNWYH&;%<ML5
MD#-7_H^6M79U_-#5?G[HO(RE!JD'RZ_Z)MV523Z[D]6RM6 \&X7Z"O'4W)=J
M*:8=?U#GY!+1>6>A6M_<YJ\E]:@./U%<'M=6/TGG.D8J5=ZRJ<TGJ) CAS<U
M7G3Z\,SXS%CMEN;3PZ>.;%ZE>N" %!/[!7:28AY@N0"\QFP*6<=<6.LLQ>@M
M8*"&VHHCT9V))XZGXC$P+LLRA(*]6GM?WNK4I3GW<XF7 =(LW(?('4?2I1@G
MK:VU!Y>2<U+VYL45[Y$'1V3-6_<47@^28KJSO!^4S W.$J@$WK<D,6 T"L))
M,0K*X5),0@Z":Q,:(G&$2"D&O-?+A![!<@]*D178*,ZT/9<)CC3J$F?,/\/$
M$!IBB!U;*\4X.NN@#(,S_RO0O?D#5#\RU0(3:'Q7R6) 1HKAV94"P@, ^RNR
M&M6,'$A EFC-2C'JQ"O3^Z28Q7*LJ;F5(!$*X6/Q<YE?J?BG0"-/HD\8'?-E
M"K6Y-/Q</H6I^4X"_:U64B" T$B;6X'(23$-43Y2#+\0U$T@\#$02GA^ME64
M8A91[#Y(,6X OFD6"]TEY-(E.L9AB!Y%#?WV0%LZ7TQCXD"4LQ&F[6#4"48O
MJ)-BFE"IL"/0+;0+W'/4[^\E<>"#5)EV1W@;3HXY&LL">&UQULSQ8'2D/"E&
M+7;Z5RDF)R]9BFD,ODIACM_YIIG9X;]1XM_1=.GSRVM0Q<EP9R6+(3QL(91+
ME[C Z&@)_+/(3=KTA3(.E 2ZIDO<;(F)GZCPWRK1\:\5?1#".N"$&(HNJBB<
M+*HSVQ6?I9@")CK66'@/KL,-24ZSDF)4ZN71KQ_YM0HCVCA_J\>'?P>"\T9S
M_@X&SDHQ\>RY74![1PO -V?9$F=VHW-8+1;^'27^K:K=N39+@,9Y8#@21]%$
MED-1K4@^@@X5)]P*.+G.61Z>@G= AJU( 0V=P3\.UA3HBBT6:,=>E6+8M,67
M@"X..D[V#[#^-X/56RX:X-;J&E8+=1.#^5-7;;7*P-_G4G,]/WQ**IY0&T_+
M.'%KU="1MZRSNLL^';U2>V/[1+SWSY>\!V*_M#DXN.;,1LVL[<I_BE=TZJ)O
M75=1OGOF8/X'W8/[,[/]MZ[[!;HW(M_D[+%]UY@@=NY$Q.J'[O<]J?K\C1MR
M/%,]CI4M-V=QW!MWW!VVV%LZN?5R-.#KX=!9.$EJ+WQA$6Y9\;%K&(GU41:F
MH"\,V<M.2+\6ZASHQZ;J=P:&!NKM9X222\Y\XGOX$M9:Z>^^/1+]&/P]1>W*
MJ,.%;K@8)7#Z4DSP#LB)GTGL&^;G/VD%.<V7,_!19HE?7T2QZM?5W_#U6K;Z
M%[Z.6J.FTHW'<H'YCX2MY2]KL[C(P^[4;N^EFS8H%>5N>O+XY9/'OZVXNG %
M-]D!R-8UA$+O0*1&Z.XM+3I1QCU3[>;'/<LKOBROWQ^@UCF8;! E>;T^(8SN
M:=U>M^Y7.D'D_'QJZ6>L-EEM7M,=^QCM#?362/[N6_V/4C_O'D_=VJH2DW8C
M:[=^J'Y\:]D>E<-W]7>=__68C_IH!^I(F9:$X__=2=+_$Y.I#WQ?0;RB@-BB
M7'?21<U.:#,+JUHU(&LZI@?#V-EZDGIK_0?D*+L>$UYMQTRQS,%,NTY&TF:W
M)W>7EDP/B+4+BJ8$'P[%D,)C$_95[L9-JM:BI XGCVA2]MS:GLEW9 ,_D1&B
M(D?'E;T?ZFSPQ":L!D6YGAJ6,7%S@]$3_NYYQ8*W@X=O&P[.=_S]=_\KV(1Z
M;8"UAL"]0\2& @J0^#GPV'$R$R7-6J?/>8Y[&B986X#FS[5\JG.'7AT_=G/"
MM4M0<:"V\@[W:;9FFL6U%*6.YLE6O9@I=#SW?#9+'E+5J"V$9? EL2IDWV"[
M7G+/6H;;.K688@,ZQD]7!T^;G!U-N_G.-<=K;(MG3*(HLXJ1J!68,'[YQ&9G
M+2\S06Z07XK@YY^3-+9V[S<]^///>Q_%W5OWZ.'S@WLQW_X6K>V:!^\C<Y!%
M9R5WZ[]=GK79F@CZ\5.BD9433' _)XXI.P-$4S=+TFK-0"P_,($#[Q%NN3FW
MI>S1Z:B]'?@*;8*BQ]NA-OY;T_"V)=Y0C(GNBWM>X:\<7R0 9R$L+P5:TP*K
M/$.4!Z"U1; 2Y)Y'<9+<1W1UO/B]3=AKV7J@J+AXO%X3]&MB:@4,F?>89D8H
M.C+-]T\P%YV!7;2AFU;+/LE.9YS*T[^N],5N,9+W ,*"V[':YHU/J8O@]8E\
MH^H;M9<TKU",<-<SMMNM'S+P7D-R>(%),\]]+W,WTN?1Z!,]QU6%.85Z.0]/
M7#AZ,#4U4JE(7BEWL=V*ZWOE0$,I1O9;R>0&I)$&'I1BW@8_IWV[::8:K.([
M-D]!:XB->'6*576'M7P.14T8' /[@NY\[VN_^,^-Q)=0_ I&+U,33]0$E9Z]
M0.^JP*D2O?SC+RW)R)I)RU0>%#!%7\6;R&XM5%E)MJT"V9Q/+=C"$*JQ<4JU
M.@_(G0>?_NIJ,QLW+5!]/7 @VS\]_B3IX3LG0^'6U9])Q 8 4R\+*3:&U6\$
M":R4:)]%PHNYG?7W^2F*%%LP.Y*O/5)]X\/3\%>D71V!H=IIV1ZZ3AFD]$U6
MSRSTXVVKMN%>3,'+QZ08^9;)XF#Q<H!U$%D\FG$J9UB*Z=/C&S"Y2:<'CSCE
MM4;P7!.'EO7 >OG^G>-IE;/F>%]</.-9X'9GN82=!FFO#5>NWODA\7,L?X0U
MI4UMXX#;@]]:(0IY^1[^GNF">6"*B!$K^MHS=;L^/;#(GU QFTRQ"R\DFX4N
M#N*XM@<Q4G"G.2>R"55.Y!HJ;:%705!\\!2[A8"ER @)VVXU,%4I:CQ\G.[2
MC(_]HN!%Y%YVC6/"A;7!QG=?^(4:W"KNXQRV>558%N[?+[-ZD?..EWL"LNE@
M.2^-P3T!^191K$#;8K#?R-EY(8(;]UGRIK1672>99ASRUL,P^M.9D^T:'2]/
M/TCK&#SS\Y;/#MH-<;_E8@!+(ACD&E7KRB= AG[-4P/.?)\;B[*$;J))J%!8
M.$R/OUO<DEWSLVJ KA)8L?C%A5>&H@/]N)@BAHG9K=:$<<5NYL;5O?M'OI4C
M=S[0:8:']''P$M7A/5UG\()A*$N\H^)6G_? X/;$$&X=<5^E7YK\:@=-K8@/
M6;#L;?DS)<4E.8/SA5; <407!*[5ZO&>X>7(;FQ='-AV[<* 7O[8D.8;TT K
M1W F)OOE;SU;+F^A!0?3O3Q^O>@6J%RS_>"=BT=O'&F+JE>&5T&7[I-\-$&Y
M!DYL]D*P-UZ938YE#ZF ?K$4BP>DXK S/6$NA6.>MEE^O@5FKS+-BMD^=ALS
M!J]OTK@NN(?EN2'R\6(S>)ND!.!VE?;[<<,:DK:,-.)4&%DA_(]U/(*R_P3)
M((<?&,ZB6E4+DVF\<)4PXRWM'.AJH*[)IO9/!I%Z:9\M=I=A5N-V(8U$\!P.
M-75XR( 6R3P!:)'=ARFTJK8K]8KCM/E<2?H%SE6BROK:?7R.UN'389Y;;L]=
M+ B^Y\(+U'2I?Y)AL]^.'Q'B5-U9M/)FQ"D3&^LV0_$:4)--B"4H3/N!4VP<
M!MK,X\2^K[DI<L$^'UK:3EF;:_/^[9>2 9<W147&_1^/8#>%R*>"YAN;CO93
MY"&]8\.DMOB+!+EZS3[8H4N#AX?#25R< FO8J.M99&!0VE1CN[]S\1&35T^*
M:R=,)N+O[5L2^8OL/>S[*429)LF>HFY&[:$Z<)K8%]6(& NK&DQ\FPFJ]5MA
M?2$^ 98I8.51'*"00A^?\7Z-O *RWX&?/NK@FZBXIYM<\SCJV59>T(J: W?4
M[9$:@&7!Y%Z?P\%JS_B<^'IC?UHE4Y BWN7")\J]XFF -(&V4+6MF;JL0]5K
M(GQ*D*75P=E3%FY#W!"113=955=><=*.5=J+G4_9 H6!KYO%SE (ER!'EG/I
MFI%G!#J[@GXQ%X*5/(CCZ8;F6JF"DL23)V6[X?<?22_:/^E;UR9Y%_\7;K;.
M _T$@ZA=72])(7 SD"6@:Y(4<P87;TEG$Y5@>Z%R2S1E[4/_^GG"D12OO;V!
M%P:*?;PLSL!R/(X*T6,>O>_(Z_7!@?<J#/!&;5^RMW*^&"&KOMV(C;+A]FZH
M$ V@6D37I9@1(K&6L!A9!*^&G@72/>!#$!&<Y9_,OV&=;GFP- 76YG&6>OFG
M;W;\X'SNF%R<J6"[D<6'N-OOTP9];PSK+TNXZRXL%YLC;3A,*!:RDA$U0KX
M:,_3GV('&HHLO(F[(" ,G&APMU7H-/-%B?AN'3=7L+;?>30M(TJQL&B0=?P6
MKN(=18JIHUP!#@)ECH)A\3</NAU1>P<'27ZEA#ZDV$&!_OQOJ5W.)>.VBX3
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MX?U$Q\@=T;Q+H=ZKD('&X-66J4BD[\-^SMCLH5O&X-+UJW^7Y!&X=!QXP'7
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M?ZXB+2S]7*.>U[-$Q<0[03=R*J(?7$Q;]"WW(@^=-WO)8P: 1EZ:L.H H@"
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M&-.=US$SIAM>:*6#:]2*1B+I/I[>WF-AYHD&*;A)K, .A4C1&]N?OA500C0
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MF%0\XF8M]^G^M $W!#3@>@LRB)?04F^8,Z)Y1&YBA*ML2/WL]Q)_ "Q[!:N
M9K<7'67J%F4K*:QODI(>6G-OMLT9I#Q2O_LIK&??GC9(P%,C=& JW*+C<^$>
M(5#6WD@EWP@AZ=IF/QGBBX E"ZM"_[KX>8P].)T::+:M5W]%1;7\8,A)K1<K
M@^(^L_6W>MW?+<XIXNG!0Q@I(A8!&3DV$<O)K[XA9-SQ4K6"%+XCF,\:;$G
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M)@-A_/+&4(DE9DK0V[>=YGTY')]>:1V^UN>W34N]=A>C9_5G&2A%4?_69X@
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MLAZ9>'>U2:Y?=MWSQ;'LD^C?9XVRUI;M/FE#4!?)B"S#)X>?EP:X&G +8XD
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M&*POMTQ0GBR&A#A'J5.]KOLK/? *_0B]KLIQ+^-AMOE5O3EK]8MWAVX2-S#
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M'0>.>&8=8E:0B\L;MZD,=W-_N^3'&_:*GDAWL:XEL7)_.XBZ/0-IH*<6QX4
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M;4M\YQ:(2HO37!)A Y*$-VW^:A4-\K\G!-)\4:PF%UW!9O\96$F$$S[3RX5
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MU%<*/QWSI8K[C?&#7R,$7L42H1JST5"1FDO!0-*Z0D#!DF_U7AQ.E!<]2]]
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M[VY<NB'E955:!USG_0\P^S\\QT,=[^1Z"($'#2A_-&_O Y@HILE;2VUC1#%
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M=B3;4 CX!I*A[<IC/V,9W.88\.4"^5?#0XG2^-7QS#N0LA!8\V,\^9VJF\A
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MRZ--ZP@WP"/^(WD-,4U %^=8;^?/O=3=%<V>B[/6$EH'T)6 EFGJ&K+1F+]
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MX(I9];#.IF3BAKOGUL#%0CHUCT[5GEM%.TVQS30U&1ZM<P*_+XTKG]:,2<
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M3*&./P;8/7>]UC<1B.0<B.<P8EA/9V]R6==<77(UNHV"258\19,FEPL@[A@
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M N(XUVNN.2U1(QWT.RHT'6\V9ZZ\=0^,F_SD'US)4@GPW@>,72%'41J:=-$
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MN>/O*J.<!V=1PZZ0;!N_G5?<UA6/JR),-PC#2#CQ'5MSTH^/G_=4HF2F,BA
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MA-J_\M;J@Z'(XAW.K"^67S%OF!)$9;S9?>\J:3:$,SA0?LC9,96_Q:$W.SK
M=G6WE7EF<;MX.883(MH@0>05 SP)0CY-08+XTI,&>E)D&)]+13LEB$9>$T94
M2?LZ)PP:%XD])0C6=PKXP'8X0H+ N&*^03AH:QFD/V4$BQ#J2! )GV#:0SV
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MQS0[A#ZRC2M"OQ0DL=?83LS4=WO^-F#;K+G#VING43DY55'5F1:&/_:LOF8
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ML8<%LB>*Y[.X]QV=,AI8"7SO[&"L46ZGV()$Z3R//Y8<#32+T2E4??<GVVO
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M5!H?^8VD5(.IA,HZX ND&RW"T6%"%R&+5CRD!6N@D\?V+"(2]/%JREY_K1H
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MT;X+241<;Z'27DWLHC5G$\^>R!!MR3HP4$<GT7'@S-,P1I-4X_Y\^EVA&R\
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M]/SM;+WCM6&;2MQ^'N,5-@[Q/%?3?H_>AX^-2UZ:#X^3+T'.P^5'U7#TY]+
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M::7:G?I,N:M6*"P9#BH>4Q+G)T<_1 Q)^=P8*XX8;AZ&#->(+@$ 71OOHDE
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MQ%6/LO_#>S!:3EME!GQN+"3M+G<M\XOA,D2=L,UKLD=T.<:VO\I654WW'6F
M;%!ZG>1:Q) C4WF:_C>#K,*XP7"A>EQ+S V5HU\];$2>I7C:-P5X7_*E\PZ"
M15@5ZT:+?:&*MQ'+OPZ7Y@R[UJO/\"X%#YV1*LY]^^*5N6.LTS^Q6*0+I(32
M0C:RX@+:-_2?3Z4ZK2EIQEZ$ZE6X)77Y-VCW_7?J\MOZC#X-Y)3=Q6P]5UTP
MA_Y(#$C?N^CDP.EALHW19'W%#UZ]]W!_.3+$;B@>,\RE5ZL\L .SLZI$\C0(
MA]@1,;A9R&+3JK60<Z8.:96*$?$^E0^Y"A=X>Z2KPO/)KO!4)?WD>%?.[V%L
M"]IR7J!JJ]RW;1I(Y>\K=Y>G+\+,285>J1Y?%JG\1G'ZM%+YV76.T13:U<9/
M@:*TC<$$=%D2L42HN>Y8F%J!HC.M;.RVDC5=@6MC!A6K]TL)\((4%VB[G5:;
MYI%M$ALAEQVW(D!NG=W*H.#TO,6=M=G95$D<1<)Z)]G&28V6/+.4C$>V]GH_
M&[:K(&.GS%0BW.?SP?"-F$,X&3["3HYA'%/TAP@6J68@%E]M?O+X;E!]_F89
M-T-Y"WO$\!K).?\(D=V+YYV7W1I.#IC'CEG+7@#5W)BM"VS^.3,819@QT5'9
M8GM$Q=@H(*&:_K=/DR#]?0+;F .!8S7^'^DINE1:1VV]\GKKFF+'A)ELMH7W
M[];/3V%"XLO=3&HD/ZFL+,*2:\.5CD<QUU"0[$[N8E'<I3&T3*006'V)]SA*
MM/VQ37PR+:F7=%;$X,1[1T'J_@'J<4Z[65:7[:IX6D"$;P@ TAINN)C<S[X!
M.!V_=)(@'B_$B)B]"_/4OM5PIE^+3(W) NTR0=B&9CHZ?GY*'YW@B-W@WN,N
M,%AI(5,A93X@'=C<)?QFQC<^\0X,O(?M=DX9M6B6P5UG5B>1M0I''^)MX>0!
M,SN+KJE(E%<JQ4DJTK6K6)P..)\1!<.VUHL VR^9=\G:\O$BL)8P_+3#+":\
MI8Y&8Q_]M%;3+T(^G7JIW<^'#'CVV!D-#!'31*NCR2HD^">2I*7M^[ )B9^"
M#)@?]P3*/^] O9M8@Z(_VANFH0=\3GA4[/PJ[D?J@<^5N:4^\*Y#Y]KXN6X3
MCI$^E1KU9'&;GO3]:YFR3I63)UA]%XV+X:>V@K2=HM9YW7NTQO6/< Q&Y@?Q
MNA/CN,T'@<PWA6>M8,N^(#-1=[,B;W$W- +>'KFO:AGN*;.CEKB(Q_+G+]S:
M+"K9F[7F"CJL2KC:9,P+I2VW,C_42H4E']W_:IE*..!BZ:^6W=,@?",DSS(+
M(T>VQ!;'< V4IK*C6GZ".,*3K2"AH&I6<?27?4BG\QDV#:><)3,-:'1"A.O1
M"Z?X:;G\G?/A#,?1G!#\5Q@02?<A=3!!Q>W['GXA:ZH%2"V-;<U=ZC/"H(\K
M27FL8YM>Q_XN?UQB[JYB'O$.$\U,E&Q7"S3N@ILY?;\F5!%YFFI\72K5NEHG
MLNRED-6KR0[.7;L*%%L/3G] BABW_J-XVXM]][6QC._:1/7VFE!_+TADSX1M
M/XB^>N@W1^2MY:\"9(M*(- Q[)W;=E8KE-9A&F43.X&SP-EU_,1Q<GDW.6P[
M,;J'LQ46V_,+>?/ZQCYK/?]C&?<G(@S$_?C&@95A[Z]&&C'(\+*#+:F5RO?M
MNI8!8J0*CPYA>,\<F'ZTSY:2$F+XWXEV$RG:&G!U R1N(A,E"/OUA.,,,%\<
M P7"ROF?:AW]MUX<3?*O@VH=SZX!NU227C(PDG]%52)G:T+PL[B;U');P[49
M9R,R[')$;53@G&O9 \1UH78'@TF%9OCOM TLDX$7F2O[V3:D\-H<IIA!\B:4
MU0(Y#.="&+FM]MQPZZ$;EK'7W?-3@J6$;YMH+(.E=3=S!_IR:%.T#Y>D7_=5
MDQ8=X:O\S:0%;,L$G5EDQW -<563$6%9V@@?+R#&11N+(F]P:&H:DV3CQO^A
MO.FR#:B$_2\NO9VS"@Z.$3 RAE;RAH_D&;B_ :[QB=4EB9&1BH/+>27FS.]=
M[_NAQ;Z(C0'B^_OE'#VV"'<?M@HU(Q:"9?UH1B5+[-!Y,Z$%"FWN[$,M%@F&
M1N*_/V5R35/=5JR>37 "8;>RK-X5MS4K<,UDUO]-(G,M&SFZ;P!MVDP.I1BC
MR"/>^K2,8XQ?<KON? I5/5-GKF%0@OOE%==06:7Z AU%1E=J&@9"78TX;BS-
MAE*\I-!&PA6#YC06 #8\M08=H[9F;.5B1M>)I@HFAW/E?96+ TG=T<Z,LX P
MNM:WY0G_S #+_73FEN))+D#%'PKWE)2JV*"XRMG>[^#I2VW^S_.7#%MA+0>5
M"2+^LR@J:9(=LVW K37GX,<6Q3H#PX5.I'SCAC89R\94<QU(DE= $TDWRO<:
MI2;$D5]FPZ<4\UEP"FK(8[_00_JU"'F',]8HF3!'5[/P2TY+/Y"7B.$HX/K]
M6BT=['QJF)M(Y3RH4_##KDK;WZP6/O!KKG0,7TCB9I$TU!&<2C6HF_B:1F#&
MJ5) .RS2V"@*8X#(A*M7'/M.(=Z.D0&EK+R4I/Z+Z;V++YLR6X#5S-#M5(+4
MH@!>A#7\Q=[!YD\L<>296*.E]5>M2.S3P]:,I2LQQA0@BU,P5B,8J,77\6P%
MN/FRGA;#$$$K@R[Y)6VQL](P;\;3Q\22\/..*K[3G^7IU>>#A"*SJX2F?0OO
M<NFR]M!IX:Y,+>>#[5&B84MT(WO:+CTQ0Y/:/HD#"OA8)9C+B$(<F2>97!"^
MR6UU:IE(],V0TTI;/<)SW\HY2^"G;5HCOX2?JT^C0Z-:59+WJB2"-CN;MOK+
M4HJ07/ 6%</^G6*16,22Q+HJC9C3CCX[/8F/!(I;R;F"W7"*X5D'^WCIQ<^:
M5.URI/;5\2NHRU+9E:3TG $GB5]N6&T2B.KGV,24A\%/5V(-:F[/0WCI#A:>
MYA\BTK;JH\"4^Z@S]O1A-?[O*>!1,%,X4$N3"%CU$#]E+%CC&N>U(^[H< *Q
M<Z&\VPYO"<^92M%19U\1G@C3EEIG2P*2QQ/N+WU?7!=*FN4"9CB<:<AW)(]P
M#VGR3AQA':836>>&XDTT\;=8Q;- Z[G'Z!<BW@!=7D(0Q7E(]2-0P1N7FV;X
M?"2Q.WM7.VH(<R)S>D9K[/J$S7Y4X(G"P:U("JWK^8&+J:_,ZUV6^.SF53U_
M?BXYC5F#.:;]>@E>,YGEU6=9S>J8Z  M[0Y51; V5+)*TY"T5#(F=]\;#"Y#
MMP28$=M>]FEX9)(\'^NP8D/"MP,+C1C++G%]3I3JN@/;DD:-D^O/(7!V!$(R
MV5\TX'QV$@#=*)W8Z-C>'+9>RN=:BU!R0H.KI7$7NE$7T.,'#6^T\Q^B?F+Y
M'J*\FYVB=#XQ53DC>A7\0L)KEQY=N$=0S@;5D(D+18T(ZH/R+IDMBAQ405C3
MND)@A*9>+;$_V?YN=_F^=JWUZO4:!+[<=Z ,))+X(777>M-V,UU# &ZLO-H^
MG>1YJ+V-"CE>2#AM#E/4$9CS')XM2:#DI"JOAJ*9%%"FL@$$/9SOD7IIK$.J
MTJ^)01IM.\76-WKT+M/O&/"Z^$PX7#B\&]W=]>GV'SXZN1.6YTLZ$5?[8#'$
M9&-F&;$C&S-&S@)WN:-;#LWK80*3Y>GQ!(JWC=-Z?AIK:KA3]T5?C&#\_FIO
MJ[6$&5XZ*#7?<^%6,#VIU*=NE+O-ZCNC(,"UWM#)DKD1NION.,8[YQE=W,R4
M[CYBUC0R9FH%UD[Q>A&]0HVT.O!@H3[>&YYL-,,M-; HA6=4[N "8YPK@#L&
MUB0H)KT[1LBZQ$7$VU/]%-1,VQ:GOI0>QFYS*KJJDV48)MDV:4,;?<G3X50.
MCG%"!1?7E1Q9"3*06D?G*W*:EY.&E]G@$6.U,7,,N@B**_DP=;H.@>XW&I-0
M0R\EV/L:V[3#2E(I]KJ:]N9!84LR-\3![+F8VW<5&?AX, UYR?H2/(J&&QIQ
MZ5,)\*5NXB"O2OD/C=*[XT,F\=[^I.VK5,EW]$])IH]=FS=BXQ/4 Q?WNX7N
MD7MX_HAA?%\/1R;8)IL217GB\U[A@Z.6K'O*J8C7J7#>TR*KP&AD2U*EM-9%
MD-AKZY(N?DH76=](F1#@\ZLV_O1\,H&OV&H*\L!\G=W7DJ-@"7?>;:J-0K28
M7G71B)K#I91BMK-+Y'-J[4LC+6,<L,E3D==8LB9+1=!FF^AC-2D]>N"(.(3L
MRN'E"<[HN7,_'PV.=V=N;Q2E?WD];"E5L$O15--9\?1M24;=$Q:B?\SBJWV/
MZ7('0L&/[F-1XS8B7ZI&E9R-X!1@H^-, ;I (UM'R_+[?=8%W+1X$!GW#WU6
MW4;0PD0]9(^XRY;B/!*\-K1SPSY_FRC"63K$WB?;5Y)XDO)6>W[.*VV5G$\M
MDE[+&CQ+C(D-*GD#&)<5OU3N?_R9DXZR6=,9F&V RV[K/</3?2V1E3K%R+,V
MKWK/@4XO(RVE#97+P@F.N -%IA#%U!A"P]Z)BUBYFL]V(E>C?NQ\"#ZJ]JE;
M]17M22'V0>Y2OH"3YW/&P/]9=+B,4: /'V\(S-?H^UAF^2@5&C,.$U%O1G8J
M"4=(K*>L:+&(FA9;-\8[261:J]C7Q9]1O5;%[Q!](:#&M%GRF+(=X^$J%'>T
M(Y)RI[$XS$<R;^',QC;9AIW;8NE*(GJJ1QA^68;K?/)*VM16:-:OY\)LNOB>
M_I08 AF6DZ[7&I@?(Y76GNJD>$*VTPC0D3PF#483$=FG@8D2H$OBZRABFP._
MFYQFH/]P=#B!>N8RV+)@OU_?^@/;^9Y/?XUFK7R-".E(VJXKLG'W@^$7-3$Q
M]:81AF !=)CNLR@@^_=6H@'U=AJ[X.S>[JB5<Z5\D+6BP2I)^(I^ 3DNC@ $
M]'#%)LR[4+2[5,IFZ1%>3A"^B2>0])3;:)J_5;.W;>M#=,E"D]XR!%E#LY"X
MR-&A&]6S,@G&JJ=1IURI]!>3\Q %YN+W41_E5,"M&SWJK7[4?8>X']YQ21.&
M^&.SIQ6TIB_DI;4KBG]8J<E;RQCOGZH'&5K=ER$*</O5@A:;(HS5W#C1/!Q=
M %[[)*8._?+3<?@TC7#'0@YUO=2#.T&+BS3P85<[T6!2HX@TKXSNG<GO)AY*
MK="3&WZR1O%!_GP^>ZVJ2MDX>^/ Y_DZCS:-L/?0@KFM:8XWP)B+P!L 3Z 5
M[>-RR^O:DYIS_!B'(_CG$V'+&P#GZR>+<H(A_RG[YWZWH=: \3%QWN^$GE@I
M+X(-Z!(P:TC8QK(8)!BN$CSB%"V4)Z"M,(X%Q[)70>Z/;X#<Q#= ]MJGZN;,
MV ]#M5U*%^S  7+G;"E7.U4[>.IFK3< 5U;:EVQKVWQ6/RIK@^FUEY@B%@9M
M)A]3*L^T(JGR<BD%6Q>#BJ,RS^A[ZJI\8>;<LB\V?..Z75TBM''LF8E40B@#
M==^GA4>I'GT8+0+R([?O#(\J$C<F"="[4BK:!\@5M4C:T];Q8J3U82MV<%G)
MZH)&+VG9^CTC.=5E,( [FM74_*"']:Y6#86UEB7V3/R-#66]C5RU-/J&/(75
MP4[;)$^L#Y;4%8(ZS<T><?Q+."X\)GS-VTR^N]82\5]E]"= -1R^"$)8K268
M4W?R=WLR^+D=(UF T=J859)*9,TGHDY4^<IRY0?F*F6IGPLD"\XLX.IGF1\)
M]_@!JM$$<?RV,R;X)LDQK"3]\2LL7<[M#/[-6]S9[@^$)+K<;&,OF:7LS78;
MU ;Y#G:3X#)=XBP^5AMW ;>53EV:[&AI-F'ED\7ZKZ_Y"L/$M#U.,V>[*[8?
M6YDVRGQ=;:W'\+3TF[)T[:%8V@-DAI/+BZ(\>E?N@F15_.D2IKN8#ED#M%<H
MF66,QD/V$[13Y_Z4D'"-Q%,VE9SR1L7%AV)>8L9_=360RW)UQ$"Q/9_A$ G%
MA$:UDD40H8^QQQ?,B:;X!C!/Q">B+G'%B]"^0_I>CJ='=W]9%_ H2F.EUA!E
M25Q -<^=V[IQ;S" 4&4_ ,5^KBX'2^TSN.D\*MY2%.X?<SS/X+KF?FD]:LD9
M3ED+T@JPTGJE6 KOUPJ(1#WTPPF/(;9<.D6P]_J4O-LI7QLS::FQ SGI.85!
M,G06*<N*;?W[!=14Z7<QL9_:"]#[)1"K:\$SB\ZFQK]X%7<]":]W-AVJ?R$
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MZN6'7I6VNMSSWX9#?SJ<*" 6)H&$)K%S!@!/D\\;LWRU/OX081]0H$H60E;
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M&'6+Y''YY0/[[]0D0;Q6/=]E:4\Z/ENQ7 #.*E*O2OSS.W"(");792_6_GS
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M8@R(X[T"J;)5M:L?[!B3)L318*[E'M[C5-N;WQL[6[$9R[5(:!AV!A6\B%R
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M3^QKK^0I%=KM]UYI%&'G&C?!<V$P[\.T_);7P?J#&/A%/XCJ[LD B F\!;A
M6:8ICY:PB__UP2A_;QQZR^0,78;3+5V!Z.X<7+,_IL"=^!/\M>O'5U5CKIHP
M/^#FWXH:G)_ O@  /C>ZZ8"M*0<VANLP6F$H!/P#3O/2UO/J$@I=/?_]\^F
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MTC$E5)A6-;Z?F46"#VH!"^=^9$TB%V(>-CEBOO;'3R14&T/+V>"R6Z;-)O0
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M\(B8,VC<=-:76IW7"W508U*]KY"MXP^TH34+'?4+LTVL$.7(",T+JU:4[R\
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M( 1N_R4<]IVK^G-6W'%_O;LE$J_];^\9$HA-B ^%Y!#288/20"RO-MN\KGN
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ME",; MQ\Y4O^4]ON W&;1V>8V2O"78"F/P_E>-<%T:/8D'!>E@BR3O^#\9%
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MB^T;-TD7MZO=_OZ (J\Y@Q _]KV4<V[C5P2-8?2$K(ZDS)?)T0!TD"^\;JI
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M0?^0F<+86%T[ \5+TL51*U*G<UZ7;71FT#V^$ 2O3O./VJ;0-%3B, G(T3-
M\8H*EYED9BR;'I?N/)8-FEZFJ";^/@4^OS6TW26]V!JHW(<T=ETE?WT41^9K
M5:14M!];<]C%%C[&%#G^8(ET+_N .-U54]MU47#D&K"DTW2H&8"]5Y3M0_1[
M_N;F/A_E@+24TZ(D;Z=RYFZVQLSW>-%&.WU]!)NCN=S>756U>>FR8"&,8.;]
MP,; ZMN!-Z@#$HK7%0XU.K\N_";X+'=@FFZ3+;C)HHE;B>8X+[_R5Q<8B\ML
M^)D82UW-N?$T^>G4YPHT8XH[[9-I$$?Y'8S-YW6V8"0-FC?NE>/7)Y&VZ?D0
M!47;0VA+V\[3*JM4J$.Z5/W[D]DO'XF^2;(>#V-DCUDDRRAY,!6 (F?BX!&Z
MJJ[2?&_P0[&PDDK(Z"+KE7&(58 $O<-V732"L%GXB\.T8,?2M=LURA+E\'Z-
M.YRE3+-!^:!"I_7*=05G3K58GZY9>K( XB65Q>^%&!N:Q.^-U]!Z165M50QV
MD]@KGDY-^6##2P'W4G4Y4!")FC]#Q2.L;3>Q"G!1X7EO1I=<[.6HO"Q**QCX
M<&(_23O;^Z6358?JCNUC,QMJB5LQO\N%95;KQP2S+YI.HY?N.E*.3?_$&$+N
M)0>-++?=KR^%N]W@,4A"P;K,$+H1F>VTG,(OW-[U377#1W9'62$X6FJ-!^O0
M ]<BQ1"W%@5#5K,FKI;;T/_I9.)N PG;6#8+&_'P48H2E7),*.<)07Q>CS&$
M52L8^6.-!!8B;:KFL*^-I!<R!;PO!D5?4#V%BI+BR\ /T;!F=F8-&4TMQW1_
M)^]"[6$G32PVX$7"O45L;48+VWE;&M9' K<*O0LORMB1'X.%''<Q@MV^4NGE
MI;,$=3NL'";O0I;V)S4/F-R.!QKP[8!<O8Z;*EJ2)Q,2^>4GPQH1V-MZW'*.
M,YF-%L5&8?U,:>79I,Z-SG6)A;UDPTHAC3)$)M.<9Q$*8DO:(YPUQ4+4@:R<
MK=TYN+WD?[57T0WR*O2F.TY6H%?3E"'M#ASR-7OX!(+^BD.U>1'+%UJT!;Z[
MSD@LE"C1D.+TZ=YR-W_%[Z/X"1.F)XWXZ7.J^!2_HK6#>60G'5U^<0[#L][K
MCP8+.X??RP]#[*?"778IA?UGU?JO [Y^+?F \A2UGG=M,O@>D3&E:0(>'R-D
M5CN/&-7$J1FE137&ERRDF_15Z(I)^;)0;@(;BA?;TN-U$;-]76BXS30M=5T9
M_525=M'^2>L[$X'/TG,=\69U HU/?$0T_>PBW=R?*?A5W_Z&M34-R*[ZOK>;
M)E<3HFB[HZ=(B>07X:[TM.:/JED8.QA7T1YT [05J1\];G0/.^%7/VT+X6B6
M0T0*$:P%GE\R+N*P:RF(XBEEF&%[JGH)<!SG]\QQU).C.^2GB"T!) F-C;XI
M3/'O\/298A/<@"@]4))U8G'XJ9+!TH48D$6/;_DE6[]<(C@N0'W<?4.X$8I8
M0*9T(:.AX???&%O-XA0(X(63*I,4?!T4=-VJ,49A,4L="^ON LC&@4A:HU8-
M?XIZ*OP++2]Y(^_5T[CP38LM (<4(-OR"D0)G%-03?6/\SHI.U IT!C#,0.]
MN\-&P)M':[[41>X25%Q=CVQ@$[G4YMX6;LV1RC/(>+C79[_\L.*CTJN_4<M-
M+7[/1YEAR.ZR?8W)&#WK-)(N']2;%_^>B9[!]#A\9A.]@G=YOB>;):VN7@I_
MF7V*+93D8"_3TI[G1(Y /='+@T*MY*<7EI:?C$69Q^ M2)2]@(_9SBI$,"?U
MUGE"N9MQ^W(@]-UN";T]9UF(:,*$%]X86.)N\$ODI$UA],6^2! ![P+AF=P#
ME!5^3>/$<*?]-T:L^3L^W0[6DK4D0982>?MEAEULC4T3*A 5=5HR_-@XD''8
M)(=<V(HVPY!8M:B\"5'QQB7=4?(:D&X4!HN9.L2@LY^7V-)L6 $RQ@Q%_+R(
MM1O"8>L4;W7&[MP>;K$5XV(VJ61J8?1MGORZ:CS<O& R,VI1COODG8&NY:Z.
MW71I4%":]G5YAL0R\8B&V%3=J*'"NK'2>]>@IS3*N2O]L!!W1JU/X;<\:N7V
MV4<:[G3"2<>$D;S8RJN<>*K]X&OTG]WH1J:FU9;B\3*!MPA,#91JL"<[*"Q:
MHBCZ) ]YO0X(O&MWU.K89M!?;G^0D]1BWT9+(*(W?!<I 4L0*YSCBL=,46"<
M?T%49+2F" GNP%YVDX^@OL>(P07DM8Q'LVVKBHN5@7#DT:*:Z]\!G-I<7A'&
MB:X-FZRY,IF!=E0HM5I?X[O&<-YNAHG/PU$]%P0CV@>AMQ"">#6Z:7X_XUV1
MT7X<[+I-%2SU<@65&S\:HJ4KN_/L3V2&E)@>=!&PTK9&G^06<LZE5.(%!^\
M20,Q2N>_39IUX"7%^'.I^2"(:R+7V?/%09#2YP'N8PI'MDH%1^[&[XKF<9-Y
M5=1M?*WJXTGW%XMMB7M3K.DP>&/_<\IZYWV(UU@'GQU1W4K9,)\B"F&^BQ*%
MF/DXL4.Z".90T/S0-^HT7+V:F".VUE+L]P::.]&:;R&<8Q9? 6D;OXB,H4>\
MHT-15><&.99O$S:I7A$FVIR!FAR+1_%[>EXK_5D70^X*<DOH93 EA8\JU&FS
MQ5[=,:*Z%$!I2BJH\ (9E?QQ?WV8I>=F[0*R +M6@Y@>4^MUQ9^3')[:J]K3
M_PZCT<TZ00M[GFH&3P^7%Z1#Y?C_WFK6 6> E9FX< \ZI_6N>4+3B$Z)YY1[
M!.(S_<'ZM? Y[Q;U; D![A!?^SIC*V@9 F)7 2V[*[I<5@R0]%>%NG>,- Q%
MC$P#A67 WA'B-^%E S='R;!M@-G(U&FLD_T8J7B/G%R<,,2 -%M,AN0T95]V
M-<1M]02W,0&HI,M[#",;8'BD"1%OW8DGY%%()5FC#_7+9?Q7:R9^!XR3O4QF
MNCW&B?CS,XR?WO/[?"P4L5GT1PD*O3J]WQ&]ME'JX.J9Z,O\W.[K?O-[RM"=
M?_ <EB L(N/W,T=X<"(@L$E$4_SIEN)A7NEVEE1![U)O;7!"NEYZ:6FTRY<*
M<@??S0Y[RG[^L)>R^*7NK-$B>C(;-A&@/R)\D4^XRR:LDO4I[?CF5L1GS99T
M 'K*&;#]YHJ(^N7;D ARIJ+AGQS;A6N&@/9J[OY=_/JJE,X;U,L+#88)Z!7#
M?HI$5T3=IX=*&=O,XZ/RW1M_X)V-VLY<=@PAL1%1]M.$1WWC_.WD:!>5^JKK
M[D78@WEZ5ZBSTK7>F9UBD _#/^1HY@Q&-_LTU=5 G7K;7_^BP)@Y>B_PS# I
MTCO?=:#37*78D0'V\\[I74JWM714T&7]5!3VN:.TW?"V;3HG07O"JVMZK4C_
MGT>=%#G@D^VL,ZQS\9AU5NJ%I0?>O"+X!& \1LV_(L I6Y8"X@QSY8XS-U_T
M4N?U.6\67L"]:U;&-#RR?1'CL(SCIPW+E7R:Y]RQ=5(ZD>^M6C?<6B_J?K&_
M'FVXGT&3&WXX=9.FGJ1LJ"DW1@V=^QPY V'R5VT</J1<?AEQ+WA#AR]:3Z?T
M#_U-J^I VP?I76[U^PQ#F$]"CHLGRZ9 I5OO1?2-DI3_U&@7NIG+ZL]7!+X)
MTN::QY'Q%H[2@='_.&#2E7J/ZEX"I]ZM =07>MB*#)&WF3)%APRK5)0Y/%2
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M"<Y\ELKSRM3 @":6*(Z<;H26W]AO]H.L49YJDDA3OO;Q/FSV?K<?+B'2VJY
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M<V0.<9Y>F#ZU.HGE]R81[Q[U'!+>3;5N[%%EI<+D[T57 /$I32 +;-'0$>$
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M/6DJ5Y_HX2=\5&&9>"BS>=]T2=#JS3=\:'ZI8:J5*I6-*.'[_8[<ZD[XX>E
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MP[-SLGQM+0;IA[\])OV)N'F(><0KA4-YG^R#[N /:OT+>FR]EGXB7&"(M:B
M@@^L1XP?ZGA-3^&[;[MQ2BWF6ZV3><QERKY-9](#<1"6U8*)*(E,V3E[4*>C
M<;5="0U#_'!^$<)7,<U1<)YM4!DFPO_$LW.8"+"E=?25M^HJ1X-LW#J^4*O@
M1->7=O- YYOT+461DHZE!B'7J?!UI,GK@U%^KMJXHS)V7F<1J_UI)JU8:9G/
MR_(:A("-H=L!C>5RW&+),E(M(A)T::,+.&$BJJ2TEE71S2:0_O2,9_,8N7%C
M]0:"8#]<"A/V+%H_&>EPCA_V13^E@;?N;Y-,V2V^(T9F;;I$ &W[%D+O7)]I
M^Y#T7;^9^J:AZ<0]BXU>F(;&!654<9H:*.7LS3G:E<S&L0.W;E=+ I;;4"_=
M%GY%'9>_.HU1)-[70]#6;]RS&9I^/$P^CEX%B>^Y%X6965BX^B$0%K6A'@\K
MKV-Z1#/B:U\A4!73C", KO6_$6A>BL=PXC:@M-C(7'N7#JG'V1+P5\=0G.9!
M>(?NA7.@05..=G5[%22*9"@KF:R!&S!?&+2!+'8@'[;QQ1\BY%QY1J=%Q,9G
M4#9XSXHJ#I7&H$_\S_8*TH"8)<9V^V56GK^Q$"OVGZ7R(7[U0>4PU"("]F.-
MLJIS8[U0M/FXH R;^@H@L:O"BO#*3HDSE[:+^SS'.6WH5NTC\[2)4#J&C%D2
M"EAZKG+@3/64,,O<R\D>;\@MQ#+XH<+R> F=_VEZ?+5P(B0;#"\%!-9?U\]!
MSX1&A_W#*W564NUYO'Y()P? 8@*!?%17-;Z38GL1%A9;_(_N]3FTLI]E:X;$
M?E+LJ0I3T%W".-Q,O>6^<I.8@^[T!JTT[N ZF8D 3_DL*\BH7A$Y:]0XK4+$
MW^QT!J3[O3'FYK!8:+0\$_D&1,.B/>$A_'4S=+H-.$6D_!;9K'(RIL2MJ19_
M3EBX%>OX*H"]'\=@[CU.?A_.&=MXM1QTOMMQ2M,=.FWX)QP/FWSX8GBM$(['
MO-%#V$#JS_M<[U>Z82:IO;UIP'$P8?,;J>.5D[POG.<,RK_*B9C+>MD?F\B7
M>1EN@XRZC-P;]6O"XF*A-JZBOIY(P>W#M&F+Q-N&XAHM_HR^HG]>?0/=7S'Y
M4-=;RC?O&5Q>_-Y7F18SXZN^\X@?U'T:/PS^*P&HED: ;E_!= P&B 3FG5:\
M=[K^&SI55ZD_8JQ%$>S9(.(X7E[6;%-R!WPJ*1G11/K\_>MKF<DN%I5RT7CP
M'?JY2XI46\8??XXB7_6-/;:_[RS=5*M*C]0?,DLAL,ODC;AE-G/ 5Y4(NZ]G
M6I\/NXH9YYAPR,8W$+[7\96.P/+!KN)Y:;;JSI,>!31O;>:=SL(C+'H7_ E4
M/;EZAT2#U\7Q#<<P5%4BVUGR<)75\-3Q?H%J,I?&:WV#MP7)9[;S' >BT*DW
M:=YWPBQ<Z)Z20_+>+-4_U_"Y*B8M 92&>6ZL89-A:ZW1#5%,$Y<4U]O/3"
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MT!GBSFT0#ZKK!\-;QB+]5YRL/G9*/=L'X2%"C6S!Q&R@/UYN[_1W@LV7L4K
MW4RCM'&+$+K<?]0,)A>E8P-VI:'UO&6U+VUFMK^P,+'<=>)8+=[U^][^MPZ
M2>G0!)UGNLLH4164NEMZU-:50WBW9CS0Y&C7IHXTBA)Q/'AH33BJ _YBG1*A
M>27W,KT0SVV[QM#<J_CJH;EEM+'(8AO_+,A3M(Q_1P4BQN4?(?7QX[^OK53.
M%S2R06W+Q8WU'L5247TXQ@GZ;5O>1Y+54^)2?Q7,SZ5=UX]J0]-CW7OZS8C3
MM1,5$K1DR15&MU0-SJMTS\! 150Y!I3=Z&#<OZ2PFEC/;N>&G;15-F1]Q9WU
MJ8OE_'2$8X<MG,7EZ6U<\+2H2:FSB+S3[\[OR<>V[_&KQ54$C0R8C+U 6KE=
MJY2#@OOG3T<)>WDY@ZL;-!/?@^J16W]O;1E]C'_LEI==@L'\V7S$-N8W][ ]
ML]WIMX.I78BGORX_5ZQS\/R)(9: \V49R1R?6;0.[6^74=!^U^=6<=W.,Z1V
M1H-4LKS XFE&:9O( F17>]%H:+YYQ$6B%.% Z17:R@R[6N.-<YS2;TVO&OJ0
MD*U >5ZP<ZGKZ(%ZJ!N@9FP%7Q@P ;C%_#:S!BO,6O[?LI5_2SZHX.-2M^=H
M*[MB:P!/N<$3HT+=X%*W$#-EZ+<GXD_8);A%DF%7]*PBXU\F?U(25 WZOX:@
ME5?M7:6"'UWL'*?<G$:ZJX8TLAA7_$Z ([7L(T:>3DJ;30C\PZP<ZN-B&&ER
M/W]52#+.<*W=PQ>0QO]06Y-.K;=8\E>JK3U-(RJ5-Q_VB8@OEQP,&O*=5X]H
M69U8S(:4;+3/*"_;[Y?8"9-[73,7. QBKVY3V_K<U @^R8,']"+H:9QC)3IX
M82O&2E2AA(,.9->]A*[4+2("5D.RHDU3RAGTW7W]?;[?KO2W;<X1=+I@!ZS6
M^*D_;MW1]LBF+.C'=E/3H)FR<BW]Y.3)SY-U#]8HNS8+TBDP?X+$Y&<9%)LS
M45H*N$'/L'+()'GUY;Y0^F3>YCC<^1FS#%.J)6>Z>7ES,%U.5 :,+5NQT2,+
M#Y@6%W!_MS\#8 0^,9T'EH6;-Z6G97.YA2=SBFI*HFGE,L0]DW667>/7Q"QT
M=:^!<U"VHF8FOO.B%HYTMU6I'XN@=:ASF7.M13B8<YT\$P0I*)D3U)@Z&ZCR
M_MM+_%^2UY+& V[I7%S;N=G" X?N,FF_93+,91EWG#8R>!?@&'9?TJ%T[V;J
M&"AZ;M3R5D H&WH1T.!MF+Y8\G[VCK^C,;LZ()2U".)66AN,_YSVSG">64M]
MP?Y4V$G0<9VZ4=A8F&6++Z]T=S?$(YIY055#36)C0;6_[XZJ;?MD2L^U/#5I
MA_JW>>5ACCHXY &HZ=K_VKP>7:[\!U!+ P04    " "!.F%4.5W*[?79 0"1
MX@$ %@   &=V,75B9S-H=S0Q=C P,# P-"YJ<&>DNF54',#S)3I8L* A)#B$
MP1D(&F1P")8$&'RP$"0,,&B0"1J<X XAN =W=_?@[H/[X/[RV_WOOK=OSW[:
M^E:G^]P^U??TK:KN?II]6@40*[U7? ] 0T/#:,%H 0">%@ R__'^K^P_(/^W
M&&A/;0 2'#0== ,,-!( .@D:!@G:4Q> %H &0,?X;Q, _V78.%C/<#'Q,-#_
M,PXE!J!AHJ-AHF%@H&%B/"-Y1H2&CH&)]0R;!(!#RO "EXSGY1LI-7)&7N-7
MTO9  6'$CZC7%)1,?!!M71?7^,3RRJJI&3PAK8R:VO:Q:7Z9+SYK)Z?JFCH.
M,?^PJ?_[LAC_[]* _P+'^3?Z@02 AH&.^<^PT-&?X6)@8*$!2!C0>3 PI=2P
MC.U/2']$93PK;Q_#?O%F[92,]Z7T*\TOT7$3Y(S\[R".SBY5#CZ30#XM9AGU
MBHZG><!SC']QDF"0 "0 =]<[P6,O,EED/P6ED(B\^2:GY5:Z<KQ3Q.7?@)/F
MD69M[6U\K4033E=2F' )X83SZGTK5E!:59MY#TWZ*2XW6IN@B0O'L1V*>9U/
MB&K#EJ@8<_+,<!$._]THT%K?YR!L/W]7>'-F<#?)ZK/.*$DR2*#5;M91J_,#
M.J3P 62EI_:WECSKW=4V_$%@OXKC^Y^!T@LN*X/@S7K\FFNFB>#BHHH&QZVR
M7LX5UI?&"X'QM''*PI+M]N1T]F^>UZXW+.9:S4>.2],GS';=>(FI;]\_#DC'
MM KXOB*%92TKUCKCVM>?[; =EOYAZ(>9U3(TPM0)]>7-JJH*2"E^(GU?=A4D
MF04&]D[),8V9\B>).3K//F2+6EYIY'8EJC!-9FQ=WYBT1'SJB>U753XU92C@
M9+T&C[_<SQDS__[FF^Q_VS56&7=;=Q7I=?MCV_NB4FX6/&L^TJ!;RNJ!DLF(
M*+4L-@4[N=+2B*']9&VH_O=K&"YNE+BF.X6_I.?=<71 ]?3'1>8VQ'WP?6I)
M7/".S)B]*_]+[K%)GO6TL"S!;_*V3'VJ#^.FK=;$9W^@63)!H[XX$7,!=R-C
M0QEP[-16P:.]CL_U*9MQ<?$LB=/=)?U_3-[QD'X6\OK4[&-P39M R#>HGV\K
MZV0?(\@[P^#-+.<,KL4(KZ3,SR'\[TS+_J_$_\=]=:V@P*Z&JX 9K0! NP&F
M21(A4X/*O8JDV4^M&TZ0$<S)3+2M3.QJ"E"O2+5-I%A>U'$F]\C' ];BN&)>
MS?TTLK>97I@GBFP*YQ),4HPWX&]RP<'V7TUSV (VNDVC3H$^=\O@-!N0DI*P
M*D9L3ND\+AT#F#9U:4YFP*/E">"I;3VDA^WI2.I !=_TFJ6V[1.\PF528)"3
M(PPG2P?_U(ATI0_'51/7WEQQJ%CZ/X3PO[F<HC/VJKMFL260B3ZUKVTU<1CM
M*K_BP4'@&U<LOQ/I(-73G:#-.GA%=5=4']V:HL4=1BJ:>O#V2KKKQA- 7A;Z
M!-BO$>2-'=+(Q< !.V1GS"F#:95BRVJ(HYX EGX@_2? [2=AE4^C'@\9G,*-
M*E\W[\Q:UCU<80XTO!NTGD;,XT:2XO>1V:Z(ZT=E2Z7@2]+2MMT5CW/%J2I;
M,=&&T9IU&FD:.$S/!@C"5\1B5PID@RB<2V%'?F=O;?D?883< P&*] !<8"H
M8^X?*V@W8B2NZ[K:*NKYON)DW66EV!.DZJ1D VV8&9,5ZX.6:)+711CMV!$F
MF=RV_PN]R+L#.>-=7D-+?HM#T#92?)W". "JJ!?>M/]3&5XU3ZI52YZ=@XNE
M1(_^_4WF DOS(IMV^<5R4&76',5BPCTG/)%WVUAHV(M(L&!$KX.SLR^72]DX
M*!)61!TR &SD=5,*38P.,23M2MPO]=B;LY; 7IB!*_29'W).[<.\EOL@7"EA
MJC1LM"#IWCF"C9-?DFBXEC0FXI*()@/$)Y$\]VFC]Y?;S8_P;?[C1BAH*M;T
MN[26(C/9O8OZIBY6RM+O[]L+?9S[MO3:TK!^$H:L@V7/R@-:#@=.A?T86ABS
M"/(]>YS 5F]N&C=(Z\=SJ:GD?)Z[DE^[5-]QZT :?PH57C .23KE92G")X5(
M8ZNR?>*^V^<1UZ1:G.QS,_2D2%-+1V-D*1X?]IMVWSW4'[*_7;E&ZM> 0N47
ME4,;J2O\F!ADTH*R_$F)ME'R=+[MC\U$'@_?MKSW1)X =%6L,Y5WSSWVK,#,
MPXEA1JLH H)8%N)Y(Y[?'/S.(3"@D&Y5*:SG$9G-L(^CI2B/+@Q@T4W+C; B
MF485/.^583R<U%6N9U*>C^'P>M>I&JQ:G*BL*_@V&/>+V)!S? X?0X[G5F)#
M"9.7L;""=C_%]JJRTKQ]7N;R+6M-??,@[$\1^9E$TU#ACJ5]OL_'3:?.L(Z^
MSRVM<Y359"/"5^K;HS%=[#7[LCT@9E8>=%E_!+%F2OT?8_R]5V8Q2Q(L%%WE
M\T/J&^@MM)HB7R]S=9&G7%9QI$:EA<KI>3T8]G!\0^"?_HY5&5-ZPJ]1$;%U
MV_VU];^^>FXD?U,HLN&(3=)T!XXFJ=83? QD?]6W0*@#F>,G9NZ$74%AETCY
M0$&.\"J:4*A]WA+;"BJO)2BS.:'Q@BLU +D4EV8R^XO*[R(J1%SW^Y336/1Z
M]BR?(EJ]"U%;:'R*1G!HNP,?6G6"@:3B:N&+%3?_LT8B1[.4E2L9"8=9^7(3
M7"X.R@F=\QZ-]HRV-\KJ45\5@Z3'NR]UKH6Q;J>U[CZ)D69M.S#)D@DD!ZXD
M2VX)G!E;1-=X*5AL?^F5QUJ?QW<T6SK4M)@&R6_P@!TI<'%5,C-_;/:QG%ZO
MWFZC7"]ZY=&Z.F%?R[SK$X(>MLZVX;5J_PZZ5&E_8_STMX-!GJT:AW[+T,$!
MZ>S.B  C_GP4<;2X.>0L*CM6B"PM5?03@'S!C/^#[])MGN>#,,F<MLF?_X-2
ME=4ZYY:(4"M!<AIR,FCU(]/(;@H,Z2.XL$_[ )$JC&-O0M0B5?K-14FI_5\/
M%W]LNOO)@ =5W*Q)M,[(6I4_MI?I'1Q'K.;+1XZY8%LY[<!;!C]0C-2@/992
M[9TVPE^./\=^0:M<H MFXD*/5*H'^+NMGCT:C5[0?PM.-K0N<XEYOA"QL4.-
M[5[]ZY>Z'.R$E?5<<=7^GW9L1!BE[>\_^ P9SJ=' Z8NIKHDM'?)#:%?_Z[X
M0+*](2_[&%>0/A(QC_JT8N&Q3P";<.6ZK5/4MD>D#SN<HKHNC>4*'6'*V0E)
M%F=GLZ<&X6-WY72QLA$Z'OO$ =+ER])QP!>J37P>W8.._C]->$@,9:U4.U[T
MJ2SZWYMF/7PE\W<@@XCETV>?]F/<]M(<VV9 36HE='6IP"O412BI5)9^7!3Q
MG_&O_< (8,ZH7SSC2R(8'VVHC]C--Z860_-V /-21!+**30XM>+F!J@^$DQ<
M4$;'U8OH&:^07O0(2.B@LK;+<2=2M(N@CQ_PD8Y8H*MMX*\,G'NLN6I8H;(G
MK F$0O7A74SP.G\L!@L=/*6_Z0H0C6@\!2"Q%&W#'^[C3$YFQ:B)=0VM)*;[
M+LF\O)_U,3D@#J.><1PE2, "GOU,BKV"68">TF_$-A4,EUV'AAC;.W_8<ZUR
M<69:*^TH_S50\6=(F,DQ8""WID/\%:C$EP-B-I!X[;0S-KFWWAZ02PG#BRP@
MS39_X+?)="]Y5O/FU7NR@/IWR-4N6XN6=;(G@)P@G)119R)!&Y.)<_"/^HA'
M2) ".(""Z:,L N"S<,# CL042H"RVQ;"1PNF[JL)$<+^@6YE4P>738(!V'KQ
M?!^9#CWNU9GQ _NKGVW*?7-WR&A2WSQ5L(J&*#P,UT7G&LE?A0IMF'+\\2-Q
M2MK)_-^S:TB_B%0PX8?8;+8/_+7H"D#2J#YJHJ]IJ)V?Y%6#3*-E'Y6)$'U&
MM9,Y"/EPGTS <_KK5T$8[7A*00H<D @@.^F2HO',/+FWS^<?=F=W;E3%/GS2
M^1D3G!*;':E2;"RSFS*70":6<!6,B.V;J_%Y'X/+<$FCN.U^TP1G@I5WXDLT
MUB$UWD@2!DB6X*PBAUYX!NN&CPH[)%K"EJXN&BR)C)HZ;I5+BF_"OAWYY8T;
M\V;?H+2FV%D]_'T:UDD>&)P8/9$5BU*2@EM>"F-$]&U?/WYF&-Q;14?P5>UM
M889;3K)_'CD@_#$Z,"\VO87,3?O:>P\3K\?N<^PM[UOU1MP3]6IR+T:L6:HL
M]_=.0A(H->B8Z+#',^.;@M5 L04<I\!45W85\7MY\#F0\"'@"2"N-(YKGAJ6
MV]1RTCQ\\%NM[XN,(&L*/8*A3^#S:&1"\BI;M3NPHC=*HARR'!YSS8ZGY,W>
M:_(U\<>42=(HB*EUZ#LF#PF[Q*/;N^!/0"+]7%&N'F/3IW]EFB21?BJ"XJ78
M#_C'Y-9H8K9ZHO3EY02]88$NM\2<2RG85KQN H42G@/?&H-<-2N /(Y)T3X/
MH))LJ<@F?;_PWN]QC[-65J5W.Y/KN_G=Q4-A<NGSK@1>0BQI9.XQBW].SN9$
M<N1K>#B4"3Y61JF7'W&&86I:41^6P?E0X:"8XM_7>#=+4P*LV&'[?'M@S0Q^
M @0X\?W+[BDDK95?5Y,QL=<&?N)SRT.]VJ!Z^NZ6&+.,WI(,4HKLBMANBX0.
M]!<77I)EQND+5_8LOP'FT+4/L].?OX*GY#J]X!92'Q"X*B2<+?PWK/3AL@AC
M0(']M#3-:CV%+()W"KO1Z+AZRPSGO/5LF\:Z]NB_!%8_[N@)T(K_6P+4?V&>
M6>%KV"2%4SA\9ORR?IJ'UV6<QH6B)X93%#IQ8?_;[)56:5=JW=FR9PWE&Y7B
MR%OE;^,/WQ9&BWOE(S/$7A%96N^]*ZD\+*BL8!4,:^FP7W"_8D^6O:?@P/MW
MWJ(LD<+#0A%T<05AXCZDL7[WGX&B-P^Q^;//PB311D[&:J?QSH\\F((T_XI2
MBG%^XP.5LMGK<7R0Q]%QZ9[]'73$,HRC@Y5#O$[J2DN/P[2HLU^R=!>+61=S
MMML\I#<]D.!L%J6A9BXL"B&>1'PRU6)W&>P=1DLRYW2]3]507;0XR*%.%3L[
M2/5OD(B] VD<,,QO;S^_4PC<&C[G*W0&\<6%RNCM$@AWC)<A6"'1D:7\C^XJ
MU"BTC9N+X_2_+L3U"Y\V=N]$8GGUI4-X?2K.K$5JH6L%"KA0+;'K0 DVJ-BC
M*PIP*]&K^5*T:OPFO+0I*M[JIE1&9A2[V**IQ=WYA"7",8,>6,Y/#Y2O_%E7
M^8L-GD<3A;_E=P_$W^5>21O;##39O*/SLO\SOR?(Q-5FV<-?YU#@0!DYY#:@
MV*_23]VGG!%<;IK-5'"!BAU<YZ^)]LFIV("\#F$B+/L1^4 IGK!?_/=98,OV
MW.C,0?H!J9D'D9WN!Z4=^V0W^C:3X1B[66LEU2[;"4J@7/VNC>#JD&E#;*J,
MY>>SWJ2U;$5TD=J$,2U[00_$<4DRF_H7TZ.NPOB[$8> .78.>TGOU)=WP?=$
MM,(LD=@;N2,>?<G?59A!!6KN0RYI%<45Q:?!DY*_]]5>QTZYOXK/K+/?G%.^
M!JK(&,NUUD7@XA/492.RMG21/I)^L\\P:R.)O+A<F$)%CA4 GRHGDST$/>4\
MT)U-<LO(R_',365"WLC6?13CE<D@E!! C6LB-\+]7Y&O4<=Q1"N "17W5@:G
M/3_<JHA=1V_-A!DWG]>?)R;4!&0GESC\+ XK-,DD>-!(:_@B\?-QH+^6&(F(
MBR<0:-.'V:<XB.Y+*1>8_:V)7>B3CK1R*$,QU/>F"8@^ODJN"T=9V8'TPAN#
M%(I*YBD._=P1?Q9NU'0ID9Z)%P&*,<M\H(\\@@)XE')F4O!/4K5]G+N]W-K,
MO>LM!F</*1;8;I&"K9%7^E5SE3ISUPNSS][85'RMD'^C,B_*?I.L.=2G$:@7
M^4=D=WJX6G".UW,N"FX1VZSUYR(W]7FPHN=W!A4ANL96+[8L!S@Z'!8P855>
MQ?%U0;P@HW="ZP5N;"M%.K$T!"R!N_HX=H!Q$-&^?;T[4SNQ6=DKA^M@MKU9
M1+3N?OLN86I*Z\O'5AHVV#FO5C7PCDW9S#15@G%P!>-LYY^.]C#E]5$8EW)K
M>KOX"B9['D[T.Q3*&$ WQ:[_ZG2JH^0PP:=*?OX%; Z9XN^,57AED#D?JRD$
MG:>&JZI=!3=_!(SVD97DEQUOU3P!LH.^8.NU-'_\0;M?[_5@]*^2WQPS^_\U
MDEY^WKA  !HPI@W@!HS9 4BP9+[1B,MF^X] _^O5(!I$JS["F'2KOKVR1L<;
M9_^:K(FA/CA7V9D*?[J2 :Q+:-X;2!J77@!$QP&^.""Y_R:G>Y6ZW?&V._/G
MR$WI]&)X#I\R=*A0^=M]-N \2'-849\Y15I^OO&S<34]T]^)0ERC8#6[3=^5
MEH[BJJ7.C?*%0 /]$#S<&HC?ZR? ?%VQ5C>L]S<.[$:0A$E'FX&;,X?'1%0X
M<-F^9\&)9[+:%1GXA=\.NCUJYW&!GWX2.8,^@XA!:X$:65F%&$.*Z9D_;L:%
MYDU'5A?LJC"51AG>0T,#7]!4Y:5"2'^T;: R530 .LD/\HSEGL:?(P]>ORLZ
M=ITP$8&VVBXE!^ZY_72GQ?AH+BK/&'@;1\A^EK-SX<3N,0M'SBGY_OS>$ ;9
MZ LQ')14:4XBU8>N+A##.:T(ALX]6QS%O-N47V<+A%^65;:-^2E=KE4UYK9G
M(P^1IU![8E6#],#PJ=Y>=Q_I<?+!,.%OJRI8@)"NNEA6OP)V!DESJ+R@.#SK
M%=QP0#S9!<E]X:Q>TSPZ$=M5D=5BP^0)#^LU7FC82>,U5O)GVGW>7E=P%TB#
M4,WFX@OM#]T852CY-9_HT6O2_,QT@/G4:V$F)5[AS#&_/!!._ZF6NL//V6S_
MA</\ ):(+!/333SK=G>MKS*,9\[>L-68'3+I=[I%&JFHR*!+[ZV[XO -%;VX
MI?QRWA=]G;;K>VK83DW=#8VFNX; RWCI9&N&JIK8ZQ-LW!,%<;;MOW210M@9
MYM'K1^\O!>'6*TROZWW_OJ5N)P)4KTR3.Y"%_AH020U[#8J>DZ!@DLWSQD&=
MKF+TWY-B2_26:-L- 0GX(ZI#JY[1?ST/^$S[_,/LQ=N/W4<RX.Z2HJ%%1#XO
MPK(GH_>+<M :VA8%MT@=^\:/02ZY$^5/A)#,B2#4&?RSFJU1&A-[DX+(<>/9
MDFVV-RZ+MUBT%\!+?4I-C68BN;'F3Y']S]D2F8[/.@G #PAWI?ZT(L3TG#VH
MJKIJBB0ZK3%TP1_"0OY%R8DG\KF9:935()268F3\_B%"28;6?2Y9RP=I9>[Z
M-Y]*&9II-E$U#KU[_19(3BGC_NX,\W3PI_:YSFK4S?8-HX\J0\9MN=T2]X5&
MJ]^KIA3^=Y?4]S,R7Z%C4R9C)C(R^#>0<7<5@#^F/YN9?+1*Y+D\&.-X;J/0
MUBCIX7$P;N,(-#HX<,+TN7PPGJJ?=2Z@E4)0I954G8#,_@V5'8OBYEH[W9$V
MA<R.SJD=)JBL])5&G%3>>YY243V%:0&M$<:$@Z[P6I)&MI5BUO]/&\:]:26C
MH!<. M7,:U3756,RX"BP0Z9SB&-SZ$ES2 & :,F=D';"]<SV[FKT\0:KXFAJ
M&^#L.+441@PR0!\:2-?/&'$3(?N%ZU7U#-0XC\YC>LXL%C23Z@2#YR;#F93M
M>\DA?@RX6,K0("7(/RE1D87J>R07;PYYMG"U=9A^"BU;#+(VT[ 9,+-4290)
M?>.0(GWOY?(S&H>VCX8D;/Z=6L_XBL@H89X3T6:<5CRWUTTSK2@OZ *Y[L]*
M/E=2&KD?6D.CI%H?DT"(80.8&)^'1D?+*3\!=GY&T-Q,P]?J^1A6CE][]%H^
M3R#74%*]9_Y:E_L:+@X )?&:%C-&5)\!J),"OQR!:\_26+YT?WN6XOS%Y?;F
M8)2S*#SCX1U,BD*YEJ>"W,#^HTB <G$U9(_47UC_0F^-=#^7-TXP3Z?,N" $
M'SX5X=]3#Q"L_JVW\\%@4&:P*;\39QNM:YZB^L+_T04W>>]QY11G3EQV=&G.
M0/>=5-#Z20OF@IDN68 !(I&X:6R#DM.<PMFIN_ P<<KIH.$VYHW26F>"7LM"
MBVJE K#;+WIZ;.6*4C!'YM=XL@4\GJ*^I3]/+5/6;[2D]]0I-S4W(_N:+;$@
MC2( =$ Z+RV;4)0'#OZ4H'EYT ME%+S:,A_=D]KQ.]QOC?/>K'JE/BT:BW0E
MU,-^/GJ0VEC2_[6GL-=&DR!VN*0F,N&#CB"79'@G9/_@IQHM^*+"3/97KAIH
M][FR^DE*S9(PFXM)*]== \H6_T)K$A0TX%2;T_^%U, B-O[O63LWB(/:E7A
M"PT[4H'M4HRJ96-N>J=>W(CQD%86L3=[I*RBJ4T3@ %@ @ B:"&5]ZD><2_=
MF.3T"WT0X(MD*8<M??':)O$?&:$4'+*(9VF3:/&^-%QF7<4]J1\O97<U$:":
M'#O?NUB--)D3(06ZOE7[1Y-K19.,,D>1OI#!E0S2"G>&3JO!+ S@W2O$,[)
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MII'6+-'*F-LC,P0FM<G%65,:9F@X&B7.N+(1C@U(M>P,WG32/ GU:UYD.H1
MT;CV.0IJ:)LTTJK[3YT9(B7P(#-<"HJ7TI#=)X I9?3\>5"K!_JTWX&G[>65
MX<>\,,6DSS89]/>A%1N64@"VC_[WOM'8]!%TLG9$0"\Q>H>):2^'9>?PV->
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M<%U37>LAEGSR(&,<G> ,5NQ]2$J5T[D.M[NEGH7&4&ZQMQ9VU;,%:/"CL K
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ML;%M!U*QQ!:(/Y"E"B-I$<C=GH?CB93P?7&TW.1C"3MX^F(-H[D+2?%9'Z$
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MG(%L25P@IQ E=5VRQ9^Y87&:(#S$Y+).;RF,5U<;)PJ//_B#4G1,9[YQH-9
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MZ$:1HBWWBX+9<S-?IB9HY&HFK_X<?8J_]5FC0J\/.@4E.L'@F6?X3@I..9Q
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MFL+%;I%GMZC661%("F9=_T9/#4])0P87 8,ITC\!2F*S'\?E 0X(ZF_/< .
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MH*EBGT^@C!/:7[[KI<G.G&5B4%<0=H^3'+TGZ8@4@0Q=I)>P7;P28*@95LI
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MD\:6"N<'R8AF@8JE-_TH[==[%))@'4&[OSY 9 01&,&]2)DP  A^195:%_(
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M,<_Z[TA@J+_H#0[H#(PI=O*?BBN!_6?^J9H._DL>+768"$86F%*3&LAW^Q^
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M0@$9@Y@O!V\&\O83)\ZQ7W]N?UR4N@N\Z$V-^VO#D:KTGNVE 7R=_0)%'96
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MLD&&E]?2+F!'0^2N#"ML.S3[5^KD0VY*FTJ4AE399>2H<@MJ22D_SQSY)/\
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M8D>CK846%7PHS$&%"@QFHT*'$BMI9CQ8T=E*68[##:$-LLMH2VTVA*$)"4@
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M4)<6&TQ@%>*XR/7Q!'"2 5@J*BKKZO+@X6#1AX='A>FDU@C]5550N;%R]S:
M&#+UF,U=1J))DB28;TAFD"==%8ZEK=PWMK%N+3*I:F6D\HBI;=:0A2N..6RI
M"P?$<'_54?05X'WYV'1B,":I<Q8G>3S/9*\<F@ @4O.X^<G]G4SUFW,_U[<5
M\B:];VE2EP-S66R5@H5QPZA#()/QD<%E:5!84>>" 1SJ.(*H!/2-K"W4<[KG
M52*K,&L["VEA'0=59_7G?1,7."+7';)^LAJ2$.3X<AI2&TD*\DS>6RE".2D)
M=0]XI 2A(2$@>#CY# QR:O#5A5DS50/TD@7JH(\,ZFDT/=WOVHQ\7!I -0Q
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M"]M)NW-SJ)%P_P!BVZ]S-&BZ0M4E00E0Y("1Y?NYYY_H?S[]?C^>>FF_U^:
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M7/BI27$J42I+JG."5@I4D*\5'\?P!UXXP\2JKPBBHU&U(IJ\1+L89VLN]1I
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M3^9F*,*FD'^[P8I!/AJ;W?PYD37G*LW52U.%15322P%6+72*8NXIPZJB6B1
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M2:U#'S/*D.M,B(V ?,N..+0/%"1Y<K4/%/L\\$]?M--%%%(IIHIHI!+4BD
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MDBK'T\:#HLFB&^:SRW'J>MWP>$P:'OB;]96[;LWRIXN")8T"I+&-=G#+ZQ^
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M4OD'0 ?@>.,,Z=U3V]J^"K42S2 C'N&A^_<*OZZ6+]OP3D[JLL09Q"6_IV2
MQ+3'![WD #33E4 X)H^H03-^\4K,M.QYWZY.O<C$LFS['H66TEX<_JQ_YM?7
M>]Z?%UF(<$#_JLZ] MBYT!!D >'<1NS[RU&V5OK%&7'K#MOR2*EJB:]-Y=("
M'$P?OZ=1%(MQB]S2AV@:JK/N15#3MX[.+:*HF,G>I'.: FG:'-9V!$(<0100
M6YJYSW^^S,+28WXFH;1+.^\[.)FB[E&<?]-N=*NUT *>S0WG52T1.:LK,]G4
MH;4XO$_8DWSU_6-E!#$-@S<*T[:W#SC$C>#I8D[%<9"1]?4/]%8,A41$A&DU
MJ:FK$V*'YJ*O#&39[NJ4%@Y()LI;T*PY<]#->:*,4#X\:Q0L3R[:?#51W].I
M84S>9=D#J@-=!D6$)!-W#/5-L2*S;,%JR<3%/6'((U1TL]^$@5.Y-0XAE^]\
MHW$.&WC_ 72#%.B-?'U<WES1N/[V#2(GRM?^J-7Z![ $D"J%1?0YMK:&$04\
M:@7S?O$'"<"O)?C#>-]QB;);4;8OD,1RE\(SJY.3)?VWK1R*6E@2L-I7@\;9
MR]@F'':;DY)YAFU:]>4E,Y!#2E9-W???"Q!\,^-V;]S"*&Z(D/]1^]6]XB+R
MT,R59X[M/:H?=A>)/F_&Q7%Q'MMF9%$? O7/-1*+Y!D%K_:C+2G'JJ/TY,E!
M+%IIK_!8&1;('POL(1>3+?BT#M$R,U0C)(Y8.5!U]\8#1(G4?_6P[ TBQQ@$
M4AL;S8>%&0 )YHVQ1*G_?+J6RO270_TU\&NPAR<C1"W54XZQ]VZ730(334BH
M3JO3LRT_ZIX!B$VD=R'M)HDW:PTB8#Z33"HJB$M<4D+.0\%9JU'0_%N#44,P
MK\''/-81+>0G3^G(O / 0C[HU//VP[W 0!'W?^,WQZ&'A.T-?4G>F^2.%J,(
MH-V#U*Y\9=!SE ZI1 X.QDTNLP*524@C^V,D_8C/49,UA/2)?MQ\X>BD"P@Q
M?)5_EQBAN4>J$*(HC>]N4H'O1Z 9]?<B0 Z[!PKB.3AY=\9PR3 U\CK2]FW/
M4<>,)NV/\/5H0XM3X%BJ,JMWGUJ=EF1437]#5NB6/(V\=#\71\,OHT-TV:!+
MOWYGHV__ &'?ZZP*/D=NY!I\, D*^/LV5/A3("W?']'O4[\<I1#Z?><G:JOJ
M+&\=A+Z29Q2-ZA8LU0^TH?S_ )SDJZ79Y7?.DWL#+#5\E<Y5([^W.2B!N%61
M+*6QS;F!2.-\*:K?MV'!Z9_&(>&J_P#4IL5:6,UQ8WIPPSW,ES\NQ^7W\VJ#
M-&TP\P,A?QL(8DVRFRW46;J9/(!LB%)RU32$<Q1W[4O;VV&3-QJ$&4;M'D+#
M_.)?"/=N5_(S7#7W(;)]??6J);/I*/]\WWX&OBPAE5GCTZHO2^[Y2S0?QV^"
M\*D0Z8KS)'RB@::(BEA+MXJ913))*&A'\!D^S;.H"=_4NH>I1Y_Z_$[[UMHU
M@%7.(\SFRJ:EG*6L%UI<GR3=@J>^\R,U;RS\U0J>1V @W24NJ:N:0>7E<OI8
MH;]JG=+V^*BM8QO%_+\#B^Q':>?BZG[K&N+A%*,1["6,H=)=UE;H^[8N-O3Z
MB)$4(B\%MF5W_3)A76');/,UB+D+,5-'>F/Z?GKR^$M/V/',IQU?S^23%?<9
M;L_W[A/UJ7JNGXN8F#$X6I.2^1#C %3)3 C2#U>";R)T"JMWYQ!)Q($]CTQ\
M1]DIEZD)^;KZMS7N0X&= SY,XSBE^%O(KZ(7A?Q[4<=AJ(32/02:J12AB29'
M=W<34-+\^NBL0]=/KG<^$GHY\M@5X@J1OY><E+\[>)6PJ2Q"1FG;5**FL@#]
MQZQ0$Q[%?E%&B\=JWJ=X;/CQ!CGMB;![W!YZZ9217"_>78#))3.,&FON*#_L
M52/Z.)V"7Q(?J4[H$D #J[L',]NF*3.0P;AI?L?*&*=17TQSS2EXFF227QGS
M_3_ U7YYX'KJ7@$L*EE#?="1)P1P+,?Z_KW<)<L_@%KB"7[/CKWL]I*(5//K
MU5VN:\N*X+$QV:*6*#AUW^L#[^4BL,AWST,+\#8/!#V!'*9J]!!%GN_$..5^
M[M%>X_U]/![%[WJK&*B\O_FR_AS$C%7&F,RG$5]H+\Y>A9P[=2661^VG6#TA
M:N=C8/S>0EZ2__P^7=>V9Z-R35::!VQ1-D_3"&21A,*[/)3E-A.'=G)[*-LV
M SM.';_[O%MT^S "N'Y\:3*<9_A;&4-2:JO%?YU?2#,8E57ZMK'CM?/T)DO]
M)KCI3&E\L7HS8QI]_CIRX&?YGRA3'G/-XAV)!<%7J:@E,)11#+X]@^)]$H=1
MKWSLA:+9^7VJ2"WHDN-XM7)\Q&R[9<[*?(F^#D.XM5W>DZ<\RFG1VXO8>_S/
M8<TWO[A?U !7JJ'<C37N*!J?<H5D1XK ^+Z3.)JM7%^QQ?@<=] SU=6MK'>;
MWAFL$$2[;^YPX0B2;-=1L3%J;%[G-G0Q)-4R13=,D,T?G?,61]"#^U"B0M;<
M*,),7,KM]E8I?!KY6ATK7!-7/VH0HP]7C3VO,N,(,OS>X/G)\KTDCH6;@M+4
M%F$KF$>LPQ0= @L.]F>9EUA;NW5R_,V/_-'(-_+0*LK-*>NL^0K"6EU=HT-9
M'7X$(MI* ON:!IT')K-Y.#W0O0;:.E/Z=K5[I#1_?;?^AW10\+!2'E'?=9%D
M^.C[["*?&7=8PH>4A94Y7,EX_Z!?*H!']RN1N*E-%Z_SO?JR%@^\4FO.9\@[
MREA]/;]S4=XBV5VG) *Z.&N'>>;&HD;69(&\A!%-"BGWFT_WL97*>MI9SK9>
M5<?U$RV,)D<6!,05X5D-AI*E13GC6E6]D*7G.J(%]N^ET?\ ;4L.PTW7+$5H
MAY:IYJH0^)S[^+!EL+J<G>]C'_%>-?'_$V@);]D#[,W,DK$BQLK5#M>Q:MV,
MD5-%48=/'0E<]^-*0/CMC]>U;M2"F1#1D:6,5UG>X[JJT35:[]A\54R9')0(
M;5XR9FLF"J2PO,,E]?G$Z%_8FEQDZ8 Z(*=%_29PB!+G5.%4Z]&J43M/86=G
MF-IX5+.SC+UERO#3D(<8E_QAG4;A4\*IG/)=R(58(,+MBW.+3^V)!0&>\X>K
MIY?1_2'WGWV&XOVVI2Q EG:]UK.&,0DF%W8V@H?F:O!+ZAMN+3B.KC].-C]3
MJ0"1[6FC*J6T:"S!]A\@%YCO"JF,82?\/L9#J+,";)M-.I)W@9I7G!'I05N!
M$HKQ:A[[<>:+XB0%,Y-VNTO@80:2DL7C/ J^Y/F3C'VTQ32?/?T,'9.':JIP
MZ$3G"+=>H)Y0NQ48G!8+J6MNJL]H+N@/P?[,(48K=5:$)JF^XT<^'W)U65N?
M?7[[M*RQ]*XD,]G"K["X;+1KZMLIWV:W3(:;9<+T5^PVA8BAE%Z!05I(]$@(
MA@Z6F4#8\LC50W.;X8$ #%WX_N[$JN.PFJDQUT;'D')V90A[\':PNJ?L@Z&4
MC(;H @'3>&#+_M)(_/9,E2V;X2/#FKZ.?+*UBRG-XYTJ4"'^>%+2)&?PY=2U
M ]E:=TR>+B67'T9,U#%Q!@YSVWWP31X *MI1Q3@),TP$:R.R:EZ4:^$>E)V0
MQ-$HRI4DF'.MNM$J2.HD<&0@9GU/ 4ON.>=FNMS%;Z>*@[BE.CF1YJMJKV\/
M[,S2%+$'"*A:(]"3V@O#DJ#^/P#,E&#E'<: 7Z*C$BHO-Y:^N8:0]6^II^V)
MQ*+-CM6VFJO-^9.&]N,A*G1G<+P3>4S)VMC[6@DL(9\+#^6K:['96%3BKE>7
M9=FE\YJ$9\+2FOKUK\79ICR-5J8*1'W@BEA=, ;8&^I/D#+C8X\K0G41)U7B
M5;YSY#5; AS7GZAV\D%HNCSQT]B;O?SJ1IW+)\7U@9+G@=-V^\5:U6&6MP4>
MWFQ3V'JBCO+YFGL[ ,&66?^+;__=_KR%.C+9FO[(GFQ2;Z8C;&"=T(QS:KDA
M>L=1)SKWWCB]MLREOWGCS' US,:X_1!D3\*9<8.'ZZ^$D_;[S:];'5"2DX%^
M^MAWI$GC5;HAO$A=Z2FJZB9$$WD2!R?D1O$(3Y7$;=XN:_)9@U_*R6LE/H-1
M3[482PVVA)Q2E]HPZ30[.?*@[)56>E,%'BO&*_\ LV-RIB2V@XF-#2PM6YH+
MJ 7&+K/>B^SW]%3"$ @*&R5E4J,L++ &&%Q["?(H+4?-"#?6LF[XN2]'P7',
MF_+ZB?1$M_1H:')@:/:NHDL?'Y/[F"8)6%A/=O-A>QBUYQ^ W@OD^?(/,#9O
MOVB>AJP[9C3=U*@7]VF_:JXJ8XMP%2\<$KXJUQRJUNH(1=10[V$U@BC5)R,F
MT^=:0F7)/1QYO*9?MN>%6;/())*7O@QSZBZC&_\*AQ)BR"M#QMNG.;AH@ 9]
MOPUA;9AM4Z<N:,K,*M00E]W:QB]OTB>T4:UO(D\1[4=?6MH3$H[72-^T65)=
MPK>;'>=DXY+*FC[0RVM1W95[#)2)S=-3EF??N[3_7Q']/S#EO7;/VLB':KO:
M8'&W46*YNR-L8K&/![O%_$(JE7!@Q:>L :&C\19*YES[JJ,0D^V,S\F Q#$K
MWU"O7565MKKQXP7UPE<W:C[C(6B+3>F@"V\S[/HAU!Q_0'S*>$9&[>*D2:*\
MNE+U;P'5E7R_U<6%_="^&>>$F. E,<G R.^ O@<7.JKH2X!]_9):D^PG"4]%
M:X*/Q1E(\Z'6E*C%Y4>BF"R]7:_U=\35-\51"4H^3.:Z$.&.@6O80*Z\*MQL
MP_3CF8INYN)\KZ>%H_R0%3?&0M)H+G.R XWC64D1WAXM#^A%\R$H=[O3'(<_
MH?#BC;#/\;$R#/GO'.]'#[UB<^:H^!JB=B;:N",'QX=@7,IH#)F/ G8R[\KW
MT1[<V/OJ7;[MX=P*=BYP$)F(I)<=51!3X1!E>7KS4LT_.AM#MW7&MM3FU71,
M_CQ7G^,/ C]0#SDX;)CB-&U-?W)G0\'%D]>B9T(:)G<4B>T6@O=_/!SG?=1[
M;-Z R#G^<=HUH_+CG5!<J'U<MO5*M/&ZI\PX;5I9"6.^*"%JIOT44LG^O:*_
MLP0N1A=P<"' SC'I,5LQ,);]@VW,)1/*1KU:NS![Y-47)AZ'$8JG"T-_U.%@
M>@B4OTO"^31%S;@H=DVEKV(T6](<W7:^X1M@ ZLJ"GF7%$BF,UW8LMVKA@-O
M!5R>Y^X$3>T\B:BI\"X,R+!%^'&O0+!:&U]LR] W@2#6C2(<\62O[5@<*KC)
M_=5MBY:2&,/3DYW32&O'1JI7Z\M70\8% 9N4]<XIH^Y07ABV1>0+3?P_P$*'
M("^P4.!I1ZHR@7>!H?F:"CFX<9N5GJ:7>V8QYNV+H(M+G7Q;+<[/$U[\VP^L
M$\O8(A$S'>^X@C#H'(R'+$-[<>-7+6_B<R1 [D5T.7ZEY$[3*W3%:YGZ-;\E
M#5W=*;Z+GE%I\A^O>+C?50V7_Y6M-</%:EZ&^!.TAER 7E(*V8O>K@I& S:I
MI'%^#0:+^=6/]O*OOI6F%':0BGA%JK#N8O79EU9>R5\P@TJ?Z9]9[A]%#%Y5
ME+$?.^P'+E_ &H9AA0OZXJ8<7UV;V.IWCHI*?0L0>_F#HB&6@SHXS>E8 DCC
MS7F"<OMJFOJ$& ?EY2R%/WE558KSW)!Q)?91E =9 #.V:/:N]D.[)Q5$^/EL
M?_H*QH>JL*)L^R&_5^JEZR@*NP(;@]_"N#.4+Z%AD>HT@_#<E6 @M<L9IR_]
MMA9!)-/6QR8H.5+,%VP1'8G^P;[^RA/*XJY\]]9TMAP:SUJ UX-5=8SKCWRE
MVFQMJ/YMM=-7GRB!Y<]?.T,:#XQ"B]8RPF21X[(C%O"S#9E1Y*4J'!!, @M^
M;1F_2 U>EO%H]G/) /\!7MLY[:UR[RYJ#RK][N8$N1<H98'2LP&0B-<OY2=Z
M,BZD\KN57>4_7%]_.+YV-)=&/^U3;_*X8BYIX4'B_G2CW_@$\T']H>/O#.62
M\@CP"H<D?;F3Z>/D%-3GK"HS(DH3]:7GU5WP]@I4'/5^2L/U,E/C>'+1OO5^
M!/0 ^@$H_M-H$42&&AD9K$O!<A\R+3&E(T/QEL0O+B%R8 EET:D'<1">;+?4
MY70ZLA25&RZ?_Y.%A#EK%-*[?OZ6G.[!R!V-Y44S]2LK&S+8W<X U !F*8^"
M&@R/SW/7P0B$UXS*H>8@H"IB=;S^5,,^\8XK>GQ[5B!92\8^>F9(2P6R%#4Z
M<_M72X+T_P$0* WBN]Q1+P3WGQS+1'R:GG!2>=4FE@N;$P+WG%4,\5@M78&C
MQP3)10JU$[L^"C?#,']YI0%K4>^B@B79/\&! '0%M</9\ZL6>"L%P?^ROK_$
M3AY%VD\!9DM[H.-8I9HYG7%3MA2U,<MAS.A0$Z,6'/3D078Q2N@?I $,E;@]
M=0H+::^8&K*@/]VPAFDJ]R67F3>G2J2FE26?3OHQ%Y:O?MB4"*(2H(!A302]
MDN47'*GE[:!^A,X1H==FTN/R$88?0@AV>7YV,LI\)7?&.H9Z(]-DL47$JM=)
MC]2!! 3^>&""H#=";!RDW"'0[^O5XJ>#<:(3*6*CBL[/M1;L1</3Q\I</D^#
MS,F"T*@ON#L>P-8K.E'1]1T/^T \N*@8M3A[A7_R5<(;S>^^>TI7%%7%>JST
MD>XSC_!LW4H=S58&.Q1'4WF:G0?"J[Q<SERJQZE:L1VJDX/IOI']Q<KPVI4Q
M9'Z_B9!]S03&XANO^GI>,B;=NC5=F[@8:V<<7-4I9$_4?K@XM.VM.^CWTW&)
M[P^</&TU)?=[%*W=+=;,.NNS[W+HESB,0:,CH@&;<;@%!_:HY G#.ZMU5Z&Q
M[=>/,H#TS#74TQ1"8/166=$/27V[;2I!"1"N[%\0PI18K,2-WU0^[$O8\2$.
MU_BR,CIMSYHP:IH9E4MARP]#(J9<#)\@II3&AR^FUE*L&)IQY"%.NR/4ET-4
MP[<C CM;;J*I+1,@G5>%YH,GL2]M:=_N_@'8%__*.'"4CKKDE1"5J.V?OO83
MRU\#GE$#Q1SNE/)_KV>:7_'Q\:>T\)*?%WQ9]6/IP5XK,)E6I3GH^=1C?X4A
MCW%YOP?]45CJ]?),'RAX #O<G9P9*N$5Z7@J'VFH9:S8>,Q4G2PJ>B1J8]FQ
MK^FARZ4O>?KPYNV,,M!QW,(K8?P4\[:HXULY]N'=XT&-0#&\-QYO-3B$<2,R
M$%Z-1ATPO/VX/7T_ZR[DRK./WYF/U>*[>=#_[I8U3YTDV[+J$1(.'=.S+V)<
MNA2;?7RAVBX].9G4(ELCPA5L30N8_QYFR66I-W\&Y6-O:EBQ$3(.JM5U&+->
M.BU-27Y'@V;\>1<#P*(W1'9I.BEU\B6)(#F?%3%&WHQC1>)Y(W/XO5%_S'M^
M[JV5S+MC=2_U8TSMXDJ3Z=E^:?%4DG@361N@O%(X.AJ,!HQT 4=##A2G$'H?
MO[U?(5I3U582WC,-J\XX/"W#(!L5#@H+5H1]+%+/?HWVD--+<W9 'I&HS8'8
M"JG-R95L_>WG>4E1:WRV84L*TNUZ8NF/^ ;Y?-K:MN<,EPO3?<=_BS^JFW#W
MV85O-!8NQ2YGE;V*M/^P:R,.F032O1K'=^/*WQ]GU38&U#5:?G)K[1 N[;-G
M8/!>BW+VA9C_7'[<VZV-^L1:G!R[U7BH$"PT4IVORG8BJ!*[<T?*P3>F+/Y<
MR&F@&YEXP2P/^TI0'AN*Q.]P^%L+\<QJOD#9F5&3S\]D5O%7*9 .??QS*FW:
M_++IG-"HC$ 8[LV20,F1RHX26 XK/*JA(1M#+(R^ Q$:P:3J/<\R#3L>>?'?
M*.^F(%+]?S[Q3V9GATM-9SJ,%Y!?AH3"!K16Q@I,DUKP,D4#7\RK"R69_C+%
M) _FL">CL/\#N%@BGAFK7XY!OGZ?H3B[&'_UM/U;#.G11<[PF.5X0FAAZ.:R
M]-[3[TC6%E\=0/=@YU8C,3R#IF[)@=W!R0]4_NCDN093?%(PRRO8VF%>V[)I
M5BV2AIT&CM%8O-Y"PZMFJT@>^YG\CT$6JN_\.FBJ"[&2VC3SA85Q+=A7W7'Q
M&N*/X$REP=95"BK[W;'A]&P>73\T6G0O7<A-2S=M]=AJD+Y%)WB,<>R*U-N<
M<J \IZ&EK3&5E!Q<OK+POIY1*>EH>@RS?@4CJ0C7XU(2JB$IGVL_*&)'9WZT
M>\.(9ZC;O9'JR4%O3N9E[6-U+=?T2%BM62*:DO$/ +3Z&IEBD!!SPG%I5\J(
MJN-K/$.2J5!)/1&=2,BRR7.ESHZ>G-K<EX:RD7K-PK7LYD5VABIC!8- *FN%
M3H0!?;6C:.Y_N**4BPGU%=AYK1'2:O,6&QN+&HN8=H?4"&["4D[2L46 BQ2J
M+?L'Z\L:PH1C!GL=>21%O-G8Q-]>EB%)2[8\U-NYGJ$S#UAARY(KIC3S^3UZ
M.GC0WS0R$LP<,&KIXYI/O'40A:=0([?$V<)8Z]QV?O!)L$V4S39C33R^ R$[
M\T)?Q0?H;)S0L(I#8T5@B9^G/W+B+R5RRCQD/,6N6=+7CPHAMRK([N+&Y-EZ
M?WIJ$Z[F7<>:!U8U1CDI6=B:=77P1V??J//R5!]4D.U%WI0N=^=%,_$VN@*-
MQQ*ZH4I<PS=G),X,F,Q3S=^[2L@D\?<PU/*':L#7E/2Y5W=B-[=\UHCL=28T
M;8\&%R4&-Q0G38>K[Z:H7+Z^1Z?"W67_3XF6P@4V+U1WAQDWR"]\<O7)$TN4
MN.G'+%PXM6B+]7NZWKY95?FS9$*L,0;"9.N#:[>B\G)'H/%-'DX]RO\ Q-6"
ME6XI>U.@?P#_1B1<M$Z2Z09G$S%>1_M.01+L!K-#S/KFWYC$N-UX#U =<-9?
M>K]@#VRE>)"C.,B3MTVW6_\5'94U7K=%9UK+MKPN4?W'%^XP/'4*L.Y7$:Y/
M5U1)9$RJ,<T$>:NF,DU,CEL:.7B:K90UTZL.5.ZZ?K,.)D+'Q$LGVC>FO_7E
M@[[-$=0I<H\SK+ 7PGLDU5;4XL'0I#< JG_^04FNN+U0V)==^U=,2LWT177X
MF<&QXS 'U9"AU(0<#@]<3@)(%Z='17/P#R U*ENSOTA!!G7&IW -*/V$@?V6
M4_%;:9U"E.R=V[$3;:]E(?LY,RN,[2K882>Y2F[SZ?7/ UVLQXZ#C>B?TV'+
M"E;ZL]=_ -$B1Q,3.^NW;?[Q)YCCW,,-OO($GF.Q25FS:=5^>'V"^A4U27X2
M86-Z$0.9O/'78 Y)W8>Y._;#&UT 8.<Z?.GQ0)#2L?VRZG926T$;^FTO/5I-
M0SP.C\QP13?YEU'K[YD^=H:JQ]@%%F$Y&+KMYP1-"C2$QF9<D!R^:]<@&>1X
M5Z@YG1?=-?XNE\'$M\MS=0W[J7>K64TWF>_T)UN21#IS(TWAE.0V]XO';F@/
M+(P2O#![8,EL!/WHLD!FFHK;ISY'DYFF._5_[2ZUG(OGRKQ3$[VA9MNFM3$K
M<_Q!QN(F'PN]S/%KOBR=&,3/G";X@FKS5Z;2KF=ZWYDM8 ?3=(3:RYJU]XO>
M%!?%)EO50 WT?A)1PH2^MYKHRZ\:)4@T"7V>=2P5>/F/)E1XD:PEB)%1>"S]
M%6\5.+AQ_X%-%S'Z&,8+(Q5_6L65HR"8D?AS6FFD97&&[!&/JKI:%MB?#:U0
MQ&4:"_N7,.T$[P)JO)M=>[W\HY([_R(7'\>O!EOC/R6#%T,8)!T+O+C3>L'4
MOTWBT!6'0Y=@$7.$-W-3M)&X>N>PRZF!1U]V1<V_YV&UY<,OP%]B1_4D5O(_
M*M_8<12\9?FHMXR-YZQKT(Q_^MTF;VTU\_$:QQ'[7WA_+=):DPV?^TQN$NY;
M.<ALHFB049Q5C3+PT=U!P0!OJ$^!YR<!M'+BRU9\EJ52\U^;UAX=#U"9/-@G
M#F&$.AY1?"?Q'T#,,%MA$]W7*.^^>)KX=WS_.>6*Y]N0)V'[M4V#@\&OW@VG
M&QN7]%R>9R)H<5%7F*#YIEW_(]U$?1-Q8*8.*A558*2>+>IB7FA,>,)8471U
M@#]P-^NXH'7]O.&H,A9%&'ON!I?ZBT_X9?Z0).Y*%DQ)0-E?K%?I_EO 0>*.
M'R/<@Z YCS,FS<U7A0^TDST"I<<^-,;AHYU0,_L]JBLU5=98B>/;Q@3X<( P
M=7V^T?K^]+AJ979.2HN.0F)M,*<S=L-NA=%+P)<S@FUMI2=Z^9'BVL=2^?TE
MJ%1PBOQ*I+ BT.?#D&9)Q_G+3<R':,X=DB[]L]*4JW.67$;U+)"&3$Q\SOA"
M\&C:Y B4W">55#*3F<EN!$7F>]D<8SSJ<&)OX+.'DN;,I7G793Y$L<$-J^[Q
M:N9N9^;99U586*ATG%':!?>8G2S;$&M.#IMHN@EQ>Y+)X8J]J31>$$S@OCLU
MI1(5J- XV[QPYAK2C8M4*3*&)=%\#]RP'ROW]")I&3RK$.OPY"8HI-E;"$$.
MZ@%Y4(H ?7\2XHCCZ%U[K3[.W1UG]_--E&6NY69::"7/G]@BCWUTB*"N3X$3
MX"GM()S*3F_^ _P'&&+Z7SSJC%J[$AI3G I#DK>&J_6'R%GBV+_FBZ[9M/42
M#NT/Y<A>*>6?Y^!<2"FV= 7:Z&FGGW<5(9RLI8^W1[I\;_*^+!SR*.+;>FG#
MYBE^5!&+!4T!WB3V-RA+L:8:VAC7#BH#]W!:]WZ?NUUKOTU?UEG&#.?!CRT\
M2^6,.%JE A;27>3 > C([D%#U=Y0N"S(8=JP0]!VU:M(T[6#2AG]7CWU9Y7?
M?0PM+1W/\8>3##XT"=!(],JH7BRY30@0NQ"WJ;#P0ER>'([TF.TU]PJ%#U4J
MQE5%KGFYEBU<'A[_UM?7U#2;T]!6,]MN[-5EOMT*[9$'1\8QQD.+'"4]=FZ$
M-L:T%B:.*)$.0OY [DMR?M<W+",6](7=?_B>)+3T.H*!0EZR=*.4I[0_%/?M
MYLIBOJH2<=79-U\F3V*CVL@Q@<,[B9\BN(Q51PU_*^ER=X=P6/D2F<GW3/;1
MF3+4F/]SOG7S=D9+@,BKR4[;ZWJWNT9FY"K50%.A9I5Q7XO48CJ-TI \0NNN
MS8_/W)G@KB==.X_V%XL(Y>^RS/''5EHPR\435/ZKQKKY(@O5[CPZZ#K_DYRF
M28OBQK@-;>F.7 +#D?F8M<5M8&0A>D/6)U!(+%[*&WW*BI2<4A0:C!T(1L/@
MEE]"FC1>>PY/5K? Q.V1%3Z&?2JS9KWT9YDE:3<A3C1A&2SNY2GY5MS[-0+.
M6M1G62+M'C?B,*2*<I!_95PFDT)NU#2 A6H(2=Z-2_*^F;W;X"=*\'WK6(,;
MVQZ5_@\9?!P\WT:=N.5WOQ?6^?F!37_Y-NG>O3OQ1^LR='MIEY(]P=A8=5<E
MYV=I?5D8[,,G05+:XRL^Y98,#ZMW=KYWW1VHM_K,QD@'Y\/R[MFZ.0-)"D[K
MR"T6TO1;@I$VC-1?9*P?FGZGE;$H 3_,A(-A%X$$14(K2=,VS -56(%YUX>[
MA1U+W:8HW.\MS@MDTGZ9.^3OVCK:HGFEG-[;L96?6EY*@HLYQV^J>^E81)-.
MF(Y<0F<WY:%:\.>80F:.^F6,BY!]LW2$FH7+:23L9M#G!5H>X3$]Z?=$6N-B
M:M\6DR-R*8:^CP+?*P1[*':PMQ (8FCK1J(94E.MX.$@VXO3E03S[1Q)/W?G
M7XL_Y5*O+66;?>>G)DQ=)+E^4 _BT<:O[DDA1ZMN=!K@9(/GPH3"1&5>L%O]
M(9>48G2L5Y<<O)==NU>'SQX@2Z'/>WGZ?7YX/)\I;?A-+1E/*2H<QUS<XXT>
MG33F+"H<50,"*6BH:$61A?0>9G[4XP^)TJ,$/52PH=Z_5X23'V"?=M@B\3Q6
M"\MFVB3MIN\&9Z[%]'LE,BN^=AJ*_2G^VPN.=L5-/&"7<Y20DW.4"F8,AXCY
MP+]AJ3%L.B]F6K/Q7^,2+$02'MOC)0MD["5N[8^<-L_X."8\8#W$$D[EG_BC
MBE#\ WCUCN=X^@1FN;SI*UBE]&Y8+O1.:T'!?E;PPHM"_)<0I*D+V1V'N;0
M8\5) )+2^L_W)3[G5YI>F+;P7Z4U-(4<-G;GT";W7%\0(NH5@FC;G0#HPK,
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M5S,W4S-FHXPSP9BZ:RDFVJ75ZI*,"VRFBJDD57UH^%ZK<DY+/U4(,# Q>0G
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MBEJ&H\\:A=0KNO!/M25=+<J68N.,,^=M!^3P[L8_;."?&K:B_5&*T]79@0^
M1ELS]Y('@(P[-$O'=6$'&A]AQGU!^R^$._W!W-%4HJ@K!E(B-7Z-+A)].1&=
M/'EE>2":['W2GP/5"Q39?9&/3WUQSA&&#[4;UJ/=E=IP/XB.>/*1OD(0E[^N
MN O5.MS(3A,RZDOS_!5/>+;#=!)YRN>.4R^MJ#*"S+WL_H;/:J%^22G+9YY-
M13\VGX#7F7Z&G@Y?YFJW1S]U<TBT.7K1G%Y1H:_BI'Q,3ROR/UF>#/XA;P7"
M!:Z_A%C1B7CE-Y9,$,4BQBD[V!5=;W6>%96<XCN,*9:LUTRN]R>E_)8# 8%K
M<XUE%&AY8VJ ?]=YP+O+ HD:HNP].*&S^;4R;GWY#V9$A+:H9+2"K%M@\%H2
M:"\BCCH^&2T@[^$ZZ"^ 60?V'*;10?_AK$#)NY2ZLVI1O=I1>YZ,D<TV:21,
M9R( JYMNS"32F,)=9?I*9\NID7R92/XX'D/&]>ZEQ93#LHITW/O>J_W@P<.R
M \IQ3CCI(%/L-%H6>D*?4^UP>7E9X"SIV6R>L+A8/GYN =3&Q ,6F!'#A3M.
M\G(^])J#(LR@M%V 1M#.=U_ ?W^IPJN0\H"MN4Y34+^9H/]4"F6ETG[+73&
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M\EK*NA*=/.!7XLPL*^K,?3@6W$#17P\':UG1-BI25XW;6E&K1NAK_63,N(C
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M4V.F:;\>4-R4M6M"M/YL[+/]"UCZ"$D<4DO.=Q?6Z@VX%_TI!#6B+HG\%Z#
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MG#T/[:?8@KL@(O'V>P[NGDU]LA<9[@9LU+78V1G'\6&-#<-$?$@-[HRU U.
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M1(-"SCV_9O_UI[MY8>;$I19>M"2NM4_')=[-#5&[B3L(3+EJ+C=_P1X-)HD
M FD%0HR(J3IS\V*-@TV>JO5W'I@>$F-;DU.1CD%0'_R>K?3 B8H<BU_(<L\,
M"&F'C;#;FE!A93$KY.PO2G(NWS%5@E-[D')BH3&'*Z$T]JK$YXZQ4I1'F5)A
M!Y VDH6S3*D0<VN7\ZO>A382T^' V,[*S_W63E^ZR'2BM8T?-G$B3#0CEDID
M&3C""$.M%T@ZN'*>+5[Q KL\!^BD(TQ6CJCI*I<A :3-O@ROHHV,V<)4J<NC
M:)P/BLHCB"5T[6R*QA=_DK8]#:BIR&=5ES+!:>S0;9[6V;-*)UJ3LCBJ5(!U
MP-%FVB[L+ID)++.UDV^G'DK%0-#^!8=[=#F..F"K;^\RV,-5JT?3^Z]<SS#?
M.A=3&Z[8X)IJE/V6+IF2Z9+T"PV3DU.(77*1<_$R+U\Z+F5?I+5@H*'(E&\K
ME.01+>V3 [Z-DD!U:JSODS-01M>2KBZ=<3A8YPEVS=7KHO0L,FIAT635Q;/.
MQ.I(RWS9S'3!BG\*XLW1WF_%/YDZ*2(R  \W%$RW 0WF77CXB0HC)4!OQJDI
M<-CBDG)&S(ZAM<O.=/&XL+),B$G)'WWH9I('. %27EU>'14^?M#5-[6/>$VY
MV&=Z*A% <Z5VI7[F(P!/7!9U($K =/\J% A2@3P*7#9=-@$;L3Y#MV.PB^8F
M9K^!3E5.I2*>29Y IP.^TGV<K%:L:7L;X2V \.85ULSJ3!(:;>W$Y[R%-:?Q
MW*-M[VK'%$2):X9$!Z;^N^Q +)HMFHT ^38/%LW4P^4C(C:+MIK^(&==I^O'
M23XN3"?+06EIL#ZVTWJ"L^[JF2N-WLP0F6:'NG"BC*G#&P!>FU;1P.Y^R+F(
MB$;XGX&E ')GM2BIQZVOENAL,T.\FE/0$$;V%'2?TW:!S&B@T0/=ND\!!1V=
M!Q(P4@6789-F!LK]"L(ST(''X@U].W2);%6@C< Y:LZ<4+3+U6M16X(Z,$1%
M^B)3\>JE^D< @&6@;Y?$> A[\>3_](HWAY?:IGIDA5:#I0:D*^0E2N,C*[@T
M3N-5W$S,$K7STH\5(^ZK4AVIUQ-/[DMWY.9R:4G%NU^_E,TBCN@@OY8((D:G
MQ5@]11[Q=ON2M=%KZH5=DJ8ZUU'<3-C;* [WN'\X7[$889+S<=W3H7E6MXRW
M=]"LV/9+<M4QTP,S$2OB,HA+G_E-+>YMUVYHBSX4I.#XQ9/;BETIJP^MY3T5
MIIY@J[ZK]#%NU%:^4P_AI?QEMJ]54N:H:AWJ?:Q1P#DC-!0S/[WJXU"ZK4U#
MDD>%MA*4L+D2"SLJVV.1BVHCE58#Z0!?0;B=PQX0".V4QXM=[ZWR)LC?,'HB
M?Q&W@1V=,VUSGN4%QGY"7RKV_16CME?E7C?TEM[M2^-1VB47?6TQ%=O& X$_
M,3@TAJ%]=.XB$*?_6V'[WX80X 550+,46.IL$_2/QL=M8R(+V,ZE#C<O2I^G
M^KVUG-PA^A$'9=@%?1VF,?=W$/?PW_-[7IH"UZA)W>'0C,@HS91V9 T!.8)Q
MV^;!YAQ3Y W^RJ/U!8()G&R_:QRYLR,EN7\Q/[R_P:9$RD!_WH39X<TG+IQ.
MSW.$&F1N;?1-2>Q/G?Z1]7&$+^KY&3'6K5>!C:)<L _Z2KF!D,L[AEP@,4Y]
M\61>K(V!GT"X4X%<$'<8;GV^</=K+O<M -Y9UARF/R?[UVGG%L W-ENRA8]E
MK54$V<P@9^1&9IZV"X:6E>,%J4,M24SL_-1232Z&R-!\T[,V6:NZ-R2OEY"Y
M^4*'IB9_HZ?Q^.D6&YA88=@0W\AJ$ZEQ +AFS5AINI0H)='1T!)/'% LW#RX
M>12S45D&UPM?F'(3YQFR.KF$NR_F+) L-MK;AQ!K1AB;BOB"*'Y.%@B.:\N8
MJX:(<DEK*5@<4-A3QTJ-V:X6ZS]4^&L[WJB]U2'L(-O@@MAC@\=\5C1L@3;
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MJ=/'204)W?IO2?I,1@Y^$E.Q3CG*>C.)YBOT'5JGC;F7TA,9+AA@#YN=GEA
M,U2<T"U/TE$X4=1+.G:)IF^F0:Q'^V/ZRD6H8'H>_Q^;,JY_6!21*AR<#!"
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M$V]M;9ND8U/2HE3M$QQ>XW;#I$9"/TUB5QPE[RILI6W2XD<!%@):]:,Q$?H
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MV"[B#R4BV?HY6PTG<MFOTGO&0SJA U?"JN:4D2;J:51)Z27MV%7GFK<3?+<
MSA<$0>^Z;G+3]]G+SH7'\L]UJ.\W"S^N03M19:%,+MOH>H3F'B7@]"V4K2Z'
MGD]\2SZ&@44)C8L64\[6%.U*Z*7C=I?TKDCP\I'/ZW[%'U,;=_1]_H55SQY:
MM!9)"GAQ0'PG'>ODP)2$;N\;CSL+ *%=J:@F)Z<TS_6ND%#V<]V%*&6"?5^M
M!;"AA9GF$74;FJ:DNU\GOL=L503&^'1%Y,9 H-O3'TI"*Z :L/0TA0"[;&IJ
MLO8.W;/FTM@V\*N(!KB!WA^/52&[!P>G5>R5*@Y-P?5!]\RTRD @B\VZ=1TJ
MGSA8AY!V:7Y=KTN4\:5J\1_.!.<^ \*2\^AW+E5GB-1#UJXJ@J\YW]!7$LN3
M$,XK+;/]?A-/-8+E(/B"=2@;F3AGE/G"JDM:V^9#*ENIDGY3$[-A[9?H@J9F
MK6&CYU3PK?VV9R(4_^[C6CS@(A6I(%N AYE;Q# ^I=,,-C&WJO%2VVKC2]3Y
M.TG5< :+$@@!DYW9ED?)?[=\F^)U4>%GY>8IQQ2[?0%]6J&KO^O+CQ7L8#;7
M\HHI+^^IPIM)FL:J^4/_)-[=ZF0K]R^@*]K?&?#X=LFQ-<&LG7;5\*\S-YLO
M]L>8AUF[BK,Q$K*A*STI? A?=;$/K/&+&U-RI@_@XOL71^$?\U[PAGQ#%](T
M<50\.C(@(:2D*'$.X*VX<[8>["N=_:O'XA!O<.^%:$=5PYH\I51<*6?*D%,F
MUZ !NZH'=[@VBQQ"W%=Y@E[WK8XJ@_"J)"L/!;G@HK]EPY\EW!2/X7;.&01D
M=PM \]K? DZ*#?U1'0&[.DMMU];M4F?00P;.6X!? $' 1JO@+:"?LRC+7Z;-
MZ#](^\FQV-CM4K.F=<+>@R(!-SDW,JTA9)0^X6E$E*Q8"U?R\T*>. B4?Y?S
MEGT;5C,3L.O"&O5AIO=]X@'\:\:A K>&N&RX25?+]A.\?5,T*/0BYA<N0"4*
MVCJ@%*%CG<8S@;NH/E+Y ]4;H8KVR; 7*F%FHFE*(E)6BAHD-&1B;AEHIHM\
MC<PCZ!G;6D81^=\GPU+A3X:PL,\HZUTH^9SWGDQO?4.WK;#DV(Z'FH=@ (*C
MH'5[6ES'>OB7$_Y#-+>JLC;_A#8*XMUJEY+IAX&.S?1I%FN$?Z ^IX 9GZ2,
M_9-, S[UJ \326GE3,F:'GJ5)[OW!V&$S+"29M$=%7#VF*K'CFY!MF.A[BX$
M2!/XZ7[?SXDYA2SN<YZ"%J E^7XR"^+.(9>_[+6PQ@YFC+*ZA*CF)J@<E#0>
M)^0Y\!KJ<8!S[,C[,#F:;?M6PL<R0:CO0+]_5P8S^66"WMR#D@D<V8_SSS@M
M_Q%"MI_LSAW C5NNO?DQ&[=)A_QS;X9^< OR MCMF+><IBKJD_ 67<!FR9%(
MW3/IRA4SZDAGE.76F,PMH4=_7H[)<#@D=-!_M4XV\I&]J.:NT;#/=7(U)N#B
MJTX $$48;2YW8LDKK;/[6/2>SE8<RN#2YTGB]S\7?58<.O2;;W""U4+2ISGE
MJ16:RA6Q-!Q9YYD;47I_-9,/=O/J':9QT<"6DQM*!,M:?$6^:=V4;'PT-*60
M.B7Z77-T))AO+)(KHN\I'D,99LN^-% ;=XU_F"OMYQ"7 % ).KWD:,%7C!&2
M=:%,VH7;;$\O CS4\""L]F<58^OX=?XB04T]*U@VIKNZ.(.0[6=%/0K->8R4
MN,?;4R-2FN]^&"@R-F$]]BBOA38W-V$;\EYHDE2H!0Z^6C1$G\9EXT\F5EO&
MLRH\2%)PA8PA/RK+^X1C3*N*A,AW\C$G[M.2YIG6^GND%>@M():0)B,2I?BF
M47I\LO9I@4_2GNZO<D05D\;V"I%"?D8/Z0V6<P;GFK$;X.95;]TRL'CA((G-
M&Z;".+M15S@VLIK"@CF?M0V4"5YM2_$7#&YQ5M.9\U2TE+VHFKG?EZ6395ZN
MJXN&O^>)Z*B3><GW:O>]WQZC>L&JF_#_@;3_[M(51M5M/Z$?]%":.G6*MK8S
M^S;;9M0? #6%%KICK@66R;P&4?BF4D9_W>1^[^$ONV7&,:L("=:W75+$]F-O
M?Q!\>\)-D/IL\"3Y\\MC)TO_J763^".UHHF"O311U#,@GA B5]0+D]HD%ILS
MKZN\,!P(M6W)>(W='25O3+5ZA)><PHS,_#;^5B,6O7%(<RTH>?_ /U$)TCX)
MB0G^8N"E?ET_FL-:/>22B09)AA?P,Y8(55X$"S_0W?F:%1T#O68+V@H7&W<D
M? ;GV2XP4X, XUB>!#*\G<AMA"R7<8\GHN]*]=D<,[<U!2,]1@6:(B6(&D&<
M8X:8S6U0K5]B]>%U1E2 #4S.P M5R8$_<I! '?KQ$MP0>]TCJFXWFJ00=M!9
M/:I:=^G1]?L9]=Z)>4!9&4GVJITV5*>+CB)..*S*2LRF.3KE$[>/ZDZK@T+J
M-D<+9<%!&2I#RS(IA38Y$KP0)Y0WN.:6^-D1D3.8IRZ0V)]E;BPI_6(VR:YN
MLK*N.[5>S_FSH.5 [8QLQ^"V3\"4=\WF]=3>Z&ZGG8;A*3;$CD@ZZ$0P8Y/(
MN+)4&\AU?SE=C6NH)M[2^AO.W'Y9HF4=1(!UP$LE:_P6)E9R*2Z=]4NMS ?M
M_E$]UM*MNC\FA@UHL?>W[?%@SSM!ENZ>;E+_HX2,<),#-T>'K$T3,N--6N(>
M_EEK 8+NRMVQJJU,-F&?%T@,#SM#<Y!R^#'U UCLO$#\,%"T+W*#:%H+^_+E
MJ $^74WX6D/".MY 2.5O"?9(F;73=-7'VF#^-,]F=HSG:'V]WCOZ<G=^S7)\
M&IU%3R@W.';2:'#^])J%41%C_5 9=P3,(D2.5NI76[43_?Z>S1INM3^G=Z4V
M?I6?U++#B)RM*3J<+:[VH)#.G6F:5 =R<#GJN"\60NMB$!-G-V\B=5@4;+=Z
MAB;UYL!I>M-IYP\*9&T($IHD+&6MI&+>/U\;JN)*V/'_V3I<Z[-5[" ;<1K"
MME4U.[MGI^=>U)G;OWU9,VUP=CD*63NW>AZO(EKA^J>DYPWW?G/-\^PYM?)O
M*QUK8O5KVA;DC<%A)QJ?+8!@RV$;3/#=O:62KG>V;N9^W.:K?*:&D1[4,Q3W
M9K*D;"2PX#98D;-*?JQ]IH"?N1Y]0<8NY6O\^4R&^=MII.[N@\117>A O''-
MM@L(8391[,6D#K1+'GJ4S/A5-J%/A&<Y#\)G(F:@5G7EK-KA$SHAMJL*1ESF
MP]5G"\"S1NJSNW-]%J93]QGF/"C4TI>XH:@R]J0M;\04]3UOAPSCB:6Q!IF4
M(\[,>KK>_2W#8(N!!F][EY[%%0JK%Z\-MV$N^!X8Z*1L^@0[@7)M4%T[O?G5
MZ1I]C'=3,8B:U=[:UE]^/NZ]9VCC?97+0 A?JG)1PD>R]VS/9:5;"I]KF\<-
M11TC+C_^YMCX7%)"9:;PY"G@_AU^2*/U;YF'=(VEH\.6_U5%GOJ',NZ1C*O=
MB*E>!!SKY^5NAM^H737YEQ9.8P5WVCS6,@)>MG,X$UX'E@K@*^JY"^/5VM,0
M?:F]0 ([HV76CLSFI@(X-'[9J:3FJ;-#FS$'ABK^M#=J#&YH>I+.]4Q:2GTM
MW\?0L8R?8-LL>^]N>_F6T[J)<B='F;,M(<>VWE:R?K0.)U40#^%PT2PB9H;K
MG7]Q46EH'XVM6,:'3W'J&IN&<R<TJSL%]ES+,=L]LR._3^"FU->B[FMK\?AH
M;W]Q8V(5SM3 0>O'6J2SO46N0FD^SZ*_<ACI&<<+1]6SMK/H7GK"5:XS7,RV
MN'+WYC<-70F%W+G+6TJZ+WWS!X1+*7&SS6M4@PS7K +9LK]JRDIS>7GJ,@D,
M"U[9G9.?P9+E"Y@MA2B\HJ9+SF(FE6H06KFM-$M/T?@>=S$X*3I3)5EC?8OI
M[TIL5&D#YZD%$[-J?UHQ%]0.933CX,&B67E<3K$[6)O?,C9H6RB<I"BXAH3M
M1(KM^O,,4 C#6WDU;1C>(I56]L?M@WJ?=LWV6K%E)C'M[)606(E!S")[D$)*
MR7)]QX(,-Y<[[XN1W9N!$9\A\;G7K)N3FH)6E,GROP3K\A[#+JXBN0PU-9<Q
M::\)^76#@-V/V=D^<S,_F11-'%;*ZE^9O+&9$G;2BV%Q-8PW:[2&@HQ9NUT(
MPE54BELP>W7<Q_F" Y )L@)+G!Y.,5J(K$"KX*><7Z&!^H=VEB1=R0CC?0WW
M?]KNBYW'/[JLV:@/OSZ&&<IN5#9 87^]JGI OMNG2OVSSSBW:Q\.X;GML5O-
M1AJF#C&XR\"9% -IEPVF)Y=,KW\TC\GBCOEY6*1,2:5.7+H_0 TO3SYUW6E1
M..:I6TK0WV[?EHT52@5RF,T:JR!*/[?,P] 4<S^[JK/7/>H_7W?9@O1$?+'3
MU]99[M$1F[H-771]/XW F=61K'UN1ZK3=3IBZ<J*A#B#J'HN4Z'EN@?*O[<Y
M'NJAWP6-_"';,S'LV:6/Q;M/[3IZVUH?2B[Z$ V"7IM3C32-LN=U"2;)@6$^
M-K0<")^W Q5[KM2;\0FS>C.B-AQABK"+/EV^!9E"</0/\7< 0!4YI? J0+ZM
M1[9SLQ2_/%7AD.'!U7?Y!@^B_>1>KS?=O^WJLO%/(K\=\_3UE1>M:T8+NV=T
M%]JQ[7P6LMQ]<TTA7&NJ6/MU3JO9 5#0!TS_5J5'5A'VF.&54LNODE\*CA_A
MPAI2#E+*F:<?\>[AE@D.S:X@'R3/^B5N?@(9MR_OK !Z2.*NFXTKB(2,O^6T
M@8F4E0N[UF1753J0KHVV$3=_0%B]=&X+#JW8#3T@D-U9M!HUJ;X<W>S,L6N8
M/9@VO8228@2(5R^3=T@:LTR97G?N[ &WV9AVQ&+?8<J[C](OMK]F8UX58G?=
M,@HLTFDYO)*2&N_96B@F&M4JLD5>2NMJD=P"7%%NC\;M<[0)^D^&-@5G5\$(
MSY0,'GE["@2DY@L8?Y-AGL;ZP*;!B%&-5;;L$NPPPZI9&Y??7UEK1C)3QP%)
MXVZXZ)7V[*P1;\G(COR+ 4GL:MKL2A@C40US9T07/GXXD [QB,W.T<,^F+L*
M2 !_YDISQ#G7.# AGV9%-&(M>/:F&H$&0O@%W*B.)Q0\?"Y:OAJ4E@6K=U)0
MXH/NZG<.^27GRT]1>OC<];#S9'.GQT(EJO)1RM,B#,N8/6=#^^3?>_\ )MMF
M(C_@QXS?3+R%Z)I\Y"@H!@^Z!QQ@Z.)8PT[J&;Y5X$R,_I HQM1U\.2EP%=>
M:]2[X5\>024=]MGMETWXICWSD]AL#QVXY6RFO42T??R*%X]IT)H7F_N!H.!N
MNRJFZC=L:C74?8V0M97Y^]KSJ.T_RNXJNP(58.("'L[7W;G(@5R"+R\#7Z6;
M_B(= -6$XV0GW7ZRO&*GN_\E3NK[O2]2*_04.I?_>QM(>>2ZIY]51_L1U\/-
MS>'BFBC-?TG^J2W62:&L;3'^@MVZQ>AOT:BY@&A1C2%$WD(ZN=.%='HNZM)4
MA??PACZ[>S%3FJFK^N_B>&SG41KDY(%(;DEE27>?^7 L7)7[K8XLS#1]?Y,\
M IJ;I_ Z?9-+?@LBS1+254W];WUILXA07V5;LT1K/R_(U'>JT15<, /#P6XX
M69&O41\^"ZH;OOY.I#5&1Z-B\'=ES$Y+"NQ756]EBP2VL'U=.CG75H KU'<(
MK@5/NF5($[97X4KY.(H<1@>P;TPD$B8M^!Q=H+K<N4PZO[]U>4Q?XHW1Q(+:
M$B)3#M2_7.XB<(Q+U/U/LW4D5!\]6PIXOM_O_SQGB;K$N2%&B$7DS$N\^V6?
MZ6H5_[DRW0=H*7<81TGB?JIQ*(0FDZ#2E4XM9GU U.A!YV'J5/.@',(._O3,
M)]S$V2Z6! L.ZJS\+$*5UH^D'C"S<CJB1MCQO2D$AMH4E'B<7<?:U$I%\]CA
M)^88A&M!X=-%Q=7( C ,C7&MG2HCQOQL5%9VIZMW+CINW)G1Q>N2_MDQ86_@
MJ&JH/S,F]8,9A]$YC690>7H]I3GR95J,(7:NK'2^!0C?N[<H[AMJ'K+&1^15
MLD%=4N7I#EDK[<JC?/2,[GU(8-!28?NVS=FCKP35A2]>2$7+Z43Z*J&[B7F$
M[G1@NL]*[TDD+WGY.LOI1PQJ9_*\BN&O-<6%1(?*4:,QW?OCRY%FUV^/^8NW
MV?F):MI<'U=LV4G+:_$R]58*&Z%AH7>JG+.2X,O?I JAMFNMBI&^V@]L=W;U
MZY$U!?&"&0H)Z_XYIL8[I5=:RU)9\-CDA7EBB]+":&O_EQAJ2.&_M,]3+$$$
MA#MJ&C,Q:P<0C<E)T7YE]: O3GQ.59N=(EKJ\/-4S^R"G(ZYITY _O-LX &%
M>T2#I-(7D\P)1WAZ=28;W%F\D*S7TN46D-2Q'[2P;+%?&2,I@L&@VTN?F2WI
MA)][IKJ,7'*/*Z91M&M[!>-,/8AJ0*D.1$DAS!%IC7-C72YVPDRY-5&#$C3*
M4=1-B)*N]I)8'NYEQUS^GRLNT]*(EDTXQM?$%!?,5ZUK_F(Q^\7^CZZ.3DPA
M+0G<R7=74R*IWP2G;=7$OO2(EBT8""SIK ",V))9?BZ**#YE_$L9=&,I J<$
MA7T^2XFXTN([<.8_-L%UB;2J"<8/6![8%'*KP)P.@C*Z1#S?XN1,M-X(KI7^
MI+%%7*><0)O^9J^4# E9MI@!#;UFCN>^_'*>S# [LA%F2,>9F*79/3SHWH%9
M(5V).YW3$7(L$K+@L?X]WG2K*P]1BP:M<97"K1O0V?J7@YM'T9T-V@^! P=2
MX?_B1.I,-^Y+R]M!I'LF+B":T"6:%X0^*QJRKO&<FCXX.*A\LWC.(<6+#DS,
M>\%(E9-\1KL0 _KE.4?R;*EADHFMTY^^WQ?463WF'(6A(%LP=Z8K<'UL&2K\
M>-&:);YO867S5WL[IB+,&GK5C1G4@0=^I01[7_GY-S5Z5 <L.NW4W +(6NIO
M =/YL(N])[> 1N.(6\!QSOU;P&)%CV?%]?%_MJMSSW"W +[R7-@YZ;77?TY^
M&^0M8:!,7?>^ISUF<I:MDF;P;D^M*C,;9L0N;1.OV]%=9;159WBC'H<-4:>P
M2!WSG"7RO41=6J?+$'B':6PC+.3AU.MQ^@7KMX"""F\E'E/%G5)?3K'=PKJI
MIAQQ8_N63'/#OQX/9H@N1=#-S0:?K>@W;%&6-K.NY9G*LDRLC;_+[6-V*O7<
MDL)K*W^"NRMMQ:A<E._^:;T>=[Y0"M\/ZM& ^8 TC$MM*4[S]O@=ADX9+3,<
MG6UB%C/;JQWS4NRSZJ_G&GZ#'.V-S W^&%BH'Z)4=#*7Q&:>]U8C*)EJ$+T9
M5C^VF[+3T["*&4V])Y4LVKW2%OP<9E*-*U^6+$1)5CF8=[ T,^F)QGZO3PJ&
M=VX!?DN_C^=]<C1Z4=9D0<4"=D,BXW8>Y D>,%F$W1&7#D%A6R,\ C*]ECK]
MT)6&&0$4=#]N)' D?V]^MUM!8[[H+LGFC\@O),$ O1L=,,:_9]?5QKV^'A9T
MYN&FJ]IOWJAS.!/3CG+>?B*2_+7K#7!W%UHS1<O[9I=@2&GEJ)XV39)72^A2
MYR+ $;RB=_.KQ?(3T'K3Q();[J7UZ*4C6,/LGKC]R\J-IA1&A=6*MN/++%Y-
MBR&5.=7R0N/>Q" #D9NYW*"_MP"<YS]FI5JN"_%:M;";4%6)D8F5L3>O_P9R
M51V1K9B3>\!X"YC)>+)ZL?4W]%"79]RVID5G3MYB5.AA)9Z\#D6X<?SCK;3H
MI_'&U6R!* <5CWB5(9<KRL\6L+\:I3#8E=@C2>V,27[@6N%TSN_<YIWIF2_5
MH>]Y7N<5>5F]A*[4&Q<1#W;4KH\%;=I4"> )A0;?.%]['3_@R*B #8+K#NU]
MKZZ@R)+1'&"0B5LCJ[/-W?NBKF\<F,U2C]%)*D;R/-,R,IH=-2G_P(,Q%_"1
MNQ>/O#Q=*Q47YZB&&1WO&KBZ/\AVN!FKCQUKHYY/;<WK/9XP.L&.4:F*SB"%
MBUA.XWGK!!=/O%J=KZNGR"@]=+R[EZG"L[H[^;_9Z:5FGCOC*U3T?>YH:K&_
M6@AB9?PH7"L0;4'T0D!H# 3:>C+':R6194=R07L(<43J>JHY1OPZ9)C9/1WL
MZN!Q<?<)FZ.)5;+RA%%(JUL;E%:+^R.3R4.?ARO-BSH00Q?[W3]\-VR0?AT/
MUEA!G:4^HV($-M]#A32ZQT<N"3.J&UP/327GS.H'(;='I:U43[U@M<=&JR.I
M_OA=!G_GR,DM8:#R"Z]ALT:5UJ&.XJRIWJ$C7P]Z5;X![EEWD.2:??4/>8L?
M4OGA][\"S @!A#WX^ U4RO]L6XT0[1,FSFM?RT6]G?9>?U;I,M(:W4 MYQBU
M? 1I0D:QCFN]YJ[+E,?96!,II!@;)?<W5H7Y"_"\_7#Q^M32!Z2_X/!VPK5R
MWPZ(0WNG03FQ;X X!I7:([!V0;RC*9$J(><[*+3OS@NV(&*IWI<4%QQ=DZ1M
M<&1R56QF%<)X<I*)ED-+K2VZ@@%[<%*3]DR27.%R B@XR7J]D>.0)'7*C2O.
M">'P&/I%[J8N?5&/4I&N/ZUPSFHUHR1JR7+'6,,UUWO\AQ@@7D?\_7*EO DG
MHC0/^F?T8 V)PG4B)WJ2W:T(+<M=['>OG/371G%:7P',[^O;ICZJ>TC>2S(]
MGU,O/KPBM.]M+^7)RM"#VXE_L'COIV/ [V;GL/[:;! LQ,[A,RPYWINR)QNM
M'R(JY!C\>8^=A2HR5-<[ZSSPW<29 PQYF.51@*C8YZ)\VPO$Y]F:)"PL#JT=
M;[I+Z!^)(+>7]<B]>5*1/XKZ-G\VOD_Z6)3"$2J3>N49K[QO_:$FA+0/:6%
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M"\PEH:EP P)2F.UT1I?+C+B_H 4U.8O@A=$B6(IZ>PVRK4%O^_9;'$\B:NX
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M08=:-\_LJZ\2'7FOO_4$G>EI'-P";YN7%PYH-ZY7[P" 1;-M4]([ ,' '6!
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MB)S2$H!.#LNN!J"Q)5P<ZW\4;N?S2OV(+KU/[P!AF@[-J+\0[K7U:IR+GK>
MYW6Q@,<=0&:6KD/?@@K2 AT^K9(5:(F.1O8(/M7AGM#IZMMVR-.RTOG\<;NT
ME$DWXR=OPY>8?PN>><[7B]>B><-Q5S+JLU6F5B//_*ET0/A?<R/3.P \(+'W
M 62=)>HV/]J0P.O^.-T@Y[1G5$\CO+)/L (D(@QE+ZO(+?^:4O<P34V!*<6.
M28E\M])%]3SL^'3WB+K?[V,_.'Q4:!8AWE-]<EM5,F7@V: -;Q[G2H\P6//=
M 74WAP3>>D:O3IVK/QS>&2^$)AI@&GBF/KQM&E]KVS(COOG0UVU\DHX_4;)
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M<HU^KR,B*YN@C_F[ZDX=SINGW_2()IIX:'AO6-%[=-RKM@((FMBM\'PO6ST
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MC@A#"V*^H@UKSC>8Z4^=)6JAQX/:5AA80#I>F?KRUH L=OC,D QATB-C83,
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M\9>,+%^U1\\67X]TSL!,J2<S*_!;:-6E'Y]:_N5]3@;3Z3[*C\!TOM0 1G'
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M7=H,A\RX(;]X/-JG@$N!G657JB=PX7C:O3Q25\N^=BTM'@>TJ6F9. 310W2
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M7UPE*HSX(;GO8-E"3.K+S_-.5D.W9TF9ZE'6!);5 (? <B(+3$:!ZBI"I_1
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M-^SXL>F&+K&HG+RKA=52GF# M(N/'@K]8I/^E59B.((!TF_P(#?F[X19L?D
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MJS\.]G60[ B<Y3DK'XS#;Q>'!,R\*4B'V'YULTHT&3+?J3:Y]+BH0J:-<3U
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MO-3.V_3 C!NTEMXO %XJV0_T>IY_=RD0^EX2Z^<[J8^GE@)] 5))3C*<X -
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M/D=.AMS ZCT9SBNW))?:0U^A)TUC.A83L51ALV-,LP8*[J;,G)2\F9$ZTSA
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MV(E6&)RT&5HLSM*;-2)SQ2N:K.)Q54!KC9(Y:815F1S?T:C3@@87 >!>U6L
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MUCKXYVEU/\B^I+EKOP;MSOGD:D2\":FY<5G0[_S$\Z#+N;+F<MBCP?U=3..
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M ;Q@=/WNY!&PED-;'_PO RM=_3^@82JG.?UB;=449 ,L\8V(@4/!R"SY$<!
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M1\[, D;A1W::- XD/LX--Y%# ]_LI5)C"U\X,+SA3"P\M>1EFLU!XOJM9C^
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M:1F97\V#9R8>B+I&[O>*%-W1R:WCO-Z&WQ+-8C?3L>7R&GN24X_S<^T:9$-
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M!G>'7-Q=PN3-FZG_I^;_^6]FNNI4G5UGU^JN7=UKKW7Z<_5S%X N*RDC"8"
M@(#J@^H# #XW &+_$?W_&O\!\O\7 ^)S ( !#]B!-(""P ! 8D! 84!\#@-(
M !  2*C_S #\YX!'@(&%0X2&@H!$^I<@A Z ^/<.@(""A()"@H2! <! 0</"
M 2 @X1$P,+&P<7#)6+[PJ."14P!%3%P\O5O:*(/Q6=E$51&IJ-D+_P$00/SG
M#(#_-B @H6%@H>#^?53&^ ?\#QD6"@8:'@+A/W#_)4/#8&"2P;*(P&%AJYBX
MD <WXK F%E[C4@S. ?\!F[KNW5#"?Z%B%U?3^-%$+9;2W/I+T\S-/:ED\7,=
M@/QOK9 84!@ (<#33:@\N0D6?(;X+RH,YFA,_[I@2$XG:X?ED)] +8>6\KV-
M6#3+YM["TOZO_=%V@21C+T*8^59;3X&"?_,=QRMI@UY4.S]$(_),JU\&G-*V
M_:YFT_TW1MO6HM4UCD?"XE6']3+98\MU8R*TSJ+BD86S6(_7CV4-:]F@^=)@
M,L0F,5P'1+3;\7=X%5$%_>-7'*VJYOUE;-^Z!@+.G5.42F#?1"'@$!0'JTAD
M7PWIB,*6J 64BD/#7Q-U&S](8&+0\U4XQL,(,!!YJ.JS^;-0[" @3.QM__Q!
M2.DF< CI$Q9@9@<#=^]FAARN2\M'\@L9[.3V3W/N);;(Z>S7'<F_J"?IN\E+
MH= Q>2&V,D#4Z+(3DF6K3"TIBWM[!T]G-8-#DV7Z"8XT.'9LL;D!^W-MJ#R?
M !PU9B,]7V@BLOW^!+VAPZ^OL0(/[(O 42E5\?<*SO4;;,EZ#E.42&KQ=#_8
MX&+Z6BJ[4TE$:J*F,B](ZFC9;)P=9)FZZ<=[309\-S&144D/DPV/04\TB@0X
M)O+R19(_/^AX'RFNN)%+[VL]\\OHT2C9FK5U>G :DUJJVZ@P*>@2YZ:-=?<%
M9#,R("G@D(P]+/NI00K1@;KDS"[A$U3*.L$Y5T$N"W!I:/D9&YNYZ=Q5@JX[
M).$+3S!;A^7W%Q3^+U:+@5FUE*2,<YHIH ,A<CA;W[D8HA!J@U_9L(<#*_R5
MD!Q3E;=_NE7B82&DNCTO6"RH!(W1I=UT/0<FFWA>,?HF5-Z]WG//-IM _N@/
MO)RU2:'5NUKL 9N<"UNS*"R(>?RD0ATW:U8X%YXQABMA0O8C/3/(V5@UV07F
M)LQ-;A3+)^H3=8Z\8%<N/+Y 'KA"$G[:P9#MO*Y.@;!S[:%JH2.)<\;:IY29
MY-"GPZR#L3'^*[@@.#L Z3!.J.<&UG3":D'@82C)A#IZHB)Z6!?LH>N,O.<-
ML1%3^9T6-XKUD)>CHEASDA(YYTE3<X$1I9N8$.GA7U[LV[LVS@+R<&K+/UN;
MD!KU>CX\/?YLQP^7H)5K4:E(A1+59H<" =5OH0K"8QCN$A<Q)1Y$:<>5Y7M+
MN7&;_:V'_FT[ OX]Q0(R=PXL6;\JJC5';I*S1JL?4&1.,D<0*.R^AV5G"''=
M'J*:F,B9L$D?Z/Y&;"A0W4VP^<*<6<54HKA)/XVV7;@OY"P6A^CN-M0DR<H2
M&SGJ=BP]/F80J2V#-@,3C5OSOL20['U)@I;E.P-!UEL%[SZY=# <K#9;0,J,
M8,?C7^0JF,!1L+"V!II7X4:Q7V95<OPN7+GF7D0\IZAK72YY:)Z B@#UIL/G
M=M0F<W($SFT.= \6I0QTMUR8K9 T7KG@4]8K_D,<W:[_LA)AL%:V'9&DY2P*
MKHH4$/4,4"X#:2T4M@F E-C=^A)L"+R-TJ5[UH2M!$9%** "#?ROO4:'+T">
M)D(,-#TOL&1[0RV;AA"3?@);UH0?J1Y,ANO)FI$CW()4"W6GE;&JN'!FFDVF
MIRZ$\<4P?8>:>I?M;V./;D.*G6+F"]=@ ;:&\;%*.-*W( %UASNEB2,04XG_
M'5*9_QOK@\7#M[O:M=-J.B^8-ZA:P['*#K@BZOOKNK?<L4I.E9.66SG26'X8
MK.B8VKT0;<2O(!M@O-[>6H3X/!<(8 [1^$?2;=:8-W=YC>.EG_Z6V38 / OL
M:B?%8(+5ZB=M9EL@&+"0%X?1H1;@1: /*X.+V@Z8T\.D7L2_#<EJHEST59BG
M?%D;V(S'V,S(XAKDIASI1KYJ%QC=>'LE3L^&3D=K(+U>VPTUX,+AC)(J'2+H
M.Q(D+A"4)LM,D^[9H\21BY#A]$U'Y9'14#LR]%M!])II79[(25OZ[_DU\C^#
MGH!5$JIM4,T'Y:V+,E_[>-^?N5;J;=WG>^)[H%6IW:RP9(T2VTI/9&0@:0^M
MRYLR\2"$\45*Q%/)_4RS:U=/15J:R*#O"31[^,=OI/8_\-2S>6/I;^Y,)%M]
MBX^5GX!XVI*G#B?:S)'L72$1(T[^TT8H^4\ IL*Y[=WBIJ;*RI\-!3I\:_&Q
M<CR&(2UYJ%B<^4] .]L.H]J5H[I^A/2R>TBW,!R?.7>>.'%TA/YW&L&K"+$>
M#>#IOGKR*\5BX,,/WZDIVR\XV%^6U,$1#+(\-,#*57&H7@<<[5A11]OW\#U9
M%!M0B6S=4+C,MVF($A3'@SS=35^>C>#G73\<8,_(>;SYZ_S="^WQET81E?N0
MB8?<UJ,S1CV,D/QPE45VO84G'#9@DQ10IQIBED2>[I13 HCN:2V^Z4Y7B?Z"
M>8Z :E%V.:&_'-Z\!YJ!ASY,^NVR4CFZ/1"7%GQCX;3-*8#@M?K(OC_=0^/9
MSK^G1+R!.RS(@=Y9Y\0;'BOUAL7"C4F)$X)$RBC!(JE7=?XV'NI\F,72.&(8
M(Q*2R'?>LQ4DR8S*!4B" &T \S)FP/YA:BI*9J\P[5D]];<&[OY!1AY7AK$-
M.W+$:M=.=+%=[W+ZZF8,>]>4-C+[#1EP6-;F)<5FP46[]"^Q;=@GE>7BJTB.
M)\?EC(ET)_@,*'" JVI4;L(GH.\NJE%4(_IWMD0=M!;IEQ@#ELGU=ZNJR>>Y
MK92)Z;V+C/EM6)!EB07TM[1KQ@4SF6)>J0HX3\SE^,M(K O(R:$%S+;4P^IB
M>["_[5$;?_/2EDN,6=7O*J/L>57GEMA\YQ>6(RG15\CL1\IFR+RP;HDUU_N'
M?6'J(\V.A:4=G$4>EE]30;&XNN@6/';EAWGM,IW2Q^&7\WX@&4L.Y,.6X!A[
MMTG_O^+?<4C_\@6J83VI;QX"1IA_U;%5V5($#,.+.RA=)+&+HM$R-=29+JA5
MKK3>>4OT8[N?(\YSTZD?F;D/GZ+!R,&7S,W^KOJS:U7FTC$X6P#:&+_(I]0-
MOS+27S?<?Q+PG)A]4=&$4_7EAW& <-K7/1B;ERV"^TJI)X+&..JJ>X7U;AJ<
M(DL0:! 0.Z>Y"64 PWTBY7O2E_\?7,^KNVR_-:I8JP,^KCFH3P)5?2?C?W>M
M/ +[KT?A*GIONRP-4&L<Q%-<\C<?U<_H7Z(5?P+&:.143GO^#O' [02,!]X*
MK6MAA+YQ%97E1VAZ'DT&&!J%OQPMY$T(JO>SN]%TV%(-YWL?3=O)^5J@R027
M6=76-RRP4=+/<H0WHN+%RNXYG#DKD=_H-.&DY+BKFF>R ;'H%W+Q(AHQ+R*]
M*"GS_>!XA:F=^%T?9SX! LLYGP PZC":FH^C'^7-(2<*S:.\IYRE2J+/;$T$
M? R#HJBQ"H)ZN!EO7EP)\@.NH*<8ZQ?L.K+:HK)-Z42C3.B"$IPN1JF2C\!^
MHQ^YA$\SR2'!BTFPK)(^YLE!/!;FM4RYOQLT_'_+Q.?ZQ(E^(,D*7]Q3!D:W
M$_NLZL)0LM[>X"M(H*7B55*VBO@QMIS3#:FFI3D4RL,X4[H@P=-?_3BF3X1B
MJ_9/D![ Y_.@( W/"X7*9]2Y.'MO*Y@]1#,D95,<,5'0:@I>(2U-LU@O=3&9
M79,VA3HDOT LZT[5L+?SX^T)=/^A/&=O\C>8TCJ#>M9Q;/F,<L'STJA^Y;"Z
M?&_&K<T3'\JM\11MDN!.'VWJ$T#CQ;]><?=@)_5;C43;EW<HQ'?_.;6Q@ZF#
MTFK1,;-$P,%$13Y7H%%8-68 9!Y18B\I;HS!XE' "!LN[*6&H/K12/:-5E47
M@H<4)7P@)PGB4.F@OX$_S5+L+DA7 M>!ZRX^27\C43*?*+9/JO2P;.7G>NR4
M;BL:7U/!,L/W-U>-VI"URD.3(UNE!H,XEX:D5C_O?"<13M.1O2;K,;;XG^V)
M?#&!>M7=5><0:=,F^KK!7_F-OTX&BYU#($N?,*";LUH0$U$8SSTF7(B[WW2K
MRI"#I2N*=(WB/@$D 3?W9Q9BC10@IX[_GO S_I>!M@QSJ\(8$$)9A5V+$;VB
MY5_7?)>A%0D)CZRH7ZOK?O?W;.NZ.@?7]6TY72P_W2]CJ#G%]^':($J&U!9^
MH0%]Q-J-O!]PWTTN'#!.^FQB0G[=M"QX2WS*.RB?)HT5?P59M23S6])_HU$,
MC+YF,IUS/>*8.#I,DH0;R1,[1,L3RLK,$WA^*>AAW_QY2ICZ.\;G&N(FS04)
M\J;9?ES?7'BE6L@^E).2+1$7 N/*\8N67 U$" PAY<J>5@!UK5L8JHOG(?)+
M$&S ^XKG77N^'1/]@O/IUUSL=THGJ-TGC$;SR03!AWI6&9Y*'P=&[:H9DN[W
M,2#TBM(#DM>SB@8GZ*.B*)_W&S!)9C//%O7[M=UU66EMS"F1M8M18\/WUL0^
M%\G7C@T?>XWT8K^D4U/68 <VR5[CJTS45Y8!SU_)T65GM649Q/@?7X_+]7K&
MZ*V@N 4[9O]TJ[L=]$\W$CS7%U$XT._.LW$B%^T%&#5TTK<MVJ;3K](FG@1T
M=IG@,Z$3@^=9[.H'1:OA-*H.ORB#Z;D%'K%VPX9C"%W'R'(<@G.L[!W>TVCY
M;C(/C@]%@X.*#83HD.\,-/Q4/7(<16@3,O&K5N9%,Z';#UQ##?K.7$N O[3)
MQU*G/+L3QSW[,FC#EZ^\%:0"_MZ GD!"C':!MT^1-M\IW'UT>U([7 8;,+3M
MK#B7YBSTJB0*T-7SR)#J"V5F2RRS)<@Q2J3Y9()N4#8Z7<:L755.4'68%U1_
MR(#C$Z#RV=KSSRP&X_R5?#)*DZUT1<K^-M0!N5!B#-<:)!<#._NK.GQ>7B[Q
MR'5%>WB1N!&(%E9J)6),F[I,6OF,!9(9NT^:U;'D:VMVD=EWC3%_2Q.?!=K<
M5!_A<D4;R;=&R6+=T]EU;%UM3;][49\&OHJ01;;\P E%Y]KXV^VA2(=,_(M]
MN?B$020\VC+*#)I-SXZ^4K(XQGV492'O.^%5?CI#BN#UTZ\1%O"$;'',=LGA
MXU:CP1*7A&%R*$.U=JL0@E, #16&-7%I-8A%'7(%$W^1=-\8^$<X&+L[M8OJ
MINE;-]7'&?CLX75+Q@<T.G!0,+/9?*<&^>MY_8XRPN!EOTNCM1!6:1)GINJK
MJHN&WB.*C94D'1SZ;V:*!"NU\<3!LIFQ4I:? [BJG)9I >V3,8X2E 088,<V
ME8JK'"(I:HKZ_,+-VSLZ*%M_G1?R74=2\1*+MIFOR]U!B_-=EUP!^H!=SE8W
MK>Z%57[+C5C.#/=EGS>VV/I6<QB_S89YQ9P"_Q=QC7?_%#B,2<*['.208Y>3
M<UZ&V*?1IXS(;4@G57KZ>1@(O9A> &9;@(L.T[?=IX8Y/GC>31SESD0Z5 (6
MXR'?!<&,!D><YAEOJH1 &9?)7NQ3[M'-QG'7&9<<JZP_%H&D[[J/,)K"D"%M
M=(^MR)P#-<6J47UW+6>1>[9YBQG)>:L:_,LFZ,D(3.QUA[=)LS*=<=*:_C\?
M--1,4@E:M]P[.8A>"%^")"77!O%F. ^[NC\!<204W5^,@RSTF4CBU@P5(/9U
MH'UY*'@)^9QX1SX!D2VHQ"C%7OVO?'_TY11<.BD</P&!;B\+*@L/RU*IS%EQ
M&[>>]7D;?V7-AHLAR3"TIQCYHVJ#Q,T&S0 ;-5UU:8ZD@.5?X475J:\75K0E
MH"+";UU;[E5;=ZW89W6OVX\:?]J0_^_4)P$!_V[Q_-Z;AKA)9XA!QAOSVB5R
MP1R6.W&(>"WXD2QITB@Z#]1UN#KIMU+W"$!UC3$K><3I-*:/ JZDZS_L2#A(
M0?O$"I&ZO=[I]WX"AL9B-;'D$:"F;PR_&Z=.%976(RT9QG30(5#8OEIQ^IC(
MF%&5)/@HLUF-8:?RGX>$(O0:"+9L)1DYK8+:]ZF:^P; A /\S3%6DW2E7<\#
M-ZJ_?=-:;52MQ1&3:P/0U ;-H("W@?C4Z _R9C]3CRJQRB4,4M/RLU'FZPPG
M@*$(X]RL%WMY\'_WCR0>52HNW:8.;T\Z] ]GA^K#%33"*_,*[DPTWN/B*GI.
MO:61!&UQ3)<4J#DY3'^)")(.5"GA&E7&!!5F8C"F?9BG:MQ'AA&V@V7L:XAW
MW=JW&8\6S[_/R5XQO4BVW8KS]WQM2-@8"\J@76W7;:^C0]PG92HS78>SYQ14
M'.+W.098-YN')\/3:!9[&]UR'[6EJO6U:5!3<T.M H0H,>7>.9[E-VMOO!K.
M1'B?2X.7ZN1F**ZJ8XS2B74",O>E-D=DX>VG:_V3+P\1J,P:'<+(OEZ OZX(
M/VX$M!^7\ PX',7L6A'K@$]F$Z 2#%J,QO*S!WW1(TH@6IM%)^1TT!B3?F-\
M(4KCC*/SQ(C[CH#1(:.&?/ASP'!5'!" W\^XRQN[W;E"1<2B_:=%#I'5)5[>
M%7_4;39K3**/HR<:,^;E%&^TCU24[L^W3T"!::HQUFWRZ&@IT?WS?.&E\6WX
M[#;=<&-,CDF3?++XSFD+!YR \]CUF>XK=CHW.- <:S+CZ.)6SRG=GTW*!V/.
MRD-NP[DHOBBQZIK5,W?)<H.!-#6%1:M:W$[V(>91UB%'] O1>4@N&B$#])9G
M^LEO_X]]^K6RS8(DGX-,_J#-N\,O7[+]U7R*K.QTO2ATRJNJ(V/G:$1MS,KE
M7V=>*RA<:?B<B\W&,]R^U)<-0 :V!^W#-?VS4<7K_6']A &? ,?6F:A!,,"D
M' J* ?I@RY'PW<J'3TO,2>KA2SK-,6>Z'M\<4JT=I&9M(N@/\Y96[1[1^"+%
M0IC-SFZL(WNO;+W X!:JBM$2O,Y$%?=Q=<4!_L9D.3]X1\#G_J@IRI#BV;+"
M&G&Y5O*6@;+UHNO0JS \^H.RT1:SM'#R%5:!7U*+IKH:'T-R;EQ^_,&,S@HC
M,0N-A.AEQUE[2%W(B_Q\8[XY3]$_CJT!-( '_8+\G8/>\CL!L6G&4J![E8J-
MU:"NCR!5"V9H[M+R^=^NUEWG>1:6:Q]"B]9H7'9!87'V+OIOQI5JF'7$14:)
MY[G5LVCKG.Z)DL5)GKQQTA1F?8%]<A!6[]H^M*MH1#'2>)NBA86GJR.49&'B
M'U"N8T7_]B1JP!PI\YF]GDS>@^!>]TANQ:VD@6&9Q(+_1:,/Q9\)UWAH5 J7
MF,.<72OJE8>0R3JWHSX._Q;'0P37Q"_F-2V!"Y&&156S%^'C2ZCSY\'1YL0$
MMISE7N2;#"EUO./&O0VK-Q>0]]=VY(PAG:3QI[Y4Q3$.':/.;"%35OCO+_:<
MNF1.D6@$@L'+S,(F%U%7&EAZ_NR\=AK;N&$.YK9$ 4IQ.IY;OKXNZ$F(;%3!
M4Q:WF$#]T9FJEX)ICU_&CVRG[7)8>DV*8]Q_X!Y]"%W'/P$>"ZTW(X>>4R4_
MQ#0G)8-E^:U6@O."XD!HL>@K4Q\"*0F;XG:.)$\;:@%\F23.+;.EJ2G=!N!3
M0VSGL]SZA2Q; 46OI?Z\'<$H V$3EM=Y)*0Z4X<T*YP@\8.$C$DIQG3_O9I
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M"0O3DI<HMEHW AJY>SJ):DN8(.92AH#P+^%-W_M[Q#3K$]$!F5,U-E>!@@;
M899G.R_C5L-TM#"$F,[67OP<:#39NG%?DB #7?%X:6T+53Y\-GZV^M'@\9!Q
MS<^KBU)"T5NF%IQCQDU*'-@IP&-VC=0Y]S?MH69HC4:XAL)%>R"U3BZ-B.YN
M,IT/Z$BB,$RFNO*0FD7*C<9W1XU9\[O#&__2@>:I:&>AR>3.3%E[ %>3JG@
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MUVJ3$+V G> B1#Z=H;P%I<N=!3O&JNS73X#@4ZB>(88KGVE,S>5RH9ZV2;2
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M1B9PM]^A<7LC/6_Z'':OH]#LS:KO5= FQ[7,-V'8V!,16AAU?!["7Y*5J7+
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MJ\E&3H'GUW=%AU\*Y]/@'C$!9^_WQT0#HI$\MGY''IK'WM8U9IGV=:1-0J6
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M_GG4,?';B]F-UPC].-2E; %NET>7E_1YH52CYGS0BI%C7RX*!R4#ML$T$8<
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MI]7VR#-%AT[[._GP-@UHQ["SW>Y0<EUCTZ/(\;,X?O/L@L@8NR,B_C6RV_I
MU+]8N_@*($8PV""6OQDQ_D;XQ/UGC18N45=_UVBNN'=R#2P($-28)D?Z!3-M
MCNJB/K?B\TMF;=_&$Q=GX*-,CNJ8F&W=-M&.2+4>B>[/WC.6L];J&)=@]/5M
M>?!E"%IUJ.]BMDO@<SO\<BO'7&)M4O!#[&[^'$.$-D+LCB2SF*-K2,B8H\GP
M1,?FIYYKDX[AX0@I,;1):U9[EF@Q$SOU$)RDW@\^L*]@'^HB5E-8."L4\]!-
MCK@9MUIYN"474=&B29+CNOGVD/HL2-]<^./89MR[O4F0)/W,:Q$,YE9CQG0F
M!R*]U6I-+G,O6/K*1B5'=#V1NU/]),&?AW8.OZF'438><ZKVVIX$2-+4;WWE
M80&D7%8[#O4A_VA UV+X8]2SY5J^N<N4^O."><2#>)%H=UNFE[3=&R,*#66(
MA_L']^7US<1>9$TS1"*R#(_\^R8YYM7= K$V'UQU]VX[#4NV%-UQ-ZBLP%Y5
MZ(W)(;W#6R#=[R(XP2&?_>#/(6B[3#=N8JE!GRDC/6=$@489H]"A_+I(MA]M
M!Z8SC+6N:J,7K'^A&)HPSS UD4@W >)!49O=GZO?;NFT?V%E"]8._60XMOO<
M^[/7]K FNOJ+6]>YF"BG-I=5RL8@'EQMA[C?"3;A/$O^_,WYI 66ZM-,>LEQ
M,K% 1P?V:N:X+VROP 6O%I^9I,K::>'JO7U"8[_]3 V]4&UZ +U0_GF<>?&P
MC19[%J8&#N2\42#[W^\.38V+1K_:BYVIW>VMCMC\%_'9Z_>MAM+MQQJSHAP;
M=:/\>7W=@]K\^F9@=A&K"XYG U3=G=DD[96ND/ @<P2L?7D4;_ P_A)O9GAU
M]"_+*G&#^V\#'0LBR-W!U59HW9&\"G_83B5&X/KS[F[XHO-!E08SGXH=$>V!
M *&*%Y4LHB' 7+.!;UZW1?^6;>)#T9>3]:NQJ$&7H5**:4PYQT&RVWT>WH-!
M+U-0 _[_Z+6A- (;DN!!I_) :;^$K LL&:.?W:!YK?X>><1^M7%[E5W=M?VY
M5/@39EA%I769WW7"<MQFA=F&N,#UIH\['\!Q'4,3M'WG0*:,H5PY/*ZNKN=*
MQ"GH() V3?XUS[T;1-PB5K!O*FS]"M@D?'\@<]5P.Z"A[5?+;L0_/9T5W#QB
MLT/Z8T/I_8J_Z&600<+_?S=7PG@B.V?'^2D'A7F"[.Y,N\-0NV;?AR@+IBN\
MVFDC AE9L] Z.\^A%$E"ZPD+<#&U.^DOO,@0(N 4]NG;$M9+OJ_DKP"%LU2O
M.)[W\2H @.FR"?H%T<K>JM?;N^-?>HG9OWQ"#5<JDBRLNMKN=:0LT9/%2=3+
M<*M3<OZ.Z][21N,)H*_OWX/3[7 (3.(%#0L+U;RVLCH9I64_&&X"<9S@B;3E
M1^KUA;G2Q][?/'$K3#ZZC<3CW%=/30T^(LEWV+*96PPE."XV9.$QG:?\L6W6
M* :'BMC\B6-M=0P32_S(&#-1,_3'TK%,G)KB-R34]IL[4E*$O0TG5TBJ*57D
M(&++_,W*CY\T,)<_CUKB:\W38\D:F<P#UM<=FEL=GC3^G?]]I0T?PR?8&[-N
MO58T?SOOX?=.3+%;!K!O]QWJ4>#;A+@276R;-$1#_<&2):E):S4BUW 3!,7*
MK&O"71YNQ PWUQFC[SO_[LKW*YWF=\5A&X_B2=5)+?V+C)76N-)*U%FL%3X\
M?,$?&0JC:M8E@6^R6'L'#:<0##V.5J>SX09V]<]/L<)%M-J#JEW@^0&-3[NQ
MP0>Q4ZHBDG.KMW: VT#HO?-&6?7_V%K5AU,Z@O[N%>!$UO<*V'A\!6 =Z0NZ
MWG4R+M]+4.XIJP[</F?XO@(<9DX>@8\=G?8=OXPW4IQH6^%JFP-<:BH2)&&\
MX,4JW_-KF+&E;TXRN>O :H7KS:DW#*:_/G-484H@^[X,87OILN. *1"RG@&W
M^J4-2X]/[+=9LMNQFA[*\&)97SA7^?NE"(0KCJ>)F@E8!++%O52OP&M#?(#O
MD!;E:8\$ELT#O_Y0>6K.//>'[6T+9XLK"/GT/F@[LO:]C!;I7 @6C:,[?XXE
M>9SD=DH8J9+@_W)E**G.(,1F=(1MQ4P9V4;UESGP6OM*\;.,^.1&P>)!&>Q_
M5:KQZNPQ94&-$\9452+T:O^UM\S! :2OC_V]68(2CS-KVB#GZ+O(RF8='U:>
M:I1ZQUJ5P=O^ZX5]L%H<9F'\/6JZ<@E12AR'EXX#GLDB3*HG268-8F13Q.?F
M[2+3<>LXDS2UO.DL=850EYBHZFQMQ=P/$C.LKL-X*ROXKJ-\^C.B'<Z<RLEN
M%-;CX@H*276K600"V^GV8-K6;;CDJ.=XDIV4EFDN*H&V&IO764'W6*:(JGS<
M[PIF[SZ,"88"OS&8SQ5X*YF$9*:C=?('>R^" VR_KV$KFX*ZK>7>):WN,[,U
MT6 )O(Y-HC6G?II+2DJ6XNYY%,/!XSSJP5U1I -HJ%QBC43.2\W)HZ!86)+R
M?'!(+[R;N+[G*2Q[HTORI_8C:((OG/O_NW_^Z@SDE:'2T-(PLV9U?U)(&T"/
M"Y?&)+-)+25V^TDN3/0GPK,L,ILFOC&4)FP5TWIM1K$CX4#3<WYV+VU3G*G.
M<0=#<RZ9U%<,PFR9%!66EQN95>GVZ;8'SV7,/32Q1JP"$J$D9$W7G -V%>7L
M%JQDK"H("()]*\WU!8GRU\_.3O!=)5PH]2NS)3I8!H9.]>\!\_3>%0,0#-VX
MTK<:UP4(:^@)=)G+Q7&)'=Y'#RC^UF=^/-USJ0X^3>-(GU@=QE8]8^PQ$G&H
M<PE;-VI]>F*$38E_]UMTM]81%REOU="97-Y?=B@LS!)4\\A4=;D8'$ 1N2\D
M^6C"/A/L</YFR)>VOG+$3BQK2@]:T4@:"3G1TG*Y:&C2>->_Y)$?6QG=%$1;
MVK<MHN;L% G<M3,0'^X@Z]R%'S92DE/NF'M#!I\"38$O*\<<'!8OLD*7BA."
MU\*SL\7GT5]D(GM)KF7/;D9>#F94?K(M-KP"DB54^ L\OM0$M6'H[31D' ZH
MGGEY5GE_Q]\W-A*\%)04*<+#;3%#?D 2/?P56X^[1%G-_^A5:C#JN:D>@57Q
M[$[^]Q5 AO=/J_0\= CI'(V'$Z],B%MFB_OZ^L#^G'"]^ /W:H]]ZD'S OC7
M0PNMPSN*UA\-^XYZ;)6H3M/U G"H>X-%4C]^D3;_H(DG&R64=$&]W"="LGAI
MB<3>[TZ'V?3@3,ITKG;'O?GBD,,Z[68);8,:_0Z7ZR4-5%]+,7NL'8A64AH<
M']V+YW:D[MZ-&_)TG_A*1QGQAH*$^RHEQ.UM>IU5-%E,ZS<W-Z_8*[U70,B[
M5T#^W<(%1'5\!W8 N;![!:B?&X_#!_ZF*Z@_G20]>CZ-:S_ZT1P^M[U(>QUU
M-AH;%X61_X="J3'\KY01QN?U]8I:K;^[G_5<N4CPN>Y^13RB:O:TO<A,K2@[
M]:E2_L[]/@B&OXS$S_P;R[TNYBMUC?D7X]MXZF7A_;MO0^3S139I]R!9TWKN
M1/>6LW>F1; B87U;.'W_!M59W0<,%9]Q'F#[*"^P"?\ZJB@RMNL/NYT\M[ID
M=CN#.#/XY?@#WVU\VS$)W\^*8V2YJJ>8"C?45 H&G\6-EA-'^^4L12PI$K(X
M X&K%;P,_% !'I 4>B)!06Q=[WPJKVUX)H)TAD6X= (^A2W0<.F%E1#E%$?Q
MXZZ48U[ G)2BJNX^<X5;&O-!4>.4U/O 33650R'7]G'+[\;JMV_8I0HHN R4
MT L@#$AG"@^I!3Z2%YJSHT/$HE5.'NRGB%4]'X6Y2279(_B5CK?FY_ZO[+C#
M_4%9FI>4A?A1G/M^8NJPM,FKX7Q<[97RW ::V(0H%XE:>?\37;+*WC.#:IH'
M^A&,W.)53/-&80V[#T\65+&#L<=R#TQ5%W^GRK#".R'<X-5W$:F>TU^G\F6&
M'']^K3"(EB> +^=EBQ:%O:<?0"F(\[GLMKZ<(+NL=*WX3[=EML>>O2N6H6]:
M&O\E&['80)40\1X>:Y[^E\P05>[%PE/:LD ^UJL3O1< H"]&C1&A$Y7^NMD5
M0/0S@#ZTV7XL#96ELCX=30O:<@U":EE%R2KZYA*I#';J[T\>$;UH"_E;'"#0
MHK>7.!;%E+;7WH6TH:&!0<=9DOE :[)N9KB'&U0=2>R\[1T"(9HTW/L &%);
MGJ@O/[04XSX\.GL;NTRBA"]7+Z'=Z1B^PX3J.3VVSH1_JWR3CP77[O%:S'W\
MDD]/=C%R]<,D?ZV<AP>Z[45ZW1\4%41!4*W"PCX[@UI6/R[0'/#L;N6,.'7X
M5K5FGVA/$A*Z4?BP5Q$;H!"S<&95NIMDN5*F:YXE0W1@/81YIED0H.MT=I>Z
M@G!HR!O!0]#4(-IB94G6\/]:4N=K/=JAE(/Y2KK=8I8NM?D#GTB+'/20/$H3
M,A 9SAG?7ZG5!A(5S,Y\,8715O7_P=RVFW(KQLS$/,URNW<+6!0K E;&&CRY
M6A>SQWS<HO,=60&3'QF:FS-\^'3@%AF4F[NGD3^ W;<BA115&YB3]HR1871J
M-DL;1V(-TEI3UU0D35WOO_U,JH7/SEMT9V9= :'8H-V@4=C[W.I:,6SA;YH_
MQ>2=9UT#>N0.+>&0H(IE+2[0WJG%2X"0$V@MD;6XY"EC@\"X#LM]RWS3G27?
M5NFY("=\#8,&:MJ6V.)6.>^RHFKJ5X_'T4,KH\)00TGH8AH$VD?1>3J$KB&Q
MD6[L(#">6H/^3R;S O#'/E4U=>\A0V(BMJ(PRSJQ;>Y*9RG%E7Y+C25,WY8G
MH"0R\T4C<Y,T_\Q.C^L2YP3J^7#&1:N.?-Y.S=)>A;7,B9J\B_=CO)XXWEZE
M:\I *-% G1 _'-+E34G:Y8B(/$!K0&</>%+RUK_)J!_#1$1/:@)6. YBOND"
M5IK_H*75H"#9S;R%_'!6Z7W[7DUB\7NI^39+;F+&(5W&ANST%+=+_G)\/KZ.
M#S98Z[#WSB='XY MG>(=))$D3[ >?SGANCNC](:ABG@@PX(28=&\M>.7H<CP
MOE6?8+@=<6_U&&T1#HE7W 91R-O^7L7Z"+*-RE,1T;^A0@^/](F)NPLT.5G-
M<]]1YL9&>21)3;E1TS[.,*<DM<\ ^,CJ(I(N2&BWC5#<M+L+1Z&/>J-SCUL8
MY-KU=2SFUN7LW 4K7#8;5_ $=9&WYG_HU*4WO=ALC=GOG =0F==%X:#].^=Z
M5H</^J:541->OMWRC)$WZ5H=+6?[G]4[!(05(UQ<&@9[*R!@\F<E:O^_.+*]
MC4^JB^030:>XD_)>U37+>"X7/)<>3<O'D1EC:/2QL?K;E>4M"J;.F<1G5S/)
M23@DO(5F8D!O;S)?#/ X*PLC-%9H7WLG1HPK>> K09[4/1M0,.K-W.^8^/TJ
ME3B2LF0ZX1B5#]M?UBC:#CHQTYRFOY.!>LF\UDA;8'I-3O-2JBJ+>FHZ!HJ.
M[2&C4_PGA;4&!Y4),C*]>^)2&HYOB7Y%3U)TR49CG;T"OD:TSJ@["9+6Y"7I
M'B[KZ4@K/;('^)?GEWA"RS=%KFZ&F#>+G1&V$AM*J7W&(N3V/M[^[&VC?FYZ
M)&E)&6DG_68DCX@F9"1(&?$YDZOXK7S/-R(UY&C*0:KJA>.5&=]6G]^GSP(F
MH^Y_92OQ'.Z3= PO,],&>I_L+,LKMM!.<6N$(&/\8O@2[CWG6I(;.4FR(V(M
M46%;(B)#E 2T%6#)"NK1V;TWX>Q'OX2\1KHO':7N=,+*.-R$(8%+KP -#>F^
MF>63"?J:25E %H0</>9=@Z7&A*TO6#7!)OYCI-Z8^\?I:UG,5T#MX3@MJ9ML
MH :+]1NY]KBTG>_NW>N="O(O#7+NA<UK]SHU.T8W12U'H.O.UJHJ&-R'WZ0F
M^#G5.K? )[?;>AG-6$>MQ'2-H<;H EK0!,85G<9!0:Q4A_>)2ONR/>I?&NN1
M21>ANJOL[Q^$"SH$Y@:WY!=BB-1I_"%"=B24(P%\^#[WY:,:3:MQEH=!=7YJ
M-=Q>:.UA*]'+)LQ (\N]_33+>^UZ_/9_.2:EZY:6YM#]446D[T(FRHOB^2L(
M2.(O^.'YMNY22W/V75A8Z!X&79TR7UQ0?#4[EO,/.F?:M!'+EC-=+5JU/F^X
MUD=$-6F1 VF\+QH4CQH=MQVMIQT/4KZNZR '7U>8P=K#?W20]U[#ME"3)AAB
M^.FB+HGHL<,7*RW^'TEQV$P6KFJD\P"9<]7.Q'_4V8Q']+LY8?\G#S4-/]UV
M;,R2@3W-X2/R].IY&?T0A6&&Y0#GHT]?-S@2+ F#@Y9"[;I? 98B;H:U]20!
MD>^5AYK?8&\NE6\9E)&'U3QJT'T19O'2UWU2'M[1/#D,6I291CB$[OZ97GGB
M_MQU<&C!'I %I'>TZ2VO" OCV@N6IXLZ.3C8?#.CJ> IB\O#X]7<&R33973+
MGY,X+GJIH"0MM[WVJU,$3W6*0 /Q<Y,)_;J%.5^%S>+:NG_A7ZQY:8QF<)_O
MF9DGHW2M-*.ST0J>EMA[4G*K'E._MFE%5663:A3SC4>7(.TA5D0MP?3XU-4)
MSZH(X)(QK3,^!F_6N=1GT@]BQXE8\=UA<=I#]':FD#(;$A+]&:BP@J,K3QSA
M!QZ2[\ " '$A?:\U!,&BX5L9^'\$(?];Y9UP9/W6[-'O)9M1XL;G/QGAJ^_&
MY0.^>3-+Z2_=@:\_L1[@]Z81]1.PD^5&N(&O>#;LZ#YQZ^#JG[:%B=)#BX+%
MKC]CFV=[\SEMK1L$7/B<#3R#IWB?+K@['T+T1]+%ZRVNGRV"WUE?O726)OV0
M.GCVJ]JA'IAY<'AX!01=OE6\CN(\<A!(.9]H:YJJI7P%, ?T^<XO4KBNE!!'
M>1TQ+T?[#!*T'3[EI?KZZ;G,5OQ;_UJ;#]@Y<_#\O3-A@E+U^1+CR;1;S4^O
MCTR$\O[4K=_O$(I&_"1E$OTPLI.9O=<\)7@DI/^8K>%970536,<7])Y_R9:9
M&5Q>??9;+0(3KKT"5J\>GOT64QRV3MY'GSHY8&9?@/8M7@$[H]=1)ZP;2<Z=
M2UCWK ?9KX \60X,B$^LIW:CR7D)\9%WP)]'H!*_@<;Y+%1?[>)A/LU16I._
M2\@QZO$(U!JGI/#K_5@C2]E#X?R.0)E;@ZF4>YU\[T2K084A+6*0<!1+R^BA
M"$?#(6=0D"<1I4<%B:*!I&542_4% 6^+?8Y.PA/()"CUFGN%N@SRG: AY39(
M-N/'Y)E(PW;DRMX/,7G >=JF*7*V*FWC'K0"H,[<!M*A@]I\0B-/IR@M<>><
M7+9+E0L^*^8L7_:.'6;ZLQ.EEH_MS[<?3H3N0:N#%D\?Z03WJWT@(0DG1#4L
MLL.0LW4WF&TX2J]LG.__NX'EKBK/RCX?3X7#LXJV'6>'W=&29\DG2U&)25TS
MQLO*0<B@R =N28O+2FJQL>&!UQ_:,?/CZ]Z!1'[JC\:B$:%X%V7?:ZJGOUB3
M)0-A=[6E=GM+ZT\"XZ@=C=?_3NK,T?6XX(NCD.[)4FOX0(:A2&_<*^ "SFE@
MO#1"*7]$_J(HMJOZC(>Y#(M[\4LD5X2] J2T?U:\ I2MZU&\6?]-X7"Q5A;I
MW'EW5'%$YW2*F=U\<Y45L8')[O0*V/]YKO&H8RGA#M>Q?&R3\)/(7OSA4]-,
MJNH^'VWW#3_<I&8@BIA7WF4YVM^P<J],:!DSI-FFWG5.[F>_3RUD1B>L31.F
MK$ER7UMTR-;)D2HP.;!4F*9X-?]50WMH]>.0_J!=FS3[P;B+@_>6;_"-;SVV
MNQV$WGE5K6!&D0P^;MA_F#J@#5L%-S2@)B?)#-173X'6G9PS!H"CKE7'1<-C
M&!BQXSQ)*6!P!2-]Q6&E+Q#+)MJ>\(?Q8*.JL=&*4 Z[6\AYU2N 8]:;P&Y"
M]/0Y_<@+=O$*"(9YO @WRDS?ZC7U<J$GM_YL"A+PWP71(P#(W44;#=S.R7"$
M>%AU<(;W?*<H,8PR5'^?F63_T1*[/%UX'PW6ZO^0*/<#%G,NE3+>G5J)R,?<
M&"WW?6,Z^^4OO"[<QP78H]SHWFUW@WO>H:D]MQ_*#MEJDUZRJ&ASLJP"UVO.
MC[BX3!I2E?\>(3<'B=:.7B!]KE:0CXPEHG.AFJ:XGSPZ5W_SFSSS//G#.2/R
M&KRJ?4I-9\$#NBOD98_:IFB@NT94T?A)UU) SYCL%LBZCL3KHRD3(JW,&Z'<
MJI&Z1R013\FMH/7$+2C 5PVZ[>#+^-HJ[-S1.G];U9B)N>-[W5EU\0 Y>G;-
M?!:T7:'4=YF2ZL6OW E3)+>0%-DR)7(23W>8LH-6M&E\7M5J0QG@L^MWU78<
MZXXP'TTKZ@;TWPOU8SH%0+>VJY:?<[]JKB*4 ^B$:?$.OY-C?9XI")3K=/5R
MB2'D#!",$R;J=)+VM"=V);3/1F&GQA2S)RLI.?%0#=P:Y^V$P9;H?Y_9[4+C
M&+ZFPK*PFE)7G9VA9'<'O9'6/BI%04#ODK-;>4 *S@+J6,.-]Q_#[^.X%9M-
M'FY!-<L#O%-#A$2&I7:N:OJK/:[\>?I,BBRK9#PZ7>,7I3L1YW4)7PYF$2-J
MI)\3#\P0?MUBGO4E*>;1IK(_/K5(-?W-=-N *L!?4F0V:]U'>'4J&_*8:"H3
M#SB:8#M[?A,BS-Z?-R\&%V47@['%3LREBIM$IWIA!R19IH4%38K%VG(FU L+
M,3G:9YH:FJA+)[S</7P58.U*%/[QU(C8,:NPHII;R*]#*Z2:I'TWUS<!^&9/
MP5ZD4PXXI21Z^[&E<7JS4Y,+VQ@H3_1'M^]YWRRIC,BA9\[OL/<V[]1L\64H
M2/S>%MX.QC1R*V:[NX^VNG[.72^QNQB1U#(ORB^)G0ZS.JI@/[4X,59:M#D\
M6MQ:H2^>0Z#)_3731ISU=P8JJD(/E_IQ)QMPRJ\]>$H@/,2908 T4<>!5]C2
MHZ&JVOMA5E/:*J]^3O#X8'-RN#4>"K''J*R3U)-41>17[S-0;?IBU)!3B%_H
M25K=3@@7X?@R3H>1NF!AZRD@N2"TD^;#1*V!3\+=^KXE _*,T*A>RAL?[053
MD-CA3]"(.#Z. ='6&5A[1&:6S<])RJKB:_$C')0R(2QT49)I-:2%"3\,7KP_
MQ\>_5.1UO&V+CY]:>P3E!\&-Z8-KES4C?3]'6QQB8KF"72?<T(Y*V6\?Z\?C
MUE7Y J>GIP=D)M!(4RF*DY SUHN/HT5UYKYX\LMNWDY8X!!?N?'4+<\GH(]_
M0:Z.'J#P:&12.D[UQIF(9-KYJ1(#Z<T<'D^S"I:+IOH7($M..3:0WTWJ5S82
MMXI48N7D^9I"-\/YZC?=/]_PU_6WV(37>UMD3EM#5D1"7IBA!5'OMV/;KGL:
M7H2+<\O*HSK#V;$G9^2_#.86/V*N;)+UAQ@HFK,%1L<T\4?QY3']X)&[RS-?
MHY<(]C6Q#<[X"+3>'LHV^*0J3)'N(*CS(0;?TI K,=XVW;]<07_X:B$\2VC'
M>25G8\F+?;G2\\@;I@_3^+HIC.8+#6)5?6_4ASY[7!:ARV9&:@Y25ZH1(#JD
MSTNM@JQL"+1\M4D 'O/([ Z>>-5&<>@,T;: F#WB[O5T5!'6G<XNYMS+L8,&
M*'T-1+48F\T_Z\8)^!=C[XIQ %\!FMYF=P%3 FR5;1=SI^BQOTC$)N]_E2-2
MQ3@R'9\5H$CXT&<$2,U$>>*5K>&N*X%RYEQQ7'8XTG,JK^O(E/F[%&7)X\/9
MJK)0@VK@6M9YM@2W B@42\6IAS8F##R3NHNE.X$75K;E;!RZ.,:CU2H#RU4-
M01Y>P<)[6E)RPUX$ VC;_#PM-J&Y&"%\3>[5'31_IV@5T:KQ?;!/LJ59%174
M8R8)D&IQJE0*4($\1#>\9'B87!QLQ,OS])$Q\BWT$A^?+4_<U%3F9@10:<:6
MLX>G5#RFSL8NO%4QEVA])7"<OI0$Z*6"'!IFE/%%B-78)?R=6Y> O"IW1B1?
MP7%)338)=?P5VX\2FT2O +.F;S9?5^^B4$K>A0V3"('![U#(%>EQK\739#JR
M=,'V])#"?A1/:RO2%C\>WS$97>L9<4BRGK1)WL3+H1NZ)T0%FY"'23%YW:52
MTE F_(=]EUGHM]P"[P0,-43U;XLZY89.2R&G&YM[8WQ?HO"VWC\N$HW?0+3X
MG&0H_JY=Z*3[SY#REIZ\Z>7#>4/[;]N&T,7)R CYA>A5P$U]ZK[P"-@XVC<V
MS65P-\]NOJ%Z^U%HG?E<]8)P'\MZM&(0/ONV GT:%R=D<.M0)Y=N,U/HY./G
M>*T;V=H+YU(.F%6]8E&+[6JGUZF"2]ZJ'U_3 =-17B6N,-.>28 G<\%I'O>F
M1X8>FSG=SI20M<>^W"4:SXQ'T,E2\1]5 T !-"G.F%CIT'R3RCL_BP$9N)2)
MMF# >"MOORV$[[J8TG#PG[C[W_WIY0R)I?ZS(,($>J26(J)=3NZ5%Y8,?V<W
M YN3Q5P35F. 3ZD:3]1K:_RZAUT>54 XR;XIW?3A.23)-O'']L/$3IVVYZMS
MFL?% (B)F,ZZTWM"_!7$'$YO<CSC' '7++@I-VC+P.7]X(B<0^,:"G(6YIVF
M:]E_L,+Y9XVA2GFU5=#:CK,B[*^.]XZ%6=V6O#]A)N1*=42F?AU,>N/D&,\>
M86%,I!V. 8186!3Z)Y(IZP\(&A C50DU-J@EA97U[&]9KH.U1&3@BI5?<U(J
MU#Q@VW6S&37K*-N*A]R/%RO; PKT3H^5+MY-+BSF8\R2])P<:.HV*O KYFI0
M$*U%MMF/7&PJ3(*=D1!IR?<V9?Y:=;3%9$7Y#>4P6OJX)FG&&6(^_R7E![NJ
M-B?BRB*[/)@L>=(?]#PK^&^QZ9%_ZR;-KQX9DK+WUPE21WF;%Q=9LQ44^0<N
MM9<R(?*00%-!.H8W!ZY271!S4R#7=#>*G2APES253@*O1G0+)QJ86*U$,[<^
MMF&V6MZ5T<$!O+1OWNEAW.NM=0L&.0UG7-1:8L[H<;2H=HCL@<[';P<,KZNJ
MQ"#>W4E;#D&RTOR^>.J_?]SM0 . )'*(R-P7R'PQDL0(9E@TM68-*Y:1-7\D
M#?A4A\"QZA-T]H"D.%@-#\RTZV> HR19=V1R9YMH[FX]+;/!_'Z,C>(]\P+%
MV]#8L9N]'\.8<L$J@N^QJ"?AM(M?A;=NV>N>91(TBEX!R4DGPHKDL#*3V&J>
M DVA ;:":5EVL*TM^^PY6UUYFE"603S>-V"<:N$FP:#N7YY4LY861H4'#:7^
M$70J;44,O&B?$W9+5WS#F!%>DF.4PM#H, S;TW4B;Q1X;#BT*$4F?WK_.13;
M[9TZNE($;>$X%UEK[+L%00;^[I[!RLF?^-I?#_#QOCZ764:V'ED)VX<]N64+
M1%W:Q G(<>#%AA+!@E1%72ZY@+E+#,694Q.(%>-T05:+;*I(<=Q5UE8%#8IM
MZO+8C=IRYMY;G $H+":>YN&*&R7%MC&JN-4INP'RU(F_Q 7;HR 1=M>G[0=^
ME+"I1TS-)Y\NI_MP.7?T?/6F&ON4)C>BQ2RY5O@YW?1.F/4OK9;T/>]31:#4
M0<61]Q@EMI,/@8(0M,3NVD>1+I$]0$$1-[>\M#AT:OA21X3HED"#_QC,$1.!
MPA#:/!*PO"AD)GQ_2/J]0[^))0S54H4C0XNUPNV^$*>W?ZI/39TF<D[5?#LS
M]G#6+,!R"YW.Q5C4J[_X2ED0M5DR&YD87\ >-,(57,C=GF3>E8IB=>M7MJPN
MUKA^J(637R>0[3V_S!%U^^(.TQ^K/:<G'UY6!.G.@$M*;*/B8*YIJ)! CE1P
M9$ >87NE:9* @,>%.%-A9 ]U5P:D$5/SRPH+LUTBMA,]NN]4<?M"*KL=M#WN
M#UZE+[FFLH\S#V/[[ 4PRA%7FM8Y*7'BN?2PMP0+J&*G,"RO3Y$Z8/3Y P'7
MN3A&F!YM_(>/H2S[5@@]J$TS:K\RFU7MC!CKM!0#$S; \7!\OC:'OAK=.YN6
MG9Z+97M!7;H\"W[2C,/=81;6TH-=AK2P/.%2D2;Z.,E5(8(D9"%@3MV5*,*?
M*2=DO&6XCRS^^*)5%LOMG#9W1:Z+3%9 4=Z;S;+2PL(0>5&U?N]Y<LDE$OT]
M9 SD+J-9SP-]PZ>'C1@M[%"N9;ICM72F([BL;"6Z[7<FY;+Q13D+QDSH47&1
MO*#>LAEYM(9RDW)#ZY-8DS%I;11KR[E8$K0VQ"0_I^F/:TF^'=^'6;6?RN3L
M>%-R^ZPL-E\YG0_IK&-KB+)(1-H_$K:RUF-BU9XE/L0%!QVRV@LL'E]=3T!+
M2HHK:: *PW?TH?5XFK.300+"5AFT+KY'BBM@VB_F8->A0YMO&>7%\_+$;>*2
M)71R5U5.)K5"C>K$R,?FR=2/0MHC"7N7\=1W$DI#[$=><%<AV,Q!VP.##.\H
MF3E%6_)HU"+Y1[JH5O2,>Z;X[8DD2@&OP(+S176S$G&3HP%LU? DOS>1UPRS
M/W]FWI1@- D%93+0FGIN)]VO&P>#4WR_IQED5^B>G<>0B1_TI.E_9PC&B,[]
M<^'(+D05:/G[]T9?L#M ]^PF#M8<['0X+9NN:,@#>PL^J++S!&@@GT@,EXUE
MMMJ.3<,73\[+'_2Z]_.70JF'F8<>C-NAQ:+%-\7]CVL/\\TPF-<(%.P9Y7%_
M[PT=/S\=%=1>_0%&+@Z8>W$*$@QH%D<UH!;6%E@83<7Y<!4?6>?.[A%/6.8B
M>A]L(%TUM;> 6_\*H&2V<YGJ*6Q:/C(6==&:=?VFWB:K0<ZNB8]5[#E.+&+F
MO8H[CDE*9;T K^DI:E+3ZM#6T%;7[""GT=:8E>;-XQB?;A!L^[W]@?]-W/O=
M<H.J& FLRXKK3IW)UOG.)]NF 8-7P'*6G,,_M0VOV#4;';RD#-%[.%U\L6GX
M2OTW<2ZV62G@4_[VUO/O8-7X*/*%71R>J%8T/D\""#I+,.VF.G)(LXEOC[L<
MUN,2M"&SYEG%&5Y_KM[0H*!G('?3>Z/Y0:0X=#0R7.HRF)"H *EB)$7?->CX
M]U;3E.*70[E#<U=%$"T(P-AN_8M[VL8:4,<GUU.R43G+%U>(:5(^^]]EMK0J
M+CQ9VUD?XO(S9N;WM'Z8&I5<*-D/$;'P]QQ(!Y/6M&O)SI=]7A@EY IP7%C*
MHU?GMRBM!7QI*R2/>.]O(MDBOG"@EX/SC?>L*?+^P[1?P(RX)$W'RA6ZS-1E
MH.H>ZBI<A^DK=SAKDO1^DGD()<6%^)QY_I#ZR9'.)R_IU(&)P()^ ]H4&71!
M=/]/:L4D5*LI:]ZA%8F-$*O"W-0SY4V:A/;$6Q'G"%M;_U'>)0@32SBH!)<R
MY"0SHCV*W9JLBG#:^,CN+06I+RF'. =A$TS3\,"$;\PV3SO5CG_^H>9BBR+)
M(VH_(KFZER^LOQ&^[J5A81^K(4&A55.,)Y&Y\&#S;8-3[L%&_^?2_3T$3U@J
M7]C;MCPBR+)8*R)0.A\C3GZ ?270P,;A\PQ,E,TW6WMP^C!?BO;Z/SS\QNQS
M #W1WGTJ7_=H5;*RFHS%"S<P)QFCM?XI;K+ G0!@X1;T[^Z/:8H]D?!THB%G
M?_O(G]]4, GRZ:\8JS9GWI[EOP+(7T!4NO2%E"79+7X<M70T@DQQGDVP4MVV
M[5AK[P*=*%I]?Y]>_X[K![=XHW3IQ#W[Y.FESJ>5SZJG[(:4$J^ YMP.+<MD
M"6RO9 G1*#_1[(4L#I'VS S%!C\_\*;GPY:3(*Y\Y@#MC"L=L];S@:/FM>N,
M\9.CCPLS6B-KDW(NINX!9[]Q2=L#'X\.Y9=PP7 Q>"CFKR3KF?[L3%"#4[W:
M$M0WV^V"]OCE?75^L+?0,A'GAC4]+46-MN@>#&A4\?>%+9I*[4;=;Z);T!/H
M->3C!)J5BXX'MRX9>B!L_664/]6?/HBW+ (=_8MS!7@F.HW+>\8@Y\Y18*?^
M:=;UA)A3I<AI4_V-;T]_$DI9I0\&I,3;T"(_[WB^LO[LPRU_Q6G'<D[ I]UW
M;02B?! ,.B&R+[J/'\,L>5@M+58'J02L[FS^CDD!MF4<*AP!VR89\-AJM/AY
M0=D1T)QQ737S!*F'* #Y F7;HK*P-3:0)Q;UPINA4I5S<F*S?_C;E-34IR@$
MH!:F!@.S#*+'UB_0Y7A+BPKE\<6:9 ;,2%%PRF$#(H$FS1JT45&2==E[T=LS
M-,YG[X%LF@E3<Z@_%U46%^9 Y6 3.B.P>3 4;=R@DW>$ I"=WXPO3\1%%LCZ
M3!NY(V6JR"U)I[*J(U6">?;MO*VY\R%QW16:A</^)OT6AK_0S(8\=YBLP6"$
M1HD]_U+H'_JKHI#3HPT]GZ:I&"'>H#O6X,$=D&=>^>91NJ)SSF]81]00L;5P
M/4]?E:XU9.D=)GI#I82KI(\[Y@>^P!9IO%G!A7[G9E?IO .K4C?9GH)!THAC
M^>'1^1O9H4A&#2_;>JF]5X"X]H<)]D'&4?9YM<]O7P'8\MOXSQ#*^NTB!" +
M('=$Z>?@=FFXTP5-@5&<@'=R=XOK]%C+J0_2;EG],ER^M-G)#E^S@GQ%-2Z
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MT;OV6OK,YL0S&SP1?=)$K7K 8R\2MHH_#>N*B1^41>*R+'<#'^GDT?%?A2)
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MP=KEB!3W[QGW2?,KIC+X0-0_[]<S2VO$37K.M1"]3PK:@O?K5B*(X A%<$.
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MG8V$0!!7/1]FN2F8%EYD@J.J])[YP#!97GU53/_W0M.38 >_-M*H0K5,5DS
M"<0S/=U?)= SW<#+]C7=3-..0(,''DM&0S@;H?6 9DUNF&Y-"W2/DC6<F'EN
M<ZKFO;I9O_BQ9LL';T2GMB"LO!'.>^<"Q#@ Z>'?RY.PF^+++#87 PT1)8W
M3X[L,CDHNU^/R#:,F)Q?UM3@EG J"+EJL&<R4<V1 W5:&FIR+PE$<9YS;OK,
M%^_>NA8@+S+2-P'RY2PE[?2_0GO&3_66-[A:>,H,,C4().3'@&$S,WDI8<C%
ME3ZZB-H005<?K;)46PUF&0-G;GDO#Y!D>?E<B\ DV ;?W[W1:%6QY@\+TF D
MEIZ#.B3M^U53BS:Y2*YRGEDS$7+;P>*L '&,AYE["1Z%1LO2BGZ7YYHB85KF
MGKX.77VI+%!IF>@Q-.+7E'=>G1!?K?4;GT.>N(/U!T+6\5I)(\C2<\J+(%/1
M"5>28S0G':\7"NPK=[:TLF_%'DM?8G4P1=9.)*ZJ8^],EGJ?L'6I3:$Q3NNA
M!>*\3C.JIYU@Q0%3'&QC)@X6[DL*J?VAG2/A$I:7MKQ4FYU*A;RX:6IEI=YU
M\J79[4KRJ&J'"M+C,4=?[)_^?2=V.QW%0((VL)_]"@,>6>5:*>.X(ED*=ZQ9
MYE2HY&(99?'GLK/=)M3-2&AXVI2=W)3K;]'Z^'X<NG^](];L?_2!;_](;73K
MN93^'-_<35M3_V ;>X<K:TJ/J$BF865AEFY%:D6%#,*43C7"]XA^:N8<YZ:(
MQU2=UD*&AM&XPUJKI<*868(8C=BH89WA>W!$CEM<>$4*,-X^<"( 4G?6RKFT
MST>X?L1@#H_\81*3]8 =)<*0E"%M+5$1N8?C)]Z(S-V+4&;1N0Z1M%>FQ0;;
M^F+I>!#JVZW;IHX*W*E,&M@2C.:\!C^VT[#J7L3';PAWX(SBN=3$R %A*77X
MOY29S&PFMO]4Y9372,&0)3:KS<K6"*:^6&%6N%9HLP&K*XP?G8-A;]:BI[&?
M3#VM7,BALV2$+:8X6])$,<-_=C'%O7;4K-*?,$O:A1!\\$4R#6Y)+:LS,]<D
M2&':6NM4-R35J7F!=DM6&'>3&1J'Z-(E'F#[:R//1*$WW%^P^[OH?;,J#4BJ
M6E(@I_ME3F&^__DS3E:BZZL/5(Z\UGI9+$.UDEUXC:^9@L/=;?>&GE_]XOU\
MVX'\.\"30B<>N3=AY!W0U:.7.WR^@$]SPQW>NXZK"+U)K-.+B9PA3$7 J&&T
M+&3>4GB,9]FPO+GH4]3,)4=!PJ.JKUA26H9N> I[CT!+12?TK8AZ7$=W<YVU
MALQA^L$^D/$PYLL6E7YHS;D!P_ZQYKCLQ(\MK@QO_<*]M8)KI$4XU^J2!K%Q
MR&_UPGGE!6T!E4TRR=5T3865NG"Y.I)MM(&Z*4\;VJL6V16(.'0"DO)N[K*-
MTS1ENNVFE$ >H=VG>+H'B6P[/X)V%JHR:^0?7$;2GK;.<M2:6P0J=XY!!=:Y
MK%5W_K;,^ 2]Q44KUA['FG&9(LDNI,9QXD'"O@W%AS%K<.KJ+W-24456CK@<
M-HEY6!$2KV.KG_/VBZ2/+,[#192<I0F8U,3">O<2Q9(&PZ),&X.'06ZY"D7S
MM<06IJ^U7$UR6O1I(YDES9:F,0_5JJ9 "POC5L7$WGYS*_=*^\UZ2M]A7OM@
MYA^R%7;S)=%(23C)K%NBV@FA464:B:67Q"\ @->E*#M1>=J-=>/_K.M9*48@
M<DOKHNDH=[G+>>@8FJ52J<MS1"UJ:Z-14]B4260<\T_#D2/3L 4!XDTR&-),
M<;6PY,D "!U4( #@*TB,-,\<6@X9!<L; "U/NP/@I\H?1W?+8*1<0B__+'T'
M&57-RG&V\%'^.5H-V[M8E3(NCVOBR#Y#^D?,-+L/;FCRSJY7>3:#3)5Q^ L4
MV.WTQ9_WHJLGN?GE3QY"0I[@$^UZ<YX;)Z/NP;305S2#KB U9U46_L, T6ZH
MZ;VXY/@,\V4%ZEMYOA7PG.>HA/ @ZZ<>ZYV@(C1]04</P@[')DOZ>2 N6E8H
MVZ=P=BE83PMST_B:^/)P'3B@ZD^M*_$W,TH976WW+^-#J1;D*0D[XF3O@&^S
M?MS@?]HD<6Q^Z&'"(_8=H.>V_5-0>Q^?,^-_%BDY:'S2;0Z7P1LZ*HQVRI)5
M>=91%_QP)AWV'T;TUMH^$4)C+W<@*D9C1"]0[=BYLMZ'FGWRJ236%.8:M;)J
M;$3&!+$W7CM-GV85Z1/R]*WA.GADL6)E75@"*?2;S^%&:LGU?I6DG>8"JQ&M
M2BG'?/NS>.)KTO'CS%=:>7P<-A.^Q,,6P<9+I=5JE2UC<*68@UH[G$K7<,88
M5GQ=O,MHIHUE@P5851QF&):,+TEP78YBR$XN!KLQ$%U&^R3"VQ8+[)N</?SV
M"+;6X8_&Y"V^UG.:F2M4?W&^5*#_>"ANI9@\)>+!,D:4-.>#W:8H,,ESL9"F
M=T& =QQFGI:9Q88EB>+W=CJ!;X)=-4&(>CPRC<<J2=2K=[K=;(02A9/Z^MD%
M0VB/7N1^%R*'$FY]Q-9RU1BMM2=Q+U.X_"R2MV)L:QLJC19'=/$RGE7J0]D2
M%,&5G2SDN87'IB5H[;WK7!1-^9%(9JYF^(B1)Q)C\'/<89HZ1IIL\@"R.*'<
MR(946#2])W5^^_<P%KTPY*"'JB"YXKA2<[4R'WT?Z'BHU%3<_!;_@@9I9@C
M\C"2:5IY<OQ&Z?^WFCG[7<-KDZ&9Z%^Z\(RVY#VJ=/0O.&?D)X3#[7OT^\#
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ME0LD\[L#F+.G9TII\9MV=WLM;O6YMCZ&"KSKF,#!W/BY(*'O&NV9%3$QT,J
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M"(4;2.L#;N 2D#$D+RGZ9=)UN=L-+J0YT3Q5I9Y0-*=A#W7$@,Q#SL/9N0C
MTHA&(J^&%Z65)')3(X[,:7M'<Z=RD1-<<I7V4A;!WD>L&![N.O1I5FF$@HPK
MEE&Q7MP"N:9%\FO,/MQ9%=S5COSX1K1>(%*V:&NJ4,I/![*OU['P)]I-V_W
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MN''16LM88HU)!? Q-"2Q79O'X-35G>#$)\6?$*MGFADA':Y"XS@C'48200?
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M73/*(X.#*'ZPS1<W0V(>:O4:-U1UOTY&ULOK?MACTLB^0X0SU,MC6>Z#EX(
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M%9@+$NW?%T/X[?+<V/)_%LNC-#K'WL3B3/A[Z+6MD6CNX"?KU4..V2':/H5
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MNDJ)VRZUT^ ^] WP9^UV(Q;C#:"OR%FO#A3FE[$U1+ZE&9,Q29A4R5U6:YP
M*I58:CB)[3BT5)2G,.FG_LBI_D[$+5#AZ.!E"=R!RN-5S#>LE$>]'(MLE4L
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M11^>?P92V!-75%'GB@OO=^0J_S,<#_\0"1^OM6#5PRD$]YN_ 6[J@#3W@-X
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M"@OPIY[G$4)$-5D5918QQ/V>8??<W3N6AW<0?LW.N9D<P9)R*.$3JH81#F?
M@=OZ<HLA05G(FN! 46:.K^Z[<0E.[U&!C$]+IZ1"8F0 UAUR<)U,66L:XOXA
M"'LC5.[F^A9>+A&Q&:%1N-@D)V[TBR&6C0G?=MBX/+3 +%*ZXJ"6A;'.6M<S
MY7F&DXA)KI/6EH9U-R8M+?)+![PXDF6*?O$6E90KOL:DN*+D/*.2%++)B2MI
M& +>[B<_PE(X."S3\Y36 W @-5;O+>4EUL%/I.<>FH>]>.\[Q+CIU\!]OC>
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MH<APJG9+E=6509DF[Q 83$_79!@LGW,4_N^Q:#YLP.F:G]>#.2$NGDC=ZQO
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M,8 @P,Q]+/+CV"8 + \,%D.X>,1<>K+<$^5C;?:9&7A0=W&_[94<@G"1%6[
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M^R(3_R-;%M&JQYP&<5/])2*T+=FF>!UL?\B/]W;I<\QUQZ=E"@OE:/K/L7'
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MPPDF_5<<Z]29/%;0 Z>#W.OT8D)$+0HS7-/X.NSLVB:%4M)3/&MB\VP<<ZG
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M*_FW8WN5*"CDC,VXBJ/C7D3N<&%2-XR/ DM5Y$1XU""#[S]@GJ80%$S6#3
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M'&[.0@8.3BWMFT[5?G4GKR>)^T.:_6 ,1I3&2E#62);(B*BM\>-D_1/D8HL
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M'025;2:LG5^.PI:)YQHU3)JLO[=0#+=WW]<[C2F*&JU5@[CF.4;(YC$BC6#
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MABTF?#\'G"0$<Y H]4D2LN.*0[/D&*B1<1.0]!@PS<Z**7IM%2L12S20R)+
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M(D8$JY>SAQDIPI6RH3Z#YH9^*]%=M6L@B+73XTY+'+ D8(WKN'+F9*^&N8&
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M7D]4Q;<OXG[F^56D>:G@&X'-NKKQ=>LIJ%Y0,;V>:$GSO%:&N@M$329HB(A
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M8KR>OWB4&)4!F3B.?0?EV:A?T$B&=] >*R>_C W,V'SA ;(@ZT<N-#^R3*S
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MSW0-2*ML'I<TXTRY[ 8N!"J\6Q9N_<J=JOIB<]7GX)OJ"Q6Y.4D3-? &Z-3
MB6M(0*'0R51MVM N:<199XPD;:P8=5*P&["1NZ%149(_.WY)!FU87D4I*^%^
MH%)7;U*DQ-H[FQ 7?27VMCI0HNT>^!8+^5DC;E)JGN@AE1]2K=)4<[GAMGH\
MK;.-"DBF#A1*RC%I&&2^VB![1UC0M4C%@U$J*&Z#]1^:T#0X*E4X[=?2CFDL
M9?H99F7E:=B>^S\F2::VV%(@89;MX3?L>'5M/ :=\E(O8XTR*%I;W4=(="F#
M:3"W?-TP/%T7I'CS#)'ADPW/I2)YS'7J>Q@,P+_V*W#D/X[S)<1T/9/XQ-1I
M?WE;4-<^+UE$<M!:ZH0^*+LCI;UW7?OJV6G^P]0SH!&R9E3Q^$I_S/@'W5A?
MK^@&I](4="C-92#/J1BS;&*^6L)LS60K2$>)81[D%"^LJB9'YA3D)YXRXL?(
MR<-H]0_0Q!7F&FO\Y[(?HD[)-<EET%@G@.S@]@TQL=Y"OMFR)VL3<26K[L\Y
M&TZ<:FHD@2@C20:8F"^4NIS?WC*</CNE[9?JEY9YLKK_VU>H3]'[_S;V/J>G
MXP<\_:]]EGM_1N<8VC#*O_GAZU/ J$0,BJZ>?,SC4?YFC_Q_*MTVM(Q/Q0]#
M__<LFK^0A0'X;1! RW F%?:B(Z;/F\ ].[G-\S[9;2_1(>O_WH'NW,:<_+\7
M@^JS!=/MCS_(PAVFS;^4&KILBP(7E35@#.D&7;"IC)]UX67\L26J;X:UPYG%
M%$K$X"4JY30&RS%X=<69G^\QM1HQ0A4(_PAR3B,HC. <^P)IY(07LM1OE(\%
M<BL@#R(=<=PO^RJ6V1M8/)J;!O4@J:0!83[?MX4W(VV9E-0_^\[]GN+&"HS/
M:ZBR(9<X/,B/ OG9*:(5N8<9KX#ZNBH&9\RW50"B3Z9?.:/M#0 =!^,XN(2G
MN&^>69-@4J?W4QAF V1D0BV*'I\Z$C?8G6^;5X4Y)C9X0#&JB#4TUXL$H:>@
M6DQ<41N/YVROB!<:ITWZLBV&&2W!LOXX@-A8<@QUILBG#&OR"97@A%C]V['M
M3=@GRHN"L30@#L&$9/[0ZWO)A= %\Z^%AH]EI]K/*X.]GFH SP*_>[P' #!]
MZ.@?KL7R_]>&XL6MK*.5SKEEY8=/[U?:="-?1L-R ]*17^T)OHDF.>T"XU^;
MYH."CCHQ,5*T928_)ZV%V;QB"^Q>_G78.KOGZ^IXXHS5HU@)-09)"\T/O.7
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MEH-2G[&_D$\B&C4BY1!?F*.1"]X]%V5J<AOS9"%\RX:SUI0XD!GR0K&$T["
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MO^B+O_ZK_OF__0O/.53_W7^,2?X]PYG'EG1;<TX5PO[_30!02P,$%     @
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M$_W$L$VW)+_;T]S3*_6V*YN82SE-Q]?9W.H%$5>7UE:OG%]T!U*Z4M2__B;
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M-X*<K"5P9W"8/]W2=J;G/;/J7-JTWB=KM#3/$MZSG$'T/08G=F$<MX[](,G
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M4 %Q+MIK!Y0=\TACO+:1 >*6/P1)F+ZM^$M_5&C5P=5H3IY'X^[V_W<AM^A
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M^I[3@7D3_*< P-P'Y4[/=!CM.@Z/S6I=1*FONR!U.F8L=8KEN^X-.65]5S-
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M[M9-3V]=L4=RN6 V&I2-5K4DG/,MQBV7>TTRWON%:7MT@Z]R.) 0=C%MXP\
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MOIU^B33U*J![D2N(.\W,L=3@1@\ CWW0,T[6)_*<EKOZ*SJJ^6/6LTQ,A=?
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MC7O(T+1%QOWJV6Q10+Z.WW>L&I4ZA_KVK4B@> ^%2Z4[G_41>:M8<G:S8P5
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M\<_U6.[:'RKO*$ 'V_!_<6?[']Q?A>MO "B2^M[_SN[DI _GX&SHEN+_N[1
M9Y:5E:F84!=&PIERX#5CS&MC_/Q)%F1Y*&IE\A:D<AI - J"=[;>$%P"CTJV
M"ZZ(Y6>Q1V-J?%L1#F-ZLV-G\1ES^:-"D5@:W]K[_1.)<N2(\9?E3>N*2,SZ
M%P(ZRFQMQRCVBUNOH+;HZ^(6#F7":G;'\S^B2A!3J=KU7BZ!<=+02,,ZJ$0,
MZ3,RH_FPPWLQ+GHY("=#ROE"_<G*<[C[)C%@BLZL4>>W!R>)SR9,SMM]DQ/H
MODHH,#94G@/]OU$WW;S9>>C[1)8^TC=(WVOB%?T#O<',5756Q;+ N$Z;M=GA
MH6W_.):@Y'+9?R_)#Q0K, NZ'),4[//(LHQM\[Z2IKT$/IKFQ"^J<3V 6=MW
M/5]FZ&;['//^?%/Q+?$*A]*3OB7XZG<%Z\NRN_!K!Y-4J^T 3P?-I Q3N;JX
M&STQNV)O , +XJ!LO-\?#+P3@S:-28F)/%J@U-8/)"?F1L3F^07*&A):H:7D
M<_3_!=V;/C8NQ1^^-WRVBEN>PD25$KUATR&W$ZT[0'(CJI%>NKYY]/!_H*X\
M_1?UBE+GWS);[?['(JV,J7AT;-2#7%^\*:.L<D7"AT(9DJK[)^,,>/K&!^L4
MV:3UVWSWJH%CU\J"PC/_P"XAOAVL<R>65 YVKCJ>Z#]S8W?6L\7[HC Z4D+(
M[+):B_9[FXG!O<P4 ).FCNWOY=-@^\'BM.I;EE'['L)8#72_N2ND>)O#WU:^
M6\V?\Y_&GL*?/(8/G@;==B'O_PI*HF4G3X\FLG.XO->"TSIIJ4?68S_9&.]?
M3?)8+;2[O-C_WZ8MYA]\"8@]<Y!CN(@W@8UY\D >OI&,97E2M'0U*T&T1/&P
M?D^W1@&3PP1[M+!TK@:+ZD2',N$4VP'"L_K%A:E+/WR(3.O+8$[KZP7Q6^R-
M[=]D-KY54A5A+FQK?Y!Y/@CH63A?KA\>>J'($(^%'9?+3J-2/O=])6) 84--
M-A4\0<Q(C2(P';5?S7KY]3_6XTUH4!/7@5#T?4(IZJHJ>7=5B&H-?<>'N=KV
M;+''E.3S1XA9;O.I@_Q5CU]\%LYE(#/2[S@@U^-8<K*C5Q?^=5*U #%5#';Y
M:Y"_TI]0_I-\W#$1?KO_O(EQ_5]GX#TS?3#=^^:[7"_9?6!O8-%>L:$K]_N5
M"U D_/.7**,B',(HA<*-(FM@^&X8.'E>N#!M-&'8:*#1A86)3]I40"RI5.$+
M>W 5@O4)Q?TQ<4\59:4G1RM;^7#JJCZ@-U.7RA$'OCTYAXS6@NM),0G2:1HR
MP>JKHY;<YL3%>E.FB3G&O_NT'RNXI2_ JU5T0]8#O.-Q>E*R6(6%8%:*RIIJ
MK;H@UI1)>_;2L*JC97VK'-XR1]MJ)%UAF7@Y.W&H.GL?WS?HK_S7@75HV*^4
M&V)B0,UC L8+WNJ!*C<Y>^85_?:%.3N%Y4\H) 4IR;AK1JI&?G<#ZYO)%9)=
MAVALD>DFNE7Q/8ZBAY^L""L9W0O^U$U&L_&[S?Q:/YT-,R@J])]2_Q&*E=5A
M0F>5S"'UUG0?;8;9AO?K>RK4R<G,3/NR48A[B[#C&&?XJ,?Z<6E =)'?((+]
MR^^*R4@YV]$[FK:Z2LH*FCXL:-V=@\WJYX=^CS="ITAA2MYG M?3I6?U([PL
M41\-8J*TI6DK&WV>O04)I)X??;@[(;?1_V2$+_+BL^9RAG,>&*=!84>Q(=L<
M2D1J17T>[US [_5A5$Y].TF,L)(5D\+0;,6Z;R*,0B^)\\ ^C*!)G)_*R/-3
MHX'.>WZMT&C,HB)^48TZWRV#)JIMV3\G^[OQCO#Y\_Z:DG^>U?.+>ZF<SL;]
MZP"1MZ7CG%/6T#FQV_JJBL""P[FFT^;DG;!TBQANV3SQO#U]UV?=)8XZM"[[
M3"TQ+B"#%P^+ZNRBRH,2TR/S%.FKT&3.GVA\;%ECD\6T9>F< L?H<[]NMZ>E
MUF7\(1HP22=:D]QRVRF)M18<1BHA"5GY%Z'QM7ERNVR6'Q.-IY1K,Q:=".!:
M9WFIO!2):M@?^:R+V!(D",50YA'*:M489]"+CZUCZ"S'-0'O#Q@HAJHZYW:)
MS$]]A]14Z[C<Q#X@=7XPQ#B,D<T(-1[]?H,BTFD^B$"ET@X#-W4;.Q&5T?Y=
M="/='),J[":C:6;(8,$7G)E-WOY7EIZ(O,WSLZTRKLJ^:MNHL^^H?[T_W_U-
ME[2<H&D!4C 4F[4(!AF3!0]S^<$WTWAAR^9N'U-T@$&*TSU[22?A^$R<3JK/
M!"$.(@S^!@Z$K:O'*K#^U0[#S/;\,QY_H-?\UEZ_/D/*YC19M+SRUX-XZXT/
MNGCV>?JWW.SH[3TL&3VC2<E9^EWIXP FT"ZQ.*4I7VQ!=+"NW935A#Y:V@LV
M]^TO$QP,WRL+7A8=%A*;VWF9UJ5F^S/@W2 C91;^?+03E9&EI0^W.MU[E*%!
M9=E-.'Y-1,@03(<%P:43^'PU BFO2*O)K,R)TR*M*Y[56WQ_3$CEW^B[J6B0
M:*C^!OR\LOA.6"0"'5*C]C"Q],M$5U#.WB(-K;HU(>#],Y[*.DX6JS<@BXS5
MX:XY^3>#<P%!G%R!]R!UDXQH-<?(3HJ]8?0&_8TP6XOX7EI'8>YO=5L^50N$
MQ%B_0M)Y3]'6<!<GFM>^1!CH9S_*)LINHD93%SP8)P2.YK.+J*D,/:$$S&>U
MC4AX71W-[7IEHT=Y'1'-EEFGVT.:CZCKI*# WSLOZY1)J]G:KJJ_WS(BR<PU
M: =GIM%\5*RM*A:V\_B@%K,QBDZBY&]"]RM5C>*.QBA.>NZIA,J [$,J!!'A
M"QX\6T9#60L1NN:GIG2OMF2^;8Q;>5!"U<3B=/'R_)M4&1J(ZZ<2?$H/3?P.
M/Y8>OC0Z6D!W:E.NR#[ORQJ*.*.8AD(;B8R5*4HKZHF9Z/D,O:8B4R3"N$(W
M?.%Q;?/31LINZW?X.B"E(\I391$[J4'F#N+Z=5Y;3.I2$A)>FTB%+SOVX@W-
MPD)M'HZC538EC,737W 4]\DWWA1EN)VZ)HA\CJ1 .ZNS0N&5$)(2S02;+4.,
M)]+S%G#EN^FITMQ7H&D&;^LOIKW:RIW>!B]I[3OJSGRCG\"PK0CV$Q0+,GL[
M75>RJ#T&G?@9+V==BQXV01.!O,3R0,V9HZ7CTTZ<?Q336;.$#A0.*&$>?O]>
M_3&1")"]AVBF6+(8G <.)"N=ES1_5[^^$+M@PN9O-G&D;A[8\?E#)AE3ZRA=
M<\%.GI:%AUW%N";_@Q$S8^%5I<C!MX:E_L]D::')["> KTJ&B@6"DSC/=8>U
MMFR5G*^6\3JQ%C@ZI/ZW/JGG(J)[PL;9EV0E#EFZE2D=I(W*Q&>F.4/G]A&Q
M:[UF586.LN>2E>A3R$+"5B5QT;.,-KB-:_]1?FQ\X3-0_X932ZRD[VK D540
MZE]^RM[.]%(B"ZRSK#.N+KZ=O&WJI _X&L;;4/+[H\,E6^IW40FGS[1E:E:U
M%]Y4Q?#+H20N85EQ+$-=);99E[A9D$*1=@;@.'31Q'-#XUQ7N5N9ZTMDY9?=
MG3IVQHYRAG(5QUBXIN3%F!=2\GR!PKZC=0SFF&5+-L8?\\?\B_YEHZ7*>XRY
MV5=A?[78VTN;S$\IMRITS&34M21?XRF1$\EQ"![ !#ZV(0_E+/O]^^TQ7)L)
MQBP.B!^6<C.ZT!5[G8#7:C:)<F.BDNQR@G)"W,FEK#UX*G0R02&)0DC80K:7
M;))>7\K,*<3Q&7&BW3-T=@O:%$T]"RW_*YM(0=O4IM?<ZE$14VMW=>E\CJ[F
M6'<?R2%U--,)^@^K6!6%.A?!J$?Y7]YDQ@NSG,+VC49$,R5"Z^FVY$N).VS>
M?<O34IZ\GC/R\]YQZM#1=O$.+M?I'H?%WGHP$ %=@22%HMD1J@A</P.TAX6M
M-YL7!]\$VL1@)\Y"=H#PL"X)_V&<"#&XS7'F05.U 6<\>)7AZIX2%3+DF!T;
MVQ4:6%"JH),%K=/235+4>B5.-D?2O' 9IU HK50_FTKU7GM+:$(GNVVN0&=!
MIPI@EC3/IV<]6CW,R0-E6!0A7^Q_177XH/RB*Y3AN(-%>&KQ XFYWVM3KSZV
MHJO9R#G]V B&Z/[7%,D3Z3KDMU18%@VE*ZCJ)$GV!ERBIU7(\A4>ZZ^YB/(=
M3*!D>!F4M=X8('"O7!TU**+,C#4-\"31D$_4I[H ,B;I&3E#REC_N5!D"@[R
MA@<(C<'VLT#5'C'K$J06NJ\BGI>MEE2JRMH35:]HVD ZD]2V^G_UT:UDEJX2
M1XIP> X76WYD@O5S9C8/I[/>O^_GG"\(H^1*\OL"0+#Z)1*P"MY>F2J#EH91
M#@#>7&%7EQ>5.'I,!H,6-Y&9D+A"QRALR6<U#"/JDK:2_/2_! ZZW_3?U?GB
M?6S))F7]7-$ZYYB.(<;&6]@<..GN:HXA$<R?/^;5T*#X/7V#I.J/,F>(AJCL
MK^\X?9_11[[ &M:$K@?6Y:V9?N* KQ]3%XH=Z*!/*)%6[%LV?[X,8+C5H)9-
M '(#.@I'+6X2%=0&L7RFOJYQ&G90RT2'&M?Y#\Z+B3B<0(OO2D/2JC]H"D);
M9  3^E3GFI*7<!!XH*<+JDZ;6JEV?]F;IK"2X/-M>D1YB^"%I:5;QI^TECXC
M? %76)HE*I_BK!'+YGJ*YBRH<5;\SM Q)AB'=:W=+6KX\&A949S>8-CQZ.!C
MBJ<OZ:>88K9*QHTU05(R>?D\W$$/^AHR-8:Z7=+VC'RBZM)4V?<1[QILZM,<
MMV74G2#V<#'1".R=;'_\]]QOZ5F5N8$<&9(/GWK$=HW'+F,5D/,$!9HKP;]2
MU-699'F_8 S&?"$_CY1'*47 WN !^G8VAU,:M'7++9^797Z KL#0P:0_(W&#
MM=!N-/O?99/W_GQOOBS$]/;G%Y"6KT!IG5JJ<>:S7K+JZ"9N"$>]+2A-V9-(
MDU%@F4ZCC#E%(8^WIQX]*Y12A9$$__X\39.1K9?05^*-MC5U,I_3A/Q\'"&+
MAP#0\SIDFT7 #LE(;*P#AX.^OV2LL,JVH!*'W>V3'1P:LI??$=/7$!$GN=5=
M1T?M2,05)7W\_?NYHGHFC:=$99(I1W-BK(U$<2P:O]CHUP8M\)]P33E'#2Q1
MK37*5>'%DM3!XZY0\>-K\D![..RTN;VZ--=DWU 7Q:)&T&EDZ LA-4?E)N47
MLS:_@>$0XFO($9+I<Y<*@7,MLU\QXLTFX"0.JZ@!KF)@W\^>5"Q('Z]&_ZTH
MD:"KB%>?)[B_P/WCKI#"9Z5GQ';1JPI?,LAAB9NO""S:<%XG6*R"X\DKD\/W
M69(@+HD18ZXK2C__2?4$N^T<^.B_B!C/>OM;Z8.YO #P1G9S2%H?AI??5ROC
M';_<;DP<,Y]?$8%1'.5W7(JK\(QSKP?*MG[*27(HJ,I:QCPMR3A;[YY(H.2Q
M-\2AD%M[F/]^RLV<+Z&5(O-EPL/MF&B#VU+,8A-XCBNVR:=UXX,:Z%#-O!EW
M:S< W^X[U_]V8\$+M4LTJFWZTLW@-H1XJ*[W^Y'@VVRAVC4<YH3?\\U)$5YT
M75\KGN<9IPR2EJ/VQ@_)0?W1%4>^EATGV[=AQ&H*:S6K>2]62;?$9P4=[>]R
M[\3R/#;XL-E=TXS?*RXJCDE?>9VGGRMD!!E(H!>L!$F?T+C1B#RA(&<G32?(
MS1_L_C#%!]\_H?0&]/JO/Z%XFRH'R=E'7!3\A$B]/GM"P;O".XM_0 8P/N 5
MT\S$/_]W6-50TLR7X7%*]>%'0X6_\JV0C>]M1HUQ)]I\?[@BFA;*ZL'[K=U1
M^>%#+G7*A^6?EIWV#ZUDKEK^N6!(?R&5.3U$R&JNBG.1JZC;(7U[J358;LO8
M.GFHZ"U]%"BFEARL,-E#/C=(?'OWT?B6@YRIR2-FE4K:\4MR,;>J2^"4]WO!
M\?]<%H6 /\[V(_T1_3;-7=NMZBV]FG05]<N)/]*YU_'_B0J!XL_'H#5];N.?
MRXGE.1(T]4(O\<=;*41%&R"V!CTF/VDWYEN$9'QNWUOT8E* NS17",DE;Z/P
M37%,F]RO )H3 9J_52/KPMIL.WKE#IX_FITW;4(NS$QCO044>%[O\2$_2\ZC
MZB[=C-A)63VA&%+H:?;_V:BM[.'#0KG/GN]8=/RPAWME+>R;%J([8NK@]37^
M@WUGY.V[SDP)T2>4K;C]H!/LUZTWL(C>A[>F(SF43RAGBEZ=UQ$O%N^1O7=[
M:]D=6C^8F[T,+EJ+:B+=*%%5*^(/3@6WS()87R6*)YO,47(I5\*8/9BFH@"&
M!Q2:8E\0=0L2B^&1,6Z%%T\H(0L'X ?(9#5SLR9T@JNZD@#K\\"EZ.;GONH!
M_P[X/JIR2V5&8IJ#AF;'&6VCPZP-K..2YPJ$>]FTPC)C&6PL37 >',3GX_&$
M,DHU\X2R1DEQ%.B\>B*M1'+&'"%]/X%T>:3]>24M[%;'>D5M?UEO[KN<[V^<
M![":)ZTE*MF0K/&R*:&\)+S.S@-M)::Y 0%WXQY' B*;Q*+P)6O 29-@G\S!
M;J.$68,Z.BVS8^JI1&9+N)A(3V$\?2:A*C\29F1P2>[R/H@X8H@7=S(/ _@E
MOZYGS5W54CS_6,_G/987@K(L"\M0;%PG0"G[/V?5U;&]=43S?TX?Q^/,&Q]6
MKG)#IR7#T>^3X1F69?AL;@NK62?:]&4AQ8"4L$NF(\?D$@:+N\P?\;EAJI#2
M"F3.W4=3P(?SA1#JL>19&ED75[/_XZP7;'$7Q2'82]6J/X1RK^C5&SJ?:?A1
ME F_N7 U:*FRJ$/\$"+]O"WF5):G!5L45,AJT(5:YZ'YG!6H"OFPA#3M8:DS
M^\ONA]Z5]#/TKW23>0\(FXUY/9RI5P(;V[/]&3FCVFN0!A2]CP @OL,)D-+H
MLZ':[X_BB .L^%\BP<++X.M)K7/+YCT.HC)=KCXX@3=F?X3)#XR<>)^A0U=#
MTWY 'DZ P2_'HTJU%0[\8HYQR-PE%3^& @X8N\,:!/I:%(P3\E'KJ$NE.%A=
MY9+($-,XLLD+<B YHM4L39R.,6]R/GHEHK['*%JG@O!V/V;//T(3'3OHCXD[
M05!E'W(.8??L-\;1?W]0.$I%XQU9PN1 "V3';T@N)?\PI1H1-7?Z5I^$1!=[
M[]V2*UN''"E\_)"_9+6O$/QY+3%X JBB_+Y1YT<5DPGQM8JWR6P=#@6A8*>,
MSN5<18(;+1.'U"\-D,C KM,]H,:^*5*9/D$3]+A_:?>LY]FH+7MN_$"6X%M6
M(FC,ERK,6+;#GI_.X)\0"$@A2L)M?Z26^A\%ST8S;*IU'#?5LZ=+^#4L]I!8
MX1Z'T9:R3DXG^="[F:756H_"=<S&GS=1W5$G4FGVKKK'-4G>&N\APHE9ECWR
M@\PSG8;L>V93:C'B +UGXD25^Z6]!684@Y8)'[^2$9\H.&!'.WE*^/N<WBGT
M5U5'\SZK13WBHX*TV15H(IS";_>;,OM>_NBL]AVE1<JDTP:VC)-=[!575OO!
M@);<>]?9/=\Y]+J++:QIAT*^JS'3SG)D=50NU:E\(K=)BED63U'L_C;RS5JG
M"TROJ]-B<#IM&(@!=%LG:2W"W9GJ$#!HB]J=-0QG-*<H/3*JLAMZKL\,HV%K
M]2- &!\X;'D;O;/BBXYTMQP0_8H=_':-EAIYCM_)3&9EHWU6ZUQTK-_Z(:M;
MF2$IO'@NL\,HF_6/!QML*/>C\]CH.WLPX<_TOL5W'!0H!]FAL@-X&@:?J 3W
MD5T:,0985DHO,S$8+!0X="%S><9",E,0C#SPBZS20TGY9-^+W515Y>5PG<H2
MK[9E-:,<JD]A0XZ^J+$US&0Q-H[/2RI$C'IXTJ+BPVTT2<)"7[\=D?\R^+:>
MI4^5U_L4-2H_*C;,GXZ-(6?>%J @WCS2 _,5&N.>Q90+X-2<:<YN^IY8KD?4
M^+,TM$+6@S@)]QB%*NW^1'*NNON-?!M! ]E^O=[Q@$)F':&2LCPBQ0:#Z8BX
MB&#PWOPJ#H2V5QG*&C7/SE8,PT'MM$EMAY<@1?*J>[,.KRG63@Z;F(!6E[7!
M.SO7J-%H.,"&KUR7_":<0M6T_U=[;Q5;"8^$"X:QP\S,S)QT.LS,.6%F9N@.
M,S-UF/$D)]AA9CQAQ@XSI]/WG[G[<.?NK+0K[<M**WVR7VRK7+*KRK)='^9W
M"^N90Y9A1QJ&R5QY4#I[&O>ZW.W 8&AY/0*3^?BH$2OJ$/BAKS- C2JQ)O?"
M,9D!#ZU)<HD7>%MZ5F,%?VUG+_J->0PA+1O+?>XOA.AF"7<+GY$S=R)/T-:>
M)+H7#W=%>IMB[4WT>8)%WAFL+4^Y8,ER9\CHD(K>D8XDF&<)Q$_E23B((8(<
M!I. X8POI4EX_3T^#V4+\OV#B 37J2"6MC_&SFX>W<G SFFCQ^EQW^]/#@$;
MS]<-RIJW'$@_95D)>9[(I>7B8K6Z<J"6YZ)J2840D7C?Y0'*6(  %0)C9J_;
M=$Q=5F7LD0%S%G.5"\B>W?W$Q&?D>GATI5W:$+-VGW?,X%1Y8!WGLJZ3EXO(
M&)CB;U:11G+1:$L"$*S;:[1";R<.D@.L@(3Z,$6^K;S+PMD!ELZD<;V^:"\H
M'9472<1*J'EL79[F"W,/UNFW@N_BP8$U'BZWVE&56]7UC07M+B56YZQ'%D17
M;6U ^NJC@6BZ?(\M3Z\51@?R[T8ROVOLWBIJOC[\/BE3^>J/HKT^JBM-)V%W
M+C"D3G1_D;1<!$1I)$<E,+'Y&I7.36LN/?5SZ"%]%!0TO%9>KX&C$+V?T[UB
M7#',[9@0NZ11C5P1Z%#&/%2"<N+I*(8<)F<@T?9\^]10LJ]*5J.=Z#+F%$["
MZQ"#@,L=M7<YG:7T:C6EU^:7ZS&BY;4.[B&\XHU_X][+D5[%(*@I6K&(*@MF
M((8K:<+#7(<VQ_>C6'1M0@2>Z(MAILEN@#"L*=?.\<8#RF1\P+EE7,5(4!.Y
M#.K+:C.6Z0=D8["O8#=SE1J=?J?43.Z)/QTU50<9J:MUIT&R0YJN6>D-F&SZ
MTR8<G:ULBGW[4O:=]:#4QOQB89<,]8.KF56_[YG1>"!YOY9BPA8:WD@NEO+K
M;N9\,80YH)E4N6_?B34W\:2$\A"7&[]"\7JK@CHK;*+?2\D(589O>)K%]!HG
MJW[K&C5>P"6 SZ7PV$_X?TUXZGGD+U,I#;:5,S%W_J[GK>4MR^RCC6\10']4
M^;KDANZGD=E Z)3FTW*K.X2VTP@^&$I4_.'8+)+U89]1HI[="<P])V2EUD$[
M0JL99FK#RH27BV*\(K!>G?M-]>2[^;& #&.TX8XN.#3(%AL6ZNH]=!J=]E20
M*$\#>>CV$BH5W8)WQCXA$7'1\W(.:EO7O!+)>DZYJAX;D+)$.:&/B<.!Y.?C
M8J*=MVG.&=;%<3;2+QV>H+K#EAX;XZ?ZTKPW8CY+.9 0DYS 2YX%/S1*B'[Z
M>SJSJSG/H*'_RGIC8YQ,!ST=%^9-T\9'? Z!&ER;O?1-KZ:9YL3+<5"+KTY:
M^PUZ>UU]#):RM%R9FD.J,!H3GP$8ABNC/3C).$1Q-?L2K*GD4ULLP!\G0]MX
M;T[=Q."#@1G5$L?48AR9)(.6Z*1+T<26>]F))IV.?]E\S#JWXV$( M"D;CCR
MK0C@^V_^6\$<T8VGB#X6[8J2G:ZO>K+]M_.AYW3IR8@4?@P;)F5@&4*F= U"
M.>U9317$JOQ'"<$#I3^!>3\F%.I_>AT-!6BYX!5FU 6Q W!6=@&I4DP%17DM
MUX FG6>BD@Q J@#MZQ9P62S;* FAPAH'F;F-.GF-IPH]+R#Y+C2_U(P*-]#-
M0XNI=;G)^NH=1&.STQP=T;FY$J[9(VWGG?XN3_BK^8P03GQ];?H'>^%RKF??
MVD1)%:U%"Q8DN$7+G=,? 3]6ZR%+"63)DR!^PL8T!J9A!>XKH7&UM55M(&)Q
M#^:V-VMX!ZRY3!_1<="D>!(FYFO@-OCERZUDIT6MY^?$Z3Y:I'CR#FT.)7!>
MUVSY)<H#V@!FB3NC@U] YLM??+@!&^0L4/&H:RTN3#;ED)6-O#D5X>ROEUH/
M(:XN<CI!,F="C(,,*^.Z3IU)5SSBAK_:MO2Z#4SY(B34\Z<LDJQ*;+.32QWD
M8)P(J!+[#E$2$RG'8HN'S,^F]6;$I5%38FACV(Q/:F9Y&3/JRVG9\+MO@P9*
M[0JRGX5+3-'*NFW:,+J,OOG%$I=T05*WV!-?+UG:)LP9N2&38\_(JA\ZV\NN
MA99.K31.;WTM\I(UF%+UJC,2\B6C:R)&<C0BG%8Z)EXHWCR>(4_2(7$_U)^J
M\,>![Q+<L_52P"2:4Q:L)1BZKQO4U5KZH<['+WE1HTY!VFK3YP6>UQL=;^..
M]V;(%:R/[Z98X0P91VFDP WXQ3YTFHZA5']UO8,L%W%W;6'L*4LPY%556W+U
MF/W[-XX_\I<3!?RD5%[<!#CI$:"!WMIW6%0H)BZP).]089*&-$P/7^1,1!KY
MM":@EGP:B?)Q;(%E1'C)EV:U2]+_SQQX)LZH>DN)4'BK]74D@<>A9[P.2'1"
M6!//6; VPCL+<5CW%T)9J.R1VE&;J+0U@-8L4F.FSU_*%M1Y3I#4\\?X"_,G
M:'QK<KP6E)%0AYPRI'^:-5BA_=Z>G'^0RE,3=X7G+7D 14HJVNWZ>[VMF\E6
MLN*J9N9%1UMORY*+HEO\4+Y>ZKR@;.DI'UII6LBQ],BI@XWGG$+#LT(C![RD
MJ3\/C3->%9^/&&VXS%-%UE@K:$:!DO.KSOS']"R)2K3,X0+_[W)HD2W#EF;_
MKI'H 6VW8S,:IBFGQ$61Q89WZRT#KI9:\MGO@)!3H&J'(>5&DA)59QU:$H %
M_IL9NBVL+U(@+!9Z@P5[DSJWSHJ'O&R.+9V#F8V= 8L_"?YZ.'$ ;N?Y40B8
MGSJ\YZN]D.CF.7<(@68D'0O3K\^,I"E[EY1R%W/M/Q+H[29W-3D%6.R41J+<
M6.^"C1B,D>1%&KNA6..&/WAM9-UFHWB)_@F$W!?,-.0>A6[&I><+ZHQ2B! [
MJF;CA:R5&T<;%+(.A<J@F7.^A. T(N[H5-$7$C#S'Z9<_M Q+;FS+Q 1SCPE
M#9/G]=?.#I($BL/CL^[U8AQK>(/DSQZ-K@!;Y>:<%7QNCIC<8EG#C'(D$$\Z
MPB+8LXDCZ>:(A.YGYNI2[R&BF3_8TP34[3KW67C.?+FT[VPLI,VDI3D=NS^/
M]3C2#[5T/XD=#%8:%)6X.%XJ\,L=;>US.N,-LEJO2<&7X=J>I9*T@R%==<MX
M)@9.ILE0[T,+J7%U7_34S=E9CB'/.YB!S7'RI*,[K7[*+ 9XRYC(^Q@6Q+)?
M?N_BW[)>!PGS[[2^CW?TA_YG^G08S<M2LC:N=@L';Q5G_?VP/*[4LR<5*F!U
M0^=8"8<B$F5$/S[LZYA*1M*X9T1OOTJ4SGPSS[K_SXM$9_$:J\#3!!0Z$=LD
MHFO/^\3W0Q*U/\B].U=([]W@I\5#T6=C_K\0/>)@LKFN/Y^[@=MG[[9W9/X-
M><$[Y&>)OP&??R%<1*\] UM>T;I79L2NDSQE'EC_0@2WDWEW]JP'1&Z?GY ]
MCPF6O.$%]VZB=6T9.XI*M2Z;6_^HR4*/E5>DM+5"CAB16=5 >%&I(2_3L#+-
M;DL;"Y41I=@9DR+DS5V@&@PP^)G!XY;*%F6P^3X=UIZ)G^O&]6^*2O)@QQHT
M\M1Q8;5KY2X%954U;7)#4&98,WUPYQKT LH8?8UZB7R@.>)=ADW\A".VZ97.
M<\UI)NF]L?W:;EGS2[HA1=E^-N;G?TYPY]\B2OR'*N"WKAI:?U(\=[Z._KE#
MK?P,W[E^AKYZUME02;86\4XP2F8,H84&>BG*;W6L7OAS(<.A(+WG#\_:G<F:
M'OI#FY&Q,]SEQ<;Q(Q%<!0DX)P:)S+-)?K)MV= ,K9O+C3=TV2;<6!$0O0]S
M@15UC?5N'P=%FH<[LJR79M/1']_:GDEG4/Y8O^Y,=(O:_H6@":@Y)NU="T;I
M;[F8[09AO)A9-WR#]@ND-'X/PA.[\8[]"^$-&[CRY^>ZB&@RVY]>Y)\O0L-_
M(;I^/!L_!=O^!//?5SPKA 1N\MWRY?B?JQIW.C'6^?^(96)/3)0Y)UM2G&Q^
M-#[7F12E.NS5%3O\F? L1O(G\?+&_)W?M4U0><IS>-)J-T3H*9BD:=JP8=NX
MX)?9Z>M+HGO!K-GXM/&C\3O=R?8SCDYIP\E?B'NQ-'^RN^"/DX/@OQ"L*&JB
M#R--6#L.Z<.G#]'!ER^&?R'ZM]G^;.+]2S*;AS?)WJ</UN#=:[S/?_0=O/:G
MHH-@= 'R;9ST[:@W,K&:3!CKL>9L)G_Q;?S1^6#CX_[L>=K]KK<@H&&_1^.>
M[0(M\24X[G/T.0^M<_%2K*6] -5"[K)':"-K2N4:?5:]B>/UO+?!.+"5E7@D
MJ/:CU_G'6\4SR0Q2P/-QP>CPQ\&GRFLPZ"H8*,+/F)_]W%HL]D7Q\;<XFDJI
MPE\(YX&33]3;X*O=ALZ_$,WO,A4+-'\AVO;<_T+ ^_0^NXB>?\Y>\DJ))0J0
M>;SP;3T'8V>7BS8VOI>9%:ZT^33?8SW=WXM5_H4PO'_4.$?K>GA!^QD\WK/3
M,!0T&DJV-KBVD4]G);A_5/\?).N0%?[04GW^'$JSE5TB'5)[N.2!,%FJB%(_
MQN!JY]^Y(!-E4-I6O"%+70=+I,D2,V24P(0F]G15IZUCYH;QRL0-HB=FO[I0
MYG9(TPT@\3Q;?C#>L:%6D@>:$8\1"G U)3GLN_G)ER6,0$1%RM<6/R&+\XHC
M7,C"VA4['84W$ZM.F:D_<4-329??=&P]=NL8)@_TX>WC5X;18"$S+FG5E3)N
M_7,03R8ZE>,6X^X67TYHUY>VQOB.H]XL_Q4D0EAO8T;S<YV*HCU>+JJ(-JC@
M8-(2)J)"QT*9C04TXQQ7;#XI;.$9\@;!*<>;MZ$#Z0Y1<P=1MV8913K,_<A?
MV[G51,F93) T,O.5A-M8X2X(V\>"TEYG:@]6"CY>*JP-G64 2DO)O)FHS5BJ
M/CQ,9\YFRQ0Z7'MN68PY:N66_X&176ACHL.<+#;:!ET(D#[#D>[]U9_V]*I^
M=63BNG[",='>X<8T\W]^#XLD:=T9HXWN"[K%W>)W:?5._;,4]&[=9L[]H$(X
M^ED>*/Z>P!X(S+ULM336^VQ\K_-<P?@+D>[ONYH(Y''X9-A#%,.-LKSN28H\
MOD8)G@1L?'[?;>C:,;84-=\)I$";WB;\"Y'1U?8'LN^]^_%)XUCD>0']8VNO
MX=6^*WB.&.W_;_E?6^HVZ'M=\H)#'9XQ&"&)?IY(?7(IM[0W ;3Q$]Z7>B0R
M)M99].7O[.G?_T+DGE7SFU?WG.^V;A@[AQBJ='&,T'4J_6-80O]W>A&926\@
M>(O$9+&1"8/+-!>@ORX[6M%5R"2+CODH"7E9; +36%-\&1W/[ 6'9$D99]/'
MH>VLUV])F.S#X %'K>I@'>%K/B(D>]Z0.E-S*H/3@2 [%B%,5G/B[W#=<*03
MS=O[4 NEI>+4#>>,MJ!;";>X#ZJ1/*+:F[6<-BXDN?]6CHU-ASK&0P0\YNO.
M7K#BZO3D:MK^VEEM2__JLOR+.XTZ2\%F*65@:!U"E,'0+!,2,FT:?L;%2I]7
M<FL=XYR2U1;G8/X5/6-OC)W=)*N(KO@Z(2ZRXTDD>/Z8[XYOR9J3$FH!]..8
MF;,5Q[RCA?.K-#EI.4LJ=JXN7.S'+&=P9T0&O@QY1M@UGF+B".N<GP$S #!2
MBOX>D'H1H4@?UL-D(F7>G,4=Q=U)Q/I%4 HO3486Q KW%:9+\R<R*WD)CK;-
MA_]3+/5>3?E994H50_WZ99YUZ)?$?ZL6_KZ5=Z;+7/$ <%_O6K]AOKY"Y&>]
M-N,YXCFS.A+(E6?N&.CZ(N+Z'@"=D)V/MQD!GK&+:M!^=\2^A$RH].9$6?\<
M=#*28?KAM7"<L9C!> L'5?K=$A.#J(O")C).I9JA-AD_2S<)OA,<,CY:.KP^
M@)!0M<AGQYNJX);N&R=97FYU*5R58\2Q(YC"LJK'ELAH=U]VT"Q01A]/(:WG
MNLK\W6O6G(>GZ7EF5E;J(CK[P6[U=2BS]O.(F5".<H:.[X,862)YQ?.PU>3Q
M?:76YPG+WI'[GH.S"<GEI6OM5SMS<5EU[>W6,X47!I?/N+T!=*DJA9TPB"31
MA)'%#%@ U/+)I:>';'K9Y-2^(;*D<<=U@+3;TT,,.77X"R'. A6!SNF(VWR?
M>UZQJ#[V0KW8'85H-?Z/#_$=99 0E&'5@Q6Q@JFR8!0<)('4*S.57OTZ=?7L
M8*WM%Y=6SW UT[KB:+#WI2[?:R1[1+JV:JA*P)E/V?!()QBJ]DUH<R*BQE[W
MD<K_K3M]7XWQ_8C.,]'#+Y.]M6QOBCU']H#:6IQ1BRWJHJ^*P"=TQ01*+BVQ
M,RL\,<.(4Y 6>%;6-51IOU7'_'M3Q/28U'+5M$"RJI!\[;$ >57P."G]Z=.?
M=;M4!*?60:].;#Y2=NY;7!7!=)R;X0W*5%W<\GKZ8CH4;>E #GA1KKGD9MI"
MK9U<VRQPA7-IQ!F+K9I]8SOC2<&8[*;*GQ7\C#G I.2%&14QMEU"'"Y31^>6
MVE]'+:'KWH%A?Z;$FC9U*$!A.O-SBH\ *QH>E2/?4UG&S/5$*D9 X^N\:2+2
MZ<CO0?G57%=P^_85<H@*]X3D"KH61'V2F:5I0PKFXX(Q^EHV#V%-";PR^L/&
M#OG6LKJ69G=^][Z?8T5Y8(,RY&A+3OQE?7IC=0[>4L'NRG-)?8[A7,*> 6R<
M'.T\Z_83BBMHCSH3CQ&1.16&@L%5$%XX3V>9XM%, B.,8+L'PA,:WAW21-"
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MZ,NK3NM75Z!(-ORGP_^#4(#1NJ/[H;N2=$J*WLXLV=&]BT%M\)*'2J(HTZ'
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M,K?=X$Y+94?\>.>YMO/YS4=:K&8&*4:4[RZ8XGG.M^W/.6OW9P%&XMG]#^P
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MGS>0%4A^E6>N$15'//WACW05[5W]JX72?A,WSBLO(?#YY&V8WI:W-H*WR($
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M!2V>)MF88 TGQ0#@?II76AYC3O#P^##C\4^OMR RQ4\R9<B[&WB(EQ0 [)_
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M9.E26*K;:V M;@G'_-N@^F#9M_RTP*7I[:/@P),.W]VM#./4F2E-99; HB<
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MXHAQD4+QL.XXQ'F!@]8F&J:D>AG[A#88B[1.DG9;.7[Q+O/ J9N8*)K6[\%
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MH)1Y4P*JQ/]Q-Q'\=^U_ %!+ P04    " "!.F%4ISR)LZQ%  #>20  %@
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MNY0M;V>R6)P\G#DDOT7$\BPU&8LP0!Q!L?.Y>K;%R]U50<RY*KP$*8FE?-U
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M:U;/E%&#)G2QS8B[EUL>D[+R-$>\&_3))]MUOI:+?L2G?O_]Y%1Q-F&!P[_
ML?^^[VX+[4.AHZ+%0\*1R4HBP;T!J!X3.G80M8J7",EW"'F?V%I7%1@"TL&H
M0C"'R6C_EA/OM9WCXMO[/LUKH^<T.QPY*T?C;+,$&=]:JUE ?NA%9:AAF,05
M2N('_7NM=ATF@_RC4J<"@=9V3T&@=8VUD&=!Z!DT-.FYAT(W5=@IH/.+DPIW
MOB;9F<KIT<:'TZZGLKGJHC< %_[M T'DIQ^772//7P/ICV7_5@.[S\E"WP#K
M_DZ]E98:.0I30D^N5":1[/5*S=F6.O-?U?9<.EM-%B[5(AQODX\B>OT728;$
M?VOK/4E381LROK_ 4]4Q<;&N[;'B\=+WOKH@1GT4!N.>9%D'+7!@\]U_6W\2
MYWD8]_"V\(*SS":_GD81"1BP'3&/*CQV'.RDC&7B0:'].!"!ITK$NKTD[0:.
MOE7.+L6"UQY,05V%F*\Z8WML^OFJ[BMCDE:WMEP_TI"/OO2_ <J#>,16N@K?
M +EM])9/OIC'@2L'77^6%'E4D3[$6TT/W)UV+<MB350Z99P)U=_C)MGHHNZ5
M-YS>/LZ/HOOK==,<;/K>+^B4$%&EBS#%;-R31N4MOO FC%(&J1Z2OTI>5_R9
M/,=_.>\Y^\).C="X+VKJ@#S;#\Y7%G;& 9J(ES2"0HFTB(5#"UDM/KTG=^D%
MCYMT%<9&1B5,0IBJENQ*"S..\HWWE@)=A,C'1W[9V>6#L@MS*FHI&S\0]R(:
MXA9CC9,1WDDVQIM$ 85BD5-Y"*[[_9=P\#UZ82N:7< $NS%5M'EV=XN$EDO(
M)Z*4Q\JU"Q!B]OT_YF^ >3&B_+/-F2]3Z^C#-S?4,]#&\:^DQ=5WKOH?XFT0
M'2$*ZQT$8RE_ TX8:@0M=Z9D$BGB4@&3P$[])V_>GT?5.47YRC\_2<XO#3?C
M2W:'QYAWS].EKU7FM^8SCYBF/$6^ =1>[+\T^DN_ 81<5/[^ \>39<)'#O[J
M=(U=[SWS5<SRITS8<\RREF">7"H"]V0F/GFE2Y.K7NEZIV0?F[\VQ^M[;AI[
M+QE?_</R)8,CZR?/Y:Z@HA8 =]DPCJ/TCKHNWG';M6""=6XRO.!0%"((C"Z^
M9CB'5VL2YVC.ZYS#-XR#9TPRKUB;,D[6QJQ%MV0_6=-BS0PFRC[0M.X=ZIDX
MOR0W)QI2%&0;U1N4;BCG-^YO^?(NRQG,[)*F2N.J^KSLD6QG<_[:=;0IMG&8
MII(9]0.;+8LI>LDYW$SX9^!OF^:&<\VQ[7G4Z1'/4\MZVW&.FMJ@T-8/Z&"*
MYOZ,TVK_^C]\G*HF4UG)XIN$MPN\U214I2*5E8%WGMTHTS>J?[ZHT#E,!.7W
MBGI"/W7F0@,.UG^3>QZ[)B=0)^PQ<2=KK2&TO>AC!+#^KMKYVJ%G&)]K5I[Z
M494E9Q\D7]ZJ3YMNO)...;\:":-YN_#LDS#WR*T\LR<[,A1HB,\X/JR@Y9ZO
MV<'=EJ3M=!Q"6 >2!DHAHHT>I!Y(:8RJ+#I.MRJR9_EXY3M4UAH#\[1U9A46
MH4_412<M6W_EPO4+4:3)BZLO8%D0/:E[P-C FQ3;6TN[&<("PS1UZB5% *4B
M(K(8^2MR'84-!?QX&E(S!8V[^;^#C\L+13SR].Z&6GM]_RC\R9]3+H4V.MR>
MK^NMKC8>+!"IT,K)\G+)%\ 6K#0^(GEP=J^4W\[,>?EB3F_GXUBZE:[(.+M3
MISMG%PZBXHXV&G5QG(L^C]EWN.1<ZQ#9AI5V.!>(C-!2+_U@.;O?K%C<%0J5
MQ\H8/>Z(>8A3Q?L,MF_]AEI;JLWC$4!LI-OBSK"<F@"U]>L2,H.PWI#10F7;
M*BY_0DMKM1Z_',](*2U9IVMM:(^#\IDG5U,TA'L6[TGLK1Q<F\%!%))EI-C1
MXR%G3XE /3&K?8?N=++3G1-PG0'%M6P?KNNB;3/+2FR)ABZ\ORIUI5>)ARZ1
MK>'2YIST_B\*%U1[2ZXH75?WE.B72@'$\"'$6@-Y-A Q,?&WX4%>:.TZ%K='
M?[K%8+UD[>^'VDV(./RKWWTJ=*E.38 RS_2/@--&E[R?8/;*!QYB;7L#/($L
M8-J@@->6<B7;@) [:Z*$?=E])45%:9)"I?"MV[$@DNER+(5 E8V#LH$839YS
MI!,/K5=WEGY"^WG8P81Y4YUEO2CZ_Y=OI$,!7:RSW.]ED-PP78UZ?;#3I&.Z
M?N#0X0F-^3A)7I<LP!.\WL4-;S18&KRGK^)46R19(NT@7A<[:JT>!4TE+EFR
M;R**52I7-O0-7!I.L@D@9'[VX3VL*0C&K7,F^FQNO6!U"-MAZ#590UD(JF6"
M_.E/22B#!'[,( <-Y'2PO$PTP,]%:Y_9W MAO/*G,&-+*3@90W 9-SPZ.Y1H
M4GZ%3SS83B8NF8'&IXF;\35L;@*-EMHP.2_]E&'5CJNM>#';C-RZOC"[:8('
M6<QGCJXU#S-V:;TFX4CP]J._H8A,N#DB9!NTM3Y=T=/#,]JK[I,K3!IJ=&7$
M]%T8&DPM5JF5Q3_&ELNH)9D["BB?B2)^'LF6,%6MSN#QZU1%/>TUIK=2W4_L
M9:XB]_LFO3)S\PD]H=N':$Y+!ENA#DD1Z\'+"+BBT 3!.XDX<V+6,>4YI',)
M-?RIMQ&*JR+%57^DCD1/L%Z$@X+V,*5I_PJ?XQ&;8] 1T"OM,FI^N=6@WC$X
M8$]LA!;CPXQ$P<4Q6W%8WM\7%4Z3K' 8$_.18=*:'5O9ZOE$JG$2<FH9TN:]
M:'>PI;^WI>^Y!,^!'%$3I;X@;:.H.TE:'SSO\C[0!MGB]5=(0N; =L/U==0O
MW;#<@^Q"].QH@AGZ#T9'R1=I_3R+X\U<X]V#3BUKXVZ_&RU<)*JM_&6K^CJS
MAYAG/S('.T4 /PQK$QG$<<0>:*":+$:5-)]!CY)>CBKT$D9Q8^=/\B_Z<'5Q
M@H-=YA@:?,MGXW,_2O]:NK(GRTPCC'M4_</;UFNW3D@9?WV>AEG)@VYUZ4CW
M;D"_;DU'HN#N$5^V9%;TT$IZ0(%M;=GX:SVE> &=\^-9EH0M14'<O#CX@U$N
M!8XXI8:SI=7:Q9.EWHRAM(1N*[SA,"Z[L5&$)#3'A%GJP**>E"Q)YR/]W087
M01I\L")Z'<_8A%;&Z<F^"%5C./.2&MY-)@9#IF^C7;!'F!>SZH635\G0@^^
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M1]UP/%_7.L<'-TZD(ESL8\>=HLR[4<(?WD=9Y]Z[]!G?-=!V[69-['WW106
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M;<EH^83X5(,'H\S'MG&!3<X<"HW6:-2 IU]O !:-?%Q<YX)[DYN'P93]K-#
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M940;Q]!P2G\YCSR(AQ1I\^?.)JSEI)4]O*OAZ;^$*U\2=E_!R/_94$L#!!0
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MS_"N()S;O)""7F]MCI+DK=ID($Q,*&5?#<Y:3JF"5*7*S/;Q4F1_M?O1OMW
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MKOD9%8N.%YUS1HKQQ<_."RH_S2-/",9^K>4-8/_<.":S\7+(]WI*#!ZS_$#
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M^S-6@H5\,([> %+-3)C7_)W=S1-JC8$%G9R_AOTI*X99UK(_X!VC$ZUX%K9
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M[AZX2EF%7,S1PG.<8+N.[!=.QR-)?3:M /L>%*PLR<RG0*DBE^F4!BSN;YA
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M*C16^;Q=^+9K=E,>]3,U4UWS6((&FTO>ZVYSRKQYF[7>7N_Q1CNH2M5>9#K
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MB]0'A/H_R7%.7&@N/G3\#?[-?Y'3LZ7FTL7F0\?[F:7F>]8V:LKHW83OA2]
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M3A]4@[8ZFB"#+8$*P1)E]LTXZ2>7UWL6&ZRI<]<EH#REF:I+S-G@?7"+S,6
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M=[:+*D1#^94Y(D/UF7N]1_4+MJ"S:G4.!0:=O)I(79"*T0"X88CUP-6[R>S
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M0Y13T=&T*M(*UT7,*/CO3S19.BO)?9>E$EH#[[^\&DIVS:GCZS9E!SRQI'Y
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M(QW\B<Y'-4_,J%:(6#I'Y7HL.[O4NU5-8S.X6M]Y)L.K1SK7V==JB)NM0X4
ME51(+R1\:G_:\< PGWP(6!P@0#0]H 237QI>S%Q@.7I(.KHD(\UA$7JI5G:.
M'.'+[)ZM:R5AAG.RH)TIT"6^OFD"Y=%&BRN@'YLR?_4MBH(3@_$4I<@4<=U)
M0A_?^V%GC,TB9 /CG3\%#^]$NOC&DWVUL\9[N.;@ V)[1T1 0<L#RM5UP!O2
M&>VNI(QF\1#R*;/]YBRVV*8,@S:O]&92 (_ C+0?';:WSQ#I<[HLRL('A)B=
M]@.MTYNI]U%GB<1N(ZZ+O!#G(I/KM6[W%1$W1HS]E%L[G?DP5V@D@>6$?EJ]
MAUB79#S.7$'66G'V8((;(( S1BY4KQ6K#]MG35+ X.QX*>_YXEE-509FZ%+5
M1SD&UX*EGIB_-[5F](V1+'X=[@_2F#GYZA^[@S^\U/2QKFO9CP=UQ E?P=&J
M:M&9]QN=B4!6WQKQDS;F<TO9BT<!8@:6-7\1A; ;7"WJ[T].9TDIG^,&G95&
M YILFS6I"=(GI85Q'79F/4!4<65X"B"/&([B< @QN<=7X2[5T+1HE*-.";:+
M1\$<"M3N^  E9NZUB=N9S=[^H)[N;H:$?J3*7CHWS?@>U@@%HUY1F:_L;J8.
MRW'X4##[)RR%%LK=W+W\4ND(/HR<P>EA[O=-;MR)A@:Z4']#*\)JO4)SW$4)
M,W[)LU=97:R";@HJ@\H5QLK7F'9L%M;U^2]QE;$>#;=:XC,_HK=(^ L&,WVP
M1T-.YCI,UWR1Y,M>@%[(7B74N+&I^/L1[HN[-)SKX_C)K'Y3SRP%2U::K/XL
M\R-S8\!V'Y[7O7J[8(HA5H.;)"45G_LV;>B3F0Y+@C9-I\S!$#'7R[#KSKF2
M9W"?FL.?&+C1[S7604'.#R$HH&;&..,Q)4LGT2WB=!G;W;W;$VEZ[=:5'PRW
M(X?3^,\-OJIN0IZ^ 3=0CSI/M+' R-=[YG'%@2I*DEA/BFW!"1$%\R\AZE-%
M(GD'#(YO(\Z$@>4*XW2 R0$\AK!"7JQZFR&K$*FZ4Z&_@]S0&,)$#K]@(@3%
M^#CZC@S=4N49;[0WL[!%I%.3AWI=E4'<7J'?Y GK-*,VKHF 3%2ML3S#1%&0
M8%Q7"!Q+9CJG6@H^RV#?WLLW!Z6&OVI:UQU<J,:H-C:Q)]'DS$WYZR:UB-:Y
MX^X-806VPM"_K[8D]*X%\^ F?@.]I]4Q0[LM-]-++Z,LF74!<I,MTG$&Y-N\
MN(TU.WZ4=BU<KO,L*1_MK0/>47W4#;(D/&+=WF\Y'QO</ \WQ$*0?O]$)W":
M]M3?#14*'8YQPNFC.H=AHT:B"CW:F=&+]_CA<N%3%<R,W==QMX%V?K2BZRFA
M)K$+?P"EHE'GOB>O54C"TFS3YY(DZ[TDBTS#E<\?0\0A7#5--+)><,GF9 QM
M7IU!^$#Z1CFVR0-3;$K?>?/$=4>S)=O.!YJ98GP>&%TX)?;3C0UU#>2_T1\\
MGU+R*'9G(-7"3G^L-:M,NE9F-4_2(J6EIRY,;CXXS8[UQP:KY$$7Y!D2M$L+
M[TC 15K.^8'-,1X3K848V2N>\L^O?U=U7E")/*8\,C]A9ZHV"U]?J#R#=V^2
MC.U_?4#\[B9W9 &NG>+ 4%R1%\9!.2PR$[!%<;-=.K)O19$-66*2-MF\?T <
M34O27]'(S<\!BUT%''(^>Q(^6CX)N9Y^_D7\7<";7-?GEZ.&Y;QH+M5(H<&7
ML@N4?AO3NEXL^&P5R&OLV=DA!* T ?(<<3>IXRB"AB,,H@XE/G<13:IJYW&0
M^]+\3J=P)X5WWU&-?GW1C\9;KF*M= H*^<RS*\R*O+#5DC1EZ=7KG9]V>T=H
M1)\3 ]H0@&4N>U+<[G,P5ZT>Q[D5HCBHKEND *<VN^0JV=[$Q"G!_0F=XT?R
MAR)CDL(@T0 /Y 5]RMM"3GMFYJ_YJ9=)^H:HW!6P #T[+Y]NIO6>XQ;$2JTP
MK0?KE%A>E5P?GSGCC60L#+?$/KLRSZ)-;'J=P0$9']A.T1]>5L&=8EO9-;%
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M6B*K=3GO"C6HM*N$H]S:9EN0VEI)=/J8]="(P8ML(E<^UM0;T7)S1\KW^]3
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M<MFX,PIO+;AUYV<UU>-<! GRR1PTU?_%:F$CN?9XZ;B67F[K7&X[--_HW\7
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M4[SG/F4E_\J55F34_](W],?*_P-02P,$%     @ @3IA5/QNO_3*PP  T\\
M !8   !G=C%U8F<S:'<T,78P,# P,3$N:G!GI'ME<!U+T]X1D\7,>,3,+(O)
MDBQF9@:+&2QF9LEBYB,FBYF9F<EBEN*;Y$=2E9M\;Z5_;,W63,WT;L/3O=W[
MN?RY#4"1D9"6 ("!@4%T070! )]K -%_[OZ_Z)]-_G_W /O\#4"%!5,#IX4
M0P6 HX)!H()]]@.( 6  <(C_L0+P/P@6#AH&'@H2 0+\GP72*  P2 BPO\\
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M_6V0^@9J_J0C5Q'WI"0 :8AR)!E_W 6;FOTHY3*GD$QF%(/7S$7-SCS)FE:
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MW5IO1L_.N6D:7R))M5+]7_%'4,\"-U((L6ZX01/]"TFS)@^RJ/$<B2!Y(<+
M<Z9O.<SG^=E3]X_O'BT[TO;L"RI;-*#&,-#+EJ@9U'/9_7Q,C:$EPHT<(.['
M!W6WP#1NQ2= ="J1K+?J9G_)X8P?M?BB] @Q)7V<H!5]PYW; S&,*.B <&3R
M?<\4VO3N=M+'P('&.GRT3#GJ^IM5D^?#2(<9,=-BAA.-34C7+SIS4!;XU;5"
M3I%"\2-JV'M'Q]I2KU6X/1K..(Z/YS=2J2Q& 4M6@@CY PCID;!()A+C63!Q
M/LLZ3-;$5$^K"JP(<\U%3E ^CE8W]=)2M@"VGM;DF$QE1N8L4* ^V5Z/D'$?
MR 8#@7:OBWZ()[$(*BHPOJ%:&&"%)L5/U#(K0A3'.."H7%B[FZI7HDBUHBU6
ME@'R>FZHK&J#+B;AKJW?BC90Z%P'8X:.7Y(N%!5>'D>[@%G#DVL). L92E-W
M7!QYY&QIMA[]D"W-C6\6NJ%]WVW"QO&RXBN9 RZQQ+XO37"C*N7)MA>7)X3W
MKYIK>&JTK^/\G[T,.W4N@\<P.D*'5+E\LQ7=;+&\E/U.9D2D ^\6&Z5)RPG$
MR2TV-?VB6%Z(77:^:.@(=63N(+^BV$-%,RTM?3/:1A*CM'%=V)(>R8VJ#"\E
M8^NOBN$""X'XA1[L[^XQ[22L4^MR;\CA@V-\NB/JLUA_$NR-ON6B>=XVH2ZX
M(XU),0NWP4&V;W'Z4!JW":!N<MS4%I?7FHNH>1+MHEHM5H>T1K/Z<NR#WV3:
M#37G(TL*'8Q1_:*77GRD2HIQ#IP8P=Q<5,]MZ+P.8'(KN#!=,?ASY@?G?I./
MBXVL_;Q9'UX7,I6]JC@I"7;4_(V>J@X<\^5F ;9#=00-ZAZ:5H1DPTD^QVF2
M<\\P@S((<E:8.=7K<*IPW$U"3LP#>3S'R(.6].A4I*LL5\ZY!Y>NU(%=HOK=
M/WF8!PD1*#B;C1@-[:12X#_CJ&U*B-**/1J#M2)I?;\LZV'[_)%J3/0)B*N)
MZ?;+N"=^RZ0E?A:V2)FTFI_GUBO<*GV8^X.??"$'?!(8YQS[L&[U7;63??*Q
M9)KP'6RL1*+-!P[.%6_P&#S_=&<:-#!W%<C GE E:3UHP3,GKMVOS+?1[HJ'
MJYLY04"MT2F9S/QRZC>D:V=WS J1(XNYN22X'?@).& &@A+ML+ R/E;.93HT
M#WCZW2N5M$672@H&3Y:9<D<B?(FO\%N+*]#/9"K:7L]&UVG#J%62>TOV=)H5
MJ8R^^ 1^62\\P5#]!KR\Y5GR+2F-C>\8378SF<]6PMQKF]UU&K@H@*,$JS-
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M]UU:\XT,QJ7Z4-TB./="*WEROJ83\:UY;[@+>_I9(< G\^;[?2&W1KJ%RGE
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MUU$TJZ9ZS>M58<;59:A?X'I_2]*6N>"(+X<J^77#J8=?EA'P3!.R$1^<ZQ-
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M("A562GC:6ML5S[W]0,(C('W8UCV;9/W.XKCR=6_T9T1FA.LC2-SKK-B9,Q
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M4$<!*;RK=RJW?K:.<6P**W/[GA.T07\U<^&^@;I)__:T^"R3D)<E+*@I6N-
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M'^7#?&YL:Q9[73"TG &C!U/1-]@ /'2&,&E-*AHQ'*ZU\"+9.(TZ7J7LAZH
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M.(AMNXD9/7:R@N?S,3YHLN<]0ACJKBEC2=-,^PJ:#NZ70Q%Y5!)7?L[.#<[
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MU+935&DT!+2](:6,[JP-]:0M>>],G]CV-D5*!HJWUXG:W&<%!P.!)K+&ND\
MDR_;D]&8+MF)/BE<&'WD C[L?USD04L$6ONLU=9\ FS30B=Z"0W5DU<)<27$
M8B 8CXA%:2O6JAA(],>J^.YBJ#5Y(_9-?8'K%.#NU(,8> -?:^:U=?U5W[PK
M$,IEJ:4U"/(W.RP"LKP8).,([*H%)" ,^M1(+=KN\C;@/)09UH?#9GG4>R*?
M!R+F3,_G O4/O',%X"B[#%@3O&*+!U4 39W[6EA/A<C.^J\AD[MPZ'^&1JLQ
M[>>7AK6ZQ6HQ518YOOV#70)LAF5D@^E8O('I@^_IQ]JT%B%:1#O$EV[W%57<
M#)SM7X=?,/V9S;B\9U"_2L.I#<+\^>ZRFDNWH<@]W4SU=XV,O.U% Y?)UUYW
M-W,[$_1-PR3PHLQV'CUYVUI5IA2P<CCK-JZ_DT/G#A9!7);GH<9/:(F?K/[^
M(Y^A<8'9+C1"]!C,1?;&.M6R?3+90\Z"RR6\DJ&/S_"C*^8%YYW<I[US<S3_
M:VHA?8"%'-R$X2VMWUS5.[PS.EDQ>'(* 29A2.,MMW0.:XF1<5'BLL3UMY@$
MC)(R"JN.1IH()8+,08U3ZGZ]@O^#G_]<'0'6.^>]RW;S(1,VSUB5D,PH[5W!
M#_FAX/C]>%75G)' 1VH7(SH9@41Q2KR ZOOLA-J@./'B$AHVR7#DMV7S?3^.
M2^0J95^YF<IL!VJZ<IN$W/QI%^N^GOVY IK:28L&4-=;&?W7%N+Q>&;_C/FU
M']*:L;4(=:?N4.K-$9%K34:BF'9#5M!<V==-DA/5$"*Q/]L2H.#WS[(RO50P
M%"R:W5MX[:V@IM3,B6EE/:-HGC)GJ1IOUS#E_! !."(4M00C_!BDLPMI-Y#&
MLOR.O_QBFH<\X&U_FH_@4DH.F=YR2ED=JAONAL,=E[BD<J0"5XI<O(+G&PU4
ME)FV!G'F3,!DVOS:AJG)PB:W(RBQDS"C,?'N>F!%*./M-L&#N8%"KQ2) WR5
M/S<D+2]2*PW!1*WQ_/]"WF$;Z?^91 XQ(I%X/QR)20MD5!3*XBJ9B5E-L9/]
MY4)1:6FL;IMVC9IHH]HT1<\M!92R*"7P>E7K,OOXP[)*9E7 ^*YH=//Y<5[U
M<OZ&8R48" 8[.QPM*QE"H&'M3!>I]&NBQ_NG$T.B3N#5=D$V9Q5)EUVZ1HO:
M::"V#75=99&0X?\FGX#C#+K=(3U[.K-,O=(8JK5<=I?>- 9GFQ>&Q(I(944S
MQ-4"'*6OO2U7?3F"'*6X)NC42!,S(*[KNQS,6J]L#5L3T<#]XQ!]]-U(R?C#
MH"1'O#ICGRN&0" V@- 0@Q.;R:XF)T)H<*S9>BKQ-[ELEHS_OJK:,;8US*3B
M:R5D/_.ZS,Y>9JPH'YQ0!/DY:AI2*:-(7F_# >MK3&P5+'@_XKT6]#?8PAAH
M;/BPH1 F1%4F\)%MMJX+_9F%Q(??ZM*:XM^['.9AW!=1U4_S7LZD7C8;ZZW6
M/3<_:L,!@4/@#$I;T$>6WF#B)4_[&N7R26ID7FORD[E<HI'-H7H/G:B0A+U4
M4DOEL]L,!6%N_^_,@) (EN+YTR"9;P34XI5HJ0.EC855?4JJ6F1O9U^_;E1<
MJRHY-\EY.@(%<JBBW5;V\3T6+:MW6\>^*U8(QO6[]U9679]L>*7!&#Z/'0X*
M[N.\IW#\Z9QMZTK0U_C.ESM=0_TSRC\O0?U@(4)Y1*EN7SA;BW1KFJ(N9QH&
M-:I D?JZLTQ?VXTRE$--K'1F9Z74.M::=)A@,G"ZI_\T'36;^!:7QL<C[&Z@
M8Z!;WD)CR%?O$T"E))!96WS)$%?]4@6!W[KIGY[XW)ECSDL(J^;IMT%$]I6$
M@ !->S_(JMM&#(;< ]G--?4TQX&N@1#>\Q.P[.]Y=UI4 R=@^55(06M[*E\B
M2["5W-TO[$36?)V5*;Y7:W.E5Q,YQI2-;VI^TXK)PF2=>)N&@X)@Q TVMG A
MD<9J]&43/4DE/4.'5E9_=>-_I&84L[+H[#'YVHY><"I0=7O'<B%:@!2MYMQM
MCDR06V*NS&>D.9Y*:C;=0CE #7THM MNMN3'314H],XB%S#*N1CT9P5U\-#3
MR7;[WBQOXL;VVS'$J5=]2255*8A<U<31C?J5AH+&6VACAG(> V9T%TTRR=04
M1PM_;(PA2"'N_88'9>=D14$/"BXR''<DMK>:HF\GMBM817)./:\P5W-'(R?3
M:'DL I-B*?:C45FP]$&.:T\9PA-AP'_K9D)8!YAEX]J/?ST>UI?\$CW3D.A>
MN)%ZKR@:J%1NLA"=<I0U%!4(ISY^7 FES03IK5DI'GPP,N=$!/&L>/A-F]=G
MPVF"*-VZ6R)N).P U26:=]3$DZF\[^):\A>[:^EC;<_N*JL',A5)7B*]JT9.
M<'-$,/>V[I8EM<,RX8]D5P+9?*7!WDB]19'X2Z;95]&H2HX+XMW9C>9VO=CP
MO1*^I]S%].SE[O,X_J\=_O'%TFZ"T>>+BIRD+XQ->$)M"O<$\V_Y<=.@,][+
M.VQV.)?1,<JM/&$\6:Y=^NW;<OV*6WH#"U$K&<KYE)JO!_F_^:<QJC.U_G2L
M1#*?:[M-Z]-6#+,-I#FC=B=):?$!X$2@.C=,Z'413!ZOD)4(A"B62S:UK+CT
MRRL-7A@"VR@>$"PT]=STPHU5Y_KIF@O^=!Z9R]#^2%@JS7B8U0;GYC3]61<)
M.1O6(1MMRK&=K2&B\=H^DVZ?(:)A-304DYT-3KCPS@596LU8I7[UJR@5HA2R
MR17)EF\BSZB)N5P5A6(@OI0V*(DL&GU%+9DZQ,B5#+F=P5..E#A-,OE;NF4Y
M[!T=>\I"6X/0_UBDJA[LDSVJ;E;02V[@73ZW1!O921J84EW<-DU4\FIVR.M5
MB51B'!OS8#= I$WP=Y\\K=.D-G^7T:.U*$6VXK^$OJ2L#+2R7Y+I/!]Z3S[:
M@CSD/<W@++&B=CO&OLB2H/&\3$5EY"7X19"R<6(M@96B&15_^")EL$PZ+Z91
MX)[4Q1#,7[[;"6TE(T^ Q^5?MAN[P7XW*L4;/GR2F$E654]#AQY+ &T62/+'
M17RP-1$:E=IXP4T#6C0"<WJJQ?03$()'Q[_XK5/!BG9,!X5@8XQ53K*W\@C:
MSQ-C*_TE+#!RI4E+-0P!K]$,8QF''T:0.3*1B40&"X:"R2[#N6P@*1[/7-(%
M*@ZO55/F0U5!V[;N&9UBFVPK,B1G])VA.R]+H/NF.1H%2JG]S@^OM]A*7'0:
M9'T/)X[1,NJ%*L#93$2F1/5B[DWA*_0'2*>)NE";4V"JXT$&Z0HL-EN5)1X>
MBMT?<]D+?!&92TL-%JBLUNFKR-^XU]XA-EV;![[I2S$'U63WQNE1J[H*<9H)
MNR^GM3%?,6X6MY'=-]8+[#^TA8&S)5N5_#F8*^9;\Z^XI84K).02N*.GFINW
MYQ$)NW/)%L (;6FW+]Y,Y]BGN5;AFT(##FMX)Y'.D;2W"CF(=:S)>I3^^:<:
MHQNCMM[+CT45C,+$U&ZB>FIFDYO?7"J61[P'O;!SBK'X:VG72&:I<2DD$NM6
M]R%>;89JR\NM"IIBNW1"4D )5C5EY2A%<E-!!%*W \8%L5)'H5C!<:/#27R^
M&Q+4K%AX5.XV2#2*T:U=^Q@U$HWVW>WV:J"4!/NHJ,K5CE.?>:Q8.WNU1ZRB
MD_/*.^5!5$*! RJO-\DM5+M!J4UX-+-MUW;;- V3V%8T5V8HX5TKS-K-9..F
M<:>ID,?Y6O:4-17COZO\&@?Z@.IRU2!R"YVGG'=K.A><UEJE;$D1:95<#3?E
M@2!1R,@3S66]^-%) .RAB'#\XM6N'<&ST+?'^C+89$^YP70<^A=<7'#VRNJT
MDK@^0Z;+3# ,T=($BAS#@:,:$D:\+<H?U]1PVLY;#OZOF0N:DY&2$B,IA\'R
M@PS;172OQEVT#TB[& S/]-.P=_?]Z;Z#!RQK"_[!Y16GJ*)1M2CBRPTF3&YD
M$4$7SN:I<-,AT0B)LLJA(W]$VO:\IN0C6!=?#Z]AW@N5'6#Z(OM-$/)>;X=:
M'9C<;./UG[O@-Z>CF7+6'$HQV0!,&SU4Q>GP8S)%1WL$HEX=4Z=RN@7K9X^T
MT5KB()MPG=>ZCW''Y1-J]YG<K@OI1/)00C2F,Q*3&7 V_DS#$_!>6U$E(U.=
MLC]>Q"'8%<T2AWML6IBRN^Q:ZK/955EGU)MZMZO#S!GXJ0;:PE($M2>-D>O?
M%ZWHF H]"\N@Q!O21**YP6CB.KVY/1"2&0G89N:;+MK*]YA]=\Q!MX,Y;K-!
M.).Q?IQL1PJ;^M_S(%M*'.N5O#XT"$N0M6:&W07M?TY!U6"WO^FG$O.0C9]/
M%Y.Z;4$!G26;9C2KFJ'&R0Y;,SOWB8TJ4JZB>>^V/R#\6@\+U$2%'SC/#03#
M2R_ <.*%Z87=M[%#(-4#9'KL&[ZSE(LO?I-M)@]'^97P4+?LSF@B91LEYT5P
M:QG"'>'2PGTA5?8;M\<^N"VZ"%A=HNRX,>7FJ=<=!KJ>K*@+FG!;M"%I\G,N
MDBY?TZ4>TWT<TSGUWAT6;/M226?S.[4".@K92MM1^REQ8 <395&/% M&XY [
M<\"F5D#D%F+^U"XE3VOE@KLKUVTV9_Q$:1_AXQY(<?9 ([?/N53L/]$O8O>?
M2UG <CJO1O4Z09\ H[="L"9;;C'V8]ZVK1MBB4&<Q3^'YHR.:FMYP'=,%]UM
MEMY.4O!?9$UD)S2*)9J\CW;01%>Z#,$E[;-C\E2J[.[)6DU9>1H2"S,GB""L
M"$TTUZ7U/M]F 4X+@:'T%YTCOOY"T!1XBC;5XRQ*5)(;:W!.B&3-:\NA%2/Z
M0CS'6# *QB:!,]E=O4-1(8X(5B\^A6HTY^OM=&)G^ BRK.VR-HK.@_-Q=1*D
MSK&.>/,SQ1W^U='+L*)5;?OUE!D'H>WZ;[.C:M:^&F8O,+]OF+S)]2\IV4X'
M0M!(USU\N'Z(B(CH;<Q_:K0^ <D_\U,I+JK&J'IH_<G/U>1,]@.D-9CFC-?Z
MBFY;_WSTTH/RT?6:I/H3;%,9X-RG&XA3E\E&@ITCI.=+3*:VD272HAUVV<M6
M4;%L&'%-D7BQHL32XH8_ :R^;.?J^]ZJ*14A6ZU53C9T5-U>[*W/)_$^FBMF
M?I4[R&?%Y*8$*G?TW-K7B-7$I>;I2+=] R8\)16$WO#QKF0(E"BL*F/$2<#>
M8.B#FG0*V^5ZB9K"1>82DV&"CUTWM"Z5)>K.)O5N[0Z7FY9EX>@F.^4^__MW
MNQLY,A+YIA:9>^YGN.P76!EB;NU5Y7HRN)MIT#3.E^$N<A>L*&JS'W<Q+-X_
MZ=7P(3&TJ5\]?21L/?]&I43)?&0L^XMU*2HXT]?&%,3E+.G;6Q_=Y?;J_20S
M]/T"J[L=ZE>IL[[JQ#$+R\ZUZ4\_CN&^I.9H']@P<YQ3W4CH)(:)DR4_?@*"
M&2FQ>6@YR0DXM3C=2G&!#10=1D,&['4YK19M42]D2S,@*H7TWD?H\M+]*AZ)
MA52]U^-^A%?Q#&XKD9'4J*S.WS+EVT[=UNW*L=FC4B364Y(I;$I;R&\I7R?9
MOW;J!R4[;@_=9SYB7LTQ1SI:6Z72LYT7WI52Y,N6XHR1*8SIVS^H&9U3(T<]
M./WN9/<R>$M_ZM"SC>E[ZKF@TG*@T4PE8SZM0\C%IDI#0^ +_NW]_1- (2F=
ME4FHG8Q1K$F(#+Y"%PDKI11E$3B3U-/2%H[99L<*X?W3(5_?6D%N[*#I$V"@
MY9_1:)6?0KSZ0J,_1A_/J<?9T%8I H3AQX6/6K^ETD:OU997QJW+$S%FYHJ1
M=9;-K(GN] 2;A8A&&\J0XC%>4-9R">?1OSR8E[/,3WEW.R5,4K&@S9CI'PL^
M:+Z"4PLQ4;-NIO*J?'%TP&HI+U O;+_&I"-8=X7 Y(6GLNO59"&>3W^7Y.6G
MQ21!A9]/_=)RIH*GI!IP2>]LQZVP1 %SG>VLYXQH]!3$S-'<JT21+GLVYRC%
M+__@<F:Q6IY3^VI-R%D;'):]:/A]P_G\$Y !;D02#165$"EAPH2! /T- <MJ
MN<'VT8KO=C:H))7=F")5)CY; V&PQR*?BJ=G8/Q_V&Y]LWTSN/9RFP43*]=8
MJ::K^;JXNWG?7U!919NE38B6$IV=T\I@CKX3Y+SOM)4-*01/PV+5N815K0H6
MR;*Q'H+/Y3X3C,Z%3U,I$SU#S<EHQM%ZB9EC.-/'5WQ+LTBX[X"OF8^=[+"[
MEQXYJ]C2RV@H3A)HM=G3_+WIH=1!6W\76!(YT\O8'9F,%R5$2ATF^*CL FY.
M%FS-_PG@ABWLRJJ:@[&)9K>46</@^YF'?Y>JG#YYR7P C93EB3_G_AQ9ZT36
M<')[9H(MIW@UZU:,*#Y.U ZEU*VLW9I)S-^Y#F%;1%(*"3X7AYG6Z_A;E)LA
M%7))56Y?C2.C.UJZC9YF&"?\&>4F\*E_SDG&82JOJ=:4#7__A@DT-\ G6T K
M4R$EPZ) J5WC835P,5F?:9RP% \G>;#BVX#+;CRYMMV0NC%".B'_! ESFL?2
MEJMPHJ1<I*><FY3#M='G*4?-:J[O^BC$:*&X!.<<V>C3*+DIB(DA%D0# 05^
M.)ZL!HS"IQHK8.B6G_L&"JW.=@Y+SLZ"J+'I,%HO(?B>HXU81^O#';DR02IX
M->O7:119AL>.K*JP7&9$7N6>=N6!(-3KC\?W_!<*@KI_JFX6ZFK;!D&P@@L-
MT;LN3JOH/S)49,CF2J%DK'>\I+? L(P$<H=KJ:INO.XKLBME\_B>;H2BI50)
M&>VI@U136TY0E)>46O38&8@']1M-/O0$7.Y8YYRV9WUGOM[7F$_V,=#"5?<Y
M.0173SZ]U4*KC,W9:/;L-C:#BRDEC%$*FPM54]U1T(54^H#3!C;YFUZP8[H?
MJXFFPIH<&]#)SJ%XY!SOBR\D4:OY.S^,5HN'G&>I+.?ITR+>>@RMQ5R %]/-
MJ#[P+;J)[GV[/X=99K_[GD]VY+9LWR$@5TE+:DU+D"HQG;CD%AW[?5(REJ-A
MLU)AN,I[Z>84H7M(W5%R?CF@#PA\9'E"" :U)$?[4!X1M,?P]S+2NGLHB/>D
M[,VTB0;/-$5#E!;2\6(QP^)[>!#Z8NSG_3'7VI-L0'K0_X65&+P!P]9R3&YM
MG\*=DCTZL_6-@N)(J-B<LW=;HY]C./;5W3"]4("51A-A%P78;::A:QC:Z/,R
M6%CZSGAVQLBWP4'EF#H_V7"<YPB_3 D<MVY,..ZN'T:TO*@W%;.B[<-5/4 S
MSI3!V>+=(RNM!^[Y*Q%4/*B^&;ZBH)]JS6S=H-S.'0:C\AIHN/7N6J?62:OL
MIMUAW>DRQZ[G^20R1:+]$)F0]2364TOZU9V$:AR<;)6)1"Z?+D>KFN1'WB&W
M7ZDYZ50L[G"-;JM@IC\4);(]X^<K3E,_BA]@I/F+G])7TA[Z+GOAN$ZHL'SU
MV#L0CF88:9>5YC(2(Y$UT!L,BX:^4^W7]_"Q'6[-F)ZZ..]-09*.^.-4%6DT
M;33J4(&F1]/?44]C&\(""N;^I8R@X-(*%[8C:89-ME(#*7;=!*%V\C$6BU,)
MO*;8<A(3]!]0&>$T+!MB@R[/,DVS([ELU\16%+FLM*%4778S]S)YC3[:]$EX
MOI6>KQN? &+]-%;HBNIQK*KR:7\OC4<CPYW%[J^M.+<KF,QERF'JI332^%^R
M"ED2%QI?)BD(];!4H9T@+23"W+7(-7P>152[K*3:CKM+WYF6>4N]W(\+*^T-
M/P&D?;&A^A^!UG#;JC.U^->(4>9L,X*0.3HKTT;Q]:(;;;2"0K%&VA)Q"+&S
M&M]M,"+1X\?!,<"(@_'B,UCP02$FC"%?0V$<^[-*MF209;EM:D1ML%DJ$//Y
M<35>G$$V,&'>Z_JE?ST3VSN(+H$K08>LBMLCF<Q5-5^!+$BRA^\WCB(K]]@)
MX%(?J_@I; AR&5DK8 \^0D@LT.$D6L 8O*(?<7XQU$VU9HNYKQG3?+WK;>Q&
MP^V5<W01%\=%4N.&*M3FDBBTG@9N;A&.H2!\Z$2V!S0M0,P<8< R1,\ND)X"
MPW6923!AJ6$"P2:7$)K^O6S-ZS0F<C%5/7MQO\-=3:9=S4%%'_(6UR'V$Z"R
MF/BCS^BNOZ'G"O9I,LWK,)B)QY6\J"9J.>,EI[;'4[0R"C2VKU0FD>#K-2B+
MJ07X*9**0=E?L<MQ"I%']COY0)ZIIE!0_O&>O#^HI_229FW"7_MF9J>*/SW7
M[50JA78A];5(O:V7###S0WR%A.6+P:8C]L\*0T<FR^FBCA N,G[TF>9W?EIM
M>E*9R]$(-JL S3?LRDH[V>EREKS?Y_97>,\&5KY&2E>^6\?=JZV)JF5$3LP$
MK0\#GOQVPV:3>CUE47K)%O<'S))7.Y?*1 H#;:Q*XC,=5T'!&J;9#NV3VWYB
MM67+W,]6"E4:U%_N"3U>](OO=3\!\3 &+?@1.,0G&>S$Q^8M(K"K57&>W3/^
M_8&Z(<#Q[5!AV^PMSMHH^DI@I6%/&!HZ6@9'H&B28]AVC:RULLV)W-OBB;^%
MC-0>#%=W=W<LY@[=;7EQAB KL#Q/NH]\1:S9SW<H(U(I&"00H?UGH6^\^)SG
M)#I9UNICV[*'/V1327O]-8&'8H%@7];6_9A<%][<ZF7]=DZ09/U J@[W6"?*
M*:>LF1G2=VS"@'CA;,NS^;F\]4M.Z:8OJZHCQ8K8DFU@7=:89^VOE?9NV='B
M1BT:)B\=IDN<#'T#8A*Z*4=PG&I*HS9R Q3?.WD:!S-_3M?L["[[U>MP/P4@
MI\XR6T]9?8U]9G@KOM<39ZV K.B:$K1&"3ESO8Q<X8*>4*P7K/:)$UNK\4-O
MH^A/B;[L'@\2?J8D82&J%ZJ/7\ WD3"8FZW9#Y8*YV49U;,.U4EWZ4TM V87
MA3&:/1,?Q$.SV+9I_$(S/9CG_H.3]G(*=51LU[/A<]'T6E*!U-[:]%(9AA,A
MGIA&C(.R$V.C1DS<?=B*5[=\U\N@[7_<*_\]67[ 'LI^P%Y:VJ-OASR)T,F1
M^-)4_^5H\A.P=!-OS4,#?MH7I@^C3A C"-WL@"@VS!N16^H'!G 6'Z^+1+D&
M6392-B$U0H=E*;D.L!07N[?HB(C7-!)GRUB1TSM.IB1G*G">IG]C6.CD"[5\
MB=(YVF.<G-'B[,D8SIZ]*PEIB:E9]34L^9%9M<HB]=PDMHOF>%%]4Y=3];Y/
M*8_I^#P4BL_05%6]Y@>_8ET5?^Y_ ?P?V&W9:G!G^MQJ*)6KA5L*@-8WT[G^
MC/>MD9#5A@O4TT.W4-NH 2]EV@"DVQO$,10I%D1!#J*K:\;D_<U/@-T87V6A
M64NR76DHAQYR5X.(]%J?[6VM!&.J)KL<E(PZZ\;: 2=G]EJK+0XF0\8'_2/9
MCG]EDO@  BO1FQ0#%]'AK47=Q_LC7K?&)=>IM*7ZUI0],X/ACN:_+47_OQ\)
M]T67U 06->+0I?1YY$273_.6E 2>]_BO]_!M?!_'?*]\[^>T]_A=>D'>N^T_
MK+KR9PF\"G6E\!=2^%EE>3(ZA+8[9Y0T!FG;4=+E?!R++5C8BP!#%7;N[UUN
MF[#)P,F(A^,QJ?LY&>J^4+N>MD.4HVT;DN205"'79#V(I4OT1)TX52G3E%-?
MJJ3*Q[H.)78ND*_'7ZEYS[O/()W5QQJDI5;&G)Y'H4<2Y:@BZBHMJ> 4@BG5
MRFIH.;?MPD/]'->5Y>@.3Z9W',>M<OL7^T;Z3B6"7*Y-/9?6E5?AMET=/]WL
M[/]40[N\>@PEY@WX/OY^+:.Z9HA4XJ[+)&/?&;Y^ )ZVJ2-B.HJ0$<XR$XA0
MW%O<7JLD-;NXN[29;^)S"B%7PU'.=""71/2]X&O8UZ],GM^-))I1L)C"Y,*B
M4*A<7#?BL9A<V!+-?_I 1A2M9%-4E&Q4NR8+@3_)Q'G-A[6T6\*2SG\=#NZS
MDDZZ@ 4/-PN,: -%N"70,8NA'A-,P!HQPYL5G+X7SU&[7V=)=@ %O!1*.6=;
M:]#_1CE $_-H#":L@0'A.&,BKC!ZB$@4^F*G0X@8@AV.&*AOA@MLVDW&$U74
M')8+35*<MCMD"V("J(=YKL2/AO!?"WH[?70:]HR]LJI*:VV$!4F37- 3"4/=
M=!&(3SV4P"G$-7'AN+-<="=*3NS@VONG;*)>>$@,OL%ILF,IKZ?B(BV%T9N!
M21-/*MATYAXXMK;U&E<FW'\"QC\!KK 4NUK^*?9C!8<R>,W)M^-VFD'\BO4_
MCM*,!#G8(C^.5&VJ-NJ;<'Z$4NQUN)3G2N*7RWWT*6'V- )/]IJE5+CT*.AI
M3^0#RGULX!L(Z;PEMB%ZC1S@VTS2CA9R[+OO[L(<3O?G-6/,V6$9#29Z/N*3
M!Y:2.R77J;XZ\VYBDG3L/G:Z=0@+&!;<&Z"R8N"BJI0-LLOJN/G<'F1;V5*'
M\Z1AB[S<'X\XS%A.I&<SQG.O.W9MDMJZ,QSYB*8X$(5.'Z.L>Q8!QI4QS8;'
M4I.Y87EV#DEIPUWSH8NZ+&NB@(_S4XK)*<>M5HN<,LZFOX(!"RT:A:  ,:C&
MN-79:"Y<=3V,4C@:S9^MX.^1]]P43JA9CKS2-'7YH:+=:AUX6@*=4B]X[X_4
MY6]>\[7LJ%4*"SM^=5:">+[!SW,[MI."!9)3D>R(X*&:]:K)(WKB?</V/[.V
MYJDF<ZP600[M<;/*K*'H-K5^)>(4Q!^O0)9(EY^MRL#9:PM.*<[?D;V](.W=
MQUX;[;4UG[T_JZWUP-W'=^U5^*R^Y/;]O!\5U3Y=W;K!&?BU"&!\X9TT T*F
MNF-D-<@4Y%.-4VZ;,:N.$X.T=M]>077LNWW=N[#+''DJ-HTM3/_C,?W_];C4
M%Y2;5D/-RS,$0U:]/VR4^'61K'1-B660)J,+#/E-!@@/_,7@;E) K/GG*#H,
M3-WXHMTN"2U1"-?GN5A(;;<7PX#1@*S,L)\Z+TM81A@V;=7-1:EI$6T(Z-X=
MJ5"T1*O?<Y?>@?A,4Y2I-F^">E,"+*XQ$AG8O=4^&7*QE!2/3V(.0G-#9TAN
MJ@TKRN[<):]F2[:ZXI2J2,<=*/OZ-OMB+0$&#RPAG#,ZOHUZH ^0(!,3U81;
M^W-^('.D(._=7&5L/D*+GLCR2-3'=_R"%3+M&\8% [E$4)9=TUYQ"E0I^D,=
MZ9C#=9YRUU,S4^^C[?L).#(F5OG^4[.-,.]=/(3YW@+0=)2\GJHV7=81$9\S
M-I2CELAM/ANM4EI,@_G+ZO<=.7^K>] VD/[*P$*$)NU>Q4?N0C/OG\R\"'Y8
M+;^2L5LS]200+F(&\X@QT8UAWAJZ]4VN3IS<6;FV'*;U&^SIZDU)13-10$9Y
M"<?I#*CVGX"RNL='+#I>_NLS6[Q_EQTG0,M3P0H9FY*A<&9BQFK L$;B)D].
M)_@J@!UD($?SU)A4A_,-;X;^?FZ7V_,8S?,%=.E17]< #51^S1]96ZZ4I*<$
M$7)OH:H^]&]$K*W1^]$E=<JU\[OO#P&,%'HHI++XG-:D>PDVIN2Y5U^ ?C9/
MO^JRDM*R=%H6R<6A_\'9^S-@MM FX/C]]!-PC0G\UU52S6_08@YVL[]IEJ;:
M>C9#<;['YJ"'N-RT!@]M:UJ0)BZJ</W*AO4@J->^*<Z\B^NLRY\\;5SGH=^E
M9N#$-2(X#D1(?$,-STX5W<.\PM MW72=$#8 :X\=ES@LWG&WO<YD0>^P45A*
M>]=QR ?D6!YG25ZA1MIER6W2X\(A&1$[(Q?O5?E" X3F^8D2AG0:A"Q-PBY'
M/TATI6BYRHS/C43-7H&=U_[3/][9HKPA^%WNYGEH#Q_8:]\%PWD9-;0]+*Q
M 4,O/MW>+KU^@I?<>SJ[CZN/@=<LSRL:7?I3-ZY+EN."4JON=-67[WO "K(N
MH<=\@^;'@&2)<>37@']T>]IXX]Q\^01H+(&"L[IEG+E]W24^ =*^ 4_.['T"
ME]_]A6\M1YY?_'(_J$NY$<36]&Q>NB[G:![W[M_KVN\_N-@U5C2>!9U-?HW_
M+W/F8'I3E^=YO61L?"_S=;^.IT&Y$>B,6:/%HE&@5HYT7ISA!0[Y?)M2+Z"
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MM3S&M]F\[C,^C9O. O7J*+$)\1][\38[F_*N^036H:1./-9;IVR^18#+T#V
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MS_F0]:KHAE?7"O@@',7M8=LY>M-]^/)[RS//G@=T[IN&02KP4S>9S%MG8YZ
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MO^^QG_QW".N@N:@GCK2G8/X*R*HW].UN?A%D%OY*<)7U?&*M39:';^EK>!)
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M'YH2"5*2BF\:"A*1,-O7G?>.'P Y3T#%L^?H>"'(5&:[(%O9X'G3BCE^R=U
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MNT3.54!:B\?5<(=#&FRL@NY#E=OZ);OI4^FY=P^O&"&9:,QWZI&L)P*:<K+
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MR_X/2:5./Q>&0,[CGUU1HFW6AJ(62K<O>9\>38M,T]JS?CGAKB1@EV2UG5W
M%MR=/0VX.#_2![7,#Y\P+30>D*/I#:!7$LCF5_Q6=+6NG%)_((/E\WL"34=]
MZ@NG,!O<W9[(E"O#D)H6Y<!@=G^@"_CF 4T6LL@HW :TEJS_X74M>[*MN']D
MS4+IM6U],1B%3.":R$0"C_M+: 55N)6Y3^PWV&C(R&8M_R<YJCMG72@,:T2C
M/@;FUEU5A1X2!!L1E:S2!4N7O)?%TNG+(\]>;J?%)6?71AY762MBS9U9W:@
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M]V:/05\O9-H7]^E0Q>S"0U<D<U_N'2B,N^QT6'</E1PTJ,I;/C);O=3!%'\
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M0 L'WRM%%A#B7;90ZLMW,>%ZJ8:EK1H6_&XS3#L1SVR$?%_U5OZUE/5<2E&
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MRPU_)FJB0\':?@R?42[?FQ#S;91RCGA5]'(2MI1BS M_8BU'5M>1)8@Y?8Q
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M("%5&_*%F:5GFTB8+_>Z@MAV%#]_O]51F^GQ)FO %)3Z.;@\<1H-8G'MM>"
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M2LV%E]G<GK3IHO;D:K1FP?^; %!+ P04    " "!.F%4/G_DIV;G   E-@$
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MR_N&D.KQA_22YFM,?!H[H!=.?40WF?EG[Z%_F?:;9?\QP][^*<M^-^P?=J$
M$KQ+N#\>'@4  8Y.63->$_U+2B[7MIW+F45-0TT@ZFK'JL7[N^'))#&=>D!J
MZ",IP/^]%X7RHZM4ZO\M_R&!\LQSTZUBR"N"E:+<\PQ2*KU\Z+O$8+('$&0V
M8(SF#MDOOK:JDKLVPJCU:#."RGS1OCML @O$&&E*Q.6@+Q_;I'*$(/;;D*/E
M:@M7"(X7F6A\_(PFV;T9Z-2&7-/G5$'=\;0YYW7Z+ ]'BX_4W!UTL,#!B*)1
M'/B:@U?.A*='LOD%"N;9:Y5Z9]"/]DFE7B8RUT,Q\D[MXM+ 7I]QG?SV^+YD
ML[6[@Z\U:#(+C73@#8K4'>4M37U'88"7H4PG?[<@\W)A(2^AA!2H9TPYWT>@
M-FY;(50?"Y JM&^5?W4Z'%MG%ME<:\*4W IGX6X@C7@XVNC@]GFYHN\9ZGY-
MCD>48I!F?U'T4K])K.N&]UO1MV+^>@)?O2[)4JG]M_RO!+0T]1!],=F1SA+H
M0ZOAJ^93Y;Y@']CFOIP)2=L\>3U/S6+&IBAKF"@IB#Y=H;Z6856YGGL<.>O,
M\ 7"3(P%).Y)Q#>*PNTKOELU,G@KKU9$Z*U6,+@M^)UN2;5$;<E! N2KL(!>
MSD\?,>NTUCL1J7.[SHU+NZ:USZ9K3"\XC!I>2H(TC[)K%EXX/LVI8W@;REI4
M%LZ:$0HL,0]4&%^S<;:=HB!ZDN.Z%=U)84BV"*O%S)]+[2.O'=<IHR-C#B=%
MY:#2I7,HJ1"[Z=KJS>G4@Q]0L0(KH5=KTFV,M#4W:1=,ER"[W:NP&O8C9+'Q
M #W.>X0:2'O/!;GC)_-*-LJA]V:*&5 >16R<+,&KIXNY[5-PMI./6, 35A\T
M" OT0NT)2FAM4:G+ O\M?R#A:\&]&R MLQ)A0(MZ9+C6+GRDJHIB'-62O1 G
MUY++T%4,'JIH4)[SOL59?R'4<JG18O'^H",62.L\QP*Q+91)BR$@=KEDSRQ#
M-'6$ #GMA'*&QV/WRG[M<'=4/[II6%A"M<#/L,Q2H6_#A5-4C$'R$A7;R%"4
MF^D$7*_,VMK!U!J$*&0CH> :C,"_')K8X'7+H]_(,L*8@KWX&\Z+5D1:0EG3
M+O]-2"1@K2$%Y4*5\>0FA7HIPU4_=U9\R8\^'A%,U9+CGTMYG[7O'(5D*)-?
M3SMYZ$@Z ^ZD.#@PQE13#!LUI#WS"&S3-RS@2)\F02<K$A^:2T0XO7C8_;G
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MA\&OR#0D:5008#!$^[_Y&V3WOCZWVQ G@ 6:WKZ6^.O7<?ZD%!C#.C_"@_9
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MNE*]R:;E[IAR9AB= BIV*\DR\X>[KX.87$GG?3S6M8TV$SF/3@&8#%IT+7[
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M4N%*#'9\(P SV#JG::7_F?98"(=!PN3<+_9_U1;^7:FQOXEN7=;VYZ?V5_?
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MOM$TD,,<MGKJ5P1O)$!7MJ7<H2A%/0&;VI<GV$TYY0K?HJH7$F;XW&FH#2$
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M0>/V'+"XRE6'2CJ^RB((40M4;KXJNCEJW6*E;N-;[ Y@DP='2A5PKMTBF"K
MKM\]EW7!@V;1BIU?T@?-%+A4NET# .+ M$UDFQ-K0&ZD_O<]6SRS/HEFAWZB
MU\X%QOBCV\=2A+*VVW*Y%69V>WX1A3^=)<[]T.,V;O0B07TV4F5<2',CW\MI
M@H:DBN.!!;0.(L"9=>\DI.*C91*G2!Q(JFX-M@ZXY,C+WG1J%\BNO.2&C,AR
M"%"+1X$VLQIIIHY')V#\^X*AK+!@T]*1'15X0^.!$5-8TBLN!<1YJOY1S:K
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M__$H?SS*?WB4[,*O9Q.HB4V_1)='_J2:CV,9?16S;$LZLKXO"0/>#\8>2<_
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MDB@+N7S2TB3!Q$8B[:T]\P@RLP'9.)H/(Y?-MP:\ZXFD_?4N*[)J$^7DZJ:
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M\<:SY9VF6SP]W?DD^9Z&R+RZDU:5A/(3:43^@5ZU.OA/"_I\,RN?7)"WZ>H
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MB%233:R8BL5V[&+@7D!.?NH,T?)AU;G:9<K9V9WGW<&0 _#QNB-KFEO,K12
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M% X>**N^M=%',=K:;.=FJP(=>10TGO% _.PLB;SK?JU=$@GT(Z?/TRAC:G^
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MN[;E<Q.<B $@ZW8I U=.[-5S7A2OS U 2L'0&F'*3<IT1O'@UVJL;V04@OH
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MH3_#ER/E;EZ^_:S1Y4VR@/3X^<4U6#%R^#>NQX?]YY\Z"<??E-Q>/T8<(@U
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M--6V-(Z=/JB0JC*D/2@LD*L<G1DZPI>,N00S/\4-3QM'F]:(][1 "F3=R"+
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M-2U"3HSCQD;G]GRU7;,S/.3.N&G%_FG,&+.[ZQ":VV(4F4&H(NJPYK8-P\6
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MI;= #FO76<W \0ZV\LB3KT/?3\/<#-X"1RJN).GL<E\P8 68<)5(H(.0WV[
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M]>X'X77J6G&:X5=T4KY[ *!-@[EEVU_J2E2)823F$WMIZ8%\S=\CA30^(%!
M! >@8M!5:Z5O%1!%HK.ZNVXLRJW'')T!:7;X!ND%?C6']?COKIV1_+'9E"$D
MFRH]#7/A?=PJQQ+J-X/H8O&M<N.+Q]+5>Q,A/TZZ!ZG-!P4)KP'3?3;T>/L^
MK1(=5D-3[]\O:I>UJK'*B[,_N2T>=J('*C:"SESC(-G&26I/U6SGE#5-4UIP
M5;[Y.9-9RW]?3Z&^R<P!IG/;4A):;%YC8?Y/M,&^;SV!05ON)TT<+[-"0#F(
M)'#UA;=H3W \W<U"%5I];^B(Y2?PH[;IEL!? O _STL!3641)?45R\.AIH,)
M[^4&G3%'+]M>O'_")7N*K+_.C:A@\_:?9BM[$0\WJP274.KVXB=MOCU\<UST
M4%)) Q9/ ;]'5Y%C.1&KSMW5US6TDMLE.L][/!3:\5$TCX"Z&KN.<H.?/MPN
M::E;H5JWI[3E?.B\O:_31 TOT_"Z_LR3XX-"'9&:U;<?7HRV2K6RM9Y/U+'+
M5JX8WA@.:>$Q6">Y)1"#Q]"#^@=#B@N_G,)N^KS8&Y!__Y*PU2_8$Q:>WLTV
MYO@.HQ_[OW5P>A*9C7V$AYW>(2,Q.O\^O&\I!I2,^@,;6P1+<DQ6$T;2WX4N
MC"Q]<8@XJ<; %8-(X"2$F$!]@20>L[CS!6%(UY,)@]J/XF_/U@6GH+GN5#?H
M2;KH!6W45>M$4VW3Z-:1%&ONHCW:EP\X[<("YI%WS38?3G9GOFB]'U?>M:AY
M-C8X[3(E&!32;6#SSF?E*_LZ'["+P-RW2NZ(C*E E?5[;_6?^G&[[%7]O<L0
M]V7<2".*J4#N47CJNY-DO,K>X2-YZ89^:H^.U9;%#IE5$EJ3'M=QF@]X"Y<<
MFJZI/?[5B79WM?7>CJ ]:KAD7C X@(G<]!KA:3*-R$.^<YDSSD%!BS^ZX\D)
M##R]S>!G9/* PKR+]EIVEC*K]>PU7,D7+Y/\5/]R%NT/AWWZ>?=#N'QG8CA5
M+\GW)>IMPL(TV2937+PPTU1E3/&I?5U_ ?8[]D]>.T^<F4:*\(LV43;T&?@Q
M&7@GZ"&MB8XA)8_3_@=G[Q[.Y./_CZ^72JE()<IAO4)"B)#S.DF(A9#CDDH(
M(6>V2E*.(91DG9CSROFX.8_$8@XQ#*.9.0S;[+S?>G\^O^OZ_7[?Z_/[7M?W
MC^V?7;ON^W[>S^?C^7C<]_/PG^:A7;/HQ+S40D+B8OU6EK_6&V?#7=<60Z)I
M9G"K1">FZ,8^H><[CC)R=TUI*_WL7RQ/,LK")RV$@1,(DD*D!A[YC?<[Z(G=
MDZ/WB*(8 : K3*7(4<W0BB8/5>]N]I;>OG=F+.Q0FOI$W?QTS9_:[2U\*2BL
MW3XUT/13#ZTA[8/XD1<[!F]).YXV*/; Y##&^;M_<OSY>Q$;DXR>R9D#E^;&
M)J7<I>]([_NV!0^"@L3H0H/#N4>D3+3F)KB@S\L)]R-=Y<Q5IW,Z-E[T+OE;
MM,&^#R*I,7," #[@X6+2DNOAS9[V^JC;!6TD\@#4F(^#_!,;LR':G:4W4+A"
M5<8]LK=OO@R\(WI)W,BYV4UG4*?@6-IUHGW:R?*;K4VV7&2N+0=$09#R#3L5
M%(*WD]\.:B!?=6+4VIS>Y!RU?Y;@.H+WL[&V"*^KPY9T\+&^YS&PEW71V"2D
MI[5+4 Z88';S188;\Y5H/!=5RXOG_S""=:8G\J5P-:N:UA<?,UX7+6SV[_Y]
MA(@NQA(A/U0Z0?%\56:<S_W'_?O>Q[QDR'T-1"C*=RP ,:QQ"G"E;%[BY7H%
MF>KW@GJIZDH#[-R.Z BB 9=7IBDR\.T=5$W7S\OC>D<Y<>#5FZ 8NHT D.?*
M_6GVFG7*N]O =ZQ_ZZT7,TC3/@VH@;!7$]<=M@O4CD4BN'K8I:9C]FL7=4VZ
MVFZG> -5B50!X'B3V].:#;X,O3*HO> N2KXJ*O1/C=6M?)*RM-[0E90O\'%N
M$C_Y>?ZGO3#=FVBJTCM^S$AB=8F1_XIEIV=+11D?&*QWQ.[FA?^E9%VRX(#&
M6;-K,LMQ,/;(Z+:'WF%_G_$-F9"O3U?MXU]+U%[]82TG 5Y0;7\!,+DM)MVR
M"JTXOW2T:M/SZYEVI3-3  E(12QK ]%UL!T!/MY[Y.WON/6'84H"0/YV=TS=
M]W^3AA;DO&Z1J#(K_EME1$+RPHNYU93G]]Y=PP;&XQ$L4_\YYK;,MT9S*YN)
MT9J'M-9AO.?[<)Y9_;-'05)YN'Q[O_<AT9YCU58<A7US%)41[H-<V7WIM2+Y
M/H:A.!$\=V&<@GRJ>*M%[]Y!CX97%^F<LA1V,%P <(S=1Y5HMY[?]WQ$+) U
MNI5FE#4N (QB?CDO_<F^WQ27\LA[;?]C!B\ZM"?&KBU2HO1NJ8WKK:^%TM6C
MTU$$DG_>!DH_LAS_N\33P.?'N/D:WA_FL;W[^5V?M-#!.#!KQ;=HQV_.WQK"
M;*^^P/@"T.6\:Z.MQ@O\_/%)M7-V2:2J=&N-\%4RPH&H):U\#V:Z6D^I8#]6
M2CM[4*2/"X4/?WH7IV,$2X.9J;7'RGES_[:2RD=$1^RN&37HKRNCPA:,IW7?
M$Q"P$81\L^%T%O/P<IQA'WV5X@[OXOG)2[2QZ2/E.XX_)/>U_U'$DBD>(WMN
M?E=!,VD,$F@8]2^OVB1Z1H9ZM'Y/KI=^:/R+R=#%>@0ZF+"!!.GVE(L?JE2N
M4)3^LL;E;S6K=;1XGI=(M!L+=:8\SIO!^['AW2K<(Z57-K9[9/NM;QZJ]JNJ
M/+(;R[XHF@:S1?=OE_'W5%#SB!ULIW=1P3M29.X\?'-"<E.HA/RX%W([[;F>
MO$\M)0<',_T?FGDUR.,R0YD^%;"[A.\^[;>@LLS#E_,,=IYAO(8WUC]Y&2=:
MK$<U.45*^ZGNW1@WKC_&F(9LHO_$;1_I*1#9<7EWX;I!MV7LYVD! -G"J;,X
MW;B-68)U?'+6:%_%;B+<Y9Z@&@4 L3NJ<O!":'Y=]K@_5!JD'3OU8QHXA^ "
M&[EYO;O=\HG "L.]AEA34(4Z/)<B %"*, 0JO]8R)A7O)@"\#M#S:5U#>< N
M69W^_/';_^'4 =6];0, [;Y!8V\V[LC=^>PTV[B2Y:]R^8\K(,WRNN&00@'@
MG'JH==,ONP2B&7<DZ>OL1@H_;"\K7P2'H%>*8CS/5U$_I Q;ZGPY>?38P] ^
M2L9J/M^QH'*=O92Z4EY1MAJDA6/_7C(QGX\SOE2;:5F4*G\Y3$W[*06^-8,V
MY!O&WDDBKYVH:VQC]4CR-I:CO?.V8"FPFBOC55/X24_YY@]7Y02 VJ5($Q\R
M9']D,D8Z.J7B3+6Q3[CE0P$@+<3?-1BUX3$^AP[*>+-Z]Y.&FS.?4N.8;CX:
MZZ+1;[7^:*"AH** 1.#R]4AYZ2]_!6EH>:=DT(&%48NDEU1@;,+%A7PB5X*%
MC:8"Y;A7 TPLY6LX"R2QBH(9 A@I-VZ37>$/@[Q3C=$[=OYQ?1PA%PI_MS+S
M[\9T!?KMBWO'>H'G/_5$Q\"IR%S^B67HB;$3#7' P<>3&.TUQ65M/'K6U#^^
M=L3$>QX_JU%>^?75U^5BS+-HVOH,ZB=5Z]G:8^Q^;&B%;[F,6W5.SCE,?T&Y
M66LD._SMS><^/Z9QPQP\HF@RT/>,"<)ZLD*VVHJQTJP2)]%_NIS.F0X.T ,9
M',W_!QAA:'""1*5AR9!OA"K$"DD V*M1^Z;_X5V=/>^-35%P89A3$[HK/U3&
MVB:#JU_H>4>7?0=@V3\ETS%(<A[_ ^Q.^HMP-O#%8WQSV;W^BX?W5^I<RH=&
M,K@4M>H:WH##-*&V((]0?\EKE_V^=Q/=ZH_Y;F;],3!+A7-A' 7UB9*CB[>Z
M?ZG*/5TRI"3-"P!SJ6NN5[M"O WFP(V,==;XZIDZ_:!:5Z4;NPU$/JVFMX6O
MVQU0MW6_+[/U^S4(Z(K-\ZBOCZNLP7O"8;UE%WL&9NQPFR#IK[Q4+2GW4NLV
M@S8_5N[\]@I]'KAO<DJO?E+Z3J/L9?%WF(ODIZN3Z*__(GX_YIBH@%92^-E$
MM"3JZ-*,:@+1_Q;V[5?);Y*99R\:" "&B%5C1!$A@GO^#_ADEI-0I%9N@Y)!
MR4W@KKA3RUX^FI_UFW?4]"_#L$RZ@MYG)H5XZJVK;M;-MEZ9<T)*# ^E2_&"
M(^$,1>KZ2^5,2]U>]V:?4Y+3S1O"@.3ZIR3R]R[.G9W]H(#/PJY)FYKNX?+A
MJ6)?(V(B6)7H\9PZN9)F))0-RV[5;(7Z;*E_XEY@HD-/G^LOE6._BU:P"5Q&
MZ3'KCP>^\ "?"#\' [?%T)#DI^A9./]H[8XOPQH] /(_"\'IMC4TWO,6[9-O
MLBSK38@\JX+G<"O;%C.%R6DM97X<^E*V6)IFQ)#>& ].WP3E$)@NZ&/9'4&C
M%P9!B^AB > P/SK,**)+*SFS6.O45R@J M8I/,Q;6#O(Y-0*F*&'-DFY@)XU
M+#G,V$WM4MKQ]<)N\#51T[C=Q@R]X H;=4BE !#^@X#3OEDTPV]MBEA'TM%;
M&L6Q%YFH+PM9#L=$/[W_MHH;^=-8 E7BWE]TLG$V!&W]IBD6PNR=@=^<$][>
M)NN3OO-^Q'#"2F_PVSP/S^Q[P&!B+__#"TVMM:K5TF!'X ) 0*W&'X=]E<T@
M8'7H=7XT2LJ=Z[]ANK+G:O%R=RA<ER[T;22>H,?VIW+F1+OBKNX!U2BB.A/Z
MPK)2B";P\4FT._\HM ^UBQK[2JE)K]);!-AX$2<7(@J"=*"*ZJC@A)4A>\*U
MVI03':_C%47DGQSCJJD96/H^7F%LU4_S8FF=/PI/-;92]-#]["8:C1L\C+[W
MP>WF$]F,L^&8F0/YDNM] H!*D7\'7P?:;[3^0I=%WV?>P)*$GSCO58!>X%]%
M?S*@V9R:?IHVHXNA/D'@375,>=7K[M@4[MXOD?66#=_SAH_ZI+Z.?4)2)+R.
MTQ:Z3T?>C0]3R(EP_"#?Q\9UN(SQ\$,6SOJ\SZ(0=1$EW-=%R-(EHY2ZX\E6
M"7*(P6ORU[BFK5B$WA0YKVNKH>#4G8\^)_+I L").'6A_)OL9S@U_R*A1VFI
MIB@'I2?=Q^1U.C_*D"'OHC4_S=NH.,6=)-HTBF4>4>IASJZNH1><G6M":VG.
MN&8!(![/WX%1NQ'B7D"?M E"0R#,\Z:WN+='8]4K7:_E'K*0"SGU:!%*V3_K
M@W!G1P=#$/#]0L+^-M9QSMKC]/1>S?V60$+_W6*Y!391WD@H0@HW[)2J:SDW
MA]Y^[5E_>_M9<!H!H9"] OMNNKK]*M;;YS:NNB/PB^SY0^+R%]@1/./AXK7,
M5/SR"K>)BZZP(9]Z0W0,Z3'J7IT(@!(22T&?UY\( /YO*T8^,7[@GQJNA6(\
MIT&\,/I4:>3L1OK".?J?%FR;PN'D3K9X0?L_]1.?0H+'0Q ((M,9L5>D,G@P
MDOA+2'BRD[;O$2#- :U[1SN6V03/<:LNNVTNJ,+23N3;Z[@F&#SZC=S6E7JT
M1?W4R[2QE4E8I)VYE/+?A]('0MOEF?PP@%>!!"C5S-82X^XMC/Y3']/TQ<%_
M9YVP8!ENYLKRGHSH51R;)3. NIN)ZO];3?"CL9>TL>ZX+KUZT%*$-['CJF@!
MFE\*WQ%-ETN[ 'RI8NJ;DD94^[J%9_M0;N2[?^!+%\&UL%C;/\/#VHL1F=5;
M-B'H81+6[!2OP$1C/KDS)L8W</-<4'_/UV>V,2DD$S8P>I4K3ZV_1KV00OYE
M?AQ3K^#Z]%=,."AQ'#>BF';[ZJ-SOS=!$+^\"Y=FX;'A"WR]MJKR76KKDE<3
M]#QMSMNKNY']41^,8!G+_2^KRVV/&IQQTJFAU@S;?5&M%W<LRD ',BBA$F[#
M#ULNWQD[__IK<=LSI1N=<&2=32RG!/K3\PBJY?SW2?S5E<4JR1V<+K;SD !@
MMODC&%["CM.F;U.<NI RLHT,C"?Z^LT[53\U=6X4:*;X_1 ;"K$VGV20*8B2
M8]"8O'MIP6UWEN?( S-6^7DV=3F3&IJQ?:"5H3E*<JB_7LLABQ3Y=G$+6QUM
M=V'._XZ)MZ[N]O;;)Y=_4@*"8#&0WR?)U:\O$.M!_=SM$J?%]Y^ N22>T;@2
M$Z:2:1NI9F]MX_Q9 - D5202H:>^:$W=_YUG4TL==(H)JN0) /O@<F1TE4I"
MN8K+\/!O'8.@[,/%I%\'0].(P/XED$2D%IC:6NIB[GLL19/0H/W$[/EC\F_G
MKRV%5RUY!NQM>FDE"A9; .L$%J@_U+3(]=)R.)"(L%T>[(]KT@M 5R;J^W1'
M_0F0Z3R+<>IJT"5B55!YZY1M^/E8&]X'DW,;&BZ5#P.R"27:0F9'1#[D%S5B
M7\"K8,]1"@2-%7VGM*4Y_ORA/:1O[% ,$D>1X?8.GJ-QC8@$'*C0BN]=*4TH
MBJ+12Z*.6E$X47.J3<T<"]G^]S:9;DA*(Y)-Z3[8!O.Y?*[KC):6RG>'[$:/
M7/78@154=+AA*JSS..2E+G;EB[]8]^)*F[G(VBK&BH6_P<LT.58,/K/EXGKN
MFO6AH4\G\N&VJ!:^'OWF@XV#F+10ID2_81DTE -UO)6"T,(4GKFJ(*5H^^.\
MM3D""7G7E[,A'IP=>D;<K.[82*XN2T5Y0$,V@/"'S:J)]5!9"9C]N> R*7']
M)$S'%(4HJ:1TP*LA+[A:.NZN;FWEB8I^Q8:B*<%,&F48E9,QM:G=N]-'F$W3
M?$O4XY]9/-S @<:^%79.:!S/0%J+6NDY#%OI1^ J<Z.A9VC!<L'=!C]T.NZ<
M<[>Y;FQC8&535..TA2:4C7Q"X'G/]JS>B/V>(")O($-, V!J_51[=Z?L)\FQ
MA[.>@ MC?%V4<I+ZM&P.F;G:AP2"G>A!S<M\+W/=LR;[<<6C>XU7COQ_.\$&
M/H:2*> B$!C#/NZW71]S2O4!TA_/_46- UDA3RNN\2*Y,*S4"6,'LZ\"@!:_
M]D+F/[]-7Z[$11_W,ZFH058BMX8%@+&%1D^3$L[@F >^GD F_;G/?-KE:MJ%
M[.E--^-$D2%I D"-65-U9&+?JZWD9P8&?! ?#?;C>3"_E)]Z-Y<\)O&-90^,
M735ETH2IY YZ+U\I,J,V2.YMRX  0/9!<[SE85K8*7AW[$U,GW,_U6YT+%\J
M"XWW@,,1)1R+!!<?4Y/.8QI'%?+Q >%)/ ?.=@RP#%1U286K^/DJ!/YCY^&1
M>\[ <61KW%N"]CX\>W8<0ZBJ.2"=Z*7(_'A,AGXYW9/$)4G1R3L5HNG($1TQ
MS32;W ZWTH/0G'JN-BOWH*-C:$N/W9AF<[7;@TS)+P#V!HU.^]H&>2A4GZD:
M%BI!&+9S#?)45B!A<?'[/#I,/Y<K'Y-<"S;<IG0;GZ"=S&LI,KW(K^DV,#1[
M$UA0L4G;Q$$:(JQ^C*'ONMG"TVE2+ D!8!=PS!P57^I2_OS8B>Q'$O9#]2S2
M)AE2.:1_$7,'!!'*::@2K/WJ8N8?OIO[A\J5!I),.U&!)0  @Y*(+>#1D.-;
M^#R[]  !0+X9:C%)/2I-R;^<6.A?NQ<L .SPA:<0OA,Z\ /.Q"O'F_&ZWS_<
MM&SXI,YOCMBY)30Z>YSA,)NLBVM1_N3Z>:>D[Z_%X">R0:9F3Z!23 ^.&/=,
M%<>CKGSL!^2GI4@ J3**R!8 C'AK52F7$6Y=7Y[77P'$:*I2KTH._RAV>O,8
M*=-W?M38='M].QMC4.A\OB(1LB5Q7C2PSB.7Y?_K[=P@V("VS;8?$8L&;O66
MQ/L4^:_F;3NLY!*]YVY/$PC0UMWHO_YXC<,'CF6SH:!?PQ9_Y:)JI5,3@9OH
M@X7"J7M/?T[*_!^;Y/]_F^/W8'<G^>M/!8\E0)]P&8KW# U$@9<=M 920F($
M %='V=8&[.97+3E)W;2V74YW+#$B L H\\;"PK!U (<2A%E0RHSPB'Y,US&Y
M7&SQE;PYT[SS5KM)_N-CIG_+E2SY.(C\SF$/,F/\EE<3*'LK[2--;YU0@\'4
M_;K=-*RAW(Y7BG3"&"A^IW I&];SYU_5FOK8%[!]PEWNWM$!AV(]F>MIZI'*
MZI?#5V%PKAG?^7#L=T9!'1?4!X+;&PL AP:*W:V5<.>.AD#OF_;15;CIE8;]
MJQ[>3N&O 8:&ID]!O5#'[K[2KQ<+G,7.VH;BD)"@#:2(,,EWR?9JFJ>]Z?%5
M-@:DY"R\-A#9P(QOD:UTM\<(%2V5C%&_T!F'V($0Q$3@*+JB(D#"8B.W:\\A
MZ=K:.%Q^\9ZH!>]Z%NT/@FE(5>F&2YN8^ZT&A"J7UTLNO)UX,18;H9"?MR8
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M1>W?IG']3X%==V[2%H1\3<BE_+AKX)3H?(/=SD1Y_&\&.ZRT'BBO9]![TL7
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MDGE**R&PD/D=X<G2].;$VC0'[8PJ#<WW9A&1KDRW>= KB/L&%?<YI&-^U0%
M,I[:'T9"CZ17P"R!U.O@B7(\N<DYZ6MUN]?^CDMO%^O0[E 7?C[):2/%?ATY
MMTCPY!U0+0YM..^KA+9AU(/1C;PC2[Z+D?[6*<'5-G7 ]!P$:_3WWEFX'7Y*
M +"R?L!--=H7BLD6LTC+/[TO'4=)NM5C2".RG"0#]%>'/(3^,O#)R2FUEKF
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M_IG^AV>Z7KBXVN\OWM.'O31!6:5X! JC?*<=U28)\0X6:/5DC\YN<@H[W5,
M&*QZ/$]KR1GGZI-Q;,K0\23U]].M-:,>9<H(V+L-_>^<V,CF>>F"/$/4[NLK
M$RUAY)3'H&'4*6;)!H)(7YQ"@.-\[J8$?R_B:W(E*:N_QVF0V2"F<OVSV..]
M0ZWE^$=1OZ-VLM-8%,]V 6"_Y.S>":<8V5/W@-UR=S=&:-B'0IF40/>S\;0/
MZA_\(0#D9HZ\G;]WM#S3%4*Z*P#, GOONB)7'>8?3!H?H]-U5$4D0@EF!8W
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M1$$QILU\4^@;0G7PB,]$' _&'BE2F;S@]??0%)YJO505^FI+#1\E )ST'@B
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MW10 @&.E957@<9J4U,#:-JS<>?ERX*[RS 'CYRF? GX^$C5<@-\.IDEQ6P2
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MDNCBBW\Q"/T "E9X;W-D#;\)JHB!U+@QK ;6T52%KGG7$FBUC+E!?\@JW\/
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MH9^S@3B4.#HA-31[2ON'=<ZQ8WO3*^S,FW+P5(%C31F'DG1N0>U/^*8<7AI
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MJ6\TU+S.\BP"_9BXLP6H>"I\Z6KDCF/)<FL.H/O]7<D4;[?J]JNV;%DPNID
M@1J]373@] Q@+>B%"0H,USC,">,GW^A-NEQW'EW[5H!I#Q<\T+N 6U5O^AH.
MAA+Q(,IIA\V&9[D39AKKE\*LIFYL T1'V+-K)-)BMH_(Y(FM8LG;/W9A'MWH
M$D8B*$-ULA.!FW$9)B<=(M\AS_+GQ%0^ZG1O*/*X^$65N.8K+&3Y]7.G:Q)>
M_KPJ%:<FM$Z6E(8\2;M61 D^;>+-("!\N2=R%:7E^F&M_6#RSVV ;-A6>[/R
M<(Z^O'G HO'OXY._Y[GAH3OYR?4;RYNK'58RIS]I4C)N<=3=B9W4O.^)>C<8
M!.M!F\#<5<<5>J;US(W:TV^V[?G$'IPG[4J<7L7>VP8X\(\.&4BQ'K3U1)OC
MYFK4]K3ML=R*?+-%)5(M JG"O<KVS8+\5GIJ$[(QISD#-8]R[P)7XO_"OO&T
MS<P-5P9.I.Z.T+WXQ%_O\/X-K(5>)K?FPE^?(^?>2'RWEKB;<*5V0GL> ,+#
M(7?K">\F:EV$75X%_);(/^OT-@&--<CC,8M>I)AHH::025)%.J9*DU.K/L 9
MZ#ML'69Z9I,FT-SWVEH66T1A"M*>?-H WKZ5FOYQ'$@%WP@PGY[8XE8S_Y0^
MO>"O]YH?&6^\S[>N^[HKHN .]8W)Q@:E2Z:1G/F0!4AXB05M \ %%^MT+MOX
M&7 =ID-V[-P^E$\HXV\9E N%7(4IGLEI>CD#VY$(I=+^A;65R$B0+!]2NQ^#
M%Q:W"GS^J@HG[ZK3JYM0I_@FLO_4><C0EBT*XKFRA5O#=:7O:-JD8WKZKXUF
M.!TX4XC34IQ,1  @L)P1I=9E  &#W,G<B12G?F*,AN/>B8GX9B,)QH/7K"Q8
MSESE,U;L=Z6 <%]('+LHYZJ>75H,]D6CGG_.M2/^$,R7H$IP!N^@3/HQQ;X2
MI+>4M$F1P]#]%-I"0=6ZGKVAF@#(?TRQZ3HD[!+);]H&M-8>(_4K!';\O4[*
M+UJE8FIT\OTD/&.^\6LN RG%8KUPF-.31B*S]T+H_?:[O3ZTR"H>;$8%_KPV
M7&;R09O%9>I=2:VA7K^,C")B?,ED.,/<WO*KI%0XET1'GAPQD*?4Y/VW>9G=
MAIPWOLYP,9OSFQ VI\];6>"-";=EI +_$2<PVW^4U"ARNE-4/;VQQMNYIJ:>
M#>Y]4).QG_0T0W-_A[T7;FA3@.XACY4%^LA>[HV#)%+Q,NBR0 =,XG5@;I[F
MU*3:K@2S'YAI/I SCNQ&?P"BJ@M3R 6-[U*G#5SJ.$&RY"+--60LS!M]C&?Z
MI;0*5NUF.W;H&3=9+V13FD]="!0[7&&C^-?_L\+\5-I=W%,X<8(K1[GB)+RB
M5!MW*TJO<#;<7F5K8PE+D/U K :^YDGGN7@!"2>*1^E=1.I]J1^N_%70*#IQ
ME:6$H/D397EW)DZ\#M\D7EYJ+SJVNO0W;R6=]AL3,-V<QR_:$(L)@>]CPH^:
M_'!IAS_.>51V*28L+LM5>\4PD#B$/@![3!2C F5@'B/TQ>:4Z6+OO=>N+MX/
M>"&\]E1&#%@ <5*HS;A:\J'#33S_ASWWE.]R-\%[LXE(FER8._52QLST_>F]
M>;:--)I;]G1B";XPT1H-GD"R%&"QS?(16O27;PZ>[K#_+O$LP;+ED.XK86 B
ML@R:):T\)]SI?)-6O0]YY+(%KM9DL'85 Z,.H4V [O"QK=FM5Q&2!7>#\QVK
MUA\2*FX>$$K_^##9E ./R,+C)L"MR+U+@?LW^+H24@"CKNPFECX$$L1ACLQ<
MDM&3ON3V6,N^+M#P@'E!=8:?:GI3W-):P3V9$]F'1,0-\Y]\7R;8?7=ITB!@
M0Z :E&T _9XW\HBNU\D7NNQ\XY:Q*$F]!KYN -@V0I7_I@HL9"8TY=@2L" N
M_PF97;O\4A#,N7/9M>;N>TWG']\N:].6]-9HEM4;I7M'A RF!?DYL,[FE#W)
MSW1>6.9&O4D>U#H^ ;$GED]M&02>S'%C810_M ^GNJV0PA6+PR<7>.HSLH>6
MKEDZWBRPWQMO_>Q;W(;02 ";65X=5*8 K'OLAEXA=, ' TTD0WJE-F2'83G;
M@+1[_4F), ;%9=@I+2TYOGG@H_+EKZ&"ZNLN#R^Z] ]L^7"'&FKZJ13?>LZ/
M-SW +V>C OCM0K*O_LNW_\2?W 6_%X)%H0MN_OQ):?GW!>!Z:9 0C^_][("Y
M@N!RNN?Y\!!!,TE'-VM"175D:@5=#G_MVG=&*$?[G^US,+P")-[59]^'P1T\
MG"[*H',Q&S\>TF8$:4IJ7D/ACB S^VW ;[.^LN?HKUA?>*CE*:+YBU "(44P
MK 0A UMAIQ !>1ZARA\UN(I8V;55&=B&K,4V8-ZQ%:4M2,W5??V'D6AQY>76
MCDQ87S2W3E1LD-8<Y5^#@!<0,\=B_:O-70G0[!/UE/&(1  KD7ZP5:!;G;,'
MYV-98'6UXLRRF+[N4T&M.!M'6F4IR'Q!.F'#?4Z=38I]U1"&U0<P@7 7"!1[
MI_GA^:]"TBPI=_P.&$9#8L(_ UH:WAM 3B9N V)**UA.HGI3?1?NEYF?/ST<
M9X?]4K8-T$(_0.R*ZUQ8L_IM5W;+I$A1L@=OKH_\3BE',$))R+'*=MB!1\DD
M(Y/>F^DR#Z'?GHKJ;@C@X)Q+T(N\QZSP(HD)_9LJ9?D':TMS;Q71"-^$RF#6
M$&14A-:<<9_#!U2#[;+0G?:UKE5V8,P:4$K00SS4",J?OBD:N]LN^<Z";&\\
MRD![Z=6;2!TL@X?5IO=>:+=+UU),'%[S6D=HFUQ@J,C5I"]#OR:Q2K+^%!R2
M"4E__*8^+E?^Z_P0EQI97@9+2^R'O0+6Q.%5O%V11(T7R1^HRC0=/:.0+3ET
MK@&Z='HO*^];V/?.Z8>J9U_*QYL0SL$;=Y%2.D'L&?R,%NT8]Q+KZRRT^EK)
M-X<I(Y_C\4ILM=K3MT]($&@;V**2;4 E"J-ZW.-4UBFWLO,]ERXGR6K4"@G+
M=N 0I*'F:]?-VQO%XZ(N<0(['F4-RUDR:CM/FM*6=S(NU&CB2:W?^UKBKNON
MHKCW8J<E H?SZYY,9CJK0LO&! FNM6:OZW1<IEC:@B#RC3K)&2FR<*V,H'J6
M>" BTGM.__+^4PN2TQJ"L\FF2.G(E]?YRI..1_=<"/U/G9K%%_9#E$%G4]Q8
M]ZA[0-+O4MT/),4/>:WY3AT#T:L36QA.2/'4)UZ/ I)2O6[9FB-*0&CXQJ>1
M^X:@(@&<#W%]%D:#DW$<MS*E+"WA5V$8Y#:@."GCD@71(F!#?/E%@7+9Q#9
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M"F-FF4N+_!+\:[G>>RM4QT\ZPMA/Q(*RZ#-AW.('*^)%GQ$<SSG 0GN6F5:
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MO+ 00A)>@MT$'Q3@=ABW#!D?5%)4YB->,/;W0*%% !Q4:(30W'I>/-OM1$Z
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MZ.N?;!=;9;-5C4:V\Z76^=L D* I$(*/U8")ON47!4H!#J6['5!;#A3<Z(@
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MH/K/6W&'@Y,J[AE-DC+51K &^/ 9;=UUY=YOC18RS19/BX9<LY<6*/EL,'_
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MM4%JEMB+/K)"2+XUGT4964-ZK2[++V>2"_S-<)'M@)<PJ8Z9_XJH:%DIL5T
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MF&K9+OZ!6+R. 587A[Q+"#':8&B[(4#7'0!2HN+!%#;O+%%?ZC>B!M-KYK_
MC.3/22H4DOD21C"WSXKRRN>\B=;:!;P*8:9W[ *$C1,T5B5O(L=N!@VV!/#E
M"MS'+N2F^+#MJ5=7ZJ8?-$LL.1Y:_:YZMNI.;H1;DI'P3V0TFTBH:3Y-+4SW
MKR8\FP[N<K]]DH(#$AAE7?#TC=MP^4C^OW3)C-]+"A7>/VW/UINX/ ]E25B5
M*=P/^CJA<[LHNSX&%,9#NVWN..VU(IH#'AIS.+/2FO>I>=HZG>$<%,,]^BL<
M]@[V<%6K;4,L3P;DKO>A4WL*\3J*3!!BSQ(;G$0DFL*Y,/9$:35NU%^E4NY1
MDG@2G,*#Z6[ZN.O8*2R'ZSJNL>Y/7&7RY9_8T?I<($?VT49%E=L/.&'\P>HK
M4$&."=.<3#EYF&(Q2&Z4^]&%JG#7/]2RQ&EBHN=SMCJ(^C'4X%_6WN<[,#5+
MXK]W 8W7+LP84E)J<<5U!K#^0H[R]'B51XYY=>ZU55]:;%*29 L_%\7ZO->=
M 1Y.D$FZ,5Q]]=C3UD*G"'?)6SH/[RAS#F"$J*/H> =Q<5IXM+JM<9AT)H;
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M4UCGX"X@US[G;<N4Q]&^\O,?/EC#CF&[Z %_5WQUC,X&"DG]'G2E5^T@IS?
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MMCU".V=/&9?KB(=*(E]/GFI H NWES:CKHP[7.RT5;CRP$MDD5-CUXR$S<<
MJ<M']</"3F4D&JTTW9%*78L4AVIL^\>!Q/X74^\9EO3[OH_3V\J&:666YFHX
M4G-5[D%34U-RYZ32,G=N7-"V3"4UM5QD[ARDN0>X34U)47&CHA&B(@+*]F>?
M__?!_P''P:/7<;TX[OL<-]=]G0-?ICI5D^UF3JT3T$9H6[ @]_)&()PK>O%:
M#0>9*JB@V#N0Q)1!6V4[8AUW "<,'Q5X(UIJ/HG_WK#NT=C5Z3*YM1C#6UKY
MEJ&MK4 KGC%QV.JUF2)%_0J^"+^[HIZ'K */D"+<?:YL*XLTBUP-FB;WUD8I
M5%84>,-+:A</+%PGJFF^WIM[D"Y0 55A(K=05%A<H(Q&:F_MV[^S:!#)]=1[
M6"#\V!S$?1OD_?BXH?#+=(RR*1+<417BV.0PYCQ+1Z7SM)1UO8-G!^9H4U.P
M7?")+H/.\@\P8[_5I97ZG"R[&!SI%?-3V/[M>N2?UKAV?+UC)^)$C<K)PD>-
MU)%[<$4!7 *#I\)\P,M#*<3<H3HFJ(5)JDPO)ZY[!E4M]1Q.G8!;L\?!SU&7
MN?<WJN6H[CY^#^]"O.'G@4BQ<I?L@-9)OXI\%YC%C5,';'R$#?N:^YS)Q;/;
M48B_F 7U>+XLU?58759TX-F@;--SHJE\TAH;FC;J@S]*WP$<[L#IX#[TQ#>C
M(NS%)>2DJ'!B-TP>O $"3N$7P6^U_H;.^KC@KK9KGDT=E=D!P,'CJ Y>/?!)
MX+LI]\QTOK1+C_=#@>USUW<=*ZIQ#4,P/]@.]%94X&Q58^DT^L$+HRFA#PEB
M 4\JFB*?I&]S:X%A:V@?6<%9M_<7UM><;98OR=\86A0T8</8C<C@#6*\?XRI
M4(C+[83*/9+WCKV$@W#_^*:GMTWV=,Q3JNS;U74DSD[3J,NO?=SO?ET4(H#+
M83ONO@9'8XX,FPB7G>JP#Q&*WEX7U-U+-(JB+S$P/G:D_N"(8=4F-^/FF*8,
M]]#2=ET?.J@,A8B##?5.O1(C]\)H\8&"V0*4^,3"O6%\V5Y%!L$X3?S!BB"P
M_RLH@U*5$N'X@Y6BZ1J40,3^2["3-AV%Z5\-WL,H_-^WN2-:A6O$OV@!'6@8
ME/PPZOK32][>Y<UO5$1M:E*3GD5O&Z/-RVHT?Q+$5P31]-V"Q_(!@MDQO6P.
M<?S+J)I_:(E<;O#;^((7O0+/0OBQW5X.YDH#4\$FIP=;C[N0 VEJ"=)F)1<:
M&PVN*[DU&L@'YG86-E@\FI7[%F]P?+^IU;\H0.AE5R:\\$ER52;DG2OQHOX>
M/)U?A+)D8J@3I/V0*WW;8G+0-5J"; ""7YF=R80[,,=*F:\+7KB4BGU*3B0"
M-7< Y[E4)DX<4IOA*5KVLFU:]%UQZ.CIM&P;2Q6P[1;T^ 9<-FLA/^G7X^\3
MWL[6Q&U9E1\K.-,\MF\TQP0"G9W<2WUD)?(K7QI57'PGA#1>G;7U98/NX9TI
M(Q)NR^5!<Z+8CLMNN*VTN<>G;(ZR@!!B;A _FA"_Q#@0^/6B^[H]P"O#J&&W
MB@G'91LJ32]\N7VL1GHZ***ZCAVZ%JB-P6Z@]CT=C#)GO?*P<;#QB0VE[0",
MBU?]X6M:"Y]G5"Q%%&4C!:',\UQ.)@-T),9FV/#VS^^S;3H;QJ$4)F=;"D?#
M1RYZAV8WC+H$R[RX,8& #; .]=?R2K5V /M=>_S5Y<,2>YZN_98)>8G%Y[$=
MQY>@NA=[*I0A3>:O9^RR:Z*[#>;&T>0)ZF4*P.M9ISTR;1SRJ<>P3V7@ZS08
MU#\HBX6G2LV;23U/:Q0Z<.;E.A"SI)1@?J219:+'1<N@TEC'-D2WUKZ/S4UA
MNQS)XBP[UL@^NM0Z$'%CQ0!'HKR"*C*!/>'#%@4KVK26M\)=H8IR00E2M+^F
M8.SVG3+==N(5[_%.1\M)[49DA.=L+0]J2IM[E$P(]J'EO\^[T-!74>&K58;F
MBKB%DI<\<D5"6.'DZ[H3G4 ==)4Q.D-,KN0J9B,YF9*<S(J&L>=O]1&?YT*
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MB^=]W6"=SOFN)BE-SC_;CF7'%,MYREKWNL<VT(+H9]^W+9::Q81^>\+F9+J
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MG8[(][EX;K]GEPU];6*+Y#[-"8&.6[NWEY":'+X"#I\340,_EH;[>;"C8-K
M$X9!L$K\W&!0Z"8EY0:MT<ALWLL(!NJ$MS,1\4%ZXVKW7,7,3 ^>^KDLR9FJ
MD%RIW:607DJ+:L<GO_>"4N$/K"[UC,9_?"#7.EWHJY99'WN%9DA<W/4Z@X[=
MN/K+<ZZ#9Y/QE$9@)-P5,82Z.F[F+?W&Z@^QD6@4![12P1J"2BK=G#:7J@1(
MN7/_!I5E;-2_,+Q!,')0<3.>\DXQRP<G'WYZC^-!8N,4P*^"XA.U*'65VP'<
M>@8:B?2X,W"\2I28\U'=$[E>&,8*9)%#JIB:&]4P*4A\SQZ?S7=>"5X/]/;A
ML$:7>UD8ABWG*+0[XV2FY6O.O:;724IZ"? %3- N)O0M.?;+;H!@$UDV3<TC
M6FY@\YC YYC/!QE@ZUX0%BD!' =W! *\<_=O+!<FG/S>?:[]=,HQB+C$&AXG
M,\:VNI;2$5-;I?'G349".OS6,*EN&VB("<FXKB[R*N>;7.M?H[JI<=+D#N S
M]4WSA@/EQN^I:P+^+\Y!;">\N$",%FN,FK&8B'Y1D-Z=_RA9JNAJKQ40(S/K
MRSZ+N])LZ05JJ((,)Y3\U,A/>&$ 0_2C56%/X!,H3%?*K*]0WEU*1I%@"([+
M"P'G0EXN!(#AW>7DPR8G\N-\"N]=5S(Q<]ZNMAAA!\0J[J&N/WA1"E+M>J@\
M>N_=YG6;]++//?H^'-(/;"OF'6I_3-AOQGMFA?JO!X5/\R.E G3;,!)$.*X0
M^L89<AS;'6X!*[YB!1=_\,-[Z"KA^0?(%ODW#?P.<:P% #WF,^+JC=MG6?"Y
M0_OR=\1U(Z#0IN\T:B]_9N2)HS9;H2+D;5K*<4_H9/O*[1X F<+D@UQ>!;MN
M%MX>27@R6M2HNB__8VC$-!(TB"CYP[C,+>V4?=UMGZ;_SFXI>&3DQR0]PGQ:
M-H:\J[S55>4C;UXT/W[-GOP20</(NGJ='&.LB6P_/?A!:=4UU!B/*";VCLL*
M&<M!%!?=4_=US+B87?Q9#@U5O&A<C.<N-JLZMNE++Z'_OA-=)]4H+6WJRBX:
M-9(V)S#"S#@E*/X"TOD@6?;Q4F;=M_'H5JB;R.F,=]]"V)5AKY/.WC!9D5?/
M18_Q_5BF-YF)BT>,0[V7/IT[-EKO0>'VJ) "#W*CZ^+%%YM2B2R[]0>YDRL0
M"B*J?<Q8N.9;CRY $(4/+/8C<(]$.E1LO+>K"8?$M->D]D1+\?3X<7I(D!(!
M:K 0B<V/+W[??5U-.20S=40;G(:N$+X3ZRZT*)??=^.(C8.WR?"/IC7:,"+X
M">Q$:(7'X\GS?;)STFT8Z"[4A&^N#%MZ7:SZE;_M!WE H>#^S?K,'#^9*[_!
M_0PV7#W/F;VV:HI%,G'^LEWP8],NAA<5@$K@Q:7[AWC%<2U>KV_N &J^CYVU
MOC[<XH?T1 14[L+FJZ$8XTZEZY$."ME?E[(S]&NSP$L[@'DR!*I$1L'>6B(^
M-\=T7Q4T<MUB[  8X<@\XZ-,W]6M\.V\J!*/WF]$I'ML8LR>6%@%V5@M_L^"
MW"9WPT5Y@D-(L;K*!\-!6/6XJ*$<KX6R)\N>3B=/_%1-"I]/FME]F:@9V:[/
M[H]R/*AI*ST95[**BE6\HRNX")A-0[%ZU_U+?L*G<[Y9I"O'I&?<K*UGT(Q>
M&5N;@#:68O5Y0&$Z6DF"-)-[>93!3_NI_HX^HT-)39H4S(U-! 4NQE[6]4[-
M16ALK83\FY\P_H3XV7.YORJT8+;1L<;=@4RL0+F#,S#[$J(X$H6QK-A3 >_9
MHZ3Z$E8D_R9CUR,@TJ3H&-9??0=/1XVYQ=OB&EMZ*R(+&'JWLPV4)"W(=*R0
MM#(>5S5757,)WXSVA1*UDWV$5RP6P?+UQ#'DI2>NE)A-(.\^+S82^4MV&M6Y
M-JZS3U+VO%)O2 T"Y/&OI-&;;X62>T*X&!:%Z;B(X)Y(7;PX=[2JU4[Q=6J>
MT6B"");*52$VU&<ZG52ZUC!8TAPZPL$/L$V'-T)M%H4D4X+AEVG>*'LLEFHL
MSU0E&(  Y(J0BW^34I:.SP<?Q,!B0G< IW&\0J@1B# -";50>:EB47?T?# ^
M^ORS@T8<KVDQEGP$=8C]9]$[?8'P:W6/D"F5B&-%=,>^XUQA.CHP:Q>-M)=?
M9=Q6?#<A/:39($M*^D? HB#)I%_YIN>^$E=7S)1'7D_5CGA/@W[S^)'A DH5
MCF\U@]^7F9_*/Y3IVU_ARVBB/)XKGI#] 5Q-+8>,RXTQ#,QDYOS,/I]_J#%Q
M9E.?EJN/&(>OB>X ]O*;QAG1D- *HQ:$ULV\<T8' <3#ZS!EW@8/P3T;N #<
M[T3Z,Z3K=?NLT)W[.H=I0L=F"(AK)/?FB(6U<XLWC+H_7LI^LRPH;NBAMTO(
M?;QH@7:]Q[*J>7'W(-$N)O8^3B%Z3^;JT(QMJ!Z<4#XM^FG1%R1JC0T)*@1E
M4JU1[T*=79#)+##G)+]C[A33NV!R):/I49./9D& VY>KTVV"I:X,"D^%\>:
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M#BYE_=A0W%*BZG2!3KLPBUVJ<V_+-[DD#(A^N*'I,1H5]B^!LA#^#"%4@9*
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M4UV6L$Z@-VK8*Q.[NOSYNH'Z;-^J:9%^*)FRA>.*9FR-4V6*"=%& JYCCU.
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M'%!U!!(O(Z!YPHA?U;TAXW3Y\W#)I;<0[++S@'E>8G:-JT&=C\\2S^O,\N:
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MEJ=MV;4ZFF)R_:?_3@RD8 \@ J/=L_['M"0R_W[D/-YH1,N*R,3^@A0<X^'
M&I%E@U8TYN?T.R\^^( W!8*3*5N\.*4=06Y;@+^!^X*K2>^@1T:_07G1<ZN'
MGP1S#<'H ;3RPNI TN:YR#N:BN]-M)VK@I?+6D%L(D-%<-"OZ["CL!S)>-:A
M(6^*B*76L%RED\N)%E*(UT)* [OA7]*#X]0H7..XP5T#\ ^P*@L->=IXSKXC
M)3Q5_G/LXV\A'1R-_]Q0FB%/5'_?ND<?KH>O./7F47W'>N<&CUZNJY59L.L%
M"G+58"N$.=!JQ1SR38M;H=RYN&\M*6+O_^'O/*0:4O<(5AW$J/Y9=0D)FAHJ
MFULE6BK+Y,08 K$PS>%+\]XVQG 5/Z4(5P0$-@N^PA'83SU=PM^&<+WLTK++
MYV\O&IPG ]0D*V3A@4@#;T;\O-!JU!PV883 -[+V^N.A03%AEFG+/B4SMG:7
M2E*F'*[=5501N0^H_/P(8)A0>KOV?>KE5.08>Y,=[8@?&;@::IOI@\F5IQH&
MC+IJHZ!0TV['(;K]XCA<_JBAK-25.@I$)=^W[NI6\EG+$43Z<8G(>?ZK_URR
MV> "!1QJ3RQZ;!EN0(8A6(157Y&US"+)4 U?>2D.(]Z)V=@/1J<M'[MT-TJ2
M_XC2Q73GI_4;A+Y-Q?'M'.UKS:TKDX29;;_U%9<P@H3VXTWO90Q.9!/= Y&Y
MF.5M8';)Y%@7U5TJ)HQ$6X,%!DW4ZZQ>6YYU.'93.]8=';+/X&NS:%4C(]9?
MP[7QRVJRH?%O&20<W+ E>ALYQ#%;@*U>@2+TPDXCW52.*H4H5<,@H#2V]UL#
M>94+V,LA=L%%)C8%,]5YEOJ&^D"-)5 R5*UY(B"@,ROW(8S5LC&3L$D"8N>!
MI\RRLZ9:TZT5X(9@6 7RBX%/.1>QY#^U$@.=8F[MZWO30; >VEE,+O:%8.3R
M.$^&&P#.XN1DM_PNN%]C7[+D4&\QTSJC?1:]Q=B1F6+A[ZNWG1"0XB^WA5NI
MU3I89*EDN^91E\=Z(#6+$QQ_]],5'GZ?>O5>'4_A>[:9L<7&;>WLGN&HCX5B
M#_AL#SW[</65Z,RW@^G%S8 ] +N*)CPG]*J,COSPK%KV3<GQ( D/E77MBBVC
M10:E 'J 5XSZYZG_//7PPP<&,>*/7T<+'-;A0K!(ALS;'7>X\4+I"5)D0\MN
M"]%:>P\@ )&/K,HW02D_GE<)C!X>IGS91?<Q^1^8&%3W=S I+WF0*XQ:+>@+
MZ4(^QD*EA7".%\B%!QPLXKD&!SFO^3Q-&>O[? E[A6\AA/(QA.6X,ESBTY+2
M?N='@<A.J9+R:#TQT!J:0#+?"+I?81Z<GYAT.L )SW0F^H$=\#&$=\\>1RT]
M3ZPT<W^9)-@\% O<O0[^Q703_=Y2U]!NG(GY]T0M(.25OO0,&AB-9S'H"UU=
MV=H.#IO(/)%?AX,*YE)>D($O.)N@=#>E;W10K^'SN'>N9@+?4Z#N@*]=<!O6
M@34&IS51)U4BM?O6Q;Y I?Z;#?_*G*C.B,4O(R&;0,=YE3.=<[31X<V=RJ#7
MNG_G5YQSIUR?[K*-RH0*%V22P/J"!H1\,Y67P*C,BB"8>R>20)S:GON3-0\4
M6-X6>IHVLV.3+0_P)]Q@,]B\MDBAU<;=:PIOYAK'-3\\)OLG#YK'Z_Z JFO@
MT<8&I36-%A:>1T\# #9) M%"\)V>N$#!Y^P!VK?L?UU8+6FV%9=]UW>BJ>UK
M\!V84C?'9-/@;E%"ZD71C"7XX?KL#S0G"@Z!L="])WOK1Y)0!VE'\'+-M'FD
M<D='^?S[]_+?UP@5E#Y>O3IF4U(HEMZ/;= E)_'"&!(E&2O4I9AHF+QHX>*H
MY4X@@K=F1(GFW^B;YO.40>[\-^OKR?OW?#$BA[Q_@6$Y1C/1QO^BJ)D>'B]A
M'6!=YGZVC:F$B5TC'%VO]GC0K=:WV K0<2%!"W>H%#N]YW#+R0K-IPC7-4+$
M!MJ4/-&CF!X6EUZVN.(TZ1B#R &!?BT87>(8C[4=GJ<@3%;F_WTZ%S'XS>U=
MC# W>@&=BF9=CEAK#%F(\[:ES:95B!^JM0 \6 +V-%^?^\_ZO1)MB9XK 3:<
M:$B ^Z)DQJBF^;5/_^E1L!L0:IDQT4@A.O&<,5U488X_*YZ+4)P>"M0D?SJ>
MX-EE!@-WL[U1?G3!*PN7GJC92YD/9 L=!WO,9BPU?' -9'$GN6.O65XHX:/'
MQI^:HS3$!U=WW*-L_S2TGVO$+D;SK9)I0O=8:96IIWRUD$%_IJ-Z"B.XI";H
M#:D=!C::V\MRI^EWL;UR?40F2FP,3GW6_RC4PA?,5\35#W&+V=5BG;5D.7]V
M[JGHE/0\?S.BG.^"J:X..<7X6>P][I=K"&'[!(M1[V0GTP=TB0.O[KAAB!30
M*V^._:>@ '5Q+;.;I9(&7A5Z(RU)V8G;6VA('^]-O[I!_JO:Z.9>?[VP[XJ9
MW*\^YJ.9<A.K$^MYC1PUAGU9FO>7+S?*G)4^WDQ.-*P9XVR+,%0[]P!O\0F)
M7N]+&\),9,7M>JVB24VRC=$DM/L>X)!,8EY<0T6YZ9_BDF#/MW.F;B6G^AC2
M$VSZO&H"V_0UHMCY3O'#4XYRYP&GJ!2>E1\3=8@6<2#GUHE/9-&>!06Q<5^'
M#*L!)R*;"RQL(O7$8G6J0"?B"\KO?0A*>C+MJ))(U >U<-H&?\CP(^IDC[M=
MESKS3\2E-0:5R$"&U-6,(F3OUS>FJ!>+VP-HUPUH^N&(M_99SX.P),S.HH-]
MM]DS@3?C[GP9J4@0#DK*XRZD2/"]*A*[5WI.[4U.2_K(0^507AKK)UWLJWV
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M/\0R;3!@9>F7]J&0#JPUW(W'&"&T'KTZ@R%!^0V/*&TW/;DT_EK!W/=YA=B
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M*VT+S9-?7VF[_/EAYZ$[&7*7)(X=Z+LGU'0M#^=G2INYAE:.T=#IO[:X%*4
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MA@"8G#@T;.Q<;[-/Z?6-(465";GU1_K>Z!U.U2[?Y2)KQ8&*"GSF8TM=;<_
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MWQ8CA<*3A1*V:7[G)R^W"J6R O>72ADS5_;L9$A!ZYS'1\,>P0OD=T'M!Z#
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M$&%C":T;D% H. 95H%%A49<SSN7 ?HJEB.*UR84D?C//EQ4R(Z7:<?[AS5V
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M9;@O7WOMU,*XI@%0\4N!7;ZKI]0\H?L7)((T4,K(Z02RY-JRBP["DS3:2N;
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MQO-0<#&L"+6B*CAA<)J5K1?L]Q68?WUO":A@2OF.%\O'&*I"$SUQ3B2 HMM
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M9X>'M/TF JZHQ?5EF!(8[!GO /5*G\59\?2Y1O>CC!1M$(%896G*N\("[3A
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M5E[X<L"\^W4[&JG?N M@/L70#!@Y+P/%8Z,<S74TJJ5_E9VN@RHZ.DW[0?.
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M8YH6NV50#]F&@MMPRQ7NH)D7E%=QH%F(,)B]J+,+ %EF<J=YN#-4X5:B\ &
M7V6BMG2:/(LP\0*TD[0UK!)" ;(,XUO]V['CYS+&H5Q#*\AH;!+ E,3/V07
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M2(I)[G>!2-7!-NIV[#-*=23A!EP>H@=[IR= L%JNX*RCI+X"K>]2J=9RV2Z
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M!HR\E.G5@U35B%=)-ZT<3F]*A+'DT12>>E5Y>7!>Y_1'<?VYR&@3*@MQAM
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MN/[#(F!;>1E9XVEWV^M/P/7?_!.[@+2,_K ,1T(0]X)\UI*M[?7VE8=J[)V
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MD WT-58DJ73/]M/K>P118OV.'MK\U D& 3FS:+.O^9J8 4AY&@:Z&XJ>>$9
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M6C(/&\;O D:BJ3MT;@9/>!$LR#O[;#-D1.U64!7=[V'"CWK('.*#M"E76))
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M249"[DDQ;A6%HG:VSF*70QKYB-R+RE=)M 3OO(O]AR-,)B>W8):AM7@Z]_M
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MG"_C$\ *6_J\P @L#(I),3N_[L17*^$CTJ8WH@QVN0T\;Y>\4A<O9 E"6]F
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MUMJ=D_4M:<!BH<N,K4^GR$5+W>IUO3!B=F=LM=$Q'D1$6( 4X&<61#E1ULA
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M63Q%2ZEL/[T3!ERU77B$(;@MPV)=5#$C&D6@4/&>2YW/ E_"<43Z#KT@.?,
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M3/NO3?*HD(;:=F4A-Q[L"A-5LF^)R<>! OUX";^H.RE.P8=NY=)E^M-+NQA
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M!>L-EUC^#D5O#Z=;/BUW6+>8\#?1(R5SO2G@ Z$Z+'D?\#V/NPL\5R.IB%U
M,K$F\@O;T=-NK!D>)M4L?2?^AD1QETN]8%+8#J=40:G<:=QV9+))QVE=QRH
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M<A,2V*V?](\9"+_.UB#/+R$G=YS_1)A"%))XH,CLE-IY\_MFR!+<5-\CPN^
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M9=S;F0/Z=>XG<Y[*=FX#'&"N&$1D?:6->5%Y T>56MEUE>ZGW&Q;P8=@9AG
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M=/\_B!\3=%BXTO5<X]DTGUVS 5Q \H25S[KHU=9=9LY_:]:8U)0.%3^[X6W
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M;(+6L1AS3!Q2>^"/]0%;6M'']Z:5>*:CRWD_XQB_U+33S>9"%];7^<&8810
M^[(&?9HT[/KTT=GP-T.9M']_FF*?)K:GZ7H5OT,?5)FBR0N=VRAC32,M8-F%
MZNC7:')\8=!8J 0"S)Y[4BC-=3M)=CK'QX,:2C.?+)N;9WT^2@UTQU?@'L^9
MQN,??Q=M']@B*7\$'N]L;MI@,Y%99;^Z-@%N1X>\"[P\Y!<>WE7-OCH/8]@U
M(VKDPUHDVULHD7H9U_RO=JTPP$'\\QSNA).Y@W4(9/W"K06UGQ&]6PL-);^U
M3:FN8@K!4Y:91[%., 1F[@N_CKW>DG.8?Y8\W?A2K63@LCO7"!G+=4,"1<9P
M!W%L;,PJ<7^L1:*?]:E=@8<)DD@N'Z@J+#50#K)HW00<ANHNWC?<&7_RI.3'
MXJ2K/5>).AUP%\[&FA7IFO1Z>OM:;Z?1Y0A5,<OOJXS.H%G'A:+&-\X4@08.
M/!#%_F5M\^1[=;K#"K^>!T6AJE'1<CFQUPRB%";=]EZGZ[U>962N\EY@LOD.
MXZ@81<D&1*7C&&$78B(8,&P072?*9X-]@[P( 8I'\1 M)?57?L&&0<=^TR$H
M#I89 -FGHM"B>FV[OC!J@HET\BRU;XD6K&?AA58O-BWF0DH*\^KARW8^"Z1-
M &(NV>#$8D_-9)&MD_OD!/%X(\$M.VS5H/W9!3,:Z%!+T8/+.#^6[1E9>39_
MCA4/M2R:S?:P>4W5VC'^/'N0+T4'G]\29PV3)E7U\&29;[V6JB6#Y6V_57:*
M,+E"F5ZFI</R<NV6*[@0XS,6CX&!P9SM?'!*T8V&[ A[2SVS*,\_,-/"^0L3
MKQ7P<@)G02)P/,/^0U_YBYQ]G@MN[C'NR_E?1%7;H=W(K$U :],F8$U$$'>&
M1+4::#0J/@0U5KG41A5!69/Y\!J!R*R<1MH$XPCD',3UI4[BG0N=N<C?=</V
M HGV4YDCE$="I\/<64Z66JK!:G)JZA;W.4/&$3+Y*AS;7.CE7O33ZI'[#]./
MN)FHR)5R[ZK,B*SN:'HPI0'HU$>8R_8/+ODV$\BS*RR!:H,W47;[ITFF3=(
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MN!3;LYWEE]IIF$3X1(\;I['M9>+_4#\T6KP)3N?"&OWH.U&\96+.5GGSE*I
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MVSC%5THQ.QPZ#R3)6#5,2;YG[ML'DES+TBUS]M8L"%@42>EF1)/:>*"X:P[
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M[.F +-FM [ZPO?@A=MH^:+&FV<K*2K@Z[04P[^M^@@Y[JEC,#'XV4B&.T*]
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M15Z.J+7MJ[)["#V^ELP :E_3ROI>\R*R_*1H5-/GO0P ZP60_COM.RX*ZZY
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M7"U^VO]KXMHNVIEET=3J,8CZ22_I9PYG4H6LH;\JQN):3UG<0:6,EU9WZE_
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M#A8IOWVSLNU)FH\CU3U)J1RHJL!^SU4YW,^6\T94I7VR-MMJ%*EQ"G]\<L)
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M()6'IQ_%L1:/JZ:-?@?JT(O;.<R4>Q$_;;]W-3@U2C@%*J- VE1HNSD\$P6
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MG63//42B YI45'K3*?ZVE*R9B)?U?EG=#ANIE^4HMJ#3P"2F>])/,&;D7:D
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M$?WP$\%G%Y'&RW,*Z1*XXI=I=( \TWH( : N7Z&\7-PZSL LOU+C'?0>8<Q
MZ$FC1O'5JRFI_DDG53V4;JQ<_TEK.5_RDA06. 32N^L^8J]3NE"AJLL&QLHE
M\&$ 1=];B?N=]WC?37K@ULOR:\L,6$7*)3.C)M0K],[\N!K!?84:]_G2XMWI
M0X@^?"OO[^C?.UGS>7J7T+W&Y7#Q?SM,>ME;35U%%//E3MS?#5)0$K!R&=L^
M$EC@RBYGVUIO,1!J#7B$W,8]2^Z5EY^!!=1_$O$9IS<L18KD=QIE4)RWB;&
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M/'7?W/K9,AK0?+/]MGPN_'8$0\NM53KA,:MMW-1R-"=)E%\8WQ&A_CWP6J,
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M\%BSS ES 2P[H)K?FHZ<M")6L+?&L_W4E5U:U4]L'OW4IH3V-9JC[NKQA_J
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M"6HX]'?YY@>IXI-T!$T5CBY9_ZKH#8A$W*8)<WR@SESOZN!Q? $$'0E R5\
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M/WPK? 0S^(EW2AI?<N:9S#'ICL8LK&0> BYH&KGWD2Z?I+*'EDWD'<^@+[N
M_C)8;:6_N_%NC(!GOJ5D[QJTL+*R9(SA R9>3V1Z33M;O !F;_XQA'-WC*;:
MO,*)R"94.21G<SNW_)%(6GN?J#R1IX0B2&5@=;A<[R4HF*H :TYRKED<7LYI
MCTZAC].EC1&EL0[]%6<E2K:Q#007ZD4#*%0\X+]> *Q= 7=GG%=<G?V@8Y.K
M=E !PV:85,%,R*Y.JIG6C)UJ!'!K!HF(S"B1BVK&HZ^^V+-RD]/5?NJ$UX8'
M2F[&^KM7SRPMA2N('@X+U'D+VM74+(;X-_,K)V',Y^GN@7S-M!-@_"$G#)QB
ML9EM[4[3SBY:V?,1/]24EW!7OOJ$\ ,IC\B',4OXVQ!^G90JQYLJ">DA\Z7M
M.!/6"VT:33O $O_>XMF)DU]SF]2=<\?9T'_X39;F&#N4:26_E0;>4X(=BQ>=
MCD@YZ[1<.U0FZ'NI6-<+_G'!0PY/-8L*HK8.RB:2.?E(F2C>_;42ITCCJ.<7
M^^3GH#H (K_H/1])V1>CAIDW+KD($CXXM8.@^L;>5+9[A@?*WBJWM.(QJ3T_
M&G$B+',ZQGT^D&Z5$<H2*RK2'^L\<_5+[/Y!HDAX3TYRIQW$0I1*M/S@'MMH
M_#S6I_H+UCV8Q,J\ME0)TV^\R+:8N KQ"O%9(])%GXM<8(9EF7HU*S=4<4T*
M=NWX2[62F1[=C([HK4W^$B,JWM[]VMR+LI>D/[0F&017JGYNG#Z<V7DW>(L]
M$)SPJ'&/K%%\F*\LS)W%$]"64*7H1Z\K-2H-BQ!GB GP&X;E^$TF_VT;'\B9
M1LYU9GJ4Z8*?Q2NOC075T:U<_P:R.JK"_XW8_$CVW&V-8"NQ(2#MA6T<*@A3
MHSBJ6M.)W5>><)TT_M%)A6IJ2$*]G/H%$HJ<2K7ARE\5L<;<4>_C7@"_LDXU
M.-5!9Z<\$!+-0>)&50&G9;B&?FD>482U2G)\OY*YR8_ F2.,N.TNU&%^(-U.
M[=CGR[2<^Z8WNF59J;*].Z/5>E%;:4%2#^R=% WER#WPKRWN[L_?A68;J?*(
MKT,6!IE>"4[R;,1\W[)^98->H&QBR+EZBS@]?EW5R-IXKI=F33RINZ-!JUS1
M\$&YYATGFLK4(*,WS$-O:53<G79B<&Y%%4&M+&8G&:2IO>#BDPS]7E1\7"]P
MOM">[#@AN%,TG+Q0V)B_Y$Q6H9<Q5GVA^T7=CUO[+,_J[VMVGU/+6>A@, !I
M6KS+ZW!5QVJM[.4T)#S,K%0F*9=ZH"GDY(;[J>+3<[$V=</.S#BZGMZ%FAVM
MJ9B$J5A*LVVE$Z:IHN/1T2#U.%@Y><]I=(U],;@P." 2UH\)%. MOWU+D8Z%
MLMN:4^($MLC^$>\,/6F DL/_K#.MQ#MQ&136#4J G+4;[IIJYK-CR.N6JW&_
MY1KC?W%FK(W\<K*_;G[J)G>G/JIA]9D"DM\V_\#"T+@8"_^A1Y1!8^24M^NK
MY<PRU$*@7S7][4?-D[Y%KP5Z$O\'@K%67=^-@NP>0ZA=EL&NKEVJD6#C-W&3
ME??JCHV,0_H=RUHNK#YWF$\!9U)I);6/$M,+J3V,"Y7@!L([=]^@=8S6$WCE
ML8?*T87)DND/E4_=C.^T/Q/6<!VBC >$2$[&Z)SMOFF.XNA->150U79;6-XE
M#R.^1EMOM2;?6.>?3L5]!VXT4Z%Z5L!&QF>)5]J++,T\HBW!8%^4O^&#DH-2
MG>J^,?GI/H9%)">*4JW&?K''00;P'32!#OKI,A+NO6]2 RJ=N0<:'=3?YW&9
MZ1J*,'*.TD/+AE<$_^:.L!P*O !0D!MH&[O"M<A-$W\? 68EZ/J*U=J\:.GV
MS$?_H!D*^1:]B(_+$&?$<$ZY&&X3AB+<<CXHHA0I=MB=#M.L*SNU+/LL&$8C
M'5K'@'>TK IEHS^:=7*Y/C/1"O]N>P-=BU38;U59[J@@6+/Y0_T)5]G.]@7P
MX'"JC*$NMXX;-*5IJCK3GOY5Y/)+^F#'JWFDQ,U"H:O:K4.P'77X@1QBGJAY
MG_54ARZR)9.,%,FX^%,Y6J@DW2BI4C3[)#>#7=C^/O]Y#2(:$0V3X>GFFTT%
M/@8K)PW?6M+=!^'S =\$:[A5ZZFB+;>"*W>3P8U&.,9*3-Y*E;:"EXNSPY(7
M[(6U*XF2'CGGY :_RE,Q#)OG5BMW2?ZG*RBR"^"PDIP2#0_WYX0$+<LD.B9Z
MSQ-,7 #ZR!!GS["?LHU[J&43=< ^*'49C&DT7WCD/Y9 KJ2K8.]C41KYULY.
M@KV4&LCX%7"I#I7#;F2*Q6#P*\Z0CV0MT+X$,D83X>')V/G\'U<U[)$5$H:T
MAV0*V$TD(FAG%2M;(T)TCZ L!([F57,]LAJ[0)(;)1]O%[WZ2:>WBT(Y/"'.
M?8ETMG#\<2M>#I;66-3\8(GFL%GI:>TH[CTLEDX;6_C-^,Z!=>3Y,@!1<S'4
M\8/]^6JP]_ 6K/.<HTNN7'YTNP;TLW8M39P)**[J+'A%?WUB'S.;_HNO<\%A
M\4<Z0["P)QGOD%[LQLJ77<_]IY5%7+PL7./^1)J4RS.0I]A]+SW"HI;@!=##
M8:J4'5DT,FV_1XTEWVEJR#<WHVR+I1@ZU8<[^2,#2:%R"SYD@IX9D7&;SADG
M)6%KO;]@+K$Y3Z7_^/$XK0[R)JYCZ(W1 Y>PEO.I^:$_OU9359'4)'C67Q2+
M$8+,%>)V:J23)_@=V1MY]TDH*3&"<34?7H=\3HKXNTXONSW#F=(*.D83N,S\
M>,(]"TFCU+)&M1,BY@TKJ=0^)/S,\&9JZ^?!M@#IJ<CO2N%;Q[+I13 5+8QP
M00H_7B+GNQG?V+'A:OB?N.:V;)7@_G"TB#UXZ?296*Q>607,"KD@MWK\G'S0
M,S;#KV'GH]*PQ6D3G\X8S>]3@]UWI2MB3*73\0 /K&ZXQ-(GWYE?1^$:\M-]
MK\',R9UFG]1PS>K_O^AZJZ@XF*!=EQ""NR6XNP5W=W<9-+B[NP0)#@,,P8/+
M,,"@P2&XNVO0P. P X&0[.]?^YQU+L[>-]5UT7==Z^EZNU>MU^WR2BZ+^"+_
MS#M688V!?A#5!\#O*="+WT1NEW.6NCIX!FNM5L89;[3(=:9Z:3%X5R?79 CJ
M\;=M&HR8_WD23'6H'8O^!O#EZ#I@<6');\MOQ#V;0AP1^/%2J$4']X$CR9_3
ML%&-PWVS0R543^/N1PF2"&;]:VF!4C,DV^U/OG6\-,^^?54D/SC\>GB3XD]C
M)\394QSA:I6Y<L:VN&T\^5^YGH8^K:HRWDZP1 \<W0_\QLMXM@-J4P*#*'&U
M)? R?N.QC*U)FZ?\'_YR^6(1N_XK09)FBY)CTR1 L<;0BRRXJ#/4K7*LQXW*
M"(R4OQ^C6_HP_:F=D-W[F?.)O*<P8W:"B%8/9#!(C_&.RZ[4HWC4PJC?^V-U
M_=H(GY*U,ON])L^(0]//O$- 833G.&2=.* .E3MW1FA+OZME2<P2G U[#E1]
M-UXF8*3PA/ P<=53#[&ZW25IH4OC$'(=N,H8CF:0TX >]3M6__;L_ TK@4Y>
M\X<KKTI.K?1H \V?W6]+#L17R#<8).Q2$80;AH*X:O=J]4RX'=YH?TRY*H;K
M\17T[.K5WJ!V>I4[NC=NFKP8$"PON;918,T;U/VP\/]"2,VA2@R;#CC.7UI#
M=7P9W(E2 70KRS;VG;L[ZJSS56I::9X)B)OY"7:!2,5"1E"2FUOD6?\AX3DS
M=<\9'ZRWDP?DS(7Y;\6F+3]W3,+[.>^PMA,D4"Y_X^JX_-[AR1F;R+[L2-PJ
MW8M/K WLP^-@-RTQ?W@SK9!G#9Z8;$H$_5C_A]17TR*-C5JNVI[K'E+OVYRZ
M&*9R;N9/@V:-';WI'C AP_!S,FY5] ?U;##'+1J?:XARG<.Y!:BA>%27QMC0
M\;-\;]!TQJ7K9.-MB&_-06IH5:D+,PB=F[TU1R&6K_GM'IOB$T]3B!JE?M^W
MHLN_7SG=U&3+[CS(S2_?9LE32X0<'G1!"GM;2.Q^A?->1G#0SLSB4DE!^70'
MHM]P4+1+4_<^QS0TV_Y#JF;%-)^T-!.6 W33YUZY).W:-NK@W20-#;<HO0')
M;1A$-(#+^Y;\/.I=,+>%J%<.J6#'"GM$CR'BM2JLU31O@#RW;@K28SE?B]V$
M,Y\A33,6$H/;FFZ[EX,ZE :MW24WCF!?,N+P;$OPAQR(:^CO+Y4X5*Z.6AE'
M]GG #Z)'V5;[K@<[^G$1<QUKM18>4YV'Z<M+WQ/^5F65R-[LY<8^7<=EU^P[
MSJSD=U6R^5L"B7#3P^YH6M*ENX0)@M==OJ8C"_JXS7MV41?6E,K&)4X=N/U-
MQVW;C !2OB]@'PFLG=P>CFRRH S3LIW[D[R@:-B<;] ZQ"';4B2WF+<QZV[6
MF+*5VJ3A'< PX<-'J(@-8 P/[J@_?\FB21 S!*IYW;BIMU4=]#;,RRA$H_!N
MV4A&L"LA7:%Q95FLXJQI1RQ<SZJM6]A/$=-9NIGLG9^8!G;+LY>M2=NEVS+4
M2K3E?/&Z+* ZDLHC6OVS-,8-?5/'KZU'3UOY:7MU7N%=6L5H'4(%F=PWQ#O7
MINH %T\E4B7P5FAQ6TVH/Z7&XUR2JNWY:O"IZ8[Q\Y_F(=&G^<F*('J5"J,C
M'U'&MX>LDK:07,/EK?QFU=N<ABF/WG1709Z2]N7F_S:YW(\>-4:-1#U,2]R.
M?;N*D$=$@CFD-O0I'907QMN?L26WN'06YZ.+P*EU6KF6$!5%R(VT:EHHXX[N
MUUM&YM3,EA4L]$#SR$OTT-DIO>Z&@J6YRNN^S8V^049O.1B],J,W!KE,$$LR
M05Y*"H-!DM=8%!9U==O9\GE:U%EGEW.!NZLZU%VG$06/$D95 TYV^G6ASKZE
MXH&Q+0<FF2C*U!,* TJ@.LK E0O"GFF$3Y1TO_W)W:D3>I+JG3_6I\!9.Z;N
M\3-XK-MAIJ?G<U$=5ZDKZK!-</:_5#)Q3Y>TW+O%DU,CY9E;]C0&=&Y1D&I^
M;E^;LU1K.V2J10PBK?5,7Y*_YS=6LK/4\"K^A]1CPO;TW+?#77+>5RYTB97<
MMV"VM%FJ)G6ZAG!U65U1YP2.9W17G@N>.ATZ/!F.A>0ZF*1_ZSD5';Y-<0C\
MJGD]P?A,./.'S0+X^^Q:293G]&^P#K6FQW\8<-6.Q66^%3 /\O87<=*O:\=X
MH=P:S:)^YT[.%E,DZ($L6$3:=^%*Q\?<UUYN?(, G=J]C>NTT6<*6DF>8Q@3
M^#B"KW/]<3\*/:!_U70'\))4F5Q;N^HW&C74N6X>I&SOMVG>?-G84&_?Z6 =
MP YWK?NCRAD4,9X0X;\N76UG<9P5TE@:HBV3"<])B9WHW0QFNIJ29\@1R.[\
M8X\'C!_:2E"D_YZ[YU[%9;B1NHX=U@G0F>]8)Y8&A)2I8"ZMK#92@TAX4\,G
M;P'JL9E[#H]>3/53/UY_5<AC1F5^?)G>7>WZ&]*0OUM4;52MOB*/$N(*=[5*
M=\"@(?V[KY%^>[UY:128.F^DT[1FK\#YB@6Z >_9/BC^)YE"0MNG0_"*@TFM
MBE7F8<UMK.RQ_I,[01!1YR]0N YXF!6K< 95_#(E?>%-,@6S*CB'6<2]*XA/
MVK"W*(2\:[6-_ D.>O3>5-=7%FB1P)<5C?M9L7BW<M@\(([H%HM%_Q"5TNU>
M=5Y54"5HIE6XM#+O]CPHM.#FMEH\?;=<V=!&9=18YZJG\F"]/CZ+"/W0_"56
M5T1K=S8R$R$V!G+]^ZA8RO/^[92DH%/+<EE9)J3;.O.*0/"ETK/04-%5*P*0
M /&UDQ/ G[Y\TV-:[ ^*)X.7SY[TN4_O"-^($)HO#Q%?G0ZS-3ASS+CX!%VF
MR'_(X&7XCO2&<ZB$JP^X9R!]<7W1PU34J#ZDM=S\I#;OY+%3+C2[==/;=EB*
MXM.:HFJ7$#5](?Z=8B?P/+B/+ PFY*EQV^?(0C;MOG;ZFXME=BK_:\(KYG)1
MM$"L'Z#OF^5&$_80E]S5+$G0R9OL)>#;M^Q+V+_BG,6L'HM"/I[7;R5>RP(\
MUM>[$@VK3%(_FXHP6(Z='H0Q6T^^+NH#T8;DM!(DE96-48&KH\E7+KH6.9"*
MA?"J[IVDM^YGBLAU]9F@;!F[?3"*AZ@$((TAY&#7Y^XT)SH+^ \)O];J4S#$
MLI/9:924X+W'9S.+\OL-AUBR 9N29DUNS;7C8PM4P8VL C+NEA?L]B++'U@O
M%J,_5R(D;M0]G'75P.'%]?WH7VP=\&CC:7OH4;T)26D1625HNKK;<#P3?Z?4
M=]VM'NZG(!([5:DQ<//*7RH1LL\S"%-HM7V0_&3;3P=,!3>?6;_B@KGO<#['
M4CA%RCO"+$M;!0T )Q![=!0U!ZQBWSAYUUH]Q;13&35(@D?NC"5S@'L/DW=9
M7@$[7)R95O"9%,O_4"0$V8X!M:E)#((=;$AD.(>1M R<YCM;VDC828[;7 *P
M*'EY.(<S1!EO:I+G>!B:1Y.GQ-EC?*L?3(_Y%\TQCTV2<[\T+8D]BN2GQC=%
MZ2N-2'&ED3W(S\78TN1@OB(7D6K(4;P44F::^:HN0<*['L&<SY"<X(K4P^+4
M[[LJ7TF\YL>QAB>5T_8Q\951B,YQPY?=+,]ZX>I\BH*NS^'91*HH27HFQ[5B
MK1E=PJ4>BREX\492WXX=GLTV4*%!ODD?/Z.P*]5QU>5)K'LRQD?E-6R?#D=(
M:I<?YQ9]LD>M[/JQ;1^9I>8>2?&DM07^R>N/.X!HKK@D^=H]J+>@B>T!V0R+
MT@Y$>O8^ S5NEN&]>K<W)QGAQ(;LQ/FH 6\!JP9,Z=0)!_5U!E&R^G-2U67!
MN?T^1N$C5U>8#5D:+E?7*B>(D$O9 /03^U-TEDQCY4Y^=*Q8)I]FP0WT$U1H
M+-H%%2EBJ?9-PHMAS\.6?EYKN*2W=6:.\V9: /JP7-G%:&?&[2,*%'@+HN7+
MD-U/"PM)@B0^6Y5Y,!+QK2[M09Q!PAQ(%+TI<%/]K6%G":+Z3/'P,4MTJ:#9
M?GC<431<6D!GC<(65 ;'G*N4^-TG/^_:K6_$'MYWO.3Z@'Q4-N%\J^*\RH$
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M<1 ,4N>$<824Q(-_ZAHZJ%_B[DM#>UY7V%=^X-47S73C"9PO';(J;<2FOG"
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M-Z9>U3L%)I[H;3EK,'O+:* "'12D5OU(*F-KYPHR8?Z*,JJWG'ZGXYLY#<2
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M\,(([3%R5%EAG.&^T^[D*OY\+JSEOBKB7C)MI -K,K+TG^WR(OW9]6[UG;6
M8M7R0K4A76VLW"@9'=6'83^!X;A8/@#0X"',)_\/EV&@&/GS><9F.339\_TH
M""N@[@^=:4_TEQCNN12$>(5!YG0C^9KW)AU0F_'>XA^2FOZJ2^F&2T!R?[RX
MS^J&937"OEJS*&DA\=N+0BY(G08S\.ENN(WQ#2&&14ZRGK1R*,^V\X.S^>GL
M#LVLOY,93W#OK64D -;*9O]% (_P8&$'JP7N&JA)?H)_>ZO3@8&>). GQB'^
MYP[T)5[(Q]QZI[<%7+LXHE:1"[.",N8_>6Z *OHC^'VV,PP:<2SG&0/CC#P.
MV9\ 4F>4E-MZ9S/$Q(+:T-*67LD= 8I0GH:<W>%(CXV-:K6V$/9"C4L4&B=.
M^_2K1]_#& X:>D0C(5'QG51@@&:\,"3NO(NF^I5A<;D&%DN5[+Y567W1(5I+
M;MM<-5 F64IG0UL+]-K/?Z<G1N6=^IX&JL4]%2D+#17F-#((8=&6*M#73Z0-
M^IXF4MY(/LL R%N?X5PJ;VY+R.@T.E;6Z5T(/-B\A"RV&,*'RH4D1;^MJ-_Z
MK\(F?+5OG/43>3@-+U6M+Z8DD_%-,WH[3Y[ % D&66'7'#^D*G>;'^K_"(>?
MA?V-T_]UFXM+H?UM9V'*H[T!*(DLE"FX39M$]K!N3PF6759_5:LH5"V35]S-
M"&]@BIOX]EYPRRE DK]RN5RO43"WD<L])Y'^/6T,7FO/+<Q1R2@Z@F-6B@$D
M36@Z:.UAS94C^7SU7P\O9L.T,B;X]<QJ]9IGPF2O'$<T(+7IOSL])R3:(?_F
M:8J!@'$ETQ7J] )Z#.Y(6M>^*-X_[6UIL @EV11*GQ&IYS'[F@PVO+*^-3LF
M]9AFY:U?H_W<D"XT?+$]=]>2,L)5.[%.QS291J6JHSKOUE@?\K<8JE89DM&6
M7$#FHF0/[-YK=+;&/@!8*FE_)K;6[PE@;/@BPY T>NV0\^Q9>NW*9E")LJ4Y
MN[F#/MRLG^O;T*GU+E@/8"F/7L&!\OD ,0IB,=E0*.0)4XS@[?_T.S+U#IK3
MM9?^%-?Y-YGS_K*_INL?DGR=HDYP*O&8B7U%MU.>A:&QWOQ)WI8W+PYU:=^&
M=6ZQQ86?6>BC66)'Z(=W*@,,!^I& ,Z=)E'&/^AQT>8T$A,LGH&\37,T'=HL
M:OX1,)=)-WC:2:%!N0''K8=>7\"6.)2#E,.H68N-!R4]T4OIPY_W9(%B1;U7
MX=,A@D]>ZYD1Z?(=6^OI3"M-O'-&X#M^353YF4I7^Q@0H8G_,IVZ>UNMLUH'
MQ-7_V7"D.X<=Q,JY$=/I)<K.G,/ B=9)M1U]/4:FM+K\$C$:1WC"&W!I6K2/
MRH;(.TSH8:,E[/T3I8*2AD&6B*!AU1=]9+M3;F1.XM/ND][YS:-^UJ&[04T9
M:I?^+82$LA-QPC OMF?@+]OX$_80=(JKX(9BPQB)),:NNT;1]Q^S08^F)CDV
MJSCV7:TPWJ=49!<8@.##=O%>HBC?E/V/Q\F18!]HG&1[NIXY=%D2L- 6:C./
M0Z/C[*S/N1C&VDJ>6B?+#J736+,'N%MFC-VRY)5SOC;1SI#>EFU]_(=DIB9T
MZ.G4:(- :K]7>WF #*::)&R%^MZ)WI6V,X^91NA7@3:W%@DJSC# U[*Z57(B
MA\JR4??_=0M/C7,E)8'2)=5S)?#J'? ";PCQKU[?G,,T*<'+PF__D)YRHI_O
MQV\+ XD6KW=GX7/:WF+T/(7R=]J"!D?DI@BQ-3148^-?<L[B>QO-GUO\3-;O
M5B#.JN8^IGN3.D77XG^,YL_8\;H0NXA-?X9K;\:R5".)WY=.=2IG8S&4'7W!
ME_^0?HGQ5/H/74VT=GP_5V<-QK;E&ZM:XT5<LC5TG<$.])2IQ@IF(+#(_\78
M6P;% 01IH$N"A1#<W6TAN%MP"Q#<E^"RN#O!W1V"!9?%%X('=X?%W=TA^,O=
M/:NKNWIO?GS54S-_IJJKI[^>[AY18M@K;[O]MM=Z_^WK;6?<;;O_ON&Y#FA8
MR?]__B*8X[>7UO0<.>\<56Q\='+KC5YO<7E;4+R&W\#9JNJ9N-JC YL$XV=+
MOLO&;2D=YN*F9T5S^BM9$FBU<3AH7JTL"\SU0T"S1$=$^.G:"3A=A8XHAWQU
MQ?\4_^7GD-!/*C3!#/=,%MR8E:N05 $7QH&[F)SI":KBCE(A0C/JT<3FIY0*
MF5&8.9#$Y'FTW7Z()/$-(%:N>[Y:BZ%[GMTQOOM4QJU/NXBLNYU%+J;Q<".4
MM7Y/0\50D_G5<@<,-NL)3W+0&L+MEW.?<?:"EN57?Y%O6<+TS4S/:E"@V&_1
MXRC_4<:2NKDJ(P0H2!2;Z"QO2G&K!Q\<;:5VQ$E)N;;\+OYNEHYDQ6)CPU3.
MI+,P_O6:*I#Z'5]KUF90Z@37HGH_>T*NY5[":EK\S9D"\Q%BW"$7T( F<<5$
MBH94Q^A3A)V$Q*GMJ]E BYIY0XS =.,V\A.IK>%'Y7GQY<EVI2,G4%$Z,P-2
M0U-7@NGIV<;E"GY##CK@T6*]HO-SA5GU8L]$W_PJQ(D-W=Y9,X/VXT2-W?C,
M\<;/IP<#D%W<*'_?YQ&>N<R!;_FS3-=WTH@.=,S8WW#_'F3(-4IX;AE@EJD%
M^^SUNX2M&+$>%K5M)4'/B>MES'=;,7J-(KTYQW!H6Z-51H MDMIP*R::*'H!
M$R07_-O$>M_6EFRJ8#_FJIU>1KYI6F!Q>]AH)VKG6;W+<\82Z->G"@4.:B %
MK#OO303]KR$L@HE=*_GI0A9&7;SL(DM00V$9$^RFL$SP'U3HK?W7\VZ[O2'!
M0$FQ)^@QZF$B^#)7MF>>\4F+*) S^GI$D>0;39P37]3A6G1TI9XKR,WU>BU:
M'5\P/J'NB*J3_B,YSN]BVH81W:=I&9-#@^(>HXI$/:33Z8]WFPWR>8XZKAR*
M<!DF&E@?(.7BIIG\NDI;/Y,&R,O]S;,U9EMC4*]TL^Y7#IN:5+<6(QEIB!8>
MG58S^R>Z)'-DBQ:+O(JM_"@=!7N)DX;[0'$:$X>^1U7OL)NL1!6OR4+,#0M$
M>T$I=&C2JUX5Z69>;*E+3';#P'G:;!/D006%DDH@<^W7C_0D(RI9K*#,Q8I;
M4*[=)\-5+495KD3+*=K3@,%4[1^87[X:U-YQP4G\RMEQ4K:3;BH]<+U7ND5P
MFX8=QA1]HAW[TFX@V2V@%E(K+&O"-F?Y/64#0TX]@Q"^O::%ZTQQW7D9RW>D
MIAJ&XPGR'?#$^82@7YVLYXO3U&0=')^FK;8J,*2V"74N/,/+JLWRHFH$+KD(
M'+.K',4QE\1Y?<-L,)%,YCXLJ26M:+*H:8+,P_(_4#'5J87V'4[S?0^0\:DF
M?O]=?N4. 66QI&(*X\C+#2VM6=FQ97F]&>_)5J9D&Q<L]P[855;4L'9B'-K8
MV$"B#65FQ5[Z>XVD(1G+2*XCM-F[O3'JW#GA^G'>_%!8/@H$]]0^3)IIV3T]
M^Y2J'4ZT+T0DP*\^.(9+4[\:D;PX79!^_ ;(OM-W"4U17#*TP@$;EX!"=%-I
M'4%(G/7* ]V>M TZ'8(AH#\'N"@!&S\*G<A*UA7,D)3F9X^YO-JENV<C)/38
MVT#WUG.98]D%BOP+\JJX,181B8@QZOT_'9R6]K(8_R_#EG"O>J1NQRZ3<;!*
M9J_Q&(WV1S(Z-B AR9-57C8*FX2MMI:*E,916C:3H1*-(*ZEJ+7(5L 6J.N7
MF<(,JDFQ_G=;)/TNOZ="PR22H5U-P6$"8NG\N!PH>\\CD*WXLON7.W-09,IM
MHI==TC02]S24/D?+L\1C,X(ZDM?-DU0=X7;GAQ6^\F/H]9?FOBOKBK[VCU,]
M<:5*A ^?-M+^RL/%V''E0GFR$'X1L6D/UY>MOP&($RFTTHF IFV-V;"&I4JN
M1^-%J []@O417@[[O9NK:4.GKR=;'VHLR.@-L/RE*^/O^S@:@UO#^M:9$^@M
MY!;I*SC'VW5K2R0OW^XJ-4,K<E(UU3_"E/R)_5GR+ WJ/2 4;7=-/P/,=E"V
M=.QZ'-&(;1[VYL6N=S\=D/RY@%-EY0QI(C5F;U7701>*8F6 :W:5G#9=YZ96
M!!O%&$4MQ$^4:Y[6'+7R"GA_;\"SYCFP,<Y+I=G3TP(O<$@M)6*0L02@0-CA
M,HP1-,7HP61Q3<=ZC2T*95H*I&-2V3R/G\3UZS0-8I;2R,;4WHVO;\\OM_2#
MUKO@(99^Y/UHI8;V%.V.[B<84P.>O..PBA<!676[SCDORDTGM&_JYC?%VWO@
MP4339=\JN%YN".<SK8WK8;L5T;.A??^WPFDQN55W05F@4LFSO&L0J(5\;CN9
M$J.+@<;YTHPZ4<GI>EHW1@][SE=--26@9Z1LIN?SL4UEETY^S8'1_$R-8,?5
MF)UX);K3GKZ8X^-Y2_NZ2*X3@=BU"Y]<9EP:\4X]-K>(_LT^?0U#SM:JE[@<
M9-$"PH:=E)*(2;<=0/-C$Y<A6>A/@G'WDEEVB[\$ZA(\@@V7_6_P9!]W+>[!
MQ-DE507!KT#UR._?WOE1N_&+/H#NS#]''_KZ#11\@[/4J.\(<O^DF-H%M*-(
M/Z2%$H2K!K;_!B^RJ$M11LI1:J8L1ECM3_M+VHG-EU!6MEV]F)5JTYK*89>-
MN7@2\QJ)3.F*\"'/9:%4X":[]*]0]D:B:EL4BB9"6J_X9S#",CX2MH-OV]V]
M"CFZK!MXJ.! /UT3F1A!IFYV!&+X+._O.WLU&.EI0A(D$]TUH6\ J&T;=^7<
MPDR1'1:6@8O+,6RVZ*-L7U8MHQA1)DP"TYH&LRU$O;)<5^EU?;DCWL^#> )7
MUS"G.<9)-.^*?MZHNEU$19%PL;&PH4*8M5RWBTI 4ZPUK^"UT*4_"OWYRVGD
M+/[%[>W@@/ VY%@XTV:OMK:)<[[M%^&HD5QQ6VZ0,%^&+I=UI7>O;Z%\?M"]
MK,;\0/$;P,H[DWB$I]$=(M)I3UCB"T[1RL>ND/DT9O.5B*&D8,W@6YG.]M\$
MA15]@651L@?\L9^JN9H'0NOC5$Y*<>:5TIVF\6TV(V&F433I=]HB[]SS=6-S
MH$(!C2$H^=JI9/S]&&M39$P:CZ<'C4_ .QME^">ZUG?R1S'8.!5,86<Z6#@?
MR%$][)GDFX2P!^A*9O444V)"CNK/R>TU@1R%FA2>U$5V[*Q>2BE_8Y!Z*4TI
MX^M^OP$XW4)Y_;D6_WNUR;#H*=& )<O9^VE/>FZDNIB>QYYVILT176B(<I..
MN''^]ZI^?.GX3,SAPYE)^ E,AG2Y#&13A?QV9))(%%TB9^_"6GGVV@HG3R:_
MBV(F*5OCOU-_OEX.KY/1FL7W4413"YEEBE[?B9(VVQ\JYG0DVA^LY^@:=C;L
MJ^#U43Y)N@2G,2UFE 3(#U\JI02C3?&Z*%#++3PC#*_C>F6<I:XEG7V.^M)Z
M'2NUTV'A21YP;=>L3Y5KXUW"K4JG57'S)&6S<WJP345( K+Z]A210"H:.<*
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MR7142@!,3$4/H2O0HYNQ91F+'5"]RP]<84>9(%@HQ.3\<HV5:E1)DIS#95D
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M'.UHL;CC4JX3-#UIA]VNUX2<!:0VG"3(@/X;-66H(">*B>$6DH;"ML?5&/8
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ML:)ZJ3(;^/0%ZK;SJ7%M97+@8C$_LB_P28%8<*;GG1N>TE_\K7 3S(&UO+O
M E&PC-]5;J2T8!:5*^5PEJ!9I[P:U:X*)R.6ZY7-$W-T\F%]W;:,YKN4)+Z2
M_(+"73C'2ZSV'IEXBF ^V*^Y5OQ"G4H^3RR"[ZB8:L]\U-J_X*E^Z-5^8?:I
MW:G=9UP6AJPV7"YV,N1XE*O]BL;BFU@\T(PM,@42Y9G+4L7H#'[><>=GEAN6
M@8D4F!K*,(DFWW8 )XC9/S>191E*QT7&S_B[OYX\8(FCJ<8;WR1CM*-(&'$M
MGP$V5'6-."2?GP'"$<^^PIXW-.0EUW=(V@K8!W]\PH2>GBXSWD\Q=VJ*0 T_
M%EU:+:P5&**6!=>3]S_NBBM=P):$?KN.R&F%9(?7BU!'FDUOYWPWGD[X::W2
M"X4<VL;1+^_Y>/GZO $ZJV<WW-!S\QXN_%FK!U]!'*L7?H>WL+SY#0LOY12+
M1]</N358>TS9@M%Z+6B]2+KD]OQZ,M+UW#P)/ZULR9A]F,TB)4.1<9?A/97\
MCJASTU_7<\F0'M\ 0CE"3I5^.=L/CUY>>Y6>^T?\DH=4_0@S7=XY0\0<+RJ'
MB[(1 @TNM N*T#(4I*_E"^1T/8/V"5&^C>'A=83T[\"&@4J?8;(<*DN> ]7D
M$P/'Z^L3A)3M<4$;/B]^'?PWMQM>E_U6YDV08SW8;;N][EH3Y/G8:_T><NSU
M'PTWGF"WKU><S&\ Q^B1.*O+":.0@RKBHS@24N6T]-+ISR0]===5<4P$N'J\
MPGZ2>LE,V_I</_RC4MPL/2F44^(2X,^'RX?7_;]=7F6N5DNX*\W:6[N'6AZ-
MT6@>*>O2>6,::+ YM9>OY,=TF<8+X$JC_-*4QN](6;*,;;*8655F&73E99Y;
MT$HRA,O<T2/ DA]A-ODM[1%HCD G1VW*P52:DA"J<7MNXE71?NT<$76C2KTD
MAL='+GE913ID42Y_W>>#VZJ5F/7[;GYFDE81GOA#])D1V]AK,W1OU(>\_^",
M14M>0)&N8W!?[Q()4Z3:Q.]9$W'<?$L]EM0I\K(@?2Z0IK!%N7NP2-GZ3AA)
MUB6V[EJ.[M<'IJ_0-\ -[-J^"5*7Y>GY9*Z;[.*;>31DMH7&UXEOJR?.L(L&
MN7^JAM]\V3Y47#AN%S<FPX:M>9U-.> P'.]SF&(\XGX^M+?*(+K0&*[L[?F*
M">>901@P)(!QW9.A?/PU[?F#W0?X^Y&ZQ<ECHL0IPXBBA4G/4Q]!I7--2R,:
M>>:OI>-QJ&:1'Y#^*J'*C\<6"RLM^RK?Y:O" G;K9X@-S"I:.=&ZY4SGA7#P
MU&Q.0'RZECE%*L#^V$K&\3JM'T37Y;#6,T]GF"_BMN-QVX](^YDKZ64X#G8-
M2PFYPT3>P^E%K<M4M"3-X/BH/>@A:9DWJ*3<MMDISB6)+,'OVUZ?&A'BLE6%
M5FA*9\QL)\(V(U<XDXPNMZ@7TTR+\- W!Z3NK,S1?$DCG!KK[5M#.6NHZXV[
MYOPI_HE3_^VIC?'+<C6,B7<]3 L(M+.H6G&X/5$&_0S0:D10]:R<^>93#!R]
MZT"PW/LUTWYQK[9]6P$/K?K:O!9C=]B4-?N5R]UKGU3J!<FX5ETATF^,%F!C
M9?*KI0%?OR9PBB:CV6!4U2#-%G%8T-:D&)9R6""K+J6* CT6[*B;$VW'46/N
M1*#5TOR;5UG+R0 :NR4FSLI6KCZ2;52T^+4U=\H<7OJ%"<Q]P]TRQ*)SV/I8
MR*K;$"H9V%;&D,!*#2DU31J,FOPM84G1BZX<KQ1,&- @9\\0.#CSB1(BHG;\
M!LC:$;SSD\G1>O[I*J_;";7GCQ#NS0'L)/TA@1O:_X&41]:S8+'_0+XEV&E-
M[UU_UY^/Z1TA7%K0G;<?HK(! -Q,E%"S_:]%P)%N*5=Z5X+G6D=VL\_;>[+C
M$ZYY+D3*W'%$Y'5>0=4:M/J!"?-*M1K=9%U\&<8!2GF6*?N%9OO:TX6T12[(
M8QU9JY:V&K:^PCY.)TV<DX$[/,PO1UZ9;M180,U83?;\&,,,F[%E$HL0R3/C
MD@9P^=*TWTY!7@7=4R6/KK6W]3+X**;L,-M@L(-IJ"ITA-MCK_+C1SV%]O@Y
M5]/0SW?\$6M4Z7O/HG6.:JVW.1.@?)EE?'86@^IA8GJ_BOL<LLO; ^RG3U+<
M[3<$R,U4-GCV4Y4_%N'3GX]_"*A\B<S3F&RZ6&RO7OC<B&S1>!&L@"6-U;!T
M&AE!BV.!]9*H@VL<UF+^O;P6\423,LSD2/[)X%SI']/8K*Y9@EC$DD)*_1!8
M0G,]4;@/7-,*ZY*K%#YY:<PU\@QT?T3U8>;T(31TL^DH*E5\3 MYI+L?;6VB
MNWY!"9M]:. %':T4NV6H>QW/[_)?;>T6(0I_UBZ'4FT=EL<@+MJ$5DO[4S)-
M5E=\37FBOBZ]Y90J7; &+\,,%I>A2K/)9?JQO5LH'TRY' =S-Y1Y?7/NJN$3
M!T<(37?*U+JM7';*9@3;<86+<XUF]3X^5D25S)\8UPJJS$G5@-D+AQ$4>%%A
M&RX%NJ,SLC6#@[&7Y:1>\!M%[[#DN;I,3>((D^"$L B9J25I&]KXQ7$$5KXG
MY%I9NJ8M.MH*+"4V,,II-K4H *DY!.I:$BLK4>IJA'#-A##$+L0 01O[+(G\
M5.Z1ZAZ[,1DTL5*F+JXT' )LJ)6%&,-_,,3@W^=JFJ3_ETYQDA^1RW4(.ESN
MZ^[YTKRJ693>TUY30[8&:MF0-<;GT$M7_>,E"!N"6 &GPQ#%N*0XVJY962?)
M&DICG&MENL49'B"SX)+;$<N@#=AONH83QT3X@T00=O6:G&8;3)<7<%>#.CR,
MDI/P)-($%U7NBF\IU5#B+KO,SWTU0H,XVT+X:7R0/ICP>QVCG.]&"M]IBM9O
M 7?IF_I9@ZCY6;O;X=&*@6^>AE469:H^!)@[3,ZDK"F/5+7&[1JTP$8E,ZK5
MS'(6.LULGHR@DJZ#<Y:#'^;QH8&I"J=L9_MZ$GI@'3MVZL6I 2L>-5DSW+.C
MPLC*(6:UGHOU4W)+\2CLKGO27_ )/7#@Z9NS,/O"#L:U3+_X:C_AO:%3ONKF
M0_=JZ27M2(^"6/5%&3= !,B:280KI>#OD#YU3?VK\#O[X=?0&RW:&XU,*'"R
MU8=+M#SP=!G5NI![3X0.7F!=ISRA!(^+QMDGLE^PWKBA6T(O12^R$B$ A^R&
MHF5UNZ]Q#OSYF-*C[-@T3>E&L ,(LS+WQCG!0O(FOJR5IF^-..9 =+[/A,S!
M&&_1"A3K)C4RB^MEIV_VSU(3*L>^"4=4@:M:'0RR;$FJZIUTI):F!XC9@*.;
M6\!*>_WZQY+?JB9[6@,MG<:!2;ONA-J)E.\/5%+LK%0+M%E<X^.^7"%JH-9J
M?7K%\IU<P/+Q_[VA[]O^N]"ZB?$">'@X./Q9O8C+;1,IM>IJM=:8H9 Z!>N9
M,;G%'2\Z9P#E3^F<JV2"5,G!BYYL9QM48#5:D*DGU3K.WM[>2)>?!&TB<NX4
M*&0].H6%]:4*>>0ADZ3H_R_O^)]A>&*T&;<^UXMXBK=X/7B=XZ3264'(U!LI
MH_GW6A@H4 #BZ'@0T\]-QF73JXU;1BH+_:QC(7O2N 8OW2?19VN[&CK>I*5?
M&;B*#NT^T_ F:ZBKG 2\[(Y(CS&YX6A(HDCP&V.-U:]J+=R<*QX3,4J]8-N"
M&W98N[,,G4;=F?J)?S=[7;=#4=29^H][>'\]@_Z<7K6Q1H\JSDYSMJ,-GATU
MP.,M?< 3<=A$H<GB_W,NKQ[L*TTA<?)Y@)9XMLOH_?LF)/U64][RX1XRI.._
M?J+7ISG@M=(@*:E'\[O9HI)&;B=*++>/X(-T-YPAW1/)MJY1$8F=,_%+JIN>
MDP5(=3[K@?U\,*34Z]J^DS-] \WW#5 "P/[S\'2]X[S]Y\IGB/Z'#YJPT./U
MG\N!'^A-M_R7'NM='.3?T*HYS0_!*3%7;P#>C)>/>G\()%URE:&-D_UO@)ET
M.4S0][^_^]^QZ7R$1O,2<VE? X("/3,\+<S!VDE#]//"@.T!LC7EX^M7?U'!
MORS5?]Z-??44I\//$)>]'&0SV6;46( #3W2_RO2$O9+_'!/+^T"C9U*H'!>7
M*&4NZXVLNN>_3BU=2[61/]%T^^R_/M$H!MR)1R=Y0C=4$B57'A@@_%!<L.0Q
M9KS5(0ST? ,4)-GKF"ZWAJ^8C5]_2<]-%0"IJE_\M+T2.'6PP@JG4UW%Q)C+
M[$BQ^5;2 O]MNI%N/Z$+:6+PQ:]3XMG'D^SG]_?DU D'PKY?7K?CZ">O_/(N
M[M?01*7W'T^QVHFJO1)-?DI]F"&-J?B)28H51!":W/J4I-"Y_"XC?O_837Y9
M/SXL5GD3T.I*6DM%7L_LD2=$AD3F<3TAFCOH^/#T(,*^&W ]@J9,EMMSX#MP
MT 7Z?M/T?=<@M6DW"^$71;H"I9J#4-O3%$P&9+>(A7^50#)IU2"/3_H1T^A'
M=(Y;C9&&YVS?B,Q'^#]%<9Q$7!Y/@<+H-<]^00-D/L_M[85.7R@>'K!\GKP3
MT7,'K_=WL^S'O=[SAE]Q?;&75.I+]3&=9<PRD9$>EL++,P,P4@O)+OM0-:R]
M =B"XPFG]J04$?<"TC]]"!3FNR>OGK^]Y6?<[[K])VW_#=!^_45FF7PKFL$\
M*[^4K#A<S?YAILRUAV8/KL*063W,4+C#W0N+2I563?UIUGF:.X/A6OZ%!SD!
MQ4AV$=.D3# &L5O8;9BP9$<KGML;B^(-0$10O*D83N"I4]%D,Z@U@G-R1; ;
M5W07?^1VH6SE6<8!55!E$"5JX^'3A!K,XL=:C^*9,>X&<IER-*M]4!<<>!=^
MK2Q<XDD?XMQO;W#4XJ)H/P8M_\GB1];.MFRO=3Y^QQ>>?E"\57[#3S,DI1>7
M3<!18H#KN%6AQ[XEN<3SZ\B6>0C:*J &&ZU3J+<BS=0>PH)Q&62,)NDJ#01+
M&];_YGSW11-:(FL3>FYD4MJ8!)NR+([LZ_C%(?L&  =^3W4]+K(BC(EZDD55
M4X^DVL.UCV+;^@Q[MFES...<$,D1L1(9?!D6!T[C9B1->%_[=?SY)08Z+Y:1
MX%"H2E]UJE/[(ZVUP-Y-BD4"P#C*7%;DFB]T3WS)*5FJ-(2CF1LAJEX].Z]E
ML<3=H7![UFG5V04>G3SCD235Y;<HPD;N$N8P9G4QR1+;X=E#_\:2&_&TJI"D
MFHG0-%O3I>JI,;S38P4&C&"YJ@P0FT%;CB9G%"F5^+8CY8EM&^BM=6%0>SEQ
MC&Q;>=6FPB*!M?MVL(X2X)\OF;0!=Z0\PH\!'P^@200 G.1$  !/FEP NGZO
MR#WX>B ?HGMKF%]=ND.F=GV)W7#V:7+3++;BQF]B%ID]>V+E0$WC[F>+@L8Q
MDE@C+>*[4N:D5)T_A2?'\EUQ+ERZK/; &[)?LBP+@8++F#BM!"RE.2C08;S
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M>0>71Q,[1 IBS]\ ^#1^  ^D(^=OPH1K!WX&FR_ 20/1A^I'_V&PJ>YI9-5
M$PM7N*,A:2!)7*Q+S3>3L9-D_D8W-7DU*\-%**N<>$98E;J.?1FOT+O:99+Z
MJ[7E[K.5Y5%AP3F7I7O?XJ[9IMD'>JY0G:1Y%.>4)]?F3W2 :Z");ID6M]JC
MF1F>APS](3LD \HU&OA )D;R0_9N__+A8>/18[CDYN966?\DT?4+:\ZF/<2M
M OVGSF'E0^8;8#OC#<#4I6TS,+]A*."==9M%RT,G47IM[=LBXX#%LP8F=(I6
M-^H>ZYB);B?_M6"VG0.W00X2>[B<>-]U>9[=%/(H.,WM[W"%SG#+JNA,+G<#
MCJ,ZX%W7<;)F%:J:-?8),PJM5F-V*6%H3(^#U7R=J72Z:U<MJ,@6>V(5JY%J
M)Y[,9$+DD[/LJ_'8B$>^ MS^8[(33:)A[Y>CD_Q^M7=6.8_W;=HIC/L"/^T*
M#.1YL=K_.#0PMRX9@7R5EKI>(S0[N*TE5M:!;YEUVF6>-)*P?0.,4J*_ >B+
MB?2J3T/5!\E>^3=\_;Y[8UX/[XH]ABL^3$ >8ZM7?*74[\YS_CE,>RBBOR &
MVTG.1_ &/<DZ)P9<KS[G9,U1P_N\XQ:%-A@QG),57[GFG&91F?7W"JEW@OPH
MFC*$G."V Y5)O,D32!X>O2X/#].X#56."B*+M$Q\NDX(00/^,;_UP&N>X/1I
M8T%B_:IT'RZ=E]A1A(+2_X.TKPR**PBWG 02""'!">ZNP=V"#>[N$ER#>R!
M@@Z#^^#N&CSH8,'=88#!?7#9O/=JZ^U6[8^M>E5=MZK_W>]VW_-]I[O/Z3_J
MMB37VNK=>'CZ6E/GKYPAZ?Z_,)F4E67D99&ASK/>YW (1(QRO+EFL$SRP#*J
MV.M,23+LTN!I//G>=V2-6410L=44\X;,V0[6^TFW9K*BIBFJT4X_S6)[/GB[
MH(W%M7$H :52DA,AL B/$B^N7=Z,H,""(HUG!V 4YY*EL6D'%F8J3UN5\^(A
MM?X<8.\P>?[I]@+0DINDA%Y6KI=TV;!%X1C_R+9:41&W8OKK_^Y 6OZ);XSR
MKK)L;(^CYA,AQ@XU*4?L-+1DV^?X<IS$;;R8#"4!#CX=D&T\+>GXF$",](:O
M"K'7^6/V2>#H1&#8GOLCEVIT$U#)I[E$GXJ%9!OXATT-T;2Q-P&NENYV+W<_
MPIRS.[;)B-EK;0G#'DL]%I/XH^[_"!5^#F)/@[&9I(NPRB)HL;\=*OUHGXXM
M=G\?Q+AG^% D'F/0==D)EN8 .R2]5W1P+[AB F'5P0ID1+M,LT,2(A-!HKRZ
M3< [!8I8,>.N<%4G-P2^B4#%O>#T7HS1J4-_@$IK<:1W* H+/&=\">*8RA A
M:J9@AX9QFU<DSS] NV60R2$SV$;+2/S8XCB0$P$@I TT>? #"?3?DQ\4>6B$
MN-O_9-P0J?K4?*$B?^<<AF!CG[7EWG729("(NP?ZHFHG$(0<8DS3653C*C">
M/;9^JP^H#:Y*8]7%GB4AH9C[]-V4G3Y6E@0;(UOX=0"TEBP(EH$SV9G?/I*M
MZSSA> Z2-^G;XFG]FS&5'.@XEL."6.>MMR[]Z2_%KJ!?C77)=?V;2/$[[XB1
M272OAT_KU:M<8#81 3\MYB 2M(3D'FF<?AD:*^+_#7@Y/B)J8#V3DO9CSH'$
M(.D\2/;^RZ9NOMM8@@!MCTVC BD95<R<O3JODYLUN%7O_HT@IO>R;JW5!]RY
M7X9@T$<]\^^/4OZ)J0ZN"*3E<9!8M0GT?#ALHSKH6JZ+V246M&(G6GH%#T)P
MT\P;EE]^]!O@9S74KQ:)""TDY*.72P$U7]X+!^'')K3T2LW0^WD!G2L-"O^R
M:%-_F+ WE;'\\Y8"$R#L-B0*WQFZ0IP?<,(X$(Q;G(]0L''IC/&F7[OGPZGR
MS@R[D/;>I*)7LR\&5G)-CV?D:F2'5>.\;1+R12E37\F\$&GV Y[*AWYI&F+T
M$'C.--7@L3 8]@<YV]_%'P3-E@7XW/O"+^ S*?%X;\8S*KZ!I(V$R&4;/8@<
M5%(W6E:XO;S"T[>DOW_2]UUZ,["CO3O;ND.05K8L8[@MJ&\[':M_<#Q#7^&D
M_/VG[K'P'04&F3\8/CU!;G(4*,MR ^EX)7F5]&;Y&"N*1=Z\$M\7;SC#.R2P
M.@">]3:);END*<JK"G.?.*)6@F0IB"V<[0N3LG#JW2"CG TC<)%S$=GU'D'(
M!Z/^KYPKTR%-2-0YOAN1UM6X$%<(7_;(%Z,&*P8VYJ>-$D@>/2U9.!71<5_B
M%A;*/_'W!%[]II*S]6$7]2;SAA_PWP7XP)8OR5I^G \G[(_O'(@UB\6:@F8P
M$J1]A)JO[X)]A:S</B:8%IOTY&03]XVH53Q91O&[@=[Q;Z:K,^?):_(:N$9^
MZ X)38XRY>OWI=S=@2T_!':\ *A01',V8H&P;I*[9W*3DLMQB' LUX0U=:G,
M748_'K^^JAJ,4&-;8M1Q%]S!P>P'B9!J__N]NDO?):7(<:I07C1%=+7M[HK+
MUZR2.SS'%S2/&(W8<'L*[!+K%3:[#Y.Z>P',?9ZZ6 )WS7[OZ%U.Q=9,>0'$
MM<R+#4ZTT5K9;%PQK<<G$7)BUA5&W&H;6#=3)+]=+"5MH4""C0^>0P^G*56H
M#_>"R+/];D'BQP <L\COH0X2<0S KT@Y$E/#V(.#9AVV3>J]O@IRMD13Q%/<
MH8?Z<W5<+ 6=,;#=29LGH3+7\F@,9@;YU;Q%YY^UI:\NS>7P2;:VG7H$@Z.4
MT%9ZL.L+=K_'BKZ>"Q]^NV.0M%+*60$475MGO]HFX\+.^0>IL4'%EU?4ZW?D
M;&[U:Y,'ZNTAFWW^T\X-R_L7AL_0=V+4E/(1-@9:C(/P+;H1QL/X?GUM<=8.
MAF[?6#DE3.#),]V*1^5X A0)HJ(!AU9W%2=<P#E>R0IG8Q3'RI+YNYX^!0FO
M0/A]J\O$%41\KS0!YEV?S<!/ K>I09M6MOBH!$L[,O,M@K=0()J"B\I\.?L8
M#<J*FYH0MO:;Q=I14T,7X)G([082+#8P* *^ Z/.)H;00P)E(2I.*"#H^K;$
MR _O!C_FZL5=)F%>[*AN'QL0YS19;$<*U@R+%_]6OV41W1TYZW<AEZ"!UMYC
M?A*X1"UZB'K'<>O)]52G%P*G>+_[0\:4[K(^&"GFJ_&]QZ8P>-'SLC0I THG
M"'81#@)MGWODDLL>ENFTU:?#58]HHX'<B<E*CD05<IN\!G*:"VD_R0,_!'@8
MHVZ=0MH,J?T?&*^V&Q:>B%4$EU=]=G:*1Q%RO*JF!;XS4L$)M..*GND^+A.3
M0=DUE-:X7Z<A;\-UB00*E-'KFTGOJ)J<ZY6+PT4,#]\V]7][FV5NJYW H!I1
MG0F\P /_C+Q.S29(S:@U.-5+"?IDK%H]]8!D(&<5/?K$,"%GQD/12L-<V)GP
MET.#00OW^AN7'')8;L+C.R 14[];BJ>MLL"JN8K=]#,^:V10JNYFX;HF<[[)
M85O52.I&?DLNC>>C4"SZL)*]\P!6\U1BC2Q<1ENQF8'VV*WTY_$'=,^M>(YS
M)*W$$0)TV6\NSRJVFU"R_!^)O/7-D[+M$TK$&GSI'4J->ILJL<1&CH[2Y'ZO
MSST78HRB'?"UT.0\C@46[QWI6J8$$#T_70)5?2O+7G\A&MCF;CGC% IC3**3
M2_YJ06HYJ4^A)"A@:SM>$[=*H3.Q=]HZ]<BT%!_SRTEZ\9R9/PW]5QU57<".
ME<P;%5O27O#&=]DX+MB<86/UPE0;4&:>:3'<+D_7H@9B(_L6>V*TFB13;DE3
M,([@-3\%%MRS3L KB 8Q7A:!=4ZU8)NC,-^.,T9+255D0V8+TS0.QQ".B \I
M4(AT]!D#6062 5O:!/[@VJ.:B]S*YB^Y-LF</27N'WC<&!SP=BC'.Y@N'U7V
MJS?4 _,Z^)/'L<MEAO>_]9T]ZEDCBZT:]Y3YR0:^ +;XRCV[ZI2SEP*A]Z)7
MB4YJ<_:>D(:3@M#+AD/CRA7-RMKZ-\N5HW5[/ A>COG2RFWQ8Y:M+15.0F.M
ML@?)"8_RKJ3&-\?*S$=N0L[ G.GJ=K*$X=*S3TPBOHOD#\GVQ GN"LBUKYU
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M%953*[%9[?Y30.7 0;/^PFRO>4LB=SJ0YWRXCBB&JB>L*)F/$_=V^"NJ0?"
M[^(!CFQ)N=;B8GC2NP:LE7B!-E2ET&0CM'<]-S6ZDXD,3KU+!K%NW(([UQT&
M71Y5(X,BDKK6.3ZP',!X^O%0%0'/"R!G1CR<4^J:QR)/!TLGO8+PNNJU?FE0
M<$RU$HA.$FL:J>TA3D-S? EZ=-\$4IAL0VLHFD;8[Y\8M0@)AUNU:>O^J11V
M.B6H9G&:'$(#A0L]A)RO5*Z\ &X#GVKT\CO7W(/4ACN4'N@.1 I%1$^+63"B
ME)G\D,ZZ @]47NV?--8],L<95DV.<U2!ZRNBC/^:Z*[1($ATJOWWQ]H8-M^_
M-ZW1Z?FVKD^0);K"&E,I2%*&]#!;U_Q1*M7ZA'9+HUA;2/YK/__M*;.[H_1Y
MPYSZPAM41_$ZSH_><J\8F4I%Y2O*#@KNF%Z)ML ?Y/?VQ:R??&9%B"XS%'*6
ME=0;B]#(_A+BL=I7R)>\IKE4K=67@YFTD8SN%92%.%8Y? -%6U ^0]=_KT,V
M^FL\V7X:Y@73;*+WUK-9CS:<O[:-210)1)7"XA*\C:#Q2/V5\WY!272Z_SA<
MIY@C^E 8/OOL?7!2)T)<JE.(2NO8P/R6[LL;*]%#2$1N\,JM6DRF0=0+(%+J
M@W-"QZG^H_[:A3<UJ+I(U@4>ZW\?Y%"S2,C_7V9H#.MJ,8B,GS-4DV@H:55\
M?ZI^Z+0/C;'<3.J6?JO/_'V17"#5K%9(HYEF$%:?;7(\/OR.\O7K\IHIECQ.
MS[_H^R7J@E#%Q1!69(["G2J[]HRHXW>LP@H?:BJ1<R5> !]G@:\)(ECI*4,^
MQ_QY(G_@7Y0V*=@JU+&:P8^^%LP/\&P32$[D]L03^U-+8DP7LMN:V/@\0HV2
M=?SZUSYNL#=;UV9&C+S87.+^T@O@G>?\$'\E=1O3+(;Y01RGXV1N7J3GH!A?
M56R#>C:=8M57/D)KI\4/9YI)F?,6BE&X,WRDUU,'!#2.M"6["Q7X3;P,J 7A
M&;DU)Z*$S0(6%HW8!\(F;\;MOF1UKR(1\Z@LD75.N3=-,1MID1('2-;.- K0
MS>N&'8VP</5EV))QV,EOD:9'NO9^#771T++TP=D2?0%X2_F=/7*&[Z1 7,L<
ME572+P7*N*OI,N+C A>0&XT2R)*:98G5JFJ01_*%2"RVW],*)L2(2LC3ZW]E
MQQGSC3IZ ;0[5'@ZCPM['O>;L0U$4MCL,F#CZ^VP?/]I/ 6^#C-&B?\4\CQ1
M,#<R8\"E_GRQVK!T;+X@V1*"JQ\/=4R4E-<]T?.AT+F=+)/[X$8D2X[F]\N@
M-AT][[^7T7)%),X%Y^OO>%#CH4K$(^YWSE+N?,  QBBG)ULRF;2A/PE!=HXE
MEQ24T^ZMQ9:MB0Q&H5^FBQHOVF@_SS3P.82)V:SH*AFIHJP_<-,Z&%F:T,[I
M?;![+-G^;(I!']UYH-5H1-RR4,;1,7.]L9]E7G;)6(S4'^3*(M=MK:=GHTK[
M2GAL3SBA3V)6R!+B<.CO5G0F*C8A5,QP*3T&,_UM9,<<%OVK65%AIF!?*&9[
MOV9PH&-*J4R(P3VTOD:I!!N?_1QLE7X>T])55]3!<U6MN6A46=W6%(*:4\T/
MW@[AA\L]G!" ^[4R:K600S$Q_,+0Q-?L&E3=G\L]*@^4^DD_KI?QS#).Y=LQ
M'BWDOC8IKWF0V=:*E:P(7Z@D42L(/F+WSM8_ &,Z8Y!>_:0XB<D4^3BU=C31
MIJ$=&&2.FSXN78J_OA#_I6YJ5Y5EV[ZGM:'F89EP(HCW>4#!"VZP&GA===+5
ML!#ZJ^ 2+W4PN6'89S,OFW/RM^D[$CYA#,5\IU8+MURL$=\27VWAF26->*'6
M\C*?8]_FPY1J>A?2]0]I=&HO@&\T%,&"5EW,M__7?LN L=[0<Y&Q:^U]4_.
MSZ=8QR31G4.VPSTB/L7]YZA#3/JY?-^^'&3I#[8[6F("8V5:MQ(P0HK!A:K4
MMP79/F9\K"2A-H]6EJ6P^)7O*  ,YVJOZ['E_L"L&V4\^WMO+&+/T(ZHW9"
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MF%;T<@T=,/N.FDF^2A%-A:K0RXW\,2*#;P.]W1I4;E?CFD]E@>.M&J>!8R\
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MG()9Z51(5 X^\#A<&\N36^Z]V[2D^B7YMZF1Q62DX"F6VF_2@;&S<R<R'G.
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M$XYU:[*@%R4$#N[_7D2U_2Z=$)&,_'L(.)WJ$%= /6;6K81:FR6?3J$>[C%
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M5UHE*IM?WC\W.;K\([35UH3YWY<E?J<8B=E;90I:G'%,@5=35>HP@:$M9PH
MX;\0'$Z/GYA'*<0!0D\T(M9"J2WTV"9NWXW=P;B451[(2.BSHJV=_)^=!!VN
M"8C]*:#82/16F\<G:^+]%3X^8(.LP'H*M3WM\7,YARL_C8J(=?XA"0UH]&RQ
MV(.O]R *Y-"3P(7C<%:8#TQ^@X"$H189$: X;@K*8"/M9JSD'[[C+6O'*U$Y
M!FL(NH<ND;IL*;ZDVJ^/D(63Q&1U@=5:9'+J@X'K>4:"[E9=2R_M5)&%.K[J
MBMVIK!_Q"!_@V2" B"3R@I\2F1$+1H&P24JG@/F$4=;/]9;= ANB1K^N=WQ4
M9.1)IYG.VB#2'Z9WS8N2NKJU>A/:=QX4ZM0"OO):O[]MTI>5?$O;^ZI#1MG=
M=\8OSL&56G:HC.T(J&0RM8Z9.UD#9,VXL]-)<\$-<0]\F1^[8?_R:<LIH#)0
M#"%5B,UZ-]3*E'K^UPTU073NC6QFDYL .M/XP,U[%MDI?RIF\^[F^1E\O?OT
MISTRN3L0F@T)M[$) [/(=SX-$M7X2]D;\)E6Z&+C;Q*Y[@"+5V7(CJA1S4F7
MT=P,XU\LL5NF\S>GC10DG5.^>0J8SA9^UDZ^V<(;?,3XY_@JG#5J 00#AB*#
M!ND62-1P&ZBJ$KRND,(X >RE1,V&DA98@G3DP$PZ@OJ$?]XQG2$X*[<<I^(X
M]\#E?VQ_3@$WBS5*[M[M&?DEV!2>\I6HAT9?NG:+22X<BE9J:^>%A+5#A5;.
M1A.\1R)4*Q@%2G)>2TVX;\K0+RMX9[CX"G/QP]#ZJ0MJ'&5:#X"XUI?T.3J^
M;#L]%:B1RJB;E_'=<L \"X&P=DO6U61LLJ=SI_[\D6YMN:+:!VT8+CHT-<,R
M+GU:!A,QO"*H&>#QHB4(\LQ]):$_K1V5YL"CW51,)4I!E"$T%2B.M"\T/S]_
MW^:R!F\4H>-LTB>6E.H.G160#Q**N$OT<@D%E!LCYVW@P?J>6O)=D[CW[.;?
ML*N]I <K5M-RC6SE)KT]GF/.:ELXH_TO$MA+WDDCEH/-=S101JM'8>VEU4VH
M2,)\!&$)'!Q>75J]\XV<%/S_K^OQ_]<C'3\R_$#:N/^YM')O#LMQ^)60\+YW
M(GH)RK-/:I23:NIR_/<O!I9DGT^]920@>3#*9W7,;.&M>0JPF2"2G<5"PR#0
MZFVJ7PU<5LQ(;LY_R%F(7_^VNG6$\_OTU.3IQKV*O?3?JT/%)M5MVOZG %_G
M4\"M2_.O<D>8G,:YW*[<GZM[3D*W[^\&+:#"H)DEJDD*!WN@CB :=&M36NLK
M-_:_F:KG)QHKS:#'N'.<DE?HAU??0A_]DI@!Z01SV'FNGE?M+ZOW3'/+B,EU
MY%*7,JF'9#BLJ*OYU]R/B>7=#B([7F5:6 XF;8Q,N!(#:A4UUQ):#>V>#=X%
MI,(===][5/;..A4!4L7=9J0D.<^+,8QY=TC]&*@T<OL:ORHNAI9-P=?O;&H@
M4O#8:A2*0B%DG0+D&4?]R11D>-; ,(["XY_B;_UV;%/BUIA&MJ$X_,+0^@MO
M3<V'5B6=(/N<Y[S2IX"7.#8N;NT8MK951Z4BF7RBQ_@^T;!^PLNTU"J$T 0V
M^:BJ?$5L5\R@3*AC>9(%%H&51[H2N\3C8)Y/G^QB_OA/IY2]!H=L?\S;F5^^
M2T&-X=8D7I=^X_IZ_;>D:7(B2_YCN](/U\<,(WPJ<D%H/ )WB:&XDS&8976\
MU-RZ+["<BS<R6;VNUYNK?;-1ZUA\U6!DNH]#;_/@VZ_Z[ ^**MRUW]EURWA%
MZZ2HVOOOK$,,\E*?^@^X&>@W_:E:6W<Y]&ZTK3=Y7JYI$AW!66@[^"8Z]:E%
MDB;@Q1^4FP(9K_C#\130#(X::H#''$#3+HE^FRVKNT]2NE#+('_\NE)YHO.5
MY$'6^1#/H) W ;'Q55Q736F2#9(3E94;VFKC:8TJA)E]VCR4EP;)UH=+BPI]
M*8]]J1_A"_K@5ZOZWJ704N9ZW]M(>5?9UG;YDO'&:](<]SP_5@U:HRNS^!*^
M;.[Y2_NT)KY[P+D-X$=5@T%9H"'*BT PF9/P1\</C%*&\N\>$% *+]> &NTI
M/43N?D6.6(ME$_//GD9E^:%3P(X=X5B70X_-*?*^\=IK@7//6Q@^63\)-.,J
MJEIB#M-R:>,C7\(LL:IL;9U 63<5\$(-""2^\X 180..0H/)^)GE5>3KXA^?
MX'[)QI?WGK'N+'UP>-/[G&_2!>N;W%VC5B'CNASUD,>.9DF/GGF'<ZZ!K<O5
MK_X*%8<.-95&X)>@(!N?:B *)_@L24,@)#CJI(6J=$1V?K];[?1U'7BS?.R'
MF+>OZY<^-IWT1M--Z5>M$_?KI^:';FANIMQTLYM)]TL?FN667!"8#)L:R,MP
M.#HT80L',+P7U8"$V2+0R_@=<. A59J]B-4>BL*2@X^@4&^_HL3!,7$%XPHN
M?I84B?%;TRV/?VEBO.ME$F.TV%*^YLHI CV[>U(]%@6:GKP/*'U\C_PP=6[*
MMX<)CVUJ2E)2:L.0DS4A/V(O!D%*4\.;JFMV"$E!^"6__;FC_*U^RVV(PC#!
MPVA82&5*_$_!V@Y.ZG95C[+6A,.F#&$^*S;&R-=6T^*C$_&*% [U+BC[<^\,
MNR*+;+$R1)ZT !I(96UJ0EC#:4C=TF08=RHC[A\,@GK*")3.I#R==?_^S\;E
MU=Q;6393PM48O^!ACA:V9T=3Z>^ 6R(/;BDX))%=TALKQA!U+ KGN<E"=$=1
MOHN]N+-X12,.3KCWN%F]&:L']LD[:&">;_[61SC\>X]%3G)$P<Z6RKY]UXN(
M*8ES+<9Q"-E30+LGNDQ,Q\+(\;+9S1\R^9@)AF2[RE7])R(GPEX/",M;I /R
M*< RBY:]HU1=8G:<61TB!,Y<TCLXUIVZ;AWD[*VN X;#<9^B/.-X!0KO]'L^
M6%@SD7]'YBMTF*]A9Z@?^OC@LJ.9D +8=P-+W*?Z=A"04&CW+IP65!78UX^:
MJY8:P>GZKN6^71VABT_Y >70*=#^<".KCZGUM5)TJL/R9,NCSAV_7C/G;+7J
M4?+ZY?4O0UQUM5*?-(&G ,FN8\HI(!P6VAFW!SC[I$T5ZP A[:$$@9<4O^LP
M5*"9^4BU7<96M>C6AJ)PX@5N]>O!K^N[QQ:BO7B5U>_HG-@9_A54-"X;T> 0
M2ONM_=G@)#3MQ$\;,UC[?XZ _M.9/V##.D90)QG%?<^=K\-X_[8JN+XQE=_=
M+^4A4PLE=+]8Y$[JA5C(/-U-)L4L7'2S"BPOQH235>JI%"-D(0Q:35C-J@4B
M":,A.[3V.UO[_6-]Q8KULR%[WP>;WRG^ZK7O&FNW;<GIOK26W3CX32B@8O(=
MLG0O6X,@/&[/4Y1^\YIUU.@-UXOET=QF[*X60< Y.B4T"L8_LQ*N\<!Z2UD9
M3S[1V#]@1%6]-O>I5)P0(^Z'"1'-GQ!+]G7N[7!'[ICQ9&.8ZVE%]HT"W7L2
ML?'4 IWK5%]O-GK#5.8H7N8PIH^Z=^TJ0H,1I434 (G,JHOQWZ(>,4X@5$@[
M5"K%.77)^;\]50>S*5&C^UA*]?E]*9M,EB98MO>U@K7KG\[A8+VT]7R61?<G
M(^:"+P_UZZ!\A7-N<1<S5H@LGI6Z%]F7?+?0[<?AT$R4#R0[BGY-*10.IX:#
MH% PR//;UX=)=N/4G4=W_'-BWGW:<X_^Q3[R58_'[N+^YW-?TJZVIV./4DN!
M"@<,XS-D&8U;#\1I7RFFGK)/;7(=3 *2?]FO&PF^8V_]JC7[/([&=T!^&@G9
MI;[YZ/\[-(1+IGP8:16]/?%Y.,LI]94)@AJ^K0K<8L#\OF'49Z^\0,I"[_'6
M,<G#7[T%RP1+I"3+GJ_H%I%D_SNFY2'.06%Z;]YTQ, Y&7RMQQ4NY-RL_%Y6
MGY;\R.-[V)QHKM;(B7)MW?N ]6>Y+8$/F LK:\JN!0E I>?/:^UL([C)OZ''
MO#4-I6N)G"G/G[7=Z/]2E#S<#[S''O7/9/EY?\TIX*'OTJ[TL$38J]_S*<_<
MFP=&%)8J*OW5O(>%!,T^F[RRE]L>-).4<XT/5=A*K%[OY=/-];9,_K%2;[L
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MIZR@+/PR\0CD0.8>C PD1!!0?[&(ZEV:6<UWG]X/D]OE0/MAYTD%M()E]"G
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MT'KJ.*WM;W84AI&0"@=],@BV%&X4O5+%/G7Y>5=&7PVZSC2UT\T\QDQ,T%Q
M5JGDS_'M!QD\9*]?7K>G;U3>9X+$YFT&]O4^2'Y=V"Q^$\<=-M%+T<T? 6:[
M>C(Z83]:"0G+/9&]PBN#\;YB]T; ?L8N+>)6)#W_@8.>CJ+C=A_(W2/DBO7O
M.>3>HXMB9>XM#I?J#E])BQCV+4FUN]VQXK0*4JJ07IQ\6OFU3)8K;L=#_]PO
M-D!%/*M24D)%4O0;;:FZ5$;^#BS@2XDA&&4W_YBK5&_RW^&+DJ+R/_%>B3S^
M3>-"62G!#5PA"MY-UQ?M-#[<-,Q0_9N-6TZP\-UQ#RQ5AVV=2$ZOC!!'CL%-
M5Q2W_((4?"AE;([YQM_Z^!F< X=#$)YV)DN0ZJ/7 4X/C_7>*IDV*C:L>;K$
MY"^<I)B4F8=ABN+XW]+E!-HG)HAB'N6VOWT^G%%O=2*(VZSB$[U<:>"AM\&G
M9BRLZ\WMJS%-&_ZIPO;/71-]<S?C8(3;U>596_$;,^V]\<9PEC;7]\CN).&!
M[XD=3"EESN#D@G/"0BG3\O2X2/W?,<A;VK&F+<YFUSF%!'\(U-VG?]<EE;0"
M)3/Z"+7,I/I/Q9X"WI.&*'JY/6G4PY(QR;$6:]F)C0#-4I\QXG6&%%\Y-@=)
MEO.-ZY%,'LMJOYX73XLP:P_Q]CQI.!3:'+EV-'#0)O?IT*BG<=0B:3!$*2!(
M[(O_+$_\R9B*C\D]P<"/&Z*#S!H+VW30S^TNV[.E1?" Z15Z[3\#C'0FMSF;
ML][21_7W[V9LJD-#@<-8>F]/O^UTRM[Z1M;'SBK5+JT!6.Z=@[ WR;6=$,N"
MNS0]$2ZV-V;P$9GZLD=.]T8:VD*)"J;67P=+3?:Z>]!]\\N65YNZ/N_0EJK\
M%:]\8@=_B[:Z>0KHYZRB=[FZ#_8?&WD3F0])D1;GL-GLI\EC5!&OQ-E]>[$U
M^,FSZ+*!P,$A*SR%J:P%NXRET"X$# KE]M](5_=>V@IE:,U'?L[8&+%-!ZJ6
MFSM-'FL^1M2BU*[",JGCRW,ZY6XOAARPW[4AI,?4*V%V],A-#0:0#RP,@HK=
M T[QM)4F:S#BD*'AK,0CT@=MG]64*2?GG*REZZR/O=7]+%^)37J'!SIF_>12
MW4N7%?ME+$47\&BD/C9/I+3I%"#@%C*7WJ;"'=Z\0 O*? '%^"Y0=JC*!.R"
MOS;USA[?II2I65CAVHQ39,9)P15&.>.\HXP?4P^LGNPM+O YO71<-Q%5U%/D
M8?>O*^XSYY@<2'+^RH[J$6[NH[834!.HKB1_?QK24YOT((0Q2Z^\VY177KS9
M?%GHQ=^/<LYXHUM"NSCU#:@DCX@]M4;IMKON<ANO(TJ3_P #'V^LU*($;D-M
MB M!^R0B_6A2$*0=&W44M(/&H4)KK*K&RR#I_60&+1&:H6ZJ=^I@88AO9P^S
M0(\I*A3N0<,[8*K<YT2;VMSJ/M^V/LCWV.5[]@>E+W] P.)/3N!@BB,4>3TX
M#4O<W\AX^8KS^JOS/,QN$=EN,;=A>QE33LQ>]4(VM(M7/Y3:G.0,^H-/_B>;
M)B5-M"SY.KG:8^R9*R/XL<#Y7N-S%POV =WZ7A%]-?.U71VW#?1@KV)#L>B,
M]WM>.L8N[827,GGOSBM),1%Z#7/"/;Z3VPMZ=^:5A9W0L$;?]$OUFE5?35HU
MHM>@J<B*BV3':V;(^"G^7/CR4@H_A3XGFV*P^Z;>R"\(U'9T"K"QAK?!H9(?
M!T,+#N\=!8>UJQ$*-Q1G-AI)$G=6K%5YW,8S,KD"FJX5-^*]^4.TA^JWM%5Q
M;<5:<TV56Q;C)&XL]/O_)O,*$QPV1T16Z_YLLIM@WHD^WTZ<'*3;>, O[97#
M+*T382!BSG1!XD(SW-U@.::HRI9X<_7[\655#H$,Y6"D OWV20@%13^/TB6]
M@D213L)]&-&8)0]IC7+S0E2 [V+N<9_1P(LB@721Y? 0HWC_3</,PU!J><C<
M8?76F6OK#0: MZ'5C*OHIF9^!$B"E7-)"=:.1R>%6[.BU @IZ5JY"/W=R@+3
ML)>DD1N/'Q5-DNM35MS+[PO--LC7/)[K<VZ1;A/19U6X*@K"];FQ._2CBSMX
M.L@4MHU_H3N$I$#2'KZ/^XB47?Z*%M:.C:"<Z;NQ+2A%(XL"J5J.C+I7W]?K
M5;!A/&55)UM5R$N8+TJ4OIUI.;^6UIAO[-C\)4S4H&3\8[]%0NK +9?/8-H/
MF^K]A25RPG\R =)E%E5#UY.A?JZQKTB5R35\RDY/!K6%C=W0(X K/KORD_\,
M.=RJO=[]&W_VJ6B02;URKYE 66)GK#)AY7U:-"U4=."V+T.--49!]!^L?(B-
M><Y^[2N'R+E%+9VDLB,75'IB]9/VAHU"A[(.S4L-T<]_MP@AZ"<01D?'838P
M8'C2/4(&F88@G0+"X'Z;_W/3.Y%@06NJ/ 54$D\!>DO.0:J2UH&M?E6I,#_2
M7D/9BO7[YW(L<H,KF"_%T1_V(@<J3 0O<MR?W(=H8=MUV$V;_PGD>:;SZ2NJ
MQ_Y==D$YD.%*T!K*BH#OLL8BQ.%HAT(.'-P];&\X\B0(9T@MEWUA=2H=EQCC
M&5[FN_N.YE1NNX.H;$[E>@^TOOBJW+]LQ+N6Q;I -'BFH4_8E/VXSNM&S<[6
M>B">[$] ,V(7P?[$%)HW*\IAC_^//QK5A2ZC)/P%WUFI@?OC7.!75H>S?I!:
M$Y1-6,'^C^Q--UX<3 H:'K[W)FZN?A2KN7_PM<C^[;#KAT2);N.1Y6A< V5Z
M$@0)MZ2U2UK?_^X[TT>FMA#2\%@(,C0L#"\3/#L0L/*HR$9K.?$K7?_R( O[
M+VO5#^\@KT6$/?@U-(LK-]",RXUN-V/>?7T2/_/+G^Q7N%E34,O^9VMGEXD_
M$GI.*8C&.+$-Q46=@^RB,OEG(HC4-BG2,Q?U.O5+8GP\#C"WWG@FQ-?'O9B+
MB^CD!%GQ2J\BS.Y,H*',]!\W'0]O*7Q%9=/-)$=67A#2/[ /8S1BFBEB';8A
MY]NOK-'CSU6>O"3N]B0-K$[7.3$SDMDFI,\FHTS?<#:733Q/&BJW@L=/UJAW
MG%OR4@!(R03E33[)=^U7WYX",-&$B,U0ET1$W$$0C>F*9&?:7Q&ECWV3(70^
MMA9)L)HE G4/L^OC_&/?_>-X(;#F[JSOEPF!Y1QX 9)=2ML: @IF7<Y40=P&
M"]&&T*YPAFMZ=ZX@CBRH(2?EE2=5+[V:(W.?%(I>VRY^"GYC4<_:#&\#B&/3
M2-C^0ZA+FTY)F9AQ0)_#WQZ1J(74$U*H')M,]]>OA]HWBEYEML4*YI&%=&3W
M7B84V(C&3L?\2YSXM.[+^ O]:U/F<Y#K$(MM&E^?HJ(<[[!9FE-Z=--44-/,
M\.T9+ER._B%^]"2@Y.OPB9HXU]C=5+W'_=OOBD'7%F???E$-8=X2=,R&S8*1
MK.T)U7M%5E:G@(KZV[.-,=KE=_N9G5+6IAYKBD*G2Z$W%_M8H2P<HK>V+=ZP
M(I_,D[!& 2ST+ +*5\\?L 1=[L!?T0^SJZG:?G!.L-%07/&5T1:+A?*%N6$>
MRQJ(M&"8W#G[,+9Z+_0I@..&P#E&)#B"=&::2DL'SU86U#&&]PT,T45C)>)D
M'&(HB,C@F'19!95ZC;XK[")\>[>5*IS_5N[ETQY.I[QO-UIN.O;5$]+C>!2=
M/'S53]@V70.#%+V^N8W5UR NGZ#S2"HFZU3[J7^G ./1=-HU]'?2JF)Z;_&%
M3P]!AD5CZ\:-Z0H8"8'B,<2-"W7%!0/@T0;*1I4^G+=NO+XQNP^X0'MW"O#6
M(&0E!S+.HV#H&30W0C_\7%AV;J5\26-L\F*.N4QFZIIIR7C_<'N+Q!VW:>.W
M9WRJ9=I466Q.'M]/R2:4P0JW7GX/2-*#5YU%[_-XF5'0=N.Y=JDBP<45N@>5
MFUH]A9J\R7_BE/N@WI[9#,7NXA*W%!ZG"9#0N%Y[1H:(U843I1.H]7R,)\L3
MIZP'FY<N+T-QSQC73/L^NS@NNM>E:D5D*(KL"%I5=*G_P/U^L_U;!-:CK'RM
M?L-C8N;(A%19:@[[Y(M&*L%IX=5;2/VPPV4T\6C9B+'BY6?B-=,=GX.]:3,V
M@*QM6*>PY4\ZM_-R0^;)8IE]DXF\>,.A&7_/AD]](U=1O[?F4PQH\^@3V-\^
M_&1"$%2:ZN\'YG_=MF=]>:SU6)K?5NRXH5M8R^U9O4JQZL22@=7KW4<'=[35
M.(1S 1M>X<&-.,UG\_5EBK 4/(K[!>0,[*F:6.,]$I:0*<DO]5_&-)3\7'_>
M#X;A">Y2+(A.7:FIW.M7QY53!56MU]1YO^"'B]RT+![K0H@-+EFJ367RJZ2"
M.:^_2T"G7A4 A8HF[9R< B0M,\'E,EZQO[_'/-_;D&S70SC=GO[SVOWR^380
M-V$IP,/\%" 6^*FE<L."EGGBH74T'MLG1'B[!ZJ>^+NQFL'X?[<?_U]Y<+X%
M;GB_SCA<C1M.U2^@<%W-?'7)]+"Q/3DQ(JZX/[(_K4C(C3/^NYMW;7M;[RD@
M6:??/%G-U4,0'$@Y#B;M T\!$F!6FW#871L!TB[M[#69BL42Y^6?V;*@;V.V
MKJ-:-&&SQ?=LF/S-)VBO*D,]@L]H_Q10C3IC*=U!$"SS(_#'#R1L (L;#4;(
M<V_-6L5_J-#.2TY-NNE4\R0Y=MY-(J5V*/%;[=3<*> !EX^.C[=;D:3KR%ZQ
MQQGI1:'+\*,TETD@'!R\"P9E(M52 Q>H;>T@4/56MO-Z\3=LOG+8 +KTG/&L
MMX;!B+V;M[ (G0X[Q++U;:_L)=?Z)S#U5#J;B+TD(R]%AB6+"H[NH%\+&D+H
M@D.AH1W"MR-0:?,A5EES.VB'L,.]+<^( ,+)U&;N8$N\E>&W&06X9)E)YBF@
M<_-JA9: 4W,FZ'VRZA]V^ZL]_.:P+96!A)=:K>,-U=-7YIMLO'%M>&34/F7I
M%&"9:A50<MN7\,<KPTQU-H!@FC'MUHAK$$=S6^]%WV$>'VTH#]8VJMP*&6]H
MPW,:4L(K_^VG/[3^R"Z[MBRLNOCW%)!D.^4JT']/1YN3\VJ?GSZ1;WP(_Z[*
MZ*J;>L5KAN0/58T-FK7@,&M:N V"F-!1<[ ;;K-!]8.2YJ]NO,J*&]"H6BFL
M,'P5UU04^S'IJGACEH#@A^Z?5BB$T1LV.B#)!W3E=Z&INEA([P=XG>&,C%_.
M6W]\Q#Z)1$!C$3 0*6G.(C6<;I>&A&H0X9Q.*5.NOM->,;>\+M=TB1>7F+G5
MKUZIQ[F./)WQ*E!4O1J]*JQ?_X%H/MYPAC2K_ZDY@_;Y";(A6XACTQ+1AI:6
M%^X5HK=-[2](F3XYKP]3E[,;ZLVYM]23,W1/4._6M0IP?_NF6_?)MSDI9GKL
M +^WPE+P6&G?GY\/\VR\0F.Z9 <_QM3IC-4S1*LWU'[&CF1E9U1BBO5B[5AL
MR!R93L7:(YLL(HU#CQ-MOHAJ(#67PO@1Z(D]Z:MT@),@JCP$^F9GE^R+LAK(
M/OY2KAGUV>3N/Z7("[(9"QMX<Y>Y#^FK^ZJ%$UQRW,OA'[L$A_72O,::-WLV
M.J4R1K=79W("0(D8/ Z+3:-0:-^Q5_I(Q-55_#)E@43 ]2K_B9IHLE$Z_-3L
M\Y%HBA&5J="]?(6CYZ&YGZ@KKC-@J#PC.Y8Y)XOC9W:@"[ZE@MH0W&?/^4T0
MV/IO5?!8H&#R;+533@*IW\_@ KV#L6D%1Y&H4(E0EB *91?LW*>JUSVYV)43
M!0Z2_SHS$YDEU5CR9\2T)%\UM?(_.;LE^4Y^< SF>LPL=TQ.4!.7+ALZ*OL<
M:XD!:UG M%S3BLA:%[H.C%7)KU!39VQ/9W^Z/2Z<"Q[XU9COI77KQ2?#!P+E
M6FY-C@P\.CH]2>D80@J:N+^_0\)XRR^@#D\!49V'$"66H)].^@DD@83%;-[7
M%O#8W/E)(DRF31Y766XS;3H]DEYL/O\[O=)'Z1T!M[W/CZC&4PC@"/PV.?04
M -H_.,"JPS/K-/9. 2)^WSY7UWZJ[NYL%QNXJ-$QXOL@%;0T/'-T-&UX_IU/
MY\XI@,=+7*8=4>M*[KQT3MG^.N(['?@A(YI_/JIS;Z?7\>_S>S>X(P,%@A@C
M2Q'6"@P(&Q@JK_='\=RM1*W[,N@A701U4L)+42>2KBVTN+>#/)(K5K]EH3__
M[(_PVOA!(H1P"M#@ZPCVQ1)6T9!V&TXZYOTEUHDFTN]+ Z'K"A9]2@;+OS7T
MBN,^]XDTM[AT>N,NW0,V9[M7UALK'*TG?_V<?.=G3(K=GAO&>2B3Z_C'PQ4E
M## OV!^+ D$9YY&LJ+_9"O@.B/P>.8@"!_ON4OV/UZW9DS+%XC85A 6X$)5H
M5.EO\"E@1\2\?:52I;]^BB$R<8NBS'Z%7?%Z&XV_FX?9055^?V=W.Q"_!@^E
M@;HP5[DB2 MAH(E=H/PA&&2Y\#W]+Q)AOW?(6[WW_%W$O3O81R%U#'&V3O.*
MI2J3NR[P+@W/WO;W*350DS+,^N'CXQ0WG_T1RLAF+GKF.&3%=C>0A)] D6DV
MN(3]"(LBHS*L'M2HO&,\OQ;C;A[PU%?E\9HY3+<8,:=P1ZH?).3%;VY4KC_>
M((*^T=9,?&\A %!BY":XF ]-<^#?ZW@UIHM[F-=_^ ^4%5=JSZ5^*%:<&ZW<
M.H. MC,M6YN&M'Y4O*/TL'KOT8"$VU!IQ0A+3[4-](^PQ^A+(>SLR<E\]SO0
M_(F'3=A8FZ#B?&^;,@,K:) &6@L\6**2.E*U""CK0,A\-2=KEH7!WPS_>47'
M.^_$YQ-]0J@.]4W/=BK#0^:G$ZD>-G.')Z$^)[9?$&!6+))Q&8OJ^K-$UX>?
M4((&_8RNLNML$>=<:6?;-G:]_HN(QWN;.=*K-^2E>YP"+DK\#,W6F3@%1!^0
M,+1FK.\"ZQ[^[G?'_YS%R <5O0QVX2^<;)54R06V&92?+RPNPJA5>RGZ'D1?
MOM_-PY)Y1T0XZ%RO^N/( 4*_5H9 H!C$0*R^49K1IRZLF-)HP?<Y79BOV>7]
M6I,=K&G2T7A8NHGS=M\O#BYV[*KVA4XE=@NQ;!ZU:M[I?'NX>)^5N+0+6CGZ
M'F\0Z80,JH9M;.42=<M4GWZ1C7_LZ<1L\[FC>_QOC/D!L?))U[GNP."@#:)V
M:&*-XG4UXL3<<;_O,K72?6Z*O_>5Y?]FUD#D69-(<MKH[R#G;,35VB]MBN>D
MM!8U7!/Y6#_5VT MN+R6Y/,;R]5/-$_NF6M/W;UOSUZ_FAZ*X4Z&N-SWQ5 0
MPR=AUF2"189'U<!K5^0EY2.67[(BG.R#<5=:MPU*LG3+I7HS[EEXP="C*M63
M*ROF:JW^>_;7^V6;XETL,*FL3?PH7@H*6@7V7]WEY*8G].UQ!^ULH?^NLX)?
MA%)<RG_X#GZA]K=S7;K [Y,G8POHG]+E]IKT++YP3_>1B)R_6&-I_X/Q49V$
MII)(3F^OY">W'&7Z[P]VT.-$2K\W'\DI5E6?2QC1A,>4<\C"<XYL?L>%%4A5
M4D5LZB_7S57"*XI9N,<^RF;M9D><O^+X_5HGV)]"53H%X![X;BK!3P&LU7LT
M,S5(]F'5M[*PMBXWPY3V@@N:\-L01>^A0988W9%#.MM1Z[QE*S;ORZ/1EG?.
M(XZ'-J1T<6_OWZF^[I#03)\<= 9$[8/T^)4S5!![H[6W0VT!AV+!QZ< \H\?
MY)#6 &"?IT7%'O+CC(%J?D$1K\@Q)( ?(X,8',JIF^H5;:,NIB9N/!WS?B3I
M? IH3J_AU24Z%;$.1*PN16 I\/"R/0PX)!4FA(9 6<+"(8Q+2O[YA$\3+7)-
MXNJ+IDNW;*MX9]PLQT\!7DV:,=/MTA5*]G6Y-U\\K:H."7C76%X[/&U>G]5<
M+!<MQ+N#K::P"N$F.BC^>P3!(%('O@-/7%="+\((>6UXW &G=_C(IZ"K5X,W
M=XQ;S+1-3 =ECI;= QIM=,T]7WK(> $7[[M\Z(J\^*(3=*$SYWBY^"U=[)SQ
M 14!A:&J4PC84CR)GN>,"]&E$_OX.R@(7$\A_7?$3?%IGN T6W>5?YRKS_M_
MO<O9\UQ8F_%Y/+6H[NT>%B'_:/6%D</Z%=&'W@5-73G^C_\]^,]%HAJ+2C^R
MDWW ;$<AI/T]T, Q4$8[?=C5"OC0<(\KW1W/52_7<,,R^YS9Y=59'Z^BHICC
M*J;%AN+P*<$KC\[,TK1L_99Y E)E!YN2C^54(#Q:,U :S]O,O'TV2;JK]^O-
M-)F>>8RUOIT>,*C0-!'@'\6M]TTL"N3&(GVGC']%"%,7_+B2J1>=NOF4SD7+
M6<L?$-;"65'T!!)$ [/"@-SZ"#T. B&J!1"EI83.BGUDW\@I(/U=W+62ETSO
MWO:5ZJIV6:S\_7O^Q4^.Q3T91]_"^$<^693Y.U?D\L$DK.+F.+Y*'":$N;2Z
M"X2X((1P?TZ42;WV*O3;I"TB@8BN'L"V UO6[J5/-[PF7"\WS"QNE[9*Y-T@
M!L^E"<\PWS9KSP^W.7"<%*\\!1P4'H\WG;@S\6[[#\-XPSC/AX!^@8DCEAF&
M$CL"/8:JR.N_XIN&N#D_I1E:^"9MVO@M-C<&W'N:RO#R$^Y"W>/A3_$*D9R@
M!YPWA"_;GBB%VU2O^V,V4&N,\R+@_L.?;O"W$R*I./-XB6!>,SE"\5_\[>0$
M@2_[XV994X?EXQ_#XQTCE^T^>GL_Z0'(U(W6"1P\1\+#HG"4;6@VACY2 PA&
ME:*XV4X!_-O;C,S=(3RX2N4'(*_Z:3%;DK)YU1A]S>#-^X+!<G:_LFSOWY,E
M6#%)<;]GAEV8R[5KNRQZ6W_&K4U(YI"PC*:03P$VT*X'X=Q!D.^48T0I:2F$
M<NR(1[80<NR6?!2FVQ[_K+PAI,B=*)%OMFY I"9HR K@HV[H&=S4;,[W6OCC
M& ?/U0@X!4R)3ZZD7IP_$<I[&:-#<N@$LY9"I?'HE']*'?N'V,?6@6":C02<
M&H+B!F5B([))_^887Y(FK#\L&_T2V_@<T_]97ZX_BV/""AS+%9?)*3J=//"%
MZLYAK-ZZ6>AT0<;J^[%8H\YD,(K[%! Z\"U)X7!G;V>+L$-)^/)*@N!:L%>3
M]U$?(OSRU?-JN2Z6:M^OFRRP#9B[IDRY9Y;,A[I^C^/QB1).GN%Q7)_JT%+4
M42 E#'%,6?+%[,H3L!/S"!\?D&08G#QY^U#O?NNZ\1],?*38YQ=+187,0:RB
M(H1HS\BW\)7Z?$E[$6W5]"+^D..'AW)O3P%=UFT=E*,%/[A2:%@HHFN"B-08
M/5Y)@2NYXC0Z+.&,7C<<0+AY#GH4NKV2INEM9<+;=I&67.GF>=.K+EU<DK?2
M2^L^X%[2G1">B#W473!2H[0Q1'2'UE[MLT>8[XT'!AHHYXH(/%U /WFG1<@S
M^FS[].>5]&0#]>\K(S/\25W>8%*Y:?*,J^%8FY#%W!,GI&N(RU<EMC6N&U5A
MN8%12S2'BH%30$+/TZS4A%, F/CY!>YGF.KS)U-\W0MEW"[,>783O.X-L\+:
ME&N.]?=]"S4%@GVI"*JS$#82*J%)1MFHA@:'!%."^@FE9X+W[YDJF">= HXQ
M'>#@2"AJCT9KN>M[^^:)W:8E(KV:8#?MS:<Y&3:?6$I53)W)U#&2W-J82^VN
M]P02M9ZA3P'YL(L(XA89MT]]$0B%V@ +L8/^NP0RB#%AWRAAX+]./->ZO4+S
M-:UO\/M^(<N%TLO7!3?'"KBU95X6]YOWT9TS<I_[,<;UM,RPU7-2[1J9P;(H
M6J3<SA' E8@!MO.R'H>#.Q')2G$+9*H"J)"PG'/%M/Q9V0V,>:(^K_#MV5?R
MKI^?!ZX8=M@"^(.],CA];![-]S8<RA/C+;"MQ=^/D\"+XY\'2:C_W9*^H\]$
M^?XE%[DFDRU__@D/4Z92O@$4G[IF<6>&3N(:GR/GM8P(M<QWF9I2+Y8>M15G
MJS#XK]O,'&P<.0+EP920E<=DYA_AS_;/;Q5:7O1YM<,GU+(W+')E]-GB>N14
M^OF'8T36C+5QF/RJ]N?JHYG+'CZ7;&17AYT'O-C])#0<-2 : VE$+'XI56,T
M+-3YHO(V_(05C.A E1X2<')_,W/NE*#LQN?M#H:(DE+UK;A?\OGB3>:^7(;<
M7MT^VJI#E<5:<Q_R_Z?FLH?Q'^:M>WUE3?]1F^#3T=60Y[F&/T;#!?4<7F$J
M'[4WA!_<$+PH:C,QV=Z2WXQJ,)^?J<% 5*A0[B[8C2'%+&!:6X#VC_AWGU#6
MM;O#IX!SAJ-CT\'6772*6:VY15(+BW=O!1-_/Z^$>>R[[_2"C<(_[-6-2(-W
MM1:.X70D-+!=4@U=C4+:8=_<[-S!(VQ0GW>(6$@>J^=<,$@^J:SNP4H=7887
M4X&<:V%ES1VUH![(NJRCWW7BQR<;RV6X>/.Q>W;2%FE(X;K1:8UN9#AN1LJ@
M P1%$6=H?CJ8P3K(O[QRU+YK(U]U0[*0Q?D)YMCD.<RYL%;_Q(UBK;'U6@0C
MU"P=%S(3G!:9BGBHMZ'G=5)?7* ;27<27A7DU6I=C'_TNH#(\XKMQ2'+@_$*
MRU'K52NV\_TS9*(8_2,-CZ'KR3'<7(/J;_DZ+RYN&BQN>M_P8??+C:$3DC^P
M0H^> H 09+0O <T;'$+&2@'N:*" >90PQAD<]@TTF=OJ4<'Z)3K_#\R+][[Z
M7K);$!N-.X2NB 1;3T]^K:V6V_G95I)Y"O@V<$?P^^UI+7Q;0S.QA;UT DN?
M#$.&4GP7_-$XBG_R]5WH0I(\87M_.[P]81++<6Q*'JE*"464A*7'JV\76<8W
M7[SHL#3:W(%\Y*5WB;OWT[Q:15+)4P==#?G,T0G"E =<QX<5&+CD2SV!HK 3
MNX.=X#>ANTHG&O3S.P>'9,*O?8OEVSDK8Q(]M^7&^%4SQH([2%ISHZT]V:,"
M4DSSAY4--VU=[2:/QAO?PE(;?-S(QTXP4/7G/9 T9>?W+7_T]@'YVBD "JNR
M]??[YM0[Y[91,)X1RV5N4BG"<L?<\$8E\<1+=/P_Y1UB!::6OX/^%- -'756
M^LZVJ0 Z:MK#*TD'LE-F2S^T72VM+X[<]N]H.D,K#GR%?<%AEA=TR_RVI1M/
MVRF@,)IX"OB)"7<@@:K"$;M]:FL0:]3\ZBE (;"H,"HS*3DNQ4D W<]@[-M5
M35@/E7[^PM[L&;J7-O$\P/59+RWL1GM"EY*2_]7@AT-"F(P]Q65]TC1Y-?ZX
MG?UQ[<3Z<"+1?6[H+:-M)907KT?\*Z)?8F&-J_3R+@LQ_-!KI#,Q,MG.,7SW
M5\E+9NL.Q0I'W>G?HG4]+XY$CX<-/+LV'D3JZ/T;Y[>QU^N+$V#OK1]-]KDK
M;Z<JG^B,BDU#;Y_!, R-R A26-J&_[ FS* FL*)5P2N<,PHG#K/T.*\,FN'#
MDG]Y21.^'Y*_6#7O?^SI&KAI><N<82DW/2=A\,^;2^?<BX696>?<(A]S#RWF
M7$+7UJ(\.I!:U#";3%3H 7W$UH+_P@DD=&<--C S$Y6^-H^#J[=PQ!.5$)\.
MXV[)DUOW[T)V1[4K9+-GKO$G_%5CNF$5)Q7OQ<M"?F=<SG=2"-DM2&UPC8A"
M-Y7N0N8'PR6D- GS%#(0HH'@/VF33E_D%@@N4[6L7N.>N:8];) <;^3X_J+^
M6,-'7/[(Z'!=Y=9?3T&NYP6/=G<M S_4;8\ ]@7"N,F4X"!JX"ZTY++6$B"0
M1""@/Y\$+_=[%@@>X/Q+%6]8?6"[YR#>-,FS\<SN>;"^AUVS=OUX_R1=>L'5
M2B^6&R7)E5[M[7@)P$(D&&7#Z]M).8&JW=\32MD@DVE0+&X'K\3[ M+3%VPC
M4?C;WZ4]HOR&Y5OO-K-<NW<*@5D?8F+X'/XDFDDVG (\Y;ATM!D*8RV"M9/5
M4(_F@@B?^;?Y1^%!M##XR2F &^-3QCH:N3/@;77FKO[T?J$*++,&O-Y,Q4GU
MY-\Y/T(^.@5@>$!7^1]\BK8,(_QF,(&\S!K@>P1K'1E:BU$[$S>2*V *' ;*
M7$;Z4TDX9R)/*V%@@[T=[O.94R1L15^I.B:F3L2FP?]+PN986P.YGD"ZPU!)
M4W+[Q..F+:5R(J%"ZB,=G6FZO!B@ AXW<P1G_<CYR0'!IY.C)F+8=$;"6S;V
MUZI/C,_B8/<L#*"@K7"B^9Q3!P2%83LZI\4+RMPF.P/G%D P\#'*!T )(JQ(
M+9)#(E[E_IH[UZ?"X<W+U'<GY5Z(*X[H>Z?7M1.9C@ Z.MVW3.WS-*Y3MW1^
M']"SBICEB3$BYT8"@*78)B1<HQKL!XU%H>J3M';Z@%2: Q%=AD<L^(]8.R";
M_WL$QT74Z+YU#U3#Q\W]=:X?%X-1-7\P=:OW^3'T80[#33G4VR;@X9/2/ O7
M9W,_BT\!]^)P,/ATRK]P29_J:LC\/.IOQ/9:6/@$CN)+(_M+28/_=[?E20EL
M?E]/*N_;-+:UYHE3L&6\R],E5Q_;DF5VE<"G(=L[TF3&@,/',AU.>TT\9\J<
M]<K,B*YO88QD'>!-4N%<81HH1F#A3)_$;L1%_EUTRN=X]?T33W3C:+\.Y05!
ME!3E-;)FJF*\B7D)#]NP[D=T*'UA1U^NG=&E(C!GT8Z:P  +A^ LMM>#&,)!
M?BHTRV _,!#>ZUXMO*>AE%/VU6X94K]8=:&176<_*=_W6L0<4;]Z>22FYAFW
M2?Q;(8',IA+M/,3*3JW0CUBFR[N/@R0J,8> $S@K?HMVM'$*F-;<P:91OX>V
MG022G1X>A(\E90Y^R8CG[D%6_GDNQ?3!S$&A2:]H>C6RW$FF(_V]R7BB?AQL
MZW=9%-#*^Z*)O_![IOJIQ[$<3Q2R[X@RMH.#C\-"TVC(\*A82"GB+[7Y+&3:
MPK4P6^I6\NOSA4H/31SRS8+_+C9@@K@>%*LU#,A[\NO,^L;>$;CM^L]LIKNE
M+D.A*&TW-._^WF*QW+#N/P!O:CAN?VM_?S#R\RXC@?2?[0OCE_\K%W>'UUC"
MG3\>OY_T]_-*70I_\M4_Y)?OY?K=:;_O(%!9#T@X6DA[+M?>6LY:9A'"/O*:
MM4$D6/OA3FJJ GYTAX*?SR/9*F%+H3"C!7]"U,D/M7MF_F_.U[VDIW__?_'V
M[O%,_^__^*22#I2.PN8L$:&$9BMD3A&B'**<(B&GL#:KR*$P9Q&6T)(TA*$8
M*2.'8;)"#FTLS6F;L;'-S^O]^7S>M^_O]OGO]WO_?O]<M^?M^<?V?%Z/Z[I?
MU_WQN*[K68NQ5W[CYW+;)[-.H3YS[;<52N-;T.L!;-'H^*A,D,S$4#SCPJ=E
MRV6[8@,^*H_00^GJHA7#'H/Y) ()#5Y'A]GA&JP@=U?BZ1@C_N5UE9,&4J,V
M.VHEV?I#FDZOQ$V71+!R$P4WI[NL+B?K>(8P@*-2JR,'OU;3BL$L &>%LTJE
M"-#XAQ(6M'LPM38F/X:*[E@&LVG,XOPCU_0Y>2+IX]LK]2(D\+;9:<<M&^IK
MO8M5M@-6D\67$@$UPW18:%:I%=G<S.[+)VD+_PQWJWN]@HO4]O4-T/OHOXUW
M;!-#ZNS?]<W+'#9JUW$IDD1!-:T^6T!E _TGR+B6HOU&JSVC/-/Y"OP+AQ>A
M)\=9L;>YA6F09ZP5.GE]@]\()"A\0%D)W^;M3DM"U/DC+7H=NAS?8UW)8:EZ
M-^,H?+R@ZF?DG3-7^0N>:U"I<RV5%KTMCLM0Z(#:&)K3&[,QA9'=0.V'OC1L
ME4Z ;WE_!C)/=NQR4I34H.C=/"6,+TVEL_ "M4%D;_,0I\Y@:+4GR?5:57G
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MQ<L-O*H)CH0#5;?)^WU.CDO9!M34SRJK4XZX6;5]?Y^*T9##F.AILH559%7
MB9'ZJD!/Z1F,>5AT9TSERA;A:UA?__B[H/ZS\Y/K.?-KM]?G!D8#K&N^PZLR
MOX[FIYQ6VH'0N[;']$UWT3'-+/-VD+:O",^_0_JIC"LFCY'2@59>EXIM;9-
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M3JH_/\$88UTUHEUO>Z%6:?RA3-S*H5318]>9,QI*5_O/\,(?)8N\<F9UWS$
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MPEG>KZ/WNO5N"ZFFFX EB40NU+>&L/:D+A=%SVCG@::SQ@VI&:0>CD"O_(I
MYEM(2<3<E2I.-#?-\8[11[\L_>^>/TRVJZ;_: BW].=('A75#0SS^OP\O.^E
MX.O1!@K6+?K^#@OJ7\,5H2<C_=A^.Z4GX(.D'L//'_>9V^95XHSKKFC5P#\X
M5P9WW=G8)P/HUKM_W5_Q*SRFKCNE]\^\=<"?-V(%=W]V.YE_UBVYD7TSVX#'
M A^<R^JB9K3SN4*HYD;? CA6_XN<B6E%^-0"K/O\7KE[+^)%]>QZ:NWFFHXD
M?<>\XBB40M>,=[[.-.GE'=Y7(8@%WXN%<;V;8K;>:SV6T&"9__]T^,;)/&QT
MU,V%NTY*/#0R][?]("/[$I:;Q!MZ6GB3-/@CT'=]X?/S.^Y[3*7Z.U4MVXKN
M?E6_/&?AX!%+\)PWORB[P>4A480I&)[:YUN%/!FCH?+6NX03W#&HUN4\$O L
M&^<<C_PJ& NUN(H0<48B>YPI:UE!.O_4/"\A^Q;<QMES*RN"6$.Y4E[<%O&?
M3 -'4S658?&?&#N)TZF)A&K<$P2DF#CBL)A=A4".FD:I=MJ2M^B#G#)2R9.Q
M,(%O">IFT[:0&8-;)?KSPOF$]*G;MT-ZTZLEY$</]U,\P??K'LD4*WPLA$>5
M+7F&SW;'5LV<=UYCXY6T=4+4-LC!Y>='HQ30V#2(N^3*5@+2=<*X"83C\A.I
MA8D\H@G=R!0I=72UQ-5V9:;A< <V<&]M$6[A_@7:KDHG%\L@:/H3%P7ZR^L\
MRL)D_@B^I5&,3)E9FN/S^(T\N$]8#X.&V&(BDZIW?C5+#,O/F#TG8VI/2OAB
M^C6^(=2BJO3]?79>O- -F%TK>V6N^>&"(R;<2(VM3_5_;"  +7%G;\91Q^%H
MRFI_7\;_/?'H-5S_Q;7'70H%"&1(\J@'C;RW1EX^#ZGQ_,Q?V@E'U/W_%OYR
M]3V/8'>^S]'VQ>Y;/;0)8*587>RL3EP(^8AE"$+7!;&H#@IX%FGLXU$;*@QP
M]\\MMCG5L+1;W=5YU5#YZ"UP5?8$!]>DF3TVC:_BHUBEUJ-159N &&V@"%"<
MFL7@(U$@^[DYQO/3'"5*6FPL!H*(!292*&?,/[L]E/T2N.%F?0BYT.F,F\..
M1_:=WUJR$*KUJ%N(U40]JTH%.L$I6U+Y5 SQZ.#0V R^@/O53I3.YBV+4%EB
MDV-0_Z.;@/LV!X1+V<WK]W%K!.ZYJL86!&,3,&S2"F5N IB\KD6E8;X L0'R
M0&&Q9#%\&@Q')L["\)@%>C_\/ANQ.Q"AEGNI!(2>+9$^48<D! ^ML X;_6L2
M&7QR-C.<3A<LT5''-P&N1&8OA5_*8=#5<8W@_)\A1=!T.+;GH-.;V$U 9^;R
M=I/1[NACP8_L WFZ3Q[>ZW1Q\ZQGZWD_1(AO*VG/>=QH-7??0,E;:<^8VB2&
M0A42'E(9$W]S)!U7F0S<6C1WPE/"Z+>OVAWY%SNM#IXX;Z%^N:/3>79AWMI(
M_*/#Q3S\>%=:BL$5U<]ETHJGRY/SY.$2=KWKDCUHJ#8TJ=?"^^\%D!V%0,U[
M?U+SF$6;HI*+()H[>&R7^7UJ6L5>B2U]LL"L\9@UIS(!";*1!MGXZ$8RH%:Z
MKJ7YB0'UTO_+6)#K!2 '*L2!HUEX]8']@?)K/35=#T4K;V7=I03\>6)MM)\1
M:IH061!VN2/%(E5W,*LVT7K_6*:4:OK:R^5X)NVQ(=\.U+,LY-$0W6T\-.03
MT!CJ$3=#/1-%D@O>\_&>T(VB\54X</2M^R%RMX=0?-N-@8([L<<OMLR=]'*0
M"JK8E7RQT,K9<#I]**NJ%,P>C@8@/N &(9\_WO94L3:=Q$$&@D*L3%9''M-E
MD9=+W>Q6BZI7Z@B?G5JJR@M=452>4]7,)N#AEG-NN=+"<TFMV#@BM"-C!8(J
MONY.U/L_"RGR(GILY,Z-U*GSOA45=_T8W[DZT'FU@AV5?X=-FYB;?[-PP9DZ
M<YO@/IO=&.53ZIU\_87QWOP:JLV9W' 038G(:^&'4SE\2/XCL 'XX!HR$;()
MP%$,CU).+$<VKQEFS+>&YC8,[VJ,8ER^9_:]'*Z<*)7\!U_N\O:L2_$ECZ3J
M1C>I99G;/I;B(-5FFS:;KT8GQ-6'?AYD=,0P21@/L>UQU,DQ-HTFTB;7TT5+
M!Q<;4ML]47:>:IB;MO<7@SZ"M&;%1+2[%A>98W3'N8+CY5*RS*A@RR[-5\9"
MK6^&G+MZ\^NI&;EW+CRNY*RYOB@E7N\84LJNMI$58<5L#P/PNSA@3!Z[&RB6
M'JV\">#"*!PJ!A)FP_IZQ_R#Y-!.-.[Z7]DW$TD^><#*\?B,;8,RKEI'I'M$
MS&&70^X?:VQZT3H?5JUS_[*>D?R.0+^]>EI/AVY]8K*I)"#FO7$T,[-5N$N6
M*T9A\! $<)HAL?BH?W44SSI[Z<X;<>.))158.Z5YWU#<C9H1JZ?ORF(22F^E
MI%I2K7!KHF$W89$?7 YR,LU7M#_[X!]-@9K!&=W2(C&+M.H9=%JT;"P!/5W$
M.IKQV5D@9S^N<N#EFS,$_0R[=T??Y%D\CC<TWF:X^GM[ACI^U*8GX^Z)//UI
MC1QE9*;CXGEL=VB76@ZXV#+8;IE#]-\+CM[3QJ12R!H#ARMUN45N_>NS48\V
MSD#='Q?K_Y[1]7U[S^]KY&QPIB"C^/7+>F<5A^^=:2HU\87WIRPSK=\;[RX*
M6E'3@D5%*:49&PL,%JAS?$@3&A\B]A'C(0F:Y2P*0*\1:W=N",W57G6(7/\S
MV(/=.&W;IS5O+*TGX1+SY:7R.3D=,Z_V@TK.?]2NO4:EU<JY'L@/.. >'U35
M^=J^:[9H&S@&> 6' \;"_B"-JR^RI[BQ2Z+%, RU'<SDZVUDE+DNZ!19C4EI
MW\:W>+?&7+W1,Q$S' +1'_YUL/9BOXU-)_O/-R?(MRZ.A6)QL!?%.]%[C6IN
MZGWJQ[?5)#-$B[%,&YC9Q6,A8TTWJ'%K+0CF E$-<VL3 &S%:'V_,WM$C'L-
MUR&5?)+SBCH>I&]Q(!^7/?\KQ=XO $V9]2JP^*9K<6ME#^W2,=6B@*HTTXY3
MY\D]8QGCK2BF*$\V$WP.K=+$CY;?!!!9?5*]>N3_MWL&#Q?=?2>[W#<!&IG
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MQWCPOT:+L?3(4'=O!:AEQ%'#:]OFY;;?1NU-]<:XI,9?Z^?4_YA(19P<$Y_
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M:J5W;FVLK[-HSNM(_1I&;Y'U7]:'^LE3=_(@\79ST?,B3@_' ATU/PD1_!1
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M=S0Q=C P,# Q-BYJ<&?LO 547-NR*+IP#00-#D&"0W"W$#Q <'>'X!"<AB1
M@CO!W6G<-4&#.XT3W((TKLUGGW?.WON^N^]_[YX_WKW__W%6CQK=<ZPYJU;-
MJC6K:LZJ?IA]^ D\E9>6DP;@X.  X\</\+  2 *HR,@HR$BH*"@H:&BHZ)CX
M3S Q,#")<?&P\<E)*"G(2<C(J&C9Z*FH66C(R!CX&%E><G!S<U/2"XCP<PJS
M<7%S_H8$#@T-#1,#D^C)$R+.YV3/.?_3U\,W  <5GA*!' &.&H#'@4/ @7OH
M!B@!  X)[F\7\/<+#AX!$0D9!14-'>.Q0]U3 !X. 0$>$0$)"1'Q\:[?XWT
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M>;<"$PH1U<L?HVV =DXH _#/0)F?%DPTZ?[[W? [3='21T.K /L)LPQ@WWT
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M3]L\9JDPN_3J6@JNDP$1VF=X5>ZC8,^G6TD2V9*S?Y-^]FMXNPLSF+_7$^?
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MS*DR:@-T$0M1AFA'FC4,M-=KDW=#RUHJ=?VT$".:=O@NY2H%N8) 4RGTUT.
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M61OGPI&>;>X=/-?J#T\V0O6D6^$>,3%+:VUAJD9V5#%R'C4_TXU>(4;U8<K
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MX*MZ/:*FKH)Y2?"$@[LI )\!C$Q=F6J?L[#IJ$J8GSXOD8,^_;R]_FTKS3T
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M]<(=L9AZB2HJ/IL+B0B16QDMPM,L'RLD1)F?KF>B=2;B9JH"SBZE.&]H-(.
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M662A8&L_6H%T>/'=3_\?4$L#!!0    ( ($Z853ZH.L\@0<$ !G:-P 5
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M@OO0[G4X"!6:B50X+QIW2/;JP:M&N[V=(WA^D-&IT%$G(/K8D>*C::>Q&,;
MGGX#"Y45TAP8"V>Q.^4LA@$O/Y$_&=J;S&V C@(6[PVHH-Q7/^(:U%[8 )(7
M:M6_]D^F&MKN_I!$:H*YR5#'=H^#+FS!B-BZ$88(3DB_K_WLDFN[CU\UG@ 1
MKGID(5PE,2K/Z)48-2]4]T+;B1/!8?7QLZLJ\E?E-/?_JEW4IIYHO?03'=K;
M>W_5JA>'TTYT"$C?.M$_ (I@;KY[^MP#$</<VP"_FG[^+['Q;.:_,^OYGSZS
MT.&1#;;P.TUT]Z_#B]K!V(F>X>/1;Y;X7#SUQQTYH7I)"$9$-O^#(;"AR7U]
M>?Y?!^=_9O/P#]M+6".*DJX@Q@V/'LY"!FH*J!W !3> JA= @VXR3E(,3]IR
MF<.[H$+_LG%^>0;J_!;H1+N* FJVKR3!7CE),(!DA22HS8@$0]IE*4A0.Y0D
M0*VQF 2UG<,9D>!@_B2PGV>Q$6K;U1F1X+"<)'AY(]1V9[01#JNE),$$&Z'^
M @F&1=_A[)2YHKFFXO\%"0?*]@T^GY1K^""!88P1L_O7WL5T4OYP=NK<NTYU
M2'G=^:L&VNN4.LWA['2Z]YSM(%/CPFY?3*NI'\Y.@9OI9,6N'L/%>W_M7HQ7
MX@HF6ZRME6ZR0WR\]]?.17UGVMD6*V9EF^TP'^-L:]LS4=#WJN\KD101_@@\
M>(S'X_X,5/0=E$C[>[NST4OVJL6"J@0D&*V9"!)4]V=%@F(!MG@2C-%,! GJ
MU?T9D:!8JKTS"=ZFH@L2'![.B@N*95T)2/#21MC?FQ4)WM=?\7H2O+P1]L9;
MJD/R;Z]:;)7/6_[)EU][MG\)HTF=X+=/P6TG2"+;=V^?X$7]TV[/"_J,->/
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MX-K]:-H-.3IMLR"8X3@)T1\D,MW0I(CM>-K<32,OEFY?6LB:P)5='L? S*2
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MY@ZHC;N[?_X H_O\MG%[_L<I?OBN_A:'L%, ZC^Q:"S'XIJ/C+ 1OO#49^U
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M<T?8[;L43F].OY.RB1C;%)].3^YNIXE_DUA*,(E'F("Q40XX;W&0MCC?K,B
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M/Q3(<UIO#CN..U@R98LIE,<S8@X<R+'@EAR<V!4XN@QZAEG^HRB;]DS'M9A
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M3X.$A,JD^(JF#'ZX#9,H9L+7A#\T;>]!%RU(1Q:.<B626R:T[P-_6$JD%;7
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MMS>_2W1M)R3>/]#!AMQ3JO+6J"WE6_B _/T(#Y^H])=\R/_T'[ H+SW#]FW
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M!!J@:KV4533.#&Q:;%%A-&N?%&*?(7$;S8U,!&QR.*"P4G\>47L=[.JTU.G
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M)T5/VG1BJ8 '-M.#8_&55,L_O.@UX%M,;0H\ ;T'\])C8BK"1- 713N\Y;A
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MTPE0AK.$O5-C[BT"K1RH ZC&HUATCNZ$C)&YZ3%$/1OL/7IA&)DX@)*JH<:
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M@;/WKM3U'H#XJ#VEH4_K(EKF)Y\N ':U>?I1_*E78MR0_K.'\?7)O0\,'=W
MLS-<RSVK]]5_DPO\S'(7[ .+P\M@%,CSD#V(_'-QCI.4 ) NT9>D],"'8>+X
M 11.4D0/H'[=TWJJ($D_%9#MI&OO5"#_>L*/7[@\>GR01R2/3J]5'GV>L_-A
M\N@?$"6_2K0L][&Y336'G($EFL@:ED(;,F_/-9 R(SEFDH=$SL2'/-^258O
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M9@:ZU'V0*?I> ?&\$FG$X:AYU;@C00K!:*%]+1VG6TD<SKFR3%K4S1TD(T?
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M'NU 7Y">_<8:+O(6OL\'URG9R@!!9[4#4W*WQ1WV'U98Z &EJ1TL.'(PDW
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M2IK#6T>[.:R1M+M<8(I<JE%4 7O92D/ET+]UY!ISKF$&.&0DM7/#+_&AX%R
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M2Y<(D$[C*ZK=P1MF' :7+G*R&W=J.0T UYA5 %I=[=%RZRW@^%4X;K=M;MG
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M9)-L"D&>]P5<HLB#P4!70,H&(B'/J3,742O5:;G+, (=#YBPSQO>\\HC4ZE
MYA8;7G6<ENUF.&@SLT,81_8[+AW$!O<;S,6]&3T;)U>#3 ^-1%XQ<MV^!V\X
MM\.1Z>O%:_!32D2XPFF/'C,@WM .IY]H[N\O;Z/>,97".*UD&82*1'.B/7HR
M9*3# E>G^].TEB2+7& @DM$R$CTE/5GX45!*3I;2'*1;Q ]MO]M?P<EUP3S5
M6/ZC!Q>1PX+9Y0A)YU2^)M-<U!LFO(';O@BJGN*P/]]A6QY\^]M54S>[0^;R
M5!@5[73?PZ&Y$E'+\FY"\FG9(?P/K=EUO8\6V*#*@2B2JE)?:PR$V^N?BQ;=
MFBW&7_#--WB^41,]+PHR(O!8?P$3Q<?B#?N_W"??=SQ##@>L7I5$9Z(J,P .
M(<WKR%IPOBIGWBDN0?M!Y3 VCI,N:M"D8P2D&%1?"*C@+Q+/:+D)-9)7Q @F
M'".$A+F1#CN4#_\ UXN_-9$AQ/Z6Z4OZ T(Q&0&CLJY5++S1M=_@P@4R-)*-
M[^%%][+W,B++K\I'WYI8Y$CV<Q99&M;@HF*^Q[=]M "C51P=  T4^SXGT\V.
MP*A6XAN<*IISH^3#M_*S&TE%CB=8!4_:32(9C(U)?F ?@E"MW.KJ ++9TW[E
M%4\S#(917,3%PB'XE@JFK-DG7&0T]!AUM#L!*ZWK$E/H/N]K6)H(H'2K3**3
M;$O&%M<J>%MR2U4_U+M$*;=Q\JQ6%K@C8 X,7W^[;2H3Y.M^76&^.&#JJ8K[
MY6H BK,T[&^F7)BUC!H,KX_U67C 9=+0=W.']CUP@UT+T,QPFG-XARW?C7=*
M8V=SQ5GJDC+-R*^"_LM49[@8<KV39)9CB 7RK86DI9<:6^281RW0F<<*P):_
M+'I0^#@<%6I9##PQ\KD&CA8#7_75N\"Q&)PLQ$<(^ZZX !A,D=/^^Q>Y;>P>
M6V,FWF5/[VY9%H6;2BKH$!%@HF"MPS%!RWFD/4C[(F@2J?6Z3=*G.H)$@^S#
MTJ-W-L/'437YZ7<2(3CH<QV;YT'5D%#MA9MG>>GG67X5S48_!OU!.8_ENRY7
MV*>R<'0!:AK=;%XX0]7X3@(R<Z!!4-^-";/8TPINXW 4@DFB3*;1& %&X"CM
M]-11QL.7,N!1& TVZ0($/P'*S_^>#Y&V3$YQ,7J070]TO38QC*G?!.*&1;>V
M\(BY4PU<"B4N=20,5.:4=Q:<UG&R@STGK4(&*I]S!--)CWA[1&D*K 2QB7%Q
M/L2#C>8SL7V"6QVP8D)@^V3*&9S3X]EFBQ%S857*5[T/-2!!MN 'YHB.,<N&
M'&)GQ9A:(+LX-RJV4'_<8Y.\K!-LQXT!3<GCF'^7*@K%1#M6D#S:2:9L,!3H
M9UR=M9IZZ@BYE#MI9$A.QZHCXD-RM;I;PJC8$6[N8<_E2$::=]A@PEN0^U6Z
M.;U\^$I9G>O+J1L/3)Y)3VE.Z+W/'C_Z[;O?^>>04K'[IG^3\!!O7C\/D-,'
MJH*;K2<&*D6DI%-J1J.0\>))3<ZQX;U 76QO\\.OI#_F!WUJ'5/V#AANR";'
M(SSD?9*WY?Y-H);JA@<@TP3@JR-N 9)XYJ-)K4,(9GJ[P-8MTW)UG?#GJ+^L
M+3=-BRD2+R1RU8(!-/SHKH>L)BI ^,)>VZ94X^HIH21"./KE9L>4J('DVF4(
MYL"DQ0WS:CQ?8J3NK^#4+<IJ4U/NS(W^3VO+2$L.%!?K--%=UWI"/!7($,$U
M)AE ,J78S80+Q Q-8JEX!VDV,N@K<W!!?=4IXS("%U"<,-3>]T+Q1O=9F_&<
MT9O<\.C],,@\3N9/$AA%O'%8ZJ6$'&V!GU'/'.^5JA#L2![L+"I)-S!(6MDJ
MS8/"..3@K1^ZL?$B,@:^B("<4TI/0V)5/BS462"AR";A[EK65MNHISF_X1?8
MOJGY]P"^R;41_!<$"MC@^99G'U)U[^&K>Y^GZMZY5?=\J$5.Q7^]_=ZQ^.RX
M#]" 0F5@*.=HBJI"HHI5[Y/GWC/^2<Z2-QQA>>37E6,*_32>Q0;3T:.#UQGJ
MN1#_0)F,,'>_8_P4"5[8I\3K!#Z$$-![WB.RU#$DC",60FYF1'Q9!2#BH?X.
ML #")J;8#GD0,-+M(7PH@\CI5,H Z056SZ92K!UW/.)9B*9(&$//>[2O'%&5
MKT1@U2F$*QP9(IPWR6] 7)<Z'D($+=Y08'G3BN773:M,UU'BE4K:GFR$W24/
M?Q="G[DI.\=A%\ ]^=ZY()(B9AGY4K#'@7L4H"('A"1KZ<[R5RIK;>UM&+Q3
M&[B&C#.P._?8QVBREV8#O-$4N9W86[+$<.X.4W>GF0I+996AI/*FXRSCY!_X
MNE(,$I_F3AE6KBI!@\9 B7M%-?UQ*VF$B!9EIRP4P4F%A2@+W',_^N?S@1QD
MS9T4]C3=33+?^[525,E(*\@ITKJD<M6B_Z^D(,IS!9<1&O'@3IZ^2)0)[PX=
M4\^9A?WY\#^0X$*E>$)(\&+DS0;\DD%XZ\9??*%J9[J!..@KQX=T3&]:8(F8
MCCSF)H(08\W&@74S^69C/6D9G%_K("&C,\KO"F\G\)WDCE.FP6VR/ZC^P8B]
M"_L^;\Q *!QTUZG.=H3Y.!6X#!/P_CP/4BFC3 K"DB%P=BN#2E.R@^:@://;
M.B2F(J" V-/%/?%?COO2@QUR%;%0[0?3AJBW"W#MK0/QQ5Y=1MO*!#\*Q&4G
M"7<^?S0W!A$.$R9S@:OR.95?268!PJOG_08#R">/'G_N3XYTWK F=R#I*XC!
M0'.I58JZ3+@M)\)^&NC@-M]3M2*J54AD$;JCX[S_;_ZHZ5EQUOA;T]A2A,<L
M<'VL5'3]&<H@/MV0MC:?34]AX!IE>N62QQ*]=8.3GA,/K(/KFFW#I?BXW4->
MR/0\Z=7IJ]3<.#;Z4Q!:E^'H^^R#!?>CT0S*]CGFQCRZ8AY0G*-7Q7I.,CR*
MM/J ;Y)(CYKZGWV]ZIR3V86WI)1AN \.-4XB:WSK;+VEN79-4$15^<Y0H$ZI
M*[@)R8OS04:I,.>K!'.'U'WPK?==N%04<&8?^ZYD;N@[>2&DWB!=TDWW':)
MD33!^?P'E25>AA+^0R#4[ R SUL1U^0)\DRX=<[5<#A[A<.[Q'T?N!!<QL%'
M'@ALC#E#]BY@X7-99S>5P'S7!NQ H]Y%7GO&4#Q$ S9 )ZMY!6LM#E/R2CY#
M]%SH&L@#C![0N[9:=;)&1J99 X[W[/A31Q#*!&ZN6QVP"'M)>#78(A:'Q;=:
M9R";]>KEMR%54S3;I]1E:O-'R]5%QH1_,:T&W""^_G&]F4_<AG*'4C9N!2-
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M,5 !2V,WMA>&0 QX>3![G6*JVZU;$>&927$;,P =<EQUNGA)[=_F;9%*FK]
M2?-9*FF>6TD3G![;U#4EA!PT"25/Q=>R7;-Z)[-+>ISDGP3N5UMQ=/'4\ 2T
M8X2B[V[!MR ( :2%4^0)86(B(*NF0T0S&AGJI?V".Y&M>&74KR_^TM)8[76
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MI=[;%C,BO9%YZ( D.6+,2F;B<H4]F8ED)I*9.&,S06A+@C[$?KTJ98:>G@;
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MX4@SE;P"-'M]1?B^"!%DS>+Q9T^&M$GX';$=%(P(H$)NI<XB@.ATPR4\VB[
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M2[PU?@%_RL&_^*$%5PBYE< \Y"ZKZ%9+,V5RT4Q)^!B='4E=<9^0TQDWR=V
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ME>+3W)Z28KRFDD1PJ5O$?OVW9U]>?[6 )Z[42?^WIY]??^Y^HYX/>M9V@3"
MQ>*E67'>Z^GC#/,^C^E[G  "6=XS-U(%H?YS$J31YS.7)B +U^]Z%FI$SUV5
M=(#_[?$77UY_J<NX7KR-$ GA/RJA\C"T>>R,XTG&(^G.C-M31+YMZEKZYRCF
MQ$O,GC\XU)LVW['%IVNR!F ;FP>320B*T5A4)M8V*TY_N>N'A],7;#"TP)V-
MWHAH!W0H[QL'41C+7HA(!\C^E<@)STB5UI-.3<=BH2>[V&#Q0$*6IM4OZDAO
M$*JDT_[>X?(@^'V/"&04QU#WOWR-+PG>B!V">I9K%F*4NM^K;Y@:?LZL;2$U
M_*2&G]3P<X8-/TYI'W4@0EQE4+^[LINMZOE*7EA*/=+DS[V<J9'S(J4SZ?6D
MUY->/T^]3GIVIA=EV$Q 2I@/LQ[II(\O4*J2/D[Z..GC,]3'#U(LT]:S*>6=
M%/9%BEU2V$EA)X5]A@K;&O-NJK56N)T.4W %5+48]/)* ^^4RDY)C\N4O*2S
MD\Y..OL,=396#EOBH"4-+0W?H*]]VSC^OK2V5]QD::,EMMIE<V-PV&15]:@P
M%\N^HR)R,*.$;CPUD<C #NOWGSU1D3CL<@M,>E/?2]#?MMKF%8)WILSW18MR
M,@+)""0C<(Y&0.<GD:7GSO&TLEZW.?R[7[DN>)J0N^KWP0R=C)=RHSLI_MNM
M(<6>5PVSVXV',[,Q!/),W( A!0]RR)C3/+5LQ@TOAV0[+O@$)-N1;$>R'6=H
M.UCO9D+(DCF 2_@-CINNC+"\W@%/ML ISG53E4U2TQ<L;$E-)S6=U/09JFGP
MLHV#$L#I;$FN9Y''3*Y\20 NY0K[_"W.3%0..S*IY<L4KJ26DUI.:OD,U3+/
M7S&VCDY4"LK)?6$<T^35'9-7WYA5CO214KNH^YV!=VEIAM\*IHW06S-EV&">
M[R3H@6R,_J^@294#8J+[=R61CV%I?(>5%@8AXX&MPD\P*D\8CX=1UHOPO=8+
MN&GK><0F "@BJ(GKQ;<WIA:<)BJXZU2DS[;1>C@W1[AKL]/4_K83$VP!EL*I
MX\T*K^#Q4[,%=1-,@1QP-T$A*<K0J9D9^WYP%*0!]A$W,>!=\@+>B<4WG:_7
M&N\J_AY!LRTL\;I%\Y3A&"CN*:-]9XKV+3Q!9D&:PF/'@":ZQ3%3OI83F!.X
MX7@>>-^6C1NB%4Y5)GN7&X3SM3RR6XQ?.D-FUOKHV)A'#\YM=S0ZOFTJ\-TL
MVI+'7_YA@91Y'3N;MTW[+L A3, W[S,W?@<\P1&>$!KY134R9@]L$+O.:9!*
M1.88WR"-E$YI'H=>'P\SCS'L]=L6EX2H@,M_\CRY8!^@I R9B+.16ADAXAT#
MA4B .V.Y&KQHP9/QHN#>)R%AW:EJ0C%U")3C+K'Y)C$WY7R*M(=7H%(6+:!H
MZ'M^\'HDO7U="?8A6(FR<D9RU)5V"A<;Z^#9@A0(I&-KJT>W\;6O#('S*H-@
MG6B51QLCCV8%YV-=MK9SR)LG0&Z>A%IZ!^KG\-4<#+YE3.8.D9'ANKD#=!$+
MHB?:0P7> 0[HP  3HM&#G_NG7R=$HU]N'7>B5\[ID7E8R^C015"Y Z4\K<DJ
M>$>&P6VSQ;Z\:;H@+_B B+G9#&3NU?T@<P.?GY;Q82"Y,;"JQY1A!W_*7PIA
MJ$(C,'Q?[JT0;+>BM5.LM>UAQ_C=P;9%Z"ZL RL=#2=<N=S..F_%#:*OJ#<4
MPY5G6G';,<BWPKT,UJVCC0'N"RAN"GLD,HQ%X7KQW&^3XLX3.HZ@PHR72<&"
M4&2?2&(:F$LPS26<3O(K72M'&%V6#ADPHP$@:UG8';%><'3&C2DK#4+"M^#E
M2^?WEP;#1<)9 CWB_(;C*&!W>\OJ0R'R$J8BEFQ4'5BI:ZG,)GHJ?S_ VDKY
M]C/+&J9\>\JWIWS[&>;; ^? U"WH-&>V.UB9]XZ"M,' ##I8ECLCI^"J0HR@
M.'OCFTP99KW1K'T-*6.60ZPX6S6WIF4O"L)"RN=V6]B9B*<<+>FJW+-%*\+T
MXP SS*%>!^!OG$GWGAQA:+,!2TT\%WP&D_5*UBM9KS.T7C'/4< FSF$>1X_P
MU[U,:JE"]ODS(8S2RA98AQ???R<L2MX E=IA'P67 YQEL7.NWC1KII(MN&")
M3K8@V8)D"\[0%@Q2O"ZK^^IO+Z\,]IZ@30CARZ(DL"!2,C,/U>3N8J6#ZUKE
M5\M;TL4A6F52\A<LJDG))R6?E/P9*GD=F96>0BFE% '9M\=+"!0S5BQ@=Z/>
M ];N5"]CX'GRTB<F C3/Y2ZL1D38TN ZUC"7+ ,\2!&3 2%")J)[=.(LI/DC
M!1&?XBE)]B79EV1?SM"^#(*($&E36@LL7--B55K4MYH=+6.<:'&VBLN9.>1.
M(AVWI24.\;@\_U.?5UJ=#Y ]L2GB:FEJLRX[A^\I)L7NL(ECUU1(]C?9C'"7
MA<DT2MK./(7V+\N*I ""-^_Z7=->Y9NZL5VYBA)EO)N;!#YQR:<PV:]DOY+]
M.D/[107I%GOL$,$N6Q1]ZZOL-$90,@FT9V:U9:%#*F&,$V'0>5"\@,IMVJ0<
M,2<)=>CBQ3<I_J3XD^(_4\4OO554O]A32=HW@D^B4&.;[GO%+TF'7[ D)AV>
M='C2X6>JP['A%-96T^PEN.G;@RU7\!#8FT30&#A>#W_@X@07LF7"D>H8?5<2
M2B@F=XIFWRDX]7LX[ N<)U[D%6Q9S;3."H.P:NH;C!ZH3(+A0KXGF #*%>5V
ML=J:7<._/V0\SVB0U:"IRH)S0\F"7/(Y2!8D69!D0<[4@N2,(TJ&P;0"+Y#?
MY&4EA8V,!B R'JG4J@'/_069(,(_<9QB\[@WF-2AB,(4F;3<WE"QQ/Q<6H>7
M+48F-"8K+!BTWGRX" 3"%/K #$9'9U;;&IY[D^*0RSX+R8HD*Y*LR!E:D; (
M+J@L[M\ZX:8$!5P.N-TV.YJC:V2^ O1_A(6@+)7QP+N?1L>6J0HO]_X-46A]
M</P#)_4W38,$._@W,$"TQ)E"?(##EI'L%#KZIZ,DP3*KP^*F)%L1E^>I,9B@
MP0CXC/%<$#$-)^AY\.3/K]]HMQJ6P9/ENN3SERQ7LES)<IVYY1K"_(B6CW!Y
M7#>2VKG6$*S3@'+G/2V20H7]O2:8DK>=BV&0\8'B(,R@58<HBJ(Y0U>N0:M6
M[I9]:PWCNB"<RA0%$2??"-.S+5VHU(*9:]IIMB$R;:#VE[+14MG'#R7S=,F'
M+)FG9)Z2>3I#\Z10E 4$*G7A\$QF$EUW1#N!R4C:^H)E+FGKI*V3MCY#;3T(
M)@).4"R-")?;-'=;B[M%_C^YX4T:\CL?Q944>U+L2;&?]<GYES!T$NPMMCCE
M&^%JT")%E''AT7*/Z;?/#]B"->^[WT=G)[3VA\,3__S1+X;6_F [G6STF6F:
M9*.3C4XV^@QM-"BZUEC+_6,'[0M#=I2H7\PW@VE3@9"@!2/G-K&U7KBL)2V=
MM'32TN>HI3MJ]Z(Z-<1(VNW;&@VP"+AD79K"<V<G&M<'#GQ>RX@/L9() 6>%
M,#(0TBZ;&T9*$ZPRPN^'R[2-MN#U%?R7:&"91\R/^D<\,$+YV1 R/P[_X,>9
M3G'I 9='S&Z*D!DSJLYP#[[U7 0Q(< 4&4 $T"P(;46#Y$=-M]B9O)9>/#_^
MI!0]1V>>A*&'$4 G'LBSQDX^+6XU;PBVPU-')&[PG9N:8PO'$8*J03-*R#9T
M1YF0&1%N:1D[^%7+?8S(VSL@8PWH</$QE#SWE%88>E3E39KFO+0-HE!0<XUP
M_TCGI"<)<B2^UXM7ZS%ML*,,"@B-E#VHVX)>VVP%5ZDZPM1[0A^I/,LRO+EC
M>.4I/$1XI7Z9IN_<WW#,@3I.$VWK??37R]Z#:P6' ]Q_>(-P"CS*HR*P#X#7
MC\EDCPR0R.M;=BB^@V\*N_5,!?XSU%WR"=@G1?;U%,K$U,S<)T)%Y1>->,%]
M:Y$'EGNE5Z M)M;)G5AZ<1Z6R<N*9(Y)@.G83:XQ^FK N@R22W.: 44I*CWB
MRD9M0(UNBQ(IUC<XF6GP =Z9JMQBWS31\)'Z272P,S3#U.'M.&.(@Q-)!FN5
M+[)R+2E:F;R"5Q CLF5#D#0?V';(0\CJ\=E3$&$DG1&#)]+(LU,6>_I:FADN
MKKK#WM#G00<Q.%V)!,.$ U20R!)_.#7F2V-[KHWK;&/ED'@Y5&%&.L!&Y7/7
M> N^:?.='5QRF5>$!+<TW2WR_3$SGYK]NSF"D. =M@G^/]Q+1T1XI\4[-]U[
M 0XD4O.!_U]:TB)@S4"V:LFUA.^^63O>C"PF*8SZ2(D&,]\8QR2U!M>FIG;;
M4#W>YCI%,J,92;_QJ3 ]GA X=;FG9R114O;K6*VC@,B@1M#KJS=0HF\(-. X
M!6O*;^&WY-,N*>P"6X\XOGU=^DD7EL)P57MP G&+Q3F>'+%WL%HC=5V1]J4V
M+D<>KSHY7+N#ZR*ZT#NT-K[0J</K7S(^?^CU3YN<V3W49U7K(DFW:+_4B1.J
MZ7RU0BPR!*A1"E!F4YEY2%:">F5F23TF+<YM:V%':G 8['9!]V&@3.K'(&G)
MNPDCK/ZCJ)6!/(/O8VK+2EU>9-L<\@KGHYC&E?*,U%&=6V[\9DM;=N)ZTXLE
M E2RS*05D9NTZ;F6R*^! V<$2C GT+CS4PVH6]F!W^7OL#<%8OH6";X+ ]*R
M*VN1/ A=X/#I"<>W+,-=VG@>OHKU $*"E?ZLK.]*V]+);(G.4UK@9=@7OX61
M1[ZBLX/\I<NRB7^%'X)?NLPNDL45X,8AM7T8L&2!7D'T[C*T6\3OBFOVWCI'
M8N@:^2@(7@.8493)G,:>T5*>E_DX;]?]1Q-3VH9DM"&2.FL54C3TSCB.#%Z.
MDJK3\9L._]J\M$:F'.1ZMT@77QM38+"-1[,.T7%1Y*-HCCJV"L;UA< ;1RM
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M<AS1TQ_P)S)H-;RB8+&;'IX< Y2FC>]/B'*.>W$88Q>]2PB/EG*?P8W4I/&
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M#QY7:=,F'M</?9RX&L,<%GA9'.$0:J8(7MVCJC\DQ] G=-HFN$(\U9,':A]
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M"@_/<MN7G82C=#>7B1IH+KB%G+51!O&4 Y^(KN=D9<SN.TX'SLP!5>")B,2
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MOHA9Q%\\X:YT7?3RT=A2^PV__D&6+,R ZHU@&[8XD7+K$H04S1=WL<6#*(-
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MA[P<R2KM7>E^0SBV#%7K/XQ8,S=-R7.QCO>D0E*9!6[AGHF.3;.O3#(M%WQ
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M\=>7S+51$'%'\$CC63Y-/CP=U0L7;8<3[+6<KT@Z@XDWZQZAF%@B3Y[A$3Z
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M98A;?;ES>EP\*7.CB%PQV+<8N70KE15)<>_H]Q'FF'PZ>C!]^I^_<N\'F,,
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MBDHUTEHQ-(TBWD36)V>*GO))R38FVYAL8Z[0QD3&8M*)?"%/9"5M'3.;5_1
M'XQZJ=8NE R66X6SFG_"PIK5?%;S6<U?J9H7P+?9=C-+'QV<DTYAQG?DP5,D
MC/J3UG9M8G[CDNKO!T4<<5]65OI/6'2STL]*/RO]*U3Z[\P?2<YGAIU)<8R]
MF0B#BFO7N!UC- \GWE/.!&G=@!')BT"',#.LA)[KE Q#KWC#./;\D)<23.]C
M*?*@]D<<U'[^GH/:V4Q?F;+)9CJ;Z6RF?[:9?I]7?OF]/LZ(_YO;O1@#ZPC
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MJ;%%^!:FE-2_#Z-.TO1KH]F6/^*+,SJ!-'!BVD&_&@KJMC/^%[."IB['"!)
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MV<!(<@I-+\9!>M6]-=MWQX!=EL9P+I.'\L5"N#8&/=WTIFATJ(%!'%H[3MS
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MSI V5>*NR12Q-[;PI,RU+B5Y2U>5&RH["S RR?!GLD*SP9Z&D?K-Q&3@Q8[
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M,?^F%BD=J.F*C.8SG.9'F>*?D+H?X2M(L,-&4<^,\"@5BZO<(GF@'V[+N"A
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MV(&D/;(Z=_U^4ZJG2TLAG/>Z*HRR'JP,%HR1]8&%_E!I(+. >%OT9#A2 3M
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MXP+WEP(R+]92?WS\^N/GI7OQ'78ORF9HA9T[="@JBPVDBNY::C5KZX/C>/^
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M!^R)-]T /S3#JV'U0U!5>VG/2*#[_YHZRW]$'J?WW=C[YC<RH_2.)<>2SOQ
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M.F%=GOA(W;>GN*\$<W*XZ:#:*2$8"*B.][;,\4CC+!>H0CT6]>JEGBC+A)>
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MM>P9)O119=0# MW8!8,VY^EXG^S5C$FGO@8RCTUF[ZJRZ\_@\+-J!RE<_,X
M^^KCD8:Y$#0U-H@$R9DFVJK=IW(M5,(<]O.IA#=[!P?Z[1!-3!V&',(Y8U;V
MSX H3:<\RPO!'@LIZ@RW%O77D39CV0L596N()3:ZFIWDO(O>/I2HH0!&QQ.X
MYQHHV+^K8Z2H@B/?MDJ:B*&FA?(H5)(07]3:N=9CQ%<@R=K;QGG%[A]=R6IA
MG5T%%4QPYD^3)WFA^^G.)*L6>P+/B%K>B) #+OL]'X,N/5^I*D!%/#8#Z"PD
MPST"OJ8RI2S6>?B=[13B&7ALD%608BX&U#WAWA$6\0( 4P%?X& WVF 1 ^(K
M#7."WQV=?J=7OLDJ]0FHOLJ5\#GG!V$T(1Y@(QGR1 M-E#V@D8$9]HQ69N'"
MVPQO(QA/$N&SS[MY/8H;:<9E756 8T:82:M39/EUD*I4*+24LK <ZUPT_5V=
M(D4U(+EO#-I 2L%/N@C[TT?83QX:87\X@V@-.UB2,KG&7;'6,@[^(A=./L%T
M3PI@I))SB50"#]+D)*><3I4&!E*>'-%E*C.0;9193PX'GLU)SH4,R(J5(_1C
MR>9("*E6TZQDW0K4&LH,!8V$?#<#]!,9AQ$F,Z5U4664+7;F\(-J)MU2EH5A
M#,8VV ]*3U 'R7LP-2UW>*5<3;>SEIY7]C0?9O:%# L;IZ'P345NG%.!<E4A
MNZZ=C-_'+:4@,*0$0*%Z1[F7C=^S4S31X4B.$ 31."['*MH[Y*W'LSEGI!4@
M"MFI:@C= (1&%;=:JI29)%VGF]WA$E81L\KHG ""1#$./T2OEW+;U80ZR*.,
MQ%,N,/(BC2I&_CX1:7W>!/4--3BGQ0(HD#F2BAMJZA(FP&(HGW42Q!'',7&P
M\'*H=#Q8AYW%!7J8S61X8QT2F !F:+=RSH@G@CQ%?[TF1KNEC%^%9X@FQ5<@
M*IW:6(MHXE\5'EF?Y8-0Y@^>A+)C&LZBOPS_"[8:FXLZHZ66Z:KL6](K$%\!
M!Z_!SK0L8&#JHW@0T["X89Z-]5=GOHAL%$/0$\I2N@5K$1-0,5D%Y0>]:%+^
M4<Q09QSEK,47*.S(/(\]JOJ[ZJQ$!KKX*QAC<TK6"O4&:+-*CYP#=S-LSPRY
MS=@MBOHH50JO<(8.\<)1JQ2@8MN.J=F$FR>DSJWFF!]Q+JPD13]6$0W4\%&[
MX+3;@K+!T#U$9FBAXC9:>]'$U/C68(H]/.AW;P3\$S4-^!\E#2NM!L-M2: :
M.K'6$WC<$=5CGQ0G/1A_UH3R&W+/ZIK*J03&]H9O^A42X0>P8E%^<T?C]G#U
M#\^"&PA;:KI5X:$5]EJ,%O"AE=%BD 5Y5+-C^1MSHR88+TV6GPDK:>]XM4DT
MA#/DCLPU1RAS7FNT<;6K+:O <[6KKG;5U:ZVL'85A8%*HN22*I C*!OF&;;,
MF&>S&R'QQN3F-4Y(?@/U"W)<HK IR'>!P4W74&:#,=#Q;L>['>]N(>^>B!RL
M<F"R"2?2-VG9F5=Q>.H<8W)#JH?0*ABBR7\3A 'U!]/1:EK1,>\-1D''O!WS
M=LR[C<P;/1F1<J57O!A]N,30!YB]-,YN0)%6G4?0K4T)G+KM"*4OX[,J!UC4
MHOW%;;9'><&R*7SHF/H&HZ9CZHZI.Z;>0J8.[X^R'+['&112EKHMD.+A@R1(
MOWCA2. 43^;B7-.#\3HK/:3RJ+ ;'M/V.34L4=&56G:9JN:8P.K>JR"1F?<E
MI=Q'S&A3GYYDL<0T%5#TU:>_=T)@@U'9"0$G!)P0:*$0$)@LP;WBJ!DAEP@V
MZ.!4]8&N=$QCICIT(0K*G9E)WW-\>H.QS?%IQZ<=GVXAGS:Y?;4Z#6XH.9C.
M9O'IYB"J'D]2#'3^36+J V#]P1=XEWI8*:[NO#!;AIZ.L3O&[AA[FQE[6([+
MA+H4JTH_QV\W&&L<OW7\UO';%O+;RNN]*-<[XPQTSBFAM'/'B3<8GQPG=IS8
M<>(6<F(KFYMKKS%;&VNLE->"*QLQD00GT*6JD1[^K+M-Z(YPBHOG/)R$2MNY
M4IJ;7'"%4)!2WPK*]BXG[#:IUXAC&5A:UKNT&#>WFTBWX=CLY("3 TX.M% .
MZ*9QV+-P OND?B<8A;S)N$1T-@S)ZKG,QG:)I34$C4:JN5%U-2)]P 2T*R5D
M^]U]W1S^5S45]MPJV?TMN-5_IMFMW%>+R[>I8<";7\]_\TV3 $SRX3YXR71O
M)!*KUMLN!*8V!"*]#J[5<)2@ZK=@-VBF;-(@-:U:=&82HXNO1[9A1PALIX9)
M11P:*;)K0=6XM +MJVK+E=VFJME!C,6Z=+@DD-B+)1?"FXH@YQDHU+++]WJ'
MC5VZ?%)( C6PBV^I>I]:*G'7"75M:MR:[NZ#QU:;Y>Z:N/N!" '_EQVY3!-=
MNMYX9;%4J;<\0H7ZTFC2X8XXKG5F(W5@$PK#<$PGQOO6N/M+"]R17NS>!VKH
M'X-3=V<<<J6[[BW"Q>[<8VB^#8(:*X ],=0P0!Q!4*;(8<U4GQD.FXM04*<Z
MT[.HZE8TTRUTKMV=ZD"->7VU!D9F-@XQ;C.$AZHPL8<'=0SA_CO-4XW<^+8-
M;BYWZL:W/4]OT67,I%:V0=,T@:J(?YR/T.#.IPLEMVGV/Q01B?PH5H,KL F+
M;N$V,[4=?WDV!F$7!J8I%@\Q"!.01#?4Y:@<LQ%O-:A&Z9S0)R8E=\4L;FFX
MJ>IZ7\YV5V.I:'.V^62%N=E>V8!:AP15HP[OKS*BYIN\+]J6V03I!:49S&,U
MM=1-0?%/8CQ)LJEP0S>^/8:^RG)?C>)J>"W*A*R&(?U5YK&,8C7Y.$BY$0NO
M20B-$M.LK%MR-:*^Z=CU1O_:VM3WJ%TUH+S5YDM/<7T%CX@)+T=]P9(@'F,2
M/* JXS<-G^!O1@);;:$N9ZX*VS!*U@,19P5HC8C2V*J+VR?.M)>VKX"LJFKU
M5YK8FY8R%ZD[A*GU6!^%ZUFRL%*?>UU0<:?V"%MZ1A^*U*+OS4 CZ=VP5JL4
M[^HJ9[\4J,^PYP]N6??706.SVH5R#,Y?:@U%]'6QU[#VK>]=KYZV^B:<5\]Y
M]9Q7KX5>/11IP-=P8!99DJ$>#@4B/Q2"6N,.:*10H7L^#L0H2(8NV+[!2.78
ML6/'CAVWE!TK'HQ3%'+M+B2C U1I=,1@6]^A-XRC$FQB-*'*8NJX\0;CE./&
MCAL[;KQIW#BX#N)44A=W.!5E,E73R#B8^K#&V\J3N<0?YY*<-AQO'<=W'-]Q
M_ WF^.3=Q\E(.+,O)<9<#3A";WLP' 9Q+G%P6I''J<MS>DA8BJ9F5:D</-.3
M>D5/)@D%"V6)*4':086=25-8-<24"#2+>,Z)#B[BX/&B@M7,Q%"0P[W3_7V?
M&ARQ[*7<HOIC-'["N_BJ$CCH10X,<5"#,:6*8U#PM7/5,5$J%9>E6$9SR,2E
M]3PH1CF$>^5Y]C.QRF<(C1. 80-9<F/F!67C"< >VVC9C(.'8P\-4YG3%.OH
M1>.1TDR/0ZK2;\(@1<2_#7 /]"T:XUZU:=2GM";+FC$M-+:VQ-&S?''75,'*
M4SE$+F@S#NL6L" <$3(+?BN?%9MK<FY#K7V:2FR0=F;#(+>E">4XS&0V,- +
M;QC3S"F3 /& C =F1R;O08=MQS0WS0P>1!0A%FI;,RJ7HVEA^EM]99[ZI-(>
M,=4B+?"\DS(''BE5\AN]<QM+P>,-<TTU9B@AWD9:=32JD%B. B;#"(=HT;0H
M'D/&12@T@C3206\SU:TVUH4&O7 <ODS52&S8H8[A<WZI#E*SD-%BA,+0M0$Q
MBIS4 U8G)@E(D 0XIB93&YO#%9Q<PU*"IMK \73^"UQ5CN'L:LXJ)A,.,+LF
MQ L0(&PHTIZ(:\"6*C@#A_MCA+.TR>JL4G0K(6-R$B*5UT>1]<6;Q/>'@9IU
MBRHEB,%Z9T :_(A3X.";E,.*LQ,7(/B-2'&"5Q7PYW&,D< 1R$%C^L#LCLRE
MX\&X/"C-D,L""J<F6[$.*,.\%9Q(Z =5#HD:"DG;LF4O7.=EE;!PBY^D">F\
M 6R8.)VPE+!'&U%WECA%K00$!Q(LH'R9&AS!J;QXAGCQTHO/OW2"EY)]*^R
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M->[JWHIR(H*(18!-GL/%I,L:&G,!EG3<B(<; 5&"*;Z/$B>* ^UQW"%QL;)
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MP"BABYU+E)Y)#)JSNJAW6$H)UM2R%[2M*(YH#*&V<Y2IN> )_5$ "0YS@Z=
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M.OVD.CV@>TS9A*J="S GX&XY&=&Y%+/83,X#^-U;,<A98ISX)(M\;ZGC"?L
MHUJ GH" LLLYD09PDK<TQI'A;.F&21"/.8AK)L1G$] ;&%^K<>,^]R:+OZ!K
M 58C^S P@\2-FR6=.<+ES$#DVFV9O=7W19UO>&.+;TI_@BUCL@%*[=)04ZK
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M2M6@43J:NN,G\=2VAE&QU#*!:9!<)C].A1.4 CA)@A0SUE7B63-!J!\PP"Q
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M\SO.Y]H!JKM[)JPU,-@:^/5[_DGWP>K"$[&]=A4]M 8VZZ4M)Y+: PLGDK8
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MQ+<5_@/"WS*SC]%S1R(,%*(D3F-4>VKB"EUK&?DE48 V/;+0=]CQS@JF[P(
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MX*;7]+J*&&C"@VV(8 R_-\$"$QS(&AD?_!;^3!.I5:@!\4_D8ZMV ,O4!H
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M8<QA!Z4H*>I#*AD'?V4YZJ)*<)H-LJF52[TJ*ICHO(<]!3GS*G,QYC0^7D6
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MUCWJ17=Y9*P8%_R;Q_O5*XV;ST;JQ<;LQ89ZL<%??//']?W5]=^,SU=??R<
M4>H+\M;YO-7M7F5\I0^K2=NQCW$UP:>DFH#_</O[G\;MD\7?;[-I)&K<0W&C
M8J]*\CK1QI-.F_UP,W$]F;2L\J:6NT54MK,(M/$/7;$:9W#K[MTJ_U)<Y<W-
M/%\OR,9;\6Y98U;[[6*6PMFH__9N5>IG<@=AZM[B*O,OG#M,^O-17GLNRCOR
M0]67/HDJ39*H4IA$E<)E424GCBHQ%262'RY[;2<'5SED0Z>\1T^BQ]2+/,:Z
M2?MOV15B>5:[F9B$^+E4UOQ;<:VMZGID@K%>;>3',TOT'BY+IX\W5$XA$;FE
MOE()<_4<>MW74M8PB3%-8K[$:#:72V3MBL+F</$C)G[HQB4"XB\:4E'LM ['
MV3.+20$20%?\GWD0Q:_RW6LUT$Q(O.Q@(O(]92KP(_-$?Q"^TZ(M_40/M9]5
M.KC\:<7<>T*&N""6@VN^/V<^E&S)P2_2:*A&96H&B^?(8C^-K\X9B$4JE3MP
MP_4X%*O4//IV+@_WG;[#?V>F1?*_0I6E[5DCE?'KCU3?EIDPIV:P++=$YJQ9
MG!VX4C5$1W-^%'2Y[9.=^J_B[[A0WW$F?O&HQAQ\#JPQ^^$'W^/NIWJ$P(6<
M-! Q66]P-^'B[\LL]9O@T?+<?\\7[HG.;X[H72_?%89"^=XV:O6F,8P__IT2
M'#E[@VN_>BS9K\X1)1U<@]3S-$2B-5=!674H9CZ)UG"ZO[TF45DJZ7O%K:+Y
M\%%.YQ"V0SL&N>B36ERC'&JJBEJ6\H*</Z0,M9!+]T'U?IJW]DD-1KK8]D9*
MWMR[7#6%1,F<D#A_WE5;_+BE*THT,"DJ4WWZQ4JMN)HW9;R'KFS<G&0B)?9&
MY?G(0HR Q<,"XB;";BJ-2;Y#$V!<QA$;I16V3)+*D#FRZ52JO&1D_9B= :S)
MA*]59L0%TY$N/N$KU>,S$XV_FR]/N8S+ U(&(/Y(^4P@J:WGBZBAE+IGM1*J
MS6E*[OE\>9(?IE^H92MI+#;A[K*$3-==*VD0WRJ+)1\B2PX$LT+?D](A)DX$
M:MRJ+,O[\<1DZ?5*;TX(M&QVRI>8N'!"5N*7F,EGZ-(D[EV*RO= D,C4F7N:
MF_26Z I,O7!=!FHS1Q8-2N<T%+H=/<5%<JM6$._>LO6_LCHSO7>+2Q!;K,R.
MGB'DQ_5ZY\:=&/F7>O&LH/2GI5J>FVJ^4R1*N>18)]-@LOF.+2S$HR6'U2FX
MXBES<J+4K' RKM99\EBK=E6Z2+.UZ(K[V9BDK!LJAJZHQD'I\JC9V#8Y?O'A
M)66/3=5Z:"3GD"Q\A2][XXWB,X"5]N>7/H<PMP]L)"8RJ0U/:8V>Z,4W,27
M#PD'ITXC!?8I+H0Y%AT(9>HG]ZE$QY']"O%.[@%(CU8^E+)$8_E0LD_$5 RY
MC.(.#X+&K?C/_)-DB_YD$J0NXHM/8NJSU@B3-HI6./]-?K#(R'-_CL<ORD^W
M$_=9T:#%G^QM_9T^4"NSI+1(SL5*:VM2W)?8*/W)R\TJ__BWC7=<5Y_]T7,\
MX4#WQ>!G1\[+_,SN/4I#DNK+X0=ZZ-?/]&PA7<2J'RJE<\N!<'RFJDJMD?A1
M#X 4!X&43B4#])9:U<CZSF2!K<4-K#_2$\A^)!68INHZDBQ)VX?EZY&R8&I]
M5RU*0B8:9(JNV/.K6?X!PAIX:1N71<>/ASQ$,9BH?SQ8=O7FUT)D^KW-7T:W
MSYOMO\A;[.3J>NX%C?-6?]W?>PU]F[U)IL)!"D9R:^ZV9G5IG5BY//T+>7__
MOG;>61S)2F_%RY=WBIFQJ3B5\'B^IN?F?DK-S;W4<W,WS8TY3(G2CONQQ 9M
ML46?YGO+" Z8^5!5$.F= ",S97X0QC2M8IZZZ\\:UVDN$JO&F\Z<NV0FY*LC
MII6;*6\*'O@^ZS")FOP^F_4N3X=3_CE6*#NZL+@MG&[I8,[FMB??Z*=#K:D7
M\-V<BK9J4QF0G7O5;+:Q^J=0]N1]<O:M]<C/X-IUC-35Q=Q5F0S)9AJ;Q+LD
M)L &CKJ)D!.X9[O@QU-V7]FO>(*P)5LEZ0.FZV4_43MB*VJ YA:M3]]ZDOO.
M2U@8!9^>%!T?(40L(=IJ;<JICH_FR0;*L6.;CC%/L$S?R2VNUDPWCK=$!P_Q
M&5PJY(SD-,2V-=$RE0R/6QKK3)1 V\.IES0'WGBOYT?9<,_\409:]2>N?'LR
MJ%YUN$\=K_1&RF]76R(#6_'KHZ? GSX^K8!F9<>H$[A)1^ ..M99'++BL]NB
MF&VG!JO$?W8"MHPGOG#^"8\ZW)@<>T7 /]7W2,NW8/S$]L]%J(116!P^F(BP
MZ/*CQF9KER$E@Y8>9?$@YOS-.EFJN(([&JEP_K//7Y[<N&W*!#J78'Z>O>:;
M5::>[T#(GS U_L%1 X]U ]"5$5MU*7A>07_P[_X/$5,<.(Z^C9QYA$(L1*Q4
M2C7<PR*XAQQ)=8<17RL+#TQ//)4*I.//&F>'B2"VBMUQ*Z%_JU-!^#O4U#67
MJZPF,WU[K\>N+ 3)AS)R^(IQT[VY$G]D_A-G-NF_0GVAD;ZQ6!P7SK]\RAU/
M>2G*-=U:[).\<C72%ENC<([DDR!^,>BSV)(J,C3%5<\.,"6.8'+WL>QFR10^
ME#@XR&."\ &?7?9#1TLM06A":E+D,;MF5 07WZ<$F@.#P'_P98SU.WM)48GF
M*7D"DO/]Q.0_,U&JU&V2DM4X1XXS:J)7RNU,9%?)LC[BZ3>+C5BV#_*SINKJ
M2%_'BTNMF:+/="KC\2;?G798T]NS!AGI9XB+<>E*?)?+E@FU?,W"R4B-A%KT
MA%*Y9OQ?H>]Y;*1OLT1V$6-Z<I-.Y]ED$?(((RV?6(@K\\R4RZ,6-7I1!UB;
M!?**-XNQNM]=BG\RF#%U4+#],$I<($=Y0%STIBI5<,$[G[72%$0KL_;$K85L
M@ZBLG#:]J0E;:=NV%L(?3_RK%^X5%ZZ"XA=SXSN3C+@7>4808ZU3RY/")"]I
MF9-VL+1?%\[NGY;L:9RQZ;CA@^CJJN^=_.6O-V=#NR)Y.A*7QLGW_& R5\1F
M8NR9*2XL)M:+5ETF[Y$<\5FZS_Z&SI]\I_;^C#(5&Z6ZB\I/[I^W\_KH>O>\
MW\Y^]JM/F"-[_!K^NJ9%4'M)BZ!K_HOM&@0M[;*TV#,HMXT\;7ZY4$7A,H;+
M3ZYJ"_EQ2P17&C6^[KQD\X@:<?K=7BVQG242^\57=]/;2>WMDSOBAG T>7(M
MT[AEGA>^C)[YL=HJF>C.9=/B:OH 5]/]72L6BUO+]V'C,K#B/J.T.XL-S.;[
MDI7G83^\E2<H?QIR7U2D%/X4-29JS%*<RQC_I$+N[ZK>J5,]Z"PW)#.&Z[/\
M?[_I%<RB#?$OONI 7K>=^N6]V"SU*[6"3N^\UOO+;_HYX^T-_1$_VJH7&A)A
M<2WB1:L;'6PJD*0['2R-6/+M%CTA_OJF\>9XX,2_^CC;2"TQK?-Z8SU>L]%A
MQ\$J;4^6!+8D7+U-3B:[PI8^W^=@,XORV*H=W]+H^I&,1WW9P,P#M1(^^7:O
MO<XXUH;+:YG=C'6Y@8"5I@Y;=:UT#5;ZA,9ADVYKV:V_^/RY]OGB *9!.]PG
MV?YC3%^0*6N["OS!=KT^,\9B2Y=:XF,H"9F+W_V\F</AU)PCSMVQ6M6##^ =
M5,F@0P1@D(<$;#LH!CB!8DH&7N4I9K?CS,$B'8<ZSI!!X&*N%N?]J8[RT @2
M8=C76 6D01$;J @)&' N@?17%P80!%UL*J\BI;LDX>K6I0V"'/Z4E&:(BF"^
MZ<RC>7E2*?7XA1X"((\D;_^SJ/ 3)653SU7)^']\<T._U:AW_[C[]":=S]^/
M\_FGX=FC94W>"YT;>([X/Y<SA1M$%U80B)*_/ZW1]+7Z%)G@;SC,=OFRPK^^
M.6N^,52=VU_?N#_YHT['CA_IOW-AL2V!3//-AWJW8;8ZW;@ ('Z.5<.FH._%
M\$IPCU.R;:^8](/M2,*R-=NU:@=@N]K.;-?LU,V6* D#V]$2K I<*=$__'UE
M812XLN&^./XA(D).*6C  ";<A0GKBTPX4S=!AOI*=X=SWHS>>CE2&[2XY%J,
M@QRDO[HP@,,$-KU&O4$0G,KK"&Z^3M$SYCM3[15FD^',N%L: @3D=(0&#."1
M7<Y"C<6ST$S[9F,5=S\1;7;SU6B9G7X'L4!JXD15U7%@@O17%P80W=X')N@(
ML0,3@6YE)3M%W6XZ/XABT&&3SC@5US,:4#4W;F14;;[:_F#67#R8:8764Q$'
MGG,CE%DU5#GP :UI-FMU,O=9&UF)M)V'I:A6'SI@ 8(M"U0@V$,1;"MW@MTC
M&])L-OL@V$)(6@7N"!O=\V:;-@KW?F2-<CK)HN=3,5@6/9\*1K'M18H]SFFU
M5C<;/5PGDA,@JMJ/ZT20(W ".1Z7'#M[D.,^=7<ML]O)+Y@+<B1VK"1<=T<<
M@=M C#R.U.QGT7!%SB\V#8_MG'2*Q&P2W(CB!5K4U\V&7I7JW8[X1P\\YS+6
MOFMVP$O-6K]&)N8*32>NZ3@D0OJK"P-X;A>>Z^7'<TM/?#,R:W?H7!]"F:MS
M4T@<@16EA/PMJ":D@1#MH"<(;SO"RW347%9->)UHW\$*"CMFOXX8)SF!HJKL
M.-M!^JL+ Z@.]81T<, MV(E;3XI/.O.'9].0Z;Q*TQ!1"ROB&V*,F!4RDC6#
M%=<3&C" 2W8X-K4SK9EO8GW[(M1-PG$S_"-D,D7D8*>FFEGKX$:,G#Q1U76<
MFB#]U84!3(>VE71PH''1=.PN+,1AD?6C!:A-0Q%X(2)T* +/_^25&060JOG>
MZYYJ=JQJ-.C<1*&RFZ[ZHW4*'2S FB6 "JQY*-;,-(W>@35?26ALY-AP#*Q9
MA,/G(5N .OY4Y  VSJM#H*I!"OT6GROKB==!6$F>W7D2Z[&ZDQT62G#P' =G
M^H,J^CU8M5RS;K8[/3*W@ZLX>:6EKY2I(-L$M()$3/4""Q0,"@8%[T/!F0ZB
MFU#P/JU;VF:[2;\/-RB8TIWLT3-9TQOYX(^</2'9=?^_N-:#.Y(%1[*ARUWD
MV]^?^'I8$,J\A>YOABB_C5[H12[G[3EHMQ@1YMVQ*C6O4@6O\CE"-&! %BDH
M!CB!8LH(7N4I!L5[QT5 -X\U1K/#SWMZ(:O*JP4-&%#!0!<;J @)&' X@?17
M%P80!%UL*J\BI;M-H3]2?&#;?"^CT)A8+Z*E&P[<14U'0#,I6ID$V4%I6M5N
ME:8=?+YWO9=?_V"H-PG? U<V)=OVBDD_R(TD+-N36W;0V0[DMGO:7-WLU+H@
M-VIR5('+HD*<Z((I<PRF9MZ3+!2KN%;0@ ',MPOS9>:<:7U+Y:8>^&37,SN-
M_,@/:EYR-<?)#M)?71A <KN07&;(V8XDM_L)KV7V:DV0'#51HG)G=^RNE/2/
M?3?S[?R3=,$7TR \%PV-MPH2J$;CK4-Q;6:^VOR@@)AR7W8_5:98-4=.10>N
M\MH!]*VD@P7HLP10@3X+,;,-G%3QZ[U&][S9IHV":@)I9ZO"* 9'7NUA5'$%
MHH'3AOVFJDU-6Y_L.ID1<,>[(ZPWS$8]O_1/Q$]+;@%P20B"!$X@R.,29&92
MS_'N%SMFJXZYJ.1DJ*KWB\1A67.YZ"6S0>A%W1 @18"T\B2;'>RS_'YQK]%X
MFPXC[_;S(UT$>\MK*' !20<+\&L)H *_X@*R!.#0N(#$Z7#)C631;R)!9>4*
MQH+K\C]+9@;4I0*VASHU-IIFK4;G*A,,3==FX-1(!PMP<16P!!>?C(LSD^HV
MYN*RW)J"BHMPE7K ;%WB"*3'T_V7P>1@NIU'-QQK;!"XMA@A7"0A%0J\RN?Q
MT( !>:Z@&. $BBDC>)6GF-)5(]+O.G,;L"$+ N;PY^.''=/X9:- QK>?#\'(
M#9_XL3Q,!S6ZF<93R1?(P]2M%=P$=Y$5,>=/:S1EMRRX$Q^RY=W#U?7G#2,N
M*Q>:Z=J1QT(S@1FYT-JY^,;ZDK#+PB^,B14(H9\RTUCS="L>J9<I5YM_)+G^
M<#"-GOR RY.SPYZO"3*M@V/5@C/E _LL>.G>KUMPV^0?(/ZW 3!J\8:5K,6P
M0L,?"N-58N.@++3ZK_&)V6S\P *C63<-(2"&Y3F9W];.TV_:028RV:[+9.(J
M#*=["_!9R&PA$S^XLQ0R;R<)SMRG[KK:5Z4WC]5F(L[+5GLSC<*(0\LID< &
M9X:P[+7D[7?YVG_=.FQN/UPI"88?5,EP^#-TE-7<V)30NRZKO(M. P8TA>7&
ME#^X%S^IL%MG[L^S)]?A2WVO;QC;J718\6J41YX:-*H*A; JI+^Z,(!.-J*3
M#NB$&&@52!&A?]BY\,=CWXOCIU*//NP71>UEIK.I[Z 50NUE)NGLO<H]XZ?:
M+.T91LV$L%./12^&FHEC[[S:K0.H]3B NFL0]3__H]W_K4JAD.WQ[6>"^AE\
M<PF&[B^)_4SD-K/2_$*+B\MMM<U6LVEV>JT-Y% $FW9XOLQMQ4Y(;*UE.ZPT
M$Y7>'8FME]MJF=UNU^S5>UN'104N<\'"J$JV8<.@J&GP'9LPOH'/;/2R<X@4
M60PDSK08BWSB,VTWKS,M%*KD"H40*:2_NC" 3C:BDQ[HA!AHR#(E ,* /[LX
M\5DC8V*Y#E^D85L3-[)&N$(@IQ\T8 #A[%)3GHD&SS3OEBO>E7>AU"X5$#I4
MVY=6MV,V.Q@!3$ZJJ&H\#EB0_NK" +[;@>^ZF=NQ??ENCX'WG;ZY_)::FJA5
M7N.1)'/\$Z!M3\?3D<@'X<HU=&V7Y+B)BBL&#1A A6\^O-V>"S/Y"5]99+D>
M<RZMP.,[':9T\)-2P5UFT4OI.-MT8D2G:W8;'3(C(Z#[6K[>T4, YS\(?G5A
M .GM1'J9I,-]26_I 7!+TJOUS5Z/SIPDZ/XRTJO&Y(EBG0S]Z(D%7#W'DX ]
M,2]TGYDQ\D/2\RCV:HE<)NVB'5E%!^L#L&\FT3RES#="ER_2JGSE<<UF7[@^
M7[/H9GAO_=SG_#GCV^ZR5'-TM*8G83L?.C%7H@J&&IQ:&*C J4>91@@ZJL+%
MX+'/A(WN>;--&QHUD3!<,G^!8A %XY#*%87%.*03I/)DFE.FIZ]<2MT_5*IJ
ML]8SV^W\1A1BB'!Y;0>.DG2P "=7 4MP\LDX.=-]>5M.WCV=MMGNF_5&?NFT
MX.0B'*4/>;WJ^-.'$3,:Y]6A9W6,'LWFBLJ>,NECM0Q0=7_;\W!-:=;P',R5
M)/)?Z,&X&X?O!B4X?([#,[TD4V.&!YYSQ%-VLVZV._3O:E?R1*6,R&EOGM:<
MLBM(XU1O 4'.(&>0\S[DG&FAO!\Y[W'<[K3-=I-.]6I1R%D)4RQ+Z\3N&*?M
M7R.+[P[_K>,^;_?P<\_ZEVV4*+V<]5^9TGV;?P\+-EF$VB-1P^W:>^KV-@?G
M)V98MDA$MKP7+IK\+Y$X/0?\UY[A\L4_!K*941")@5;1$PN9,70]R[-=>7%M
M16S,'R,\W[J%[3&0./A7KH6ZWI@LL_M'7,4AMB)O):\W:OIYGH+X@2;6(SM[
M")CU_<P:\N=Y;XU^6"_A&^/74P-.2<:V6X2&[(&S[-9P[XKM[>]_&K=/%O_)
M9M/(Y2P<FL:59V>L17&?47HY=_>#^\O?+Z_O[[[=W%Y^'=Q?W5S??;NX^?WV
MZ^7?+Z_OKOZ\_/;EYN[NS8>[Q&(*>WHS88$E_ \5L)S+(C>^Z(*0<NS3A[>N
MQ_G#GX;\2;D4L)\VXZZ-[(PN'YYO1?S3F'M84?CN=+JGW0KI96C'[*]O:MPG
M9:.1<+TX4R8_:Z=._CRWT/?6-/)_TVX==ZE&UB1D[^-__&9HUZ]6T]7 F2N$
M(SF?[>YYZY27_)4-.,3!GY-O?MH<K/+]>YOX_KGBP%<B6LO^]4V=:];IPP>M
MVL:YX"M# 9O:[*+@]K_,"HQ+OBSGY.?G8YR+:6SZYG?012"0$FM'P=FE:L@D
M?-.@0#?U^GFWDU,Z6&5P34\1RN'H5)3'%M?5(.#JVO6=C ,,/PQ_:7"MKN&O
MP?##\%=7\6'0RXEK90UZO7]R@TZI\H,&+%0Z**RT,3H$=Y+M/\+=H;XG]1Z-
MRY\3YH4L?+]"2TZT_Y*5R[K[5 LF-^#42J7<4L6IMIG_4^V<6JK@5:QU+E48
M#L(OV'4P3"EP L,4&#PP# D8P#!@&. $ABDA>)5GF-,TJ3E@M)+^N(^O+&16
M8#_)V@:'/;.1/Q%U'SO%+0]W-[4GZ]/'@6Y/@4K9)(+M !2E5YNQMZ[D[V?:
MU\:&;N YGV9F3M_3O-)CI\;__Y[-=CIFJ]\D4\X/?2=N=G'*A?"#[$!VFY%=
MIB_L'F17B\EN]^8UC:;9;X+LR D65;,+LH/P@^Q =IN17::!ZNYD5^]KLJOW
M=R>[FMG-<58)])U8=#F?1O7':UY"/]3Y-^8QT:U-1)PM9^QZ;AB)M-EG=I)D
MV>.V-Z$/#]W;,8R(*0A4\[?0>\$%YV?.^<DTJ-7&E/L^@SE3>JS =J-N]FHU
MC(4IA+S1&-6&26TGAP(L6P*HP+*'8ME>KBR;0T2]7C?YLL"RA9 WL"R@ ,N6
M!2JP[*%8MI\GR^81RF^;O6Y^\]! LD4([Q-H+;L5+(WN>;--&QHUY=1/>F$P
MW0OC)"GEQW6'"H .W70$C(@O"Y8;5J'!J<K;J:K7:HM.5=*3*&Y)=/ K@7;/
M;!#*=8<?1=>$(%A!!@HP<Q6P!#.?C)GK>S)S#M<(S9;9;S7 S(60,# SH  S
M5P9+,//)F+FQ'S/G4D70,3O-+IBY$!)&I;1@I3&I0N,:,7;8& ;^.+YI\+W=
M;AC(MJJCCP'5.WMTJRL&3AOZ/-7V9]YN[] T5SHT5Y[MCYFPG?M< X12<,Y.
M<Q^ _GLY"=8[>@B@$P#H$CB!+H]+EYE><5O3Y?K8_'9TF7.0'G0)NBSFAE,U
MPZ#+8N $NCP,76:ZS6U+EZ\$S+>CRYPCYZ#+0]!EZ1J[$]_\F^B)!88KU=%X
MJQ/PW^TVC!)]_\IUT5PQ.T05AAJ:_Y'%!BI" @;P X2_LC" '^AB Q4A 0/X
M <)?61C #W2QJ;R*(!_VZ"!<>1$+6!CIJ)]I>&RW(8YDKROI8T#U)JSR]H@&
M#*#L7:IS,O,^8DNG;AMUB<XUB_;*:$WN$ULM.GTVH='$-1HG4 A_96$ G>U"
M9YD)#KO1V2L9IPF===IUT!DUJ:&JT: S"']E80"=[4)GF5$).]%9'BT4ZF:S
M!JXC)U)5;=1,/UJY/$FT EV:Z4-#]V(+_:0* E4-<RL.Y/(D<RLFX^?)>VE%
MKWW/GR^"T8Z/_&L^@>E&?LX-VD.5UR*@<2,9*,"C)8 */'JH0M)Z+5\BW; )
M0RIBT,*4@F((U\Z]%\"F%3#18-/"0 4V/1B;UG-ETTU[-,S8-+_)B>!2XHT9
M\AEM>;Q8?*M^7FO31D4/3<PO)%^L.=(%0(CJO36&0)0'RPU;5L%_RCVJ7\\.
M@5CK0>64;-ZMD<E8@-=$UV(@#$$&"A!Q%; $$9^,B+/#"_8@XDW3Y-NU_,(7
M(.+R6@P0,1DH0,15P!)$?#(BSHY%V)V(\TGPIS1&""Q=A*S_E8:E"BUAY(C$
M!\9?QXQ)X#^[H5!\_F-\PQ!9/]EN0Q/)-G6CCPK5JWF,M2@&3AMZ1-7V=G;(
MG\B,M9A-L_@<^.,+_D6N-^68W"3S9C]*VZI>=R]LZ>5/OCP.C.M9P<M5Q,8A
M=Y>$6Q3XHY%TF%1QY!&'+W;-7H-.FB/*(D^=T8CJ?UJ[#MHM!DZ@W</0[I+V
M;B>BW9R'.+::+= N-0$%[<*<@W8+A!-H]S"TNZ0-W6EH-]]AD&VSV0+MDA/0
M"M8<-+KG3>(9[;?YW@D4*[>B /A0O9-'O65AH$*]Y:&R(Y8T/M2.D<Z'^,@\
M-G1SZDJ?8P@?B0_E-01(3R0#!>BS!%"!/@]%G_U<Z'/C+OA@ST+($=@34( ]
MRP(5V/- [-FHY<&>KT7>#]#9!^R)I/N2IW=?L\@8^2'2ZD\N_%1N^I!H4 2<
MD&APD$2#1GW15>$&<I9K<-Q$^%9^<0"D!B CKY@;3M4 @RB+@1.(\C!$F6E
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MQFU[:^B"3DXPB9H,\"6$O[(P@"]QG"*# TD- 3U ^"L+ ^@!]$ &!Y(: GJ
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MZJ)&M/:ZOAZ;>.,J9?*(0B7]FUS *K4/=.).*QNI5=KD0;5 2-6# H14?*A
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M@#:0@ %\L7VSO4XFVKRNN]ZQ3F(#9_T\YCQZ[R%\352&B5H7<"T)&* -)&
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MV41[;&I"3M3\@(Q)P !M( $#R!B'-S(XD-00\ 4)&* -)&  7X OR.! 4D/
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MK?BW+1)EIR%S#->;9<ENW3>G0%NCG #UWW0V,#*#B4&$6S_  &>M6-! 0TC
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MO3-<3_V+_T-><YCJLH/]:^IR-/CR0].P/&>OSN,%V)6Y[N,!"Z/ M2/FR,U
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M( L--(0$#(BY0OJK"P/X@2PTE=<0-((G ,L644(]4N&!\6?S^*Z*;O$3>1V
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M6_UAGSEM"%B$<R'Z\"?;^#?QG:\E2ZS:G<T[[K>X#6EFLRD4[7+*U#O$G<=
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MWU>O08K5O#35&XNBM'"XM,+T@A>:]+SV!8\B9SV.6\^^*OL5R2Z\TD[)7I"
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M:7_B7@HI.9)N@6Q=\"R9=9:=XL\)0\!TDH&0&INK*'^>:QU*6U'#J^4V;I[
MK8GKB$B9LD:/4XLC$#%6?"&Y7VLO%T1%*G+T,M'C'A139\VFJ1O/B'E=3PM&
M,W)'J<+"E692^';6R)81JZRO$^<4N9JXY++C]ODBD"T_3-D9F<49B?:B4F92
MAH;;()?OKQ48.C"I+T1%P$L->5O"5:Z7>E_B(#+OV0U\.55N^5D,J2F'3DWI
M(#4%J2D%?DZDII0@-66CS))UJ2E#Q^EU'GJ-LX[C=,]:/:MYUK,[K;-ZO_Y@
M/3P\M!M6;UVOQ\S BMM >%O1R^U(]/#W''%S+EM9(:. VT^].5+XDITI3][
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ME^':M6"I8.SPG4BC/4ZSPG%/N*FL/^D,!IU^<V@.!\T>N,_@^>J=)NN.NOI
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M40(N&4Z52&U'6DNEJ)^B8),P;]R.+<=%3U@T3M[0RG^4%TJ1W5Y]&"M\(<C
MP.M'#XE3DC7/"7\PJ4R^G !+[)D<D244'O4G5LT@P@)MG.B566O4/K$DJS96
M%I7^:'V#-_O<"7TNU)\V\K6>2X2R>ING6)9Q) M;67NVF<-K5'&!)NFZ->S[
M'Q/?L1?@,^?(]X5;HN7YG.LT7'OWG+Y%EHBZQI%^!.#Z$W'K.K6#'^2XW\MA
M?X6)[7OA0K_2.#R%OUW98.9AS=^XT?P)N9K,30C[3?WJ[?\QWRMR]HU\BI"H
M-2>AUHR(6D/4FC.>)U%K+H!:LQ4S9AVU9FRU>SVCWV\.]'ZWV=,9/*HSZ#3-
MWJ3=UXWQ:#SMK*?6'.G,@CI K1T3OPG-"QAP?GP2&'&U%M>DDVO5>/4^$+<"
MGOF-Z?3=LE)P-B(JWB'A,3Y/AT^9+8Z$A0OR+(I('KEL_VGJ!=D8/)97]+R]
M^]*(W7'NZ4X"%C?H7#IAW2H&+2T,&0<M,/D'FY6>+/"4I0\^+[^.(]WN:^X
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M4&QJKYSRU\W\J(H"!+ZD_02^!+[;@>_X[,#W0Q#:V%?ERS3Y "%OK6R/JA!
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M4042AD+I?JKV_6(,ZF,?$5*Y[Q,XJ(5RWU5F=K8Z6APU!GIU%Y7J4@B\CCA
M#I(ZLB!,)DPF3#X*)G<*I?:KS!=M27 =M;N$R=2<8Y=BY86F 5LW$>@O*_R-
M-Y_;(9+;L%W #0P 5(*Y9JY7P#T[O%P]_Z3MPN:Z#M/A_&69;OA7W^QTC4[?
M;'9'@T$37&6C:4S-3I--!FUCU&7#=GMZ"5T&!KDN YFEYS>Y<HN_HNY]7,Z_
M./_L?(L%_C,#SZ[!#L9Z%T;6@OD&3D7[G1E!=7,Y#:K<NMJ_(I=A2Y=^@W<G
MP'NQAONLL1_,C$)F:0:\VS4-UV0.;Q[@)0O@X +P]C'&8N%[/\#\A\QYUM9
M513ZP7^G80ZG"FU6KGUF?)E^98;S(0CAD7'KJ#4;-/##;_A65+A_,N\!;/7,
M!ARZ_F$'?R'W]0:68Q+YS["R_V)^P)X_\3+1V/*DWQYTVUE\N_W\<1W O>UT
M&_#5!5S3@O]& !S:E+$0>SW <GFP4I[_W%AYJU'T>O&F4]MD&D<:S7:U>+ -
MK@ABO&*=77@9D-MPM FN/<(4?M5VS6)*5U_/,81OQ=/?P<._PK/OF/^-3^JC
MYZWS$BI=?AV+T+7*%ABT(%ED&%!+NY_9@0:VF]_BEIH)V\<(LJK\C[^-8/Z_
M!)HIO!UMQ@P+GQ+"2%K:F@W<T<]J!P_S.]B;A(;MX@YV-?2&<(U <;;8S1,O
M"G?=Q86B-2^\BX>[[N+!CILXW9ZXR ',%2;B+_!5^(E7@=2,,+M%4=GP/_@&
M>.6 3=H[]28MK"YN4GV[37H-&Q(-8.2$<0N<C#KR56V 2Q[.A H&VI/M.-@^
MQX9'K/+V>IW\9;X$ECDJ?\ /<Z, BV-[UG%6I> 39K7-PF?"E\ZPK1ISK][*
M7:KKRPYM R8<(C+ 9N1Z$7JH.F! X&=#XP\!<]3D/Z#=MX/T([9K^GSC@EZF
MD  &$,6 2\W7M,'W=;3 1^>M 8ZNM6:5"[R]WUD0,)9?[O?@#/OV8D.;L0I7
M^NV[C+K $CB1!4J%]1OGN&:P(MH<;%_(7+1TN4YW!^S"P1J-^Y1^G6RL]0+;
MLI@NAVW9W697%O4'=F;W)]0XWJ+*]H-0:!Z^P SP7#"J=RW#YRJC69&/H)%H
MF ;F;\Z=&5QZUWC@\T$SB@]8L^8_)KYC+R .RRWU*+?4GY('?@35FV8,']I=
M>.GEEC?.;C1QI0O+_%-LX)*MV"J$KR4=&67T?_56D\WS[C,P#AZ.-W'L!P.=
M<=B_"P/\0FX9P.=N@@H:L4T 08+=Y&"KA<8/)B*O%.%Y!0UXEQ,_"D>Z\-G<
MAFW4.G\_Z#IZB$!M :Y&*V*9-7J(JL!W<DX/QSD]!!F"9GR9?LZZ4'D[$*SO
MLSAJCT2?1?@AKUK+[DHS8":Z+$^>;P6('^&35]S6:YTY<&Z_N*RB,$TOIA./
MX.!] \]S]LZ/W.#)-K^7."(;UVT/-P^7YM%&E8KFC:S'A]OG 9#8AWVU'*/Q
MD6K)4+.A&L8E+/$"#=>-<O&:O6WCU%(Q=%[$%=Q=#F /._U6?POHJ0HD]!<$
MB7W68V>HT/8S^[8;1#[W<[@MC^8'0P$?R*:FR"MKX&^)&!M2PDMPL=3.\I!*
M_/L/HFK,ZG2[<CXS/Y[0 C2U.0'Y?6\:4YC/&\-Y,IX!5GX^QKQ7I'ZW.GW8
M=]9WG_[4[F8&_&:R*,1M!@I[ZYH%#^2,Y_C9PSP4[*N/-L8$B .)@2FDC,]X
MGH4^X;)!N.@A<2&3?,5S/EX4P-P"<"9-M@BU8(: AK/E^"9^F_.>U:]/8*2R
MZY(_3@,++D^G1)8T>V"VPPG5NB.N=GMB=JW1L&E,3+W9&\,_AJEWF]-IMZ\;
MS-(!8TN/N-9 Q2F/VK,AV@G'(1QWD0C#-$<<':HROI59(UU_H=S<-FY9+M[:
MD*&#J*@L0Z?8NC<215@I@.X: 7S%W*+AW#-_7E'B;E<Q*+.22XE7Q>2<SP,K
M-KA\6EJQP8G02+%![9RT5VS\:\\0XK&NRW:><.PBI T8V#A+)L0@P,8)+>=U
M?F<_P%"&GMO0/AE!8)BS*&!A&&!&T0@3-%9,-JN1H/<"4&RBV^L_?[K>&7*3
ME*W>51YT5YW2\<PJV&C6#&%(#>54(SL.S"HW[1_-F6U!:/%&ZD@?L&;F,];,
M[62E9@$;+V1N  N_3795K;'OG^P='#W9N[QU"TE=?526U%5LA4MSS)Q&D$#M
MY2C%<)U2W,KY6B^C'9VRPV;%5KJH'"%WLAAGWHG#;6XZ.!<B,7_G?AJ:'H.:
M\DC!9R:S'SFE4[I +J:CX$\<P_AA1&0[%K*_8&%Z>EM[QRQXR=*^A3Z>E"WY
M1]?Y(XLG\& ?X&DN]P\=QWOBIQ+;LRYR:IX_>KV.'_?%?<=FAC/],D4FBN=_
M]/P;SPU"/^(/_@(OH$/W#?VYBM2^(_V9938 /WK,%#<=%$N;8N@VX>.-CWL<
M/FJ^*&9FW/ARUA5M:>EY%@K.>W!!69#7" "7KJT1E @3I&2'@<;O0S2]:?./
M -\(7BPWB_"5!G_%L5TFB)+I\\ -\**'&6H OL!)'<G X5MR'._K %\KI("%
MTOD,&3AXUB1@.1D=GA'+5^2Y4TZE8CH)EE  5=U=<;J%@^KW;,I\'^O>NN$-
M_->NQ!YNJD(V*)9VOPBRJ0$.E_^<D72\_0/[P<T8%]3PW2@&W15,\-]!;0])
M3]WYJ'V@7^7$LMWX!/UVHS_J;.2-RKV,&ZY (07\05Y&7(99^[?QC'LV&6:.
M2Y#=<+GS8:2;6?R,">V[P_"DE^^[E _--Z[MYPC/VM3WYEF&^;_P$6O'@^^!
MW_&LF*='U_ %NX,7Y MND&N.,'B/P7N&J<;#"5P^8?#6S&A=+COXP!_#K/^%
ME3O^5+BNOM7;W1(.Z8Q#P>9@KPNF:0IV.!OKI<&5#&[%M00[D%HF* (^6SBH
MOEX$OL*3!Q^R TXFF!JFO$_(/\;IT2*=$G#JI2DY!A. L3DKI>9/HS""W9-5
MU.4IMK0[XYG#800C\@42"HER3Y\CQCYX4>@0EY>Q_-9UQ*XJQ9O%DWZ")P-P
M+\:M8EU+#5# X=F(C7J\CB^=Z/$G3,Y<NR^IS^L31)\,A)JBPN<]SS6>[=:W
M8W(Z4: ]QUH [N:=[YF,6<%',*3W2/D-$^?TU#K2:Y4@4ZPBW/ ON:!&SN//
MWEA*"7'+-Y0:8B_#HMMSP) @)1"EV!3CQ#JR:\;!96!(YH**A%ZG/4>SPGEB
MXD0=!Y=\77JI4#*_^:?FPA<&]RYUJ(4N+*3HM*<92RYG.,_:'%Y=9C''%=8%
M]\^//>@H\:"C!3P:>>8,A(6/S0%T)GA<M1&[Q?;.? MB^X5[9'%6<1_U8!]3
MF6OO]S)^A;=(/1""0@);'+6*M>>T= %6A9!$O(-3-##KC]LU>+/"%]^.D[&S
M*[Y$8).WJ?GE:GD?_;<KB%Q,YCBXRT MD]_E77;^>VZL;_C]7GF;'43F&(N
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M]0I\YY?+_>B-[KA(>E>M7205^-^ZP/^Z@D\OQX]9S9W*WV;]9LZ8%3D,[X*
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M=A@QC1_,G/,/6^)#)GP"WDU=^'+^:(N:<]=PB3WFPR#TB1JF^ K7]AV-B3_
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M:^.)%'B*94,+T1NDVB5!=S^;3=SE/-;9K'P6=IQ011I;D=47(P0B!$J@)X3
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M_OR;F9#9;_!&S[VR(. U;/TW9_OES/P4\#)%HU/K]I2D!NQ@5H'_#4#/]2#
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M[BX$$(:!F  M9D5GYD&&=O!VL2V/R5=G\$&S)K*F.=MD!GO/,34<<0H_-D6
MQ_><L?N&875X"&Y=8R4LXZYLN>->"*#3ASVN^F&[@H-DT96GB!@T2"_G'F_I
MXSQQ'#L5WNMU[;Y!C[%D<Q@),V9>,'G&[Q&#]Q1Z6)VN&/:(\>^9TBB?8<T0
MJ _:=>(\76P[%0@X1E(GY,G?\;[UBDR7BP;D],2/2KF8G&5"NL>T2'2^%8U(
M" /BL$"Y->*[3!QDQC2>&%)HXZ$!"(&!.$T])(66Z!J 8X1]Z_2% 576WOH+
MTR@H,:IU9$2)3>82WVH[N*<IG8O#]]"FA&D(2R)\[[74(QF8KBWNA?R':0LK
MYTMD-3]T-5Z"M3WV^<):W [A"\KU1:9/Y.*6@=LB&X>/:L1X2WJ8RB(I=[2<
M>BQ1@N]<C'#>?#DL\]3Y%;ZHW A S,HF9N&'[958C#^8SQ\&RUUH-L?RPE#Z
MC4[61[&Q[SVF!7YT/Y(-:8NYGR\7B&G?G%G:6Y-9^M76Q!K;+;OT=F*8L'S,
MV<2@-7+++,N=FT_4,FBRG&%A!;G"<6-2RP&26CK%2VHIU'WC+P\/-W</5]>7
M-W??!O=7-]?@'1)7(O+(>>$7GJ-[W5(,*-*Y1$/J2S4:SHY+-)Q-E^2E&N0-
M!(12#<@A5\N+T&DJ*Q0N+_O-]23204JLAEIFJ%(44#GC!5'.OMX,O]]=/-Q=
M_#:X.[^Z_NT!,.;BZK?KAS^^WP7^G?3/&O%2#<NB#I>VPS@C_H</6S3="+=]
M8H-U&VX7KZR@+"G\X6WU3H)K,KE:I!<[L4Q,!N/(#.+(DP+%D07.5+X=W-V3
MJZNK1,69_=BPC<7A7SGCV8$?>[.W4YH/X.[N+L[N;^Z&#Q?_<W'V_?[JSXN'
MRZNS"_C%V<W=;;Q\C]+<6+YGD4Y<2][A"?CB,]N9"7:(_,9I-<'-[\QS%A*U
M[T7MOS65:*+Z"P;'DV?#-(,<D_# -U94E89%@,-TTF7N]B;!UL)4T^@3_'WA
MCS?B(/6;N)7HAJFVPP",0BV?O*<?R!=Q!S"X;O5LP5OY'<#%\9[(= G(P>A)
MX9TC/3P_?.+'3O;/^9+5%D=,XH@DN#@[9<P+3Z_C&8%AJLV$F2+AX _?8D$:
M7O![7H%'7RW!$Q#Z(P;?S\A@YA@F:34#7B/D-ADOG@1C&49C"0XUN.@M+1*?
M3C@G#(\<B6,?S@_O8:$;G$&O ,Y >8BY@+.;;[<7U\-P7QWS <I&'[!<^/'*
MW>EC@K><*I1D9:\7X6(UQY;QZSX@MC#7K !< ,D%H#X\@#_Y?G=U_^^'F[^N
M 0)_O[I] "B\'UQ=/WRYN+Y860GJQI40YN;-8ZX3O-Q9>$:=<*U"%]]6CSZC
MGBVQ6SR1TT;4W&MMK44T?F]$-"40"K*G4WB2$/G>2P[@]")(88\O87++T_AB
M_ 2NSEU79^MAL13O+KX*8.+K<QB\NCA_N%]9G:W-I2;#=7@7*V_@KBRZ>&7I
M6EC;-- ]J#!* <;P=<^%^+K\;V%UPI/B:D (/,HB:S\\W-Y=79]=W0Z^/BSO
MY#Y<7EP, 1SO_KQ:663MC8OL=E$F,G:=Z9*%*5S#L$0_KJ"]5M =%=U=%NDC
M@]G,-BPONARR]%$>YR6C.P[A-;.X/@QG>J U@LQ?!LQ?%YF_XS%_?VXK-;V#
MQ>9Z?J%T^";^]ZLO5_?#A\NKZP&X<O#DPWN(D'B%]X?A2FUWI;-E-S\Q1D:8
M[+G,\%YZAJ$V8;IOKJO1G;2%_2!SSS3YPR/FYU#&HJC%_QPA6W/=T@M;NGK!
M;0711_G7=\UW1&.FR9O<@H=?O [;XHK7*]9]*OJ2AEV88;0FG;GL-/KA$PF;
MYS:;8:ORH*WLYHZ^P?M/&LW>LKES.-^U_9T/TX!W?1O5WD$M(E@O.Q^\RCNC
MH+5AND;.B4[KZW0N'CNC//&V/'I_>>D[K:Q:_49;W6>-[ &T\DKOG+F:8XCH
M=H/P8 Y96=EQ)/="=*NMEM+91KOQRAPK8!F\FNI1?$]AK.*D<7*"9L$[<%S;
M#32-5=-H5=XRCABNR&07$*KSC+]?WZGO7IEML]%L5]Y*P']PYNL<=K&I PX0
MG,2.=XN92#682-0?PRWDRXWDU-!UDVW=2/*!'7$7N?:>Y"M+;^TLE%]R&N'6
M(%JV(8FH5[9!23BD( Z4;512"JHEWZ DE)/:Z/7D&U6WH>1FYN'C M@)XHF0
M03WE8/,:E*TSQ>;!1)S/Z52<]VHUE!WC[K)*(K5UA_3? <W[Z#46_DG)Q.'W
MJR>>-SO]^/'Y^;GA,JWQ:#]]'#C:A/<H^<CT1^I\U*E'/RK!#>R/_#*VTF\I
M:D=MJIUN3VU^U/N=CMK1V<^6TIAXTQ<7.\68=%X619R GXJ#<@CK&2_+$[;]
M"]))PEX^/.,D.#!GP?EX=)@=J^,1')3#1+UX^T#Q<]@--"AB$I1J6-P7_$@_
M[^_Z#Q>3[WZ6NV^(EO<<LK;B7OU?%5+HNECR().0)AEGQ9-L/*E]]QF<4KW5
M[[3ZL1N5E3&*1-R<]QRRMH+-$4MQ%;J.CE@SFX &Q"6?7/)#7@9-5 U7^^+^
M4'/7M1\PA7D&MQDQ;DBHE6!?CX0:$FI(J"&AAH1:$4+254)-14(-";5#$&IJ
M%H3:NKI/V[[DRUSTN%A/M2&]AO1:216*]!K2:]6DUS;%+\55*-)K2*\AO8:[
M?*37D%Y#>@WI-:37"A62QDFE-N:K(;VVI-=FTZ=9G?UL*P_*KNEFL?NKHI;8
MLBEK@NM:X;02!=/S,07RYMUW_N&W%(Q:N-<1Q13R-.EM=BL^^.ZSTN047+G5
M?FS>K0AZSXYQDU[YI>?7-@<P15$?LFEO9-.^B?Y=+4&D*4BD(9&6MSM (@V)
M-$F&A$0:$FE(I!V%2,,\-232=LU36W;?74U5:S>5EOI1[ZMJN]O4.2&71:[:
ME06/YV7"PQ;MY(Y/W"4#WN@Z: :CBS?^X9MSHG2#H^D:+V_,OX=.;>OQ!94G
M_J"%9<S#EN+Q'C;EI/KRWD3+3OX59^\XK.^\8RR^-6 NWB9S:+7J:KMWHG:K
M:!3'X0H+9Q."82RG-<A&/>9H#<N4O':4D5=*!O&X^[*T6]_C[I'VWY ??LN2
M#:%RN-69*;<IXS +,<BC17#5$.813TE+(4LIXX;])7M(!-\Z*CE .G_*L-UH
M21$8'&AKA43G9J*SW^DVXT3GKI=RAS.FP5PM\$FB9:D@'P4C&2MSMR7]4$+O
M6W .,,]-7%WY.*B02H\;!N9T@3+&R55(L15(W,.+L1+-Z'!\FJH@H8:$&A)J
M2*A)/$@DU)!00T(-";4"1URKA%I;BL  ";4C5KA3U'ZSWU4_ZBJ\[*F<36OO
MR*;Q5J-!7P@N%-]AR)7),H?LN;+68'A7(9U6ABP[ 9=0/FY%DG S+[)L$YX7
M5Z%2QKSYJ/=&\^QEZEGZ"\W%8LKP\FJY[]#AY56\O(J75W,8$EY>Q<NK.\<<
M$%@I_UT@DNB0=!D23]E?656:N]Y9C9-/4RM(W^+5Y!;74\F(><^,6>ONH#*J
M3:(+J+KA,(W?<PW^\I-IO@?3@#_#=[Z\E%JV;57^I%;A;GCA)5 TAY5+H'@+
M%(WBA5'P<*FLYB ;$U<XXUAS>12KT"&1)YN3P%0S&0:)J6:8:B;E(-?1B#*.
M<QVQF-\XD6I,0S6J2#4BU7BH2Z-*<]=;HVI3:9&+__4-;TZN+.XQ.#]X:U)+
M]&&E0?6\FN /^;1$$PNZX"&]"7.8^#ZD$G$G^()*Y#=0R\D32!#3%LX@D$R4
M:@Z'"&U*IU'D S/C Y>77Y$01$)0-B^!A* ,@T1"$ E!*0>)A" 2@H>*FEM(
M""(A>#A"L+4S(:@VUQ."&SA %TE ) &1!$02$$E B0+R_,*9TFD424 D 9$$
M1'Y @@"P"K)$$A!)0"D'B20@DH"'BIK;2 (B"7@X$G#7ZG<!"3B=F?:<,3(4
MG21N?1@"=9$+E",4+-XN$+E - CD JO$!6*I/ESTR 4B%U@IF@"Y0.0"I1PD
M<H'(!2(7*'_4W$$N$+G PQ4C[.S(!08TH+CM>S,>0^#^E7G@-&H$GLMT,O ?
M?=<C2C>(YFMD-!?DX)8*A>?TR=#)[PWR#?8)-7([:9PC68C;1"Q$B%0A4H58
MB'"'0H2=LIH#\HR9\8Q8B!!IQL(W-L".(ON'4/F/2DI!84<1["B")-ZA2+P3
M)/&0Q#L<B7>2.XGWEV&YGFV1?_G68YR\BX\H1Q-LE'5GB&0BDHE()B*9B&1B
MUF3B25G- <E$)!.13$1. \E$)!.13$0R$<G$(I%I$)=UD4Q$,O%P9&+W,&1B
M+SV9^)49)B4#TX07-?(-\P%Q!X84'E)X2.$AA;<3A5=:<T *#RD\I/!D81)D
MO.F'UX[QVK&4@\1KQWCM.-]Q(LF8AF3L_1>2C$@R1B3C;/HTJW-RL/?0:BG9
M$H27;.3XU)D3516QN)+JTC!C,^,')7]0T_8HOS5,G2D2A06>0_%G<-PX$=4@
M0X19<2W(1D0=4B=(^2#ED__N19(@H.2R1,H'*1\I!XF4#U(^AZ)\^IA7AI3/
MX?+*^GO11HS%^LZ>V=,9LUSQ7M%X OD>/-?'Q#!,#,/$,$P,VR$QK%]6<Y"-
MCRN<<6!B&+*$I280D"5$EE#*02)+B"PALH22LV00.2I-I F1)CP<30@FMAM/
M>#:AUB,CAD7.8*R.;8H$L2%[8C 3C9%;VS2T.3*%N-%#IA"90F0*D2G<@2E4
M=B: BF(/2!4B58A4(;((^<>.59 E4H5(%4HY2*0*#TP5PC]T9#+XKVX\I1L^
M'ZRB+D>;G$[V\"]3Q)HY:]GNA5.<.-$<9_21U4<.HS_J= Q3/*7F,YV[[\A'
M2>(Q&$5H,,)^2&!KO[YKOB,:,WGHHX&Y+5Z'YB=>KXS]E/J>_2GX-(]A33IS
MV6GTPR<2Q?G-<'55DM>6I4\%WW$J_[U](X$T.]+L&=#LN][B'DP9O-(%N7['
M7$_<W4['O9-;ZGB&9LR"Q-W!H\,8OPZ.3:.1X4>&'QE^9/B1X<^/X2^MET"&
M'QE^9/B1_,L_=JR"+)'A1X9?RD$BPX_)P <C*U5,!D:6\H LI5IHEC+>%1OI
M2=Q<(CV)]"32DTA/[D)/JF6U!Z0GD9Y$>A*9B_QCQRK($NE)I">E'"32DTA/
M'HR>;"$]B?3D >G)EGST)/;9EC;.+-X.$SE*- ?D*)&C?(6C;)75'I"C1(X2
M.4JD+_*/':L@2^0HD:.4<I#(42)'>3".LOW?V&H;2<IDJVVE_=!J]>0A&/^@
MEFC3K021O(IMNJ6.%2O>F5B6*!/5($-\6G$MR$9C'5(GQ2*,CAODIMU9'#?P
MW'^_<_@XL+Q[6B2ND+B2<I!(7&5!\N<.[_M+]I (OG54<H!T?DQ4ITC9<A(&
M"\7-;.MWNLW5S+;.CL33C>^YAL[(N>$PS;.=%[VZL0</)@>L2R_[."AKZH@$
MT6+A# (3S- HUB:8=<IJ#[*%[H6SCHHEF"%?B'PA\H5%ER7RA<@7(E^(?&'!
M^<(3*<(!I LEN A[LFO3;MMR?=,SK,<MB68\H%=.TN29#1S+-OF%UB?X>FP'
M@AM%O,N*5"-2C4@U[DXUGI35'F2+^@MG'4@U(M4HT?:AZ"Q$_C%L%62)5"-2
MC4@U(M58<*JQ6Z0[LA(&"S+<9^T^M-K-#'G";W1.5$$2\G]?)PGO#&U"'9W\
MSN8PXS4L8=I!U0AU"0UOVMH6^<,WYX03E7PD9=T^2A*N5?PFGRR!'JI!AA"Q
MXEJ0,KC$:ZW('2%WA-Q1"62)W!%R1\@=(7=4<.ZH)T4X@-21!&EJNY93^\JH
MR]8Q3S ,TA+Y:9TTU-,9TZE#OCBV_0,^TX3/?+U=89'@*_C'+@W']8@HXL:?
M1SR;!$,(>SS,',,DJCA^5KJ8X8;Y"9CAAAENF.&&&6Z[9+CURFH/LFT8"F<=
MF.&&+*5$.X^B$QCYQ[!5D"6RE,A2(DN)+&7!6<J^%.$ LI1O2'#K/^QZ#78#
MOQC=@.VE3V[[\NVN?G-]0>XNAA>#N[/?R5^#?Y.O7\^0))1E#MD[C?J_*J11
M&?/;LE9ILZG46_U.:Q,6E%.OTB7,'1/>BZM2*0/??!0<.P_D"> 2A-I(ELG%
M2B%9AF29#(-$L@S),B3+D"PK<+ %UL$/)B4(!Y L.U1*WYI\/D7M-_M=]:.N
MPLN>RO/YU%U[5,R8Q7/W?C"/#*FYAGBC+K''Y$;S[.4A.*??-O-N?[#QF#D&
M2._KUS/DVB290];V.ZRW!L.["NFT"FR;2) [ 0^C5DJQY:?;&N53J)2!<S[J
M?8'.4@3K2+?)Q6LAW89TFPR#1+H-Z3:DVY!N*W"XI2H-!8NO%91N"W/35$5Y
M:+5VI<N^&J['Z;"A/W(-W:"<Y4*&JZAS*/X,9.2D*JD&Z1BDTFI!R@ .*YPA
M/X/\#/(S)9 E\C/(SR _@_Q,D?F9%O(SA>=G6LI#?^?B9+PV/LR&4S17\.L9
M$Y,+$Y28PW1RZX],0R,#3;-]2Q31OS2<*5X)+.P<BC\#)'&DF &2.$CB((F#
M) Z2.$CB%%V62.(@B8,D#I(X129QVDCB%);$^=OMS5\7=P^#^_N;N^N+?^_
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M64=\_#?H,1Y<UO^Y,T4>8DH&\"SE:-[)A,<+2>E*HH-L(7*#,8)SZ&+A "K
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MM"1&OK?8)CF&CH>1KS2V2HS"2S7RW4=]8BRWH:G\BN2>11*&[0PE#-?=K[]
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M@!"]+N47L\8B]\:#4IB=._\7AU$R+>_@W'&296!YUY;KG/O'UJ,;6=XMFN0
M6Q .'A0T(HEA<@/0K S="-PB4\RU08KU#;#A0[J8?K.\&+#(/SPO[9!NJR+\
MR<_3%Z3DW1!<+9*E>?68&*5HI2(.5M!//CP/PQ@X/Y"J"$Z1@H%K )+/K^/
M7B)NKSW+IYH+HM\XF,0)HO+%9GFME 54&HRRSDGF:5B6(Y?.85D2/-15BIT,
MSU!2MQ%7/]:7X#GY$Y/*IZ6H?$Q%2K=)D$M'M2)'-,GO5A!8:$.A5D+,=$5R
MGR CGOE&LNI736H)XY-3Q2HF]IRPU43Q)N6K3 8:M"_BFM?(Y/*L,'31L24Q
MS-!9!Y]'86 %ZSN(&%A9/K+OT@--.B[4DYN+MI0A9>*,90@9"7,-64$P T[8
M'M>'NI1AH^.-?_OCHR]'"26 7\41=CSCHS238ME^6,5X':-M;(W>/E_!V(_F
M412X]W%D(36&E@;BT(]Z#!8-<263M,_ ==.2MP-F'BYVG5CWM!RVT7(%X4G5
M8?<]\U4S\-]&1J(@QV($:2 C19!&-RJ[,)VDY B$=_O,_7&2Q6L89*AYVDBV
M?QY(TT293[[,P_S%9;2S&XE(LCXCA!EP3JW 1TH\9)_\313D>*!M.U[%.&+E
M-#G^V25B("K)S5[KS>80K)V0)+5;N&-Y%.W6PU*8SLPZ- \@/C*QJZD& @8S
M+U_-;K 1<JO:>D)RA;G#IP$N[K,GY;)[@33\.?J1#_#2TU6V2?!\'M@5RE9@
MYU2SA G*'*#TF44 5^V,9"^#S0C# )T2OKZ9[>_/]M_N[[_9>40G[@#-G*]O
MT-R/0\01?$S5*2*7I(=\L:$?@9?HU$L(?7T3@H=5>I;,_N[!$#A?WT3!=D11
M+!BUZ26MX%2G9!TP]0N'X/2N&Z<A1:[)KVH5N%6A0 K]1R1_KXWD%>T^A.!E
ML3\J%KN:\E4G<_OF!UM-"R+GY_'(V6$#%C+/#D<D,[U!3^17O:0%RM]T1"/"
M*E[(0VQ6VP=J(NXG;=0UU4;5Z&" 78X0(K)J%<:V0_%)7)+W@,)F4[Q\6QQ?
ME7VIP[=(1-9?8].)W.H;+L1]I[^"9A&WP:=/Q-7?UJ(]9FV'8 HIW^^/1,KN
M:!F1^6"<,M-$00D(JL^.PJ9WVTA_&(F0?,D)!0X?5-M??7'HDYU2H/!Q++J.
M,=&H ."3Z<N!/[.,8&#Z4A"4,)@#,E/N1!P8$.I\T@*1F>EZ@BN[N!#_P'3S
MB"\SG,C_&C1$S?XX>V?ZO*?2!+62F[XQT@QY0RU.#L+!X:L8_DX43)\*@Q3G
M%?"\,UTYBB[9+) 9S8%Z^,+> K,/IB^V_%L;Q>"%@)_&,BF&J_+/L3K<I[8[
M_[*W 15B_9=^K3-2G]L21.B@6B3*2.JC4?MNXYMJ5*72IN,"V2[PO[@WU#$,
MZ0I!Q;QG2B0=92+IN#(QIX(<W0IRS*Q?&449R)27/.4EFYN7W)+JI3R<(#GO
MR8"47)%)0 9DYHI, IHISFI34%0P4QW^49-:/Z;TX[;4>M69QW+=E(TG9I+$
M21WU&-3K1/J+ITYFS_*3E5R(WNHWZGQ:D>>GF2\I1JN]!$[L >QL(DYJ/ '.
M8)!XL(^P!_O:6N-9-,>!X(?4/37WO*RA-]I'BB]N4@F/UH5$=PBL(_30+R:[
M6 V#<DX,A6S;@CQ;@5,.O."P0,+T'"W25?J9"%3%O%D97.7AK,2I\(T$2%6)
MA8CU;7SMJY[AW1+&H>4[=\]H0-:-H35ZAPHG82G#BE]X::T NWME\TFCV)56
MJYZ_EM7]4WU.BQ5>5N]'ZWK5Q>XL$O=2>9W.VKAL8I+/+R7@;6K\6.)@@H-,
MEM?B,A.^IF&3CM+1P=962UFKF6ND,[:XGTU LSR&#78 Y#:V3/(?JE&N-":W
M/CXZG5#L<[8SRBTV,*)2?1#$_T8-O"3_&Q)[E2+K.T=QB+ +PQ0<RU\3/^.Y
MO\B_>(*[/7BLGKK>[U'NT^.70$IV@Q4N\?^QU_S)\I(9ZSNW2QA$=R!8G?M/
M(',?,V4],%!5TD^RU'HE2YUC$8^&FJQKF3#,UP%\<M%T/5K_0+KEW+]"ACF:
M2?Y#MD4R-MEGH3K=/C5=#='N>PJ@#8 3GJ%=.H\N)>HOC[TQ.:2ZB7$Y7#OI
M?@LH9QX3.3GST?+R"H[+&-M-F1T29A$__PX9*Z%E1Z7S.]7L8Z(K6]3K(*VL
M2%CB%&N#AGKM8?YU3%-V])0=/37'GY*+.XA($>(*C3\^G2<'D=0;PCZ-6HA(
M$>+\^HJ=Z=)#TDT0:X5^+)D&[+.>AMHHQ9+7VSR^#UW'M8)UB2GFY=U,A,M&
MOPH>+-_](W.9^2'T7"?WJR -'J+UE_Q*'?WEH3HHY]L>2%'<7RB*Q/84'_(-
MTLC#JCU6 Z1:GJ8%4;O5%615LX9%604C8%88EF$;AK4VD%%A5RYA6ZQ4;3JK
MR])[-(VX53?<D%R=I;P+MX*NU+J7+ F>[1WE3,J[V:DI9SI0O;M+*F>B3Q^0
M+F?_(P*KH[M 1>,F9@)1:8QG$!ST[58V" X4X2K2WU[?=G^"#M>TP4H"B>J]
M0L9TH8@T$T!4'Y.5:U>&OL'[&G<1%8=60Z>[_??ZWO\B5'CJ_"&"C+[7Q(A#
MAB9QC""BKW$J#A&63$&"C&[9L+?Q:F4%:V12N ]^TG+?C]#8X@M&L*9$R-BX
MP:.XM%AQ+U2>'RM %"F1^B5.Z3[W2ZRA7=!V$6SDHUM\N8H5..&/1[04P#F2
M+$+;I.6=+A; 9LHQ%?,^.8'T7+%? "L$%ZYU[WK)E1H,8?0F$@H$N'$?EM'5
M FU:\S $3(/604A.2@G'Q)D[J>(\03\//4FK[](;$J+A!D4#OT9.(G5V\BWF
MZ6T:YF1+JFXFHG?U\YGE!DEO[5*IT^G+(U*4R/QRL:WJ.S>,*T ",W)48$/G
M:GQ^F3^A719[F'&MDU4^UI'N0J13-8.V%/9.69GL:,9'2:%6A(Q4;+(^)M[H
M,'+QQNL@3;^(O0LD"%N;!3;"D@IFPBAP\63$UCF+-)M/2F'W!-Q'I2FR,7E(
M^_6\[SJ+0.RTY66*5RZLO(116EM\^XB,)^*3N<$Z:<:<,\Y$6Y'(-P#S4>*L
MGY0UY*0(UF@>'.S//L\.V#,\*0DJ%^[#OF#A2@2E"'>'^+U:Y#8MNRSUSQO+
MNK04U5)?0Z2(+\%SV>B&/OK1SNJO&=-6&0ES)832N3S8$EF9: [(];:W3PSG
M%RI36'E%ASR#\QK25WE60'U74YI%:EI"*Y]R@]VJV;"TUD%P,"NYM763ALPV
MD4FIKB)$+]FZVJ3^=<75>FPV3"<; HAJK:@"D*X#+4%'\WP% >BP>SA([MCX
M%].F0XO(KN_V(4IV1M>D,4D^ J 1Y[TV)CM(A"(>/EY2P/E!\]Q- 7"VQ.((
M#*IM_>%AZ!5Y+8#Z./[YTC]@3]#2/ U8A(IO3^<@4(S?$&A,T"$@Z'NB5+EZ
MMG.R"L0^4===R&KJZ?H6$@?GV"&3-UYEV9C%UOL=C3WZ6O)Y >=V]F:S]7-L
M!<$:9P"O,%@5VB%G?U"-6%:>2JD%&%*B/U@!A\6["0),D9YF(E)"6#]NO\$G
M$/B)B?L ?*Q^JB=Q]I@</4U)_;J"1XCV#=!7K@Y"<N*EN$!L 8(D01T$3VB_
M\!^N%G6+#KLNP_H_L3<&$OO>"2K*]TH+9=>PP!JT;B0A1X!<A9[[CW$47H G
MX!VRK_%6,LH$X<A/:26C3)"9&$%F:@0IFR[%AW]WT:$DL)=K=DW!2/@5"2M/
M[^4,'*VW>4GF&K,:I*0HIVMLYB%'>TS.2XVMR;XHV>C*,?.R8\$-0$9:!)ST
M>"!$6F;2<J<N>3]V&F3'HAX+M)6>G"QW!#/VR$1B9RT36=GJIZ06CZS09<X9
M["0E1:#OT ?K[U;P"T1GL>]PG+*:*,@=C_1<G@'I7/DW^+B'.PXD@/[PX7V(
M3'OLGTC,$O1GB&Q?STTB24?KY/&D752/=2B<APG"GCRH,$L(#STTPB81%3,!
M'8=SEWWB-=D:$_2%2^@'E2%BOD95X$N- 6D[7B )J M%^=##@@<'F4TCSZ@>
M;M'7#<>V1C,MO;I;PS=/0Z'[F6'IV%K@9E;Z]N 6&>RVWK7)^=9.D=4?UDA;
M7-7Y0,SJK/4@"SE/XP0/?=,3N1PS_0%1G0+%JK9IYP<=C 0'U=O7<!.#V?]H
MTEW)O*"PN:"U:3.NW?[3&J0@!2C&;4,TX9PZ1&C#4_J4<K$JX"&1*>.B;S/-
M?L'..FSJ@M,F=7@?!(F:LD>#]B.12!QN(S'M0VTY0Z2^S9"-IR-_JEP/+C@_
M3)\R2+J-2 U299STWY@&R5VLW-/1FLI*H-)_YQH:*OIL9A-J<J5%3EH2VSFJ
MMS2L/1'82%OT:XVJ 5'>5#OU5EN5JR*.T31/ VTEA#KR5MK(R,F]J>$ +5I;
MC"QE2LK$Z2N$M%S$:CE3E'OPDMG/EGK83DF:.*Q,3_5+4T' 5! PIH* <6;(
M3]6!FI6\305OKR+3NMK0"LV;#4NG_E-V(?N]9X(BE-Q3N9X)UJ791L68M-XI
M]WG*?9YRGZ?<YVZ59EKR,X62;^Q]R;YO&9;A+ \<L]*8A9A)4ZJR^!"]1BG*
M6L>=9U/<F3;NK#J95Y.EQYJE.5/=\5C35$352;\:I2*JSA'2)Q5QTL8\J2T&
MS9^A#L:;'?A5G[DT@:0M3$W HFXW.UZPZA,32 -^_163$HC*"2@F])57"M;Q
M-E+4-I"D9+O\6H_RC1Z7("IZ C?\G2_%3LS+E"?6]11#Z0W5EX I!ZV=CJQ+
M8^-5[.$;9D[ (UJ1;I:<B(8_42 ^+L4,(O>/Y/-&CEG$%O=.M?>1?PL8;[CN
MHL1U76BJ<B]AA*C:P#GW4S.:H7<<%1DI4">7'N#KPY(M)/_E?/48("-^Q1<2
MIJ<I)R 8!TB)(CV'DX7=%_P3AU!M5"3E%*W0P1,$Q13FR29J("$I]=9>(HLC
MJ.PC' DF;634JB=\7F;/<Z(B-U+!I&6 -/)RM,;<L*:"4)&3(MBMO01.[ %B
MIFW#S9KR04]3[=AM'V#Z#-V%XMP+!C$ASUB1$"2%+\#<? GF!4%S*61Y61,<
M]0F,M.5%L*@^&BRJVEN?8#]5F&@X,#2*\5/XCUBV>DAI?)G43HM3_D8+VJ1X
M/*?L;2<@;6+LPXE/?ZHUJ5$6(QA4C@N3(N1\1E>76XG$@U7WT1L* 7$>11-N
MUAYHMEQ6[EI]3YWQ)BF6@C:[E1OE=?;',+D$- WH"^Q3T/,MRJ,GO/Q+.3G'
M@;U$.Q7A\0;@28XX_([^7<591\3T[Q$!A.H@S4Y<CD<D1J<[Q%=Z:3V3WV/C
M2:[H0$[D=S=:W@$?+?FKQ0+MCK>/:+,\]1U\MRY 2YP*:U:*XCF^C:P@$LSS
M)LU>7)^^/+I!NLGPL;A-0,HTK=X[C9A IU>FV=I 0(Y+SEJG&70P0+N;#8 3
MGJ&=,AWIN>?!9\NWF:2AI<@U5ZI0A:>9^O^.E#7.[O\7L.C#=E2T%,R@'$#^
M*40H" ,Y9%^6761$3@ 1 R]QP.<!L*X6%Y;/M$^7GY+"Y@E8@"  S@V:3,?H
MORY3KD+=TWQA^EQI7/E'8&EY"P0""$,8(!6#S#2<RFICK7^U*&U-]-%[/NI<
MDIQC,];RCM"TPZ@@\R3 4]!!2^+VW[$5@#,(J3!FH28I_2 , :BN+,04>+:\
M.Q"LV+(..D@)4!PE>B<@M ,W.9AQ:I F8EQ\7L;XU'JUP/F,>%8FM]QO:"QJ
M/NF(<?'YW?*MA\1==H8&:Y%/0C3W;/0?]"=J)BDH*9O"C).#FI2 *?P=G= B
M;%39N<G(IT48J0K@G-O0[R(C0B<+4<4J-'!J'=P RSL-(RLJDD'9+8PZ&ES0
M7@<NFD<1]"_!\S] $((U8V9=,P$&2$-@OWV 3WLV]F$$ZQ31[)>$Z83A[(.?
MW^<TW)6_S7?HA7&T/ IB/WQV[5^\^'10X>+L.+#\^SA8\_+4^#S/*@B#J+0"
MT&^;LQ]]]/,VS67X!N!#8#TN7=ORZ'.<.@@8R#1O*A8=VU@M;+Z7-NFJ@P#?
M=&WVVA+7+G7B%#/)X7B^8,F)XB(K-3FJC^"08V!&WE2&=^[#SE5H2K<8.FT$
M*92E(1U@Q BL4Z)7<YR6;H>$72:'"8E<;*)V6'PFI.]0"UPVLDTHS&<;R>:S
M#4FDT'<0>V[GW0=.4IFJNG_08"!0> X("JHWXV%1Z/+LD$M!],TM$H]#IS.N
M@.73:!<)M4N58#'NI4+A+B=0Z-M/0P04=.&- HW/H]U.&8)2.1HSFN(A,]&@
M#B02+/0]"0U@8S0%B@LX-"[[$ $'9\2?P#-:K=J6NE&(K_RR9TFGDC31AHC]
MFG:/C:0H L*X%657RAK!05]_DJ UT)116$"@<:^_ ==#-3N4@#%Z8XHVK9=
M,EI5T9&W72#P3M^:,1$KI#GMGB P6C7)7AM1@*)Q!\?!0:D6N1!(1J\K-BN2
M"M$_C'8;[5%>1M"A/FI)*Z7TGP!:UV@TKX/LE'0;0?N7T$+*'N_0H(R2AWN^
M-)J&-Z5_2 SWP&4H!: G**?^T<+-;Q(&DM=B=PT:"+9*R$8:LCH^%:;B>1C&
MV$;,O%'72".Z-MH; .YCRR(3 U%)#?T:I@WV,H97"S)[6*1DH2KG^E"PPK=S
M!&M<]AZM+UST'R=K"H#Y0YL"UQ1EH]NKJ"*-L"/PCJ 5.%>+$S< -N(L//4
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M0G%"G'#(:MNMB)E#KR3A;J!%#R4I1M-2_61L5IW8-T2]S<@;U Q!LY(0J0U
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MLWS)+?L^[#"G3/(AMXO99+P23X[^2>(L&PC]:8,@H/\=C#Q;:.]#HS[E_<,
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MXY8(X IDZ(%*C'0[KG4^L,L;(S.4WW1@;YR2CZ[F19T5S@&:#=55WV8L%<7
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M-RZ"N1.J-;N>RB'O<$;7AGB=9W+I>U\7!9N2B&T4_?:7O\";<-7WXFA,?QH
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M;1O%/?_ P4O%;F@HJ68GE1(!"1XBDHT1/90Y.3<11<Z X@>P^Q WIC,<2+2
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MVVE%N0PHK @!P<Y,L":F^C:RQHXT]'K=U@=2.;I7-DH3TH:VJ<_*BXD:O\.
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MFE9L7%FF%ENON?O56H()>0E3.,6_'=A#9SPS &#&V'?$%OG2=UFS@GS^E.*
M"@R7FPUFNVE<Z.Z.SMQL.H]7813RN.8B,ICP<6$>^GQ]ESP1 4&D;8(K^.K$
M,%I#A"D0<S:"EB!1B%(-$$P:5!<'5)"XD$G\5%91E&D1NRZUHLG"A55HL?0:
M%7))N#'(LE=L(P6N68^M2;1&!@,<9@I_2SQH@WX10ROG(FVULL(Z)[ST+J81
M"QN^UU"F:8&V(@_/)9;D;47E_.0+JUQ'GN+P'Q)ZN3:$XN>Z>!-3G<\%VZ@.
M:WV!7V,,9,Y>4)'68;1G:XVRY.;EZRK:K_'Z$X6;[5?VF3R@:?:?L*V<YHR[
MD^)<CJ3Q_%:29*QY5!!%!W0AI:T_]2JKJZ)<>,0<%YT'T6H?%>6-^;?IWVI=
M6 "U7_%HI>UEX)SB__8LLF5=4A6P6K*WL+M/W.Y*(?GFYKBQ#(Q@V-0?*Q:[
M8CV4A:,X.>#08^%D6ZO#TF_LJAH"_2?\P&-F$>TG&_HPS!3]MO.,8Y?G@HB&
MX7(><E]^ZC8A*XS7*8M"^>-G?A:\E?E+/R74_)2?,ZB2,\QN5R/OY>E"SEJL
M$T+)G#?-$"L+\7SAB0D X=F")K#$0,/O3 QNF3P%=+<FKRWS<G.B]>@MQ2G7
M^+5.<KHI94,SU.;DQ2*K4IQ0*ZS(P0^]=A5)(%BD.?+$3N]>[53Y*;\)5<_V
MZ?"]]#=BFT?OZ$WU/1]DJRO5*GM4X\^7*54)U&HH !USY&&XO@Z4'U.ZOPR2
MPWU0E&71?>??0\3F6+&#J(<-5%!Y! %D@S2("U%6%5@,BK/<G OB2!3U>J:I
M'5 9*GL#OMP\)$&<!BOFIOKU!%2H60 T2/W;\!9UR(B^\N##$U60*;R'%S"@
M_ZKPU*]GX*JG].U2O;!!RY<LNA;G1#RTB;Y=PC#_8^V23@6 T:2TV2MTBY:3
MO7U?ON"$Y11G;.\A<NGU[;2'B+FV.XFZM^,OK'3OUR1DOX-AT,.P$&5-@84@
MWR10+JA@(Q]T*#@$\,,FXVW?M6HM \"#-]G_N1IWL?9@BP!V!(O7%WO6F?$6
M)R%9B^*E-_@K_Y.C\>Y(&K(+RH<*Z#=[9L!LH9B*>JET]#T/D;ROY6^3<(7S
M.QK#%7R#AI.%88VFARIA^\<H7%$8-IBWY]PQ=OPZ, 5T'3@$4_NJO45U4"%I
M7:%S/N6%W90;7>ZL\GE8*J+&55S9.9AN>8?INME=#?'Q,*F)B3HC9<FQZDT>
M.,=2A[ACBZRFXCG!V;YM%O-6_KPP18(]Z^54$<!^:3+F771M0E"ZB#X1-]'S
M&F;4&"%/C<J9RI=A91+?3]8#S"UW<(QNAD<W"H]$&\=XJ(FSXB!O<,8ZR_.'
M4VN\/CM\29E3%JU!9'9UZ&I-6;59WM)^GXHF<Z1H1A(4+,>>.IE [/_+1%#V
M:N'^F20970-OK^(7G/+]G-8]B@Y5\SBKSL4/D"=HQ>#$)?L3?J>[#9)?<<8S
ME-(BSQ'&-&H -S%7^'R@C2KNR?^GPIAO<3EKQ'BC"G/KGH?YBX/[\"D.-^&*
M=5]?K5CO1;;/I;MLEO]_K9T!I$W7M-&='A\_O0W+=S%I*04-J;D8:"?E@)!?
M88HXL=&X4=Z/&B>]K!\MFEYMTE_&SUNTQ_9L'VU-SP71MF=W;!M5@;/DCW(!
MW"7ZC#[@R/U8_2Q7%^O_VLNY]Q-);O#7BEH2$M,?5[)4D&;FCR9A\Y6-%B/W
MYES!\CZCB]4@H1NO+SO6Z!K&"M4,86*EX%FA*7VUPIE7G**\:XY:XSY1 M(#
M'>1RLU@3P_OH]N];-$9LH?<-NE@O+$1%71 AD'[!&/#GAI+%9!D9I1D45B",
MX./[#W]\_U'?&Q0)6@0S%08>_.7^"V(<3M]_A.$?>L@1(P7. J5H,* )GB!]
M[(</CGVL0M />@4#;S[VP^F'&?C8,7**/M90X"Q04O(QRM-A(M4DIW:F>^IK
MEUE4DXS<8'.M-&A/N13LLNV91&N*EVCJ?8=?&';\#_>[*,RT4BA4R%E<M0^3
M=V^^DH5\Z)PR)FB-TU42[H9OU$=+F-# D1@H= :8Y8Y7X9?WJ<\A%!?HG.?T
MCG9#LHH.SDG,9*0&=<=.EC_8>=T0;9=P]O,:QQ]7!5?$[M@)5*=4Q+S70U7T
M/3=\>WR7L:\Z+BHE0$*$L5WY C]F946CQ4L01NQTG)6S#R+,*O,%$:O+]U,0
MQM>*543,:9M#K<O+PSYE2Y(L3S0G&Q3D,IQN2'*:LORV-1427%Z%L0406^W/
M#6WIV(QYM0I8P5ZT3V! EQ(@)@(O_S2V9]_A-$O"58;7+"M$QV^;WS3'J4[)
MQ_29T^?Y3# <JD/QI%\ML)0<'>GWO%>_GCK()RS/,.,]4;)%O&:SZ([="A6-
MR[ZD>+./KL,7K#4S:1*V:)"NP\A+GC%GSW/[<,[[I-+X;<_9HXCQA^$^9J 3
M*YW/"N"H@2UGS3/]"N85@ 5[=#T,L.J+S.P9)ZS$88*?<9P6C038'-><B2MS
M=''G>X.SY>8A>/61C\UE8[G7I7#HMQ$5['<H%!6*D[+L]+Z<I/EG,/W4$YVM
M4T07<*V)L#R1FZWMLN!U-AW"66M'WMFQTGF/-6%A4?TB9'GD\9KU7-#:I/L7
M9H+^T*K"N8_3.1>TEFS0(<1]+S5'W?F/9GDNVHSK@?CFK2P_C+!N4E[I$%MM
MX5E8;BXZ[]\R=G#,WZH5#V'N\9/VRX\>(N9FTDG4?1 I'WN7KW-2R0U&)!F&
MB2AK#BPD40V-Y085?-#](!J>7DH],Q^_BJL9?G0]%.XBW'E=S).0\%K'@:S8
M6#RX,6?KX10PS]UB)X#E_6A:7(SO.7_T2Y;02+H)HG0HZWJT]U4.C(0X1&7&
M!B%#@)"#/5JN9;=*45!/W@22XLPF4+!::II["'M>$UB(Y.TU\[89*TY0D <5
M.(FXSBS%1<BHH3)WJW 4/)BY7$RP%"]6.]>8[B+RSFT'G<C02<*BC%@[2?=^
MS.FC"%JOPB%4B**J@"(@?:9<:0L8"BYSF$>OMNS -@F#2+1%]3V7'O,;-W(V
M^8\\IX8%>X0Y_S>R).\T(\N)MAVNMV R]A-N*9=L:3QVO*F>*1XU;_U,8^$^
MP>ME?,=N,E@%.OJ!&\*Z;HI_LB9%ZL_A/3 U-R-G0K@//_43T[9>MKE\:!FC
M0D+^J:J,O(>4XA/ML2*3>X,CWC!],\8536-7GD/6V8&/XCP*4NVG[SU$'*#>
M).IAA<+H(\X F%]WHM+FI^V* HO L1^='5 %BHF>G#>B34M\X0[[)2:/*4Y>
MF-=>Q;M]1O],@:6^SV_TJBK3[Y3A3P9G4=B93-^2._LRJ>Y9VS%,;]5\.N?T
M]CE<3-E561$7%M6E/0IH$[4<^4QB?/C,4ZD^[>-UJO^JN8N"N3VT4W0?##@?
M)!@AS@E&3!C A*AI"J;^HR[53_;,O[*4D1[-<X.8&ULL=MM).5EPM9'VX!PE
M%Q'38/B&*EKMB^!NU0%'IG5!? 311,OB6_:LBL2+K%!%\<-%F*XBPJ34GUBT
MR%KDAZNS\7H"53+CC_/18LM.,]G* &^"?90!.5<R 9M8:'M&P$HGE7S1(JNF
M9+8C/?FD5\K"C$[:G,6NM)>>@R#;0]^K=U9B+0P_U$*P;38<U.0<T#J>%[O#
MZ#0;K/,@20YT8WB'=S0NX+60Q\D$J4W:IF2Z%BL?)?&% !)/&#YHBBVQ5.S,
M<(P:$.;,)9; IL;\8=YRXW8YJT?7'&(=/CZG3!@N:H0FL='FG)"3GIDS9F\A
MX"]9SP[%C_\>XH0:P_/A&K]0FS(_KNFEZ.1LH(>#UX5KP8Z_,+]9_ S#+S71
M;#_.&=3I/)!K/=QIA9 SGOKRL[(52H]U8[%W5"/L %,51M^T4VI!W.:;ZAJ>
M%9S'GEKEW>ZS4VT\"TWPZ\>4AXX/^LO67C(.P#LFZ][S_I\]8=L-WDB6-\?C
M7?BPO']*T6]%7/WP.V!NV(-<F]-UJ1(P2L<.)3B)F>[#](O-RL -*G[WDG$+
MB[?JWM5ZPJ)ZR[*1VE XT$? #M13]7M0G8"1ZG>@Z8KGMPW\>S<.]+T?!_I^
M# <ZS@LJG.=[P,[31&[ >;[WYSQ.4>IWGN^G<YXP#N)5&$17<9HEO/^?]ME&
M%PD+.-I)>M@HY8Q0R0F(;PP 0Q2U!12$J%O_4S7Y8KWD-]0V6(->&C?#51@_
M+3<M6DA9;Z:T_4_Z9Q)N^5ITM'(HQSB."B1/S(OA$)_ O"4CD8&D$$QTN<Y%
MX]<,;::#N'C=?Y[L#I\D.Y($&:Y7M3:XL>\G9'&OVT?8PVU\SJY291N&WZM!
M1;0T!QJ6J(E(L_CY5(O8+_<_D1><Q'R)\H1CUGS(UG_4:9ICILK#O5>5?,&Y
ME3:8Q%2A<P%.^MT7=(\JN.5\P7BABP?2UWG+,J.3&S>,IWTB?NVO79WKM^+7
MJBWMYE2(X-@"'1<C: #\IJSM^)1K/$/SU)F5R]^2&Z43H'J(6/3V["+J/G \
MD(QNCS;%1BG@K&'X_#! 1%EG8,&0?B6=J359;OQD\_29^BO[#^LT\1)$;-^L
M>W;<1\4F];B+JH]L\?29I];P'RKL8+B' DQ$77%P(8DJ:"Q:T)CH4+G>CNE8
M >V_U=^MVO%QU6Y*C^\WYXM.C*&S<YB)\N<,O/3X1E>R=N?O"0LNNI&/> 97
M;W'4>13G9#C>4[+J@Y&9<=Y$=YH,TR;Z1R>BCWNV5!]'Y7A)V:#\+2]U%Y*V
MZQ,_$Q*,N:>K^Z2+GI/..TU.T5ZRN3+-\C>$/(SHFF(?)3M%=U/VM)["T)91
MBD@1/;W!1J6ZO:DN7Q89*MZZ#CR%]%34JVB-6,X5.L[2_GV+@E(M]-Q L"-I
MR%+Y'ZJ5B\K&D-"NT7J!(2H*@PA"9*QW"]%OJ+;W24(=SJTE'1M1V5T4Q053
M;^,Z'WU0@R/RU"YU]8S7^P@O-YT=>K4+GJO3M&@KJ<C#0R*YY,P2I'I["X,J
M1*Z-,S'5]5PPC5S#.7)O][,#R]/3O550(N>AS7=)WD,O(1(_G;+&W6OT0"4,
M663E]T$P7$\'097V[$U5S@ MZ6N]_G5VX(FG4U5/[(PX5";]S'4E<AZ *\G_
MMYOU(*CB9DU5S@ M%3<3/C95G>M@]1S&.#E4M6!0[+J/C,W>K).LA\J^.3/T
MS\%V]R\E0C"\204IHJ$ZP*A$34 :Z[Z)<D99^_D]M1@+/^DD89-+WTK2Q^,&
MP0C(F=$0&D1114 U']65#L#\/^V3.,SV":;>^"E\93\9)'_T4;%(+^VDZB$S
M.><EYXF<'PRW4$")J.L-+B)1$PPV1^2,)O,1WKWUF41KGN&<_^-JNTO(BRB&
MI.\QZC3-T5+EX:GM,&.&JMQ@^)(VFL14HW-!+FJ )I/E6S'4=\+=]D5XUH>/
MTJ_8;V2^\@W)Z.YIA==7L7@QJU%K5HF,/@8*9-VH?4U6_*DO;Y%4I%;')$,[
MSI35[DH%V^^F=1T=P(B&!@&#<]1'+464(;HMD)$\K:[&1AM-U#60JV(@D\VN
MG<<VUR8O\52H>3ABNO;W9J[_MN0:V@LX#3A5C@>O7;U5&PLZE</!*9^3=>KA
MIX2D;EQ-4O* %:?LZW79+H>,Y>]C6.>$BJBI>%1%A[ 14O$DSF[T%YDKNG#;
M1T&&UQ=XE^"5Z'))?XXP;\(4LU8321;^@_^^4U<ZSN:.I\430T<R6)K'#\(\
M8OS$)"EVG&GZ(ZI(B-85$6$XL7.[(;ZPF;V---:]%;.H2H4*L7A8J0K6FZ3B
M)!^N<^@WV-'H,S:M-5>1M<GM!,5]]\J*._G5*MGC]1U.,2L"3H=RP1ZC$,[A
MG*19GN:GOJE7IVBZA53EX&>K+[BC1++GH*Q+ ="*29#G*H+8_&MC3,PT_6Z,
M"?PO)/F5+O_8-0R.4PY*7AKBH&&K6N3,0ZH">0]G'M)$5Q6N,&91'?"(@19G
M )2<UB0_5&58U#@YH','R=M3!,LV,^R/E+,;8E0?7<Z6KS(JC!'G/ RDGRC)
MZ]]+$2N5<PP"Y! E<Y?KI^S>'D5/@$#B%I4<8<1&1<B(G@)APQ-5D<D]JEKI
MR44<K&QOO)I:9<7.#Z5LU^9+NNBG\T+\Q&_S+E]W82+V73@)R5IY03Y$QG 5
MWD_6R]*[8(DBQA/A@BG:<:X05MN*J!$--?:OJY6LYW,0QAEF%;@8#[K@P)3!
M_=_W08(_$:*^N].DZL2V!KB,8FK;4@9F=DP(9G,HY6*@#94#GO&I@MYNBTIJ
M-S+-ST$<//&4A$\8+S=GE-D=_0<EOV((/"F]I%.E9&B"@Y2]F%W)%6TP1F2#
M'IGUL4F*F9MD#<'2U#$D>AHULJBKF,[G052A:1#;^HD8VE$?42\F)!G6#0=:
MG%+"BRBKT,AFZ,Y[&V8\,8J5FB(QBWRR8$Y1%_%:)X_!B*RA7>FQ\6)I%1'X
MUGY5%0*M"RD@&)PAV,1"V_Z,4OFUN39)G\;H\%WR6S?$HV?F1EJ>"9B-%RT%
MDKS@7@W):F]WE<(!$$<;N1ZHTOEAFF25LT/ZK^:Y(?W5W^ZI/_'UV4^8/"7!
M[CE<!<JMZ@<(Z-MB+T$/+2TJ'*8-$VI0$"4-@52[=(&""ZJR<?.V7<W>\5-S
MD.JOV <(&"J^B^";M_=!*(B2AD"J/;=WP:5A[;JOS+O6C4D0/^Z3PPW^^A\,
MY8/F4XS.[YLN(MKI^5G^25XGB')#@AV(I=X )D1%5Q#U7UNQM2C?P:K,I_A1
M7?**X,X>2-V3??9\ENSC]&NX^M74*0>H&)I&+U4O#LHYHH(E-#]5 XNHJP\N
M,+4B;=VHV#OP"&.)6H=AY<VUQ62*5]\]D1=J/OLX2PYB/2G_P5V>N[O\Q=\^
M+U3<NOII?2LIO^WCU>\KW7]F)#Y!GX,T#5;/^Q1G4[_[;=$N.=;#])J4MOAY
M>;<\/U_:SAZW24@U0K$PG3BZ"1B&IBZ"7J:+@AFTB6(0%Z*D+I 8U%\MM@!@
M/R?X'4#4D%UO(H!\[6)V0'JM^K@4ZK"U3TJ51NSI55F"@^7F#@?19<J.M?(7
M&RH1>YB&Q8N>#IH>DGTI)Y:O0!J),_G#3!@YEH,X$57=0<4DJL"QW"#&!@D^
MQ:LH^W#@/ZFA:EJ#&0US&%!4'POCA!@K1'DAP0Q]<C*6,1(S:VG50UF9\QA2
MU!P-YX5*9NC6RVA&R6[LPTLAM7&68^X M,(;2>;J/NBK1EF:8EQ7T05.5TFX
MXSLBC47$("F;NE:]I+T;Z@E:E]Q@+"=4@2.:6@0.4I0?&3%>J.E@%ZHH 4K#
MK5<=5LG!G<W0HJ-1?<*\DT-M"3(X*K63JYL]VV<O-ZSG#8NP$4M>J5NC>B:E
M&C'#TQ05XEY.MP1C9E9QE75SXY1"./#2@I-H:]9%JO=5O$H8R;63G.\N:FZ2
MO]NICY0%'N;,9Y //@!J1V)XGWH=/*&B+/#7('K R59S<:9!S,F#J7;BH[R3
M2@1K1"?4;76]!L'(M.!L?Q/5IUGP$U%UD:,Z"]DO<\8;7U0;&EWAU%@VUZD.
MAC:>U_7MW[M<;D[CZ]BK2Y:(\53;5XRW0:^HPW:#7B/E=N]7(3W"!KUJBG!W
MZ&W(#>S0C]0('*7^'7K5K9R?G?M<Y/;?"G2N<&<UQLZ+@H*I\7%E5PVX*")?
MV3RYC,_P<Q!MEAMF."3Y1))S$J=9LE^QJ+ND?]B$*WR_"\HA#=>#,Z-N6AO.
MA)N?.G&Y)(C$Z)'+PI9;$9>&FF7"GJD5\O"K4RX12IE($-;+=G9![!&9GPW4
M;L1]&@!P/41-%2QC)&1@ZW(A!8U=":K*P?XD)$%<E+%7>1=X@Y.$%1*+LW/Z
MWU"K3E;;M\U7"<?4W!OH'697?VQ9D$^?]#_A"Y1Z6#UPD&%%P5.]](F<O)C4
M!0.WE:+2R]<,QVN\_BL.U'-&>VDX.9:JT1SC-"H]05BR1 ?*$\*DJ@)5^]E3
MB_H<G&H*JJEM6;%C,@Y-IB3KV6JNJU:3JF:P3&8W+:CUF4Y3C<ZLA]KD9Q)G
MK/*FBY!3I^4V]%1ICQ*"R@BT9:QY?0K@L:@5RX&8=*S748I!BUS*:ZI4G:5:
M]5NV>9R,BJ<>?"B0.;7Y40:&TD>\1>U'B;.E8N"H.-^6R.181MCU*;F'14[[
MD>MUVPIG!J-I/^I/4<X)_=7;.%RO(WK.PK47$5#&U M/JI(&ZZF@=6WLM\&!
MOPC1B?I=%"PJ)+=2'.&>92=9P9@-!J A:@J#"4/'Q>2M$@"@UJE]P:IKD3JC
MX0U.*YPE?T'6/\%XZMPG#>8326X3LL)XG7ZB3O3 $M&SXIA4)YRI4K3H$Z?$
MP4-'/\X A67G8A3DW&!$/$TTB9E.YX&<=+R<)3_5SYDBQA5)/!?#&'IL 9\N
M'M,L"59:9_K-;UHV!2\HN6_]G:)?<N) >LEV:+W9D+VADU%.#>J3$NO38KZ.
M%-]VM7AAU/QGC+&^.S",I >)SF5CJ2-X6N]8+I[W*MR/D?\<)"'+>S2R\98O
MFRO[B)A["\]9@#/P;A3(H(+ :3QJ*'LZXS8R:B?&[-J(FTV#P%EPK^4ZLU@_
MECJ=@2[2%/-:*95N4R(;TV0=JD+-XI1]D+K_<^P?81B[!FQ$7X'P(<HO2#@[
M?EA2;<8FTXE5=QI&:[&B!::O^-HL4*/4!W",?<A?</CTG.'UXH7^]@D7V5G\
MCRQ5^X/Y+D6%MJO5]# O]^$DYWD:"*8H*7+;!,K\<<QOV9EF^CL8H<88_,Z-
MD:KBYP9TQZ8J9X\D?U3F,XH/<!% ^32K5L8J3]ZQLD_BT;TSGVZE[0GJ%EXC
M^/1:<D54," 'P<9HJSIQIZ;GAJRJ$^<"H#M>LDR(X&&=X?::D K_2,HBC4'Z
MC'9!N.99_L&6C2=E^=71GMU$A3'*GC':4C'VB;C?X.\")EZ-W#$DEILO*>;+
MO^5C1J,I7E_%EZ^K9ZI=_(DD'6LUG2!FQ<;<ZBW8>DKO6J- ++.)E(49!I;2
M<,N)\5>SY>J8(="%V1"'.,W81&2,Y'*P_#0J">*BH%P6=!6C7!I^T]:,IX5$
MMD\*VIZI%L3SX'E#M;2YPWDZRL5>_5F@,7W#?&!#?EYRA.4^NLNU#T5^SPD-
M 7QR2'#YJ_4>Q.M 6P,A+H 9P1C"[>.>1NZ<[PU^S1Z^XN@%\X02#]E>U!<_
MVB?>@!MB<23;^B2]$*U(K4(W.!,5;*OB(2H?8@(B(:%(ZW&0AV6A+Y9/]/"5
M>+&$[]_.R!P: ).+&@"97CET#O60 46!__U;&IMSZ)EHDROH$]6#%^S_\(:&
MYAIZ)MGTZ@E?_'C]']_0T)PC3R7SK)X'<H9O@W#=6&XN-A0F?[@_/.,$!XS'
MFQF>*O8/!)VQ;/IP7:*?BX6X7*-A[WL/>'P3N0WC<+O?YHTRG#TIF'28YEY?
MX$YE@5#@K9#U2YS?/.#UY>N*?G3!CW3U<H^,&+@M,S;(T-($?A F$..G@!*^
M+BWA1[20A^ )WE&2F+?P81G^^XR?>U)'QW 2GFQL8:"0G"($\\)=T_6K4B A
MAK2/:2]K93<(\QO9@H"KRSE)T$?IGSC+FWW \+I^*#JO2VL: JGVCHO/RR'E
M*S8:WC]&4N1:3QSE<_AN J9=;#L(^NDL+)D=-QV"<$0^" Y1TIE1G9:<Y%_"
M[%D\P*H4>;O/@H39HJ&M*-&T-!\%'GXMZBL5 &7BZ5JU,!]*I1  #4T'[*;M
M*2O<O3E>T@6!6V.L4_1ABE4.$QDBYB+,Q0Q;058RPF-5@YR::KW5.^<E!ZW5
MO8XB:@S 0_^[T4-\*S*J\7V&XVUBR!CGK["K!591SGP<:-V'3#U@:_%R=F-5
M!E6PGJA,3R[>5;PB6ZVM=/.;YINY.B6/EA9R!C#VSQV*)_UJ@:7DIHE?#>C7
M4ZD6*O8S?XV8-QXO'A9\%B?VXK!*_#W#6J4'#8A;E '19>;>5W(1T*ILXP[#
M8<QA)M8:GAVD40/-DGWEU8T40)[EHD*$L1WX 6]W) F2P^7?]V%V.#N<1T&:
M+C?W&5G]^L!>KNMXK HU<SR'J?NHKR1Y(L$4G1T09\ONX3AC] MG#:22C :>
M1%^S\+&+W,&F>%A#EXXXO<=X?4[B%TRW")3J;2(+UW-6GS%KLJ9^6*-.T71O
MK\K!SV$-YXY2RIYU]<CYHUTN -U54@E '-)H@TO,5#P/(&L+>X$BXXT*C@XV
MBN..*#H>3(5O.; \9@C>ZD'#U4Z1R[<P#2M*9"RV-]UDO=G=0M7H1MM3*D!$
M-'0&&(ZH"PD07G+FQDLZR-C"TDK6FY><P?22?HB.O*1'9X#AB+J0,/62W@7H
MA=O5YS YJQ7+$'F?Z\Z+>2PZE0$E!IJ= 7@MT>RB;VWF:NDYSN@B]8&YFD[3
M)*M,I?1?S6F4_NIO=^RQ].(U5&H6T/B"OE'5"'@P&^;Y:1:N@@A]+@M(3.OB
M[5HFK<H H5%IJIPJ^H71'<\2U>>NHZ]8Z,Y;& -MC\?32JM"@.BU;I4C1DAY
M<*]GF8TOF>FP1L2]=4KRTUMCNX9)IQ+ :#.J*7)<JPQ>#:RR_B5#/5:)>+!*
M01Z 5;9JF'0J 8PVHYHB%:Q28Q-]=;MT*6J],MA5'&8AG2J7&[H<YEDZ"4O<
MR0BO"':[?XS"U<37I==AC*\RO-7JK=5-P]GU6D%SA O17Q@SQ+G!O ,]!JG[
MYK.A.*B =-URJF$QBFO</P=T9(M]]DR2\!]ZB3^#I)SATB3MWE_.NP^;3E#*
MV:.@X _2@3JA[/:C=KT"AZW+JP0WM%! :137N@V29<(VDWC]<Q#M6>U1+J*%
MBW63=(99%XN176X7).B%\6>YS<(!03K=(,C=SM>OZ9D VN6,E"M:)DCP19PQ
M2]\63@IBSKM*T[V#^2XGXSAH"K(>DE<[YK:0\P/I8JUP#<UI5?T!AF9@+KM2
M0,5F*,M]EF8!?UPQGJF1DJF_D;E>=-3WO(VA*:\,H9A=_VA48@$HJ^L:CKB8
M6_JUM_,@20Z4MD@17V19$C[N,Y:T^D#H+.BLVGRS'KO@*A9)DY^OT/^LQ;M-
MKGRLV?A7C9[#;7X+?0\ET4LV<H&+P;3[U4*P[R"F4Y-S0*MK^JTB=ZN G!\O
MZTQQJ$X(7W8D%A],6?J,AM,9D3='U8"=CSWG=DLQ+><YWO1Q3[G*="/&%H:'
MVJ!/'*A]ADA'QP<+S<5 ;6&-F!#H7 %X3YFP%7WP6Q.3(Z(>(A9IEUU$/:1;
M5#>@=)YDET? SGR&<2+*J@.+252#0SJ(N,M3.+C1&,=M0E88K]-/5,>,34#U
MO]QT!@T_6P0A F(XBWF "L&Z4O0DG8X='2["EW"-XW5:UX=.;.@D86Z%'23=
MQX6"T4D3"+3&JR@ DRP_A!-15!Y03*(&'.H9O6J)\3=[EIFPW(@,A72Y.2-!
MLEYN+L($KZAIIY<1_2]>GQW^G41K_HGZ,'\FK-[+(KVG_QMA_GQ4Q4<\,C?,
MV_8AC)<4?2$H"Y=;(2K[\9$)RWY8Y^(B+.1%CP?T+"1F?V]Z\PN7&@4I2KG<
M:,4$AY#B[]4TB7?4C:K:&8@C-E53^.(0Y_$<L5\2@%ZXJNZ$WY0+*IJCA?^I
M@/WFYH#JVFR,"<#^I1!<748U-2XW2(K(?N1"LA\*,9&4DU7'D)*ROS>/-H2T
M:)$B(:^HI#&)&L>(AN[L42$4OEDM.K%$>:IJ9H;3W5 Y2,@:H.OW#L3?F5SE
M1E@<!T6M5UG0SNF,0->\W/*4I34"P'J770;96AT[BLZ3O?+@G1\S*F\4U D:
M+L)4&7A9UO>D15;NJ,1!.805NC:\Q$C+_9M9WS>N#SC9IODAM;.+UA:J'F[=
MCKB,G,J;,?[EV?H,;EB[T5:Y6.W0]WR05;A&Y9S%TF^JR].V:R3Y%DT\.LL?
MI.FXJ@91BX*GJDS<.^I/"4E3M K29^JGU3NP'6?,BHMSSC <5!]B8JSEV< 9
M-:XP&5N4\T7Y:TS!N7B4Z>3B]CZ(L"P%ZN'^N7Y#6[PFU4H(@+>X4YPECU9V
M<QNGPIQ1\A5I!9/=IU?.58PNTVO?=W!K6Z'G]1J]=LX%] Z]#9NV"_0CG4'$
MX>CJO'I09EU0CH7#LR!E)5BWK/$>WS\NDH356F'[R;-#^1'9FG;Q-4C6^4FD
M?"CQ$H01RX+\1)++[2XB!XQ%B)>%T6^I!I6WYN,*95H?;40A_93(8_S1(Q./
M.74Q!!248V!GW&GE<[(5,0K80%!<')CG;YOSP: -21"6PY&Q8I?7R-_1$4$X
M<YC$]LEDYC/*V<?]ZAFO]\4*3Y9^U^XMT$O&(OFQFZR'E%3)K*Q"7]2E!]5%
M0 4RHJ%#P/!$]LCX<1ONV0]T7*KE&#N^:*[[&B'WSL#)(T8?AM&W*YSTZ@.4
M<J.F7MV4:S1[?= WCZ5=$UFIE'C-9JF;8(LO".N9HS53>.%OF5_O6)ZW[XY>
MK:CYK,(+.F_18O+IDF\ .'=4%1%59613:/6#4DXD+*T2IJBLB F+F+3H%R'O
MZ&&KME9>[MAP])L']! Q-X=.HNZC@*!>/-,)*#+*S]S'B@S#0!%EW8$%13I:
MSB4O.<#Y3-9AH]JTZ]JD]F$' 8LKS#:"'D[8&[W#KJ'5/.Q'AB@I#"0*D04
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M./-.-UCR9F7M7NBOW^Q\J&VE#B=)/:2_%8MT/IU*LV9M=/(!L"J"[-<VU>&
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MX-[3)%ON:'7&,'Q-#TABI,]9@!;5\5H<X36YSRTB[D)XW;ZOE>+I.)TJ17,
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M+WM20=$C$P9E!&$N#BNZO>$"H8!+!"'_W\XLB#T@1@]1NOD)TND%N2&98.K
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MW] 3-/0I,WC-V+9<]F_LU86@V4TL=RF;$8^4AR?LH^AW#P&0[87.@?FD&IB
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MM N5WFB9:0@R+0'$.A6JQ-Y5(6(IZ9[M0!DC389ZEV)S*U*EXBFDJE_QT*.
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M3BQ1+J?F @66XX)K.C4=IP?GJ[P,6O(="RN</RXQ"::(K*Z]9^3'.4"@9$<
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M)JTGS8+RPKP @=JI!9'5NT=SS>2I&9Q<B!KHH4IZNM5/3BE&UGX#O5-,2HM
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M3E^H^)M23Y4\TX*$]2S \,E'_P@I0Y?/]'\D"IX5$^B">?:L(Q'S4$ZD*R'
M1<3*2"C: M'+.#T_Z5^<9S6+OYRDGC0LZ1"93H);TD&A"V/[.]VA+=*/M$T"
M89H.J@4D[A./C,Z,SP?DLFP)Y@3S(RZ?<ESZ,F$V34?J_(E*$53%83Q-%\L
M@WX4;6I<IJ2&$B%4J-(+4!E::$]Y4 [8DAA@B([ZW5EJ6VYOU%-ST:VQSZNQ
MVMN^IV8'0-5?R<KQVMNWIV:?JF!55^<Q&$II/7'@JOQ#O-"9V04<VST>%+@4
M>:$TL_>[0F>OHDC2SZ:7^%,+>4O/*WPZS$[U;V$RNGL3Y!4*S8[&[O4.2A^\
M^628':_=S@FB./J"3X;9Y7#ZI,Y@P42\&_UH<.F:H=(8.-Z7W7#/0+]T%RA.
MDS<<'P][_7,$CECFTS6>0/#ITA3'SQLSCWJO1Y-4DM(RE(;W/=. XBE>?((T
M.!'TITWNI*$G6J1AWJ00T3XE3E8SK"U@]:E^)3]5VUO,G;QM9($2^MKDHM]Q
MOXD O\5JW9NERF"*V8]R<DT6"X(65#5TEP/5@,F#F(3<9:X[D"N8T)L&DO"S
MS00D9*W5X?4M*#5J:>>6\X#82R>=XW/L11*%ECM%9-65UA1G[R" +]%4N;W5
MQ_E0R?5!3!-<LE.=\R'%7B=*NHR]&V>N7V6+,7,0%D&YADS]C/?$@66N:6/I
M(  &J[S.<&_*Z4%,1P]Q%V3I#]<Y=FO5;^=E?<M>*;2AK9BSPX#["I,Y<E@$
M0O\ !_-V&)!7OO%TAS:$K7X ;:S&-@O@!^RZ<TS8ASW$>HN[@X ]9^:*5S5J
M<?"# *W>1M6/I3A/!P%QIUCN#:[7ZF5/5'%PX$5(* _Q(1H'0N7?K[*8-1 V
M$M0/8L44&'@ZUTSA\ <!W+:M]IU@7T]QG*KA._'N/:# (;!";.V,>Q#+IE\:
M^O! 8[;B5:>6[!8'_8;O #JLB=D(^EK\14QEA[@^I0;GJ%>(29H1^GGJ%6K;
MAWCG@.VRTRNLM)L94'YZA5;\XUR*&Z2,95><C8=IR^U*6[H!E.T0F*FFC95^
M+[.;0RVUJK#.JF21U;%:HPRS8[7&L5KC6*U1_6(9JS6.U1K':HU=E3"K+<,U
M5FGL21FN$[/7K,*+0..J$(!+$I\>,ZM$Z;[XZFTD^U%YX8AU_-X=6"08X-1U
MY1'C12/--'A,F\H]IS OMJ>N5-BW> *]*)5U-DYANX\@O+Z8NH-PG$'M[W[9
M-'XULTB/:9-8\.#-Z\B961;+0),TC>[@5>>4VS&Q87KI=:Y&V[GPM1W Q(N7
M&>X/:3<$K9V9VBO:^$FY*[E']SI]4]5._&DV2Y_55?COEZ5X>)NI,$PZFZ@O
MH^NQ']-4:;*??%5W- U^/TGDL:3S0(4:YZ$G&Z8TURJ;K).63 43+&WMTR6>
M9IC-WZGA;8(.9NX*TFVS2?HP&A"=7F6%L\JS&?MDIN^H!_4$],]P;EK5=V(Q
M^V+<YN2JK'*23?!7,\,0#)M:<+F@;'Z_F?DL8]C\ NMOI;/[X60\=7LPNVIK
MV663>SJ^Z1S&!#<M$IG-^(>Q[UW_9UNX%&LVK3IZ>1SBM+87B2M6C#B;($,[
M%NLO,KV[S9[JQWT";_:*,MS9C'XUTX%TT#.JLM!].M$?#6VW>- 3+=5A(IO1
M4S.5<8]/R[)N*]F4?##3@-'1*:>=>V199]./G\UT"!S83#5HF97-Y%<S[X)=
MS*2:HVROQ5PV5=\,[]5XZ0?.BL639'TLMSL7_O2I2CIS+?M/^@VEYJ?;@/YJ
MQ.D//$.NLBZ/K;#3S_Z0:D7M=7V>JAZIOV&7DG'IUF)=4G]8K\XJ7(%JE6CD
MJM]ED  "44.]AS"G7!TNS-L=?SM&=YN9?O>/JY)#7]L^ 2X.;VT^./Z?5P0Q
M(P?1\R[H@YZMY,D0B#O6L94\]1OB?7=(+^KY%</BDR '"?W;+AST1W\D:UN\
MO%_!1^TQ%Z\*('/;'[7&W .;/AAK6Y^TRYAH <&=#\;*@0*#CI4#Q\J!8^5
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M,B"VXGODU=B4)X_W[.%&<MT6>;JU=BXN?[1)_H7]SQ.=\W___U!+ P04
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M^Y[H1_P_[.*U<0I_5I_GU.7.ZN*.NRPB']F2?/9=ZEWVWOSHS:+@\FH0O,F
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M7U ".(L%@Q^,@(#9)VKL[9__2FX7%-9NL1A61YWHA'SP+(.\E(.12^O=^&Y
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MV[[OUP81 7\)UWBPA=G2= T*1$&2!FA&.%[]R#G5CK(T@S3A(4L2Q]2B:+F
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M<^3GB_(J1A.L+2JQ))I._'2-VW"9C$"9H@,63$7[D8U-\'VO?V[$TI7=0$H
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MW#_<5&YSV)FA9'IOE$PO^QM02P,$%     @ @3IA5'U#7J%M P  T@T  !(
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MAK@]LE;+MK"LQ>8R*P.[6J5#QG3"B&(3SJ;,!R3@FC3#,*&"]%@D54P +2Y
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M=C%U8F<S:'<T,78P,# P,#<N:G!G4$L! A0#%     @ @3IA5(="U(E0P@
MP<P  !8              ( !<BX* &=V,75B9S-H=S0Q=C P,# P."YJ<&=0
M2P$"% ,4    " "!.F%4ISR)LZQ%  #>20  %@              @ 'V\ H
M9W8Q=6)G,VAW-#%V,# P,# Y+FIP9U!+ 0(4 Q0    ( ($Z852!M=:HE7T
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M              "  5R6& !P;79P+65X,3 X7S,S,2YH=&U02P$"% ,4
M" "!.F%4/J2(LK8!  !*!   $@              @ &NK1@ <&UV<"UE>#(Q
M,5\S,S(N:'1M4$L! A0#%     @ @3IA5'U#7J%M P  T@T  !(
M     ( !E*\8 '!M=G M97@R,S%?.3$X+FAT;5!+ 0(4 Q0    ( ($Z852Z
M0-O\&@H  /1<   2              "  3&S& !P;79P+65X,S$R7S,S-2YH
M=&U02P$"% ,4    " "!.F%400!E(C<&  "Z*0  $@              @ %[
MO1@ <&UV<"UE>#,R,5\S,S8N:'1M4$L! A0#%     @ @3IA5"A>_NE1!@
MGRL  !(              ( !XL,8 '!M=G M97@S,C)?,S,W+FAT;5!+!08
1    '0 = (\'  !CRA@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
